PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	COLLINS, JA				COLLINS, JA			A COUPLE WITH INFERTILITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							GAMETE INTRAFALLOPIAN TRANSFER; HUMAN CHORIONIC-GONADOTROPIN; UNEXPLAINED INFERTILITY; INVITRO FERTILIZATION; CLOMIPHENE CITRATE; INTRAUTERINE INSEMINATION; EMBRYO TRANSFER; ENDOMETRIAL BIOPSY; TRIAL; FECUNDITY		MCMASTER UNIV,DEPT OBSTET & GYNECOL,HAMILTON,ON,CANADA	McMaster University				Winker, Margaret/0000-0002-4708-5641				[Anonymous], 1994, FERTIL STERIL, V62, P1121; BALASCH J, 1992, HUM REPROD, V7, P973, DOI 10.1093/oxfordjournals.humrep.a137782; COLLINS JA, 1995, FERTIL STERIL, V64, P538, DOI 10.1016/S0015-0282(16)57789-9; COLLINS JA, 1995, FERTIL STERIL, V64, P22, DOI 10.1016/s0015-0282(16)57650-x; COLLINS JA, 1993, INT J GYNECOL OBSTET, V39, P267; CROSIGNANI PG, 1991, HUM REPROD, V6, P953, DOI 10.1093/oxfordjournals.humrep.a137468; CROSIGNANI PG, 1993, HUM REPROD, V8, P977, DOI 10.1093/oxfordjournals.humrep.a138177; DEATON JL, 1990, FERTIL STERIL, V54, P1083; DRIESSEN F, 1980, INT J FERTIL, V25, P112; FISCH P, 1989, FERTIL STERIL, V51, P828; FLUKER MR, 1993, FERTIL STERIL, V60, P515; GLAZENER CMA, 1990, GYNECOL ENDOCRINOL, V4, P75, DOI 10.3109/09513599009012324; GOEREE R, 1993, NEW REPROD TECHNOLOG, P569; GRIFFITH CS, 1990, AM J OBSTET GYNECOL, V162, P616; HARRISON RF, 1983, IRISH MED J, V76, P273; HUGHES EG, 1993, FERTIL STERIL, V59, P963; KIRBY CA, 1991, FERTIL STERIL, V56, P102; LEETON J, 1987, FERTIL STERIL, V48, P605; LENTON EA, 1992, BAILLIERE CLIN OB GY, V6, P229, DOI 10.1016/S0950-3552(05)80084-7; LESSEY BA, 1995, FERTIL STERIL, V63, P535, DOI 10.1016/S0015-0282(16)57422-6; LI TC, 1989, FERTIL STERIL, V51, P759; Maguiness S D, 1992, Obstet Gynecol Surv, V47, P587, DOI 10.1097/00006254-199209000-00001; MARTINEZ AR, 1990, FERTIL STERIL, V53, P847; MOSHER WD, 1991, FERTIL STERIL, V56, P192; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; NAVOT D, 1992, FERTIL STERIL, V58, P249; NEUMANN PJ, 1994, NEW ENGL J MED, V331, P239, DOI 10.1056/NEJM199407283310406; NEUMANN PJ, 1994, MED CARE, V32, P686, DOI 10.1097/00005650-199407000-00003; PAULSON RJ, 1994, HUM REPROD, V9, P1571, DOI 10.1093/oxfordjournals.humrep.a138751; PETERSON CM, 1994, FERTIL STERIL, V62, P535; ROSE G, 1990, BMJ-BRIT MED J, V300, P1229; ROSSING MA, 1994, NEW ENGL J MED, V331, P771, DOI 10.1056/NEJM199409223311204; SCHENKER JG, 1994, FERTIL STERIL, V61, P411; SOLIMAN S, 1994, FERTIL STERIL, V61, P1068; TANBO T, 1990, HUM REPROD, V5, P266, DOI 10.1093/oxfordjournals.humrep.a137086; TONER JP, 1991, HUM REPROD, V6, P284, DOI 10.1093/oxfordjournals.humrep.a137323; TOURNAYE H, 1992, FERTIL STERIL, V58, P344; YEH J, 1990, INT J FERTIL, V35, P116; 1988, INFERTILITY MED SOCI, P3; 1992, GUIDELINE PRACTICE U, P1	40	12	13	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1159	1164		10.1001/jama.274.14.1159	http://dx.doi.org/10.1001/jama.274.14.1159			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563488				2022-12-28	WOS:A1995RY05600032
J	NEUMANN, HPH; ENG, C; MULLIGAN, LM; GLAVAC, D; ZAUNER, I; PONDER, BAJ; CROSSEY, PA; MAHER, ER; BRAUCH, H				NEUMANN, HPH; ENG, C; MULLIGAN, LM; GLAVAC, D; ZAUNER, I; PONDER, BAJ; CROSSEY, PA; MAHER, ER; BRAUCH, H			CONSEQUENCES OF DIRECT GENETIC TESTING FOR GERMLINE MUTATIONS IN THE CLINICAL MANAGEMENT OF FAMILIES WITH MULTIPLE ENDOCRINE NEOPLASIA, TYPE-II	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VONHIPPEL-LINDAU DISEASE; RET PROTOONCOGENE; PHEOCHROMOCYTOMAS; FEATURES	Objective.-Multiple endocrine neoplasia, type II (MEN-II) is an autosomal dominant disorder characterized by tumors of thyroid C cells and pheochromocytoma. Recently, germline mutations in the RET proto-oncogene have been identified in patients with MEN-II. The aims of this study were (1) to define the mutations in clinically diagnosed MEN-II families, (2) to compare the results of genetic and biochemical testing, and (3) to evaluate the impact of mutation analyses for the members of these families. Design.-Register-based survey study of clinically affected and unaffected members of MEN-II families. Setting.-Register of families from Germany and Spain with pheochromocytomas. Two research laboratories at Cambridge University in the United Kingdom. Patients.-We investigated consenting affected and unaffected members belonging to a series of 10 families who met the clinical criteria for MEN-II. Main Outcome Measures.-(1) Presence or absence of germline mutation in the RET proto-oncogene in affected and unaffected members of the 10 families, and (2) in the absence of RET mutation in a given family, presence or absence of germline mutation in the von Hippel-Lindau (VHL) gene, which is the susceptibility gene involved in a closely related syndrome, von Hippel-Lindau disease. Results.-In eight of these families, RET mutations were identified. The specific mutations were detected in all affected members. The remaining two families without RET mutations were subsequently shown to have a mutation within the VHL gene. The VHL mutations were identified in both families and represent a previously undescribed base change, After identification of the mutation, premorbid genetic testing was performed in all MEN-II and VHL families, resulting in detection of asymptomatic carriers in the MEN-II families. Clinically, the two VHL families differed from the eight MEN-II families by the presence of a C-cell tumor in only one individual from each family and extra-adrenal pheochromocytoma in three of nine affected individuals in the two families combined. Conclusions.-The diagnosis of MEN-II should be confirmed by molecular genetic analysis and the diagnosis of VHL syndrome should be considered for families with an absence of RET mutations and a preponderance of pheochromocytomas.	UNIV CAMBRIDGE,DEPT PATHOL,CRC,HUMAN CANC GENET RES GRP,CAMBRIDGE,ENGLAND; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,BOSTON,MA 02115; QUEENS UNIV,DEPT PAEDIAT,KINGSTON,ON,CANADA; QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA; TECH UNIV MUNICH,DEPT PATHOL,W-8000 MUNICH,GERMANY; NATL INST CHEM,LJUBLJANA,SLOVENIA; UNIV CAMBRIDGE,DEPT PATHOL,MOLEC GENET GRP,CAMBRIDGE,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN GENET,CAMBRIDGE,ENGLAND	University of Cambridge; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Queens University - Canada; Queens University - Canada; Technical University of Munich; National Institute of Chemistry - Slovenia; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	NEUMANN, HPH (corresponding author), UNIV FREIBURG,DEPT HYPERTENS & NEPHROL,HUGSTETTER STR 55,D-79106 FREIBURG,GERMANY.		MAHER, EAMONN R/A-9507-2008	MAHER, EAMONN R/0000-0002-6226-6918; Eng, Charis/0000-0002-3693-5145; Brauch, Hiltrud/0000-0001-7531-2736				BRAUCH H, 1995, HUM GENET, V95, P551, DOI 10.1007/BF00223868; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CROSSEY PA, 1994, HUM MOL GENET, V8, P1303; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; HOFFMAN RW, 1982, ARCH INTERN MED, V142, P1962, DOI 10.1001/archinte.142.10.1962; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; LAMIELL JM, 1989, MEDICINE, V68, P1; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LIPS CJM, 1994, NEW ENGL J MED, V331, P828, DOI 10.1056/NEJM199409293311302; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; MULLIGAN LM, IN PRESS J INTERN ME; NEUMANN HPH, 1993, NEW ENGL J MED, V329, P1531, DOI 10.1056/NEJM199311183292103; NEUMANN HPH, 1987, VASA-J VASCULAR DIS, V16, P220; NEUMANN HPH, 1991, LANCET, V337, P1052, DOI 10.1016/0140-6736(91)91705-Y; SCHIMKE RN, 1990, AM J MED GENET, V37, P375, DOI 10.1002/ajmg.1320370317; WHALEY JM, 1994, AM J HUM GENET, V55, P1092	21	78	80	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1149	1151						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563486				2022-12-28	WOS:A1995RY05600030
J	BROE, GA; BENNETT, HP				BROE, GA; BENNETT, HP			MULTIPLE SUBCORTICAL INFARCTION - CADASIL IN CONTEXT	LANCET			English	Editorial Material							DEMENTIA; DISEASE		CONCORD RG HOSP,CONCORD,NSW,AUSTRALIA	Concord Repatriation General Hospital	BROE, GA (corresponding author), UNIV SYDNEY,CTR EDUC & RES AGING,SYDNEY,NSW 2006,AUSTRALIA.							AYLWARD EH, 1994, AM J PSYCHIAT, V151, P687; BABIKIAN V, 1987, STROKE, V18, P2, DOI 10.1161/01.STR.18.1.2; BRUN A, 1986, ANN NEUROL, V19, P253, DOI 10.1002/ana.410190306; CAPLAN LR, 1978, NEUROLOGY, V28, P1206, DOI 10.1212/WNL.28.12.1206; CHABRIAT H, 1995, NEUROLOGY, V45, P1086, DOI 10.1212/WNL.45.6.1086; CORBETT A, 1994, ARCH NEUROL-CHICAGO, V51, P999, DOI 10.1001/archneur.1994.00540220045013; FISHER CM, 1982, NEUROLOGY, V32, P871, DOI 10.1212/WNL.32.8.871; ISHII N, 1986, NEUROLOGY, V36, P340, DOI 10.1212/WNL.36.3.340; ROBBINS L, 1992, HEADACHE, V32, P507, DOI 10.1111/j.1526-4610.1992.hed3210507.x	9	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					919	920		10.1016/S0140-6736(95)91551-6	http://dx.doi.org/10.1016/S0140-6736(95)91551-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564722				2022-12-28	WOS:A1995RY80800003
J	KAUPPILA, LI				KAUPPILA, LI			CAN LOW-BACK-PAIN BE DUE TO LUMBAR-ARTERY DISEASE	LANCET			English	Note									HELSINKI UNIV,DEPT FORENS MED,SF-00014 HELSINKI,FINLAND	University of Helsinki								CHIRAS J, 1979, J NEURORADIOLOGY, V6, P169; CLUROE AD, 1992, PATHOLOGY, V24, P140, DOI 10.3109/00313029209063161; Crock H.V., 1977, BLOOD SUPPLY VERTEBR; EDWARDS EA, 1955, SURGERY, V38, P950; Kauppila L I, 1993, Duodecim, V109, P1929; KAUPPILA LI, 1995, J BONE JOINT SURG AM, V77A, P26, DOI 10.2106/00004623-199501000-00004; KAUPPILA LI, 1994, ACTA RADIOL, V35, P541; KAUPPILA LI, 1993, J SPINAL DISORD, V6, P124; KAUPPILA LI, 1994, SPINE, V19, P923, DOI 10.1097/00007632-199404150-00010; VIHERT AM, 1976, B WORLD HEALTH ORGAN, V53, P501; WALTER BJ, 1979, GEN PATHOLOGY, P509	11	45	47	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 30	1995	346	8979					888	889		10.1016/S0140-6736(95)92714-X	http://dx.doi.org/10.1016/S0140-6736(95)92714-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX196	7564676				2022-12-28	WOS:A1995RX19600014
J	MARINO, JP; GREGORIAN, RS; CSANKOVSZKI, G; CROTHERS, DM				MARINO, JP; GREGORIAN, RS; CSANKOVSZKI, G; CROTHERS, DM			BENT HELIX FORMATION BETWEEN RNA HAIRPINS WITH COMPLEMENTARY LOOPS	SCIENCE			English	Article							COLE1 PLASMID REPLICATION; ROP ROM PROTEIN; NMR-SPECTROSCOPY; ANTISENSE RNA; SPIN-ECHO; TAR RNA; BINDING; CONFORMATION; PSEUDOKNOTS; POLYMERASE	The initial interaction between the CoIE1 plasmid specific transcripts RNA I and RNA II, which function as antisense regulators of plasmid replication, comprises a transient complex between complementary loops found within the RNA secondary structures. Multidimensional heteronuclear magnetic resonance spectroscopy was used to characterize complexes formed between model RNA hairpins having seven nucleotide complementary loops. Seven base pairs are formed in the loop-loop helix, with continuous helical stacking of the loop residues on the 3' side of their helical stems. A sharp bend in the loop-loop helix, documented by gel electrophoresis, narrows the major groove and allows bridging of the phosphodiester backbones across the major groove in order to close the hairpin loops at their 5'-ends. The bend is further enhanced by the binding of Rom, a ColE1 encoded protein that regulates replication.	YALE UNIV, DEPT CHEM, NEW HAVEN, CT 06511 USA	Yale University				Csankovszki, Gyorgyi/0000-0001-5918-034X	NIGMS NIH HHS [GM 21966] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021966, R01GM021966] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BANNER DW, 1983, MECHANISMS DNA REPLI, P327; BATEY RT, 1992, NUCLEIC ACIDS RES, V20, P4515, DOI 10.1093/nar/20.17.4515; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CASCONE PJ, 1993, SCIENCE, V260, P801, DOI 10.1126/science.8484119; CASTAGNOLI L, 1989, EMBO J, V8, P621, DOI 10.1002/j.1460-2075.1989.tb03417.x; CHANG KY, 1994, P NATL ACAD SCI USA, V91, P8705, DOI 10.1073/pnas.91.18.8705; CHASTAIN M, 1991, PROG NUCLEIC ACID RE, V41, P131; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P46; CROTHERS DM, 1991, METHOD ENZYMOL, V208, P118; EBERLE W, 1991, Journal of Biomolecular NMR, V1, P71, DOI 10.1007/BF01874570; EBERLE W, 1990, BIOCHEMISTRY-US, V29, P7402, DOI 10.1021/bi00484a007; EGUCHI Y, 1991, J MOL BIOL, V220, P831, DOI 10.1016/0022-2836(91)90356-B; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; GREGORIAN RS, IN PRESS J MOL BIOL; GREGORIAN RS, 1994, THESIS YALE U; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM JL, 1993, NATURE, V356, P512; LEFFERS H, 1987, J MOL BIOL, V195, P43, DOI 10.1016/0022-2836(87)90326-3; LEGAULT P, 1994, J MAGN RESON SER B, V103, P82, DOI 10.1006/jmrb.1994.1012; MAIZELS N, 1994, P NATL ACAD SCI USA, V91, P6729, DOI 10.1073/pnas.91.15.6729; MARINO JP, 1995, THESIS YALE U; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MUESING M, 1984, GENE, V31, P155, DOI 10.1016/0378-1119(84)90206-3; NIKONOWICZ EP, 1992, NUCLEIC ACIDS RES, V20, P4507, DOI 10.1093/nar/20.17.4507; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; PERSSON C, 1990, EMBO J, V9, P3767, DOI 10.1002/j.1460-2075.1990.tb07590.x; PLEIJ CWA, 1985, NUCLEIC ACIDS RES, V13, P1717, DOI 10.1093/nar/13.5.1717; PUGLISI JD, 1991, ACCOUNTS CHEM RES, V24, P152, DOI 10.1021/ar00005a005; PUGLISI JD, 1993, P NATL ACAD SCI USA, V90, P3680, DOI 10.1073/pnas.90.8.3680; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; SAENGER W, 1988, PRINCIPLES NUCLEIC A; SCHIMMEL P, 1994, P NATL ACAD SCI USA, V91, P11283, DOI 10.1073/pnas.91.24.11283; SIMONS RW, 1988, ANNU REV GENET, V22, P567, DOI 10.1146/annurev.ge.22.120188.003031; SKLENAR V, 1987, J MAGN RESON, V74, P469, DOI 10.1016/0022-2364(87)90269-1; SZEWCZAK AA, 1993, FEBS LETT, V327, P261, DOI 10.1016/0014-5793(93)81000-P; TANG RS, 1990, BIOCHEMISTRY-US, V29, P5232, DOI 10.1021/bi00474a003; TOMIZAWA J, 1990, J MOL BIOL, V212, P695, DOI 10.1016/0022-2836(90)90231-A; TOMIZAWA J, 1984, CELL, V38, P861, DOI 10.1016/0092-8674(84)90281-2; TOMIZAWA J, 1990, J MOL BIOL, V212, P683, DOI 10.1016/0022-2836(90)90230-J; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; Wuthrich K., 1986, NMR PROTEINS NUCL AC; Wyatt J. R., 1993, RNA WORLD, P465; WYATT JR, 1990, J MOL BIOL, V214, P455, DOI 10.1016/0022-2836(90)90193-P	47	113	114	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 9	1995	268	5216					1448	1454		10.1126/science.7539549	http://dx.doi.org/10.1126/science.7539549			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7539549				2022-12-28	WOS:A1995RC19000026
J	POTTER, S; DUROVIC, P; DENNIS, PP				POTTER, S; DUROVIC, P; DENNIS, PP			RIBOSOMAL-RNA PRECURSOR PROCESSING BY A EUKARYOTIC U3 SMALL NUCLEOLAR RNA-LIKE MOLECULE IN AN ARCHAEON	SCIENCE			English	Article							PRERIBOSOMAL RNA; YEAST; SNRNA; SEQUENCE; ARCHAEBACTERIA; FIBRILLARIN; BINDING; INTRON	An RNA-containing endonuclease that catalyzes the excision and maturation of the 16S ribosomal RNA (rRNA) from the rRNA primary transcript (pre-rRNA) in the hyperthermophilic archaeon Sulfolobus acidocaldarius has been characterized. The ribonucleoprotein was inactivated by micrococcal nuclease treatment and inactivation was reversed by reconstitution with bulk RNA. A 159-nucleotide RNA with sequence and structural similarity to U3 small nucleolar RNAs of eukaryotes copurified with the endonuclease activity. Oligonucleotide-targeted ribonuclease H inactivation of the US-like RNA component also abolished processing activity. A motif within the U3 homolog is complementary to the region around the three cleavage sites in the pre-RNA substrate. Thus, US-mediated processing of pre-rRNA is not specific to eukaryotes; its origin predates the divergence of archaea and eukaryotes.	UNIV BRITISH COLUMBIA, DEPT BIOCHEM & MOLEC BIOL, VANCOUVER, BC V6T 1Z3, CANADA; UNIV BRITISH COLUMBIA, CANADIAN INST ADV RES, VANCOUVER, BC V6T 1Z3, CANADA	University of British Columbia; Canadian Institute for Advanced Research (CIFAR); University of British Columbia								AMIRI KA, 1994, J BACTERIOL, V176, P2124, DOI 10.1128/jb.176.7.2124-2127.1994; Baserga S., 1993, RNA WORLD, P359; BASERGA SJ, 1991, EMBO J, V10, P2645, DOI 10.1002/j.1460-2075.1991.tb07807.x; BELTRAME M, 1992, EMBO J, V11, P1531, DOI 10.1002/j.1460-2075.1992.tb05198.x; CHANT J, 1986, EMBO J, V5, P1091, DOI 10.1002/j.1460-2075.1986.tb04327.x; Court D, 1993, CONTROL MRNA STABILI; DENNIS PP, 1991, NATO ADV SCI I A-LIF, V201, P251; DENNIS PP, IN PRESS ARCHAEA LAB; DUROVIC P, 1994, MOL MICROBIOL, V13, P229, DOI 10.1111/j.1365-2958.1994.tb00418.x; FOURNIER MJ, 1993, TRENDS BIOCHEM SCI, V18, P131, DOI 10.1016/0968-0004(93)90020-N; GARRETT RA, 1991, TRENDS BIOCHEM SCI, V16, P22, DOI 10.1016/0968-0004(91)90011-J; HARTSHORNE T, 1994, NUCLEIC ACIDS RES, V22, P3354, DOI 10.1093/nar/22.16.3354; HUGHES JMX, 1987, EMBO J, V6, P2145, DOI 10.1002/j.1460-2075.1987.tb02482.x; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; JEPPESEN C, 1988, NUCLEIC ACIDS RES, V16, P2127, DOI 10.1093/nar/16.5.2127; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; PARKER KA, 1987, MOL CELL BIOL, V7, P2899, DOI 10.1128/MCB.7.8.2899; POTTER S, UNPUB; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; SOLLNERWEBB B, IN PRESS RIBOSOMAL R; THOMPSON LD, 1989, CAN J MICROBIOL, V35, P36, DOI 10.1139/m89-006; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TYCOWSKI KT, 1993, GENE DEV, V7, P1176, DOI 10.1101/gad.7.7a.1176; ZUCKER M, 1981, NUCLEIC ACIDS RES, V9, P133	24	40	40	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1056	1060		10.1126/science.7538698	http://dx.doi.org/10.1126/science.7538698			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7538698				2022-12-28	WOS:A1995QY93400043
J	STANGER, BZ; LEDER, P; LEE, TH; KIM, E; SEED, B				STANGER, BZ; LEDER, P; LEE, TH; KIM, E; SEED, B			RIP - A NOVEL PROTEIN CONTAINING A DEATH DOMAIN THAT INTERACTS WITH FAS/APO-1 (CD95) IN YEAST AND CAUSES CELL-DEATH	CELL			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR RECEPTOR SUPERFAMILY; FAS ANTIGEN; MONOCLONAL-ANTIBODY; SURFACE ANTIGEN; CONSERVED FEATURES; DNA FRAGMENTATION; CROSS-LINKING; KINASE FAMILY; TNF RECEPTOR	Ligation of the extracellular domain of the cell surface receptor Fas/APO-1 (CD95) elicits a characteristic programmed death response in susceptible cells. Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of Pas: Pas itself, and a novel 74 kDa protein we have named RIP, for receptor interacting protein. RIP also interacts weakly with the p55 tumor necrosis factor receptor (TNFR1) intracellular domain, but not with a mutant version of Pas corresponding to the murine lpr(cg) mutation. RIP contains an N-terminal region with homology to protein kinases and a C-terminal region containing a cytoplasmic motif (death domain) present in the Pas and TNFR1 intracellular domains. Transient overexpression of RIP causes transfected cells to undergo the morphological changes characteristic of apoptosis. Taken together, these properties indicate that RIP is a novel form of apoptosis-inducing protein.	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	STANGER, BZ (corresponding author), HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA.				NIDDK NIH HHS [DK43031] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043031] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; CRISPE IN, 1994, IMMUNITY, V1, P347; DHEIN J, 1992, J IMMUNOL, V149, P3166; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG XH, 1993, BIOCHIM BIOPHYS ACTA, V1172, P200, DOI 10.1016/0167-4781(93)90295-O; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1991, METHOD ENZYMOL, V200, P525; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HELLER RA, 1993, CELL, V73, P216, DOI 10.1016/0092-8674(93)90223-D; HELLER RA, 1992, CELL, V70, P47; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; KOJIMA H, 1994, IMMUNITY, V1, P357, DOI 10.1016/1074-7613(94)90066-3; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE SC, 1993, J BIOL CHEM, V268, P12164; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MATSUZAWA A, 1990, J EXP MED, V171, P519, DOI 10.1084/jem.171.2.519; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7053; Miller J.H., 1972, EXPT MOL GENETICS; NEKART PA, 1994, IMMUNITY, V1, P343; OEHM A, 1992, J BIOL CHEM, V267, P10709; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; Rose M. D., 1990, METHODS YEAST GENETI, P155; Sambrook J, 1989, MOL CLONING LABORATO; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SHEN MM, 1992, P NATL ACAD SCI USA, V89, P8240, DOI 10.1073/pnas.89.17.8240; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WONG GHW, 1994, J IMMUNOL, V152, P1751; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	56	842	896	1	29	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 19	1995	81	4					513	523		10.1016/0092-8674(95)90072-1	http://dx.doi.org/10.1016/0092-8674(95)90072-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7538908	Bronze			2022-12-28	WOS:A1995QZ71000008
J	KUCHROO, VK; DAS, MP; BROWN, JA; RANGER, AM; ZAMVIL, SS; SOBEL, RA; WEINER, HL; NABAVI, N; GLIMCHER, LH				KUCHROO, VK; DAS, MP; BROWN, JA; RANGER, AM; ZAMVIL, SS; SOBEL, RA; WEINER, HL; NABAVI, N; GLIMCHER, LH			B7-1 AND B7-2 COSTIMULATORY MOLECULES ACTIVATE DIFFERENTIALLY THE TH1/TH2 DEVELOPMENTAL PATHWAYS - APPLICATION TO AUTOIMMUNE-DISEASE THERAPY	CELL			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MYELIN PROTEOLIPID PROTEIN; CTLA-4 COUNTER-RECEPTOR; CELL ACTIVATION; BASIC-PROTEIN; LYMPHOCYTE-T; EXPRESSION; CD28; MICE; IDENTIFICATION	CD4 T helper precursor cells mature along two alternative pathways, Th1 and Th2. Here we show that these pathways are differentially activated by two costimulatory molecules, B7-1 and B7-2. Using anti-B7 antibodies, this developmental step was manipulated both in vitro and in vivo in experimental allergic encephalomyelitis (EAE). Anti-B7-1 reduced the incidence of disease while anti-B7-2 increased disease severity. Neither antibody affected overall T cell induction but rather altered cytokine profile. Administration of anti-B7-1 at immunization resulted in predominant generation of Th2 clones whose transfer both prevented induction of EAE and abrogated established disease. Since cotreatment with anti-IL-4 antibody prevented disease amelioration, costimulatory molecules may directly affect initial cytokine secretion. Thus, interaction of B7-1 and B7-2 with shared counterreceptors CD28 and CTLA-4 results in very different outcomes in clinical disease by influencing commitment of precursors to a Th1 or Th2 lineage.	BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; STANFORD UNIV,SCH MED,DEPT PATHOL,PALO ALTO,CA 94304; VET AFFAIRS MED CTR,LAB SERV,PALO ALTO,CA 94304; HOFFMANN LA ROCHE INC,RES CTR,DEPT INFLAMMAT & AUTOIMMUNE DIS,NUTLEY,NJ 07110	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Roche Holding	KUCHROO, VK (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115, USA.			Sobel, Raymond/0000-0002-0477-9002	NIAID NIH HHS [AI-21569] Funding Source: Medline; NINDS NIH HHS [NS-30843, NS-26773] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI021569, R01AI021569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS030843, R01NS026773, R37NS030843, R01NS030843] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; BASKAR S, 1995, IN PRESS J EXP MED; CHEN CY, 1994, IMMUNITY, V1, P147, DOI 10.1016/1074-7613(94)90108-2; CHEN CY, 1994, J IMMUNOL, V152, P2105; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; COHEN J, 1993, SCIENCE, V262, P175, DOI 10.1126/science.8211135; FINCK BK, 1994, SCIENCE, V265, P1225, DOI 10.1126/science.7520604; FREEMAN GJ, 1993, SCIENCE, V262, P907, DOI 10.1126/science.7694362; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; GUERDER S, 1994, IMMUNITY, V1, P155; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HATHCOCK KS, 1994, J EXP MED, V180, P631, DOI 10.1084/jem.180.2.631; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; JIANG H, 1992, SCIENCE, V256, P1213, DOI 10.1126/science.256.5060.1213; KHOURY SJ, 1992, J EXP MED, V176, P1355, DOI 10.1084/jem.176.5.1355; KUCHROO VK, 1993, J IMMUNOL, V151, P4371; LAFAILLE JJ, 1994, CELL, V78, P399, DOI 10.1016/0092-8674(94)90419-7; LAURSEN RA, 1984, P NATL ACAD SCI-BIOL, V81, P2912, DOI 10.1073/pnas.81.9.2912; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; NEWMAN S, 1987, P NATL ACAD SCI USA, V84, P886, DOI 10.1073/pnas.84.3.886; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; POWRIE F, 1993, IMMUNOL TODAY, V14, P270, DOI 10.1016/0167-5699(93)90044-L; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; RAZIWOLF Z, 1992, P NATL ACAD SCI USA, V89, P4210, DOI 10.1073/pnas.89.9.4210; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SIMON AK, 1994, P NATL ACAD SCI USA, V91, P8562, DOI 10.1073/pnas.91.18.8562; SOBEL RA, 1989, J NEUROPATHOL EXP NE, V49, P468; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TRINCHIERI G, 1993, IMMUNOL TODAY, V14, P335, DOI 10.1016/0167-5699(93)90230-I; TUOHY VK, 1989, J IMMUNOL, V142, P1523; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	45	1618	1703	1	26	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					707	718		10.1016/0092-8674(95)90349-6	http://dx.doi.org/10.1016/0092-8674(95)90349-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7534215	Bronze			2022-12-28	WOS:A1995QM39900007
J	WUCHERPFENNIG, KW; STROMINGER, JL				WUCHERPFENNIG, KW; STROMINGER, JL			MOLECULAR MIMICRY IN T-CELL-MEDIATED AUTOIMMUNITY - VIRAL PEPTIDES ACTIVATE HUMAN T-CELL CLONES SPECIFIC FOR MYELIN BASIC-PROTEIN	CELL			English	Article							GLUTAMIC-ACID DECARBOXYLASE; MULTIPLE-SCLEROSIS PATIENTS; EPSTEIN-BARR VIRUS; LYMPHOCYTE-T; SUPERANTIGEN MAM; RECOGNITION; ENCEPHALOMYELITIS; ARTHRITIS; LINES; HEMAGGLUTININ	Structural similarity between viral T cell epitopes and self-peptides could lead to the induction of an autoaggressive T cell response. Based on the structural requirements for both MHC class II binding and TCR recognition of an immunodominant myelin basic protein (MBP) peptide, criteria for a data base search were developed in which the degeneracy of amino acid side chains required for MHC class II binding and the conservation of those required for T cell activation were considered. A panel of 129 peptides that matched the molecular mimicry motif was tested on seven MBP-specific T cell clones from multiple sclerosis patients. Seven viral and one bacterial peptide efficiently activated three of these clones. Only one peptide could have been identified as a molecular mimic by sequence alignment. The observation that a single T cell receptor can recognize quite distinct but structurally related peptides from multiple pathogens has important implications for understanding the pathogenesis of autoimmunity.			WUCHERPFENNIG, KW (corresponding author), HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA.				NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI045198] Funding Source: NIH RePORTER; NCI NIH HHS [CA47554] Funding Source: Medline; NIAID NIH HHS [N01 AI 45198] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEGRETTA M, 1990, SCIENCE, V247, P718, DOI 10.1126/science.1689076; BAIG S, 1989, CLIN EXP IMMUNOL, V78, P390; BROCKE S, 1993, NATURE, V365, P642, DOI 10.1038/365642a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BROWN LR, 1991, J IMMUNOL, V147, P2677; BURNS J, 1983, CELL IMMUNOL, V81, P435, DOI 10.1016/0008-8749(83)90250-2; BURROWS SR, 1994, J EXP MED, V179, P1155, DOI 10.1084/jem.179.4.1155; BUSCH R, 1991, J IMMUNOL, V147, P1292; CHAMBERS TM, 1989, VIROLOGY, V172, P180, DOI 10.1016/0042-6822(89)90119-0; COLE BC, 1993, ARTHRITIS RHEUM-US, V36, P994, DOI 10.1002/art.1780360717; CONRAD B, 1994, NATURE, V371, P351, DOI 10.1038/371351a0; DATTA AK, 1980, J BIOL CHEM, V255, P5120; EPSTEIN MA, 1977, LANCET, V2, P1270; FRIEDMAN SM, 1991, J EXP MED, V174, P891, DOI 10.1084/jem.174.4.891; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; JOHNSON RT, 1984, NEW ENGL J MED, V310, P137, DOI 10.1056/NEJM198401193100301; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; Koetssier, 1985, HDB CLIN NEUROLOGY, V3, P259; KURTZKE JF, 1979, ANN NEUROL, V5, P6, DOI 10.1002/ana.410050104; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MARTIN R, 1990, J IMMUNOL, V145, P540; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; OLERUP O, 1989, P NATL ACAD SCI USA, V86, P7113, DOI 10.1073/pnas.86.18.7113; OTA K, 1990, NATURE, V346, P183, DOI 10.1038/346183a0; PETTE M, 1990, P NATL ACAD SCI USA, V87, P7968, DOI 10.1073/pnas.87.20.7968; RAY CG, 1980, CLIN ENDOCRINOL, V12, P375, DOI 10.1111/j.1365-2265.1980.tb02723.x; REAY PA, 1994, J IMMUNOL, V152, P3946; ROSE NR, 1986, ANN NY ACAD SCI, V475, P146, DOI 10.1111/j.1749-6632.1986.tb20864.x; SCHLUESENER HJ, 1985, J IMMUNOL, V135, P3128; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SPIELMAN RS, 1982, EPIDEMIOL REV, V4, P45, DOI 10.1093/oxfordjournals.epirev.a036251; SPRUANCE S, 1945, J CLIN MICROBIOL, V22, P366; STADT D, 1990, EUR NEUROL, V30, P305, DOI 10.1159/000117361; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; TOVEY MG, 1978, NATURE, V276, P270, DOI 10.1038/276270a0; VANEDEN W, 1985, P NATL ACAD SCI USA, V82, P5117; VANEDEN W, 1988, NATURE, V331, P171, DOI 10.1038/331171a0; VOGT AB, 1994, J IMMUNOL, V153, P1665; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; WUCHERPFENNIG KW, 1994, J IMMUNOL, V152, P5581; WUCHERPFENNIG KW, 1991, IMMUNOL TODAY, V12, P277, DOI 10.1016/0167-5699(91)90126-E; WUCHERPFENNIG KW, 1994, J EXP MED, V179, P279, DOI 10.1084/jem.179.1.279; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051; ZHANG JW, 1994, J EXP MED, V179, P973, DOI 10.1084/jem.179.3.973	49	1213	1238	0	46	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 10	1995	80	5					695	705		10.1016/0092-8674(95)90348-8	http://dx.doi.org/10.1016/0092-8674(95)90348-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7534214	Bronze, Green Published			2022-12-28	WOS:A1995QM39900006
J	GOTODA, T; ARITA, M; ARAI, H; INOUE, K; YOKOTA, T; FUKUO, Y; YAZAKI, Y; YAMADA, N				GOTODA, T; ARITA, M; ARAI, H; INOUE, K; YOKOTA, T; FUKUO, Y; YAZAKI, Y; YAMADA, N			ADULT-ONSET SPINOCEREBELLAR DYSFUNCTION CAUSED BY A MUTATION IN THE GENE FOR THE ALPHA-TOCOPHEROL-TRANSFER PROTEIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VITAMIN-E-DEFICIENCY; RAT-LIVER; BINDING-PROTEIN; ABSORPTION; DISEASE; FAT; PURIFICATION; CHOLESTEROL; LUNG	Background. Patients with isolated vitamin E deficiency have an impaired ability to incorporate alpha-tocopherol into lipoproteins in the liver and usually have symptoms and signs of spinocerebellar dysfunction before adolescence. Accumulated evidence suggests that the alpha-tocopherol-transfer protein, which is presumed to function in the intracellular transport of alpha-tocopherol, is abnormal in these patients. Methods. We studied a patient from an isolated Japanese island who began to have ataxia, dysarthria, and sensory disturbances in the sixth decade of life. His serum vitamin E concentration was low (1.2 mu g per milliliter [2.8 mu mol per liter]). Exons of his gene for the alpha-tocopherol-transfer protein were analyzed by DNA sequencing. We also screened an additional 801 inhabitants of the island for the mutation. Both the normal and mutant alpha-tocopherol-transfer proteins were expressed in COS-7 cells and studied by immunoblot analysis and assay for alpha-tocopherol-transfer activity. Results. The patient was homozygous for a point mutation that replaces histidine (CAT) with glutamine (GAG) at position 101 of the gene for the alpha-tocopherol-transfer protein. When expressed in COS-7 cells, the missense mutation produced a functionally defective alpha-tocopherol-transfer protein with approximately 11 percent of the transfer activity of the wild-type protein. Of the 801 island inhabitants examined, 21 were heterozygous for the His101Gln mutation. In all affected subjects, including the patient, this mutation cosegregated with an intron-sequence polymorphism. The heterozygotes were phenotypically normal and had serum vitamin E concentrations that were on average 25 percent lower than those of normal subjects (mean [+/-SD], 7.5+/-2.2 vs. 10.1+/-2.8 mu g per milliliter [17.4+/-5.1 vs. 23.4+/-6.5 mu mol per liter]; P=0.002). Conclusions. alpha-Tocopherol-transfer protein is a determinant of serum vitamin E concentrations. An abnormality in this protein is a cause of spinocerebellar dysfunction.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, TOKYO 113, JAPAN; UNIV TOKYO, FAC PHARMACEUT SCI, DEPT HLTH CHEM, TOKYO 113, JAPAN; TOKYO MED & DENT UNIV, FAC MED, DEPT NEUROL, TOKYO 113, JAPAN; NIPPON MED COLL, FAC MED, DEPT INTERNAL MED 2, TOKYO, JAPAN	University of Tokyo; University of Tokyo; Tokyo Medical & Dental University (TMDU); Nippon Medical School				Arita, Makoto/0000-0001-9902-0463				ARITA M, 1995, BIOCHEM J, V306, P437, DOI 10.1042/bj3060437; BENHAMIDA C, 1993, NAT GENET, V5, P195, DOI 10.1038/ng1093-195; BENHAMIDA M, 1993, NEUROLOGY, V43, P2179, DOI 10.1212/WNL.43.11.2179; BURCK U, 1981, NEUROPEDIATRICS, V12, P267, DOI 10.1055/s-2008-1059657; CATIGNANI GL, 1977, BIOCHIM BIOPHYS ACTA, V497, P349, DOI 10.1016/0304-4165(77)90192-1; ELIAS E, 1981, LANCET, V2, P1319; GOTODA T, 1991, J CLIN INVEST, V88, P1856, DOI 10.1172/JCI115507; GOTODA T, 1991, LANCET, V338, P778, DOI 10.1016/0140-6736(91)90665-C; HARDING AE, 1985, NEW ENGL J MED, V313, P32, DOI 10.1056/NEJM198507043130107; HOWARD L, 1982, AM J CLIN NUTR, V36, P1243, DOI 10.1093/ajcn/36.6.1243; KAYDEN HJ, 1993, J LIPID RES, V34, P343; KOHLSCHUTTER A, 1988, J INHERIT METAB DIS, V11, P149, DOI 10.1007/BF01804221; KRENDEL DA, 1987, NEUROLOGY, V37, P538, DOI 10.1212/WNL.37.3.538; LAPLANTE P, 1984, CAN J NEUROL SCI, V11, P561, DOI 10.1017/S0317167100035046; LEWIS JS, 1973, AM J CLIN NUTR, V26, P136, DOI 10.1093/ajcn/26.2.136; MENKES MS, 1986, NEW ENGL J MED, V315, P1250, DOI 10.1056/NEJM198611133152003; MULLER DPR, 1983, LANCET, V1, P225; MURPHY DJ, 1981, J BIOL CHEM, V256, P464; OUAHCHI K, 1995, NAT GENET, V9, P141, DOI 10.1038/ng0295-141; ROSENBLUM JL, 1981, NEW ENGL J MED, V304, P503, DOI 10.1056/NEJM198102263040902; SATO Y, 1993, J BIOL CHEM, V268, P17705; SATO Y, 1991, FEBS LETT, V288, P41, DOI 10.1016/0014-5793(91)80999-J; SOKOL RJ, 1988, J LAB CLIN MED, V111, P548; SOKOL RJ, 1988, ANNU REV NUTR, V8, P351, DOI 10.1146/annurev.nu.08.070188.002031; STUMPF DA, 1987, NEUROLOGY, V37, P68, DOI 10.1212/WNL.37.1.68; TRABER MG, 1990, J CLIN INVEST, V85, P397, DOI 10.1172/JCI114452; TRABER MG, 1993, J LIPID RES, V34, P201; TRABER MG, 1987, NEW ENGL J MED, V317, P262, DOI 10.1056/NEJM198707303170502; TRABERT W, 1989, FORTSCHR NEUROL PSYC, V57, P495, DOI 10.1055/s-2007-1001146; YOKOTA T, 1987, ANN NEUROL, V22, P84, DOI 10.1002/ana.410220119; YOSHIDA H, 1992, J LIPID RES, V33, P343	31	158	161	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 16	1995	333	20					1313	1318		10.1056/NEJM199511163332003	http://dx.doi.org/10.1056/NEJM199511163332003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE365	7566022	Bronze			2022-12-28	WOS:A1995TE36500003
J	ROSENBERG, SN; ALLEN, DR; HANDTE, JS; JACKSON, TC; LETO, L; RODSTEIN, BM; STRATTON, SD; WESTFALL, G; YASSER, R				ROSENBERG, SN; ALLEN, DR; HANDTE, JS; JACKSON, TC; LETO, L; RODSTEIN, BM; STRATTON, SD; WESTFALL, G; YASSER, R			EFFECT OF UTILIZATION REVIEW IN A FEE-FOR-SERVICE HEALTH-INSURANCE PLAN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXPENDITURES; MANAGEMENT; PROGRAMS; CARE	Background, Although utilization review is widely used to control health care costs, its effect on patterns of health care is uncertain. Methods. In 1989, New York City and its unions temporarily replaced actual utilization review with sham review for half the participants in the city's fee-for-service health insurance plan. We compared the health services provided to 3702 enrollees whose requests were subjected to utilization review (the review group) with the services provided to 3743 enrollees whose requests received sham review and were automatically approved for insurance coverage (the nonreview group). The enrollees, physicians, and hospitals were all unaware of the group assignments. Results. During the study period (mean duration, eight months), the members of the review group underwent 1255 procedures in 20 categories of procedures for which second opinions were required (such as breast, cataract, foot, hernia, and hip-replacement surgery, as well as hysterectomy and coronary bypass surgery), and the members of the nonreview group underwent 1365 procedures (P=0.02). The members of the review group had 124 fewer procedures in doctors' offices and hospital outpatient departments (P=0.002). In the following year, the members of the review group underwent 248 procedures from the 20 categories, and the members of the nonreview group underwent 234 (P=0.46), No other differences in patterns of care were found between the groups, including rates of hospital admission to medical-surgical, substance-abuse, or psychiatric units; average lengths of hospital stay; the percentage of enrollees who received preadmission testing; or rates of use of home care, During the study period, the mean age-adjusted insurance payments per person were $7,355 in the review group and $6,858 in the nonreview group (P=0.06). Conclusions. The utilization-review program reduced the number of diagnostic and surgical procedures performed that required second opinions and did not merely delay them until the following year. Otherwise, the program had little effect. Alternatively, actual review and sham review may both have decreased the use of hospital services, with patients or their physicians choosing more efficient treatment when they believed that care would be reviewed.	NEW YORK CITY MUNICIPAL LABOR COMM,SUBCOMM HLTH,NEW YORK,NY; NEW YORK CITY OFF LABOR RELAT,HLTH BENEFITS PROGRAM,NEW YORK,NY; EMPIRE BLUE CROSS & BLUE SHIELD,NEW YORK,NY		ROSENBERG, SN (corresponding author), COLUMBIA UNIV,SCH PUBL HLTH,DIV HLTH POLICY & MANAGEMENT,600 W 168TH ST,NEW YORK,NY 10032, USA.							Bailit H L, 1991, Health Care Financ Rev Annu Suppl, P87; DANIEL WW, 1991, BIOSTATISTICS F ANAL, P121; EPSTEIN AM, 1990, NEW ENGL J MED, V323, P266, DOI 10.1056/NEJM199007263230410; ERMANN D, 1988, J HEALTH POLIT POLIC, V13, P683, DOI 10.1215/03616878-13-4-683; FELDSTEIN PJ, 1988, NEW ENGL J MED, V318, P1310, DOI 10.1056/NEJM198805193182006; HENDERSON MG, 1988, HEALTH CARE FINANC R, P89; KHANDKER RK, 1992, MED CARE, V30, P1043, DOI 10.1097/00005650-199211000-00007; KORDA H, 1994, AM J MED QUAL, V9, P554; LAGOE RJ, 1990, AM J PUBLIC HEALTH, V80, P869, DOI 10.2105/AJPH.80.7.869; MECHANIC D, 1994, INQUIRY-J HEALTH CAR, V31, P124; Payne S M, 1992, QRB Qual Rev Bull, V18, P340; ROSENBERG SN, 1989, MED CARE, V27, P466, DOI 10.1097/00005650-198905000-00003; ROSENBERG SN, 1992, MANAGING EMPLOYEE HL, V1, P27; SCHEFFLER RM, 1991, INQUIRY-J HEALTH CAR, V28, P263; Wickizer T M, 1990, Med Care Rev, V47, P327, DOI 10.1177/107755879004700303; WICKIZER TM, 1991, AM J PUBLIC HEALTH, V81, P482, DOI 10.2105/AJPH.81.4.482; WICKIZER TM, 1989, MED CARE, V27, P632, DOI 10.1097/00005650-198906000-00006; WICKIZER TM, 1991, HLTH SERV RES, V27, P103; Winer B.J., 1971, STAT PRINCIPLES EXPT, P752; ZUSMAN J, 1990, HOSP COMMUNITY PSYCH, V41, P531; 1990, PROVIDING EMPLOYEE H; 1991, AHA HOSPITAL STATIST, P156; 1993, GAOHRD943 GEN ACC OF	23	36	36	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	1995	333	20					1326	1330		10.1056/NEJM199511163332006	http://dx.doi.org/10.1056/NEJM199511163332006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TE365	7566025				2022-12-28	WOS:A1995TE36500006
J	GARRED, P; MADSEN, HO; HOFMANN, B; SVEJGAARD, A				GARRED, P; MADSEN, HO; HOFMANN, B; SVEJGAARD, A			INCREASED FREQUENCY OF HOMOZYGOSITY OF ABNORMAL MANNAN-BINDING-PROTEIN ALLELES IN PATIENTS WITH SUSPECTED IMMUNODEFICIENCY	LANCET			English	Note							CHILDREN; GENE	A low plasma concentration of mannan-binding protein (MBP) impairs opsonisation and phagocytosis. Three different mutations in the MBP gene have a dominant effect on MBP concentration. We investigated the frequency of the abnormal MBP alleles in 228 unrelated patients suspected of various non-HIV-related immunodeficiencies. The frequency of heterozygotes for the abnormal alleles was not different from that in the background population (36.0% and 37.4%, respectively). By contrast, the frequency of homozygotes for the abnormal alleles was significantly increased (8.3% and 0.8%, respectively; p=0.0017). This finding implies that homozygotes for abnormal MBP alleles are predisposed to recurrent infections.			GARRED, P (corresponding author), RIGSHOSP,DEPT CLIN IMMUNOL,TISSUE TYPING LAB,DK-2200 COPENHAGEN,DENMARK.		Madsen, Hans O/Q-2035-2015	Madsen, Hans O/0000-0001-5551-4787; Garred, Peter/0000-0002-2876-8586				GARRED P, 1992, CLIN EXP IMMUNOL, V90, P517; GARRED P, 1993, CLIN EXP IMMUNOL, V94, P99; GARRED P, 1994, EUR J IMMUNOGENET, V21, P125, DOI 10.1111/j.1744-313X.1994.tb00183.x; GARRED P, 1992, EUR J IMMUNOGENET, V19, P403, DOI 10.1111/j.1744-313X.1992.tb00083.x; Lipscombe R. J., 1992, Human Molecular Genetics, V1, P709, DOI 10.1093/hmg/1.9.709; LIPSCOMBE RJ, 1995, IMMUNOLOGY, V85, P660; MADSEN HO, 1995, J IMMUNOL, V155, P3013; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8	10	223	243	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					941	943		10.1016/S0140-6736(95)91559-1	http://dx.doi.org/10.1016/S0140-6736(95)91559-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564730				2022-12-28	WOS:A1995RY80800011
J	RABOUILLE, C; LEVINE, TP; PETERS, JM; WARREN, G				RABOUILLE, C; LEVINE, TP; PETERS, JM; WARREN, G			AN NSF-LIKE ATPASE, P97, AND NSF MEDIATE CISTERNAL REGROWTH FROM MITOTIC GOLGI FRAGMENTS	CELL			English	Article							HELA-CELLS; VESICULAR TRANSPORT; PUTATIVE ATPASES; MEMBRANE-FUSION; PROTEIN; FAMILY; YEAST; GENE; MEMBER; IDENTIFICATION	Golgi cisternae regrew in a cell-free system from mitotic Golgi fragments incubated with buffer alone. Pretreatment with NEM or salt washing inhibited regrowth, but this could be restored either by p97, an NSF-like ATPase, or by NSF together with SNAPs and p115, a vesicle docking protein. The morphology of cisternae regrown with p97 and NSF-SNAPs-p115 differed, suggesting that they play distinct roles in rebuilding Golgi cisternae after mitosis.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	RABOUILLE, C (corresponding author), IMPERIAL CANC RES FUND,CELL BIOL LAB,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.			Levine, Timothy/0000-0002-7231-0775				ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; ACHARYA U, 1995, J CELL BIOL, V129, P577, DOI 10.1083/jcb.129.3.577; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DAHAN S, 1994, J CELL BIOL, V127, P1859, DOI 10.1083/jcb.127.6.1859; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KIRSCHNER MW, 1995, CELL, V81, P279; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; LATTERICH M, 1994, CELL, V78, P87, DOI 10.1016/0092-8674(94)90575-4; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LUCOCQ JM, 1987, J CELL BIOL, V104, P865, DOI 10.1083/jcb.104.4.865; LUCOCQ JM, 1987, EMBO J, V6, P3239, DOI 10.1002/j.1460-2075.1987.tb02641.x; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; MISTELI T, 1995, J CELL BIOL, V130, P1; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; PETERS JM, 1991, THESIS U HEIDELBERG; PLEASURE IT, 1993, NATURE, V365, P459, DOI 10.1038/365459a0; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SLUSAREWICZ P, 1994, CELL BIOL LAB HDB, P509; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SOUTER E, 1993, J CELL BIOL, V122, P533, DOI 10.1083/jcb.122.3.533; STUART RA, 1993, J BIOL CHEM, V268, P4050; THORSNESS PE, 1993, YEAST, V9, P1267, DOI 10.1002/yea.320091114; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; WEIDMAN P, 1993, CELL, V75, P123, DOI 10.1016/S0092-8674(05)80089-3; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; ZHANG L, 1994, J CELL BIOL, V127, P1871, DOI 10.1083/jcb.127.6.1871	46	304	311	1	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					905	914		10.1016/0092-8674(95)90270-8	http://dx.doi.org/10.1016/0092-8674(95)90270-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553851	Bronze			2022-12-28	WOS:A1995RW69300007
J	ROCHE, S; FUMAGALLI, S; COURTNEIDGE, SA				ROCHE, S; FUMAGALLI, S; COURTNEIDGE, SA			REQUIREMENT FOR SRC FAMILY PROTEIN-TYROSINE KINASES IN G(2) FOR FIBROBLAST CELL-DIVISION	SCIENCE			English	Article							GROWTH-FACTOR; C-SRC; IDENTIFICATION; ASSOCIATION; RECEPTOR	The protein tyrosine kinase c-Src is transiently activated at the transition from the G(2) phase to mitosis in the cell cycle of mammalian fibroblasts. Fyn and Yes, the other members of the Src family present in fibroblasts, were also found to be activated at mitosis. In cells microinjected with a neutralizing antibody specific for Src, Fyn, and Yes (anti-cst.1) during G(2), cell division was inhibited by 75 percent. The block occurred before nuclear envelope breakdown. Antibodies specific for phosphatidylinositol-3 kinase alpha and phospholipase C-gamma 1 had no effect. Microinjection of the Src homology 2 (SH2) domain of Fyn was also inhibitory. Functional redundancy between members of the Src family was observed; a Src-specific antibody had no effect in NIH 3T3 cells but inhibited cell division in fibroblasts in which the only functional Src family kinase was Src itself. Thus, Src family kinases and proteins associating with their SH2 domains are required for entry into mitosis.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			FUMAGALLI, Stefano/C-2914-2019	roche, serge/0000-0003-3413-3859; Fumagalli, Stefano/0000-0001-5832-8680				Atherton-Fessler S, 1993, Semin Cell Biol, V4, P433, DOI 10.1006/scel.1993.1051; CHACKALAPARAMPI.I, 1988, CELL, V52, P801; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; Courtneidge Sara A., 1994, Trends in Cell Biology, V4, P345, DOI 10.1016/0962-8924(94)90074-4; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DURKIN JP, 1991, CELL SIGNAL, V3, P93, DOI 10.1016/0898-6568(91)90015-M; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FUMAGALLI S, UNPUB; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HEIDER H, 1994, EUR J BIOCHEM, V219, P513, DOI 10.1111/j.1432-1033.1994.tb19966.x; KORNBLUTH S, 1994, J CELL BIOL, V125, P705, DOI 10.1083/jcb.125.4.705; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROCHE S, UNPUB; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; TAYLOR SJ, 1994, NATURE, V368, P871; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696	23	236	240	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 15	1995	269	5230					1567	1569		10.1126/science.7545311	http://dx.doi.org/10.1126/science.7545311			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7545311				2022-12-28	WOS:A1995RU81300038
J	BRENMAN, JE; CHAO, DS; XIA, HH; ALDAPE, K; BREDT, DS				BRENMAN, JE; CHAO, DS; XIA, HH; ALDAPE, K; BREDT, DS			NITRIC-OXIDE SYNTHASE COMPLEXED WITH DYSTROPHIN AND ABSENT FROM SKELETAL-MUSCLE SARCOLEMMA IN DUCHENNE MUSCULAR-DYSTROPHY	CELL			English	Article							TUMOR-SUPPRESSOR PROTEIN; MEMBRANE-PROTEIN; REACTIVE OXYGEN; MDX MOUSE; PURIFICATION; BRAIN; CALMODULIN; TORPEDO; TISSUE; KINASE	Nitric oxide (NO) is synthesized in skeletal muscle by neuronal-type NO synthase (nNOS), which is localized to sarcolemma of fast-twitch fibers. Synthesis of NO in active muscle opposes contractile force. We show that nNOS partitions with skeletal muscle membranes owing to association of nNOS with dystrophin, the protein mutated in Duchenne muscular dystrophy (DMD). The dystrophin complex interacts with an N-terminal domain of nNOS that contains a GLGF motif. mdx mice and humans with DMD evince a selective loss of nNOS protein and catalytic activity from muscle membranes, demonstrating a novel role for dystrophin in localizing a signaling enzyme to the myocyte sarcolemma. Aberrant regulation of nNOS may contribute to preferential degeneration of fast-twitch muscle fibers in DMD.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM BIOMED SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	BRENMAN, JE (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.			Chao, Daniel/0000-0002-3544-5283				ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1994, P NATL ACAD SCI USA, V91, P4446, DOI 10.1073/pnas.91.10.4446; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; AOKI C, 1993, BRAIN RES, V620, P97, DOI 10.1016/0006-8993(93)90275-R; BREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRYANT PJ, 1992, CELL, V68, P621, DOI 10.1016/0092-8674(92)90136-Z; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; DAVISON A, 1988, MOL CELL BIOCHEM, V84, P199, DOI 10.1007/BF00421055; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; Ervasti JM, 1993, CURR OPIN CELL BIOL, V5, P82, DOI 10.1016/S0955-0674(05)80012-2; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; HAUNG Z, 1994, SCIENCE, V265, P1883; HECKER M, 1994, J NEUROCHEM, V62, P1524; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LEE KH, 1994, J BIOL CHEM, V269, P14371; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MITCHELL RD, 1983, J CELL BIOL, V96, P1008, DOI 10.1083/jcb.96.4.1008; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; RAFAEL JA, 1994, HUM MOL GENET, V3, P1725, DOI 10.1093/hmg/3.10.1725; REID MB, 1992, J APPL PHYSIOL, V73, P1797, DOI 10.1152/jappl.1992.73.5.1797; REID MB, 1992, J APPL PHYSIOL, V73, P1805, DOI 10.1152/jappl.1992.73.5.1805; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; SEALOCK R, 1991, J CELL BIOL, V113, P1133, DOI 10.1083/jcb.113.5.1133; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; SUZUKI A, 1995, J CELL BIOL, V128, P373, DOI 10.1083/jcb.128.3.373; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; WANG T, 1995, NATURE, V374, P262, DOI 10.1038/374262a0; WEBSTER C, 1988, CELL, V52, P503, DOI 10.1016/0092-8674(88)90463-1; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WU HH, 1994, SCIENCE, V265, P1593, DOI 10.1126/science.7521541; YANG B, 1995, J BIOL CHEM, V270, P4975, DOI 10.1074/jbc.270.10.4975	56	808	826	1	16	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					743	752		10.1016/0092-8674(95)90471-9	http://dx.doi.org/10.1016/0092-8674(95)90471-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7545544	Bronze			2022-12-28	WOS:A1995RU75500009
J	SHAKIL, AO; CONRYCANTILENA, C; ALTER, HJ; HAYASHI, P; KLEINER, DE; TEDESCHI, V; KRAWCZYNSKI, K; CONJEEVARAM, HS; SALLIE, R; DIBISCEGLIE, AM; MELPOLDER, JC; HOOFNAGLE, JH				SHAKIL, AO; CONRYCANTILENA, C; ALTER, HJ; HAYASHI, P; KLEINER, DE; TEDESCHI, V; KRAWCZYNSKI, K; CONJEEVARAM, HS; SALLIE, R; DIBISCEGLIE, AM; MELPOLDER, JC; HOOFNAGLE, JH			VOLUNTEER BLOOD-DONORS WITH ANTIBODY TO HEPATITIS-C VIRUS - CLINICAL, BIOCHEMICAL, VIROLOGICAL, AND HISTOLOGIC FEATURES	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS C; HEPATITIS C VIRUSES; HEPATITIS ANTIBODIES; BLOOD DONORS; ALANINE AMINOTRANSFERASE	NON-B-HEPATITIS; NON-A-HEPATITIS; LIVER-DISEASE; POSTTRANSFUSION HEPATITIS; UNITED-STATES; INFECTION; SERUM; HCV; RNA; HISTORY	Objective: To assess the clinical significance of antibody to hepatitis C virus (anti-HCV) in volunteer blood donors. Design: Prospective cohort study. Setting: National Institutes of Health Clinical Center, a tertiary referral research hospital. Patients: 60 anti-HCV-positive blood donors, divided into three groups of 20 persons each: Group I had normal alanine aminotransferase levels, group II had levels elevated to values less than twice the normal range, and group HI had levels elevated to values greater than twice the normal range. Measurements: Medical history, results of laboratory and virologic testing, and percutaneous liver biopsy findings. Results: Participants with normal alanine aminotransferase levels were older and more often female than those with abnormal levels. The source of infection, duration of disease, symptom score, and amount of alcohol consumed were similar in the three groups. Hepatitis C virus RNA was detectable in 85% of participants, more commonly in the groups with elevated alanine aminotransferase levels (95%) than in the group with normal levels (65%); however, titers were similar in all groups. Examination of liver biopsy specimens showed chronic hepatitis in 54 participants (90%) and cirrhosis in 1 participant. The only normal liver biopsy specimens (n = 3) were those from participants who were HCV RNA negative and had normal alanine aminotransferase levels. Conclusions: Most blood donors with anti-HCV have chronic hepatitis C regardless of their serum alanine aminotransferase levels. Donors with normal alanine aminotransferase levels and no HCV RNA in their serum generally have normal liver histologic findings or minimal changes and have probably recovered from HCV infection.	NIH, LIVER DIS SECT, BETHESDA, MD 20892 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA USA	National Institutes of Health (NIH) - USA; Centers for Disease Control & Prevention - USA			Shaikh, Obaid/AAL-5339-2021; Kleiner, David E/N-2770-2013	Shaikh, Obaid/0000-0002-4955-9222; Kleiner, David E/0000-0003-3442-4453				AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; ALBERTI A, 1991, ANN INTERN MED, V114, P1010, DOI 10.7326/0003-4819-114-12-1010; ALBERTI A, 1992, LANCET, V340, P697, DOI 10.1016/0140-6736(92)92234-7; ALONSO C, 1994, TRANSFUSION, V34, P527, DOI 10.1046/j.1537-2995.1994.34694295070.x; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; ALTER MJ, 1993, INFECT AGENT DIS, V2, P155; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CONRYCANTILENA C, 1992, TRANSFUSION, V32, pS46; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; HARDIMAN RP, 1993, AUST NZ J MED, V23, P176, DOI 10.1111/j.1445-5994.1993.tb01813.x; HOOFNAGLE JH, 1994, ADV INTERNAL MED, V39, P241; IRVING WL, 1994, BRIT MED J, V308, P695, DOI 10.1136/bmj.308.6930.695; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KORETZ RL, 1993, ANN INTERN MED, V119, P110, DOI 10.7326/0003-4819-119-2-199307150-00003; KRAWCZYNSKI K, 1992, GASTROENTEROLOGY, V103, P622, DOI 10.1016/0016-5085(92)90856-T; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LAI ME, 1993, J MED VIROL, V41, P282, DOI 10.1002/jmv.1890410405; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; LELBACH WK, 1975, ANN NY ACAD SCI, V252, P85, DOI 10.1111/j.1749-6632.1975.tb19146.x; MCGUINNESS PH, 1993, HEPATOLOGY, V18, P485, DOI 10.1002/hep.1840180303; MUTIMER D, 1993, GUT, pS54; NAITO M, 1994, HEPATOLOGY, V19, P871, DOI 10.1002/hep.1840190411; NORDOY I, 1994, SCAND J GASTROENTERO, V29, P77, DOI 10.3109/00365529409090441; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SKINNER HA, 1982, J STUD ALCOHOL, V43, P1157, DOI 10.15288/jsa.1982.43.1157; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; TAKANO S, 1994, GASTROENTEROLOGY, V107, P805, DOI 10.1016/0016-5085(94)90130-9; Urdea M S, 1991, Nucleic Acids Symp Ser, P197; WANG JT, 1993, ARCH PATHOL LAB MED, V117, P152; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; YUN ZB, 1993, J MED VIROL, V39, P57, DOI 10.1002/jmv.1890390111; 1991, MMWR MORBMORTAL WKLY, V40, P1	38	226	234	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1995	123	5					330	337		10.7326/0003-4819-123-5-199509010-00002	http://dx.doi.org/10.7326/0003-4819-123-5-199509010-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ988	7542854				2022-12-28	WOS:A1995RQ98800002
J	KOLESNIKOV, SS; MARGOLSKEE, RF				KOLESNIKOV, SS; MARGOLSKEE, RF			A CYCLIC-NUCLEOTIDE-SUPPRESSIBLE CONDUCTANCE ACTIVATED BY TRANSDUCIN IN TASTE CELLS	NATURE			English	Article							ADENYLATE-CYCLASE; GATED CONDUCTANCE; RECEPTOR-CELLS; OUTER SEGMENT; PROTEIN; PHOSPHODIESTERASE; MEMBRANE; STIMULI; GMP	TASTE can be divided into four primary sensations: salty, sour, sweet and bitter, Salty and sour are directly transduced by apical channels(1-4), whereas sweet and bitter utilize cyclic nucleotide second messengers(5-11). We have shown that rod transducin is present in mammalian taste receptor cells, where it is activated by a bitter receptor and in turn activates a phosphodiesterase(12). Here we introduce into frog taste cells peptides derived from transducin's phosphodiesterase-interaction region, which cause an inward whole-cell current in a subset of cells, We find that the peptides' effects are reversibly suppressed by IBMX and forskolin, indicative of a transducin-activated phosphodiesterase. Cyclic nucleotides suppress the whole-cell current, indicating that cyclic nucleotides may regulate taste-cell conductance. IBMX modifies taste-cell responses to two taste stimuli, implicating phosphodiesterase in taste transduction. Submicromolar cyclic nucleotides directly suppress the conductance of inside-out patches derived from the taste-cell plasma membrane, independently of protein phosphorylation. The channels are unusual in that they are suppressed, rather than activated by cyclic nucleotides, We propose that transducin, via phosphodiesterase, decreases cyclic nucleotide levels to activate the cyclic-nucleotide-suppressible conductance, leading to Ca2+ influx and taste-cell depolarization.	ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110; RUSSIAN ACAD SCI,INST CELL BIOPHYS,PUSHCHINO 142292,RUSSIA	Roche Holding; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Cell Biophysics RAS			Kolesnikov, Stasnislav S/C-8468-2015	Margolskee, Robert/0000-0002-9572-2887				AVENET P, 1989, J MEMBRANE BIOL, V112, P1, DOI 10.1007/BF01871158; AVENET P, 1988, NATURE, V331, P351, DOI 10.1038/331351a0; AVENET P, 1989, J MEMBRANE BIOL, V97, P223; BIEL M, 1994, P NATL ACAD SCI USA, V91, P3505, DOI 10.1073/pnas.91.9.3505; CUMMINGS TA, 1993, J NEUROPHYSIOL, V70, P2326, DOI 10.1152/jn.1993.70.6.2326; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; Gilbertson Timothy A., 1993, Current Opinion in Neurobiology, V3, P532, DOI 10.1016/0959-4388(93)90052-Z; HAYNES L, 1985, NATURE, V317, P61, DOI 10.1038/317061a0; HESENKO EF, 1993, NATURE, V19, P1428; KALINOSKI DL, 1989, CHEM SENSES RECEPTOR, P85; KINNAMON SC, 1988, TRENDS NEUROSCI, V11, P491, DOI 10.1016/0166-2236(88)90010-0; KOLESNIKOV SS, 1991, FEBS LETT, V290, P167, DOI 10.1016/0014-5793(91)81251-3; KURIHARA K, 1972, FEBS LETT, V27, P279, DOI 10.1016/0014-5793(72)80640-9; Margolskee Robert F., 1993, Current Opinion in Neurobiology, V3, P526, DOI 10.1016/0959-4388(93)90051-Y; MCBRIDE DW, 1991, J MEMBRANE BIOL, V124, P85, DOI 10.1007/BF01871367; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; PRICE S, 1973, NATURE, V241, P54, DOI 10.1038/241054a0; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; RUIZAVILA L, 1995, NATURE, V376, P80, DOI 10.1038/376080a0; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; SPICKOFSKY N, 1994, NAT STRUCT BIOL, V1, P771, DOI 10.1038/nsb1194-771; STRIEM B J, 1991, Cellular Physiology and Biochemistry, V1, P46, DOI 10.1159/000154592; STRIEM BJ, 1989, BIOCHEM J, V260, P121, DOI 10.1042/bj2600121; STRYER L, 1991, J BIOL CHEM, V266, P10711; TANG JM, 1990, PFLUG ARCH EUR J PHY, V416, P347, DOI 10.1007/BF00392072; TONOSAKI K, 1988, NATURE, V331, P354, DOI 10.1038/331354a0	28	100	105	1	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					85	88		10.1038/376085a0	http://dx.doi.org/10.1038/376085a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7541117				2022-12-28	WOS:A1995RH11100067
J	ZUNIGAPFLUCKER, JC; JIANG, D; LENARDO, MJ				ZUNIGAPFLUCKER, JC; JIANG, D; LENARDO, MJ			REQUIREMENT FOR TNF-ALPHA AND IL-1-ALPHA IN FETAL THYMOCYTE COMMITMENT AND DIFFERENTIATION	SCIENCE			English	Article							HEMATOPOIETIC STEM-CELLS; TUMOR-NECROSIS-FACTOR; POLYMERASE CHAIN-REACTION; CYTOKINE GENE-EXPRESSION; T-CELLS; PRECURSOR CELLS; C-KIT; INTERLEUKIN-2 RECEPTORS; IMMATURE THYMOCYTES; THYMUS DEVELOPMENT	CD25 expression occurs early in thymocyte differentiation. The mechanism of induction of CD25 before T cell receptor rearrangement and the importance of this mechanism for T cell development are unknown. In a thymus reconstitution assay, tumor necrosis factor alpha (TNF-alpha) and interleukin-1 alpha (IL-1 alpha), two cytokines produced within the thymic microenvironment, induced CD25 expression on early immature thymocytes. Either TNF-alpha or IL-1 alpha was necessary for further thymocyte maturation and CD4(+)CD8(+) differentiation. In irradiated mice reconstituted with CD117(+)CD25(+) thymocytes, commitment to the T cell lineage was marked by the loss of precursor multipotency.	NIAID, IMMUNOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Zuniga-Pflucker, Juan C/H-1295-2012	Zuniga-Pflucker, Juan Carlos/0000-0003-2538-3178				ANTICA M, 1993, J IMMUNOL, V151, P5887; BELL SE, 1991, EUR J IMMUNOL, V21, P2931, DOI 10.1002/eji.1830211206; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; CARDING SR, 1991, IMMUNOL TODAY, V12, P239, DOI 10.1016/0167-5699(91)90037-T; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CHEN D, 1993, MOL CELL BIOL, V13, P228, DOI 10.1128/MCB.13.1.228; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; GIROIR BP, 1992, P NATL ACAD SCI USA, V89, P4864, DOI 10.1073/pnas.89.11.4864; GODFREY DI, 1992, J IMMUNOL, V149, P2281; GODFREY DI, 1994, J IMMUNOL, V152, P4783; GODFREY DI, 1993, J IMMUNOL, V150, P4244; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; HENNEY CS, 1989, IMMUNOL TODAY, V10, P170, DOI 10.1016/0167-5699(89)90175-8; HUSMANN LA, 1988, J IMMUNOL, V141, P736; IKUTA K, 1992, P NATL ACAD SCI USA, V89, P1502, DOI 10.1073/pnas.89.4.1502; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; IVANOV V, 1992, INT IMMUNOL, V4, P729, DOI 10.1093/intimm/4.7.729; JENKINSON EJ, 1982, EUR J IMMUNOL, V12, P583, DOI 10.1002/eji.1830120710; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KINGSTON R, 1985, NATURE, V317, P811, DOI 10.1038/317811a0; MONTGOMERY RA, 1991, J IMMUNOL, V147, P554; MOORE NC, 1993, EUR J IMMUNOL, V23, P922, DOI 10.1002/eji.1830230424; MOORE T, 1994, J IMMUNOL, V153, P4978; NIKOLICZUGIC J, 1991, IMMUNOL TODAY, V12, P65, DOI 10.1016/0167-5699(91)90160-U; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RAULET DH, 1985, NATURE, V314, P101, DOI 10.1038/314101a0; ROCK KL, 1989, IMMUNOL REV, V111, P195, DOI 10.1111/j.1600-065X.1989.tb00547.x; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; ROTHENBERG EV, 1994, EUR J IMMUNOL, V24, P24, DOI 10.1002/eji.1830240105; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SCOLLAY R, 1991, CURR OPIN IMMUNOL, V3, P204, DOI 10.1016/0952-7915(91)90051-2; SCOLLAY R, 1988, IMMUNOL REV, V104, P81, DOI 10.1111/j.1600-065X.1988.tb00760.x; SEN J, 1994, J EXP MED, V180, P2321, DOI 10.1084/jem.180.6.2321; SHIMONKEVITZ RP, 1987, NATURE, V329, P157, DOI 10.1038/329157a0; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SUDA T, 1990, J IMMUNOL, V144, P3039; WATSON JD, 1989, J IMMUNOL, V143, P1215; WU L, 1991, J EXP MED, V174, P1617, DOI 10.1084/jem.174.6.1617; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0; ZUNIGAPFLUCKER JC, 1993, J EXP MED, V178, P1139, DOI 10.1084/jem.178.4.1139; ZUNIGAPFLUCKER JC, UNPUB	45	125	127	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 30	1995	268	5219					1906	1909		10.1126/science.7541554	http://dx.doi.org/10.1126/science.7541554			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7541554				2022-12-28	WOS:A1995RF99000040
J	LEVITSKAYA, J; CORAM, M; LEVITSKY, V; IMREH, S; STEIGERWALDMULLEN, PM; KLEIN, G; KURILLA, MG; MASUCCI, MG				LEVITSKAYA, J; CORAM, M; LEVITSKY, V; IMREH, S; STEIGERWALDMULLEN, PM; KLEIN, G; KURILLA, MG; MASUCCI, MG			INHIBITION OF ANTIGEN-PROCESSING BY THE INTERNAL REPEAT REGION OF THE EPSTEIN-BARR-VIRUS NUCLEAR ANTIGEN-1	NATURE			English	Article							LYMPHOCYTES-T; DNA-BINDING; INVIVO; RECOGNITION; EXPRESSION; SEQUENCE; EBNA-1; ESCAPE; CELLS	THE Epstein-Barr virus (EBV)-encoded nuclear antigen (EBNA1) is expressed in latently EBV-infected B lymphocytes that persist for life in healthy virus carriers(1,2) and is the only viral protein regularly detected in all malignancies associated with EBV(3,4). Major histocompatibility complex (MHC) class I-restricted, EBNA1-specific cytotoxic T lymphocyte (CTL) responses have not been demonstrated(3,5). Using recombinant vaccinia viruses encoding chimaeric proteins containing an immunodominant human leukocyte antigen A11-restricted CTL epitope, amino acids 416-424 of the EBNA4 protein(6), inserted within the intact EBNA1, or within an EBNA1 deletion mutant devoid of the internal Gly-Ala repetitive sequence, we demonstrate that the Gly-Ala repeats generate a cis-acting inhibitory signal that interferes with antigen processing and MHC class I-restricted presentation. Insertion of the Gly-Ala repeats downstream of the 416-424 epitope inhibited CTL recognition of a chimaeric EBNA4 protein. The results highlight a previously unknown mechanism of viral escape from CTL surveillance, and support the view that the resistance of cells expressing EBNA1 to rejection mediated by CTL is a critical requirement for EBV persistence and pathogenesis.	KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN; UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22908	Karolinska Institutet; University of Virginia			Masucci, Maria/AAC-6666-2019; Masucci, Maria G/B-8588-2009	Masucci, Maria/0000-0002-5541-2809; 				BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BANGHAM CRM, 1986, J IMMUNOL, V137, P3973; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; BURGERT HG, 1987, P NATL ACAD SCI USA, V84, P1356, DOI 10.1073/pnas.84.5.1356; BYRNE JA, 1984, J VIROL, V51, P682, DOI 10.1128/JVI.51.3.682-686.1984; CHEN F, IN PRESS J VIROL; CHEN MR, 1993, J VIROL, V67, P4875, DOI 10.1128/JVI.67.8.4875-4885.1993; Clechanover A., 1994, CELL, V79, P13; DECAMPOSLIMA PO, 1994, J EXP MED, V179, P1297, DOI 10.1084/jem.179.4.1297; DILLNER J, 1984, P NATL ACAD SCI-BIOL, V81, P4652, DOI 10.1073/pnas.81.15.4652; GAVIOLI R, 1993, J VIROL, V67, P1572, DOI 10.1128/JVI.67.3.1572-1578.1993; KLEIN G, 1994, CELL, V77, P791, DOI 10.1016/0092-8674(94)90125-2; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; LEE PY, 1993, J VIROL, V67, P4252, DOI 10.1128/JVI.67.7.4252-4263.1993; LUKACHER AE, 1984, J EXP MED, V160, P814, DOI 10.1084/jem.160.3.814; Masucci Maria G., 1994, Trends in Microbiology, V2, P125, DOI 10.1016/0966-842X(94)90599-1; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REEDMAN BM, 1973, INT J CANCER, V11, P499, DOI 10.1002/ijc.2910110302; Rickinson A. M., 1992, NEW LOOK TUMOR IMMUN, P53; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; STEIGEWALDMULLE.PM, IN PRESS J GEN VIROL; TIEMEY RJ, 1994, J VIROL, V68, P7374; TISHON A, 1993, VIROLOGY, V195, P397, DOI 10.1006/viro.1993.1389; TSUBOTA H, 1989, J EXP MED, V169, P1421, DOI 10.1084/jem.169.4.1421	29	638	672	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					685	688		10.1038/375685a0	http://dx.doi.org/10.1038/375685a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7540727				2022-12-28	WOS:A1995RE57600061
J	PINET, V; VERGELLI, M; MARTIN, R; BAKKE, O; LONG, EO				PINET, V; VERGELLI, M; MARTIN, R; BAKKE, O; LONG, EO			ANTIGEN PRESENTATION MEDIATED BY RECYCLING OF SURFACE HLA-DR MOLECULES	NATURE			English	Article							CLASS-II MOLECULES; INVARIANT-CHAIN; PROTEIN-SYNTHESIS; MHC MOLECULES; MICE LACKING; LIVING CELLS; ENDOCYTOSIS; PEPTIDES; EXPRESSION; IA	CLASS II histocompatibility molecules associate with peptides derived from antigens that are processed in endocytic compartments. Antigen presentation to class II-restricted T cells generally requires newly synthesized class II molecules(1), associated invariant chain(2,3), and HLA-DM(4,5). Exceptions to these rules have been reported(6-10), but without description of an underlying mechanism. Here we show that presentation of immunodominant epitopes in the haemagglutinin protein of influenza virus and in myelin basic protein correlates,vith recycling of surface KLA-DR molecules. Truncation of either one of the alpha or beta cytoplasmic tails virtually eliminated internalization of HLA-DR molecules and presentation of haemagglutinin from inactive virus particles. In contrast, the invariant chain-dependent presentation of matrix antigen from the same virus particles was unaffected by these truncations. Thus HLA-DR cytoplasmic tails are not required for the conventional presentation pathway, but jointly contribute a signal for an alternative pathway involving internalization of HLA-DR molecules.	NIAID,IMMUNOGENET LAB,ROCKVILLE,MD 20852; NINCDS,NEUROIMMUNOL BRANCH,BETHESDA,MD 20892; UNIV OSLO,DEPT BIOL,N-0316 OSLO,NORWAY	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Oslo			Long, Eric O/G-5475-2011; PINET, Valérie/G-6085-2012	Long, Eric O/0000-0002-7793-3728; PINET, Valérie/0000-0002-4044-6440; Bakke, Oddmund/0000-0003-4843-7626				ADORINI L, 1989, NATURE, V342, P800, DOI 10.1038/342800a0; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BODMER H, 1994, SCIENCE, V263, P1284, DOI 10.1126/science.7510069; BROOKS AG, 1994, J IMMUNOL, V153, P5382; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DAVIS JE, 1990, J IMMUNOL, V144, P990; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; HARDING CV, 1989, J IMMUNOL, V142, P12; KAKIUCHI T, 1990, J IMMUNOL, V145, P1653; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LONG EO, 1994, J IMMUNOL, V153, P1487; MARTIN R, 1992, J IMMUNOL, V148, P1359; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NABAVI N, 1989, J IMMUNOL, V142, P1444; NADIMI F, 1991, EUR J IMMUNOL, V21, P1255, DOI 10.1002/eji.1830210524; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; PINET V, 1994, J IMMUNOL, V152, P4852; RADKA SF, 1984, HUM IMMUNOL, V10, P177, DOI 10.1016/0198-8859(84)90038-7; REID PA, 1992, IMMUNOLOGY, V77, P539; RICCIO P, 1994, NEUROREPORT, V5, P689, DOI 10.1097/00001756-199402000-00007; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; SIMONSEN A, 1993, INT IMMUNOL, V5, P903, DOI 10.1093/intimm/5.8.903; STEBBINS CC, 1995, J EXP MED, V181, P223, DOI 10.1084/jem.181.1.223; STPIERRE Y, 1989, J IMMUNOL, V143, P808; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z	30	241	243	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					603	606		10.1038/375603a0	http://dx.doi.org/10.1038/375603a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7540726				2022-12-28	WOS:A1995RD28700055
J	GRANGE, JM; STANFORD, JL; ROOK, GAW				GRANGE, JM; STANFORD, JL; ROOK, GAW			TUBERCULOSIS AND CANCER - PARALLELS IN HOST RESPONSES AND THERAPEUTIC APPROACHES	LANCET			English	Note							HEAT-SHOCK PROTEIN; T-CELLS; CYTOKINE PRODUCTION; BCG VACCINATION; RESPONSIVENESS; LEPROSY; HYPERSENSITIVITY; MYCOBACTERIA; AUTOIMMUNITY; RECOGNITION	Mycobacteria elicit two quite different immune responses. One is protective and is partly based on recognition and lysis of stressed, bacilli-laden cells expressing heat-shock proteins. The other suppresses this recognition and instead leads to indiscriminate necrosis of tissues containing mycobacteria (the Koch phenomenon). The type of response depends on the predominant T-cell maturation pathway, Th1 or Th2, which in turn is determined by priming by prior contact with environmental mycobacteria. Vaccination by BCG induces whichever response the recipient is primed to make, and this is a likely explanation of the variable efficacy of this vaccine in prevention of tuberculosis and therapy of cancer. Thus, BCG is a two-edged sword. We postulate that by using other mycobacterial preparations, such as killed Mycobacterium vaccae, it might be possible to suppress the indiscriminate necrosis and enhance Th1-regulated selective destruction of tumour cells.	UCL, SCH MED, DEPT MED MICROBIOL, LONDON W1N 8AA, ENGLAND	University of London; University College London; UCL Medical School	GRANGE, JM (corresponding author), ROYAL BROMPTON HOSP, NATL HEART & LUNG INST, DEPT MICROBIOL, LONDON SW3 6NP, ENGLAND.			Rook, Graham/0000-0002-8041-8110				ABE O, 1992, LANCET, V339, P71; BAHR GM, 1989, ANN RHEUM DIS, V48, P63, DOI 10.1136/ard.48.1.63; BARNES PF, 1993, INFECT IMMUN, V61, P3482, DOI 10.1128/IAI.61.8.3482-3489.1993; BOOM WH, 1991, INFECT IMMUN, V59, P2737, DOI 10.1128/IAI.59.8.2737-2743.1991; BOTHAMLEY GH, 1989, J INFECT DIS, V159, P549, DOI 10.1093/infdis/159.3.549; BOTHAMLEY GH, 1991, TUBERCLE, V72, P7, DOI 10.1016/0041-3879(91)90018-N; BOTTASSO OA, 1994, LANCET, V344, P1540, DOI 10.1016/S0140-6736(94)90351-4; BRETSCHER PA, 1992, IMMUNOL TODAY, V13, P342, DOI 10.1016/0167-5699(92)90168-7; BROWN JAK, 1966, BMJ-BRIT MED J, V1, P7, DOI 10.1136/bmj.1.5478.7; COHEN IR, 1991, IMMUNOL TODAY, V12, P105, DOI 10.1016/0167-5699(91)90093-9; COMSTOCK GW, 1991, TUBERCLE, V72, P304, DOI 10.1016/0041-3879(91)90059-2; DEVRIES RRP, 1991, TUBERCLE, V72, P161, DOI 10.1016/0041-3879(91)90001-9; DORAK MT, 1994, LEUKEMIA LYMPHOMA, V12, P211, DOI 10.3109/10428199409059592; DORAK MT, IN PRESS LEUKEMIA; DUVALL E, 1985, IMMUNOLOGY, V56, P351; FINE PEM, 1994, LANCET, V344, P1245, DOI 10.1016/S0140-6736(94)90748-X; FINE PEM, 1994, TUBERCULOSIS BACK FU, P53; FLYNN JL, 1992, P NATL ACAD SCI USA, V89, P12013, DOI 10.1073/pnas.89.24.12013; GRANGE JM, 1990, TUBERCLE, V71, P61, DOI 10.1016/0041-3879(90)90063-E; HALL SS, 1994, SCIENCE, V263, P1685, DOI 10.1126/science.7907819; HERNANDEZPANDO R, 1994, IMMUNOLOGY, V82, P591; KARDJITO T, 1986, EUR J RESPIR DIS, V69, P142; KHOO SH, 1993, 9 INT C AIDS BERL; KOGA T, 1989, SCIENCE, V245, P1112, DOI 10.1126/science.2788923; LOCKWOOD DNJ, 1987, EUR J RESPIR DIS, V71, P348; LUKACS KV, 1993, J EXP MED, V178, P343, DOI 10.1084/jem.178.1.343; MOSMANN TR, 1991, INT ARCH ALLER A IMM, V94, P110, DOI 10.1159/000235340; NAUTS HC, 1989, CANCER SURV, V8, P713; SCHAUF V, 1993, J INFECT DIS, V168, P1056, DOI 10.1093/infdis/168.4.1056; SRIVASTAVA PK, 1991, CURR TOP MICROBIOL, V167, P109; STANFORD JL, 1987, TUBERCLE, V68, P39, DOI 10.1016/0041-3879(87)90006-7; STANFORD JL, 1981, LEPROSY REV, V52, P321; STANFORD JL, 1994, TROP GEOGR MED, V46, P93; STANFORD JL, 1991, TUBERCLE, V72, P241, DOI 10.1016/0041-3879(91)90047-V; STARNES CO, 1992, NATURE, V357, P11, DOI 10.1038/357011a0; STEINHOFF U, 1990, INT IMMUNOL, V2, P279, DOI 10.1093/intimm/2.3.279; ULLRICH SJ, 1986, P NATL ACAD SCI USA, V83, P3121, DOI 10.1073/pnas.83.10.3121; VANEDEN W, 1983, CLIN EXP IMMUNOL, V52, P287; YONG AJ, 1989, TUBERCLE, V70, P273, DOI 10.1016/0041-3879(89)90021-4; YOUNG DB, 1992, CURR OPIN IMMUNOL, V4, P396, DOI 10.1016/S0952-7915(06)80029-4	40	56	57	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 27	1995	345	8961					1350	1352		10.1016/S0140-6736(95)92542-2	http://dx.doi.org/10.1016/S0140-6736(95)92542-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7538622				2022-12-28	WOS:A1995RA14800013
J	ROTHSTEIN, TL; WANG, JKM; PANKA, DJ; FOOTE, LC; WANG, ZH; STANGER, B; CUI, H; JU, ST; MARSHAKROTHSTEIN, A				ROTHSTEIN, TL; WANG, JKM; PANKA, DJ; FOOTE, LC; WANG, ZH; STANGER, B; CUI, H; JU, ST; MARSHAKROTHSTEIN, A			PROTECTION AGAINST FAS-DEPENDENT TH1-MEDIATED APOPTOSIS BY ANTIGEN RECEPTOR ENGAGEMENT IN B-CELLS	NATURE			English	Article							CD40 LIGAND; LYMPHOCYTES; ANTIBODY; SIGNAL; MICE	CYTOTOXIC CD4(+) Th1-cells induce cell death by triggering a Fas-dependent apoptotic pathway(1-6). Potential targets include activated B cells(3,7), but it is not known whether the mode of B-cell stimulation influences susceptibility to Th1-mediated cytotoxicity. Here we report that CD40-ligand-stimulated B cells were extremely sensitive, whereas anti-IgM-stimulated B cells were resistant, to Fas-mediated apoptosis, B cells stimulated by both CD4DL and anti-IgM were not susceptible to cytolysis, demonstrating that anti-IgM-mediated protection is an active, dominant process. Resistance to Th1-mediated cytotoxicity was similarly observed in CD40L-stimulated 3-83 (anti-H-2K(k,b))(8) transgenic B cells co-cultured with H-2K(k) or H-2K(b) (but not H-2K(d)) splenocytes, These results indicate that B cells can participate in regulating their own destruction. Protection against Fas-dependent apoptosis afforded by immunoglobulin-receptor engagement may constitute a fail-safe mechanism that eliminates bystander B cells activated by CD40L-expressing T cells, but ensures survival of antigen-specific B cells.	BOSTON UNIV,MED CTR,DEPT MICROBIOL,BOSTON,MA 02118; BOSTON UNIV,MED CTR,DEPT PATHOL,BOSTON,MA 02118; BOSTON UNIV,MED CTR,EVANS MEM DEPT CLIN RES,BOSTON,MA 02118; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Boston University; Boston University; Boston University; Harvard University; Harvard Medical School	ROTHSTEIN, TL (corresponding author), BOSTON UNIV,MED CTR,DEPT MED,88 E NEWTON ST,BOSTON,MA 02118, USA.							BALK SP, 1981, J IMMUNOL, V126, P2177; DANIEL PT, 1994, J IMMUNOL, V152, P5624; ERB P, 1990, J IMMUNOL, V144, P790; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FRANCIS DA, 1995, INT IMMUNOL, V7, P151, DOI 10.1093/intimm/7.2.151; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; HEATH AW, 1993, CELL IMMUNOL, V152, P468, DOI 10.1006/cimm.1993.1305; HENKART PA, 1994, IMMUNITY, V1, P343, DOI 10.1016/1074-7613(94)90063-9; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2368, DOI 10.1002/eji.1830230948; JU ST, 1990, J IMMUNOL, V144, P23; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; LANE P, 1993, J EXP MED, V177, P1209, DOI 10.1084/jem.177.4.1209; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; PARRY SL, 1994, J IMMUNOL, V152, P2821; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; SANTOSARGUMEDO L, 1994, CELL IMMUNOL, V156, P272, DOI 10.1006/cimm.1994.1174; STALDER T, 1994, J IMMUNOL, V152, P1127; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TAYLOR RB, 1971, NATURE-NEW BIOL, V233, P225, DOI 10.1038/newbio233225a0; TRENN G, 1987, NATURE, V330, P72, DOI 10.1038/330072a0; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0	28	416	417	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					163	165		10.1038/374163a0	http://dx.doi.org/10.1038/374163a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7533263				2022-12-28	WOS:A1995QL39700059
J	HYDE, TM; WEINBERGER, DR				HYDE, TM; WEINBERGER, DR			TOURETTES-SYNDROME - A MODEL NEUROPSYCHIATRIC DISORDER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							BASAL GANGLIA; DELATOURETTES,GILLES SYNDROME; MONOZYGOTIC TWINS; CHILDREN		ST ELIZABETH HOSP, NIMH,CTR NEUROSCI,CLIN BRAIN DISORDERS BRANCH, INTRAMURAL RES PROGRA, WASHINGTON, DC 20032 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)								ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; BALTHASAR K, 1957, Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr, V195, P531, DOI 10.1007/BF00343129; BONTHALA CM, 1983, BRIT J PSYCHIAT, V143, P300, DOI 10.1192/bjp.143.3.300; BORNSTEIN RA, 1990, PSYCHIAT RES, V33, P73, DOI 10.1016/0165-1781(90)90150-4; BRUUN RD, 1984, J AM ACAD CHILD PSY, V23, P126, DOI 10.1097/00004583-198403000-00002; BRUUN RD, 1992, ADV NEUROL, V58, P1; BURD L, 1986, AM J PSYCHIAT, V143, P787; CAINE ED, 1988, NEUROLOGY, V38, P472, DOI 10.1212/WNL.38.3.472; COMINGS DE, 1985, AM J HUM GENET, V37, P435; Dewulf A, 1941, MON PSYCHIATR NEUROL, V104, P53; Gilles de la Tourette G., 1885, ARCH NEUROL-CHICAGO, V9, P158; Gilles de la Tourette G, 1885, ARCH NEUROL-CHICAGO, V9, P158; HABER SN, 1992, ADV NEUROL, V58, P145; HYDE TM, 1992, NEUROLOGY, V42, P652, DOI 10.1212/WNL.42.3.652; HYDE TM, 1994, BRIT J PSYCHIAT, V164, P811, DOI 10.1192/bjp.164.6.811; HYDE TM, IN PRESS NEUROLOGY; Itard JMG, 1825, ARCH GEN MED, V8, P385; JANKOVIC J, 1992, ADV NEUROL, V58, P7; KIDD KK, 1980, ARCH GEN PSYCHIAT, V37, P1336; KLAWANS HL, 1978, NEUROLOGY, V28, P1064, DOI 10.1212/WNL.28.10.1064; LECKMAN JF, 1987, ARCH GEN PSYCHIAT, V44, P100; LUNDH H, 1981, J NEUROL NEUROSUR PS, V44, P728, DOI 10.1136/jnnp.44.8.728; PAULS DL, 1986, ARCH GEN PSYCHIAT, V43, P1180; PAULS DL, 1986, NEW ENGL J MED, V315, P993, DOI 10.1056/NEJM198610163151604; PETERSON B, 1993, NEUROLOGY, V43, P941, DOI 10.1212/WNL.43.5.941; PRICE RA, 1985, ARCH GEN PSYCHIAT, V42, P815; RANDOLPH C, 1993, ARCH NEUROL-CHICAGO, V50, P725, DOI 10.1001/archneur.1993.00540070045013; ROBERTSON MM, 1989, BRIT J PSYCHIAT, V154, P147, DOI 10.1192/bjp.154.2.147; SHAPIRO AK, 1982, SEMIN NEUROL, V2, P373; SHAPIRO E, 1986, REV NEUROL, V142, P824; SINGER HS, 1993, NEUROLOGY, V43, P950, DOI 10.1212/WNL.43.5.950; SINGER HS, 1991, ANN NEUROL, V30, P558, DOI 10.1002/ana.410300408; 1996, ARCH NEUROL-CHICAGO, V50, P1013	33	33	34	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	1995	273	6					498	501		10.1001/jama.273.6.498	http://dx.doi.org/10.1001/jama.273.6.498			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QE498	7530781				2022-12-28	WOS:A1995QE49800035
J	STUCKI, A; CORDEY, AS; MONAI, N; DEFLAUGERGUES, JC; SCHAPIRA, H; SPERTINI, O				STUCKI, A; CORDEY, AS; MONAI, N; DEFLAUGERGUES, JC; SCHAPIRA, H; SPERTINI, O			CLEAVED L-SELECTIN CONCENTRATIONS IN MENINGEAL LEUKEMIA	LANCET			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CEREBROSPINAL-FLUID; CHILDHOOD; RELAPSE; CELLS	Involvement of the central nervous system has important therapeutic implications in acute leukaemia. Because the identification of blast cells in cerebrospinal fluid (CSF) is often difficult, there is a need for sensitive markers of leukaemic infiltration. Since the shed form of L-selectin (sL-selectin) is frequently increased in acute leukaemia (sL-selectin(+) leukaemia), we examined whether assay of sL-selectin in CSF could improve our ability to detect such meningeal involvement. CSF sL-selectin was significantly (p<0.001) higher in 15 patients with sL-selectin(+) meningeal leukaemia (median 60 ng/ml, range 34-150) than in 20 patients with acute leukaemia without meningeal involvement (12 ng/mL, 1-39) or 88 control patients (14 ng/ml, 0-37). Serial measurements of sL-selectin in patients with sL-selectin(+) leukaemic meningitis showed increased CSF concentrations of the cleaved receptor in 4 patients with therapy-resistant meningeal leukaemia and sustained normal concentrations in 9 patients in remission. Our results suggest that CSF sL-selectin may be a useful marker in the detection of meningeal involvement by blast cells in patients with sL-selectin(+) leukaemia.	CHU VAUDOIS,DIV HAEMATOL,CH-1011 LAUSANNE,SWITZERLAND; CHU VAUDOIS,SERV NEUROL,CH-1011 LAUSANNE,SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)								ADAMS DH, 1994, LANCET, V343, P831, DOI 10.1016/S0140-6736(94)92029-X; BENETT JM, 1985, ANN INTERN MED, V103, P620; BIGNER SH, 1981, ACTA CYTOL, V25, P335; BLEYER WA, 1988, PEDIATR CLIN N AM, V35, P789; DONELLY SC, 1994, LANCET, V344, P215; DUNN OJ, 1964, TECHNOMETRICS, V6, P241, DOI 10.2307/1266041; KOMADA Y, 1990, BLOOD, V76, P112; LASKY LA, 1992, SCIENCE, V258, P962; MAHMOUD HH, 1993, NEW ENGL J MED, V329, P314, DOI 10.1056/NEJM199307293290504; NIES BA, 1965, CANCER, V18, P546, DOI 10.1002/1097-0142(196505)18:5<546::AID-CNCR2820180503>3.0.CO;2-E; OCHS JJ, 1985, J CLIN ONCOL, V3, P622, DOI 10.1200/JCO.1985.3.5.622; ORTEGA JA, 1987, J CLIN ONCOL, V5, P1646, DOI 10.1200/JCO.1987.5.10.1646; PINKEL D, 1994, BLOOD, V84, P355, DOI 10.1182/blood.V84.2.355.bloodjournal842355; SAIKIA TK, 1993, AM J HEMATOL, V43, P10, DOI 10.1002/ajh.2830430104; SPERTINI O, 1994, BLOOD, V84, P1249, DOI 10.1182/blood.V84.4.1249.bloodjournal8441249; SPERTINI O, 1992, J IMMUNOL METHODS, V156, P115, DOI 10.1016/0022-1759(92)90017-N; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9	17	30	32	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					286	289		10.1016/S0140-6736(95)90276-7	http://dx.doi.org/10.1016/S0140-6736(95)90276-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7530792				2022-12-28	WOS:A1995QE73100010
J	PRESTI, JC				PRESTI, JC			INDOMETHACIN AND SYMPTOMATIC RELIEF OF BENIGN PROSTATIC HYPERPLASIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											PRESTI, JC (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143, USA.							BALL AJ, 1981, BRIT J UROL, V53, P613, DOI 10.1111/j.1464-410X.1981.tb03273.x; BARHAM CP, 1993, BRIT J UROL, V72, P314, DOI 10.1111/j.1464-410X.1993.tb00725.x; Birkhoff J D, 1976, Urology, V7, P48, DOI 10.1016/0090-4295(76)90560-4; CAINE M, 1986, J UROLOGY, V136, P1; Craigen A A, 1969, J R Coll Gen Pract, V18, P226; HELLSTROM WJG, 1987, UROLOGY, V30, P183, DOI 10.1016/0090-4295(87)90193-2; LEPOR H, 1992, J UROLOGY, V148, P1467, DOI 10.1016/S0022-5347(17)36941-0	7	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	1995	273	4					347	347		10.1001/jama.273.4.347	http://dx.doi.org/10.1001/jama.273.4.347			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC057	7529343				2022-12-28	WOS:A1995QC05700040
J	BERGLUND, J; EITREM, R; ORNSTEIN, K; LINDBERG, A; RINGNER, A; ELMRUD, H; CARLSSON, M; RUNEHAGEN, A; SVANBORG, C; NORRBY, R				BERGLUND, J; EITREM, R; ORNSTEIN, K; LINDBERG, A; RINGNER, A; ELMRUD, H; CARLSSON, M; RUNEHAGEN, A; SVANBORG, C; NORRBY, R			AN EPIDEMIOLOGIC-STUDY OF LYME-DISEASE IN SOUTHERN SWEDEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LATE CUTANEOUS MANIFESTATIONS; TICK-BORNE ENCEPHALITIS; CENTRAL-NERVOUS-SYSTEM; BORRELIA-BURGDORFERI; FORESTRY WORKERS; PREVALENCE; SERODIAGNOSIS; ANTIBODIES; POPULATION; ARTHRITIS	Background. Lyme disease is the most common vector-borne infection in some temperate regions of the Northern Hemisphere, However, for most areas of endemic disease reliable epidemiologic data are sparse. Methods. Over a one-year period, we conducted a prospective, population-based survey of cases of Lyme disease in southern Sweden. The diagnosis was made on the basis of the presence of erythema migrans at least 5 cm in diameter or characteristic clinical manifestations such as arthritis, neuroborreliosis, and carditis. Results. We identified 1471 patients with Lyme disease, for an overall annual incidence of 69 cases per 100,000 inhabitants. The incidence varied markedly according to geographic region, and there were several areas where disease was widely prevalent. The incidence varied according to age, with the highest rates among people 5 to 9 and 60 to 74 years of age, but not according to sex. The most frequent clinical manifestation was erythema migrans (seen in 77 percent of all cases), followed by neuroborreliosis (16 percent) and arthritis (7 percent). Carditis was rare. A preceding tick bite was reported by 79 percent of the patients. Bites in the head and neck region were more common among children than among adults and were associated with an increased risk of neuroborreliosis. Conclusions. Lyme disease is very common in southern Sweden, with a relatively high frequency of neurologic complications and arthritis. With the exception of the low incidence of carditis, the pattern of disease we found in Sweden was similar to that reported in the United States.	LUND UNIV, DEPT COMMUNITY HLTH SCI, LUND, SWEDEN; LUND UNIV, DEPT INFECT DIS, LUND, SWEDEN; LUND UNIV, DEPT MED MICROBIOL, LUND, SWEDEN; DEPT INFECT DIS CONTROL BLEKINGE CTY, KARLSKRONA, SWEDEN; DEPT INFECT DIS CONTROL HALLAND CTY, HALMSTAD, SWEDEN; DEPT INFECT DIS CONTROL KALMAR CTY, KALMAR, SWEDEN; DEPT INFECT DIS CONTROL KRISTIANSTAD CTY, KRISTIANSTAD, SWEDEN; DEPT INFECT DIS CONTROL JONKOPING CTY, JONKOPING, SWEDEN; DEPT INFECT DIS CONTROL KRONOBERG CTY, VAXJO, SWEDEN	Lund University; Lund University; Lund University			Sanmartin Berglund, Johan/HGB-0471-2022					AESCHLIMANN A, 1986, Zentralblatt fuer Bakteriologie Mikrobiologie und Hygiene Series A, V263, P450; AGUEROROSENFELD ME, 1993, J CLIN MICROBIOL, V31, P3090, DOI 10.1128/JCM.31.12.3090-3095.1993; AGUEROROSENFELD ME, 1994, J CLIN MICROBIOL, V32, P860; ANANJEVA LP, 1995, ARTHRITIS RHHEUM, V22, P689; ASBRINK E, 1988, ANN NY ACAD SCI, V539, P4, DOI 10.1111/j.1749-6632.1988.tb31833.x; ASBRINK E, 1984, ACTA DERM-VENEREOL, V64, P506; BERGLUND J, 1993, SCAND J INFECT DIS, V25, P67, DOI 10.3109/00365549309169672; BERGLUND J, 1995, J RHEUMATOL, V22, P695; BLAAUW I, 1991, J RHEUMATOL, V18, P1819; CANICA MM, 1993, SCAND J INFECT DIS, V25, P441, DOI 10.3109/00365549309008525; CHRISTEN HJ, 1993, ACTA PAEDIATR, V82, P1, DOI 10.1111/j.1651-2227.1993.tb18082.x; DEKONENKO EJ, 1988, J INFECT DIS, V158, P748, DOI 10.1093/infdis/158.4.748; DENNIS DT, 1993, LYME DISEASE, V27, P37; DRESSLER F, 1994, CLIN EXP RHEUMATOL, V12, pS49; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; FAHRER H, 1991, J INFECT DIS, V163, P305, DOI 10.1093/infdis/163.2.305; GARCIAMONCO JC, 1990, J INFECT DIS, V161, P1187, DOI 10.1093/infdis/161.6.1187; GUSTAFSON R, 1993, SCAND J INFECT DIS, V25, P605, DOI 10.3109/00365549309008549; Gustafson R, 1994, Scand J Infect Dis Suppl, V92, P1; HAMMERSBERGGREN S, 1993, STROKE, V24, P1393, DOI 10.1161/01.STR.24.9.1393; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; HANSEN K, 1988, J CLIN MICROBIOL, V26, P338, DOI 10.1128/JCM.26.2.338-346.1988; HORST H, 1990, NIEDERSACHSISCH ARZT, V63, P32; KRYGER P, 1990, SCAND J RHEUMATOL, V19, P77, DOI 10.3109/03009749009092625; KUIPER H, 1993, EUR J CLIN MICROBIOL, V12, P413, DOI 10.1007/BF01967434; LEY C, 1994, WESTERN J MED, V160, P534; Linde M. R. van der, 1993, Aspects of Lyme borreliosis., P131; LUFT BJ, 1992, JAMA-J AM MED ASSOC, V267, P1364, DOI 10.1001/jama.267.10.1364; LUFT BJ, 1992, JAMA-J AM MED ASSOC, V268, P873, DOI 10.1001/jama.1992.03490070050034; MITCHELL PD, 1994, J CLIN MICROBIOL, V32, P1958, DOI 10.1128/JCM.32.8.1958-1962.1994; MITCHELL PD, 1994, J CLIN MICROBIOL, V32, P2343; NADAL D, 1989, EUR J CLIN MICROBIOL, V8, P992, DOI 10.1007/BF01967572; SCHMID GP, 1985, REV INFECT DIS, V7, P41; SCHMUTZHARD E, 1988, INFECTION, V16, P269, DOI 10.1007/BF01645068; SCHWARTZ BS, 1994, AM J EPIDEMIOL, V139, P504, DOI 10.1093/oxfordjournals.aje.a117033; STANEK G, 1988, ANN NY ACAD SCI, V539, P274, DOI 10.1111/j.1749-6632.1988.tb31861.x; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; WILSKE B, 1988, ANN NY ACAD SCI, V539, P126, DOI 10.1111/j.1749-6632.1988.tb31846.x; 1990, MMWR-MORBID MORTAL W, V39, P19; 1995, MMWR MORTAL WKLY REP, V44, P459; 1994, MMWR MORTAL WKLY REP, V43, P564	43	294	302	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 16	1995	333	20					1319	1324		10.1056/NEJM199511163332004	http://dx.doi.org/10.1056/NEJM199511163332004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE365	7566023				2022-12-28	WOS:A1995TE36500004
J	BERN, C; PHILEN, RM; FREDMAN, D; BOWMAN, BA; NEWMAN, NJ; GERR, F; RIDEL, GM; PENA, EZ; MALILAY, J; MILLER, DT; SOWELL, AL; MILLER, MA; FLANDERS, WD; FALTER, KH; OLSON, DR; KILBOURNE, EM; SINKS, T; ING, R; STAEHLING, N; BOYD, M; GUNTER, EW; PASCHAL, DC; MUELLER, PW; SPIERTO, FW; NEEDHAM, LL; HILL, RH; ASHLEY, DL; HANNON, WH; MARQUEZ, AR; FERNANDEZ, JRD; HADAD, JH; MILORD, DR; CRISTIA, RP; PEREZ, MAH; VERDURA, CS; ALBA, MAM; HODELIN, MT; GORBEA, MB; DIAZ, ED; HIORTLORENZEN, CLC; CLUA, AM; GUTIERREZ, PM; ACOSTA, SJ; CABRERA, A; FERNANDEZ, MM; FREIXAS, RS; ESTRADA, R; ARIAS, L; MESTRE, PF; PLA, E; ROMERO, MC; FERRET, AC; LLANOS, G; JIMENEZ, JS; ROMAN, GC; OBERMEYER, W; CASTRO, MD; RUIZ, CAP; RICO, NS; BETANCOURT, IP; FUENTES, BEE; CABRERA, AP; CALDELLICEHIO, LET; MEDINA, AG; GOMEZ, N; MOJARRIETA, MS; VARA, JAC; PORTALES, JMR; HERNANDEZ, GR; GINALY, SM; GARCIA, PP; GARCIA, M; HERNANDEZ, CS; DIAZ, EI; RECIO, EM; GARCIA, SH; SANCHEZ, AL; VALDES, P; RODRIGUEZ, OM; OLIVA, NB; DIAZ, D; PEREZ, MC; HERNANDEZ, MCR; GONEZ, JMR; AMADO, SN; DELLLANO, AC; BREIJO, DH; ACOSTA, AC; GONZALEZ, MM; ROMERO, RM; CHAVEZ, OC; VALDES, MH; OTERO, GR; CABALLERO, MM; VALDES, AG; OLIVERA, BR; BENITEZ, EE; BEADE, C; LEON, LS; MARIMON, FD; ROMAN, AS; RODRIGUEZ, R; RODRIGUEZ, FD; ALVAREZ, MR; COLUMBE, MS; MARRERO, A; ZULUETA, D; GARCIA, CR; SANTOS, JPA; PEDROSO, F; RODRIGUEZ, HM; VALDES, NM; ACOSTA, MS; CHOBEL, ER; GODOY, MM; LUGO, MM; LOPEZ, LL; DIAZ, EM; MARTINEZ, JCB; DELGADO, NA; VALDES, MT; MORENO, ARD; SANCHEZ, SH; HERNANDEZ, LEP; VALDES, OM; MARTINEZ, AO; DOMINGUEZ, I; DEARMAS, MR; IGLESIAS, OR; CASTELL, OR; TRUJILLO, OG; BEUNE, MDM; RODRIGUEZ, FM; MEDINA, RM; RUIZCALDERON, JC; FERNANDEZ, B; BARROSO, EV; MACHIN, JL; ARMENTEROS, LR; MENDEZ, CV; PEREZ, JH; CAMPOS, AC; DIAZ, NA; PEREZ, AO; MILIAN, J; LEON, OH; CAPOTE, BR; LEZCANOS, MR; EZMORIZ, LP; MOYA, O; VITRIAGO, A; MURGUIA, AU				BERN, C; PHILEN, RM; FREDMAN, D; BOWMAN, BA; NEWMAN, NJ; GERR, F; RIDEL, GM; PENA, EZ; MALILAY, J; MILLER, DT; SOWELL, AL; MILLER, MA; FLANDERS, WD; FALTER, KH; OLSON, DR; KILBOURNE, EM; SINKS, T; ING, R; STAEHLING, N; BOYD, M; GUNTER, EW; PASCHAL, DC; MUELLER, PW; SPIERTO, FW; NEEDHAM, LL; HILL, RH; ASHLEY, DL; HANNON, WH; MARQUEZ, AR; FERNANDEZ, JRD; HADAD, JH; MILORD, DR; CRISTIA, RP; PEREZ, MAH; VERDURA, CS; ALBA, MAM; HODELIN, MT; GORBEA, MB; DIAZ, ED; HIORTLORENZEN, CLC; CLUA, AM; GUTIERREZ, PM; ACOSTA, SJ; CABRERA, A; FERNANDEZ, MM; FREIXAS, RS; ESTRADA, R; ARIAS, L; MESTRE, PF; PLA, E; ROMERO, MC; FERRET, AC; LLANOS, G; JIMENEZ, JS; ROMAN, GC; OBERMEYER, W; CASTRO, MD; RUIZ, CAP; RICO, NS; BETANCOURT, IP; FUENTES, BEE; CABRERA, AP; CALDELLICEHIO, LET; MEDINA, AG; GOMEZ, N; MOJARRIETA, MS; VARA, JAC; PORTALES, JMR; HERNANDEZ, GR; GINALY, SM; GARCIA, PP; GARCIA, M; HERNANDEZ, CS; DIAZ, EI; RECIO, EM; GARCIA, SH; SANCHEZ, AL; VALDES, P; RODRIGUEZ, OM; OLIVA, NB; DIAZ, D; PEREZ, MC; HERNANDEZ, MCR; GONEZ, JMR; AMADO, SN; DELLLANO, AC; BREIJO, DH; ACOSTA, AC; GONZALEZ, MM; ROMERO, RM; CHAVEZ, OC; VALDES, MH; OTERO, GR; CABALLERO, MM; VALDES, AG; OLIVERA, BR; BENITEZ, EE; BEADE, C; LEON, LS; MARIMON, FD; ROMAN, AS; RODRIGUEZ, R; RODRIGUEZ, FD; ALVAREZ, MR; COLUMBE, MS; MARRERO, A; ZULUETA, D; GARCIA, CR; SANTOS, JPA; PEDROSO, F; RODRIGUEZ, HM; VALDES, NM; ACOSTA, MS; CHOBEL, ER; GODOY, MM; LUGO, MM; LOPEZ, LL; DIAZ, EM; MARTINEZ, JCB; DELGADO, NA; VALDES, MT; MORENO, ARD; SANCHEZ, SH; HERNANDEZ, LEP; VALDES, OM; MARTINEZ, AO; DOMINGUEZ, I; DEARMAS, MR; IGLESIAS, OR; CASTELL, OR; TRUJILLO, OG; BEUNE, MDM; RODRIGUEZ, FM; MEDINA, RM; RUIZCALDERON, JC; FERNANDEZ, B; BARROSO, EV; MACHIN, JL; ARMENTEROS, LR; MENDEZ, CV; PEREZ, JH; CAMPOS, AC; DIAZ, NA; PEREZ, AO; MILIAN, J; LEON, OH; CAPOTE, BR; LEZCANOS, MR; EZMORIZ, LP; MOYA, O; VITRIAGO, A; MURGUIA, AU			EPIDEMIC OPTIC NEUROPATHY IN CUBA - CLINICAL CHARACTERIZATION AND RISK-FACTORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMBLYOPIA	Background. From 1991 to 1993, epidemic optic and peripheral neuropathy affected more than 50,000 people in Cuba. The number of new cases decreased after the initiation of vitamin supplementation in the population. In September 1993, Cuban and U.S. investigators conducted a study to characterize and identify risk factors for the optic form of the syndrome. Methods. We conducted ophthalmologic and neurologic examinations, assessed exposure to potential toxins, administered a semiquantitative food-frequency questionnaire, and assessed serum measures of nutritional status in 123 patients with severe optic neuropathy, matched for sex and age to randomly chosen normal subjects. Results. In the case patients, prominent clinical features were subacute loss of visual acuity with field defects, diminished color vision, optic-nerve pallor, and decreased sensitivity to vibration and temperature in the legs. Tobacco use, particularly cigar smoking, was associated with an increased risk of optic neuropathy. The risk was reduced among subjects with higher dietary intakes of methionine, vitamin B-12, riboflavin, and niacin and higher serum concentrations of antioxidant carotenoids, The risk was also reduced among subjects who raised chickens at home or had relatives living overseas - factors that may be indirect measures of increased food availability. Conclusions. The epidemic of optic and peripheral neuropathy in Cuba between 1991 and 1993 appears to be linked to reduced nutrient intake caused by the country's deteriorating economic situation and the high prevalence of tobacco use.	CTR DIS CONTROL & PREVENT, ATLANTA, GA 30341 USA; EMORY UNIV, ATLANTA, GA 30322 USA; MINIST PUBL HLTH CUBA, HAVANA, CUBA; PAN AMER HLTH ORG, WASHINGTON, DC USA; NIH, BETHESDA, MD 20892 USA; US FDA, ROCKVILLE, MD 20857 USA	Centers for Disease Control & Prevention - USA; Emory University; Pan American Health Organization; National Institutes of Health (NIH) - USA; US Food & Drug Administration (FDA)			Needham, Larry/E-4930-2011; Hernandez-Triana, Manuel T/B-4513-2015; Newman, Nancy/AAB-2532-2021	Hernandez-Triana, Manuel T/0000-0002-2752-2592; Santos Hernandez, Carmen/0000-0002-8433-554X				BOVE FJ, 1989, J OCCUP ENVIRON MED, V31, P320; Breslow NE, 1980, IARC SCI PUBL, V32, P248; BROWN CC, 1994, AM J EPIDEMIOL, V139, P323, DOI 10.1093/oxfordjournals.aje.a117000; Costagliola C, 1990, Metab Pediatr Syst Ophthalmol (1985), V13, P96; DANG CV, 1981, MED HYPOTHESES, V7, P1317, DOI 10.1016/0306-9877(81)90122-5; DI MASCIO P, 1989, ARCH BIOCHEM BIOPHYS, V274, P532, DOI 10.1016/0003-9861(89)90467-0; DIXON ZR, 1994, FREE RADICAL BIO MED, V17, P537, DOI 10.1016/0891-5849(94)90093-0; Gay John, 1994, Boletin de la Oficina Sanitaria Panamericana, V117, P389; GERR F, 1990, ARCH ENVIRON HEALTH, V45, P148, DOI 10.1080/00039896.1990.9936708; Hernandez Teresa, 1995, Natural Toxins, V3, P114, DOI 10.1002/nt.2620030210; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KNOX DL, 1982, RETINA-J RET VIT DIS, V2, P288, DOI 10.1097/00006982-198202040-00014; LANNAN S, 1994, AM J PHYSIOL, V266, pL92, DOI 10.1152/ajplung.1994.266.1.L92; LESSELL S, 1971, ARCH OPHTHALMOL-CHIC, V86, P194; LETZ R, 1994, NEUROTOXICOLOGY, V15, P603; LINCOFF NS, 1994, JAMA-J AM MED ASSOC, V271, P664; LINCOFF NS, 1993, JAMA-J AM MED ASSOC, V270, P511, DOI 10.1001/jama.270.4.511; MADAN D, 1898, CRONICA MED QUIRURGI, V24, P81; MATHIOWETZ V, 1985, ARCH PHYS MED REHAB, V66, P69; McCormick DB., 1994, MODERN NUTR HLTH DIS, P366; MILLER NR, 1982, WALSH HOYTS CLIN NEU, P289; NEWMAN NJ, 1993, ARCH NEUROL-CHICAGO, V50, P540, DOI 10.1001/archneur.1993.00540050082021; NEWMAN NJ, 1994, AM J OPHTHALMOL, V118, P158, DOI 10.1016/S0002-9394(14)72895-8; PASCHAL DC, 1986, ATOM SPECTROSC, V7, P75; Pennington JA, 1994, BOWES CHURCHS FOOD V; RIZZO JF, 1993, AM J OPHTHALMOL, V116, P84, DOI 10.1016/S0002-9394(14)71749-0; RODRIGUEZ A, 1992, NUTRISIS VERSIION 4; Schaumburg H. H., 1992, DISORDERS PERIPHERAL; SOWELL AL, 1994, CLIN CHEM, V40, P411; SPILLANE JD, 1947, NUTRITIONAL DISORDER; TOPPING MD, 1986, CLIN CHEM, V32, P1863; TORRONI A, 1995, HUM MUTAT, V5, P310, DOI 10.1002/humu.1380050407; WALL M, 1986, ARCH OPHTHALMOL-CHIC, V104, P520, DOI 10.1001/archopht.1986.01050160076015; WILLETT W, 1990, MONOGRAPHS EPIDEMIOL, V15, P245; 1984, B WORLD HEALTH ORGAN, V62, P477; 1993, EPIDEMIC NEUROPATHY; 1994, MMWR-MORBID MORTAL W, V43, P183; 1986, AGR HDB SERIES DEP A, V8	38	113	116	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 2	1995	333	18					1176	1182						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB560	7565972				2022-12-28	WOS:A1995TB56000003
J	SANDLER, RS; NYREN, O; EKBOM, A; EISEN, GM; YUEN, J; JOSEFSSON, S				SANDLER, RS; NYREN, O; EKBOM, A; EISEN, GM; YUEN, J; JOSEFSSON, S			THE RISK OF ESOPHAGEAL CANCER IN PATIENTS WITH ACHALASIA - A POPULATION-BASED STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARCINOMA	Objective.-To determine more precise and accurate cancer risk estimates for achalasia that could be used to plan surveillance. Design.-Cohort. Setting.-Swedish population. Participants.--All patients with achalasia listed in the population-based Swedish Inpatient Register from 1964 through 1989. Main Outcome Measures.-The observed number of cancers in the cohort was compared with expected numbers of cancers (standardized incidence ratio [SIR]) for each 5-year age group and calendar year of observation, calculated using data from the Swedish Cancer Registry. Results.-A total of 1062 patients with achalasia accumulated 9864 years of follow-up. The mean age at entry was 57.2 years, and the mean age at cancer diagnosis was 71.0 years. Esophageal cancer occurred in 24 patients, The risk of esophageal cancer in the first year after achalasia diagnosis was extremely high (SIR, 126.3; 95% confidence interval [CI], 63.0 to 226.1) as a consequence of prevalent cancers leading to distal esophageal obstruction simulating achalasia. During years 1 to 24, the risk was increased more than 16-fold (SIR, 16.6; 95% CI, 8.8 to 28.3). Annual surveillance after the first year would require 406 endoscopic examinations in men and 2220 in women to detect one cancer. Conclusions.-Patients with achalasia are at markedly increased risk of developing esophageal cancer. A substantial number of surveillance examinations might be required to screen for cancers, especially in women. It is not known whether surveillance will result in improved survival.	UNIV N CAROLINA,CTR GASTROINTESTINAL BIOL & DIS,CHAPEL HILL,NC 27599; UPPSALA UNIV,DEPT EPIDEMIOL,UPPSALA,SWEDEN; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	University of North Carolina; University of North Carolina Chapel Hill; Uppsala University; Harvard University; Harvard T.H. Chan School of Public Health	SANDLER, RS (corresponding author), UNIV N CAROLINA,DEPT MED,DIV DIGEST DIS & NUTR,CB 7080,423A BURNETT WOMACK BLDG,CHAPEL HILL,NC 27599, USA.		Yuen, Jonathan/AAI-2035-2021	Yuen, Jonathan/0000-0003-2944-9226	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP085636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007634, P30DK034987] Funding Source: NIH RePORTER; NCI NIH HHS [CP85636] Funding Source: Medline; NIDDK NIH HHS [T32 DK 07634, P30 DK34987] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGGESTRUP S, 1992, CHEST, V102, P1013, DOI 10.1378/chest.102.4.1013; Bolivar J C, 1970, Ann Thorac Surg, V10, P81; CAMARALOPES LH, 1981, AM J DIG DIS, V6, P742; CARTER R, 1975, AM J SURG, V130, P114, DOI 10.1016/0002-9610(75)90358-X; CHUONG JJH, 1984, DIGEST DIS SCI, V29, P1105, DOI 10.1007/BF01317084; CODINI RT, 1981, PRACTICAL GASTRO NOV, P6; DENT TL, 1989, SURG CLIN N AM, V69, P1205; FAGGE CH, 1872, GUYS HOSP REP, V17, P43; FRANK MS, 1979, AM J GASTROENTEROL, V71, P206; HANKINS JR, 1975, J THORAC CARDIOV SUR, V69, P355; HEISS FW, 1984, DIGEST DIS SCI, V29, P1066, DOI 10.1007/BF01311263; JUSTVIERA JO, 1976, SURG GYNECOL OBSTET, V128, P1081; LORTATJA.JL, 1969, SURGERY, V66, P969; LUNDE AS, 1985, DHHS PHS801358 PUBL; MEIJSSEN MAC, 1992, GUT, V33, P155, DOI 10.1136/gut.33.2.155; NAESSEN T, 1989, AM J EPIDEMIOL, V130, P289, DOI 10.1093/oxfordjournals.aje.a115335; PERACCHIA A, 1991, HEPATO-GASTROENTEROL, V38, P514; PIERCE WS, 1970, J THORAC CARDIOV SUR, V59, P335, DOI 10.1016/S0022-5223(19)42467-7; SELIGER G, 1972, AM J GASTROENTEROL, V57, P20; SONNENBERG A, 1993, DIGEST DIS SCI, V38, P233, DOI 10.1007/BF01307540; TUCKER HJ, 1978, ANN INTERN MED, V89, P315, DOI 10.7326/0003-4819-89-3-315; WYCHULIS AR, 1971, J AMER MED ASSOC, V215, P1638, DOI 10.1001/jama.215.10.1638; 1965, CAUSES DEATH SWEDEN; 1988, GASTROINTEST ENDOS S, V34, pS18; 1960, 1960 1988 SWED BOARD; 1991, PATIENT REGISTER INP, P20	26	114	119	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	1995	274	17					1359	1362		10.1001/jama.274.17.1359	http://dx.doi.org/10.1001/jama.274.17.1359			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB278	7563560				2022-12-28	WOS:A1995TB27800026
J	DOBSON, S; SCHEIFELE, D; BELL, A				DOBSON, S; SCHEIFELE, D; BELL, A			ASSESSMENT OF A UNIVERSAL, SCHOOL-BASED HEPATITIS-B VACCINATION PROGRAM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To assess a hepatitis B vaccination program offered to all grade 6 students in British Columbia in 1992. Design.-Cohort study. Setting.-British Columbia, Canada. Participants.-All grade 6 students were offered vaccine. Subsets of 454 and 259 students participated in studies of minor adverse events and seroresponse, respectively. Intervention.-The vaccine used was Engerix-B, 20 mu g, given at intervals of 0, 1, and 6 months. Main Outcome Measures.-Province-wide acceptance and series completion rates and reports of severe adverse events. Minor adverse events and immunogenicity in subsamples. Results.-A total of 127 922 vaccine doses were administered. initial enrollment totaled 43 358 students or 95.4% of those eligible. The series was completed by 41 594 students (95.6%). Minor adverse events were infrequent in the cohort assessed: no absenteeism or physician visits resulted from vaccination. Sixty-nine reported severe adverse events met surveillance definitions, the major categories being injection site reactions (23% of reports), fainting (20%), and rashes (17%). There was one instance of anaphylaxis. Only 13 of these events resulted in recommendations to discontinue the series. Of students tested following the series, 98% had levels of antibody to hepatitis B surface antigen considered to be protective (greater than or equal to 10 IU/L), the geometric mean titer being 690 IU/L (95% confidence interval, 498 to 957 IU/J). Conclusion.-Our experience indicates that school-based programs for universal vaccination of preadolescents can be highly acceptable and efficient.	BRITISH COLUMBIA CTR DIS CONTROL, DIV EPIDEMIOL, VANCOUVER, BC, CANADA		DOBSON, S (corresponding author), BRITISH COLUMBIA CHILDRENS HOSP, CTR VACCINE EVALUAT, 4500 OAK ST, ROOM L427, VANCOUVER, BC V5Z 4H4, CANADA.			Scheifele, David/0000-0001-6078-7843				ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; ANDRE FE, 1989, AM J MED, V87, pS14, DOI 10.1016/0002-9343(89)90525-1; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; DELAGE G, 1992, CAN FAM PHYSICIAN, V38, P2656; HALL CB, 1992, PEDIATRICS, V89, P795; HUTTON F, 1993, BC HLTH DIS SURVEILL, V2, P2; SCHIFF GM, 1995, J ADOLESCENT HEALTH, V16, P12, DOI 10.1016/1054-139X(94)00105-N; WEST DJ, 1989, AM J INFECT CONTROL, V17, P172, DOI 10.1016/0196-6553(89)90213-7; WONG VK, 1994, PEDIATR INFECT DIS J, V13, P936, DOI 10.1097/00006454-199410000-00019; 1995, INFECT DIS CHILD, V8, P14; 1994, MMWR-MORBID MORTAL W, V43, P605; 1991, CAN DIS WKLY REP, V17, P165; 1992, CAN MED ASSOC J, V146, P25; 1994, CAN COMMUN DIS REP, V20, P105	14	69	69	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	1995	274	15					1209	1213		10.1001/jama.274.15.1209	http://dx.doi.org/10.1001/jama.274.15.1209			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ120	7563510				2022-12-28	WOS:A1995RZ12000029
J	MIRVIS, DM; CHANG, CF; HALL, CJ; ZAAR, GT; APPLEGATE, WB				MIRVIS, DM; CHANG, CF; HALL, CJ; ZAAR, GT; APPLEGATE, WB			TENNCARE - HEALTH SYSTEM REFORM FOR TENNESSEE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAID; SERVICES; ACCESS	TennCare, the health care system reform plan implemented in Tennessee on January 1, 1994, was developed with the dual objectives of controlling the rapidly rising cost of the state's Medicaid program and extending health insurance coverage to most Tennesseans without access to employer-sponsored or other government-sponsored health insurance. Beneficiaries enroll in competing, state-chartered managed care organizations that are responsible for providing broad preventive, inpatient, and outpatient services and are reimbursed by the state on a capitation basis at a rate based on a statewide global budget for health care. The program initially proposed to enroll up to 1 775 000 citizens and was projected to result in a cumulative cost savings to Tennessee and the federal government of $7.2 billion by the end of the 5-year demonstration period. However, major start-up problems encountered by the state and by managed care organizations and limitations imposed by the government have significantly constrained these expectations. At the end of its first year, more than 1.2 million citizens were enrolled, but the program incurred a $99 million deficit. Managed care organizations and hospitals have reported major financial problems, and constituency groups-especially those representing physicians-have attempted to block the program. Our objective is to describe the design and rationale of TennCare and discuss key issues the plan continues to face that may affect its long-term success.	UNIV TENNESSEE,DEPT MED,MEMPHIS,TN 38163; MEMPHIS STATE UNIV,FOGELMAN COLL BUSINESS & ECON,DEPT ECON,MEMPHIS,TN 38152	University of Tennessee System; University of Tennessee Health Science Center; University of Memphis	MIRVIS, DM (corresponding author), UNIV TENNESSEE,DEPT PREVENT MED,956 COURT AVE,ROOM F208,MEMPHIS,TN 38163, USA.							BLENDON RJ, 1993, HEALTH AFFAIR, V12, P132, DOI 10.1377/hlthaff.12.1.132; CROMWELL J, 1995, HEALTH CARE FINANC R, V16, P75; FLEMING GV, 1986, MED CARE, V24, P565, DOI 10.1097/00005650-198607000-00001; Freund D A, 1989, Health Care Financ Rev, V11, P81; HURLEY RE, 1993, MANAGED CARE MEDICAI; IGLEHART JK, 1994, NEW ENGL J MED, V330, P75, DOI 10.1056/NEJM199401063300128; KIRKMANLIFF BL, 1987, HEALTH AFFAIR, V6, P46, DOI 10.1377/hlthaff.6.4.46; LONG SH, 1986, J HEALTH ECON, V5, P235, DOI 10.1016/0167-6296(86)90016-0; MCCALL N, 1994, HEALTH AFFAIR, V13, P234, DOI 10.1377/hlthaff.13.2.234; MCWHERTER N, 1993, TENNCARE NEW DIRECTI; SILVERMAN HA, 1993, MEDICAID RECIPIENTS; ZWANZIGER J, 1991, MED CARE, V29, P142, DOI 10.1097/00005650-199102000-00006; 1994, 1993 US BUR CENS STA; 1994, MANAGED CARE DIGEST; 1994, EFFECTS FORMULARY RE; 1993, ASSESSING DESIGN IMP; 1995, MEDICAID SPENDING PR	17	74	74	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	1995	274	15					1235	1241		10.1001/jama.274.15.1235	http://dx.doi.org/10.1001/jama.274.15.1235			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ120	7563515				2022-12-28	WOS:A1995RZ12000034
J	MACKNESS, MI; DURRINGTON, PN				MACKNESS, MI; DURRINGTON, PN			PARAOXONASE - ANOTHER FACTOR IN NIDDM CARDIOVASCULAR-DISEASE	LANCET			English	Editorial Material							LOW-DENSITY-LIPOPROTEIN				MACKNESS, MI (corresponding author), UNIV MANCHESTER,MANCHESTER ROYAL INFIRM,DEPT MED,MANCHESTER M13 9WL,LANCS,ENGLAND.							MACKNESS MI, 1989, BIOCHEM PHARMACOL, V38, P385, DOI 10.1016/0006-2952(89)90376-6; MACKNESS MI, 1995, ATHEROSCLEROSIS, V115, P243, DOI 10.1016/0021-9150(94)05524-M; MACKNESS MI, 1993, BIOCHEM J, V294, P829, DOI 10.1042/bj2940829; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; URIEL J, 1961, ANN I PASTEUR PARIS, V101, P104; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499	6	19	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 30	1995	346	8979					856	856		10.1016/S0140-6736(95)92702-6	http://dx.doi.org/10.1016/S0140-6736(95)92702-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX196	7564664				2022-12-28	WOS:A1995RX19600002
J	RAEBURN, JA				RAEBURN, JA			PREIMPLANTATION DIAGNOSIS RAISES A PHILOSOPHICAL DILEMMA - COMMENTARY	BRITISH MEDICAL JOURNAL			English	Note											RAEBURN, JA (corresponding author), CITY HOSP,CTR MED GENET,NOTTINGHAM NG5 1PB,ENGLAND.							CUI KH, 1995, BRIT MED J, V311, P536, DOI 10.1136/bmj.311.7004.536	1	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					540	540		10.1136/bmj.311.7004.540	http://dx.doi.org/10.1136/bmj.311.7004.540			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR737	7545044	Green Published			2022-12-28	WOS:A1995RR73700018
J	RICKERT, RC; RAJEWSKY, K; ROES, J				RICKERT, RC; RAJEWSKY, K; ROES, J			IMPAIRMENT OF T-CELL-DEPENDENT B-CELL RESPONSES AND B-1 CELL-DEVELOPMENT IN CD19-DEFICIENT MICE	NATURE			English	Article							COMPLEMENT RECEPTOR TYPE-2; HUMAN LYMPHOCYTES-B; ANTIGEN RECEPTOR; IMMUNE-RESPONSE; ANTIBODY; INVIVO; CD19; LIGANDS; GROWTH; IGM	CD19 is the hallmark differentiation antigen of the B lineage. Its early expression has implicated a role for CD19 during the antigen-independent phases of B-cell development, whereas in mature B cells CD19 can act synergistically with surface immunoglobulin to induce activation(1). We have generated CD19-deficient mice and found that development of conventional B cells is unperturbed. However, mature CD19(-/-) B cells show a profound deficiency in responding to protein antigens that require T-cell help. This is accompanied by a lack of germinal centre formation and affinity maturation of serum antibodies. Thus CD19 is crucial for both initial B-cell activation by T-cell-dependent antigens and the maturation and/or selection of the activated cells into the memory compartment. An impairment in ligand-driven selection may also be responsible for the observation of a striking reduction in the B-1 (formerly Ly-1) B-cell subset, thought to develop under the control of self-antigens and bacterial antigens (reviewed in ref. 2).			RICKERT, RC (corresponding author), UNIV COLOGNE,INST GENET,WEYERTAL 121,D-50931 COLOGNE,GERMANY.			Rajewsky, Klaus/0000-0002-6633-6370; Roes, Jurgen/0000-0003-3235-2345				BOHNSACK JF, 1988, J IMMUNOL, V141, P2569; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CARTER RH, 1988, J IMMUNOL, V141, P457; CARTER RH, 1989, J IMMUNOL, V143, P1755; CUMANO A, 1986, EMBO J, P2459; FEARON DT, 1993, CURR OPIN IMMUNOL, V5, P341, DOI 10.1016/0952-7915(93)90051-S; FORSTER I, 1987, EUR J IMMUNOL, V17, P521, DOI 10.1002/eji.1830170414; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HARDY RR, 1994, ADV IMMUNOL, V55, P297; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; HEYMAN B, 1990, J EXP MED, V172, P665, DOI 10.1084/jem.172.2.665; HEYMAN B, 1994, NEW ASPECTS COMPLEME, P59; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; LIU Y, 1991, INT IMMUNOL, V3, P323, DOI 10.1093/intimm/3.4.323; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; MCHEYZERWILLIAM.MG, 1993, J EXP MED, V178, P295; MELCHERS F, 1985, NATURE, V317, P264, DOI 10.1038/317264a0; MERCOLINO TJ, 1988, J EXP MED, V168, P687, DOI 10.1084/jem.168.2.687; RETH M, 1978, EUR J IMMUNOL, V8, P393, DOI 10.1002/eji.1830080605; ROES J, 1993, J EXP MED, V177, P45, DOI 10.1084/jem.177.1.45; TEDDER TE, 1994, IMMUNOL TODAY, V15, P437, DOI 10.1016/0167-5699(94)90274-7; THYPHRONITIS G, 1991, J IMMUNOL, V147, P224; TORRES R, IN PRESS COLOGNE GUI; TSOKOS GC, 1990, J IMMUNOL, V144, P1640; VANNOESEL CJM, 1993, IMMUNOL TODAY, V14, P8, DOI 10.1016/0167-5699(93)90316-D; WELLS SM, 1994, J IMMUNOL, V153, P5503; ZHOU LJ, 1992, IMMUNOGENETICS, V35, P102, DOI 10.1007/BF00189519	29	573	590	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					352	355		10.1038/376352a0	http://dx.doi.org/10.1038/376352a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7543183				2022-12-28	WOS:A1995RL44300050
J	SCOTT, WG; FINCH, JT; KLUG, A				SCOTT, WG; FINCH, JT; KLUG, A			THE CRYSTAL-STRUCTURE OF AN ALL-RNA HAMMERHEAD RIBOZYME - A PROPOSED MECHANISM FOR RNA CATALYTIC CLEAVAGE	CELL			English	Article							PHENYLALANINE TRANSFER-RNA; RESOLUTION; OLIGORIBONUCLEOTIDES; PHOSPHOROTHIOATE; BINDING; DNA	We have solved the crystal structure of an all-RNA hammerhead ribozyme having a single 2'-O-methyl cytosine incorporated at the active site to prevent cleavage. The conditions used differ from those in another recent solution in four significant ways: first, it is an all-RNA ribozyme rather than a DNA-RNA hybrid; second, the connectivity of the ribozyme backbone strands is different; third, the crystals were grown in the presence of a much lower concentration of salt; and fourth, the crystal packing scheme is very different. Nevertheless, the three-dimensional structure of the all-RNA hammerhead ribozyme is similar to the previous structure. Five potential Mg(II)-binding sites are Identified, including one positioned near the ribozyme catalytic pocket. Upon this basis, as well as upon comparisons with the metal-binding sites in the structurally homologous uridine turn of tRNA(Phe), We propose a mechanism for RNA catalytic cleavage.			SCOTT, WG (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.			Scott, William/0000-0002-9273-3564				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARINAGA M, 1993, SCIENCE, V262, P1512, DOI 10.1126/science.8248799; BROWN RS, 1983, NATURE, V303, P543, DOI 10.1038/303543a0; BROWN RS, 1985, BIOCHEMISTRY-US, V24, P4785, DOI 10.1021/bi00339a012; BUGG CE, 1971, BIOPOLYMERS, V10, P175, DOI 10.1002/bip.360100113; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; DAHM SC, 1993, BIOCHEMISTRY-US, V32, P13040, DOI 10.1021/bi00211a013; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; DAHM SC, 1990, BIOCHIMIE, V72, P819, DOI 10.1016/0300-9084(90)90191-I; GAIT MJ, 1991, OLIGONUCLEOTIDES ANA, P25; Gesteland RF., 1993, RNA WORLD NATURE MOD; GOPALAN V, 1994, RNA PROTEIN INTERACT, P103; HOLBROOK SR, 1977, NUCLEIC ACIDS RES, V4, P2811, DOI 10.1093/nar/4.8.2811; JACK A, 1977, J MOL BIOL, V111, P315, DOI 10.1016/S0022-2836(77)80054-5; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P5145, DOI 10.1021/bi00235a005; MURRAY JB, 1995, IN PRESS BIOCH J; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCOTT WG, 1995, IN PRESS J MOL BIOL; SHELDRICK GM, 1991, P CCP4 STUDY WEEKEND, P23; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; TAIRA K, 1990, PROTEIN ENG, V3, P691, DOI 10.1093/protein/3.8.691; THOMAS KA, 1982, P NATL ACAD SCI-BIOL, V79, P4843, DOI 10.1073/pnas.79.16.4843; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; VANTOL H, 1990, NUCLEIC ACIDS RES, V18, P1971, DOI 10.1093/nar/18.8.1971; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0; WANG BC, 1985, METHOD ENZYMOL, V115, P90	36	691	732	1	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 30	1995	81	7					991	1002		10.1016/S0092-8674(05)80004-2	http://dx.doi.org/10.1016/S0092-8674(05)80004-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7541315	Bronze, Green Published			2022-12-28	WOS:A1995RG91000004
J	KANNO, K; SASAKI, S; HIRATA, Y; ISHIKAWA, S; FUSHIMI, K; NAKANISHI, S; BICHET, DG; MARUMO, F				KANNO, K; SASAKI, S; HIRATA, Y; ISHIKAWA, S; FUSHIMI, K; NAKANISHI, S; BICHET, DG; MARUMO, F			URINARY-EXCRETION OF AQUAPORIN-2 IN PATIENTS WITH DIABETES-INSIPIDUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							KIDNEY COLLECTING TUBULE; WATER CHANNEL; RECEPTOR GENE; RAT-KIDNEY; VASOPRESSIN; MUTATIONS; CELLS; PERMEABILITY; ENDOSOMES	Background. Urine-concentrating ability is regulated by vasopressin. Recently, the specific water-channel protein of the renal collecting duct, known as aquaporin-2, was cloned. However, it is not certain whether this molecule is responsive to vasopressin. Methods. We measured the urinary excretion of aquaporin-2 and its response to vasopressin in 11 normal subjects and 9 patients with central or nephrogenic diabetes insipidus. The urine samples were collected during periods of dehydration and hydration and after the administration of vasopressin. Urine samples were analyzed for aquaporin-2 by the Western blot assay and immunogold labeling, and the amount of aquaporin-2 was determined by radioimmunoassay. Results. Aquaporin-2 was detectable in the urine in both soluble and membrane-bound forms. In the five normal subjects tested, the mean (+/-SE) urinary excretion of aquaporin-2 was 11.2+/-2.2 pmol per milligram of creatinine after a period of dehydration, and it decreased to 3.9+/-1.9 pmol per milligram of creatinine (P=0.03) during the second hour after a period of hydration. In the six other normal subjects, an infusion of desmopressin (1-desamino-8-D-arginine vasopressin) increased the urinary excretion of aquaporin-2 from 0.8+/-0.3 to 11.2+/-1.6 pmol per milligram of creatinine (P<0.001). The five patients with central diabetes insipidus also had increases in urinary excretion of aquaporin-2 in response to the administration of vasopressin, but the four patients with X-linked or non-X-linked nephrogenic diabetes insipidus did not. Conclusions. Aquaporin-2 is detectable in the urine, and changes in the urinary excretion of this protein can be used as an index of the action of vasopressin on the kidney.	TOKYO MED & DENT UNIV,SCH MED,DEPT INTERNAL MED 2,BUNKYO KU,TOKYO 113,JAPAN; JICHI MED SCH,DEPT ENDOCRINOL & METAB,MINAMI KAWACHI,TOCHIGI,JAPAN; JT INC,CENT PHARMACEUT RES INST,PHARMACEUT BASIC RES LABS,KANAGAWA,JAPAN; UNIV MONTREAL,HOP SACRE COEUR,CTR RECH,MONTREAL,PQ,CANADA	Tokyo Medical & Dental University (TMDU); Jichi Medical University; Universite de Montreal			Nakanishi, Setsuko/G-5871-2015	Nakanishi, Setsuko/0000-0003-4909-2113				AGRE P, 1993, AM J PHYSIOL, V265, pF463; AGRE P, 1993, AM J PHYSIOL, V265, pF461, DOI 10.1152/ajprenal.1993.265.3.F461; BICHET DG, 1993, J CLIN INVEST, V92, P1262, DOI 10.1172/JCI116698; BICHET DG, 1988, NEW ENGL J MED, V318, P881, DOI 10.1056/NEJM198804073181403; BROWN D, 1989, AM J PHYSIOL, V256, pF1, DOI 10.1152/ajprenal.1989.256.1.F1; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; DIGIOVANNI SR, 1994, P NATL ACAD SCI USA, V91, P8984, DOI 10.1073/pnas.91.19.8984; FUSHIMI K, 1994, AM J PHYSIOL-RENAL, V267, pF573, DOI 10.1152/ajprenal.1994.267.4.F573; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HANDLER JS, 1988, AM J PHYSIOL, V255, pF375, DOI 10.1152/ajprenal.1988.255.3.F375; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; HAYASHI M, 1994, J CLIN INVEST, V94, P1778, DOI 10.1172/JCI117525; HIRATA Y, 1988, BIOCHEM BIOPH RES CO, V154, P868, DOI 10.1016/0006-291X(88)90220-3; LANGLEY JM, 1991, AM J MED GENET, V38, P90, DOI 10.1002/ajmg.1320380120; Lonergan Michele, 1993, Journal of the American Society of Nephrology, V4, P264; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; PAN Y, 1992, NAT GENET, V2, P103, DOI 10.1038/ng1092-103; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; ROSENTHAL W, 1992, NATURE, V359, P233, DOI 10.1038/359233a0; SASAKI S, 1994, J CLIN INVEST, V93, P1250, DOI 10.1172/JCI117079; SASAKI S, 1994, J CLIN INVEST, V94, P216; SHI LB, 1990, J GEN PHYSIOL, V96, P789, DOI 10.1085/jgp.96.4.789; UCHIDA S, 1994, J BIOL CHEM, V269, P23451; VANDENOUWELAND AMW, 1992, NAT GENET, V2, P99, DOI 10.1038/ng1092-99; VANLIEBURG AF, 1994, AM J HUM GENET, V55, P648; VERKMAN AS, 1989, AM J PHYSIOL, V257, pC837, DOI 10.1152/ajpcell.1989.257.5.C837; VERKMAN AS, 1988, NATURE, V333, P268, DOI 10.1038/333268a0; Wade J B, 1981, Ann N Y Acad Sci, V372, P106, DOI 10.1111/j.1749-6632.1981.tb15464.x	29	237	244	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 8	1995	332	23					1540	1545		10.1056/NEJM199506083322303	http://dx.doi.org/10.1056/NEJM199506083322303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB196	7537863	Bronze			2022-12-28	WOS:A1995RB19600003
J	IZAURRALDE, E; MATTAJ, IW				IZAURRALDE, E; MATTAJ, IW			RNA EXPORT	CELL			English	Review							PRE-MESSENGER-RNA; NUCLEAR TRANSPORT; NUCLEOCYTOPLASMIC TRANSPORT; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEINS; CYTOPLASM; MUTANT; TRANSLOCATION; INITIATION; PRP20				IZAURRALDE, E (corresponding author), EUROPEAN MOLEC BIOL LAB, MEYERHOFSTR 1, D-69117 HEIDELBERG, GERMANY.		Izaurralde, Elisa/G-3239-2012	Mattaj, Iain/0000-0002-5537-8284; Izaurralde, Elisa/0000-0001-7365-2649				AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; CULLEN BR, 1991, TRENDS BIOCHEM SCI, V16, P346, DOI 10.1016/0968-0004(91)90141-H; DELEON DV, 1983, DEV BIOL, V100, P197, DOI 10.1016/0012-1606(83)90211-7; DEVEGVAR HEN, 1990, MOL CELL BIOL, V10, P3365, DOI 10.1128/MCB.10.7.3365; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; FABRE E, 1994, CELL, V78, P275, DOI 10.1016/0092-8674(94)90297-6; FEATHERSTONE C, 1988, J CELL BIOL, V107, P1289, DOI 10.1083/jcb.107.4.1289; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; FLACH J, 1994, MOL CELL BIOL, V14, P8399, DOI 10.1128/MCB.14.12.8399; FORRESTER W, 1992, GENE DEV, V6, P1914, DOI 10.1101/gad.6.10.1914; FORTES P, 1994, EMBO J, V13, P704, DOI 10.1002/j.1460-2075.1994.tb06310.x; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORSCH LC, 1995, IN PRESS J CELL BIOL; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HE XP, 1994, J CELL SCI, V107, P903; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KADOWAKI T, 1992, P NATL ACAD SCI USA, V89, P2312, DOI 10.1073/pnas.89.6.2312; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; KADOWAKI T, 1994, MOL BIOL CELL, V5, P1253, DOI 10.1091/mbc.5.11.1253; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436; Krug RM, 1993, CURR OPIN CELL BIOL, V5, P944, DOI 10.1016/0955-0674(93)90074-Z; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LI O, 1995, IN PRESS MOL CELL BI; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; Mehlin Hans, 1993, Trends in Cell Biology, V3, P443, DOI 10.1016/0962-8924(93)90034-X; MELCHIOR F, 1993, MOL BIOL CELL, V4, P569, DOI 10.1091/mbc.4.6.569; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Pinol-Roma Serafin, 1993, Trends in Cell Biology, V3, P151, DOI 10.1016/0962-8924(93)90135-N; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; ROSBASH M, 1993, CELL, V75, P399, DOI 10.1016/0092-8674(93)90373-X; RUSSELL I, 1995, EUR J CELL BIOL, V66, P293; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SCHRODER HC, 1987, PROG NUCLEIC ACID RE, V34, P89, DOI 10.1016/S0079-6603(08)60494-8; SHIOKAWA K, 1974, P NATL ACAD SCI USA, V71, P2658, DOI 10.1073/pnas.71.7.2658; SHOWMAN RM, 1982, P NATL ACAD SCI-BIOL, V79, P5944, DOI 10.1073/pnas.79.19.5944; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; SINGLETON DR, 1995, IN PRESS J CELL SCI, V108; STJOHNSTON D, 1995, STUT, V81, P161; STUTZ F, 1994, EMBO J, V13, P4096, DOI 10.1002/j.1460-2075.1994.tb06727.x; TERNS MP, 1994, SCIENCE, V264, P959, DOI 10.1126/science.8178154; TERNS MP, 1993, GENE DEV, V7, P1898, DOI 10.1101/gad.7.10.1898; TOBIAN JA, 1985, CELL, V43, P415, DOI 10.1016/0092-8674(85)90171-0; WENTE SR, 1993, J CELL BIOL, V123, P275, DOI 10.1083/jcb.123.2.275; WENTE SR, 1994, J CELL BIOL, V125, P955, DOI 10.1083/jcb.125.5.955; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; WILSON SM, 1994, J CELL BIOL, V127, P1173, DOI 10.1083/jcb.127.5.1173; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; ZASLOFF M, 1982, NATURE, V300, P81, DOI 10.1038/300081a0; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	66	213	218	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 21	1995	81	2					153	159		10.1016/0092-8674(95)90323-2	http://dx.doi.org/10.1016/0092-8674(95)90323-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7537634	Bronze			2022-12-28	WOS:A1995QV41000002
J	SPENCE, RA; KATI, WM; ANDERSON, KS; JOHNSON, KA				SPENCE, RA; KATI, WM; ANDERSON, KS; JOHNSON, KA			MECHANISM OF INHIBITION OF HIV-1 REVERSE-TRANSCRIPTASE BY NONNUCLEOSIDE INHIBITORS	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PYRIDINONE DERIVATIVES; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; KINETIC-ANALYSIS; ZIDOVUDINE AZT; BINDING-SITE; AIDS VIRUS; TYPE-1; DNA	The mechanism of inhibition of HIV-1 reverse transcriptase by three nonnucleoside inhibitors is described. Nevirapine, O-TIBO, and Cl-TIBO each bind to a hydrophobic pocket in the enzyme-DNA complex close to the active site catalytic residues. Pre-steady-state kinetic analysis was used to establish the mechanism of inhibition by these noncompetitive inhibitors. Analysis of the pre-steady-state burst of DNA polymerization indicated that inhibitors blocked the chemical reaction, but did not interfere with nucleotide binding or the nucleotide-induced conformational change. Rather, in the presence of saturating concentrations of the inhibitors, the nucleoside triphosphate bound tightly (K-d, 100 nM), but nonproductively. The data suggest that an inhibitor combining the functionalities of a nonnucleoside inhibitor and a nucleotide analog could bind very lightly and specifically to reverse transcriptase and could be effective in the treatment of AIDS.	PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, UNIVERSITY PK, PA 16802 USA; ABBOTT LABS, DEPT ANTIINFECT RES, ABBOTT PK, IL 60064 USA; YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06510 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Abbott Laboratories; Yale University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049551, R01GM044613] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM084741, GM49551, GM44613] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTHAUS IW, 1993, J BIOL CHEM, V268, P6119; ANDERSON KS, 1988, BIOCHEMISTRY-US, V27, P7395, DOI 10.1021/bi00419a034; BALZARINI J, 1993, VIROLOGY, V192, P246, DOI 10.1006/viro.1993.1027; CARROLL SS, 1993, J BIOL CHEM, V268, P276; COHEN KA, 1991, J BIOL CHEM, V266, P14670; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DECLERCQ E, 1994, BIOCHEM PHARMACOL, V47, P155, DOI 10.1016/0006-2952(94)90001-9; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; DUEWEKE TJ, 1993, P NATL ACAD SCI USA, V90, P4713, DOI 10.1073/pnas.90.10.4713; FRANK KB, 1991, J BIOL CHEM, V266, P14232; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; GOPALAKRISHNAN V, 1994, J BIOL CHEM, V269, P4110; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; JOHNSTON L, 1992, INT J SOCIOL LAW, V20, P1; KATI WM, 1992, J BIOL CHEM, V267, P25988; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1992, ANTIMICROB AGENTS CH, V36, P2664, DOI 10.1128/AAC.36.12.2664; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LOWE DM, 1991, FEBS LETT, V282, P231, DOI 10.1016/0014-5793(91)80484-K; MELLORS JW, 1992, MOL PHARMACOL, V41, P446; MELLORS JW, 1993, MOL PHARMACOL, V43, P11; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; MULLER B, 1989, J BIOL CHEM, V264, P13975; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RICHMAN D, 1991, ANTIMICROB AGENTS CH, V35, P305, DOI 10.1128/AAC.35.2.305; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; RITTINGER K, UNPUB; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; TAYLOR PB, 1994, J BIOL CHEM, V269, P6325; TRAMONTANO E, 1992, BIOCHEM PHARMACOL, V43, P1371; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106	47	426	445	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 17	1995	267	5200					988	993		10.1126/science.7532321	http://dx.doi.org/10.1126/science.7532321			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7532321	Green Accepted			2022-12-28	WOS:A1995QG99000028
J	GHOSH, G; VANDUYNE, G; GHOSH, S; SIGLER, PB				GHOSH, G; VANDUYNE, G; GHOSH, S; SIGLER, PB			STRUCTURE OF NF-KAPPA-B P50 HOMODIMER BOUND TO A KAPPA-B SITE	NATURE			English	Article							DNA-BINDING SUBUNIT; CRYSTAL-STRUCTURE; PROTEIN MODELS; COGNATE DNA; REL; INHIBITION; ACTIVATION; COMPLEX; ERRORS; MOTIF	The 2.3-Angstrom crystal structure of the transcription factor NF-kappa B p50 homodimer bound to a palindromic kappa B site reveals that the Rel homology region folds into two distinct domains, similar to those in the immunoglobulin superfamily. The p50 dimer envelopes an undistorted B-DNA helix, making specific contacts along the 10-base-pair kappa B recognition site mainly through loops connecting secondary structure elements in both domains. The carboxy-terminal domains form a dimerization interface between beta-sheets using residues that are strongly conserved in the Rel family.	YALE UNIV, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA; YALE UNIV, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06510 USA; YALE UNIV, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University								BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BROWNELL E, 1989, ONCOGENE, V4, P935; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIMITRIS T, 1992, CELL, V71, P777; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRILLI M, 1993, INT REV CYTOL, V143, P1; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HULTMARK D, 1994, NATURE, V367, P116, DOI 10.1038/367116a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOPP E, 1994, ADV IMMUNOL, V58, P1; KUMAR S, 1993, P NATL ACAD SCI USA, V90, P8962, DOI 10.1073/pnas.90.19.8962; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIU J, 1994, P NATL ACAD SCI USA, V91, P908, DOI 10.1073/pnas.91.3.908; Liu J, 1994, CHEM BIOL, V1, P47, DOI 10.1016/1074-5521(94)90040-X; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; TONY Y, 1993, CELL, V75, P753; VANROEY P, 1989, P NATL ACAD SCI USA, V86, P6587, DOI 10.1073/pnas.86.17.6587; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	39	506	532	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 26	1995	373	6512					303	310		10.1038/373303a0	http://dx.doi.org/10.1038/373303a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7530332				2022-12-28	WOS:A1995QD40400048
J	DOLL, DC				DOLL, DC			SPUR CELLS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											DOLL, DC (corresponding author), HARRY S TRUMAN VET AFFAIRS MED CTR,COLUMBIA,MO 65201, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 2	1995	333	18					1183	1183		10.1056/NEJM199511023331804	http://dx.doi.org/10.1056/NEJM199511023331804			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB560	7565973				2022-12-28	WOS:A1995TB56000004
J	WALSH, JME; GRADY, D				WALSH, JME; GRADY, D			TREATMENT OF HYPERLIPIDEMIA IN WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY HEART-DISEASE; FOLLOW-UP; PROSPECTIVE POPULATION; SECONDARY PREVENTION; CHOLESTEROL LEVELS; BLOOD CHOLESTEROL; SERUM-CHOLESTEROL; NICOTINIC-ACID; RISK-FACTORS; MORTALITY	Objective.-To assess the evidence that lipid lowering prevents coronary heart disease (CHD) events in women. Data Sources.-English-language literature assessing the effects of cholesterol lowering with dietary and/or drug interventions as primary or secondary prevention on CHD events in women. Main Outcome Measures.-Coronary heart disease and total mortality were the primary outcomes assessed. Angiographic regression of coronary atherosclerosis was a secondary outcome. Study Selection, Data Extraction, and Data Synthesis.-All nine of the identified studies that met the criteria were included. Relative risks for CHD and total mortality were calculated from available data. Summary relative risks were calculated using meta-analytic techniques. Conclusions.-There is no evidence from primary prevention trials that cholesterol lowering affects total mortality in healthy women, although the available data are limited. Limited evidence suggests that treatment of hypercholesterolemia in women with coronary disease may decrease CHD mortality. Future research should address the role of dietary and other nondrug treatment of hypercholesterolemia in women at high risk for CHD.	VET AFFAIRS MED CTR, GEN INTERNAL MED SECT, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, SAN FRANCISCO, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	WALSH, JME (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MED, BOX 1610, SAN FRANCISCO, CA 94115 USA.							ACHESON J, 1972, ATHEROSCLEROSIS, V15, P177, DOI 10.1016/0021-9150(72)90067-6; [Anonymous], 1965, LANCET, V2, P501; [Anonymous], 1968, LANCET, V2, P693; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; ARONOW WS, 1989, J AM GERIATR SOC, V37, P501, DOI 10.1111/j.1532-5415.1989.tb05679.x; BARRETTCONNOR E, 1983, AM J EPIDEMIOL, V118, P489, DOI 10.1093/oxfordjournals.aje.a113654; BENGTSSON C, 1993, BMJ-BRIT MED J, V307, P1385, DOI 10.1136/bmj.307.6916.1385; BROWN MA, 1989, ENERG BUILDINGS, V13, P51, DOI 10.1016/0378-7788(89)90017-0; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; BUCHWALD H, 1992, ANN SURG, V216, P389, DOI 10.1097/00000658-199210000-00001; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; CARLSON LA, 1977, ATHEROSCLEROSIS, V28, P81, DOI 10.1016/0021-9150(77)90201-5; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CORTI MC, 1995, JAMA-J AM MED ASSOC, V274, P539, DOI 10.1001/jama.274.7.539; CRIQUI MH, 1993, NEW ENGL J MED, V328, P1220, DOI 10.1056/NEJM199304293281702; DAYTON S, 1969, CIRCULATION       S2, V40, P1; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HULLEY SB, 1993, JAMA-J AM MED ASSOC, V269, P1416, DOI 10.1001/jama.269.11.1416; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; Kannel W B, 1992, Ann Epidemiol, V2, P5; KANNEL WB, 1979, AM J CARDIOL, V44, P53, DOI 10.1016/0002-9149(79)90250-9; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; KANNEL WB, 1974, DHEW NIH74599 PUBL; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; LEREN P, 1966, ACTA MED SCAND  S466, V181, P1; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; Manolio T A, 1992, Ann Epidemiol, V2, P161, DOI 10.1016/1047-2797(92)90051-Q; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; MIETTINEN M, 1972, LANCET, V2, P835; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; PAN WH, 1986, AM J EPIDEMIOL, V123, P504, DOI 10.1093/oxfordjournals.aje.a114266; PEDERSEN TR, 1994, LANCET, V344, P1383; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROSE GA, 1965, BMJ-BRIT MED J, V1, P1531, DOI 10.1136/bmj.1.5449.1531; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; SIMONS LA, 1986, AM J CARDIOL, V57, pG5, DOI 10.1016/0002-9149(86)90659-4; STAMPFER MJ, 1987, CORONARY HEART DISEA, P112; THOM TJ, 1987, CORONARY HEART DISEA, P270; Trial of clofibrate in the treatment of ischaemic heart disease, 1971, BRIT MED J, V4, P767, DOI DOI 10.1136/BMJ.4.5790.767; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; Woodhill J M, 1978, Adv Exp Med Biol, V109, P317; 1991, VITAL STATISTICS U A, V2; 1980, 801527 US DEP HLTH H; 1971, BRIT MED J, V4, P775	54	61	61	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1152	1158		10.1001/jama.274.14.1152	http://dx.doi.org/10.1001/jama.274.14.1152			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563487				2022-12-28	WOS:A1995RY05600031
J	FISHER, RP; JIN, P; CHAMBERLIN, HM; MORGAN, DO				FISHER, RP; JIN, P; CHAMBERLIN, HM; MORGAN, DO			ALTERNATIVE MECHANISMS OF CAK ASSEMBLY REQUIRE AN ASSEMBLY FACTOR OR AN ACTIVATING KINASE	CELL			English	Article							MYC TRANSGENIC MICE; ZINC-FINGER; VIRUS TYPE-1; CATALYTIC SUBUNIT; PROTEIN-KINASE; COILED COILS; RING FINGER; IDENTIFICATION; MOTIF; PURIFICATION	We have cloned a mouse cDNA that encodes p36, a novel subunit of the CDK-activating kinase (CAK). p36 contains a C3HC4 zinc-binding domain or RING finger and is associated both with a TFIIH-bound form of CAK and with a free trimeric form. p36 promotes the assembly of CDK7 and cyclin H in vitro, stabilizing the transient CDK7-cyclin H complex. Stabilization and activation of CAK by p36 is independent of the phosphorylation state of T170, the conserved activating residue of CDK7. Assembly of active CDK7-cyclin H dimers can also occur through an alternative p36-independent pathway that requires phosphorylation of T170 by a CAK-activating kinase, or CAKAK. Thus, CDK7-cyclin H complex formation can be achieved by multiple mechanisms.			FISHER, RP (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, BOX 0444, SAN FRANCISCO, CA 94143 USA.			Morgan, David/0000-0001-8753-4416				BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BROWN AJ, 1994, MOL BIOL CELL, V5, P921, DOI 10.1091/mbc.5.8.921; CHAN WK, 1991, CHEM ENG PROG, V87, P63; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVERETT RD, 1988, J MOL BIOL, V202, P87, DOI 10.1016/0022-2836(88)90521-9; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GU Y, 1990, NEURON, V5, P147, DOI 10.1016/0896-6273(90)90305-Y; HARLOW E, 1988, ANTIBODIES LABORATOR; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LABBE JC, 1994, EMBO J, V13, P5155, DOI 10.1002/j.1460-2075.1994.tb06845.x; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; O'Reilly DR, 1993, BACULOVIRUS EXPRESSI; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; POON RYC, 1994, J CELL SCI, V107, P2789; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REDDY BA, 1991, DEV BIOL, V148, P107, DOI 10.1016/0012-1606(91)90321-S; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; ROSENBLATT J, 1993, J MOL BIOL, V230, P1317, DOI 10.1006/jmbi.1993.1248; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHLEKHATTAR R, 1995, NATURE, V374, P283; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TASSAN JP, 1995, IN PRESS EMBO J; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VONARNIM AG, 1993, J BIOL CHEM, V268, P19626	47	212	215	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 6	1995	83	1					47	57		10.1016/0092-8674(95)90233-3	http://dx.doi.org/10.1016/0092-8674(95)90233-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553872	Bronze			2022-12-28	WOS:A1995RY58300009
J	HUTSON, HR; ANGLIN, D; KYRIACOU, DN; HART, J; SPEARS, K				HUTSON, HR; ANGLIN, D; KYRIACOU, DN; HART, J; SPEARS, K			THE EPIDEMIC OF GANG-RELATED HOMICIDES IN LOS-ANGELES-COUNTY FROM 1979 THROUGH 1994	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FIREARM INJURIES; VIOLENCE; DEATHS	Objective.-To determine trends in gang homicides and the population at greatest risk for homicide by reviewing all gang-related homicides in Los Angeles County, California, from January 1979 to December 1994. Design.-Homicide files of the Los Angeles Police Department and the Los Angeles County Sheriff's Department from 1979 to 1994 involving violent street gang activity were reviewed. Gang files were reviewed for demographic data, weapons used, homicides by drive-by shootings, and times and geographic areas of occurrence. Setting.-Los Angeles County from January 1, 1979, to December 31, 1994. Main Outcome Measures.-Age, race, and sex of gang-related homicide victims; frequency of weapon use; and the change in gang-related homicide rates during the study period. Results.-A total of 7288 gang-related homicides occurred in Los Angeles County from 1979 through 1994; 5541 of these homicides occurred in Los Angeles Police Department and Los Angeles County Sheriff's Department jurisdictions. During the study period, the proportion of all homicides that were gang related increased from 18.1% to 43.0% (P<.001). Of the 5541 gang-related homicide victims, 4580 (85.6%) were aged 15 to 34 years, 93.3% were African American or Hispanic, 5157 (93.2%) were male, 3559 (64.2%) were gang members, and 1408 (25.4%) occurred during drive-by shootings. Firearms were used in an increasing proportion of homicides, from 71.4% in 1979 to 94.5% in 1994. Homicides by semiautomatic handguns dramatically increased during the study period. Gang-related homicide rates for African-American males aged 15 to 19 years increased from 60.50 per 100 000 population per year in 1979 to 1981 to 192.41 per 100 000 population per year in 1989 to 1991. Conclusions.-Gang related homicides in Los Angeles County have reached epidemic proportions and are a major public health problem. To prevent gang violence, the root causes of violent street gang formation must be alleviated, the cycle of violent street gang involvement must be broken, and access to firearms must be limited.	UNIV SO CALIF,LOS ANGELES CTY MED CTR,DEPT EMERGENCY MED,LOS ANGELES,CA 90033; OLIVE VIEW UCLA MED CTR,DEPT EMERGENCY MED,LOS ANGELES,CA; CALIF STATE UNIV LOS ANGELES,LOS ANGELES,CA 90032; MARTIN LUTHER KING CHARLES DREW MED CTR,DEPT EMERGENCY MED,LOS ANGELES,CA	University of Southern California; University of California System; University of California Los Angeles; California State University System; California State University Los Angeles; Charles R. Drew University of Medicine & Science	HUTSON, HR (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT EMERGENCY MED,75 FRANCIS ST,BOSTON,MA 02115, USA.							CHRISTOFFEL KK, 1991, PEDIATRICS, V88, P294; COTTON P, 1992, JAMA-J AM MED ASSOC, V268, P443, DOI 10.1001/jama.268.4.443; DEAN AG, 1990, EPIINFO VERSION 5 WO; DECKER SH, BREAKING BONDS MEMBE; FINGERHUT LA, 1994, ADV DATA VITAL HLTH, V242; Hutson H. Range, 1994, Journal of Emergency Medicine, V12, P385, DOI 10.1016/0736-4679(94)90282-8; HUTSON HR, 1994, NEW ENGL J MED, V330, P324, DOI 10.1056/NEJM199402033300506; HUTSON HR, 1992, ANN EMERG MED, V21, P1291; HUTSON HR, 1992, ANN EMERG MED, V21, P1234; JACKSON RK, 1991, UNDERSTANDING STREET; KELLERMANN AL, 1991, ANNU REV PUBL HEALTH, V12, P17; Klein M., 1995, AM STREET GANG; KLEIN MW, 1991, CRIMINOLOGY, V29, P701; KOCHANEK KD, 1994, MONTHLY VITAL STA S6, V43; MARTINEZ FB, 1992, SUBSTANCE ABUSE GANG, P61; Maxson C.L., 1990, GANGS AM, V1, P70; Maxson CL, 1985, CRIMINOLOGY, V23, P209, DOI 10.1111/j.1745-9125.1985.tb00334.x; MCGONIGAL MD, 1993, J TRAUMA, V35, P532, DOI 10.1097/00005373-199310000-00006; MEEHAN PJ, 1992, AM J DIS CHILD, V146, P683, DOI 10.1001/archpedi.1992.02160180041014; MILLER T, 1995, TXB PENETRATING TRAU; Miller WB., 1990, GANGS AM, P263; MORALES A, 1992, SUBSTANCE ABUSE GANG, P105; NIETO M, 1994, CRBIS94007 CAL RES B; Rosenberg M., 1991, VIOLENCE AM PUBLIC H, P14; TERET SP, 1992, JAMA-J AM MED ASSOC, V267, P3073, DOI 10.1001/jama.267.22.3073; Vigil J.D., 1988, BARRIO GANGS STREET; WINTEMUTE GJ, 1992, J TRAUMA, V33, P556, DOI 10.1097/00005373-199210000-00011; WRIGHT JD, 1995, SOCIETY          MAR, P63; ZIMRING FE, 1993, HEALTH AFFAIR, V12, P109, DOI 10.1377/hlthaff.12.4.109; 1993, 1990CPH3215B BUR CEN; 1993, INTELLIGENCE OPERATI, V2; 1994, CRIME US 1993 UNIFOR; 1990, 8 LOS ANG POL DEP OR; 1986, 8639 COUNT LOS ANG S; 1983, PHC802226 BUR CENS P; 1991, PUBLIC HLTH REP, V106, P225; 1994, MMWR-MORBID MORTAL W, V43, P725; 1994, EPIC PROPORTIONS, V4	38	52	52	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1031	1036		10.1001/jama.274.13.1031	http://dx.doi.org/10.1001/jama.274.13.1031			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX108	7563453				2022-12-28	WOS:A1995RX10800025
J	STREETLY, A; GRANT, C; POLLITT, RJ; ADDISON, GM				STREETLY, A; GRANT, C; POLLITT, RJ; ADDISON, GM			SURREY OF SCOPE OF NEONATAL SCREENING IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article									LAMBETH SOUTHWARK & LEWISHAM HLTH COMMISS,LONDON SE1 7RJ,ENGLAND; SHEFFIELD CHILDRENS HOSP,TRENT REG SCREENING LAB,SHEFFIELD S10 2TH,S YORKSHIRE,ENGLAND; ROYAL MANCHESTER CHILDRENS HOSP,NATL COMM DIRECTORS NEONATAL SCREENING LABS,MANCHESTER M27 1HA,LANCS,ENGLAND	Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; Royal Manchester Children's Hospital	STREETLY, A (corresponding author), UNITED MED & DENT SCH,DEPT PUBL HLTH MED,ST THOMAS CAMPUS,LONDON SE1 7EH,ENGLAND.							POLLITT RJ, 1982, J INHERIT METAB DIS, V5, P51, DOI 10.1007/BF01799824; SMITH R, 1994, BRIT MED J, V308, P357, DOI 10.1136/bmj.308.6925.357a; STREETLY A, 1994, BRIT MED J, V309, P372, DOI 10.1136/bmj.309.6951.372; WILSON JMG, 1968, WHO34 PUBL HLTH PAP; 1993, GENETIC SCREENING ET	5	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	1995	311	7007					726	726		10.1136/bmj.311.7007.726	http://dx.doi.org/10.1136/bmj.311.7007.726			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV874	7549688	Green Published			2022-12-28	WOS:A1995RV87400022
J	MEREDITH, J; TAKADA, Y; FORNARO, M; LANGUINO, LR; SCHWARTZ, MA				MEREDITH, J; TAKADA, Y; FORNARO, M; LANGUINO, LR; SCHWARTZ, MA			INHIBITION OF CELL-CYCLE PROGRESSION BY THE ALTERNATIVELY SPLICED INTEGRIN BETA(1C)	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; CYTOPLASMIC DOMAIN; BETA-1; EXPRESSION; ADHESION; VARIANT; SUBUNIT; FORM	Integrins regulate cell growth, differentiation, and behavior in many systems. Integrin beta(1C) (beta(1S)) is an alternatively spliced variant of integrin beta(1) with a specific cytoplasmic domain and is expressed in several human tissues. Human beta(1C) transiently expressed in mouse 10T1/2 fibroblasts showed a diffuse pattern of cell surface staining, whereas beta(1) localized to focal adhesions. Moderate concentrations of beta(1C) had no effect on actin stress fibers or focal adhesions, but markedly inhibited DNA synthesis. Inhibition by beta(1C) mapped to the late G(1) phase of the cell cycle, near the G(1)-S boundary. Thus, alternative splicing of beta(1) results in transmission of distinct signals that may regulate growth in vivo.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06520 USA	Yale University	MEREDITH, J (corresponding author), SCRIPPS RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037 USA.			Languino, Lucia/0000-0001-9011-7031; schwartz, martin/0000-0002-2071-1243; takada, yoshikazu/0000-0001-5481-9589	NHLBI NIH HHS [P01 HL48728] Funding Source: Medline; NIGMS NIH HHS [R01 GM47214, R01GM47157] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047214, R01GM047157] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALZAC F, 1993, J CELL BIOL, V121, P171, DOI 10.1083/jcb.121.1.171; BODARY S C, 1991, Journal of Cell Biology, V115, p289A; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DANA N, 1991, P NATL ACAD SCI USA, V88, P3106, DOI 10.1073/pnas.88.8.3106; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FORNARO M, UNPUB; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; LANGUINO LR, 1992, J BIOL CHEM, V267, P7116; LANGUINO LR, UNPUB; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MEREDITH JC, UNPUB; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; SCHWARTZ MA, 1994, J BIOL CHEM, V269, P11133; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; SOLOWSKA J, 1991, J CELL BIOL, V114, P1079, DOI 10.1083/jcb.114.5.1079; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913	24	116	117	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	1995	269	5230					1570	1572		10.1126/science.7545312	http://dx.doi.org/10.1126/science.7545312			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7545312				2022-12-28	WOS:A1995RU81300039
J	BOHLER, C; NIELSEN, PE; ORGEL, LE				BOHLER, C; NIELSEN, PE; ORGEL, LE			TEMPLATE SWITCHING BETWEEN PNA AND RNA OLIGONUCLEOTIDES	NATURE			English	Article							DIRECTED SYNTHESIS	THE origin of the RNA world(1) is not easily understood, as effective prebiotic syntheses of the components of RNA, the beta-ribofuranoside-5'-phosphates, are hard to envisage(2). Recognition of this difficulty has led to the proposal(1,3) that other genetic systems, the components of which are more easily formed, may have preceded RNA. This raises the question of how transitions between one genetic system and another could occur. Peptide nucleic acid (PNA) resembles RNA in its ability to form double-helical complexes stabilized by Watson-Crick hydrogen bonding between adenine and thymine and between cytosine and guanine(4-6), but has a backbone that is held together by amide rather than by phosphodiester bonds. Oligonucleotides based on RNA are known to act as templates that catalyse the non-enzymatic synthesis of their complements from activated mononucleotides(7-9), we now show that RNA oligonucleotides facilitate the synthesis of complementary PNA strands and vice versa. This suggests that a transition between different genetic systems can occur without less of information.	SALK INST BIOL STUDIES,SAN DIEGO,CA 92186; PANUM INST,IMBG,CTR BIOMOLEC RECOGNIT,DK-2100 COPENHAGEN N,DENMARK	Salk Institute								CAIRNSSMITH AG, 1982, GENETIC TAKEOVER; CAIRNSSMITH AG, 1977, ENCY IGNORANCE; CHEN CB, 1985, J MOL BIOL, V181, P271, DOI 10.1016/0022-2836(85)90091-9; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; Gesteland RF., 1993, RNA WORLD NATURE MOD; HILL AR, 1993, ORIGINS LIFE EVOL B, V23, P285, DOI 10.1007/BF01582078; INOUE T, 1981, J AM CHEM SOC, V103, P7666, DOI 10.1021/ja00415a051; INOUE T, 1984, J MOL BIOL, V178, P669, DOI 10.1016/0022-2836(84)90244-4; JOYCE GF, 1984, NATURE, V310, P602, DOI 10.1038/310602a0; JOYCE GF, 1987, COLD SPRING HARB SYM, V52, P41, DOI 10.1101/SQB.1987.052.01.008; JOYCE GF, 1984, J MOL BIOL, V176, P279, DOI 10.1016/0022-2836(84)90425-X; Joyce GF., 1993, COLD SPRING HARB MON, V24, P1; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; ORGEL LE, 1992, NATURE, V358, P203, DOI 10.1038/358203a0; WITTUNG P, 1994, NATURE, V368, P561, DOI 10.1038/368561a0	15	189	194	4	39	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					578	581		10.1038/376578a0	http://dx.doi.org/10.1038/376578a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7543656				2022-12-28	WOS:A1995RP75600046
J	KOCH, AE; HALLORAN, MM; HASKELL, CJ; SHAH, MR; POLVERINI, PJ				KOCH, AE; HALLORAN, MM; HASKELL, CJ; SHAH, MR; POLVERINI, PJ			ANGIOGENESIS MEDIATED BY SOLUBLE FORMS OF E-SELECTIN AND VASCULAR CELL-ADHESION MOLECULE-1	NATURE			English	Article							HUMAN-ENDOTHELIAL-CELLS; TUMOR NECROSIS FACTOR; EXPRESSION; DISTINCT; EPITOPES; LEWIS	ENDOTHELIAL adhesion molecules facilitate the entry of leukocytes into inflamed tissues. This in turn promotes neovascularization, a process central to the progression of rheumatoid arthritis, tumour growth and wound repair(1). Here we test the hypothesis that soluble endothelial adhesion molecules promote angiogenesis(2-4), Human recombinant soluble E-selectin and soluble vascular cell adhesion molecule-1 induced chemotaxis of human endothelial cells in vitro and were angiogenic in rat cornea. Soluble E-selectin acted on endothelial cells in part through a sialyl Lewis-X-dependent mechanism, while soluble vascular cell adhesion molecule-1 acted on endothelial cells in part through a very late antigen (VLA)-4 dependent mechanism, The chemotactic activity of rheumatoid synovial fluid for endothelial cells, and also its angiogenic activity, were blocked by antibodies to either soluble E-selectin or soluble vascular cell adhesion molecule-1. These results suggest a novel function for soluble endothelial adhesion molecules as mediators of angiogenesis.	LAKESIDE VET ADM MED CTR,CHICAGO,IL 60611; UNIV MICHIGAN,SCH DENT,MOLEC PATHOGENESIS LAB,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	KOCH, AE (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ARTHRIT & CONNECT TISSUE DIS SECT,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.		Koch, Alisa E/B-6894-2011; Polverini, Peter/AAJ-8392-2020					BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; CARLOS TM, 1990, BLOOD, V76, P965; CARSON CW, 1994, J RHEUMATOL, V21, P605; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GAMBLE JR, 1993, J CELL BIOL, V121, P931, DOI 10.1083/jcb.121.4.931; GILLARD BK, 1987, ARCH BIOCHEM BIOPHYS, V256, P435, DOI 10.1016/0003-9861(87)90600-X; JOHNSON BA, 1993, ARTHRITIS RHEUM, V36, P137, DOI 10.1002/art.1780360203; KLAGSBRUN M, 1991, REV PHYSL, V53, P217; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KOCH AE, 1991, LAB INVEST, V64, P313; KOCH AE, 1993, CLIN IMMUNOL IMMUNOP, V69, P29, DOI 10.1006/clin.1993.1146; KOCH AE, 1994, J IMMUNOL, V152, P149; LEIBOVICH SJ, 1994, P NATL ACAD SCI USA, V91, P4190, DOI 10.1073/pnas.91.10.4190; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; LOBB RR, 1991, J IMMUNOL, V147, P124; MASSIA SP, 1992, J BIOL CHEM, V267, P14109; MUNRO JM, 1992, AM J PATHOL, V141, P1392; NGUYEN M, 1993, NATURE, V365, P267, DOI 10.1038/365267a0; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; PAAVONEN T, 1992, AM J PATHOL, V141, P1259; POBER JS, 1986, J IMMUNOL, V136, P1680; PULIDO R, 1991, J BIOL CHEM, V266, P10241; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed	25	511	551	2	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					517	519		10.1038/376517a0	http://dx.doi.org/10.1038/376517a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7543654	Green Submitted			2022-12-28	WOS:A1995RN62200045
J	KREDER, KJ				KREDER, KJ			COMBINATION-DRUG THERAPY FOR BENIGN PROSTATIC HYPERPLASIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											KREDER, KJ (corresponding author), UNIV IOWA,IOWA CITY,IA 52242, USA.			Kreder, Karl/0000-0002-8981-5286					0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					359	359		10.1001/jama.274.4.359	http://dx.doi.org/10.1001/jama.274.4.359			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7541871				2022-12-28	WOS:A1995RJ89800045
J	THOMPSON, CB				THOMPSON, CB			DISTINCT ROLES FOR THE COSTIMULATORY LIGANDS B7-1 AND B7-2 IN T-HELPER CELL-DIFFERENTIATION	CELL			English	Review							MICE		UNIV CHICAGO,GWEN KNAPP CTR LUPUS & IMMUNOL RES,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637	University of Chicago	THOMPSON, CB (corresponding author), UNIV CHICAGO,DEPT MED,HOWARD HUGHES MED INST,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.							ALLISON JP, 1994, CURR OPIN IMMUNOL, V6, P414, DOI 10.1016/0952-7915(94)90120-1; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; CORRY DB, 1994, J IMMUNOL, V153, P4142; CROFT M, 1994, J IMMUNOL, V152, P2675; FINCK BK, 1994, SCIENCE, V265, P1225, DOI 10.1126/science.7520604; FREEMAN GJ, 1995, IMMUNITY, V2, P523, DOI 10.1016/1074-7613(95)90032-2; GREEN JM, 1994, IMMUNITY, V1, P501, DOI 10.1016/1074-7613(94)90092-2; HATHCOCK KS, 1994, J EXP MED, V180, P631, DOI 10.1084/jem.180.2.631; KALINSKI P, 1995, J IMMUNOL, V154, P3753; KING CL, 1995, EUR J IMMUNOL, V25, P587, DOI 10.1002/eji.1830250242; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; LANIER LL, 1995, J IMMUNOL, V154, P97; LENSCHOW DJ, 1995, J EXP MED, V181, P1145, DOI 10.1084/jem.181.3.1145; LEVINE BL, 1995, IN PRESS INT IMMUNOL; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; LU P, 1994, J EXP MED, V180, P593; MCARTHUR JG, 1993, J EXP MED, V178, P1645, DOI 10.1084/jem.178.5.1645; MCKNIGHT AJ, 1994, J IMMUNOL, V152, P5220; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; SAYEGH MH, 1995, J EXP MED, V181, P1869, DOI 10.1084/jem.181.5.1869; SEDER RA, 1994, J EXP MED, V179, P299, DOI 10.1084/jem.179.1.299; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139	23	354	360	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 30	1995	81	7					979	982		10.1016/S0092-8674(05)80001-7	http://dx.doi.org/10.1016/S0092-8674(05)80001-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7541314	Bronze			2022-12-28	WOS:A1995RG91000001
J	LEIGHTON, PA; INGRAM, RS; EGGENSCHWILER, J; EFSTRATIADIS, A; TILGHMAN, SM				LEIGHTON, PA; INGRAM, RS; EGGENSCHWILER, J; EFSTRATIADIS, A; TILGHMAN, SM			DISRUPTION OF IMPRINTING CAUSED BY DELETION OF THE H19 GENE REGION IN MICE	NATURE			English	Article							GROWTH FACTOR-II; EARLY MOUSE EMBRYOGENESIS; BETA-GLOBIN; PGK-1 GENE; XIST GENE; EXPRESSION; RNA; DNA; PROMOTER; FRAGMENTS	The imprinted H19 gene, which encodes an untranslated RNA, lies at the end of a cluster of Imprinted genes in the mouse. Imprinting of the insulin-2 and insulin-like growth factor 2 genes, which lie about 100 kilobases upstream of H19, can be disrupted by maternal inheritance of a targeted deletion of the H19 gene and its flanking sequence. Animals inheriting the H19 mutation from their mothers are 27% heavier than those inheriting It from their fathers. Paternal inheritance of the disruption has no effect, which presumably reflects the normally silent state of the paternal gene. The somatic overgrowth of heterozygotes for the maternal deletion is attributed to a gain of function of insulin-like growth factor 2, rather than a loss of function of H19.	PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA; COLUMBIA UNIV, DEPT GENET & DEV, NEW YORK, NY 10032 USA	Princeton University; Columbia University	LEIGHTON, PA (corresponding author), PRINCETON UNIV, HOWARD HUGHES MED INST, PRINCETON, NJ 08544 USA.			eggenschwiler, jonathan/0000-0001-6444-8865				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Bartolomei M.S., 1992, SEMIN DEV BIOL, V3, P107; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; FOLEY KP, 1992, GENE DEV, V6, P730, DOI 10.1101/gad.6.5.730; GIDDINGS SJ, 1994, NAT GENET, V6, P310, DOI 10.1038/ng0394-310; GUILLEMOT F, 1995, NAT GENET, V9, P235, DOI 10.1038/ng0395-235; GUILLEMOT F, 1994, GIDD, V371, P333; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HENDRICH BD, 1993, HUM MOL GENET, V2, P663, DOI 10.1093/hmg/2.6.663; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; LEE JE, 1990, DEVELOPMENT, V110, P151; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; OHLSSON H, 1991, MOL ENDOCRINOL, V5, P897, DOI 10.1210/mend-5-7-897; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PFEIFER K, 1994, GENE DEV, V8, P1867, DOI 10.1101/gad.8.16.1867; POIRIER F, 1991, DEVELOPMENT, V113, P1105; REIS A, 1994, AM J HUM GENET, V54, P741; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; SOLTER D, 1988, ANNU REV GENET, V22, P127; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; WEVRICK R, 1994, HUM MOL GENET, V3, P1877, DOI 10.1093/hmg/3.10.1877; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707; ZACHAR V, 1993, NUCLEIC ACIDS RES, V21, P2017, DOI 10.1093/nar/21.8.2017; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61	50	660	670	0	17	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 4	1995	375	6526					34	39		10.1038/375034a0	http://dx.doi.org/10.1038/375034a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7536897				2022-12-28	WOS:A1995QW60400046
J	WHITE, K; CEBON, J				WHITE, K; CEBON, J			TRANSIENT HYPOXEMIA DURING NEUTROPHIL RECOVERY IN FEBRILE PATIENTS	LANCET			English	Note							G-CSF; LEUKEMIA	In previous anecdotal reports, treatment with granulocyte colony-stimulating factor has been associated with pulmonary toxicity. In 35 consecutive admissions for chemotherapy-induced febrile neutropenia, transient hypoxia occurred in 12. 10 of the 12 followed treatment with filgrastim to induce neutrophil recovery. There was no consistent association with cytotoxic regimen.	AUSTIN HOSP,LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,HEIDELBERG,VIC 3084,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT CLIN HAEMATOL & MED ONCOL,MELBOURNE,VIC,AUSTRALIA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; Royal Melbourne Hospital			Cebon, Jonathan S/H-1643-2013	Cebon, Jonathan/0000-0002-3898-950X				BASTION Y, 1994, LANCET, V343, P1221, DOI 10.1016/S0140-6736(94)92426-0; IKI S, 1993, ANN HEMATOL, V66, P217, DOI 10.1007/BF01703240; LIESCHKE GJ, 1992, BRIT J HAEMATOL, V82, P589, DOI 10.1111/j.1365-2141.1992.tb06472.x; LIESCHKE GJ, 1989, BLOOD, V74, P2634; LUNDJOHANSEN F, 1993, J LEUKOCYTE BIOL, V54, P47, DOI 10.1002/jlb.54.1.47; MAHER DW, 1994, ANN INTERN MED, V121, P492, DOI 10.7326/0003-4819-121-7-199410010-00004; MATTHEWS JH, 1994, LANCET, V342, P988; MORSTYN G, 1989, LANCET, V1, P667; VAN WOENSEL JBM, 1994, LANCET, V344, P759, DOI 10.1016/S0140-6736(94)92253-5; WHITE KL, 1992, AUST NZ J MED, V22, P449; WILEY JS, 1993, BLOOD, V82, P3511	11	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 22	1995	345	8956					1022	1024		10.1016/S0140-6736(95)90759-9	http://dx.doi.org/10.1016/S0140-6736(95)90759-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7536871				2022-12-28	WOS:A1995QU57300011
J	CHEN, CY; SARNOW, P				CHEN, CY; SARNOW, P			INITIATION OF PROTEIN-SYNTHESIS BY THE EUKARYOTIC TRANSLATIONAL APPARATUS ON CIRCULAR RNAS	SCIENCE			English	Article							5' NONTRANSLATED REGION; INTERNAL RIBOSOMAL ENTRY; MESSENGER-RNA; VIRUS-RNA; POLIOVIRUS RNA; PICORNAVIRUS RNA; BINDING-PROTEIN; SITE; SEQUENCE; ELEMENTS	The ribosome scanning model predicts that eukaryotic ribosomal 40S subunits enter all messenger RNAs at their 5' ends. Here, it is reported that eukaryotic ribosomes can initiate translation on circular RNAs, but only if the RNAs contain internal ribosome entry site elements, Long-repeating polypeptide chains were synthesized from RNA circles with continuous open reading frames. These results indicate that ribosomes can translate such RNA circles for multiple consecutive rounds and that the free 5' end of a messenger RNA is not necessarily the entry point for 40S subunits.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DYDE LAB,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Sarnow, Peter/0000-0002-2043-2770				CAPEL B, 1993, CELL, V73, P1019, DOI 10.1016/0092-8674(93)90279-Y; CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; COCQUERELLE C, 1993, FASEB J, V7, P155, DOI 10.1096/fasebj.7.1.7678559; COOPER G, 1994, J BIOTECHNOL, V33, P123, DOI 10.1016/0168-1656(94)90105-8; DUKE GM, 1992, J VIROL, V66, P1602, DOI 10.1128/JVI.66.3.1602-1609.1992; EDERY I, 1983, J BIOL CHEM, V258, P1398; FORD E, 1994, P NATL ACAD SCI USA, V91, P3117, DOI 10.1073/pnas.91.8.3117; GRABOWSKI PJ, 1981, CELL, V23, P467, DOI 10.1016/0092-8674(81)90142-2; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; HAMBIDGE SJ, 1991, J VIROL, V65, P6312, DOI 10.1128/JVI.65.11.6312-6315.1991; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; KONARSKA M, 1981, EUR J BIOCHEM, V114, P221, DOI 10.1111/j.1432-1033.1981.tb05139.x; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1979, NATURE, V280, P82, DOI 10.1038/280082a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LUZ N, 1990, FEBS LETT, V169, P311; MACEJAK DG, 1990, NEW ASPECTS OF POSITIVE-STRAND RNA VIRUSES, P152; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MEEROVITCH K, 1991, J VIROL, V65, P5895, DOI 10.1128/JVI.65.11.5895-5901.1991; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MOLLA A, 1992, NATURE, V356, P255, DOI 10.1038/356255a0; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PESTOVA TV, 1991, J VIROL, V65, P6194, DOI 10.1128/JVI.65.11.6194-6204.1991; PILIPENKO EV, 1992, CELL, V68, P119, DOI 10.1016/0092-8674(92)90211-T; ROBERTSON HD, 1992, CURR TOP MICROBIOL, V176, P213; TAHARA SM, 1981, J BIOL CHEM, V256, P7691; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992	33	498	554	4	71	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					415	417		10.1126/science.7536344	http://dx.doi.org/10.1126/science.7536344			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7536344				2022-12-28	WOS:A1995QU57200039
J	VONAHSEN, U; NOLLER, HF				VONAHSEN, U; NOLLER, HF			IDENTIFICATION OF BASES IN 16S-RIBOSOMAL RNA ESSENTIAL FOR TRANSFER-RNA BINDING AT THE 30S-RIBOSOMAL P-SITE	SCIENCE			English	Article							ANTICODON INTERACTION SITE; TRANSFER-RNA; SUBUNIT; LOCALIZATION; CROSSLINKING; NUCLEOTIDES	Previous studies suggest that the mechanism of action of the ribosome in translation involves crucial transfer RNA (tRNA)-ribosomal RNA (rRNA) interactions. Here, a selection scheme was developed to identify bases in 16S rRNA that are essential for tRNA binding to the P site of the small (30S) ribosamal subunit. Modification of the N-1 and N-2 positions of 2-methylguanine 966 and of the N-7 position of guanine 1401 interfered with messenger RNA (mRNA)-dependent binding of tRNA to the P site. Modification of the same positions as well as of the N-1 and N-2 positions of guanine 926 interfered with mRNA-independent binding of tRNA at high magnesium ion concentration. These results suggest that these three bases are involved in intermolecular contacts between ribosomes and tRNA.	UNIV CALIF SANTA CRUZ, SINSHEIMER LABS, SANTA CRUZ, CA 95064 USA	University of California System; University of California Santa Cruz					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017129, R01GM017129] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17129] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CUNNINGHAM PR, 1992, BIOCHEMISTRY-US, V31, P7629, DOI 10.1021/bi00148a026; DENMAN R, 1988, NUCLEIC ACIDS RES, V16, P165, DOI 10.1093/nar/16.1.165; GORNICKI P, 1984, J BIOL CHEM, V259, P493; GRAJEVSKAJA RA, 1973, FEBS LETT, V33, P11, DOI 10.1016/0014-5793(73)80147-4; HERR W, 1979, J MOL BIOL, V130, P433, DOI 10.1016/0022-2836(79)90433-9; HUTTENHOFER A, 1992, P NATL ACAD SCI USA, V89, P7851, DOI 10.1073/pnas.89.17.7851; KIRILLOV SV, 1980, NUCLEIC ACIDS RES, V8, P183, DOI 10.1093/nar/8.1.183; LARSEN N, 1993, NUCLEIC ACIDS RES, V21, P3021, DOI 10.1093/nar/21.13.3021; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; NOLLER HF, 1972, P NATL ACAD SCI USA, V69, P3115, DOI 10.1073/pnas.69.11.3115; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; ROSE SJ, 1983, J MOL BIOL, V167, P103, DOI 10.1016/S0022-2836(83)80036-9; STERN S, 1988, METHOD ENZYMOL, V164, P481; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; VONAHSEN U, UNPUB; WAGENKNECHT T, 1988, J MOL BIOL, V203, P753, DOI 10.1016/0022-2836(88)90207-0	18	103	105	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 13	1995	267	5195					234	237		10.1126/science.7528943	http://dx.doi.org/10.1126/science.7528943			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7528943				2022-12-28	WOS:A1995QB15300034
J	DING, JM; CHEN, D; WEBER, ET; FAIMAN, LE; REA, MA; GILLETTE, MU				DING, JM; CHEN, D; WEBER, ET; FAIMAN, LE; REA, MA; GILLETTE, MU			RESETTING THE BIOLOGICAL CLOCK - MEDIATION OF NOCTURNAL CIRCADIAN SHIFTS BY GLUTAMATE AND NO	SCIENCE			English	Article							NITRIC-OXIDE SYNTHASE; CYCLIC-GMP FORMATION; SUPRACHIASMATIC NUCLEUS; RECEPTOR ANTAGONISTS; RAT HYPOTHALAMUS; GOLDEN-HAMSTER; NMDA RECEPTORS; FOS EXPRESSION; PHASE-SHIFTS; OPTIC-NERVE	Circadian rhythms of mammals are timed by an endogenous clock with a period of about 24 hours located in the suprachiasmatic nucleus (SCN) of the hypothalamus. Light synchronizes this clock to the external environment by daily adjustments in the phase of the circadian oscillation. The mechanism has been thought to involve the release of excitatory amino acids from retinal afferents to the SCN. Brief treatment of rat SCN in vitro with glutamate (Glu), N-methyl-D-aspartate (NMDA), or nitric oxide (NO) generators produced lightlike phase shifts of circadian rhythms. The SCN exhibited calcium-dependent nitric oxide synthase (NOS) activity. Antagonists of NMDA or NOS pathways blocked Glu effects in vitro, and intracerebroventricular injection of a NOS inhibitor in vivo blocked the light-induced resetting of behavioral rhythms. Together, these data indicate that Glu release, NMDA receptor activation, NOS stimulation, and NO production link light activation of the retina to cellular changes within the SCN mediating the phase resetting of the biological clock.	UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801; UNIV ILLINOIS,DEPT PHYSIOL,URBANA,IL 61801; UNIV ILLINOIS,NEUROSCI PROGRAM,URBANA,IL 61801; ARMSTRONG LAB,BIOL RHYTHMS & INTEGRAT NEUROSCI RES INST,BROOKS AFB,TX 78235	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; United States Department of Defense; United States Air Force					NINDS NIH HHS [NS22155, R01 NS022155] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022155] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMIR S, 1992, BRAIN RES, V586, P336, DOI 10.1016/0006-8993(92)91644-T; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BRUNE B, 1989, J BIOL CHEM, V264, P8455; BRUNE B, 1993, LIFE SCI, V54, P61; CASTEL M, 1993, EUR J NEUROSCI, V5, P368, DOI 10.1111/j.1460-9568.1993.tb00504.x; Chen D.-Y., UNPUB; COLWELL CS, 1990, BRAIN RES, V523, P117, DOI 10.1016/0006-8993(90)91643-U; COLWELL CS, 1992, J BIOL RHYTHM, V7, P125, DOI 10.1177/074873049200700204; COSTA A, 1993, BRAIN RES, V605, P187, DOI 10.1016/0006-8993(93)91739-F; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DECOURSEY PJ, 1960, SCIENCE, V131, P33, DOI 10.1126/science.131.3392.33; DEMASTER EG, 1989, BIOCHEM BIOPH RES CO, V163, P527, DOI 10.1016/0006-291X(89)92169-4; DEVRIES MJ, 1993, BRAIN RES, V612, P213; Ding J. M., 1993, Society for Neuroscience Abstracts, V19, P1815; DWYER MA, 1991, BIOCHEM BIOPH RES CO, V176, P1136, DOI 10.1016/0006-291X(91)90403-T; EAST SJ, 1990, EUR J PHARMACOL, V184, P311, DOI 10.1016/0014-2999(90)90623-E; Edmunds LN, 1988, CELLULAR MOL BASES B; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GELPERIN A, 1994, NATURE, V369, P61, DOI 10.1038/369061a0; Gillette MU, 1991, SUPRACHIASMATIC NUCL, P125; GILLETTE MU, CIBA F S, V183, P134; HALEY JE, 1992, NEURON, V8, P221; HAMADA T, 1993, AM J PHYSIOL, V265, pR1199, DOI 10.1152/ajpregu.1993.265.5.R1199; HASTINGS MH, 1985, NEUROENDOCRINOLOGY, V40, P316, DOI 10.1159/000124093; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; IGNARRO LJ, 1990, PHARMACOL TOXICOL, V67, P1, DOI 10.1111/j.1600-0773.1990.tb00772.x; JOHNSON RF, 1988, BRAIN RES, V462, P301, DOI 10.1016/0006-8993(88)90558-6; KAMISAKI Y, 1994, BRAIN RES, V644, P128, DOI 10.1016/0006-8993(94)90355-7; KIM YI, 1991, J PHYSIOL-LONDON, V444, P269, DOI 10.1113/jphysiol.1991.sp018877; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KOWALUK EA, 1990, J PHARMACOL EXP THER, V255, P1256; LIOU SY, 1986, BRAIN RES BULL, V16, P527, DOI 10.1016/0361-9230(86)90182-6; MARTIN W, 1985, J PHARMACOL EXP THER, V232, P708; MEDANIC M, 1992, J PHYSIOL-LONDON, V450, P629, DOI 10.1113/jphysiol.1992.sp019147; MEIJER JH, 1988, NEUROSCI LETT, V86, P177, DOI 10.1016/0304-3940(88)90567-8; MEIJER JH, 1989, PHYSIOL REV, V69, P671, DOI 10.1152/physrev.1989.69.3.671; MEIJER JH, 1993, BRAIN RES, V603, P284, DOI 10.1016/0006-8993(93)91249-R; MOFFETT JR, 1990, P NATL ACAD SCI USA, V87, P8065, DOI 10.1073/pnas.87.20.8065; MOFFETT JR, 1991, BRAIN RES, V538, P86, DOI 10.1016/0006-8993(91)90380-E; MONTAGUE PR, 1994, SCIENCE, V263, P973, DOI 10.1126/science.7508638; MOORE RY, 1971, J COMP NEUROL, V146, P1; MORIN LP, 1994, BRAIN RES REV, V67, P102; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; ODELL TJ, 1994, SCIENCE, V265, P542, DOI 10.1126/science.7518615; PAPE HC, 1992, NEURON, V9, P441, DOI 10.1016/0896-6273(92)90182-D; PICKARD GE, 1982, J COMP NEUROL, V211, P65, DOI 10.1002/cne.902110107; PITTENDRIGH CS, 1981, HDB BEHAV NEUROBIOL, V4, P59; PROSSER RA, 1989, J NEUROSCI, V9, P1073; PROSSER RA, 1989, P NATL ACAD SCI USA, V86, P6912; REA MA, 1993, J BIOL RHYTHM, V8, pS59; REA MA, 1993, AM J PHYSIOL, V265, pR1191, DOI 10.1152/ajpregu.1993.265.5.R1191; SHIBATA S, 1986, NEUROPHARMACOLOGY, V25, P403, DOI 10.1016/0028-3908(86)90235-2; SHIBATA S, 1994, AM J PHYSIOL, V267, pR360, DOI 10.1152/ajpregu.1994.267.2.R360; SHIBATA S, 1992, BRAIN RES, V597, P257, DOI 10.1016/0006-8993(92)91482-T; SHIRAKAWA T, 1994, NEUROSCI LETT, V178, P47, DOI 10.1016/0304-3940(94)90286-0; SIEGEL G, 1991, BASIC NEUROCHEMISTRY, P558; SOUTHAM E, 1992, NEUROSCI LETT, V137, P241, DOI 10.1016/0304-3940(92)90413-2; SOUTHAM E, 1991, NEUROSCI LETT, V130, P107, DOI 10.1016/0304-3940(91)90239-P; SUMMER TL, 1984, AM J PHYSIOL, V246, pR299, DOI 10.1152/ajpregu.1984.246.3.R299; TAKEUCHI Y, 1991, BRAIN RES, V563, P127, DOI 10.1016/0006-8993(91)91524-5; VANDENPOL AN, 1991, J NEUROSCI, V11, P2087; VINCENT SR, 1992, TRENDS NEUROSCI, V15, P108, DOI 10.1016/0166-2236(92)90021-Y; VINCENT SR, 1992, NEUROSCIENCE, V46, P755, DOI 10.1016/0306-4522(92)90184-4; WATANABE A, 1994, BRAIN RES, V646, P161, DOI 10.1016/0006-8993(94)90071-X; WENDLAND B, 1994, P NATL ACAD SCI USA, V91, P2151, DOI 10.1073/pnas.91.6.2151	69	485	494	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1713	1717		10.1126/science.7527589	http://dx.doi.org/10.1126/science.7527589			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7527589				2022-12-28	WOS:A1994PW30800042
J	DEVECIANA, M; MAJOR, CA; MORGAN, MA; ASRAT, T; TOOHEY, JS; LIEN, JM; EVANS, AT				DEVECIANA, M; MAJOR, CA; MORGAN, MA; ASRAT, T; TOOHEY, JS; LIEN, JM; EVANS, AT			POSTPRANDIAL VERSUS PREPRANDIAL BLOOD-GLUCOSE MONITORING IN WOMAN WITH GESTATIONAL DIABETES-MELLITUS REQUIRING INSULIN THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BIRTH-WEIGHT; PERINATAL MORBIDITY; PREGNANCY; MACROSOMIA; COMPLICATIONS; MANAGEMENT; WOMEN	Background. The fetuses of women with gestational diabetes mellitus are at risk for macrosomia and its attendant complications, The best method of achieving euglycemia in these women and reducing morbidity in their infants is not known, We compared the efficacy of postprandial and preprandial monitoring in achieving glycemic control in women with gestational diabetes. Methods. We studied 66 women with gestational diabetes mellitus who required insulin therapy at 30 weeks of gestation or earlier, The women were randomly assigned to have their diabetes managed according to the results of preprandial monitoring or postprandial monitoring (one hour after meals) of blood glucose concentrations, Both groups were also monitored with fasting blood glucose measurements. The goal of insulin therapy was a preprandial value of 60 to 105 mg per deciliter (3.3 to 5.9 mmol per liter) or a postprandial value of less than 140 mg per deciliter (7.8 mmol per liter). Obstetrical data and information on neonatal outcomes were collected. Results. The prepregnancy weight, weight gain during pregnancy, gestational age at the diagnosis of diabetes and at delivery, degree of compliance with therapy, and degree of achievement of target blood glucose concentrations were similar in the two groups, The mean (+/- SD),change in the glycosylated hemoglobin value was greater in the group in which postprandial measurements were used (-3.0+/-2.2 percent vs, -0.6+/-1.6 percent, P<0.001) and the infants' birth weight was lower (3469+/-668 vs, 3848+/-434 g, P=0.01). Similarly, the infants born to the women in the postprandial-monitoring group had a lower rate of neonatal hypoglycemia (3 percent vs, 21 percent, P=0.05), were less often large for gestational age (12 percent vs. 42 percent, P=0.01) and were less often delivered by cesarean section because of cephalopelvic disproportion (12 percent vs. 36 percent, P=0.04) than those in the preprandial-monitoring group. Conclusions. Adjustment of insulin therapy in women with gestational diabetes according to the results of postprandial, rather than preprandial, blood glucose values improves glycemic control and decreases the risk of neonatal hypoglycemia, macrosomia, and cesarean delivery.	UNIV CALIF IRVINE, IRVINE, CA 92717 USA; UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA; LONG BEACH MEM MED CTR, LONG BEACH, CA USA	University of California System; University of California Irvine; University of Pennsylvania	DEVECIANA, M (corresponding author), EASTERN VIRGINIA MED SCH, DEPT OBSTET & GYNECOL, DIV MATERNAL FETAL MED, 825 FAIRFAX AVE, SUITE 310, NORFOLK, VA 23507 USA.							COMBS CA, 1992, DIABETES CARE, V15, P1251, DOI 10.2337/diacare.15.10.1251; DOOLEY SL, 1991, DIABETES, V40, P25, DOI 10.2337/diab.40.2.S25; DREXEL H, 1988, DIABETES CARE, V11, P761, DOI 10.2337/diacare.11.10.761; EDIDIN DV, 1983, PEDIATR RES, V17, pA288; FREINKEL N, 1980, DIABETES, V29, P1023, DOI 10.2337/diabetes.29.12.1023; GABBE SG, 1977, AM J OBSTET GYNECOL, V127, P465, DOI 10.1016/0002-9378(77)90436-7; GABBE SG, 1985, AM J OBSTET GYNECOL, V153, P824, DOI 10.1016/0002-9378(85)90683-0; GOLDBERG JD, 1986, AM J OBSTET GYNECOL, V154, P546, DOI 10.1016/0002-9378(86)90599-5; GOULD BJ, 1982, CLIN CHIM ACTA, V125, P41, DOI 10.1016/0009-8981(82)90043-2; GREEN JR, 1991, OBSTET GYNECOL, V78, P235; HAHM S, 1983, PEDIATR RES, V17, pA315; HOD M, 1991, DIABETES, V40, P74, DOI 10.2337/diab.40.2.S74; JARRETT RJ, 1981, LANCET, V2, P1220; JOVANOVIC L, 1981, AM J MED, V71, P921, DOI 10.1016/0002-9343(81)90301-6; JOVANOVIC L, 1982, DIABETES CARE, V5, P24; JOVANOVICPETERSON L, 1991, AM J OBSTET GYNECOL, V164, P103, DOI 10.1016/0002-9378(91)90637-7; KITZMILLER JL, 1978, AM J OBSTET GYNECOL, V131, P560, DOI 10.1016/0002-9378(78)90120-5; LANGER O, 1988, AM J OBSTET GYNECOL, V159, P1478, DOI 10.1016/0002-9378(88)90578-9; LAVIN JP, 1983, AM J OBSTET GYNECOL, V147, P742, DOI 10.1016/0002-9378(83)90029-7; Major C. A., 1993, American Journal of Obstetrics and Gynecology, V168, P406; MARESH M, 1989, OBSTET GYNECOL, V74, P342; METZGER BE, 1991, DIABETES, V40, P197, DOI 10.2337/diab.40.2.S197; MODANLOU HD, 1982, OBSTET GYNECOL, V60, P417; OSULLIVAN JB, 1964, DIABETES, V13, P278; SPELLACY WN, 1985, OBSTET GYNECOL, V66, P158; WILLIAMS RL, 1982, OBSTET GYNECOL, V59, P624; WILLMAN SP, 1986, AM J OBSTET GYNECOL, V154, P470, DOI 10.1016/0002-9378(86)90692-7	27	423	438	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 9	1995	333	19					1237	1241		10.1056/NEJM199511093331901	http://dx.doi.org/10.1056/NEJM199511093331901			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC715	7565999				2022-12-28	WOS:A1995TC71500001
J	CROSS, SS; HARRISON, RF; KENNEDY, RL				CROSS, SS; HARRISON, RF; KENNEDY, RL			INTRODUCTION TO NEURAL NETWORKS	LANCET			English	Note									UNIV SHEFFIELD,DEPT AUTOMAT CONTROL & SYST ENGN,SHEFFIELD,S YORKSHIRE,ENGLAND; UNIV EDINBURGH,DEPT MED,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND	University of Sheffield; University of Edinburgh	CROSS, SS (corresponding author), UNIV SHEFFIELD,SCH MED,DEPT PATHOL,BEECH HILL RD,SHEFFIELD S10 2UL,S YORKSHIRE,ENGLAND.		Harrison, Robert/B-9034-2008					Ash T., 1989, Connection Science, V1, P365, DOI 10.1080/09540098908915647; BRAHAMS D, 1989, LANCET, V1, P632; CARPENTER GA, 1991, NEURAL NETWORKS, V4, P565, DOI 10.1016/0893-6080(91)90012-T; CARPENTER GA, 1987, COMPUT VISION GRAPH, V37, P54, DOI 10.1016/S0734-189X(87)80014-2; CARPENTER GA, 1993, P WORLD C NEURAL NET, V1, P501; Cybenko G., 1989, Mathematics of Control, Signals, and Systems, V2, P303, DOI 10.1007/BF02551274; Fausett LV, 2006, FUNDAMENTALS NEURAL; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Harrison R. F., 1994, Journal of Artificial Neural Networks, V1, P183; HART A, 1990, MED INFORM, V15, P229, DOI 10.3109/14639239009025270; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; Kohonen Teuvo, 1984, SELF ORG ASS MEMORY; McCulloch Warren S., 1943, BULL MATH BIOPHYS, V5, P115, DOI 10.1007/BF02478259; Moody J, 1989, NEURAL COMPUT, V1, P281, DOI 10.1162/neco.1989.1.2.281; Mozer M. C., 1989, Connection Science, V1, P3, DOI 10.1080/09540098908915626; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; STEEN PM, 1994, ANN THORAC SURG, V58, P1836, DOI 10.1016/0003-4975(94)91723-X; WYATT J, 1991, 15TH P ANN S COMP AP, P3	19	378	383	1	30	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1075	1079		10.1016/S0140-6736(95)91746-2	http://dx.doi.org/10.1016/S0140-6736(95)91746-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564791				2022-12-28	WOS:A1995TA69700015
J	HERNANDEZRODRIGUEZ, NA; CAMBREY, AD; HARRISON, NK; CHAMBERS, RC; GRAY, AJ; SOUTHCOTT, AM; DUBOIS, RM; BLACK, CM; SCULLY, MF; MCANULTY, RJ; LAURENT, GJ				HERNANDEZRODRIGUEZ, NA; CAMBREY, AD; HARRISON, NK; CHAMBERS, RC; GRAY, AJ; SOUTHCOTT, AM; DUBOIS, RM; BLACK, CM; SCULLY, MF; MCANULTY, RJ; LAURENT, GJ			ROLE OF THROMBIN IN PULMONARY FIBROSIS	LANCET			English	Note							GROWTH-FACTORS	Pulmonary fibrosis commonly develops in systemic sclerosis. We assessed the role of thrombin in promoting fibroblast proliferation in the lungs in this disorder. Bronchoalveolar lavage fluid (BALF) thrombin concentrations were higher in ten patients with systemic sclerosis than in 12 healthy controls (14.6 vs 3.6 nmol/L, p<0.02), but values in patients with cryptogenic fibrosing alveolitis (n=10) or sarcoidosis (n=10) were not increased. BALF from all patients induced fibroblast proliferation. This proliferation was attenuated by thrombin inhibitors for BALF from systemic sclerosis patients only. We suggest thrombin contributes to lung fibroblast proliferation in this disorder.	UNIV LONDON UNIV COLL,SCH MED,CTR CARDIOPULM BIOCHEM & RESP MED,LONDON WC1E 6JJ,ENGLAND; MORRISTON HOSP,RESP UNIT,SWANSEA,W GLAM,WALES; NATL HEART & LUNG INST,INTERSTITIAL LUNG DIS UNIT,LONDON,ENGLAND; ROYAL FREE HOSP,DEPT RHEUMATOL,LONDON,ENGLAND; THROMBOSIS RES INST,LONDON SW3 6LR,ENGLAND	University of London; University College London; UCL Medical School; Morriston Hospital; Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Thrombosis Research Institute			McAnulty, Robin J/C-2502-2008	McAnulty, Robin J/0000-0003-1936-4245; Chambers, Rachel/0000-0003-1370-9417				ANTONIADES HN, 1990, J CLIN INVEST, V86, P1055, DOI 10.1172/JCI114808; CAMBREY AD, 1994, AM J RESP CELL MOL, V11, P439, DOI 10.1165/ajrcmb.11.4.7917311; DAWES KE, 1993, EUR J CELL BIOL, V61, P126; GRAY AJ, 1990, J CELL SCI, V96, P271; HARRISON NK, 1991, AM REV RESPIR DIS, V144, P706, DOI 10.1164/ajrccm/144.3_Pt_1.706; HARRISON NK, 1994, CLIN SCI, V86, P141, DOI 10.1042/cs0860141; HARRISON NK, 1993, RESP MED, P190; IDELL S, 1987, AM REV RESPIR DIS, V136, P1466, DOI 10.1164/ajrccm/136.6.1466; LEROY EC, 1988, TXB MED, P1211; OLIVER MH, 1989, J CELL SCI, V92, P513	10	117	118	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1071	1073		10.1016/S0140-6736(95)91744-6	http://dx.doi.org/10.1016/S0140-6736(95)91744-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564789				2022-12-28	WOS:A1995TA69700013
J	CATALONA, WJ; SMITH, DS; WOLFERT, RL; WANG, TJ; RITTENHOUSE, HG; RATLIFF, TL; NADLER, RB				CATALONA, WJ; SMITH, DS; WOLFERT, RL; WANG, TJ; RITTENHOUSE, HG; RATLIFF, TL; NADLER, RB			EVALUATION OF PERCENTAGE OF FREE SERUM PROSTATE-SPECIFIC ANTIGEN TO IMPROVE SPECIFICITY OF PROSTATE-CANCER SCREENING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALPHA-1-ANTICHYMOTRYPSIN; COMPLEX; MEN; DISEASE; ASSAY	Objective.-To evaluate measurement of percentage of free prostate-specific antigen (PSA) in serum to improve the specificity of prostate cancer screening in men with serum PSA levels between 4.1 and 10.0 ng/mL. Design.-Retrospective, nonrandomized analysis using a research assay for measuring free PSA in frozen serum from men with a spectrum of prostate sizes and digital rectal examination results. Setting.-General community outpatient prostate cancer screening program at a university center. Patients.-One hundred thirteen men aged 50 years or older, 99% of whom were white, with serum PSA concentrations of 4.1 to 10.0 ng/mL, including 63 men with histologically confirmed benign prostatic hyperplasia, 30 with prostate cancer with an enlarged gland, and 20 with cancer with a normal-sized gland. All study volunteers had undergone prostatic ultrasonography and biopsy. Main Outcome Measures.-Percentage of free PSA in serum and percentage of free PSA cutoff that maintained at least 90% sensitivity for prostate cancer detection. Results.-Median percentage of free PSA was 9.2% in men with cancer and a normal-sized gland, 15.9% in men with cancer and an enlarged gland, and 18.8% in men with benign prostatic hyperplasia (P<.001). The percentage of free PSA cutoff was higher in men with an enlarged gland and in those with a palpably benign gland. In men with an enlarged, palpably benign gland, a free PSA cutoff of 23.4% or lower detected at least 90% of cancers and would have eliminated 31.3% of negative biopsies. Conclusions.-Measurement of percentage of free serum PSA improves specificity of prostate cancer screening in selected men with elevated total serum PSA levels and can reduce unnecessary prostate biopsies with minimal effects on the cancer detection rate; however, further studies are needed to define optimal cutoffs. Final evaluation of PSA screening also must consider the ability of current treatments to improve the prognosis of screen-detected prostate cancer.	HYBRITECH INC,DEPT RES & DEV,SAN DIEGO,CA		CATALONA, WJ (corresponding author), WASHINGTON UNIV,SCH MED,DEPT SURG,DIV UROL SURG,4960 CHILDRENS PL,ST LOUIS,MO 63110, USA.				NATIONAL CANCER INSTITUTE [P20CA058193] Funding Source: NIH RePORTER; NCI NIH HHS [P20 CA58193] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENSON MC, 1992, J UROLOGY, V147, P815, DOI 10.1016/S0022-5347(17)37393-7; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CATALONA WJ, 1994, J UROLOGY, V152, P2037, DOI 10.1016/S0022-5347(17)32300-5; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; CATALONA WJ, 1994, J UROLOGY, V152, P2031, DOI 10.1016/S0022-5347(17)32299-1; CATALONA WJ, 1991, NEW ENGL J MED, V325, pA132; CHRISTENSSON A, 1993, J UROLOGY, V150, P100, DOI 10.1016/S0022-5347(17)35408-3; DALKIN BL, 1993, J UROLOGY, V150, P1837, DOI 10.1016/S0022-5347(17)35910-4; EPSTEIN JI, 1994, JAMA-J AM MED ASSOC, V271, P368, DOI 10.1001/jama.271.5.368; GANN PH, 1995, JAMA-J AM MED ASSOC, V23, P289; HAYES WL, 1981, STATISTICS, P435; Hosmer D.W., 1989, APPL LOGISTIC REGRES, P16; KEETCH DW, 1994, J UROLOGY, V151, P1571, DOI 10.1016/S0022-5347(17)35304-1; LEINONEN J, 1993, CLIN CHEM, V39, P2098; LILJA H, 1991, CLIN CHEM, V37, P1618; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; METTLIN C, 1994, CANCER, V74, P1615, DOI 10.1002/1097-0142(19940901)74:5<1615::AID-CNCR2820740520>3.0.CO;2-6; OESTERLING JE, 1993, JAMA-J AM MED ASSOC, V270, P860, DOI 10.1001/jama.270.7.860; Seaman E., 1993, Journal of Urology, V149, p414A; SMITH DS, 1994, J UROLOGY, V152, P1163, DOI 10.1016/S0022-5347(17)32528-4; SMITH DS, 1994, J UROLOGY, V152, P1732, DOI 10.1016/S0022-5347(17)32372-8; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STENMAN UH, 1991, CANCER RES, V51, P222; STENMAN UH, 1994, LANCET, V344, P1594, DOI 10.1016/S0140-6736(94)90405-7; STORMONT TJ, 1993, UROLOGY, V41, P3, DOI 10.1016/0090-4295(93)90233-Z; TERRIS MK, 1991, J UROLOGY, V145, P984, DOI 10.1016/S0022-5347(17)38508-7	28	463	473	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	1995	274	15					1214	1220						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ120	7563511				2022-12-28	WOS:A1995RZ12000030
J	SCHUMACHER, MA; CHOI, KY; LU, F; ZALKIN, H; BRENNAN, RG				SCHUMACHER, MA; CHOI, KY; LU, F; ZALKIN, H; BRENNAN, RG			MECHANISM OF COREPRESSOR-MEDIATED SPECIFIC DNA-BINDING BY THE PURINE REPRESSOR	CELL			English	Article							ESCHERICHIA-COLI; CYTR REPRESSOR; MET REPRESSOR; X-RAY; PROTEIN; LIGAND; COMPLEX; CAMP; CRP; CRYSTALLIZATION	The modulation of the affinity of DNA-binding proteins by small molecule effecters for cognate DNA sites is common to both prokaryotes and eukaryotes. However, the mechanisms by which effector binding to one domain affects DNA binding by a distal domain are poorly understood structurally. In initial studies to provide insight into the mechanism of effector-modulated DNA binding of the lactose repressor family, we determined the crystal structure of the purine repressor bound to a corepressor and purF operator. To extend our understanding, we have determined the structure of the corepressor-free corepressor-binding domain of the purine repressor at 2.2 Angstrom resolution. In the unliganded state, structural changes in the corepressor-binding pocket cause each subunit to rotate open by as much as 23 degrees, the consequences of which are the disengagement of the minor groove-binding hinge helices and repressor-DNA dissociation.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus	SCHUMACHER, MA (corresponding author), OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201, USA.			Brennan, Richard/0000-0001-7647-485X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049244, R37GM024658, R01GM024658] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-49244, GM-24658] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CAREAGA CL, 1995, BIOCHEMISTRY-US, V34, P3048, DOI 10.1021/bi00009a036; CHOI KY, 1992, J BACTERIOL, V174, P6207, DOI 10.1128/JB.174.19.6207-6214.1992; CHOI KY, 1994, J BIOL CHEM, V269, P24066; CHOI KY, 1994, J BACTERIOL, V176, P1767, DOI 10.1128/jb.176.6.1767-1772.1994; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; GRALLA JD, 1992, TRANSCRIPTIONAL REGU, V2, P629; Hammer-Jespersen K., 1983, METABOLISM NUCLEOTID, P203; HUECK CJ, 1995, MOL MICROBIOL, V15, P395, DOI 10.1111/j.1365-2958.1995.tb02252.x; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MAUZY CA, 1992, PROTEIN SCI, V1, P843, DOI 10.1002/pro.5560010702; MOLLEGAARD NE, 1993, J BIOL CHEM, V268, P17471; NAGADOI A, 1995, IN PRESS STRUCTURE; OH BH, 1993, J BIOL CHEM, V268, P11348; OLAH GA, 1993, J BIOL CHEM, V268, P16241; OTWINOWSKI Z, 1988, NATURE, V334, P321; PACE HC, 1990, P NATL ACAD SCI USA, V87, P1870, DOI 10.1073/pnas.87.5.1870; PEARL L, 1994, EMBO J, V13, P5810, DOI 10.1002/j.1460-2075.1994.tb06924.x; PEDERSEN H, 1992, J MOL BIOL, V227, P396, DOI 10.1016/0022-2836(92)90896-R; PHILLIPS K, 1994, STRUCTURE, V2, P309, DOI 10.1016/S0969-2126(00)00032-0; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; ROLFES RJ, 1990, J BACTERIOL, V172, P5637, DOI 10.1128/jb.172.10.5637-5642.1990; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SAIER MH, 1995, TRENDS BIOCHEM SCI, V20, P267, DOI 10.1016/S0968-0004(00)89041-6; SCHUMACHER MA, 1992, J MOL BIOL, V225, P1131, DOI 10.1016/0022-2836(92)90111-V; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SOGAARDANDERSEN L, 1993, CELL, V75, P557, DOI 10.1016/0092-8674(93)90389-8; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; SOMERVILLE R, 1992, PROG NUCLEIC ACID RE, V42, P1, DOI 10.1016/S0079-6603(08)60572-3; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; ZALKIN H, 1992, PROG NUCLEIC ACID RE, V42, P259, DOI 10.1016/S0079-6603(08)60578-4	42	91	94	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					147	155		10.1016/0092-8674(95)90243-0	http://dx.doi.org/10.1016/0092-8674(95)90243-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553867	Bronze			2022-12-28	WOS:A1995RY58300019
J	BOUSHEY, CJ; BERESFORD, SAA; OMENN, GS; MOTULSKY, AG				BOUSHEY, CJ; BERESFORD, SAA; OMENN, GS; MOTULSKY, AG			A QUANTITATIVE ASSESSMENT OF PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR VASCULAR-DISEASE - PROBABLE BENEFITS OF INCREASING FOLIC-ACID INTAKES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY-ARTERY DISEASE; LOW-DENSITY LIPOPROTEIN; ISCHEMIC-HEART-DISEASE; BETA-SYNTHASE DEFICIENCY; ENDOTHELIAL-CELL INJURY; CONTAINING AMINO-ACIDS; SMOOTH-MUSCLE CELLS; MYOCARDIAL-INFARCTION; METHYLENETETRAHYDROFOLATE REDUCTASE; HOMOCYST(E)INE LEVELS	Objectives.-To determine the risk of elevated total homocysteine (tHcy) levels for arteriosclerotic vascular disease, estimate the reduction of tHcy by folic acid, and calculate the potential reduction of coronary artery disease (CAD) mortality by increasing folic acid intake. Data Sources.-MEDLINE search for meta-analysis of 27 studies relating homocysteine to arteriosclerotic vascular disease and 11 studies of folio acid effects on tHcy levels. Study Selection and Data Extraction.-Studies dealing with CAD, cerebrovascular disease, and peripheral arterial vascular disease were selected. Three prospective and six population-based case-control studies were considered of high quality. Five cross-sectional and 13 other case-control studies were also included. Causality of tHcy's role in the pathogenesis of vascular disease was inferred because of consistency across studies by different investigators using different methods in different populations. Data Synthesis.-Elevations in tHcy were considered an independent graded risk factor for arteriosclerotic vascular diseases, The odds ratio (OR) for CAD of a 5-mu mol/LtHcy increment is 1.6 (95% confidence interval [CI], 1.4 to 1.7) for men and 1.8 (95% CI, 1.3 to 1.9) for women. A total of 10% of the population's CAD risk appears attributable to tHcy. The OR for cerebrovascular disease (5-mu mol/L tHcy increment) is 1.5 (95% CI, 1.3 to 1.9), Peripheral arterial disease also showed a strong association. Increased folio acid intake (approximately 200 mu g/d) reduces tHcy levels by approximately 4 mu mol/L. Assuming that lower tHcy levels decrease CAD mortality, we calculated the effect of (1) increased dietary folate, (2) supplementation by tablets, and (3) grain fortification. Under different assumptions, 13 500 to 50 000 CAD deaths annually could be avoided; fortification of food had the largest impact. Conclusions.-A 5-mu mol/L tHcy increment elevates CAD risk by as much as cholesterol increases of 0.5 mmol/L (20 mg/dL). Higher folic acid intake by reducing tHcy levels promises to prevent arteriosclerotic vascular disease. Clinical trials are urgently needed. Concerns about masking cobalamin deficiency by folic acid could be lessened by adding 1 mg of cobalamin to folic acid supplements.	UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV WASHINGTON,NW PREVENT EFFECTIVENESS CTR,SEATTLE,WA 98195; UNIV WASHINGTON,NUTR SCI PROGRAM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT ENVIRONM HLTH,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				Omenn, Gilbert S./0000-0002-8976-6074	PHS HHS [U48/CCU 009654] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; ALLEN RH, 1990, AM J HEMATOL, V34, P90, DOI 10.1002/ajh.2830340204; ANDERSSON A, 1991, ATHEROSCLEROSIS, V88, P143, DOI 10.1016/0021-9150(91)90076-F; ANDERSSON A, 1992, EUR J CLIN INVEST, V22, P79, DOI 10.1111/j.1365-2362.1992.tb01940.x; ARAKI A, 1989, ATHEROSCLEROSIS, V79, P139, DOI 10.1016/0021-9150(89)90118-4; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BENDER MM, 1992, J AM DIET ASSOC, V92, P1096; BERESFORD SAA, 1994, AM J PUBLIC HEALTH, V84, P348, DOI 10.2105/AJPH.84.3.348; BERG K, 1992, CLIN GENET, V41, P315; BERGMARK C, 1993, EUR J VASCULAR SURG, V7, P391, DOI 10.1016/S0950-821X(05)80255-5; BLANN AD, 1994, ATHEROSCLEROSIS, V94, P89; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BRATTSTROM L, 1988, METABOLISM, V37, P175, DOI 10.1016/S0026-0495(98)90014-2; BRATTSTROM L, 1990, ATHEROSCLEROSIS, V81, P51, DOI 10.1016/0021-9150(90)90058-Q; BRATTSTROM L, 1992, EUR J CLIN INVEST, V22, P214, DOI 10.1111/j.1365-2362.1992.tb01829.x; BRATTSTROM L, 1994, J INTERN MED, V236, P633, DOI 10.1111/j.1365-2796.1994.tb00856.x; BRATTSTROM L, 1992, NEUROL RES, V14, P81, DOI 10.1080/01616412.1992.11740017; BRATTSTROM LE, 1984, STROKE, V15, P1012, DOI 10.1161/01.STR.15.6.1012; BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; BRATTSTROM LE, 1985, METABOLISM, V34, P1073, DOI 10.1016/0026-0495(85)90082-4; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; CLARKE R, 1992, IRISH J MED SCI, V161, P61, DOI 10.1007/BF02983714; COULL BM, 1990, STROKE, V21, P572, DOI 10.1161/01.STR.21.4.572; DALY L, 1994, APR ANN SCI M WORK G; DAVIS BA, 1994, FASEB J, V8, pA248; Dean A. G., 1990, EPI INFO VERSION 5 W; DENHEIJER M, 1995, LANCET, V345, P882, DOI 10.1016/S0140-6736(95)90008-X; DUDMAN NPB, 1991, ATHEROSCLEROSIS, V91, P77, DOI 10.1016/0021-9150(91)90189-A; DUDMAN NPB, 1993, ARTERIOSCLER THROMB, V13, P1253, DOI 10.1161/01.ATV.13.9.1253; ENGBERSEN AMT, 1995, AM J HUM GENET, V56, P142; FENTON WA, 1995, METABOLIC MOL BASES, P3129; FRANKEN DG, 1994, ARTERIOSCLER THROMB, V14, P465, DOI 10.1161/01.ATV.14.3.465; FRIEDENREICH CM, 1993, EPIDEMIOLOGY, V4, P295, DOI 10.1097/00001648-199307000-00004; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; GENEST JJ, 1990, J AM COLL CARDIOL, V16, P1114, DOI 10.1016/0735-1097(90)90542-W; GENEST JJ, 1991, ARTERIOSCLER THROMB, V11, P1129, DOI 10.1161/01.ATV.11.5.1129; Graham I., 1994, European Heart Journal, V15, P530; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; HARKER LA, 1974, NEW ENGL J MED, V291, P537, DOI 10.1056/NEJM197409122911101; HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; HEINECKE JW, 1984, J CLIN INVEST, V74, P1890, DOI 10.1172/JCI111609; Hennekens C.H., 1987, EPIDEMIOLOGY MED; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; ISRAELSSON B, 1988, ATHEROSCLEROSIS, V71, P227, DOI 10.1016/0021-9150(88)90147-5; JACOB RA, 1994, J NUTR, V124, P1072, DOI 10.1093/jn/124.7.1072; JACOBSEN DW, 1994, CLIN CHEM, V40, P873; KANG SS, 1988, AM J HUM GENET, V43, P414; KANG SS, 1991, AM J HUM GENET, V48, P536; KANG SS, 1986, J CLIN INVEST, V77, P1482, DOI 10.1172/JCI112461; KANG SS, 1987, METABOLISM, V36, P458, DOI 10.1016/0026-0495(87)90043-6; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; LEWIS CA, 1992, ANN NY ACAD SCI, V669, P360; LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; LINDENBAUM J, 1994, AM J CLIN NUTR, V60, P2, DOI 10.1093/ajcn/60.1.2; LINDER MC, 1985, NUTRITIONAL BIOCH ME, P69; LINDGREN A, 1995, STROKE, V26, P795, DOI 10.1161/01.STR.26.5.795; MALINOW MR, 1989, CIRCULATION, V79, P1180, DOI 10.1161/01.CIR.79.6.1180; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; MALINOW MR, 1990, CORONARY ARTERY DIS, V1, P215, DOI 10.1097/00019501-199003000-00010; MCCULLY KS, 1969, AM J PATHOL, V56, P111; MEREAURICHARD C, 1991, CLIN CHEM, V37, P126; MOLGAARD J, 1992, J INTERN MED, V231, P273; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; MURPHYCHUTORIAN DR, 1985, J AM COLL CARDIOL, V6, P725, DOI 10.1016/S0735-1097(85)80473-3; NIGHTINGALE SL, 1993, JAMA-J AM MED ASSOC, V270, P2283, DOI 10.1001/jama.270.19.2283; NYGARD O, IN PRESS JAMA; OLSZEWSKI AJ, 1991, ATHEROSCLEROSIS, V88, P97, DOI 10.1016/0021-9150(91)90262-2; OLSZEWSKI AJ, 1989, ATHEROSCLEROSIS, V75, P1, DOI 10.1016/0021-9150(89)90200-1; OLSZEWSKI AJ, 1988, ATHEROSCLEROSIS, V69, P109, DOI 10.1016/0021-9150(88)90003-2; PANCHARUNITI N, 1994, AM J CLIN NUTR, V59, P940, DOI 10.1093/ajcn/59.4.940; PARTHASARATHY S, 1987, BIOCHIM BIOPHYS ACTA, V917, P337, DOI 10.1016/0005-2760(87)90139-1; Petitti D, 1994, METAANALYSIS DECISIO; REED T, 1991, CLIN GENET, V39, P425; Rosenblatt DS., 1995, METABOLIC MOL BASES, P3111; RUBBA P, 1990, METABOLISM, V39, P1191, DOI 10.1016/0026-0495(90)90093-R; SAUBERLICH HE, 1987, AM J CLIN NUTR, V46, P1016, DOI 10.1093/ajcn/46.6.1016; SAUBERLICH HE, 1990, FOLIC ACID METABOLIS, P212; Savage D.G., 1995, FOLATE HLTH DIS, V1st, P237; SCHAFER LW, 1985, MAYO CLIN PROC, V60, P444, DOI 10.1016/S0025-6196(12)60867-2; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STABLER SP, 1988, J CLIN INVEST, V81, P466, DOI 10.1172/JCI113343; STAMPFER MJ, 1995, NEW ENGL J MED, V332, P328, DOI 10.1056/NEJM199502023320511; STAMPFER MJ, 1993, JAMA-J AM MED ASSOC, V270, P2726, DOI 10.1001/jama.270.22.2726; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; SUBAR AF, 1989, AM J CLIN NUTR, V520, P508; TAYLOR LM, 1991, J VASC SURG, V13, P128, DOI 10.1016/0741-5214(91)90020-U; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; UBBINK JB, 1993, AM J CLIN NUTR, V57, P47, DOI 10.1093/ajcn/57.1.47; UBBINK JB, 1991, KLIN WOCHENSCHR, V69, P527, DOI 10.1007/BF01649290; UBBINK JB, 1994, J NUTR, V124, P1927, DOI 10.1093/jn/124.10.1927; UBBINK JB, 1993, CLIN INVESTIGATOR, V71, P993, DOI 10.1007/BF00180030; UELAND PM, 1993, CLIN CHEM, V39, P1764; VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924; VONECKARDSTEIN A, 1994, ARTERIOSCLER THROMB, V14, P460, DOI 10.1161/01.ATV.14.3.460; WALL RT, 1980, THROMB RES, V18, P113, DOI 10.1016/0049-3848(80)90175-9; WILCKEN DEL, 1983, NEW ENGL J MED, V309, P448, DOI 10.1056/NEJM198308253090802; WILCKEN DEL, 1983, METABOLISM, V32, P363, DOI 10.1016/0026-0495(83)90045-8; WILCKEN DEL, 1976, J CLIN INVEST, V57, P1079, DOI 10.1172/JCI108350; Willet W. C., 1990, NUTRITIONAL EPIDEMIO, P341; WILLIAMS RR, 1990, CORONARY ARTERY DIS, V1, P681, DOI 10.1097/00019501-199011000-00008; WILSON PWF, 1994, JAMA-J AM MED ASSOC, V272, P1666, DOI 10.1001/jama.272.21.1666; WU LL, 1994, CLIN CHEM, V40, P552; 1993, STATISTICAL ABSTRACT; 1993, FED REG         1014, V58, P53254; 1993, FED REG         1014, V58, P55305; 1992, MMWR-MORBID MORTAL W, V41, P1	108	3025	3216	1	193	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1049	1057		10.1001/jama.274.13.1049	http://dx.doi.org/10.1001/jama.274.13.1049			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX108	7563456				2022-12-28	WOS:A1995RX10800028
J	LINGNER, J; COOPER, JP; CECH, TR				LINGNER, J; COOPER, JP; CECH, TR			TELOMERASE AND DNA END REPLICATION - NO LONGER A LAGGING-STRAND PROBLEM	SCIENCE			English	Editorial Material							TERMINAL TRANSFERASE-ACTIVITY; 3' TERMINUS; S-PHASE; SEQUENCES; MOLECULES; ORIGIN				LINGNER, J (corresponding author), UNIV COLORADO,DEPT CHEM & BIOCHEM,HOWARD HUGHES MED INST,BOULDER,CO 80309, USA.			Lingner, Joachim/0000-0002-2853-5803; cooper, julia promisel/0000-0003-2171-2587				BATEMAN AJ, 1975, NATURE, V253, P379, DOI 10.1038/253379a0; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; CAVALIER.T, 1974, NATURE, V250, P467, DOI 10.1038/250467a0; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; LEE MS, 1993, COLD SPRING HARB SYM, V58, P707, DOI 10.1101/SQB.1993.058.01.078; LINGNER J, UNPUB; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; Nakamura T., UNPUB; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WELLINGER RJ, 1993, MOL CELL BIOL, V13, P4057, DOI 10.1128/MCB.13.7.4057; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953	20	307	320	0	30	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 15	1995	269	5230					1533	1534		10.1126/science.7545310	http://dx.doi.org/10.1126/science.7545310			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7545310				2022-12-28	WOS:A1995RU81300029
J	VESPA, J; WATSON, F				VESPA, J; WATSON, F			WHO IS NUTRITIONALLY VULNERABLE IN BOSNIA-HERZEGOVINA	BRITISH MEDICAL JOURNAL			English	Article								Objective-To monitor nutritional status and food security in order to identify nutritionally vulnerable groups. Design-Members of five different household groups (urban and rural residents, displaced people in collective centres and private accommodation, elderly people living without younger family) and ail residents of two old people's homes were prospectively followed. Households were selected from 20 local communities and nine collective centres. Setting-Monitoring carried out in three besieged areas of Bosnia-Hercegovina (Sarajevo, Tuzla, and Zenica). Subjects-1739 individuals sampled. Interventions-Data collected every month from December 1993 to May 1994, Information on household food security was collected through structured questionnaires. AU subjects were weighed and their heights measured, Weight for age Z scores were calculated far children; body mass index was calculated for adults and elderly people. Results-From December 1993 to February 1994, before a temporary cease fire, access to food was reduced, In February 1994 no significant signs of undernutrition were detected among children or adults, but elderly people had higher than expected levels of undernutrition (15.5% with body mass index <18.5), a higher rate of weight loss than adults (1.2 kg over two months), and a higher prevalence of self reported illness. Conclusions-Elderly people in Bosnia-Hercegovina are at greater risk of undernutrition than other age groups, Undernutrition may be precipitated in elderly people by sickness, cold, stress, and problems related to food preparation, The health and welfare of elderly people during the emergency in Bosnia-Hercegovina require special attention, and integrated age care programmes are needed.	WHO,REG OFF EUROPE,ZAGREB AREA OFF,ZAGREB 4100,CROATIA	World Health Organization								BENNET GJ, 1992, ESSENTIALS HLTH CARE, P108; DEAN AD, 1990, EPI INFO SOFTWARE VE; EVNAS JG, 1992, OXFORD TXB GERIATRIC, P4; Gregory F., 1990, DIETARY NUTR SURVEY; JAMES WPT, 1994, J EUR CLIN NUTR S3, V48, P179; MURPHY E, 1985, PREVENTION DISEASE E, P156; ROBERTSON A, 1994, NUTRITION VACCINATIO; SHETTY PS, 1994, FAO56 FOOD NUTR PAP; 1992, REPORT HLTH SOCIAL S, V43; 1976, NCHS GROWTH CHARTS; 1992, MWMK, V41, P809; 1994, REPORT FOOD DELIVERI	12	24	24	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	1995	311	7006					652	654		10.1136/bmj.311.7006.652	http://dx.doi.org/10.1136/bmj.311.7006.652			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU753	7549631	Green Published			2022-12-28	WOS:A1995RU75300015
J	ROTHE, M; SARMA, V; DIXIT, VW; GOEDDEL, DV				ROTHE, M; SARMA, V; DIXIT, VW; GOEDDEL, DV			TRAF2-MEDIATED ACTIVATION OF NF-KAPPA-B BY TNF RECEPTOR-2 AND CD40	SCIENCE			English	Article							NECROSIS-FACTOR RECEPTORS	TNF receptor-associated factor (TRAF) proteins are candidate signal transducers that associate with the cytoplasmic domains of members of the tumor necrosis factor (TNF) receptor superfamily. The role of TRAFs in the TNF-R2 and CD40 signal transduction pathways, which result in the activation of transcription factor NF-kappa B, was investigated. Overexpression of TRAF2, but not TRAF1 or TRAF3, was sufficient to induce NF-kappa B activation. A truncated derivative of TRAF2 lacking an amino-terminal RING finger domain was a dominant-negative inhibitor of NF-kappa B activation mediated by TNF-R2 and CD40. Thus, TRAF2 is a common mediator of TNF-R2 and CD40 signaling.	TULARIK INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NCI NIH HHS [CA64803] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; CHANG G, 1995, SCIENCE, V267, P1494; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hsu H.-J., UNPUB; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HU HM, 1994, J BIOL CHEM, V269, P30069; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PENNICA D, 1992, J BIOL CHEM, V267, P21172; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; ROTHE M, UNPUB; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997	24	948	983	1	17	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 8	1995	269	5229					1424	1427		10.1126/science.7544915	http://dx.doi.org/10.1126/science.7544915			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7544915				2022-12-28	WOS:A1995RT80600045
J	GRETCH, DR; DELAROSA, C; CARITHERS, RL; WILLSON, RA; WILLIAMS, B; COREY, L				GRETCH, DR; DELAROSA, C; CARITHERS, RL; WILLSON, RA; WILLIAMS, B; COREY, L			ASSESSMENT OF HEPATITIS-C VIREMIA USING MOLECULAR AMPLIFICATION TECHNOLOGIES - CORRELATIONS AND CLINICAL IMPLICATIONS	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS C; VIREMIA; HEPATITIS C VIRUSES; RNA POLYMERASES; POLYMERASE CHAIN REACTION	POLYMERASE CHAIN-REACTION; NON-B-HEPATITIS; VIRUS-RNA; NON-A; ANTIBODIES; INFECTION; CRYOGLOBULINEMIA; DIAGNOSIS; DISEASE; PRIMERS	Objective: To compare two recently developed molecular techniques for quantitating the levels of hepatitis C virus (HCV) RNA in the serum of patients with a wide spectrum of chronic hepatitis C. Design: Serum samples from 299 patients with HCV viremia, 101 control patients without HCV infection, and 19 consecutive patients receiving systemic interferon therapy were evaluated by a commercially available branched-chain DNA (bDNA) assay and a quantitative competitive polymerase chain reaction (PCR). Setting: University-based hepatology clinics and reference virology laboratory. Patients: Patients with HCV viremia as defined by results of qualitative RNA PCR, including 53 HCV-infected blood donors, 34 patients receiving renal dialysis, and 212 patients attending a hepatology clinic. Results: Results of in vitro and in vivo experiments indicated that the sensitivity and dynamic range of the PCR assays were greater than those of the bDNA assay. Detection of HCV viremia by the bDNA assay was highly dependent on viral RNA titers, with a sensitivity of 5% at HCV RNA titers of 5.0 logs per mL or less and 94% at titers of 5.5 logs per mt or greater. The best correlation between assays was observed in specimens with HCV RNA titers between 6.0 and 7.5 logs per mL (r = 0.73). In patients with high-titer HCV viremia, including liver transplant recipients and patients with cirrhosis, quantitative PCR results were an average of 12-fold higher than bDNA assay results. Results of repetitive testing of discordant specimens showed that these discrepancies were caused by a high kit-to-kit coefficient of variation (112%) in the bDNA assay. Of 19 patients receiving interferon therapy, 9 (47%) became bDNA negative, but only 5 became quantitative PCR negative. The bDNA-negative, quantitative PCR-positive patients all had relapse when therapy was discontinued. Conclusions: The bDNA assay has a narrower linear range for quantitation of HCV viremia than quantitative PCR. Because persons with low HCV titers may respond well to therapy, seropositive persons with negative bDNA results should be retested with PCR-based assays. Similarly, the bDNA assay may underestimate the true degree of HCV viremia in persons with endstage infection (>10(7) RNA equivalents/mL of sera). Despite these limitations, the combination of bDNA- and PCR-based assays appears to be optimal for selecting and following patients during interferon therapy.	WASHINGTON UNIV, MED CTR, SEATTLE, WA USA; UNIV WASHINGTON, HARBORVIEW MED CTR, SEATTLE, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle			Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436				ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; CASATO M, 1991, LANCET, V337, P1047, DOI 10.1016/0140-6736(91)92715-E; CHAZOUILLERES O, 1994, GASTROENTEROLOGY, V106, P994, DOI 10.1016/0016-5085(94)90759-5; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DAVIS GL, 1994, HEPATOLOGY, V19, P1337, DOI 10.1002/hep.1840190603; ENOMOTO N, 1990, BIOCHEM BIOPH RES CO, V170, P1021, DOI 10.1016/0006-291X(90)90494-8; ESTEBAN JI, 1989, LANCET, V2, P294; FARUKI H, 1994, HEPATOLOGY, V20, pA238; FERRI C, 1991, ARTHRITIS RHEUM, V34, P1606; GANE EJ, 1994, HEPATOLOGY, V20, pA136; GRETCH D, 1992, J CLIN MICROBIOL, V30, P2145, DOI 10.1128/JCM.30.8.2145-2149.1992; GRETCH D, 1994, J INFECT DIS, V169, P1219, DOI 10.1093/infdis/169.6.1219; GRETCH D, 1993, HEPATOLOGY, V18, pA88, DOI 10.1016/0270-9139(93)91879-W; GRETCH DR, 1993, J CLIN MICROBIOL, V31, P289, DOI 10.1128/JCM.31.2.289-291.1993; HAGIWARA H, 1993, HEPATOLOGY, V17, P545, DOI 10.1002/hep.1840170404; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; JOHNSON RJ, 1993, NEW ENGL J MED, V328, P465, DOI 10.1056/NEJM199302183280703; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; MISIANI R, 1992, ANN INTERN MED, V117, P573, DOI 10.7326/0003-4819-117-7-573; OKAMOTO H, 1990, JPN J EXP MED, V60, P215; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; URDEA MS, 1993, NUCL ACID S SER, V23, P197; VANDERPOEL CL, 1989, LANCET, V2, P297; YUN ZB, 1994, SCAND J INFECT DIS, V26, P263, DOI 10.3109/00365549409011794	25	131	136	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1995	123	5					321	329		10.7326/0003-4819-123-5-199509010-00001	http://dx.doi.org/10.7326/0003-4819-123-5-199509010-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ988	7542853				2022-12-28	WOS:A1995RQ98800001
J	LEV, S; MORENO, H; MARTINEZ, R; CANOLL, P; PELES, E; MUSACCHIO, JM; PLOWMAN, GD; RUDY, B; SCHLESSINGER, J				LEV, S; MORENO, H; MARTINEZ, R; CANOLL, P; PELES, E; MUSACCHIO, JM; PLOWMAN, GD; RUDY, B; SCHLESSINGER, J			PROTEIN-TYROSINE KINASE PYK2 INVOLVED IN CA2+-INDUCED REGULATION OF ION-CHANNEL AND MAP KINASE FUNCTIONS	NATURE			English	Article							NERVE GROWTH-FACTOR; POTASSIUM CHANNEL; ACETYLCHOLINE-RECEPTOR; PC12 CELLS; RAS; PHOSPHORYLATION; ACTIVATION; GENE; TRANSFORMATION; DOMAINS	The protein tyrosine kinase PYK2, which is highly expressed in the central nervous system, is rapidly phosphorylated on tyrosine residues in response to various stimuli that elevate the intracellular calcium concentration, as well as by protein kinase C activation. Activation of PYK2 leads to modulation of ion channel function and activation of the MAP kinase signalling pathway. PYK2 activation may provide a mechanism for a variety of short- and long-term calcium-dependent signalling events in the nervous system.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; NYU,MED CTR,DEPT PHYSIOL,NEW YORK,NY 10016; SUGEN INC,REDWOOD CITY,CA 94063	New York University; New York University			Lev, Sima/AAP-7880-2020; PLOWMAN, Greg D/E-2012-2011	Lev, Sima/0000-0002-2108-3330; Peles, Elior/0000-0002-3325-0597; Plowman, Gregory D/0000-0002-6465-309X; Rudy, Bernardo/0000-0001-5748-6900				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHANDY KG, 1991, NATURE, V352, P26, DOI 10.1038/352026b0; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; FASOLATO C, 1988, J BIOL CHEM, V263, P17350; GHOSH A, 1994, J NEUROBIOL, V25, P294, DOI 10.1002/neu.480250309; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hille B., 1992, IONIC CHANNELS EXCIT; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; IVERSON LE, 1990, J NEUROSCI, V10, P2903; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LAMMERS R, 1993, J BIOL CHEM, V248, P24456; LEV S, 1992, J BIOL CHEM, V267, P15970; Levitan IB, 1991, NEURON CELL MOL BIOL; LI M, 1993, SCIENCE, V261, P1439, DOI 10.1126/science.8396273; LI N, 1993, NATURE, V263, P85; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANES E, 1993, NATURE, V363, P364; MARIAS R, 1993, CELL, V73, P381; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; MCKINNON D, 1989, J BIOL CHEM, V264, P8230; MESSING RO, 1989, J NEUROSCI, V9, P507; Moreno H., 1994, Society for Neuroscience Abstracts, V20, P725; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PAULMICHL M, 1991, P NATL ACAD SCI USA, V88, P7892, DOI 10.1073/pnas.88.17.7892; PAWSON A, 1993, CURR BIOL, V3, P4345; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; REPP H, 1993, P NATL ACAD SCI USA, V90, P3403, DOI 10.1073/pnas.90.8.3403; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; Wagner K R, 1991, Curr Opin Neurobiol, V1, P65, DOI 10.1016/0959-4388(91)90011-U; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	50	1252	1275	0	37	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					737	745		10.1038/376737a0	http://dx.doi.org/10.1038/376737a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7544443				2022-12-28	WOS:A1995RR83600031
J	UMBHAUER, M; MARSHALL, CJ; MASON, CS; OLD, RW; SMITH, JC				UMBHAUER, M; MARSHALL, CJ; MASON, CS; OLD, RW; SMITH, JC			MESODERM INDUCTION IN XENOPUS CAUSED BY ACTIVATION OF MAP KINASE	NATURE			English	Article							MIDBLASTULA TRANSITION; SPEMANN ORGANIZER; RAF-1 KINASE; EXPRESSION; FGF; EMBRYOS; TRANSCRIPTION; P21RAS; NOGGIN; LAEVIS	MESODERM induction is a critical early step in vertebrate development, involving changes in gene expression and morphogenesis(1), In Xenopus, normal mesoderm formation depends on signalling through the fibroblast growth factor (FGF) tyrosine kinase receptor(2-4). One important signalling pathway from receptor tyrosine kinases involves p21(ras) (ref, 5). Ras associates with the serine kinase c-Raf-1 in a GTP-dependent manner, and this complex phosphorylates and activates MAPK/ERK kinase (MEK), a protein kinase with dual specificity, MEK then activates p42(mapk); and (at least in mammals) p44(mapk), members of the mitogen-activated protein (MAP) kinase family(6), FGF activates MAP kinase during mesoderm induction(7-9), and the use of dominant-negative constructs suggests that mesoderm induction by FGF requires both Res and Raf(10,11). However, these experiments Bo not reveal whether Ras and Raf do act through MAP kinase to induce mesoderm or whether another pathway, such as the phosphatidylinositol 3-kinase cascade(12), is involved. Here we show that expression of active forms of MEK or of MAP kinase induces ventral mesoderm of the hind elicited by FGF, Overexpression of a Xenopus MAP kinase phosphatase Mocks mesoderm induction by FGF, and causes characteristic defects in mesoderm formation in intact embryos, whereas inhibition of the P13 kinase and p70 S6 kinase pathways has no effect on mesoderm induction by FGF, FGF induces different types of mesoderm in a dose-dependent manner(13); strikingly, this is mimicked by expressing different levels of activated MEK. Together, these experiments demonstrate that activation of MAP kinases is necessary and sufficient for mesoderm formation.	INST CANC RES,CRC,CTR CELLULAR & MOLEC BIOL,LONDON SW3 6JB,ENGLAND; UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Warwick	UMBHAUER, M (corresponding author), NATL INST MED RES,DIV DEV BIOL,THE RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.			Umbhauer, Muriel/0000-0001-7419-8070; Smith, Jim/0000-0003-2413-9392; Mason, Clive/0000-0003-3179-6622				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BASSEZ T, 1990, DEVELOPMENT, V110, P966; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CORNELL RA, 1994, DEVELOPMENT, V120, P453; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUNLIFFE V, 1994, EMBO J, V13, P349, DOI 10.1002/j.1460-2075.1994.tb06268.x; GRAVES LM, 1994, P NATL ACAD SCI USA, V91, P1662, DOI 10.1073/pnas.91.5.1662; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GREEN JBA, 1990, DEVELOPMENT, V108, P229; HARTLEY RS, 1994, DEV BIOL, V163, P521, DOI 10.1006/dbio.1994.1168; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ISAACS HV, 1994, EMBO J, V13, P4469, DOI 10.1002/j.1460-2075.1994.tb06769.x; KRIEG PA, 1987, P NATL ACAD SCI USA, V84, P2331, DOI 10.1073/pnas.84.8.2331; LABONNE C, 1994, DEVELOPMENT, V120, P463; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MOHUN TJ, 1986, EMBO J, V5, P3185, DOI 10.1002/j.1460-2075.1986.tb04628.x; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; Nieuwkoop P. D., 1975, NORMAL TABLE XENOPUS; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SMITH JC, 1993, EMBO J, V12, P4463, DOI 10.1002/j.1460-2075.1993.tb06135.x; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH JC, 1993, CELLULAR INTERACTION, P181; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0	34	203	204	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					58	62		10.1038/376058a0	http://dx.doi.org/10.1038/376058a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7541116				2022-12-28	WOS:A1995RH11100061
J	CARMAN, WF; KORULA, J; WALLACE, L; MACPHEE, R; MIMMS, L; DECKER, R				CARMAN, WF; KORULA, J; WALLACE, L; MACPHEE, R; MIMMS, L; DECKER, R			FULMINANT REACTIVATION OF HEPATITIS-B DUE TO ENVELOPE PROTEIN MUTANT THAT ESCAPED DETECTION BY MONOCLONAL HBSAG ELISA	LANCET			English	Note							SURFACE-ANTIGEN; VIRUS; DETERMINANT	The detection of a fatal case of reactivation of hepatitis B, in a previously vaccinated Indonesian patient after withdrawal of chemotherapy for lymphoma, was delayed because HBsAg was negative in a widely used monoclonal-antibody-based ELISA. The serum was later found to be strongly reactive for HBsAg by the polyclonal radioimmunoassay and for HBV DNA. PCR sequencing revealed a substitution of arginine for glycine at position 145 of HBsAg in the major neutralising epitope cluster, the a determinant, as well as a 2-aminoacid insertion of asparagine and threonine between positions 122 and 123, immediately upstream of this determinant.	UNIV SO CALIF,DIV GASTROINTESTINAL & LIVER DIS,LOS ANGELES,CA; UNIV SO CALIF,DEPT PATHOL,LOS ANGELES,CA; ABBOTT LABS,EXPTL BIOL RES,N CHICAGO,IL 60064	University of Southern California; University of Southern California; Abbott Laboratories	CARMAN, WF (corresponding author), UNIV GLASGOW,INST VIROL,CHURCH ST,GLASGOW G11 5JR,LANARK,SCOTLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CARMAN WF, 1990, LANCET, V336, P325, DOI 10.1016/0140-6736(90)91874-A; CARMAN WF, 1991, HEPATOLOGY, V14, P219, DOI 10.1002/hep.1840140203; HARRISON TJ, 1991, J HEPATOL, V13, pS105, DOI 10.1016/0168-8278(91)90037-C; KARTHIGESU VD, 1994, J GEN VIROL, V75, P443, DOI 10.1099/0022-1317-75-2-443; KOSAKA Y, 1991, GASTROENTEROLOGY, V324, P1087; PETERSON DL, 1984, J IMMUNOL, V132, P920; SASTROSOEWIGNJO RI, 1991, J GASTROEN HEPATOL, V6, P491, DOI 10.1111/j.1440-1746.1991.tb00894.x; WALLACE LA, 1994, J INFECT DIS, V170, P1300, DOI 10.1093/infdis/170.5.1300; WATERS JA, 1992, J CLIN INVEST, V90, P2543, DOI 10.1172/JCI116148; YAMAMOTO K, 1994, J VIROL, V68, P2671, DOI 10.1128/JVI.68.4.2671-2676.1994	10	183	198	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 3	1995	345	8962					1406	1407		10.1016/S0140-6736(95)92599-6	http://dx.doi.org/10.1016/S0140-6736(95)92599-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7539089				2022-12-28	WOS:A1995RB44100011
J	CHINNAIYAN, AM; OROURKE, K; TEWARI, M; DIXIT, VM				CHINNAIYAN, AM; OROURKE, K; TEWARI, M; DIXIT, VM			FADD, A NOVEL DEATH DOMAIN-CONTAINING PROTEIN, INTERACTS WITH THE DEATH DOMAIN OF FAS AND INITIATES APOPTOSIS	CELL			English	Article							INTERLEUKIN-1-BETA CONVERTING ENZYME; CELL-DEATH; MONOCLONAL-ANTIBODY; GENE CED-3; ANTIGEN; INHIBITOR; INDUCTION; RECEPTOR; ENCODES	Using the cytoplasmic domain of Pas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Pas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8. FADD contains a death domain homologous to the death domains of Pas and TNFR-1. A point mutation in FADD, analogous to the lpr mutation of Fas, abolishes its ability to bind Pas, suggesting a death domain to death domain interaction. Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Pas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme; These findings suggest that FADD may play an important role in the proximal signal transduction of Fas.			CHINNAIYAN, AM (corresponding author), UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109, USA.		dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326				BAGLIONI C, 1992, TUMOR NECROSIS FACTO; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; HARPER JW, 1993, CELL, V75, P805; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HU HM, 1994, J BIOL CHEM, V369, P30069; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RON D, 1992, BIOTECHNIQUES, V13, P866; RON D, 1992, BIOTECHNIQUES, V14, P221; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sambrook J, 1989, MOL CLONING LABORATO; SONG HY, 1994, J BIOL CHEM, V269, P22492; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	34	2045	2152	3	64	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					505	512		10.1016/0092-8674(95)90071-3	http://dx.doi.org/10.1016/0092-8674(95)90071-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7538907	Bronze			2022-12-28	WOS:A1995QZ71000007
J	PANDEY, A; SHAO, HN; MARKS, RM; POLVERINI, PJ; DIXIT, VM				PANDEY, A; SHAO, HN; MARKS, RM; POLVERINI, PJ; DIXIT, VM			ROLE OF B61, THE LIGAND FOR THE ECK RECEPTOR TYROSINE KINASE, IN TNF-ALPHA-INDUCED ANGIOGENESIS	SCIENCE			English	Article							NECROSIS-FACTOR-ALPHA; RESPONSE GENE; PROTEIN; CLONING	B61, a cytokine-inducible endothelial gene product, is the ligand for the Eck receptor protein tyrosine kinase (RPTK), Expression of a B61-immunoglobulin chimera showed that B61 could act as an angiogenic factor in vivo and a chemoattractant for endothelial cells in vitro, The Eck RPTK was activated by tumor necrosis factor-alpha (TNF-alpha) through induction of B61, and an antibody to B61 attenuated angiogenesis induced by TNF-alpha but not by basic fibroblast growth factor, This finding suggests the existence of an autocrine or paracrine loop involving activation of the Eck RPTK by its inducible ligand B61 after an inflammatory stimulus, the net effect of which would be to promote angiogenesis, a hallmark of chronic inflammation,	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH DENT,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Polverini, Peter/AAJ-8392-2020; dixit, vishva m/A-4496-2012; Pandey, Akhilesh/B-4127-2009	dixit, vishva m/0000-0001-6983-0326; Pandey, Akhilesh/0000-0001-9943-6127	NHLBI NIH HHS [HL 39926] Funding Source: Medline; NIAID NIH HHS [P0 1AI331890004] Funding Source: Medline; NIDDK NIH HHS [DK 39255] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039255] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BAGLIONI C, 1992, TUMOR NECROSIS FACTO, P425; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; FAJARDO LF, 1992, AM J PATHOL, V140, P539; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MONTRUCCHIO G, 1994, J EXP MED, V180, P377, DOI 10.1084/jem.180.1.377; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, UNPUB; SARMA V, 1992, J IMMUNOL, V148, P3302; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; SHAO HN, 1994, J BIOL CHEM, V269, P26606; STREITER RM, 1992, AM J PATHOL, V141, P1279	17	343	374	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 28	1995	268	5210					567	569		10.1126/science.7536959	http://dx.doi.org/10.1126/science.7536959			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7536959				2022-12-28	WOS:A1995QV40700037
J	ATKISON, P; JOUBERT, G; BARRON, A; GRANT, D; PARADIS, K; SEIDMAN, E; WALL, W; ROSENBERG, H; HOWARD, J; WILLIAMS, S; STILLER, C				ATKISON, P; JOUBERT, G; BARRON, A; GRANT, D; PARADIS, K; SEIDMAN, E; WALL, W; ROSENBERG, H; HOWARD, J; WILLIAMS, S; STILLER, C			HYPERTROPHIC CARDIOMYOPATHY ASSOCIATED WITH TACROLIMUS IN PEDIATRIC TRANSPLANT PATIENTS	LANCET			English	Note							LIVER-TRANSPLANTATION; ALLOGRAFT RECIPIENTS; RENAL-FUNCTION; CYCLOSPORINE; FK-506	Reported side-effects of tacrolimus, a potent immunosuppressive agent, have not included cardiotoxicity. We describe 5 consecutive paediatric transplant recipients (3 small bowel with or without liver and 2 liver) who received tacrolimus. 2 developed congestive heart failure and hypertrophic obstructive cardiomyopathy which resolved after changing to cyclosporin. In the other 3 patients the cardiomyopathy regressed or improved with a lower dose of tacrolimus or after stopping the drug.	UNIV MONTREAL,HOP ST JUSTINE,MONTREAL,PQ H3T 1C5,CANADA	Universite de Montreal	ATKISON, P (corresponding author), UNIV WESTERN ONTARIO,CHILDRENS HOSP WESTERN ONTARIO,800 COMMISSIONERS RD E,LONDON,ON N6C 2V5,CANADA.							ABUELMAGD K, 1992, TRANSPLANT P, V24, P1243; DEMETRIS AJ, 1992, TRANSPLANTATION, V53, P1056, DOI 10.1097/00007890-199205000-00017; MCCAULEY J, 1990, TRANSPLANT P, V22, P17; MCDIARMID SV, 1993, TRANSPLANTATION, V56, P847, DOI 10.1097/00007890-199310000-00014; Noto S, 1994, TRANSPLANT P, V26, P855; TEXTOR SC, 1993, TRANSPLANTATION, V55, P855; THIRU S, 1987, TRANSPLANT P, V19, P98; WHITINGTON PF, 1994, SEMIN LIVER DIS, V14, P303, DOI 10.1055/s-2007-1007320; WIEDERRECHT G, 1994, ANN NY ACAD SCI, V696, P9; 1994, LANCET, V344, P423	10	168	172	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					894	896		10.1016/S0140-6736(95)90011-X	http://dx.doi.org/10.1016/S0140-6736(95)90011-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7535875				2022-12-28	WOS:A1995QR06700011
J	KUIDA, K; LIPPKE, JA; KU, G; HARDING, MW; LIVINGSTON, DJ; SU, MSS; FLAVELL, RA				KUIDA, K; LIPPKE, JA; KU, G; HARDING, MW; LIVINGSTON, DJ; SU, MSS; FLAVELL, RA			ALTERED CYTOKINE EXPORT AND APOPTOSIS IN MICE DEFICIENT IN INTERLEUKIN-1-BETA CONVERTING-ENZYME	SCIENCE			English	Article							DEATH GENE CED-3; CELL-DEATH; PRECURSOR; PROTEASE; ELEGANS; BCL-2; FAS; SPECIFICITY; ACTIVATION; IL-1-ALPHA	The interleukin-1 beta (IL-1 beta) converting enzyme (ICE) processes the inactive IL-1 beta precursor to the proinflammatory cytokine. Adherent monocytes from mice harboring a disrupted ICE gene (ICE(-/-)) did not export IL-1 beta or interleukin-1 alpha (IL-1 alpha) after stimulation with lipopolysaccharide. Export of tumor necrosis factor-alpha and interleukin-6 (IL-6) from these cells was also diminished. Thymocytes from ICE(-/-) mice were sensitive to apoptosis induced by dexamethasone or ionizing radiation, but were resistant to apoptosis induced by Fas antibody. Despite this defect in apoptosis, ICE(-/-) mice proceed normally through development.	VERTEX PHARMACEUT INC,CAMBRIDGE,MA 02139; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	Vertex Pharmaceuticals; Howard Hughes Medical Institute; Yale University; Yale University			Roszak, Joanna/F-4003-2010					AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BLACK RA, 1988, J BIOL CHEM, V263, P9437; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CARRUTH LM, 1991, J BIOL CHEM, V266, P12162; CASANO FJ, 1994, GENOMICS, V20, P474, DOI 10.1006/geno.1994.1203; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN JJ, 1984, J IMMUNOL, V132, P38; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; FAUCHEU C, UNPUB; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HAZUDA DJ, 1990, J BIOL CHEM, V265, P6318; HOWARD AD, 1991, J IMMUNOL, V147, P2964; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PERREGAUX D, 1992, J IMMUNOL, V149, P1294; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SIDERS WM, 1993, J BIOL CHEM, V268, P22170; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VELS DJ, 1993, CELL, V75, P229; VOELKELJOHNSON C, 1995, J IMMUNOL, V154, P1707; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEAVER VM, 1993, BIOCHEM CELL BIOL, V71, P488, DOI 10.1139/o93-071; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	42	1451	1484	0	28	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					2000	2003		10.1126/science.7535475	http://dx.doi.org/10.1126/science.7535475			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7535475				2022-12-28	WOS:A1995QQ06800046
J	ELLING, CE; NIELSEN, SM; SCHWARTZ, TW				ELLING, CE; NIELSEN, SM; SCHWARTZ, TW			CONVERSION OF ANTAGONIST-BINDING SITE TO METAL-ION SITE IN THE TACHYKININ NK-1 RECEPTOR	NATURE			English	Article							NEUROKININ-1 RECEPTOR; PROTEIN; NK1; IDENTIFICATION; EPITOPES; DOMAINS; DESIGN	MUTATIONAL analysis of the tachykinin NK-1 (refs 1-7), NK-2 (ref. 8) and angiotensin AT-1 (refs 9, 10) receptors indicates that non-peptide antagonists act through residues located between the seven transmembrane segments, whereas natural peptide agonists bind to residues scattered in the exterior part of the receptor(1-4,11-13). The presumed contact points for the prototype NK-1 antagonist CP96,345 cluster on opposing faces of the outer portions of transmembrane helices V and VI (refs 1-5). Here we show that systematic introduction of histidyl residues at this antagonist-binding site in the human NK-1 receptor gradually converts it into a high-affinity metal-ion-binding site without affecting agonist binding. In a double mutant with histidine residues substituted at the top of transmembrane segments V and VI, respectively, Zn2+ inhibits binding of radiolabelled agonist peptide and efficiently blocks phosphoinositol turnover induced by substance P. We propose that Zn2+ and CP96,345 act as 'allosteric competitive' antagonists by stabilizing inactive conformations of the mutant and the wild-type receptor respectively. Introduction of metal-ion-binding sites could be used as a general tool in the structural and functional characterization of helix-helix interactions in G-protein-coupled receptors, as well as in other membrane proteins.	RIGSHOSP,DEPT CLIN BIOCHEM,MOLEC ENDOCRINOL LAB,DK-2100 COPENHAGEN,DENMARK	Rigshospitalet; University of Copenhagen				Schwartz, Thue W./0000-0002-0261-6904				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BETZ SF, 1993, CURR OPIN STRUC BIOL, V3, P601, DOI 10.1016/0959-440X(93)90090-8; CASCIERI MA, 1994, J BIOL CHEM, V269, P6587; CHAKRABARTI P, 1990, PROTEIN ENG, V4, P57, DOI 10.1093/protein/4.1.57; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; FONG TM, 1994, J BIOL CHEM, V269, P2728; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1993, NATURE, V362, P350; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, J BIOL CHEM, V268, P7893; GETHER U, 1993, P NATL ACAD SCI USA, V90, P6194, DOI 10.1073/pnas.90.13.6194; GETHER U, 1994, J BIOL CHEM, V269, P23959; GETHER U, 1994, MOL PHARMACOL, V45, P500; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P3; HANDEL TM, 1993, SCIENCE, V261, P879, DOI 10.1126/science.8346440; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; JERIGAN R, 1994, CURR OPIN STRUCT BIO, V4, P256; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; REGAN L, 1993, ANNU REV BIOPH BIOM, V22, P257, DOI 10.1146/annurev.bb.22.060193.001353; ROSENKILDE MM, 1994, J BIOL CHEM, V269, P28160; SAMAMA P, 1993, MOL PHARMACOL, V45, P390; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; STAPPERT J, 1992, NUCLEIC ACIDS RES, V20, P624, DOI 10.1093/nar/20.3.624; SURYANARAYANA S, 1992, J BIOL CHEM, V267, P21991; ZHOU W, 1994, MOL PHARMACOL, V45, P165; ZOFFMANN S, 1993, FEBS LETT, V336, P506, DOI 10.1016/0014-5793(93)80865-R	30	160	164	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					74	77		10.1038/374074a0	http://dx.doi.org/10.1038/374074a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7532789				2022-12-28	WOS:A1995QK07900056
J	MIETTINEN, TA; PUSKA, P; GYLLING, H; VANHANEN, H; VARTIAINEN, E				MIETTINEN, TA; PUSKA, P; GYLLING, H; VANHANEN, H; VARTIAINEN, E			REDUCTION OF SERUM-CHOLESTEROL WITH SITOSTANOL-ESTER MARGARINE IN A MILDLY HYPERCHOLESTEROLEMIC POPULATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DENSITY-LIPOPROTEIN; PLANT STEROLS; ABSORPTION; PRECURSORS	Background. Dietary plant sterols, especially sitostanol, reduce serum cholesterol by inhibiting cholesterol absorption. Soluble sitostanol may be more effective than a less soluble preparation. We tested the tolerability and cholesterol-lowering effect of margarine containing sitostanol ester in a population with mild hypercholesterolemia. Methods. We conducted a one-year, randomized, double-blind study in 153 randomly selected subjects with mild hypercholesterolemia. Fifty-one consumed margarine without sitostanol ester (the control group), and 102 consumed margarine containing sitostanol ester (1.8 or 2.6 g of sitostanol per day). Results. The margarine containing sitostanol ester was well tolerated. The mean one-year reduction in serum cholesterol was 10.2 percent in the sitostanol group, as compared with an increase of 0.1 percent in the control group. The difference in the change in serum cholesterol concentration between the two groups was -24 mg per deciliter (95 percent confidence interval, -17 to -32; P<0.001). The respective reductions in low-density lipoprotein (LDL) cholesterol were 14.1 percent in the sitostanol group and 1.1 percent in the control group. The difference in the change in LDL cholesterol concentration between the two groups was -21 mg per deciliter (95 percent confidence interval, -14 to -29; P<0.001). Neither serum triglyceride nor high-density lipoprotein cholesterol concentrations were affected by sitostanol. Serum campesterol, a dietary plant sterol whose levels reflect cholesterol absorption, was decreased by 36 percent in the sitostanol group, and the reduction was directly correlated with the reduction in total cholesterol (r=0.57, P<0.001). Conclusions, Substituting sitostanol-ester margarine for part of the daily fat intake in subjects with mild hypercholesterolemia was effective in lowering serum total cholesterol and LDL cholesterol.	NATL PUBL HLTH INST, DEPT EPIDEMIOL & HLTH PROMOT, HELSINKI, FINLAND	Finland National Institute for Health & Welfare	MIETTINEN, TA (corresponding author), UNIV HELSINKI, DEPT MED, DIV INTERNAL MED, HAARTMANINKATU 4, SF-00290 HELSINKI, FINLAND.							BECKER M, 1993, J PEDIATR-US, V122, P292, DOI 10.1016/S0022-3476(06)80136-8; DENKE MA, 1995, AM J CLIN NUTR, V61, P392, DOI 10.1093/ajcn/61.2.392; FARQUHAR JW, 1956, CIRCULATION, V14, P77, DOI 10.1161/01.CIR.14.1.77; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; GRUNDY SM, 1969, J LIPID RES, V10, P304; GYLLING H, 1994, DIABETOLOGIA, V37, P773, DOI 10.1007/s001250050178; HEINEMANN T, 1986, ATHEROSCLEROSIS, V61, P219, DOI 10.1016/0021-9150(86)90141-3; HEINEMANN T, 1991, EUR J CLIN PHARMACOL, V40, pS59, DOI 10.1007/BF01409411; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LEES AM, 1977, ATHEROSCLEROSIS, V28, P325, DOI 10.1016/0021-9150(77)90180-0; LEES RS, 1976, LIPOPROTEIN METABOLI, P119; MATTSON FH, 1982, AM J CLIN NUTR, V35, P697, DOI 10.1093/ajcn/35.4.697; MIETTINEN TA, 1994, ATHEROSCLEROSIS, V105, P217, DOI 10.1016/0021-9150(94)90052-3; MIETTINEN TA, 1990, AM J EPIDEMIOL, V131, P20, DOI 10.1093/oxfordjournals.aje.a115479; Miettinen TA, 1983, BILE ACIDS CHOLESTER, P183; OSTER P, 1976, DEUT MED WOCHENSCHR, V101, P1308, DOI 10.1055/s-0028-1104262; SCHWARTZKOPFF W, 1978, MUNCHEN MED WOCHEN, V120, P1575; TILVIS RS, 1986, AM J CLIN NUTR, V43, P92, DOI 10.1093/ajcn/43.1.92; VANHANEN HT, 1994, CLIN SCI, V87, P61, DOI 10.1042/cs0870061; VANHANEN HT, 1993, J LIPID RES, V34, P1535; VARTIAINEN E, 1994, INT J EPIDEMIOL, V23, P495, DOI 10.1093/ije/23.3.495; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499	23	587	626	0	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 16	1995	333	20					1308	1312		10.1056/NEJM199511163332002	http://dx.doi.org/10.1056/NEJM199511163332002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE365	7566021				2022-12-28	WOS:A1995TE36500002
J	BOSMA, PJ; CHOWDHURY, JR; BAKKER, C; GANTLA, S; DEBOER, A; OOSTRA, BA; LINDHOUT, D; TYTGAT, GNJ; JANSEN, PLM; ELFERINK, RPJO; CHOWDHURY, NR				BOSMA, PJ; CHOWDHURY, JR; BAKKER, C; GANTLA, S; DEBOER, A; OOSTRA, BA; LINDHOUT, D; TYTGAT, GNJ; JANSEN, PLM; ELFERINK, RPJO; CHOWDHURY, NR			THE GENETIC-BASIS OF THE REDUCED EXPRESSION OF BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE-1 IN GILBERTS-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CRIGLER-NAJJAR SYNDROME; RNA POLYMERASE-II; BETA-GLOBIN GENE; COMPLEX LOCUS; MUTATION; IDENTIFICATION; TRANSCRIPTION; PATIENT; HYPERBILIRUBINEMIA; DISEASE	Background. People with Gilbert's syndrome have mild, chronic unconjugated hyperbilirubinemia in the absence of liver disease or overt hemolysis. Hepatic glucuronidating activity, essential for efficient biliary excretion of bilirubin, is reduced to about 30 percent of normal. Methods. We sequenced the coding and promoter regions of the gene for bilirubin UDP-glucuronosyltransferase 1 (bilirubin/uridine diphosphoglucuronate-glucuronosyltransferase 1) - the only enzyme that contributes substantially to bi[irubin glucuronidation - in 10 unrelated patients with Gilbert's syndrome, 16 members of a kindred with a history of Crigler-Najjar syndrome type II, and 55 normal subjects. Results. The coding region of the gene for the enzyme was normal in the 10 patients with Gilbert's syndrome. These patients were homozygous for two extra bases (TA) in the TATAA element of the 5' promoter region of the gene (A(TA)(7)TAA rather than the normal A(TA)(6)TAA). The presence of the. longer TATAA element resulted in the reduced expression of a reporter gene, encoding firefly luciferase, in a human hepatoma cell line. The frequency of the abnormal allele was 40 percent among the normal subjects. The 3 men in the control group who were homozygous for the longer TATAA element had significantly higher serum bilirubin levels than the other 52 normal subjects (P = 0.009). Among the kindred with a history of Crigler-Najjar syndrome type II, only the six heterozygous carriers who had a longer TATAA element on the structurally normal allele had mild hyperbilirubinemia, characteristic of Gilbert's syndrome. Conclusions. Reduced expression of bilirubin UDP-glucuronosyltransferase 1 due to an abnormality in the promoter region of the gene for this enzyme appears to be necessary for Gilbert's syndrome but not sufficient for the complete manifestation of the syndrome.	ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,DEPT MED,DIV GASTROENTEROL & LIVER DIS,BRONX,NY; ALBERT EINSTEIN COLL MED,DEPT MOLEC GENET,BRONX,NY; ERASMUS UNIV ROTTERDAM,DEPT CLIN GENET,3000 DR ROTTERDAM,NETHERLANDS; ACAD HOSP GRONINGEN,DEPT GASTROENTEROL & HEPATOL,GRONINGEN,NETHERLANDS	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Erasmus University Rotterdam; University of Groningen	BOSMA, PJ (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT GASTROENTEROL & HEPATOL,FO-116,MEIBERGDREEF 9,1105 AZ AMSTERDAM,NETHERLANDS.		Jansen, Peter LM/I-4509-2013; Lindhout, Dick/AAH-5765-2019	Lindhout, Dick/0000-0001-9580-624X	NIDDK NIH HHS [R01-DK46057, R01-DK39137, P30-DK41296] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046057, R01DK039137, P30DK041296] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altman DG, 1991, PRACTICAL STATISTICS; ARIAS IM, 1969, AM J MED, V47, P395, DOI 10.1016/0002-9343(69)90224-1; ARIAS IM, 1957, SCIENCE, V126, P563, DOI 10.1126/science.126.3273.563; BAILEY A, 1977, LANCET, V1, P931; BENSINGER TA, 1973, P SOC EXP BIOL MED, V144, P417, DOI 10.3181/00379727-144-37603; BERK PD, 1972, ANN INTERN MED, V77, P527, DOI 10.7326/0003-4819-77-4-527; BERK PD, 1972, GASTROENTEROLOGY, V63, P472; BILLING BH, 1964, CLIN SCI, V27, P245; BLACK M, 1969, NEW ENGL J MED, V280, P1266, DOI 10.1056/NEJM196906052802303; BOSMA PJ, 1993, GASTROENTEROLOGY, V105, P216, DOI 10.1016/0016-5085(93)90029-C; BOSMA PJ, 1992, FASEB J, V6, P2859, DOI 10.1096/fasebj.6.10.1634050; BOSMA PJ, 1994, J BIOL CHEM, V269, P17960; BOSMA PJ, 1992, HEPATOLOGY, V15, P941, DOI 10.1002/hep.1840150531; BOSMA PJ, 1994, J BIOL CHEM, V269, P2542; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chowdhury Jayanta Roy, 1994, P471; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; ERPS LT, 1994, J CLIN INVEST, V93, P564, DOI 10.1172/JCI117008; FELSHER BF, 1979, J LAB CLIN MED, V93, P414; FEVERY J, 1977, J CLIN INVEST, V60, P970, DOI 10.1172/JCI108877; Gilbert A., 1901, SEMAINE MEDICALE, V21, P241; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GROSVELD GC, 1982, NATURE, V295, P120, DOI 10.1038/295120a0; HUNTER JO, 1973, GUT, V14, P46, DOI 10.1136/gut.14.1.46; Jendrassik L, 1938, BIOCHEM Z, V297, P81; LABRUNE P, 1993, HEPATOLOGY, V18, pA126, DOI 10.1016/0270-9139(93)92034-W; LUNDH B, 1972, SCAND J CLIN LAB INV, V30, P421, DOI 10.3109/00365517209080280; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MARTIN JF, 1976, GASTROENTEROLOGY, V70, P385; MOGHRABI N, 1993, GENOMICS, V18, P171, DOI 10.1006/geno.1993.1451; MOGHRABI N, 1993, AM J HUM GENET, V53, P722; MURACA M, 1984, GASTROENTEROLOGY, V87, P308; OWENS D, 1975, J MED GENET, V12, P152, DOI 10.1136/jmg.12.2.152; OWENS IS, 1992, PHARMACOGENETICS, V2, P93, DOI 10.1097/00008571-199206000-00001; PLATT T, 1972, EXPT MOL GENETICS, P352; POWELL LW, 1967, NEW ENGL J MED, V277, P1108, DOI 10.1056/NEJM196711232772102; RITTER JK, 1992, J CLIN INVEST, V90, P150, DOI 10.1172/JCI115829; RITTER JK, 1993, J BIOL CHEM, V268, P23573; RITTER JK, 1992, J BIOL CHEM, V267, P3257; RITTER JK, 1991, J BIOL CHEM, V266, P1043; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SEPPEN J, 1994, J CLIN INVEST, V94, P2385, DOI 10.1172/JCI117604; SIEG A, 1987, DEUT MED WOCHENSCHR, V112, P1206, DOI 10.1055/s-2008-1068222; SPIVAK W, 1985, BIOCHEM J, V225, P787, DOI 10.1042/bj2250787; Thompson R.P.H., 1981, FAMILIAL HYPERBILIRU, P91	45	1125	1173	1	30	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 2	1995	333	18					1171	1175		10.1056/NEJM199511023331802	http://dx.doi.org/10.1056/NEJM199511023331802			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB560	7565971				2022-12-28	WOS:A1995TB56000002
J	DESJARLAIS, DC; HAGAN, H; FRIEDMAN, SR; FRIEDMANN, P; GOLDBERG, D; FRISCHER, M; GREEN, S; TUNVING, K; LJUNGBERG, B; WODAK, A; ROSS, M; PURCHASE, D; MILLSON, ME; MYERS, T				DESJARLAIS, DC; HAGAN, H; FRIEDMAN, SR; FRIEDMANN, P; GOLDBERG, D; FRISCHER, M; GREEN, S; TUNVING, K; LJUNGBERG, B; WODAK, A; ROSS, M; PURCHASE, D; MILLSON, ME; MYERS, T			MAINTAINING LOW HIV SEROPREVALENCE IN POPULATIONS OF INJECTING DRUG-USERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYRINGE EXCHANGE; INFECTION; AIDS; PREVENTION; BEHAVIORS; SAMPLES; GLASGOW; SWEDEN; HEALTH	Objectives.-To describe prevention activities and risk behavior in cities where human immunodeficiency virus (HIV) was introduced into the local population of injecting drug users (IDUs), but where seroprevalence has nevertheless remained low (<5%) during at least 5 years. Design and Setting.-A literature search identified five such cities: Glasgow, Scotland; Lund, Sweden; Sydney, New South Wales, Australia; Tacoma, Wash; and Toronto, Ontario, Case histories were prepared for each city, including data on prevention activities and current levels of risk behavior among IDUs. Participants.-Injecting drug users recruited from both drug treatment and nontreatment settings in each city. Interventions.-A variety of HIV prevention activities for IDUs had been implemented in each of the five cities. Results.-There were three common prevention components present in all five cities: (1) implementation of prevention activities when HIV seroprevalence was still low, (2) provision of sterile injection equipment, and (3) community outreach to IDUs, Moderate levels of risk behavior continued with one third or more of the IDUs reporting recent unsafe injections. Conclusions.-In low-seroprevalence areas, it appears possible to severely limit transmission of HIV among populations of IDUs, despite continuing risk behavior among a substantial proportion of the population. Pending further studies, the common prevention components (beginning early, community outreach, and access to sterile injection equipment) should be implemented wherever populations of IDUs are at risk for rapid spread of HIV.	NATL DEV & RES INST INC,NEW YORK,NY; TACOMA PIERCE CTY HLTH DEPT,TACOMA,WA; POINT DEFIANCE AIDS PREVENT PROJECT,TACOMA,WA; RUCHILL HOSP,COMMUNICABLE DIS SCOTLAND UNIT,GLASGOW G20 9NB,LANARK,SCOTLAND; LUND UNIV,DEPT PSYCHIAT & NEUROCHEM,S-22101 LUND,SWEDEN; LUND UNIV,DEPT INFECT DIS,S-22101 LUND,SWEDEN; ST VINCENTS HOSP,ALCOHOL & DRUG SERV,SYDNEY,NSW 2010,AUSTRALIA; NATL CTR HIV SOCIAL RES,SYDNEY,NSW,AUSTRALIA; UNIV TORONTO,DEPT PREVENT MED & BIOSTAT,TORONTO,ON,CANADA; UNIV TORONTO,DEPT HLTH ADM,TORONTO,ON,CANADA	National Development & Research Institutes, Inc; Lund University; Lund University; St Vincents Hospital Sydney; University of Toronto; University of Toronto	DESJARLAIS, DC (corresponding author), BETH ISRAEL MED CTR,INST CHEM DEPENDENCY,11 BEACH ST,NEW YORK,NY 10013, USA.			Ross, Michael/0000-0002-5718-9989	NIDA NIH HHS [DA03574] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003574] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ANDERSON RM, 1991, NATURE, V352, P581, DOI 10.1038/352581a0; BAKER M, 1991, 7TH INT C AIDS FLOR; BROWN BS, 1993, HDB RISK AIDS; CARR SV, 1992, AIDS, V6, P1553, DOI 10.1097/00002030-199212000-00028; CHITWOOD DD, 1994, AM J PUBLIC HEALTH, V84, P350, DOI 10.2105/AJPH.84.3.350; CHRISTENSSON B, 1991, INT J ADDICT, V26, P1293, DOI 10.3109/10826089109062161; CORDERO LA, 1986, REV ROUM MATH PURE A, V31, P9; DESJARLAIS DC, 1994, AM J PUBLIC HEALTH, V84, P452, DOI 10.2105/AJPH.84.3.452; DESJARLAIS DC, 1992, AIDS, V6, P1053, DOI 10.1097/00002030-199210000-00001; DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008; DESJARLAIS DC, 1994, FINAL REPORT WHO PRO; DESJARLAIS DC, 1992, AIDS OTHER MANIFESTA, P645; DESJARLAIS DC, 1994, 10TH INT C AIDS YOK; DICLEMENTE RJ, 1994, PREVENTING AIDS THEO; Dolan K A, 1993, Drug Alcohol Rev, V12, P133, DOI 10.1080/09595239300185561; EKSTRAND ML, 1990, AM J PUBLIC HEALTH, V80, P973, DOI 10.2105/AJPH.80.8.973; FRIEDMAN S R, 1991, AIDS Care, V3, P239, DOI 10.1080/09540129108253069; FRIEDMAN SR, 1993, AIDS, V7, pS263, DOI 10.1097/00002030-199301001-00037; FRISCHER M, 1992, AIDS, V6, P1371, DOI 10.1097/00002030-199211000-00022; FRISCHER M, 1992, INT J STD AIDS, V3, P288, DOI 10.1177/095646249200300412; FRISCHER M, 1993, INT J ADDICT, V28, P129, DOI 10.3109/10826089309039619; FRISCHER M, 1993, ADDICTION, V88, P681, DOI 10.1111/j.1360-0443.1993.tb02081.x; HAGAN H, 1993, ADDICTION, V88, P1691, DOI 10.1111/j.1360-0443.1993.tb02044.x; HAGAN H, 1991, Journal of Addictive Diseases, V10, P81, DOI 10.1300/J069v10n04_06; HAGAN H, 1993, HIV 1 SEROPREVALENCE; Kaldor J, 1993, Drug Alcohol Rev, V12, P175, DOI 10.1080/09595239300185611; Lamothe F, 1992, Can Commun Dis Rep, V18, P98; LAMPINEN TM, 1992, AIDS, V6, P123, DOI 10.1097/00002030-199201000-00017; LJUNGBERG B, 1991, J ACQ IMMUN DEF SYND, V4, P890; LURIE P, 1993, PUBLIC HLTH IMPACT N, V1; MILLSON P, 1991, NHRDP66064333AIDS NA; MILLSON P, 1993, 9 INT C AIDS BERL; MILLSON P, 1992, 2ND ANN CAN NAT C HI; NAIK TN, 1991, AIDS, V5, P117, DOI 10.1097/00002030-199101000-00026; NEAIGUS A, 1994, SOC SCI MED, V38, P67, DOI 10.1016/0277-9536(94)90301-8; OSMOND DH, 1992, ONDCP B, V7; PAPAEVANGELOU G, 1991, 7 INT C AIDS FLOR; ROBERTSON JR, 1986, BRIT MED J, V292, P527, DOI 10.1136/bmj.292.6519.527; ROSS MW, 1992, AIDS CARE, V4, P139, DOI 10.1080/09540129208253085; ROSS MW, IN PRESS J R SOC HLT; ROSS MW, IN PRESS AIDS CARE; STALL R, 1993, J ACQ IMMUN DEF SYND, V3, P1181; STIMSON GV, 1995, 6TH INT C RED DRUG R; STIMSON GV, IN PRESS SOC SCI MED; STIMSON GV, 1990, 6TH INT C AIDS SAN F; TAYLOR A, IN PRESS ADDICTION; TUNVING K, 1992, 8TH INT C AIDS AMST; VANICHSENI S, 1990, 6TH INT C AIDS SAN F	48	189	193	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	1995	274	15					1226	1231		10.1001/jama.274.15.1226	http://dx.doi.org/10.1001/jama.274.15.1226			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RZ120	7563513				2022-12-28	WOS:A1995RZ12000032
J	LEIJTEN, FSS; HARNICKDEWEERD, JE; POORTVLIET, DCJ; DEWEERD, AW				LEIJTEN, FSS; HARNICKDEWEERD, JE; POORTVLIET, DCJ; DEWEERD, AW			THE ROLE OF POLYNEUROPATHY IN MOTOR CONVALESCENCE AFTER PROLONGED MECHANICAL VENTILATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICAL ILLNESS POLYNEUROPATHY; MULTIPLE-ORGAN FAILURE; ILL PATIENTS; SEPSIS; DEFINITIONS; NEUROPATHY; SEVERITY	Objective.-To test the hypothesis that prolonged motor recovery after longterm ventilation may be due to polyneuropathy and can be foreseen at an early stage by electromyography (EMG). Design.-Cohort study with an entry period of 18 months. Polyneuropathy was identified by EMG studies in the intensive care unit (ICU). During a 1-year followup, amount of time was recorded to reach a rehabilitation end point. Setting.-The general ICU of a community hospital. Patients.-Fifty patients younger than 75 years who were receiving mechanical ventilation for more than 7 days. Main Outcome Measures.-A rehabilitation end point was defined as return of normal muscle strength and ability to walk 50 m independently. Results.-In 29 of 50 patients, an EMG diagnosis of polyneuropathy was made in the ICU. Patients with polyneuropathy had a higher mortality in the ICU (14 vs 4; P=.03), probably related to multiple organ failure (22 vs 11; P=.08) oraminoglycoside treatment of suspected gram-negative sepsis (17 vs 4; P=.05). Rehabilitation was more prolonged in 12 patients with polyneuropathy than in 12 without polyneuropathy (P=.001). Of nine patients with delays beyond 4 weeks, eight had polyneuropathy, five of whom had persistent motor handicap after 1 year. In particular, axonal polyneuropathy with conduction slowing on EMG indicated a poor prognosis. Conclusions.-Polyneuropathy in the critically ill is related to multiple organ failure and gram-negative sepsis, is associated with higher mortality, and causes important rehabilitation problems. EMG recordings in the ICU can identify patients at risk.	WESTEINDE ZIEKENHUIS,DEPT NEUROL,THE HAGUE,NETHERLANDS; WESTEINDE ZIEKENHUIS,DEPT CLIN NEUROPHYSIOL,THE HAGUE,NETHERLANDS; WESTEINDE ZIEKENHUIS,DEPT ANESTHESIOL & INTENS CARE,THE HAGUE,NETHERLANDS									[Anonymous], 1976, AIDS INVESTIGATION P; ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707; BARAT M, 1987, REV NEUROL, V143, P823; BOLTON CF, 1986, J NEUROL NEUROSUR PS, V49, P563, DOI 10.1136/jnnp.49.5.563; BOLTON CF, 1984, J NEUROL NEUROSUR PS, V47, P1223, DOI 10.1136/jnnp.47.11.1223; Bolton CF, 1983, NEUROLOGY CLEVELA S2, V33, P186; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; COAKLEY JH, 1993, INTENS CARE MED, V19, P323, DOI 10.1007/BF01694705; CORONEL B, 1990, CRIT CARE MED, V18, P486, DOI 10.1097/00003246-199005000-00004; DECOUL AAW, 1983, CLIN NEUROL NEUROSUR, V85, P197; DECOUL AAWO, 1985, CLIN NEUROL NEUROSUR, V87, P17, DOI 10.1016/0303-8467(85)90060-5; DECOUL AAWO, 1991, CLIN NEUROL NEUROSUR, V93, P27, DOI 10.1016/0303-8467(91)90005-A; DODSON BA, 1995, CRIT CARE MED, V23, P815, DOI 10.1097/00003246-199505000-00007; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; GORSON KC, 1993, CRIT CARE MED, V21, P267, DOI 10.1097/00003246-199302000-00020; KELLY BJ, 1993, CHEST, V104, P1818, DOI 10.1378/chest.104.6.1818; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEIJTEN FSS, 1994, CLIN NEUROL NEUROSUR, V96, P10, DOI 10.1016/0303-8467(94)90023-X; LEMAIRE F, 1993, INTENS CARE MED, V19, pS69, DOI 10.1007/BF01708804; MESSA JBL, 1990, INTENS CARE MED, V16, P159, DOI 10.1007/BF01724794; NIJHOLT JLA, 1987, HDB CLIN NEUROLOGY, V7, P575; REPINE JE, 1992, LANCET, V339, P466, DOI 10.1016/0140-6736(92)91067-I; RIVNER MH, 1983, NEUROLOGY S2, V33, P164; Roelofs RI, 1983, NEUROLOGY S, V33, P240; SEISER A, 1992, WIEN KLIN WOCHENSCHR, V104, P294; SPITZER AR, 1992, MUSCLE NERVE, V15, P682, DOI 10.1002/mus.880150609; SPRUNG CL, 1991, CRIT CARE MED, V19, P849; WILLIAMS AC, 1986, BRIT MED J, V293, P790, DOI 10.1136/bmj.293.6550.790-a; WITT NJ, 1991, CHEST, V99, P176, DOI 10.1378/chest.99.1.176; ZOCHODNE DW, 1987, BRAIN, V110, P819, DOI 10.1093/brain/110.4.819	30	201	204	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	1995	274	15					1221	1225		10.1001/jama.274.15.1221	http://dx.doi.org/10.1001/jama.274.15.1221			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ120	7563512				2022-12-28	WOS:A1995RZ12000031
J	KLEINER, DE; EMMERTBUCK, MR; LIOTTA, LA				KLEINER, DE; EMMERTBUCK, MR; LIOTTA, LA			NECROPSY AS A RESEARCH METHOD IN THE AGE OF MOLECULAR PATHOLOGY	LANCET			English	Review							IMMUNE-DEFICIENCY SYNDROME; PARAFFIN-EMBEDDED TISSUES; POLYMERASE CHAIN-REACTION; AUTOPSY; DNA; LIVER; POSTMORTEM; AUDIT; RNA				KLEINER, DE (corresponding author), NCI,PATHOL LAB,BETHESDA,MD 20892, USA.		Kleiner, David E/N-2770-2013	Kleiner, David E/0000-0003-3442-4453				ABRAMS HL, 1950, CANCER, V3, P74, DOI 10.1002/1097-0142(1950)3:1<74::AID-CNCR2820030111>3.0.CO;2-7; Alafuzoff I, 1993, Qual Assur Health Care, V5, P345; ALBRO J, 1993, CYTOMETRY, V14, P673, DOI 10.1002/cyto.990140612; ARCIDI JM, 1981, AM J PATHOL, V104, P159; BARENDREGT WB, 1992, SURG GYNECOL OBSTET, V175, P227; BARTONROGERS B, 1990, AM J PATHOL, V136, P541; EMMERTBUCK MR, 1994, AM J PATHOL, V145, P1285; FELDMANN H, 1993, VIRUS RES, V30, P351, DOI 10.1016/0168-1702(93)90101-R; FINGER JM, 1987, CLIN CHIM ACTA, V170, P209, DOI 10.1016/0009-8981(87)90130-6; GOWAN AD, 1993, APPL IMMUNOHISTOCHEM, V1, P256; HARRIS A, 1993, J ROY COLL PHYS LOND, V27, P116; HILL RB, 1992, CA-CANCER J CLIN, V42, P47, DOI 10.3322/canjclin.42.1.47; HSU IC, 1985, IN VITRO CELL DEV B, V21, P154; HUI AN, 1984, HUM PATHOL, V15, P670; HUMPHREYS-BEHER M G, 1986, Biotechnology and Applied Biochemistry, V8, P392; IKENBERG H, 1994, GYNECOL ONCOL, V54, P316, DOI 10.1006/gyno.1994.1216; KIENE P, 1992, VIRCHOWS ARCH A, V420, P269, DOI 10.1007/BF01600280; KING EMFO, 1993, AGE AGEING, V22, P209, DOI 10.1093/ageing/22.3.209; LARSEN S, 1992, APMIS, V100, P498, DOI 10.1111/j.1699-0463.1992.tb00902.x; MCKELVIE PA, 1992, MED J AUSTRALIA, V156, P456, DOI 10.5694/j.1326-5377.1992.tb126470.x; MOIN K, 1992, BIOCHEM J, V285, P427, DOI 10.1042/bj2850427; MOSQUERA DA, 1993, ANN ROY COLL SURG, V75, P115; REICHERT CM, 1983, AM J PATHOL, V112, P357; SANO N, 1991, ACTA PATHOL JAPON, V41, P668; SEI S, 1994, J INFECT DIS, V170, P325, DOI 10.1093/infdis/170.2.325; SETO E, 1987, AM J PATHOL, V127, P409; TRUMP BF, 1979, HUM PATHOL, V10, P245, DOI 10.1016/S0046-8177(79)80019-2; TURNER PC, 1993, J INFECTION, V27, P43, DOI 10.1016/0163-4453(93)93663-O; Veress B, 1993, Qual Assur Health Care, V5, P281; WELCH K, 1984, JAMA-J AM MED ASSOC, V252, P1152, DOI 10.1001/jama.252.9.1152; ZHUANG ZP, 1995, CANCER RES, V55, P467	31	28	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					945	948		10.1016/S0140-6736(95)91561-3	http://dx.doi.org/10.1016/S0140-6736(95)91561-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564732				2022-12-28	WOS:A1995RY80800013
J	COUNTS, JL; GOODMAN, JI				COUNTS, JL; GOODMAN, JI			ALTERATIONS IN DNA METHYLATION MAY PLAY A VARIETY OF ROLES IN CARCINOGENESIS	CELL			English	Review											COUNTS, JL (corresponding author), MICHIGAN STATE UNIV,DEPT PHARMACOL & TOXICOL,E LANSING,MI 48824, USA.							COUNTS JL, 1994, MOL CARCINOGEN, V11, P185, DOI 10.1002/mc.2940110402; COUNTS JL, 1995, LIVER REGENERATION C, P227; FERGUSON AT, 1995, CANCER RES, V55, P2279; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; GAMMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883; GREGER V, 1984, HUM GENET, V94, P491; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PITOT HC, 1991, FASEB J, V5, P2280, DOI 10.1096/fasebj.5.9.1860619; RAY JS, 1994, MOL CARCINOGEN, V9, P155, DOI 10.1002/mc.2940090307; RAZIN A, 1994, PROG NUCLEIC ACID RE, V48, P53, DOI 10.1016/S0079-6603(08)60853-3; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; TORNALETTI S, 1995, ONCOGENE, V10, P1493; YANG AS, 1995, NUCLEIC ACIDS RES, V23, P1380, DOI 10.1093/nar/23.8.1380	17	207	212	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					13	15		10.1016/0092-8674(95)90228-7	http://dx.doi.org/10.1016/0092-8674(95)90228-7			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553865	Bronze			2022-12-28	WOS:A1995RY58300004
J	LEVACHER, S; LETOUMELIN, P; PATERON, D; BLAISE, M; LAPANDRY, C; POURRIAT, JL				LEVACHER, S; LETOUMELIN, P; PATERON, D; BLAISE, M; LAPANDRY, C; POURRIAT, JL			EARLY ADMINISTRATION OF TERLIPRESSIN PLUS GLYCERYL TRINITRATE TO CONTROL ACTIVE UPPER GASTROINTESTINAL-BLEEDING IN CIRRHOTIC-PATIENTS	LANCET			English	Article							RANDOMIZED CONTROLLED TRIAL; ACUTE VARICEAL HEMORRHAGE; PLACEBO-CONTROLLED TRIAL; ESOPHAGEAL-VARICES; PORTAL-HYPERTENSION; DOUBLE-BLIND; VASOPRESSIN; NITROGLYCERIN; MULTICENTER; MANAGEMENT	Upper gastrointestinal bleeding (GIB) is major complication in cirrhotic patients. Endoscopy and oesophageal sclerosis are reference treatments and must be done as soon as possible. However, such treatment is not possible unless the patient is admitted to hospital. In a prospective, randomised, double-blind trial, we compared the efficacy of terlipressin combined with glyceryl trinitrate (TER-GTN), administered as early as possible to 76 patients with cirrhosis who had active GIB (84 bleeding episodes). Infusion was done at the patient's home by the physician on the emergency team (a mobile intensive care unit) if the patient had GIB and a history and clinical signs of cirrhosis. Patients received either an intravenous injection (1 to 2 mg) of TER-GTN or a double placebo injection, and then another injection at 4 and 8 h. Control of bleeding, rebleeding, and mortality rate at days 15 and 42 were evaluated. In most patients, endoscopy confirmed the rupture of oesophageal varices (75.7%), Bleeding control was significantly better in the TER-GTN group (n=41) than in the double-placebo group (n=43) (p=0.034). Mortality due to bleeding episodes was significantly lower in the TER-GTN group than in the double-placebo group at day 15 (p=0.035) and at day 42 (p=0.06). There were no serious side-effects. Early administration of TER-GTN lowers the deleterious consequences of prolonged hypovolaemia on the hepatic function of these patients.	UNIV PARIS 13,CHU JEAN VERDIER,DEPT ANESTHESIE REANIMAT,F-93140 BONDY,FRANCE; UNIV PARIS 13,CHU JEAN VERDIER,SERV AIDE MED URGENTE SAMU 93,F-93140 BONDY,FRANCE; UNIV PARIS 13,CHU JEAN VERDIER,DEPT ANESTHESIE REANIMAT,F-93140 BONDY,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Universite Paris 13								ARCIDIACONO R, 1992, CURR THER RES CLIN E, V52, P186, DOI 10.1016/S0011-393X(05)80451-5; BOSCH J, 1988, HEPATOLOGY, V8, P861, DOI 10.1002/hep.1840080427; BURROUGHS AK, 1988, Q J MED, V67, P447; BURROUGHS AK, 1989, HEPATOLOGY, V9, P801, DOI 10.1002/hep.1840090602; DAMICO G, 1994, J HEPATOL, V20, P206, DOI 10.1016/S0168-8278(05)80059-5; DEFRANCHIS R, 1993, HEPATOLOGY, V18, P1102; FLEISCHER D, 1983, GASTROENTEROLOGY, V84, P538; FORT E, 1990, HEPATOLOGY, V11, P678, DOI 10.1002/hep.1840110423; FREEMAN JG, 1989, J CLIN GASTROENTEROL, V11, P58, DOI 10.1097/00004836-198902000-00014; FREEMAN JG, 1982, LANCET, V2, P66; LIN HC, 1990, J HEPATOL, V10, P370, DOI 10.1016/0168-8278(90)90149-L; MATLOFF DS, 1992, GASTROENTEROL CLIN N, V21, P103; POYNARD T, 1990, GASTROEN CLIN BIOL, V14, pB21; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; READY JB, 1989, DRUGS, V37, P13, DOI 10.2165/00003495-198900372-00004; SILVAIN C, 1993, HEPATOLOGY, V18, P61, DOI 10.1016/0270-9139(93)90507-J; SODERLUND C, 1990, SCAND J GASTROENTERO, V25, P622, DOI 10.3109/00365529009095539; WALKER S, 1986, HEPATOLOGY, V6, P112, DOI 10.1002/hep.1840060121; WESTABY D, 1988, GUT, V29, P372, DOI 10.1136/gut.29.3.372	19	219	226	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 30	1995	346	8979					865	868		10.1016/S0140-6736(95)92708-5	http://dx.doi.org/10.1016/S0140-6736(95)92708-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX196	7564670				2022-12-28	WOS:A1995RX19600008
J	SAMAHA, RR; GREEN, R; NOLLER, HF				SAMAHA, RR; GREEN, R; NOLLER, HF			A BASE-PAIR BETWEEN TRANSFER-RNA AND 23S RIBOSOMAL-RNA IN THE PEPTIDYL TRANSFERASE CENTER OF THE RIBOSOME	NATURE			English	Article							ESCHERICHIA-COLI; TRANSFER-RNA; P-SITES; COMPLEX; IDENTIFICATION; NUCLEOTIDES; PROTEIN; END	Interaction of the conserved CCA terminus of tRNA with rRNA in the peptidyl transferase P site has been studied by in vitro genetics. A Watson-Crick G-C pair between G2252 in a conserved hairpin loop of 235 rRNA and C74 at the acceptor end of tRNA is required for proper functional interaction of the CCA end of tRNA with the ribosomal P site. These findings establish a direct role for 23S rRNA in protein synthesis.	UNIV CALIF SANTA CRUZ, SINSHEIMER LABS, CTR MOLEC BIOL RNA, SANTA CRUZ, CA 95064 USA	University of California System; University of California Santa Cruz								AAGAARD C, 1991, BIOCHIMIE, V73, P1439, DOI 10.1016/0300-9084(91)90176-2; BARTA A, 1984, P NATL ACAD SCI-BIOL, V81, P3607, DOI 10.1073/pnas.81.12.3607; BREITMEYER JB, 1976, J MOL BIOL, V101, P297, DOI 10.1016/0022-2836(76)90149-2; CANNON M, 1963, J MOL BIOL, V7, P360, DOI 10.1016/S0022-2836(63)80030-3; DORING T, 1994, EMBO J, V13, P2677, DOI 10.1002/j.1460-2075.1994.tb06558.x; DOUTHWAITE S, 1983, EUR J BIOCHEM, V131, P261, DOI 10.1111/j.1432-1033.1983.tb07258.x; Evnin L B, 1988, Ann N Y Acad Sci, V542, P61, DOI 10.1111/j.1749-6632.1988.tb25808.x; GRAJEVSKAJA RA, 1973, FEBS LETT, V33, P11, DOI 10.1016/0014-5793(73)80147-4; GREGORY ST, 1994, NUCLEIC ACIDS RES, V22, P279, DOI 10.1093/nar/22.3.279; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; KAJI H, 1966, J BIOL CHEM, V241, P1251; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIEBERMAN KR, 1994, J BIOL CHEM, V269, P16163; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MITCHELL P, 1993, NUCLEIC ACIDS RES, V21, P887, DOI 10.1093/nar/21.4.887; MOAZED D, 1991, P NATL ACAD SCI USA, V88, P3725, DOI 10.1073/pnas.88.9.3725; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MONRO RE, 1968, P NATL ACAD SCI USA, V61, P1042, DOI 10.1073/pnas.61.3.1042; MONRO RE, 1969, NATURE, V222, P356, DOI 10.1038/222356a0; Nierhaus K., 1990, RIBOSOMES PROTEIN SY, P161; NIERHAUS KH, 1974, P NATL ACAD SCI USA, V71, P4713, DOI 10.1073/pnas.71.12.4713; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; NOLLER HF, 1993, FASEB J, V7, P87, DOI 10.1096/fasebj.7.1.8422979; NOLLER HF, 1993, J BACTERIOL, V175, P5297, DOI 10.1128/JB.175.17.5297-5300.1993; NOLLER HF, 1981, NUCLEIC ACIDS RES, V8, P2275; PEATTIE DA, 1981, P NATL ACAD SCI-BIOL, V78, P2273, DOI 10.1073/pnas.78.4.2273; POWERS T, 1991, EMBO J, V10, P2203, DOI 10.1002/j.1460-2075.1991.tb07756.x; POWERS T, 1993, GENE, V123, P75, DOI 10.1016/0378-1119(93)90542-B; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; SAMPSON JR, 1989, SCIENCE, V243, P1363; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STERN S, 1988, METHOD ENZYMOL, V164, P481; TAPPRICH WE, 1986, P NATL ACAD SCI USA, V83, P556, DOI 10.1073/pnas.83.3.556; TRIMAN K, 1989, J MOL BIOL, V209, P645, DOI 10.1016/0022-2836(89)92000-7; VONAHSEN U, 1995, SCIENCE, V267, P234, DOI 10.1126/science.7528943; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232	39	216	218	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 28	1995	377	6547					309	314		10.1038/377309a0	http://dx.doi.org/10.1038/377309a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566085				2022-12-28	WOS:A1995RX11100046
J	VANDERSTICHELE, RH; DEZEURE, EM; BOGAERT, MG				VANDERSTICHELE, RH; DEZEURE, EM; BOGAERT, MG			SYSTEMATIC REVIEW OF CLINICAL EFFICACY OF TOPICAL TREATMENTS FOR HEAD LICE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PEDICULOSIS CAPITIS; LOUSE INFESTATION; COMPARATIVE TRIAL; MALATHION LOTION; LINDANE SHAMPOO; CREME RINSE; INSECTICIDES; PYRETHRINS; RESISTANCE; INFECTION	Objectives-To collect and evaluate all trials on clinical efficacy of topical treatments for head lice. Design-Systematic review of randomised trials identified from following data sources: Medline, International Pharmaceutical Abstracts, Science Citation Index,letters to key authors and companies, and hand search of journals. Setting-Trials in schools or communities. Subjects-Patients infested with lice. Main outcome measure-Cure rate (absence of Live lice and viable nits) on day 14 after treatment. Results-Total of 28 trials were identified and evaluated according to eight general and 18 lice specific criteria. Of the 14 trials rated as having low to moderate risk of bias, seven were selected as they used the main outcome measure. These seven trials described 21 evaluations of eight different compounds and placebo (all but two evaluations were of single applications). Only permethrin 1% creme rinse showed efficacy in more than two studies with the lower 95% confidence limit of cure rate above 90%. Conclusions-Only for permethrin has sufficient evidence been published to show efficacy. Less expensive treatments such as malathion and carbaryl need more evidence of efficacy. Lindane and the natural pyrethrines are not sufficiently effective to justify their use.			VANDERSTICHELE, RH (corresponding author), STATE UNIV GHENT, HEYMANS INST PHARMACOL, DE PINTELAAN 185, B-9000 GHENT, BELGIUM.		Stichele, Robert Vander/K-7203-2015	Stichele, Robert Vander/0000-0001-9118-9651				ANDREWS EB, 1992, AM J PUBLIC HEALTH, V82, P857, DOI 10.2105/AJPH.82.6.857; ARMONI M, 1988, PEDIATR DERMATOL, V5, P273, DOI 10.1111/j.1525-1470.1988.tb00903.x; Beaver PC, 1984, CLIN PARASITOLOGY, V9th; BLOMMERS L, 1978, ENTOMOL EXP APPL, V23, P243, DOI 10.1007/BF00334159; BOWERMAN JG, 1987, PEDIATR INFECT DIS J, V6, P252, DOI 10.1097/00006454-198703000-00008; BRANDENBURG K, 1986, AM J DIS CHILD, V140, P894, DOI 10.1001/archpedi.1986.02140230064034; BROOKES BC, 1969, NATURE, V224, P953, DOI 10.1038/224953a0; BURGESS IF, 1994, CLIN THER, V16, P57; CARSON DS, 1988, AM J DIS CHILD, V142, P768, DOI 10.1001/archpedi.1988.02150070082031; Chalmers I, 1989, EFFECTIVE CARE PREGN, V1, P39; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CHOSIDOW O, 1994, LANCET, V344, P1724, DOI 10.1016/S0140-6736(94)92884-3; CHUNGE RN, 1991, CAN J PUBLIC HEALTH, V82, P196; Clore E R, 1993, J Pediatr Health Care, V7, P55, DOI 10.1016/0891-5245(93)90074-R; Coates K. G., 1971, Community Medicine, V126, P148; de Boer R, 1984, Acta Leiden, V52, P53; de Boer R, 1985, Ned Tijdschr Geneeskd, V129, P793; DICKERSIN K, 1994, COCHRANE COLLABORATI, P1; DINAPOLI JB, 1988, AM J PUBLIC HEALTH, V78, P978, DOI 10.2105/AJPH.78.8.978; DONALDSON RJ, 1986, J ROY SOC HEALTH, V106, P39, DOI 10.1177/146642408610600201; DOSS S, 1991, J ROY SOC HEALTH, V111, P47, DOI 10.1177/146642409111100202; FAN P-C, 1992, Kaohsiung Journal of Medical Sciences, V8, P255; HARPER EI, 1990, BQ10908 WELLC F LTD, P1; HAYNES RB, 1990, ANN INTERN MED, V113, P69, DOI 10.7326/0003-4819-113-1-69; JOLLEY JH, 1991, J ROY SOC HEALTH, V111, P90, DOI 10.1177/146642409111100302; KUCIRKA SA, 1983, INT J DERMATOL, V22, P551, DOI 10.1111/j.1365-4362.1983.tb02123.x; KYLE DR, 1990, J ROY SOC HEALTH, V110, P62, DOI 10.1177/146642409011000210; LINDSAY SW, 1993, J ROY SOC HEALTH, V113, P181, DOI 10.1177/146642409311300406; MAGUIRE J., 1972, Community Medicine, V128, P374; MATHIAS RG, 1990, CAN J PUBLIC HEALTH, V81, P237; MATHIAS RG, 1984, CAN MED ASSOC J, V130, P407; MATHIAS RG, 1989, CAN J PUBLIC HEALTH, V80, P461; MAUNDER B, 1985, J ROY SOC HEALTH, V105, P61, DOI 10.1177/146642408510500206; Maunder J.W., 1983, Proceedings of the Royal Institution of Great Britain, V55, P1; MAUNDER JW, 1991, J ROY SOC HEALTH, V111, P24, DOI 10.1177/146642409111100109; MAUNDER JW, 1981, CLIN EXP DERMATOL, V6, P605, DOI 10.1111/j.1365-2230.1981.tb02364.x; Maunder JW, 1971, MED OFFICERS, V125, P27, DOI DOI 10.1542/peds.2008-3762; MAZAS EA, 1985, INT J DERMATOL, V24, P603; MAZAS MEA, 1988, INT J DERMATOL, V27, P267, DOI 10.1111/j.1365-4362.1988.tb03228.x; MEINKING TL, 1986, ARCH DERMATOL, V122, P267, DOI 10.1001/archderm.122.3.267; MILLER AJ, 1988, J ROY SOC HEALTH, V108, P11, DOI 10.1177/146642408810800107; MULROW CD, 1994, BRIT MED J, V309, P597, DOI 10.1136/bmj.309.6954.597; MUMCUOGLU KY, 1990, INT J DERMATOL, V29, P502, DOI 10.1111/j.1365-4362.1990.tb04845.x; PRESTON S, 1979, ROY SOC HEALTH J, V99, P173, DOI 10.1177/146642407909900414; ROUSSET JJ, 1988, EXTRAIT COMPTES REND, V67, P1; SEXTON C, 1991, CURR MED RES OPIN, V12, P466, DOI 10.1185/03007999109111518; TAPLIN D, 1982, JAMA-J AM MED ASSOC, V247, P3103, DOI 10.1001/jama.247.22.3103; Taplin D, 1986, Pediatr Dermatol, V3, P344, DOI 10.1111/j.1525-1470.1986.tb00538.x; TAPLIN D, 1990, ARCH DERMATOL, V126, P213, DOI 10.1001/archderm.126.2.213; URCUYO FG, 1986, INT J DERMATOL, V25, P60, DOI 10.1111/j.1365-4362.1986.tb03408.x; van EVERDINGEN W A G, 1950, Ned Tijdschr Geneeskd, V94, P2640; 1975, BRIT MED J, V2, P1043	52	76	79	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 2	1995	311	7005					604	608						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RT723	7545045	Green Published			2022-12-28	WOS:A1995RT72300020
J	ELLIS, LM; FIDLER, IJ				ELLIS, LM; FIDLER, IJ			ANGIOGENESIS AND BREAST-CANCER METASTASIS	LANCET			English	Editorial Material							INDEPENDENT PROGNOSTIC INDICATOR; TUMOR ANGIOGENESIS; CARCINOMA		UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	ELLIS, LM (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT SURG,HOUSTON,TX 77030, USA.							BOSARI S, 1992, HUM PATHOL, V23, P755, DOI 10.1016/0046-8177(92)90344-3; FIDLER IJ, 1990, CANCER RES, V50, P6130; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GASPARINI G, 1994, J CLIN ONCOL, V12, P454, DOI 10.1200/JCO.1994.12.3.454; GASPARINI G, 1995, J CLIN ONCOL, V13, P765, DOI 10.1200/JCO.1995.13.3.765; Hall N R, 1992, Surg Oncol, V1, P223, DOI 10.1016/0960-7404(92)90068-V; HARRIS JR, 1991, BREAST DISEASES, P327; HORAK ER, 1992, LANCET, V340, P1120, DOI 10.1016/0140-6736(92)93150-L; KITADAI Y, IN PRESS CLIN CANCER; OBERMAIR A, 1994, CHIRURG, V65, P611; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; Singh R. K., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P87; TOI M, 1993, INT J CANCER, V55, P371, DOI 10.1002/ijc.2910550305; VANHOEF MEHM, 1993, EUR J CANCER, V29A, P1141; VISSCHER DW, 1993, ANAL QUANT CYTOL, V15, P88; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	18	58	60	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					388	390		10.1016/S0140-6736(95)92774-3	http://dx.doi.org/10.1016/S0140-6736(95)92774-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7542721	Bronze			2022-12-28	WOS:A1995RN65600003
J	CASTANO, AR; TANGRI, S; MILLER, JEW; HOLCOMBE, HR; JACKSON, MR; HUSE, WD; KRONENBERG, M; PETERSON, PA				CASTANO, AR; TANGRI, S; MILLER, JEW; HOLCOMBE, HR; JACKSON, MR; HUSE, WD; KRONENBERG, M; PETERSON, PA			PEPTIDE BINDING AND PRESENTATION BY MOUSE CD1	SCIENCE			English	Article							LYMPHOCYTES-T; MOLECULES; CELLS; RECOGNITION; SPECIFICITY; ANTIGENS; AFFINITY; HLA-DR1; GENES	CD1 molecules are distantly related to the major histocompatibility complex (MHC) class proteins. They are of unknown function. Screening random peptide phage display libraries with soluble empty mouse CD1 (mCD1) identified a peptide binding motif. It consists of three anchor positions occupied by aromatic or bulky hydrophobic amino acids, Equilibrium binding studies demonstrated that mCD1 binds peptides containing the appropriate motif with relatively high affinity. However, in contrast to classical MHC class I molecules, strong binding to mCD1 required relatively long peptides. Peptide-specific, mCD1-restricted T cell responses can be raised, which suggests that the findings are of immunological significance.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90095 USA; IXSYS, SAN DIEGO, CA 92121 USA	Scripps Research Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Castaño, A. Raul/A-5905-2012	Castaño, A. Raul/0000-0003-2107-8862				BALK SP, 1991, J IMMUNOL, V146, P768; BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BENDELAC A, 1995, SCIENCE, V268, P83; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRADBURY A, 1988, EMBO J, V7, P3081, DOI 10.1002/j.1460-2075.1988.tb03173.x; CALABI F, 1989, EUR J IMMUNOL, V19, P285, DOI 10.1002/eji.1830190211; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; CASTANO AM, UNPUB; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; FAHNESTOCK ML, 1994, BIOCHEMISTRY-US, V33, P8149, DOI 10.1021/bi00192a020; FANG TAT, 1990, J IMMUNOL, V144, P1744; FITHIAN E, 1981, P NATL ACAD SCI-BIOL, V78, P2541, DOI 10.1073/pnas.78.4.2541; HAMMER J, 1992, J EXP MED, V176, P1007, DOI 10.1084/jem.176.4.1007; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; HARBOW E, 1988, ANTIBODIES LABORATOR, P336; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; MILLER JA, UNPUB; MULLER R, 1983, METHOD ENZYMOL, V92, P589; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SAITO Y, 1993, J BIOL CHEM, V268, P21309; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SHAWAR SM, 1991, J EXP MED, V174, P941, DOI 10.1084/jem.174.4.941; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; TANGRI S, UNPUB; TEITELL M, UNPUB; TERHORST C, 1981, CELL, V23, P771, DOI 10.1016/0092-8674(81)90441-4; VANDERIJN M, 1984, HUM IMMUNOL, V9, P201, DOI 10.1016/0198-8859(84)90025-9; WANG CB, IN PRESS	33	223	236	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					223	226		10.1126/science.7542403	http://dx.doi.org/10.1126/science.7542403			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7542403				2022-12-28	WOS:A1995RJ02900040
J	DENHAAN, JMM; SHERMAN, NE; BLOKLAND, E; HUCZKO, E; KONING, F; DRIJFHOUT, JW; SKIPPER, J; SHABANOWITZ, J; HUNT, DF; ENGELHARD, VH; GOULMY, E				DENHAAN, JMM; SHERMAN, NE; BLOKLAND, E; HUCZKO, E; KONING, F; DRIJFHOUT, JW; SKIPPER, J; SHABANOWITZ, J; HUNT, DF; ENGELHARD, VH; GOULMY, E			IDENTIFICATION OF A GRAFT-VERSUS-HOST DISEASE-ASSOCIATED HUMAN MINOR HISTOCOMPATIBILITY ANTIGEN	SCIENCE			English	Article							TOXIC LYMPHOCYTES-T; MARROW TRANSPLANTATION; MASS-SPECTROMETRY; TISSUE DISTRIBUTION; UNRELATED DONORS; PEPTIDES; HLA; CELLS; PROTEIN; BETA-2-MICROGLOBULIN	Minor histocompatibility antigen disparities between human leukocyte antigen (HLA)-matched bone marrow donors and recipients are a major risk factor for graft versus host disease (GVHD). An HLA-A2.1-restricted cytotoxic T cell clone that recognized the minor histocompatibility antigen HA-2 was previously isolated from a patient with severe GVHD after HLA-identical bone marrow transplantation. The HLA-A2.1-bound peptide representing HA-2 has now been identified. This peptide appears to originate from a member of the non-filament-forming class I myosin family. Because HA-2 has a phenotype frequency of 95 percent in the HLA-A2.1-positive population, it is a candidate for immunotherapeutic intervention in bone marrow transplantation.	UNIV LEIDEN HOSP,DEPT IMMUNOHAEMATOL,2300 RC LEIDEN,NETHERLANDS; UNIV LEIDEN HOSP,BLOOD BANK,2300 RC LEIDEN,NETHERLANDS; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22903; UNIV VIRGINIA,DEPT PATHOL,CHARLOTTESVILLE,VA 22903; UNIV VIRGINIA,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,BEIRNE CARTER CTR IMMUNOL RES,CHARLOTTESVILLE,VA 22908	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); University of Virginia; University of Virginia; University of Virginia; University of Virginia			den Haan, Joke MM/A-4281-2010; Drijfhout, Jan Wouter/ABA-6318-2021; Hunt, Donald F/I-6936-2012	den Haan, Joke MM/0000-0002-4421-6917; Drijfhout, Jan Wouter/0000-0003-4808-5296; Hunt, Donald F/0000-0003-2815-6368; Sherman, Nicholas/0000-0003-3206-3113; Koning, Frits/0000-0002-4007-5715; Engelhard, Victor/0000-0002-1741-0925	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020963, R01AI033993, R37AI033993, R01AI020963] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20963, AI33993] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEATTY PG, 1991, TRANSPLANTATION, V51, P443, DOI 10.1097/00007890-199102000-00034; BEATTY PG, 1989, GRAFT VERSUS HOST DI, P415; BEMENT WM, 1994, J MOL BIOL, V243, P356, DOI 10.1006/jmbi.1994.1662; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; BORTIN MM, 1991, TRANSPLANT P, V23, P61; BORTIN MM, 1970, TRANSPLANTATION, V9, P571, DOI 10.1097/00007890-197006000-00006; CHEN Y, 1994, J IMMUNOL, V152, P2874; COUDRIER E, 1992, FEBS LETT, V307, P87, DOI 10.1016/0014-5793(92)80907-X; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; DEBUEGER M, 1992, J IMMUNOL, V149, P1788; DEBUEGER M, 1993, EUR J IMMUNOL, V23, P614, DOI 10.1002/eji.1830230305; DENHAAN JMM, UNPUB; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FRANKSSON L, 1993, EUR J IMMUNOL, V23, P2606, DOI 10.1002/eji.1830231034; GOULMY E, 1983, NATURE, V302, P159, DOI 10.1038/302159a0; GOULMY E, UNPUB; GOULMY E, 1988, TRANSPLANT REV, V2, P29, DOI DOI 10.1016/S0955-470X(88)80005-3; HENDERSON RA, 1993, P NATL ACAD SCI USA, V90, P10275, DOI 10.1073/pnas.90.21.10275; HUCZKO EL, 1993, J IMMUNOL, V151, P2572; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; IRLE C, 1985, TRANSPLANTATION, V40, P329, DOI 10.1097/00007890-198509000-00021; IRSCHICK EU, 1992, BLOOD, V79, P1622; KURTZ ME, 1985, J IMMUNOL, V135, P2847; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; MANDELBOIM O, 1994, NATURE, V369, P67, DOI 10.1038/369067a0; MARTIN PJ, 1991, BONE MARROW TRANSPL, V8, P217; MOOSEKER M, 1993, CURR BIOL, V3, P245, DOI 10.1016/0960-9822(93)90346-P; NIEDERWIESER D, 1993, BLOOD, V81, P2200; PERARNAU B, 1990, NATURE, V346, P751, DOI 10.1038/346751a0; RAMMENSEE HG, 1986, NATURE, V319, P502, DOI 10.1038/319502a0; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; RUPPERT J, 1993, CELL, V74, P829; SCHREUDER GMT, 1993, IMMUNOGENETICS, V38, P98, DOI 10.1007/BF00190897; SEKIMATA M, 1992, INT IMMUNOL, V4, P301, DOI 10.1093/intimm/4.2.301; Titus MA, 1993, CURR OPIN CELL BIOL, V5, P77, DOI 10.1016/S0955-0674(05)80011-0; TSOI MS, 1983, TRANSPLANT P, V15, P1484; TSOI MS, 1980, J IMMUNOL, V125, P2258; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; UENAKA A, 1994, J EXP MED, V180, P1599, DOI 10.1084/jem.180.5.1599; VANDERHARST D, 1994, BLOOD, V84, P1060; VANELS CACM, 1992, IMMUNOGENETICS, V35, P161, DOI 10.1007/BF00185109; VANELS CACM, 1990, TRANSPLANTATION, V50, P62, DOI 10.1097/00007890-199007000-00011; WALLNY HJ, 1990, NATURE, V343, P275, DOI 10.1038/343275a0	44	327	350	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1476	1480		10.1126/science.7539551	http://dx.doi.org/10.1126/science.7539551			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7539551	Green Submitted			2022-12-28	WOS:A1995RC19000034
J	ROOP, D				ROOP, D			DEFECTS IN THE BARRIER	SCIENCE			English	Editorial Material							INTERMEDIATE FILAMENTS; TGF-ALPHA; ICHTHYOSIS; DISORDERS; EPIDERMIS		BAYLOR COLL MED,DEPT DERMATOL,HOUSTON,TX 77030	Baylor College of Medicine	ROOP, D (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030, USA.							DAVIES PJA, 1992, PHYSL BIOCH MOL BIOL, P385; DOMINEY AM, 1993, CELL GROWTH DIFFER, V4, P1071; DOWNING DT, 1992, J LIPID RES, V33, P301; FINZI E, 1991, J INVEST DERMATOL, V96, P328, DOI 10.1111/1523-1747.ep12465223; Green Kathleen J., 1994, P157; HOHL D, 1993, ARCH DERMATOL, V129, P618, DOI 10.1001/archderm.129.5.618; Hohl Daniel, 1993, P151; HOLLERAN WM, 1994, J CLIN INVEST, V93, P1756, DOI 10.1172/JCI117160; HUBER M, 1985, SCIENCE, V267, P525; IMAKADO S, 1995, GENE DEV, V9, P317, DOI 10.1101/gad.9.3.317; NANNEY LB, 1990, PEDIATR DERMATOL, V7, P256, DOI 10.1111/j.1525-1470.1990.tb01021.x; NIEMI KM, 1991, ARCH DERMATOL RES, V283, P211, DOI 10.1007/BF01106104; Reichert Uwe, 1993, P107; Rothnagel JA, 1995, CURR OPIN DERMATOL, V2, P211; STEINERT PM, 1981, P NATL ACAD SCI-BIOL, V78, P4097, DOI 10.1073/pnas.78.7.4097; STEINERT PM, 1993, J INVEST DERMATOL, V100, P729, DOI 10.1111/1523-1747.ep12475665; TRAUPE H, 1989, ICHTHYOSES GUIDE CLI, P139; TUBULEWIZ VLJ, 1992, NATURE, V357, P407; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WERTZ PW, 1992, PHYSL BIOCH MOL BIOL, P205; WILLIAMS ML, 1993, ARCH DERMATOL, V129, P626, DOI 10.1001/archderm.129.5.626; WILLIAMS ML, 1991, ADV LIPID RES, V24, P211	22	162	164	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 27	1995	267	5197					474	475		10.1126/science.7529942	http://dx.doi.org/10.1126/science.7529942			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD403	7529942				2022-12-28	WOS:A1995QD40300029
J	NIERMEYER, S; YANG, P; SHANMINA; DROLKAR; ZHUANG, JG; MOORE, LG				NIERMEYER, S; YANG, P; SHANMINA; DROLKAR; ZHUANG, JG; MOORE, LG			ARTERIAL OXYGEN-SATURATION IN TIBETAN AND HAN INFANTS BORN IN LHASA, TIBET	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIGH-ALTITUDE; PULSE OXIMETRY; HEMOGLOBIN; TRANSPORT; GROWTH	Background. Reduced oxygen availability at high altitude is associated with increased neonatal and infant mortality. We hypothesized that native Tibetan infants, whose ancestors have inhabited the Himalayan Plateau for approximately 25,000 years, are better able to maintain adequate oxygenation at high altitude than Han infants, whose ancestors moved to Tibet from lowland areas of China after the Chinese military entered Tibet in 1951. Methods. We compared arterial oxygen saturation, signs of hypoxemia, and other indexes of neonatal wellbeing at birth and during the first four months of life in 15 Tibetan infants and 15 Han infants at 3658 m above sea level in Lhasa, Tibet. The Han mothers had migrated from lowland China about two years previously. A pulse oximeter was placed on each infant's foot to provide measurements of arterial oxygen saturation distal to the ductus arteriosus. Results. The two groups had similar gestational ages (about 38.9 weeks) and Apgar scores. The Han infants had lower birth weights (mean [+/-SE], 2773+/-92 g) than the Tibetan infants (3067+/-107 g), higher concentrations of cord-blood hemoglobin (18.6+/-0.8 g per deciliter, vs, 16.7+/-0.4 in the Tibetans), and higher hematocrit values (58.5+/-2.4 percent, vs. 51.4+/-1.2 percent in the Tibetans). In both groups, arterial oxygen saturation was highest in the first two days after birth and was lower when the infants were asleep than when they were awake. Oxygen saturation values were lower in the Han than in the Tibetan infants at all times and under all conditions during all activities. The values declined in the Han infants from 92+/-3 percent while they were awake and 90+/-5 percent during quiet sleep at birth to 85+/-4 percent while awake and 76+/-5 percent during quiet sleep at four months of age, In the Tibetan infants, oxygen saturation values averaged 94+/-2 percent while they were awake and 94+/-3 percent during quiet sleep at birth and 88+/-2 percent while awake and 86+/-5 percent during quiet sleep at four months. Han infants had clinical signs of hypoxemia - such as cyanosis during sleep and while feeding - more frequently than Tibetans. Conclusions. In Lhasa, Tibet, we found that Tibetan newborns had higher arterial oxygen saturation at birth and during the first four months of life than Han newborns, Genetic adaptations may permit adequate oxygenation and confer resistance to the syndrome of pulmonary hypertension and right-heart failure (subacute infantile mountain sickness).	UNIV COLORADO,SCH MED,DEPT PEDIAT,NEONATOL SECT,DENVER,CO; PEOPLES HOSP TIBET AUTONOMOUS REG,TIBET INST MED SCI,LHASA,PEOPLES R CHINA; UNIV COLORADO,HLTH SCI CTR,CARDIOVASC PULM RES LAB,DENVER,CO 80262; UNIV COLORADO,DEPT ANTHROPOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Tibet University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Denver					PHS HHS [14985] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AN ZM, 1982, CURR ANTHROPOL, V23, P493, DOI 10.1086/202891; BALLARD JL, 1979, J PEDIATR-US, V95, P769, DOI 10.1016/S0022-3476(79)80734-9; BALLEW C, 1986, AM J OBSTET GYNECOL, V155, P166, DOI 10.1016/0002-9378(86)90104-3; BATTAGLI.FC, 1967, J PEDIATR-US, V71, P159, DOI 10.1016/S0022-3476(67)80066-0; CLENCH J, 1982, AM J PHYSIOL, V242, pR447, DOI 10.1152/ajpregu.1982.242.5.R447; COLE JWL, 1966, BIOMETRICS, V22, P810, DOI 10.2307/2528076; DELIVORIAPAPADO.M, 1971, PEDIATR RES, V5, P235; Deming J, 1935, AM J DIS CHILD, V49, P108, DOI 10.1001/archpedi.1935.01970010117013; DENNELL RW, 1988, CURR ANTHROPOL, V29, P495, DOI 10.1086/203666; EMMANOUILIDES GC, 1964, J PEDIATR-US, V65, P327, DOI 10.1016/S0022-3476(64)80395-4; GAMBOA R, 1971, ARCH I BIOL ANDINA, V4, P55; HAY WW, 1991, CLIN PERINATOL, V18, P441, DOI 10.1016/S0095-5108(18)30507-4; HAY WW, 1989, PEDIATRICS, V83, P717; LENFANT C, 1968, J CLIN INVEST, V47, P2652, DOI 10.1172/JCI105948; LOCKHART A, 1981, CLIN SCI, V60, P599, DOI 10.1042/cs0600599; LUBCHENCO LO, 1966, PEDIATRICS, V37, P403; Lubchenco LO, 1964, SOC PED RES PROGR AB, P50; MIAO CY, 1988, J AM COLL CARDIOL, V12, P224, DOI 10.1016/0735-1097(88)90378-6; MOK JYQ, 1986, J PEDIATR-US, V108, P365; MOORE LG, 1990, AM J HUM BIOL, V2, P627, DOI 10.1002/ajhb.1310020606; NIERMEYER S, 1993, J PEDIATR-US, V123, P767, DOI 10.1016/S0022-3476(05)80857-1; OSKI FA, 1982, MAJOR PROBLEMS CLIN, V4, P10; Pologe J A, 1987, J Perinatol, V7, P324; PRECHTL HFR, 1974, BRAIN RES, V76, P185, DOI 10.1016/0006-8993(74)90454-5; SIME F, 1963, AM J CARDIOL, V11, P143, DOI 10.1016/0002-9149(63)90054-7; SUI GJ, 1988, J PATHOL, V155, P161, DOI 10.1002/path.1711550213; SWENSON ER, 1991, RESP PHYSIOL, V86, P333, DOI 10.1016/0034-5687(91)90104-Q; THILO EH, 1991, AM J DIS CHILD, V145, P1137, DOI 10.1001/archpedi.1991.02160100069025; VONSCHENCK H, 1986, CLIN CHEM, V32, P526; YIP R, 1987, J PEDIATR-US, V111, P869, DOI 10.1016/S0022-3476(87)80209-3; ZAMUDIO S, 1993, AM J PHYS ANTHROPOL, V91, P215, DOI 10.1002/ajpa.1330910207; 1983, HIGH ALTITUDE MED, P288; 1991, MANAGEMENT YOUNG CHI, P13	33	159	168	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	1995	333	19					1248	1252		10.1056/NEJM199511093331903	http://dx.doi.org/10.1056/NEJM199511093331903			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC715	7566001				2022-12-28	WOS:A1995TC71500003
J	CAPLAN, LR; DALEY, J				CAPLAN, LR; DALEY, J			A 79-YEAR-OLD MUSICIAN WITH ASYMPTOMATIC CAROTID-ARTERY DISEASE - DISCUSSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							CEREBRAL BLOOD-FLOW; TRANSIENT ISCHEMIC ATTACK; NATURAL-HISTORY; CEREBROVASCULAR-DISEASE; DOPPLER ULTRASOUND; VASCULAR-SURGERY; STENOSIS; ENDARTERECTOMY; STROKE; RISK		TUFTS UNIV, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, BOSTON, MA 02111 USA	Tufts University; Tufts Medical Center								ANDERSON CM, 1992, AM J NEURORADIOL, V13, P989; BARNETT HJM, 1978, NEUROLOGY, V28, P769; BOGOUSSLAVSKY J, 1986, NEUROLOGY, V36, P861, DOI 10.1212/WNL.36.6.861; BREEN JC, IN PRESS NEUROLOGY; BROOK RH, 1990, ANN INTERN MED, V113, P747, DOI 10.7326/0003-4819-113-10-747; BROTT T, 1984, STROKE, V15, P950, DOI 10.1161/01.STR.15.6.950; CAPLAN LR, 1988, NEUROLOGY, V38, P791, DOI 10.1212/WNL.38.5.791; CAPLAN LR, 1990, NEUROLOGY, V40, P696, DOI 10.1212/WNL.40.4.696; CAPLAN LR, 1986, STROKE, V17, P648, DOI 10.1161/01.STR.17.4.648; CAPLAN LR, 1988, ANNU REV MED, V39, P273, DOI 10.1146/annurev.med.39.1.273; CAPLAN LR, 1994, CEREBROVASC DIS, V4, P32, DOI 10.1159/000108559; CAPLAN LR, 1995, NEUROIMAGING, P435; CAPLAN LR, 1994, STROKE CLIN APPROACH; CARTER JE, 1985, STROKE, V16, P721, DOI 10.1161/01.STR.16.4.721; CHAMBERS BR, 1986, NEW ENGL J MED, V315, P860, DOI 10.1056/NEJM198610023151404; COLGAN MP, 1985, BRIT J SURG, V72, P313, DOI 10.1002/bjs.1800720424; COTE R, 1983, STROKE, V14, P898, DOI 10.1161/01.STR.14.6.898; COULL BM, 1991, STROKE, V22, P162, DOI 10.1161/01.STR.22.2.162; DURWARD QJ, 1982, STROKE, V13, P459, DOI 10.1161/01.STR.13.4.459; EASTON JD, 1977, STROKE, V8, P565, DOI 10.1161/01.STR.8.5.565; ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008; Feinberg W. M., 1995, BRAIN ISCHEMIA BASIC, P85; FISHER M, 1992, ANN NEUROL, V32, P115, DOI 10.1002/ana.410320202; FISHER M, 1995, BASIC CONCEPTS CLIN, P135; FODE NC, 1986, STROKE, V17, P370, DOI 10.1161/01.STR.17.3.370; FORD CS, 1986, ARCH NEUROL-CHICAGO, V43, P219, DOI 10.1001/archneur.1986.00520030011004; GORELICK PB, 1984, NEUROLOGY, V34, P54, DOI 10.1212/WNL.34.1.54; GROTTA J, 1982, STROKE, V13, P296, DOI 10.1161/01.STR.13.3.296; HARRISON MJG, 1981, LANCET, V2, P114, DOI 10.1016/S0140-6736(81)90298-1; HEDGES TR, 1995, BASIC CONCEPTS CLIN, P61; HENNERICI M, 1985, LANCET, V1, P1415; HENNERICI M, 1991, STROKE, V22, P989, DOI 10.1161/01.STR.22.8.989; HENNERICI M, 1987, BRAIN, V110, P777, DOI 10.1093/brain/110.3.777; HERTZER N R, 1984, Journal of Vascular Surgery, V1, P13, DOI 10.1067/mva.1984.avs0010013; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; HUMPHRIES AW, 1976, SURGERY, V80, P695; KIDO DK, 1991, ARCH NEUROL-CHICAGO, V48, P484, DOI 10.1001/archneur.1991.00530170044019; Lehv MS, 1970, STROKE, V1, P307, DOI 10.1161/01.STR.1.5.307; MARKUS HS, 1994, LANCET, V343, P1011, DOI 10.1016/S0140-6736(94)90129-5; MOHR JP, 1978, NEUROLOGY, V28, P754, DOI 10.1212/WNL.28.8.754; Muller H R, 1995, J Neuroimaging, V5, P71; MURROS KE, 1989, J NEUROL, V236, P182, DOI 10.1007/BF00314339; NICOLAIDES A, 1993, CEREBRAL REVASCULARI, P159; NORRIS JW, 1991, STROKE, V22, P1485, DOI 10.1161/01.STR.22.12.1485; NORRIS JW, 1992, CEREBROVASC DIS, V2, P2, DOI 10.1159/000109055; NORRIS JW, 1992, STROKE, V23, P483, DOI 10.1161/01.STR.23.4.483; PIEPGRAS A, 1990, STROKE, V21, P1303; PLECHA FR, 1985, J VASC SURG, V2, P769, DOI 10.1067/mva.1985.avs0020769; RIES S, 1995, CEREBROVASC DIS, V5, P124, DOI 10.1159/000107836; RILES TS, 1992, STROKE, V23, P341, DOI 10.1161/01.STR.23.3.341; RINGELSTEIN EB, 1988, STROKE, V19, P963, DOI 10.1161/01.STR.19.8.963; ROEDERER GO, 1984, STROKE, V15, P605, DOI 10.1161/01.STR.15.4.605; STEINKE W, 1990, AM J NEURORADIOL, V11, P259; STEINKE W, 1992, NEUROLOGY, V42, P131, DOI 10.1212/WNL.42.1.131; SUNDT TM, 1981, MAYO CLIN PROC, V56, P533; SUNDT TM, 1975, MAYO CLIN PROC, V50, P301; THOMAS DJ, 1977, LANCET, V2, P941, DOI 10.1016/S0140-6736(77)90885-6; VONREUTERN GM, 1993, ULTRASOUND DIAGNOSIS; 1991, LANCET, V337, P1235; 1986, STROKE, V17, P848; 1991, STROKE, V22, P1229; 1995, JAMA-J AM MED ASSOC, V273, P1421; 1991, NEW ENGL J MED, V325, P445	63	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	1995	274	17					1383	1389		10.1001/jama.274.17.1383	http://dx.doi.org/10.1001/jama.274.17.1383			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB278	7563565				2022-12-28	WOS:A1995TB27800031
J	MOGENSEN, CE; KEANE, WF; BENNETT, PH; JERUMS, G; PARVING, HH; PASSA, P; STEFFES, MW; STRIKER, GE; VIBERTI, GC				MOGENSEN, CE; KEANE, WF; BENNETT, PH; JERUMS, G; PARVING, HH; PASSA, P; STEFFES, MW; STRIKER, GE; VIBERTI, GC			PREVENTION OF DIABETIC RENAL-DISEASE WITH SPECIAL REFERENCE TO MICROALBUMINURIA	LANCET			English	Review							URINARY ALBUMIN EXCRETION; CONVERTING ENZYME-INHIBITION; GLOMERULAR-FILTRATION RATE; NEPHROPATHY; PREDICTOR; HYPERTENSION; INTERVENTION; PROTEINURIA; CREATININE; MORTALITY		HENNEPIN CTY MED CTR, MINNEAPOLIS, MN USA; NIDDK, PHOENIX, AZ USA; NIDDK, BETHESDA, MD USA; AUSTIN HOSP, HEIDELBERG, VIC 3084, AUSTRALIA; STENO DIABET CTR, GENTOFTE, DENMARK; HOP ST LOUIS, PARIS, FRANCE; UNIV MINNESOTA, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55455 USA; GUYS HOSP, LONDON SE1 9RT, ENGLAND	Hennepin County Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Steno Diabetes Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Minnesota System; University of Minnesota Twin Cities; Guy's & St Thomas' NHS Foundation Trust	MOGENSEN, CE (corresponding author), AARHUS KOMMUNE HOSP, DK-8000 AARHUS, DENMARK.		Bennett, Peter/AAH-9605-2021					[Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1994, Diabetes Care, V17, P1357; BENNETT PH, 1995, AM J KIDNEY DIS, V25, P107; BORCHJOHNSEN K, 1993, BRIT MED J, V306, P1722, DOI 10.1136/bmj.306.6894.1722; COWELL CT, 1986, DIABETOLOGIA, V29, P97, DOI 10.1007/BF00456117; DAHLJORGENSEN K, 1994, DIABETOLOGIA, V37, P1172, DOI 10.1007/BF00399789; DAMSGAARD EM, 1990, BRIT MED J, V300, P297, DOI 10.1136/bmj.300.6720.297; FELDTRASMUSSEN B, 1994, J DIABETES COMPLICAT, V8, P137, DOI 10.1016/1056-8727(94)90030-2; GATLING W, 1985, DIABETIC MED, V2, P451, DOI 10.1111/j.1464-5491.1985.tb00681.x; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; HANSEN KW, 1992, J INTERN MED, V232, P161, DOI 10.1111/j.1365-2796.1992.tb00566.x; HASSLACHER C, 1989, DIABETES METAB, V15, P338; HUTCHISON AS, 1988, CLIN CHEM, V34, P2019; Jarrett R J, 1984, Diabet Med, V1, P17; JERUMS G, 1994, MED J AUSTRALIA, V161, P265, DOI 10.5694/j.1326-5377.1994.tb127422.x; KROLEWSKI AS, 1995, NEW ENGL J MED, V332, P1251, DOI 10.1056/NEJM199505113321902; LANE PH, 1992, DIABETES, V41, P581, DOI 10.2337/diabetes.41.5.581; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; MARSHALL SM, 1986, ANN CLIN BIOCHEM, V23, P195, DOI 10.1177/000456328602300209; MATHIESEN ER, 1989, DIABETOLOGIA, V32, P884, DOI 10.1007/BF00297455; MATHIESEN ER, 1995, DIABETOLOGIA, V38, pA46; MOGENSEN CE, 1994, J INTERN MED, V235, P297, DOI 10.1111/j.1365-2796.1994.tb01080.x; MOGENSEN CE, 1995, ANNU REV MED, V46, P79; MOGENSEN CE, 1993, AM J KIDNEY DIS, V22, P174, DOI 10.1016/S0272-6386(12)70184-1; MOGENSEN CE, 1987, KIDNEY INT, V31, P673, DOI 10.1038/ki.1987.50; MOGENSEN CE, 1995, DIABETIC MED, V12, P756, DOI 10.1111/j.1464-5491.1995.tb02077.x; MOGENSEN CE, 1995, DIABETES CARE, V18, P572, DOI 10.2337/diacare.18.4.572; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; MOGENSEN CE, 1994, J DIABETES COMPLICAT, V8, P135, DOI 10.1016/1056-8727(94)90029-9; MOGENSEN CE, 1993, CONCEPTS IDEAL DIABE, P289; MOGENSEN CE, 1994, BR HEART J S, V72, P38; OSTERBY R, 1995, NEPHROL DIAL TRANSPL, V10, P12; Parving H H, 1994, Curr Opin Nephrol Hypertens, V3, P292, DOI 10.1097/00041552-199405000-00010; PARVING HH, 1989, BRIT MED J, V299, P230, DOI 10.1136/bmj.299.6693.230; PARVING HH, 1974, LANCET, V1, P1190; POULSEN PL, 1995, DIABETES CARE, V18, P732, DOI 10.2337/diacare.18.5.732; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; SCHMITZ A, 1993, DIABETOLOGIA, V36, P985, DOI 10.1007/BF02374488; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SOWERS JR, 1994, HYPERTENSION, V23, P145; STRIKER GE, 1995, NEPHROL DIAL TRANSPL, V10, P290; TSALAMANDRIS C, 1994, DIABETES, V43, P649, DOI 10.2337/diabetes.43.5.649; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; VIBERTI G, 1995, NEW ENGL J MED, V332, P1293, DOI 10.1056/NEJM199505113321909; VIBERTI GC, 1994, KIDNEY HYPERTENSION, P515; WEIDMANN P, 1991, DIABETES CARE, V14, P220, DOI 10.2337/diacare.14.3.220; YUDKIN JS, 1988, LANCET, V2, P530; ZANCHETTI A, 1993, CLIN EXP HYPERTENS, V15, P1363; 1994, WHO TECH REP SER, V844, P55	49	462	488	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 21	1995	346	8982					1080	1084		10.1016/S0140-6736(95)91747-0	http://dx.doi.org/10.1016/S0140-6736(95)91747-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564792				2022-12-28	WOS:A1995TA69700016
J	ALEXANDER, M; GRUMBACH, K; SELBY, J; BROWN, AF; WASHINGTON, E				ALEXANDER, M; GRUMBACH, K; SELBY, J; BROWN, AF; WASHINGTON, E			HOSPITALIZATION FOR CONGESTIVE-HEART-FAILURE - EXPLAINING RACIAL-DIFFERENCES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; MORTALITY CROSSOVER; PREVALENCE; POPULATION; SYSTEM; RATES; CARE	Objective.-To determine whether the higher rate of hospitalization among African Americans for congestive heart failure (CHF) could be explained by racial differences in the prevalence of clinical risk factors for CHF. Design.-Retrospective cohort study. Setting.-A large health maintenance organization (HMO). Patients.-A sample of 64 877 enrollees (27% African American and 73% white) of the Northern California Kaiser Permanente Medical Care Program who took at least one multiphasic health checkup (MHC) at or after the age of 40 years and were free of CHF at that time. Main Outcome Measures.-First hospitalization with a principal diagnosis of CHF. Results.-Among cohort members younger than 60 years at baseline MHC, the age-adjusted risk ratio (RR) (African American/white) for CHF hospitalization was 2.14 for men and 2.73 for women, while for persons 60 years of age and older at MHC, the age-adjusted RR was 1.48 for both sexes. Cox proportional hazards models were used to adjust for risk factors and length of follow-up. In persons aged 60 years and older, the race difference was explained by greater prevalence of hypertension and diabetes in African Americans (RR=1.12; 95% confidence interval [CI], 0.94 to 1.34 after adjustment for hypertension and diabetes). In those younger than 60 years, findings differed by sex. For men, African-American race was no longer a significant predictor of CHF after adjusting for hypertension, diabetes, left ventricular hypertrophy on electrocardiogram, and body mass index (adjusted RR=1.16; 95% CI, 0.86 to 1.56). However, among younger women, African Americans continued at increased risk despite adjustment for these variables as well as smoking, plasma cholesterol, renal function, alcohol use, and myocardial infarction (adjusted RR=1.49; 95% CI, 1.00 to 2.21). Conclusions.-In this HMO population, the race differences in first hospitalization for CHF are largely explained by known clinical and behavioral risk factors, although in younger women these risk factors do not completely explain the excess risk among African Americans. These findings highlight the role of hypertension and diabetes in the development of CHF, particularly among African Americans.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; KAISER PERMANENTE MED CARE PROGRAM NO CALIF REG,DIV RES,OAKLAND,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kaiser Permanente	ALEXANDER, M (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,MED EFFECTIVENESS RES CTR DIVERSE POPULAT,BOX 0856,SAN FRANCISCO,CA 94143, USA.		Grumbach, Kevin/L-9222-2016	Brown, Arleen/0000-0001-9948-8955	AHRQ HHS [HS07373] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; BINDMAN AB, 1992, JAMA-J AM MED ASSOC, V268, P2426, DOI 10.1001/jama.268.17.2426; COLLEN MF, 1973, INT C SERIES, P332; GARFIELD SR, 1970, NEW ENGL J MED, V283, P1087, DOI 10.1056/NEJM197011122832006; GARFIELD SR, 1970, SCI AM, V222, P15, DOI 10.1038/scientificamerican0470-15; GARRISON GE, 1966, AM J EPIDEMIOL, V83, P338, DOI 10.1093/oxfordjournals.aje.a120589; GHALI JK, 1988, ARCH INTERN MED, V148, P2013, DOI 10.1001/archinte.148.9.2013; GHALI JK, 1990, ARCH INTERN MED, V150, P769, DOI 10.1001/archinte.150.4.769; GILLUM RF, 1987, AM HEART J, V113, P1043, DOI 10.1016/0002-8703(87)90077-9; GILLUM RF, 1991, CARDIOVASCULAR DIS B, P3; GRAVES EJ, 1994, ADV DATA VITAL HLTH, V249; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; NAM CB, 1978, SOC BIOL, V25, P306, DOI 10.1080/19485565.1978.9988352; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; RODEHEFFER RJ, 1993, MAYO CLIN PROC, V68, P1143, DOI 10.1016/S0025-6196(12)60063-9; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; WING S, 1985, J GERONTOL, V40, P78, DOI 10.1093/geronj/40.1.78; YUSEF S, 1989, HYPERTENSION S1, V13, P74; 1994, MMWR-MORBID MORTAL W, V43, P77	27	98	98	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1037	1042		10.1001/jama.274.13.1037	http://dx.doi.org/10.1001/jama.274.13.1037			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RX108	7563454				2022-12-28	WOS:A1995RX10800026
J	HATFIELD, MO				HATFIELD, MO			THE WAR AGAINST DISEASE AND DISABILITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									US SENATE,WASHINGTON,DC 20510									LEVIT KR, 1994, HEALTH CARE FINANC R, V16, P247; 1994, GROWING TOBACCO FREE; 1995, FY1995 OFF UND DEF N; 1994, MMWR-MORBID MORTAL W, V43, P469; 1994, SURVEY US ATTITUDES	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1077	1077		10.1001/jama.274.13.1077	http://dx.doi.org/10.1001/jama.274.13.1077			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RX108	7563465				2022-12-28	WOS:A1995RX10800037
J	ZINKERNAGEL, RM				ZINKERNAGEL, RM			MHC-RESTRICTED T-CELL RECOGNITION - THE BASIS OF IMMUNE SURVEILLANCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LYMPHOCYTIC CHORIOMENINGITIS; MEDIATED CYTOTOXICITY; ANTIGENS; DISEASE; THYMUS; HLA				ZINKERNAGEL, RM (corresponding author), UNIV ZURICH HOSP,INST EXPTL IMMUNOL,SCHMELZBERGSTR 12,CH-8091 ZURICH,SWITZERLAND.							DAUSSET J, 1977, HLA DISEASE, V9; DOHERTY PC, 1974, TRANSPLANT REV-DENMA, V19, P89; DOHERTY PC, 1995, JAMA-J AM MED ASSOC, V274, P1067, DOI 10.1001/jama.274.13.1067; DOHERTY PC, 1975, LANCET, V2, P1406; FINK PJ, 1978, J EXP MED, V148, P766, DOI 10.1084/jem.148.3.766; GOULMY E, 1977, NATURE, V266, P544, DOI 10.1038/266544a0; KATZ DH, 1973, J EXP MED, V137, P1405, DOI 10.1084/jem.137.6.1405; KLEIN J, 1979, SCIENCE, V203, P516, DOI 10.1126/science.104386; MCMICHAEL AJ, 1977, NATURE, V270, P524, DOI 10.1038/270524a0; MILLER JF, 1961, LANCET, V2, P748; OLDSTONE MB, 1973, J EXP MED, V137, P1201, DOI 10.1084/jem.137.5.1201; ROSENTHA.AS, 1973, J EXP MED, V138, P1194, DOI 10.1084/jem.138.5.1194; SHEARER GM, 1974, EUR J IMMUNOL, V4, P527, DOI 10.1002/eji.1830040802; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0; ZINKERNA.RM, 1974, NATURE, V251, P547, DOI 10.1038/251547a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882; ZINKERNAGEL RM, 1979, ANNU REV MICROBIOL, V33, P201, DOI 10.1146/annurev.mi.33.100179.001221; ZINKERNAGEL RM, 1991, IMMUNOL REV, V122, P133, DOI 10.1111/j.1600-065X.1991.tb00601.x	19	3	3	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1069	1071		10.1001/jama.274.13.1069	http://dx.doi.org/10.1001/jama.274.13.1069			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX108	7563462				2022-12-28	WOS:A1995RX10800034
J	CROOKE, E				CROOKE, E			REGULATION OF CHROMOSOMAL REPLICATION IN ESCHERICHIA-COLI - SEQUESTRATION AND BEYOND	CELL			English	Review							ESCHERICHIA-COLI; DNA-REPLICATION; DAM METHYLTRANSFERASE; PREVENTS				CROOKE, E (corresponding author), GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC 20007, USA.							BAKKER A, 1989, J BACTERIOL, V171, P5738, DOI 10.1128/jb.171.10.5738-5742.1989; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; BOYE E, 1988, BIOCHIM BIOPHYS ACTA, V951, P359, DOI 10.1016/0167-4781(88)90107-8; BRENDLER T, 1995, EMBO J, V14, P4083, DOI 10.1002/j.1460-2075.1995.tb00080.x; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; CHAKRABORTI A, 1992, J BACTERIOL, V174, P7202, DOI 10.1128/jb.174.22.7202-7206.1992; HERRICK J, 1994, EMBO J, V13, P4695, DOI 10.1002/j.1460-2075.1994.tb06793.x; KATAYAMA T, 1995, J BIOL CHEM, V270, P9265, DOI 10.1074/jbc.270.16.9265; LANDOULSI A, 1990, CELL, V63, P1053, DOI 10.1016/0092-8674(90)90508-C; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MESSER W, 1995, ESCHERICHIA COLI SAL; OGDEN GB, 1988, CELL, V54, P127, DOI 10.1016/0092-8674(88)90186-9; RUSSELL DW, 1987, CELL, V50, P1071, DOI 10.1016/0092-8674(87)90173-5; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; SLATER S, 1995, CELL, V82, P927, DOI 10.1016/0092-8674(95)90272-4; VONFREIESLEBEN U, 1994, MOL MICROBIOL, V14, P763; XIA WM, 1995, P NATL ACAD SCI USA, V92, P783, DOI 10.1073/pnas.92.3.783	18	37	37	2	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					877	880		10.1016/0092-8674(95)90020-9	http://dx.doi.org/10.1016/0092-8674(95)90020-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553847	Bronze			2022-12-28	WOS:A1995RW69300003
J	MIDDLE, C; JOHNSON, A; PETTY, T; SIMS, L; MACFARLANE, A				MIDDLE, C; JOHNSON, A; PETTY, T; SIMS, L; MACFARLANE, A			ETHICS APPROVAL FOR A NATIONAL POSTAL SURVEY - RECENT EXPERIENCE	BRITISH MEDICAL JOURNAL			English	Article							COMMITTEES		RADCLIFFE INFIRM,NATL PERINATAL EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; University of Oxford								GILBERT C, 1989, BRIT MED J, V299, P1437, DOI 10.1136/bmj.299.6713.1437; LOCK S, 1990, BRIT MED J, V300, P61, DOI 10.1136/bmj.300.6717.61; WARNOCK M, 1988, BRIT MED J, V297, P1626, DOI 10.1136/bmj.297.6664.1626; 1994, MED RES ETHICS COMMI; 1994, LOCAL RES ETHICS COM	5	55	55	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	1995	311	7006					659	660		10.1136/bmj.311.7006.659	http://dx.doi.org/10.1136/bmj.311.7006.659			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RU753	7549633	Green Published			2022-12-28	WOS:A1995RU75300017
J	PUKKALA, E; AUVINEN, A; WAHLBERG, G				PUKKALA, E; AUVINEN, A; WAHLBERG, G			INCIDENCE OF CANCER AMONG FINNISH AIRLINE CABIN ATTENDANTS, 1967-92	BRITISH MEDICAL JOURNAL			English	Article							RADIATION EXPOSURE; COSMIC-RADIATION; BREAST-CANCER; RISK	Objective-To assess whether occupational exposure among commercial airline cabin attendants are associated with risk of cancer. Design-Record linkage study. Setting-Finland. Subjects-1577 female and 187 male cabin attendants who had worked for the Finnish airline companies. Main outcome measure-Standardised incidence ratio; expected number of cases based on national cancer incidences. Results-A significant excess of breast cancer (standardised incidence ratio 1.87 (95% confidence interval 1.15 to 2.23)) and bone cancer (15.10 (1.82 to 54.40)) was found among female workers. The risk of breast cancer was most prominent 15 years after recruitment. Risks of leukaemia (3.57 (0.43 to 12.9)) and skin melanoma (2.11 (0.43 to 6.15) were not significantly raised. Among men, one lymphoma and one Kaposi's sarcoma were found (expected number of cases 1.6). Conclusions-Although the lifestyle of cabin attendants is different fi om that of the reference population-for example, in terms of social status and parity-concentration of the excess risks to primary sites sensitive to radiation suggests that ionising radiation during flights may add to the cancer risk of all flight personnel. Otherwise the lifestyle of cabin attendants did not seem to affect their risks of cancer. Estimates of the effect of reproductive risk factors only partly explained the increased risk of breast cancer. If present estimates of health hazards due to radiation are also valid for cosmic radiation, then the radiation doses of cabin attendants seem too small to account entirely for the observed excess risk.	FINNISH CTR RADIAT NUCL SAFETY,SF-00881 HELSINKI,FINLAND; FINNISH FLIGHT ATTENDANTS ASSOC,SF-00520 HELSINKI,FINLAND	Radiation & Nuclear Safety Authority (STUK)	PUKKALA, E (corresponding author), FINNISH CANC REGISTRY,LIISANKATU 21 B,SF-00170 HELSINKI,FINLAND.		Auvinen, Anssi/AAD-9311-2020; Auvinen, Anssi/AAL-2111-2020	Auvinen, Anssi/0000-0003-1125-4818				[Anonymous], 1990, HLTH EFFECTS EXPOSUR; [Anonymous], 1994, SOURCES EFFECTS IONI; BAND PR, 1990, AVIAT SPACE ENVIR MD, V61, P299; BOUVILLE A, 1988, RADIAT PROT DOSIM, V24, P293; EWERTZ M, 1990, INT J CANCER, V46, P597, DOI 10.1002/ijc.2910460408; FRIEDBERG W, 1989, AVIAT SPACE ENVIR MD, V60, P1104; HIGGINSON J, 1992, HUMAN CANCER EPIDEMI; LAND CE, 1994, CANCER CAUSE CONTROL, V5, P167, DOI 10.1007/BF01830263; MONTAGNE C, 1993, RADIAT PROT DOSIM, V48, P79; OBRIEN K, 1972, HEALTH PHYS, V22, P225, DOI 10.1097/00004032-197203000-00002; PARETZKE HG, 1993, RADIAT PROT DOSIM, V48, P33; Pukkala E, 1992, GEOGRAPHICAL ENV EPI, P125; Pukkala E, 1995, CONTRIBUTIONS EPIDEM, V7; SINCLAIR WK, 1985, RADIAT PROT DOSIM, V13, P319; SOINI I, 1977, INT J EPIDEMIOL, V6, P365, DOI 10.1093/ije/6.4.365; TEPPO L, 1994, ACTA ONCOL, V33, P365, DOI 10.3109/02841869409098430; THOMPSON DE, 1994, RAD RES S, V37, pS17; 1994, LANCET, V344, P1039	18	187	191	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	1995	311	7006					649	652		10.1136/bmj.311.7006.649	http://dx.doi.org/10.1136/bmj.311.7006.649			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU753	7549630	Green Published			2022-12-28	WOS:A1995RU75300014
J	JACOBSON, MD; RAFF, MC				JACOBSON, MD; RAFF, MC			PROGRAMMED CELL-DEATH AND BCL-2 PROTECTION IN VERY-LOW OXYGEN	NATURE			English	Article							APOPTOSIS; INDUCTION	PROGRAMMED cell death (PCD) is a fundamental feature of animal cells', but the mechanism remains unknown, Similarly, the Bcl-2 oncoprotein can suppress PCD in a variety of cell types and circumstances(2), but it is not known how it does so, It has been suggested that PCD involves the generation of reactive oxygen species (ROS) and that Bcl-2 protects against PCD by inhibiting the generation or action of ROS(3-6). To determine whether ROS are required for PCD, we cultured cells in a near-anaerobic atmosphere where the generation of ROS would be expected not to occur, or at least to be greatly reduced, We find that these conditions inhibit PCD induced by ROS-generating agents but do not inhibit PCD induced by other means, Furthermore, we show that Bcl-2 can protect cells from PCD in these anaerobic conditions. These results suggest that ROS are not required for PCD, and that Bcl-2 protects against PCD in ways that do not depend on the inhibition of ROS production or activity.	UNIV LONDON UNIV COLL,MRC,MOLEC CELL BIOL LAB,LONDON WC1E 6BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT BIOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London; University of London; University College London	JACOBSON, MD (corresponding author), UNIV LONDON UNIV COLL,MRC,DEV NEUROBIOL PROGRAMME,TORRINGTON PL,LONDON WC1E 6BT,ENGLAND.							ABELLO PA, 1994, ARCH SURG-CHICAGO, V129, P134; ABRAMS JS, 1988, J IMMUNOL, V140, P131; BAUDRY M, 1993, BIOCHEM BIOPH RES CO, V192, P964, DOI 10.1006/bbrc.1993.1509; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; DEXTER TM, 1994, PHIL T R SOC B, V345, P231; Franklin J. L., 1994, Society for Neuroscience Abstracts, V20, P432; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; MARVEL J, 1994, ONCOGENE, V9, P1117; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NOUROOZZADEH J, 1994, ANAL BIOCHEM, V220, P403, DOI 10.1006/abio.1994.1357; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RATAN RR, 1994, J NEUROCHEM, V62, P376; RATAN RR, 1994, J NEUROSCI, V14, P4385; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SANDSTROM PA, 1994, J LEUKOCYTE BIOL, V55, P221, DOI 10.1002/jlb.55.2.221; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WOLFE JT, 1994, FEBS LETT, V352, P58, DOI 10.1016/0014-5793(94)00920-1; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112	29	628	647	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					814	816		10.1038/374814a0	http://dx.doi.org/10.1038/374814a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV315	7536895				2022-12-28	WOS:A1995QV31500048
J	CHENG, GH; CLEARY, AM; YE, ZS; HONG, DI; LEDERMAN, S; BALTIMORE, D				CHENG, GH; CLEARY, AM; YE, ZS; HONG, DI; LEDERMAN, S; BALTIMORE, D			INVOLVEMENT OF CRAF1, A RELATIVE OF TRAF, IN CD40 SIGNALING	SCIENCE			English	Article							FOLLICULAR DENDRITIC CELLS; X-LINKED IMMUNODEFICIENCY; HYPER-IGM SYNDROME; B-CELLS; T-CELLS; ACTIVATION MOLECULE; LYMPHOCYTES-B; LIGAND; ANTIGEN; EXPRESSION	CD40 is a receptor on the surface of B lymphocytes, the activation of which leads to B cell survival, growth, and differentiation. A yeast two-hybrid screen identified a gene, CRAF1, encoding a protein that interacts directly with the CD40 cytoplasmic tail through a region of similarity to the tumor necrosis factor-alpha (TNF-alpha) receptor-associated factors. Overexpression of a truncated CRAF1 gene inhibited CD40-mediated up-regulation of CD23. A region of CRAF1 was similar to the TNF-alpha receptor-associated factors TRAF1 and TRAF2 and so defined a shared TRAF-C domain that was necessary and sufficient for CD40 binding and homodimerization. The CRAF1 sequence also predicted a long amphipathic helix, a pattern of five zinc fingers, and a zinc ring finger. It is likely that other members of the TNF receptor superfamily use CRAF-related proteins in their signal transduction processes.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; COLUMBIA UNIV,DEPT MED,NEW YORK,NY 10032; ROCKEFELLER UNIV,NEW YORK,NY 10021	Massachusetts Institute of Technology (MIT); Columbia University; Rockefeller University				Lederman, Seth/0000-0003-2781-1455	NATIONAL CANCER INSTITUTE [R01CA055713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007367] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA55713] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM07367] Funding Source: Medline; PHS HHS [A122346] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BERBERICH I, 1994, J IMMUNOL, V15, P4357; CALLARD RE, 1994, J IMMUNOL, V153, P3295; CHENG G, UNPUB; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; CLARK EA, 1992, J IMMUNOL, V148, P3327; CLEARY AM, UNPUB; CRAWFORD DH, 1993, IMMUNOLOGY, V80, P40; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; DURIE FH, 1994, IMMUNOL TODAY, V15, P406, DOI 10.1016/0167-5699(94)90269-0; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FREMONT PS, 1991, CELL, V64, P483; GALY AHM, 1992, J IMMUNOL, V149, P775; GAUCHAT JF, 1993, FEBS LETT, V315, P259, DOI 10.1016/0014-5793(93)81175-Y; GORDON J, 1988, J IMMUNOL, V140, P1425; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; GRILLI M, 1991, INT REV CYTOL, V143, P1; GRUBER MF, 1989, J IMMUNOL, V142, P4144; HART DNJ, 1988, J EXP MED, V168, P157, DOI 10.1084/jem.168.1.157; HEATH AW, 1993, CELL IMMUNOL, V152, P468, DOI 10.1006/cimm.1993.1305; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2368, DOI 10.1002/eji.1830230948; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; HU HM, 1994, J BIOL CHEM, V269, P30069; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANE P, 1993, J EXP MED, V177, P1209, DOI 10.1084/jem.177.4.1209; LEDERMAN S, 1992, J IMMUNOL, V149, P3817; LEDERMAN S, 1992, J EXP MED, V175, P1091, DOI 10.1084/jem.175.4.1091; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; Miller J.H., 1972, EXPT MOL GENETICS; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PARRY SL, 1994, J IMMUNOL, V152, P2821; PAULIE S, 1985, CANCER IMMUNOL IMMUN, V20, P23; RAMESH N, 1993, INT IMMUNOL, V5, P769, DOI 10.1093/intimm/5.7.769; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHRIEVER F, 1989, J EXP MED, V169, P2043, DOI 10.1084/jem.169.6.2043; SIEGEL JP, 1990, J IMMUNOL METHODS, V132, P287, DOI 10.1016/0022-1759(90)90040-3; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; TARAGLIS LA, 1993, CELL, V74, P845; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; YELLIN MJ, 1994, J IMMUNOL, V153, P666	51	432	457	0	12	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1494	1498		10.1126/science.7533327	http://dx.doi.org/10.1126/science.7533327			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7533327				2022-12-28	WOS:A1995QL49700037
J	MAGRELLI, A; LANGENKEMPER, K; DEHIO, C; SCHELL, J; SPENA, A				MAGRELLI, A; LANGENKEMPER, K; DEHIO, C; SCHELL, J; SPENA, A			SPLICING OF THE ROLA TRANSCRIPT OF AGROBACTERIUM-RHIZOGENES IN ARABIDOPSIS	SCIENCE			English	Article							PRE-MESSENGER-RNA; INTRONS; GENE; DNA; SEQUENCES; BACTERIA; PLASMID; BACTERIOPHAGE-T4; IDENTIFICATION; EXPRESSION	The rolA gene encoded on the Ri plasmid A4 of Agrobacterium rhizogenes is one of the transferred (T-L-DNA) genes involved in the pathogenesis of hairy-root disease in plants. The function of the 100-amino acid protein product of rolA is unknown, although its expression causes physiological and developmental alterations in transgenic plants. The rolA gene of A. rhizogenes contains an intron in its untranslated leader region that has features typical of plant pre-messenger RNA introns. Transcription and splicing of the rolA pre-messenger RNA occur in the plant cell.	MAX PLANCK INST ZUCHTUNGSFORSCH,D-50829 COLOGNE,GERMANY	Max Planck Society			Magrelli, Armando/A-5478-2010; Dehio, Christoph/R-8277-2016; Dehio, Christoph/AAD-5572-2019; Magrelli, Armando/K-4330-2019	Magrelli, Armando/0000-0002-5036-3710; Dehio, Christoph/0000-0001-7288-1052; Dehio, Christoph/0000-0001-7288-1052; Magrelli, Armando/0000-0002-5036-3710				CARNEIRO M, 1993, PLANT J, V3, P785, DOI 10.1111/j.1365-313X.1993.00785.x; CHU FK, 1984, P NATL ACAD SCI-BIOL, V81, P3049, DOI 10.1073/pnas.81.10.3049; CSANK C, 1990, NUCLEIC ACIDS RES, V18, P5133, DOI 10.1093/nar/18.17.5133; DEHIO C, 1993, MOL GEN GENET, V241, P359, DOI 10.1007/BF00284689; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; GOODALL GJ, 1990, PLANT MOL BIOL, V14, P727, DOI 10.1007/BF00016505; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; GOODRICHBLAIR H, 1990, CELL, V63, P417, DOI 10.1016/0092-8674(90)90174-D; JANSSENS A, 1984, MOL GEN GENET, V195, P341, DOI 10.1007/BF00332769; KOVACS SA, 1993, J BACTERIOL, V175, P1871, DOI 10.1128/JB.175.7.1871-1878.1993; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; MAGRELLI A, UNPUB; Maniatis T, 1989, DECONTAMINATION DILU; MICHAEL T, IN PRESS METHODS MOL; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; REINHOLDHUREK B, 1992, NATURE, V357, P173, DOI 10.1038/357173a0; SCHRODER G, 1983, EMBO J, V2, P403, DOI 10.1002/j.1460-2075.1983.tb01437.x; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SINKAR VP, 1988, GENE DEV, V2, P688, DOI 10.1101/gad.2.6.688; SJOBERG BM, 1986, EMBO J, V5, P2031, DOI 10.1002/j.1460-2075.1986.tb04460.x; SLIGHTOM JL, 1986, J BIOL CHEM, V261, P108; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; WHITE FF, 1985, J BACTERIOL, V164, P33, DOI 10.1128/JB.164.1.33-44.1985; XU MQ, 1990, SCIENCE, V250, P1566, DOI 10.1126/science.2125747	27	21	23	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					1986	1988		10.1126/science.7528444	http://dx.doi.org/10.1126/science.7528444			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7528444				2022-12-28	WOS:A1994PZ26700028
J	GRAHAM, BS; WRIGHT, PF				GRAHAM, BS; WRIGHT, PF			DRUG-THERAPY - CANDIDATE AIDS VACCINES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIBODY-DEPENDENT ENHANCEMENT; TOXIC LYMPHOCYTES-T; ENVELOPE GLYCOPROTEIN GP160; CYNOMOLGUS MONKEYS; CONFERS PROTECTION; NEUTRALIZING ANTIBODIES; MONOCLONAL-ANTIBODIES; PASSIVE-IMMUNIZATION; RECOMBINANT GP160		VANDERBILT UNIV, SCH MED, DEPT PEDIAT, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, NASHVILLE, TN 37232 USA	Vanderbilt University; Vanderbilt University	GRAHAM, BS (corresponding author), VANDERBILT UNIV, SCH MED, DEPT MED, A-3310 MCN, 1161 21ST AVE S, NASHVILLE, TN 37232 USA.		Graham, Barney S./AAC-5898-2019	Graham, Barney S./0000-0001-8112-0853	NIAID NIH HHS [N01-AI-05062, N01-AI-45210] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI045210, N01AI005062] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADA GL, 1990, LANCET, V335, P523, DOI 10.1016/0140-6736(90)90748-T; AGY MB, 1992, SCIENCE, V257, P103, DOI 10.1126/science.1621083; ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; BELSHE RB, 1993, J INFECT DIS, V168, P1387, DOI 10.1093/infdis/168.6.1387; BELSHE RB, 1994, ANN INTERN MED, V121, P584, DOI 10.7326/0003-4819-121-8-199410150-00005; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; BRENNER TJ, 1991, LANCET, V337, P1001, DOI 10.1016/0140-6736(91)92660-T; BURKE DS, 1992, PERSPECT BIOL MED, V35, P511; BYRNE JA, 1984, J VIROL, V51, P682, DOI 10.1128/JVI.51.3.682-686.1984; CICHUTEK K, 1992, P NATL ACAD SCI USA, V89, P7365, DOI 10.1073/pnas.89.16.7365; COONEY EL, 1993, P NATL ACAD SCI USA, V90, P1882, DOI 10.1073/pnas.90.5.1882; COX WI, 1993, VIROLOGY, V195, P845, DOI 10.1006/viro.1993.1442; CRANAGE MP, 1992, LANCET, V339, P273, DOI 10.1016/0140-6736(92)91335-6; CRANAGE MP, 1993, AIDS RES HUM RETROV, V9, P13, DOI 10.1089/aid.1993.9.13; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DEFOORT JP, 1992, P NATL ACAD SCI USA, V89, P3879, DOI 10.1073/pnas.89.9.3879; DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0; DESROSIERS RC, 1992, AIDS RES HUM RETROV, V8, P411, DOI 10.1089/aid.1992.8.411; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; ELDAHER N, 1993, J INFECT DIS, V168, P306, DOI 10.1093/infdis/168.2.306; ELDRIDGE JH, 1991, MOL IMMUNOL, V28, P287, DOI 10.1016/0161-5890(91)90076-V; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; FULTZ PN, 1992, SCIENCE, V256, P1687, DOI 10.1126/science.256.5064.1687; FULTZ PN, 1987, J VIROL, V61, P4026, DOI 10.1128/JVI.61.12.4026-4029.1987; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; GARDNER MB, 1990, AIDS RES HUM RETROV, V6, P835, DOI 10.1089/aid.1990.6.835; GEORGE JR, 1992, LANCET, V340, P337, DOI 10.1016/0140-6736(92)91406-X; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; GOLDING H, 1989, J CLIN INVEST, V83, P1430, DOI 10.1172/JCI114034; GOLDING H, 1988, J EXP MED, V167, P914, DOI 10.1084/jem.167.3.914; GRAHAM BS, 1994, J INFECT DIS, V170, P782, DOI 10.1093/infdis/170.4.782; GRAHAM BS, 1990, J CLIN MICROBIOL, V28, P2608, DOI 10.1128/JCM.28.12.2608-2611.1990; HAFFAR O, 1990, J VIROL, V64, P2653, DOI 10.1128/JVI.64.6.2653-2659.1990; HAMMOND SA, 1992, J EXP MED, V176, P1531, DOI 10.1084/jem.176.6.1531; HANSON CV, 1994, AIDS RES HUM RETROV, V10, P645, DOI 10.1089/aid.1994.10.645; HILLEMAN MR, 1983, J INFECT S1, V7, pS3; HIRSCH VM, 1994, J INFECT DIS, V170, P51, DOI 10.1093/infdis/170.1.51; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOMSY J, 1989, SCIENCE, V244, P1357, DOI 10.1126/science.2786647; HU SL, 1992, SCIENCE, V255, P456, DOI 10.1126/science.1531159; Jezek Z, 1988, HUMAN MONKEYPOX; JOHNSON PR, 1992, P NATL ACAD SCI USA, V89, P2175, DOI 10.1073/pnas.89.6.2175; KEAY S, 1992, AIDS RES HUM RETROV, V8, P1091, DOI 10.1089/aid.1992.8.1091; KEEFER MC, 1994, AIDS RES HUM RETROV, V10, pS139; KORBER B, 1992, AIDS RES HUM RETROV, V8, P1461, DOI 10.1089/aid.1992.8.1461; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LANGLOIS AJ, 1992, SCIENCE, V255, P292, DOI 10.1126/science.1549775; LAROSA GJ, 1991, SCIENCE, V251, P811, DOI 10.1126/science.1990444; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LEE MR, 1987, SCIENCE, V237, P1047, DOI 10.1126/science.3039662; LEHNER T, 1992, SCIENCE, V258, P1365, DOI 10.1126/science.1360702; LI J, 1992, J ACQ IMMUN DEF SYND, V5, P639; LIN YL, 1981, J EXP MED, V154, P225, DOI 10.1084/jem.154.2.225; MACKETT M, 1982, P NATL ACAD SCI-BIOL, V79, P7415, DOI 10.1073/pnas.79.23.7415; MARX PA, 1993, SCIENCE, V260, P1323, DOI 10.1126/science.8493576; MASCOLA JR, 1993, AIDS RES HUM RETROV, V9, P1175, DOI 10.1089/aid.1993.9.1175; MILLER CJ, 1993, LAB INVEST, V68, P129; MONTEFIORI DC, 1991, AIDS, V5, P513, DOI 10.1097/00002030-199105000-00006; MONTEFIORI DC, 1993, J CLIN INVEST, V92, P840, DOI 10.1172/JCI116658; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; MOWAT AM, 1991, IMMUNOLOGY, V72, P317; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; NARA PL, 1990, J VIROL, V64, P3779, DOI 10.1128/JVI.64.8.3779-3791.1990; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; PALKER TJ, 1989, J IMMUNOL, V142, P3612; PANICALI D, 1982, P NATL ACAD SCI-BIOL, V79, P4927, DOI 10.1073/pnas.79.16.4927; PEETERS M, 1992, LANCET, V340, P339, DOI 10.1016/0140-6736(92)91407-Y; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PINCUS SH, 1993, J CLIN INVEST, V91, P1987, DOI 10.1172/JCI116420; PORTERFIELD JS, 1986, ADV VIRUS RES, V31, P335, DOI 10.1016/S0065-3527(08)60268-7; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; PRINCE AM, 1991, AIDS RES HUM RETROV, V7, P971, DOI 10.1089/aid.1991.7.971; PUTKONEN P, 1991, NATURE, V352, P436, DOI 10.1038/352436a0; PUTKONEN P, 1990, AIDS, V4, P783, DOI 10.1097/00002030-199008000-00010; REDFIELD RR, 1991, NEW ENGL J MED, V324, P1677, DOI 10.1056/NEJM199106133242401; REIHER WE, 1986, P NATL ACAD SCI USA, V83, P9188, DOI 10.1073/pnas.83.23.9188; REIHER WE, 1987, P NATL ACAD SCI USA, V84, P564; REIMANN KA, 1994, J VIROL, V68, P2362, DOI 10.1128/JVI.68.4.2362-2370.1994; ROBINSON WE, 1988, LANCET, V1, P790; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; SALK J, 1993, SCIENCE, V260, P1270, DOI 10.1126/science.8098553; SCHWARTZ DH, 1994, IMMUNOL TODAY, V15, P54, DOI 10.1016/0167-5699(94)90133-3; SHAFFERMAN A, 1991, P NATL ACAD SCI USA, V88, P7126, DOI 10.1073/pnas.88.16.7126; SHIBATA R, 1995, J VIROL, V69, P4453, DOI 10.1128/JVI.69.7.4453-4462.1995; STEIMER KS, 1991, SCIENCE, V254, P105, DOI 10.1126/science.1718036; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; TAKEDA A, 1992, J CLIN INVEST, V89, P1952, DOI 10.1172/JCI115802; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TYLER DS, 1990, J IMMUNOL, V144, P3375; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WARREN HS, 1986, ANNU REV IMMUNOL, V4, P369, DOI 10.1146/annurev.iy.04.040186.002101; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WILKS D, 1991, J INFECT DIS, V163, P389, DOI 10.1093/infdis/163.2.389; WOLFS TFW, 1992, VIROLOGY, V189, P103, DOI 10.1016/0042-6822(92)90685-I; WRIGHT PF, 1991, NEW ENGL J MED, V325, P1774, DOI 10.1056/NEJM199112193252504; ZAGURY JF, 1993, P NATL ACAD SCI USA, V90, P7573, DOI 10.1073/pnas.90.16.7573; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; 1995, AIDS, V9	102	100	120	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 16	1995	333	20					1331	1339		10.1056/NEJM199511163332007	http://dx.doi.org/10.1056/NEJM199511163332007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE365	7566026				2022-12-28	WOS:A1995TE36500007
J	POLVIKOSKI, T; SULKAVA, R; HALTIA, M; KAINULAINEN, K; VUORIO, A; VERKKONIEMI, A; NIINISTO, L; HALONEN, P; KONTULA, K				POLVIKOSKI, T; SULKAVA, R; HALTIA, M; KAINULAINEN, K; VUORIO, A; VERKKONIEMI, A; NIINISTO, L; HALONEN, P; KONTULA, K			APOLIPOPROTEIN-E, DEMENTIA, AND CORTICAL DEPOSITION OF BETA-AMYLOID PROTEIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SPORADIC ALZHEIMERS-DISEASE; SENILE PLAQUES; E POLYMORPHISM; TYPE-4 ALLELE; E GENOTYPE; BINDING; METHENAMINE; DIAGNOSIS; PEPTIDE; HEALTH	Background. The epsilon 4 allele of apolipoprotein E has been associated with an increased risk of late-onset Alzheimer's disease. In a cohort of elderly subjects we prospectively investigated the relation between the apolipoprotein E genotype, dementia, and the accumulation of beta-amyloid protein in the cerebral cortex. Methods. Autopsy involving neuropathological analysis and DNA analysis of frozen blood samples was performed in 92 of 271 persons who were at least 85 years of age, who had been living in Vantaa, Finland, on April 1, 1991, and who had died between that time and the end of 1993. All subjects had been tested for dementia, Apolipoprotein E genotyping was done with a solid-phase minisequencing technique. The percentage of the cortex occupied by methenamine silver-stained plaques was used as an estimate of the extent of beta-amyloid protein deposition. Results. The frequency of the epsilon 4 allele was significantly higher in the subjects with Alzheimer's disease than in the subjects without dementia (30 percent vs, 8 percent, P<0.001), There was a greater accumulation of beta-amyloid protein in the brain and more neurofibrillary tangles in the subjects with the epsilon 4 allele than in those without it (P<0.001), The deposition of beta-amyloid protein varied according to the genotype in both the subjects with dementia and those without dementia: it was lowest in those with the epsilon 2/epsilon 3 genotype, intermediate in those with the epsilon 3/epsilon 3 genotype, and highest in those with the epsilon 3/epsilon 4 genotype. A single subject had the epsilon 4/epsilon 4 genotype and had dementia. Conclusions. The epsilon 4 allele of apolipoprotein E is significantly associated with Alzheimer's disease. Even in elderly subjects without dementia, the apolipoprotein E genotype is related to the degree of deposition of beta-amyloid protein in the cerebral cortex.	HELSINKI UNIV,DEPT NEUROL,HELSINKI,FINLAND; KUOPIO UNIV,DEPT COMMUNITY HLTH & GEN PRACTICE,KUOPIO,FINLAND; KATARIINA GERIATR HOSP,VANTAA,FINLAND	University of Helsinki; University of Eastern Finland	POLVIKOSKI, T (corresponding author), HELSINKI UNIV,DEPT PATHOL,POB 21,HAARTMANINKATU 3,SF-00014 HELSINKI,FINLAND.		Vuorio, Alpo/I-3116-2019					ALLSOP D, 1989, NEUROPATH APPL NEURO, V15, P531, DOI 10.1111/j.1365-2990.1989.tb01252.x; AMOUYEL P, 1993, LANCET, V342, P1309; ANWAR N, 1993, LANCET, V342, P1308, DOI 10.1016/0140-6736(93)92404-H; BORGAONKAR DS, 1993, LANCET, V342, P625, DOI 10.1016/0140-6736(93)91458-X; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; HOULDEN H, 1994, NEUROSCI LETT, V174, P222, DOI 10.1016/0304-3940(94)90026-4; KONDOH H, 1993, BIOTECH HISTOCHEM, V68, P113, DOI 10.3109/10520299309104677; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LOUHIJA J, 1994, ARTERIOSCLER THROMB, V14, P1084, DOI 10.1161/01.ATV.14.7.1084; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MIETTINEN HE, 1994, HUM GENET, V94, P189; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NOGUCHI S, 1993, LANCET, V342, P737, DOI 10.1016/0140-6736(93)91728-5; PAYAMI H, 1994, JAMA-J AM MED ASSOC, V271, P1316, DOI 10.1001/jama.271.17.1316; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; REBECK GW, 1993, NEURON, V11, P575; RICHEY PL, 1995, BIOCHEM BIOPH RES CO, V208, P657, DOI 10.1006/bbrc.1995.1389; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; ROSES AD, 1994, LANCET, V343, P1564, DOI 10.1016/S0140-6736(94)92960-2; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SOBEL E, 1995, NEUROLOGY, V45, P903, DOI 10.1212/WNL.45.5.903; STGEORGEHYSLOP P, 1994, SCIENCE, V263, P904; STGEORGEHYSLOP P, 1994, SCIENCE, V263, P537, DOI 10.1126/science.8290965; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; SYVANEN AC, 1993, AM J HUM GENET, V52, P46; TALBOT C, 1994, LANCET, V343, P1432, DOI 10.1016/S0140-6736(94)92557-7; UTERMANN G, 1987, AM HEART J, V113, P433, DOI 10.1016/0002-8703(87)90610-7; VAN BROECKHOVEN C, 1994, NEUROSCI LETT, V169, P179, DOI 10.1016/0304-3940(94)90385-9; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WISNIEWSKI T, 1993, BIOCHEM BIOPH RES CO, V192, P359, DOI 10.1006/bbrc.1993.1423; YAMAGUCHI H, 1990, ACTA NEUROPATHOL, V79, P569, DOI 10.1007/BF00296119; 1987, DIAGNOSTIC STATISTIC	41	423	435	1	25	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	1995	333	19					1242	1247		10.1056/NEJM199511093331902	http://dx.doi.org/10.1056/NEJM199511093331902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC715	7566000				2022-12-28	WOS:A1995TC71500002
J	SLOAND, EM; PITT, E; KLEIN, HG				SLOAND, EM; PITT, E; KLEIN, HG			SAFETY OF THE BLOOD-SUPPLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; T-CELL LEUKEMIA; HTLV-II INFECTION; NON-B HEPATITIS; TRANSFUSION-ASSOCIATED HEPATITIS; POLYMERASE CHAIN-REACTION; INTRAVENOUS-DRUG-USERS; LYMPHOTROPIC VIRUS; TRYPANOSOMA-CRUZI		NIH, WARREN GRANT MAGNUSON CLIN CTR, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA	SLOAND, EM (corresponding author), NHLBI, 31 CTR DR, MSC 2490, BLDG 31, ROOM 4A11, BETHESDA, MD 20892 USA.							AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; Aach RD, 1978, VIRAL HEPATITIS, P383; ADLER SP, 1989, TRANSFUSION, V29, P667, DOI 10.1046/j.1537-2995.1989.29890020436.x; ALI AM, 1987, BLOOD S, V70, pA325; ALTER HJ, 1990, NEW ENGL J MED, V323, P1312, DOI 10.1056/NEJM199011083231905; ALTER HJ, 1966, BLOOD-J HEMATOL, V27, P297, DOI 10.1182/blood.V27.3.297.297; ALTER HJ, 1975, LANCET, V2, P838, DOI 10.1016/S0140-6736(75)90234-2; ALTER HJ, 1991, TRANSFUSION, V31, P771, DOI 10.1046/j.1537-2995.1991.31892023507.x; Alter HJ, 1987, TRANSFUSION TRANSMIT, P53; [Anonymous], 1995, JAMA, V274, P1374; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; APPLEMAN MD, 1993, TRANSFUSION, V33, P61, DOI 10.1046/j.1537-2995.1993.33193142312.x; BACKER U, 1988, 4TH P INT C AIDS STO, V2, P364; BARRETT BB, 1993, TRANSFUSION, V33, P228, DOI 10.1046/j.1537-2995.1993.33393174449.x; BLOCH M, 1982, REV I INVEST MED, V11, P148; BOWDEN R, 1990, TRANSFUSION, V30, P762, DOI 10.1046/j.1537-2995.1990.30891020340.x; BOWDEN RA, 1992, BLOOD SAFETY CURRENT, P201; BRAINE HG, 1986, TRANSFUSION, V26, P391, DOI 10.1046/j.1537-2995.1986.26486262752.x; BRECHOT C, 1985, NEW ENGL J MED, V312, P270, DOI 10.1056/NEJM198501313120503; BRYSON YJ, 1995, NEW ENGL J MED, V332, P833, DOI 10.1056/NEJM199503303321301; BUCHHOLZ DH, 1992, TRANSFUSION, V32, P667, DOI 10.1046/j.1537-2995.1992.32792391043.x; BUCHHOLZ DH, 1971, NEW ENGL J MED, V285, P429, DOI 10.1056/NEJM197108192850803; BUSCH M, 1994, SEP FOOD DRUG ADM C; BUSCH MP, 1990, NEW ENGL J MED, V323, P1308, DOI 10.1056/NEJM199011083231904; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; BUSCH MP, 1991, TRANSFUSION, V31, P4, DOI 10.1046/j.1537-2995.1991.31191096183.x; CARVALHO MR, 1993, TRANSFUSION, V33, P830, DOI 10.1046/j.1537-2995.1993.331094054620.x; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; DESCHRYVER A, 1990, TRANSFUSION, V30, P844; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; DODD RY, 1988, INFECT CONT HOSP EP, V9, P357; DOLL LS, 1991, TRANSFUSION, V31, P704, DOI 10.1046/j.1537-2995.1991.31892023494.x; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; DONAHUE JG, 1990, NEW ENGL J MED, V323, P1709; DONDERO TJ, 1994, LANCET, V343, P1376, DOI 10.1016/S0140-6736(94)92517-8; DONEGAN E, 1990, ANN INTERN MED, V113, P733, DOI 10.7326/0003-4819-113-10-733; DONEGAN E, 1990, TRANSFUSION, V30, P851, DOI 10.1046/j.1537-2995.1990.30991048798.x; ESTEBAN JI, 1985, LANCET, V2, P1083; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; FARZADEGAN H, 1988, ANN INTERN MED, V108, P785, DOI 10.7326/0003-4819-108-6-785; FEIGAL E, 1991, J INFECT DIS, V164, P36, DOI 10.1093/infdis/164.1.36; GILBERT GL, 1989, LANCET, V1, P1228, DOI 10.1016/S0140-6736(89)92330-1; GOLDMAN M, 1991, Transfusion Medicine Reviews, V5, P73, DOI 10.1016/S0887-7963(91)70194-6; GRANT IH, 1989, ANN INTERN MED, V111, P849, DOI 10.7326/0003-4819-111-10-849; HJELLE B, 1992, LANCET, V339, P645, DOI 10.1016/0140-6736(92)90797-7; HOOFNAGLE JH, 1990, TRANSFUSION, V30, P384, DOI 10.1046/j.1537-2995.1990.30590296367.x; HORSBURGH CR, 1989, LANCET, V2, P637; JACOBSON MA, 1988, ANN INTERN MED, V108, P585, DOI 10.7326/0003-4819-108-4-585; KALYANARAMAN VS, 1982, P NATL ACAD SCI-BIOL, V79, P1653, DOI 10.1073/pnas.79.5.1653; KERNDT PR, 1991, TRANSFUSION, V31, P814, DOI 10.1046/j.1537-2995.1991.31992094668.x; KHABBAZ RF, 1992, NEW ENGL J MED, V326, P375, DOI 10.1056/NEJM199202063260604; KHABBAZ RF, 1993, ANN INTERN MED, V118, P448; KIM DM, 1992, TRANSFUSION, V32, P221, DOI 10.1046/j.1537-2995.1992.32392213804.x; KLEINMAN S, 1991, Transfusion (Bethesda), V31, p41S; KORELITZ JJ, 1994, TRANSFUSION, V34, P870, DOI 10.1046/j.1537-2995.1994.341095026972.x; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KRECH U, 1973, B WORLD HEALTH ORGAN, V49, P103; LANDER JJ, 1978, VOX SANG, V34, P77, DOI 10.1111/j.1423-0410.1978.tb03726.x; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; LEFRERE JJ, 1990, LANCET, V335, P1400, DOI 10.1016/0140-6736(90)91277-H; LEITMAN SF, 1989, NEW ENGL J MED, V321, P917, DOI 10.1056/NEJM198910053211401; LINDEN JV, 1992, TRANSFUSION, V32, P601, DOI 10.1046/j.1537-2995.1992.32792391030.x; LOIACONO BR, 1989, TRANSFUSION, V29, P823, DOI 10.1046/j.1537-2995.1989.29990070189.x; MACKINNON S, 1988, J CLIN PATHOL, V41, P948, DOI 10.1136/jcp.41.9.948; MANEZ R, 1993, TRANSFUSION, V33, P594, DOI 10.1046/j.1537-2995.1993.33793325057.x; MANNS A, 1992, INT J CANCER, V51, P886, DOI 10.1002/ijc.2910510609; MAURICE J, 1987, TROPICAL DISEASE RES, P89; MORDUCHOWICZ G, 1991, REV INFECT DIS, V13, P307; MORROW JF, 1991, JAMA-J AM MED ASSOC, V266, P555; MURPHY EL, 1993, LANCET, V341, P757, DOI 10.1016/0140-6736(93)90529-P; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; NELSON KE, 1992, ANN INTERN MED, V117, P554, DOI 10.7326/0003-4819-117-7-554; NICKERSON P, 1989, ANN INTERN MED, V111, P851, DOI 10.7326/0003-4819-111-10-851; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; PETERSEN LR, 1991, TRANSFUSION, V31, P698, DOI 10.1046/j.1537-2995.1991.31892023493.x; PETERSEN LR, 1994, TRANSFUSION, V34, P865, DOI 10.1046/j.1537-2995.1994.341095026971.x; PETERSEN LR, 1994, TRANSFUSION, V34, P283, DOI 10.1046/j.1537-2995.1994.34494233574.x; PINDYCK J, 1985, TRANSFUSION, V25, P3, DOI 10.1046/j.1537-2995.1985.25185116497.x; ROBERTGUROFF M, 1982, SCIENCE, V215, P975, DOI 10.1126/science.6760397; ROY MJ, 1993, JAMA-J AM MED ASSOC, V269, P2876, DOI 10.1001/jama.269.22.2876; SARIN PS, 1989, P NATL ACAD SCI USA, V86, P2021, DOI 10.1073/pnas.86.6.2021; SAYERS MH, 1992, ANN INTERN MED, V116, P55, DOI 10.7326/0003-4819-116-1-55; SCHMIDT PJ, 1994, ARCH PATHOL LAB MED, V118, P454; SCHMUNIS GA, 1991, TRANSFUSION, V31, P547, DOI 10.1046/j.1537-2995.1991.31691306255.x; SCHOECHETMAN G, 1994, SEP FOOD DRUG ADM C; Selbie FR, 1943, BRIT J EXP PATHOL, V24, P150; SELIK RM, 1993, TRANSFUSION, V33, P890, DOI 10.1046/j.1537-2995.1993.331194082377.x; SHIH LN, 1990, J MED VIROL, V32, P257, DOI 10.1002/jmv.1890320412; SILVER H, 1970, Transfusion (Bethesda), V10, P315; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; STARKEY JM, 1989, JAMA-J AM MED ASSOC, V262, P3452, DOI 10.1001/jama.262.24.3452; STEVENS CE, 1984, ANN INTERN MED, V101, P733, DOI 10.7326/0003-4819-101-6-733; SULLIVAN MT, 1991, ARCH INTERN MED, V151, P2043, DOI 10.1001/archinte.151.10.2043; TAYLOR PE, 1990, TRANSFUSION, V30, P783, DOI 10.1046/j.1537-2995.1990.30991048782.x; THIERS V, 1988, LANCET, V2, P1273; THOMPSON KS, 1992, TRANSFUSION, V32, pS65; TIPPLE MA, 1990, TRANSFUSION, V30, P207, DOI 10.1046/j.1537-2995.1990.30390194338.x; VISCIDI RP, 1991, J ACQ IMMUN DEF SYND, V4, P1190; WARD JW, 1988, NEW ENGL J MED, V318, P473, DOI 10.1056/NEJM198802253180803; WIKTOR SZ, 1991, LANCET, V338, P512, DOI 10.1016/0140-6736(91)90585-D; WRENN HE, 1974, TRANSFUSION, V14, P171, DOI 10.1111/j.1537-2995.1974.tb04512.x; ZIERDT CH, 1983, J CLIN MICROBIOL, V17, P628, DOI 10.1128/JCM.17.4.628-630.1983; 1993, ATTITUDES US ADULTS; 1991, MMWR-MORBID MORTAL W, V40, P176; 1991, TRANSFUSION S8S, V31, pS41	107	69	73	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	1995	274	17					1368	1373		10.1001/jama.274.17.1368	http://dx.doi.org/10.1001/jama.274.17.1368			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB278	7563562				2022-12-28	WOS:A1995TB27800028
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CIDOFOVIR AVAILABLE UNDER TREATMENT IND FOR CMV RETINITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1109	1109						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563473				2022-12-28	WOS:A1995RY05600008
J	KANE, JM; MCGLASHAN, TH				KANE, JM; MCGLASHAN, TH			TREATMENT OF SCHIZOPHRENIA	LANCET			English	Article							CLOZAPINE-INDUCED AGRANULOCYTOSIS; NEUROLEPTICS; INTERVENTION; TRIAL		YALE UNIV, SCH MED, INST PSYCHIAT, NEW HAVEN, CT USA	Yale University	KANE, JM (corresponding author), LONG ISL JEWISH MED CTR, HILLSIDE HOSP, DEPT PSYCHIAT, 7559 263RD ST, GLEN OAKS, NY 11004 USA.							ALVIR JMJ, 1993, NEW ENGL J MED, V329, P162, DOI 10.1056/NEJM199307153290303; Baldessarini RJ, 1990, SCHIZOPHRENIA TREATM, P61; BREIER A, 1994, AM J PSYCHIAT, V151, P20; CHADWICK P, 1994, BRIT J PSYCHIAT, V164, P190, DOI 10.1192/bjp.164.2.190; CHITTICK RA, 1961, VERMONT STORY REHABI; CHOUINARD G, 1993, J CLIN PSYCHOPHARM, V13, P25; DAVIS JM, 1993, J CLIN PSYCHIAT, V54, P24; DAVIS JM, 1989, COMPREHENSIVE TXB PS, P1591; DRAKE RE, 1994, COMMUNITY MENT HLT J, V30, P519, DOI 10.1007/BF02189068; FALLOON IRH, 1992, PSYCHIATRY, V55, P4; FENTON WS, 1995, COMPREHENSIVE TXB PS; FITTON A, 1990, DRUGS, V40, P727, DOI 10.2165/00003495-199040050-00007; Fromm-Reichmann F., 1950, PRINCIPLES INTENSIVE; GOLDSTEIN MJ, 1994, ACTA PSYCHIAT SCAND, V89, P54, DOI 10.1111/j.1600-0447.1994.tb05866.x; GUNDERSON JG, 1984, SCHIZOPHRENIA BULL, V10, P564, DOI 10.1093/schbul/10.4.564; HARDING CM, 1987, AM J PSYCHIAT, V144, P727; HOFFMAN RE, 1993, SCHIZOPHRENIA BULL, V19, P119, DOI 10.1093/schbul/19.1.119; HOGARTY GE, 1995, SCHIZOPHRENIA BULL, V21, P379, DOI 10.1093/schbul/21.3.379; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; KANE JM, 1993, SCHIZOPHRENIA BULL, V19, P287, DOI 10.1093/schbul/19.2.287; KANE JM, 1993, J CLIN PSYCHIAT, V54, P327; KINGDON D, 1994, BRIT J PSYCHIAT, V164, P581, DOI 10.1192/bjp.164.5.581; LEFF J, 1982, BRIT J PSYCHIAT, V141, P121, DOI 10.1192/bjp.141.2.121; LIEBERMAN JA, 1990, ARCH GEN PSYCHIAT, V47, P945; MALLYA AR, 1992, J CLIN PSYCHIAT, V53, P395; MARDER SR, 1994, AM J PSYCHIAT, V151, P825; May PRA, 1968, TREATMENT SCHIZOPHRE; MCFARLANE WR, 1995, ARCH GEN PSYCHIAT, V52, P679; MCGLASHAN TH, 1984, ARCH GEN PSYCHIAT, V41, P586; OKAYLI G, 1994, SCHIZOPHR RES, V11, P103; PERRIS C, 1989, COGNITIVE THERAPY SC; SCHOFFERMAN J, 1993, CLIN J PAIN, V9, P260, DOI 10.1097/00002508-199312000-00007; SCHOOLER N, 1994, 1994 ANN M AM COLL N; SEEMAN P, 1992, NEUROPSYCHOPHARMACOL, V7, P261; STEIN LI, 1980, ARCH GEN PSYCHIAT, V37, P392; Sullivan HS, 1931, AM J PSYCHIAT, V11, P519; WALLACE CJ, 1985, PSYCHIAT RES, V15, P239, DOI 10.1016/0165-1781(85)90081-2; WYATT RJ, 1991, SCHIZOPHRENIA BULL, V17, P325, DOI 10.1093/schbul/17.2.325	38	63	63	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 23	1995	346	8978					820	825		10.1016/S0140-6736(95)91630-X	http://dx.doi.org/10.1016/S0140-6736(95)91630-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RW258	7545770	hybrid			2022-12-28	WOS:A1995RW25800021
J	FISHER, M				FISHER, M			TREATMENT OF ACUTE ANAPHYLAXIS	BRITISH MEDICAL JOURNAL			English	Article							NONCARDIOGENIC PULMONARY-EDEMA; CARDIOVASCULAR COLLAPSE; CARDIOPULMONARY BYPASS; HUMAN-HEART; EPINEPHRINE; ANESTHESIA; HISTAMINE; PLASMA; DRUGS; SHOCK				FISHER, M (corresponding author), ROYAL N SHORE HOSP,INTENS THERAPY UNIT,ST LEONARDS,NSW 2065,AUSTRALIA.							ASSEM ESK, 1988, INT ARCH ALLER A IMM, V87, P101, DOI 10.1159/000234657; BARACH EM, 1984, JAMA-J AM MED ASSOC, V251, P2118, DOI 10.1001/jama.251.16.2118; BOXER MB, 1989, ANN ALLERGY, V62, P201; BRISTOW MR, 1982, AM J CARDIOL, V49, P249, DOI 10.1016/0002-9149(82)90298-3; CULLIFORD AT, 1980, J THORAC CARDIOV SUR, V80, P868; DOUGLAS DM, 1994, J ALLERGY CLIN IMMUN, V93, P977, DOI 10.1016/S0091-6749(94)70044-3; FISHER M, 1992, BRIT MED J, V305, P1107, DOI 10.1136/bmj.305.6862.1107; FISHER M, 1994, EUR J ANAESTH, V11, P263; Fisher M, 1987, Dis Mon, V33, P433; FISHER M, 1977, BRIT J ANAESTH, V49, P1023, DOI 10.1093/bja/49.10.1023; FISHER MM, 1989, CRIT CARE MED, V17, P686, DOI 10.1097/00003246-198907000-00018; FISHER MM, 1986, ANAESTH INTENS CARE, V14, P17, DOI 10.1177/0310057X8601400105; GREENBERGER PA, 1984, J ALLERGY CLIN IMMUN, V74, P540, DOI 10.1016/0091-6749(84)90391-9; GUPTA S, 1988, MED J AUSTRALIA, V149, P602, DOI 10.5694/j.1326-5377.1988.tb120799.x; HASHIM SW, 1984, AM J SURG, V147, P560, DOI 10.1016/0002-9610(84)90022-9; HEILBORN H, 1986, J ALLERGY CLIN IMMUN, V78, P1174, DOI 10.1016/0091-6749(86)90268-X; KAMBAM JR, 1989, CAN J ANAESTH, V36, P463, DOI 10.1007/BF03005349; LAROCHE D, 1991, ANESTHESIOLOGY, V75, P945, DOI 10.1097/00000542-199112000-00004; LEVI R, HUMAN INFLAMMATORY D, V93, P105; LIEBERMAN P, 1990, J ALLERGY CLIN IMMUN, V86, P684, DOI 10.1016/S0091-6749(05)80241-6; LOWENSTEIN E, 1983, ANESTHESIOLOGY, V59, pA70; MCKINNON RP, 1994, ANAESTHESIA, V49, P309, DOI 10.1111/j.1365-2044.1994.tb14180.x; OLINGER GN, 1980, ANN THORAC SURG, V29, P20, DOI 10.1016/S0003-4975(10)61620-7; PONTEN J, 1985, ACTA ANAESTH SCAND, V29, P639, DOI 10.1111/j.1399-6576.1985.tb02272.x; RAPER RF, 1988, LANCET, V1, P386; SOREIDE E, 1988, ACTA ANAESTH SCAND, V32, P339; WALDHAUSEN E, 1987, ANAESTHESIST, V36, P150; WATKINS J, 1989, ANAESTHESIA, V44, P157, DOI 10.1111/j.1365-2044.1989.tb11170.x; YARBROUGH JA, 1989, ANN ALLERGY, V63, P235	29	61	62	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	1995	311	7007					731	733		10.1136/bmj.311.7007.731	http://dx.doi.org/10.1136/bmj.311.7007.731			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV874	7549690	Green Published			2022-12-28	WOS:A1995RV87400025
J	WAGER, E; TOOLEY, PJH; EMANUEL, MB; WOOD, SF				WAGER, E; TOOLEY, PJH; EMANUEL, MB; WOOD, SF			GET PATIENTS CONSENT TO ENTER CLINICAL-TRIALS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFORMED CONSENT; PSYCHIATRIC-PATIENTS; INFORMATION; QUALITY; ETHICS	Gaining patients' consent to enter clinical trials is essential, but not easy. Giving careful thought to the design of the study itself, information which patients receive, and the use of a signed consent form may all help. To be properly informed, patients need to know something about their condition, the proposed study, and alternative options. The type and amount of information will vary and investigators need to judge the level appropriate for each person. Patients should understand that taking part in a clinical trial is voluntary and that their decision will not affect the quality of care they receive. The process of obtaining consent requires time and good communication. Working with young, elderly, or mentally impaired patients, or those particularly vulnerable to coercion, requires special sensitivity to the potential dangers.	UNIV GLASGOW, DEPT GEN PRACTICE, GLASGOW G20 7LR, LANARK, SCOTLAND	University of Glasgow	WAGER, E (corresponding author), JANSSEN CILAG, POB 79, WYCOMBE HP14 4HJ, BUCKS, ENGLAND.			Wager, Elizabeth/0000-0002-4202-7813				ALBERT T, 1992, BRIT MED J, V305, P1266, DOI 10.1136/bmj.305.6864.1266; APPELBAUM PS, 1988, NEW ENGL J MED, V319, P1635, DOI 10.1056/NEJM198812223192504; BRAHAMS D, 1989, LANCET, V1, P340; BRAHAMS D, 1993, LANCET, V341, P1143, DOI 10.1016/0140-6736(93)93151-P; BREWIN CR, 1989, BRIT MED J, V299, P313, DOI 10.1136/bmj.299.6694.313; BROWN L, 1994, GOOD CLIN PRACTICE J, V1, P20; BYRNE DJ, 1988, BRIT MED J, V296, P839, DOI 10.1136/bmj.296.6625.839; CHOPRA S, 1994, PHARM STUDY COMP MIC; CORNBLEET MA, 1992, LANCET, V340, P488, DOI 10.1016/0140-6736(92)91811-L; DAWES PJD, 1994, J ROY SOC MED, V87, P149; FALLOWFIELD L, 1994, LANCET, V344, P1576, DOI 10.1016/S0140-6736(94)90386-7; FINCH E, 1994, LANCET, V344, P688, DOI 10.1016/S0140-6736(94)92124-5; FITTEN LJ, 1993, INT J GERIATR PSYCH, V8, P33, DOI 10.1002/gps.930080107; FULFORD KWM, 1993, J MED ETHICS, V19, P85, DOI 10.1136/jme.19.2.85; GOODMAN NW, 1984, ANAESTHESIA, V39, P911, DOI 10.1111/j.1365-2044.1984.tb06582.x; Helmchen H, 1990, Med Law, V9, P1206; HENEGHAN C, 1994, BRIT J ANAESTH, V73, P25, DOI 10.1093/bja/73.1.25; KERRIGAN DD, 1993, BRIT MED J, V306, P298, DOI 10.1136/bmj.306.6873.298; KESSEL AS, 1994, BRIT J HOSP MED, V52, P235; LAVELLEJONES C, 1993, BRIT MED J, V306, P885, DOI 10.1136/bmj.306.6882.885; LYNOE N, 1991, BRIT MED J, V303, P610, DOI 10.1136/bmj.303.6803.610; PRIESTLEY KA, 1992, BRIT MED J, V305, P1263, DOI 10.1136/bmj.305.6864.1263; RANSON P, 1994, GOOD CLIN PRACTICE, V1, P24; SAMUELS A, 1992, MED SCI LAW, V32, P35, DOI 10.1177/002580249203200108; SAW KC, 1994, J ROY SOC MED, V87, P143; SHIELD JP, 1994, BRIT MED J, V308, P1182, DOI 10.1136/bmj.308.6938.1182; SILVERMAN WA, 1989, J MED ETHICS, V15, P6, DOI 10.1136/jme.15.1.6; SIMES RJ, 1986, BRIT MED J, V293, P1065, DOI 10.1136/bmj.293.6554.1065; SKEGG PDG, 1977, LANCET, V2, P754; SMITH T, 1992, BRIT MED J, V305, P1242, DOI 10.1136/bmj.305.6864.1242; THORNTON H, 1994, LANCET, V344, P689; TOBIAS JS, 1993, BRIT MED J, V307, P1199, DOI 10.1136/bmj.307.6913.1199; WARREN JW, 1986, NEW ENGL J MED, V315, P1124, DOI 10.1056/NEJM198610303151804; WHITE LJ, 1989, ANN INTERN MED, V111, P843, DOI 10.7326/0003-4819-111-10-843; 1990, RES INVOLVING PATIEN; 1992, LANCET, V340, P23	36	39	41	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 16	1995	311	7007					734	737		10.1136/bmj.311.7007.734	http://dx.doi.org/10.1136/bmj.311.7007.734			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RV874	7549691	Green Published			2022-12-28	WOS:A1995RV87400026
J	WEINBERGER, DR				WEINBERGER, DR			FROM NEUROPATHOLOGY TO NEURODEVELOPMENT	LANCET			English	Article							CHRONIC-SCHIZOPHRENIA; ABNORMALITIES; BRAIN; DISTURBANCES; LOBE				WEINBERGER, DR (corresponding author), NIMH,NEUROSCI CTR ST ELIZABETHS,CLIN BRAIN DISORDERS BRANCH,INTRAMURAL RES PROGRAM,WASHINGTON,DC 20032, USA.							AKBARIAN S, 1993, ARCH GEN PSYCHIAT, V50, P169; ANDREASEN NC, 1994, JAMA-J AM MED ASSOC, V272, P1763, DOI 10.1001/jama.272.22.1763; ARNOLD SE, 1991, ARCH GEN PSYCHIAT, V48, P625; AYLWARD E, 1984, SCHIZOPHRENIA BULL, V10, P430, DOI 10.1093/schbul/10.3.430; BENES FM, 1991, ARCH GEN PSYCHIAT, V48, P990; BILDER RM, 1994, AM J PSYCHIAT, V151, P1437; BOGERTS B, 1990, PSYCHIAT RES-NEUROIM, V35, P1; BOGERTS B, 1985, ARCH GEN PSYCHIAT, V42, P784; BRUTON CJ, 1990, PSYCHOL MED, V20, P285, DOI 10.1017/S0033291700017608; CROW TJ, 1994, BRIT J PSYCHIAT, V164, P588, DOI 10.1192/bjp.164.5.588; CROW TJ, 1989, ARCH GEN PSYCHIAT, V46, P1145; DEGREEF G, 1992, ARCH GEN PSYCHIAT, V49, P531; DELISI LE, 1991, BIOL PSYCHIAT, V129, P159; DONE DJ, 1994, BRIT MED J, V309, P699, DOI 10.1136/bmj.309.6956.699; FALKAI P, 1995, SCHIZOPHRENIA, P477; FISH B, 1977, ARCH GEN PSYCHIAT, V34, P1297; GREEN MF, 1994, SCHIZOPHRENIA BULL, V20, P433, DOI 10.1093/schbul/20.3.433; GUNTHERGENTA F, 1994, BRIT J PSYCHIAT, V164, P165, DOI 10.1192/bjp.164.2.165; GUR RE, 1991, ARCH GEN PSYCHIAT, V48, P407; JAKOB H, 1986, J NEURAL TRANSM, V65, P303, DOI 10.1007/BF01249090; JASKIW GE, 1994, SCHIZOPHR RES, V14, P23, DOI 10.1016/0920-9964(94)90005-1; JOHNSTONE EC, 1976, LANCET, V2, P924; JONES P, 1994, LANCET, V344, P1398, DOI 10.1016/S0140-6736(94)90569-X; Liddle P. F., 1995, P425; LIPSKA BK, 1994, NEUROPSYCHOPHARMACOL, V10, P199, DOI 10.1038/npp.1994.22; MEDNICK SA, 1988, ARCH GEN PSYCHIAT, V45, P189, DOI 10.1001/archpsyc.1988.01800260109013; NOGA JT, IN PRESS ARCH GEN PS; OWEN MJ, 1988, PSYCHOL MED, V18, P331, DOI 10.1017/S003329170000787X; PAKKENBERG B, 1987, BRIT J PSYCHIAT, V151, P744, DOI 10.1192/bjp.151.6.744; PFEFFERBAUM A, 1988, ARCH GEN PSYCHIAT, V45, P633; REVELEY AM, 1982, LANCET, V2, P540; SCHLAEPFER TE, 1994, AM J PSYCHIAT, V151, P842; SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; SUSSER E, IN PRESS LANCET; VITA A, 1988, ACTA PSYCHIAT SCAND, V78, P618, DOI 10.1111/j.1600-0447.1988.tb06394.x; WALKER EF, 1994, SCHIZOPHRENIA BULL, V20, P441, DOI 10.1093/schbul/20.3.441; WEINBERGER DR, 1980, AM J PSYCHIAT, V137, P1410; WEINBERGER DR, 1995, SCHIZOPHRENIA, P295; ZIPURSKY RB, 1994, BIOL PSYCHIAT, V35, P501, DOI 10.1016/0006-3223(94)90097-3	40	480	490	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					552	557		10.1016/S0140-6736(95)91386-6	http://dx.doi.org/10.1016/S0140-6736(95)91386-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RQ986	7544856				2022-12-28	WOS:A1995RQ98600014
J	LEE, N				LEE, N			ABC OF MEDICAL COMPUTING - ILLUSTRATING AND PRESENTING YOUR DATA	BRITISH MEDICAL JOURNAL			English	Article									HILLINGDON HOSP,LONDON,ENGLAND	Brunel University; Imperial College London	LEE, N (corresponding author), WESTERN EYE HOSP,LONDON,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					319	322		10.1136/bmj.311.7000.319	http://dx.doi.org/10.1136/bmj.311.7000.319			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7543312	Green Published			2022-12-28	WOS:A1995RM71900037
J	ENARI, M; HUG, H; NAGATA, S				ENARI, M; HUG, H; NAGATA, S			INVOLVEMENT OF AN ICE-LIKE PROTEASE IN FAS-MEDIATED APOPTOSIS	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; DEATH GENE CED-3; CELL-DEATH; COWPOX VIRUS; ANTI-FAS; EXPRESSION; ENZYME; INHIBITOR; RECEPTOR; ENCODES	FAS is a type-I membrane protein that transduces an apoptotic signal(1,2). Binding of Fas ligand or agonistic anti-Fas antibody to Fas kills the cells by apoptosis(3). Studies in the nematode Caenorhabditis elegans have suggested that proteases such as interleukin-1 beta-converting enzyme (ICE) or the product of the C. elegans cell-death gene ced-3 are involved in apoptotic signal transduction(4). The activity of ICE can be inhibited by the product of crmA, a cytokine-response modifier gene encoded by cowpox virus(5-7). We report here that expression of crmA inhibits cytotoxicity induced by anti-pas antibody or tumour necrosis factor (TNF). We have found a specific ICE inhibitor tetrapeptide (acetyl-Tyr-Val-Ala-Asp-chloromethylketone)(8,9) that also prevents apoptosis induced by anti-Fas antibody. These results suggest an involvement of an ICE-like protease in Fas-mediated apoptosis and TNF-induced cytotoxicity.	YOKOHAMA CITY UNIV,GRAD SCH INTEGRATED SCI,YOKOHAMA,KANAGAWA 236,JAPAN	Yokohama City University	ENARI, M (corresponding author), OSAKA BIOSCI INST,6-2-4 FURUEDAI,SUITA,OSAKA 565,JAPAN.		Nagata, Shigekazu/AAG-3203-2019; Enari, Masato/E-5507-2014	Nagata, Shigekazu/0000-0001-9758-8426; Enari, Masato/0000-0003-4293-3848				CEHM A, 1992, J BIOL CHEM, V267, P10709; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUMAR S, 1991, J BIOL CHEM, V266, P20960; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NISHIZAWA M, 1990, J BIOL CHEM, V265, P5897; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PICKUP DJ, 1986, P NATL ACAD SCI USA, V83, P7698, DOI 10.1073/pnas.83.20.7698; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; WONG GHW, 1994, J IMMUNOL, V152, P1751; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	30	800	835	1	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					78	81		10.1038/375078a0	http://dx.doi.org/10.1038/375078a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7536900				2022-12-28	WOS:A1995QW60400059
J	GOOD, MF				GOOD, MF			HARNESSING CYTOTOXIC T-LYMPHOCYTES FOR VACCINE DESIGN	LANCET			English	Editorial Material							FALCIPARUM CIRCUMSPOROZOITE PROTEIN; PLASMODIUM-FALCIPARUM; MALARIA SPOROZOITES; CELLS				GOOD, MF (corresponding author), ROYAL BRISBANE HOSP,QUEENSLAND INST MED RES,BRISBANE,QLD 4029,AUSTRALIA.							AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DOOLAN DL, 1991, INT IMMUNOL, V3, P511, DOI 10.1093/intimm/3.6.511; GOOD MF, 1988, IMMUNOL TODAY, V9, P351, DOI 10.1016/0167-5699(88)91336-9; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; KUMAR S, 1988, NATURE, V334, P258, DOI 10.1038/334258a0; MALIK A, 1991, P NATL ACAD SCI USA, V88, P3300, DOI 10.1073/pnas.88.8.3300; NUSSENZWEIG RS, 1984, PHILOS T ROY SOC B, V307, P117, DOI 10.1098/rstb.1984.0113; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; QUAKYI IA, 1994, J IMMUNOL, V153, P2082; SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0; SEDEGAH M, 1992, J IMMUNOL, V149, P966; UDHAYAKUMAR V, 1994, INFECT IMMUN, V62, P1410, DOI 10.1128/IAI.62.4.1410-1413.1994; WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573	14	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 22	1995	345	8956					999	1000		10.1016/S0140-6736(95)90750-5	http://dx.doi.org/10.1016/S0140-6736(95)90750-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7536872				2022-12-28	WOS:A1995QU57300002
J	POTOSKY, AL; MILLER, BA; ALBERTSEN, PC; KRAMER, BS				POTOSKY, AL; MILLER, BA; ALBERTSEN, PC; KRAMER, BS			THE ROLE OF INCREASING DETECTION IN THE RISING INCIDENCE OF PROSTATE-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GEOGRAPHIC-VARIATION; TRENDS	Objective.-To assess the reasons for the dramatic surge in prostate cancer incidence from 1986 to 1991. Design.-Population-based study of incidence rates and procedures used to detect and diagnose prostate cancer derived from Medicare claims data and the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program from 1986 to 1991. Setting.-Four SEER areas (Connecticut; Atlanta, Ga; Detroit, Mich; and Seattle-Puget Sound, Wash) covering approximately 6% of the US population. Participants.-A 5% random sample of male fee-for-service Medicare beneficiaries aged 65 years and older without cancer, and all men with prostate cancer diagnosed at 65 years of age and older residing in the four areas. Main Outcome Measures.-The age-adjusted rates of prostate cancer incidence, prostate needle biopsy, transurethral resection of the prostate, serum prostate-specific antigen (PSA) testing, and transrectal ultrasound. Results.-The age-adjusted incidence rate of prostate cancer among men aged 65 years and older in the four SEER areas rose 82% from 1986 to 1991, with the largest annual increases occurring in 1990 (20%) and 1991 (19%). Prostate needle biopsy rates increased while the use of transurethral resection of the prostate declined from 1986 to 1991. The rising needle biopsy rate has been driven by an exponential increase in PSA testing in the general population from 1988 to 1991 and, to a much lesser extent, the increasing use of transrectal ultrasound since 1986. The use of PSA or transrectal ultrasound has increased across age and race groups and in different geographic areas. However, there remain wide geographic variations in the use of PSA screening. Conclusions.-The recent dramatic epidemic of prostate cancer is likely the result of the increasing detection of tumors resulting from increased PSA screening. The magnitude and rapidity of the incidence rise suggest that changes in the intensity of medical surveillance is the most plausible explanation for this trend. Implications.-The rapid diffusion of screening interventions that have the ability to detect latent asymptomatic disease leads to important concerns regarding costs and patient quality of life for men aged 65 years and older, Geographic variability in the adoption of PSA testing underscores uncertainty and disagreement about its value for reducing prostate cancer mortality. More research is required to determine the effectiveness of screening for prostate cancer.	NCI,CANC STAT BRANCH,SURVEILLANCE PROGRAM,BETHESDA,MD; NCI,DIV CANC PREVENT & CONTROL,EARLY DETECT & COMMUNITY ONCOL PROGRAM,BETHESDA,MD; UNIV CONNECTICUT,CTR HLTH,DIV UROL,FARMINGTON,CT	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Connecticut	POTOSKY, AL (corresponding author), NCI,APPL RES BRANCH,6130 EXECUT BLVD,EPN ROOM 313,BETHESDA,MD 20892, USA.							ALDER J, 1993, NEWSWEEK        1227, P40; AUSTIN DF, 1989, NEW ENGL J MED, V321, P1197; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BOSLAND MC, 1988, ADV CANCER RES, V51, P1, DOI 10.1016/S0065-230X(08)60220-1; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; DEMERS RY, 1994, ARCH INTERN MED, V154, P1211, DOI 10.1001/archinte.154.11.1211; DEVESA SS, 1987, J NATL CANCER I, V79, P701; FARROW DC, 1992, NEW ENGL J MED, V326, P1097, DOI 10.1056/NEJM199204233261701; Fleming C, 1993, JAMA, V269, P2650; FOWLER FJ, 1993, UROLOGY, V42, P622, DOI 10.1016/0090-4295(93)90524-E; GILLILAND F, 1994, CANCER EPIDEM BIOMAR, V3, P105; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; KRAMER BS, 1993, ANN INTERN MED, V119, P914, DOI 10.7326/0003-4819-119-9-199311010-00009; LEVY IG, 1993, CAN MED ASSOC J, V149, P617; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; LUYAO GL, 1994, LANCET, V343, P251, DOI 10.1016/S0140-6736(94)91109-6; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; NATTINGER AB, 1992, NEW ENGL J MED, V26, P1102; NOMURA AMY, 1991, EPIDEMIOL REV, V13, P200, DOI 10.1093/oxfordjournals.epirev.a036069; OPTENBERG SA, 1990, UROL CLIN N AM, V17, P719; POTOSKY AL, 1990, J NATL CANCER I, V82, P1624, DOI 10.1093/jnci/82.20.1624; POTOSKY AL, 1993, MED CARE, V31, P732; PROROK PC, 1981, J CHRON DIS, V34, P159, DOI 10.1016/0021-9681(81)90026-6; RIES LA, 1994, NIH942789 NCI PUBL; ROOS NP, 1980, MED CARE, V20, P945; SERVAAS C, 1992, SATURDAY EVENING POS, V264, P58; SIWEK J, 1991, WASHINGTON POST 0709, pZ15; Stuart M E, 1992, HMO Pract, V6, P5; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; WENNBERG JE, 1991, JAMA-J AM MED ASSOC, V265, P1306, DOI 10.1001/jama.265.10.1306; WHITMORE WF, 1993, JAMA-J AM MED ASSOC, V269, P2676, DOI 10.1001/jama.269.20.2676	33	520	534	1	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	1995	273	7					548	552		10.1001/jama.273.7.548	http://dx.doi.org/10.1001/jama.273.7.548			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF686	7530782				2022-12-28	WOS:A1995QF68600024
J	[Anonymous]				[Anonymous]			DYING FOR PALLIATIVE CARE	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1696	1699						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7529608				2022-12-28	WOS:A1994PY71700021
J	SHEPHERD, J; COBBE, SM; FORD, I; ISLES, CG; LORIMER, AR; MACFARLANE, PW; MCKILLOP, JH; PACKARD, CJ				SHEPHERD, J; COBBE, SM; FORD, I; ISLES, CG; LORIMER, AR; MACFARLANE, PW; MCKILLOP, JH; PACKARD, CJ			PREVENTION OF CORONARY HEART-DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK-FACTORS; CHOLESTEROL	Background. Lowering the blood cholesterol level may reduce the risk of coronary heart disease. This double-blind study was designed to determine whether the administration of pravastatin to men with hypercholesterolemia and no history of myocardial infarction reduced the combined incidence of nonfatal myocardial infarction and death from coronary heart disease. Methods. We randomly assigned 6595 men, 45 to 64 years of age, with a mean (+/-SD) plasma cholesterol level of 272+/-23 mg per deciliter (7.0+/-0.6 mmol per liter) to receive pravastatin (40 mg each evening) or placebo. The average follow-up period was 4.9 years. Medical records, electrocardiographic recordings, and the national death registry were used to determine the clinical end points. Results. Pravastatin lowered plasma cholesterol levels by 20 percent and low-density lipoprotein cholesterol levels by 26 percent, whereas there was no change with placebo. There were 248 definite coronary events (specified as nonfatal myocardial infarction or death from coronary heart disease) in the placebo group, and 174 in the pravastatin group (relative reduction in risk with pravastatin, 31 percent; 95 percent confidence interval, 17 to 43 percent; P<0.001). There were similar reductions in the risk of definite nonfatal myocardial infarctions (31 percent reduction, P<0.001), death from coronary heart disease (definite cases alone: 28 percent reduction, P=0.13; definite plus suspected cases: 33 percent reduction, P=0.042), and death from all cardiovascular causes (32 percent reduction, P=0.033). There was no excess of deaths from noncardiovascular causes in the pravastatin group. We observed a 22 percent reduction in the risk of death from any cause in the pravastatin group (95 percent confidence interval, 0 to 40 percent; P=0.051). Conclusions. Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of myocardial infarction.	UNIV GLASGOW, ROBERTSON CTR BIOSTAT, GLASGOW G12 8QQ, LANARK, SCOTLAND; UNIV GLASGOW, DEPT PATHOL BIOCHEM, GLASGOW G12 8QQ, LANARK, SCOTLAND; UNIV GLASGOW, DEPT MED CARDIOL, GLASGOW G12 8QQ, LANARK, SCOTLAND; UNIV GLASGOW, DEPT MED, GLASGOW G12 8QQ, LANARK, SCOTLAND; ROYAL INFIRM, GLASGOW G31 2ER, LANARK, SCOTLAND; DUMFRIES & GALLOWAY DIST GEN HOSP, DEPT MED, DUMFRIES, SCOTLAND	University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; Royal Infirmary of Edinburgh			Ford, Ian/ABE-6145-2020					[Anonymous], 1993, Am J Cardiol, V72, P1031; [Anonymous], 1992, NUTR METAB CARDIOVAS, V2, P113; Collett D, 1994, MODELLING SURVIVAL D; CROUSE JR, 1995, AM J CARDIOL, V75, P455, DOI 10.1016/S0002-9149(99)80580-3; CROUSE JR, 1995, AM J CARDIOL, V75, P862; CROW RS, 1989, AM J CARDIOL, V64, P454, DOI 10.1016/0002-9149(89)90420-7; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HULLEY SB, 1992, CIRCULATION, V86, P1026, DOI 10.1161/01.CIR.86.3.1026; JONES PH, 1991, CLIN CARDIOL, V14, P146, DOI 10.1002/clc.4960140211; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; LORD I, 1992, J CLIN EPIDEMIOL, V45, P849, DOI 10.1016/0895-4356(92)90068-X; MACFARLANE P W, 1990, European Heart Journal, V11, P411; MACFARLANE PW, 1990, METHOD INFORM MED, V29, P354; MANN JI, 1988, BRIT MED J, V296, P1702, DOI 10.1136/bmj.296.6638.1702; MIALL WE, 1987, MILD HYPERTENSION TH; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OLIVER MF, 1994, LANCET, V344, P633; OLIVER MF, 1991, LANCET, V337, P1529, DOI 10.1016/0140-6736(91)93208-Q; PEDERSEN TR, 1994, LANCET, V344, P1383; PITT B, IN PRESS J AM COLL C; Prineas R., 1982, MINNESOTA CODE MANUA; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SHEPHERD J, 1995, AM J CARDIOL, V76, P485; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; 1994, LANCET, V344, P762; 1975, DHEW NIH85 LIP RES C; IN PRESS J CLIN EPID	33	6332	6505	3	227	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 16	1995	333	20					1301	1307		10.1056/NEJM199511163332001	http://dx.doi.org/10.1056/NEJM199511163332001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE365	7566020				2022-12-28	WOS:A1995TE36500001
J	IKEGAMI, N; CAMPBELL, JC				IKEGAMI, N; CAMPBELL, JC			MEDICAL-CARE IN JAPAN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REGULATED FEES; SYSTEM		KEIO UNIV,SCH MED,SCH POLICY MANAGEMENT,TOKYO 160,JAPAN; UNIV MICHIGAN,DEPT POLIT SCI,ANN ARBOR,MI	Keio University; University of Michigan System; University of Michigan	IKEGAMI, N (corresponding author), KEIO UNIV,SCH MED,DEPT HOSP & MED ADM,SHINJUKU KU,35 SHINANOMACHI,TOKYO 160,JAPAN.							Campbell J.C., 1992, POLICIES CHANGE JAPA; GLASER WA, 1993, JAMA-J AM MED ASSOC, V270, P980, DOI 10.1001/jama.270.8.980; HASEGAWA T, IN PRESS CONTAINING; HISASHIGE A, IN PRESS CONTAINING; IGLEHART JK, 1988, NEW ENGL J MED, V319, P807, DOI 10.1056/NEJM198809223191234; IKEGAMI N, 1994, GERONTOLOGIST, V34, P628, DOI 10.1093/geront/34.5.628; IKEGAMI N, 1994, PHARMACOECONOMICS, V6, P424, DOI 10.2165/00019053-199406050-00004; IKEGAMI N, 1992, J HEALTH POLIT POLIC, V17, P689, DOI 10.1215/03616878-17-4-689; IKEGAMI N, 1994, DAEDALUS, V123, P113; IKEGAMI N, 1991, HEALTH AFFAIR, V10, P87, DOI 10.1377/hlthaff.10.3.87; IKEGAMI N, 1993, SHAKAIHOKEN JYUNPOU, V1800, P6; IKEGAMI N, 1995, DOES HLTH RES IMPACT, P24; IKEGAMI N, 1993, SHAKAIHOKEN JYUNPOU, V1801, P10; IKEGAMI N, IN PRESS CONTAINING; IKEGAMI N, 1993, GEKA, V55, P850; KATSUMATA Y, IN PRESS CONTAINING; Masuyama Mikitaka, 1994, KIKAN SHAKAI HOSHOU, V29, P359; TAKAGI Y, IN PRESS CONTAINING; White Joseph, 1995, COMPETING SOLUTIONS; 1992, KOUSEI TOUKEI KYOKAI, V176, P394; 1994, KOUSEI NO SHIHYOU, V41, P103; 1982, 1980 1992 MIN HLTH W; 1994, HLTH INSURANCE INFOR, P1; 1972, 1970 1992 MIN HLTH W	24	105	107	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	1995	333	19					1295	1299		10.1056/NEJM199511093331922	http://dx.doi.org/10.1056/NEJM199511093331922			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TC715	7566019				2022-12-28	WOS:A1995TC71500028
J	BRODIE, MJ; PELLOCK, JM				BRODIE, MJ; PELLOCK, JM			TAMING THE BRAIN STORMS - FELBAMATE UPDATED	LANCET			English	Editorial Material									VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,RICHMOND,VA 23298	Virginia Commonwealth University	BRODIE, MJ (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP,DEPT MED & THERAPEUT,EPILEPSY RES UNIT,GLASGOW,LANARK,SCOTLAND.							BRODIE MJ, 1993, LANCET, V341, P1445, DOI 10.1016/0140-6736(93)90888-N; LEPPIK IE, 1995, EPILEPSIA, V36, pS66, DOI 10.1111/j.1528-1157.1995.tb06000.x; MCCABE RT, 1993, J PHARMACOL EXP THER, V264, P1248	3	26	26	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					918	919		10.1016/S0140-6736(95)91550-8	http://dx.doi.org/10.1016/S0140-6736(95)91550-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564721				2022-12-28	WOS:A1995RY80800002
J	MAIZELS, N				MAIZELS, N			SOMATIC HYPERMUTATION - HOW MANY MECHANISMS DIVERSIFY V-REGION SEQUENCES	CELL			English	Review							GENE CONVERSION; IMMUNOGLOBULIN; CHICKEN; TRANSGENES; GENERATION; PATCHES				MAIZELS, N (corresponding author), YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,333 CEDAR ST,NEW HAVEN,CT 06520, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039799] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM039799] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHL J, 1995, NATURE, V375, P285, DOI 10.1038/375285c0; BECKER RS, 1990, CELL, V63, P987, DOI 10.1016/0092-8674(90)90502-6; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; BETZ AG, 1993, IMMUNOL TODAY, V14, P405, DOI 10.1016/0167-5699(93)90144-A; BETZ AG, 1993, P NATL ACAD SCI USA, V90, P2385, DOI 10.1073/pnas.90.6.2385; DAVID V, 1992, GENETICS, V132, P799; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; GONZALEZFERNAND.A, 1994, P NATL ACAD SCI USA, V91, P12614; GONZALEZFERNANDEZ, 1993, P NATL ACAD SCI USA, V90, P9862; GREENBERG AS, 1995, NATURE, V374, P168, DOI 10.1038/374168a0; HENGSTSCHLAGER M, 1995, PROG NUCLEIC ACID RE, V50, P67, DOI 10.1016/S0079-6603(08)60811-9; HENGSTSCHLAGER MM, 1995, EUR J IMMUNOL, V24, P1649; KELSOE G, 1995, NATURE, V375, P286, DOI 10.1038/375286a0; KNIGHT KL, 1990, CELL, V60, P963, DOI 10.1016/0092-8674(90)90344-E; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MAIZELS N, 1989, TRENDS GENET, V5, P4, DOI 10.1016/0168-9525(89)90004-8; NOSSAL GJV, 1992, CELL, V68, P1, DOI 10.1016/0092-8674(92)90198-L; PASCUAL V, 1994, J EXP MED, V180, P329, DOI 10.1084/jem.180.1.329; REYNAUD CA, 1989, CELL, V59, P171, DOI 10.1016/0092-8674(89)90879-9; REYNAUD CA, 1991, CELL, V64, P995, DOI 10.1016/0092-8674(91)90323-Q; REYNAUD CA, 1995, CELL, V80, P115, DOI 10.1016/0092-8674(95)90456-5; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; THOMPSON CB, 1987, CELL, V48, P369, DOI 10.1016/0092-8674(87)90188-7; WEINSTEIN PD, 1994, IMMUNITY, V1, P647, DOI 10.1016/1074-7613(94)90036-1; XU B, 1994, SCIENCE, V265, P1590, DOI 10.1126/science.8079173; YELAMOS J, 1995, NATURE, V376, P225; ZHENG B, 1994, NATURE, V372, P556, DOI 10.1038/372556a0	27	103	105	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					9	12		10.1016/0092-8674(95)90227-9	http://dx.doi.org/10.1016/0092-8674(95)90227-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553877	hybrid			2022-12-28	WOS:A1995RY58300003
J	BORGMANN, A; SCHMID, H; HARTMANN, R; BAUMGARTEN, E; HERMANN, K; KLINGEBIEL, T; EBELL, W; ZINTL, F; GADNER, H; HENZE, G				BORGMANN, A; SCHMID, H; HARTMANN, R; BAUMGARTEN, E; HERMANN, K; KLINGEBIEL, T; EBELL, W; ZINTL, F; GADNER, H; HENZE, G			AUTOLOGOUS BONE-MARROW TRANSPLANTS COMPARED WITH CHEMOTHERAPY FOR CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA IN A 2ND REMISSION - A MATCHED-PAIR ANALYSIS	LANCET			English	Article							2ND REMISSION; LEUKEMIA; CHILDHOOD; RELAPSE; THERAPY; MAINTENANCE; EXPERIENCE; ADULTS	It is unclear how best to treat children with acute lymphoblastic leukaemia (ALL) who are in a second remission. Treatment with bone-marrow transplants from HLA-identical siblings results in a statistically greater likelihood of leukaemia-free survival than does chemotherapy. Less than 25% of relapsed patients are able to benefit from this therapy due to a lack of matching donors; chemoradiotherapy or autologous BMT are considered for the rest. We compared treatment results for children who underwent autologous BMT those who had chemotherapy. All patients were registered between 1983-94 in the multicentre trials. We selected groups of patients by matching variables associated with treatment outcome and duration of second remission. 52 matched-pairs were studied. The probability of event-free survival at 9 years was 0.32 (SD 0.07) for patients receiving chemotherapy versus 0.26 (SD 0.07) for patients who underwent autologous BMT. For two groups-children with prognostic factors indicating high risk of relapse and those with factors indicating lower risk-the outcome from transplantation did not differ significantly from that of chemotherapy: no advantage of autologous BMT over chemotherapy as post-induction treatment for children with ALL in a second remission could be detected with regard to event-free survival. Because autologous BMT has been used as the final step of treatment it is possible that its relative ineffectiveness has been due to the lack of continuation therapy after transplant. Attempts should be made to complement autologous BMT by subsequent immunotherapy, molecular biotherapy, chemotherapy, or a combination of these.	HUMBOLDT UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW,PADIAT HAMATOL ONKOL ABT,D-13347 BERLIN,GERMANY; FREE UNIV BERLIN,INST MOLEC BIOL & BIOINFORMAT,W-1000 BERLIN,GERMANY; UNIV TUBINGEN,CHILDRENS HOSP,D-72076 TUBINGEN,GERMANY; HANNOVER MED SCH,HANNOVER,GERMANY; UNIV JENA,CHILDRENS HOSP,O-6900 JENA,GERMANY; ST ANNA CHILDRENS HOSP,A-1090 VIENNA,AUSTRIA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; Hannover Medical School; Friedrich Schiller University of Jena; Saint Anna Children's Hospital				Borgmann-Staudt, Anja/0000-0001-7341-0578				BARRETT AJ, 1989, BLOOD, V74, P862; BARRETT AJ, 1994, NEW ENGL J MED, V331, P1253, DOI 10.1056/NEJM199411103311902; BAUMGARTEN E, 1994, LEUKEMIA, V8, P850; BILLETT AL, 1993, BLOOD, V81, P1651; BORGMANN A, 1995, BONE MARROW TRANSPL, V15, P515; BUHRER C, 1993, MED PEDIATR ONCOL, V21, P470, DOI 10.1002/mpo.2950210703; BUTTURINI A, 1987, LANCET, V1, P429; CAHN JY, 1991, BONE MARROW TRANSPL, V7, P1; CHESSELLS JM, 1992, BLOOD REV, V6, P193, DOI 10.1016/0268-960X(92)90015-I; CHESSELLS JM, 1986, J CLIN ONCOL, V4, P1758, DOI 10.1200/JCO.1986.4.12.1758; DOPFER R, 1991, BLOOD, V78, P2780; GALE RP, 1991, LANCET, V338, P1315, DOI 10.1016/0140-6736(91)92604-Z; Hartmann R, 1994, HAEMATOL BLOOD TRANS, V36, P374; HENZE G, 1991, BLOOD, V78, P1166; Henze G, 1981, Haematol Blood Transfus, V26, P87; HOELZER D, 1989, BONE MARROW TRANSPL, V4, P98; JACKSON GH, 1994, BLOOD REV, V8, P161, DOI 10.1016/0268-960X(94)90077-U; JANKA GE, 1986, KLIN PADIATR, V198, P171, DOI 10.1055/s-2008-1026873; ORTEGA JJ, 1993, MED PEDIATR ONCOL, V21, P557; PARDOLL DM, 1993, CURR OPIN IMMUNOL, V5, P719, DOI 10.1016/0952-7915(93)90127-E; PETO J, 1986, LANCET, V1, P408; PUI CH, 1988, MED PEDIATR ONCOL, V16, P21, DOI 10.1002/mpo.2950160106; Riehm H, 1990, Haematol Blood Transfus, V33, P439; RIEHM H, 1986, CANCER CHILDREN CLIN, P101; RIVERA GK, 1993, NEW ENGL J MED, V329, P1289, DOI 10.1056/NEJM199310283291801; SADOWITZ PD, 1993, BLOOD, V81, P602; SALLAN SE, 1989, J CLIN ONCOL, V7, P1594, DOI 10.1200/JCO.1989.7.11.1594; SANDERS JE, 1987, BLOOD, V70, P324; SCHROEDER H, 1991, BONE MARROW TRANSPL, V7, P11; STRYCKMANS PA, 1983, BLOOD, V62, P606	30	49	49	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 30	1995	346	8979					873	876		10.1016/S0140-6736(95)92710-7	http://dx.doi.org/10.1016/S0140-6736(95)92710-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX196	7564672				2022-12-28	WOS:A1995RX19600010
J	KNOWLES, MR; HOHNEKER, KW; ZHOU, ZQ; OLSEN, JC; NOAH, TL; HU, PC; LEIGH, MW; ENGELHARDT, JF; EDWARDS, LJ; JONES, KR; GROSSMAN, M; WILSON, JM; JOHNSON, LG; BOUCHER, RC				KNOWLES, MR; HOHNEKER, KW; ZHOU, ZQ; OLSEN, JC; NOAH, TL; HU, PC; LEIGH, MW; ENGELHARDT, JF; EDWARDS, LJ; JONES, KR; GROSSMAN, M; WILSON, JM; JOHNSON, LG; BOUCHER, RC			A CONTROLLED-STUDY OF ADENOVIRAL-VECTOR-MEDIATED GENE-TRANSFER IN THE NASAL EPITHELIUM OF PATIENTS WITH CYSTIC-FIBROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY EPITHELIA; TRANSPORT; INVIVO; CELLS; IDENTIFICATION; INFECTION; OZONE	Background. Cystic fibrosis is a monogenic disease that deranges multiple systems of ion transport in the airways, culminating in chronic infection and destruction of the lung. The introduction of a normal copy of the cystic fibrosis transmembrane conductance regulator (CFTR) gene into the airway epithelium through gene transfer is an attractive approach to correcting the underlying defects in patients with cystic fibrosis. We tested the feasibility of gene therapy using adenoviral vectors in the nasal epithelium of such patients. Methods. An adenoviral vector containing the normal CFTR complementary DNA in four logarithmically increasing doses (estimated multiplicity of infection, 1, 10, 100, and 1000), or vehicle alone, was administered in a randomized, blinded fashion to the nasal epithelium of 12 patients with cystic fibrosis. Gene transfer was quantitated by molecular techniques that detected the expression of CFTR messenger RNA and by functional measurements of transepithelial potential differences (PDs) to assess abnormalities of ion transport specific to cystic fibrosis. The safety of this treatment was monitored by nasal lavage and biopsy to assess inflammation and vector replication. Results. The adenoviral Vector was detected in nasal-lavage fluid by culture, the polymerase chain reaction (PCR), or both in a dose-dependent fashion for up to eight days after vector administration. There was molecular evidence of gene transfer by reverse-transcriptase PCR assays or in situ hybridization in five of six patients treated at the two highest doses. However, the percentage of epithelial cells transfected by the vector was very low (<1 percent), and measurement of PD across the epithelium revealed no significant restoration of chloride transport or normalization of sodium transport. At the lower doses of vector, there were no toxic effects. However, at the highest dose there was mucosal inflammation in two of three patients. Conclusions. In patients with cystic fibrosis, adenoviral-vector-mediated transfer of the CFTR gene did not correct functional defects in nasal epithelium, and local inflammatory responses limited the dose of adenovirus that could be administered to overcome the inefficiency of gene transfer.	UNIV N CAROLINA, SCH PUBL HLTH, DEPT PEDIAT, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH PUBL HLTH, DEPT BIOSTAT, CHAPEL HILL, NC 27599 USA; UNIV PENN, INST HUMAN GENE THERAPY, PHILADELPHIA, PA USA; UNIV PENN, DEPT MOLEC & CELLULAR ENGN, PHILADELPHIA, PA USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania; University of Pennsylvania	KNOWLES, MR (corresponding author), UNIV N CAROLINA, SCH PUBL HLTH, CTR CYST FIBROSIS PULM RES & TREATMENT, DEPT MED, CHAPEL HILL, NC 27599 USA.		Edwards, Lloyd/N-2759-2019; Wilson, James M/F-9220-2011	Edwards, Lloyd/0000-0002-7788-4575; Wilson, James M/0000-0002-9630-3131; Engelhardt, John/0000-0003-2389-9277	NHLBI NIH HHS [HL42384, HL51818] Funding Source: Medline; NIDDK NIH HHS [P30 DK47757, R01 DK047967] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK047757, R01DK047967] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATEMAN ED, 1995, AM J RESP CRIT CARE, V151, P170, DOI 10.1164/ajrccm.151.1.7812549; Boat T.J., 1989, METABOLIC BASIS INHE, P2649; BOUCHER RC, 1994, HUM GENE THER, V5, P615, DOI 10.1089/hum.1994.5.5-615; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P581, DOI 10.1164/ajrccm.150.2.8049852; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; CURTIS JL, 1993, AM J RESP CELL MOL, V9, P90, DOI 10.1165/ajrcmb/9.1.90; DAVIS PB, 1993, LUNG BIOL HLTH DISEA, V64, P193; ENGELHARDT JF, 1992, J CLIN INVEST, V90, P2598, DOI 10.1172/JCI116155; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; GRUBB BR, 1994, NATURE, V371, P802, DOI 10.1038/371802a0; HENDERSON FW, 1988, AM REV RESPIR DIS, V137, P1124, DOI 10.1164/ajrccm/137.5.1124; Hierholzer JC, 1989, DIAGNOSTIC PROCEDURE, P219; HIGHSMITH WE, 1994, NEW ENGL J MED, V331, P974, DOI 10.1056/NEJM199410133311503; JOHNSON LG, 1992, NAT GENET, V2, P21, DOI 10.1038/ng0992-21; JOHNSON LG, 1995, J CLIN INVEST, V95, P1377, DOI 10.1172/JCI117789; JOHNSON LG, IN PRESS HUM GENE TH; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES MR, 1995, HUM GENE THER, V6, P445, DOI 10.1089/hum.1995.6.4-445; KNOWLES MR, 1981, AM REV RESPIR DIS, V124, P484; MERCER RR, 1994, AM J RESP CELL MOL, V10, P613, DOI 10.1165/ajrcmb.10.6.8003339; MIDDLETON PG, 1994, EUR RESPIR J, V7, P2050; MUFSON MA, 1976, J UROLOGY, V115, P191, DOI 10.1016/S0022-5347(17)59130-2; NACLERIO RM, 1988, J INFECT DIS, V157, P133, DOI 10.1093/infdis/157.1.133; NOAH TL, 1995, J INFECT DIS, V171, P584, DOI 10.1093/infdis/171.3.584; PEDEN DB, 1993, AM REV RESPIR DIS, V148, P455, DOI 10.1164/ajrccm/148.2.455; PIEDIMONTE G, 1995, PEDIATR PULM S, V12, P224; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RIORDAN JR, 1989, SCIENCE, V245, P1437; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771; STALDER H, 1977, J CLIN MICROBIOL, V6, P257; STUTTS MJ, 1985, P NATL ACAD SCI USA, V82, P6677, DOI 10.1073/pnas.82.19.6677; WIDDICOMBE JH, 1985, P NATL ACAD SCI USA, V82, P6167, DOI 10.1073/pnas.82.18.6167; WILSON JM, 1994, HUM GENE THER, V5, P501, DOI 10.1089/hum.1994.5.4-501; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362; YANKASKAS JR, 1993, AM REV RESPIR DIS, V147, pA26; YEI SP, 1994, HUM GENE THER, V5, P731, DOI 10.1089/hum.1994.5.6-731; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K; ZABNER J, 1994, HUM GENE THER, V5, P585, DOI 10.1089/hum.1994.5.5-585; ZEGER SL, 1992, STAT MED, V11, P1825, DOI 10.1002/sim.4780111406	46	496	509	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 28	1995	333	13					823	831		10.1056/NEJM199509283331302	http://dx.doi.org/10.1056/NEJM199509283331302			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW883	7544439	Green Published, Bronze			2022-12-28	WOS:A1995RW88300002
J	JONES, BW; FETTER, RD; TEAR, G; GOODMAN, CS				JONES, BW; FETTER, RD; TEAR, G; GOODMAN, CS			GLIAL-CELLS MISSING - A GENETIC SWITCH THAT CONTROLS GLIAL VERSUS NEURONAL FATE	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; GROWTH CONE GUIDANCE; RAT CEREBRAL-CORTEX; DROSOPHILA EMBRYOS; COMMON PROGENITOR; NEURAL CREST; LINEAGE; MIDLINE; CNS; EXPRESSION	The glial cells missing (gem) gene in Drosophila encodes a novel nuclear protein that is transiently expressed early in the development of nearly all glia, In loss-of-function gem mutant alleles, nearly all glia fail to differentiate, and, where we can follow them in the PNS, are transformed into neurons. In gain-of-function gem conditions using transgenic constructs that drive ectopic gem expression, many presumptive neurons are transformed into glia. Thus, gem appears to function as a binary genetic switch for glia versus neurons. In the presence of gem protein, presumptive neurons become glia, while in its absence, presumptive glia become neurons.			JONES, BW (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV NEUROBIOL,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.		Tear, Guy/C-5444-2009					ABRAMS JM, 1993, DEVELOPMENT, V117, P29; AULD VJ, 1995, CELL, V81, P757, DOI 10.1016/0092-8674(95)90537-5; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BOSSING T, 1994, DEVELOPMENT, V120, P1895; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAMPBELL G, 1994, DEVELOPMENT, V120, P2957; Campos-Ortega Jose A., 1993, P1091; CONDRON BG, 1994, J NEUROSCI, V14, P5766; CONDRON BG, 1995, CURR BIOL, V5, P51, DOI 10.1016/S0960-9822(95)00016-9; CONDRON BG, 1994, NEURON, V13, P541, DOI 10.1016/0896-6273(94)90024-8; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; EBENS AJ, 1993, CELL, V74, P15, DOI 10.1016/0092-8674(93)90291-W; FRANK E, 1991, DEVELOPMENT, V111, P895; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GALILEO DS, 1990, P NATL ACAD SCI USA, V87, P458, DOI 10.1073/pnas.87.1.458; GHYSEN A, 1986, ROUX ARCH DEV BIOL, V195, P281, DOI 10.1007/BF00376060; Goodman Corey S., 1993, P1131; GROVE EA, 1993, DEVELOPMENT, V117, P553; HALTER DA, 1995, DEVELOPMENT, V121, P317; HATTEN ME, 1988, DEV BIOL, V125, P280, DOI 10.1016/0012-1606(88)90211-4; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; HOSOYA T, 1995, CELL, V82, P1025, DOI 10.1016/0092-8674(95)90281-3; JACOBS JR, 1989, NEURON, V2, P1625; JACOBS JR, 1989, J NEUROSCI, V9, P2402; Jan Yuh Nung, 1993, P1207; KANIA A, 1995, GENETICS, V139, P1663; KLAES A, 1994, CELL, V78, P149, DOI 10.1016/0092-8674(94)90581-9; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLAMBT C, 1991, GLIA, V4, P205, DOI 10.1002/glia.440040212; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KOPCZYNSKI CC, 1992, J CELL BIOL, V199, P503; LANE ME, 1993, GENE DEV, V7, P1228; LEBER SM, 1990, J NEUROSCI, V10, P2451; LEDOUARIN N, 1991, GLIA, V4, P175; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; LUSKIN MB, 1993, J NEUROSCI, V13, P1730; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; TEPASS U, 1994, DEVELOPMENT, V120, P1829; TROPEA M, 1988, GLIA, V1, P380, DOI 10.1002/glia.440010605; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; UDOLPH G, 1993, DEVELOPMENT, V118, P765; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; WETTS R, 1988, DEV BIOL, V136, P254; WILLIAMS BP, 1995, NEURON, V14, P1181, DOI 10.1016/0896-6273(95)90265-1; XIONG WC, 1995, NEURON, V14, P581, DOI 10.1016/0896-6273(95)90314-3; XIONG WC, 1994, GENE DEV, V8, P981, DOI 10.1101/gad.8.8.981; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	52	389	396	0	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					1013	1023		10.1016/0092-8674(95)90280-5	http://dx.doi.org/10.1016/0092-8674(95)90280-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553843	Bronze			2022-12-28	WOS:A1995RW69300017
J	LATTERICH, M; FROHLICH, KU; SCHEKMAN, R				LATTERICH, M; FROHLICH, KU; SCHEKMAN, R			MEMBRANE-FUSION AND THE CELL-CYCLE - CDC48P PARTICIPATES IN THE FUSION OF ER MEMBRANES	CELL			English	Article							DIVISION-CYCLE; VESICULAR TRANSPORT; PUTATIVE ATPASES; GENETIC CONTROL; GOLGI STACK; YEAST; PROTEIN; FAMILY; MEMBER; VCP	The fusion of endoplasmic reticulum (ER) membranes in yeast is an essential process required for normal progression of the nuclear cell cycle, karyogamy, and the maintenance of an intact organellar compartment. We showed previously that this process requires a novel fusion machinery distinct from the classic membrane docking/fusion machinery containing Sec17p (alpha-SNAP) and Sec18p (NSF), Here we show that Cdc48p, a cell-cycle protein with homology to Sec18p, is required in ER fusion. A temperature-sensitive cdc48 mutant is conditionally defective in ER fusion in vitro. Addition of purified Cdc48p restores the fusion of isolated cdc48 mutant ER membranes, We propose that Cdc48p is part of an evolutionarily conserved fusion/docking machinery involved in multiple homotypic fusion events.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; UNIV TUBINGEN, DEPT PHYSIOL CHEM, D-72076 TUBINGEN, GERMANY	University of California System; University of California Berkeley; Eberhard Karls University of Tubingen	LATTERICH, M (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA.							ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; Bernardi G, 1971, METHOD ENZYMOL, V22, P325; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; CULOTTI J, 1971, EXP CELL RES, V67, P389, DOI 10.1016/0014-4827(71)90424-1; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; FROHLICH KU, 1995, IN PRESS BIOCH BIOPH; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; HARTWELL LH, 1970, P NATL ACAD SCI USA, V66, P352, DOI 10.1073/pnas.66.2.352; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; KURIHARA LJ, 1994, J CELL BIOL, V126, P911, DOI 10.1083/jcb.126.4.911; LATTERICH M, 1994, CELL, V78, P87, DOI 10.1016/0092-8674(94)90575-4; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MOIR D, 1982, GENETICS, V100, P547; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PLEASURE IT, 1993, NATURE, V365, P459, DOI 10.1038/365459a0; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROSE MD, 1991, ANNU REV MICROBIOL, V45, P539; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; RSOE MD, 1990, METHODS YEAST GENETI; Sambrook J, 1989, MOL CLONING LABORATO; SCHULTE RJ, 1994, J IMMUNOL, V153, P5465; SOGAARD M, 1994, CELL, V78, P938; THORSNESS PE, 1993, YEAST, V9, P1267, DOI 10.1002/yea.320091114; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; ZHANG L, 1994, J CELL BIOL, V127, P1871, DOI 10.1083/jcb.127.6.1871	35	325	329	1	8	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 22	1995	82	6					885	893		10.1016/0092-8674(95)90268-6	http://dx.doi.org/10.1016/0092-8674(95)90268-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553849	Bronze			2022-12-28	WOS:A1995RW69300005
J	SANDVIK, L; ERIKSSEN, G; THAULOW, E				SANDVIK, L; ERIKSSEN, G; THAULOW, E			LONG-TERM EFFECTS OF SMOKING ON PHYSICAL-FITNESS AND LUNG-FUNCTION - A LONGITUDINAL-STUDY OF 1393 MIDDLE-AGED NORWEGIAN MEN FOR 7 YEARS	BRITISH MEDICAL JOURNAL			English	Article							CIGARETTE-SMOKING; BLOOD-PRESSURE; EXERCISE; SMOKERS; CARDIOMYOPATHY; OBSTRUCTION; EPINEPHRINE; NONSMOKERS; POPULATION; PREDICTOR	Objective-To study association between smoking habits and long term decline in physical fitness and lung function in middle aged men who remained healthy. Design-Baseline and follow up measurements performed during 1972-5 and 1980-2 respectively. Setting-National University Hospital of Oslo, Norway. Subjects-1393 men aged 40-59 at baseline who were all healthy at baseline and at follow up. Main outcome measures-Forced expiratory volume in one second and physical fitness (defined as total work done during a symptom limited bicycle ergometer test divided by body weight. Results-Initial fitness was substantially lower among 347 persistent smokers than among 791 persistent non-smokers (1349 J/kg v 1618 J/kg), as was initial forced expiratory volume (3341 ml v 3638 ml). Mean (95% confidence interval) decline in fitness over 7.2 years was 217 (185 to 249) J/kg among smokers compared with 86 (59 to 113) J/kg among non-smokers (P<0.001). Corresponding declines in forced expiratory volume were 271 (226 to 316) ml in smokers and 116 (85 to 147) ml in non-smokers (P<0.001). Differences between smokers and non-smokers remained practically unchanged after adjustment for age and level of physical activity. Changes in fitness and forced expiratory volume among 199 men who had stopped smoking mimicked the findings for persistent non-smokers, and 56 men who started smoking presented findings close to those of persistent smokers. Conclusion-Decline in physical fitness and lung function among healthy middle aged men was considerably greater among smokers than among nonsmokers and could not be explained by differences in age and physical activity.	CENT HOSP AKERSHUS,DEPT MED,N-1474 NORDBYHAGEN,NORWAY	University of Oslo								Astrand PO., 1986, TXB WORK PHYSL, P391; BURROWS B, 1987, NEW ENGL J MED, V317, P1309, DOI 10.1056/NEJM198711193172103; CONWAY TL, 1992, PREV MED, V21, P723, DOI 10.1016/0091-7435(92)90079-W; COOPER MJH, 1968, JAMA-J AM MED ASSOC, V203, P123; CRYER PE, 1976, NEW ENGL J MED, V295, P573, DOI 10.1056/NEJM197609092951101; Dressendorfer R H, 1983, Phys Sportsmed, V11, P108, DOI 10.1080/00913847.1986.11708539; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; ERIKSSEN G, 1994, 67TH AM HEART ASS AN; ERIKSSEN J, 1977, SCAND J CLIN LAB INV, V37, P243, DOI 10.3109/00365517709091489; ERIKSSEN J, 1978, ACTA MED SCAND, V203, P532; ERIKSSEN J, 1978, THESIS U HOSPITAL OS; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; GREEN MS, 1986, AM HEART J, V111, P932, DOI 10.1016/0002-8703(86)90645-9; GYNTELBERG F, 1973, DAN MED BULL, V20, P1; HAF JI, 1974, PROGR CARDIOVASC DIS, V17, P73; HANDA K, 1990, ATHEROSCLEROSIS, V84, P189, DOI 10.1016/0021-9150(90)90090-6; Hoad N A, 1992, J R Army Med Corps, V138, P115; JOHNSON BD, 1992, J APPL PHYSIOL, V73, P874, DOI 10.1152/jappl.1992.73.3.874; LAUSTIOLA KE, 1988, CIRCULATION, V78, P1234, DOI 10.1161/01.CIR.78.5.1234; MCHENRY PI, 1977, AM J CARDIOL, V39, P393; PENNY WJ, 1986, INT J CARDIOL, V11, P293, DOI 10.1016/0167-5273(86)90034-3; POWERS SK, 1989, J APPL PHYSIOL, V66, P2491, DOI 10.1152/jappl.1989.66.6.2491; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; SHAVER LG, 1973, J AM COLL HEALTH ASS, V21, P489; SIDNEY S, 1993, MED SCI SPORT EXER, V25, P911; SINGAL PK, 1982, CAN J PHYSIOL PHARM, V60, P1390, DOI 10.1139/y82-207; TRAPJENSEN J, 1988, AM HEART J, V115, P263, DOI 10.1016/0002-8703(88)90647-3; YATES JC, 1981, AM HEART J, V102, P210, DOI 10.1016/S0002-8703(81)80012-9; 1990, PHS DHSS CDS908416 P; 1984, DHHS PHS8450205 PUBL	30	64	67	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	1995	311	7007					715	718		10.1136/bmj.311.7007.715	http://dx.doi.org/10.1136/bmj.311.7007.715			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV874	7549684	Green Published			2022-12-28	WOS:A1995RV87400018
J	LAWSON, MA; MAXFIELD, FR				LAWSON, MA; MAXFIELD, FR			CA2+ AND CALCINEURIN-DEPENDENT RECYCLING OF AN INTEGRIN TO THE FRONT OF MIGRATING NEUTROPHILS	NATURE			English	Article							POLYMORPHONUCLEAR LEUKOCYTES; ACTIVATED PLATELETS; CELL-ADHESION; ALPHA-ACTININ; SUBUNIT; VITRONECTIN; RECEPTOR; FIBRONECTIN; ADHERENCE; LAMININ	CHEMOATTRACTANTS stimulate neutrophil migration by activating signalling pathways(1) including repeated transient increases in intracellular free calcium, [Ca2+](i) (refs 2, 3). A motile neutrophil sends out many pseudopods, some of which adhere to the substrate; to continue moving forward the cell must release these attachments(4,5). Adhesion can be actively regulated, and neutrophils in which [Ca2+](i) transients are inhibited become stuck on fibronectin or vitronectin(6,7), extracellular matrix proteins that neutrophils encounter in vivo. Function-blocking antibodies to beta 3 integrins or the alpha v beta 3 heterodimer restore motility on vitronectin to [Ca2+](i)-buffered cells (B, Hendey, M.A.L., E. Marcantonio and F.R.M., manuscript submitted), indicating that an alpha v beta 3-like integrin is responsible for the [Ca2+](i)-sensitive adhesion. We show that the density of alpha v beta 3 integrins in the adherent membrane of neutrophils migrating on vitronectin is much higher at the leading edge than at the rear, but [Ca2+](i) buffering or inhibition of Ca2+-calmodulin-activated protein phosphatase 2B (calcineurin) leads to accumulation of alpha v beta 3 on the adherent surface at the rear of the cell. We show that the polarized distribution of alpha v beta 3 integrins in migrating neutrophils is maintained by [Ca2+](i)-dependent release of adhesion followed by endocytosis of these integrins and recycling to the leading edge.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	Columbia University			Maxfield, Fred/M-6747-2019; Maxfield, Fred/A-1718-2011	Maxfield, Fred/0000-0003-4396-8866; 				ABELDA SM, 1994, FASEB J, V8, P504; ABERCROMBIE M, 1970, EXP CELL RES, V62, P389, DOI 10.1016/0014-4827(70)90570-7; ALTANKOV G, 1993, J CELL BIOL, V120, P1449, DOI 10.1083/jcb.120.6.1449; BERTAGNOLLI ME, 1993, J CELL BIOL, V121, P1329, DOI 10.1083/jcb.121.6.1329; BOYLES J, 1979, J CELL BIOL, V82, P347, DOI 10.1083/jcb.82.2.347; BRETCHER MS, 1988, J CELL BIOL, V106, P235, DOI 10.1083/jcb.106.2.235; BRETSCHER MS, 1992, EMBO J, V11, P405, DOI 10.1002/j.1460-2075.1992.tb05068.x; BRETSCHER MS, 1984, SCIENCE, V224, P261; CHAMBERS JD, 1993, J LEUKOCYTE BIOL, V53, P462, DOI 10.1002/jlb.53.4.462; CHERESH DA, 1987, J BIOL CHEM, V262, P1434; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; GHOSH RN, 1994, J CELL SCI, V107, P2177; HASTON WS, 1987, J CELL SCI, V88, P495; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JACONI MEE, 1991, J CELL BIOL, V112, P1249, DOI 10.1083/jcb.112.6.1249; KOUNS WC, 1991, J BIOL CHEM, V266, P13891; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; MARKS PW, 1991, J CELL BIOL, V112, P149, DOI 10.1083/jcb.112.1.149; MASSIA SP, 1993, J BIOL CHEM, V268, P8053; MAXFIELD F, 1993, TRENDS CELL BIOL, V4, P386; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; SCHMIDT CE, 1994, BIOPHYS J, V67, P461, DOI 10.1016/S0006-3495(94)80502-8; SINGER II, 1989, J CELL BIOL, V109, P3169, DOI 10.1083/jcb.109.6.3169; YLANNE J, 1990, BLOOD, V76, P570	28	476	479	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 7	1995	377	6544					75	79		10.1038/377075a0	http://dx.doi.org/10.1038/377075a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7544874				2022-12-28	WOS:A1995RT72500060
J	FISCHER, U; HUBER, J; BOELENS, WC; MATTAJ, IW; LUHRMANN, R				FISCHER, U; HUBER, J; BOELENS, WC; MATTAJ, IW; LUHRMANN, R			THE HIV-1 REV ACTIVATION DOMAIN IS A NUCLEAR EXPORT SIGNAL THAT ACCESSES AN EXPORT PATHWAY USED BY SPECIFIC CELLULAR RNAS	CELL			English	Article							VIRAL MESSENGER-RNA; VIRUS TYPE-1 REV; TRANS-ACTIVATOR; PROTEINS; BINDING; MUTANTS; IDENTIFICATION; LOCALIZATION; EXPRESSION; DEFINITION	HIV-1 Rev protein directs nuclear export of pre-mRNAs and mRNAs containing its binding site, the Rev response element (RRE). To define how Rev acts, we used conjugates between bovine serum albumin (BSA) and peptides comprising the Rev activation domain (BSA-R). BSA-R inhibited Rev-mediated nuclear RNA export, whereas a mutant activation domain peptide conjugate did not. BSA-R did not affect the export of mRNA, tRNA, or ribosomal subunits, but did inhibit export of 5S rRNA and spliceosomal U snRNAs. BSA-R was itself exported from the nucleus in an active, saturable manner. Thus, the Rev activation domain constitutes a nuclear export signal that redirects RRE-containing viral RNAs to a non-mRNA export pathway.	EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	FISCHER, U (corresponding author), INST MOLEKBIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,D-35037 MARBURG,GERMANY.		Fischer, Utz/AAT-8422-2020; Fischer, Utz/A-4090-2016; Boelens, Wilbert/D-8877-2012	Fischer, Utz/0000-0002-1465-6591; Fischer, Utz/0000-0002-1465-6591; Mattaj, Iain/0000-0002-5537-8284				BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BERGER J, 1991, VIROLOGY, V183, P630, DOI 10.1016/0042-6822(91)90992-K; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FISCHER U, 1994, J CELL BIOL, V125, P971, DOI 10.1083/jcb.125.5.971; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRALDE E, 1995, IN PRESS NATURE; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436; KHANNAGUPTA A, 1989, P NATL ACAD SCI USA, V86, P1791, DOI 10.1073/pnas.86.6.1791; KJEMS J, 1993, J VIROL, V67, P4769, DOI 10.1128/JVI.67.8.4769-4776.1993; KJEMS J, 1991, REV CELL, V67, P169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1993, MOL CELL BIOL, V13, P6180, DOI 10.1128/MCB.13.10.6180; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MERMER B, 1990, NUCLEIC ACIDS RES, V18, P2037, DOI 10.1093/nar/18.8.2037; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; POWERS MA, 1995, CELL, V79, P931; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; STUTZ F, 1994, EMBO J, V13, P4096, DOI 10.1002/j.1460-2075.1994.tb06727.x; VENKATESH LK, 1990, VIROLOGY, V178, P327, DOI 10.1016/0042-6822(90)90414-M; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992; WOLFF B, 1995, EXP CELL RES, V217, P31, DOI 10.1006/excr.1995.1060; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	42	963	991	0	30	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					475	483		10.1016/0092-8674(95)90436-0	http://dx.doi.org/10.1016/0092-8674(95)90436-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7543368	Bronze			2022-12-28	WOS:A1995RP24200017
J	CANO, RJ; BORUCKI, MK				CANO, RJ; BORUCKI, MK			REVIVAL AND IDENTIFICATION OF BACTERIAL-SPORES IN 25-MILLION-YEAR-OLD TO 40-MILLION-YEAR-OLD DOMINICAN AMBER	SCIENCE			English	Article							LARVAL PROVISIONS; APIS-MELLIFERA; GENUS BACILLUS; STINGLESS BEE; SOLITARY BEES; MICROORGANISMS; POLLEN; MICROBIOLOGY; HONEY; DNA	A bacterial spore was revived, cultured, and identified from the abdominal contents of extinct bees preserved for 25 to 40 million years in buried Dominican amber. Rigorous surface decontamination of the amber and aseptic procedures were used during the recovery of the bacterium. Several lines of evidence indicated that the isolated bacterium was of ancient origin and not an extant contaminant. The characteristic enzymatic, biochemical, and 16S ribosomal DNA profiles indicated that the ancient bacterium is most closely related to extant Bacillus sphaericus.			CANO, RJ (corresponding author), CALIF POLYTECH STATE UNIV SAN LUIS OBISPO,SAN LUIS OBISPO,CA 93407, USA.							CANO RJ, 1994, APPL ENVIRON MICROB, V60, P2164, DOI 10.1128/AEM.60.6.2164-2167.1994; CANO RJ, 1993, NATURE, V363, P536, DOI 10.1038/363536a0; CANO RJ, 1993, BIOTECHNIQUES, V15, P8; Claus D., 1986, BERGEYS MANUAL SYSTE; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; GEST H, 1987, MICROBIOL SCI, V4, P69; GILLIAM M, 1978, APIDOLOGIE, V9, P213, DOI 10.1051/apido:19780305; GILLIAM M, 1990, APIDOLOGIE, V21, P89, DOI 10.1051/apido:19900201; GILLIAM M, 1985, BIOTROPICA, V17, P28, DOI 10.2307/2388374; GILLIAM M, 1979, APIDOLOGIE, V10, P269, DOI 10.1051/apido:19790304; GILLIAM M, 1976, J INVERTEBR PATHOL, V28, P275, DOI 10.1016/0022-2011(76)90137-3; GILLIAM M, 1984, APIDOLOGIE, V15, P1, DOI 10.1051/apido:19840101; GILLIAM M, 1990, APIDOLOGIE, V21, P99, DOI 10.1051/apido:19900202; GILLIAM M, 1988, MICROBIOS, V55, P95; GILLIAM M, 1991, J INVERTEBR PATHOL, V58, P286, DOI 10.1016/0022-2011(91)90077-4; Gordon RE, 1973, THE GENUS BACILLUS; GOUY M, 1990, RIBOSOME; KENNEDY MJ, 1994, MICROBIOL-SGM, V140, P2513, DOI 10.1099/00221287-140-10-2513; LI WH, 1991, FUNDAMENTALS MOL EVO; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MACHADO J O, 1971, Ciencia e Cultura (Sao Paulo), V23, P625; MORAN NA, 1993, P ROY SOC B-BIOL SCI, V253, P167, DOI 10.1098/rspb.1993.0098; NEEFS JM, 1990, NUCLEIC ACIDS RES, V18, P2237, DOI 10.1093/nar/18.suppl.2237; OCHMAN H, 1987, J MOL EVOL, V26, P74, DOI 10.1007/BF02111283; Poinar GO., 1992, LIFE AMBER; POTTS M, 1994, MICROBIOL REV, V58, P755, DOI 10.1128/MMBR.58.4.755-805.1994; Roubik D.W., 1990, ECOLOGY NATURAL HIST, V1st ed., P526, DOI [10.1126/science.248.4958.1026, DOI 10.1126/SCIENCE.248.4958.1026]; SEAWARD MRD, 1976, NATURE, V261, P407, DOI 10.1038/261407a0; SETLOW P, 1988, ANNU REV MICROBIOL, V42, P319, DOI 10.1146/annurev.mi.42.100188.001535; SETLOW P, 1993, APPL BACTERIOL S S, V76, pS49; WILLE ALVARO, 1964, REV BIOL TROP, V12, P187; WOESE CR, 1991, EVOLUTION MOL LEVEL	32	372	406	0	109	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1060	1064		10.1126/science.7538699	http://dx.doi.org/10.1126/science.7538699			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7538699				2022-12-28	WOS:A1995QY93400044
J	DEFELIPE, C; PINNOCK, RD; HUNT, SP				DEFELIPE, C; PINNOCK, RD; HUNT, SP			MODULATION OF CHEMOTROPISM IN THE DEVELOPING SPINAL-CORD BY SUBSTANCE-P	SCIENCE			English	Article							DEVELOPING AXONS; NEURONS; GROWTH; EXTENSION; RECEPTORS; GUIDANCE; CELLS	Developing axons find their targets through direct contact with cues in the extracellular environment and in response to gradients of diffusible factors. The floor plate, a neuroepithelial structure, guides developing commissural axons in the spinal cord by release of chemoattractants. Floor plate cells express neurokinin-1 receptors, and a transiently appearing subpopulation of commissural axons contains substance P, the neuropeptide ligand for this receptor, Substance P increases the amount of axon outgrowth from dorsal horn explants cocultured with floor plate explants. Results of experiments with embryonic rats suggest that substance P released from pioneering neuronal pathways may regulate the release of chemoattractants from floor plate cells.	MRC,DIV NEUROBIOL,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; PARKE DAVIS & CO,NEUROSCI RES UNIT,CAMBRIDGE CB2 2QB,ENGLAND	MRC Laboratory Molecular Biology; University of Cambridge			HUNT, STEPHEN P/C-1646-2008; de Felipe, Carmen/D-3813-2012	Hunt, Stephen/0000-0001-9453-5505				ALTMAN J, 1984, DEV RAT SPINAL CORD; BOLOVENTA P, 1990, DEVELOPMENT, V109, P435; CAJAL SRY, 1909, HIST SYSTEME NERVEUX, V1, P592; CAMPBELL RM, 1993, DEVELOPMENT, V119, P1217; DEFELIPE C, UNPUB; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; GHOSH A, 1993, DEVELOPMENT, V117, P1031; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEFFNER CD, 1990, SCIENCE, V247, P217, DOI 10.1126/science.2294603; HOKFELT T, 1991, NEURON, V7, P867, DOI 10.1016/0896-6273(91)90333-U; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; MAGGI CA, 1993, J AUTON PHARMACOL, V13, P23, DOI 10.1111/j.1474-8673.1993.tb00396.x; NAGY JI, 1982, NEUROSCIENCE, V7, P89, DOI 10.1016/0306-4522(82)90155-5; NARUMI S, 1978, J NEUROCHEM, V30, P1321, DOI 10.1111/j.1471-4159.1978.tb10462.x; NILSSON J, 1985, NATURE, V315, P61, DOI 10.1038/315061a0; PERNOW B, 1983, PHARMACOL REV, V35, P85; PLACZEK M, 1990, DEVELOPMENT, V110, P19; SEABROOK GR, 1993, NEUROSCI LETT, V152, P9, DOI 10.1016/0304-3940(93)90470-6; TESSIERLAVIGNE M, 1991, TRENDS NEUROSCI, V14, P303, DOI 10.1016/0166-2236(91)90142-H; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; VIGNA SR, 1994, J NEUROSCI, V14, P834	24	44	44	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 10	1995	267	5199					899	902		10.1126/science.7531367	http://dx.doi.org/10.1126/science.7531367			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7531367				2022-12-28	WOS:A1995QG20700063
J	VIGNERI, S; TERMINI, R; LEANDRO, G; BADALAMENTI, S; PANTALENA, M; SAVARINO, V; DIMARIO, F; BATTAGLIA, G; MELA, GS; PILOTTO, A; PLEBANI, M; DAVI, G				VIGNERI, S; TERMINI, R; LEANDRO, G; BADALAMENTI, S; PANTALENA, M; SAVARINO, V; DIMARIO, F; BATTAGLIA, G; MELA, GS; PILOTTO, A; PLEBANI, M; DAVI, G			A COMPARISON OF 5 MAINTENANCE THERAPIES FOR REFLUX ESOPHAGITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLE-BLIND; OMEPRAZOLE; RANITIDINE; CISAPRIDE; RELAPSE; SAFETY	Background. Patients with reflux esophagitis have a high rate of relapse within one year after therapy is discontinued. Methods. We enrolled 175 adults with endoscopy-confirmed reflux esophagitis in a prospective study comparing five maintenance therapies. All the patients were initially treated with omeprazole (40 mg orally once a day) for four to eight weeks, and healing was confirmed by endoscopy. Participants were then stratified according to their initial grade of esophagitis and randomly assigned to 12 months of treatment with one of the following: cisapride (10 mg three times a day), ranitidine (150 mg three times a day), omeprazole (20 mg per day), ranitidine plus cisapride, or omeprazole plus cisapride. Endoscopy was repeated after 6 and 12 months of treatment; the endoscopists were blinded to the treatment assignments. Remission was defined as the absence of esophageal lesions on scheduled or unscheduled follow-up endoscopy. Results. In an intention-to-treat analysis, the numbers of patients in continued remission at 12 months were 19 of 35 (54 percent) in the cisapride group, 17 of 35 (49 percent) in the ranitidine group, 28 of 35 (80 percent) in the omeprazole group, 23 of 35 (66 percent) in the ranitidine-plus-cisapride group, and 31 of 35 (89 percent) in the omeprazole-plus-cisapride group. Omeprazole was significantly more effective than cisapride (P=0.02) or ranitidine (P=0.003), and combination therapy with omeprazole plus cisapride was significantly more effective than cisapride alone (P=0.003), ranitidine alone (P<0.001), or ranitidine plus cisapride (P=0.03). Ranitidine plus cisapride was significantly better than ranitidine alone (P=0.05). Conclusions. For maintenance treatment of reflux esophagitis, omeprazole alone or in combination with cisapride is more effective than ranitidine alone or cisapride alone, and the combination of omeprazole and cisapride is more effective than ranitidine plus cisapride.	HOSP S DE BELLIS, BARI, ITALY; UNIV GENOA, DEPT INTERNAL MED, I-16126 GENOA, ITALY; UNIV PADUA, DEPT GASTROENTEROL, I-35100 PADUA, ITALY; HOSP VENICE, GASTROENTEROL & ENDOSCOPY UNIT, VENICE, ITALY; HOSP SCHIO, GERIATR UNIT, VICENZA, ITALY; UNIV CHIETI, DEPT MED, CHIETI, ITALY	IRCCS Saverio de Bellis; University of Genoa; University of Padua; G d'Annunzio University of Chieti-Pescara	VIGNERI, S (corresponding author), UNIV PALERMO, INST INTERNAL MED GERIATR, VIA VESPRO 143, I-90127 PALERMO, ITALY.		Mela, Giuseppe S/F-6072-2010; Plebani, Mario/AAF-4953-2020	Leandro, Gioacchino/0000-0001-6624-4532; BADALAMENTI, SALVATORE/0000-0002-0394-0730				ARMITAGE P, 1987, STATISTICAL METHODS; BARDIHAN KD, 1992, ADV DRUG THERAPY GAS, P246; DENT J, 1990, AUG WORLD C GASTR SY; DIXON WJ, 1992, BMDP STATISTICAL SOF; GELDOF H, 1993, ALIMENT PHARM THERAP, V7, P409; GLISE H, 1989, SCAND J GASTROENTERO, V24, P57, DOI 10.3109/00365528909091039; Harris EK, 1991, SURVIVORSHIP ANAL CL; HETZEL DJ, 1988, GASTROENTEROLOGY, V95, P903, DOI 10.1016/0016-5085(88)90162-X; JANISCH HD, 1988, HEPATO-GASTROENTEROL, V35, P125; JOELSON, 1992, DIGESTION, V53, P213; JOELSON S, 1992, DIGESTION, V51, P93, DOI 10.1159/000200922; KLINKENBERGKNOL EC, 1989, SCAND J GASTROENTERO, V24, P88, DOI 10.3109/00365528909091251; KOELZ HR, 1986, GASTROENTEROLOGY, V91, P1198, DOI 10.1016/S0016-5085(86)80017-8; LEPOUTRE L, 1990, DIGESTION, V45, P109, DOI 10.1159/000200231; LUNDELL L, 1991, SCAND J GASTROENTERO, V26, P248, DOI 10.3109/00365529109025038; MCTAVISH D, 1991, DRUGS, V42, P138, DOI 10.2165/00003495-199142010-00008; OLLYO JB, 1990, GASTROENTEROLOGY A, V98; RICHTER JE, 1989, SCAND J GASTROENTERO, V24, P19, DOI 10.3109/00365528909091227; SANDMARK S, 1988, SCAND J GASTROENTERO, V23, P625, DOI 10.3109/00365528809093923; SONTAG S, 1992, AM J GASTROENTEROL, V87, P1258; SPECHLER SJ, 1992, NEW ENGL J MED, V326, P786, DOI 10.1056/NEJM199203193261202; TOUSSAINT J, 1991, GUT, V32, P1280, DOI 10.1136/gut.32.11.1280; ZEITOUN P, 1989, HEPATO-GASTROENTEROL, V36, P279	23	440	455	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 26	1995	333	17					1106	1110		10.1056/NEJM199510263331703	http://dx.doi.org/10.1056/NEJM199510263331703			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA372	7565948				2022-12-28	WOS:A1995TA37200003
J	CHIN, DP; HOPEWELL, PC				CHIN, DP; HOPEWELL, PC			HOW TO TREAT BACTEREMIC MYCOBACTERIUM-AVIUM COMPLEX DISEASE	LANCET			English	Editorial Material							INFECTION; AIDS; CIPROFLOXACIN; ETHAMBUTOL; RIFAMPIN		UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	CHIN, DP (corresponding author), SAN FRANCISCO GEN HOSP,DIV PULM & CRIT CARE MED,SAN FRANCISCO,CA 94110, USA.							CHAISSON RE, 1994, ANN INTERN MED, V121, P905, DOI 10.7326/0003-4819-121-12-199412150-00001; CHIN DP, 1994, J INFECT DIS, V170, P578, DOI 10.1093/infdis/170.3.578; CHIU J, 1990, ANN INTERN MED, V113, P358, DOI 10.7326/0003-4819-113-5-358; DAUTZENBERG B, 1991, AM REV RESPIR DIS, V144, P564, DOI 10.1164/ajrccm/144.3_Pt_1.564; GORDON SM, 1993, J INFECT DIS, V168, P1559, DOI 10.1093/infdis/168.6.1559; HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1332, DOI 10.1056/NEJM199105093241906; ISEMAN MD, 1991, AM REV RESPIR DIS, V143, P697, DOI 10.1164/ajrccm/143.4_Pt_1.697; KEMPER CA, 1994, J INFECT DIS, V170, P157, DOI 10.1093/infdis/170.1.157; KEMPER CA, 1992, ANN INTERN MED, V116, P466, DOI 10.7326/0003-4819-116-6-466; MASUR H, 1993, NEW ENGL J MED, V329, P898, DOI 10.1056/NEJM199309163291228; SHAFRAN SD, 1994, NEW ENGL J MED, V330, P438, DOI 10.1056/NEJM199402103300616; WALLACE RJ, 1995, J INFECT DIS, V171, P747, DOI 10.1093/infdis/171.3.747; YOUNG LS, 1991, LANCET, V338, P1107, DOI 10.1016/0140-6736(91)91965-W	13	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					920	921		10.1016/S0140-6736(95)91552-4	http://dx.doi.org/10.1016/S0140-6736(95)91552-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564723				2022-12-28	WOS:A1995RY80800004
J	MEDAER, R; STINISSEN, P; TRUYEN, L; RAUS, J; ZHANG, JW				MEDAER, R; STINISSEN, P; TRUYEN, L; RAUS, J; ZHANG, JW			DEPLETION OF MYELIN-BASIC-PROTEIN AUTOREACTIVE T-CELLS BY T-CELL VACCINATION - PILOT TRIAL IN MULTIPLE-SCLEROSIS	LANCET			English	Note								In a pilot trial, eight patients with multiple sclerosis were matched to control patients and received T-cell vaccination with irradiated T cells reactive to myelin basic protein (MBP) to deplete circulating MBP-reactive T cells. In the 2 years before and after vaccination, exacerbations decreased in five vaccinated patients (numbers 1, 2, 6-8) with relapsing-remitting disease from sixteen to three, respectively, and from twelve to ten in their matched controls. Magnetic resonance imaging showed a mean 8.0% increase in brain lesion size in the vaccinated patients compared with a 39.5% increase in the controls. Lesions and/or relapses worsened in three cases after Vaccination in association with reappearance of circulating MBP-reactive T cells.	FREE UNIV AMSTERDAM,ACAD HOSP,DEPT DIAGNOST RADIOL,AMSTERDAM,NETHERLANDS; CLIN DE MICK,MULTIPLE SCLEROSIS REHABIL UNIT,BRASSCHAAT,BELGIUM	Vrije Universiteit Amsterdam	MEDAER, R (corresponding author), LIMBURGS UNIV CENTRUM,DR L WILLEMS INST,MULTIPLE SCLEROSIS RES & IMMUNOL UNIT,B-3590 DLEPENBEEK,BELGIUM.							BENNUN A, 1981, NATURE, V292, P60, DOI 10.1038/292060a0; CHOU YK, 1992, J NEUROIMMUNOL, V38, P105, DOI 10.1016/0165-5728(92)90095-3; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; TRUYEN L, 1990, J NEUROL SCI, V96, P173, DOI 10.1016/0022-510X(90)90130-F; VANDEVYVER C, 1995, EUR J IMMUNOL, V25, P958, DOI 10.1002/eji.1830250416; Zhang J, 1992, Int Rev Immunol, V9, P183, DOI 10.3109/08830189209061790; ZHANG JW, 1994, J EXP MED, V179, P973, DOI 10.1084/jem.179.3.973; ZHANG JW, 1993, SCIENCE, V261, P1451, DOI 10.1126/science.7690157	8	108	117	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 23	1995	346	8978					807	808		10.1016/S0140-6736(95)91622-9	http://dx.doi.org/10.1016/S0140-6736(95)91622-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7545769				2022-12-28	WOS:A1995RW25800013
J	BURRIGHT, EN; CLARK, HB; SERVADIO, A; MATILLA, T; FEDDERSEN, RM; YUNIS, WS; DUVICK, LA; ZOGHBI, HY; ORR, HT				BURRIGHT, EN; CLARK, HB; SERVADIO, A; MATILLA, T; FEDDERSEN, RM; YUNIS, WS; DUVICK, LA; ZOGHBI, HY; ORR, HT			SCA1 TRANSGENIC MICE - A MODEL FOR NEURODEGENERATION CAUSED BY AN EXPANDED CAG TRINUCLEOTIDE REPEAT	CELL			English	Article							BULBAR MUSCULAR-ATROPHY; ANDROGEN RECEPTOR GENE; SPINOCEREBELLAR ATAXIA; PURKINJE-CELLS; LARGE KINDREDS; EXPRESSION; DEFINITION; DELETION; PROMOTER; ANTIGEN	Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant inherited disorder characterized by degeneration of cerebellar Purkinje cells, spinocerebellar tracts, and selective brainstem neurons owing to the expansion of an unstable CAG trinucleotide repeat. To gain insight into the pathogenesis of the SCA1 mutation and the intergenerational stability of trinucleotide repeats in mice, we have generated transgenic mice expressing the human SCA1 gene with either a normal or an expanded CAG tract. Both transgenes were stable in parent to offspring transmissions. While all six transgenic lines expressing the unexpanded human SCA1 allele had normal Purkinje cells, transgenic animals from five of six lines with the expanded SCA1 allele developed ataxia and Purkinje cell degeneration. These data indicate that expanded CAG repeats expressed in Purkinje cells are sufficient to produce degeneration and ataxia and demonstrate that a mouse model can be established for neurodegeneration caused by CAG repeat expansions.	UNIV MINNESOTA, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT NEUROL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA; BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MOLEC & HUMAN GENET, HOUSTON, TX 77030 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Baylor College of Medicine; Baylor College of Medicine	BURRIGHT, EN (corresponding author), UNIV MINNESOTA, INST HUMAN GENET, MINNEAPOLIS, MN 55455 USA.		MATILLA-DUEÑAS, ANTONI/C-7980-2011	MATILLA-DUEÑAS, ANTONI/0000-0002-3514-4181; Zoghbi, Huda/0000-0002-0700-3349; Orr, Harry/0000-0001-6118-741X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS033718, R01NS027699] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33718, NS27699, NS09724-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARBIZU T, 1983, J NEUROL SCI, V59, P371, DOI 10.1016/0022-510X(83)90022-9; BANFI S, 1994, NAT GENET, V7, P513, DOI 10.1038/ng0894-513; BANFI S, 1993, GENOMICS, V18, P627, DOI 10.1016/S0888-7543(05)80365-9; BINGHAM PM, 1995, NAT GENET, V9, P191, DOI 10.1038/ng0295-191; BURKE JR, 1994, NAT GENET, V7, P521, DOI 10.1038/ng0894-521; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG SS, 1995, NAT GENET, V10, P344, DOI 10.1038/ng0795-344; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; FEDDERSEN RM, 1992, NEURON, V9, P955, DOI 10.1016/0896-6273(92)90247-B; FEDDERSEN RM, 1995, MOL CELL NEUROSCI, V6, P153, DOI 10.1006/mcne.1995.1014; GACY AM, 1995, CELL, V81, P533; GANDELMAN KY, 1992, AM J HUM GENET, V51, P571; HAINES JL, 1984, NEUROLOGY, V34, P1542, DOI 10.1212/WNL.34.12.1542; HANLEY T, 1991, BIOTECHNIQUES, V10, P56; HOGAN B, 1986, MANIPULATING MOUSE E; JODICE C, 1994, AM J HUM GENET, V54, P959; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KOEPPEN AH, 1984, OLIVOPONTOCEREBELLAR, P13; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; KWIATKOWSKI TJ, 1993, AM J HUM GENET, V53, P391; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Lebowitz P, 1979, Curr Top Microbiol Immunol, V87, P43; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MATILLA T, 1993, HUM MOL GENET, V2, P2123, DOI 10.1093/hmg/2.12.2123; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; OBERDICK J, 1990, SCIENCE, V248, P223, DOI 10.1126/science.2109351; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; QUIGLEY CA, 1992, J CLIN ENDOCR METAB, V74, P927, DOI 10.1210/jc.74.4.927; RANUM LPW, 1994, AM J HUM GENET, V55, P244; RANUM LPW, 1991, AM J HUM GENET, V49, P31; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; SMEYNE RJ, 1991, SCIENCE, V254, P719, DOI 10.1126/science.1948052; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; VANDAELE S, 1991, GENE DEV, V5, P1136, DOI 10.1101/gad.5.7.1136; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0; Zoghbi H. Y., 1995, METABOLIC MOL BASES, P4559; ZOGHBI HY, 1995, SEMIN CELL BIOL, V6, P29, DOI 10.1016/1043-4682(95)90012-8; ZOGHBI HY, 1988, ANN NEUROL, V23, P580, DOI 10.1002/ana.410230609; ZOGHBI HY, 1991, AM J HUM GENET, V49, P23	41	481	507	1	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 22	1995	82	6					937	948		10.1016/0092-8674(95)90273-2	http://dx.doi.org/10.1016/0092-8674(95)90273-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553854	Bronze			2022-12-28	WOS:A1995RW69300010
J	DEJONGE, ETM; MAKIN, JD; MANEFELDT, E; DEWET, GH; PATTINSON, RC				DEJONGE, ETM; MAKIN, JD; MANEFELDT, E; DEWET, GH; PATTINSON, RC			RANDOMIZED CLINICAL-TRIAL OF MEDICAL EVACUATION AND SURGICAL CURETTAGE FOR INCOMPLETE MISCARRIAGE	BRITISH MEDICAL JOURNAL			English	Article											DEJONGE, ETM (corresponding author), UNIV PRETORIA,KALAFONG HOSP,DEPT OBSTET & GYNAECOL,PRIVATE BAG X 396,PRETORIA 0001,SOUTH AFRICA.							DEJONGE ETM, 1994, S AFR MED J, V84, P481; DICKEY RP, 1993, BRIT MED J, V307, P259, DOI 10.1136/bmj.307.6898.259-b; Greenslade FC, 1993, MANUAL VACUUM ASPIRA; HENSHAW RC, 1993, BMJ-BRIT MED J, V306, P894, DOI 10.1136/bmj.306.6882.894; SMITH LFP, 1993, BRIT MED J, V306, P1540, DOI 10.1136/bmj.306.6891.1540-c	5	60	60	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	1995	311	7006					662	662		10.1136/bmj.311.7006.662	http://dx.doi.org/10.1136/bmj.311.7006.662			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU753	7549636	Green Published			2022-12-28	WOS:A1995RU75300020
J	WESTENDORP, MO; FRANK, R; OCHSENBAUER, C; STRICKER, K; DHEIN, J; WALCZAK, H; DEBATIN, KM; KRAMMER, PH				WESTENDORP, MO; FRANK, R; OCHSENBAUER, C; STRICKER, K; DHEIN, J; WALCZAK, H; DEBATIN, KM; KRAMMER, PH			SENSITIZATION OF T-CELLS TO CD95-MEDIATED APOPTOSIS BY HIV-1 TAT AND GP120	NATURE			English	Article							MONOCLONAL-ANTIBODY; INFECTION; AIDS; PROTEIN; CD4	THE depletion of CD4(+) T cells in AIDS is correlated with high turnover of the human immunodeficiency virus HIV-1(1,2) acid associated with apoptosis(3-5). The molecular mechanism of apoptosis in HIV infection, however, is largely unknown, T-cell apoptosis might be affected by viral proteins such as HIV-1 Tat(6-9) and gp120 (refs 10, 11). T-cell-receptor (TCR)-induced apoptosis was recently shown to involve the CD95 (APO-1/Fas) receptor(12). We show here that HIV-1 Tat strongly sensitizes TCR- and CD4(gp120)-induced apoptosis by upregulation of CD95 ligand expression. Concentrations of Tat found to be effective in cultures of HIV-1-infected cells were also observed in sera from HIV-1-infected individuals. Taken together, our results indicate that HIV-1 Tat and gp120 accelerate CD95-mediated, activation-induced T-cell apoptosis, a mechanism that may contribute to CD4(+) T-cell depletion(5,13,14) in AIDS.	GERMAN CANC RES CTR, TUMORIMMUNOL PROGRAM, D-69120 HEIDELBERG, GERMANY; UNIV HEIDELBERG, CTR BIOL MOLEC, W-6900 HEIDELBERG, GERMANY; UNIV HEIDELBERG, CHILDRENS HOSP, W-6900 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg			Walczak, Henning/AAV-2214-2020; Debatin, Klaus-Michael/J-9704-2014	Walczak, Henning/0000-0002-6312-4591; Debatin, Klaus-Michael/0000-0002-8397-1886; Dhein, Jens/0000-0002-7200-2967				AMEISEN JC, 1995, CELL DEATH DIFFER, V2, P285; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; DEBATIN KM, 1994, BLOOD, V83, P3101, DOI 10.1182/blood.V83.10.3101a.3101a; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Gougeon M L, 1995, Cell Death Differ, V2, P1; HAIGWOOD NL, 1990, VACCINES 90, P313; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KRAFT M, 1995, PEPTIDES 1994, P349; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; LU YY, 1994, J VIROL, V68, P390, DOI 10.1128/JVI.68.1.390-399.1994; OYAIZU N, 1993, BLOOD, V82, P3392; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; SCANDELLA CJ, 1993, AIDS RES HUM RETROV, V9, P1233, DOI 10.1089/aid.1993.9.1233; SGONC R, 1994, TRENDS GENET, V10, P41, DOI 10.1016/0168-9525(94)90140-6; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WANG ZQ, 1994, EUR J IMMUNOL, V24, P1549, DOI 10.1002/eji.1830240714; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WESTENDORP MO, 1994, J VIROL, V68, P4177, DOI 10.1128/JVI.68.7.4177-4185.1994; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; WILK T, 1992, VIROLOGY, V189, P167, DOI 10.1016/0042-6822(92)90692-I; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZAULI G, 1993, CANCER RES, V53, P4481	30	878	905	0	17	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 8	1995	375	6531					497	500		10.1038/375497a0	http://dx.doi.org/10.1038/375497a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7539892				2022-12-28	WOS:A1995RC18800050
J	COHEN, SN				COHEN, SN			SURPRISES AT THE 3'-END OF PROKARYOTIC RNA	CELL			English	Review							ESCHERICHIA-COLI; ANTISENSE RNAI; COPY NUMBER; AMS GENE; DEGRADATION; PLASMIDS; PCNB; RIBONUCLEASE; MUTATIONS				COHEN, SN (corresponding author), STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305, USA.							AUGUST T, 1962, J BIOL CHEM, V237, P3786; Baker EJ, 1993, CONTROL MESSENGER RN, P367; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P10380, DOI 10.1073/pnas.89.21.10380; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P7546, DOI 10.1073/pnas.89.16.7546; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CASAREGOLA S, 1992, J MOL BIOL, V228, P30, DOI 10.1016/0022-2836(92)90489-7; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; HAJNSDORF E, 1994, EMBO J, V13, P3368, DOI 10.1002/j.1460-2075.1994.tb06639.x; HAJNSDORF E, 1995, IN PRESS P NATL ACAD; HE L, 1993, MOL MICROBIOL, V9, P1131, DOI 10.1111/j.1365-2958.1993.tb01243.x; Higgins C.F., 1993, CONTROL MESSENGER RN, P13; KING TC, 1987, ESCHERICHIA COLI SAL, P703; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LITTAUER UZ, 1982, ENZYMES, P518; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; MCDOWALL KJ, 1993, J BACTERIOL, V175, P4245, DOI 10.1128/JB.175.13.4245-4249.1993; MELEFORS O, 1993, CONTROL MESSENGER RN, P53; NAKAZATO H, 1975, NATURE, V256, P144, DOI 10.1038/256144a0; NOSSAL NG, 1968, J BIOL CHEM, V243, P913; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; PEPE CM, 1994, MOL MICROBIOL, V13, P1133, DOI 10.1111/j.1365-2958.1994.tb00504.x; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; SACHS A, 1993, J BIOL CHEM, V268, P22955; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SHEN V, 1982, ENZYMES, P518; Soll D., 1993, RNA WORLD, P157; SRINIVASAN PR, 1975, P NATL ACAD SCI USA, V72, P2910, DOI 10.1073/pnas.72.8.2910; THANG MN, 1971, EUR J BIOCHEM, V19, P194; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756	33	104	105	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					829	832		10.1016/0092-8674(95)90284-8	http://dx.doi.org/10.1016/0092-8674(95)90284-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7535193	Bronze			2022-12-28	WOS:A1995QP61200002
J	KAUFMANN, M; HEIDER, KH; SINN, HP; VONMINCKWITZ, G; PONTA, H; HERRLICH, P				KAUFMANN, M; HEIDER, KH; SINN, HP; VONMINCKWITZ, G; PONTA, H; HERRLICH, P			CD44 VARIANT EXON EPITOPES IN PRIMARY BREAST-CANCER AND LENGTH OF SURVIVAL	LANCET			English	Article							METASTASIS-ASSOCIATED VARIANT; EXPRESSION; CARCINOMAS; AMPLIFICATION; ONCOGENE; HOMOLOG; RELAPSE	CD44 designates a group of closely related cell-surface proteins generated by alternative splicing. We have previously shown that splice variants carrying sequences encoded by exon v6 are preferentially expressed in metastatic animal cancer cell lines and that they confer metastatic behaviour on non-metastatic animal tumour cell lines. In this study we set out to assess the expression of CD44 epitopes specific for variant exon sequences in human breast cancer and their potential for determining prognosis. We used affinity-purified polyclonal sera and four monoclonal antibodies raised against the human homologues of CD44 variant exon sequences to investigate the presence of CD44 on 100 primary invasive breast tumours, 12 local recurrences, 18 lymph node metastases, and normal tissue controls. Whereas normal mammary ductal epithelial cells and cells derived from hyperplastic lesions do not express CD44 variant exons, expression of v3, v5, and v6 epitopes was found in most tumour samples. The Dill (exon v6) epitope was present in 84% of the primary tumours and in 100% of axillary lymph node metastases and local recurrences. The presence of these CD44 epitopes is correlated with poor overall survival. 15 patients with exon-v6-negative tumours had good survival compared with 76 patients with exon-v6-positive tumours (p=0.005; log rank test). Multivariate analysis showed that the CD44 epitope encoded by exon v6 was a good marker for prognosis independent of progesterone receptor, lymph node status, tumour size, and grade.	FORSCHUNGSZENTRUM KARLSRUHE,INST GENET,KARLSRUHE,GERMANY; UNIV HEIDELBERG,DEPT PATHOL,D-69115 HEIDELBERG,GERMANY	Helmholtz Association; Karlsruhe Institute of Technology; Ruprecht Karls University Heidelberg	KAUFMANN, M (corresponding author), UNIV HEIDELBERG,DEPT OBSTET & GYNAECOL,D-69115 HEIDELBERG,GERMANY.		Sinn, Hans-Peter/C-5661-2008	Sinn, Hans-Peter/0000-0003-2836-6699				ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; BERGER MS, 1988, CANCER RES, V48, P1238; CLARK GM, 1989, NEW ENGL J MED, V320, P627, DOI 10.1056/NEJM198903093201003; COX DR, 1972, J R STAT SOC B, V34, P187; DALL P, 1994, CANCER RES, V54, P3337; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; HEIDER KH, 1993, CANCER RES, V53, P4197; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; Hermanek P, 1987, TNM CLASSIFICATION M; JOENSUU H, 1993, AM J PATHOL, V143, P867; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; SAINSBURY JRC, 1987, LANCET, V1, P1398; SINN HP, IN PRESS BREAST CANC; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; VONMINCKWITZ G, 1994, BREAST, V2, P229; WIELENGA VJM, 1993, CANCER RES, V53, P4754	21	358	374	1	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					615	619		10.1016/S0140-6736(95)90521-9	http://dx.doi.org/10.1016/S0140-6736(95)90521-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7534855				2022-12-28	WOS:A1995QM07500009
J	TANAKA, T; AKIRA, S; YOSHIDA, K; UMEMOTO, M; YONEDA, Y; SHIRAFUJI, N; FUJIWARA, H; SUEMATSU, S; YOSHIDA, N; KISHIMOTO, T				TANAKA, T; AKIRA, S; YOSHIDA, K; UMEMOTO, M; YONEDA, Y; SHIRAFUJI, N; FUJIWARA, H; SUEMATSU, S; YOSHIDA, N; KISHIMOTO, T			TARGETED DISRUPTION OF THE NF-IL6 GENE DISCLOSES ITS ESSENTIAL ROLE IN BACTERIA KILLING AND TUMOR-CYTOTOXICITY BY MACROPHAGES	CELL			English	Article							C/EBP FAMILY MEMBERS; NF-KAPPA-B; LISTERIA-MONOCYTOGENES; TRANSCRIPTION FACTOR; INTERFERON-GAMMA; NECROSIS-FACTOR; INFLAMMATORY CYTOKINES; MYELOMONOCYTIC CELLS; BINDING PROTEIN; NUCLEAR FACTOR	To investigate the role of NF-IL6 in vivo, we have generated NF-IL6 (-/-) mice by gene targeting. NF-IL6 (-/-) mice were highly susceptible to infection by Listeria monocytogenes. Electron microscopic observation revealed the escape of a large number of pathogens from the phagosome to the cytoplasm in activated macrophages from NF-IL6 (-/-) mice. Furthermore, the tumor cytotoxicity of macrophages from NF-IL6 (-/-) mice was severely impaired. However, cytokines involved in macrophage activation, such as TNF and IFN gamma, were induced normally in NF-IL6 (-/-) mice. Nitric oxide (NO) formation was induced to a similar extent in macrophages from both wild-type and NF-IL6 (-/-) mice. These results demonstrate the crucial role of NF-IL6 in macrophage bactericidal and tumoricidal activities as well as the existence of a NO-independent mechanism of these activities. We also demonstrate that NF-IL6 is essential for the induction of G-CSF in macrophages and fibroblasts.	OSAKA UNIV, INST MOLEC & CELLULAR BIOL, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT ANAT & CELL BIOL, SUITA, OSAKA 565, JAPAN; OSAKA MED CTR MATERNAL & CHILD HLTH, RES INST, OSAKA 59002, JAPAN; OSAKA UNIV, SCH MED, DEPT MED 3, SUITA, OSAKA 565, JAPAN	Osaka University; Osaka University; Osaka University			Tanaka, Takashi/O-8254-2015; Kishimoto, Tadamitsu/C-8470-2009; Akira, Shizuo/C-3134-2009					ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ADAMS DO, 1987, IMMUNOL REV, V97, P5, DOI 10.1111/j.1600-065X.1987.tb00514.x; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; BUCHMEIER NA, 1985, P NATL ACAD SCI USA, V82, P7404, DOI 10.1073/pnas.82.21.7404; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DING AH, 1988, J IMMUNOL, V141, P2407; HARPE JD, 1985, J IMMUNOL METHODS, V78, P323; HAVELL EA, 1987, J IMMUNOL, V139, P4225; HIBBS JB, 1987, J IMMUNOL, V138, P550; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KAPLAN AM, 1981, METHODS STUDYING MON, P775; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.immunol.11.1.129; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KIDERLEN AF, 1984, EUR J IMMUNOL, V14, P964, DOI 10.1002/eji.1830141019; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MELTZER MS, 1981, METHODS STUDYING MON, P785; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NATSUKA S, 1992, BLOOD, V79, P460; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NISHIZAWA M, 1990, MOL CELL BIOL, V10, P2002, DOI 10.1128/MCB.10.5.2002; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PORTNOY DA, 1989, J EXP MED, V170, P2141, DOI 10.1084/jem.170.6.2141; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SCOTT LM, 1992, BLOOD, V80, P1725; SERUSHAGO BA, 1992, IMMUNOLOGY, V75, P475; Shannon MF, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046923; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; TSUNAWAKI S, 1984, J BIOL CHEM, V259, P4305; UMEMOTO M, 1993, ACTA OTO-LARYNGOL, P66; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831	50	472	479	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	1995	80	2					353	361		10.1016/0092-8674(95)90418-2	http://dx.doi.org/10.1016/0092-8674(95)90418-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7530603	Bronze			2022-12-28	WOS:A1995QD92400018
J	HART, BL; EATON, RP				HART, BL; EATON, RP			IMAGES IN CLINICAL MEDICINE - OSMOTIC MYELINOLYSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											HART, BL (corresponding author), UNIV NEW MEXICO,SCH MED,ALBUQUERQUE,NM 87131, USA.								0	5	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	1995	333	19					1259	1259		10.1056/NEJM199511093331905	http://dx.doi.org/10.1056/NEJM199511093331905			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC715	7566003				2022-12-28	WOS:A1995TC71500005
J	GALLO, C; PERRONE, F; DEPLACIDO, S; GIUSTI, C				GALLO, C; PERRONE, F; DEPLACIDO, S; GIUSTI, C			INFORMED VERSUS RANDOMIZED CONSENT TO CLINICAL-TRIALS	LANCET			English	Article							BREAST-CANCER; PREFERENCES; DESIGNS	We compared different procedures for seeking consent to participate in a sham randomised clinical trial and assessed whether refusal is affected by awareness of the severity of outlook. 2035 healthy subjects aged between 20 and 80 years, who visited a scientific exhibition, were enrolled in a hypothetical trial of experimental versus standard therapy, and randomly assigned to groups asked for conventional informed consent or prerandomisation consent. There were four study groups: one-sided informed consent for randomisation (subjects who refused would receive standard treatment); two-sided informed consent for randomisation (subjects who refused could choose between standard and experimental treatment); randomised consent to experimental treatment (subjects who refused would receive standard treatment); and randomised consent to standard treatment (subjects who refused would receive experimental treatment). The refusal rates were 16.2%, 19.9%, 12.1%, and 49.2%, respectively. The perceived severity of the simulated disease affected the refusal rate: the worse the outlook, the lower the refusal rate for informed consent or for consent after randomisation to new treatment, and the higher the refusal rate for consent after randomisation to standard treatment. The prerandomisation design seems to be efficient in a one-sided clinical scenario (eg, a trial of a new drug that would not be given outside the trial) because the refusal rate was substantially lower for prerandomisation to the new treatment than for conventional one-sided informed consent. However, in a two-sided clinical scenario (eg, a trial comparing similar treatments) the prerandomisation design is potentially highly inefficient; the refusal rate was much higher for prerandomisation to standard treatment than for conventional two-sided informed consent.	CNR,ACRO,CTR ELABORAZ DATI CLIN MEZZOGIORNO,I-80125 NAPLES,ITALY; UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,CATTEDRA ONCOL MED,NAPLES,ITALY; FDN IDIS,IST DIFFUS & VALORIZZAZ CULTURA SCI,NAPLES,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	GALLO, C (corresponding author), UNIV NAPLES 2,FAC MED & CHIRURG,CATTEDRA STAT MED & BIOMET,VIA L ARMANNI 5,I-80138 NAPLES,ITALY.		Gallo, Ciro/AAA-9241-2019	Gallo, Ciro/0000-0002-7939-3104				BAUM M, 1989, BRIT MED J, V299, P251, DOI 10.1136/bmj.299.6693.251; BAUM M, 1993, LANCET, V341, P812, DOI 10.1016/0140-6736(93)90573-Y; BREWIN CR, 1989, BRIT MED J, V299, P313, DOI 10.1136/bmj.299.6694.313; DEHN TCB, 1994, BRIT MED J, V309, P126, DOI 10.1136/bmj.309.6947.126; ELLENBERG SS, 1984, NEW ENGL J MED, V310, P1404, DOI 10.1056/NEJM198405243102141; FOST NC, 1975, JAMA-J AM MED ASSOC, V233, P800, DOI 10.1001/jama.1975.03260070058024; HELLMAN S, 1991, NEW ENGL J MED, V324, P1585, DOI 10.1056/NEJM199105303242208; HENSHAW RC, 1993, BRIT MED J, V307, P714, DOI 10.1136/bmj.307.6906.714; INGELFINGER FJ, 1972, NEW ENGL J MED, V287, P465, DOI 10.1056/NEJM197208312870912; JENSEN AB, 1993, EUR J CANCER, V29A, P2235, DOI 10.1016/0959-8049(93)90213-Y; LYNOE N, 1991, BRIT MED J, V303, P610, DOI 10.1136/bmj.303.6803.610; MCNEIL BJ, 1982, NEW ENGL J MED, V306, P1259, DOI 10.1056/NEJM198205273062103; MEISEL A, 1981, JAMA-J AM MED ASSOC, V246, P2473, DOI 10.1001/jama.246.21.2473; SILVERMAN WA, 1994, LANCET, V343, P1586, DOI 10.1016/S0140-6736(94)93053-8; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P771, DOI 10.1016/0895-4356(91)90129-W; SIMES RJ, 1986, BRIT MED J, V293, P1065, DOI 10.1136/bmj.293.6554.1065; SKOVLUND E, 1991, LANCET, V337, P1041, DOI 10.1016/0140-6736(91)92701-3; TAYLOR KM, 1994, J CLIN ONCOL, V12, P1796, DOI 10.1200/JCO.1994.12.9.1796; TAYLOR KM, 1984, NEW ENGL J MED, V310, P1363, DOI 10.1056/NEJM198405243102106; THORNTON HM, 1992, LANCET, V339, P44, DOI 10.1016/0140-6736(92)90157-X; TOBIAS JS, 1993, BRIT MED J, V307, P1199, DOI 10.1136/bmj.307.6913.1199; TOBIAS JS, 1994, EUR J CANCER, V30A, P897, DOI 10.1016/0959-8049(94)90107-4; Williams C, 1992, INTRO NEW TREATMENTS, P49; WILLIAMS CJ, 1994, EUR J CANCER, V30A, P907, DOI 10.1016/0959-8049(94)90111-2; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203; ZELEN M, 1990, STAT MED, V9, P645, DOI 10.1002/sim.4780090611	26	43	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1060	1064		10.1016/S0140-6736(95)91741-1	http://dx.doi.org/10.1016/S0140-6736(95)91741-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564786				2022-12-28	WOS:A1995TA69700010
J	KINN, S; LEE, N; MILLMAN, A				KINN, S; LEE, N; MILLMAN, A			ABC OF MEDICAL COMPUTING - USING COMPUTERS IN CLINICAL AUDIT	BRITISH MEDICAL JOURNAL			English	Article									WESTERN EYE HOSP,LONDON,ENGLAND; HILLINGDON HOSP,HILLINGDON,ENGLAND; GLOUCESTERSHIRE ROYAL HOSP,GLOUCESTER GL1 3NN,ENGLAND	Gloucestershire Royal Hospital	KINN, S (corresponding author), UNIV GLASGOW,SCOTTISH CLIN AUDIT RESOURCE CTR,GLASGOW G61 1BD,LANARK,SCOTLAND.								0	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	1995	311	7007					739	742		10.1136/bmj.311.7007.739	http://dx.doi.org/10.1136/bmj.311.7007.739			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV874	7549693	Green Published			2022-12-28	WOS:A1995RV87400028
J	THOMAS, C; DESAINTBASILE, G; LEDEIST, F; THEOPHILE, D; BENKERROU, M; HADDAD, E; BLANCHE, S; FISCHER, A				THOMAS, C; DESAINTBASILE, G; LEDEIST, F; THEOPHILE, D; BENKERROU, M; HADDAD, E; BLANCHE, S; FISCHER, A			BRIEF REPORT - CORRECTION OF X-LINKED HYPER-IGM SYNDROME BY ALLOGENEIC BONE-MARROW TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CD40 LIGAND; DEFECTIVE EXPRESSION; T-CELLS; IMMUNODEFICIENCY; DEFICIENCY; ACTIVATION		HOP ENFANTS MALAD,INSERM,U429,UNITE IMMUNOHEMATOL,PARIS,FRANCE; HOP ENFANTS MALAD,CYTOGENET LAB,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP			Haddad, Elie/AAQ-4971-2020; de Saint Basile, Genevieve/G-9731-2017	de Saint Basile, Genevieve/0000-0002-1913-5269; Haddad, Elie/0000-0003-2446-6879				ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BANATVALA N, 1994, ARCH DIS CHILD, V71, P150, DOI 10.1136/adc.71.2.150; BENKERROU M, 1990, ARCH FR PEDIATR, V47, P345; CALLARD RE, 1994, J IMMUNOL, V15, P3295; DISANTO JP, 1994, NEW ENGL J MED, V330, P969, DOI 10.1056/NEJM199404073301404; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; ESPANOL T, 1994, 6TH WORLD HLTH ORG I; Filipovich A H, 1994, Immunodeficiency, V5, P91; FISCHER A, 1990, LANCET, V336, P850, DOI 10.1016/0140-6736(90)92348-L; FISCHER A, 1994, BLOOD, V83, P1149; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; HENDRIKS RW, 1990, EUR J IMMUNOL, V20, P2603, DOI 10.1002/eji.1830201212; HOSTOFFER RW, 1994, PEDIATRICS, V94, P234; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LANE P, 1992, EUR J IMMUNOL, V22, P2573, DOI 10.1002/eji.1830221016; LEDEIST F, 1989, BLOOD, V74, P512; LEVITT D, 1983, J CLIN INVEST, V72, P1650, DOI 10.1172/JCI111124; LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701; MARSHALL WC, 1964, ARCH DIS CHILD, V39, P18, DOI 10.1136/adc.39.203.18; MULLEN CA, 1993, BLOOD, V82, P2961; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; SCHRIEVER F, 1989, J EXP MED, V169, P2043, DOI 10.1084/jem.169.6.2043; TU RK, 1991, AM J ROENTGENOL, V157, P381, DOI 10.2214/ajr.157.2.1853826; WILLIAMS LL, 1993, LANCET, V342, P587, DOI 10.1016/0140-6736(93)91413-G	26	76	77	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 17	1995	333	7					426	429		10.1056/NEJM199508173330705	http://dx.doi.org/10.1056/NEJM199508173330705			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP243	7542361				2022-12-28	WOS:A1995RP24300005
J	TIZZANO, EF; BUCHWALD, M				TIZZANO, EF; BUCHWALD, M			CFTR EXPRESSION AND ORGAN DAMAGE IN CYSTIC-FIBROSIS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							TRANSMEMBRANE CONDUCTANCE REGULATOR; CONGENITAL BILATERAL ABSENCE; PANCREATIC FUNCTION; CHLORIDE CHANNEL; VAS-DEFERENS; LOCALIZATION; GLANDS; GENE	The cloning of the defective gene in cystic fibrosis (CFTR) is the most important step to date toward understanding the pathogenesis of the disease and developing novel therapeutic strategies. Although many studies have provided insights into the molecular defects and knowledge of the expression and role of the gene, the basic defect and its pathogenesis are still unclear. We hypothesize that organ damage in cystic fibrosis is the result of a combination of at least three main factors: the genotype (the type of mutation that alters the function of the cystic fibrosis transmembrane regulator [CFTR]), the rate of CFTR-mediated chloride secretion in the epithelium of each organ (inferred from the level of expression of the gene), and the anatomical and physiologic characteristics of the affected organs (the size and contents of the ducts). Confirmation of this hypothesis should allow a better understanding of the pathogenesis of the disease and help prevent organ damage.	HOSP SICK CHILDREN, DEPT GENET, TORONTO, ON M5G 1X8, CANADA; HOSP SANTA CRUZ & SAN PABLO, BARCELONA, SPAIN	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; BOUE A, 1986, HUM GENET, V74, P288; BROWN RK, 1994, PEDIATR RES, V36, P487, DOI 10.1203/00006450-199410000-00013; CHENG SH, 1994, INT PEDIATR S2, V9, P11; COLOMBO C, 1994, J PEDIATR-US, V124, P393, DOI 10.1016/S0022-3476(94)70361-2; COREY M, 1989, J PEDIATR-US, V115, P274, DOI 10.1016/S0022-3476(89)80082-4; ENGELHARDT JF, 1994, J CLIN INVEST, V93, P737, DOI 10.1172/JCI117028; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; Forstner G G, 1987, Prog Clin Biol Res, V254, P7; GAN KH, 1994, NEW ENGL J MED, V330, P865; HAMOSH A, 1993, NEW ENGL J MED, V329, P1308; JACQUOT J, 1993, EUR RESPIR J, V6, P169; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM E, 1989, J PEDIATR-US, V114, P767, DOI 10.1016/S0022-3476(89)80134-9; KIESEWETTER S, 1993, NAT GENET, V5, P274, DOI 10.1038/ng1193-274; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; MCCRAY PB, 1992, J CLIN INVEST, V90, P619, DOI 10.1172/JCI115901; ONEAL WK, 1994, HUM MOL GENET, V3, P1497, DOI 10.1093/hmg/3.suppl_1.1497; Oppenheimer E H, 1975, Perspect Pediatr Pathol, V2, P241; OSBORNE LR, 1993, HUM MOL GENET, V2, P1605, DOI 10.1093/hmg/2.10.1605; Robaire B., 1988, P999; TIZZANO EF, 1994, AM J RESP CELL MOL, V10, P355, DOI 10.1165/ajrcmb.10.4.7510983; TIZZANO EF, 1993, HUM MOL GENET, V2, P219, DOI 10.1093/hmg/2.3.219; TIZZANO EF, 1994, AM J PATHOL, V144, P906; TIZZANO EF, 1992, J PEDIATR-US, V120, P337, DOI 10.1016/S0022-3476(05)80895-9; TREZISE AEO, 1993, HUM MOL GENET, V2, P213, DOI 10.1093/hmg/2.3.213; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WELSH MJ, 1994, METABOLIC BASIS INHE, P3799	29	42	45	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1995	123	4					305	308		10.7326/0003-4819-123-4-199508150-00009	http://dx.doi.org/10.7326/0003-4819-123-4-199508150-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN665	7541969				2022-12-28	WOS:A1995RN66500009
J	TOWBIN, JA				TOWBIN, JA			CLINICAL IMPLICATIONS OF BASIC RESEARCH - NEW REVELATIONS ABOUT THE LONG-QT SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											TOWBIN, JA (corresponding author), BAYLOR COLL MED,HOUSTON,TX 77030, USA.		Towbin, Jeffrey A./J-5595-2019	Towbin, Jeffrey A./0000-0002-6585-714X				CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; JIANG CA, 1994, NAT GENET, V8, P141, DOI 10.1038/ng1094-141; KEATING M, 1991, SCIENCE, V252, P704, DOI 10.1126/science.1673802; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3	5	29	31	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 10	1995	333	6					384	385		10.1056/NEJM199508103330613	http://dx.doi.org/10.1056/NEJM199508103330613			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN082	7541894				2022-12-28	WOS:A1995RN08200013
J	KOUNNAS, MZ; MOIR, RD; REBECK, GW; BUSH, AI; ARGRAVES, WS; TANZI, RE; HYMAN, BT; STRICKLAND, DK				KOUNNAS, MZ; MOIR, RD; REBECK, GW; BUSH, AI; ARGRAVES, WS; TANZI, RE; HYMAN, BT; STRICKLAND, DK			LDL RECEPTOR-RELATED PROTEIN, A MULTIFUNCTIONAL APOE RECEPTOR, BINDS SECRETED BETA-AMYLOID PRECURSOR PROTEIN AND MEDIATES ITS DEGRADATION	CELL			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; SPORADIC ALZHEIMERS-DISEASE; ACTIVATOR INHIBITOR TYPE-1; ALPHA-2-MACROGLOBULIN RECEPTOR; APOLIPOPROTEIN-E; PLASMINOGEN-ACTIVATOR; MESSENGER-RNA; NEXIN-II; CELL; PURIFICATION	The secreted form of beta-amyloid precursor protein (APP) containing the Kunitz proteinase inhibitor (KPI) domain, also called protease nexin II, is internalized and degraded by cells. We show that the low density lipoprotein (LDL) receptor-related protein (LRP) is responsible for the endocytosis of secreted APP. APP(S)770 degradation is inhibited by an LRP antagonist called the receptor-associated protein (RAP) and by LRP antibodies and is greatly diminished in fibroblasts genetically deficient in LRP. APP(S)695, which lacks the KPI domain, isa poor LRP ligand, Since LRP also binds apolipoprotein E (apoE)-enriched lipoproteins and inheritance of the epsilon 4 allele of the apoE gene is a risk factor for Alzheimer's disease (AD), these data link in a single metabolic pathway two molecules strongly implicated in the pathophysiology of AD.	AMER RED CROSS,HOLLAND LABS,DEPT BIOCHEM,ROCKVILLE,MD 20855; MASSACHUSETTS GEN HOSP,GENET & AGING LAB,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,NEUROL SERV,BOSTON,MA 02114	American Red Cross; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital			Rebeck, George William/J-2192-2012; Moir, Robert D./M-7612-2017; Bush, Ashley/Y-2457-2019; Tanzi, Rudolph/AAE-9622-2019; Bush, Ashley I/A-1186-2007	Rebeck, George William/0000-0001-6276-248X; Moir, Robert D./0000-0001-5431-3553; Bush, Ashley/0000-0001-8259-9069; Tanzi, Rudolph/0000-0002-7032-1454; Bush, Ashley I/0000-0001-8259-9069	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50787] Funding Source: Medline; NIDDK NIH HHS [DK45598] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; BREEN KC, 1992, MOL CHEM NEUROPATHOL, V16, P109, DOI 10.1007/BF03159964; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BUSH AI, 1993, J BIOL CHEM, V268, P16109; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HERZ J, 1991, J BIOL CHEM, V266, P21232; HYMAN BT, 1995, P NATL ACAD SCI USA, V92, P3586, DOI 10.1073/pnas.92.8.3586; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; JIN LW, 1994, J NEUROSCI, V14, P5461; JOHNSONWOOD KL, 1994, BIOCHEM BIOPH RES CO, V200, P1685, DOI 10.1006/bbrc.1994.1646; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KNAUER DJ, 1982, P NATL ACAD SCI-BIOL, V79, P2310, DOI 10.1073/pnas.79.7.2310; KNAUER DJ, 1983, J CELL PHYSIOL, V117, P385, DOI 10.1002/jcp.1041170314; KOO EH, 1990, NEURON, V2, P97; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOUNNAS MZ, 1994, IN VIVO, V8, P342; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1995, IN PRESS APOLIPOPROT; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOIR RD, 1992, J NEUROCHEM, V59, P1490, DOI 10.1111/j.1471-4159.1992.tb08465.x; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; POLLER W, 1995, J BIOL CHEM, V270, P2841, DOI 10.1074/jbc.270.6.2841; QUI WQ, 1995, J NEUROSCI, V15, P2157; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; REBECK GW, 1993, NEURON, V11, P575; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHMAIER AH, 1993, J CLIN INVEST, V92, P2540, DOI 10.1172/JCI116863; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STRICKLAND DK, 1995, IN PRESS FASEB J; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1987, J BIOL CHEM, V262, P8508; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; VANNOSTRAND WE, 1989, NATURE, V341, P546; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, J CELL SCI, V107, P719; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	76	435	457	0	15	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					331	340		10.1016/0092-8674(95)90320-8	http://dx.doi.org/10.1016/0092-8674(95)90320-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7543026	Bronze			2022-12-28	WOS:A1995RL76000020
J	MACSWEENEY, EJ; OADES, PJ; BUCHDAHL, R; ROSENTHAL, M; BUSH, A				MACSWEENEY, EJ; OADES, PJ; BUCHDAHL, R; ROSENTHAL, M; BUSH, A			RELATION OF THICKENING OF COLON WALL TO PANCREATIC-ENZYME TREATMENT IN CYSTIC-FIBROSIS	LANCET			English	Article							TRANSIT-TIME; CHILDREN; APPENDICITIS	Fibrotic strictures of the colon in association with colon-wall thickening on abdominal ultrasound have been described in children with cystic fibrosis. We determined the prevalence of colon-wall thickening in 99 children with cystic fibrosis (aged 6 months to 17 years, 45 male) and 38 healthy controls (aged 1 month to 39 years, 21 male). In controls, peristalsis was uniformly rapid and maximum wall thickness of the fully relaxed colon was 0.8 mm (median 0.6 mm). 24% of the patients had a colon-wall thickness of 1.5 mm or more (maximum 3.4 mm); 48% of children on high-strength pancreatin receiving more than 265 units/kg per day of protease had thickening of more than 1.5 mm compared with less than 12% of children on any other dose. Children on high-strength pancreatin were 5.2 (95% CI 1.2-21) times more likely to have colon-wall thickness of 1.5 mm or more than children taking less than 265 units/kg per day of protease in a standard-strength preparation. This risk rose to 10 (2.5-39) times more likely if laxatives were taken with a high-strength preparation. Lipase or amylase intake, age, sex, genotype, and other medical or drug history were not significantly associated with colon-wall thickening. 1 child required a hemicolectomy for bowel obstruction and another developed haemorrhagic colitis. In 17 children, 2 months after stopping high-strength, high protease, preparations and efforts to reduce enzyme intake, colon-wall thickness had regressed from a median 2.0 mm (range 1.0-3.4) to 1.8 mm (0.9-2.7) (p=0.005). The use of high-strength pancreatin preparations in conjunction with a high protease intake probably causes thickening of the wall of the colon.	ROYAL BROMPTON NATL HEART & LUNG HOSP,DEPT PAEDIAT RESP MED,LONDON SW3 6NP,ENGLAND; RIVERSIDE HOSP,DEPT RADIOL,LONDON,ENGLAND	Imperial College London				Oades, Patrick/0000-0001-5265-6923				Atkinson SN., 1991, EUR J CLIN RES, V1, P37; BALI A, 1983, BRIT MED J, V287, P1011, DOI 10.1136/bmj.287.6398.1011; BOWLER IM, 1993, ARCH DIS CHILD, V68, P227, DOI 10.1136/adc.68.2.227; CAMPBELL CA, 1994, LANCET, V343, P109; CRADY SK, 1993, ANN EMERG MED, V22, P1125, DOI 10.1016/S0196-0644(05)80976-X; DALZELL AM, 1990, ARCH DIS CHILD, V65, P585, DOI 10.1136/adc.65.6.585; DALZELL AM, 1990, ARCH DIS CHILD, V65, P540, DOI 10.1136/adc.65.5.540; Feigelson J, 1990, Acta Univ Carol Med (Praha), V36, P144; GROSS K, 1985, J PEDIATR SURG, V20, P431, DOI 10.1016/S0022-3468(85)80235-9; HOLMES M, 1991, ARCH DIS CHILD, V66, P726, DOI 10.1136/adc.66.6.726; INNES JA, 1994, LANCET, V343, P599; KEDAR RP, 1994, CLIN RADIOL, V49, P24, DOI 10.1016/S0009-9260(05)82909-5; KEELING JW, 1992, OXFORD TXB PATHOLOGY, P1192; KNABE N, 1994, LANCET, V343, P1230, DOI 10.1016/S0140-6736(94)92443-0; MAHONY MJ, 1994, LANCET, V343, P600; MILLA CE, 1994, LANCET, V343, P599, DOI 10.1016/S0140-6736(94)91551-2; MORRISON G, 1991, LANCET, V338, P1596, DOI 10.1016/0140-6736(91)92421-W; OADES PJ, 1994, LANCET, V343, P109, DOI 10.1016/S0140-6736(94)90836-2; OKEEFFE FN, 1991, RADIOLOGY, V178, P827, DOI 10.1148/radiology.178.3.1994426; ROBINSON PJ, 1990, ARCH DIS CHILD, V65, P311, DOI 10.1136/adc.65.3.311; SIEGEL MJ, 1991, JAMA-J AM MED ASSOC, V266, P1987, DOI 10.1001/jama.266.14.1987; SIVIT CJ, 1993, AM J ROENTGENOL, V161, P147, DOI 10.2214/ajr.161.1.8517294; SMYTH RL, 1994, LANCET, V343, P85, DOI 10.1016/S0140-6736(94)90817-6; TAYLOR CJ, 1994, LANCET, V343, P110; ZENTLERMUNRO PL, 1987, GUT, V28, P1531, DOI 10.1136/gut.28.11.1531; ZENTLERMUNRO PL, 1984, GUT, V25, P500, DOI 10.1136/gut.25.5.500; 1994, DATA SHEET CONPENDIU, P385	27	62	62	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					752	756						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7534369				2022-12-28	WOS:A1995QN70100010
J	PICKAR, D				PICKAR, D			PROSPECTS FOR PHARMACOTHERAPY OF SCHIZOPHRENIA	LANCET			English	Review							D2-DOPAMINE RECEPTOR OCCUPANCY; PHOTON-EMISSION TOMOGRAPHY; PLASMA HOMOVANILLIC-ACID; ANTIPSYCHOTIC-DRUGS; TARDIVE-DYSKINESIA; HUMAN-BRAIN; CLOZAPINE; DOPAMINE; FLUPHENAZINE; NEUROLEPTICS				PICKAR, D (corresponding author), NIMH,EXPTL THERAPEUT BRANCH,NIH BLDG 10-4N212,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.			Pickar, David/0000-0002-8596-3687				BENNETT JP, 1993, NEUROLOGY, V43, P1551, DOI 10.1212/WNL.43.8.1551; BREIER A, 1994, AM J PSYCHIAT, V151, P20; Brier A., 1991, ARCH GEN PSYCHIAT, V48, P239; CALDWELL CB, 1992, SUICIDE LIFE-THREAT, V22, P479; CARLSSON A, 1988, NEUROPSYCHOPHARMACOL, V1, P179, DOI 10.1016/0893-133X(88)90012-7; CHOUINARD G, 1993, J CLIN PSYCHOPHARM, V13, P25; COHEN RM, UNPUB BRAIN METABOLI; CREESE I, 1976, SCIENCE, V192, P481, DOI 10.1126/science.3854; DAVIS KL, 1991, AM J PSYCHIAT, V148, P1474; DEUTCH AY, 1992, MOL CELL NEUROSCI, V3, P332, DOI 10.1016/1044-7431(92)90030-6; FABOE L, 1990, 17TH C CINP KYOT, V2; FARDE L, 1988, ARCH GEN PSYCHIAT, V45, P71; FARDE L, 1986, SCIENCE, V231, P258, DOI 10.1126/science.2867601; FARDE L, 1992, ARCH GEN PSYCHIAT, V49, P538; GOLDBERG TE, 1993, BRIT J PSYCHIAT, V162, P43, DOI 10.1192/bjp.162.1.43; HIRSCH SR, 1994, SCHIZOPHRENIA; HYMAN SE, 1993, MOL F PSYCHIATRY; JANSSEN PAJ, 1988, J PHARMACOL EXP THER, V244, P685; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; KANE JM, 1987, SCHIZOPHRENIA BULL, V13, P133, DOI 10.1093/schbul/13.1.133; KANE JM, 1993, J CLIN PSYCHIAT, V54, P327; LEWANDER T, 1990, ACTA PSYCHIAT SCAND, V82, P92, DOI 10.1111/j.1600-0447.1990.tb05297.x; LEYSEN JE, 1992, MOL PHARMACOL, V41, P494; LIEBERMAN JA, 1991, BRIT J PSYCHIAT, V158, P503, DOI 10.1192/bjp.158.4.503; LIPSKA BK, 1993, NEUROPSYCHOPHARMACOL, V9, P67, DOI 10.1038/npp.1993.44; LITMAN RE, 1993, J CLIN PSYCHOPHARM, V13, P264; MANJI HK, 1994, SYNAPSE, V16, P11, DOI 10.1002/syn.890160103; MELTZER HR, 1989, J PHARMACOL EXP THER, V251, P3238; MELTZER HY, 1979, AM J PSYCHIAT, V136, P1550; MELTZER HY, 1993, AM J PSYCHIAT, V150, P1630; Moore NA., 1993, CURR OPIN INVEST DR, V2, P281; MRDER SR, 1994, AM J PSYCHIAT, V151, P825; OWEN RR, 1993, ARCH GEN PSYCHIAT, V50, P636; PEROUTKA SJ, 1980, AM J PSYCHIAT, V137, P1518; PICKAR D, 1992, ARCH GEN PSYCHIAT, V49, P345; PICKAR D, 1984, SCIENCE, V225, P954, DOI 10.1126/science.6474162; PICKAR D, 1988, SCHIZOPHRENIA BULL, V14, P255, DOI 10.1093/schbul/14.2.255; PICKAR D, 1990, ARCH GEN PSYCHIAT, V47, P641; PICKAR D, 1986, ARCH GEN PSYCHIAT, V43, P669; PILOWSKY LS, 1993, NEUROPSYCHOPHARMACOL, V9, P83, DOI 10.1038/npp.1993.46; PILOWSKY LS, 1992, LANCET, V340, P199, DOI 10.1016/0140-6736(92)90467-H; RAO PA, 1994, ARCH GEN PSYCHIAT, V51, P912; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; RICHELSON E, 1984, EUR J PHARMACOL, V103, P197, DOI 10.1016/0014-2999(84)90478-3; ROTH BL, 1994, J PHARMACOL EXP THER, V268, P1403; RUPP A, 1993, PSYCHIAT CLIN N AM, V16, P413; SANCHEZ C, 1991, DRUG DEVELOP RES, V22, P239, DOI 10.1002/ddr.430220306; SEEGER TF, 1993, SOC NEUR ABSTS, V19; SEEMAN P, 1976, NATURE, V261, P717, DOI 10.1038/261717a0; SEEMAN P, 1992, NEUROPSYCHOPHARMACOL, V7, P261; SU TP, 1994, UNPUB; TALBOTT JA, 1987, PSYCHIAT ANN, V17, P577, DOI 10.3928/0048-5713-19870901-05; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; WEINBERGER DR, 1994, SCHIZOPHRENIA; WEINBERGER DR, 1988, SCHIZOPHR B, V14, P179; WHITE FJ, 1983, SCIENCE, V221, P1054, DOI 10.1126/science.6136093; WOLKIN A, 1989, AM J PSYCHIAT, V146, P905; WOLKIN A, 1989, ARCH GEN PSYCHIAT, V46, P482; WONG DF, 1992, SYNAPSE, V12, P236, DOI 10.1002/syn.890120309	59	120	120	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					557	562		10.1016/S0140-6736(95)90469-7	http://dx.doi.org/10.1016/S0140-6736(95)90469-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QK444	7539875				2022-12-28	WOS:A1995QK44400014
J	SANCHEZTAPIAS, JM; RODES, J				SANCHEZTAPIAS, JM; RODES, J			DILEMMAS OF ORGAN-TRANSPLANTATION FROM ANTI-HCV-POSITIVE DONORS	LANCET			English	Editorial Material							HEPATITIS-C VIRUS; RECIPIENTS				SANCHEZTAPIAS, JM (corresponding author), UNIV BARCELONA,HOSP CLIN,LIVER UNIT,BARCELONA,SPAIN.							FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801; KROES ACM, 1994, J HEPATOL, V21, P1113, DOI 10.1016/S0168-8278(05)80627-0; LIM HL, 1994, GASTROENTEROLOGY, V106, P248, DOI 10.1016/S0016-5085(94)95829-7; MARTELL M, 1992, J VIROL, V66, P3225, DOI 10.1128/JVI.66.5.3225-3229.1992; MILFRED SK, 1994, TRANSPLANTATION, V57, P568; MORALES JM, 1995, KIDNEY INT, V47, P236, DOI 10.1038/ki.1995.29; PEREIRA BJG, 1992, NEW ENGL J MED, V327, P910, DOI 10.1056/NEJM199209243271302; RAMOS EL, 1994, TRANSPLANTATION, V57, P490; ROTH D, 1992, ANN INTERN MED, V117, P470, DOI 10.7326/0003-4819-117-6-470; SIMMONDS P, 1993, J CLIN MICROBIOL, V31, P1493, DOI 10.1128/JCM.31.6.1493-1503.1993; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7; TESI RJ, 1994, TRANSPLANTATION, V57, P826, DOI 10.1097/00007890-199403270-00010; VINCENTI F, 1993, TRANSPLANTATION, V55, P674; ZUCKER K, 1994, TRANSPLANTATION, V57, P832, DOI 10.1097/00007890-199403270-00011	14	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					469	470		10.1016/S0140-6736(95)90579-0	http://dx.doi.org/10.1016/S0140-6736(95)90579-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7532253				2022-12-28	WOS:A1995QH92900006
J	KAVANAUGH, WM; WILLIAMS, LT				KAVANAUGH, WM; WILLIAMS, LT			AN ALTERNATIVE TO SH2 DOMAINS FOR BINDING TYROSINE-PHOSPHORYLATED PROTEINS	SCIENCE			English	Article							GROWTH-FACTOR RECEPTORS; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL-3 KINASE; TRANSFORMING ACTIVITY; POINT MUTATIONS; PHOSPHOTYROSINE; ASSOCIATION; ACTIVATION; SEQUENCE; RESIDUES	Src homology 2 (SH2) domains bind specifically to tyrosine-phosphorylated proteins that participate in signaling by growth factors and oncogenes. A protein domain was identified that bound specifically to the tyrosine-phosphorylated form of its target protein but differs from known SH2 sequences. Phosphotyrosine-binding (PTB) domains were found in two proteins: SHC, a protein implicated in signaling through Ras; and SCK, encoded by a previously uncharacterized gene. The PTB domain of SHC specifically bound to a tyrosine-phosphorylated 145-kilodalton protein. PTB domains are an alternative to SH2 domains for specifically recruiting tyrosine-phosphorylated proteins into signaling complexes and are likely to take part in signaling by many growth factors.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898, Z01HL002714] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL32898, K11 HL02714] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KATZAV S, 1993, ONCOGENE, V8, P1757; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KAVANAUGH WM, UNPUB; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAXTON TM, 1994, J IMMUNOL, V153, P623; Summers MD, 1987, MANUAL METHODS BACUL; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	22	471	492	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1862	1865		10.1126/science.7527937	http://dx.doi.org/10.1126/science.7527937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7527937				2022-12-28	WOS:A1994PX38300035
J	MCWHINNEY, IR; BASS, MJ; DONNER, A				MCWHINNEY, IR; BASS, MJ; DONNER, A			EVALUATION OF A PALLIATIVE CARE SERVICE - PROBLEMS AND PITFALLS	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; CANCER-PATIENTS; HOSPICE; INDEX	Objective-To evaluate a palliative care home support team based on an inpatient unit. Design-Randomised controlled trial with waiting list. Patients in the study group received the service immediately, those in the control group received it after one month. Main comparison point was at one month. Setting-A city of 300 000 people with a publicly funded home care service and about 200 general practitioners, most of whom provide home care. Main outcome measures-Pain and nausea levels were measured at entry to trial and at one month, as were quality of life for patients and care givers' health. Results-Because of early deaths, problems with recruitment, and a low compliance rate for completion of questionnaires, the required sample size was not attained. Conclusion-in designing evaluations of palliative care services, investigators should be prepared to deal with the following issues: attrition due to early death, opposition to randomisation by patients and referral sources, ethical problems raised by randomisation of dying patients, the appropriate timing of comparison points, and difficulties of collecting data from sick or exhausted patients and care givers. Investigators may choose to evaluate a service from various perspectives using different methods: controlled trials, qualitative studies, surveys, and audits. Randomised trials may prove to be impracticable for evaluation of palliative care.			MCWHINNEY, IR (corresponding author), UNIV WESTERN ONTARIO,CTR STUDIES FAMILY MED,THAMES VALLEY FAMILY PRACTICE RES UNIT,LONDON N6A 5C1,ON,CANADA.							ADDINGTONHALL JM, 1992, BRIT MED J, V305, P1317, DOI 10.1136/bmj.305.6865.1317; AIKEN LH, 1986, J CHRON DIS, V39, P1, DOI 10.1016/0021-9681(86)90101-3; BAUM M, 1993, LANCET, V341, P812, DOI 10.1016/0140-6736(93)90573-Y; BLOOM BS, 1980, J AM GERIATR SOC, V28, P451, DOI 10.1111/j.1532-5415.1980.tb01118.x; DUSH DM, 1984, HOSPICE J, V1, P55; EVANS C, 1985, LANCET, V1, P1204; Goldberg DP, 1972, DETECTION PSYCHIAT I; KANE RL, 1984, LANCET, V1, P890; MELZACK R, 1985, CAN MED ASSOC J, V133, P755; Melzack R, 1985, CAN MED ASSOC J, V133, P761; Melzack R., 1983, PAIN MEASUREMENT ASS; MOR V, 1987, HOSPICE CARE SYSTEMS; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; SCHIPPER H, 1984, J CLIN ONCOL, V2, P472, DOI 10.1200/JCO.1984.2.5.472; SILVERMAN WA, 1994, LANCET, V343, P1586, DOI 10.1016/S0140-6736(94)93053-8; ZIMMER JG, 1985, AM J PUBLIC HEALTH, V75, P134, DOI 10.2105/AJPH.75.2.134	16	178	179	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 19	1994	309	6965					1340	1342		10.1136/bmj.309.6965.1340	http://dx.doi.org/10.1136/bmj.309.6965.1340			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7532501	Green Published			2022-12-28	WOS:A1994PT62500025
J	MIKI, Y; SWENSEN, J; SHATTUCKEIDENS, D; FUTREAL, PA; HARSHMAN, K; TAVTIGIAN, S; LIU, QY; COCHRAN, C; BENNETT, LM; DING, W; BELL, R; ROSENTHAL, J; HUSSEY, C; TRAN, T; MCCLURE, M; FRYE, C; HATTIER, T; PHELPS, R; HAUGENSTRANO, A; KATCHER, H; YAKUMO, K; GHOLAMI, Z; SHAFFER, D; STONE, S; BAYER, S; WRAY, C; BOGDEN, R; DAYANANTH, P; WARD, J; TONIN, P; NAROD, S; BRISTOW, PK; NORRIS, FH; HELVERING, L; MORRISON, P; ROSTECK, P; LAI, M; BARRETT, JC; LEWIS, C; NEUHAUSEN, S; CANNONALBRIGHT, L; GOLDGAR, D; WISEMAN, R; KAMB, A; SKOLNICK, MH				MIKI, Y; SWENSEN, J; SHATTUCKEIDENS, D; FUTREAL, PA; HARSHMAN, K; TAVTIGIAN, S; LIU, QY; COCHRAN, C; BENNETT, LM; DING, W; BELL, R; ROSENTHAL, J; HUSSEY, C; TRAN, T; MCCLURE, M; FRYE, C; HATTIER, T; PHELPS, R; HAUGENSTRANO, A; KATCHER, H; YAKUMO, K; GHOLAMI, Z; SHAFFER, D; STONE, S; BAYER, S; WRAY, C; BOGDEN, R; DAYANANTH, P; WARD, J; TONIN, P; NAROD, S; BRISTOW, PK; NORRIS, FH; HELVERING, L; MORRISON, P; ROSTECK, P; LAI, M; BARRETT, JC; LEWIS, C; NEUHAUSEN, S; CANNONALBRIGHT, L; GOLDGAR, D; WISEMAN, R; KAMB, A; SKOLNICK, MH			A STRONG CANDIDATE FOR THE BREAST AND OVARIAN-CANCER SUSCEPTIBILITY GENE BRCA1	SCIENCE			English	Article							FAMILIAL BREAST; ZINC FINGER; WILMS-TUMOR; ATAXIA-TELANGIECTASIA; DNA-BINDING; WT1 GENE; CHROMOSOME-17Q21; IDENTIFICATION; MUTATIONS; P53	A strong candidate for the 17q-linked BRCA1 gene, which influences susceptibility to breast and ovarian cancer, has been identified by positional cloning methods. Probable predisposing mutations have been detected in five of eight kindreds presumed to segregate BRCA1 susceptibility alleles. The mutations include an 11-base pair deletion, a 1-base pair insertion, a stop codon, a missense substitution, and an inferred regulatory mutation. The BRCA1 gene is expressed in numerous tissues, including breast and ovary, and encodes a predicted protein of 1863 amino acids. This protein contains a zinc finger domain in its amino-terminal region, but is otherwise unrelated to previously described proteins, identification of BRCA1 should facilitate early diagnosis of breast and ovarian cancer susceptibility in some individuals as well as a better understanding of breast cancer biology.	UNIV UTAH,MED CTR,DEPT MED INFORMAT,SALT LAKE CITY,UT 84132; MYRIAD GENET,SALT LAKE CITY,UT 84108; NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709; UNIV UTAH,MED CTR,DEPT INTERNAL MED,SALT LAKE CITY,UT 84132; MCGILL UNIV,DEPT MED GENET,MONTREAL H3G 1A4,PQ,CANADA; ELI LILLY & CO,LILLY RES LABS,INDIANAPOLIS,IN 46285; UNIV UTAH,MED CTR,DEPT MED INFORMAT,SALT LAKE CITY,UT 84108	Utah System of Higher Education; University of Utah; Myriad Genetics, Inc; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Utah System of Higher Education; University of Utah; McGill University; Eli Lilly; Utah System of Higher Education; University of Utah			Pinheiro, Maísa/E-7424-2012; Narod, Steven A/AAA-6112-2022; Lewis, Cathryn/M-8766-2019; Lewis, Cathryn M/A-5225-2010	Lewis, Cathryn/0000-0002-8249-8476; Lewis, Cathryn M/0000-0002-8249-8476; Miki, Yoshio/0000-0003-0114-392X; albright, lisa/0000-0003-2602-3668	NCI NIH HHS [CA-54936, CA-48711, CA-55914] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA054936, P01CA048711, R01CA055914] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P195; ANDERSON DM, UNPUB; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BOWCOCK AM, 1993, AM J HUM GENET, V52, P718; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; CANNONALBRIGHT LA, 1994, CANCER RES, V54, P2378; CLAUS EB, 1991, AM J HUM GENET, V48, P232; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; EASTON DF, 1993, AM J HUM GENET, V52, P678; FEUNTEUN J, 1993, AM J HUM GENET, V52, P736; FUTREAL PA, 1994, HUM MOL GENET, V3, P1359, DOI 10.1093/hmg/3.8.1359; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GOLDGAR DE, 1994, J NATL CANCER I, V86, P200, DOI 10.1093/jnci/86.3.200; GOLDGAR DE, UNPUB; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KELSELL DP, 1993, HUM MOL GENET, V2, P1823; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LITTLE MH, 1993, HUM MOL GENET, V2, P259, DOI 10.1093/hmg/2.3.259; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; METTLIN C, 1990, AM J EPIDEMIOL, V131, P973, DOI 10.1093/oxfordjournals.aje.a115617; NAROD SA, 1991, LANCET, V338, P82; NEUHAUSEN S, IN PRESS CANCER RES; NEUHAUSEN SL, IN PRESS HUM MOL GEN; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; Sambrook J, 1989, MOL CLONING LABORATO; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SIMARD J, 1993, HUM MOL GENET, V2, P1193, DOI 10.1093/hmg/2.8.1193; SMITH HS, 1993, J CELL BIOCH SG, V14, P144; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; SU LK, 1993, CANCER RES, V53, P2728; SWIFT M, 1976, CANCER RES, V36, P209; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; THOMAS A, IN PRESS IMA J MATH; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563; WESTIN G, 1984, P NATL ACAD SCI-BIOL, V81, P3811, DOI 10.1073/pnas.81.12.3811; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; 1994, CANCER FACTS FIGURES, P13	44	4862	5084	6	432	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					66	71		10.1126/science.7545954	http://dx.doi.org/10.1126/science.7545954			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7545954				2022-12-28	WOS:A1994PK58200026
J	RICH, MW; BECKHAM, V; WITTENBERG, C; LEVEN, CL; FREEDLAND, KE; CARNEY, RM				RICH, MW; BECKHAM, V; WITTENBERG, C; LEVEN, CL; FREEDLAND, KE; CARNEY, RM			A MULTIDISCIPLINARY INTERVENTION TO PREVENT THE READMISSION OF ELDERLY PATIENTS WITH CONGESTIVE-HEART-FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLUS ISOSORBIDE DINITRATE; GERIATRIC CONSULTATION; CONTROLLED TRIAL; HOSPITALIZATION; ENALAPRIL; REDUCTION; STAY; CARE	Background. Congestive heart failure is the most common indication for admission to the hospital among older adults. Behavioral factors, such as poor compliance with treatment, frequently contribute to exacerbations of heart failure, a fact suggesting that many admissions could be prevented. Methods. We conducted a prospective, randomized trial of the effect of a nurse-directed, multidisciplinary intervention on rates of readmission within 90 days of hospital discharge, quality of life, and costs of care for high-risk patients 70 years of age or older who were hospitalized with congestive heart failure. The intervention consisted of comprehensive education of the patient and family, a prescribed diet, social-service consultation and planning for an early discharge, a review of medications, and intensive follow-up. Results. Survival for 90 days without readmission, the primary outcome measure, was achieved in 91 of the 142 patients in the treatment group, as compared with 75 of the 140 patients in the control group, who received conventional care (P = 0.09). There were 94 readmissions in the control group and 53 in the treatment group (risk ratio, 0.56; P = 0.02). The number of readmissions for heart failure was reduced by 56.2 percent in the treatment group (54, vs. 24 in the control group; P = 0.04), whereas the number of readmissions for other causes was reduced by 28.5 percent (40 vs. 29, P not significant). In the control group, 23 patients (16.4 percent) had more than one readmission, as compared with 9 patients (6.3 percent) in the treatment group (risk ratio, 0.39; P = 0.01). In a subgroup of 126 patients, quality-of-life scores at 90 days improved more from base line for patients in the treatment group (P = 0.001). Because of the reduction in hospital admissions, the overall cost of care was $460 less per patient in the treatment group. Conclusions. A nurse-directed, multidisciplinary intervention can improve quality of life and reduce hospital use and medical costs for elderly patients with congestive heart failure.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,DEPT PSYCHIAT,BEHAV MED SECT,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT ECON,ST LOUIS,MO 63130	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL)	RICH, MW (corresponding author), WASHINGTON UNIV,JEWISH HOSP ST LOUIS,DIV CARDIOL,GERIATR CARDIOL SECT,216 S KINGSHIGHWAY BLVD,ST LOUIS,MO 63110, USA.		Greiver, Michelle/N-8764-2015; Rich, Michael/AAD-6167-2022	Greiver, Michelle/0000-0001-8957-0285; Rich, Michael/0000-0002-4243-9391	NHLBI NIH HHS [HL44739] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL044739] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS K, 1986, J AM GERIATR SOC, V34, P5, DOI 10.1111/j.1532-5415.1986.tb06333.x; CAMPION EW, 1983, J AM GERIATR SOC, V31, P792, DOI 10.1111/j.1532-5415.1983.tb03401.x; CUMMINGS JE, 1990, ARCH INTERN MED, V150, P1274, DOI 10.1001/archinte.150.6.1274; FISHER LD, 1993, BIOSTATISTICS METHOD, P188; FITZGERALD JF, 1994, ARCH INTERN MED, V154, P1721, DOI 10.1001/archinte.154.15.1721; GHALI JK, 1988, ARCH INTERN MED, V148, P2013, DOI 10.1001/archinte.148.9.2013; GHALI JK, 1990, ARCH INTERN MED, V150, P769, DOI 10.1001/archinte.150.4.769; GOODING J, 1985, J AM GERIATR SOC, V33, P595, DOI 10.1111/j.1532-5415.1985.tb06315.x; GRAVES EJ, 1991, ADV DATA VITAL HLTH, V199, P1; GUYATT GH, 1989, J GEN INTERN MED, V4, P101, DOI 10.1007/BF02602348; GUYATT GH, 1993, J AM COLL CARDIOL, V22, pA185, DOI 10.1016/0735-1097(93)90488-M; KENNEDY L, 1987, GERONTOLOGIST, V27, P577, DOI 10.1093/geront/27.5.577; KONSTAM M, 1994, CLIN PRACTICE GUIDEL, V11; LOEB HS, 1993, CIRCULATION, V87, P78; MOZES B, 1987, LANCET, V1, P968; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; PAUL SD, 1994, ARCH INTERN MED, V154, P1143, DOI 10.1001/archinte.154.10.1143; RECTOR TS, 1993, CIRCULATION, V87, P71; RICH MW, 1993, J GEN INTERN MED, V8, P585, DOI 10.1007/BF02599709; RICH MW, 1988, AM J PUBLIC HEALTH, V78, P680, DOI 10.2105/AJPH.78.6.680; ROGERS WJ, 1994, J AM COLL CARDIOL, V23, P393, DOI 10.1016/0735-1097(94)90426-X; SMITH DM, 1988, MED CARE, V26, P699, DOI 10.1097/00005650-198807000-00005; TOWNSEND J, 1988, BMJ-BRIT MED J, V297, P544, DOI 10.1136/bmj.297.6647.544; VANROSSUM E, 1993, BMJ-BRIT MED J, V307, P27, DOI 10.1136/bmj.307.6895.27; VINSON JM, 1990, J AM GERIATR SOC, V38, P1290, DOI 10.1111/j.1532-5415.1990.tb03450.x; WEINBERGER M, 1988, MED CARE, V26, P1092, DOI 10.1097/00005650-198811000-00007; WINOGRAD CH, 1993, ARCH INTERN MED, V153, P2017, DOI 10.1001/archinte.153.17.2017; 1991, NEW ENGL J MED, V325, P293; 1992, SAS P229 TECHN REP, P433	29	1606	1648	2	107	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 2	1995	333	18					1190	1195		10.1056/NEJM199511023331806	http://dx.doi.org/10.1056/NEJM199511023331806			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TB560	7565975				2022-12-28	WOS:A1995TB56000006
J	BOCHKAREV, A; BARWELL, JA; PFUETZNER, RA; FUREY, W; EDWARDS, AM; FRAPPIER, L				BOCHKAREV, A; BARWELL, JA; PFUETZNER, RA; FUREY, W; EDWARDS, AM; FRAPPIER, L			CRYSTAL-STRUCTURE OF THE DNA-BINDING DOMAIN OF THE EPSTEIN-BARR-VIRUS ORIGIN-BINDING PROTEIN EBNA1	CELL			English	Article							LATENT REPLICATION ORIGIN; NUCLEAR ANTIGEN EBNA-1; FUNCTIONAL DOMAINS; HUMAN-CELLS; E1 PROTEIN; E2; ACTIVATION; PLASMIDS; COMPLEX; IDENTIFICATION	The crystal structure of the DNA-binding and dimerization domains of the Epstein-Barr virus nuclear antigen 1 (EBNA1), which binds to and activates DNA replication from the latent origin of replication in Epstein-Barr virus, was solved at 2.5 Angstrom resolution. EBNA1 appears to bind DNA via two independent regions termed the core and the flanking DNA-binding domains. The core DNA-binding domain, which comprises both the dimerization domain and a helix predicted to bind the inner portion of the EBNA1 DNA recognition element, was remarkably similar to the structure of the papillomavirus E2 protein, despite a complete lack of sequence conservation. The flanking DNA-binding domain, only a portion of which is contained in the current structure, consists in part of an a helix whose N-terminus contacts the outer regions of the EBNA1 DNA recognition element.	UNIV PITTSBURGH,VET ADM MED CTR,BIOCRYSTALLOG LAB,PITTSBURGH,PA 15240; UNIV PITTSBURGH,DEPT CRYSTALLOG,PITTSBURGH,PA 15240	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	BOCHKAREV, A (corresponding author), MCMASTER UNIV,DEPT PATHOL,INST MOLEC BIOL & BIOTECHNOL,CANC RES GRP,1200 MAIN ST W,HAMILTON,ON L8N 3Z5,CANADA.			Edwards, Aled/0000-0002-4782-6016				ADAMS A, 1987, J VIROL, V61, P1743, DOI 10.1128/JVI.61.5.1743-1746.1987; AMBINDER RF, 1990, J VIROL, V64, P2369, DOI 10.1128/JVI.64.5.2369-2379.1990; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; BARWELL JA, 1995, J BIOL CHEM, V270; BONNEANDREA C, 1995, J VIROL, V69, P3201, DOI 10.1128/JVI.69.5.3201-3205.1995; CHEN MR, 1994, VIROLOGY, V205, P486, DOI 10.1006/viro.1994.1669; CHEN MR, 1993, J VIROL, V67, P4875, DOI 10.1128/JVI.67.8.4875-4885.1993; FRAPPIER L, 1991, P NATL ACAD SCI USA, V88, P10875, DOI 10.1073/pnas.88.23.10875; FRAPPIER L, 1992, J VIROL, V66, P1786, DOI 10.1128/JVI.66.3.1786-1790.1992; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; FRAPPIER L, 1994, J BIOL CHEM, V269, P1057; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; FUREY W, 1982, J APPL CRYSTALLOGR, V15, P160, DOI 10.1107/S0021889882011716; FUREY W, 1995, IN PRESS METH ENZYMO; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; GOLDSMITH K, 1993, J VIROL, V67, P3418, DOI 10.1128/JVI.67.6.3418-3426.1993; HARRISON S, 1994, J VIROL, V68, P1913, DOI 10.1128/JVI.68.3.1913-1925.1994; HEARING J, 1992, J VIROL, V66, P694, DOI 10.1128/JVI.66.2.694-705.1992; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HSIEH DJ, 1993, EMBO J, V12, P4933, DOI 10.1002/j.1460-2075.1993.tb06187.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEIN G, 1989, CELL, V58, P5, DOI 10.1016/0092-8674(89)90394-2; KNIGHT JD, 1991, P NATL ACAD SCI USA, V88, P3204, DOI 10.1073/pnas.88.8.3204; KRYSAN PJ, 1989, MOL CELL BIOL, V9, P1026, DOI 10.1128/MCB.9.3.1026; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MILLER G, 1990, VIROLOGY, P1921; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; PRAKASH SS, 1992, GENE DEV, V6, P105, DOI 10.1101/gad.6.1.105; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; ROIZMANN B, 1990, VIROLOGY; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; STEGER G, 1995, EMBO J, V14, P329, DOI 10.1002/j.1460-2075.1995.tb07007.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SU W, 1991, P NATL ACAD SCI USA, V88, P10870, DOI 10.1073/pnas.88.23.10870; SUGDEN B, 1989, J VIROL, V63, P2644, DOI 10.1128/JVI.63.6.2644-2649.1989; USTAV M, 1991, EMBO J, V10, P4321, DOI 10.1002/j.1460-2075.1991.tb05010.x; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YATES JL, 1991, J VIROL, V65, P483, DOI 10.1128/JVI.65.1.483-488.1991	46	128	133	1	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					39	46		10.1016/0092-8674(95)90232-5	http://dx.doi.org/10.1016/0092-8674(95)90232-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553871	Bronze			2022-12-28	WOS:A1995RY58300008
J	GRUPE, A; HULTGREN, B; RYAN, A; MA, YH; BAUER, M; STEWART, TA				GRUPE, A; HULTGREN, B; RYAN, A; MA, YH; BAUER, M; STEWART, TA			TRANSGENIC KNOCKOUTS REVEAL A CRITICAL REQUIREMENT FOR PANCREATIC BETA-CELL GLUCOKINASE IN MAINTAINING GLUCOSE-HOMEOSTASIS	CELL			English	Article							DEPENDENT DIABETES-MELLITUS; GENETIC-MARKER; INSULIN; MUTATIONS; EXPRESSION; ISLETS; LIVER; LINKAGE; LOCUS; NIDDM	The secretion of insulin is controlled by the rate of glucose metabolism in the pancreatic beta cells. As phosphorylation by glucokinase (GLK) appears to be the rate-limiting step for glucose catabolism in beta cells, this enzyme may be the glucose sensor. To test this possibility and to resolve the relative roles of liver and beta cell GLK in maintaining glucose levels, we have generated mice completely deficient in GLK and transgenic mice in which GLK is expressed only in beta cells. In mice with only one GLK allele, blood glucose levels are elevated and insulin secretion is reduced. GLK-deficient mice die perinatally with severe hyperglycemia. Expression of GLK in beta cells in the absence of expression in the liver is sufficient for survival. These mice demonstrate the critical need for beta cell GLK in maintaining normal glucose levels and provide a novel model for one form of noninsulin-dependent diabetes.			GRUPE, A (corresponding author), GENENTECH INC, DEPT MOLEC BIOL, San Francisco, CA 94080 USA.							BECKER TC, 1994, J BIOL CHEM, V269, P21234; BEDOYA FJ, 1986, J BIOL CHEM, V261, P760; BYRNE MM, 1994, J CLIN INVEST, V93, P1120, DOI 10.1172/JCI117064; CARO JF, 1995, HORM METAB RES, V27, P19, DOI 10.1055/s-2007-979899; CHEN C, 1994, J CLIN INVEST, V94, P1616, DOI 10.1172/JCI117503; CHIU KC, 1992, DIABETES, V41, P843, DOI 10.2337/diabetes.41.7.843; CHIU KC, 1993, DIABETES, V42, P579, DOI 10.2337/diabetes.42.4.579; CHIU KC, 1992, DIABETOLOGIA, V35, P632, DOI 10.1007/BF00400254; COOK DL, 1990, DIABETES MELLITUS TH, P89; COORE HG, 1964, BIOCHEM J, V93, P66, DOI 10.1042/bj0930066; CORNISHBOWDEN A, 1991, TRENDS BIOCHEM SCI, V16, P281, DOI 10.1016/0968-0004(91)90115-C; DAVIS SN, 1994, ROLE LIVER MAINTAINI, P85; EFRAT S, 1994, P NATL ACAD SCI USA, V91, P2051, DOI 10.1073/pnas.91.6.2051; ELBEIN SC, 1993, DIABETOLOGIA, V36, P141, DOI 10.1007/BF00400695; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GIDHJAIN M, 1993, P NATL ACAD SCI USA, V90, P1932, DOI 10.1073/pnas.90.5.1932; GRODSKY GM, 1963, AM J PHYSIOL, V205, P638, DOI 10.1152/ajplegacy.1963.205.4.638; HATTERSLEY AT, 1992, LANCET, V339, P1307, DOI 10.1016/0140-6736(92)91958-B; HOGAN B, 1986, MANIPULATING MOUSE E; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; JETTON TL, 1994, J BIOL CHEM, V269, P3641; KATAGIRI H, 1992, LANCET, V340, P1316, DOI 10.1016/0140-6736(92)92494-Z; KORANYI LI, 1992, DIABETES, V41, P807, DOI 10.2337/diabetes.41.7.807; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LIANG Y, 1991, J BIOL CHEM, V266, P6999; LIANG Y, 1994, J CLIN INVEST, V93, P2473, DOI 10.1172/JCI117256; MA YH, 1994, ENDOCRINOLOGY, V134, P42, DOI 10.1210/en.134.1.42; MAGNUSON MA, 1992, J CELL BIOCHEM, V48, P115, DOI 10.1002/jcb.240480202; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; MCCARTHY MI, 1993, DIABETOLOGIA, V36, P633, DOI 10.1007/BF00404073; MUECKLER M, 1993, P NATL ACAD SCI USA, V90, P784, DOI 10.1073/pnas.90.3.784; NODA K, 1993, DIABETES, V42, P1147, DOI 10.2337/diabetes.42.8.1147; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSSETTI L, 1993, J CLIN INVEST, V92, P1126, DOI 10.1172/JCI116681; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SPEARS G, 1971, BIOCHEM J, V125, P1149, DOI 10.1042/bj1251149; STOFFEL M, 1992, P NATL ACAD SCI USA, V89, P7698, DOI 10.1073/pnas.89.16.7698; STOFFEL M, 1993, DIABETES, V42, P937, DOI 10.2337/diabetes.42.6.937; STURIS J, 1994, DIABETES, V43, P718, DOI 10.2337/diabetes.43.5.718; SUN F, 1993, J CLIN INVEST, V92, P1174, DOI 10.1172/JCI116687; TAKEDA J, 1993, J BIOL CHEM, V268, P15200; TAL M, 1992, J BIOL CHEM, V267, P17241; TANIZAWA Y, 1993, DIABETOLOGIA, V36, P409, DOI 10.1007/BF00402276; TRUS MD, 1981, DIABETES, V30, P911, DOI 10.2337/diabetes.30.11.911; VELHO G, 1992, LANCET, V340, P444, DOI 10.1016/0140-6736(92)91768-4; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; VOSSMCCOWAN ME, 1994, J BIOL CHEM, V269, P15814; YIN L, 1992, DIABETES, V41, P792	50	224	252	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 6	1995	83	1					69	78		10.1016/0092-8674(95)90235-X	http://dx.doi.org/10.1016/0092-8674(95)90235-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553875	Bronze			2022-12-28	WOS:A1995RY58300011
J	GENTILELLO, LM; DONOVAN, DM; DUNN, CW; RIVARA, FP				GENTILELLO, LM; DONOVAN, DM; DUNN, CW; RIVARA, FP			ALCOHOL INTERVENTIONS IN TRAUMA CENTERS - CURRENT PRACTICE AND FUTURE-DIRECTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SCREENING-TEST; PROBLEM DRINKING; BLOOD-ALCOHOL; INTOXICATION; QUESTIONNAIRE; ABUSE; CARE; DEPENDENCE; EMERGENCY; MORTALITY	Nearly half of all trauma beds are occupied by patients who were injured while under the influence of alcohol. Alcoholism plays such a significant role in trauma that efforts to reduce injury recurrence are unlikely to be successful if it remains untreated. An injury requiring hospitalization creates a unique opportunity to intervene and to motivate patients to alter their drinking behavior, thereby making trauma centers ideal sites to implement an alcohol screening, intervention, and referral program. However, despite emphasis on injury control and prevention, little has been done to incorporate alcohol intervention programs into care of the injured patient. Effective means of intervention exist that are consistent with the time, financial, and staffing constraints of trauma centers, and they should be implemented.	UNIV WASHINGTON, HARBORVIEW MED CTR, SCH MED, DEPT PSYCHIAT & BEHAV SCI, SEATTLE, WA 98104 USA; UNIV WASHINGTON, HARBORVIEW MED CTR, SCH MED, DEPT PEDIAT, SEATTLE, WA 98104 USA; UNIV WASHINGTON, INST ALCOHOL & DRUG ABUSE, SEATTLE, WA 98195 USA; HARBORVIEW INJURY PREVENT & RES CTR, SEATTLE, WA USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	GENTILELLO, LM (corresponding author), UNIV WASHINGTON, HARBORVIEW MED CTR,SCH MED,DEPT SURG,325 9TH AVE, MAILSTOP ZA-16, SEATTLE, WA 98104 USA.			Donovan, Dennis/0000-0003-2237-4292	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009045] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01-AAO9045] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Babor T., 1989, ALCOHOL HEALTH RES W, V13, P371; BABOR TF, 1986, BRIT J ADDICT, V81, P23; BABOR TF, 1992, REPORT PHASE 2 RANDO; Babor TF., 1989, ALCOHOL USE DISORDER, V1, P45; BERNADT MW, 1982, LANCET, V1, P325; BIEN TH, 1993, ADDICTION, V88, P315, DOI 10.1111/j.1360-0443.1993.tb00820.x; BLOSE JO, 1991, AM J PUBLIC HEALTH, V81, P1571, DOI 10.2105/AJPH.81.12.1571; Braiker H.B., 1980, COURSE ALCOHOLISM 4; CALES RH, 1984, ANN EMERG MED, V13, P1, DOI 10.1016/S0196-0644(84)80375-3; CHANG G, 1988, JAMA-J AM MED ASSOC, V260, P2533, DOI 10.1001/jama.260.17.2533; CHERPITEL CJ, 1993, ALCOHOL CLIN EXP RES, V17, P762, DOI 10.1111/j.1530-0277.1993.tb00837.x; CHERPITEL CJS, 1989, DRUG ALCOHOL DEPEN, V24, P195; COLQUITT M, 1987, NEW ENGL J MED, V317, P1262, DOI 10.1056/NEJM198711123172005; DAVIDSON R, 1987, BRIT J CLIN PSYCHOL, V26, P243, DOI 10.1111/j.2044-8260.1987.tb01358.x; DAVIDSON R, 1986, BRIT J ADDICT, V81, P217; DiClemente C C, 1990, J Subst Abuse, V2, P217, DOI 10.1016/S0899-3289(05)80057-4; ELVY GA, 1988, BRIT J ADDICT, V83, P83; EVANS L, 1990, ACCIDENT ANAL PREV, V22, P587, DOI 10.1016/0001-4575(90)90030-O; GENTILELLO LM, 1988, AM J SURG, V156, P558, DOI 10.1016/S0002-9610(88)80553-1; GENTILELLO LM, 1993, J TRAUMA, V34, P669, DOI 10.1097/00005373-199305000-00009; GERBERICH SG, 1989, J TRAUMA, V29, P338, DOI 10.1097/00005373-198903000-00010; GOLDBERG HI, 1991, MED CARE, V29, pJS49; GOODMAN RA, 1991, J STUD ALCOHOL, V52, P156, DOI 10.15288/jsa.1991.52.156; HABERMAN PW, 1986, J STUD ALCOHOL, V47, P316, DOI 10.15288/jsa.1986.47.316; HEATHER N, 1989, HDB ALCOHOLISM TREAT, P93; HOLDER H, 1991, J STUD ALCOHOL, V52, P517, DOI 10.15288/jsa.1991.52.517; HOLDER HD, 1992, J STUD ALCOHOL, V53, P293, DOI 10.15288/jsa.1992.53.293; JACOBS LM, 1988, TRAUMA, P15; Jacobson GR, 1989, HDB ALCOHOLISM TREAT, P17; Jones K R, 1979, Med Care, V17, P1; JURKOVICH GJ, 1992, ANN EMERG MED, V21, P704, DOI 10.1016/S0196-0644(05)82783-0; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; KITCHENS JM, 1994, JAMA-J AM MED ASSOC, V272, P1782, DOI 10.1001/jama.272.22.1782; KLATSKY AL, 1981, ANN INTERN MED, V95, P139, DOI 10.7326/0003-4819-95-2-139; LOWENSTEIN SR, 1990, J TRAUMA, V30, P1252, DOI 10.1097/00005373-199010000-00010; Marlatt G. A., 1988, ASSESSMENT ADDICTIVE; MAULL KI, 1982, SOUTHERN MED J, V75, P794, DOI 10.1097/00007611-198207000-00005; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MAYNARD A, 1994, BRIT MED BULL, V50, P221, DOI 10.1093/oxfordjournals.bmb.a072880; MCLELLAN BA, 1990, J TRAUMA, V30, P418, DOI 10.1097/00005373-199030040-00008; Miller W, 2002, MOTIVATIONAL INTERVI, V2nd; Miller W. R., 1986, TREATING ADDICTIVE B, P121; Miller WR, 1989, HDB ALCOHOLISM TREAT, P3; MILLER WR, 1989, HDB ALCOHOLISM TREAT, P67; MILLER WR, 1989, HDB ALCOHOLISM TREAT, P261; MORRIS JA, 1990, JAMA-J AM MED ASSOC, V263, P1942, DOI 10.1001/jama.263.14.1942; NILSSEN O, 1991, PREV MED, V20, P518, DOI 10.1016/0091-7435(91)90049-A; NILSSEN O, 1994, J TRAUMA, V36, P784, DOI 10.1097/00005373-199406000-00006; REYNA TM, 1985, ANN SURG, V201, P194; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; RIVARA FP, 1992, J ADOLESCENT HEALTH, V13, P663, DOI 10.1016/1054-139X(92)90060-O; RIVARA FP, 1981, B AM COLL SURG, V66, P5; Robins L. N., 1989, NIMH DIAGNOSTIC INTE; ROLLNICK S, 1992, BRIT J ADDICT, V87, P743; RUSSELL M, 1994, ALCOHOL CLIN EXP RES, V18, P1156, DOI 10.1111/j.1530-0277.1994.tb00097.x; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SAXE L, 1983, OTAHCS22 OFF TECHN A; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SILVER BA, 1990, PSYCHOSOMATICS, V31, P420, DOI 10.1016/S0033-3182(90)72138-X; SODERSTROM CA, 1994, J TRAUMA, V36, P68, DOI 10.1097/00005373-199401000-00010; SODERSTROM CA, 1987, ARCH SURG-CHICAGO, V122, P1067; SODERSTROM CA, 1992, JAMA-J AM MED ASSOC, V267, P2756, DOI 10.1001/jama.267.20.2756; SWENSON WM, 1975, MAYO CLIN PROC, V50, P204; WALLER JA, 1990, J TRAUMA, V30, P1298; WALLER JA, 1990, J TRAUMA, V30, P1548, DOI 10.1097/00005373-199012000-00020; WEISBESKI D, 1989, J TRAUMA, V29, P940, DOI 10.1097/00005373-198907000-00006; WELTE JW, 1987, DRUG ALCOHOL DEPEN, V19, P313, DOI 10.1016/0376-8716(87)90018-4; WHITFIELD RA, 1985, ACCIDENT ANAL PREV, V17, P367, DOI 10.1016/0001-4575(85)90090-9; WIECZOREK WF, 1990, J CRIM JUST, V18, P217, DOI 10.1016/0047-2352(90)90002-S; WIECZOREK WF, 1990, PROBLEM DRINKER DRIV, P90; Zuska J J, 1983, Bull Am Coll Surg, V68, P22; Zuska J J, 1981, Bull Am Coll Surg, V66, P5; 1985, MMWR-MORBID MORTAL W, V34, P161; 1986, MMWR-MORBID MORTAL W, V35, P703; 1991, SCREENING ALCOHOL OT; 1987, DIAGNOSTIC STATISTIC; 1966, PHS1071A13 PUBL; 1990, BROADENING BASE TREA; 1989, GUIDE CLIN PREVENTIV, P277; 1993, 3RD NEW YORK STAT OF; 1987, SCREENING ALCOHOLISM; 1993, RESOURCES OPTIMAL CA; 1993, 8TH NAT I ALC AB ALC; 1985, MMWR-MORBID MORTAL W, V34, P493; 1991, PUBLIC POLICY STATEM	86	134	136	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1043	1048		10.1001/jama.274.13.1043	http://dx.doi.org/10.1001/jama.274.13.1043			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RX108	7563455				2022-12-28	WOS:A1995RX10800027
J	THORNTON, JG; LILFORD, RJ				THORNTON, JG; LILFORD, RJ			CLINICAL ETHICS COMMITTEE	BRITISH MEDICAL JOURNAL			English	Article							HUNTINGTONS-DISEASE; SURGICAL ABORTION; CONSULTANTS; DECISIONS; MORALITY	An informal clinical ethics committee was set up to advise on ethical problems in prenatal diagnosis in Leeds. It was used twice in six months but was not called on again in the subsequent year, and we describe this experience. In North America similar committees are often used to advise on clinical moral dilemmas, and we review the published evidence from there and discuss some of the advantages and problems. Our committee's advice may have altered clinicians' actions considerably, but perhaps doctors in Britain are not yet ready to surrender this aspect of clinical autonomy.			THORNTON, JG (corresponding author), INST EPIDEMIOL & HLTH SERV RES,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND.		Thornton, Jim/B-8336-2008	Thornton, Jim/0000-0001-9764-6876				Andereck W S, 1992, Camb Q Healthc Ethics, V1, P41; Anzia Daniel J, 1992, J Clin Ethics, V3, P131; Carter B S, 1993, J Perinatol, V13, P144; FLEETWOOD J, 1994, ANN INTERN MED, V120, P320, DOI 10.7326/0003-4819-120-4-199402150-00010; FOST N, 1985, JAMA-J AM MED ASSOC, V253, P2687, DOI 10.1001/jama.253.18.2687; HARPER PS, 1990, BRIT MED J, V300, P1089, DOI 10.1136/bmj.300.6732.1089; LAPUMA J, 1989, ARCH INTERN MED, V149, P1109, DOI 10.1001/archinte.149.5.1109; LILFORD RJ, 1989, J MED ETHICS, V15, P82, DOI 10.1136/jme.15.2.82; LILFORD RJ, 1993, LANCET, V342, P499, DOI 10.1016/0140-6736(93)91627-X; LO B, 1987, NEW ENGL J MED, V317, P46, DOI 10.1056/NEJM198707023170110; MOSS AH, 1993, J AM SOC NEPHROL, V4, P229; Perkins Henry S, 1992, J Clin Ethics, V3, P133; PERKINS HS, 1988, AM J MED, V85, P761; ROSNER F, 1985, JAMA-J AM MED ASSOC, V253, P2693, DOI 10.1001/jama.253.18.2693; Simpson K H, 1992, J Clin Ethics, V3, P124; SONNENBLICK M, 1993, J AM GERIATR SOC, V41, P599, DOI 10.1111/j.1532-5415.1993.tb06729.x; SWENSON MD, 1992, ARCH INTERN MED, V152, P694, DOI 10.1001/archinte.152.4.694; THORNTON JG, 1990, J MED ETHICS, V16, P53, DOI 10.1136/jme.16.1.53; TYLER A, 1990, J MED ETHICS, V16, P41, DOI 10.1136/jme.16.1.41; 1985, JAMA-J AM MED ASSOC, V253, P2698; 1990, J NEUROL SCI, V94, P327	21	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	1995	311	7006					667	669		10.1136/bmj.311.7006.667	http://dx.doi.org/10.1136/bmj.311.7006.667			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RU753	7549638	Green Published			2022-12-28	WOS:A1995RU75300022
J	MANTYH, PW; DEMASTER, E; MALHOTRA, A; GHILARDI, JR; ROGERS, SD; MANTYH, CR; LIU, HT; BASBAUM, AI; VIGNA, SR; MAGGIO, JE; SIMONE, DA				MANTYH, PW; DEMASTER, E; MALHOTRA, A; GHILARDI, JR; ROGERS, SD; MANTYH, CR; LIU, HT; BASBAUM, AI; VIGNA, SR; MAGGIO, JE; SIMONE, DA			RECEPTOR ENDOCYTOSIS AND DENDRITE RESHAPING IN SPINAL NEURONS AFTER SOMATOSENSORY STIMULATION	SCIENCE			English	Article							PROTEIN-COUPLED RECEPTORS; EXCITATORY AMINO-ACIDS; PRIMARY SENSORY NEURONS; SUBSTANCE-P RECEPTORS; INTRADERMAL INJECTION; GUINEA-PIG; CORD; RAT; CAT; LOCALIZATION	In vivo somatosensory stimuli evoked the release of substance P from primary afferent neurons that terminate in the spinal cord and stimulated endocytosis of substance P receptors in rat spinal cord neurons. The distal dendrites that showed substance P receptor internalization underwent morphological reorganization, changing from a tubular structure to one characterized by swollen varicosities connected by thin segments. This internalization and dendritic structural reorganization provided a specific image of neurons activated by substance P. Thus receptor internalization can drive reversible structural changes in central nervous system neurons in vivo. Both of these processes may be involved in neuronal plasticity.	UNIV MINNESOTA, DEPT PSYCHIAT, MINNEAPOLIS, MN 55455 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT SURG, DURHAM, NC 27710 USA; UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, WM KECK FDN CTR INTEGRAT NEUROSCI, SAN FRANCISCO, CA 94143 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	University of Minnesota System; University of Minnesota Twin Cities; Duke University; Duke University; Duke University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Harvard Medical School	MANTYH, PW (corresponding author), VET ADM MED CTR, MOLEC NEUROBIOL LAB 151, MINNEAPOLIS, MN 55417 USA.		mantyh, christopher/AAJ-9140-2021		NINDS NIH HHS [NS23970, NS21445, NS14627] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS023970, R01NS023970, R01NS014627, P50NS021445, P01NS021445] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIGOT D, 1990, NEUROSCI LETT, V111, P275, DOI 10.1016/0304-3940(90)90274-D; BIGOT D, 1991, NEUROSCI LETT, V131, P21, DOI 10.1016/0304-3940(91)90328-Q; BIGOT D, 1991, EUR J NEUROSCI, V3, P551, DOI 10.1111/j.1460-9568.1991.tb00842.x; BOEHMER CG, 1989, PEPTIDES, V10, P1179, DOI 10.1016/0196-9781(89)90011-9; BOWDEN JJ, 1994, P NATL ACAD SCI USA, V91, P8964, DOI 10.1073/pnas.91.19.8964; BRELJE TC, 1989, DIABETES, V38, P808, DOI 10.2337/diabetes.38.6.808; BREWER GJ, 1989, NEUROSCI LETT, V99, P268, DOI 10.1016/0304-3940(89)90458-8; BRIMIJOIN S, 1980, BRAIN RES, V191, P443, DOI 10.1016/0006-8993(80)91293-7; CARON MG, 1993, RECENT PROG HORM RES, V48, P277; CASTEL MN, 1992, NEUROSCIENCE, V50, P269, DOI 10.1016/0306-4522(92)90422-X; COLLINS S, 1992, TRENDS BIOCHEM SCI, V17, P37, DOI 10.1016/0968-0004(92)90425-9; DALSGAARD CJ, 1984, NEUROSCI LETT, V51, P139, DOI 10.1016/0304-3940(84)90275-1; DUBNER R, 1991, PAIN RES CLIN MANAGE, V5, P263; DUGGAN AW, 1991, NEUROSCI LETT, V122, P191, DOI 10.1016/0304-3940(91)90855-N; GARLAND AM, 1994, BIOCHEM J, V303, P177, DOI 10.1042/bj3030177; HOKFELT T, 1975, BRAIN RES, V100, P235, DOI 10.1016/0006-8993(75)90481-3; JACK J, 1979, NEUROSCIENCES 4TH ST, P423; KATZ B, 1966, NERVE MUSCLE SYNAPSE, P12; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; LEFKOWITZ RJ, 1993, ADV SEC MESS PHOSPH, V28, P1; LEVINE JD, 1993, J NEUROSCI, V13, P2273, DOI 10.1523/JNEUROSCI.13-06-02273.1993; LIU HT, 1994, P NATL ACAD SCI USA, V91, P1009, DOI 10.1073/pnas.91.3.1009; MANTYH PW, 1995, J NEUROSCI, V15, P152; MANTYH PW, 1984, NATURE, V309, P795, DOI 10.1038/309795a0; MANTYH PW, 1985, BRAIN RES, V332, P315, DOI 10.1016/0006-8993(85)90600-6; MANTYH PW, UNPUB; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; REUBI JC, 1990, METABOLISM, V39, P78, DOI 10.1016/0026-0495(90)90217-Z; SALTER MW, 1991, NEUROSCIENCE, V43, P601, DOI 10.1016/0306-4522(91)90319-J; SCHAIBLE HG, 1990, BRAIN RES, V529, P214, DOI 10.1016/0006-8993(90)90830-5; SIMONE DA, 1987, BRAIN RES, V418, P201, DOI 10.1016/0006-8993(87)90982-6; SIMONE DA, 1991, J NEUROPHYSIOL, V66, P228, DOI 10.1152/jn.1991.66.1.228; SIMONE DA, 1989, PAIN, V38, P99, DOI 10.1016/0304-3959(89)90079-1; SJODIN L, 1980, ACTA PHYSIOL SCAND, V109, P97, DOI 10.1111/j.1748-1716.1980.tb06570.x; VIGNA SR, 1994, J NEUROSCI, V14, P834; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; WILCOX GL, 1988, ANN NY ACAD SCI, V525, P228, DOI 10.1111/j.1749-6632.1988.tb38608.x; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; YASHPAL K, 1990, BRAIN RES, V506, P259, DOI 10.1016/0006-8993(90)91260-N	39	419	421	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 16	1995	268	5217					1629	1632		10.1126/science.7539937	http://dx.doi.org/10.1126/science.7539937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7539937				2022-12-28	WOS:A1995RD45900041
J	MACMICKING, JD; NATHAN, C; HOM, G; CHARTRAIN, N; FLETCHER, DS; TRUMBAUER, M; STEVENS, K; XIE, QW; SOKOL, K; HUTCHINSON, N; CHEN, H; MUDGETT, JS				MACMICKING, JD; NATHAN, C; HOM, G; CHARTRAIN, N; FLETCHER, DS; TRUMBAUER, M; STEVENS, K; XIE, QW; SOKOL, K; HUTCHINSON, N; CHEN, H; MUDGETT, JS			ALTERED RESPONSES TO BACTERIAL-INFECTION AND ENDOTOXIC-SHOCK IN MICE LACKING INDUCIBLE NITRIC-OXIDE SYNTHASE	CELL			English	Article							METHYL-L-ARGININE; INTERFERON-GAMMA; SEPTIC SHOCK; MOLECULAR-CLONING; LISTERIA-MONOCYTOGENES; MACROPHAGE ACTIVATION; PASSIVE-IMMUNIZATION; MOUSE MACROPHAGES; CARDIAC MYOCYTES; INHIBITION	Mice deficient in inducible nitric oxide synthase (iNOS) were generated to test the idea that iNOS defends the host against infectious agents and tumor cells at the risk of contributing to tissue damage and shock. iNOS(-/-) mice failed to restrain the replication of Listeria monocytogenes in vivo or lymphoma cells in vitro. Bacterial endotoxic lipopolysaccharide (LPS) caused shock and death in anesthetized wild-type mice, but in iNOS(-/-) mice, the fall in central arterial blood pressure was markedly attenuated and early death averted. However, unanesthetized iNOS(-/-) mice suffered as much LPS-induced liver damage as wild type, and when primed with Propionobacterium acnes and challenged with LPS, they succumbed at the same rate as wild type. Thus, there exist both iNOS-dependent and iNOS-independent routes to LPS-induced hypotension and death.	MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT IMMUNOL,RAHWAY,NJ 07065; MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT INFLAMMAT,RAHWAY,NJ 07065; MERCK & CO INC,MERCK SHARP & DOHME RES LABS,ANIM RESOURCES LAB,RAHWAY,NJ 07065; CORNELL UNIV,LAB ANIM RES CTR,NEW YORK,NY 10021	Merck & Company; Merck & Company; Merck & Company; Cornell University	MACMICKING, JD (corresponding author), CORNELL UNIV,COLL MED,DEPT MED,BEATRICE & SAMUEL A SEAVER LAB,NEW YORK,NY 10021, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051967] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI034543, R01AI034543] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51967] Funding Source: Medline; NIAID NIH HHS [AI34543] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLIGAND JL, 1993, J CLIN INVEST, V91, P2314, DOI 10.1172/JCI116461; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; BELENKY SN, 1993, J LEUKOCYTE BIOL, V53, P498, DOI 10.1002/jlb.53.5.498; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BLOCK MI, 1993, J EXP MED, V178, P1085, DOI 10.1084/jem.178.3.1085; BONE RC, 1992, CRIT CARE MED, V20, P884, DOI 10.1097/00003246-199206000-00028; BOOCKVAR KS, 1994, INFECT IMMUN, V62, P1089, DOI 10.1128/IAI.62.3.1089-1100.1994; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; COBB JP, 1992, J EXP MED, V176, P1175, DOI 10.1084/jem.176.4.1175; CONLAN JW, 1994, J EXP MED, V179, P259, DOI 10.1084/jem.179.1.259; CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529; DING AH, 1988, J IMMUNOL, V141, P2407; EVANS TG, 1993, J IMMUNOL, V151, P907; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; FLETCHER DS, 1995, J INTERF CYTOK RES, V15, P243, DOI 10.1089/jir.1995.15.243; FLORQUIN S, 1994, J EXP MED, V180, P1153, DOI 10.1084/jem.180.3.1153; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GRANGER DL, 1991, J IMMUNOL, V146, P1294; GREGORY SH, 1993, J IMMUNOL, V150, P2901; HARBRECHT BG, 1992, J LEUKOCYTE BIOL, V52, P390, DOI 10.1002/jlb.52.4.390; HARBRECHT BG, 1994, HEPATOLOGY, V20, P1055, DOI 10.1002/hep.1840200439; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HIBBS JB, 1990, NITRIC OXIDE L ARGIN, P189; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; KAMIJO R, 1993, J EXP MED, V178, P1435, DOI 10.1084/jem.178.4.1435; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KILBOURN RG, 1990, BIOCHEM BIOPH RES CO, V172, P1132, DOI 10.1016/0006-291X(90)91565-A; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KOHLER J, 1993, J IMMUNOL, V151, P916; LAI CS, 1994, FEBS LETT, V345, P120, DOI 10.1016/0014-5793(94)00422-6; LORENTE JA, 1993, CRIT CARE MED, V21, P1287, DOI 10.1097/00003246-199309000-00010; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MACNAUL KL, 1993, BIOCHEM BIOPH RES CO, V196, P1330, DOI 10.1006/bbrc.1993.2398; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MINNARD EA, 1994, ARCH SURG-CHICAGO, V129, P142; MOHAUPT MG, 1994, KIDNEY INT, V46, P653, DOI 10.1038/ki.1994.318; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUDGETT JS, 1990, GENOMICS, V8, P623, DOI 10.1016/0888-7543(90)90248-S; MUDGETT JS, 1995, IN PRESS ELECTROPORA; MULLIGAN MS, 1991, P NATL ACAD SCI USA, V88, P6338, DOI 10.1073/pnas.88.14.6338; NATANSON C, 1994, ANN INTERN MED, V120, P771, DOI 10.7326/0003-4819-120-9-199405010-00009; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NAVA E, 1991, LANCET, V338, P1555, DOI 10.1016/0140-6736(91)92375-C; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; OHISSON K, 1990, NATURE, V348, P550; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; PASTOR C, 1994, CRIT CARE MED, V22, P465, DOI 10.1097/00003246-199403000-00017; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; PETROS A, 1994, CARDIOVASC RES, V28, P34, DOI 10.1093/cvr/28.1.34; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SALVEMINI D, 1990, P NATL ACAD SCI USA, V87, P6077; SCHILLING J, 1993, INTENS CARE MED, V19, P227, DOI 10.1007/BF01694775; SLADEK SM, 1993, AM J OBSTET GYNECOL, V169, P1285, DOI 10.1016/0002-9378(93)90295-T; STEINMAN RM, 1980, J EXP MED, V151, P1248; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; STUEHR DJ, 1987, J IMMUNOL, V139, P518; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; SZABO C, 1994, P NATL ACAD SCI USA, V91, P12472, DOI 10.1073/pnas.91.26.12472; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; TEALE DM, 1992, J ANTIMICROB CHEMOTH, V30, P839, DOI 10.1093/jac/30.6.839; Thiemermann C, 1994, Adv Pharmacol, V28, P45, DOI 10.1016/S1054-3589(08)60493-7; THIEMERMANN C, 1990, EUR J PHARMACOL, V182, P591, DOI 10.1016/0014-2999(90)90062-B; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95; YALLAMPALLI C, 1994, AM J OBSTET GYNECOL, V170, P175	81	1260	1306	0	31	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					641	650		10.1016/0092-8674(95)90085-3	http://dx.doi.org/10.1016/0092-8674(95)90085-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7538909	hybrid			2022-12-28	WOS:A1995QZ71000021
J	CUNNINGHAM, D; HILL, ME; WATSON, M; NORMAN, AR				CUNNINGHAM, D; HILL, ME; WATSON, M; NORMAN, AR			SURVIVAL AFTER SYSTEMIC THERAPY FOR METASTATIC COLORECTAL-CANCER	LANCET			English	Letter									ROYAL MARSDEN HOSP,GI UNIT,SUTTON SM2 5PT,SURREY,ENGLAND; INST CANC RES,SUTTON SM2 5PT,SURREY,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	CUNNINGHAM, D (corresponding author), ROYAL MARSDEN HOSP,CRC,MED SECT,DOWNS RD,SUTTON SM2 5PT,SURREY,ENGLAND.			Cunningham, David/0000-0001-5158-1069				ALLENMERSH, 1994, LANCET, V344, P1255; HILL ME, 1994, ANN ONCOL, V5, P238; SCHEITHAUER W, 1993, BRIT MED J, V306, P752, DOI 10.1136/bmj.306.6880.752	3	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					328	329		10.1016/S0140-6736(95)90321-6	http://dx.doi.org/10.1016/S0140-6736(95)90321-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7530796				2022-12-28	WOS:A1995QE73100060
J	PERRINFAYOLLE, M				PERRINFAYOLLE, M			SALBUTAMOL IN THE TREATMENT OF ASTHMA	LANCET			English	Letter											PERRINFAYOLLE, M (corresponding author), CTR HOSP LYON SUD,F-69230 ST GENIS LAVAL,FRANCE.							COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; MAZZONI L, 1994, PULM PHARMACOL, V7, P367, DOI 10.1006/pulp.1994.1043; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; WALLE UK, 1993, BRIT J CLIN PHARMACO, V35, P413, DOI 10.1111/j.1365-2125.1993.tb04159.x; WANG ZL, 1994, AM J RESP CRIT CARE, V149, P960, DOI 10.1164/ajrccm.149.4.8143062	5	45	45	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1101	1101		10.1016/S0140-6736(95)91775-6	http://dx.doi.org/10.1016/S0140-6736(95)91775-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564810				2022-12-28	WOS:A1995TA69700048
J	KIMMEL, SE; BERLIN, JA; LASKEY, WK				KIMMEL, SE; BERLIN, JA; LASKEY, WK			THE RELATIONSHIP BETWEEN CORONARY ANGIOPLASTY PROCEDURE VOLUME AND MAJOR COMPLICATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIAC-ANGIOGRAPHY; SURGICAL VOLUME; REGISTRY; INTERVENTIONS; OPERATIONS; MORTALITY; SURGERY; SOCIETY	Objective.-To assess the relationship between the volume of percutaneous transluminal coronary angioplasty (PTCA) procedures performed in a cardiac catheterization laboratory and major complications after adjusting for case mix and to evaluate the applicability of current guidelines for minimum laboratory volume. Design.-Cohort study using the 1992 and 1993 registries of the Society for Cardiac Angiography and Interventions. Setting.-Forty-eight cardiac catheterization laboratories from throughout the United States and Canada. Patients.-All 19 594 consecutive patients without an acute myocardial infarction (MI) undergoing a first coronary balloon angioplasty. Main Outcome Measures.-Emergency bypass surgery, MI, or in-hospital death. Results.-There was a significant decrease in the rates of in-hospital mortality (P=.04), emergency bypass surgery (P<.001), MI (P=.001), and major complications (defined as one or more of these outcomes; P<.001) with increasing cardiac catheterization laboratory volume. After adjustment for case mix using multivariable analysis, these associations persisted, although the association with mortality was no longer statistically significant. There was no significant difference in outcomes in laboratories performing at least 200 vs fewer than 200 procedures per year, the currently recommended minimum laboratory volume (odds ratio [OR] for major complications, 0.81; 95% confidence interval [CI], 0.53 to 1.25). However, a statistically significant decrease in major complications was observed in laboratories performing more than 400 procedures per year (adjusted OR, 0.66; 95% CI, 0.46 to 0.96; P=.03; and OR, 0.54; 95% CI, 0.38 to 0.78; P=.001) when laboratories performing 400 through 599 procedures and at least 600 procedures per year, respectively, are compared with those performing fewer than 200 per year. Conclusions.-An inverse association between cardiac catheterization laboratory procedure volume and major complications during PTCA exists independent of differences in patients' risk profiles. Our data suggest that the currently recommended minimum laboratory volume may be too low to distinguish higher-risk from lower-risk laboratories.	HOSP UNIV PENN,DEPT MED,DIV CARDIOVASC,PHILADELPHIA,PA; UNIV PENN,SCH MED,CTR CLIN EPIDEMIOL & BIOSTAT,PHILADELPHIA,PA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine								ANDERSON HV, 1991, COMPLICATIONS CORONA, P88; CAMERON DE, 1990, ANN THORAC SURG, V50, P35, DOI 10.1016/0003-4975(90)90078-K; Fleiss J, 1981, STAT METHODS RATES P, P38; HANNAN EL, 1991, MED CARE, V29, P1094, DOI 10.1097/00005650-199111000-00003; HARTZ AJ, 1992, AM J PUBLIC HEALTH, V82, P1631, DOI 10.2105/AJPH.82.12.1631; HOLMES D, 1991, CIRCULATION, V84, P1828, DOI 10.1161/01.CIR.84.4.1828; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; JOLLIS JG, 1994, NEW ENGL J MED, V331, P1625, DOI 10.1056/NEJM199412153312406; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KRONE RJ, 1993, CIRCULATION, V88, P300; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; MIETTINEN OS, 1976, AM J EPIDEMIOL, V104, P609, DOI 10.1093/oxfordjournals.aje.a112339; MOCK MB, 1984, AM J CARDIOL, V53, pC67, DOI 10.1016/0002-9149(84)90749-5; NOTO TJ, 1991, CATHETER CARDIO DIAG, V24, P75, DOI 10.1002/ccd.1810240202; RITCHIE JL, 1993, CIRCULATION, V88, P2735, DOI 10.1161/01.CIR.88.6.2735; ROUBIN GS, 1986, AM J CARDIOL, V57, P873, DOI 10.1016/0002-9149(86)90630-2; RYAN TJ, 1993, CIRCULATION, V88, P2987, DOI 10.1161/01.CIR.88.6.2987; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P785, DOI 10.1001/jama.257.6.785	18	164	164	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1137	1142		10.1001/jama.274.14.1137	http://dx.doi.org/10.1001/jama.274.14.1137			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563484				2022-12-28	WOS:A1995RY05600028
J	RAO, JK; ALLEN, NB; FEUSSNER, JR; WEINBERGER, M				RAO, JK; ALLEN, NB; FEUSSNER, JR; WEINBERGER, M			A PROSPECTIVE-STUDY OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (C-ANCA) AND CLINICAL-CRITERIA IN DIAGNOSING WEGENERS GRANULOMATOSIS	LANCET			English	Article							ANTICYTOPLASMIC AUTOANTIBODIES; TEMPORAL ARTERITIS; GLOMERULONEPHRITIS; CLASSIFICATION; DISEASE; TESTS; BIAS	Antineutrophil cytoplasmic antibody (c-ANCA) has a reported sensitivity and specificity greater than 90% for active Wegener's granulomatosis in selected patients with previously-defined disease. Because of these reports, some clinicians believe that a positive c-ANCA result provides strong circumstantial evidence for the diagnosis of Wegener's granulomatosis in patients with compatible clinical symptoms. However, this approach has not been examined prospectively. We prospectively studied 346 consecutive patients suspected of having vasculitis; those with previously established Wegener's granulomatosis (n=29) or receiving immunosuppressives other than corticosteroids (n=65) at baseline were excluded. Measures included a baseline cANCA, blinded chart reviews to record symptoms, physical findings, and corticosteroid use at baseline, and 2 to 8 months later to record final diagnoses and biopsy results. Wegener's granulomatosis was defined using the 1990 American College of Rheumatology (ACR) criteria, which does not require a biopsy. Follow-up information was available for 212 (84%) of the 252 patients eligible for this study (no corticosteroids: n=174; corticosteroids: n=78). 25 patients with compatible symptoms were classified with Wegener's granulomatosis by ACR criteria; only 6 of the 25 had biopsy-proven disease. 14 of these 212 patients had positive c-ANCA results. The overall sensitivity of c-ANCA for ACR-defined Wegener's granulomatosis were 28% (95% CI, 10%-46%) and 96% respectively. The positive and negative and 0.91. The specificity regardless of baseline corticosteroid use or disease activity; however, the sensitivity and positive predictive value remained poor. For Wegener's granulomatosis defined by biopsy criteria and compatible clinical symptoms, the sensitivity was 83% (53%-100%); however, the positive predictive value was 36%. These results raise serious questions about the use of positive c-ANCA tests in diagnosing Wegener's granulomatosis in patients with clinical symptoms alone.	VET AFFAIRS MED CTR,CTR HLTH SERV RES PRIMARY CARE,DURHAM,NC 27705; DUKE UNIV,MED CTR,DIV RHEUMATOL & IMMUNOL,DURHAM,NC; DUKE UNIV,MED CTR,DIV GEN INTERNAL MED,DURHAM,NC 27710	US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; Duke University	RAO, JK (corresponding author), RICHARD L ROUDEBUSH VET AFFAIRS MED CTR,1481 W 10TH ST,INDIANAPOLIS,IN 46208, USA.							ANDRASSY K, 1989, CLIN NEPHROL, V32, P159; AYMARD B, 1990, DIS COLON RECTUM, V33, P427, DOI 10.1007/BF02156272; BEGG CB, 1988, RADIOLOGY, V167, P565, DOI 10.1148/radiology.167.2.3357976; BRAY VJ, 1991, AM J KIDNEY DIS, V17, P578, DOI 10.1016/S0272-6386(12)80500-2; COHENTERVAERT JW, 1991, AM J MED, V91, P59; DAVENPORT A, 1992, CLIN NEPHROL, V37, P124; DAVIES DJ, 1982, BMJ-BRIT MED J, V285, P606, DOI 10.1136/bmj.285.6342.606; DEREMEE RA, 1976, MAYO CLIN PROC, V51, P777; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; GROSS WL, 1986, LANCET, V1, P806; HAYNES BF, 1986, MED CLIN N AM, V70, P355, DOI 10.1016/S0025-7125(16)30958-0; HERREROBEAUMONT G, 1991, BRIT J RHEUMATOL, V30, P382; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; JENNETTE J C, 1992, Current Opinion in Rheumatology, V4, P9; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807; LICHTENSTEIN MJ, 1988, J GEN INTERN MED, V3, P435, DOI 10.1007/BF02595919; MAINS B, 1989, J LARYNGOL OTOL, V103, P524, DOI 10.1017/S0022215100156774; MANDELL BF, 1994, RHEUM DIS CLIN N AM, V20, P409; MUSTONEN J, 1990, AM J NEPHROL, V10, P482, DOI 10.1159/000168173; NOLLE B, 1989, ANN INTERN MED, V111, P28, DOI 10.7326/0003-4819-111-1-28; ONEIL KM, 1992, DIGEST DIS SCI, V37, P702, DOI 10.1007/BF01296425; PALAIC M, 1991, NEUROLOGY, V41, P1694, DOI 10.1212/WNL.41.10.1694-a; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; SHMERLING RH, 1992, ARCH INTERN MED, V152, P2417, DOI 10.1001/archinte.152.12.2417; SMALL P, 1991, ARTHRITIS RHEUM, V34, P220, DOI 10.1002/art.1780340215; SPECKS U, 1989, MAYO CLIN PROC, V64, P28, DOI 10.1016/S0025-6196(12)65300-2; VANDERWOUDE FJ, 1985, LANCET, V1, P425; VANDERWOUDE FJ, 1985, LANCET, V2, P48; 1989, APMIS S, V97, P5	29	94	98	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					926	931		10.1016/S0140-6736(95)91555-9	http://dx.doi.org/10.1016/S0140-6736(95)91555-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564726				2022-12-28	WOS:A1995RY80800007
J	JENSEN, TJ; LOO, MA; PIND, S; WILLIAMS, DB; GOLDBERG, AL; RIORDAN, JR				JENSEN, TJ; LOO, MA; PIND, S; WILLIAMS, DB; GOLDBERG, AL; RIORDAN, JR			MULTIPLE PROTEOLYTIC SYSTEMS, INCLUDING THE PROTEASOME, CONTRIBUTE TO CFTR PROCESSING	CELL			English	Article							CYSTIC-FIBROSIS GENE; TRANSMEMBRANE CONDUCTANCE REGULATOR; ENDOPLASMIC-RETICULUM; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; RAPID DEGRADATION; SWEAT GLAND; PROTEIN; CELLS; IDENTIFICATION; COMPARTMENT	The molecular components of the quality control system that rapid ly degrades abnormal membrane and secretory proteins have not been identified. The cystic fibrosis transmembrane conductance regulator (CFTR) is an integral membrane protein to which this quality control is stringently applied; similar to 75% of the wild-type precursor and 100% of the Delta F508 CFTR variant found in most CF patients are rapid ly degraded before exiting from the ER. We now show that this ER degradation is sensitive to inhibitors of the cytosolic proteasome, including lactacystin and certain peptide aldehydes. One of the latter compounds, MG-132, also completely blocks the ATP-dependent conversion of the wild-type precursor to the native folded form that enables escape from degradation. Hence, CFTR and presumably other intrinsic membrane proteins are substrates for proteasomal degradation during their maturation within the ER.	UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	University of Toronto; Harvard University; Harvard Medical School	JENSEN, TJ (corresponding author), MAYO CLIN SCOTTSDALE,SC JOHNSON MED RES CTR,13400 E SHEA BLVD,SCOTTSDALE,AZ 85259, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049184] Funding Source: NIH RePORTER; NIDDK NIH HHS [P50-DK49184] Funding Source: Medline; PHS HHS [46147] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADELI K, 1994, J BIOL CHEM, V269, P9166; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COHN JA, 1991, BIOCHEM BIOPH RES CO, V181, P36, DOI 10.1016/S0006-291X(05)81378-6; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DIAMOND G, 1991, J BIOL CHEM, V266, P22761; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GARDNER AM, 1993, J BIOL CHEM, V268, P25940; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; GOLDBERG AL, 1995, IN PRESS CURR BIOL; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOU D, 1994, J BIOL CHEM, V269, P14244; INOUE S, 1992, J BIOL CHEM, V267, P9080; INOUE S, 1991, J BIOL CHEM, V266, P13311; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; LOO TW, 1994, J BIOL CHEM, V269, P28683; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PIND S, 1994, J BIOL CHEM, V269, P12784; RIORDAN JR, 1994, J EXP BIOL, V196, P405; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SHERMAN M, 1995, IN PRESS STRESS INDU; SHERMAN MY, 1992, EMBO J, V11, P71; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; WARD CL, 1994, J BIOL CHEM, V269, P25710; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; WILEMAN T, 1991, CELL REGUL, V2, P753, DOI 10.1091/mbc.2.9.753; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480	44	742	757	1	25	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					129	135		10.1016/0092-8674(95)90241-4	http://dx.doi.org/10.1016/0092-8674(95)90241-4			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553864	Bronze			2022-12-28	WOS:A1995RY58300017
J	MARTINEZBALBAS, MA; DEY, A; RABINDRAN, SK; OZATO, K; WU, C				MARTINEZBALBAS, MA; DEY, A; RABINDRAN, SK; OZATO, K; WU, C			DISPLACEMENT OF SEQUENCE-SPECIFIC TRANSCRIPTION FACTORS FROM MITOTIC CHROMATIN	CELL			English	Article							LIGATION-MEDIATED PCR; HEAT-SHOCK FACTOR; CELL-CYCLE; DNASE-I; HISTONE MODIFICATIONS; NUCLEAR-PROTEIN; EXPRESSION; ACETYLATION; BINDING; GENE	The general inhibition in transcriptional activity during mitosis abolishes the stress-inducible expression of the human hsp70 gene. Among the four transcription factors that bind to the human hsp70 promoter, the DNA-binding activities of three (C/EBP, GBF, and HSF1) were normal, while Sp1 showed reduced binding activity in mitotic cell extracts. In vivo footprinting and immunocytochemical analyses revealed that all of the sequence-specific transcription factors were displaced from promoter sequences as well as from bulk chromatin during mitosis. The correlation of transcription factor displacement with chromatin condensation suggests an involvement of chromatin structure in mitotic repression. However, retention of DNase I hypersensitivity suggests that the hsp70 promoter was not organized in a canonical nucleosome structure in mitotic chromatin. Displacement of transcription factors from mitotic chromosomes could present another window in the cell cycle for resetting transcriptional programs.	NICHHD, MOLEC GROWTH REGULAT LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	MARTINEZBALBAS, MA (corresponding author), NCI, BIOCHEM LAB, BETHESDA, MD 20892 USA.			Martinez-Balbas, Marian/0000-0003-0173-0964				ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; BECKER PB, 1994, BIOESSAYS, V16, P541, DOI 10.1002/bies.950160807; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRADBURY EM, 1992, BIOESSAYS, V14, P9; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; CHAHAL SS, 1980, NATURE, V287, P76, DOI 10.1038/287076a0; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; DANNA JA, 1983, EXP CELL RES, V147, P407, DOI 10.1016/0014-4827(83)90222-7; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; DEY A, 1992, MOL CELL BIOL, V12, P3590, DOI 10.1128/MCB.12.8.3590; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GOTTESFELD JM, 1994, SCIENCE, V263, P81, DOI 10.1126/science.8272869; HAHN GM, 1993, CANCER MED, P566; HAPGOOD J, 1994, MOL CELL BIOL, V14, P1402, DOI 10.1128/MCB.14.2.1402; HARTL P, 1993, J CELL BIOL, V120, P613, DOI 10.1083/jcb.120.3.613; HOUGAARD DM, 1988, EUR J CELL BIOL, V45, P311; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JEPPESEN P, 1992, CHROMOSOMA, V101, P322, DOI 10.1007/BF00346011; JOHNSON TC, 1965, J CELL BIOL, V27, P565, DOI 10.1083/jcb.27.3.565; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KRAWCZYK Z, 1987, ANAL BIOCHEM, V165, P20, DOI 10.1016/0003-2697(87)90195-3; KUO MT, 1982, NUCLEIC ACIDS RES, V10, P4565, DOI 10.1093/nar/10.15.4565; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; LITTAU VC, 1964, P NATL ACAD SCI USA, V52, P93, DOI 10.1073/pnas.52.1.93; MATTHEWS HR, 1993, BIOESSAYS, V15, P561, DOI 10.1002/bies.950150811; MCCORMICK F, 1978, ANAL BIOCHEM, V89, P87; MCGHEE JD, 1979, P NATL ACAD SCI USA, V76, P2133, DOI 10.1073/pnas.76.5.2133; McKnight SL, 1992, TRANSCRIPTIONAL REGU, P771; MIRZABEKOV AD, 1977, EUR J BIOCHEM, V75, P379, DOI 10.1111/j.1432-1033.1977.tb11539.x; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PETERSON CL, 1994, CELL, V79, P389, DOI 10.1016/0092-8674(94)90247-X; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; ROBERTS SB, 1991, SCIENCE, V253, P1022, DOI 10.1126/science.1887216; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; ROTHE M, 1992, NATURE, V359, P156, DOI 10.1038/359156a0; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHMID N, 1991, BIOCHEMISTRY-US, V30, P4357, DOI 10.1021/bi00231a035; SCHWARZ PM, 1994, J BIOL CHEM, V269, P16284; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; STEIN GS, 1972, J CELL BIOL, V52, P292, DOI 10.1083/jcb.52.2.292; TAYLOR JH, 1960, ANN NY ACAD SCI, V90, P409, DOI 10.1111/j.1749-6632.1960.tb23259.x; TURNER BM, 1989, EUR J BIOCHEM, V179, P131, DOI 10.1111/j.1432-1033.1989.tb14530.x; TURNER BM, 1989, EXP CELL RES, V182, P206, DOI 10.1016/0014-4827(89)90292-9; WEMMER DE, 1985, J MOL BIOL, V185, P457, DOI 10.1016/0022-2836(85)90418-8; WESTRA A, 1971, INT J RADIAT BIOL RE, V19, P467, DOI 10.1080/09553007114550601; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WIDOM J, 1986, J MOL BIOL, V190, P411, DOI 10.1016/0022-2836(86)90012-4; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; WU C, 1989, METHOD ENZYMOL, V170, P269; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; Wu C., 1994, BIOL HEAT SHOCK PROT, P395; WU C, 1994, METHOD ENZYMOL, P395; YE BHH, 1993, CANCER RES, V53, P2732	68	354	355	1	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 6	1995	83	1					29	38		10.1016/0092-8674(95)90231-7	http://dx.doi.org/10.1016/0092-8674(95)90231-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553870	Bronze			2022-12-28	WOS:A1995RY58300007
J	LEVY, DT; VERNICK, JS; HOWARD, KA				LEVY, DT; VERNICK, JS; HOWARD, KA			RELATIONSHIP BETWEEN DRIVERS LICENSE RENEWAL POLICIES AND FATAL CRASHES INVOLVING DRIVERS 70 YEARS OR OLDER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AGE; INVOLVEMENT; SAFETY; YOUTH	Objective.-To assess the relationship between state driver's license renewal policies and fatal crashes involving drivers aged 70 years or older (seniors). Design and Analysis.-Poisson regression methods were used to isolate the relationship between different state policies mandating vision tests, knowledge tests, or road tests for driver's license renewal and fatal crashes involving senior drivers. The analysis controlled for differences among states, other than their renewal policies, likely to influence senior motor vehicle crashes. Setting.-United States, 1985 through 1989. Participants.-All fatal crashes identified in the National Highway Traffic Safety Administration Fatal Accident Reporting System involving at least one driver aged 70 years or older. Main Outcome Measure.-The number of fatal crashes per state in which at least one of the drivers was aged 70 years or older. When a single fatal crash involved more than one senior driver, each was included. Results.-State-mandated tests of visual acuity, adjusted for license renewal period, were associated with lower fatal crash risk for senior drivers (relative risk, 0.93; 95% confidence interval, 0.89 to 0.97). Knowledge tests, when added to vision tests and applied only to seniors, provided a nonsignificant reduction in the senior fatal crash risk (relative risk, 0.91; 95% confidence interval, 0.79 to 1.05). Conclusion.-Tests of vision and knowledge for senior drivers at license renewal merit further attention as a means of improving senior traffic safety.	JOHNS HOPKINS UNIV,CTR INJURY RES & POLICY,SCH HYG & PUBL HLTH,BALTIMORE,MD	Johns Hopkins University	LEVY, DT (corresponding author), UNIV BALTIMORE,ROBERT G MERRICK SCH BUSINESS,DEPT ECON,1420 N CHARLES ST,BALTIMORE,MD 21201, USA.				PHS HHS [R49/CCR304542-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANNAPOLLE J, 1992, SURVEY LICENSING PRO; ASCH P, 1987, J POLICY ANAL MANAG, V2, P180; BAKER S, 1991, INJURY FACT BOOK; BARR RA, 1991, HUM FACTORS, V33, P597, DOI 10.1177/001872089103300510; BRESLOW NE, 1984, APPL STAT-J ROY ST C, V33, P38; CAMERON A, 1986, J APPL EC, V1, P1; CERRELLI EC, 1989, 807402 US DEP TRANSP; CHANG BH, 1993, ACCIDENT ANAL PREV, V25, P85, DOI 10.1016/0001-4575(93)90099-I; COX J, 1989, ASSESSING DRIVING AB; EVANS L, 1988, J GERONTOL, V43, pS186, DOI 10.1093/geronj/43.6.S186; FITTEN LJ, 1995, JAMA-J AM MED ASSOC, V273, P1360, DOI 10.1001/jama.273.17.1360; GREENE W, 1992, LIMDEP; Greene W.H, 2002, ECONOMETRIC ANAL, Vfourth; GROEMPLING U, 1993, GEE MACRO SAS VERSIO; HAWLEY HV, 1989, 807443 US DEP TRANSP; KELSEY SL, 1985, J SAFETY RES, V16, P149, DOI 10.1016/0022-4375(85)90002-7; KELTNER JL, 1987, OPHTHALMOLOGY, V94, P1180; LAUER AR, 1964, ACCIDENT RES METHODS; LEVY D, 1988, RISK ANAL, V8, P565; LEVY DT, 1995, ACCIDENT ANAL PREV, V27, P461, DOI 10.1016/0001-4575(94)00081-V; LEVY DT, 1990, ACCIDENT ANAL PREV, V22, P327, DOI 10.1016/0001-4575(90)90048-P; LEVY DT, 1989, AM ECON REV, V79, P913; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; MOURANT RR, 1973, ACCIDENT ANAL PREV, V11, P247; NELSON DE, 1992, NEW ENGL J MED, V326, P1784; PETRUCELLI E, 1992, STATUS MED REV DRIVE; PLANEK TW, 1972, AGING HIGHWAY SAFETY, V7, P3; Retchin S M, 1993, Clin Geriatr Med, V9, P279; SAFFER H, 1987, J LEGAL STUD, V16, P351, DOI 10.1086/467834; SIVAK M, 1982, ACCIDENT ANAL PREV, V14, P87, DOI 10.1016/0001-4575(82)90075-6; STUTTS JC, 1992, ACCIDENT ANAL PREV, V24, P317, DOI 10.1016/0001-4575(92)90044-J; TASCA L, 1992, REV LIT SENIOR DRIVI; TEMPLE LL, 1992, GRADUATED LICENSING; WILLIAMS AF, 1989, AM J PUBLIC HEALTH, V79, P326, DOI 10.2105/AJPH.79.3.326; YANIK AJ, 1985, 851688 SOC AUT ENG T; ZAIDEL DM, 1986, J SAFETY RES, V17, P111, DOI 10.1016/0022-4375(86)90025-3; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1992, DRIVER LICENSE ADM R; 1985, HIGHWAY STATISTICS; 1982, COMP DATA STATE PROV; 1989, HIGHWAY STATISTICS; 1988, HLTH PROMOTION AGING; 1993, 808022 US DEP TRANSP; 1986, COMP DATA STATE PROV; 1984, DRIVER LICENSE ADM R; 1986, DRIVER LICENSE ADM R; 1986, STATISTICAL ABSTRACT; 1985, STATISTICAL ABSTRACT; 1988, DRIVER LICENSE ADM R; 1990, DRIVER LICENSE ADM R; 1992, GRADUATED DRIVER LIC; 1984, COMP DATA STATE PROV; 1987, HIGHWAY STATISTICS; 1988, HIGHWAY STATISTICS; 1988, 218 NAT RES COUNC RE, V2; 1989, STATISTICAL ABSTRACT; 1988, 218 NAT RES COUNC RE, V1; 1988, STATISTICAL ABSTRACT; [No title captured]; 1986, HIGHWAY STATISTICS	60	67	67	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1026	1030		10.1001/jama.274.13.1026	http://dx.doi.org/10.1001/jama.274.13.1026			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RX108	7563452				2022-12-28	WOS:A1995RX10800024
J	SINGARAM, C; ASHRAF, W; GAUMNITZ, EA; TORBEY, C; SENGUPTA, A; PFEIFFER, R; QUIGLEY, EMM				SINGARAM, C; ASHRAF, W; GAUMNITZ, EA; TORBEY, C; SENGUPTA, A; PFEIFFER, R; QUIGLEY, EMM			DOPAMINERGIC DEFECT OF ENTERIC NERVOUS-SYSTEM IN PARKINSONS-DISEASE PATIENTS WITH CHRONIC CONSTIPATION	LANCET			English	Article							PEPTIDERGIC INNERVATION; LEWY BODIES; NEURONS	Clinical studies suggest that gut disorders are common in Parkinson's disease, but the morphological basis is unknown. Depletion of dopamine-containing neurons in the central nervous system is a basic defect in Parkinson's disease. We compared colonic tissue from 11 patients with advanced Parkinson's disease, 17 with adenocarcinoma (normal tissue was studied), and five who underwent colectomy for severe constipation. Immunohistochemistry was used to stain myenteric and submucosal neurons for dopamine, tyrosine hydroxylase, and vasoactive intestinal polypeptide (VIP). Each class of neurons was quantified as a percentage of the total neuronal population stained for the marker protein gene product 9.5. Nine of the 11 Parkinson's disease patients had substantially fewer dopaminergic myenteric neurons than the other subjects (mean 0.4 [SE 0.2] vs 6.9 [2.3] in controls and 5.7 [2.0] in constipated subjects). There was very little difference between the groups in numbers of tyrosine-hydroxylase and VIP neurons. Two Parkinson's disease patients had similar distributions of all types of neurons, including dopaminergic myenteric neurons, to the controls. High-performance liquid chromatography showed lower levels of dopamine in the muscularis externa (but not mucosa) in four Parkinson's disease patients than in four controls (7.3 [5.1] vs 24.2 [4.6] nmol per g protein), but levels of dopamine metabolites were similar in the two groups. The identification of this defect of dopaminergic neurons in the enteric nervous system in Parkinson's disease may lead to better treatment of colorectal dysfunction in this disease.	UNIV NEBRASKA,MED CTR,DEPT INTERNAL MED,OMAHA,NE; BOSTON UNIV,SCH MED,DIV PEDIAT GASTROENTEROL & NUTR,BOSTON,MA 02118; UNIV TENNESSEE,COLL MED,DEPT NEUROL,MEMPHIS,TN	University of Nebraska System; University of Nebraska Medical Center; Boston University; University of Tennessee System; University of Tennessee Health Science Center	SINGARAM, C (corresponding author), UNIV WISCONSIN,DEPT INTERNAL MED,DIV GASTROENTEROL,H6-516,CSC,600 HIGHLAND AVE,MADISON,WI 53705, USA.							CAPURSO L, 1968, GUT, V9, P678, DOI 10.1136/gut.9.6.678; EDWARDS LL, 1992, NEUROLOGY, V42, P726, DOI 10.1212/WNL.42.4.726; GAUMNITZ E, 1995, NEUROPEPTIDES, V29, P1, DOI 10.1016/0143-4179(95)90050-0; KUPSKY WJ, 1987, NEUROLOGY, V37, P1253, DOI 10.1212/WNL.37.7.1253; LOWRY OH, 1951, J BIOL CHEM, V193, P265; QUALMAN SJ, 1984, GASTROENTEROLOGY, V87, P848; SCHULTZBERG M, 1980, NEUROSCIENCE, V5, P639; SINGARAM C, 1990, J AUTONOM NERV SYST, V29, P231, DOI 10.1016/0165-1838(90)90149-D; SINGARAM C, 1991, GASTROENTEROLOGY, V101, P1256, DOI 10.1016/0016-5085(91)90075-V; TUNEKAWA K, 1970, SAIISHIN IGAKU, V25, P2068; WAKABAYASHI K, 1990, ACTA NEUROPATHOL, V79, P581, DOI 10.1007/BF00294234; WAKABAYASHI K, 1989, NEUROSCI LETT, V96, P259, DOI 10.1016/0304-3940(89)90388-1	12	261	274	1	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 30	1995	346	8979					861	864		10.1016/S0140-6736(95)92707-7	http://dx.doi.org/10.1016/S0140-6736(95)92707-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX196	7564669				2022-12-28	WOS:A1995RX19600007
J	IPUGE, YAI; RIEDER, HL; ENARSON, DA				IPUGE, YAI; RIEDER, HL; ENARSON, DA			ADVERSE CUTANEOUS REACTIONS TO THIACETAZONE FOR TUBERCULOSIS TREATMENT IN TANZANIA	LANCET			English	Article							HYPERSENSITIVITY REACTIONS; PULMONARY TUBERCULOSIS; HIV-INFECTION; CHEMOTHERAPY	Because thiacetazone has been linked with serious adverse cutaneous reactions, we undertook 1 year of systematic surveillance for cutaneous thiacetazone-associated adverse reactions within the national tuberculosis programme of Tanzania, For individual cases, we collected information on age, sex, interval between commencing thiacetazone-containing treatment and occurrence of adverse reaction, most severe clinical presentation (toxic epidermal necrolysis, rash without necrolysis, itching without rash), and outcome (dead or alive) within 2 weeks of onset, Univariate and multivariate analyses were done of variables relevant to outcome. 1273 patients with adverse reactions were reported, The frequency of fatal outcome from any cutaneous reaction was 3.1 per 1000 among all tuberculosis patients, and 19.1% among patients with toxic epidermal necrolysis. About 60% of all adverse reactions and deaths occurred within 20 days of starling thiacetazone. Case fatality from adverse cutaneous reactions was considerably less frequent than reported previously, suggesting that improved management might allow retention of thiacetazone in the armamentarium of national tuberculosis programmes even where infection with HIV is prevalent,	MINIST HLTH,TANZANIA NATL TB LEPROSY PROGRAMME,DAR ES SALAAM,TANZANIA; INT UNION AGAINST TB & LUNG DIS,PARIS,FRANCE									[Anonymous], 1980, Tubercle, V61, P59; [Anonymous], 1983, Tubercle, V64, P153; Chum H. J., 1994, Tubercle and Lung Disease, V75, P24, DOI 10.1016/0962-8479(94)90769-2; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P1082, DOI 10.1164/ajrccm/139.5.1082; DATTA M, 1993, TUBERCLE LUNG DIS, V74, P180, DOI 10.1016/0962-8479(93)90008-L; DOMAGK G, 1946, NATURWISSENSCHAFTEN, V33, P315, DOI 10.1007/BF00624524; DUKES CS, 1992, TROP GEOGR MED, V44, P308; ELLIOTT AM, 1990, BRIT MED J, V301, P412, DOI 10.1136/bmj.301.6749.412; Enarson D A, 1991, Bull Int Union Tuberc Lung Dis, V66, P195; ENARSON DA, 1994, TUBERCULOSIS GUIDE L; ERIKI PP, 1991, AM REV RESPIR DIS, V143, P185, DOI 10.1164/ajrccm/143.1.185; KELLY P, 1994, T ROY SOC TROP MED H, V88, P113, DOI 10.1016/0035-9203(94)90529-0; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; LUO C, 1994, TUBERCLE LUNG DIS, V75, P110, DOI 10.1016/0962-8479(94)90039-6; Miller A B, 1966, Tubercle, V47, P33; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; NUNN P, 1993, T ROY SOC TROP MED H, V87, P578, DOI 10.1016/0035-9203(93)90096-9; NUNN P, 1991, LANCET, V337, P627; RAVIGLIONE MC, 1988, ARCH INTERN MED, V148, P2683, DOI 10.1001/archinte.148.12.2683; Rouillon A, 1991, Bull Int Union Tuberc Lung Dis, V66, P159; 1960, TUBERCLE, V41, P399; 1987, MANUAL NATIONAL TUBE; 1993, 29 INT UN TUB LUNG D; 1966, TUBERCLE, V47, P315; 1963, TUBERCLE, V44, P301; 1966, TUBERCLE, V47, P1; 1994, 32 INT UN TUB LUNG D; 1970, TUBERCLE, V51, P123; 1985, AM REV RESPIR DIS, V131, P727	29	16	16	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					657	660		10.1016/S0140-6736(95)92278-4	http://dx.doi.org/10.1016/S0140-6736(95)92278-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7544858				2022-12-28	WOS:A1995RU04800007
J	SAEZ, E; RUTBERG, SE; MUELLER, E; OPPENHEIM, H; SMOLUK, J; YUSPA, SH; SPIEGELMAN, BM				SAEZ, E; RUTBERG, SE; MUELLER, E; OPPENHEIM, H; SMOLUK, J; YUSPA, SH; SPIEGELMAN, BM			C-FOS IS REQUIRED FOR MALIGNANT PROGRESSION OF SKIN TUMORS	CELL			English	Article							MOUSE SKIN; TRANSGENIC MICE; GENE-EXPRESSION; CELL CARCINOMAS; PHORBOL ESTERS; RETINOIC ACID; NULL MUTATION; BENIGN-TUMORS; HUMAN-BREAST; JUN	The proto-oncogene c-fos is a major nuclear target for signal transduction pathways involved in the regulation of cell growth, differentiation, and transformation. Using the multistep skin carcinogenesis model, we have directly tested the ability of c-fos-deficient mice to develop cancer. Upon treatment with a tumor promoter, c-fos knockout mice carrying a v-H-ras transgene were able to develop benign tumors with similar kinetics and relative incidence as wild-type animals. However, c-fos-deficient papillomas quickly became very dry and hyperkeratinized, taking on an elongated, horny appearance. While wild-type papillomas eventually progressed into malignant tumors, c-fos-deficient tumors failed to undergo malignant conversion. Experiments in which v-H-ras-expressing keratinocytes were grafted onto nude mice suggest that c-fos-deficient cells have an intrinsic defect that hinders tumorigenesis. These results demonstrate that a member of the AP-1 family of transcription factors is required for the development of a malignant tumor.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20892	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SAEZ, E (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027295] Funding Source: NIH RePORTER; NICHD NIH HHS [HD27295] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BIUNNO I, 1988, BRIT J CANCER, V57, P464, DOI 10.1038/bjc.1988.108; BORCHERS AH, 1994, EXP CELL RES, V213, P143, DOI 10.1006/excr.1994.1183; BREMNER R, 1994, MOL CARCINOGEN, V11, P90, DOI 10.1002/mc.2940110206; BUCHMANN A, 1991, CANCER RES, V51, P4097; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DE LUCA LM, 1993, CARCINOGENESIS, V14, P539, DOI 10.1093/carcin/14.3.539; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; FISHER C, 1991, DEVELOPMENT, V11, P253; FRENCH JE, 1994, MOL CARCINOGEN, V11, P215, DOI 10.1002/mc.2940110407; GIMENEZCONTI I, 1990, CARCINOGENESIS, V11, P1995, DOI 10.1093/carcin/11.11.1995; HANSEN LA, 1994, MOL CARCINOGEN, V9, P143, DOI 10.1002/mc.2940090306; HANSEN LA, 1994, P NATL ACAD SCI USA, V91, P7822, DOI 10.1073/pnas.91.16.7822; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HENNINGS H, 1993, P SOC EXP BIOL MED, V202, P1; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HONOKI K, 1992, MOL CARCINOGEN, V6, P122, DOI 10.1002/mc.2940060207; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; KLEINSZANTO AJP, 1989, CARCINOGENESIS, V10, P2169, DOI 10.1093/carcin/10.11.2169; KRIEG P, 1988, CARCINOGENESIS, V9, P95, DOI 10.1093/carcin/9.1.95; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Liotta L A, 1990, Semin Cancer Biol, V1, P99; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MCDONNELL S, 1990, CANCER METAST REV, V9, P305; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; PAWELETZ N, 1994, CRIT REV ONCOGENESIS, V5, P69, DOI 10.1615/CritRevOncog.v5.i1.40; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMOLA H, 1993, J CELL BIOL, V122, P417, DOI 10.1083/jcb.122.2.417; SPALDING JW, 1993, CARCINOGENESIS, V14, P1335, DOI 10.1093/carcin/14.7.1335; STRAWHECKER JM, 1992, CARCINOGENESIS, V13, P2075, DOI 10.1093/carcin/13.11.2075; STRICKLAND JE, 1993, CARCINOGENESIS, V14, P205, DOI 10.1093/carcin/14.2.205; URABE A, 1992, J PATHOL, V168, P281, DOI 10.1002/path.1711680307; VOLM M, 1992, INT J ONCOL, V1, P69; WALKER RA, 1991, J PATHOL, V163, P323, DOI 10.1002/path.1711630409; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WODRICH W, 1993, CARCINOGENESIS, V14, P1121, DOI 10.1093/carcin/14.6.1121; YUSPA SH, 1994, CANCER RES, V54, P1178; YUSPA SH, 1976, CANCER RES, V36, P4062; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	60	322	332	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					721	732		10.1016/0092-8674(95)90469-7	http://dx.doi.org/10.1016/0092-8674(95)90469-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7545543	Bronze			2022-12-28	WOS:A1995RU75500007
J	ROBINSON, RG; PRESTON, DF; SCHIEFELBEIN, M; BAXTER, KG				ROBINSON, RG; PRESTON, DF; SCHIEFELBEIN, M; BAXTER, KG			STRONTIUM-89 THERAPY FOR THE PALLIATION OF PAIN DUE TO OSSEOUS METASTASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							DOUBLE-BLIND CROSSOVER; PROSTATE-CANCER; BONE CANCER; SR-89 THERAPY; MANAGEMENT; CARCINOMA; EFFICACY; BREAST	Objective.-To present the current state of systemic radiopharmaceutical therapy for the palliation of pain in individuals with metastatic cancer and to evaluate the palliative effect and degree of hemotoxicity of strontium chloride 89 (Sr-89) in patients with painful osteoblastic metastases primarily from prostate and breast cancer. Data Sources and Study Selection.-A MEDLINE search through December 1994 was performed to identify English-language studies that met the following criteria. All eligible studies reported treatment of patients with painful osteoblastic bony metastases primarily from prostate or breast cancer treated with intravenous Sr-89. For study eligibility, evaluation of clinical response as assessed by the Karnofsky index, need for pain medication, or changes in mobility or sleep patterns was required. Hemotoxicity data were a requirement. A minimum of 10 prostate cancer cases was necessary for study inclusion. Only those studies assessing clinical response following one injection of Sr-89 were included. Preliminary reports of cooperative studies were not included. Doses of Sr-89 ranged from 0.6 MBq/kg (16 mu Ci/kg) to 400 MBq (10.8 mCi) per patient. Evaluation of patients for at least 3 months following Sr-89 treatment was required. In addition, two studies examining issues of cost with regard to Sr-89 treatment were identified. Data Extraction.-Baseline pain assessment and periodic pain estimates as measured by the Karnofsky index, medication diaries, changes in mobility, sleep patterns, and/or ability to work were the basis for assessment of response. Baseline and periodic complete blood cell counts were the basis for hemotoxicity evaluation. Data Synthesis.-Palliation and hemotoxicity data were analyzed separately for each study. Some improvement occurred in as many as approximately 80% of patients. Several studies demonstrated complete relief of pain in at least 10% of patients. The nadir of platelet and white blood cell counts appears at approximately 4 to 8 weeks following injection, with a partial return to baseline by 12 weeks. As many as 10 injections spaced 3 months apart have been given to some patients with repeated palliative effect and without serious hemotoxicity. Reinjection may be limited by a platelet count below 60x10(9)/L, a white blood cell count below 2.4x10(9)/L, or the absence of osteoblastic skeletal metastasis as seen on bone scan. Studies examining treatment costs suggest that Sr-89 may decrease costs associated with palliation of pain due to metastatic disease. Conclusions.-As many as 80% of selected patients with painful osteoblastic bony metastases from prostate or breast cancer may experience some pain relief following Sr-89 administration. In addition, as many as 10% or more may become pain free. Duration of clinical response may average 3 to 6 months in some cases. Hemotoxicity is mild. A decrease in treatment costs with administration of Sr-89 to patients with painful osteoblastic bony metastases from prostate cancer may occur. These observations reflect the preliminary nature of knowledge in this field and point to the need for larger clinical trials of the use of Sr-89 palliation.	UNIV KANSAS,MED CTR,DEPT RADIOL,DIV NUCL MED,KANSAS CITY,KS 66160	University of Kansas; University of Kansas Medical Center								ATKINS HL, 1993, RADIOLOGY, V186, P279, DOI 10.1148/radiology.186.1.7677974; BLAKE GM, 1986, EUR J NUCL MED, V12, P447, DOI 10.1007/BF00254749; BONICA JJ, 1990, MANAGEMENT PAIN, P400; CHEUNG A, 1980, RADIOLOGY, V134, P209, DOI 10.1148/radiology.134.1.6153129; CRANE VS, 1990, ANN PHARMACOTHER, V24, P524; Dearnaley D P, 1992, Clin Oncol (R Coll Radiol), V4, P101, DOI 10.1016/S0936-6555(05)80975-6; DEKLERK JMH, 1994, J NUCL MED, V35, P1423; DENIS L, 1993, CANCER-AM CANCER SOC, V71, P1050, DOI 10.1002/1097-0142(19930201)71:3+<1050::AID-CNCR2820711425>3.0.CO;2-#; Dickinson C.Z., 1993, J NUCL MED TECHNOL, V21, P133; DUSING RW, 1993, CLIN NUCL MED, V19, P624; FARHANGHI M, 1992, J NUCL MED, V33, P1451; HOLMES RA, 1993, SEMIN ONCOL, V20, P22; HOLMES RA, 1992, SEMIN NUCL MED, V22, P41, DOI 10.1016/S0001-2998(05)80156-4; HURST LC, 1986, CLIN ORTHOPAEDICS, V206, P290; JOHNSON DE, 1977, J UROLOGY, V9, P137; LAING AH, 1991, BRIT J RADIOL, V64, P816, DOI 10.1259/0007-1285-64-765-816; LEWINGTON VJ, 1991, EUR J CANCER, V27, P954, DOI 10.1016/0277-5379(91)90257-E; MAXON HR, 1991, J NUCL MED, V32, P1877; MAXON HR, 1992, SEMIN NUCL MED, V22, P33, DOI 10.1016/S0001-2998(05)80155-2; MCEWAN AJB, 1994, NUCL MED COMMUN, V15, P499, DOI 10.1097/00006231-199407000-00002; MCGOWAN D, 1994, ONCOLOGY S, V8, P30; NIELSEN OS, 1991, J CLIN ONCOL, V9, P509, DOI 10.1200/JCO.1991.9.3.509; PEREZ C, 1987, PRINCIPLES PRACTISE, P1276; Porter A T, 1994, Oncology (Williston Park), V8, P93; PORTER AT, 1993, INT J RADIAT ONCOL, V25, P805, DOI 10.1016/0360-3016(93)90309-J; PORTER AT, 1994, ONCOLOGY HUNTINGT S, V8, P25; QUILTY PM, 1994, RADIOTHER ONCOL, V31, P33, DOI 10.1016/0167-8140(94)90411-1; REDDY EK, 1986, J NATL MED ASSOC, V78, P27; Robinson R G, 1989, Radiographics, V9, P271; ROBINSON RG, 1993, SEMIN ONCOL, V20, P44; ROBINSON RG, 1992, SEMIN NUCL MED, V22, P28, DOI 10.1016/S0001-2998(05)80154-0; ROBINSON RG, 1990, J NUCL MED, V31, P1326; ROBINSON RG, 1993, APPL RADIOL, V22, P44; SILBERSTEIN EB, 1985, J NUCL MED, V26, P345; Twycross R G, 1981, Int Rehabil Med, V3, P135; TWYCROSS R G, 1991, Henry Ford Hospital Medical Journal, V39, P77; 1994, CLIN PRACTICE GUIDEL, V9; 1993, METASTRON PRESCRIBIN	38	137	160	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	1995	274	5					420	424		10.1001/jama.274.5.420	http://dx.doi.org/10.1001/jama.274.5.420			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL416	7542352				2022-12-28	WOS:A1995RL41600030
J	SINGH, SN; FLETCHER, RD; FISHER, SG; SINGH, BN; LEWIS, HD; DEEDWANIA, PC; MASSIE, BM; COLLING, C; LAZZERI, D				SINGH, SN; FLETCHER, RD; FISHER, SG; SINGH, BN; LEWIS, HD; DEEDWANIA, PC; MASSIE, BM; COLLING, C; LAZZERI, D			AMIODARONE IN PATIENTS WITH CONGESTIVE-HEART-FAILURE AND ASYMPTOMATIC VENTRICULAR ARRHYTHMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IDIOPATHIC DILATED CARDIOMYOPATHY; PLACEBO-CONTROLLED TRIAL; LOW-DOSE AMIODARONE; DRUG-THERAPY; MYOCARDIAL-INFARCTION; CARDIAC-FAILURE; DOUBLE-BLIND; MORTALITY	Background. Asymptomatic ventricular arrhythmias in patients with congestive heart failure are associated with increased rates of overall mortality and sudden death. Amiodarone is now used widely to prevent ventricular tachycardia and fibrillation. We conducted a trial to determine whether amiodarone can reduce overall mortality in patients with congestive heart failure and asymptomatic ventricular arrhythmias. Methods. We used a double-blind, placebo-controlled protocol in which 674 patients with symptoms of congestive heart failure, cardiac enlargement, 10 or more premature ventricular contractions per hour, and a left ventricular ejection fraction of 40 percent or less were randomly assigned to receive amiodarone (336 patients) or placebo (338 patients). The primary end point was overall mortality, and the median follow-up was 45 months (range, 0 to 54). Results. There was no significant difference in overall mortality between the two treatment groups (P=0.6). The two-year actuarial survival rate was 69.4 percent (95 percent confidence interval, 64.2 to 74.6) for the patients in the amiodarone group and 70.8 percent (95 percent confidence interval, 65.7 to 75.9) for those in the placebo group. At two years, the rate of sudden death was 15 percent in the amiodarone group and 19 percent in the placebo group (P=0.43). There was a trend toward a reduction in overall mortality among the patients with nonischemic cardiomyopathy who received amiodarone (P=0.07). Amiodarone was significantly more effective in suppressing ventricular arrhythmias and increased the left ventricular ejection fraction by 42 percent at two years. Conclusions. Although amiodarone was effective in suppressing ventricular arrhythmias and improving ventricular function, it did not reduce the incidence of sudden death or prolong survival among patients with heart failure, except for a trend toward reduced mortality among those with nonischemic cardiomyopathy.	VET AFFAIRS COOPERAT STUDIES COORDINATING CTR, HINES, IL USA; LOYOLA UNIV, MED CTR, MAYWOOD, IL USA; WADSWORTH VET AFFAIRS MED CTR, DEPT CARDIOL, LOS ANGELES, CA USA; VET AFFAIRS MED CTR, DEPT CARDIOL, KANSAS CITY, MO USA; VET AFFAIRS MED CTR, DEPT CARDIOL, FRESNO, CA USA; VET AFFAIRS MED CTR, DEPT CARDIOL, SAN FRANCISCO, CA USA; VET AFFAIRS MED CTR, COOPERAT STUDIES PROGRAM, ALBUQUERQUE, NM USA	Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)	SINGH, SN (corresponding author), VET AFFAIRS MED CTR, DEPT CARDIOL, DIV CARDIOL, 50 IRVING ST NW, WASHINGTON, DC 20422 USA.							[Anonymous], 1989, NEW ENGL J MED, V321, P406; CEREMUZYNSKI L, 1992, J AM COLL CARDIOL, V20, P1056, DOI 10.1016/0735-1097(92)90357-S; CHAKKO CS, 1985, AM HEART J, V109, P497, DOI 10.1016/0002-8703(85)90554-X; CHATTERJEE K, 1989, J AM COLL CARDIOL, V14, P1775, DOI 10.1016/0735-1097(89)90031-4; CINGOLANI HE, 1990, J MOL CELL CARDIOL, V22, P1025, DOI 10.1016/0022-2828(90)91042-6; CLELAND JGF, 1987, BRIT HEART J, V57, P436; COHN JN, 1988, CIRCULATION, V78, P1099, DOI 10.1161/01.CIR.78.5.1099; COHN JN, 1977, NEW ENGL J MED, V297, P27; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; GREENE HL, 1993, AM J CARDIOL, V72, pF70, DOI 10.1016/0002-9149(93)90966-G; HAMER AWF, 1989, J AM COLL CARDIOL, V14, P1768, DOI 10.1016/0735-1097(89)90030-2; HERRE JM, 1989, J AM COLL CARDIOL, V13, P442, DOI 10.1016/0735-1097(89)90525-1; HOHNLOSER SH, 1994, ANN INTERN MED, V121, P529, DOI 10.7326/0003-4819-121-7-199410010-00009; HOLMES J, 1985, AM J CARDIOL, V55, P146, DOI 10.1016/0002-9149(85)90317-0; KULICK DL, 1991, JAMA-J AM MED ASSOC, V265, P2995; MEINERTZ T, 1984, AM J CARDIOL, V53, P902, DOI 10.1016/0002-9149(84)90522-8; NICKLAS JM, 1991, AM HEART J, V122, P1016, DOI 10.1016/0002-8703(91)90466-U; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; Packer M., 1990, CIRCULATION S1, V82, P177; PFISTERER M, 1992, AM J CARDIOL, V69, P1399, DOI 10.1016/0002-9149(92)90889-7; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; SINGH BN, 1983, AM HEART J, V106, P788, DOI 10.1016/0002-8703(83)90002-9; SINGH BN, 1993, AM J CARDIOL, V72, pF114, DOI 10.1016/0002-9149(93)90974-H; SINGH SN, 1993, AM J CARDIOL, V72, pF99, DOI 10.1016/0002-9149(93)90971-E; UNVERFERTH DV, 1984, AM J CARDIOL, V54, P147, DOI 10.1016/0002-9149(84)90320-5; VONOLSHAUSEN K, 1984, BRIT HEART J, V51, P195; YUSUF S, 1990, CIRCULATION, V82, P673	28	862	890	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 13	1995	333	2					77	82		10.1056/NEJM199507133330201	http://dx.doi.org/10.1056/NEJM199507133330201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH225	7539890				2022-12-28	WOS:A1995RH22500001
J	EATON, WA; HOFRICHTER, J				EATON, WA; HOFRICHTER, J			THE BIOPHYSICS OF SICKLE-CELL HYDROXYUREA THERAPY	SCIENCE			English	Editorial Material							HEMOGLOBIN-S; DEOXYHEMOGLOBIN-S; CRYSTAL-STRUCTURE; GELATION; POLYMERIZATION; RESOLUTION; MECHANISM; KINETICS; DISEASE; FIBERS				EATON, WA (corresponding author), NIDDKD, CHEM PHYS LAB, BLDG 5, BETHESDA, MD 20892 USA.							BRIDGES K, UNPUB; BRIEHL RW, 1995, J MOL BIOL, V245, P710, DOI 10.1006/jmbi.1994.0057; BUNN HF, 1974, BIOCHEMISTRY-US, V13, P988, DOI 10.1021/bi00702a024; Bunn HF, 1986, HEMOGLOBIN MOL GENET; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; CRETEGNY I, 1993, J MOL BIOL, V230, P733, DOI 10.1006/jmbi.1993.1195; DYKES G, 1978, NATURE, V272, P506, DOI 10.1038/272506a0; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; EATON WA, 1987, BLOOD, V70, P1245; FERRONE FA, 1985, J MOL BIOL, V183, P611, DOI 10.1016/0022-2836(85)90175-5; GOLDBERG MA, 1977, J BIOL CHEM, V252, P3414; HOFRICHTER J, 1974, P NATL ACAD SCI USA, V71, P4864, DOI 10.1073/pnas.71.12.4864; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; MINTON AP, 1977, J MOL BIOL, V110, P89, DOI 10.1016/S0022-2836(77)80100-9; MOZZARELLI A, 1987, SCIENCE, V237, P500, DOI 10.1126/science.3603036; NAGEL RL, 1979, P NATL ACAD SCI USA, V76, P670, DOI 10.1073/pnas.76.2.670; NAGEL RL, 1980, NATURE, V283, P832, DOI 10.1038/283832a0; PADLAN EA, 1985, J BIOL CHEM, V260, P8272; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; PLATT OS, 1984, J CLIN INVEST, V74, P652, DOI 10.1172/JCI111464; ROSS PD, 1977, J MOL BIOL, V115, P111, DOI 10.1016/0022-2836(77)90093-6; ROSS PD, 1978, BIOPOLYMERS, V17, P2285, DOI 10.1002/bip.1978.360170920; SINGER K, 1953, BLOOD, V8, P1008, DOI 10.1182/blood.V8.11.1008.1008; SUNSHINE HR, 1978, NATURE, V275, P238, DOI 10.1038/275238a0; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2	25	95	98	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	1995	268	5214					1142	1143		10.1126/science.7539154	http://dx.doi.org/10.1126/science.7539154			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7539154				2022-12-28	WOS:A1995RA60400026
J	HAMILL, RJ; HOUSTON, ED; GEORGHIOU, PR; WRIGHT, CE; KOZA, MA; CADLE, RM; GOEPFERT, PA; LEWIS, DA; ZENON, GJ; CLARRIDGE, JE				HAMILL, RJ; HOUSTON, ED; GEORGHIOU, PR; WRIGHT, CE; KOZA, MA; CADLE, RM; GOEPFERT, PA; LEWIS, DA; ZENON, GJ; CLARRIDGE, JE			AN OUTBREAK OF BURKHOLDERIA (FORMERLY PSEUDOMONAS) CEPACIA RESPIRATORY-TRACT COLONIZATION AND INFECTION ASSOCIATED WITH NEBULIZED ALBUTEROL THERAPY	ANNALS OF INTERNAL MEDICINE			English	Note							POLYMERASE CHAIN-REACTION; BENZALKONIUM CHLORIDE; EPIDEMIOLOGY	Objective: To investigate an outbreak of Burkholderia (formerly Pseudomonas) cepacia respiratory tract colonization and infection in mechanically ventilated patients. Design: A retrospective case-control and bacteriologic study, Setting: Veterans Affairs medical center. Patients: 42 mechanically ventilated patients who developed respiratory tract colonization or infection with B. cepacia and 135 ventilator-dependent controls who were not colonized and did not develop infections. Measurements: Clinical and demographic data; benzalkonium chloride concentrations and pH levels in albuterol sulfate solutions; repetitive-element polymerase chain reaction (PCR)-mediated molecular fingerprinting on eight patient isolates and three environmental B. cepacia isolates that were available for study. Results: 42 patients had B. cepacia respiratory tract colonization or infection. Observation of intensive care unit and respiratory care personnel showed faulty infection control procedures (for example, the same multiple-dose bottle of albuterol was used for many mechanically ventilated patients). More case patients (39 [92.9%]) than controls (95 [70.4%]; P = 0.006) received nebulized albuterol, and case patients (67.5 treatments) received more treatments than controls (18 treatments; P < 0.001). In-use albuterol solutions had pH values that were unstable, and benzalkonium chloride concentrations declined over time to levels capable of supporting bacterial growth. Medication nebulizers and in-use bottles of albuterol harbored B. cepacia. Molecular fingerprints of patient isolates and environmental B. cepacia isolates were identical using repetitive-element PCR. No further isolates of B. cepacia were identified after institution of appropriate infection control procedures. Conclusions: Multiple-dose medications and reliance on benzalkonium chloride as a medication preservative provide a mechanism for nosocomial spread of microorganisms, particularly if infection control procedures are not carefully followed. Repetitive-element PCR is a useful fingerprinting technique for molecular epidemiologic studies of B. cepacia.	TEXAS SO UNIV, HOUSTON, TX 77004 USA	Texas Southern University	HAMILL, RJ (corresponding author), BAYLOR COLL MED, VET AFFAIRS MED CTR, INFECT DIS SECT 111G, 2002 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.							BARKER MJ, 1990, AM J INFECT CONTROL, V18, P139; BINGEN EH, 1993, J CLIN MICROBIOL, V31, P2589, DOI 10.1128/JCM.31.10.2589-2593.1993; CRAVEN DE, 1984, AM J MED, V77, P834, DOI 10.1016/0002-9343(84)90520-5; DONOWITZ LG, 1991, INFECT CONT HOSP EP, V12, P186, DOI 10.2307/30146937; FRANK MJ, 1976, JAMA-J AM MED ASSOC, V236, P2418, DOI 10.1001/jama.236.21.2418; GEFTIC SG, 1979, APPL ENVIRON MICROB, V37, P505, DOI 10.1128/AEM.37.3.505-510.1979; GEORGHIOU PR, 1995, CLIN INFECT DIS, V20, P84, DOI 10.1093/clinids/20.1.84; JARVIS WR, 1987, EUR J EPIDEMIOL, V3, P233, DOI 10.1007/BF00149729; KARABIT MS, 1988, INT J PHARM, V46, P141, DOI 10.1016/0378-5173(88)90019-1; KUNDSIN RB, 1957, ARCH SURG-CHICAGO, V75, P1036; MARTONE WJ, 1987, EUR J EPIDEMIOL, V3, P222, DOI 10.1007/BF00149728; RABKIN CS, 1989, REV INFECT DIS, V11, P600; REBOLI AC, 1994, J CLIN MICROBIOL, V32, P2635, DOI 10.1128/JCM.32.11.2635-2640.1994; REBOLI AC, 1993, 1993 INF DIS  SOC AM, V17, P555; RICHARDSON NE, 1977, J PHARM PHARMACOL, V29, P717, DOI 10.1111/j.2042-7158.1977.tb11448.x; SIMMONS BP, 1982, INFECT CONT HOSP EP, V3, P327, DOI 10.1017/S0195941700056423; THOMAS JM, 1989, MOD SYN MET, V5, P249; VERSALOVIC J, 1991, NUCLEIC ACIDS RES, V19, P6823, DOI 10.1093/nar/19.24.6823; WOODS CR, 1993, J CLIN MICROBIOL, V31, P1927, DOI 10.1128/JCM.31.7.1927-1931.1993; WOODS CR, 1992, J CLIN MICROBIOL, V30, P2921, DOI 10.1128/JCM.30.11.2921-2929.1992	20	94	96	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1995	122	10					762	766		10.7326/0003-4819-122-10-199505150-00005	http://dx.doi.org/10.7326/0003-4819-122-10-199505150-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX147	7536401				2022-12-28	WOS:A1995QX14700005
J	HICKISH, TF; SMITH, IE; MIDDLETON, G; NICOLSON, M				HICKISH, TF; SMITH, IE; MIDDLETON, G; NICOLSON, M			PATIENT PREFERENCE FOR EXTENDED PALLIATIVE CHEMOTHERAPY FOR NONSMALL CELL LUNG-CANCER	LANCET			English	Letter									ROYAL MARSDEN HOSP,SUTTON SM2 5PT,SURREY,ENGLAND; ABERDEEN ROYAL INFIRM,ABERDEEN,SCOTLAND	Royal Marsden NHS Foundation Trust; University of Aberdeen				Hickish, Tamas/0000-0001-6770-7279				COATES A, 1993, LANCET, V342, P4, DOI 10.1016/0140-6736(93)91876-N; CULLEN MH, LUNG CANCER, V9, pS81; ELLIS PA, 1995, BRIT J CANCER, V71, P366, DOI 10.1038/bjc.1995.74; JAAKKIMAINEN L, 1990, J CLIN ONCOL, V8, P1301, DOI 10.1200/JCO.1990.8.8.1301; SOUQUET PJ, 1993, LANCET, V342, P19	5	9	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 1	1995	345	8953					857	858		10.1016/S0140-6736(95)92993-2	http://dx.doi.org/10.1016/S0140-6736(95)92993-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7534859				2022-12-28	WOS:A1995QQ19500040
J	MCDOWALL, KJ; KABERDIN, VR; WU, SW; COHEN, SN; LINCHAO, S				MCDOWALL, KJ; KABERDIN, VR; WU, SW; COHEN, SN; LINCHAO, S			SITE-SPECIFIC RNASE-E CLEAVAGE OF OLIGONUCLEOTIDES AND INHIBITION BY STEM-LOOPS	NATURE			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; RIBOSOMAL-RNA; DEGRADATION; REPLICATION	THE enzyme RNase E (ref. 1) cuts RNA at specific sites within single-stranded segments(2-6). The role of adjacent regions of secondary structure in such cleavages is controversial(7-10). Here we report that 10-13-nucleotide oligomers lacking any stem-loop but containing the RNase E-cleaved sequence of RNA I11-13, the antisense repressor of replication of ColE1-type plasmids, are cut at the same phosphodiester bond as, and 20 times more efficiently than, RNA I. These findings indicate that, contrary to previous proposals(8,9), stem-loops do not serve as entry sites for RNase E, but instead limit cleavage at potentially susceptible sites. Cleavage was reduced further by mutations in a non-adjacent stem-loop, suggesting that distant conformational changes can also affect enzyme access. Modulation of RNase E cleavages by stem-loop regions and to a lesser extent by higher-order structure may explain why this enzyme, which does not have stringent sequence specificity(6,12,13), cleaves complex RNAs at a limited number of sites.	ACAD SINICA, INST MOL BIOL, TAIPEI, 94305, TAIWAN; STANFORD UNIV, SCH MED, DEPT GENET, STANFORD, CA USA	Academia Sinica - Taiwan; Stanford University			Lin-Chao, Sue/AAZ-8246-2021; Lin-Chao, Sue/AGI-2030-2022; Kaberdin, Vladimir/C-3870-2017	Lin-Chao, Sue/0000-0002-8415-9304; Lin-Chao, Sue/0000-0002-8415-9304; Kaberdin, Vladimir/0000-0002-7166-5136				APIRION D, 1978, J BIOL CHEM, V253, P1738; APIRION D, 1992, MOL BIOL LIFE SCI AD, V11, P221; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; EHRETSMANN CP, 1992, FASEB J, V6, P3186, DOI 10.1096/fasebj.6.13.1397840; GOLDBLUM K, 1981, CELL, V15, P1055; HELMERCITTERICH M, 1988, EMBO J, V7, P557, DOI 10.1002/j.1460-2075.1988.tb02845.x; Higgins CF, 1992, CURR OPIN GENET DEV, V2, P739, DOI 10.1016/S0959-437X(05)80134-0; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; Lin-Chao S, 1992, MOL MICROBIOL, V6, P3385, DOI 10.1111/j.1365-2958.1992.tb02206.x; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; MACKIE GA, 1992, J BIOL CHEM, V267, P1054; MACKIE GA, 1993, J MOL BIOL, V234, P998, DOI 10.1006/jmbi.1993.1654; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; MELEFORS O, 1993, CONTROL MESSENGER RN, P53; MISRA TK, 1978, J BIOL CHEM, V253, P5594; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; TAKAHASHI K, 1961, J BIOCHEM-TOKYO, V49, P1; TAMM J, 1983, NUCLEIC ACIDS RES, V11, P6381, DOI 10.1093/nar/11.18.6381; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; TUCKER WT, 1984, CELL, V38, P191, DOI 10.1016/0092-8674(84)90540-3	24	124	126	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 16	1995	374	6519					287	290		10.1038/374287a0	http://dx.doi.org/10.1038/374287a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7533896				2022-12-28	WOS:A1995QM38700057
J	HOFFMAN, EP; LEHMANNHORN, F; RUDEL, R				HOFFMAN, EP; LEHMANNHORN, F; RUDEL, R			OVEREXCITED OR INACTIVE - ION CHANNELS IN MUSCLE DISEASE	CELL			English	Review							HYPERKALEMIC PERIODIC PARALYSIS; SKELETAL-MUSCLE; PARAMYOTONIA-CONGENITA; MYOTONIA-CONGENITA; QUARTER HORSES; ALPHA-SUBUNIT; SODIUM; GENE; MUTATION; CONDUCTANCE		UNIV PITTSBURGH,SCH MED,DEPT HUMAN GENET,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT PEDIAT,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	HOFFMAN, EP (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261, USA.			Hoffman, Eric/0000-0001-6470-5139				ARMSTRONG CM, 1973, J GEN PHYSIOL, V62, P375, DOI 10.1085/jgp.62.4.375; BRYANT SH, 1969, J PHYSIOL-LONDON, V204, P539, DOI 10.1113/jphysiol.1969.sp008930; CANNON SC, 1993, NEURON, V10, P317, DOI 10.1016/0896-6273(93)90321-H; CANNON SC, 1993, BIOPHYS J, V65, P270, DOI 10.1016/S0006-3495(93)81045-2; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHAHINE M, 1994, NEURON, V12, P281, DOI 10.1016/0896-6273(94)90271-2; EBERS GC, 1991, ANN NEUROL, V30, P810, DOI 10.1002/ana.410300610; FONTAINE B, 1990, SCIENCE, V250, P1000, DOI 10.1126/science.2173143; FONTAINE B, 1994, NAT GENET, V6, P267, DOI 10.1038/ng0394-267; GEORGE AL, 1993, NAT GENET, V3, P305, DOI 10.1038/ng0493-305; HEINE R, 1994, HUM MOL GENET, V3, P1123, DOI 10.1093/hmg/3.7.1123; JURKATROTT K, 1994, HUM MOL GENET, V3, P1415, DOI 10.1093/hmg/3.8.1415; KOCH MC, 1991, HUM GENET, V88, P71, DOI 10.1007/BF00204932; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; LEHMANNHORN F, 1981, MUSCLE NERVE, V4, P396, DOI 10.1002/mus.880040508; LEHMANNHORN F, 1987, MUSCLE NERVE, V10, P363, DOI 10.1002/mus.880100414; LEHMANNHORN F, 1995, IN PRESS P SOC GEN P; LERCHE H, 1993, J PHYSIOL-LONDON, V470, P13, DOI 10.1113/jphysiol.1993.sp019843; LI KX, 1993, J CELL PHYSIOL, V157, P631, DOI 10.1002/jcp.1041570324; LIPICKY RJ, 1971, J CLIN INVEST, V50, P2091, DOI 10.1172/JCI106703; LORENZ C, 1994, HUM MOL GENET, V3, P941, DOI 10.1093/hmg/3.6.941; MCCLATCHEY AI, 1992, CELL, V68, P769, DOI 10.1016/0092-8674(92)90151-2; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; MITROVIC N, 1994, J PHYSIOL-LONDON, V478, P395, DOI 10.1113/jphysiol.1994.sp020260; NAYLOR JM, 1994, J AM VET MED ASSOC, V204, P926; PALADE PT, 1977, J GEN PHYSIOL, V69, P325, DOI 10.1085/jgp.69.3.325; PTACEK LJ, 1991, AM J HUM GENET, V49, P851; PTACEK LJ, 1991, CELL, V67, P1021; PTACEK LJ, 1994, CELL, V77, P863; PUSCH M, 1994, BIOPHYS J, V66, P149, DOI 10.1016/S0006-3495(94)80753-2; ROJAS CV, 1991, NATURE, V354, P387, DOI 10.1038/354387a0; RUDEL R, 1993, ARCH NEUROL-CHICAGO, V50, P1241, DOI 10.1001/archneur.1993.00540110113011; RUDEL R, 1988, MUSCLE NERVE, V11, P202, DOI 10.1002/mus.880110303; RUDOLPH JA, 1992, NAT GENET, V2, P144, DOI 10.1038/ng1092-144; RUDOLPH JA, 1992, ANIM GENET, V23, P241, DOI 10.1111/j.1365-2052.1992.tb00136.x; SIPOS I, 1995, J PHYSIOL-LONDON, V483, P299, DOI 10.1113/jphysiol.1995.sp020586; SPIER SJ, 1990, J AM VET MED ASSOC, V197, P1009; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x; WANG JZ, 1995, IN PRESS P SOC GEN P; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; ZHOU JH, 1994, HUM MOL GENET, V3, P1599, DOI 10.1093/hmg/3.9.1599	41	109	112	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					681	686		10.1016/0092-8674(95)90345-3	http://dx.doi.org/10.1016/0092-8674(95)90345-3			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7534212	Bronze			2022-12-28	WOS:A1995QM39900003
J	RINCK, G; KLEIJNEN, J; VANDENBOS, TGAM; DEHAES, HJCJM; SCHADE, E; VEENHOF, CHN				RINCK, G; KLEIJNEN, J; VANDENBOS, TGAM; DEHAES, HJCJM; SCHADE, E; VEENHOF, CHN			TRIALS IN PALLIATIVE CARE	BRITISH MEDICAL JOURNAL			English	Letter									ACAD MED CTR,INST SOCIAL MED,AMSTERDAM,NETHERLANDS; ACAD MED CTR,DEPT PSYCHOL MED,AMSTERDAM,NETHERLANDS; ACAD MED CTR,DEPT GEN FAMILY MED,AMSTERDAM,NETHERLANDS; ACAD MED CTR,DEPT INTERNAL MED,DIV MED ONCOL,AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	RINCK, G (corresponding author), UNIV HOSP AMSTERDAM,ACAD MED CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,POB 22700,1100 DE AMSTERDAM,NETHERLANDS.							MCWHINNEY IR, 1994, BRIT MED J, V309, P1340, DOI 10.1136/bmj.309.6965.1340; OVESEN L, 1993, J CLIN ONCOL, V11, P2043, DOI 10.1200/JCO.1993.11.10.2043	2	22	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					598	599		10.1136/bmj.310.6979.598c	http://dx.doi.org/10.1136/bmj.310.6979.598c			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK700	7534157	Green Published			2022-12-28	WOS:A1995QK70000053
J	JONES, EY; HARLOS, K; BOTTOMLEY, MJ; ROBINSON, RC; DRISCOLL, PC; EDWARDS, RM; CLEMENTS, JM; DUDGEON, TJ; STUART, DI				JONES, EY; HARLOS, K; BOTTOMLEY, MJ; ROBINSON, RC; DRISCOLL, PC; EDWARDS, RM; CLEMENTS, JM; DUDGEON, TJ; STUART, DI			CRYSTAL-STRUCTURE OF AN INTEGRIN-BINDING FRAGMENT OF VASCULAR CELL-ADHESION MOLECULE-1 AT 1.8 ANGSTROM RESOLUTION	NATURE			English	Article							IMMUNOGLOBULIN-LIKE DOMAINS; SOLUBLE FORM; HUMAN CD4; PROTEIN; FIBRONECTIN; SITE; KINASE	THE cell-surface glycoprotein vascular cell adhesion molecule-1 (VCAM-1; ref. 1) mediates intercellular adhesion(2) by specific binding to the integrin very-late antigen-4 (VLA-4, alpha(4) beta(1); ref. 3). VCAM-1, with the intercellular adhesion molecules ICAM-1, ICAM-2, ICAM-3 and the mucosal vascular addressin MAd-CAM-1, forms an integrin-binding subgroup of the immunoglobulin superfamily. In addition to their clinical relevance in inflammation, these molecules act as cellular receptors for viral and parasitic agents(2). The predominant form of VCAM-1 in vivo has an amino-terminal extracellular region comprising seven immunoglobulin-like domains. Functional studies(4-7) have identified a conserved integrin-binding motif in domains 1 and 4, variants of which are present in the N-terminal domain of all members of the immunoglobulin superfamily subgroup. We report here the crystal structure of a VLA-4-binding fragment composed of the first two domains of VCAM-1. The integrin-binding motif (Q38IDSPL) is highly exposed and forms the N-terminal region of the loop between beta-strands C and D of domain 1. This motif exhibits a distinctive conformation which we predict will be common to all the integrin-binding IgSF molecules. These, and additional data, map VLA-4 binding to the face of the CFG beta-sheet, the surface previously identified(8) as the site for intercellular adhesive interactions between members of the immunoglobulin superfamily.	UNIV OXFORD, CTR MOLEC SCI, OXFORD OX1 3QU, ENGLAND; UNIV OXFORD, DEPT BIOCHEM, OXFORD OX1 3QU, ENGLAND; BRITISH BIOTECHNOL LTD, OXFORD OX4 5LY, ENGLAND; NEURES LTD, ABINGDON OX14 3YS, OXON, ENGLAND	University of Oxford; University of Oxford	JONES, EY (corresponding author), LAB MOLEC BIOPHYS, S PARKS RD, OXFORD OX1 3QU, ENGLAND.		Jones, Yvonne/N-8111-2019; Driscoll, Paul C/B-8007-2010; Robinson, Robert/G-9702-2011; Jones, Yvonne/J-2293-2016	Jones, Yvonne/0000-0002-3834-1893; Driscoll, Paul C/0000-0002-4124-6950; Robinson, Robert/0000-0001-6367-6903; Jones, Yvonne/0000-0002-3834-1893; Stuart, David/0000-0002-3426-4210				BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; BOTTOMLEY MJ, 1994, J MOL BIOL, V244, P464, DOI 10.1006/jmbi.1994.1743; CARDARELLI PM, 1994, J BIOL CHEM, V269, P18668; CLEMENTS JM, 1994, J CELL SCI, V107, P2127; DUDGEON TJ, 1994, EUR J BIOCHEM, V226, P517, DOI 10.1111/j.1432-1033.1994.tb20076.x; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; HOLNESS CL, IN PRESS J BIOL CHEM; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LOGAN D, 1993, NATURE, V362, P566, DOI 10.1038/362566a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; RENZ ME, 1994, J CELL BIOL, V125, P1395, DOI 10.1083/jcb.125.6.1395; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAUL FA, 1978, J BIOL CHEM, V253, P585; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0	28	180	184	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	1995	373	6514					539	544		10.1038/373539a0	http://dx.doi.org/10.1038/373539a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7531291				2022-12-28	WOS:A1995QF72400064
J	CLACKSON, T; WELLS, JA				CLACKSON, T; WELLS, JA			A HOT-SPOT OF BINDING-ENERGY IN A HORMONE-RECEPTOR INTERFACE	SCIENCE			English	Article							HUMAN GROWTH-HORMONE; ANTIBODY-ANTIGEN INTERACTIONS; PROTEIN-PROTEIN RECOGNITION; CRYSTAL-STRUCTURE; EXTRACELLULAR DOMAIN; SCANNING MUTAGENESIS; FUNCTIONAL EPITOPE; RATIONAL DESIGN; COMPLEX; RESOLUTION	The x-ray crystal structure of the complex between human growth hormone (hGH) and the extracellular domain of its first bound receptor (hGHbp) shows that about 30 side chains from each protein make contact. Individual replacement of contact residues in the hGHbp with alanine showed that a central hydrophobic region, dominated by two tryptophan residues, accounts for more than three-quarters of the binding free energy. This ''functional epitope'' is surrounded by less important contact residues that are generally hydrophilic and partially hydrated, so that the interface resembles a cross section through a globular protein. The functionally important residues on the hGHbp directly contact those on hGH. Thus, only a small and complementary set of contact residues maintains binding affinity, a property that may be general to protein-protein interfaces.	GENENTECH INC, DEPT PROT ENGN, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech			Wells, Jim A/O-9854-2016					ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; ATWELL S, UNPUB; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BARNARD R, 1984, ENDOCRINOLOGY, V115, P1805, DOI 10.1210/endo-115-5-1805; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BUCKLE AM, 1994, BIOCHEMISTRY-US, V33, P8878, DOI 10.1021/bi00196a004; CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0; CHOTHIA C, 1974, NATURE, V254, P101; CLACKSON T, UNPUB; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DEVOS AM, UNPUB; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FUH G, 1990, J BIOL CHEM, V265, P3111; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; HAWKINS RE, 1993, J MOL BIOL, V234, P958, DOI 10.1006/jmbi.1993.1650; HORTON N, 1992, PROTEIN SCI, V1, P169; JANIN J, 1990, J BIOL CHEM, V265, P16027; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; NUSS JM, 1993, PROTEINS, V15, P121, DOI 10.1002/prot.340150204; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; TULIP WR, 1994, BIOCHEMISTRY-US, V33, P7986, DOI 10.1021/bi00192a002; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WELLS JA, 1993, RECENT PROG HORM RES, V48, P253; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WELLS JC, UNPUB; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C; YOUNG L, 1994, PROTEIN SCI, V3, P717	43	1707	1826	4	205	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	1995	267	5196					383	386		10.1126/science.7529940	http://dx.doi.org/10.1126/science.7529940			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC273	7529940				2022-12-28	WOS:A1995QC27300037
J	BISHOP, DK				BISHOP, DK			RECA HOMOLOGS DMC1 AND RAD51 INTERACT TO FORM MULTIPLE NUCLEAR-COMPLEXES PRIOR TO MEIOTIC CHROMOSOME SYNAPSIS	CELL			English	Article							LYCOPERSICON-ESCULENTUM TOMATO; TWO-DIMENSIONAL SPREADS; DOUBLE-STRAND BREAKS; SYNAPTONEMAL COMPLEX; RECOMBINATION NODULES; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; SORDARIA-MACROSPORA; SOLANACEOUS PLANTS; WILD-TYPE	Dmc1 and Rad51, yeast homologs of the E. coli RecA protein, are shown by immunostaining to localize to as many as 64 sites within spread meiotic nuclei. Genetic requirements for this punctate pattern suggest It represents recombination intermediates. Dmc1 and Rad51 colocalize and are therefore likely to act together during recombination. Despite their similarities, the two proteins have specialized functions: Dmc1 complexes do not form in rad51 mutants, while Rad51 complexes are retained indefinitely in dmc1 mutants. Dmc1 and, by inference, Rad51 form complexes before synapsis as monitored by immunostaining for Zip1 protein. Analysis of zip1 mutants shows that Zip1 promotes dissociation of Dmc1 complexes. Colocalization of Dmc1 and Zip1 raises the possibility that Dmc1 and Rad51 are components of recombination nodules.			BISHOP, DK (corresponding author), UNIV CHICAGO,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60638, USA.				NIGMS NIH HHS [GM50936, GM44794] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; ALBINI SM, 1987, CHROMOSOMA, V95, P324, DOI 10.1007/BF00293179; ALBINI SM, 1984, EXP CELL RES, V155, P588, DOI 10.1016/0014-4827(84)90219-2; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BYERS B, 1975, P NATL ACAD SCI USA, V72, P5056, DOI 10.1073/pnas.72.12.5056; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1979, CHROMOSOMA, V75, P259, DOI 10.1007/BF00293472; CARPENTER ATC, 1979, GENETICS, V92, P511; Carpenter ATC, 1988, GENETIC RECOMBINATIO, P529, DOI [10.1038/ng1287, DOI 10.1038/NG1287]; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; ESPOSITO RE, 1981, MOL BIOL YEAST SACCH, P181; FOGEL S, 1983, YEAST GENETICS FUNDA, P65; Harlow E., 1988, ANTIBODIES LAB MANUA, P553; HOLLINGSWORTH NM, 1989, GENETICS, V121, P445; KADYK LC, 1992, GENETICS, V132, P387; KING JS, 1990, GENETICS, V126, P1127; KLAPHOLZ S, 1985, GENETICS, V110, P187; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; MOENS PB, 1978, CAN J GENET CYTOL, V20, P567, DOI 10.1139/g78-066; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; PRINGLE JR, 1991, METHODS ENZYMOLOGY G, P565; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RASMUSSEN SW, 1978, CARLSBERG RES COMMUN, V43, P275, DOI 10.1007/BF02906106; RESNICK M A, 1987, P157; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; ROSSMACDONALD P, 1994, CELL, V79; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; Sherman F., 1986, METHODS YEAST GENETI; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; STACK S, 1986, CHROMOSOMA, V94, P253, DOI 10.1007/BF00290853; STACK SM, 1986, AM J BOT, V73, P264, DOI 10.2307/2444181; STAHL FW, 1994, GENETICS, V138, P241; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; STUDIER FW, 1992, METHOD ENZYMOL, V185, P60; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WU TC, 1994, SCIENCE, V263, P515, DOI 10.1126/science.8290959; ZICKLER D, 1977, CHROMOSOMA, V61, P289, DOI 10.1007/BF00288615; ZICKLER D, 1992, GENETICS, V132, P135	47	395	412	2	21	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					1081	1092		10.1016/0092-8674(94)90038-8	http://dx.doi.org/10.1016/0092-8674(94)90038-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	7528104				2022-12-28	WOS:A1994PY08600017
J	KOBZIK, L; REID, MB; BREDT, DS; STAMLER, JS				KOBZIK, L; REID, MB; BREDT, DS; STAMLER, JS			NITRIC-OXIDE IN SKELETAL-MUSCLE	NATURE			English	Article							REACTIVE OXYGEN; SARCOPLASMIC-RETICULUM; SYNTHASE; LOCALIZATION; SULFHYDRYLS; MECHANISM; OXIDATION; PROTEINS; RELEASE; FORMS	REACTIVE oxygen intermediates modulate skeletal muscle contraction(1,2), but little is known about the role of nitric oxide (NO). Here we show that rat skeletal muscle expresses neuronal-type NO synthase and that activity varies among several respiratory and limb muscles. Immunohistochemistry showed prominent staining of type II (fast) fibre cell membranes with antibodies against neuronal-type NO synthase. NO synthase activity in muscles correlated with type II fibre density. Resting diaphragm muscle produced detectable NOx, but no reactive oxygen intermediates. In contrast, actively contracting muscle generated increased levels of reactive oxygen intermediates. Contractile function was augmented by blockers of NO synthase, extracellular NO chelation, and guanylyl cyclase inhibition; it was depressed by NO donors and by increased levels of cyclic GMP. Force-frequency plots of different muscles showed an inverse correlation between NO synthase activity and force development. Our results support two physiological functions of NO in skeletal muscle. The first is to promote relaxation through the cGMP pathway(3,4). The second is to modulate increases In contraction that are dependent on reactive oxygen intermediates and which are thought to occur through reactions with regulatory thiols on the sarcoplasmic reticulum(5,6).	DUKE UNIV,MED CTR,DEPT MED,DIV PULM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DIV CARDIOVASC,DURHAM,NC 27710; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; BAYLOR COLL MED,HOUSTON,TX 77030; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	Duke University; Duke University; Duke University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Baylor College of Medicine; University of California System; University of California San Francisco				Stamler, Jonathan/0000-0002-6866-1572				ABRAMSON JJ, 1989, J BIOENERG BIOMEMBR, V21, P283, DOI 10.1007/BF00812073; ARMSTRONG RB, 1984, AM J ANAT, V171, P259, DOI 10.1002/aja.1001710303; ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BELL LC, 1991, BIOCHEM J, V273, P423, DOI 10.1042/bj2730423; BIANCHI CP, 1975, CELLULAR PHARM EXCIT, P485; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BYRD SK, 1993, FASEB J, V7, pA526; EHRENBERG A, 1960, ACTA CHEM SCAND, V14, P1684, DOI 10.3891/acta.chem.scand.14-1684; KANNER J, 1992, LIPIDS, V27, P46, DOI 10.1007/BF02537058; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; KUCERA I, 1987, BIOCHIM BIOPHYS ACTA, V894, P120, DOI 10.1016/0005-2728(87)90181-2; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; METZGER JM, 1985, J APPL PHYSIOL, V58, P1085, DOI 10.1152/jappl.1985.58.4.1085; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; REID MB, 1993, J APPL PHYSIOL, V75, P1081, DOI 10.1152/jappl.1993.75.3.1081; REID MB, 1992, J APPL PHYSIOL, V73, P1797, DOI 10.1152/jappl.1992.73.5.1797; REID MB, 1992, J APPL PHYSIOL, V73, P1805, DOI 10.1152/jappl.1992.73.5.1805; SCHERER NM, 1986, ARCH BIOCHEM BIOPHYS, V246, P589, DOI 10.1016/0003-9861(86)90314-0; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1995, CELL, V78, P931; Stull J T, 1980, Adv Cyclic Nucleotide Res, V13, P39; TRIMM JL, 1986, J BIOL CHEM, V261, P6092; WEISHAAR RE, 1986, BIOCHEM PHARMACOL, V35, P787, DOI 10.1016/0006-2952(86)90247-9; WESCOTT SL, 1985, J CYCLIC NUCL PROT, V10, P189; WU M, 1994, AM J PHYSIOL, V268, pH2108	28	837	856	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					546	548		10.1038/372546a0	http://dx.doi.org/10.1038/372546a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7527495				2022-12-28	WOS:A1994PW08200051
J	MCKENZIE, R; FRIED, MW; SALLIE, R; CONJEEVARAM, H; DIBISCEGLIE, AM; PARK, Y; SAVARESE, B; KLEINER, D; TSOKOS, M; LUCIANO, C; PRUETT, T; STOTKA, JL; STRAUS, SE; HOOFNAGLE, JH				MCKENZIE, R; FRIED, MW; SALLIE, R; CONJEEVARAM, H; DIBISCEGLIE, AM; PARK, Y; SAVARESE, B; KLEINER, D; TSOKOS, M; LUCIANO, C; PRUETT, T; STOTKA, JL; STRAUS, SE; HOOFNAGLE, JH			HEPATIC-FAILURE AND LACTIC-ACIDOSIS DUE TO FIALURIDINE (FIAU), AN INVESTIGATIONAL NUCLEOSIDE ANALOG FOR CHRONIC HEPATITIS-B	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PLACEBO-CONTROLLED TRIAL; MITOCHONDRIAL-DNA; ULTRASTRUCTURAL-CHANGES; ADENINE-ARABINOSIDE; ALPHA-INTERFERON; VIRUS-INFECTION; E-ANTIGEN; THERAPY; MYOPATHY	Background. We describe severe and unexpected multisystem toxicity that occurred during a study of the antiviral nucleoside analogue fialuridine (1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodouracil, or FIAU) as therapy for chronic hepatitis B virus infection. Methods. Fifteen patients with chronic hepatitis B were randomly assigned to receive fialuridine at a dose of either 0.10 or 0.25 mg per kilogram of body weight per day for 24 weeks and were monitored every 1 to 2 weeks by means of a physical examination, blood tests, and testing for hepatitis B virus markers. Results. During the 13th week lactic acidosis and liver failure suddenly developed in one patient. The study was terminated on an emergency basis, and all treatment with fialuridine was discontinued. Seven patients were found to have severe hepatotoxicity, with progressive lactic acidosis, worsening jaundice, and deteriorating hepatic synthetic function despite the discontinuation of fialuridine. Three other patients had mild hepatotoxicity. Several patients also had pancreatitis, neuropathy, or myopathy. Of the seven patients with severe hepatotoxicity, five died and two survived after liver transplantation. Histologic analysis of liver tissue revealed marked accumulation of microvesicular and macrovesicular fat, with minimal necrosis of hepatocytes or architectural changes. Electron microscopy showed abnormal mitochondria and the accumulation of fat in hepatocytes. Conclusions. In patients with chronic hepatitis B, treatment with fialuridine induced a severe toxic reaction characterized by hepatic failure, lactic acidosis, pancreatitis, neuropathy, and myopathy This toxic reaction was probably caused by widespread mitochondrial damage and may occur infrequently with other nucleoside analogues.	NIDDKD,DIGEST DIS BRANCH,LIVER DIS SECT,BETHESDA,MD 20892; NIAID,CLIN INVEST LAB,BETHESDA,MD; NCI,CTR CLIN,DEPT NURSING,BETHESDA,MD; NCI,DEPT PATHOL,BETHESDA,MD; NINCDS,ELECTROMYOG SECT,BETHESDA,MD 20892; UNIV VIRGINIA,MED CTR,DEPT SURG,CHARLOTTESVILLE,VA; LILLY RES LABS,INDIANAPOLIS,IN	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Virginia; Eli Lilly			Kleiner, David E/N-2770-2013	Kleiner, David E/0000-0003-3442-4453				ALEXANDER GJM, 1987, J MED VIROL, V21, P81, DOI 10.1002/jmv.1890210111; ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5; Balistreri WF., 1990, PEDIAT HEPATOLOGY, P183; BISSUEL F, 1994, J INTERN MED, V235, P367, DOI 10.1111/j.1365-2796.1994.tb01088.x; CHATTHA G, 1993, ANN INTERN MED, V118, P37, DOI 10.7326/0003-4819-118-1-199301010-00007; CHEN CH, 1992, J BIOL CHEM, V267, P2856; CHEN CH, 1991, MOL PHARMACOL, V39, P625; COLACINO JM, 1994, ANTIMICROB AGENTS CH, V38, P1997, DOI 10.1128/AAC.38.9.1997; CUI LX, 1995, J CLIN INVEST, V95, P555, DOI 10.1172/JCI117698; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DOONG SL, 1991, P NATL ACAD SCI USA, V88, P8495, DOI 10.1073/pnas.88.19.8495; Dusheiko G., 1991, OXFORD TXB CLIN HEPA, P571; FOUREL I, 1992, J MED VIROL, V37, P122, DOI 10.1002/jmv.1890370209; FREIMAN JP, 1993, AIDS, V7, P379, DOI 10.1097/00002030-199303000-00012; FRIED MW, 1992, HEPATOLOGY, V16, P861, DOI 10.1002/hep.1840160402; FRIED MW, 1994, J HEPATOL, V21, P145, DOI 10.1016/S0168-8278(05)80387-3; FRIED MW, 1992, HEPATOLOGY, V16, pA127; GARCIA G, 1987, ANN INTERN MED, V107, P278, DOI 10.7326/0003-4819-107-2-278; GOPINATH R, 1992, J AM SOC NEPHROL, V3, P1212; GRADON JD, 1992, J INTERN MED, V231, P317, DOI 10.1111/j.1365-2796.1992.tb00542.x; GREM JL, 1991, INVEST NEW DRUG, V9, P281; HODGE RAV, 1989, ANTIMICROB AGENTS CH, V33, P223, DOI 10.1128/AAC.33.2.223; HOOFNAGLE JH, 1988, GASTROENTEROLOGY, V95, P1318, DOI 10.1016/0016-5085(88)90367-8; JANSSEN HLA, 1993, HEPATOLOGY, V17, P383; KLECKER RW, 1994, MOL PHARMACOL, V46, P1204; KORBA BE, 1992, ANTIVIR RES, V19, P55, DOI 10.1016/0166-3542(92)90056-B; KORBA BE, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P663; KUHNS MC, 1989, J MED VIROL, V27, P274, DOI 10.1002/jmv.1890270404; LAI KK, 1991, ANN INTERN MED, V115, P283, DOI 10.7326/0003-4819-115-4-283; LEWIS LD, 1992, ANTIMICROB AGENTS CH, V36, P2061, DOI 10.1128/AAC.36.9.2061; LEWIS W, 1992, J CLIN INVEST, V89, P1354, DOI 10.1172/JCI115722; LOK ASF, 1992, GASTROENTEROLOGY, V102, P2091, DOI 10.1016/0016-5085(92)90337-X; MANNING FJ, 1995, REV FIALURIDE FIAU C; MAXSON CJ, 1992, AM J GASTROENTEROL, V87, P708; PAAR DP, 1992, 32ND INT C ANT AG CH, P264; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; RICHARDSON FC, 1994, P NATL ACAD SCI USA, V91, P12003, DOI 10.1073/pnas.91.25.12003; SCULLARD GH, 1981, HEPATOLOGY, V1, P228, DOI 10.1002/hep.1840010306; SEITER K, 1993, CANCER, V71, P1875, DOI 10.1002/1097-0142(19930301)71:5<1875::AID-CNCR2820710526>3.0.CO;2-9; STASCHKE KA, 1994, J VIROL, V68, P8265, DOI 10.1128/JVI.68.12.8265-8269.1994; STEVENSON W, 1995, TRANSPLANT P, V27, P1219; SUSSMAN NL, 1992, HEPATOLOGY, V16, P60, DOI 10.1002/hep.1840160112; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011	43	442	469	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 26	1995	333	17					1099	1105		10.1056/NEJM199510263331702	http://dx.doi.org/10.1056/NEJM199510263331702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA372	7565947	Bronze			2022-12-28	WOS:A1995TA37200002
J	DICLEMENTE, RJ; WINGOOD, GM				DICLEMENTE, RJ; WINGOOD, GM			A RANDOMIZED CONTROLLED TRIAL OF AN HIV SEXUAL RISK-REDUCTION INTERVENTION FOR YOUNG AFRICAN-AMERICAN WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLACK-ADOLESCENT WOMEN; CONDOM-USE INTENTIONS; UNITED-STATES; AIDS; PREVENTION; BEHAVIOR; PREVALENCE; INFECTION; EDUCATION; PARTNERS	Objective.-To evaluate the efficacy of a community-based social skills human immunodeficiency virus (HIV) prevention intervention to enhance consistent condom use. Design.-A randomized, single-blind controlled trial. Setting.-Bayview-Hunter's Point neighborhood of San Francisco, Calif, a predominantly African-American community that is economically disadvantaged. Participants.-A sample of 128 sexually active, heterosexual, African-American women 18 through 29 years of age was recruited using street outreach techniques, Participants completed a structured baseline interview; 100 women (78.1%) completed 8-month follow-up interviews. Intervention.-Women randomized to the social skills intervention completed five sessions that emphasized ethnic and gender pride, HIV risk-reduction information, sexual self-control, sexual assertiveness and communication skills, proper condom use skills, and developing partner norms supportive of consistent condom use. Women randomized to the HIV education condition participated in a single session that provided HIV risk-reduction information. Women randomized to the delayed HIV education control condition received no HIV risk-reduction information until all follow-up interviews were completed. Main Outcome Measures.-Consistent condom use, HIV risk-reduction knowledge, sexual self-control, sexual assertiveness, sexual communication, and partner norms supportive of consistent condom use. Results.-Compared with the delayed HIV education control condition, women in the social skills intervention demonstrated increased consistent condom use (adjusted odds ratio [OR], 2.1; 95% confidence interval [CI], 1.03 to 4.15; P=.04), greater sexual self-control (adjusted OR, 1.9; 95% CI, 1.00 to 3.60; P=.05), greater sexual communication (adjusted OR, 4.1, 95% CI, 1.67 to 10.01; P=.002), greater sexual assertiveness (adjusted OR, 1.8; 95% CI, 1.01 to 3.27; P=.05), and increased partners' adoption of norms supporting consistent condom use (adjusted OR, 2.1; 95% CI, 1.08 to 3.87; P=.03). No statistically significant differences in out come variables were observed between the HIV education condition relative to the delayed HIV education control condition. Conclusion.-Community-based HIV risk-reduction programs that are gender relevant and culturally sensitive and provide social skills training can effectively enhance consistent condom use.	UNIV ALABAMA,SCH MED,DEPT PEDIAT,DIV ADOLESCENT MED,BIRMINGHAM,AL; UNIV ALABAMA,CTR AIDS RES,BIRMINGHAM,AL; UNIV ALABAMA,CTR HLTH PROMOT,BIRMINGHAM,AL	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	DICLEMENTE, RJ (corresponding author), UNIV ALABAMA,SCH PUBL HLTH,DEPT HLTH BEHAV,1825 UNIV BLVD,SUITE 121,BIRMINGHAM,AL 35294, USA.							AUERBACH JD, 1994, AIDS BEHAVIOR INTEGR; Bandura A., 1994, PREVENTING AIDS THEO, V26; Bandura A, 1994, SOCIAL COGNITIVE THE, P25, DOI DOI 10.1007/978-1-4899-1193-3_3; Barnett Rosalind C., 1987, GENDER STRESS; Bowser BP, 1988, URBAN ANTHROP, V17, P383; CATANIA JA, 1990, PSYCHOL BULL, V108, P339, DOI 10.1037/0033-2909.108.3.339; CATES W, 1992, FAM PLANN PERSPECT, V24, P75, DOI 10.2307/2135469; CHOI KH, 1994, AIDS, V8, P1371, DOI 10.1097/00002030-199410000-00003; COATES TJ, 1990, J CONSULT CLIN PSYCH, V58, P57, DOI 10.1037/0022-006X.58.1.57; Connell R., 1987, GENDER POWER SOC PER; CONWAY GA, 1993, JAMA-J AM MED ASSOC, V269, P2887, DOI 10.1001/jama.269.22.2887; DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601; DICLEMENTE RJ, 1994, PREVENTING AIDS THEO, P1; DICLEMENTE RJ, 1994, PREVENTING AIDS THEO; FINEBERG HV, 1988, SCIENCE, V239, P592, DOI 10.1126/science.3340845; FISHER JD, 1992, PSYCHOL BULL, V111, P455, DOI 10.1037/0033-2909.111.3.455; Flaskerud J H, 1990, J Community Health, V15, P343, DOI 10.1007/BF01324297; FLEISS JL, 1973, STATISTICAL METHODS; FULLILOVE MT, 1990, J SEX RES, V27, P47, DOI 10.1080/00224499009551541; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HANSEN WB, 1985, J BEHAV MED, V8, P261, DOI 10.1007/BF00870313; HOBFOLL SE, 1994, HEALTH PSYCHOL, V13, P397, DOI 10.1037/0278-6133.13.5.397; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; ICKOVICS JR, 1992, HEALTH PSYCHOL, V11, P1, DOI 10.1037/0278-6133.11.1.1; JEMMOTT JB, 1992, J ADOLESCENT HEALTH, V13, P512, DOI 10.1016/1054-139X(92)90016-5; JEMMOTT LS, 1992, NURS RES, V41, P273; KELLY JA, 1992, J CONSULT CLIN PSYCH, V60, P576, DOI 10.1037/0022-006X.60.4.576; KELLY JA, 1994, AM J PUBLIC HEALTH, V84, P1918, DOI 10.2105/AJPH.84.12.1918; KELLY JA, 1991, AM J PUBLIC HEALTH, V81, P168, DOI 10.2105/AJPH.81.2.168; KRAUTH MR, 1991, AIDS EDUC PREV, V3, P207; LAURIAN Y, 1989, NEW ENGL J MED, V320, P183; MEICHENBAUM DH, 1977, COGNITIVE BEHAVIOR M; PLICHTA SB, 1992, J ADOLESCENT HEALTH, V13, P506, DOI 10.1016/1054-139X(92)90015-4; Pocock S, 1993, CLIN TRIALS PRACTICA; ROPER WL, 1993, AM J PUBLIC HEALTH, V83, P501, DOI 10.2105/AJPH.83.4.501; SACCO WP, 1991, PSYCHOL ASSESSMENT J, V3, P265, DOI DOI 10.1037/1040-3590.3.2.265; SARACCO A, 1993, J ACQ IMMUN DEF SYND, V6, P497; SOLOMON MZ, 1989, AM J PUBLIC HEALTH, V79, P453, DOI 10.2105/AJPH.79.4.453; UPCHURCH DM, 1991, AM J EPIDEMIOL, V134, P1159, DOI 10.1093/oxfordjournals.aje.a116019; Wingood Gina M., 1992, Ethnicity and Disease, V2, P381; WINGOOD GM, 1995, AM J PUBLIC HEALTH, V85, P592, DOI 10.2105/AJPH.85.4.592; Wingood GM., 1993, J BLACK PSYCHOL, V19, P190, DOI [DOI 10.1177/00957984930192008, 10.1177/00957984930192008]; 1995, MMWR-MORBID MORTAL W, V44, P81	43	352	353	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	1995	274	16					1271	1276		10.1001/jama.274.16.1271	http://dx.doi.org/10.1001/jama.274.16.1271			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TA104	7563531				2022-12-28	WOS:A1995TA10400021
J	MOUL, JW; SESTERHENN, IA; CONNELLY, RR; DOUGLAS, T; SRIVASTAVA, S; MOSTOFI, FK; MCLEOD, DG				MOUL, JW; SESTERHENN, IA; CONNELLY, RR; DOUGLAS, T; SRIVASTAVA, S; MOSTOFI, FK; MCLEOD, DG			PROSTATE-SPECIFIC ANTIGEN VALUES AT THE TIME OF PROSTATE-CANCER DIAGNOSIS IN AFRICAN-AMERICAN MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To determine if African-American men with newly diagnosed prostate cancer (PC) have higher pretreatment serum prostate-specific antigen (PSA) values after adjustment for clinical stage, age, and tumor grade, and to determine if any difference detected is related to tumor volume difference. Design.-Consecutive case series of newly diagnosed PC patients between January 1990 and September 1994 and cohort analytic study of PC patients treated by radical prostatectomy (RP) and who had whole-mount pathologic tumor volume assessment between May 1993 December 1994. Setting.-Tertiary care military medical center. Patients.-A total of 541 evaluable newly diagnosed PC patients (408 white and 133 black) having pretreatment PSA assessment at one laboratory; 91 patients undergoing RP had whole-mount tumor volume analysis. Interventions.-Medical record review for pretreatment PSA value, race, tumor grade, clinical stage, and age, as well as whole-mount pathologic assessment of RP specimen and measurement of tumor volume. Main Outcome Measures.-The PSA differences between black and white PC patients with adjustments for age, biopsy tumor grade (Gleason score), and clinical stage (TNM stage); PSA differences between black and white PC patients undergoing RP with adjustment for age, RP grade, clinical stage, and tumor volume. Results.-The mean (geometric) PSA value for 133 black men was 14.00 ng/mL compared with 8.29 ng/mL for 408 white men (P<.001). The black patients had higher PSA values across all stage, grade, and age categories. The racial difference in PSA levels remained statistically significant when stage, grade, and age were simultaneously controlled for (P<.001). Multivariable odds ratio testing revealed that even after adjustment for stage, grade, and age, black patients were 2.2 times as likely as white patients to have a PSA value greater than 10.0 ng/mL (95% confidence interval, 1.3 to 3.6). Tumor volume (geometric mean) was 5.42 cm(3) and 2.10 cm(3) for black and white RP patients, respectively (P=.002). Across all clinical stages (T1a to T3), black men had tumor volumes 1.3 to 2.5 times greater than those of white men. Multivariable analysis of covariance revealed that tumor volume and stage of disease were important predictors of PSA level, but race, grade, and age were not. (The percentage of white and black patients whose cancer was detected by screening [75.4% vs 70.4%] or who had symptoms [37.7% vs 29.6%] was not significantly different.) Conclusions.-As a group, African-American men with newly diagnosed PC have higher PSA values at initial diagnosis than white men. This PSA difference appears to be due to larger tumor volumes within clinical (TNM) stage categories among black patients. Elevated PSA value was a surrogate for larger tu mor volume in this cohort of black men. This stage-for-stage tumor volume disparity even in an equal-access health care environment should prompt further study of screening behavior and/or biological differences of PC in the black population.	WALTER REED ARMY MED CTR,DEPT SURG,WASHINGTON,DC 20307; WALTER REED ARMY MED CTR,DEPT CLIN INVEST,WASHINGTON,DC 20307; ARMED FORCES INST PATHOL,DEPT GENITOURINARY PATHOL,WASHINGTON,DC 20306	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense	MOUL, JW (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DEPT SURG,CTR PROSTATE DIS RES,4301 JONES BRIDGE RD,BETHESDA,MD 20814, USA.							BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; Bullock Arnold, 1994, Journal of Urology, V151, p292A; CLARK JY, 1994, SOUTHERN MED J, V87, P1141, DOI 10.1097/00007611-199411000-00017; GLESON DF, 1977, UROLOGIC PATHOLOGY P, P171; McLeod David G., 1994, Journal of Urology, V151, p304A; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; MORTON RA, 1994, UROLOGY, V44, P637, DOI 10.1016/S0090-4295(94)80196-7; MOSTOFI FK, 1980, INT HISTOLOGICAL CLA, V22; OESTERLING JE, 1993, UROL CLIN N AM, V20, P687; OHORI M, 1994, CANCER-AM CANCER SOC, V74, P104, DOI 10.1002/1097-0142(19940701)74:1<104::AID-CNCR2820740119>3.0.CO;2-5; PARTIN AW, 1994, J UROLOGY, V152, P1358, DOI 10.1016/S0022-5347(17)32422-9; PIENTA KJ, 1995, UROLOGY, V45, P93, DOI 10.1016/S0090-4295(95)96996-9; Powell Isaac J., 1994, Journal of Urology, V151, p413A; ROSS RK, 1992, LANCET, V339, P887, DOI 10.1016/0140-6736(92)90927-U; Staggers Frank M., 1994, Journal of Urology, V151, p291A; VIJAYAKUMAR S, 1992, CANCER EPIDEM BIOMAR, V1, P541	16	222	232	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	1995	274	16					1277	1281		10.1001/jama.274.16.1277	http://dx.doi.org/10.1001/jama.274.16.1277			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA104	7563532				2022-12-28	WOS:A1995TA10400022
J	MASELLIS, M; PATERSON, AD; BADRI, F; LIEBERMAN, JA; MELTZER, HY; CAVAZZONI, P; KENNEDY, JL				MASELLIS, M; PATERSON, AD; BADRI, F; LIEBERMAN, JA; MELTZER, HY; CAVAZZONI, P; KENNEDY, JL			GENETIC-VARIATION OF 5-HT2A RECEPTOR AND RESPONSE TO CLOZAPINE	LANCET			English	Letter									CLARKE INST PSYCHIAT,NEUROGENET SECT,TORONTO,ON M5T 1R8,CANADA; HILLSIDE HOSP,GLEN OAKS,NY 11004; CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106; BRONX VET ADM,BRONX,NY; MCMASTER UNIV,DEPT PSYCHIAT,HAMILTON,ON,CANADA; ROYAL OTTAWA HOSP,DEPT PSYCHIAT,OTTAWA,ON K1Z 7K4,CANADA	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; Northwell Health; Case Western Reserve University; McMaster University; University of Ottawa			Meltzer, Herbert Y/E-8131-2013; Paterson, Andrew D/A-4088-2011	Paterson, Andrew D/0000-0002-9169-118X				ARRANZ, LANCET          0729, P281; MELTZER HY, 1994, J CLIN PSYCHIAT, V55, pB47	2	67	68	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1108	1108		10.1016/S0140-6736(95)91785-3	http://dx.doi.org/10.1016/S0140-6736(95)91785-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564821				2022-12-28	WOS:A1995TA69700060
J	FRANCIS, GS				FRANCIS, GS			ROTATING TOURNIQUETS FOR ACUTE CARDIOGENIC PULMONARY-EDEMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											FRANCIS, GS (corresponding author), UNIV MINNESOTA,MINNEAPOLIS,MN 55455, USA.							INGRAM RH, 1992, HEART DIS TXB CARDIO, P563	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	1995	274	15					1192	1192		10.1001/jama.274.15.1192	http://dx.doi.org/10.1001/jama.274.15.1192			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ120	7563500				2022-12-28	WOS:A1995RZ12000011
J	CHABRIAT, H; VAHEDI, K; IBAZIZEN, MT; JOUTEL, A; NIBBIO, A; NAGY, TG; KREBS, MO; JULIEN, J; DUBOIS, B; DUCROCQ, X; LEVASSEUR, M; HOMEYER, P; MAS, JL; LYONCAEN, O; LASSERVE, ET; BOUSSER, MG				CHABRIAT, H; VAHEDI, K; IBAZIZEN, MT; JOUTEL, A; NIBBIO, A; NAGY, TG; KREBS, MO; JULIEN, J; DUBOIS, B; DUCROCQ, X; LEVASSEUR, M; HOMEYER, P; MAS, JL; LYONCAEN, O; LASSERVE, ET; BOUSSER, MG			CLINICAL SPECTRUM OF CADASIL - A STUDY OF 7 FAMILIES	LANCET			English	Article							MULTI-INFARCT DEMENTIA; MIGRAINE; LEUKOENCEPHALOPATHY; DISEASE; HEADACHES; STROKES; BRAIN	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited arterial disease of the brain recently mapped to chromosome 19. We studied 148 subjects belonging to seven families by magnetic resonance imaging and genetic linkage analysis. 45 family members (23 males and 22 females) were clinically affected. Frequent signs were recurrent subcortical ischaemic events (84%), progressive or stepwise subcortical dementia with pseudobulbar palsy (31%), migraine with aura (22%), and mood disorders with severe depressive episodes (20%). All symptomatic subjects had prominent signal abnormalities on MRI with hyperintense lesions on T2-weighted images in the subcortical white-matter and basal ganglia which were also present in 19 asymptomatic subjects. The age at onset of symptoms was mean 45 (SD [10.6]) years, with attacks of migraine with aura occurring earlier in life (38.1[8.03] years) than ischaemic events (49.3 [10.7] years). The mean age at death was 64.5 (10.6) years. On the basis of MRI data, the penetrance of the disease appears complete between 30 and 40 years of age. Genetic analysis showed strong linkage to the CADASIL locus for all seven families, suggesting genetic homogeneity. CADASIL is a hereditary cause of stroke, migraine with aura, mood disorders and dementia. The diagnosis should be considered not only in patients with recurrent small subcortical infarcts leading to dementia, but also in patients with transient ischaemic attacks, migraine with aura or severe mood disturbances, whenever MRI reveals prominent signal abnormalities in the subcortical white-matter and basal ganglia. Clinical and MRI investigations of family members are then crucial for the diagnosis which can be confirmed by genetic linkage analysis. The disease is probably largely undiagnosed.	HOP ST ANTOINE,SERV NEUROL,PARIS 12,FRANCE; HOP QUINZE VINGTS,SERV NEURORADIOL,PARIS,FRANCE; FAC MED NECKER ENFANTS MALAD,INSERM,U25,PARIS,FRANCE; HOP ST ANNE,SERV PSYCHIAT PR LOO,F-75674 PARIS,FRANCE; CHU BORDEAUX,SERV NEUROL,BORDEAUX,FRANCE; CHU NANCY,SERV NEUROL,NANCY,FRANCE; CHG ORSAY,SERV MED INTERNE,ORSAY,FRANCE; HOP ST ANNE,SERV NEUROL,F-75674 PARIS,FRANCE; HOP LA PITIE SALPETRIERE,FEDERAT NEUROL,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; CHNO des Quinze-Vingts; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite; CHU Bordeaux; CHU de Nancy; GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite			Joutel, Anne/K-5601-2017; Krebs, Marie-Odile/O-2104-2017; Chabriat, Hugues/G-5699-2010	Joutel, Anne/0000-0003-3963-3860; Krebs, Marie-Odile/0000-0002-4715-9890; Chabriat, Hugues/0000-0001-8436-6074				AYLWARD ED, 1994, AM J PSYCHIAT, V5, P687; BABIKIAN V, 1987, STROKE, V18, P2, DOI 10.1161/01.STR.18.1.2; BAUDRIMONT M, 1993, STROKE, V24, P122, DOI 10.1161/01.STR.24.1.122; BHATIA KP, 1994, BRAIN, V117, P859, DOI 10.1093/brain/117.4.859; COLMANT HJ, 1980, PATHOLOGIE, V124, P163; Davous P, 1991, REV NEUROL-FRANCE, V5, P376; De Reuck J, 1972, Acta Neurol Belg, V72, P323; FERBERT A, 1991, STROKE, V22, P1010, DOI 10.1161/01.STR.22.8.1010; GRENBERG SM, 1993, NEUROLOGY, V43, P2073; GUTIERREZMOLINA M, 1994, ACTA NEUROPATHOL, V87, P98; HUGHES GRV, 1993, LANCET, V342, P341, DOI 10.1016/0140-6736(93)91477-4; IGARASHI H, 1991, CEPHALALGIA, V11, P69, DOI 10.1046/j.1468-2982.1991.1102069.x; JOUTEL A, 1993, NAT GENET, V5, P40, DOI 10.1038/ng0993-40; LOPEZ OL, 1994, NEUROLOGY, V44, P1240, DOI 10.1212/WNL.44.7.1240; MAS JL, 1992, NEUROLOGY, V42, P1015, DOI 10.1212/WNL.42.5.1015; MONTAGNA P, 1988, NEUROLOGY, V38, P751, DOI 10.1212/WNL.38.5.751; OSBORN RE, 1991, AM J NEURORADIOL, V12, P521; RASMUSSEN BK, 1992, NEUROLOGY, V42, P1225, DOI 10.1212/WNL.42.6.1225; SALVI F, 1992, ITAL J NEUROL SCI, V13, P135, DOI 10.1007/BF02226962; SCHELTENS P, 1992, BRAIN, V115, P735, DOI 10.1093/brain/115.3.735; SCHYER B, 1990, SCHEDULE AFFECTIVE D; SONNINEN V, 1987, EUR NEUROL, V27, P209, DOI 10.1159/000116158; SOURANDER P, 1977, ACTA NEUROPATHOL, V39, P247, DOI 10.1007/BF00691704; STCLAIR D, 1995, J MED GENET, V32, P57, DOI 10.1136/jmg.32.1.57; STEVENS DL, 1977, LANCET, V2, P1364; TOKUNAGA M, 1994, ANN NEUROL, V35, P413, DOI 10.1002/ana.410350407; TOURNIERLASSERV.E, 1994, AM J HUM GENET, V55, pA205; TOURNIERLASSERV.E, 1993, NAT GENET, V3, P356; TOURNIERLASSERVE E, 1991, STROKE, V22, P1297, DOI 10.1161/01.STR.22.10.1297; VAHEDI K, 1995, ANN NEUROL, V37, P289, DOI 10.1002/ana.410370304; VANBOGAERT L, 1955, MED HELLEN, V24, P961; VERIN M, 1994, NEUROLOGY, V44, P288; WEISSENBACH J, 1992, NATURE, V359, P494; 1987, DIAGNOSTIC STATISTIC; 1988, CEPHALALGIA S, V7, P8	35	523	541	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					934	939		10.1016/S0140-6736(95)91557-5	http://dx.doi.org/10.1016/S0140-6736(95)91557-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564728				2022-12-28	WOS:A1995RY80800009
J	KLYMKOWSKY, MW; PARR, B				KLYMKOWSKY, MW; PARR, B			THE BODY LANGUAGE OF CELLS - THE INTIMATE CONNECTION BETWEEN CELL-ADHESION AND BEHAVIOR	CELL			English	Review							XENOPUS		HARVARD UNIV,CAMBRIDGE,MA 02138	Harvard University	KLYMKOWSKY, MW (corresponding author), UNIV COLORADO,BOULDER,CO 80309, USA.			Klymkowsky, Mike/0000-0001-5816-9771				ARTAVANISTSAKON.S, 1995, SCIENCE, V266, P225; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; COUSO JP, 1994, CELL, V79, P259, DOI 10.1016/0092-8674(94)90195-3; COWIN P, 1994, P NATL ACAD SCI USA, V91, P10759, DOI 10.1073/pnas.91.23.10759; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HEAYSMAN JE, 1973, EXP CELL RES, V78, P71, DOI 10.1016/0014-4827(73)90039-6; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; KARNOVSKY A, 1995, P NATL ACAD SCI USA, V92, P4522, DOI 10.1073/pnas.92.10.4522; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; KOWALCZYK AP, 1994, J BIOL CHEM, V269, P31214; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; MOON RT, 1993, BIOESSAYS, V15, P91, DOI 10.1002/bies.950150204; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; PARR BA, 1996, NATURE, V374, P350; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; PIERCE SB, 1995, DEVELOPMENT, V121, P755; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SOKOL SY, 1995, DEVELOPMENT, V121, P1637; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X	25	99	102	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					5	8		10.1016/0092-8674(95)90226-0	http://dx.doi.org/10.1016/0092-8674(95)90226-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553873	Bronze			2022-12-28	WOS:A1995RY58300002
J	SADIQ, ST; GLASGOW, KW; DRAKELEY, CJ; MULLER, O; GREENWOOD, BM; MABEY, DCW; BAILEY, RL				SADIQ, ST; GLASGOW, KW; DRAKELEY, CJ; MULLER, O; GREENWOOD, BM; MABEY, DCW; BAILEY, RL			EFFECTS OF AZITHROMYCIN ON MALARIOMETRIC INDEXES IN THE GAMBIA	LANCET			English	Note							ERYTHROMYCIN	Azithromycin (a macrolide-like antibiotic) has antimalarial effects in vitro and in animal models. In the course of a randomised trial of trachoma control we examined the effects of azithromycin on parasite and spleen rates in the population aged 5-14 years from eight villages in the Farafenni study area in The Gambia, West Africa. The entire population of four treatment villages received three doses of azithromycin 20 mg/kg weekly (days 1, 8, and 15) and four control villages received daily tetracycline eye ointment topically (days 1-42). Among 226 children studied before treatment and at day 28, reduced the proportions with Plasmodium parasites (rate ratio 0.56, 95% confidence interval 0.44-0.71; p<0.0001), with palpable spleens (RR 0.50, 95% CI 0.36-0.70; p<0.0001), with febrile parasitaemia (RR 0.45, 95% CI 0.27-0.75; p<0.01), and with P malariae infection (p<0.001). This effect was related more to resolution of parasitaemia than to prevention of new infections.	UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND; MRC LABS,FAJARA,SENEGAL	University of London; London School of Hygiene & Tropical Medicine				Sadiq, S Tariq/0000-0002-0608-3818; Mabey, David/0000-0002-0031-8276				ANDERSEN SL, 1995, AM J TROP MED HYG, V52, P159, DOI 10.4269/ajtmh.1995.52.159; BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9; GINGRAS BA, 1992, AM J TROP MED HYG, V47, P378, DOI 10.4269/ajtmh.1992.47.378; GINGRAS BA, 1993, AM J TROP MED HYG, V49, P101, DOI 10.4269/ajtmh.1993.49.101; GREENWOOD BM, 1993, T R SOC TROP MED S2, V87; HOPKINS S, 1991, AM J MED, V91, pS40, DOI 10.1016/0002-9343(91)90401-I; KUSCHNER RA, 1994, LANCET, V343, P1396, DOI 10.1016/S0140-6736(94)92526-7; LULAT AG, 1993, THESIS U LONDON; WHITE NJ, 1992, J ANTIMICROB CHEMOTH, V30, P571, DOI 10.1093/jac/30.5.571; 1983, B WORLD HEALTH ORGAN, V61, P169	10	52	53	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 30	1995	346	8979					881	882		10.1016/S0140-6736(95)92712-3	http://dx.doi.org/10.1016/S0140-6736(95)92712-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX196	7564674				2022-12-28	WOS:A1995RX19600012
J	JENTSCH, S; SCHLENKER, S				JENTSCH, S; SCHLENKER, S			SELECTIVE PROTEIN-DEGRADATION - A JOURNEYS END WITHIN THE PROTEASOME	CELL			English	Review							UBIQUITIN				JENTSCH, S (corresponding author), UNIV HEIDELBERG ZMBH,ZENTRUM MOLEK BIOL,NEUENHEIMER FELD 282,D-69120 HEIDELBERG,GERMANY.							AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; CHEN P, 1995, EMBO J, V14, P2620, DOI 10.1002/j.1460-2075.1995.tb07260.x; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; FEHLING HJ, 1994, SCIENCE, V265, P1237; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; HADARI T, 1992, J BIOL CHEM, V267, P719; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; TAMURA T, 1995, CURR BIOL, V5, P766, DOI 10.1016/S0960-9822(95)00153-9; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765	23	239	242	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					881	884		10.1016/0092-8674(95)90021-7	http://dx.doi.org/10.1016/0092-8674(95)90021-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553848	Bronze			2022-12-28	WOS:A1995RW69300004
J	HUANG, PL; HUANG, ZH; MASHIMO, H; BLOCH, KD; MOSKOWITZ, MA; BEVAN, JA; FISHMAN, MC				HUANG, PL; HUANG, ZH; MASHIMO, H; BLOCH, KD; MOSKOWITZ, MA; BEVAN, JA; FISHMAN, MC			HYPERTENSION IN MICE LACKING THE GENE FOR ENDOTHELIAL NITRIC-OXIDE SYNTHASE	NATURE			English	Article							NADPH DIAPHORASE; RELAXING FACTOR; BLOOD-PRESSURE; L-ARGININE; INHIBITORS; NEURONS; INVIVO; NERVE	NITRIC oxide (NO), a potent vasodilator produced by endothelial cells, is thought to be the endothelium-dependent relaxing factor (EDRF) which mediates vascular relaxation in response to acetylcholine, bradykinin and substance P in many vascular besds(1-6). NO has been implicated in the regulation of blood pressure and regional blood flow(4-6), and also affects vascular smooth-muscle proliferation and inhibits platelet aggregation and leukocyte adhesion. Abnormalities in endothelial production of NO occur in atherosclerosis, diabetes and hypertension(7). Pharmacological blockade of NO production with arginine analogues such as L-nitroarginine (L-NA) or L-N-arginine methyl ester affects multiple isoforms of nitric oxide synthase (NOS), and so cannot distinguish their physiological roles(8,9). To study the role of endothelial NOS (eNOS) in vascular function, we disrupted the gene encoding eNOS in mice. Endothelium-derived relaxing factor activity, as assayed by acetylcholine-induced relaxation, is absent, and the eNOS mutant mice are hypertensive. Thus eNOS mediates basal vasodilation. Responses to NOS blockade in the mutant mice suggest that non-endothelial isoforms of NOS mag be involved in maintaining blood pressure.	MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,MED SERV,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,DEPT NEUROL,STROKE RES LAB,BOSTON,MA 02129; UNIV VERMONT,COLL MED,DEPT PHARMACOL,BURLINGTON,VT 05405	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of Vermont			Moskowitz, Michael A/D-9916-2011					ANDERSON CR, 1992, NEUROSCI LETT, V139, P280, DOI 10.1016/0304-3940(92)90571-N; AYAJIKI K, 1993, NEUROSCIENCE, V54, P819, DOI 10.1016/0306-4522(93)90251-A; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; DASILVA SV, 1994, HYPERTENSION S1, V23, P60; FORSTERMANN U, 1994, METHOD ENZYMOL, V233, P258; FREY C, 1994, J BIOL CHEM, V269, P26083; GARDINER SM, 1992, EUR J PHARMACOL, V213, P449, DOI 10.1016/0014-2999(92)90636-I; HEVEL JM, 1994, METHOD ENZYMOL, V233, P250; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; IADECOLA C, 1993, BRAIN RES, V603, P173, DOI 10.1016/0006-8993(93)91318-M; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; IRIKURA K, 1995, P NATL ACAD SCI USA, V92, P6823, DOI 10.1073/pnas.92.15.6823; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MATSUDA T, 1995, CIRC RES, V76, P426, DOI 10.1161/01.RES.76.3.426; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PEART WS, 1983, HYPERTENSION; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; SAKUMA I, 1992, CIRC RES, V70, P607, DOI 10.1161/01.RES.70.3.607; SCROGIN KE, 1994, HYPERTENSION, V23, P982, DOI 10.1161/01.HYP.23.6.982; SNYDER SH, 1994, NATURE, V372, P504, DOI 10.1038/372504a0; TODA N, 1993, J VASC RES, V30, P61, DOI 10.1159/000158976; TOGASHI H, 1992, J PHARMACOL EXP THER, V262, P343; VINCENT SR, 1992, NEUROSCIENCE, V48, P755; [No title captured]	27	1683	1735	1	69	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					239	242		10.1038/377239a0	http://dx.doi.org/10.1038/377239a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7545787				2022-12-28	WOS:A1995RV87200042
J	YU, CL; MEYER, DJ; CAMPBELL, GS; LARNER, AC; CARTERSU, C; SCHWARTZ, J; JOVE, R				YU, CL; MEYER, DJ; CAMPBELL, GS; LARNER, AC; CARTERSU, C; SCHWARTZ, J; JOVE, R			ENHANCED DNA-BINDING ACTIVITY OF A STAT3-RELATED PROTEIN IN CELLS TRANSFORMED BY THE SRC ONCOPROTEIN	SCIENCE			English	Article							TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; INTERFERON-GAMMA; GENE; INDUCIBILITY; ACTIVATION; ELEMENT; KINASE; JAK	Cytokines and growth factors induce tyrosine phosphorylation of signal transducers and activators of transcription (STATs) that directly activate gene expression. Cells stably transformed by the Src oncogene tyrosine kinase were examined for STAT protein activation. Assays of electrophoretic mobility, DNA-binding specificity, and antigenicity indicated that Stat3 or a closely related STAT family member was constitutively activated by the Src oncoprotein. Induction of this DNA-binding activity was accompanied by tyrosine phosphorylation of Stat3 and correlated with Src transformation. These findings demonstrate that Src can activate STAT signaling pathways and raise the possibility that Stat3 contributes to oncogenesis by Src.	UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,CTR COMPREHENS CANC,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Food & Drug Administration (FDA)			Yu, Chao-Lan/D-1834-2011	Yu, Chao-Lan/0000-0002-9381-6011	NCI NIH HHS [CA55652] Funding Source: Medline; NIDDK NIH HHS [DK34171, R01 DK034171] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034171, R37DK034171] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BHAVSAR D, COMMUNICATION; CAMPBELL GK, UNPUB; CAMPBELL GS, IN PRESS J BIOL CHEM; COCHRAN BH, UNPUB; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; RAZ R, 1994, J BIOL CHEM, V269, P24391; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YU CH, UNPUB; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	29	797	832	0	40	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					81	83		10.1126/science.7541555	http://dx.doi.org/10.1126/science.7541555			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7541555				2022-12-28	WOS:A1995RG98000038
J	SHI, YG; BERG, JM				SHI, YG; BERG, JM			SPECIFIC DNA-RNA HYBRID BINDING BY ZINC-FINGER PROTEINS	SCIENCE			English	Article							CRYSTAL-STRUCTURE; 5S RNA; RECOGNITION; RULES	Zinc finger proteins of the Cys(2)His(2) type represent a large class of proteins that have been assumed to function by means of specific interactions with DNA. Experiments motivated by structural characteristics of zinc finger protein-DNA complexes revealed that certain zinc finger proteins bound DNA-RNA hybrids with affinities comparable to or greater than those for DNA duplexes. The interactions between the zinc finger proteins and the DNA-RNA hybrids were dependent on which strand was RNA and were sequence-specific. Thus, interactions with DNA-RNA hybrids should be considered with regard to the biological roles of zinc finger proteins.			SHI, YG (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205, USA.		Berg, Jeremy/GRY-6706-2022	Berg, Jeremy/0000-0002-2444-8139; Shi, Yigong/0000-0003-2030-168X; Berg, Jeremy/0000-0003-3022-0963	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046257] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46257] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN A, 1989, CURRENT PROTOCOLS MO, V2; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; CLEMENS KR, 1993, SCIENCE, V260, P530, DOI 10.1126/science.8475383; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; JOHO KE, 1990, CELL, V61, P293, DOI 10.1016/0092-8674(90)90809-S; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; NEKLUDOVA L, 1994, P NATL ACAD SCI USA, V91, P6948, DOI 10.1073/pnas.91.15.6948; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; RHODES D, 1993, SCI AM, V268, P56, DOI 10.1038/scientificamerican0293-56; SALAZAR M, 1993, BIOCHEMISTRY-US, V32, P4207, DOI 10.1021/bi00067a007; Shi Y. G., UNPUB	15	82	124	3	43	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					282	284		10.1126/science.7536342	http://dx.doi.org/10.1126/science.7536342			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7536342				2022-12-28	WOS:A1995QT18500036
J	NOBES, CD; HALL, A				NOBES, CD; HALL, A			RHO, RAC, AND CDC42 GTPASES REGULATE THE ASSEMBLY OF MULTIMOLECULAR FOCAL COMPLEXES ASSOCIATED WITH ACTIN STRESS FIBERS, LAMELLIPODIA, AND FILOPODIA	CELL			English	Article							PROTEIN-KINASE-C; GTP-BINDING PROTEIN; GROWTH CONE FILOPODIA; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; ADHESION PLAQUES; ANIMAL-CELLS; LEADING-EDGE; FIBROBLASTS; CONTACTS	Rho and rac, two members of the ras-related superfamily of small GTPases, regulate the polymerization of actin to produce stress fibers and lamellipodia, respectively. We report here that cdc42, another member of the rho family, triggers the formation of a third type of actin-based structure found at the cell periphery, filopodia. In addition to stress fibers, rho controls the assembly of focal adhesion complexes. We now show that rac and cdc42 also stimulate the assembly of multimolecular focal complexes at the plasma membrane. These complexes, which are associated with lamellipodia and filopodia, contain vinculin, paxillin, and focal adhesion kinase, but are distinct from and formed independently of rho-induced focal adhesions. Activation of cdc42 in Swiss 3T3 cells leads to the sequential activation of rac and then rho, suggesting a molecular model for the coordinated control of cell motility by members of the rho family of GTPases.	UNIV LONDON UNIV COLL,DEPT BIOCHEM,LONDON WC1E 6BT,ENGLAND	University of London; University College London	NOBES, CD (corresponding author), CANC RES CAMPAIGN,ONCOGENE & SIGNAL TRANSDUCT GRP,MRC,MOLEC CELL BIOL LAB,LONDON WC1E 6BT,ENGLAND.							ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ALBRECHTBUEHLER G, 1976, J CELL BIOL, V69, P275, DOI 10.1083/jcb.69.2.275; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BURRIDGE K, 1983, CELL MOTIL CYTOSKEL, V3, P405, DOI 10.1002/cm.970030509; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CAO LG, 1990, J CELL BIOL, V110, P1089, DOI 10.1083/jcb.110.4.1089; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; DEPASQUALE JA, 1991, J CELL BIOL, V113, P1351, DOI 10.1083/jcb.113.6.1351; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; FLANAGAN MD, 1980, J BIOL CHEM, V255, P835; GUMBINER BM, 1993, NEURON, V11, P551, DOI 10.1016/0896-6273(93)90068-3; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1994, J BIOL CHEM, V269, P62; HEATH JP, 1978, J CELL SCI, V29, P197; IZZARD CS, 1988, CELL MOTIL CYTOSKEL, V10, P137, DOI 10.1002/cm.970100118; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; Lee Juliet, 1993, Trends in Cell Biology, V3, P366, DOI 10.1016/0962-8924(93)90084-E; Machesky Laura M., 1993, Trends in Cell Biology, V3, P381, DOI 10.1016/0962-8924(93)90087-H; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; NOBES CD, 1995, J CELL SCI, V108, P225; OCONNOR TP, 1993, J CELL BIOL, V123, P935, DOI 10.1083/jcb.123.4.935; OKABE S, 1989, J CELL BIOL, V109, P1581, DOI 10.1083/jcb.109.4.1581; OSTER GF, 1987, J CELL SCI S, V8, P35; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RINNERTHALER G, 1988, J CELL BIOL, V106, P747, DOI 10.1083/jcb.106.3.747; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHANNON M, 1993, NATURE, V365, P661; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Small JV, 1989, CURR OPIN CELL BIOL, V1, P75, DOI 10.1016/S0955-0674(89)80040-7; SMALL JV, 1995, TRENDS CELL BIOL, V5, P52, DOI 10.1016/S0962-8924(00)88939-4; SMALL JV, 1981, J CELL BIOL, V91, P695, DOI 10.1083/jcb.91.3.695; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SYMONS MH, 1991, J CELL BIOL, V114, P503, DOI 10.1083/jcb.114.3.503; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; VUORI K, 1993, J BIOL CHEM, V268, P21459; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; WOODS A, 1992, J CELL SCI, V101, P277; WU DY, 1993, J CELL BIOL, V123, P653, DOI 10.1083/jcb.123.3.653; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; Zigmond SH, 1989, CURR OPIN CELL BIOL, V1, P80, DOI 10.1016/S0955-0674(89)80041-9	57	3655	3709	9	283	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					53	62		10.1016/0092-8674(95)90370-4	http://dx.doi.org/10.1016/0092-8674(95)90370-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7536630	Bronze			2022-12-28	WOS:A1995QR97000007
J	BRUNNER, T; MOGIL, RJ; LAFACE, D; YOO, NJ; MAHBOUBI, A; ECHEVERRI, F; MARTIN, SJ; FORCE, WR; LYNCH, DH; WARE, CF; GREEN, DR				BRUNNER, T; MOGIL, RJ; LAFACE, D; YOO, NJ; MAHBOUBI, A; ECHEVERRI, F; MARTIN, SJ; FORCE, WR; LYNCH, DH; WARE, CF; GREEN, DR			CELL-AUTONOMOUS FAS (CD95) FAS-LIGAND INTERACTION MEDIATES ACTIVATION-INDUCED APOPTOSIS IN T-CELL HYBRIDOMAS	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; MONOCLONAL-ANTIBODY; DNA FRAGMENTATION; CYCLOSPORINE-A; CYCLE BLOCK; DEATH; RECEPTOR; REQUIREMENTS; INVOLVEMENT; THYMOCYTES	A NUMBER of murine T-cell hybridomas undergo apoptosis within a few hours of activation by specific antigens, mitogens, antibodies against the T-cell antigen receptor, or a combination of phorbol ester and calcium ionophore(1-3). This phenomenon has been extensively studied as a model for cional deletion in the immune system, in which potentially autoreactive T cells eliminate themselves by apoptosis after activation, either in the thymus(4) or in the periphery(5). Here we show that the Fas/CD95 receptor, which can transduce a potent apoptotic signal when ligated(6,7), is rapidly expressed following activation of T-cell hybridomas, as is its functional, membrane-bound ligands, Interference with the ensuing Fas/Fas-ligand interaction inhibits activation-induced apoptosis, Because T-cell receptor ligation can induce apoptosis in a single T hybridoma cell, we suggest that the Fas/Fas-ligand interaction can induce cell death in a cell-autonomous manner.	UNIV CALIF RIVERSIDE,DIV BIOMED SCI,RIVERSIDE,CA 92521; IMMUNEX RES & DEV CORP,DEPT IMMUNOL,SEATTLE,WA 98101	University of California System; University of California Riverside	BRUNNER, T (corresponding author), LA JOLLA INST ALLERGY & IMMUNOL,DIV CELLULAR IMMUNOL,11149 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417; Martin, Seamus/0000-0002-8539-3143				ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BISSONNETTE RP, 1994, J EXP MED, V180, P2413, DOI 10.1084/jem.180.6.2413; CROWE PD, 1994, J IMMUNOL METHODS, V168, P79, DOI 10.1016/0022-1759(94)90212-7; FOTEDAR R, MOL CELL BIOL; Green D R, 1992, Semin Immunol, V4, P379; IWATA M, 1991, EUR J IMMUNOL, V21, P643, DOI 10.1002/eji.1830210316; IWATA M, 1991, J IMMUNOL, V149, P3302; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MCGAHON AJ, IN PRESS CELL DEATH; MERCEP M, 1989, J IMMUNOL, V142, P4085; RAMSDELL F, 1994, EUR J IMMUNOL, V24, P928, DOI 10.1002/eji.1830240422; RAMSDELL F, 1994, INT IMMUNOL, V6, P1545, DOI 10.1093/intimm/6.10.1545; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1993, P NATL ACAD SCI USA, V88, P4409; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SHI YF, 1990, J IMMUNOL, V144, P3326; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; UCKER DS, 1989, J IMMUNOL, V143, P3461; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; YANG YL, 1993, P NATL ACAD SCI USA, V90, P6170, DOI 10.1073/pnas.90.13.6170; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037	30	1253	1273	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					441	444		10.1038/373441a0	http://dx.doi.org/10.1038/373441a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7530336				2022-12-28	WOS:A1995QE67000060
J	GROSSHANS, J; BERGMANN, A; HAFFTER, P; NUSSLEINVOLHARD, C				GROSSHANS, J; BERGMANN, A; HAFFTER, P; NUSSLEINVOLHARD, C			ACTIVATION OF THE KINASE PELLE BY TUBE IN THE DORSOVENTRAL SIGNAL-TRANSDUCTION PATHWAY OF DROSOPHILA EMBRYO	NATURE			English	Article							DORSAL-VENTRAL POLARITY; TOLL GENE-PRODUCT; NUCLEAR-LOCALIZATION; PROTO-ONCOGENE; ESTABLISHMENT; PATTERN; CACTUS; MORPHOGEN; GRADIENT; RECEPTOR	THE concentration of Dorsal protein in the nucleus determines cell fate along the dorsoventral axis of the Drosophila embryo(1-13). The dorsal-group genes and the cactus gene are required for production and transmission of a localized signal an the ventral side of the embryo(4,5) which determines the position of the highest nuclear concentration of Dorsal protein(1-3) The ventralizing signal produced in somatic cells(6) is transmitted through the perivitelline space(7) to the integral membrane protein Toll(8). Inside the embryo it leads to dissociation of the cytoplasmic Dorsal-Cactus complex and subsequent nuclear localization of Dorsal protein(9,10). Two components are known to mediate the signal transduction between Toll and Dorsal-Cactus(11,12): Pelle, a serine/threonine protein kinase(13), and Tube, a protein with an unknown biochemical activity(14). Here we construct gain-of-function alleles of pelle and tube and show that pelle functions downstream of tube. In addition, Pelle and Tube interact directly with one another. We propose that Tube is a direct activator of the protein kinase Pelle.			GROSSHANS, J (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,GENET ABT 3,SPEMANNSTR 35,D-72076 TUBINGEN,GERMANY.		Großhans, Jörg/AAE-9387-2020	Großhans, Jörg/0000-0003-1114-9233				ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAGENMEIER S, 1992, THESIS U TUBINGEN; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HECHT PM, 1993, GENETICS, V135, P405; ISODA K, 1994, P NATL ACAD SCI USA, V91, P5350, DOI 10.1073/pnas.91.12.5350; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; MARCEY D, 1991, EMBO J, V10, P4259, DOI 10.1002/j.1460-2075.1991.tb05004.x; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1991, DEVELOPMENT, V112, P371; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523; Wieschaus E., 1986, P199	30	107	112	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					563	566		10.1038/372563a0	http://dx.doi.org/10.1038/372563a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7527496				2022-12-28	WOS:A1994PW08200056
J	STOUTHAMER, R; BREEUWER, JAJ; LUCK, RF; WERREN, JH				STOUTHAMER, R; BREEUWER, JAJ; LUCK, RF; WERREN, JH			MOLECULAR-IDENTIFICATION OF MICROORGANISMS ASSOCIATED WITH PARTHENOGENESIS	NATURE			English	Article							TRICHOGRAMMA HYMENOPTERA; DROSOPHILA-SIMULANS; INCOMPATIBILITY; POPULATIONS; MORMONIELLA	CYTOPLASMICALLY inherited microorganisms are widespread in insects and have been implicated as causes of female parthenogenesis (females developing from unfertilized eggs) and cytoplasmic incompatibility1-15. Normal sexual reproduction can be restored by treatment with antibiotics1-4. Sequence analysis of the DNA encoding 16S ribosomal RNA has shown that cytoplasmic incompatibility bacteria from diverse insect taxa are closely related (they share >95% sequence similarity) and belong to the alpha subdivision of Proteobacteria5-7. Here we show that parthenogenesis-associated bacteria from parasitoid Hymenoptera also fall into this bacterial group, having up to 99% sequence similarity to some incompatibility microorganisms. Both incompatibility and parthenogenesis microorganisms alter host chromosome behaviour during early mitotic divisions of the egg13-17. Incompatibility bacteria act by interfering with paternal chromosome incorporation in fertilized eggs, whereas parthenogenesis bacteria prevent segregation of chromosomes in unfertilized eggs. These traits are adaptive for the microorganisms. On the basis of their sequence similarities, we conclude that parthenogenesis bacteria and cytoplasmic incompatibility bacteria form a monophyletic group of microorganisms that 'specialize' in manipulating chromosome behaviour and reproduction of insects.	UNIV CALIF RIVERSIDE,DEPT BIOL,RIVERSIDE,CA 92521; UNIV CALIF RIVERSIDE,DEPT ENTOMOL,RIVERSIDE,CA 92521	University of California System; University of California Riverside; University of California System; University of California Riverside	STOUTHAMER, R (corresponding author), AGR UNIV WAGENINGEN,DEPT ENTOMOL,POB 8031,6700 EH WAGENINGEN,NETHERLANDS.			Werren, John/0000-0001-9353-2070				ANDERSON BE, 1991, J CLIN MICROBIOL, V29, P2838, DOI 10.1128/JCM.29.12.2838-2842.1991; Breeuwer J.A.J., 1992, Insect Molecular Biology, V1, P25, DOI 10.1111/j.1365-2583.1993.tb00074.x; BREEUWER JAJ, 1990, NATURE, V346, P558, DOI 10.1038/346558a0; BROSIUS J, 1978, P NATL ACAD SCI USA, V75, P4801, DOI 10.1073/pnas.75.10.4801; CASPARI E, 1959, EVOLUTION, V13, P568, DOI 10.2307/2406138; HOFFMANN AA, 1986, EVOLUTION, V40, P692, DOI 10.1111/j.1558-5646.1986.tb00531.x; JABLONKA E, 1989, J THEOR BIOL, V139, P69, DOI 10.1016/S0022-5193(89)80058-X; JOST E, 1970, ROUX ARCH DEV BIOL, V166, P173, DOI 10.1007/BF00576992; KELLEN WR, 1981, J INVERTEBR PATHOL, V37, P273, DOI 10.1016/0022-2011(81)90087-2; Lane DJ, 1991, NUCL ACID TECHNIQUES, P115, DOI DOI 10.1007/S00227-012-2133-0; LEGNER EF, 1985, CAN ENTOMOL, V117, P383, DOI 10.4039/Ent117383-3; ONEILL SL, 1992, P NATL ACAD SCI USA, V89, P2699, DOI 10.1073/pnas.89.7.2699; ONEILL SL, 1990, NATURE, V348, P178, DOI 10.1038/348178a0; RICHARDSON PM, 1987, J INVERTEBR PATHOL, V50, P176, DOI 10.1016/0022-2011(87)90080-2; ROUSSET F, 1992, P ROY SOC B-BIOL SCI, V247, P163, DOI 10.1098/rspb.1992.0023; RYAN SL, 1985, J HERED, V76, P21, DOI 10.1093/oxfordjournals.jhered.a110011; RYAN SL, 1968, MOL GEN GENET, V103, P29, DOI 10.1007/BF00271154; STOUTHAMER R, 1990, P NATL ACAD SCI USA, V87, P2424, DOI 10.1073/pnas.87.7.2424; STOUTHAMER R, 1990, ANN ENTOMOL SOC AM, V83, P475, DOI 10.1093/aesa/83.3.475; STOUTHAMER R, IN PRESS J INVERT PA; SWOFFORD DL, 1990, PAUP V30; VANVLIET AHM, 1992, INT J SYST BACTERIOL, V42, P494, DOI 10.1099/00207713-42-3-494; WADE MJ, 1985, SCIENCE, V278, P527; WEISBURG WG, 1991, J BACTERIOL, V173, P697, DOI 10.1128/JB.173.2.697-703.1991; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YEN JH, 1973, J INVERTEBR PATHOL, V22, P242, DOI 10.1016/0022-2011(73)90141-9; ZCHORIFEIN E, 1992, EXPERIENTIA, V48, P102, DOI 10.1007/BF01923619	27	396	437	1	59	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 7	1993	361	6407					66	68		10.1038/361066a0	http://dx.doi.org/10.1038/361066a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	7538198				2022-12-28	WOS:A1993KF71800049
J	MCMANUS, ML; CHURCHWELL, KB; STRANGE, K				MCMANUS, ML; CHURCHWELL, KB; STRANGE, K			MECHANISMS OF DISEASE - REGULATION OF CELL-VOLUME IN HEALTH AND DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BRAIN GLIAL-CELLS; PIGMENT EPITHELIAL-CELLS; RED-BLOOD-CELLS; ALDOSE REDUCTASE; ION-TRANSPORT; DIABETIC COMPLICATIONS; MYOINOSITOL DEPLETION; EXTRACELLULAR NACL; ORGANIC OSMOLYTES; MEDULLARY CELLS		CHILDRENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	MCMANUS, ML (corresponding author), CHILDRENS HOSP, DEPT ANESTHESIA, CRIT CARE RES LABS, MICU OFF, FARLEY 517, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030591] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45628] Funding Source: Medline; NINDS NIH HHS [NS30591] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAGNASCO SM, 1987, P NATL ACAD SCI USA, V84, P1718, DOI 10.1073/pnas.84.6.1718; BEDFORD JJ, 1987, J BIOL CHEM, V262, P14255; BEYERMEARS A, 1992, CURR EYE RES, V11, P25, DOI 10.3109/02713689209069164; Bookchin R M, 1987, Prog Clin Biol Res, V240, P193; BRUGNARA C, 1993, J CLIN INVEST, V92, P520, DOI 10.1172/JCI116597; BURG MB, 1988, J CLIN INVEST, V81, P635, DOI 10.1172/JCI113366; CALA PM, 1983, MOL PHYSIOL, V4, P33; CANESSA M, 1987, BLOOD, V70, P1861; CANESSA M, 1991, HEMATOL ONCOL CLIN N, V5, P495, DOI 10.1016/S0889-8588(18)30427-1; CSERR HF, 1991, J PHYSIOL-LONDON, V442, P277, DOI 10.1113/jphysiol.1991.sp018793; CSERR HF, 1991, ADV COMP ENV PHYSL, V9, P61, DOI DOI 10.1007/978-3-642-76226-0_3; DEFRANCESCHI L, 1994, J CLIN INVEST, V93, P1670, DOI 10.1172/JCI117149; DELMONTE MA, 1991, DIABETES, V40, P1335, DOI 10.2337/diabetes.40.10.1335; DONATO T, 1994, ANESTH ANALG, V78, P58; EATON WA, 1976, BLOOD, V47, P621; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; GARCIAPEREZ A, 1991, J MEMBRANE BIOL, V119, P1, DOI 10.1007/BF01868535; GREENE DA, 1993, DIABETES METAB REV, V9, P189, DOI 10.1002/dmr.5610090304; GREENE DA, 1987, NEW ENGL J MED, V316, P599; GREENE DA, 1987, J CLIN INVEST, V79, P1479, DOI 10.1172/JCI112977; GREENE DA, 1992, DIABETES CARE, V15, P1902, DOI 10.2337/diacare.15.12.1902; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HENRY DN, 1993, J CLIN INVEST, V92, P617, DOI 10.1172/JCI116629; JOINER CH, 1993, AM J PHYSIOL, V264, pC251, DOI 10.1152/ajpcell.1993.264.2.C251; KINOSHIT.JH, 1974, INVEST OPHTH VISUAL, V13, P713; Kwon H. Moo, 1993, Journal of the American Society of Nephrology, V4, P890; LEE JH, 1994, NEW ENGL J MED, V331, P439, DOI 10.1056/NEJM199408183310704; LIN LR, 1991, EXP EYE RES, V52, P93, DOI 10.1016/0014-4835(91)90132-X; LOHR JW, 1986, J CLIN INVEST, V78, P1165, DOI 10.1172/JCI112698; MCDOWELL ME, 1955, AM J PHYSIOL, V180, P545, DOI 10.1152/ajplegacy.1955.180.3.545; MCMANUS ML, 1993, ANESTHESIOLOGY, V78, P1132, DOI 10.1097/00000542-199306000-00017; McManus ML., 2020, CELLULAR MOL PHYSL C, P63; MEYER M, 1991, J BIOL CHEM, V266, P8230; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; PANET R, 1985, BIOCHIM BIOPHYS ACTA, V813, P141, DOI 10.1016/0005-2736(85)90355-4; PAREDES A, 1992, AM J PHYSIOL, V263, pC1282, DOI 10.1152/ajpcell.1992.263.6.C1282; PARKER JC, 1993, AM J PHYSIOL, V265, pC1191, DOI 10.1152/ajpcell.1993.265.5.C1191; REDDY VN, 1992, INVEST OPHTH VIS SCI, V33, P2334; SAPIRSTEIN VS, 1984, J NEUROCHEM, V43, P1098, DOI 10.1111/j.1471-4159.1984.tb12849.x; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; STEVENS MJ, 1993, DIABETOLOGIA, V36, P608, DOI 10.1007/BF00404069; STEVENS MJ, 1993, AM J PHYSIOL, V265, pE428, DOI 10.1152/ajpendo.1993.265.3.E428; STRANGE K, 1994, NEWS PHYSIOL SCI, V9, P223; STRANGE K, 1994, GLIA, V12, P35, DOI 10.1002/glia.440120105; STRANGE K, 1992, J AM SOC NEPHROL, V3, P12; STRANGE K, 1993, AM J PHYSIOL, V265, pC244, DOI 10.1152/ajpcell.1993.265.1.C244; STRANGE K, 1992, AM J PHYSIOL, V263, pC412, DOI 10.1152/ajpcell.1992.263.2.C412; STRANGE K, IN PRESS KIDNEY INT; Weed LH, 1919, AM J PHYSIOL, V48, P512, DOI 10.1152/ajplegacy.1919.48.4.512; Weed LH, 1919, AM J PHYSIOL, V48, P531, DOI 10.1152/ajplegacy.1919.48.4.531; WRIGHT CE, 1986, ANNU REV BIOCHEM, V55, P427, DOI 10.1146/annurev.bi.55.070186.002235; Yancey P.H., 1994, CELLULAR MOL PHYSL C, P81	53	342	351	2	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 9	1995	333	19					1260	1266		10.1056/NEJM199511093331906	http://dx.doi.org/10.1056/NEJM199511093331906			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC715	7566004				2022-12-28	WOS:A1995TC71500006
J	GORFINE, SR				GORFINE, SR			TOPICAL NITROGLYCERIN THERAPY FOR ANAL FISSURES AND ULCERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											GORFINE, SR (corresponding author), CUNY MT SINAI SCH MED,NEW YORK,NY 10029, USA.							GORFINE SR, 1995, DIS COLON RECTUM, V38, P453, DOI 10.1007/BF02148842; LODER PB, 1994, BRIT J SURG, V81, P1386, DOI 10.1002/bjs.1800810949; OKELLY T, 1993, GUT, V34, P689, DOI 10.1136/gut.34.5.689; OKELLY TJ, 1994, DIS COLON RECTUM, V37, P350, DOI 10.1007/BF02053596	4	67	71	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 26	1995	333	17					1156	1157		10.1056/NEJM199510263331718	http://dx.doi.org/10.1056/NEJM199510263331718			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA372	7565967				2022-12-28	WOS:A1995TA37200029
J	SHARP, D				SHARP, D			FROM BLACK-BOX TO BEDSIDE, ONE-DAY	LANCET			English	Editorial Material																		HART A, 1990, MED INFORM, V15, P229, DOI 10.3109/14639239009025270	1	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1050	1050		10.1016/S0140-6736(95)91738-1	http://dx.doi.org/10.1016/S0140-6736(95)91738-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564783				2022-12-28	WOS:A1995TA69700007
J	VLADECK, BC				VLADECK, BC			MEDICARE EXPANDS COVERAGE OF INVESTIGATIONAL DEVICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											VLADECK, BC (corresponding author), US HLTH CARE FINANCING ADM,BALTIMORE,MD 21207, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	1995	274	15					1186	1186						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ120	7563494				2022-12-28	WOS:A1995RZ12000005
J	WARD, CL; OMURA, S; KOPITO, RR				WARD, CL; OMURA, S; KOPITO, RR			DEGRADATION OF CFTR BY THE UBIQUITIN-PROTEASOME PATHWAY	CELL			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; SITE-DIRECTED MUTAGENESIS; CYSTIC-FIBROSIS GENE; ENDOPLASMIC-RETICULUM; DELTA-F508; PROTEIN; IDENTIFICATION; TRANSLOCATION; MUTATIONS; CHAIN	Most cases of cystic fibrosis are caused by mutations that interfere with the biosynthetic folding of the cystic fibrosis transmembrane conductance regulator (CFTR), leading to the rapid degradation of CFTR molecules that have not matured beyond the endoplasmic reticulum (ER). The mechanism by which integral membrane proteins including CFTR are recognized and targeted for ER degradation and the proteolytic machinery involved in this process are not well understood. We show here that the degradation of both wild-type and mutant CFTR is inhibited by two potent proteasome inhibitors that induce the accumulation of polyubiquitinated forms of immature CFTR. CFTR degradation was also inhibited by coexpression of a dominant negative ubiquitin mutant and in cells bearing a temperature-sensitive mutation in the ubiquitin-activating enzyme, confirming that ubiquitination is required for rapid CFTR degradation.	KITASATO INST,MINATO KU,TOKYO 108,JAPAN		WARD, CL (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043994] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43994] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Fra A, 1993, Subcell Biochem, V21, P143; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KULKA RG, 1988, J BIOL CHEM, V162, P15726; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEE BS, 1991, J BIOL CHEM, V266, P11448; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; MARSHALL J, 1994, J BIOL CHEM, V269, P2978; Olson TS, 1989, CURR OPIN CELL BIOL, V1, P1194, DOI 10.1016/S0955-0674(89)80071-7; OMURA S, 1991, J ANTIBIOT, V44, P117, DOI 10.7164/antibiotics.44.117; PIND S, 1994, J BIOL CHEM, V269, P12784; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SHIN J, 1993, SCIENCE, V259, P1901, DOI 10.1126/science.8456316; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; WARD CL, 1994, J BIOL CHEM, V269, P25710; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480	31	1101	1130	1	90	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					121	127		10.1016/0092-8674(95)90240-6	http://dx.doi.org/10.1016/0092-8674(95)90240-6			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553863	Bronze			2022-12-28	WOS:A1995RY58300016
J	WU, H; LIU, X; JAENISCH, R; LODISH, HF				WU, H; LIU, X; JAENISCH, R; LODISH, HF			GENERATION OF COMMITTED ERYTHROID BFU-E AND CFU-E PROGENITORS DOES NOT REQUIRE ERYTHROPOIETIN OR THE ERYTHROPOIETIN RECEPTOR	CELL			English	Article							COLONY-FORMING CELLS; HEMATOPOIETIC PROGENITORS; INSITU HYBRIDIZATION; GENE; EXPRESSION; MICE; CLONING; PURIFICATION; LOCALIZATION; MATURATION	Erythropoietin (EPO) is the principal growth factor regulating the production of circulating erythrocytes. We introduced null mutations into both Epo and the EPO receptor (EpoR) gene. Both heterozygotes appeared normal. Homozygous animals exhibited reduced primitive erythropoiesis and died around embryonic day 13, owing to failure of definitive fetal liver erythropoiesis. Both types of mutations exhibited identical phenotypes, indicating that EPO and the EPOR are crucial for definitive erythropoiesis in vivo and that no other ligands or receptors can replace them. Committed erythroid BFU-E and CFU-E progenitors were present in both homozygous fetal livers. Thus, neither EPO nor the EPOR is required for erythroid lineage commitment or for the proliferation and differentiation of BFU-E to CFU-E progenitors. EPO and the EPOR are crucial in vivo for the proliferation and survival of CFU-E progenitors and their irreversible terminal differentiation.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	WU, H (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.				NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262, P01HL041484] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA44339] Funding Source: Medline; NHLBI NIH HHS [HL32262, P01-HL-41484] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANAGNOSTOU A, 1994, P NATL ACAD SCI USA, V91, P3974, DOI 10.1073/pnas.91.9.3974; COLE RJ, 1966, J EMBRYOL EXP MORPH, V15, P245; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DESSYPRIS EN, 1988, BLOOD, V72, P2060; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; EMERSON SG, 1985, J CLIN INVEST, V76, P1286, DOI 10.1172/JCI112087; GREGORY CJ, 1978, BLOOD, V51, P527; GREGORY CJ, 1977, BLOOD, V49, P855; HARA H, 1977, EXP HEMATOL, V5, P141; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KOURY MJ, 1988, J CLIN INVEST, V82, P154, DOI 10.1172/JCI113564; KOURY ST, 1988, BLOOD, V71, P524; KOURY ST, 1991, BLOOD, V77, P2497; KRANTZ SB, 1991, BLOOD, V77, P419; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MCDONALD JD, 1986, MOL CELL BIOL, V6, P842, DOI 10.1128/MCB.6.3.842; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; PESCHLE C, 1979, EXP HEMATOL, V7, P87; PHARR PN, 1993, P NATL ACAD SCI USA, V90, P938, DOI 10.1073/pnas.90.3.938; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SAWADA K, 1988, J CELL PHYSIOL, V137, P337, DOI 10.1002/jcp.1041370218; SAWADA K, 1990, J CELL PHYSIOL, V142, P219, DOI 10.1002/jcp.1041420202; SHOEMAKER CB, 1986, MOL CELL BIOL, V6, P849, DOI 10.1128/MCB.6.3.849; Tavassoli M, 1983, BONE MARROW STRUCTUR; WU H, 1994, P NATL ACAD SCI USA, V91, P2819, DOI 10.1073/pnas.91.7.2819; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223; ZANJANI ED, 1993, PATHOBIOLOGY, V61, P211, DOI 10.1159/000163796	31	807	843	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 6	1995	83	1					59	67		10.1016/0092-8674(95)90234-1	http://dx.doi.org/10.1016/0092-8674(95)90234-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553874	Bronze			2022-12-28	WOS:A1995RY58300010
J	DOHERTY, PC				DOHERTY, PC			THE KEYS TO CELL-MEDIATED-IMMUNITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TOXIC LYMPHOCYTES-T; BIOLOGICAL ROLE; NUCLEOPROTEIN; ANTIGENS				DOHERTY, PC (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT IMMUNOL, 332 N LAUDERDALE ST, MEMPHIS, TN 38105 USA.		Doherty, Peter Charles/C-4185-2013	Doherty, Peter Charles/0000-0002-5028-3489				AMOS DB, 1972, FED PROC, V31, P1087; Benacerraf B, 1975, Adv Cancer Res, V21, P121, DOI 10.1016/S0065-230X(08)60972-0; BLANDEN RV, 1974, TRANSPLANT REV, V19, P56; DOHERTY PC, 1975, LANCET, V1, P1406, DOI 10.1016/S0140-6736(75)92610-0; DOHERTY PC, 1974, TRANSPLANT REV-DENMA, V19, P89; DOHERTY PC, 1977, P NATL ACAD SCI USA, V74, P1209, DOI 10.1073/pnas.74.3.1209; McDevitt H O, 1969, Adv Immunol, V11, P31, DOI 10.1016/S0065-2776(08)60477-0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; YEWDELL JW, 1985, P NATL ACAD SCI USA, V82, P1785, DOI 10.1073/pnas.82.6.1785; ZINKERNA.RM, 1974, NATURE, V251, P547, DOI 10.1038/251547a0; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X; ZINKERNAGEL RM, 1995, JAMA-J AM MED ASSOC, V274, P1069, DOI 10.1001/jama.274.13.1069	12	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1067	1068		10.1001/jama.274.13.1067	http://dx.doi.org/10.1001/jama.274.13.1067			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX108	7563461				2022-12-28	WOS:A1995RX10800033
J	WYSS, DF; CHOI, JS; LI, J; KNOPPERS, MH; WILLIS, KJ; ARULANANDAM, ARN; SMOLYAR, A; REINHERZ, EL; WAGNER, G				WYSS, DF; CHOI, JS; LI, J; KNOPPERS, MH; WILLIS, KJ; ARULANANDAM, ARN; SMOLYAR, A; REINHERZ, EL; WAGNER, G			CONFORMATION AND FUNCTION OF THE N-LINKED GLYCAN IN THE ADHESION DOMAIN OF HUMAN CD2	SCIENCE			English	Article							CELL-SURFACE LIGAND; LYMPHOCYTE-T; ALTERNATIVE PATHWAY; COUPLING-CONSTANTS; MAGNETIC-RESONANCE; BINDING-SITE; PROTEIN; ACTIVATION; RESOLUTION; GLYCOSYLATION	The adhesion domain of human CD2 bears a single N-linked carbohydrate. The solution structure of a fragment of CD2 containing the covalently bound high-mannose N-glycan [-(N-acetylglucosamine)(2)-(mannose)5-8] was solved by nuclear magnetic resonance. The stem and two of three branches of the carbohydrate structure are well defined and the mobility of proximal glycan residues is restricted. Mutagenesis of all residues in the vicinity of the glycan suggests that the glycan is not a component of the CD2-CD58 interface; rather, the carbohydrate stabilizes the protein fold by counterbalancing an unfavorable clustering of five positive charges centered about lysine-61 of CD2.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; PROCEPT INC,CAMBRIDGE,MA 02139; DANA FARBER CANC INST,IMMUNOBIOL LAB,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School								ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; ARULANANDAM ARN, 1993, P NATL ACAD SCI USA, V90, P11613, DOI 10.1073/pnas.90.24.11613; ARULANANDAM ARN, 1994, J EXP MED, V180, P1861, DOI 10.1084/jem.180.5.1861; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BODE W, 1989, BIOCHEMISTRY-US, V28, P1952; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; CLORE G M, 1991, Journal of Biomolecular NMR, V1, P13, DOI 10.1007/BF01874566; DAVIS SJ, 1995, J BIOL CHEM, V270, P369, DOI 10.1074/jbc.270.1.369; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; DWEK RA, COMMUNICATION; FREYMANN D, 1990, J MOL BIOL, V216, P141, DOI 10.1016/S0022-2836(05)80066-X; GARRETT DS, 1994, J MAGN RESON SER B, V104, P99, DOI 10.1006/jmrb.1994.1061; GOLLOB JA, IN PRESS J EXP MED; Hahn W. C., 1993, LYMPHOCYTE ADHESION, P105; HAVEL TF, 1991, PROG BIOPHYS MOL BIO, V56, P43, DOI 10.1016/0079-6107(91)90007-F; HUNIG T, 1987, NATURE, V326, P298, DOI 10.1038/326298a0; JOAO HC, 1992, FEBS LETT, V307, P343, DOI 10.1016/0014-5793(92)80709-P; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KATO K, 1992, J EXP MED, V176, P1241, DOI 10.1084/jem.176.5.1241; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; MADSEN JC, 1993, J BIOMOL NMR, V3, P239; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MOINGEON P, 1989, IMMUNOL REV, V111, P111, DOI 10.1111/j.1600-065X.1989.tb00544.x; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; QIN LH, 1994, J EXP MED, V179, P341, DOI 10.1084/jem.179.1.341; RECNY MA, 1990, J BIOL CHEM, V265, P8542; RECNY MA, 1992, J BIOL CHEM, V267, P22428; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SHAW S, 1986, NATURE, V323, P262, DOI 10.1038/323262a0; SILICIANO RF, 1985, NATURE, V317, P428, DOI 10.1038/317428a0; SOMOZA C, 1993, J EXP MED, V178, P549, DOI 10.1084/jem.178.2.549; TAVERNOR AS, 1994, EUR J BIOCHEM, V219, P969, DOI 10.1111/j.1432-1033.1994.tb18579.x; VANDENEIJNDEN DH, 1986, CARBOHYD RES, V151, P329, DOI 10.1016/S0008-6215(00)90352-5; VANDERMERWE PA, 1993, EUR J IMMUNOL, V23, P1373, DOI 10.1002/eji.1830230628; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WITHKA JM, 1993, STRUCTURE, V1, P69, DOI 10.1016/0969-2126(93)90009-6; WONG YW, 1990, J EXP MED, V171, P2115, DOI 10.1084/jem.171.6.2115; WOOTEN EW, 1990, EUR BIOPHYS J, V18, P139, DOI 10.1007/BF02427373; WYSS DF, 1995, BIOCHEMISTRY-US, V34, P1622, DOI 10.1021/bi00005a019; WYSS DF, 1993, BIOCHEMISTRY-US, V32, P10995, DOI 10.1021/bi00092a008; WYSS DF, UNPUB; YANG SY, 1986, J IMMUNOL, V137, P1097	50	301	312	1	18	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1273	1278		10.1126/science.7544493	http://dx.doi.org/10.1126/science.7544493			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7544493				2022-12-28	WOS:A1995RR84200037
J	MACDONALD, SM; RAFNAR, T; LANGDON, J; LICHTENSTEIN, LM				MACDONALD, SM; RAFNAR, T; LANGDON, J; LICHTENSTEIN, LM			MOLECULAR-IDENTIFICATION OF AN IGE-DEPENDENT HISTAMINE-RELEASING FACTOR	SCIENCE			English	Article							HUMAN BASOPHILS; TRANSLATIONAL CONTROL; ACTIVATING FACTOR; RESPONSES; CHALLENGE; SEQUENCE; AIRWAYS; TUMOR; RNA	An immunoglobulin E (IgE)-dependent histamine-releasing factor (HRF) produced by lymphocytes of atopic children and present in biological fluids of allergic patients has been identified and purified. Amino-terminal sequencing revealed extensive homology to a mouse protein, p21, and its human homolog, p23. Both recombinant proteins caused histamine release from the human basophils of a subpopulation of donors, and this release was dependent on IgE. Polyclonal antibodies recognized and removed the biological activity of recombinant and native HRF. HRF identifies a heterogeneity of IgE and is believed to play a prominent role in chronic allergic disease processes.			MACDONALD, SM (corresponding author), JOHNS HOPKINS UNIV,JOHNS HOPKINS ASTHMA & ALLERGY CTR,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21224, USA.				NIAID NIH HHS [AI 32651, AI 07290] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032651, R01AI032651] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALAM R, 1992, J CLIN INVEST, V89, P723, DOI 10.1172/JCI115648; AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0; BOHM H, 1989, BIOCHEM INT, V19, P277; BOHM H, 1991, BIOMED BIOCHIM ACTA, V12, P1193; CHITPATIMA ST, 1988, NUCLEIC ACIDS RES, V16, P2350, DOI 10.1093/nar/16.5.2350; DAHLNDEN CA, 1994, J EXP MED, V179, P751; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; ILIOPOULOS O, 1987, J ALLERGY CLIN IMMUN, V79, P253; KOSHINO T, 1993, CLIN EXP ALLERGY, V23, P919, DOI 10.1111/j.1365-2222.1993.tb00276.x; KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY DA, 1966, J IMMUNOL, V97, P203; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; MACDONALD SM, 1989, J IMMUNOL, V142, P3527; MACDONALD SM, 1987, J IMMUNOL, V139, P506; MACDONALD SM, 1993, ALLERGY PRINCIPLES P, P1; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; THUESON DO, 1979, J IMMUNOL, V123, P633; WARNER JA, 1986, J IMMUNOL, V136, P2583; ZHANG K, 1992, J EXP MED, V176, P233, DOI 10.1084/jem.176.1.233	27	299	324	0	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					688	690		10.1126/science.7542803	http://dx.doi.org/10.1126/science.7542803			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7542803				2022-12-28	WOS:A1995RM70200033
J	GUNDERSON, KL; KOPITO, RR				GUNDERSON, KL; KOPITO, RR			CONFORMATIONAL STATES OF CFTR ASSOCIATED WITH CHANNEL GATING - THE ROLE OF ATP BINDING AND HYDROLYSIS	CELL			English	Article							SITE-DIRECTED MUTAGENESIS; CYSTIC-FIBROSIS; NUCLEOTIDE-BINDING; ESCHERICHIA-COLI; MULTIDRUG RESISTANCE; CHLORIDE CHANNEL; TRIPHOSPHATE CONFORMATION; CRYSTAL-STRUCTURE; TRANSPORT; PROTEINS	CFTR is a member of the traffic ATPase superfamily and a C1(-) ion channel that appears to require ATP hydrolysis for gating. Analysis of single CFTR C1(-) channels reconstituted into planar lipid bilayers revealed the presence of two open conductance states that are connected to each other and to the closed state by an asymmetric cycle of gating events. We show here that the transition between the two open conductance states is directly coupled to ATP hydrolysis by one of the consensus nucleotide-binding folds, designated NBF2. Moreover, the transition between the closed state and one of the open states is linked to the binding of ATP. This analysis permits real-time visualization of conformational changes associated with a single cycle of ATP hydrolysis by a single protein molecule and suggests a model describing a role for ATP in CFTR gating.	STANFORD UNIV,BIOPHYS PROGRAM,STANFORD,CA 94305	Stanford University	GUNDERSON, KL (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NIDDK NIH HHS [DK43994] Funding Source: Medline; NIGMS NIH HHS [GM08294] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043994] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES GF, 1992, FASEB J, V6, P2660, DOI 10.1096/fasebj.6.9.1377140; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BELL CL, 1993, AM J PHYSIOL, V264, pC925, DOI 10.1152/ajpcell.1993.264.4.C925; CARSON MR, 1993, AM J PHYSIOL, V265, pL27, DOI 10.1152/ajplung.1993.265.1.L27; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; GADSBY DC, 1994, TRENDS BIOCHEM SCI, V19, P513, DOI 10.1016/0968-0004(94)90141-4; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HIGGINS CF, 1990, RES MICROBIOL, V141, P353, DOI 10.1016/0923-2508(90)90011-E; HSIEH S, 1992, NUCLEIC ACIDS RES, V20, P5647, DOI 10.1093/nar/20.21.5647; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JOHN J, 1993, J BIOL CHEM, V268, P923; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KUCHLER K, 1992, ENDOCR REV, V13, P499, DOI 10.1210/er.13.3.499; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PANAGIOTIDIS CH, 1993, J BIOL CHEM, V268, P23685; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; REDDY M, 1994, PEDIATR PULM S, V10, P183; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RICHARD EA, 1990, SCIENCE, V247, P1208, DOI 10.1126/science.2156338; RICHARME G, 1992, BIOCHIM BIOPHYS ACTA, V1104, P201, DOI 10.1016/0005-2736(92)90151-B; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHNEIDER E, 1994, J BIOL CHEM, V269, P20456; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARD CL, 1994, J BIOL CHEM, V269, P26710	47	184	187	0	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					231	239		10.1016/0092-8674(95)90310-0	http://dx.doi.org/10.1016/0092-8674(95)90310-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7543023	Bronze			2022-12-28	WOS:A1995RL76000010
J	LIN, HH; GROSSCHEDL, R				LIN, HH; GROSSCHEDL, R			FAILURE OF B-CELL DIFFERENTIATION IN MISE LACKING THE TRANSCRIPTION FACTOR EBF	NATURE			English	Article							GENE-TRANSCRIPTION; IMMUNOGLOBULIN HEAVY; ANTIGEN RECEPTOR; BONE-MARROW; EXPRESSION; LINEAGE; REARRANGEMENT; MB-1; REGULATOR; CLONING	EARLY B-cell factor (EBF) is a cell type-specific transcription factor that is expressed at all antigen-independent stages of B-lymphocyte differentiation and participates in the regulation of the mb-1 gene(1-4). Here we show, by targeted gene disruption in mice, that EBF is necessary for the generation of immunoglobulin-expressing B cells. EBF-deficient mice lack B cells that have rearranged their immunoglobulin D and J(H) gene segments, but contain B220(+)CD43(+) progenitor cells that express germline mu and IL-7 receptor transcripts. Various non-lymphoid tissues that express EBF are apparently normal in homozygous mutant mice, including olfactory neurons in which EBF was identified as Olf-1 (refs 5, 6). Together, these data suggest that EBF plays a specific and important role in the transcriptional control of B-cell differentiation at a stage before Ig (immunoglobulin) gene rearrangement but after commitment of cells to the B-lymphoid lineage.			LIN, HH (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.							BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; FELDHAUS AL, 1992, MOL CELL BIOL, V12, P1126, DOI 10.1128/MCB.12.3.1126; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; HAGMAN J, 1991, EMBO J, V10, P3409, DOI 10.1002/j.1460-2075.1991.tb04905.x; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; HAGMAN J, 1995, EMBO J, V14, P2907, DOI 10.1002/j.1460-2075.1995.tb07290.x; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; KANTOR AB, 1993, ANNU REV IMMUNOL, V11, P501, DOI 10.1146/annurev.immunol.11.1.501; KUDRYCKI K, 1993, MOL CELL BIOL, V13, P3002, DOI 10.1128/MCB.13.5.3002; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; MILATOVICH A, 1994, MAMM GENOME, V5, P211, DOI 10.1007/BF00360547; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V255, P855; ROLINK A, 1993, CURR OPIN IMMUNOL, V5, P207, DOI 10.1016/0952-7915(93)90006-E; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; TRAVIS A, 1993, MOL CELL BIOL, V13, P3392, DOI 10.1128/MCB.13.6.3392; URBANEK P, 1994, CELL, V7, P901; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; ZHANG Y, 1994, CELL, V79, P875	30	517	527	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 20	1995	376	6537					263	267		10.1038/376263a0	http://dx.doi.org/10.1038/376263a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7542362				2022-12-28	WOS:A1995RK33100049
J	SIELING, PA; CHATTERJEE, D; PORCELLI, SA; PRIGOZY, TI; MAZZACCARO, RJ; SORIANO, T; BLOOM, BR; BRENNER, MB; KRONENBERG, M; BRENNAN, PJ; MODLIN, RL				SIELING, PA; CHATTERJEE, D; PORCELLI, SA; PRIGOZY, TI; MAZZACCARO, RJ; SORIANO, T; BLOOM, BR; BRENNER, MB; KRONENBERG, M; BRENNAN, PJ; MODLIN, RL			CD1-RESTRICTED T-CELL RECOGNITION OF MICROBIAL LIPOGLYCAN ANTIGENS	SCIENCE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; LIPOARABINOMANNAN; GLYCOPEPTIDES; LYMPHOCYTES; CD1B	It has long been the paradigm that T cells recognize peptide antigens presented by major histocompatibility complex (MHC) molecules. However, nonpeptide antigens can be presented to T cells by human CD1b molecules, which are not encoded by the MHC. A major class of microbial antigens associated with pathogenicity are lipoglycans. It is shown here that human CD1b presents the defined mycobacterial lipoglycan lipoarabinomannan (LAM) to alpha beta T cell receptor-bearing lymphocytes. Presentation of these lipoglycan antigens required internalization and endosomal acidification. The T cell recognition required mannosides with alpha(1-->2) linkages and a phosphatidylinositol unit. T cells activated by LAM produced interferon gamma and were cytolytic. Thus, an important class of microbial molecules, the lipoglycans, is a part of the universe of foreign antigens recognized by human T cells.	UNIV CALIF LOS ANGELES,SCH MED,DIV DERMATOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90095; COLORADO STATE UNIV,DEPT MICROBIOL,FT COLLINS,CO 80523; BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL & IMMUNOL,BOSTON,MA 02115; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,LOS ANGELES,CA 90095; YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10461	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Colorado State University; Harvard University; Brigham & Women's Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine			Modlin, Robert L/M-7941-2014	Modlin, Robert L/0000-0003-4720-031X	NIAID NIH HHS [AI 28973, AI 07118, AI 18357] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018357, R01AI028973, R01AI018357, R37AI028973, R22AI018357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BRODSKY FM, 1982, J IMMUNOL, V128, P129; CALABI F, 1991, TISSUE ANTIGENS, V37, P1, DOI 10.1111/j.1399-0039.1991.tb01836.x; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CHATTERJEE D, 1993, GLYCOBIOLOGY, V3, P497, DOI 10.1093/glycob/3.5.497; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; Chatterjee D., UNPUB; DELASALLE H, 1994, SCIENCE, V265, P237, DOI 10.1126/science.7517574; FAVALORO EJ, 1986, DIS MARKERS, V4, P261; HARDING CV, 1993, J IMMUNOL, V151, P2419; HAURUM JS, 1994, J EXP MED, V180, P739, DOI 10.1084/jem.180.2.739; HUNTER SW, 1982, J BIOL CHEM, V257, P5072; HUNTER SW, 1990, J BIOL CHEM, V265, P14065; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; ISHIOKA GY, 1992, J IMMUNOL, V148, P2446; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; MARTIN LH, 1987, P NATL ACAD SCI USA, V84, P9189, DOI 10.1073/pnas.84.24.9189; MICHAELSSON E, 1994, J EXP MED, V180, P745, DOI 10.1084/jem.180.2.745; PORCELI S, UNPUB; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; SHIUE L, 1988, J EXP MED, V168, P1993, DOI 10.1084/jem.168.6.1993; SIELING PA, UNPUB; WOO J, 1995, EUR J BIOCHEM, V207, P383; XU SM, 1994, J IMMUNOL, V153, P2568	27	673	684	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					227	230		10.1126/science.7542404	http://dx.doi.org/10.1126/science.7542404			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7542404				2022-12-28	WOS:A1995RJ02900041
J	DOMBRET, H; CHASTANG, C; FENAUX, P; REIFFERS, J; BORDESSOULE, D; BOUABDALLAH, R; MANDELLI, F; FERRANT, A; AUZANNEAU, G; TILLY, H; YVER, A; DEGOS, L				DOMBRET, H; CHASTANG, C; FENAUX, P; REIFFERS, J; BORDESSOULE, D; BOUABDALLAH, R; MANDELLI, F; FERRANT, A; AUZANNEAU, G; TILLY, H; YVER, A; DEGOS, L			A CONTROLLED-STUDY OF RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IN ELDERLY PATIENTS AFTER TREATMENT FOR ACUTE MYELOGENOUS LEUKEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; CONSOLIDATION THERAPY; CYTOSINE-ARABINOSIDE; COOPERATIVE GROUP; PHASE-III; GROUP-B; ARA-C; CHEMOTHERAPY; REMISSION	Background. Intensive chemotherapy for acute myelogenous leukemia (AML) continues to yield low rates of complete remission and survival among patients over the age of 65 years. Infection-related mortality is particularly high among these patients during the period of neutropenia that follows chemotherapy. We determined the effect of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) on mortality at eight weeks (the main end point) and the rate of complete remission among patients with AML who were 65 years old or older. Methods. After induction chemotherapy with daunorubicin (45 mg per square meter of body-surface area per day for 4 days) and cytarabine (200 mg per square meter per day for 7 days), 173 patients with newly diagnosed AML were randomly assigned on day 8 to receive either lenograstim (5 mu g per kilogram of body weight per day) or placebo, starting on day 9, until there was neutrophil recovery or a treatment failure, or for a maximum of 28 days. Salvage chemotherapy was also followed by lenograstim or placebo. Patients with a complete remission received two consolidation courses of chemotherapy without lenograstim or placebo. Results. The mortality rate at eight weeks was similar in the lenograstim and placebo groups (23 and 27 percent, respectively; P = 0.60), as was the incidence of severe infections. The median duration of neutropenia (absolute neutrophil count, less than or equal to 1000 per cubic millimeter) was shorter in the lenograstim group (21 days, as compared with 27 days in the placebo group; P<0.001). Eight percent of the patients in both groups had regrowth of AML cells. The rate of complete remission was significantly higher in the lenograstim group (70 percent, as compared with 47 percent in the placebo group; P = 0.002). Overall survival, however, was similar in the two groups (P = 0.76). Conclusions. The administration of lenograstim after chemotherapy for AML did not decrease the mortality rate at eight weeks among patients over the age of 65 years. The patients who received lenograstim had a significantly higher rate of complete remission than those who received placebo. Nevertheless, the overall survival in the two groups did not differ significantly.	HOP VAL DE GRACE,PARIS,FRANCE; HOP CLAUDE HURIEZ,LILLE,FRANCE; HOP HAUT LEVEQUE,PESSAC,FRANCE; HOP DUPUYTREN,LIMOGES,FRANCE; INST J PAOLI I CALMETTES,F-13009 MARSEILLE,FRANCE; CTR HENRI BECQUEREL,F-76038 ROUEN,FRANCE; CHUGAI RHONE POULENC,ANTONY,FRANCE; UNIV ROMA LA SAPIENZA,ROME,ITALY; CLIN UNIV ST LUC,B-1200 BRUSSELS,BELGIUM	Val-de-Grace Hospital; Universite de Lille - ISITE; CHU Lille; CHU Bordeaux; CHU Limoges; UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Centre Henri Becquerel; Chugai Pharmaceutical Co., Ltd.; Sapienza University Rome; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	DOMBRET, H (corresponding author), HOP ST LOUIS,SERV CLIN MALAD SANG,1 AVE CLAUDE VELLEFAUX,F-75010 PARIS,FRANCE.							[Anonymous], 1992, DESIGN ANAL SEQUENTI; ARCHIMBAUD E, 1993, LEUKEMIA, V7, P372; ARMITAGE P, 1987, STATISTICAL METHODS; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BETTELHEIM P, 1991, BLOOD, V77, P700; BLOOMFIELD CD, 1994, BLOOD, V84, pA111; BRINCKER H, 1985, CANCER TREAT REP, V69, P5; BUCHNER T, 1991, BLOOD, V78, P1190; BUCHNER T, 1993, P AN M AM SOC CLIN, V12, P301; CASTAIGNE S, 1990, NOUV REV FR HEMATOL, V32, P297; CHESON BD, 1990, J CLIN ONCOL, V8, P813, DOI 10.1200/JCO.1990.8.5.813; COX DR, 1972, J R STAT SOC B, V34, P187; DILLMAN RO, 1991, BLOOD, V78, P2520; ESTEY E, 1994, J CLIN ONCOL, V12, P671, DOI 10.1200/JCO.1994.12.4.671; ESTEY E, 1992, BLOOD, V79, P2246; ESTEY EH, 1990, BLOOD, V75, P1766; ESTEY EH, 1982, BLOOD, V60, P309; FENAUX P, 1989, BRIT J HAEMATOL, V73, P61, DOI 10.1111/j.1365-2141.1989.tb00221.x; FIALKOW PJ, 1987, NEW ENGL J MED, V317, P468, DOI 10.1056/NEJM198708203170802; GAIL M, 1985, BIOMETRICS, V41, P361, DOI 10.2307/2530862; JOHNSON PRE, 1991, HAEMATOLOGICA S4, V76, P130; KAHN SB, 1984, J CLIN ONCOL, V2, P865, DOI 10.1200/JCO.1984.2.8.865; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LOWENBERG B, 1993, BLOOD, V81, P281; OHNO R, 1994, BLOOD, V83, P2086; OHNO R, 1990, NEW ENGL J MED, V323, P871, DOI 10.1056/NEJM199009273231304; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; PREISLER H, 1987, BLOOD, V69, P1441; PREISLER HD, 1987, J CLIN ONCOL, V5, P722, DOI 10.1200/JCO.1987.5.5.722; REES JKH, 1987, SEMIN ONCOL, V14, P32; REES JKH, 1986, LANCET, V2, P1236; ROWE JM, 1993, BLOOD, V82, pA329; ROWLEY JD, 1982, BLOOD, V59, P1013; SCHIFFER CA, 1989, BLOOD, V73, P263; STONE R, 1994, P AN M AM SOC CLIN, V13, P304; TILLY H, 1990, J CLIN ONCOL, V8, P272, DOI 10.1200/JCO.1990.8.2.272; TUCKER J, 1990, HEMATOL ONCOL, V8, P13, DOI 10.1002/hon.2900080103; YIN JAL, 1991, BRIT J HAEMATOL, V79, P415, DOI 10.1111/j.1365-2141.1991.tb08049.x; ZITTOUN R, 1989, BLOOD, V73, P896; 1987, CANCER, V60, P1385	40	271	276	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 22	1995	332	25					1678	1683		10.1056/NEJM199506223322504	http://dx.doi.org/10.1056/NEJM199506223322504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD996	7539109				2022-12-28	WOS:A1995RD99600004
J	SCOTT, J				SCOTT, J			A PLACE IN THE WORLD FOR RNA EDITING	CELL			English	Review							MESSENGER-RNA; ANTICODON; CODON				SCOTT, J (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,DU CANE RD,LONDON W12 0NN,ENGLAND.							BEIER H, 1992, NUCLEIC ACIDS RES, V20, P2679, DOI 10.1093/nar/20.11.2679; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; COVELLO PS, 1993, TRENDS GENET, V9, P265, DOI 10.1016/0168-9525(93)90011-6; DRISCOLL DM, 1994, J BIOL CHEM, V269, P19843; GRAY MW, 1993, CURR OPIN GENET DEV, V3, P884, DOI 10.1016/0959-437X(93)90009-E; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; HENTZE MW, 1994, TRENDS BIOCHEM SCI, V19, P101, DOI 10.1016/0968-0004(94)90198-8; HIESEL R, 1994, P NATL ACAD SCI USA, V91, P634, DOI 10.1073/pnas.91.2.634; HOCH B, 1991, NATURE, V353, P178, DOI 10.1038/353178a0; JANKE A, 1993, NUCLEIC ACIDS RES, V21, P1523, DOI 10.1093/nar/21.7.1523; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; MELCHER T, 1995, IN PRESS J BIOL CHEM, V270; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; POLSON AG, 1994, EMBO J, V13, P5701, DOI 10.1002/j.1460-2075.1994.tb06908.x; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; SCHUSTER W, 1994, ANNU REV PLANT PHYS, V45, P61, DOI 10.1146/annurev.pp.45.060194.000425; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; SIMPSON L, 1995, CELL, V81; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0; ZELTZ P, 1993, EMBO J, V12, P4291, DOI 10.1002/j.1460-2075.1993.tb06113.x	26	99	103	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					833	836		10.1016/0092-8674(95)90002-0	http://dx.doi.org/10.1016/0092-8674(95)90002-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7540116	Bronze			2022-12-28	WOS:A1995RD76800003
J	TRAVERS, K; MBOUP, S; MARLINK, R; GUEYENDIAYE, A; SIBY, T; THIOR, I; TRAORE, I; DIENGSARR, A; SANKALE, JL; MULLINS, C; NDOYE, I; HSIEH, CC; ESSEX, M; KANKI, P				TRAVERS, K; MBOUP, S; MARLINK, R; GUEYENDIAYE, A; SIBY, T; THIOR, I; TRAORE, I; DIENGSARR, A; SANKALE, JL; MULLINS, C; NDOYE, I; HSIEH, CC; ESSEX, M; KANKI, P			NATURAL PROTECTION AGAINST HIV-1 INFECTION PROVIDED BY HIV-2	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CD8+ T-CELLS; WEST-AFRICA; NEUTRALIZING ANTIBODIES; VERTICAL TRANSMISSION; CROSS-NEUTRALIZATION; HIV-2-INFECTED CELLS; TYPE-2 HIV-2; IVORY-COAST; AIDS	Significant differences have been observed in the rates of transmission and disease development in human immunodeficiency virus (HIV) types 1 and 2. Because many HIV-2-infected people remain asymptomatic for prolonged periods, the hypothesis that HIV-2 might protect against subsequent infection by HIV-1 was considered. During a 9-year period in Dakar, Senegal, the seroincidence of both HIV types was measured in a cohort of commercial sex workers. Despite a higher incidence of other sexually transmitted diseases (STDs), HIV-2-infected women had a lower incidence of HIV-1 than did HIV-seronegative women, with a relative risk of 0.32 (P = 0.008). An understanding of the cross-protective mechanisms involved may be directly relevant to HIV-1 vaccine development.	HARVARD UNIV, SCH PUBL HLTH, DEPT CANC BIOL, BOSTON, MA 02115 USA; UNIV CHEIKH ANTA DIOP, VIROL & BACTERIOL LAB, DAKAR, SENEGAL; INST SOCIAL HYG, DAKAR, SENEGAL; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; University Cheikh Anta Diop Dakar; Harvard University; Harvard T.H. Chan School of Public Health				Travers, Karin/0000-0002-9097-1710	NATIONAL CANCER INSTITUTE [R35CA039805] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39805] Funding Source: Medline; PHS HHS [P01 A1 30795] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDREASSON PA, 1993, AIDS, V7, P989, DOI 10.1097/00002030-199307000-00013; Arya Suresh K., 1994, AIDS Research and Human Retroviruses, V10, pS158; BARIN F, 1985, LANCET, V2, P1387; BJORLING E, 1993, VIROLOGY, V193, P528, DOI 10.1006/viro.1993.1160; BOTTIGER B, 1990, J VIROL, V64, P3492; BOTTIGER B, 1989, AIDS RES HUM RETROV, V5, P525, DOI 10.1089/aid.1989.5.525; Breslow NE, 1987, STATISTICAL METHODS, P1; CLAVEL F, 1987, NEW ENGL J MED, V316, P1180, DOI 10.1056/NEJM198705073161903; DECOCK KM, 1989, AIDS, V3, pS89, DOI 10.1097/00002030-198901001-00013; DECOCK KM, 1989, LANCET, V2, P408; DENIS F, 1987, LANCET, V1, P408; DONNELLY C, 1993, B MATH BIOL, V55, P731, DOI 10.1007/BF02460671; EVANS LA, 1988, LANCET, V2, P1389; GRANKVIST O, 1990, AIDS, V5, P286; GUEYENDIAYE A, 1993, AIDS, V7, P481; HART AR, 1990, VIROLOGY, V177, P1, DOI 10.1016/0042-6822(90)90454-Y; HORSBURGH CR, 1988, TRANSFUSION, V28, P92; KANKI P, 1992, AM J EPIDEMIOL, V136, P895, DOI 10.1093/aje/136.7.895; KANKI PJ, 1990, ADV AP BIOT, V7, P255; KANKI PJ, 1987, SCIENCE, V236, P827, DOI 10.1126/science.3033826; KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5; Kanki PJ, 1994, AIDS S1, V8, pS85; KANNAGI M, 1990, J VIROL, V64, P3399, DOI 10.1128/JVI.64.7.3399-3406.1990; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; LEGUERN M, 1992, P NATL ACAD SCI USA, V89, P363, DOI 10.1073/pnas.89.1.363; MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856; MARLINK RG, 1988, AIDS RES HUM RETROV, V4, P137, DOI 10.1089/aid.1988.4.137; NIXON DF, 1990, AIDS, V4, P841, DOI 10.1097/00002030-199009000-00002; NORLEY SG, 1990, J IMMUNOL, V145, P1700; PFUTZNER A, 1992, J ACQ IMMUN DEF SYND, V5, P972; POULSEN AG, 1992, J ACQ IMMUN DEF SYND, V5, P25; RAYFIELD M, 1988, J INFECT DIS, V158, P1170, DOI 10.1093/infdis/158.6.1170; ROBERTGUROFF M, 1992, J VIROL, V66, P3602, DOI 10.1128/JVI.66.6.3602-3608.1992; ROMIEU I, 1990, J ACQ IMMUN DEF SYND, V3, P220; SIMMOND P, 1992, J VIROL, V64, P864; SMALLMANRAYNOR M, 1991, INT J EPIDEMIOL, V20, P480, DOI 10.1093/ije/20.2.480; TRAVERS K, UNPUB; VONDALNOK GK, 1993, ARCH VIROL, V131, P419, DOI 10.1007/BF01378642; VONGEGERFELT A, 1993, AIDS RES HUM RETROV, V9, P883, DOI 10.1089/aid.1993.9.883; WALKER CM, 1991, CELL IMMUNOL, V137, P420, DOI 10.1016/0008-8749(91)90090-X; WEIR SS, 1994, AIDS, V8, P1605, DOI 10.1097/00002030-199411000-00013	41	176	180	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 16	1995	268	5217					1612	1615		10.1126/science.7539936	http://dx.doi.org/10.1126/science.7539936			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7539936				2022-12-28	WOS:A1995RD45900036
J	KAVANAUGH, WM; TURCK, CW; WILLIAMS, LT				KAVANAUGH, WM; TURCK, CW; WILLIAMS, LT			PTB DOMAIN BINDING TO SIGNALING PROTEINS THROUGH A SEQUENCE MOTIF CONTAINING PHOSPHOTYROSINE	SCIENCE			English	Article							SRC SH2 DOMAIN; RECEPTOR; KINASE; AUTOPHOSPHORYLATION; IDENTIFICATION; SITES	Src homology 2 (SH2) domains mediate assembly of signaling complexes by binding specifically to tyrosine-phosphorylated proteins. A phosphotyrosine binding (PTB) domain has been identified which also binds specifically to tyrosine-phosphorylated targets, but is structurally different from SH2 domains, Expression cloning was used to identify targets of PTB domains. PTB domains bound to phosphotyrosine within a sequence motif, asparagine-X(1)-X(2)-phosphotyrosine (where X represents any amino acid), that is found in many signaling proteins and is not recognized by SH2 domains. Mutational studies indicated that high affinity binding of PTB domains may require a specific conformation of the motif.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco					NHLBI NIH HHS [R01 HL 32898, K11 HL02714] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAVANAUGH WM, UNPUB; KORNBLUTH S, 1990, J VIROL, V64, P1584, DOI 10.1128/JVI.64.4.1584-1589.1990; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Sambrook J, 1989, MOL CLONING LABORATO; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1993, ONCOGENE, V8, P2105; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Summers MD, 1987, MANUAL METHODS BACUL; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	25	223	229	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 26	1995	268	5214					1177	1179		10.1126/science.7539155	http://dx.doi.org/10.1126/science.7539155			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7539155				2022-12-28	WOS:A1995RA60400037
J	ARPIN, C; DECHANET, J; VANKOOTEN, C; MERVILLE, P; GROUARD, G; BRIERE, F; BANCHEREAU, J; LIU, YJ				ARPIN, C; DECHANET, J; VANKOOTEN, C; MERVILLE, P; GROUARD, G; BRIERE, F; BANCHEREAU, J; LIU, YJ			GENERATION OF MEMORY B-CELLS AND PLASMA-CELLS IN-VITRO	SCIENCE			English	Article							GERMINAL-CENTERS; IMMUNE-RESPONSE; ANTIGEN; CD40; LYMPHOCYTES; EXPRESSION; IGM	After germinal center B cells undergo somatic mutation and antigen selection, they become either memory B cells or plasma cells, but the signal requirements that control entry into either pathway have been unclear. When purified human germinal center cells were cultured with interleukin-2, interleukin-10, and cells expressing CD40 ligand, cells with characteristics of memory B cells were generated. Removal of CD40 ligand from the system resulted in terminal differentiation of germinal center B cells into cells with the characteristics of plasma cells. These results indicate that CD40 ligand directs the differentiation of germinal center B cells toward memory B cells rather than toward plasma cells.	SCHERING PLOUGH CORP,IMMUNOL RES LAB,F-69571 DARDILLY,FRANCE	Merck & Company; Schering Plough Corporation			Arpin, Christophe/M-3862-2014; van Kooten, Cees/E-5694-2018	Arpin, Christophe/0000-0003-0915-5554; van Kooten, Cees/0000-0002-6257-0899				ANDERSSON J, 1994, IMMUNOLOGY, V83, P16; BANCHEREAU J, 1991, NATURE, V353, P678, DOI 10.1038/353678a0; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BUTCH AW, 1993, J IMMUNOL, V150, P39; CASAMAJORPALLEJ.M, IN PRESS J EXP MED; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; COLCO RF, 1983, J IMMUNOL, V131, P2254; FLUCKIGER AC, 1993, J EXP MED, V178, P1473, DOI 10.1084/jem.178.5.1473; FOY TM, 1994, J EXP MED, V180, P157, DOI 10.1084/jem.180.1.157; GRAY D, 1994, J EXP MED, V180, P141, DOI 10.1084/jem.180.1.141; HARADA H, 1993, BLOOD, V81, P2658; HOLDER MJ, 1993, INT IMMUNOL, V5, P1059, DOI 10.1093/intimm/5.9.1059; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JACOB J, 1992, J EXP MED, V176, P679, DOI 10.1084/jem.176.3.679; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KLAUS GGB, 1980, IMMUNOL REV, V53, P3, DOI 10.1111/j.1600-065X.1980.tb01038.x; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KOSCO MH, 1989, IMMUNOLOGY, V68, P312; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; LEDERMAN S, 1992, J IMMUNOL, V149, P3817; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1991, EUR J IMMUNOL, V21, P2951, DOI 10.1002/eji.1830211209; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; LIU YJ, IN PRESS IMMUNITY; LIU YJ, IN PRESS HDB EXPT IM, V2; MACHEYZERWILLIA.MG, 1993, J EXP MED, V178, P295; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; PASCUAL V, 1994, J EXP MED, V180, P329, DOI 10.1084/jem.180.1.329; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; STROBER S, 1976, J IMMUNOL, V117, P1288; THORBECKE GJ, 1994, FASEB J, V8, P832, DOI 10.1096/fasebj.8.11.8070632; VANKOOTEN C, 1994, EUR J IMMUNOL, V24, P787, DOI 10.1002/eji.1830240402; VANKOOTEN C, UNPUB; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	34	489	496	0	22	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					720	722		10.1126/science.7537388	http://dx.doi.org/10.1126/science.7537388			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7537388				2022-12-28	WOS:A1995QW60300049
J	ALON, R; HAMMER, DA; SPRINGER, TA				ALON, R; HAMMER, DA; SPRINGER, TA			LIFETIME OF THE P-SELECTIN-CARBOHYDRATE BOND AND ITS RESPONSE TO TENSILE FORCE IN HYDRODYNAMIC FLOW	NATURE			English	Article							NEUTROPHIL ADHESION; GLYCOPROTEIN LIGAND; MYELOID CELLS; SHEAR-FLOW; BINDING; IDENTIFICATION; RECOGNITION; DETACHMENT; VENULES	SELECTINS tether to the blood vessel wall leukocytes that are flowing in the bloodstream and support subsequent labile rolling interactions as the leukocytes are subjected to hydrodynamic drag forces(1,2). To support this rolling, selectins have been proposed to have rapid bond association and dissociation rate constants, and special mechanical properties linking tensile forces and bond dissociation(3-6). We have visualized transient tethering and release of neutrophils in hydrodynamic flow on lipid bilayers containing densities of P-selectin below those required to support rolling. We report here that transient tethers had first-order kinetics and other characteristics suggesting a unimolecular interaction between P-selectin and its glycoprotein ligand (PSGL-1). The unstressed dissociation constant (off rate) was 1s(-1) Hydrodynamic shear stresses of up to 1.1 dyn cm(-2), corresponding to a force on the bond of up to 110 pN, increased the off rate only modestly, to 3.5 s(-1). The data was adequately matched by a proposed equation(7) relating off rate to the exponential of tensile force on the bond and the bond interaction distance, and gave a bond interaction distance of 0.5 Angstrom. This distance is compatible with hydrogen and metal coordination bonds between P-selectin and PSGL-1. Fast on and off rates, together with the high tensile strength of the selectin bond, appear necessary to support rolling at physiological shear stresses.	HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; CORNELL UNIV,SCH CHEM ENGN,ITHACA,NY 14853	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Cornell University								BELL GI, 1984, BIOPHYS J, V45, P1051, DOI 10.1016/S0006-3495(84)84252-6; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; CHAN PY, 1991, J CELL BIOL, V115, P245, DOI 10.1083/jcb.115.1.245; DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038; DOWDY S, 1985, STATISTICS RES; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; ERICKSON HP, 1994, P NATL ACAD SCI USA, V91, P10114, DOI 10.1073/pnas.91.21.10114; EVANS E, 1991, BIOPHYS J, V59, P838, DOI 10.1016/S0006-3495(91)82296-2; Fersht A., 1985, ENZYME STRUCTURE MEC; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P653, DOI 10.1016/0009-2509(67)80048-4; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HAMMER DA, 1992, BIOPHYS J, V63, P35, DOI 10.1016/S0006-3495(92)81577-1; JANIN J, 1990, J BIOL CHEM, V265, P16027; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KAPLANSKI G, 1993, BIOPHYS J, V64, P1922, DOI 10.1016/S0006-3495(93)81563-7; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LAWRENCE MB, 1994, IMMUNITY, V1, P137, DOI 10.1016/1074-7613(94)90107-4; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; MASON DW, 1986, HDB EXPT IMMUNOLOG 1, V4; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V289, P23318; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PRESS WH, 1986, NUMERICAL RECIPES AR; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEININGER CN, 1992, BIOCHEM BIOPH RES CO, V188, P760, DOI 10.1016/0006-291X(92)91121-6; TEMPELMAN LA, 1994, BIOPHYS J, V66, P1231, DOI 10.1016/S0006-3495(94)80907-5; TOZEREN A, 1992, BIOPHYS J, V63, P700, DOI 10.1016/S0006-3495(92)81660-0; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229	30	577	592	2	49	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					539	542		10.1038/374539a0	http://dx.doi.org/10.1038/374539a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7535385				2022-12-28	WOS:A1995QR06900051
J	LOVEDAY, C; KAYE, S; TENANTFLOWERS, M; SEMPLE, M; AYLIFFE, U; WELLER, IVD; TEDDER, RS				LOVEDAY, C; KAYE, S; TENANTFLOWERS, M; SEMPLE, M; AYLIFFE, U; WELLER, IVD; TEDDER, RS			HIV-1 RNA SERUM-LOAD AND RESISTANT VIRAL GENOTYPES DURING EARLY ZIDOVUDINE THERAPY	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PLACEBO-CONTROLLED TRIAL; HIGH-LEVEL RESISTANCE; AIDS-RELATED COMPLEX; REVERSE-TRANSCRIPTASE; PLASMA VIREMIA; DOUBLE-BLIND; TYPE-1; AZT; 3'-AZIDO-3'-DEOXYTHYMIDINE	The response of HIV-1 to initial zidovudine (ZDV) treatment was assessed in 11 patients with severe HIV disease. We quantified serum HIV-1 concentrations and mutations associated with ZDV resistance by culture-independent methods. There was a prompt fall in serum HIV-1 RNA within 1-2 days of treatment with maximum suppression by seven days, which was paralleled by changes in serum p24 antigen (p24 Ag). Serum RNA started to return to pretreatment levels within weeks. The HIV reverse transcriptase (RT) gene in most patients developed mutations associated with drug resistance within months and as early as 25 days on therapy in one patient. The codon changes were not sufficient to explain the early return of serum HIV-1 RNA levels and their patterns continued to evolve after patients stopped taking ZDV. The significance of these findings is discussed in relation to the limited long-term efficacy of ZDV. The dynamic time course of viral load and RT responses to ZDV is of particular importance in short-term interventions such as pregnancy.	UCL, SCH MED, ACAD DEPT GENITOURINARY MED, LONDON, ENGLAND; UCL HOSP, LONDON, ENGLAND; CAMDEN & ISLIMGTON COMMUNITY HLTH SERV TRUSTS, LONDON, ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London	LOVEDAY, C (corresponding author), UCL, SCH MED, DIV VIROL, LONDON, ENGLAND.		Semple, Malcolm Gracie/A-8790-2008	Semple, Malcolm Gracie/0000-0001-9700-0418; Tedder, Richard/0000-0002-9672-5721	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; BOUCHER CAB, THESIS U AMSTERDAM, P105; BUKRINSKY M, 1993, J VIROL, V67, P6863, DOI 10.1128/JVI.67.11.6863-6865.1993; COLLIER AC, 1990, NEW ENGL J MED, V323, P1015, DOI 10.1056/NEJM199010113231502; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; COOPER DA, 1994, AIDS S4, V3; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KAYE S, 1992, J MED VIROL, V37, P241, DOI 10.1002/jmv.1890370402; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; KOZEL MJ, 1993, J INFECT DIS, V167, P526; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LARDER BA, 1994, AIDS S4, V8; LOVEDAY C, 1993, J VIROL METHODS, V41, P181, DOI 10.1016/0166-0934(93)90125-B; LOVEDAY C, 1994, 3RD INT WORKSH HIV D; LOVEDAY C, 1995, 1994 ANN SCI M ASS C; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; RICHMAN DD, 1990, REV INFECT DIS S5, V12, P507; SAAG M, 1991, J INFECT DIS, V165, P72; SCHUUMAN R, 1994, 3RD INT WORKSH HIV D; SELIGMANN M, 1994, LANCET, V343, P871; SEMPLE MG, 1993, J VIROL METHODS, V41, P167, DOI 10.1016/0166-0934(93)90124-A; STEVENSON M, 1990, J VIROL, V64, P2421, DOI 10.1128/JVI.64.5.2421-2425.1990; YARCHOAN R, 1986, LANCET, V1, P575; YARCHOAN R, 1987, NEW ENGL J MED, V316, P557, DOI 10.1056/NEJM198702263160925; ZHANG LQ, 1991, AIDS, V5, P675, DOI 10.1097/00002030-199106000-00006; 1994, LANCET, V344, P207; 1987, MMWR-MORBID M     S1, V36, P1	32	95	95	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 1	1995	345	8953					820	824		10.1016/S0140-6736(95)92963-0	http://dx.doi.org/10.1016/S0140-6736(95)92963-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7534858				2022-12-28	WOS:A1995QQ19500008
J	DAVIS, KL; POWCHIK, P				DAVIS, KL; POWCHIK, P			TACRINE	LANCET			English	Article							ALZHEIMERS-DISEASE; SENILE DEMENTIA; TETRAHYDROAMINOACRIDINE; LECITHIN; PHARMACOKINETICS; MULTICENTER; RAT; THA				DAVIS, KL (corresponding author), CUNY MT SINAI SCH MED, DEPT PSYCHIAT, 1 GUSTAVE L LEVY PL, NEW YORK, NY 10029 USA.							ADEM A, 1989, NEUROSCI LETT, V107, P313, DOI 10.1016/0304-3940(89)90837-9; ADEM A, 1990, J NEURAL TRANSM-PARK, V2, P113, DOI 10.1007/BF02252923; ALHAINEN K, 1991, NEUROSCI LETT, V127, P113, DOI 10.1016/0304-3940(91)90907-B; CHATELLIER G, 1990, BRIT MED J, V300, P495, DOI 10.1136/bmj.300.6723.495; CUTLER NR, 1990, PSYCHOPHARMACOL BULL, V26, P231; DAVIS KL, 1992, NEW ENGL J MED, V327, P1253, DOI 10.1056/NEJM199210293271801; DRUKARCH B, 1988, LIFE SCI, V42, P1011, DOI 10.1016/0024-3205(88)90431-6; EAGGER S, 1992, INT J GERIATR PSYCH, V7, P115, DOI 10.1002/gps.930070208; EAGGER SA, 1991, LANCET, V337, P989, DOI 10.1016/0140-6736(91)92656-M; FARLOW M, 1992, JAMA-J AM MED ASSOC, V268, P2523, DOI 10.1001/jama.268.18.2523; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FORSYTH DR, 1989, CLIN PHARMACOL THER, V46, P634, DOI 10.1038/clpt.1989.199; FREEMAN SE, 1991, PROG NEUROBIOL, V36, P257, DOI 10.1016/0301-0082(91)90002-I; GAUTHIER S, 1990, NEW ENGL J MED, V322, P1272, DOI 10.1056/NEJM199005033221804; HARTVIG P, 1990, EUR J CLIN PHARMACOL, V38, P259, DOI 10.1007/BF00315027; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; HOLFORD NHG, 1992, P NATL ACAD SCI USA, V89, P11471, DOI 10.1073/pnas.89.23.11471; HSU RS, 1990, DRUG METAB DISPOS, V18, P779; KNAPP MJ, 1994, JAMA-J AM MED ASSOC, V271, P985, DOI 10.1001/jama.271.13.985; MALTBY N, 1994, BMJ-BRIT MED J, V308, P879, DOI 10.1136/bmj.308.6933.879; MOHS RC, 1985, AM J PSYCHIAT, V142, P28; MURPHY MF, 1991, ANN NY ACAD SCI, V640, P253; NAGAI T, 1983, NEUROSCI LETT, V36, P195, DOI 10.1016/0304-3940(83)90264-1; PERRY EK, 1978, BRIT MED J, V2, P1457, DOI 10.1136/bmj.2.6150.1457; RELMAN AS, 1991, NEW ENGL J MED, V324, P349, DOI 10.1056/NEJM199101313240525; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; ROSSOR M, 1986, BRIT MED BULL, V42, P70, DOI 10.1093/oxfordjournals.bmb.a072101; SCHNEIDER LS, 1991, PSYCHOPHARMACOL BULL, V27, P309; SCHNEIDER LS, 1991, NEUROLOGY S4, V43, pS64; STERN RG, 1994, AM J PSYCHIAT, V151, P390; STERN RG, 1995, PRINCIPLES PHARM BAS; SUMMERS WK, 1986, NEW ENGL J MED, V315, P1241, DOI 10.1056/NEJM198611133152001; WATKINS PB, 1994, JAMA-J AM MED ASSOC, V271, P992, DOI 10.1001/jama.271.13.992; WATKINS PB, 1994, ALZ DIS ASSOC DIS, V8, pS32; WILCOCK GK, 1993, AGE AGEING, V22, P316, DOI 10.1093/ageing/22.5.316; WINKER MA, 1994, JAMA-J AM MED ASSOC, V271, P1023, DOI 10.1001/jama.271.13.1023	36	198	208	2	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 11	1995	345	8950					625	630		10.1016/S0140-6736(95)90526-X	http://dx.doi.org/10.1016/S0140-6736(95)90526-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7534856				2022-12-28	WOS:A1995QM07500014
J	PEREIRA, BJG; WRIGHT, TL; SCHMID, CH; LEVEY, AS				PEREIRA, BJG; WRIGHT, TL; SCHMID, CH; LEVEY, AS			A CONTROLLED-STUDY OF HEPATITIS-C TRANSMISSION BY ORGAN-TRANSPLANTATION	LANCET			English	Article							RENAL-TRANSPLANTATION; VIRUS; DONORS; RECIPIENTS; ANTIBODY; DISEASE; IMPACT; KIDNEY	Hepatitis C virus (HCV) can be transmitted by transplantation of cadaver organs from donors with antibody to HCV (anti-HCV); therefore, transplantation of organs from anti-HCV positive donors to anti-HCV-negative recipients has been discouraged. We have looked at outcomes in recipients of organs from anti-HCV positive and negative donors to determine whether this advice is well-founded. Stored sera from 716 consecutive cadaver organ donors procured by the New England Organ Bank between 1986 and 1990 were tested for anti-HCV by a first-generation ELISA (ELISA1); 13 (1.8%) were positive. 29 recipients who received organs from these donors were the study group. 37 donors were randomly selected from 703 ELISA1-negative cadaver organ donors. 74 recipients of organs from these 37 donors were the control group. Clinical records were reviewed and recipient sera were tested for anti-HCV with a second-generation ELISA (ELISA2), and HCV RNA was tested for by polymerase chain reaction. Median post-transplant follow-up was 42 and 49 months for study and control groups. Post-transplantation prevalence of anti-HCV and HCV RNA was 67% and 96% among recipients from anti-HCV-positive donors, and 20% and 18% among recipients from anti-HCV-negative donors (p<0.001). Post-transplantation non-A, non-B hepatitis, graft loss, and death were observed in 55%, 52%, and 31% among recipients of organs from anti-HCV-positive donors, and 16%, 53%, and 33% among recipients from anti-HCV-negative donors. In a proportional hazards model, the relative risks for non-A, non-B hepatitis, graft loss, and death among recipients from anti-HCV-positive donors were 4.37 (95% Cl 1.97-9.70), 0.93 (0.51-1.70), and 0.89 (0.41-1.93). Transmission of HCV infection by organ transplantation increased the risk of liver disease among recipients. However, after 3.5 years, donor HCV infection did not adversely affect patient survival or graft survival.			PEREIRA, BJG (corresponding author), NEW ENGLAND ORGAN BANK INC,1 GATEWAY PL,WASHINGTON ST & NEWTON CORNER,NEWTON,MA 02158, USA.		Schmid, Christopher H./J-2398-2014	Schmid, Christopher H./0000-0002-0855-5313				AEDER MI, 1993, TRANSPLANT P, V25, P1469; DIETHELM AG, 1992, NEW ENGL J MED, V326, P410, DOI 10.1056/NEJM199202063260612; HUANG CC, 1993, TRANSPLANT P, V25, P1474; LAQUAGLIA MP, 1981, TRANSPLANTATION, V32, P504, DOI 10.1097/00007890-198112000-00011; MAHONY JF, 1989, TRANSPLANT P, V21, P1433; MENDEZ R, 1993, TRANSPLANT P, V25, P1487; MILFRED SK, 1994, TRANSPLANTATION, V57, P568; MORALES JM, IN PRESS KID INT; PEREIRA BJG, 1994, KIDNEY INT, V46, P886, DOI 10.1038/ki.1994.346; PEREIRA BJG, 1992, NEW ENGL J MED, V327, P910, DOI 10.1056/NEJM199209243271302; PEREIRA BJG, 1991, NEW ENGL J MED, V325, P454, DOI 10.1056/NEJM199108153250702; PEREIRA BJG, IN PRESS PEDIATR NEP; ROTH D, 1992, ANN INTERN MED, V117, P470, DOI 10.7326/0003-4819-117-6-470; SLIEFF JL, 1981, STATISTICAL METHODS; TESI RJ, 1994, TRANSPLANTATION, V57, P826, DOI 10.1097/00007890-199403270-00010; TRIOLO G, 1992, NEPHRON, V61, P276, DOI 10.1159/000186904; WEIR MR, 1985, KIDNEY INT, V28, P839, DOI 10.1038/ki.1985.206; 1994, UNOS UPDATE, V10, P27; 1991, MMWR-MORBID MORTAL W, V40, P1	19	101	103	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					484	487		10.1016/S0140-6736(95)90583-9	http://dx.doi.org/10.1016/S0140-6736(95)90583-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7532254				2022-12-28	WOS:A1995QH92900010
J	PAWSON, T				PAWSON, T			PROTEIN MODULES AND SIGNALING NETWORKS	NATURE			English	Review							GROWTH-FACTOR RECEPTOR; AFFINITY PHOSPHOTYROSYL PEPTIDE; DIFFERENT SIGNALING PATHWAYS; GUANINE-NUCLEOTIDE EXCHANGE; FAMILY TYROSINE KINASES; PHOSPHOLIPASE-C-GAMMA; PDGF BETA-RECEPTOR; SH3 DOMAINS; INTERFERON-GAMMA; AUTOPHOSPHORYLATION SITES	Communication between cells assumes particular importance in multicellular organisms. The growth, migration and differentiation of cells in the embryo, and their organization into specific tissues, depend on signals transmitted from one cell to another. In the adult, cell signalling orchestrates normal cellular behaviour and responses to wounding and infection. The consequences of breakdowns in this signalling underlie cancer, diabetes and disorders of the immune and cardiovascular systems. Conserved protein domains that act as key regulatory participants in many of these different signalling pathways are highlighted.			PAWSON, T (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO, ON M5G 1X5, CANADA.		Pawson, Tony J/E-4578-2013					ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN TA, 1994, ONCOGENE, V9, P1253; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Courtneidge Sara A., 1994, Trends in Cell Biology, V4, P345, DOI 10.1016/0962-8924(94)90074-4; DAMELL JE, 1994, SCIENCE, V264, P1415; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FINAN P, 1994, J BIOL CHEM, V269, P13752; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GUSTAFSON TA, IN PRESS MOL CELL BI; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KYOTA RM, 1990, CELL, V62, P481; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARUYAMA K, 1994, J BIOL CHEM, V269, P5976; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MCPHAIL LC, 1994, J EXP MED, V180, P2011, DOI 10.1084/jem.180.6.2011; MIKI H, 1994, J BIOL CHEM, V269, P5489; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RICHARD S, IN PRESS MOL CELL BI; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; RIDDIHOUGH G, 1994, NAT STRUCT BIOL, V1, P755; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSEN MK, IN PRESS NATURE; ROTIN D, 1992, J BIOL CHEM, V267, P9678; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, IN PRESS SCIENCE; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WITTEKIND M, 1994, BIOCHEMISTRY-US, V33, P13531, DOI 10.1021/bi00250a004; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	131	2215	2281	3	158	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 16	1995	373	6515					573	580		10.1038/373573a0	http://dx.doi.org/10.1038/373573a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7531822				2022-12-28	WOS:A1995QG99700043
J	GANN, PH; HENNEKENS, CH; STAMPFER, MJ				GANN, PH; HENNEKENS, CH; STAMPFER, MJ			A PROSPECTIVE EVALUATION OF PLASMA PROSTATE-SPECIFIC ANTIGEN FOR DETECTION OF PROSTATIC-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIGITAL RECTAL EXAMINATION; RADICAL PROSTATECTOMY; SCREENING-TEST; DIAGNOSIS; SERUM; ULTRASONOGRAPHY; ADENOCARCINOMA; DISEASE; TRENDS; MEN	Objective.-To evaluate the validity of prostate-specific antigen (PSA) in identifying men who subsequently were or were not clinically diagnosed with prostate cancer, assess optimal test cutoff, measure lead time, and estimate relative risks (RRs) associated with discrete PSA levels. Design.-Nested case-control study of men providing plasma samples before a 10-year follow-up. Setting.-The Physicians' Health Study, an ongoing randomized trial that enrolled 22071 men aged 40 to 84 years in 1982. Participants.-A total of 366 men (cases) diagnosed with prostate cancer and 1098 men (three controls per case), matched by age, randomly selected from all cohort members at risk at the time of case diagnosis. Main Outcome Measures.-Sensitivity and specificity for each year of followup and for aggressive and nonaggressive cancers separately. Results.-At a cutoff of 4.0 ng/mL, sensitivity for the entire 10-year follow-up was 46% for total cases. Sensitivities for detection of total, aggressive, and nonaggressive cancers occurring in the first 4 years were 73%, 87%, and 53%. Overall, specificity was 91% and changed little by year of follow-up. Optimal validity was achieved at a cutoff of 3.3 ng/mL, Estimated mean lead time for all cancers was 5.5 years. Only 40% of cancers detected more than 5 years from baseline were nonaggressive. Compared with men with PSA levels less than 1.0 ng/mL, those with PSA levels between 2.0 and 3.0 ng/mL had an RR of 5.5 (95% confidence interval, 3.7 to 9.2). Conclusions.-A single PSA measurement had a relatively high sensitivity and specificity for detection of prostate cancers that arose within 4 years. prostate-specific antigen values less than the usual cutoff were associated with substantial increases in risk compared with the lowest levels. Final evaluation of PSA screening must also consider cost and the ability of current treatments to improve the prognosis of screen-detected cases.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CHANNING LAB,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV PREVENT MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health					NCI NIH HHS [CA-34944] Funding Source: Medline; NHLBI NIH HHS [HL-34595, HL-26490] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1989, NEW ENGL J MED, V321, P129; BABAIAN RJ, 1992, CANCER, V69, P1195; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CATALONA WJ, 1987, ARCH INTERN MED, V147, P361, DOI 10.1001/archinte.147.2.361; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; EPSTEIN JI, 1994, JAMA-J AM MED ASSOC, V271, P368, DOI 10.1001/jama.271.5.368; GORMLEY GJ, 1992, NEW ENGL J MED, V327, P1185, DOI 10.1056/NEJM199210223271701; GRAVES HCB, 1990, J UROLOGY, V144, P1516, DOI 10.1016/S0022-5347(17)39789-6; HELZLSOUER KJ, 1992, CANCER EPIDEM BIOMAR, V1, P537; HOLUND B, 1980, SCAND J UROL NEPHROL, V14, P29, DOI 10.3109/00365598009181186; HORTIN GL, 1988, J UROLOGY, V139, P762, DOI 10.1016/S0022-5347(17)42627-9; LABRIE F, 1992, J UROLOGY, V147, P846, DOI 10.1016/S0022-5347(17)37402-5; LIEDTKE RJ, 1984, CLIN CHEM, V30, P649; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; LUYAO GL, 1994, LANCET, V343, P251, DOI 10.1016/S0140-6736(94)91109-6; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; METTLIN C, 1993, CA-CANCER J CLIN, V43, P83, DOI 10.3322/canjclin.43.2.83; MORRISON AS, 1992, SCREENING CHRONIC DI; MURPHY GP, 1994, CA-CANCER J CLIN, V44, P91, DOI 10.3322/canjclin.44.2.91; RUCKLE HC, 1994, MAYO CLIN PROC, V69, P59, DOI 10.1016/S0025-6196(12)61614-0; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STAMEY TA, 1989, J UROLOGY, V141, P1076, DOI 10.1016/S0022-5347(17)41175-X; WALSH PC, 1992, J UROLOGY, V147, P853, DOI 10.1016/S0022-5347(17)37404-9; WALTER SD, 1983, AM J EPIDEMIOL, V118, P865, DOI 10.1093/oxfordjournals.aje.a113705; 1992, AM UROLOGICAL ASS EX; 1976, CAN MED ASSOC J, V114, P1003	28	571	592	0	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	1995	273	4					289	294		10.1001/jama.273.4.289	http://dx.doi.org/10.1001/jama.273.4.289			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC057	7529341				2022-12-28	WOS:A1995QC05700026
J	NANGAKU, M; SATOYOSHITAKE, R; OKADA, Y; NODA, Y; TAKEMURA, R; YAMAZAKI, H; HIROKAWA, N				NANGAKU, M; SATOYOSHITAKE, R; OKADA, Y; NODA, Y; TAKEMURA, R; YAMAZAKI, H; HIROKAWA, N			KIF1B, A NOVEL MICROTUBULE PLUS END-DIRECTED MONOMERIC MOTOR PROTEIN FOR TRANSPORT OF MITOCHONDRIA	CELL			English	Article							KINESIN HEAVY-CHAIN; FAST AXONAL-TRANSPORT; BOVINE BRAIN KINESIN; SQUID GIANT-AXON; MEMBRANOUS ORGANELLES; MITOTIC SPINDLE; DROSOPHILA KINESIN; SYNAPTIC VESICLES; NERVOUS-SYSTEM; C-ELEGANS	To further elucidate the mechanism of organelle transport, we cloned a navel member of the mouse kinesin superfamily, KIF1B. This N-terminal-type motor protein is expressed ubiquitously in various kinds of tissues. In situ hybridization revealed that KIF1B is expressed abundantly in differentiated nerve cells. Interestingly, KIF1B works as a monomer, having a microtubule plus end-directed motility, Our rotary shadowing electron microscopy revealed mostly single globular structures. Immunocytochemically, KIF1B was colocalized with mitochondria in vivo. Furthermore, a subcellular fractionation study showed that KIF1B was concentrated in the mitochondrial fraction, and purified KIF1B could transport mitochondria along microtubules in vitro. These data strongly suggested that KIF1B works as a monomeric motor for anterograde transport of mitochondria.	OKINAKA MEM INST MED RES, TOKYO 105, JAPAN		NANGAKU, M (corresponding author), UNIV TOKYO, SCH MED, DEPT ANAT & CELL BIOL, TOKYO 113, JAPAN.		Okada, Yasushi/N-5067-2015	Okada, Yasushi/0000-0003-2601-3689				AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; ALLEN RD, 1985, J CELL BIOL, V100, P1736, DOI 10.1083/jcb.100.5.1736; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOOM G S, 1992, Current Opinion in Cell Biology, V4, P66, DOI 10.1016/0955-0674(92)90060-P; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BRADY ST, 1982, SCIENCE, V218, P1129, DOI 10.1126/science.6183745; BRADY ST, 1991, NEURON, V7, P521, DOI 10.1016/0896-6273(91)90365-7; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DECUEVAS M, 1992, J CELL BIOL, V116, P957, DOI 10.1083/jcb.116.4.957; ENDOW SA, 1991, TRENDS BIOCHEM SCI, V16, P221, DOI 10.1016/0968-0004(91)90089-E; FORMAN DS, 1987, BRAIN RES, V412, P96, DOI 10.1016/0006-8993(87)91443-0; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GHO M, 1992, SCIENCE, V258, P313, DOI 10.1126/science.1384131; Goldstein L S, 1991, Trends Cell Biol, V1, P93, DOI 10.1016/0962-8924(91)90036-9; GRAFSTEIN B, 1980, PHYSIOL REV, V60, P1167, DOI 10.1152/physrev.1980.60.4.1167; HACKNEY DD, 1991, BIOCHEM BIOPH RES CO, V174, P810, DOI 10.1016/0006-291X(91)91490-4; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HEGGENESS MH, 1978, P NATL ACAD SCI USA, V75, P3863, DOI 10.1073/pnas.75.8.3863; HENSON JH, 1992, J CELL SCI, V103, P309; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1986, CELL MOTIL CYTOSKEL, V6, P458, DOI 10.1002/cm.970060504; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; HIROKAWA N, 1986, J CELL BIOL, V103, P33, DOI 10.1083/jcb.103.1.33; HIROKAWA N, 1991, NEURONAL CYTOSKELETO, P5; Hirokawa Nobutaka, 1993, Current Opinion in Neurobiology, V3, P724, DOI 10.1016/0959-4388(93)90144-N; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; HUANG TG, 1994, J BIOL CHEM, V269, P16493; JOHNSON LV, 1981, J CELL BIOL, V88, P526, DOI 10.1083/jcb.88.3.526; KONDO S, 1994, J CELL BIOL, V125, P1095, DOI 10.1083/jcb.125.5.1095; LASEK RJ, 1984, J CELL BIOL, V99, pS212, DOI 10.1083/jcb.99.1.212s; LEOPOLD PL, 1992, CELL MOTIL CYTOSKEL, V23, P19, DOI 10.1002/cm.970230104; LORENZ T, 1978, P NATL ACAD SCI USA, V75, P505, DOI 10.1073/pnas.75.1.505; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARTZ D, 1984, CELL MOTIL CYTOSKEL, V4, P89, DOI 10.1002/cm.970040203; MILLER RH, 1985, J CELL BIOL, V101, P2181, DOI 10.1083/jcb.101.6.2181; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; PARTLOW LM, 1972, J GEN PHYSIOL, V60, P388, DOI 10.1085/jgp.60.4.388; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; Sambrook J, 1989, MOL CLONING LABORATO; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; SCHNAPP BJ, 1992, J CELL BIOL, V119, P389, DOI 10.1083/jcb.119.2.389; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; Scholey J. M., 1993, MOTILITY ASSAYS MOTO; SCHOLEY JM, 1985, NATURE, V318, P483, DOI 10.1038/318483a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SEKINE Y, 1994, J CELL BIOL, V127, P187, DOI 10.1083/jcb.127.1.187; STAHL WL, 1963, J CELL BIOL, V19, P293, DOI 10.1083/jcb.19.2.293; TAKEMURA R, 1991, NEUROSCIENCE, V44, P393, DOI 10.1016/0306-4522(91)90064-U; TERASAKI M, 1989, METHOD CELL BIOL, V29, P125; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; UEDA T, 1979, J CELL BIOL, V83, P308, DOI 10.1083/jcb.83.2.308; Vale R D, 1990, Adv Biophys, V26, P97, DOI 10.1016/0065-227X(90)90009-I; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V40, P559, DOI 10.1016/0092-8674(85)90204-1; VALE RD, 1989, CELL, V59, P915, DOI 10.1016/0092-8674(89)90614-4; VANBLERKOM J, 1991, P NATL ACAD SCI USA, V88, P5031, DOI 10.1073/pnas.88.11.5031; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429; WHITAKER JE, 1991, BIOCHEM BIOPH RES CO, V175, P387, DOI 10.1016/0006-291X(91)91576-X; WITMAN GB, 1986, METHOD ENZYMOL, V134, P280; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P	72	475	489	0	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 30	1994	79	7					1209	1220		10.1016/0092-8674(94)90012-4	http://dx.doi.org/10.1016/0092-8674(94)90012-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	7528108				2022-12-28	WOS:A1994PZ86000012
J	PADGETT, RA; PODAR, M; BOULANGER, SC; PERLMAN, PS				PADGETT, RA; PODAR, M; BOULANGER, SC; PERLMAN, PS			THE STEREOCHEMICAL COURSE OF GROUP-II INTRON SELF-SPLICING	SCIENCE			English	Article							TETRAHYMENA RIBOZYME; RNA-POLYMERASE; PHOSPHOROTHIOATE; STEP; SPLICEOSOME; MECHANISM; CLEAVAGE; PRODUCTS; DNA	The stereochemical specificities and reaction courses for both self-splicing steps of a group II intron have been determined by phosphorothioate substitution at the 5' and 3' splice site phosphodiester bonds. Both steps of the splicing reaction proceeded with a phosphorothioate in the Sp configuration but were blocked by the Rp diastereomer. Both steps also proceeded with inversion of stereochemical configuration around phosphorus, consistent with a concerted transesterification reaction. These results are identical to those found for nuclear precursor mRNA (pre-mRNA) splicing and provide support for the hypothesis that group II introns and nuclear pre-mRNA introns share a common evolutionary history.			PADGETT, RA (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Podar, Mircea/B-7299-2012	Podar, Mircea/0000-0003-2776-0205	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031480, R01GM045371] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31480, GM45371] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGERS PMJ, 1978, P NATL ACAD SCI USA, V75, P4798, DOI 10.1073/pnas.75.10.4798; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; GISH G, 1988, SCIENCE, V240, P1520, DOI 10.1126/science.2453926; GRIFFITHS AD, 1987, NUCLEIC ACIDS RES, V15, P4145, DOI 10.1093/nar/15.10.4145; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JARRELL KA, 1988, J BIOL CHEM, V263, P3432; MASCHHOFF KL, 1993, NUCLEIC ACIDS RES, V21, P5456, DOI 10.1093/nar/21.23.5456; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; NELSON PS, 1984, J ORG CHEM, V49, P2314, DOI 10.1021/jo00187a003; PERLMAN PS, 1990, INTERVENING SEQUENCE, P112; PODAR M, UNPUB; POTTER BVL, 1983, BIOCHEMISTRY-US, V22, P1369, DOI 10.1021/bi00275a008; RAJAGOPAL J, 1989, SCIENCE, V244, P692, DOI 10.1126/science.2470151; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; SUH E, 1992, NUCLEIC ACIDS RES, V20, P6303, DOI 10.1093/nar/20.23.6303; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; YARUS M, 1993, FASEB J, V7, P31, DOI 10.1096/fasebj.7.1.8422972	23	93	97	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1685	1688		10.1126/science.7527587	http://dx.doi.org/10.1126/science.7527587			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7527587				2022-12-28	WOS:A1994PW30800034
J	KOKUBO, T; GONG, DW; WOOTTON, JC; HORIKOSHI, M; ROEDER, RG; NAKATANI, Y				KOKUBO, T; GONG, DW; WOOTTON, JC; HORIKOSHI, M; ROEDER, RG; NAKATANI, Y			MOLECULAR-CLONING OF DROSOPHILA TFIID SUBUNITS	NATURE			English	Article							MAJOR LATE PROMOTER; RNA POLYMERASE-II; TATA BOX-BINDING; TRANSCRIPTION FACTOR; PREINITIATION COMPLEX; PROTEIN; NUCLEOSOME; COACTIVATORS; INITIATION	TRANSCRIPTION initiation factor TFIID is a multisubunit complex containing a TATA-box-binding factor (TFIIDtau/TBP) and associated polypeptide factors (TAFs) with sizes ranging from M(r) approximately 20,000 to >200,000 (refs 1-7). As a result of direct promoter interactions8,9, TFIID nucleates the assembly of RNA polymerase II and other initiation factors into a functional preinitiation complex10. Although the native TFIID complex mediates both basal and activator-dependent transcription in reconstituted systems, TBP itself is competent for only basal transcription. Thus, TAFs are essential cofactors for regulated transcription. The complementary DNAs encoding the p230 (M(r) 230,000), p110 and p85 subunits of TFIID have recently been cloned11-18. Here we report the molecular cloning and characterization of the p62, p42, p28 and p22 subunits. These participate in a network of heterogeneous protein-protein interactions within TFIID. Sequence similarities between p62/p42 and the histones H4/H3, respectively, suggest that these subunits have a functional relationship with chromatin.	NICHHD,BETHESDA,MD 20892; NINCDS,BETHESDA,MD 20892; NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20892; ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021; UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Rockefeller University; University of Tokyo								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GASH A, 1990, NATURE, V346, P390; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1993, J BIOL CHEM, V268, P17554; KOKUBO T, 1993, P NATL ACAD SCI USA, V90, P5896, DOI 10.1073/pnas.90.13.5896; KOKUBO T, 1993, MOL CELL BIOL, V13, P7859, DOI 10.1128/MCB.13.12.7859; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; TABASSUM R, 1992, J BACTERIOL, V174, P7890, DOI 10.1128/JB.174.24.7890-7895.1992; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; Wolffe Alan P., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P167; WOOTTON JC, 1993, COMPUT CHEM, V17, P149, DOI 10.1016/0097-8485(93)85006-X; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	30	105	109	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					484	487		10.1038/367484a0	http://dx.doi.org/10.1038/367484a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	7545910				2022-12-28	WOS:A1994MU67900061
J	HOLLANDER, JE				HOLLANDER, JE			CURRENT CONCEPTS - THE MANAGEMENT OF COCAINE-ASSOCIATED MYOCARDIAL-ISCHEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INDUCED CORONARY VASOCONSTRICTION; CALCIUM-CHANNEL ANTAGONISTS; INDUCED CHEST PAIN; ARTERY DISEASE; CONSCIOUS DOG; INFARCTION; LABETALOL; TOXICITY; POTENTIATION; LETHALITY				HOLLANDER, JE (corresponding author), SUNY STONY BROOK,UNIV MED CTR,LEVEL 4,RM 515,STONY BROOK,NY 11794, USA.			Hollander, Judd/0000-0002-1318-2785				ADAMS JE, 1993, CIRCULATION, V88, P101, DOI 10.1161/01.CIR.88.1.101; AMIN M, 1990, AM J CARDIOL, V66, P1434, DOI 10.1016/0002-9149(90)90529-A; BECKMAN KJ, 1991, CIRCULATION, V83, P1799, DOI 10.1161/01.CIR.83.5.1799; BEMENT C L, 1989, FASEB Journal, V3, pA297; BILLMAN GE, 1993, J PHARMACOL EXP THER, V266, P407; BOEHRER JD, 1993, AM J MED, V94, P608, DOI 10.1016/0002-9343(93)90212-8; BRICKNER ME, 1991, CIRCULATION, V84, P1130, DOI 10.1161/01.CIR.84.3.1130; BRIGGS RSJ, 1978, LANCET, V1, P1045; BRODY SL, 1990, AM J MED, V88, P325, DOI 10.1016/0002-9343(90)90484-U; BROGAN WC, 1991, J AM COLL CARDIOL, V18, P581, DOI 10.1016/0735-1097(91)90617-I; BUSH HS, 1988, CHEST, V94, P878, DOI 10.1378/chest.94.4.878; CATRAVAS JD, 1978, ARCH INT PHARMACOD T, V235, P328; CATRAVAS JD, 1981, J PHARMACOL EXP THER, V217, P350; COLLIVER JD, 1991, PUBLIC HEALTH REP, V106, P59; CREGLER LL, 1985, AM J CARDIOL, V56, P794, DOI 10.1016/0002-9149(85)91140-3; DERLET RW, 1989, AM J EMERG MED, V7, P464, DOI 10.1016/0735-6757(89)90246-5; DERLET RW, 1991, ANN EMERG MED, V20, P135, DOI 10.1016/S0196-0644(05)81210-7; DRESSLER FA, 1990, AM J CARDIOL, V65, P303, DOI 10.1016/0002-9149(90)90292-9; DUSENBERRY SJ, 1987, ANN EMERG MED, V16, P235, DOI 10.1016/S0196-0644(87)80038-0; EICHHORN E J, 1992, Journal of the American College of Cardiology, V19, p105A; FLORES ED, 1990, J AM COLL CARDIOL, V16, P74, DOI 10.1016/0735-1097(90)90459-3; GAY GR, 1988, ANN EMERG MED, V17, P282, DOI 10.1016/S0196-0644(88)80124-0; GIOIA G, 1995, AM J CARDIOL, V75, P396, DOI 10.1016/S0002-9149(99)80563-3; GITTER MJ, 1991, ANN INTERN MED, V115, P277, DOI 10.7326/0003-4819-115-4-277; GOLDFRANK LR, 1991, ANN EMERG MED, V20, P165, DOI 10.1016/S0196-0644(05)81217-X; GUINN MM, 1980, CLIN TOXICOL, V16, P499, DOI 10.3109/15563658008989979; Heit J, 1994, Acad Emerg Med, V1, P438; Hollander J. E., 1994, Veterinary and Human Toxicology, V36, P376; Hollander J E, 1994, Acad Emerg Med, V1, P330; HOLLANDER J E, 1992, Journal of Emergency Medicine, V10, P169, DOI 10.1016/0736-4679(92)90212-C; HOLLANDER JE, 1995, ARCH INTERN MED, V155, P1081, DOI 10.1001/archinte.155.10.1081; HOLLANDER JE, 1995, CHEST, V107, P1237, DOI 10.1378/chest.107.5.1237; HOLLANDER JE, 1995, ACAD EMERG MED, V2, P179, DOI 10.1111/j.1553-2712.1995.tb03191.x; HOLLANDER JE, 1995, ACAD EMERG MED, V2, P238, DOI 10.1111/j.1553-2712.1995.tb03208.x; HOLLANDER JE, 1992, NEW ENGL J MED, V327, P361; HOLLANDER JE, 1994, J TOXICOL-CLIN TOXIC, V32, P243, DOI 10.3109/15563659409017957; HOLLANDER JE, 1995, ACAD EMERG MED, V2, P456; Hollander Judd E., 1994, Journal of Emergency Medicine, V12, P199, DOI 10.1016/0736-4679(94)90699-8; KNUEPFER MM, 1993, J CARDIOVASC PHARM, V21, P390, DOI 10.1097/00005344-199303000-00007; LANGE RA, 1989, NEW ENGL J MED, V321, P1557, DOI 10.1056/NEJM198912073212301; LANGE RA, 1990, ANN INTERN MED, V112, P897, DOI 10.7326/0003-4819-112-12-897; LANGNER R O, 1989, FASEB Journal, V3, pA297; MACDONALD DI, 1987, JAMA-J AM MED ASSOC, V258, P2029; MAJID PA, 1990, AM J CARDIOL, V65, P812, DOI 10.1016/0002-9149(90)91396-N; MCLAURIN MD, 1994, CIRCULATION, V90, P278; MCNAGNY SE, 1992, JAMA-J AM MED ASSOC, V267, P1106, DOI 10.1001/jama.267.8.1106; MINOR RL, 1991, ANN INTERN MED, V115, P797, DOI 10.7326/0003-4819-115-10-797; MITTLEMAN RE, 1987, J FORENSIC SCI, V32, P11; MOLITERNO DJ, 1994, AM J MED, V96, P492, DOI 10.1016/0002-9343(94)90087-6; MOLITERNO DJ, 1994, NEW ENGL J MED, V330, P454, DOI 10.1056/NEJM199402173300702; NADEMANEE K, 1989, ANN INTERN MED, V111, P876, DOI 10.7326/0003-4819-111-11-876; NEGUS BH, 1994, AM J CARDIOL, V73, P510, DOI 10.1016/0002-9149(94)90684-X; OM A, 1992, AM J CARDIOL, V69, P1549, DOI 10.1016/0002-9149(92)90701-Y; REZKALLA SH, 1993, AM J CARDIOL, V72, P243, DOI 10.1016/0002-9149(93)90173-A; SAND IC, 1991, AM J EMERG MED, V9, P161, DOI 10.1016/0735-6757(91)90182-J; SCHNETZER GW, 1972, AM HEART J, V83, P552, DOI 10.1016/0002-8703(72)90048-8; Shih R. D., 1994, Veterinary and Human Toxicology, V36, P349; SPIVEY WH, 1990, ANN EMERG MED, V19, P467; TARDIFF K, 1989, J FORENSIC SCI, V34, P53; TODD KH, 1995, ACAD EMERG MED, V2, P344; TOGNA G, 1985, HAEMOSTASIS, V15, P100; TOKARSKI GF, 1990, ANN EMERG MED, V19, P1088, DOI 10.1016/S0196-0644(05)81509-4; TROUVE R, 1990, ARCH INT PHARMACOD T, V305, P197; WINNIFORD MD, 1986, CIRCULATION, V73, P662, DOI 10.1161/01.CIR.73.4.662; ZIMMERMAN JL, 1991, ANN EMERG MED, V20, P611, DOI 10.1016/S0196-0644(05)82377-7; 1992, DHHS ADM921887 PUBL	66	169	171	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	1995	333	19					1267	1272		10.1056/NEJM199511093331907	http://dx.doi.org/10.1056/NEJM199511093331907			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC715	7566005				2022-12-28	WOS:A1995TC71500007
J	SMITH, DG				SMITH, DG			RESPECT FOR THE DEAD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	1995	274	17					1408	1408		10.1001/jama.274.17.1408	http://dx.doi.org/10.1001/jama.274.17.1408			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB278	7563571				2022-12-28	WOS:A1995TB27800035
J	MINKOFF, H; WILLOUGHBY, A				MINKOFF, H; WILLOUGHBY, A			PEDIATRIC HIV DISEASE, ZIDOVUDINE IN PREGNANCY, AND UNBLINDING HEELSTICK SURVEYS - REFRAMING THE DEBATE ON PRENATAL HIV TESTING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; WOMEN; POPULATION		NICHHD,CTR RES MOTHERS & CHILDREN,PEDIAT ADOLESCENT & MATERNAL AIDS BRANCH,ROCKVILLE,MD	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	MINKOFF, H (corresponding author), SUNY HLTH SCI CTR,DEPT OBSTET & GYNECOL,450 CLARKSON AVE,BOX 24,BROOKLYN,NY 11203, USA.							BAYER R, 1991, NEW ENGL J MED, V324, P1500, DOI 10.1056/NEJM199105233242111; BAYER R, 1995, WASHINGTON POST 0526, pA27; BAYER R, 1994, NEW ENGL J MED, V318, P1223; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; COTTON P, 1994, JAMA-J AM MED ASSOC, V271, P807, DOI 10.1001/jama.271.11.807; KRASINSKI K, 1988, NEW ENGL J MED, V318, P185; LANDESMAN S, 1987, JAMA-J AM MED ASSOC, V258, P2701, DOI 10.1001/jama.258.19.2701; LINDSAY MK, 1989, OBSTET GYNECOL, V74, P289; MINKOFF HL, 1988, NEW ENGL J MED, V319, P1018; SPERLING RS, 1992, NEW ENGL J MED, V326, P857, DOI 10.1056/NEJM199203263261303; WHEAT ME, 1993, AM J PREV MED, V9, P307, DOI 10.1016/S0749-3797(18)30707-4; 1994, MMWR-MORBID MORTAL W, V43, P1; 1994, NATIONAL HIV SEROSUR, P3; 1992, HUMAN IMMUNODEFICIEN, V162, P1	14	32	32	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1165	1168		10.1001/jama.274.14.1165	http://dx.doi.org/10.1001/jama.274.14.1165			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563489				2022-12-28	WOS:A1995RY05600033
J	JENNEY, MEM				JENNEY, MEM			UMBILICAL CORD-BLOOD TRANSPLANTATION - IS THERE A FUTURE	LANCET			English	Editorial Material							MARROW TRANSPLANTATION; BANKING; GROWTH; CELLS				JENNEY, MEM (corresponding author), ROYAL MANCHESTER CHILDRENS HOSP,ONCOL HAEMATOL DIRECTORATE,MANCHESTER M27 1HA,LANCS,ENGLAND.							BEATTY PG, 1988, TRANSPLANTATION, V45, P714, DOI 10.1097/00007890-198804000-00010; CHANG RS, 1979, LANCET, V2, P201; DEACOCK SJ, 1992, TRANSPLANTATION, V53, P1128, DOI 10.1097/00007890-199205000-00028; DUNN PM, 1992, LANCET, V340, P309, DOI 10.1016/0140-6736(92)92400-A; ENDE N, 1992, BLOOD, V80, P1623; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; GLUCKMAN E, 1993, BONE MARROW TRANSPL, V11, P199; HARRIS DT, 1992, P NATL ACAD SCI USA, V89, P10006, DOI 10.1073/pnas.89.21.10006; HOWS JM, 1992, LANCET, V340, P73, DOI 10.1016/0140-6736(92)90396-K; KNUDTZON S, 1974, BLOOD, V43, P357, DOI 10.1182/blood.V43.3.357.357; LINCH DC, 1989, NATURE, V340, P676, DOI 10.1038/340676a0; RONCAROLO MG, 1994, BLOOD CELLS, V20, P573; STAGNO S, 1986, JAMA-J AM MED ASSOC, V256, P1904, DOI 10.1001/jama.256.14.1904; Vilmer E, 1991, Bone Marrow Transplant, V7 Suppl 2, P125; WAGNER JE, 1992, BLOOD, V79, P1874; WAGNER JE, 1995, LANCET, V346, P214, DOI 10.1016/S0140-6736(95)91268-1; WEISDORF D, 1991, TRANSPLANTATION, V51, P1197, DOI 10.1097/00007890-199106000-00010	17	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					921	922		10.1016/S0140-6736(95)91553-2	http://dx.doi.org/10.1016/S0140-6736(95)91553-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564724				2022-12-28	WOS:A1995RY80800005
J	NATHAN, C				NATHAN, C			NATURAL-RESISTANCE AND NITRIC-OXIDE	CELL			English	Review							INHIBITION				NATHAN, C (corresponding author), CORNELL UNIV MED COLL,DEPT MED,BEATRICE & SAMUEL A SEAVER LAB,NEW YORK,NY 10021, USA.							BARTON CH, 1994, J EXP MED, V179, P1683, DOI 10.1084/jem.179.5.1683; BARTON CH, 1995, MOL MED, V3, P267; BLACKWELL JM, 1994, IMMUNOL LETT, V43, P99, DOI 10.1016/0165-2478(94)00161-8; BLACKWELL JM, 1995, MOL MED, V2, P194; BROWN DH, 1995, IN PRES INFECT IMMUN; CELLIER M, 1994, J EXP MED, V180, P1741, DOI 10.1084/jem.180.5.1741; CELLIER M, 1995, IN PRESS P NATL ACAD; CUNNINGHAM JM, 1995, IN PRES MOL BIOL PAT; DEGROOTE MA, 1995, P NATL ACAD SCI USA, V92, P6399, DOI 10.1073/pnas.92.14.6399; DEGROOTE MA, 1995, IN PRESS CLIN INFECT; DONG YJ, 1995, EMBO J, V12, P2700; GOVONI G, 1995, IN PRESS GENOMICS; GRUENHEID S, 1995, GENOMICS, V25, P514, DOI 10.1016/0888-7543(95)80053-O; HOFFMANN JA, 1994, PHYLOGENETIC PERSPEC; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MALO D, 1994, GENOMICS, V23, P51, DOI 10.1006/geno.1994.1458; PACELLI R, 1995, IN PRESS J EXP MED; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; RYAN CA, 1995, P NATL ACAD SCI USA, V92, P4075, DOI 10.1073/pnas.92.10.4075; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STENGER S, 1994, J EXP MED, V180, P783, DOI 10.1084/jem.180.3.783; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; VIDAL S, 1995, J EXP MED, V182, P655, DOI 10.1084/jem.182.3.655; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0	30	139	144	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					873	876		10.1016/0092-8674(95)90019-5	http://dx.doi.org/10.1016/0092-8674(95)90019-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553846	hybrid			2022-12-28	WOS:A1995RW69300002
J	ZHANG, H; KOBAYASHI, R; GALAKTIONOV, K; BEACH, D				ZHANG, H; KOBAYASHI, R; GALAKTIONOV, K; BEACH, D			P19(SKP1) AND P45(SKP2) ARE ESSENTIAL ELEMENTS OF THE CYCLIN A-CDK2 S-PHASE KINASE	CELL			English	Article							DNA-REPLICATION; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; DEPENDENT KINASES; GENE; PROTEIN; SEQUENCE; EXPRESSION; INHIBITOR; SITES	In normal human fibroblasts, cyclin A-CDK2 exists in a quaternary complex that contains p21 and PCNA. In many transformed cells, p21 disappears, and a substantial fraction of cyclin A-CDK2 complexes with p9(CKS1/CKS2), p19 and p45. To investigate the significance of these rearrangements, we have isolated cDNAs encoding pig and p45. In vitro reconstitution demonstrated that binding of pie to cyclin A-CDK2 requires p45. Addition of these proteins to the kinase had no substantial effect on the kinase activity in vitro. Interference with p45 function in vivo by microinjection of antibodies or antisense oligonucleotides prevented entry into S phase in both normal and transformed cells. Cyclin A-CDKS has previously been identified as a kinase whose activity is essential for S phase. Our results identify p45 as an essential element of this activity. The abundance of p45 is greatly increased in many transformed cells. This could result in changes in cell cycle control that contribute to the process of cellular transformation.			ZHANG, H (corresponding author), COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA.				NATIONAL CANCER INSTITUTE [P30CA045508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039620] Funding Source: NIH RePORTER; NCI NIH HHS [5P30-CA45508-08] Funding Source: Medline; NIGMS NIH HHS [GM39620-07] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GRABHERR R, 1992, VIROLOGY, V188, P721, DOI 10.1016/0042-6822(92)90527-V; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HARPER JW, 1993, CELL, V75, P805; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOZAROV E, 1995, J BIOL CHEM, V270, P3022, DOI 10.1074/jbc.270.7.3022; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LU Z, 1995, IN PRESS VIROLOGY, V206; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; OHKURA H, 1991, CELL, V64, P149, DOI 10.1016/0092-8674(91)90216-L; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PEROZZI G, 1986, MOL CELL BIOL, V6, P1497, DOI 10.1128/MCB.6.5.1497; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	37	419	465	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 22	1995	82	6					915	925		10.1016/0092-8674(95)90271-6	http://dx.doi.org/10.1016/0092-8674(95)90271-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553852	Bronze			2022-12-28	WOS:A1995RW69300008
J	HELLER, D				HELLER, D			LESSON OF THE WEEK - LUMBAR PHYSIOLOGICAL STRIAE IN ADOLESCENCE SUSPECTED TO BE NONACCIDENTAL INJURY	BRITISH MEDICAL JOURNAL			English	Article											HELLER, D (corresponding author), FRENCHAY HLTH CARE SERV TRUST,COMMUNITY SERV DIRECTORATE,BRISTOL BS16 5EB,AVON,ENGLAND.							CARR RD, 1969, ARCH DERMATOL, V99, P26, DOI 10.1001/archderm.99.1.26; GRANTHAM VA, 1982, PRACTITIONER, V226, P1311; SHELLEY WB, 1964, ARCH DERMATOL, V90, P193, DOI 10.1001/archderm.1964.01600020061014; SISSON WR, 1954, J PEDIATR-US, V45, P520, DOI 10.1016/S0022-3476(54)80114-4; Weber FP, 1935, LANCET, V2, P885	5	9	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	1995	311	7007					738	738		10.1136/bmj.311.7007.738	http://dx.doi.org/10.1136/bmj.311.7007.738			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV874	7549692	Green Published			2022-12-28	WOS:A1995RV87400027
J	SUTO, R; SRIVASTAVA, PK				SUTO, R; SRIVASTAVA, PK			A MECHANISM FOR THE SPECIFIC IMMUNOGENICITY OF HEAT-SHOCK PROTEIN-CHAPERONED PEPTIDES	SCIENCE			English	Article							ANTIGEN; CELLS; CANCER	Endogenously synthesized antigenic determinants are generally presented on major histocompatibility complex (MHC) class I molecules, whereas exogenous determinants are presented by MHC class II molecules. Here, it is shown that exogenous antigens chaperoned by a heat shock protein can be channeled into the endogenous pathway, presented by MHC class I molecules, and recognized by CD8(+) T lymphocytes. This pathway is functional only in a subset of macrophages among the cell types tested. These observations provide a basis for the tumor-specific and virus-specific immunogenicity of cognate heat shock protein preparations and offer a mechanism for the classical phenomenon of cross-priming.	FORDHAM UNIV, DEPT BIOL SCI, BRONX, NY 10458 USA	Fordham University					NCI NIH HHS [CA44786] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA044786, R01CA044786] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BLACHERE NE, 1993, J IMMUNOTHER, V14, P352, DOI 10.1097/00002371-199311000-00016; GOODING LR, 1980, J IMMUNOL, V124, P1258; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; Li Z.B., UNPUB; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; PALLADINO MA, 1987, CANCER RES, V47, P5074; PUDDINGTON L, 1986, J VIROL, V60, P708, DOI 10.1128/JVI.60.2.708-717.1986; ROCK KL, 1993, J IMMUNOL, V150, P438; SCHIRMBECK R, 1994, EUR J IMMUNOL, V24, P1088, DOI 10.1002/eji.1830240512; SCHIRMBECK R, 1995, EUR J IMMUNOL, V25, P1063, DOI 10.1002/eji.1830250431; SRIVASTAVA PK, 1984, INT J CANCER, V33, P417, DOI 10.1002/ijc.2910330321; SRIVASTAVA PK, 1991, CURR TOP MICROBIOL, V167, P109; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; SRIVASTAVA PK, UNPUB; SUTO RK, UNPUB; UDONO H, 1994, P NATL ACAD SCI USA, V91, P3077, DOI 10.1073/pnas.91.8.3077; UDONO H, 1994, J IMMUNOL, V152, P5398; UDONO H, 1993, J EXP MED, V178, P1391, DOI 10.1084/jem.178.4.1391; UDONO H, UNPUB	20	711	826	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	1995	269	5230					1585	1588		10.1126/science.7545313	http://dx.doi.org/10.1126/science.7545313			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7545313				2022-12-28	WOS:A1995RU81300045
J	LANNG, S; HANSEN, A; THORSTEINSSON, B; NERUP, J; KOCH, C				LANNG, S; HANSEN, A; THORSTEINSSON, B; NERUP, J; KOCH, C			GLUCOSE-TOLERANCE IN PATIENTS WITH CYSTIC-FIBROSIS - 5-YEAR PROSPECTIVE-STUDY	BRITISH MEDICAL JOURNAL			English	Article							DIABETES-MELLITUS; GLYCOSYLATED HEMOGLOBIN; DELTA-F508 MUTATION; PANCREATIC FUNCTION; ENDOCRINE; EXOCRINE; INTOLERANCE; ADOLESCENTS	Objectives-To study prevalence and incidence of diabetes mellitus in patients with cystic fibrosis. Design-Five year prospective study with annual oral glucose tolerance tests. Setting-CF Center Copenhagen, Denmark. Subjects-191 patients with cystic fibrosis aged above 2 years. Main outcome measures-Glucose tolerance, plasma glucose concentrations after fasting and after glucose loading, and haemoglobin A(1c) levels. Results-Prevalence of diabetes increased from 11% (n=21) to 24% (n=46) during study, with annual age dependent incidence of 4-9%. Diabetes was diagnosed at median age of 21 (range 3-40). At diagnosis of diabetes, symptoms of hyperglycaemia were present in 33% of patients, fasting hyperglycaemia (greater than or equal to 7.8 mmol/l was seen in 16%, and increased haemoglobin A(1c) levels (>6.4%) were seen in 16%. Impaired glucose tolerance implied higher risk for development of diabetes than normal glucose tolerance (odds ratio 5.6). In 58% of cases with impaired glucose tolerance, however, glucose tolerance was normal at next annual test. Normal glucose tolerance was found in only 37% of patients at all five tests. Within this group of patients, median plasma glucose concentrations after fasting and after glucose loading and haemoglobin A(1c) levels increased by 6-8% during study. Conclusions-Prevalence and incidence of diabetes in cystic fibrosis patients was high and increased with age. Since hyperglycaemic symptoms, fasting hyperglycaemia, and increased levels of glycated haemoglobin did not reliably identify diabetes mellitus, we recommend annual oral glucose tolerance tests in all cystic fibrosis patients aged over 10 years.	HILLEROD HOSP,DEPT MED F,HILLEROD,DENMARK; STENO DIABET CTR,GENTOFTE,DENMARK	University of Copenhagen; Steno Diabetes Center	LANNG, S (corresponding author), RIGSHOSP,CF CTR COPENHAGEN,DEPT PAEDIAT,DK-2100 COPENHAGEN,DENMARK.							ABDULKARIM FW, 1986, ARCH PATHOL LAB MED, V110, P602; ARRIGO T, 1993, ACTA PAEDIATR, V82, P249, DOI 10.1111/j.1651-2227.1993.tb12653.x; ARTAL R, 1984, AM J OBSTET GYNECOL, V148, P412, DOI 10.1016/0002-9378(84)90717-8; BANAUCH D, 1975, Z KLIN CHEM KLIN BIO, V13, P101; BANK S, 1975, AM J GASTROENTEROL, V64, P13; BISTRITZER T, 1983, ISRAEL J MED SCI, V19, P600; ELBORN JS, 1991, THORAX, V46, P881, DOI 10.1136/thx.46.12.881; FINKELSTEIN SM, 1988, J PEDIATR-US, V112, P373, DOI 10.1016/S0022-3476(88)80315-9; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; GEFFNER ME, 1984, PEDIATR RES, V18, P1107, DOI 10.1203/00006450-198411000-00011; GIBSON LE, 1959, PEDIATRICS, V23, P545; HANDWERG.S, 1969, NEW ENGL J MED, V281, P451, DOI 10.1056/NEJM196908282810901; HOIBY N, 1977, ACTA PATHOLOGIC S262, V85, P3; IANNUCCI A, 1984, HUM PATHOL, V15, P278, DOI 10.1016/S0046-8177(84)80191-4; LAMERS CBHW, 1990, PANCREAS, V5, P65; LANNG S, 1994, ACTA PAEDIATR, V83, P72, DOI 10.1111/j.1651-2227.1994.tb12956.x; LANNG S, 1991, CLIN GENET, V40, P345; LANNG S, 1992, EUR J PEDIATR, V151, P684, DOI 10.1007/BF01957574; LANNG S, 1991, ARCH DIS CHILD, V66, P612, DOI 10.1136/adc.66.5.612; LANNG S, 1994, ACTA PAEDIATR, V83, P849, DOI 10.1111/j.1651-2227.1994.tb13156.x; LANNG S, 1993, ACTA ENDOCRINOL-COP, V128, P207, DOI 10.1530/acta.0.1280207; LANNG S, 1993, ACTA PAEDIATR, V82, P150, DOI 10.1111/j.1651-2227.1993.tb12628.x; LITTLE RR, 1994, DIABETOLOGIA, V37, P252, DOI 10.1007/BF00398051; MORAN A, 1991, J PEDIATR-US, V118, P715, DOI 10.1016/S0022-3476(05)80032-0; NIELSEN O H, 1981, Ugeskrift for Laeger, V143, P2302; NIR M, IN PRESS THORAX; POLGAR G, 1971, PULMONARY FUNCTION T, P88; REISMAN J, 1990, PEDIATRICS, V150, P374; ROBERT JJ, 1992, ARCH FR PEDIATR, V49, P17; RODMAN HM, 1986, MEDICINE, V65, P389, DOI 10.1097/00005792-198611000-00004; SCHWARTZ M, 1990, HUM GENET, V85, P427, DOI 10.1007/BF02428297; SOIJIMA K, 1986, PEDIATR PATHOL, V6, P25; STUTCHFIELD PR, 1987, ARCH DIS CHILD, V62, P805, DOI 10.1136/adc.62.8.805; SVENDSEN PA, 1982, DIABETOLOGIA, V23, P403; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; World Health Organization, 1985, DIAB MELL REP WHO ST, V727; WULFF HR, 1988, MEDSTAT VERSION 2; YUDKIN JS, 1990, BRIT MED J, V301, P397, DOI 10.1136/bmj.301.6749.397	38	175	175	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	1995	311	7006					655	659		10.1136/bmj.311.7006.655	http://dx.doi.org/10.1136/bmj.311.7006.655			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU753	7549632	Green Published			2022-12-28	WOS:A1995RU75300016
J	GREGORIO, CC; WEBER, A; BONDAD, M; PENNISE, CR; FOWLER, VM				GREGORIO, CC; WEBER, A; BONDAD, M; PENNISE, CR; FOWLER, VM			REQUIREMENT OF POINTED-END CAPPING BY TROPOMODULIN TO MAINTAIN ACTIN FILAMENT LENGTH IN EMBRYONIC CHICK CARDIAC MYOCYTES	NATURE			English	Article							TROPOMYOSIN-BINDING; MECHANISMS; PROTEIN; MUSCLE; CELLS	CONTROL of actin filament length and dynamics is important for cell motility and architecture and is regulated in part by capping proteins that block elongation and depolymerization at both the fast-growing (barbed) and slow-growing (pointed) ends(1-4). Tropomodulin is a capping protein for the pointed end of the actin filament(5,6); it is associated with the free, pointed ends of the thin filaments in striated muscle, where it is thought to bind to both tropomyosin and actin(7,8). In embryonic chick cardiac myocytes, tropomodulin assembles after the thin, as well as the thick, filaments have become organized into periodic I and A bands(8), suggesting that tropomodulin might be involved in maintaining actin filament length. Here we show that microinjection of an antibody that inhibits tropomodulin's pointed-end-capping activity in vitro results in a marked elongation of actin filaments from their pointed ends and a >80% reduction in the percentage of beating cells. This demonstrates that pointed-end capping by tropomodulin is required to maintain actin filament length in vivo and that this is essential for contractile function in embryonic chick cardiac myocytes.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV PENN, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA	Scripps Research Institute; University of Pennsylvania								BABCOCK GG, 1994, J BIOL CHEM, V269, P27510; Carlier Marie-France, 1994, Seminars in Cell Biology, V5, P183, DOI 10.1006/scel.1994.1023; COLUCCIO LM, 1994, J CELL BIOL, V127, P1497, DOI 10.1083/jcb.127.6.1497; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; FOWLER VM, 1993, J CELL BIOL, V120, P411, DOI 10.1083/jcb.120.2.411; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; GREGORIO CC, 1995, J CELL BIOL, V129, P683, DOI 10.1083/jcb.129.3.683; ITO M, 1995, DEV BIOL, V167, P317, DOI 10.1006/dbio.1995.1026; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SHUBEITA HE, 1992, CIRCULATION, V85, P2236, DOI 10.1161/01.CIR.85.6.2236; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SUNG KLP, 1994, MOL BIOL CELL, V5, pA54; SUNG LA, 1992, J BIOL CHEM, V267, P2616; SUSSMAN MA, 1994, CIRC RES, V75, P221, DOI 10.1161/01.RES.75.2.221; SUSSMAN MA, 1994, DEV BRAIN RES, V80, P45, DOI 10.1016/0165-3806(94)90088-4; URSITTI JA, 1994, J CELL SCI, V107, P1633; WEBER A, 1994, J CELL BIOL, V127, P1627, DOI 10.1083/jcb.127.6.1627; WEBER A, 1973, PHYSIOL REV, V53, P612, DOI 10.1152/physrev.1973.53.3.612; Weeds A, 1993, CURR OPIN CELL BIOL, V5, P63, DOI 10.1016/S0955-0674(05)80009-2; WEGNER A, 1979, J MOL BIOL, V131, P839, DOI 10.1016/0022-2836(79)90204-3; WOO MK, 1994, J CELL SCI, V107, P1359	21	146	148	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 7	1995	377	6544					83	86		10.1038/377083a0	http://dx.doi.org/10.1038/377083a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7544875				2022-12-28	WOS:A1995RT72500062
J	DONG, F; BRYNES, RK; TIDOW, N; WELTE, K; LOWENBERG, B; TOUW, IP				DONG, F; BRYNES, RK; TIDOW, N; WELTE, K; LOWENBERG, B; TOUW, IP			MUTATIONS IN THE GENE FOR THE GRANULOCYTE COLONY-STIMULATING-FACTOR RECEPTOR IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA PRECEDED BY SEVERE CONGENITAL NEUTROPENIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEMATOPOIETIN RECEPTOR; CYTOPLASMIC DOMAIN; AGRANULOCYTOSIS; REGIONS; GRANULOPOIESIS; PROLIFERATION; INDUCTION; CELLS	Background. In severe congenital neutropenia the maturation of myeloid progenitor cells is arrested, The myelodysplastic syndrome and acute myeloid leukemia develop in some patients with severe congenital neutropenia, Abnormalities in the signal-transduction pathways for granulocyte colony-stimulating factor (G-CSF) may play a part in the progression to acute myeloid leukemia. Methods. We isolated genomic DNA and RNA from hematopoietic cells obtained from two patients with acute myeloid leukemia and histories of severe congenital neutropenia. The nucleotide sequences encoding the cytoplasmic domain of the G-CSF receptor were amplified by means of the polymerase chain reaction and sequenced, Murine myeloid 32D.C10 cells were transfected with complementary DNA encoding the wild-type or mutant G-CSF receptors and tested for their responses to G-CSF. Results. Point mutations in the gene for the G-CSF receptor were identified in both patients. The mutations, a substitution of thymine for cytosine at the codon for glutamine at position 718 (Gln718) in one patient and at the codon for glutamine at position 731 (Gln731) in the other, caused a truncation of the C-terminal cytoplasmic region of the receptor. Both mutant and wild-type genes for the G-CSF receptor were present in leukemic cells from the two patients, in one patient, the mutation was also found in the neutropenic stage, before the progression to acute myeloid leukemia. The 32D.C10 cells expressing mutant receptors had abnormally high proliferative responses but failed to mature when cultured in G-CSF. The mutant G-CSF receptors also interfered with terminal maturation mediated by the wild-type G-CSF receptor in the 32D.C10 cells that coexpressed the wildtype and mutant receptors. Conclusions. Mutations in the gene for the G-CSF receptor that interrupt signals required for the maturation of myeloid cells are involved in the pathogenesis of severe congenital neutropenia and associated with the progression to acute myeloid leukemia.	DR DANIEL DEN HOED CANC CTR,DEPT HEMATOL,3008 AE ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,INST HEMATOL,ROTTERDAM,NETHERLANDS; CITY HOPE NATL MED CTR,DEPT CLIN PATHOL,DUARTE,CA 91010; HANNOVER MED SCH,DEPT PEDIAT HEMATOL & ONCOL,W-3000 HANNOVER,GERMANY	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; City of Hope; Hannover Medical School								AMATO D, 1976, BLOOD, V47, P531; BONILLA MA, 1994, BRIT J HAEMATOL, V88, P723, DOI 10.1111/j.1365-2141.1994.tb05110.x; BONILLA MA, 1989, NEW ENGL J MED, V320, P1574, DOI 10.1056/NEJM198906153202402; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DALE DC, 1993, BLOOD, V81, P2496; DEMETRI GD, 1991, BLOOD, V78, P2791; DONG F, 1995, BLOOD, V85, P902, DOI 10.1182/blood.V85.4.902.bloodjournal854902; DONG F, 1994, P NATL ACAD SCI USA, V91, P4480, DOI 10.1073/pnas.91.10.4480; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; GILLIO AP, 1993, BLOOD, V81, P1669; GILMAN PA, 1970, BLOOD-J HEMATOL, V36, P576, DOI 10.1182/blood.V36.5.576.576; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GUBA SC, 1993, BLOOD, V82, pA23; HAYHOE FGJ, 1992, HEMATOLOGICAL CYTOLO, P378; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HIRAOKA O, 1994, FEBS LETT, V356, P255, DOI 10.1016/0014-5793(94)01278-4; IMASHUKU S, 1995, BRIT J HAEMATOL, V89, P188, DOI 10.1111/j.1365-2141.1995.tb08928.x; KAWAGUCHI Y, 1985, AM J HEMATOL, V20, P223, DOI 10.1002/ajh.2830200304; KOBAYASHI M, 1990, BLOOD, V75, P2143; KOSTMANN R, 1975, ACTA PAEDIATR SCAND, V64, P362, DOI 10.1111/j.1651-2227.1975.tb03847.x; KOSTMANN RO, 1956, ACTA PAEDIATR SC   S, V105, P1; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; RODIN AE, 1973, AM J DIS CHILD, V126, P818, DOI 10.1001/archpedi.1973.02110190660016; ROSEN RB, 1979, J PEDIATR-US, V94, P406, DOI 10.1016/S0022-3476(79)80581-8; SANDOVAL C, 1993, BLOOD, V82, pA185; SETO Y, 1992, J IMMUNOL, V148, P259; WEINBLATT ME, 1995, J PEDIATR-US, V126, P263, DOI 10.1016/S0022-3476(95)70557-0; WELTE K, 1990, BLOOD, V75, P1056; WONG WY, 1993, AM J HEMATOL, V43, P133, DOI 10.1002/ajh.2830430212; WRIEDT K, 1970, NEW ENGL J MED, V283, P1072, DOI 10.1056/NEJM197011122832002; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	37	363	369	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 24	1995	333	8					487	493		10.1056/NEJM199508243330804	http://dx.doi.org/10.1056/NEJM199508243330804			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP759	7542747	Green Published			2022-12-28	WOS:A1995RP75900004
J	SRETAVAN, DW; PURE, E; SIEGEL, MW; REICHARDT, LF				SRETAVAN, DW; PURE, E; SIEGEL, MW; REICHARDT, LF			DISRUPTION OF RETINAL AXON INGROWTH BY ABLATION OF EMBRYONIC MOUSE OPTIC CHIASM NEURONS	SCIENCE			English	Article							SUBPLATE NEURONS; CONNECTIONS; OUTGROWTH; CELLS	Mouse retinal ganglion cell axons growing from the eye encounter embryonic neurons at the future site of the optic chiasm. After in vivo ablation of these chiasm neurons with a monoclonal antibody and complement, retinal axons did not cross the midline and stalled at approximately the entry site into the chiasm region. Thus, in the mouse, the presence of early-generated neurons that reside at the site of the future chiasm is required for formation of the optic chiasm by retinal ganglion cell axons.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; GENENTECH INC,DEPT METAB & PHARMACOKINET,S SAN FRANCISCO,CA 94080; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,NEUROSCI PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	The Wistar Institute; Roche Holding; Genentech; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	SRETAVAN, DW (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT OPHTHALMOL K107,NEUROSCI PROGRAM,10 KIRKHAM ST,SAN FRANCISCO,CA 94143, USA.				NATIONAL EYE INSTITUTE [R01EY010688] Funding Source: NIH RePORTER; NEI NIH HHS [EY10688] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; COLELLO RJ, 1990, DEVELOPMENT, V108, P515; DRAZBA J, 1990, DEV BIOL, V138, P82, DOI 10.1016/0012-1606(90)90178-L; EASTER SS, 1993, J NEUROSCI, V13, P285; GHOSH A, 1990, NATURE, V347, P179, DOI 10.1038/347179a0; GHOSH A, 1993, DEVELOPMENT, V117, P1031; GODEMENT P, 1990, NEURON, V5, P173, DOI 10.1016/0896-6273(90)90307-2; HENRY C, 1980, SELECTED METHODS CEL, P211; KLOSE M, 1989, SCIENCE, V245, P982, DOI 10.1126/science.2772651; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; SCHLAGGAR BL, 1991, SCIENCE, V252, P1556, DOI 10.1126/science.2047863; SRETAVAN DW, 1994, NEURON, V12, P957, DOI 10.1016/0896-6273(94)90307-7; SRETAVAN DW, 1990, J NEUROSCI, V10, P1995; SRETAVAN DW, 1993, NEURON, V10, P761, DOI 10.1016/0896-6273(93)90176-R; SRETAVAN DW, UNPUB; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; WILLIAMS RW, 1994, NATURE, V367, P637, DOI 10.1038/367637a0; WISENMANN A, 1993, DEVELOPMENT, V117, P725	19	70	70	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					98	101		10.1126/science.7541558	http://dx.doi.org/10.1126/science.7541558			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7541558				2022-12-28	WOS:A1995RG98000044
J	DEVALK, HW; BANGA, JD; WESTER, JWJ; BROUWER, CB; VANHESSEN, MWJ; MEUWISSEN, OJAT; HART, HC; SIXMA, JJ; NIEUWENHUIS, HK				DEVALK, HW; BANGA, JD; WESTER, JWJ; BROUWER, CB; VANHESSEN, MWJ; MEUWISSEN, OJAT; HART, HC; SIXMA, JJ; NIEUWENHUIS, HK			COMPARING SUBCUTANEOUS DANAPAROID WITH INTRAVENOUS UNFRACTIONATED HEPARIN FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM - A RANDOMIZED CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						DANAPAROID; HEPARIN; THROMBOEMBOLISM; THROMBOPHLEBITIS; PULMONARY EMBOLISM	MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; ORGARAN ORG-10172; PULMONARY-EMBOLISM; DOUBLE-BLIND; INDUCED THROMBOCYTOPENIA; VENTILATION-PERFUSION; STANDARD HEPARIN; GLYCOSAMINOGLYCANS; HEMODIALYSIS	Objective: To compare the efficacy and safety of two subcutaneous doses of danaparoid with that of continuous intravenous administration of unfractionated heparin in the treatment of venous thromboembolism. Design: An open-label, randomized, multicenter clinical trial. Setting: One university hospital and two university-affiliated hospitals. Patients: 209 patients suspected to have venous thromboembolism. Of these, 188 had a confirmed diagnosis (by ventilation-perfusion lung scan and ultrasonography or contrast venography of the leg) and received study medication. Interventions: Patients were randomly assigned to either low-dose danaparoid (intravenous loading dose of 1250 U followed by 1250 U administered subcutaneously twice dairy [n = 65]); high-dose danaparoid (intravenous loading dose of 2000 U followed by 2000 U administered subcutaneously twice daily [n = 63]); or unfractionated heparin (intravenous loading dose of 2500 U followed by dose-adjusted continuous infusion [n = 60]). Treatment lasted at least 5 days and was continued until anticoagulation (achieved with acenocoumarol) was adequate. Measurements: Efficacy determined clinically and by repeated imaging tests on treatment days 5 to 8; safety determined by daily assessment for bleeding. Results: Two lung scans were done in each of 179 patients; ultrasonography or venography of the leg was done twice in each of 173 patients; and both repeated leg and lung tests were done in 166 patients. A significant reduction in recurrence or extension of venous thromboembolism was seen in patients receiving high-dose danaparoid (8 of 63 [13%]) compared with patients receiving intravenous unfractionated heparin (17 of 60 [28%]; relative risk, 0.45 [95% CI, 0.21 to 0.96]). Four of 61 patients receiving high-dose danaparoid (7%) and 14 of 58 patients receiving unfractionated heparin (24%) had recurrence of pulmonary embolism (relative risk, 0.27 [CI, 0.09 to 0.78]); 3 of 58 patients receiving high-dose danaparoid (5%) and 6 of 54 patients receiving unfractionated heparin (11%) had recurrence of deep venous thrombosis (relative risk, 0.47 [CI, 0.12 to 1.77]). Occurrence of major and minor bleeding was similar in the three groups; major bleeding occurred in 1 patient receiving low-dose danaparoid, 1 patient receiving high-dose danaparoid, and 2 patients receiving heparin. Conclusions: Our results suggest that high-dose danaparoid is safer and more effective than unfractionated heparin for the treatment of venous thromboembolism.	ACAD HOSP UTRECHT,DEPT INTERNAL MED,3508 GA UTRECHT,NETHERLANDS; ST ANTONIUS HOSP,DEPT INTERNAL MED,3435 CM NIEUWEGEIN,NETHERLANDS; ACAD HOSP UTRECHT,DEPT CARDIOL,3508 GA UTRECHT,NETHERLANDS; EEMLAND HOSP DE LICHTENBERG,DEPT INTERNAL MED,3800 ED AMERSFOORT,NETHERLANDS; ACAD HOSP UTRECHT,DEPT HAEMATOL,3508 GA UTRECHT,NETHERLANDS	Utrecht University; Utrecht University Medical Center; St. Antonius Hospital Utrecht; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center								ALBADA J, 1989, CIRCULATION, V80, P935, DOI 10.1161/01.CIR.80.4.935; BERGQVIST D, 1991, SURGERY, V109, P617; BIELLO DR, 1979, AM J ROENTGENOL, V133, P1033, DOI 10.2214/ajr.133.6.1033; BONEU B, 1985, THROMB RES, V40, P81, DOI 10.1016/0049-3848(85)90352-4; BOUNAMEAUX H, 1992, INVEST RADIOL, V27, P1009, DOI 10.1097/00004424-199212000-00004; BRATT G, 1990, THROMB HAEMOSTASIS, V64, P506; CHONG BH, 1989, BLOOD, V73, P1592; FERNANDEZ FA, 1987, THROMB HAEMOSTASIS, V57, P286; GALLUS A, 1993, THROMB HAEMOSTASIS, V70, P562; HENNY CP, 1985, THROMB HAEMOSTASIS, V54, P460; HIRSH J, 1994, CIRCULATION, V89, P1449, DOI 10.1161/01.CIR.89.3.1449; HIRSH J, 1994, CIRCULATION, V89, P1469, DOI 10.1161/01.CIR.89.3.1469; HOEK JA, 1992, THROMB HAEMOSTASIS, V67, P28; HUISMAN MV, 1989, CHEST, V95, P498, DOI 10.1378/chest.95.3.498; HULL RD, 1992, ARCH INTERN MED, V152, P1589, DOI 10.1001/archinte.152.8.1589; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; IRELAND H, 1986, THROMB HAEMOSTASIS, V55, P271; LEIZOROVICZ A, 1994, BMJ-BRIT MED J, V309, P299, DOI 10.1136/bmj.309.6950.299; LENSING AWA, 1992, THROMB HAEMOSTASIS, V68, P245; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LOPACIUK S, 1992, THROMB HAEMOSTASIS, V68, P14; MAGNANI HN, 1993, THROMB HAEMOSTASIS, V70, P554; MEULEMAN DG, 1992, HAEMOSTASIS, V22, P58; MEULEMAN DG, 1982, THROMB RES, V27, P353, DOI 10.1016/0049-3848(82)90082-2; NIEUWENHUIS HK, 1991, BLOOD, V78, P2337, DOI 10.1182/blood.V78.9.2337.2337; NIEUWENHUIS HK, 1986, CANCER, V58, P761, DOI 10.1002/1097-0142(19860801)58:3<761::AID-CNCR2820580325>3.0.CO;2-6; NURMOHAMED MT, 1991, SEMIN THROMB HEMOST, V17, P205; OCKELFORD PA, 1985, PATHOLOGY, V17, P78, DOI 10.3109/00313028509063731; OFOSU FA, 1992, HAEMOSTASIS, V22, P66; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; STIEKEMA JCJ, 1989, BRIT J CLIN PHARMACO, V27, P39, DOI 10.1111/j.1365-2125.1989.tb05333.x; TENCATE H, 1984, ANN NEUROL, V15, P268; TURPIE AGG, 1987, LANCET, V1, P523; van Ramshorst B, 1991, Eur J Vasc Surg, V5, P255, DOI 10.1016/S0950-821X(05)80506-7; 1990, JAMA-J AM MED ASSOC, V263, P2753	36	85	87	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	JUL 1	1995	123	1					1	9						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE665	7539233				2022-12-28	WOS:A1995RE66500001
J	ROTH, S; NEUMANSILBERBERG, FS; BARCELO, G; SCHUPBACH, T				ROTH, S; NEUMANSILBERBERG, FS; BARCELO, G; SCHUPBACH, T			CORNICHON AND THE EGF RECEPTOR SIGNALING PROCESS ARE NECESSARY FOR BOTH ANTERIOR-POSTERIOR AND DORSAL-VENTRAL PATTERN-FORMATION IN DROSOPHILA	CELL			English	Article							FAINT-LITTLE-BALL; DORSOVENTRAL PATTERN; BICOID RNA; FEMALE GERMLINE; TGF-ALPHA; OOGENESIS; GENE; LOCALIZATION; MELANOGASTER; HOMOLOG	In Drosophila, the dorsal-ventral polarity of the egg chamber depends on the localization of the oocyte nucleus and the gurken RNA to the dorsal-anterior corner of the oocyte. Gurken protein presumably acts as a ligand for the Drosophila EGF receptor (torpedo/DER) expressed in the somatic follicle cells surrounding the oocyte. cornichon is a gene required in the germline for dorsal-ventral signaling, cornichon, gurken, and torpedo also function in an earlier signaling event that establishes posterior follicle cell fates and specifies the anterior-posterior polarity of the egg chamber. Mutations in all three genes prevent the formation of a correctly polarized microtubule cytoskeleton required for proper localization of the anterior and posterior determinants bicoid and oskar and for the asymmetric positioning of the oocyte nucleus.			ROTH, S (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,SPEMANNSTR 35-LL,D-72076 TUBINGEN,GERMANY.		Roth, Siegfried/E-8241-2010	Roth, Siegfried/0000-0001-5772-3558	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040558] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPHEY L, 1992, CELL, V69, P977, DOI 10.1016/0092-8674(92)90616-K; ASHBURNER M, 1990, GENETICS, V126, P679; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BROWER DL, 1981, J EMBRYOL EXP MORPH, V63, P233; CAROLL SB, 1985, CELL, V43, P47; CHOU TB, 1992, GENETICS, V131, P643; CHOU TB, 1993, DEVELOPMENT, V119, P1359; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; CLIFFORD R, 1992, DEVELOPMENT, V115, P853; CLIFFORD RJ, 1989, GENETICS, V123, P771; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; EPHRUSSI A, 1991, CELL, V66, P23; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GONZALEZREYES A, 1994, SCIENCE, V266, P639, DOI 10.1126/science.7939717; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KOCH EA, 1983, CELL TISSUE RES, V228, P21; KYTE J, 1982, J MOL BIOL, V157, P133; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; Lehmann Ruth, 1995, Seminars in Developmental Biology, V6, P25, DOI 10.1016/S1044-5781(06)80082-4; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; Maniatis T, 1989, DECONTAMINATION DILU; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; MULLINS MC, 1989, GENE DEV, V3, P729, DOI 10.1101/gad.3.5.729; NEUMANSILBERBER.FS, 1993, CELL, V75, P165; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; ROBERTSON HM, 1988, GENETICS, V118, P461; ROTH S, 1994, DEVELOPMENT, V120, P2245; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; RUOHOLABAKER H, 1994, TRENDS GENET, V10, P89, DOI 10.1016/0168-9525(94)90231-3; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHUPACH T, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P163; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Spradling Allan C., 1993, P1; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; Thummel CS, 1992, DROS INF SERV, V71, P150; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wieschaus E., 1986, P199	52	417	426	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					967	978		10.1016/0092-8674(95)90016-0	http://dx.doi.org/10.1016/0092-8674(95)90016-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7540118	Bronze			2022-12-28	WOS:A1995RD76800017
J	DHEIN, J; WALCZAK, H; BAUMLER, C; DEBATIN, KM; KRAMMER, PH				DHEIN, J; WALCZAK, H; BAUMLER, C; DEBATIN, KM; KRAMMER, PH			AUTOCRINE T-CELL SUICIDE MEDIATED BY APO-1/(FAS/CD95)	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; MONOCLONAL-ANTIBODY; SURFACE ANTIGEN; MOLECULAR-CLONING; FAS ANTIGEN; APOPTOSIS; RECEPTOR; INDUCTION; MEMBER; MICE	THE APO-1/(Fas/CD95) cell surface receptor is a member of the nerve growth factor (NGF)/tumour necrosis factor (TNF) receptor superfamily and mediates apoptosis(1-4). Peripheral activated T cells (ATC) from lymphoproliferation (lpr/lpr) mutant mice that express a reduced number of APO-1 receptors have a defect in T-cell receptor (TCR)-induced apoptosis(5,6). This suggests that TCR-induced apoptosis involves APO-1. We tested this hypothesis in various human T cells: (1) malignant Jurkat cells, (2) an alloreactive T-cell clone (S13), and (3) peripheral ATC. TCR triggering through immobilized anti-CD3 antibodies or Staphylococcus enterotoxin B (SEB) superantigen induced expression of the APO-1 ligand and apoptosis in these cells. Anti-CD3-induced apoptosis of Jurkat cells was demonstrated even in single-cell cultures. In all cases apoptosis was substantially inhibited by blocking anti-APO-1 antibody fragments and soluble APO-I receptor decoys. The APO-1 ligand was found in the supernatant of activated Jurkat cells as a soluble cytokine. We propose that TCR-induced apoptosis in ATC can occur through an APO-1 ligand-mediated autocrine suicide. These results provide a mechanism for suppression of the immune response and for peripheral tolerance by T-cell deletion.	GERMAN CANC RES CTR,TUMORIMMUNOL PROGRAM,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG,CHILDRENS HOSP,D-69120 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg			Walczak, Henning/AAV-2214-2020; Debatin, Klaus-Michael/J-9704-2014	Walczak, Henning/0000-0002-6312-4591; Debatin, Klaus-Michael/0000-0002-8397-1886; Dhein, Jens/0000-0002-7200-2967				DEBATIN KM, 1994, EUR J IMMUNOL, V24, P753, DOI 10.1002/eji.1830240339; DHEIN J, 1992, J IMMUNOL, V149, P3166; GILLETTEFERGUSO.I, 1994, EUR J IMMUNOL, V24, P1181; Haight F. A., 1967, HDB POISSON DISTRIBU; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; KABELITZ D, 1989, J EXP MED, V170, P559, DOI 10.1084/jem.170.2.559; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OEHM A, 1992, J BIOL CHEM, V267, P10709; PEPPEL K, 1991, J EXP MED, V174, P1483, DOI 10.1084/jem.174.6.1483; RAMSDELL F, 1994, EUR J IMMUNOL, V24, P928, DOI 10.1002/eji.1830240422; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; STALDER T, 1994, J IMMUNOL, V152, P1127; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	25	1570	1611	0	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					438	441		10.1038/373438a0	http://dx.doi.org/10.1038/373438a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7530335				2022-12-28	WOS:A1995QE67000059
J	PREDKI, PF; NAYAK, LM; GOTTLIEB, MBC; REGAN, L				PREDKI, PF; NAYAK, LM; GOTTLIEB, MBC; REGAN, L			DISSECTING RNA-PROTEIN INTERACTIONS - RNA-RNA RECOGNITION BY ROP	CELL			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; COLE1 PLASMID REPLICATION; CRYSTAL-STRUCTURE; PRIMER TRANSCRIPT; STEM-LOOPS; BINDING; SYNTHETASE; RESOLUTION; DNA; IDENTIFICATION	The ColE1 plasmid of E. coli encodes a small RNA-binding protein, Rop, which is involved in the regulation of plasmid copy number, Rop, a 4-helix bundle protein, facilitates sense-antisense RNA pairing by binding to the transiently formed hairpin pairs of RNA I and the complementary RNA II. We have identified the residues of Rop that are involved in RNA recognition. The residues form a narrow stripe down one face of the bundle and are symmetrically arranged, with recognition centered about two phenylalanine residues. Our results suggest that these phenylalanine residues interact with the loop region of the hairpin pair, with additional interactions between eight polar residues and the phosphate backbone. By modifying the identity of residue 14, we have created a variant of Rop that displays altered RNA binding specificity. The results of our studies allow us to present a detailed picture of RNA-protein recognition in a novel model system.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511	Yale University					NIGMS NIH HHS [GM49146, GM45340] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049146, R29GM049146] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BHAT TN, 1982, J MOL BIOL, V158, P699, DOI 10.1016/0022-2836(82)90255-8; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRICK P, 1988, J MOL BIOL, V208, P83; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CASTAGNOLI L, 1989, EMBO J, V8, P621, DOI 10.1002/j.1460-2075.1989.tb03417.x; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; EBERLE W, 1991, Journal of Biomolecular NMR, V1, P71, DOI 10.1007/BF01874570; EBERLE W, 1990, BIOCHEMISTRY-US, V29, P7402, DOI 10.1021/bi00484a007; EGUCHI Y, 1991, J MOL BIOL, V220, P831, DOI 10.1016/0022-2836(91)90356-B; EGUCHI Y, 1990, CELL, V60, P199, DOI 10.1016/0092-8674(90)90736-X; FOLKERS PJM, 1991, EUR J BIOCHEM, V200, P139, DOI 10.1111/j.1432-1033.1991.tb21060.x; HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LYU PC, 1990, SCIENCE, V260, P669; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; MUNSON M, 1994, GENE, V144, P59, DOI 10.1016/0378-1119(94)90203-8; MUNSON M, 1994, IN PRESS PROT SCI; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; POLISKY B, 1988, CELL, V55, P929, DOI 10.1016/0092-8674(88)90235-8; PRIGODICH RV, 1986, BIOCHEMISTRY-US, V25, P3666, DOI 10.1021/bi00360a029; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; RUTENBER E, 1993, PROT STRUCT FUNCT GE, V10, P240; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SMITH CK, 1994, IN PRESS TECH PROT C; STEIF C, 1993, BIOCHEMISTRY-US, V32, P3867, DOI 10.1021/bi00066a005; TOMIZAWA J, 1984, CELL, V38, P861, DOI 10.1016/0092-8674(84)90281-2; TOMIZAWA J, 1984, CELL, V38, P871, DOI 10.1016/0092-8674(84)90282-4; TOMIZAWA J, 1981, CELL, V31, P575; ZELWER C, 1982, J MOL BIOL, V155, P63, DOI 10.1016/0022-2836(82)90492-2	45	90	91	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					41	50		10.1016/0092-8674(95)90449-2	http://dx.doi.org/10.1016/0092-8674(95)90449-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7529141	hybrid			2022-12-28	WOS:A1995QB91000008
J	RESSLER, KJ; SULLIVAN, SL; BUCK, LB				RESSLER, KJ; SULLIVAN, SL; BUCK, LB			INFORMATION CODING IN THE OLFACTORY SYSTEM - EVIDENCE FOR A STEREOTYPED AND HIGHLY ORGANIZED EPITOPE MAP IN THE OLFACTORY-BULB	CELL			English	Article							ODORANT RECEPTOR EXPRESSION; FUNCTIONAL-ORGANIZATION; 2-DEOXYGLUCOSE METHOD; EPITHELIUM; NEURONS; RAT; PROJECTIONS; NERVES; CELLS; GENE	In the mammalian olfactory system, information from similar to 1000 different odorant receptor types is organized in the nose into four spatial zones. Each zone is a mosaic of randomly distributed neurons expressing different receptor types. in these studies, we have obtained evidence that information highly distributed in the nose is transformed in the olfactory bulb of the brain into a highly organized spatial map. We find that specific odorant receptor gene probes hybridize in situ to small, and distinct, subsets of olfactory bulb glomeruli. The spatial and numerical characteristics of the patterns of hybridization that we observe with different receptor probes indicate that, in the olfactory bulb, olfactory information undergoes a remarkable organization into a fine, and perhaps stereotyped, spatial map. In our view, this map is in essence an epitope map, whose similar to 1000 distinct components are used in a multitude of different combinations to discriminate a vast array of different odors.			RESSLER, KJ (corresponding author), HARVARD UNIV, SCH MED, DEPT NEUROBIOL, BOSTON, MA 02115 USA.		Ressler, Kerry J/N-8741-2018	Ressler, Kerry J/0000-0002-5158-1103	NIDCD NIH HHS [5-F32-DC00188-01, 1-RO1-DC01662-01] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [F32DC000188, R01DC001662] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ADRIAN ED, 1950, BRIT MED BULL, V6, P330, DOI 10.1093/oxfordjournals.bmb.a073625; ALLISON AC, 1949, BRAIN, V72, P186, DOI 10.1093/brain/72.2.186; [Anonymous], [No title captured]; ASTIC L, 1983, DEV BRAIN RES, V10, P257, DOI 10.1016/0165-3806(83)90142-6; BRUNJES PC, 1994, BRAIN RES REV, V19, P146; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Buck LB, 1992, CURR OPIN GENET DEV, V2, P467, DOI 10.1016/S0959-437X(05)80159-5; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CLARK WL, 1957, PROC R SOC SER B-BIO, V146, P299, DOI 10.1098/rspb.1957.0013; COOPERSMITH R, 1986, DEV BRAIN RES, V27, P191, DOI 10.1016/0165-3806(86)90245-2; COSTANZO RM, 1978, BRAIN RES, V139, P327, DOI 10.1016/0006-8993(78)90932-0; DANCIGER E, 1989, P NATL ACAD SCI USA, V86, P8565, DOI 10.1073/pnas.86.21.8565; DAVIS L, 1992, J NEUROSCI, V12, P4867; FIRESTEIN S, 1993, CIBA F SYMP, V179, P115; Gall JG, 1971, METHOD ENZYMOL, V21, P470; GIOIO AE, 1994, J NEUROCHEM, V63, P13; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GRAZIADEI PPC, 1986, NEUROSCIENCE, V19, P1025, DOI 10.1016/0306-4522(86)90119-3; GREER CA, 1981, BRAIN RES, V217, P279, DOI 10.1016/0006-8993(81)90004-4; GUTHRIE KM, 1993, P NATL ACAD SCI USA, V90, P3329, DOI 10.1073/pnas.90.8.3329; IMAMURA K, 1992, J NEUROPHYSIOL, V68, P1986, DOI 10.1152/jn.1992.68.6.1986; JOURDAN F, 1980, BRAIN RES, V188, P139, DOI 10.1016/0006-8993(80)90563-6; Kauer J.S., 1987, P205; KAUER JS, 1993, MICROSC RES TECHNIQ, V24, P157, DOI 10.1002/jemt.1070240207; KLEIMAN R, 1994, J NEUROSCI, V14, P1130, DOI 10.1523/JNEUROSCI.14-03-01130.1994; LANCET D, 1993, CURR BIOL, V3, P668, DOI 10.1016/0960-9822(93)90064-U; LAND LJ, 1973, BRAIN RES, V63, P153, DOI 10.1016/0006-8993(73)90084-X; LAW MI, 1981, J NEUROSCI, V1, P741, DOI 10.1523/JNEUROSCI.01-07-00741.1981; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; MACKAYSIM A, 1991, EUR J NEUROSCI, V3, P209, DOI 10.1111/j.1460-9568.1991.tb00081.x; MONTIGRAZIADEI GA, 1980, NEUROSCIENCE, V5, P1239; MORI K, 1992, J NEUROPHYSIOL, V67, P786, DOI 10.1152/jn.1992.67.3.786; MORI K, 1994, SEMIN CELL BIOL, V13, P771; NEF P, 1992, P NATL ACAD SCI USA, V89, P8948, DOI 10.1073/pnas.89.19.8948; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; ONODA N, 1992, NEUROSCI LETT, V137, P157, DOI 10.1016/0304-3940(92)90393-L; PINCHING AJ, 1971, J CELL SCI, V8, P253; PINCHING AJ, 1974, BRAIN RES, V82, P195, DOI 10.1016/0006-8993(74)90598-8; POMEROY SL, 1990, J NEUROSCI, V10, P1952; Reed Randall R., 1994, Seminars in Cell Biology, V5, P33, DOI 10.1006/scel.1994.1005; Ressler Kerry J., 1994, Current Opinion in Neurobiology, V4, P588, DOI 10.1016/0959-4388(94)90061-2; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; ROYET JP, 1988, J COMP NEUROL, V270, P559, DOI 10.1002/cne.902700409; SALLAZ M, 1993, NEUROREPORT, V4, P55, DOI 10.1097/00001756-199301000-00014; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SAUCIER D, 1986, BRAIN RES BULL, V16, P455, DOI 10.1016/0361-9230(86)90173-5; SCHOENFELD TA, 1994, BRAIN RES BULL, V34, P183, DOI 10.1016/0361-9230(94)90059-0; SCHWARTING GA, 1991, BRAIN RES, V547, P239, DOI 10.1016/0006-8993(91)90967-Z; SCHWOB JE, 1986, J NEUROSCI, V6, P3393; SCOTT JW, 1993, MICROSC RES TECHNIQ, V24, P142, DOI 10.1002/jemt.1070240206; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; Shepherd G. M., 1988, NEUROBIOLOGY; Shepherd G. M., 1990, SYNAPTIC ORG BRAIN, P133; SHEPHERD GM, 1994, NEURON, V13, P771, DOI 10.1016/0896-6273(94)90245-3; SICARD G, 1984, BRAIN RES, V292, P283, DOI 10.1016/0006-8993(84)90764-9; SKUTELLA T, 1994, MOL BRAIN RES, V23, P179, DOI 10.1016/0169-328X(94)90224-0; STEWARD O, 1992, TRENDS NEUROSCI, V15, P180, DOI 10.1016/0166-2236(92)90170-D; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; STEWART WB, 1987, BRAIN RES, V411, P248, DOI 10.1016/0006-8993(87)91076-6; STONE DM, 1991, J COMP NEUROL, V311, P223, DOI 10.1002/cne.903110205; STROTMANN J, 1994, CELL TISSUE RES, V278, P11, DOI 10.1007/s004410050189; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; WALTER J, 1987, DEVELOPMENT, V101, P685	66	924	940	1	59	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 30	1994	79	7					1245	1255		10.1016/0092-8674(94)90015-9	http://dx.doi.org/10.1016/0092-8674(94)90015-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	7528109				2022-12-28	WOS:A1994PZ86000015
J	HEASMAN, J; CRAWFORD, A; GOLDSTONE, K; GARNERHAMRICK, P; GUMBINER, B; MCCREA, P; KINTNER, C; NORO, CY; WYLIE, C				HEASMAN, J; CRAWFORD, A; GOLDSTONE, K; GARNERHAMRICK, P; GUMBINER, B; MCCREA, P; KINTNER, C; NORO, CY; WYLIE, C			OVEREXPRESSION OF CADHERINS AND UNDEREXPRESSION OF BETA-CATENIN INHIBIT DORSAL MESODERM INDUCTION IN EARLY XENOPUS EMBRYOS	CELL			English	Article							CELL-ADHESION MOLECULE; POLARITY GENE ARMADILLO; N-CADHERIN; ECTOPIC EXPRESSION; CYTOPLASMIC DOMAIN; LAEVIS EMBRYOS; EARLY RESPONSE; BODY AXIS; PROTEIN; DROSOPHILA	The cadherin-catenin complex has an important role in cell-cell adhesion and may also function in signaling pathways. We report that overexpression of three cadherin types in Xenopus embryos causes them to develop with reduced dorsal axial structures. The same phenotype is produced in embryos that have been depleted of maternal beta-catenin protein by an antisense oligodeoxynucleotide complementary to beta-catenin mRNA. They show an inhibition in the expression of dorsal mesodermal markers MyoD and goosecoid, but not of ventral and general mesodermal markers. They lack notochords, somites, and neural tubes and are defective in dorsal mesodermal signaling in Nieuwkoop assays. The phenotype can be rescued by the injection of beta-catenin mRNA and not by the injection of Xwnt-8 mRNA. These results show that beta-catenin has an important role in dorsal mesoderm induction. They directly demonstrate the activity of a maternal mRNA in axis specification.	UNIV MINNESOTA, DEPT CELL BIOL & NEUROANAT, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT PEDIAT, MINNEAPOLIS, MN 55455 USA; WELLCOME CANC RES CTR INST, CAMBRIDGE CB2 1QR, ENGLAND; DEPT ZOOL, CAMBRIDGE CB2 1QR, ENGLAND; MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, NEW YORK, NY 10021 USA; SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, SAN DIEGO, CA 92037 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Memorial Sloan Kettering Cancer Center; Salk Institute	HEASMAN, J (corresponding author), UNIV MINNESOTA, INST HUMAN GENET, MINNEAPOLIS, MN 55455 USA.			Yoshida-Noro, Chikako/0000-0001-9147-4743	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANGRES B, 1991, DEVELOPMENT, V111, P829; BECKERLE MC, 1986, J CELL BIOL, V103, P1679, DOI 10.1083/jcb.103.5.1679; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; CHAKRABARTI A, 1992, DEVELOPMENT, V115, P355; CHOI YS, 1989, J CELL BIOL, V108, P2449, DOI 10.1083/jcb.108.6.2449; CHOI YS, 1990, J CELL BIOL, V110, P1575, DOI 10.1083/jcb.110.5.1575; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; DEMARAIS AA, 1992, DEV BIOL, V153, P337, DOI 10.1016/0012-1606(92)90118-Z; DETRICK RJ, 1990, NEURON, V4, P493, DOI 10.1016/0896-6273(90)90108-R; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; FUJIMORI T, 1990, DEVELOPMENT, V110, P97; GEIGER B, 1990, J CELL SCI, V97, P607; GERHART J, 1989, DEVELOPMENT, V107, P37; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GINSBERG D, 1991, DEVELOPMENT, V111, P315; GUMBINER BM, 1993, NEURON, V11, P551, DOI 10.1016/0896-6273(93)90068-3; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; HEASMAN J, 1994, DEVELOPMENT, V120, P49; HEASMAN J, 1991, METHOD CELL BIOL, V36, P213; HEASMAN J, 1981, CELL, V27, P437, DOI 10.1016/0092-8674(81)90385-8; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HOLWILL S, 1987, DEVELOPMENT, V100, P735; HOPWOOD ND, 1992, DEVELOPMENT, V114, P31; HOPWOOD ND, 1990, NATURE, V347, P197, DOI 10.1038/347197a0; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE E, 1994, IN PRESS DEVELOPMENT, V120; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; MCCREA PD, 1992, SCIENCE, V257, P1144, DOI 10.1126/science.257.5073.1144; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NIEUWKOOP PD, 1973, ADV MORPHOGEN, V10, P2; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, DEVELOPMENT, V118, P1191; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PEIFER M, 1992, TRENDS GENET, V8, P243, DOI 10.1016/0168-9525(92)90394-J; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SCHNEIDER S, 1993, DEVELOPMENT, V118, P629; SHARPE CR, 1988, DEVELOPMENT, V103, P269; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TURNER AP, 1992, EMBO J, V11, P3845, DOI 10.1002/j.1460-2075.1992.tb05477.x; WIESCHAUS E, 1987, CELL, V49, P177, DOI 10.1016/0092-8674(87)90558-7; WOLDA SL, 1993, DEV BIOL, V155, P46, DOI 10.1006/dbio.1993.1005	54	561	573	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 2	1994	79	5					791	803		10.1016/0092-8674(94)90069-8	http://dx.doi.org/10.1016/0092-8674(94)90069-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PW054	7528101				2022-12-28	WOS:A1994PW05400007
J	LUDWIG, J; GORES, GJ				LUDWIG, J; GORES, GJ			INFARCT CAVITIES IN A HEPATIC ALLOGRAFT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											LUDWIG, J (corresponding author), MAYO CLIN,ROCHESTER,MN 55905, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 26	1995	333	17					1117	1117		10.1056/NEJM199510263331705	http://dx.doi.org/10.1056/NEJM199510263331705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA372	7565950				2022-12-28	WOS:A1995TA37200005
J	SCHLUGER, LK; BODENHEIMER, H				SCHLUGER, LK; BODENHEIMER, H			TACKLING LIVER-CANCER WITH INTERFERON	LANCET			English	Editorial Material							HEPATITIS-C VIRUS; HEPATOCELLULAR-CARCINOMA; ANTIBODIES; CIRRHOSIS; INFECTION				SCHLUGER, LK (corresponding author), MT SINAI MED CTR,LIVER TRANSPLANTAT PROGRAM,NEW YORK,NY 10029, USA.							[Anonymous], 1990, Cancer, V66, P135; BRUIX J, 1989, LANCET, V2, P1004; COLOMBO M, 1991, AM J HEMATOL, V37, P243, DOI 10.1002/ajh.2830370406; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; GERBER MA, 1992, AM J PATHOL, V141, P1271; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; KIYOSAWA K, 1987, AM J GASTROENTEROL, V78, P777; LEVRERO M, 1991, J HEPATOL, V12, P60, DOI 10.1016/0168-8278(91)90910-4; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MUCHMORE E, 1988, J MED PRIMATOL, V17, P235; NALPAS B, 1991, J HEPATOL, V12, P70, DOI 10.1016/0168-8278(91)90912-U; OKUDA K, 1982, HEPATOLOGY, V2, P113; SIMONETTI RG, 1992, ANN INTERN MED, V116, P97, DOI 10.7326/0003-4819-116-2-97	13	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1049	1050						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564782				2022-12-28	WOS:A1995TA69700006
J	HULKA, BS; STARK, AT				HULKA, BS; STARK, AT			BREAST-CANCER - CAUSE AND PREVENTION	LANCET			English	Review							FAMILY HISTORY; REPRODUCTIVE FACTORS; CELL-PROLIFERATION; OVARIAN-CANCER; DIETARY-FAT; RISK; DISEASE; MORTALITY; WOMEN; CONSUMPTION				HULKA, BS (corresponding author), UNIV N CAROLINA, SCH PUBL HLTH, DEPT EPIDEMIOL, MCGAVRAN GREENBERG HALL, CHAPEL HILL, NC 27599 USA.							ABE O, 1992, LANCET, V339, P71; Ambrosone C. B., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P283; Bassett LW, 1994, QUALITY DETERMINANTS; BERNSTEIN L, 1995, CANCER EPIDEM BIOMAR, V4, P437; BIESECKER BB, 1993, JAMA-J AM MED ASSOC, V269, P1970, DOI 10.1001/jama.269.15.1970; BOYD NF, 1993, BRIT J CANCER, V68, P627, DOI 10.1038/bjc.1993.398; BRENNER H, 1992, AM J EPIDEMIOL, V135, P85, DOI 10.1093/oxfordjournals.aje.a116205; CAULEY JA, 1989, AM J EPIDEMIOL, V129, P1120, DOI 10.1093/oxfordjournals.aje.a115234; Colditz Graham A., 1990, Annals of Epidemiology, V1, P167, DOI 10.1016/1047-2797(90)90007-F; COLEMAN MP, 1993, IARC PUBLICATIONS, V121; COLSTON KW, 1989, LANCET, V1, P188; COSTA A, 1994, CANCER RES, V54, pS2032; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; FRIEDENREICH CM, 1995, EPIDEMIOLOGY, V6, P311, DOI 10.1097/00001648-199505000-00021; GIOVANNUCCI E, 1993, AM J EPIDEMIOL, V137, P502, DOI 10.1093/oxfordjournals.aje.a116703; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRAHAM S, 1992, AM J EPIDEMIOL, V136, P1327, DOI 10.1093/oxfordjournals.aje.a116445; HANCOCK SL, 1993, J NATL CANCER I, V85, P25, DOI 10.1093/jnci/85.1.25; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; HULKA BS, 1994, CANCER, V74, P1111, DOI 10.1002/1097-0142(19940801)74:3+<1111::AID-CNCR2820741520>3.0.CO;2-L; HUNTER DJ, 1993, NEW ENGL J MED, V329, P234, DOI 10.1056/NEJM199307223290403; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; KING MC, 1993, JAMA-J AM MED ASSOC, V269, P1975, DOI 10.1001/jama.269.15.1975; KRIEGER N, 1994, JNCI-J NATL CANCER I, V86, P589, DOI 10.1093/jnci/86.8.589; LONDON SJ, 1992, JAMA-J AM MED ASSOC, V267, P941, DOI 10.1001/jama.267.7.941; LONGNECKER MP, 1994, CANCER CAUSE CONTROL, V5, P73, DOI 10.1007/BF01830729; LOOMIS DP, 1955, JNCI-J NATL CANCER I, V86, P921; LYON JL, 1994, CANCER CAUSE CONTROL, V5, P149, DOI 10.1007/BF01830261; MARCIAL VA, 1994, CANCER, V74, P450, DOI 10.1002/cncr.2820741334; MEHTA RS, 1993, CARCINOGENESIS, V14, P1693, DOI 10.1093/carcin/14.8.1693; MESSINA M, 1991, JNCI-J NATL CANCER I, V83, P541, DOI 10.1093/jnci/83.8.541; Michnovicz J J, 1988, Steroids, V52, P69, DOI 10.1016/0039-128X(88)90218-8; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILLER AB, 1989, NEW ENGL J MED, V321, P1285, DOI 10.1056/NEJM198911093211902; MILLER BA, 1993, NIH932789 US DEP HLT; MILLS P, 1989, CANCER-AM CANCER SOC, V64, P582, DOI 10.1002/1097-0142(19890801)64:3&lt;582::AID-CNCR2820640304&gt;3.0.CO;2-V; MILNE R, 1992, J PUBLIC HEALTH MED, V14, P9; NEWCOMB PA, 1994, NEW ENGL J MED, V330, P81, DOI 10.1056/NEJM199401133300201; OZA AM, 1993, EPIDEMIOL REV, V15, P196, DOI 10.1093/oxfordjournals.epirev.a036105; PARKIN DM, 1992, CANCER INCIDENCE 5 C, V6; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; PIKE MC, 1993, J CELL BIOCHEM, P26; PISANI P, 1993, INT J CANCER, V55, P891, DOI 10.1002/ijc.2910550604; PRENTICE RL, 1990, CANCER CAUSE CONTROL, V1, P81, DOI 10.1007/BF00053187; REICHMAN ME, 1993, J NATL CANCER I, V85, P722, DOI 10.1093/jnci/85.9.722; ROSE DP, 1995, JNCI-J NATL CANCER I, V87, P587, DOI 10.1093/jnci/87.8.587; ROSNER B, 1994, AM J EPIDEMIOL, V139, P819, DOI 10.1093/oxfordjournals.aje.a117079; Russo I H, 1993, Eur J Cancer Prev, V2 Suppl 3, P101; RUSSO J, 1994, CANCER EPIDEM BIOMAR, V3, P353; SCHENKER JG, 1993, HUM REPROD, V8, P969, DOI 10.1093/oxfordjournals.humrep.a138176; SELLERS TA, 1992, NEW ENGL J MED, V326, P1323, DOI 10.1056/NEJM199205143262004; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SIMOES EJ, 1995, AM J PUBLIC HEALTH, V85, P240, DOI 10.2105/AJPH.85.2.240; SIMPSON ER, 1990, ADIPOSE TISSUE REPRO; SLATTERY ML, 1993, JAMA-J AM MED ASSOC, V270, P1563, DOI 10.1001/jama.270.13.1563; SPICER DV, 1994, J NATL CANCER I, V86, P431, DOI 10.1093/jnci/86.6.431; STANFORD JL, 1995, EPIDEMIOLOGY, V6, P181, DOI 10.1097/00001648-199503000-00017; SUGIMURA T, 1994, J NATL CANCER I, V86, P2, DOI 10.1093/jnci/86.1.2; SWANN CA, 1987, AM J ROENTGENOL, V148, P525, DOI 10.2214/ajr.148.3.525; THOMAS DB, 1990, BRIT J CANCER, V61, P110; TRICHOPOULOU A, 1995, JNCI-J NATL CANCER I, V87, P110, DOI 10.1093/jnci/87.2.110; VENA JE, 1991, AM J EPIDEMIOL, V134, P180, DOI 10.1093/oxfordjournals.aje.a116070; WEBER BL, 1993, JAMA-J AM MED ASSOC, V270, P1602, DOI 10.1001/jama.270.13.1602; WOLFF MS, 1993, JNCI-J NATL CANCER I, V85, P648, DOI 10.1093/jnci/85.8.648; WOOSTER K, 1944, SCIENCE, V265, P2088; YOO KY, 1992, AM J EPIDEMIOL, V135, P726, DOI 10.1093/oxfordjournals.aje.a116359	66	183	194	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 30	1995	346	8979					883	887		10.1016/S0140-6736(95)92713-1	http://dx.doi.org/10.1016/S0140-6736(95)92713-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX196	7564675				2022-12-28	WOS:A1995RX19600013
J	FENG, GP; DEAK, P; CHOPRA, M; HALL, LM				FENG, GP; DEAK, P; CHOPRA, M; HALL, LM			CLONING AND FUNCTIONAL-ANALYSIS OF TIPE, A NOVEL MEMBRANE-PROTEIN THAT ENHANCES DROSOPHILA PARA SODIUM-CHANNEL FUNCTION	CELL			English	Article							TEMPERATURE-SENSITIVE MUTATIONS; CYCLOPHILIN HOMOLOG NINAA; CIS-TRANS ISOMERASE; A-BINDING-PROTEIN; RAT-BRAIN; RETINOTECTAL PROJECTION; SEQUENCE-ANALYSIS; NERVE-CONDUCTION; SKELETAL-MUSCLE; GENE	Voltage-dependent sodium channels are involved in the initiation and propagation of action potentials in many excitable cells. Here we report that tipE, a gene defined by a temperature-sensitive paralytic mutation in Drosophila, encodes a novel integral membrane protein that dramatically stimulates functional expression in Xenopus oocytes of the Drosophila sodium channel a subunit encoded by the paralytic (para) locus. Using a heat shock promoter to control tipE(+) gene expression in transgenic flies, we demonstrate that tipE(+) gene expression is required during pupal development to rescue adult paralysis. In addition, we demonstrate a role for the tipE gene product in adults.	SUNY BUFFALO,DEPT BIOCHEM PHARMACOL,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Deák, Péter/M-5674-2018; Deak, Peter/F-7751-2012; Feng, Guoping/Y-2827-2019	Deak, Peter/0000-0002-8849-0352	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016204] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16204] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashburner M., 1978, GENETICS BIOL DROS A, P1; AURON PE, 1987, BIOTECHNIQUES, V5, P672; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BROADIE K, 1993, NEURON, V11, P607, DOI 10.1016/0896-6273(93)90073-Z; BURG MG, 1993, J NEUROBIOL, V24, P803, DOI 10.1002/neu.480240608; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FAWCETT JW, 1985, TRENDS NEUROSCI, V8, P201, DOI 10.1016/0166-2236(85)90079-7; FENG GP, 1995, GENETICS, V139, P1679; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GANETZKY B, 1986, J NEUROGENET, V3, P19, DOI 10.3109/01677068609106892; GAUTRON S, 1992, P NATL ACAD SCI USA, V89, P7272, DOI 10.1073/pnas.89.15.7272; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; Hille B., 1992, IONIC CHANNELS EXCIT; HODGES D, 1994, ADV GENET, V31, P207, DOI 10.1016/S0065-2660(08)60399-5; HONG CS, 1994, J NEUROSCI, V14, P5160; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; ITOH N, 1985, DROS INF SERVICE, V61, P89; JACKSON FR, 1985, J NEUROSCI, V5, P1144; JACKSON FR, 1986, J NEUROGENET, V3, P1, DOI 10.3109/01677068609106891; JACKSON FR, 1984, NATURE, V308, P189, DOI 10.1038/308189a0; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KERNAN MJ, 1991, CELL, V66, P949, DOI 10.1016/0092-8674(91)90440-A; KOBAYASHI T, 1990, DEV BRAIN RES, V57, P29, DOI 10.1016/0165-3806(90)90181-W; KRAFTE DS, 1988, J NEUROSCI, V8, P2859; KULKARNI SJ, 1982, GENET RES, V40, P191, DOI 10.1017/S0016672300019054; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; MEYER RL, 1982, SCIENCE, V218, P589, DOI 10.1126/science.7123262; MEYER RL, 1983, DEV BRAIN RES, V6, P293, DOI 10.1016/0165-3806(83)90068-8; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; ODOWD DK, 1988, J NEUROSCI, V8, P3633; ODOWD DK, 1989, NEURON, V2, P1301, DOI 10.1016/0896-6273(89)90068-8; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT J, 1985, P NATL ACAD SCI USA, V82, P4847, DOI 10.1073/pnas.82.14.4847; SCHMIDT JT, 1983, BRAIN RES, V269, P29, DOI 10.1016/0006-8993(83)90959-9; SCHMIDT JW, 1986, CELL, V46, P437, DOI 10.1016/0092-8674(86)90664-1; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P453, DOI 10.1007/BF00388310; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; SUZUKI DT, 1970, SCIENCE, V170, P695, DOI 10.1126/science.170.3959.695; SUZUKI DT, 1971, P NATL ACAD SCI USA, V68, P890, DOI 10.1073/pnas.68.5.890; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thummel CS, 1992, DROS INF SERV, V71, P150; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; TRUMAN JW, 1993, DEV DROSOPHILA MELAN, V2, P1245; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WOLLNER DA, 1987, J BIOL CHEM, V262, P14709; Wu C F, 1992, Ion Channels, V3, P261; WU CF, 1978, P NATL ACAD SCI USA, V75, P4047, DOI 10.1073/pnas.75.8.4047; YOST CS, 1983, CELL, V34, P759; ZHENG W, 1995, J NEUROSCI, V15, P1132	65	180	190	3	17	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					1001	1011		10.1016/0092-8674(95)90279-1	http://dx.doi.org/10.1016/0092-8674(95)90279-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553842	Bronze			2022-12-28	WOS:A1995RW69300016
J	FLEISCHMANN, RD; ADAMS, MD; WHITE, O; CLAYTON, RA; KIRKNESS, EF; KERLAVAGE, AR; BULT, CJ; TOMB, JF; DOUGHERTY, BA; MERRICK, JM; MCKENNEY, K; SUTTON, G; FITZHUGH, W; FIELDS, C; GOCAYNE, JD; SCOTT, J; SHIRLEY, R; LIU, LI; GLODEK, A; KELLEY, JM; WEIDMAN, JF; PHILLIPS, CA; SPRIGGS, T; HEDBLOM, E; COTTON, MD; UTTERBACK, TR; HANNA, MC; NGUYEN, DT; SAUDEK, DM; BRANDON, RC; FINE, LD; FRITCHMAN, JL; FUHRMANN, JL; GEOGHAGEN, NSM; GNEHM, CL; MCDONALD, LA; SMALL, KV; FRASER, CM; SMITH, HO; VENTER, JC				FLEISCHMANN, RD; ADAMS, MD; WHITE, O; CLAYTON, RA; KIRKNESS, EF; KERLAVAGE, AR; BULT, CJ; TOMB, JF; DOUGHERTY, BA; MERRICK, JM; MCKENNEY, K; SUTTON, G; FITZHUGH, W; FIELDS, C; GOCAYNE, JD; SCOTT, J; SHIRLEY, R; LIU, LI; GLODEK, A; KELLEY, JM; WEIDMAN, JF; PHILLIPS, CA; SPRIGGS, T; HEDBLOM, E; COTTON, MD; UTTERBACK, TR; HANNA, MC; NGUYEN, DT; SAUDEK, DM; BRANDON, RC; FINE, LD; FRITCHMAN, JL; FUHRMANN, JL; GEOGHAGEN, NSM; GNEHM, CL; MCDONALD, LA; SMALL, KV; FRASER, CM; SMITH, HO; VENTER, JC			WHOLE-GENOME RANDOM SEQUENCING AND ASSEMBLY OF HAEMOPHILUS-INFLUENZAE RD	SCIENCE			English	Article							ESCHERICHIA-COLI GENOME; HEMOPHILUS TRANSFORMATION; DNA-SEQUENCE; GENE; PROTEIN; ORGANIZATION; PROJECT; RECOGNITION; COMPETENCE; COMPUTER	An approach for genome analysis based on sequencing and assembly of unselected pieces of DNA from the whole chromosome has been applied to obtain the complete nucleotide sequence (1,830,137 base pairs) of the genome from the bacterium Haemophilus influenzae Rd. This approach eliminates the need for initial mapping efforts and is therefore applicable to the vast array of microbial species for which genome maps are unavailable. The H. influenzae Rd genome sequence (Genome Sequence DataBase accession number L42023) represents the only complete genome sequence from a free-living organism.	INST GENOM RES, GAITHERSBURG, MD 20878 USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA; SUNY BUFFALO, DEPT MICROBIOL, BUFFALO, NY 14214 USA; NIST, GAITHERSBURG, MD 20878 USA	J. Craig Venter Institute; Johns Hopkins University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; National Institute of Standards & Technology (NIST) - USA			Puigbò, Pere/A-2214-2008	Kerlavage, Anthony/0000-0002-3954-9653; Fraser, Claire/0000-0003-1462-2428; Fields, Chris/0000-0002-4812-0744				Adams M. D., 1994, AUTOMATED DNA SEQUEN; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1994, NATURE, V368, P474, DOI 10.1038/368474a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ADAMS MD, IN PRESS NATURE; ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bankier A T, 1991, DNA Seq, V2, P1, DOI 10.3109/10425179109008433; BAROUKI R, 1985, J BACTERIOL, V163, P629, DOI 10.1128/JB.163.2.629-634.1985; BODMER WF, 1994, REV INVEST CLIN S, P3; BORODOVSKY M, 1993, COMPUT CHEM, V17, P123, DOI 10.1016/0097-8485(93)85004-V; BRUTLAG DL, 1993, COMPUT CHEM, V17, P203, DOI 10.1016/0097-8485(93)85011-Z; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; CHANDLER MS, 1992, P NATL ACAD SCI USA, V89, P1626, DOI 10.1073/pnas.89.5.1626; CLAVERIE JM, 1993, J MOL BIOL, V234, P1140, DOI 10.1006/jmbi.1993.1666; DANNER DB, 1980, GENE, V11, P311, DOI 10.1016/0378-1119(80)90071-2; DANNER DB, 1982, P NATL ACAD SCI-BIOL, V79, P2393, DOI 10.1073/pnas.79.7.2393; DOROCICZ IR, 1993, J BACTERIOL, V175, P7142, DOI 10.1128/JB.175.22.7142-7149.1993; DOUGHERTY B, UNPUB; GLASER P, 1993, MOL MICROBIOL, V10, P371, DOI 10.1111/j.1365-2958.1993.tb01963.x; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GREENER A, 1990, STRATEGIES MOL BIOL, V3, P5; HARTL DL, 1993, GENOME RES MOL MED V, P115; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HONG GF, 1982, J MOL BIOL, V162, P72; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; KAHN ME, 1984, J MEMBRANE BIOL, V138, P155; KERLAVAGE A, 1993, 26TH P HAW INT C SYS, P585; KERLAVAGE AR, IN PRESS IEEE COMPUT; KIRKNESS EF, 1991, GENOMICS, V10, P985, DOI 10.1016/0888-7543(91)90189-L; KLEIN RD, 1979, J GEN MICROBIOL, V113, P409, DOI 10.1099/00221287-113-2-409; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDER E S, 1988, Genomics, V2, P231; LEE JJ, 1989, J BACTERIOL, V171, P3016, DOI 10.1128/jb.171.6.3016-3024.1989; LEVY J, 1994, YEAST, V10, P1689, DOI 10.1002/yea.320101304; LEWIN B, 1994, GENES, V5, pCH18; LEWIN B, 1994, GENES, V5, pCH19; MASSUNG RF, 1993, NATURE, V366, P748, DOI 10.1038/366748a0; ODA K, 1992, J MOL BIOL, V223, P1, DOI 10.1016/0022-2836(92)90708-R; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REDFIELD RJ, 1991, J BACTERIOL, V173, P5612, DOI 10.1128/jb.173.18.5612-5618.1991; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; SANGER F, 1977, NATURE, V265, P687, DOI 10.1038/265687a0; SMITH HO, 1995, SCIENCE, V269, P538, DOI 10.1126/science.7542802; SOFIA HJ, 1994, NUCLEIC ACIDS RES, V22, P2576, DOI 10.1093/nar/22.13.2576; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TOMB JF, 1991, GENE, V104, P1, DOI 10.1016/0378-1119(91)90457-M; TOMB JF, 1992, P NATL ACAD SCI USA, V89, P10252, DOI 10.1073/pnas.89.21.10252; TTOMB JF, UNPUB; UTTERBACK TR, UNPUB; VANHAM SM, 1994, MOL MICROBIOL, V13, P673; WATERMAN MS, 1988, METHOD ENZYMOL, V164, P765; WEISER JN, 1989, CELL, V59, P657, DOI 10.1016/0092-8674(89)90011-1; WILCOX KW, 1975, J BACTERIOL, V122, P443, DOI 10.1128/JB.122.2.443-453.1975; YURA T, 1992, NUCLEIC ACIDS RES, V20, P3305, DOI 10.1093/nar/20.13.3305	57	4337	6350	4	351	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 28	1995	269	5223					496	512		10.1126/science.7542800	http://dx.doi.org/10.1126/science.7542800			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7542800				2022-12-28	WOS:A1995RL49500017
J	ROSENBLOOM, AJ; PINSKY, MR; BRYANT, JL; SHIN, A; TRAN, T; WHITESIDE, T				ROSENBLOOM, AJ; PINSKY, MR; BRYANT, JL; SHIN, A; TRAN, T; WHITESIDE, T			LEUKOCYTE ACTIVATION IN THE PERIPHERAL-BLOOD OF PATIENTS WITH CIRRHOSIS OF THE LIVER AND SIRS - CORRELATION WITH SERUM INTERLEUKIN-6 LEVELS AND ORGAN DYSFUNCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NECROSIS-FACTOR-ALPHA; SEPTIC SHOCK; UP-REGULATION; TRANSENDOTHELIAL MIGRATION; COMPLEMENT RECEPTOR-1; HYDROGEN-PEROXIDE; FLOW-CYTOMETRY; SEVERE SEPSIS; CD11B CD18; HLA-DR	Objective.-Leukocyte adhesion plays an important role in inflammation. Adhesion molecules such as CD11b on polymorphonuclear neutrophil leukocytes (PMNs) up-regulate in response to tumor necrosis factor-alpha, interleukin-8 (IL-8), and other mediators that are involved in systemic inflammatory response syndrome (SIRS). This study examined the behavior of CD11b and other membrane molecules in SIRS in relation to serum cytokines and the severity of illness. Design.-Survey study. Setting.-Liver transplantation intensive care unit at a tertiary care center. Patients.-A consecutive sample of 22 patients admitted to the liver transplantation intensive care unit for complications related to cirrhosis of the liver in the absence of other disease. Sixteen of the patients developed SIRS and multiple organ dysfunction syndrome with suspected bacterial infections. Seven control subjects were also studied. Main Outcome Measures.-Modified Goris organ failure score and Acute Physiology and Chronic Health Evaluation II score. Results.-Mean serum IL-6 levels, but not IL-1 beta or tumor necrosis factor-alpha levels, correlated with organ failure (r=0.79, P<.001). Leukocyte cell-surface markers fluctuated from day to day. The mean of several values was more stable. Mean CD11b and CD35 on PMNs correlated with serum IL-6 level (r=0.75, P<.001,and r=0.77, P<.005, respectively). Up-regulation of both CD11b and CD35 display on PMNs correlated with organ failure (r=0.74, P<.001, and r=0.71, P<.01, respectively). Polymorphonuclear neutrophil leukocyte L-selectin, CD31, and CD16 were simultaneously decreased, consistent with PMN activation. Monocytes appeared to be activated, but the pattern of surface molecule display was different. Conclusions.-In human SIRS, the circulating monocyte and PMN pools undergo alterations suggestive of leukocyte activation, including up-regulation of PMN CD11b in correlation with the serum IL-6 level and severity of organ dysfunction.	UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA; UNIV PITTSBURGH,SCH MED,DEPT OTOLARYNGOL,PITTSBURGH,PA; UNIV PITTSBURGH,INST CANC,PITTSBURGH,PA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	ROSENBLOOM, AJ (corresponding author), UNIV PITTSBURGH,MED CTR,DEPT ANESTHESIOL,DIV CRIT CARE MED,200 LOTHROP ST,PITTSBURGH,PA 15213, USA.							ALBERS I, 1989, SCAND J GASTROENTERO, V24, P269, DOI 10.3109/00365528909093045; BERG O, 1989, ACTA OTO-LARYNGOL, V107, P130, DOI 10.3109/00016488909127489; BRIGHAM KL, 1991, KLIN WOCHENSCHR, V69, P1004, DOI 10.1007/BF01645147; BURCH RM, 1993, J IMMUNOL, V150, P3397; BYL B, 1993, GASTROENTEROLOGY, V104, P1492, DOI 10.1016/0016-5085(93)90361-F; CALANDRA T, 1991, AM J MED, V91, P23, DOI 10.1016/0002-9343(91)90069-A; CHULUYAN HE, 1993, J CLIN INVEST, V92, P2768, DOI 10.1172/JCI116895; CREASEY AA, 1991, CIRC SHOCK, V33, P84; CROCKARD AD, 1992, CLIN IMMUNOL IMMUNOP, V65, P135, DOI 10.1016/0090-1229(92)90216-B; DAMAS P, 1992, ANN SURG, V215, P356, DOI 10.1097/00000658-199204000-00009; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIXON WJ, 1983, INTRO STATISTICAL AN, P562; DOFFERHOFF ASM, 1992, CRIT CARE MED, V20, P185, DOI 10.1097/00003246-199202000-00007; ELSNER J, 1992, EUR J HAEMATOL, V48, P10; FABIAN TC, 1994, ANN SURG, V220, P552, DOI 10.1097/00000658-199410000-00013; GLANTZ SA, 1992, PRIMER BIOSTATISTICS, P320; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; HAMBLIN A, 1992, J IMMUNOL METHODS, V146, P219, DOI 10.1016/0022-1759(92)90231-H; HED J, 1988, SCAND J IMMUNOL, V28, P339, DOI 10.1111/j.1365-3083.1988.tb01458.x; HUGHES BJ, 1992, J CLIN INVEST, V90, P1687, DOI 10.1172/JCI116041; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KUO CH, 1991, LIVER, V11, P334; LIMB GA, 1992, IMMUNOLOGY, V77, P88; LIMB GA, 1991, IMMUNOLOGY, V74, P696; LIN RY, 1993, CHEST, V104, P847, DOI 10.1378/chest.104.3.847; MAURER D, 1991, ANN HEMATOL, V62, P135, DOI 10.1007/BF01702927; MCCARTHY D, 1992, ANN RHEUM DIS, V51, P307, DOI 10.1136/ard.51.3.307; MEERSCHAERT J, 1994, J IMMUNOL, V152, P1915; MOREAU R, 1992, CRIT CARE MED, V20, P746, DOI 10.1097/00003246-199206000-00008; MUNOZ C, 1991, EUR J IMMUNOL, V21, P2177, DOI 10.1002/eji.1830210928; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; Noreen E. W., 1989, COMPUTER INTENSIVE M; OVERTON WR, 1988, CYTOMETRY, V9, P619, DOI 10.1002/cyto.990090617; OVERTON WR, 1989, CYTOMETRY, V10, P492; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; SCHLEIFFENBAUM B, 1990, J CLIN INVEST, V86, P184, DOI 10.1172/JCI114683; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; SPERTINI O, 1992, J IMMUNOL METHODS, V156, P115, DOI 10.1016/0022-1759(92)90017-N; STEPHENS KE, 1988, AM REV RESPIR DIS, V138, P1300, DOI 10.1164/ajrccm/138.5.1300; STOCKINGER H, 1990, J IMMUNOL, V145, P3889; TAKAHASHI M, 1994, ATHEROSCLEROSIS, V108, P73, DOI 10.1016/0021-9150(94)90038-8; TILG H, 1993, HEPATOLOGY, V18, P1132; VANDEVENTER SJH, 1990, BLOOD, V76, P2520; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; WAKEFIELD CH, 1993, ARCH SURG-CHICAGO, V128, P390; WALSH CJ, 1991, SURGERY, V110, P205; WITTHAUT R, 1994, J LEUKOCYTE BIOL, V55, P105, DOI 10.1002/jlb.55.1.105; ZENTELLA A, 1991, PROG CLIN BIOL RES, V367, P9	50	143	151	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	1995	274	1					58	65		10.1001/jama.274.1.58	http://dx.doi.org/10.1001/jama.274.1.58			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG233	7540697				2022-12-28	WOS:A1995RG23300031
J	FISHER, GH; ROSENBERG, FJ; STRAUS, SE; DALE, JK; MIDDELTON, LA; LIN, AY; STROBER, W; LENARDO, MJ; PUCK, JM				FISHER, GH; ROSENBERG, FJ; STRAUS, SE; DALE, JK; MIDDELTON, LA; LIN, AY; STROBER, W; LENARDO, MJ; PUCK, JM			DOMINANT INTERFERING FAS GENE-MUTATIONS IMPAIR APOPTOSIS IN A HUMAN AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME	CELL			English	Article							MATURE T-CELLS; TUMOR-NECROSIS-FACTOR; CLONAL ELIMINATION; MONOCLONAL-ANTIBODY; RECEPTOR; ANTIGEN; MICE; TOLERANCE; ACTIVATION; DEATH	Five unrelated children are described with a rare autoimmune lymphoproliferative syndrome (ALPS) characterized by massive nonmalignant lymphadenopathy, autoimmune phenomena, and expanded populations of TCR-CD3(+)CD4(-)CD8(-) lymphocytes. These findings, suggesting a genetic defect in the ability of T lymphocytes to respond to normal immunoregulatory mechanisms, prompted an evaluation of lymphocyte apoptosis. Each child had defective Fas-mediated T lymphocyte apoptosis associated with a unique, deleterious Fas gene mutation. One mutation appeared to cause a simple loss of function; however, four others had a dominant negative phenotype when coexpressed with normal Fas. Family studies demonstrated the inheritance of the mutant Fas alleles. The occurrence of Fas mutations together with abnormal T cell apoptosis in ALPS patients suggests an involvement of Fas in this recently recognized disorder of lymphocyte homeostasis and peripheral self-tolerance.	NIH,NATL CTR HUMAN GENOME RES,GENE TRANSFER LAB,BETHESDA,MD 20892; NIAID,IMMUNOL LAB,BETHESDA,MD 20892; NIAID,CLIN INVEST LAB,BETHESDA,MD 20892; NIH,NATL CTR HUMAN GENOME RES,MED GENET BRANCH,BETHESDA,MD 20892; NCI,GENET EPIDEMIOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEHRMANN I, 1994, J IMMUNOL, V24, P3057; BOEHME SA, 1993, EUR J IMMUNOL, V23, P1552, DOI 10.1002/eji.1830230724; Burnet F Macfarlane, 1969, CELLULAR IMMUNOLOGY; Critchfield Jeffrey M., 1995, P55; CRITCHFIELD JM, 1994, SCIENCE, V263, P1139, DOI 10.1126/science.7509084; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FIUCCI G, 1994, IMMUNOGENETICS, V39, P437; GIESE T, 1995, J IMMUNOL, V154, P4986; GILLETTEFERGUSO.I, 1994, EUR J IMMUNOL, V24, P1181; HENGARTNER H, 1988, NATURE, V336, P388, DOI 10.1038/336388a0; HYASHI K, 1992, PCR GENET ANAT TECH, V9, P73; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; ITOH N, 1993, J BIOL CHEM, V266, P10932; JONES LA, 1990, SCIENCE, V250, P1726, DOI 10.1126/science.2125368; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KENNEDY GC, 1995, NAT GENET, V9, P293, DOI 10.1038/ng0395-293; Kimura M, 1994, Int Rev Immunol, V11, P193, DOI 10.3109/08830189409061727; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KRAWCZAK M, 1992, HUM GENET, V90, P41; KYBURZ D, 1993, EUR J IMMUNOL, V253, P1956; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; LOS M, 1995, NATURE, V353, P81; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MCHEYZERWILLIAM.MG, 1995, SCIENCE, V268, P106; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1994, Semin Immunol, V6, P3, DOI 10.1006/smim.1994.1002; PELFREY CM, 1995, J IMMUNOL, V154, P6191; PUCK JM, 1995, J CLIN INVEST, V95, P895, DOI 10.1172/JCI117740; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; RUSSELL JH, 1991, P NATL ACAD SCI USA, V88, P2151, DOI 10.1073/pnas.88.6.2151; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SNELLER MC, 1992, J CLIN INVEST, V90, P334, DOI 10.1172/JCI115867; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THEOPHILOPOULOS AN, 1968, ADV IMMUNOL, V37, P269; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WACHOLTZ MC, 1993, J IMMUNOL, V150, P5338; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WHITE J, 1989, J IMMUNOL, V143, P1822; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZUNIGAPFLUCKER JC, 1993, J EXP MED, V178, P1139, DOI 10.1084/jem.178.4.1139	56	1222	1266	1	19	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					935	946		10.1016/0092-8674(95)90013-6	http://dx.doi.org/10.1016/0092-8674(95)90013-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7540117	Bronze			2022-12-28	WOS:A1995RD76800014
J	OKADA, Y; YAMAZAKI, H; SEKINEAIZAWA, Y; HIROKAWA, N				OKADA, Y; YAMAZAKI, H; SEKINEAIZAWA, Y; HIROKAWA, N			THE NEURON-SPECIFIC KINESIN SUPERFAMILY PROTEIN KIF1A IS A UNIQUE MONOMERIC MOTOR FOR ANTEROGRADE AXONAL-TRANSPORT OF SYNAPTIC VESICLE PRECURSORS	CELL			English	Article							HEAVY-CHAIN; MONOCLONAL-ANTIBODY; MEMBRANOUS ORGANELLES; SECRETORY VESICLES; C-ELEGANS; IDENTIFICATION; SYNAPTOPHYSIN; MICROTUBULES; DOMAINS; GLYCOPROTEIN	Axonal transport has been intensively examined as a good model for studying the mechanism of organelle transport in cells, but it is still unclear how different types of membrane organelles are transported through the nerve axon. To elucidate the function of this mechanism, we have cloned KIF1A, a novel neuron-specific kinesin superfamily motor that was discovered to be a monomeric, globular molecule and that had the fastest reported anterograde motor activity (1.2 mu m/s). To identify its cargo, membranous organelles were isolated from the axon. KIF1A was associated with organelles that contained synaptic vesicle proteins such as synaptotagmin, synaptophysin, and Rab3A. However, this organelle did not contain SV2, another synaptic vesicle protein, nor did it contain presynaptic membrane proteins, such as syntaxin 1A or SNAP-25, or other known anterograde motor proteins, such as kinesin and KIF3. Thus, we suggest that the membrane proteins are sorted into different classes of transport organelles in the cell body and are transported by their specific motor proteins through the axon.	UNIV TOKYO, FAC MED, DEPT ANAT & CELL BIOL, TOKYO 113, JAPAN	University of Tokyo			Okada, Yasushi/N-5067-2015	Okada, Yasushi/0000-0003-2601-3689				AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BERLINER E, 1994, J BIOL CHEM, V269, P8610; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; DAVIES AH, 1993, BIO-TECHNOL, V11, P933, DOI 10.1038/nbt0893-933; DECUEVAS M, 1992, J CELL BIOL, V116, P957, DOI 10.1083/jcb.116.4.957; ENDOW SA, 1991, TRENDS BIOCHEM SCI, V16, P221, DOI 10.1016/0968-0004(91)90089-E; GHO M, 1992, SCIENCE, V258, P313, DOI 10.1126/science.1384131; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; HIROKAWA N, 1993, NEUROSCI RES, V18, P1, DOI 10.1016/0168-0102(93)90099-C; Hirokawa Nobutaka, 1993, Current Opinion in Neurobiology, V3, P724, DOI 10.1016/0959-4388(93)90144-N; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; HOYT MA, 1993, GENETICS, V135, P35; HOYT MA, 1994, CURR OPIN CELL BIOL, V6, P63, DOI 10.1016/0955-0674(94)90117-1; HUANG TG, 1994, J BIOL CHEM, V269, P16502; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KONDO S, 1994, J CELL BIOL, V125, P1095, DOI 10.1083/jcb.125.5.1095; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MALIK F, 1994, P NATL ACAD SCI USA, V91, P4584, DOI 10.1073/pnas.91.10.4584; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; MIZOGUCHI A, 1989, BIOCHEM BIOPH RES CO, V162, P1438, DOI 10.1016/0006-291X(89)90835-8; MUNDIGL O, 1993, J CELL BIOL, V122, P1207, DOI 10.1083/jcb.122.6.1207; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; NICLAS J, 1994, NEURON, V12, P1059, DOI 10.1016/0896-6273(94)90314-X; NODA Y, 1995, J CELL BIOL, V129, P157, DOI 10.1083/jcb.129.1.157; OBATA K, 1986, BRAIN RES, V375, P37, DOI 10.1016/0006-8993(86)90956-X; OKADA Y, 1995, J NEUROSCI, V15, P3053; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PATEL N, 1993, P NATL ACAD SCI USA, V90, P9181, DOI 10.1073/pnas.90.19.9181; PESAVENTO PA, 1994, J CELL BIOL, V127, P1041, DOI 10.1083/jcb.127.4.1041; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; SATO YR, 1992, J BIOL CHEM, V267, P23930; SCHMIDLE T, 1991, BIOCHIM BIOPHYS ACTA, V1060, P251, DOI 10.1016/S0005-2728(05)80314-7; SEKINE Y, 1994, J CELL BIOL, V127, P187, DOI 10.1083/jcb.127.1.187; SMITH RS, 1980, J NEUROCYTOL, V9, P39, DOI 10.1007/BF01205226; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	58	482	492	3	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 2	1995	81	5					769	780		10.1016/0092-8674(95)90538-3	http://dx.doi.org/10.1016/0092-8674(95)90538-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7539720	Bronze			2022-12-28	WOS:A1995RB96100015
J	RIEUXLAUCAT, F; LEDEIST, F; HIVROZ, C; ROBERTS, IAG; DEBATIN, KM; FISCHER, A; DEVILLARTAY, JP				RIEUXLAUCAT, F; LEDEIST, F; HIVROZ, C; ROBERTS, IAG; DEBATIN, KM; FISCHER, A; DEVILLARTAY, JP			MUTATIONS IN FAS ASSOCIATED WITH HUMAN LYMPHOPROLIFERATIVE SYNDROME AND AUTOIMMUNITY	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; SURFACE ANTIGEN; APOPTOSIS; MICE; LPR	Fas (also known as Apo1 and CD95) is a cell surface receptor involved in apoptotic cell death. Fas expression and function were analyzed in three children (including two siblings) with a lymphoproliferative syndrome, two of whom also had autoimmune disorders. A targe deletion in the gene encoding Fas and no detectable cell surface expression characterized the most affected patient. Clinical manifestations in the two related patients were less severe: Fas-mediated apoptosis was impaired and a deletion within the intracytoplasmic domain was detected. These findings illustrate the crucial regulatory role of Fas and may provide a molecular basis for some autoimmune diseases in humans.	HOP NECKER ENFANTS MALAD,INSERM,U429,F-75743 PARIS 15,FRANCE; HAMMERSMITH HOSP,DEPT HAEMATOL,LONDON W12 0NN,ENGLAND; UNIV HEIDELBERG,CHILDRENS HOSP,HAEMATOL SECT,D-69120 HEIDELBERG,GERMANY	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Imperial College London; Ruprecht Karls University Heidelberg			de Villartay, jean pierre/H-9353-2017; Hivroz, Claire/H-2711-2014; Debatin, Klaus-Michael/J-9704-2014; Rieux-Laucat, Frédéric/A-7916-2017	de Villartay, jean pierre/0000-0001-5987-0463; Hivroz, Claire/0000-0002-6794-2890; Debatin, Klaus-Michael/0000-0002-8397-1886; Rieux-Laucat, Frédéric/0000-0001-7858-7866				COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; DEBATIN KM, 1994, EUR J IMMUNOL, V24, P753, DOI 10.1002/eji.1830240339; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HERON LR, 1993, J IMMUNOL, V151, P3450; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; KRAMMER P H, 1992, Current Biology, V2, P383, DOI 10.1016/0960-9822(92)90084-N; KWITEKBLACK AE, 1993, NAT GENET, V5, P392, DOI 10.1038/ng1293-392; LANDOLFI MMT, 1993, J IMMUNOL, V151, P1086; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OEHM A, 1992, J BIOL CHEM, V267, P10709; RIEUXLAUCAT F, 1993, EUR J IMMUNOL, V23, P928, DOI 10.1002/eji.1830230425; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0	17	1113	1145	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 2	1995	268	5215					1347	1349		10.1126/science.7539157	http://dx.doi.org/10.1126/science.7539157			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7539157				2022-12-28	WOS:A1995RB19800038
J	SHIEKHATTAR, R; MERMELSTEIN, F; FISHER, RP; DRAPKIN, R; DYNLACHT, B; WESSLING, HC; MORGAN, DO; REINBERG, D				SHIEKHATTAR, R; MERMELSTEIN, F; FISHER, RP; DRAPKIN, R; DYNLACHT, B; WESSLING, HC; MORGAN, DO; REINBERG, D			CDK-ACTIVATING KINASE COMPLEX IS A COMPONENT OF HUMAN TRANSCRIPTION FACTOR TFIIH	NATURE			English	Article							RNA POLYMERASE-II; CARBOXYL-TERMINAL-DOMAIN; INITIATION	TRANSCRIPTION factor IIH (TFIIH) contains a kinase capable of phosphorylating the carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II (RNAPII)1-3. Here we report the identification of the Cdk-activating kinase (Cak) complex (Cdk7 and cyclin H) as a component of TFIIH after extensive purification of TFIIH by chromatography. We find that affinity-purified antibodies directed against cyclin H inhibit TFIIH-dependent transcription and that both cyclin H and Cdk7 antibodies inhibit phosphorylation of the CTD of the largest subunit of the RNAPII in the preinitiation complex. Cak is present in at least two distinct complexes, TFIIH and a smaller complex that is unable to phosphorylate RNAPII in the preinitiation complex. Both Cak complexes, as well as recombinant Cak, phosphorylate a CTD peptide. Finally, TFIIH was shown to phosphorylate both Cdc2 and Cdk2, suggesting that there could be a link between transcription and the cell cycle machinery.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT BIOCHEM, HOWARD HUGHES MED INST, PISCATAWAY, NJ 08854 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; MASSACHUSETTS GEN HOSP, CTR CANC, MOLEC ONCOL LAB, BOSTON, MA 02129 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of California System; University of California San Francisco; Harvard University; Massachusetts General Hospital			Drapkin, Ronny/E-9944-2016	Drapkin, Ronny/0000-0002-6912-6977; Morgan, David/0000-0001-8753-4416; Reinberg, Danny/0000-0003-4288-2016				CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CISEK LJ, 1991, METHOD ENZYMOL, V200, P301; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FLORES O, 1992, J BIOL CHEM, V267, P2786; HARLOW E, 1988, ANTIBODIES LABORATOR; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; ZAWEL L, 1993, COLD SPRING HARB SYM, V58, P187, DOI 10.1101/SQB.1993.058.01.023	17	364	385	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 16	1995	374	6519					283	287		10.1038/374283a0	http://dx.doi.org/10.1038/374283a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7533895				2022-12-28	WOS:A1995QM38700056
J	NAGATA, S; GOLSTEIN, P				NAGATA, S; GOLSTEIN, P			THE FAS DEATH FACTOR	SCIENCE			English	Review							MATURE T-CELLS; TUMOR-NECROSIS-FACTOR; FORMING PROTEIN PERFORIN; MRL-LPR MICE; MONOCLONAL-ANTIBODY; SURFACE ANTIGEN; LYMPHOCYTE-T; MOUSE CHROMOSOME-19; MEDIATED CYTOLYSIS; MOLECULAR-CLONING	Fas ligand (FasL), a cell surface molecule belonging to the tumor necrosis factor family, binds to its receptor Fas, thus inducing apoptosis of Fas-bearing cells. Various cells express Fas, whereas FasL is expressed predominantly in activated T cells. In the immune system, Fas and Fast are involved in down-regulation of immune reactions as well as in T cell-mediated cytotoxicity. Malfunction of the Fas system causes lymphoproliferative disorders and accelerates autoimmune diseases, whereas its exacerbation may cause tissue destruction.	CNRS MARSEILLE LUMINY,INSERM,CTR IMMUNOL,F-13288 MARSEILLE 9,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	NAGATA, S (corresponding author), OSAKA BIOSCI INST,6-2-4 FURUEDAI,SUITA,OSAKA 565,JAPAN.		Golstein, Pierre/A-4954-2014; Nagata, Shigekazu/AAG-3203-2019	Golstein, Pierre/0000-0003-1750-3483; Nagata, Shigekazu/0000-0001-9758-8426				ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ALLEN RD, 1990, J EXP MED, V172, P1367, DOI 10.1084/jem.172.5.1367; ANDJELIC S, 1994, INT IMMUNOL, V6, P73, DOI 10.1093/intimm/6.1.73; ANDO K, 1993, J EXP MED, V178, P1541, DOI 10.1084/jem.178.5.1541; ANDREWS BS, 1978, J EXP MED, V148, P1198, DOI 10.1084/jem.148.5.1198; ANEL A, 1994, EUR J IMMUNOL, V24, P2469, DOI 10.1002/eji.1830241032; BAUM PR, 1994, EMBO J, V13, P3992, DOI 10.1002/j.1460-2075.1994.tb06715.x; BEHRMANN I, 1994, EUR J IMMUNOL, V24, P3057, DOI 10.1002/eji.1830241221; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; CHU JL, 1993, J EXP MED, V178, P723, DOI 10.1084/jem.178.2.723; CHU JL, 1995, J EXP MED, V181, P393, DOI 10.1084/jem.181.1.393; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; CRISPE IN, 1994, IMMUNITY, V1, P347; DANIEL PT, 1994, J IMMUNOL, V152, P5624; DEBATIN KM, 1994, BLOOD, V83, P3101, DOI 10.1182/blood.V83.10.3101a.3101a; DEBATIN KM, 1990, LANCET, V335, P497, DOI 10.1016/0140-6736(90)90735-N; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DHEIN J, 1992, J IMMUNOL, V149, P3166; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; FALK MH, 1992, BLOOD, V79, P3300; GILLETTEFERGUSO.I, 1994, EUR J IMMUNOL, V24, P1181; GOLSTEIN P, 1994, APOPTOSIS IMMUNE RES, P143; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HERRON LR, 1993, J IMMUNOL, V151, P3450; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606; HIROMATSU K, 1994, EUR J IMMUNOL, V24, P2446, DOI 10.1002/eji.1830241028; HU HM, 1994, J BIOL CHEM, V269, P30069; HUG H, 1994, FEBS LETT, V351, P311, DOI 10.1016/0014-5793(94)00852-3; INAZAWA J, 1992, GENOMICS, V14, P821, DOI 10.1016/S0888-7543(05)80200-9; ISHIURA S, 1990, MOL IMMUNOL, V27, P803; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; IZUI S, 1984, J IMMUNOL, V133, P227; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; KABELITZ D, 1993, IMMUNOL TODAY, V14, P338, DOI 10.1016/0167-5699(93)90231-9; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; KOBAYASHI N, 1990, P NATL ACAD SCI USA, V87, P9620, DOI 10.1073/pnas.87.24.9620; KOBAYASHI S, 1993, BIOCHEM BIOPH RES CO, V191, P617, DOI 10.1006/bbrc.1993.1262; KOJIMA H, 1994, IMMUNITY, V1, P357, DOI 10.1016/1074-7613(94)90066-3; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LAOUAR Y, 1994, J IMMUNOL, V153, P3948; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LICHTER P, 1992, GENOMICS, V14, P179, DOI 10.1016/S0888-7543(05)80302-7; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; LOWRANCE JH, 1994, J EXP MED, V180, P1693, DOI 10.1084/jem.180.5.1693; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MACDONALD HR, 1991, EUR J IMMUNOL, V21, P1963, DOI 10.1002/eji.1830210827; MACLENNAN ICM, 1980, IMMUNOLOGY, V39, P109; MATSUZAWA A, 1990, J EXP MED, V171, P519, DOI 10.1084/jem.171.2.519; MCCORMACK JE, 1993, J IMMUNOL, V150, P3785; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; MOLLER P, 1993, BLOOD, V81, P2067; MOSMANN TR, 1991, IMMUNOL REV, V123, P209, DOI 10.1111/j.1600-065X.1991.tb00612.x; MUSETTE P, 1994, EUR J IMMUNOL, V24, P2761, DOI 10.1002/eji.1830241128; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; NAGATA S, 1994, ADV IMMUNOL, V57, P129, DOI 10.1016/S0065-2776(08)60672-0; NAGATA S, 1993, APOPTOSIS, V2, P313; NAKAJIMA H, IN PRESS J EXP MED; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NI R, 1995, EXP CELL RES, V215, P332; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OSTERGAARD HL, 1987, NATURE, V330, P71, DOI 10.1038/330071a0; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; OYAIZU N, 1994, BLOOD, V84, P2622; PAPIERNIK M, UNPUB; PODACK ER, 1985, IMMUNOL TODAY, V6, P21, DOI 10.1016/0167-5699(85)90164-1; PODACK ER, 1985, P NATL ACAD SCI USA, V82, P8629, DOI 10.1073/pnas.82.24.8629; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RAJEWSKY K, 1992, CURR OPIN IMMUNOL, V4, P171, DOI 10.1016/0952-7915(92)90008-3; RAMSDELL F, 1994, EUR J IMMUNOL, V24, P928, DOI 10.1002/eji.1830240422; RAMSDELL F, 1994, INT IMMUNOL, V6, P1545, DOI 10.1093/intimm/6.10.1545; RATHMELL JC, 1994, J IMMUNOL, V153, P2831; RIEUXLAUCAT F, 1994, 12TH EUR IMM M BARC; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; ROTHS JB, 1984, J EXP MED, V159, P1, DOI 10.1084/jem.159.1.1; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; SCOLLAY RG, 1980, EUR J IMMUNOL, V10, P210, DOI 10.1002/eji.1830100310; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; SIDMAN CL, 1992, EUR J IMMUNOL, V22, P499, DOI 10.1002/eji.1830220231; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SNELLER MC, 1992, J CLIN INVEST, V90, P334, DOI 10.1172/JCI115867; STALDER T, 1994, J IMMUNOL, V152, P1127; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUDA T, UNPUB; SUDA T, IN PRESS J IMMUNOL; TAKAHASHI S, 1993, EUR J IMMUNOL, V23, P1935, DOI 10.1002/eji.1830230831; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TANAKA M, IN PRESS EMBO J; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THEOFILOPOULOS AN, 1985, J EXP MED, V162, P1, DOI 10.1084/jem.162.1.1; TIROSH R, 1985, CELL IMMUNOL, V95, P113, DOI 10.1016/0008-8749(85)90300-4; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TRENN G, 1987, NATURE, V330, P72, DOI 10.1038/330072a0; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421; VIGNAUX F, 1995, J EXP MED, V181, P781, DOI 10.1084/jem.181.2.781; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18; WALSH CM, 1994, J IMMUNOL, V153, P2506; WANG ZQ, 1994, EUR J IMMUNOL, V24, P1549, DOI 10.1002/eji.1830240714; WATANABE D, 1995, EMBO J, V14, P12, DOI 10.1002/j.1460-2075.1995.tb06970.x; WATANABE D, UNPUB; WATANABE T, 1991, BIOCHEM GENET, V29, P325, DOI 10.1007/BF00554140; WATANABEFUKUNAG.R, UNPUB; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WATSON ML, 1992, MAMM GENOME, V2, P158, DOI 10.1007/BF00302874; WATSON ML, 1992, J EXP MED, V176, P1645, DOI 10.1084/jem.176.6.1645; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEBB SR, 1994, J IMMUNOL, V152, P586; WEINBERG JB, 1994, J EXP MED, V179, P651, DOI 10.1084/jem.179.2.651; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WONG GHW, 1994, J IMMUNOL, V152, P1751; WU JG, 1993, J EXP MED, V178, P461, DOI 10.1084/jem.178.2.461; WU JG, 1994, P NATL ACAD SCI USA, V91, P2344, DOI 10.1073/pnas.91.6.2344; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YOUNG JDE, 1987, J EXP MED, V165, P1371, DOI 10.1084/jem.165.5.1371; YOUNG JDE, 1987, J EXP MED, V166, P1894, DOI 10.1084/jem.166.6.1894	146	3795	4051	2	134	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1449	1456		10.1126/science.7533326	http://dx.doi.org/10.1126/science.7533326			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7533326				2022-12-28	WOS:A1995QL49700025
J	HUISMAN, GW; KOLTER, R				HUISMAN, GW; KOLTER, R			SENSING STARVATION - A HOMOSERINE LACTONE-DEPENDENT SIGNALING PATHWAY IN ESCHERICHIA-COLI	SCIENCE			English	Article							CELL-DIVISION GENES; STREPTOMYCES-AMBOFACIENS; SIGMA-FACTOR; STRUCTURAL IDENTIFICATION; LUMINESCENCE SYSTEM; MANDELATE RACEMASE; ERWINIA-CAROTOVORA; CARBON-STARVATION; KATF; AUTOINDUCER	When nutrients become limiting, many bacteria differentiate and become resistant to environmental stresses. For Escherichia coli, this process is mediated by the sigma(s) subunit of RNA polymerase. Expression of sigma(s) was induced by homoserine lactone, a metabolite synthesized from intermediates in threonine biosynthesis. Homoserine lactone-dependent synthesis of oS was prevented by overexpression of a newly identified protein, RspA. The function of homoserine lactone derivatives in many cell density-dependent phenomena and the similarity of RspA to a Streptomyces ambofaciens protein suggest that synthesis of homoserine lactone may be a general signal of starvation.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School				Huisman, Gjalt/0000-0003-1955-1120				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARONSON BD, 1989, J BIOL CHEM, V264, P5226; BERG CM, 1992, GENE, V113, P9, DOI 10.1016/0378-1119(92)90664-B; BOHANNON DE, 1991, J BACTERIOL, V173, P4482, DOI 10.1128/JB.173.14.4482-4492.1991; CAO JG, 1989, J BIOL CHEM, V264, P21670; CASHEL M, 1987, ESCHERICHIA COLI SAL, V2, pCH87; DUNLAP PV, 1992, J BACTERIOL, V174, P2440, DOI 10.1128/jb.174.8.2440-2448.1992; EBERHARD A, 1981, BIOCHEMISTRY-US, V20, P2444, DOI 10.1021/bi00512a013; EBERHARD A, 1991, ARCH MICROBIOL, V155, P294, DOI 10.1007/BF00252215; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; GALINIER A, 1991, GENE, V97, P149, DOI 10.1016/0378-1119(91)90024-6; GENTRY DR, 1993, J BACTERIOL, V175, P7982, DOI 10.1128/JB.175.24.7982-7989.1993; HENGGEARONIS R, 1993, CELL, V72, P165, DOI 10.1016/0092-8674(93)90655-A; HOFFMAN M, 1991, SCIENCE, V251, P31, DOI 10.1126/science.1986411; HUISMAN G, 1994, REGULATION OF BACTERIAL DIFFERENTIATION, P21; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JONES S, 1993, EMBO J, V12, P2477, DOI 10.1002/j.1460-2075.1993.tb05902.x; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KUO AA, UNPUB; LEBLOND P, 1989, J BACTERIOL, V171, P419, DOI 10.1128/jb.171.1.419-423.1989; LOEWEN PC, 1993, J BACTERIOL, V175, P2150, DOI 10.1128/JB.175.7.2150-2153.1993; MATIN A, 1991, MOL MICROBIOL, V5, P3, DOI 10.1111/j.1365-2958.1991.tb01819.x; MCCANN MP, 1993, J BACTERIOL, V175, P2143, DOI 10.1128/JB.175.7.2143-2149.1993; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; MRACHKO G, UNPUB; MULVEY MR, 1989, NUCLEIC ACIDS RES, V17, P9979, DOI 10.1093/nar/17.23.9979; NEIDHART DJ, 1991, BIOCHEMISTRY-US, V30, P9264, DOI 10.1021/bi00102a019; NEIDHART DJ, 1990, NATURE, V347, P692, DOI 10.1038/347692a0; NGUYEN LH, 1993, BIOCHEMISTRY-US, V32, P11112, DOI 10.1021/bi00092a021; PEARSON JP, 1994, P NATL ACAD SCI USA, V91, P197, DOI 10.1073/pnas.91.1.197; PIPER KR, 1993, NATURE, V362, P448, DOI 10.1038/362448a0; PIRHONEN M, 1993, EMBO J, V12, P2467, DOI 10.1002/j.1460-2075.1993.tb05901.x; PSSADOR L, 1993, SCIENCE, V260, P1127; ROBINSON AC, 1984, J BACTERIOL, V160, P546, DOI 10.1128/JB.160.2.546-555.1984; RON EZ, 1975, J BACTERIOL, V124, P243, DOI 10.1128/JB.124.1.243-246.1975; SCHELLHORN HE, 1992, J BACTERIOL, V174, P4769, DOI 10.1128/JB.174.14.4769-4776.1992; SCHNEIDER D, 1993, J GEN MICROBIOL, V139, P2559, DOI 10.1099/00221287-139-11-2559; SIEGELE DA, 1992, J BACTERIOL, V174, P345, DOI 10.1128/jb.174.2.345-348.1992; SIMONET JM, 1992, GENE, V115, P49, DOI 10.1016/0378-1119(92)90539-2; SUN HW, 1992, J MOL EVOL, V34, P522, DOI 10.1007/BF00160465; TANAKA K, 1993, P NATL ACAD SCI USA, V90, P3511, DOI 10.1073/pnas.90.8.3511; WANG XD, 1991, EMBO J, V10, P3363, DOI 10.1002/j.1460-2075.1991.tb04900.x; WYMAN A, 1975, J BIOL CHEM, V250, P3904; ZAMBRANO MM, 1993, SCIENCE, V259, P1757, DOI 10.1126/science.7681219; ZHANG LH, 1993, NATURE, V362, P446, DOI 10.1038/362446a0	45	185	198	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					537	539		10.1126/science.7545940	http://dx.doi.org/10.1126/science.7545940			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	7545940				2022-12-28	WOS:A1994NY21600035
J	MANTON, KG; VAUPEL, JW				MANTON, KG; VAUPEL, JW			SURVIVAL AFTER THE AGE OF 80 IN THE UNITED-STATES, SWEDEN, FRANCE, ENGLAND, AND JAPAN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSTMENOPAUSAL WOMEN; HEALTH-CARE; MORTALITY; CHOLESTEROL; ADULTS	Background. In many developed countries, life expectancy at birth is higher than in the United States. Newly available data permit, for the first time, reliable cross-national comparisons of mortality among persons 80 years of age or older. Such comparisons are important, because in many developed countries more than half of women and a third of men now die after the age of 80. Methods. We used extinct-cohort methods to assess mortality in Japan, Sweden, France, and England (including Wales) and among U.S. whites for cohorts born from 1880 to 1894, and used cross-sectional data for the year 1987. Extinct-cohort methods rely on continuously collected data from death certificates and do not use the less reliable data from censuses. Results. In the United States, life expectancy at the age of 80 and survival from the ages of 80 to 100 significantly exceeded life expectancy in Sweden, France, England, and Japan (P<0.01). This finding was confirmed with accurate cross-sectional data for 1987. The average life expectancy in the United States is 9.1 years for 80-year-old white women and 7.0 years for 80-year-old white men. Conclusions. For people 80 years old or older, life expectancy is greater in the United States than it is in Sweden, France, England, or Japan.	DUKE UNIV, SANFORD INST PUBL POLICY, DURHAM, NC USA; ODENSE UNIV, SCH MED, ODENSE, DENMARK	Duke University; University of Southern Denmark	MANTON, KG (corresponding author), DUKE UNIV, CTR DEMOG STUDIES, 2117 CAMPUS DR, BOX 90408, DURHAM, NC 27708 USA.			Vaupel, James/0000-0003-0783-3905	NIA NIH HHS [AG01159, AG08761] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG001159, P01AG008761] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADLER NE, 1994, AM PSYCHOL, V49, P15, DOI 10.1037/0003-066X.49.1.15; BAYO FR, 1985, T SOC ACTUARIES, V35, P37; BELLANTONI MF, 1991, J GERONTOL, V46, pM216, DOI 10.1093/geronj/46.6.M216; CAMPION EW, 1994, NEW ENGL J MED, V330, P1819, DOI 10.1056/NEJM199406233302509; Condran G.A., 1991, POPULATION B UN, V30; DIXON J, 1992, BMJ-BRIT MED J, V305, P878, DOI 10.1136/bmj.305.6858.878; ELO IT, 1992, POPUL INDEX, V58, P186, DOI 10.2307/3644718; ELO IT, 1994, DEMOGRAPHY, V31, P427, DOI 10.2307/2061751; FRANKS P, 1993, JAMA-J AM MED ASSOC, V270, P737, DOI 10.1001/jama.270.6.737; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; HOFFMEISTER H, 1994, PREV MED, V23, P197, DOI 10.1006/pmed.1994.1027; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; KANNISTO AU, 1994, DEV ODLEST OLD MORTA; KANNISTO V, 1994, POPUL DEV REV, V20, P793, DOI 10.2307/2137662; KASCH FW, 1993, AGE AGEING, V22, P5, DOI 10.1093/ageing/22.1.5; KESTENBAUM B, 1992, DEMOGRAPHY, V29, P565, DOI 10.2307/2061852; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; LUBITZ J, 1995, NEW ENGL J MED, V332, P999, DOI 10.1056/NEJM199504133321506; MANTON KG, 1994, J GERONTOL, V49, pB169, DOI 10.1093/geronj/49.4.B169; MANTON KG, 1986, J AM STAT ASSOC, V81, P635, DOI 10.2307/2288991; MANTON KG, 1991, POPUL DEV REV, V17, P603, DOI 10.2307/1973599; MANTON KG, 1994, DEC WORKSH RAC ETHN; MORRIS JK, 1994, BMJ-BRIT MED J, V308, P1135, DOI 10.1136/bmj.308.6937.1135; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; OKAMOTO Y, 1992, BRIT MED J, V305, P403, DOI 10.1136/bmj.305.6850.403; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; PAUL SD, 1994, ARCH INTERN MED, V154, P1143, DOI 10.1001/archinte.154.10.1143; ROSENWAIKE I, 1985, EXTREME AGED AM PORT; SEMPOS CT, 1993, JAMA-J AM MED ASSOC, V269, P3009, DOI 10.1001/jama.269.23.3009; SORLIE PD, 1993, JAMA-J AM MED ASSOC, V270, P2464, DOI 10.1001/jama.270.20.2464; SUZMAN RM, 1992, OLDEST OLD; SWARTZ K, 1994, JAMA J AM MED ASS, V0271; Vaupel J. W., 1995, EXCEPTIONAL LONGEVIT; VERSCHUREN WMM, 1994, INT J EPIDEMIOL, V23, P948, DOI 10.1093/ije/23.5.948; 1993, CURRENT POPU P251104; 1994, WORLD HLTH STATISTIC; 1993, STATISTICAL ABSTRACT; 1993, DHHS PHS941232 NAT C; [No title captured]; 1992, ACTUARIAL STUDY, V107	40	215	220	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 2	1995	333	18					1232	1235		10.1056/NEJM199511023331824	http://dx.doi.org/10.1056/NEJM199511023331824			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TB560	7565998	Bronze			2022-12-28	WOS:A1995TB56000035
J	VANDERPUT, NMJ; STEEGERSTHEUNISSEN, RPM; FROSST, P; TRIJBELS, FJM; ESKES, TKAB; VANDENHEUVEL, LP; MARIMAN, ECM; DENHEYER, M; ROZEN, R; BLOM, HJ				VANDERPUT, NMJ; STEEGERSTHEUNISSEN, RPM; FROSST, P; TRIJBELS, FJM; ESKES, TKAB; VANDENHEUVEL, LP; MARIMAN, ECM; DENHEYER, M; ROZEN, R; BLOM, HJ			MUTATED METHYLENETETRAHYDROFOLATE REDUCTASE AS A RISK FACTOR FOR SPINA-BIFIDA	LANCET			English	Note								Periconceptional folate supplementation reduces the risk of neural-tube defects. We studied the frequency of the 677C-->T mutation in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene in 55 patients with spina bifida and parents of such patients (70 mothers, 60 fathers). 5% of 207 controls were homozygous for the 677C-->T mutation compared with 16% of mothers, 10% of fathers, and 13% of patients. The mutation was associated with decreased MTHFR activity, low plasma folate, and high plasma homocysteine and red-cell folate concentrations. The 677C-->7 mutation should be regarded as a genetic risk factor for spina bifida.	UNIV NIJMEGEN HOSP,DEPT PEDIAT,6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN HOSP,DEPT OBSTET & GYNECOL,6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN HOSP,DEPT EPIDEMIOL,6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN HOSP,DEPT HUMAN GENET,6500 HB NIJMEGEN,NETHERLANDS; MUNICIPAL HOSP LEYENBURG,DEPT HEMATOL,THE HAGUE,NETHERLANDS; MCGILL UNIV,DEPT HUMAN GENET,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT PEDIAT,MONTREAL,PQ H3A 2T5,CANADA; MCGILL UNIV,DEPT BIOL,MONTREAL,PQ,CANADA	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; McGill University; McGill University; McGill University			van den Heuvel, L.P.W.J./H-8044-2014; van den Heuvel, Lambertus/AAM-1772-2021; Rozen, Rima/AAE-9294-2020	van den Heuvel, L.P.W.J./0000-0003-3917-6727; van den Heuvel, Lambertus/0000-0003-3917-6727; Blom, Henk/0000-0001-5202-9241				CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; DENHEIJER M, 1995, LANCET, V345, P882, DOI 10.1016/S0140-6736(95)90008-X; ENGBERSEN AMT, 1995, AM J HUM GENET, V56, P142; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; GOYETTE P, 1994, NAT GENET, V7, P195, DOI 10.1038/ng0694-195; KANG SS, 1991, AM J HUM GENET, V48, P536; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; STEEGERSTHEUNIS.RP, 1994, METABOLISM, V43, P1475; Te Poele-Pothoff M. T. W. B., 1995, Annals of Clinical Biochemistry, V32, P218; 1991, LANCET, V338, P131	10	738	756	0	37	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1070	1071		10.1016/S0140-6736(95)91743-8	http://dx.doi.org/10.1016/S0140-6736(95)91743-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564788	Green Submitted, Bronze			2022-12-28	WOS:A1995TA69700012
J	MASSAD, S				MASSAD, S			ASHES, ASHES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1102	1102						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563469				2022-12-28	WOS:A1995RY05600002
J	REES, MR; MICHALIS, LK				REES, MR; MICHALIS, LK			ACTIVATED-GUIDEWIRE TECHNIQUE FOR TREATING CHRONIC CORONARY-ARTERY OCCLUSION	LANCET			English	Note							ANGIOPLASTY; RECANALIZATION; SYSTEMS	Coronary angioplasty was successfully carried out with an activated guidewire technique in 33 of 47 patients who had undergone a failed attempt at conventional angioplasty for the treatment of chronic coronary artery occlusion. 80% of these occlusions were stump-like occlusions. This technique involves the attachment of a hand-held battery-driven motorised device to standard angioplasty equipment and can be used at any time during the procedure. The device generates complex vibratory movement in the guidewire to facilitate crossing of occluded vessels.	KEELE UNIV,POSTGRAD MED SCH,STOKE ON TRENT,STAFFS,ENGLAND	Keele University			Rees, Michael/Y-4640-2019	Mihalis, Lampros/0000-0001-8834-4462				ABELA GS, 1986, J AM COLL CARDIOL, P184; DANCHIN N, 1995, AM J CARDIOL, V75, P330, DOI 10.1016/S0002-9149(99)80548-7; GRAY DF, 1993, CATHETER CARDIO DIAG, V30, P293, DOI 10.1002/ccd.1810300406; HAMM CW, 1990, AM J CARDIOL, V66, P1459, DOI 10.1016/0002-9149(90)90534-8; MEIER B, 1990, TXB INTERVENTIONAL C, P300; MILKER JP, 1987, AM J CARDIOL, V59, P535; PANDE AK, 1992, AM HEART J, V123, P1182, DOI 10.1016/0002-8703(92)91020-2; SANBORN TA, 1993, CIRCULATION, V88, P504; TIWARI P, 1995, P ROENTGEN CENTURARY, V1, P365	9	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					943	944		10.1016/S0140-6736(95)91560-5	http://dx.doi.org/10.1016/S0140-6736(95)91560-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564731				2022-12-28	WOS:A1995RY80800012
J	HERMAN, MA; VASSILIEVA, LL; HORVITZ, HR; SHAW, JE; HERMAN, RK				HERMAN, MA; VASSILIEVA, LL; HORVITZ, HR; SHAW, JE; HERMAN, RK			THE C-ELEGANS GENE LIN-44, WHICH CONTROLS THE POLARITY OF CERTAIN ASYMMETRIC CELL DIVISIONS, ENCODES A WNT PROTEIN AND ACTS CELL NONAUTONOMOUSLY	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; DROSOPHILA HOMOLOG; EXPRESSION; WINGLESS; YEAST; REGION; PLAKOGLOBIN; SEQUENCES; VECTORS; LINEAGE	Mutations in the C. elegans gene lin-44 lead to reversals in the polarity of certain asymmetric cell divisions. We have discovered that lin-44 is a member of the Wnt family of genes, which encode secretory glycoproteins implicated in intercellular signaling. Both in situ hybridization experiments using lin-44 transcripts and experiments using reporter constructs designed to mimic patterns of lin-44 expression indicate that lin-44 is expressed in hypodermal cells at the tip of the tail and posterior to the cells with polarities affected by lin-44 mutations. Our mosaic analysis indicates that lin-44 acts cell nonautonomously. We propose that LIN-44 protein is secreted by tail hypodermal cells and affects the polarity of asymmetric cell divisions that occur more anteriorly in the tail.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	HERMAN, MA (corresponding author), UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108, USA.			Herman, Michael/0000-0001-6796-1568	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024943, R01GM022387] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22163] Funding Source: Medline; NIGMS NIH HHS [GM24943, GM22387] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHISHOLM AD, 1989, GENE DEV, V3, P1413, DOI 10.1101/gad.3.9.1413; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; DEVENISH RJ, 1982, GENE, V18, P277, DOI 10.1016/0378-1119(82)90166-4; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HERMAN MA, 1994, DEVELOPMENT, V120, P1035; HERMAN RK, 1989, J NEUROGENET, V5, P1, DOI 10.3109/01677068909167261; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HOWELL AM, 1990, GENETICS, V126, P583; Kaiser K, 1985, DNA CLONING PRACTICA, P1; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; KRASNOW RE, 1994, DEVELOPMENT, V120, P1883; LACKNER MR, 1994, GENE DEV, V8, P160, DOI 10.1101/gad.8.2.160; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1995, IN PRESS METH CELL B; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PODBILEWICZ B, 1994, DEV BIOL, V161, P408, DOI 10.1006/dbio.1994.1041; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; RUSSELL J, 1992, DEVELOPMENT, V115, P475; SAMBROOK J, 1989, MO LCLONING LABORATO; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SEYDOUX G, 1995, IN PRES METH CELL BI; SHACKLEFORD GM, 1993, ONCOGENE, V8, P1857; SIDOW A, 1992, P NATL ACAD SCI USA, V89, P5098, DOI 10.1073/pnas.89.11.5098; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; Sulston J., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; THEISEN H, 1994, DEVELOPMENT, V120, P347; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1994, CELL, V77, P9909; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATERSTON RH, 1981, GENETICS, V97, P307; WYMAN AR, 1987, METHOD ENZYMOL, V152, P173	48	166	173	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					101	110		10.1016/0092-8674(95)90238-4	http://dx.doi.org/10.1016/0092-8674(95)90238-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553861	Bronze			2022-12-28	WOS:A1995RY58300014
J	MCMAHON, HT; MISSLER, M; LI, C; SUDHOF, TC				MCMAHON, HT; MISSLER, M; LI, C; SUDHOF, TC			COMPLEXINS - CYTOSOLIC PROTEINS THAT REGULATE SNAP RECEPTOR FUNCTION	CELL			English	Article							FUSION PROTEIN; VESICULAR TRANSPORT; VESICLE; SYNTAXIN; REQUIRES; CLEAVAGE; DOCKING	A family of proteins called complexins was discovered that compete with alpha-SNAP, but not synaptotagmin, for SNAP receptor binding. Complexins I and II are highly homologous hydrophilic proteins that are tightly conserved, with 100% identity among mouse, rat, and human complexin II. They are enriched in neurons where they colocalize with syntaxin and SNAP-25; in addition, complexin II is expressed ubiquitously at low levels. Complexins bind weakly to syntaxin alone and not at all to synaptobrevin and SNAP-25, but strongly to the SNAP receptor-core complex composed of these three molecules. They compete with alpha-SNAP for binding to the core complex but not with other interacting molecules, including synaptotagmin I, suggesting that the complexins regulate the sequential interactions of alpha-SNAP and synaptotagmins with the SNAP receptor during exocytosis.	UNIV TEXAS,SW MED SCH,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED SCH,DEPT MOLEC GENET,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Missler, Markus/0000-0001-8008-984X				BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BARNSTABLE CJ, 1983, COLD SPRING HARB SYM, V48, P863, DOI 10.1101/SQB.1983.048.01.089; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DUC C, 1995, J COMP NEUROL, V356, P152, DOI 10.1002/cne.903560111; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FLETCHER TL, 1994, J NEUROSCI, V14, P6695; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; JORGENSEN EM, 1995, IN PRESS SEMIN DEV B; KOH S, 1993, J NEUROCYTOL, V22, P995, DOI 10.1007/BF01218356; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LLEN C, 1994, P NATL ACAD SCI USA, V91, P10380; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHULZE KL, 1995, CELL, V80, P311, DOI 10.1016/0092-8674(95)90414-X; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TAKIZAWA PA, 1993, CELL, V75, P593, DOI 10.1016/0092-8674(93)90477-8; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; YOSHIDA A, 1992, J BIOL CHEM, V267, P25925	35	371	393	0	15	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					111	119		10.1016/0092-8674(95)90239-2	http://dx.doi.org/10.1016/0092-8674(95)90239-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553862	Bronze			2022-12-28	WOS:A1995RY58300015
J	BRENNER, MK				BRENNER, MK			AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA	LANCET			English	Editorial Material											BRENNER, MK (corresponding author), ST JUDE CHILDRENS RES HOSP, DIV BONE MARROW TRANSPLANTAT, 332 N LAUDERDALE ST, MEMPHIS, TN 38105 USA.		Brenner, Malcolm/Y-2509-2019					APPLEBAUM FR, 1994, MED ONCOL, V11, P69, DOI 10.1007/BF02988833; BRENNER MK, 1993, LANCET, V341, P85, DOI 10.1016/0140-6736(93)92560-G; GRIBBEN JG, 1991, NEW ENGL J MED, V325, P1525, DOI 10.1056/NEJM199111283252201; NANDA NK, 1995, CELL, V82, P13, DOI 10.1016/0092-8674(95)90047-0; PETERS W P, 1992, Current Opinion in Oncology, V4, P279, DOI 10.1097/00001622-199204000-00007; PUI CH, 1995, NEW ENGL J MED, V332, P1618, DOI 10.1056/NEJM199506153322407; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; TEPPER RI, 1994, HUM GENE THER, V5, P153, DOI 10.1089/hum.1994.5.2-153; WEISDORF DJ, 1993, TRANSPLANTATION, V55, P61, DOI 10.1097/00007890-199301000-00012	9	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 30	1995	346	8979					856	857		10.1016/S0140-6736(95)92703-4	http://dx.doi.org/10.1016/S0140-6736(95)92703-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX196	7564665				2022-12-28	WOS:A1995RX19600003
J	KALKSTEIN, LS				KALKSTEIN, LS			LESSONS FROM A VERY HOT SUMMER	LANCET			English	Editorial Material							IMPACTS				KALKSTEIN, LS (corresponding author), UNIV DELAWARE,CTR CLIMAT RES,DEPT GEOG,NEWARK,DE 19711, USA.							HAINES A, 1993, LANCET, V342, P1464, DOI 10.1016/0140-6736(93)92937-O; Kalkstein L.S., 1993, EXPERIENTIA, V49, P469; KALKSTEIN LS, 1993, LANCET, V342, P1397, DOI 10.1016/0140-6736(93)92757-K; MCKENZIE D, 1995, NEW SCI, P4; ROGOT E, 1992, AM J EPIDEMIOL, V136, P106, DOI 10.1093/oxfordjournals.aje.a116413; IN PRESS ASSESSING I; 1994, NATIONAL CLIMATE SUR; IN PRESS HUMAN HLTH; 1995, MMWR-MORBID MORTAL W, V44, P577	9	20	20	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 30	1995	346	8979					857	859						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX196	7564666				2022-12-28	WOS:A1995RX19600004
J	ANDERSSON, N; DASOUSA, CP; PAREDES, S				ANDERSSON, N; DASOUSA, CP; PAREDES, S			SOCIAL COST OF LAND MINES IN 4 COUNTRIES - AFGHANISTAN, BOSNIA, CAMBODIA, AND MOZAMBIQUE	BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY	Objectives-To document the effects of land mines on the health and social conditions of communities in four affected countries. Design-A cross design of cluster survey and rapid appraisal methods including a household questionnaire and qualitative data from key informants, institutional reviews, and focus groups of survivors of landmines from the same communities. Setting-206 communities, 37 in Afghanistan, 66 in Bosnia, 38 in Cambodia, and 65 in Mozambique. Subjects-174 489 people living in 32 904 households in the selected communities. Main outcome measures-Effects of land mines on food security, residence, livestock, and land use; risk factors: extent of individual land mine injuries; physical, psychological, social, and economic costs of injuries during medical care and rehabilitation. Results-Between 25% and 87% of households had daily activities affected by land mines. Based on expected production without the mines, agricultural production could increase by 88-200% in different regions of Afghanistan, 11% in Bosnia, 135% in Cambodia, and 3.6% in Mozambique. A total of 54 554 animals was lost because of land mines, with a minimum cash value of $6.5m, or nearly $200 per household. Overall, 6% of households (1964) reported a land mine victim; a third of victims died in the blast. One in 10 of the victims was a child. The most frequent activities associated with land mine incidents were agricultural or pastoral, except in Bosnia where more than half resulted from military activities, usually during patrols. Incidences have more than doubled between 1980-3 and 1990-3, excluding the incidents in Bosnia. Some 22% of victims (455/2100) were from households reporting attempts to remove land mines; in these households there was a greatly increased risk of injury (odds ratio 4.2 and risk difference 19% across the four countries). Lethality of the mines varied; in Bosnia each blast killed an average of 0.54 people and injured 1.4, whereas in Mozambique each blast killed 1.45 people and wounded 1.27. Households with a land mine victim were 40% more likely to experience difficulty in providing food for the family. Family relationships were affected for around one in every four victims and relationships with colleagues in 40%. Conclusions-Land mines seriously undermine the economy and food security in affected countries; they kill and maim civilians at an increasing rate. The expense of medical care and rehabilitation add economic disability to the physical burden. Awareness of land mines can be targeted at high risk attitudes, such as those associated with tampering with mines.			ANDERSSON, N (corresponding author), CIETINT,847A 2ND AVE,SUITE 387,NEW YORK,NY 10017, USA.							Andersson N., 1989, Health Policy and Planning, V4, P197, DOI 10.1093/heapol/4.3.197; ANDERSSON N, 1992, HEALTH POLICY PLANN, V7, P352, DOI 10.1093/heapol/7.4.352; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; Coupland Robin M., 1994, MED GLOBAL SURVIVAL, V1, P18; Kakar F, 1995, DIRECT INDIRECT CONS; LEDOGAR RJ, 1993, THIRD WORLD PLAN REV, V15, P263; MANTEL N, 1959, J NATL CANCER I, V22, P719; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MIETTINEN OS, 1974, AM J EPIDEMIOL, V100, P515; RUIJTER JM, 1991, CONVERGENCE, V34, P3; ZELEN M, 1971, BIOMETRIKA, V58, P129, DOI 10.1093/biomet/58.1.129; 1994, UN A49357 REP; 1993, HIDDEN KILLERS GLOBA; 1994, MAY C DOC CERT CONV; 1993, UNICEF MINE AWARENES; 1994, PROGRAMME TECHNICAL; 1994, INT REV RED CROSS; 1993, LANDMINES DEADLY LEG	19	106	108	0	33	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	1995	311	7007					718	721		10.1136/bmj.311.7007.718	http://dx.doi.org/10.1136/bmj.311.7007.718			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RV874	7549685	Green Published			2022-12-28	WOS:A1995RV87400019
J	DIXON, J; GLENNERSTER, H				DIXON, J; GLENNERSTER, H			WHAT DO WE KNOW ABOUT FUNDHOLDING IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							PATTERNS; COSTS; NHS	The general practice fundholding scheme was introduced four years ago. So far its impact has not been formally evaluated nationally, but review of published research shows some trends. Fundholding has curbed prescribing costs and given general practitioners greater power to lever improvements in hospital services-for example, reducing waiting times for hospital treatment-but fundholding practices may have received more money than non-fundholding practices. The impact of fundholding on transactions costs, equity, and quality of care (particularly for patients of non-fundholding general practitioners) is unknown. Research into costly reforms such as fundholding needs to be coordinated.	UNIV LONDON LONDON SCH HYG & TROP MED,HLTH SERV RES UNIT,LONDON WC1E 7HT,ENGLAND; UNIV LONDON LONDON SCH ECON & POLIT SCI,SUNTORY & TOYOTA INT CTR ECON & RELATED DISCIPLIN,LONDON WC2A 2AE,ENGLAND	University of London; London School of Hygiene & Tropical Medicine; University of London; London School Economics & Political Science								BAILEY JJ, 1994, BRIT MED J, V308, P1083, DOI 10.1136/bmj.308.6936.1083; BAIN J, 1994, BRIT MED J, V309, P396, DOI 10.1136/bmj.309.6951.396; BAIN J, 1992, BRIT MED J, V304, P971, DOI 10.1136/bmj.304.6832.971; BLACK DG, 1994, BRIT MED J, V309, P930, DOI 10.1136/bmj.309.6959.930; BOWIE C, 1994, BRIT MED J, V309, P34, DOI 10.1136/bmj.309.6946.34; BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; BRINDLE D, 1995, GUARDIAN        0317, P5; BUTLER J, 1992, PATIENTS POLICIES PO; CORNEY R, 1994, BRIT J GEN PRACT, V44, P34; Corney Roslyn, 1992, International Review of Psychiatry, V4, P331, DOI 10.3109/09540269209066337; COULTER A, 1995, BRIT J GEN PRACT, V45, P119; COULTER A, 1993, BRIT MED J, V306, P433, DOI 10.1136/bmj.306.6875.433; DAVIES J, 1995, FUNDHOLDING     0118, P22; DIXON J, 1994, BRIT MED J, V308, P772, DOI 10.1136/bmj.308.6931.772; DIXON J, 1994, BRIT MED J, V309, P30, DOI 10.1136/bmj.309.6946.30; DOWELL JS, 1995, BRIT MED J, V310, P505, DOI 10.1136/bmj.310.6978.505; FISHER A, 1993, BRIT MED J, V306, P1003, DOI 10.1136/bmj.306.6883.1003-a; GLENNERSTER H, 1992, 12 KINGS FUND I RES; Glennerster H., 1992, IMPLEMENTING GP FUND; GLENNERSTER H, 1994, EVALUATING NHS REFOR; GRAFFY JP, 1994, BRIT MED J, V308, P391, DOI 10.1136/bmj.308.6925.391; HAM C, 1995, BRIT MED J, V310, P71, DOI 10.1136/bmj.310.6972.71; HARRIS A, 1994, BRIT MED J, V308, P1053, DOI 10.1136/bmj.308.6936.1053; HOWIE JGR, 1995, BRIT J GEN PRACT, V45, P121; HOWIE JGR, 1994, BRIT MED J, V309, P705, DOI 10.1136/bmj.309.6956.705; HOWIE JGR, 1995, GENERAL PRACTICE FUN; ILLIFFE S, 1994, BRIT MED J, V308, P3; KEELEY D, 1994, BRIT MED J, V308, P206, DOI 10.1136/bmj.308.6922.206c; KING M, 1994, BRIT J GEN PRACT, V44, P229; LANG H, 1995, COMMISSIONING NHS PO; LUXTON DEA, 1993, BRIT MED J, V306, P206, DOI 10.1136/bmj.306.6871.206-c; MACRAE TE, 1993, BR J HOSP MED, V50, P636; MAHON A, 1994, EVALUATING NHS REFOR; MATSAGANIS M, 1994, J HEALTH ECON, V13, P31, DOI 10.1016/0167-6296(94)90003-5; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; MCAVOY BR, 1993, BRIT MED J, V306, P694, DOI 10.1136/bmj.306.6879.694; MCCULLOUGH CJ, 1993, BRIT MED J, V306, P141, DOI 10.1136/bmj.306.6870.141-b; MIHIL C, 1993, GUARDIAN        1010, P5; MOORE L, 1993, BRIT MED J, V307, P1270, DOI 10.1136/bmj.307.6914.1270; NEWTON J, 1993, BRIT MED J, V306, P375, DOI 10.1136/bmj.306.6874.375; ROLAND M, 1991, BRIT MED J, V303, P171, DOI 10.1136/bmj.303.6795.171; SAMUEL O, 1992, BRIT MED J, V305, P1497, DOI 10.1136/bmj.305.6867.1497; SHELDON TA, 1994, BRIT MED J, V309, P1059, DOI 10.1136/bmj.309.6961.1059; TIMMINS N, 1995, INDEPENDENT     0228, P4; WHYNES DK, 1994, BRIT J GEN PRACT, V44, P557; WISELY ICF, 1991, BRIT MED J, V303, P171; 1994, GENERAL PRACTITIONER; 1989, WORKING PATIENTS; 1991, PATIENTS CHARTER; 1992, HLTH NATION; 1994, HLTH NEWS BRIEFING; 1994, DEV NHS PURCHASING G; 1994, PRIMARY CARE LED NHS	53	51	51	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	1995	311	7007					727	730		10.1136/bmj.311.7007.727	http://dx.doi.org/10.1136/bmj.311.7007.727			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV874	7549689	Green Published			2022-12-28	WOS:A1995RV87400023
J	GARFIELD, P				GARFIELD, P			CROSS DISTRICT COMPARISON OF APPLICATIONS TO RESEARCH ETHICS COMMITTEES	BRITISH MEDICAL JOURNAL			English	Article											GARFIELD, P (corresponding author), GREENWOOD INST CHILD HLTH,LEICESTER LE3 0QU,LEICS,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		COOKSON JB, 1992, J ROY COLL PHYS LOND, V26, P181; HOTOPF M, 1995, J ROY SOC MED, V88, P31; MEADE TW, 1994, J ROY COLL PHYS LOND, V28, P102; WARNOCK M, 1988, BRIT MED J, V297, P1626, DOI 10.1136/bmj.297.6664.1626; 1991, LOCAL RES ETHICS COM	5	41	41	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	1995	311	7006					660	661		10.1136/bmj.311.7006.660	http://dx.doi.org/10.1136/bmj.311.7006.660			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RU753	7549634	Green Published			2022-12-28	WOS:A1995RU75300018
J	LOCK, S				LOCK, S			HOW TO DO IT - WRITE AN OBITUARY FOR THE BMJ	BRITISH MEDICAL JOURNAL			English	Article																		Cochrane A. L., 1988, BRIT MED J, V297, P63; LOCK S, 1995, BRIT MED J, V311, P143, DOI 10.1136/bmj.311.6998.143; Renier G. J., 1931, ENGLISH ARE THEY HUM; 1995, BRIT MED J, V310, P660	4	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	1995	311	7006					680	681		10.1136/bmj.311.7006.680	http://dx.doi.org/10.1136/bmj.311.7006.680			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU753	7549642	Green Published			2022-12-28	WOS:A1995RU75300033
J	CROVELLO, CS; FURIE, BC; FURIE, B				CROVELLO, CS; FURIE, BC; FURIE, B			HISTIDINE PHOSPHORYLATION OF P-SELECTIN UPON STIMULATION OF HUMAN PLATELETS - A NOVEL PATHWAY FOR ACTIVATION-DEPENDENT SIGNAL-TRANSDUCTION	CELL			English	Article							GRANULE MEMBRANE-PROTEIN; LABILE HISTONE PHOSPHATES; PHYSARUM-POLYCEPHALUM; DEHYDROGENASE KINASE; SEQUENCE SIMILARITY; MOLECULAR-CLONING; NUCLEAR PROTEINS; PLASMA-MEMBRANE; RAT-LIVER; ADHESION	Transient phosphorylation of histidine characterizes the two-component systems in prokaryotes that control important physiological functions, but analogous events have not been implicated in signal transduction in mammalian cells. To explore histidine phosphorylation during activation of human cells, stimulated platelets were analyzed for the formation of protein phosphohistidine in a model system employing P-selectin. P-selectin, a leukocyte adhesion molecule, undergoes rapid phosphorylation and selective dephosphorylation of tyrosine, serine, and threonine. We now establish that phosphorylation following platelet activation with thrombin or collagen generates phosphohistidine at histidines on the cytoplasmic tail of P-selectin. With thrombin stimulation, the kinetics of phosphohistidine appearance and disappearance on P-selectin are very rapid. Platelets exhibit a novel ligand-induced signaling pathway to generate phosphohistidine. These results provide direct biochemical evidence for the induction of rapid and reversible histidine phosphorylation in mammalian cells upon cell activation and represent a novel paradigm for mammalian cell signaling.	TUFTS UNIV, SCH MED, DEPT MED, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA	Tufts University; Tufts University	CROVELLO, CS (corresponding author), TUFTS UNIV, NEW ENGLAND MED CTR, SCH MED, CTR HEMOSTASIS & THROMBOSIS RES, DIV HEMATOL ONCOL, BOSTON, MA 02111 USA.				NHLBI NIH HHS [HL51926] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051926] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; CELI A, 1994, P NATL ACAD SCI USA, V91, P8767, DOI 10.1073/pnas.91.19.8767; CHEN CC, 1977, BIOCHEMISTRY-US, V16, P4852, DOI 10.1021/bi00641a016; CHEN CC, 1974, BIOCHEMISTRY-US, V13, P3785, DOI 10.1021/bi00715a026; CHONG BH, 1994, BLOOD, V83, P1535; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COUGHLIN SR, 1994, P NATL ACAD SCI USA, V91, P9200, DOI 10.1073/pnas.91.20.9200; CROVELLO CS, 1993, J BIOL CHEM, V268, P14590; FUJIMOTO T, 1993, BLOOD, V82, P1758; FUJIMOTO T, 1993, J BIOL CHEM, V268, P11394; FUJITAKI JM, 1981, BIOCHEMISTRY-US, V20, P3658, DOI 10.1021/bi00515a055; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; HUANG JM, 1991, J BIOL CHEM, V266, P9023; HUEBNER VD, 1985, J BIOL CHEM, V260, P6106; HUNG DT, 1992, J BIOL CHEM, V267, P20831; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KIM YH, 1993, J BIOL CHEM, V268, P18513; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOTOJIMA K, 1993, FEBS LETT, V319, P75, DOI 10.1016/0014-5793(93)80040-2; MOTOJIMA K, 1994, J BIOL CHEM, V269, P9030; OHMORI H, 1993, J BIOL CHEM, V268, P7625; PESIS KH, 1988, FEBS LETT, V239, P151, DOI 10.1016/0014-5793(88)80563-5; POPOV KM, 1992, J BIOL CHEM, V267, P13127; POPOV KM, 1993, J BIOL CHEM, V268, P26602; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SHATTIL SJ, 1993, THROMB HAEMOSTASIS, V70, P224; Sheridan R. C., 2007, INORG SYN, P23; SMITH DL, 1974, BIOCHEMISTRY-US, V13, P3780, DOI 10.1021/bi00715a025; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALINDER O, 1969, J BIOL CHEM, V244, P1065; WALINDER O, 1968, J BIOL CHEM, V243, P3947; WATSON SP, 1985, BIOCHEM J, V226, P831, DOI 10.1042/bj2260831; WEI YF, 1993, METHOD ENZYMOL, V200, P388; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186; WIELAND T, 1993, J BIOL CHEM, V268, P18111; WONG C, 1993, BIOCHEM J, V296, P293, DOI 10.1042/bj2960293; ZETTERQVIST O, 1967, BIOCHIM BIOPHYS ACTA, V136, P279, DOI 10.1016/0304-4165(67)90073-6; ZHANG J, 1993, J BIOL CHEM, V268, P22251	53	88	90	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 28	1995	82	2					279	286		10.1016/0092-8674(95)90315-1	http://dx.doi.org/10.1016/0092-8674(95)90315-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7543025	Bronze			2022-12-28	WOS:A1995RL76000015
J	SATO, T; IRIE, S; KITADA, S; REED, JC				SATO, T; IRIE, S; KITADA, S; REED, JC			FAP-1 - A PROTEIN-TYROSINE-PHOSPHATASE THAT ASSOCIATES WITH FAS	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; MONOCLONAL-ANTIBODY; APOPTOSIS; ANTIGEN; EXPRESSION; INTERACTS; BCL-2; CELLS	Fas is a cell surface receptor that controls a poorly understood signal transduction pathway that leads to cell death by means of apoptosis. A protein tyrosine phosphatase, FAP-1, capable of interacting with the cytosolic domain of Fas, was identified. The carboxyl terminal 15 amino acids of Fas are necessary and sufficient for interaction with FAP-1. FAP-1 expression is highest in tissues and cell lines that are relatively resistant to Fas-mediated cytotoxicity. Gene transfer-mediated elevations in FAP-1 partially abolished Fas-induced apoptosis in a T cell line. These findings are consistent with an inhibitory effect of FAP-1 on Fas signal transduction.	LA JOLLA CANC RES FDN,ONCOGENE & TUMOR SUPPRESSOR GENE PROGRAM,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute								ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; GORCZYCA W, 1993, CANCER RES, V53, P1945; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MAPARA MY, 1993, EUR J IMMUNOL, V23, P702, DOI 10.1002/eji.1830230320; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SATO TJ, UNPUB; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI S, 1993, EUR J IMMUNOL, V23, P1935, DOI 10.1002/eji.1830230831; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	25	684	724	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					411	415		10.1126/science.7536343	http://dx.doi.org/10.1126/science.7536343			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7536343				2022-12-28	WOS:A1995QU57200038
J	RICKMAN, LS; FREEMAN, WR; GREEN, WR; FELDMAN, ST; SULLIVAN, J; RUSSACK, V; RELMAN, DA				RICKMAN, LS; FREEMAN, WR; GREEN, WR; FELDMAN, ST; SULLIVAN, J; RUSSACK, V; RELMAN, DA			UVEITIS CAUSED BY TROPHERYMA-WHIPPELII (WHIPPLE BACILLUS)	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							NERVOUS-SYSTEM; DISEASE; IDENTIFICATION; MANIFESTATIONS; INVOLVEMENT; INFECTIONS; GRANULOMAS; BRAIN		UNIV CALIF SAN DIEGO,DEPT OPHTHALMOL,SAN DIEGO,CA 92103; UNIV CALIF SAN DIEGO,DEPT INTERNAL MED,SAN DIEGO,CA 92103; UNIV CALIF SAN DIEGO,DEPT PATHOL,SAN DIEGO,CA 92103; JOHNS HOPKINS UNIV,BALTIMORE,MD; STANFORD UNIV,DEPT MED,STANFORD,CA 94305; STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305; VET AFFAIRS MED CTR,PALO ALTO,CA 94304	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Johns Hopkins University; Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	RICKMAN, LS (corresponding author), UNIV CALIF SAN DIEGO,MED CTR,DIV INFECT DIS,EPIDEMIOL UNIT,200 W ARBOR DR,SAN DIEGO,CA 92103, USA.			Relman, David A./0000-0001-8331-1354	NEI NIH HHS [EYO7366] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007366] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMS M, 1987, ANN NEUROL, V21, P104, DOI 10.1002/ana.410210121; AVILA MP, 1984, ARCH OPHTHALMOL-CHIC, V102, P384; CHO C, 1984, GASTROENTEROLOGY, V87, P941; DOBBINS WO, 1987, WHIPPLES DIS, P242; FEURLE GE, 1979, NEW ENGL J MED, V300, P907, DOI 10.1056/NEJM197904193001607; KEINATH RD, 1985, GASTROENTEROLOGY, V88, P1867, DOI 10.1016/0016-5085(85)90012-5; KITAMURA T, 1975, ACTA NEUROPATHOL, V33, P275, DOI 10.1007/BF00688400; KNOX DL, 1976, MEDICINE, V55, P467, DOI 10.1097/00005792-197611000-00003; KUHAJDA FP, 1982, GASTROENTEROLOGY, V82, P46; LOWSKY R, 1994, NEW ENGL J MED, V331, P1343, DOI 10.1056/NEJM199411173312004; MAIZEL H, 1970, MEDICINE, V49, P175, DOI 10.1097/00005792-197005000-00001; MANSBACH CM, 1978, ANN INTERN MED, V89, P64, DOI 10.7326/0003-4819-89-1-64; MEIERWILLERSEN HJ, 1993, DEUT MED WOCHENSCHR, V118, P854, DOI 10.1055/s-2008-1059397; MOORTHY S, 1977, GUT, V18, P152, DOI 10.1136/gut.18.2.152; MULLER C, 1993, LANCET, V341, P701, DOI 10.1016/0140-6736(93)90475-V; PAULLEY JW, 1952, GASTROENTEROLOGY, V22, P128; POLLOCK S, 1981, J NEUROL NEUROSUR PS, V44, P1104, DOI 10.1136/jnnp.44.12.1104; RELMAN DA, 1993, J INFECT DIS, V168, P1; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; Relman David A., 1993, P496; ROMANUL FCA, 1977, J NEUROL NEUROSUR PS, V40, P901, DOI 10.1136/jnnp.40.9.901; ROOK GAW, 1992, IMMUNOL TODAY, V13, P160, DOI 10.1016/0167-5699(92)90119-R; SOUTHERN JF, 1989, JAMA-J AM MED ASSOC, V261, P1467, DOI 10.1001/jama.261.10.1467; SPAPEN HDM, 1989, DIGEST DIS SCI, V34, P640, DOI 10.1007/BF01536345; TRIER JS, 1965, GASTROENTEROLOGY, V48, P684; Whipple GH, 1907, B JOHNS HOPKINS HOSP, V18, P382; WILSON KH, 1991, LANCET, V338, P474, DOI 10.1016/0140-6736(91)90545-Z; WROE SJ, 1991, J NEUROL NEUROSUR PS, V54, P989, DOI 10.1136/jnnp.54.11.989	28	142	145	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 9	1995	332	6					363	366		10.1056/NEJM199502093320604	http://dx.doi.org/10.1056/NEJM199502093320604			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF300	7529892	Bronze			2022-12-28	WOS:A1995QF30000004
J	BLAU, HM; SPRINGER, ML				BLAU, HM; SPRINGER, ML			GENE-THERAPY - A NOVEL FORM OF DRUG-DELIVERY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											BLAU, HM (corresponding author), STANFORD UNIV,SCH MED,DEPT MOLEC PHARMACOL,STANFORD,CA 94305, USA.							FRIEDMANN T, 1992, NAT GENET, V2, P93, DOI 10.1038/ng1092-93; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530	3	103	119	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 2	1995	333	18					1204	1207		10.1056/NEJM199511023331808	http://dx.doi.org/10.1056/NEJM199511023331808			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB560	7565977				2022-12-28	WOS:A1995TB56000008
J	BROWN, SS; EISENBERG, L				BROWN, SS; EISENBERG, L			UNINTENDED PREGNANCY AND THE WELL-BEING OF CHILDREN AND FAMILIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School	BROWN, SS (corresponding author), NATL ACAD SCI,INST MED,WASHINGTON,DC 20418, USA.								0	12	12	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	1995	274	17					1332	1332		10.1001/jama.274.17.1332	http://dx.doi.org/10.1001/jama.274.17.1332			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB278	7563544				2022-12-28	WOS:A1995TB27800003
J	JORENBY, DE; SMITH, SS; FIORE, MC; HURT, RD; OFFORD, KP; CROGHAN, IT; HAYS, JT; LEWIS, SF; BAKER, TB				JORENBY, DE; SMITH, SS; FIORE, MC; HURT, RD; OFFORD, KP; CROGHAN, IT; HAYS, JT; LEWIS, SF; BAKER, TB			VARYING NICOTINE PATCH DOSE AND TYPE OF SMOKING CESSATION COUNSELING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPENDENCE	Objective.-To compare the efficacy and safety of 22-mg and 44-mg doses of transdermal nicotine therapy. when it is paired with minimal, individual, or group counseling to improve smoking cessation rates. Design.-An 8-week clinical trial (4 weeks double-blind followed by 4 weeks open label) using random assignment of participants to both dose (22 or 44 mg) and counseling (minimal, individual, or group) conditions. Participants.-Daily cigarette smokers (greater than or equal to 15 cigarettes per day for at least 1 year) who volunteered to participate in a study of smoking cessation treatment. A total of 504 participants were enrolled at two sites. Intervention.-Four weeks of 22- or 44-mg transdermal nicotine therapy followed by 4 weeks of dosage reduction (2 weeks of 22 mg followed by 2 weeks of 11 mg). Counseling consisted of a self-help pamphlet (minimal); a self-help pamphlet, a brief physician motivational message, and three brief (<15 minutes) follow-up visits with a nurse (individual); or the pamphlet, the motivational message, and eight weekly 1-hour group smoking cessation counseling visits (group). All participants returned weekly to turn in questionnaires and for assessment of their smoking status. Main Outcome Measures.-Abstinence from smoking was based on self-report, confirmed by an expired carbon monoxide concentration lower than 10 ppm. Withdrawal severity was assessed by means of an eight-item self-report questionnaire completed daily. Results.-Smoking cessation rates for the two nicotine patch doses and three levels of counseling did not differ significantly at either 8 weeks or 26 weeks following the quit date. Among those receiving minimal contact, the 44-mg dose produced greater abstinence at 4 weeks than did the 22-mg dose (68% vs 45%; P<.01). Participants receiving minimal-contact adjuvant treatment were less likely to be abstinent at the end of 4 weeks than those receiving individual or group counseling (56% vs 67%; P<.05), The 44-mg dose decreased desire to smoke more than the 22-mg dose, but this effect was not related to success in quitting smoking. Transdermal nicotine therapy at doses of 44 mg produced a significantly greater frequency of nausea (28%), vomiting (10%), and erythema with edema at the patch site (30%) than did a 22-mg dose (10%, 2%, and 13%, respectively; P<.01 for each adverse effect). Three serious adverse events occurred during use of the 44-mg patch dose. Conclusions.-There does not appear to be any general, sustained benefit of initiating transdermal nicotine therapy with a 44-mg patch dose or of providing intense adjuvant smoking cessation treatment. The two doses and all adjuvant treatments produced equivalent effects at the 26-week follow-up, and the higher patch dose produced more adverse effects. Higher-dose (44-mg) nicotine replacement does not appear to be indicated for general clinical populations, although it may provide short-term benefit to some smokers attempting to quit with minimal adjuvant treatment.	UNIV WISCONSIN,DEPT PSYCHOL,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,DEPT MED,DIV GEN INTERNAL MED,MADISON,WI; MAYO CLIN,NICOTINE RES CTR,ROCHESTER,MN; MAYO CLIN,DIV COMMUNITY INTERNAL MED,ROCHESTER,MN; MAYO CLIN,BIOSTAT SECT,ROCHESTER,MN; MAYO CLIN,DIV GEN INTERNAL MED,ROCHESTER,MN	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	JORENBY, DE (corresponding author), UNIV WISCONSIN,SCH MED,CTR TOBACCO RES & INTERVENT,1300 UNIV AVE,7275 MSC,MADISON,WI 53706, USA.			Smith, Stevens/0000-0002-6824-2829				BENOWITZ NL, 1993, DRUGS, V45, P157, DOI 10.2165/00003495-199345020-00001; FAGERSTROM KO, 1978, ADDICT BEHAV, V3, P235, DOI 10.1016/0306-4603(78)90024-2; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; FIORE MC, 1994, CHEST, V105, P524, DOI 10.1378/chest.105.2.524; GLYNN TJ, 1990, PHS NIH903064 US DEP; HUGHES JR, 1986, ARCH GEN PSYCHIAT, V43, P289; HUGHES JR, 1993, DRUG SAFETY, V8, P49, DOI 10.2165/00002018-199308010-00006; HURT RD, 1994, JAMA-J AM MED ASSOC, V271, P595, DOI 10.1001/jama.271.8.595; HURT RD, 1992, MAYO CLIN PROC, V67, P823, DOI 10.1016/S0025-6196(12)60819-2; NORREGAARD J, 1993, PREV MED, V22, P261, DOI 10.1006/pmed.1993.1021; PALMER KJ, 1992, DRUGS, V44, P498, DOI 10.2165/00003495-199244030-00011; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; TANG JL, 1991, BRIT MED J, V308, P21; ZELMAN DC, 1992, J CONSULT CLIN PSYCH, V60, P943, DOI 10.1037/0022-006X.60.6.943; 1993, BRIT MED J, V306, P1304; 1989, NCI PHS NIH891647 US; 1991, JAMA-J AM MED ASSOC, V266, P3133	17	179	181	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	1995	274	17					1347	1352		10.1001/jama.274.17.1347	http://dx.doi.org/10.1001/jama.274.17.1347			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TB278	7563558				2022-12-28	WOS:A1995TB27800024
J	HAIRE, WD; RUBY, EI; GORDON, BG; PATIL, KD; STEPHENS, LC; KOTULAK, GD; REED, EC; VOSE, JM; BIERMAN, PJ; KESSINGER, A; ARMITAGE, JO				HAIRE, WD; RUBY, EI; GORDON, BG; PATIL, KD; STEPHENS, LC; KOTULAK, GD; REED, EC; VOSE, JM; BIERMAN, PJ; KESSINGER, A; ARMITAGE, JO			MULTIPLE ORGAN DYSFUNCTION SYNDROME IN BONE-MARROW TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISSEMINATED INTRAVASCULAR COAGULATION; RESPIRATORY-DISTRESS SYNDROME; TUMOR-NECROSIS-FACTOR; HEPATIC VENOOCCLUSIVE DISEASE; ESCHERICHIA-COLI INFUSION; VENO-OCCLUSIVE DISEASE; PROTEIN-C DEFICIENCY; ANTITHROMBIN-III; SEPTIC SHOCK; MULTIORGAN FAILURE	Objective.-To define the frequency and outcome of organ dysfunction in bone marrow transplantation (BMT) and to determine if patients with organ dysfunction have lower levels of protein C (PC) and/or antithrombin III (ATIII) than those without organ dysfunction. Design.-Inception cohort of patients undergoing BMT, followed for 28 days, until hospital dismissal, or until death. Setting.-Bone marrow transplant department of a university hospital. Patients.-A total of 199 consecutive patients admitted for BMT. Interventions.-Standard supportive care was given to all patients. Main Outcome Measures.-Definitions of organ dysfunction were arrived at prior to beginning the study. They include pulmonary, central nervous system (CNS), hepatic, and renal dysfunction. Protein C and ATIII levels were measured prior to beginning the preparative regimen and weekly thereafter. Results.-Single organ dysfunction, manifesting as pulmonary, CNS, or hepatic dysfunction, occurred in 33 (48.5%) of the 199 patients and was a strong predictor of multiple organ dysfunction syndrome (MODS) and death, Death occurred in 14 (7.0%) of the patients. Cause of death was precisely identified in only four patients. Low levels of either PC or ATIII were associated with death and pulmonary, CNS, and hepatic dysfunction, Multivariate analysis showed ATIII and PC levels were associated with single organ dysfunction independent of the type of transplant, the type of preparative regimen, and the presence of bacteremia. Conclusions.-Single organ dysfunction during BRAT is a marker for a systemic abnormality that has a high likelihood of progressing to MODS, similar to that seen in other critically ill patient populations. MODS is the leading cause of death in series of BMT patients. Low levels of ATIII and PC are markers of and may be involved in the pathogenesis of MODS in BMT.	UNIV NEBRASKA,MED CTR,DEPT PEDIAT,OMAHA,NE 68182; UNIV NEBRASKA,MED CTR,DEPT PREVENT & SOCIAL MED,OMAHA,NE 68182	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	HAIRE, WD (corresponding author), UNIV NEBRASKA,MED CTR,DEPT INTERNAL MED,OMAHA,NE 68198, USA.							AMBRUS JL, 1990, J MED, V21, P67; ARMITAGE JO, 1991, AM J MED, V91, P605, DOI 10.1016/0002-9343(91)90213-H; AYASH LJ, 1990, J CLIN ONCOL, V8, P1699, DOI 10.1200/JCO.1990.8.10.1699; BAGGE L, 1989, SCAND J CLIN LAB INV, V49, P63, DOI 10.3109/00365518909089079; BARTON R, 1989, CHEST, V96, P1153, DOI 10.1378/chest.96.5.1153; BEAL AL, 1994, JAMA-J AM MED ASSOC, V271, P226, DOI 10.1001/jama.271.3.226; BERNAUER W, 1991, ANN INTERN MED, V115, P925, DOI 10.7326/0003-4819-115-12-925; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; BONE RC, 1992, CHEST, V101, P320, DOI 10.1378/chest.101.2.320; BONE RC, 1992, ARCH INTERN MED, V152, P1381, DOI 10.1001/archinte.152.7.1381; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BONE RC, 1992, CHEST, V101, P594, DOI 10.1378/chest.101.3.594; BRANDTZAEG P, 1989, THROMB RES, V55, P459, DOI 10.1016/0049-3848(89)90054-6; CARRERAS E, 1993, ANN HEMATOL, V66, P77, DOI 10.1007/BF01695888; CARVALHO AC, 1988, J LAB CLIN MED, V112, P270; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; CLARK JG, 1993, AM REV RESPIR DIS, V147, P1601, DOI 10.1164/ajrccm/147.6_Pt_1.1601; DICKNEITE G, 1993, THROMB HAEMOSTASIS, V69, P98; EMERSON TE, 1987, CIRC SHOCK, V21, P1; ESMON CT, 1991, THROMB HAEMOSTASIS, V66, P160; FAIONI EM, 1993, BLOOD, V81, P3458; FAIST FN, 1983, J TRAUMA, V9, P775; FOURRIER F, 1992, CHEST, V101, P816, DOI 10.1378/chest.101.3.816; FOURRIER F, 1990, INTENS CARE MED, V16, P121, DOI 10.1007/BF01699858; FOURRIER F, 1993, CHEST, V104, P882, DOI 10.1378/chest.104.3.882; FUGGER R, 1993, EUR J SURG, V159, P525; GORDON B, 1991, BONE MARROW TRANSPL, V8, P497; GORDON BG, 1993, BONE MARROW TRANSPL, V11, P61; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; HARPER PL, 1990, BONE MARROW TRANSPL, V5, P39; HENAO FJ, 1991, J TRAUMA, V31, P74, DOI 10.1097/00005373-199101000-00014; HESSELVIK JF, 1991, THROMB HAEMOSTASIS, V65, P126; HESSELVIK JF, 1989, CRIT CARE MED, V17, P724, DOI 10.1097/00003246-198908000-00002; HOLLER E, 1990, BLOOD, V75, P1011; KAUFMAN PA, 1990, CANCER, V66, P515, DOI 10.1002/1097-0142(19900801)66:3<515::AID-CNCR2820660319>3.0.CO;2-7; KESSINGER A, 1989, BLOOD, V74, P1260; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; LAMMLE B, 1984, AM J CLIN PATHOL, V823, P396; LAURELL CB, 1966, ANAL BIOCHEM, V15, P45, DOI 10.1016/0003-2697(66)90246-6; LORENTE JA, 1993, CHEST, V103, P1536, DOI 10.1378/chest.103.5.1536; MARSHALL WG, 1983, J TRAUMA, V23, P102, DOI 10.1097/00005373-198302000-00005; MARTINOLI JL, 1986, THROMB RES, V43, P253, DOI 10.1016/0049-3848(86)90145-3; MCDONALD GB, 1993, ANN INTERN MED, V118, P255, DOI 10.7326/0003-4819-118-4-199302150-00003; MCDONALD GB, 1984, HEPATOLOGY, V4, P116, DOI 10.1002/hep.1840040121; MILLER RS, 1994, J TRAUMA, V37, P442, DOI 10.1097/00005373-199409000-00019; MODIG J, 1983, ACTA ANAESTH SCAND, V27, P369, DOI 10.1111/j.1399-6576.1983.tb01970.x; NEDORN E, 1991, KLIN WOCHENSCHR, V69, P817, DOI 10.1007/BF01744277; PRELLWITZ W, 1982, CLIN CHEM, V28, P2249; REDENS TB, 1988, CIRC SHOCK, V26, P15; SCHIPPER HG, 1981, THROMB RES, V21, P73, DOI 10.1016/0049-3848(84)90034-3; SHETH SB, 1991, AM J HEMATOL, V36, P14, DOI 10.1002/ajh.2830360104; STRIETER RM, 1993, CRIT CARE MED, V21, pS447, DOI 10.1097/00003246-199310001-00006; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; TAYLOR FB, 1991, BLOOD, V78, P364; TAYLOR FB, 1988, CIRC SHOCK, V26, P227; TRACEY KJ, 1993, CRIT CARE MED, V21, pS415; WINGARD JR, 1989, BONE MARROW TRANSPL, V4, P685	57	59	63	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	1995	274	16					1289	1295		10.1001/jama.274.16.1289	http://dx.doi.org/10.1001/jama.274.16.1289			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA104	7563534				2022-12-28	WOS:A1995TA10400024
J	SAARINEN, UM; KAJOSAARI, M				SAARINEN, UM; KAJOSAARI, M			BREAST-FEEDING AS PROPHYLAXIS AGAINST ATOPIC DISEASE - PROSPECTIVE FOLLOW-UP-STUDY UNTIL 17 YEARS OLD	LANCET			English	Article							ALLERGIC DISEASES; NATURAL-HISTORY; CHILDHOOD; CHILDREN; ASTHMA; BREAST; MILK; INFANTS; ECZEMA; DIET	Atopic diseases constitute a common health problem. For infants at hereditary risk, prophylaxis of atopy has been sought in elimination diets and other preventive measures. We followed up healthy infants during their first year, and then at ages 1, 3, 5, 10, and 17 years to determine the effect on atopic disease of breastfeeding. Of the initial 236 infants, 150 completed the follow-up, which included history taking, physical examination, and laboratory tests for allergy. The subjects were divided into three groups: prolonged (>6 months), intermediate (1-6 months), and short or no (<1 month) breastfeeding. The prevalence of manifest atopy throughout follow-up was highest in the group who had little or no breastfeeding (p<0.05, analysis of variance and covariance with repeated measures [ANOVA]), Prevalence of eczema at ages 1 and 3 years was lowest (p=0.03, ANOVA) in the prolonged breastfeeding group, prevalence of food allery was highest in the little or no groups (p=0.02, ANOVA) at 1-3 years, and respiratory allergy was also most prevalent in the latter group (p=0.01, ANOVA) having risen to 65% at 17 years of age, Prevalences in the prolonged, intermediate, and little or no groups at age 17 were 42 (95% CI 31-52)%, 36 (28-44)%, and 65 (56-74)% (p=0.02, trend test) for atopy, respectively, and 8 (6-10)%, 23 (21-25)%, and 54 (52-56)% (p=0.0001, trend test) for substantial atopy. We conclude that breastfeeding is prophylactic against atopic disease-including atopic eczema, food allergy, and respiratory allergy-throughout childhood and adolescence.	UNIV HELSINKI,HOSP ALLERG DIS,HELSINKI,FINLAND	University of Helsinki	SAARINEN, UM (corresponding author), UNIV HELSINKI,CHILDRENS HOSP,STENBACKINKATU 11,SF-00290 HELSINKI,FINLAND.							AAS K, 1980, ALLERGY, V35, P250, DOI 10.1111/j.1398-9995.1980.tb01763.x; ABERG N, 1990, ACTA PAEDIATR SCAND, V79, P206, DOI 10.1111/j.1651-2227.1990.tb11440.x; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; BJORKSTEN F, 1976, CLIN ALLERGY, V6, P165, DOI 10.1111/j.1365-2222.1976.tb01894.x; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BUSINCO L, 1987, ANN ALLERGY, V59, P183; COGSWELL JJ, 1987, ARCH DIS CHILD, V62, P338, DOI 10.1136/adc.62.4.338; COHEN GA, 1985, ANN ALLERGY, V4, P112; CRONER S, 1990, PEDIATR ALLERGY IMMU, V1, P14, DOI DOI 10.1111/J.1399-3038.1990.TB00003.X; FERGUSSON DM, 1990, PEDIATRICS, V86, P541; FRICK OL, 1979, J ALLERGY CLIN IMMUN, V63, P228, DOI 10.1016/0091-6749(79)90106-4; GORDON RR, 1982, LANCET, V1, P910; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HIDE DW, 1981, ARCH DIS CHILD, V56, P172, DOI 10.1136/adc.56.3.172; JACKSON PG, 1981, LANCET, V1, P1285; Kajosaari M, 1994, Pediatr Allergy Immunol, V5, P26, DOI 10.1111/j.1399-3038.1994.tb00344.x; LILJA G, 1989, CLIN EXP ALLERGY, V19, P473, DOI 10.1111/j.1365-2222.1989.tb02416.x; OWNBY DR, 1990, J ALLERGY CLIN IMMUN, V86, P279, DOI 10.1016/S0091-6749(05)80088-0; SAARINEN UM, 1979, LANCET, V2, P163; SAARINEN UM, 1979, CLIN ALLERGY, V9, P339, DOI 10.1111/j.1365-2222.1979.tb02492.x; SAARINEN UM, 1980, LANCET, V1, P166; SAARINEN UM, 1982, ALLERGY, V37, P345, DOI 10.1111/j.1398-9995.1982.tb01920.x; SARFATI M, 1986, EUR J IMMUNOL, V16, P1005, DOI 10.1002/eji.1830160822; SAVILAHTI E, 1981, ALLERGY, V36, P73, DOI 10.1111/j.1398-9995.1981.tb04101.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STRANGERT K, 1976, PEDIATRICS, V57, P191; VANASPEREN PP, 1984, CLIN ALLERGY, V14, P525; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WALKER WA, 1977, M JOHNSON S PERINAT, V2, P111; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; WICKMAN M, 1992, PEDIATRIC ALLERGY IM, V3, P128; Zeiger R, 1992, PEDIAT ALLERG IMM-UK, V3, P110, DOI [DOI 10.1111/J.1399-3038.1992.TB00035.X, 10.1111/j.1399-3038.1992.tb00035.x]	33	489	514	1	28	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1065	1069		10.1016/S0140-6736(95)91742-X	http://dx.doi.org/10.1016/S0140-6736(95)91742-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564787				2022-12-28	WOS:A1995TA69700011
J	WESTABY, D				WESTABY, D			PROGNOSTIC VALUE OF PORTAL HEMODYNAMICS	LANCET			English	Editorial Material							ESOPHAGEAL-VARICES; ENDOSCOPIC MEASUREMENT; PORTOHEPATIC GRADIENT; ALCOHOLIC CIRRHOSIS; PROPRANOLOL; PREVENTION; HYPERTENSION; HEMORRHAGE; PRESSURE; TRIAL				WESTABY, D (corresponding author), CHELSEA & WESTMINSTER HOSP,GASTROINTESTINAL UNIT,LONDON,ENGLAND.							Gludd C, 1988, HEPATOLOGY, V8, P222; GROSZMANN RJ, 1990, GASTROENTEROLOGY, V99, P1401, DOI 10.1016/0016-5085(90)91168-6; LEBREC D, 1981, NEW ENGL J MED, V305, P1371, DOI 10.1056/NEJM198112033052302; LEBREC D, 1980, GASTROENTEROLOGY, V79, P1139; MERKEL C, 1992, GASTROENTEROLOGY, V102, P973, DOI 10.1016/0016-5085(92)90185-2; MYERS JD, 1951, J CLIN INVEST, V30, P662; POYNARD T, 1987, HEPATOLOGY, V7, P447, DOI 10.1002/hep.1840070306; RIGAU J, 1989, GASTROENTEROLOGY, V96, P873; STARITZ M, 1988, J HEPATOL, V7, P126, DOI 10.1016/S0168-8278(88)80516-6; VIALLET A, 1975, GASTROENTEROLOGY, V69, P1297; VINEL JP, 1986, HEPATOLOGY, V6, P116, DOI 10.1002/hep.1840060122; WESTABY D, 1990, HEPATOLOGY, V11, P353, DOI 10.1002/hep.1840110304	12	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1046	1047		10.1016/S0140-6736(95)91734-9	http://dx.doi.org/10.1016/S0140-6736(95)91734-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564779	Bronze			2022-12-28	WOS:A1995TA69700003
J	EARLY, A; ABE, T; WILLIAMS, J				EARLY, A; ABE, T; WILLIAMS, J			EVIDENCE FOR POSITIONAL DIFFERENTIATION OF PRESTALK CELLS AND FOR A MORPHOGENETIC GRADIENT IN DICTYOSTELIUM	CELL			English	Article							ANTERIOR-LIKE CELLS; GENE-EXPRESSION; CYCLE PHASE; STALK-CELL; PATTERN-FORMATION; PRESPORE PATTERN; DISCOIDEUM; SLUG; CAMP; DIF	We present evidence that Dictyostelium slug tip cells, the pstA cells, may arise by positional differentiation, but at a site remote from that which they will eventually occupy. When first detectable, the pstA cells form a peripheral ring surrounding the other prestalk cell subtype, the pstO cells, but subsequently move above the pstO cells to form the tip. Because pstA cell differentiation requires a 10-fold higher concentration of differention-inducing factor, the stalk cell inducer, the initial patterning seems likely to reflect the existence of a morphogenetic gradient. The subsequent redistribution of the two cell types is explicable by their different rates of chemotaxis to cyclic AMP, These results help reconcile the two apparently opposing views of pattern formation in Dictyostelium, that there is positional differentiation and that pattern formation occurs by cell sorting.	UNIV LONDON UNIV COLL,DEPT BIOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London	EARLY, A (corresponding author), UNIV LONDON UNIV COLL,MRC,MOLEC CELL BIOL LAB,TORRINGTON PL,LONDON WC1E 6BT,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABE T, 1994, CELL, V77, P687, DOI 10.1016/0092-8674(94)90053-1; ARAKI T, 1994, DEV BIOL, V162, P221, DOI 10.1006/dbio.1994.1080; BROOKMAN JJ, 1982, DEV BIOL, V91, P191, DOI 10.1016/0012-1606(82)90022-7; BROOKMAN JJ, 1987, DEVELOPMENT, V100, P119; BUHL B, 1993, DEV BIOL, V156, P481, DOI 10.1006/dbio.1993.1094; CECCARELLI A, 1991, CELL, V65, P983, DOI 10.1016/0092-8674(91)90550-I; DATTA S, 1986, MOL CELL BIOL, V6, P811, DOI 10.1128/MCB.6.3.811; DETTERBECK S, 1994, DEVELOPMENT, V120, P2847; DEVINE KM, 1985, DEV BIOL, V107, P364, DOI 10.1016/0012-1606(85)90318-5; DINGERMANN T, 1989, GENE, V85, P353, DOI 10.1016/0378-1119(89)90428-9; DURSTON AJ, 1976, NATURE, V263, P126, DOI 10.1038/263126a0; EARLY AE, 1987, GENE, V59, P99, DOI 10.1016/0378-1119(87)90270-8; EARLY AE, 1993, DEVELOPMENT, V118, P353; EARLY AE, 1989, NUCLEIC ACIDS RES, V17, P6473; ESCH RK, 1991, GENE DEV, V5, P9, DOI 10.1101/gad.5.1.9; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GOMER RH, 1987, SCIENCE, V237, P758, DOI 10.1126/science.3039657; GROSS JD, 1994, MICROBIOL REV, V58, P330, DOI 10.1128/MMBR.58.3.330-351.1994; HOWARD PK, 1992, CELL, V71, P637, DOI 10.1016/0092-8674(92)90597-6; INSALL R, 1992, EMBO J, V11, P2849, DOI 10.1002/j.1460-2075.1992.tb05352.x; JERMYN KA, 1991, DEVELOPMENT, V111, P779; JERMYN KA, 1989, NATURE, V340, P144, DOI 10.1038/340144a0; JERMYN KA, 1987, DEVELOPMENT, V100, P745; KAY RR, 1983, NATURE, V303, P242, DOI 10.1038/303242a0; KAY RR, 1993, P NATL ACAD SCI USA, V90, P487, DOI 10.1073/pnas.90.2.487; KOPACHIK W, 1983, CELL, V33, P397, DOI 10.1016/0092-8674(83)90421-X; KOPACHIK WJ, 1985, DIFFERENTIATION, V28, P209, DOI 10.1111/j.1432-0436.1985.tb00827.x; MAEDA Y, 1989, DIFFERENTIATION, V41, P169, DOI 10.1111/j.1432-0436.1989.tb00744.x; MAEDA Y, 1993, DEV GROWTH DIFFER, V35, P609; MATSUKUMA S, 1979, J EMBRYOL EXP MORPH, V50, P243; MCDONALD SA, 1986, DEV BIOL, V117, P546, DOI 10.1016/0012-1606(86)90322-2; MCDONALD SA, 1984, J CELL SCI, V66, P195; MCROBBIE SJ, 1988, DEVELOPMENT, V104, P275; MEE JD, 1986, BIOCHEM CELL BIOL, V64, P722, DOI 10.1139/o86-099; MEINHARDT H, 1983, DIFFERENTIATION, V24, P191, DOI 10.1111/j.1432-0436.1983.tb01319.x; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; MORRISON A, 1992, EXP CELL RES, V199, P383, DOI 10.1016/0014-4827(92)90449-I; NAYLER O, 1992, EUR J BIOCHEM, V208, P531, DOI 10.1111/j.1432-1033.1992.tb17217.x; OHMORI T, 1987, CELL DIFFER DEV, V22, P11, DOI 10.1016/0045-6039(87)90409-X; PEARS CJ, 1988, NUCLEIC ACIDS RES, V16, P8467, DOI 10.1093/nar/16.17.8467; RAPER KENNETH B., 1940, JOUR ELISHA MITCHELL SCI SOC, V56, P241; RUBIN J, 1975, J EMBRYOL EXP MORPH, V33, P227; SCHAAP P, 1986, DIFFERENTIATION, V33, P1, DOI 10.1111/j.1432-0436.1986.tb00404.x; SIEGERT F, 1992, P NATL ACAD SCI USA, V89, P6433, DOI 10.1073/pnas.89.14.6433; STERNFELD J, 1981, DIFFERENTIATION, V20, P10, DOI 10.1111/j.1432-0436.1981.tb01150.x; STERNFELD J, 1982, DEV BIOL, V93, P111, DOI 10.1016/0012-1606(82)90244-5; TAKEUCHI I, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P249; TAKEUCHI I, 1978, BOT MAG TOKYO, V1, P47; TOWN CD, 1976, NATURE, V262, P717, DOI 10.1038/262717a0; TRAYNOR D, 1992, P NATL ACAD SCI USA, V89, P8303, DOI 10.1073/pnas.89.17.8303; WANG M, 1985, DIFFERENTIATION, V30, P7, DOI 10.1111/j.1432-0436.1985.tb00506.x; WANG M, 1988, DEV BIOL, V125, P410, DOI 10.1016/0012-1606(88)90221-7; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WEEKS G, 1991, BIOCHEM CELL BIOL, V69, P608, DOI 10.1139/o91-090; WEIJER CJ, 1984, J CELL SCI, V70, P133; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9; WOLPERT L, 1971, CURR TOP DEV BIOL, V6, P183; ZIMMERMAN W, 1993, DEV BIOL, V160, P178, DOI 10.1006/dbio.1993.1296	59	123	124	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					91	99		10.1016/0092-8674(95)90237-6	http://dx.doi.org/10.1016/0092-8674(95)90237-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553878	Bronze			2022-12-28	WOS:A1995RY58300013
J	WHILE, AE				WHILE, AE			ETHICS COMMITTEES - IMPEDIMENTS TO RESEARCH OR GUARDIANS OF ETHICAL STANDARDS	BRITISH MEDICAL JOURNAL			English	Article											WHILE, AE (corresponding author), UNIV LONDON KINGS COLL,DEPT NURSING STUDIES,CORNWALL HOUSE,LONDON SE1 8WA,ENGLAND.							BENSON PR, 1989, SOC SCI MED, V29, P1, DOI 10.1016/0277-9536(89)90122-6; GILBERT C, 1989, BRIT MED J, V299, P1437, DOI 10.1136/bmj.299.6713.1437; NICHOLSEN RH, 1986, MED RES CHILDREN ETH; Oakley A., 1992, SOCIAL SUPPORT MOTHE; 1991, LOCAL ETHICS COMMITT, P5	5	33	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	1995	311	7006					661	661		10.1136/bmj.311.7006.661	http://dx.doi.org/10.1136/bmj.311.7006.661			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RU753	7549635	Green Published			2022-12-28	WOS:A1995RU75300019
J	HALL, CL; YANG, BH; YANG, XW; ZHANG, SW; TURLEY, M; SAMUEL, S; LANGE, LA; WANG, C; CURPEN, GD; SAVANI, RC; GREENBERG, AH; TURLEY, EA				HALL, CL; YANG, BH; YANG, XW; ZHANG, SW; TURLEY, M; SAMUEL, S; LANGE, LA; WANG, C; CURPEN, GD; SAVANI, RC; GREENBERG, AH; TURLEY, EA			OVEREXPRESSION OF THE HYALURONAN RECEPTOR RHAMM IS TRANSFORMING AND IS ALSO REQUIRED FOR H-RAS TRANSFORMATION	CELL			English	Article							CELL-MATRIX INTERACTIONS; DOMINANT NEGATIVE MUTATION; EXTRACELLULAR-MATRIX; FOCAL ADHESIONS; SIGNAL TRANSDUCTION; TISSUE INHIBITOR; BINDING PROTEINS; CARCINOMA-CELLS; GENE-EXPRESSION; GROWTH	Overexpression of the RHAMM gene by transfection into fibroblasts is transforming and causes spontaneous metastases in the lung. H-ras-transformed fibrosarcomas transfected with a dominant suppressor mutant of RHAMM exhibit a so-called revertant phenotype end are completely nontumorigenic and nonmetastatic. Conversely, fibroblasts stably expressing low levels of RHAMM as a result of antisense transfection are resistant to res transformation. Collectively, these results indicate that RHAMM acts downstream of res. The loss of functional RHAMM ablates signaling within focal adhesions, in particular changes in focal adhesion kinase phosphorylation, and as a result these focal adhesions are unable to turn over in response to hyaluronan. These results provide evidence of the oncogenic potential of a novel extracellular matrix receptor and establish a functional link between transformation by ras and signaling within focal adhesions that are required for transformation by this oncogene.	UNIV MANITOBA, DEPT PEDIAT, WINNIPEG, MB R3E 0V9, CANADA	University of Manitoba	HALL, CL (corresponding author), UNIV MANITOBA, MANITOBA INST CELL BIOL, WINNIPEG, MB R3E 0V9, CANADA.		Rashmin C. Savani, MBChB/AAG-2041-2021	Rashmin C. Savani, MBChB/0000-0002-9533-5422				ALEXANDER CM, 1992, J CELL BIOL, V118, P727, DOI 10.1083/jcb.118.3.727; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BEHREND EI, 1994, CANCER RES, V54, P832; BORSI L, 1992, INT J CANCER, V52, P688, DOI 10.1002/ijc.2910520504; BRAND T, 1993, J BIOL CHEM, V268, P11500; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CASTLE VP, 1993, J BIOL CHEM, V268, P2899; CHONG ASF, 1992, CELL IMMUNOL, V144, P69, DOI 10.1016/0008-8749(92)90226-F; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; ENTWISTLE J, 1995, IN PRESS GENE; EVANS SC, 1993, J CELL BIOL, V120, P1045, DOI 10.1083/jcb.120.4.1045; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; FRASER R, 1993, FASEB J, V6, P2397; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Gunthert U, 1993, Curr Top Microbiol Immunol, V184, P47; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; HIRO D, 1986, BIOCHEM BIOPH RES CO, V140, P715, DOI 10.1016/0006-291X(86)90790-4; HOARE K, 1993, CONNECT TISSUE RES, V30, P117, DOI 10.3109/03008209309041327; HOWLETT AR, 1993, EPITHELIAL CELL BIOL, V2, P79; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jones Peter Lloyd, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P137; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KARIKO K, 1993, CANCER RES, V53, P3109; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KHOKHA R, 1992, J NATL CANCER I, V84, P1017, DOI 10.1093/jnci/84.13.1017; KLEWES L, 1993, BIOCHEM J, V290, P791, DOI 10.1042/bj2900791; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; LIEBL EC, 1992, ONCOGENE, V7, P2417; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; RATNER S, 1992, INVAS METAST, V12, P82; RUOSLAHTI E, 1994, KIDNEY INT, V45, pS17; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; SAMUEL SK, 1993, J CELL BIOL, V123, P749, DOI 10.1083/jcb.123.3.749; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; SHAPIRO SD, 1993, BIOCHEMISTRY-US, V32, P4286, DOI 10.1021/bi00067a018; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; TURLEY E, 1987, JNCI-J NATL CANCER I, V78, P787; TURLEY EA, 1991, J CELL BIOL, V112, P1041, DOI 10.1083/jcb.112.5.1041; TURLEY EA, 1985, CANCER RES, V45, P5098; TURLEY EA, 1992, CANCER METAST REV, V11, P21, DOI 10.1007/BF00047600; VARNER JA, 1992, MOL BIOL CELL, V3, pA232; WEHRLEHALLER B, 1993, J CELL SCI, V106, P597; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WOODS A, 1988, COLLAGEN REL RES, V8, P155; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	62	251	267	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 14	1995	82	1					19	28		10.1016/0092-8674(95)90048-9	http://dx.doi.org/10.1016/0092-8674(95)90048-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7541721	Bronze			2022-12-28	WOS:A1995RK42400005
J	COHEN, J				COHEN, J			THE CULTURE OF CREDIT	SCIENCE			English	Article								Scientific ideals call for collaboration and sharing. But in today's competitive scientific enterprise, a tremendous premium is placed on individual credit, setting the stage for conflict.											0	13	13	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 23	1995	268	5218					1706	1711		10.1126/science.7540770	http://dx.doi.org/10.1126/science.7540770			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RE668	7540770				2022-12-28	WOS:A1995RE66800023
J	BOUDREAU, N; SYMPSON, CJ; WERB, Z; BISSELL, MJ				BOUDREAU, N; SYMPSON, CJ; WERB, Z; BISSELL, MJ			SUPPRESSION OF ICE AND APOPTOSIS IN MAMMARY EPITHELIAL-CELLS BY EXTRACELLULAR-MATRIX	SCIENCE			English	Article							DEATH GENE CED-3; INVOLUTION; ENZYME; DIFFERENTIATION; GLYCOPROTEINS; PROTEINASES; COLLAGENASE; INHIBITION; SECRETION; ENCODES	Apoptosis (programmed cell death) plays a major role in development and tissue regeneration. Basement membrane extracellular matrix (ECM), but not fibronectin or collagen, was shown to suppress apoptosis of mammary epithelial cells in tissue culture and in vivo. Apoptosis was induced by antibodies to beta(1) integrins or by overexpression of stromelysin-1, which degrades ECM. Expression of interleukin-1 beta converting enzyme (ICE) correlated with the loss of ECM, and inhibitors of ICE activity prevented apoptosis. These results suggest that ECM regulates apoptosis in mammary epithelial cells through an integrin-dependent negative regulation of ICE expression.	UNIV CALIF SAN FRANCISCO,RADIOBIOL & ENVIRONM HLTH LAB,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	BOUDREAU, N (corresponding author), UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV LIFE SCI,1 CYCLOTRON RD,BLDG 83,BERKELEY,CA 94720, USA.				NATIONAL CANCER INSTITUTE [R01CA057621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007106] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA057621, R01 CA057621-07, CA 57621] Funding Source: Medline; NIEHS NIH HHS [ES 07106, T32 ES007106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BOUDREAU N, UNPUB; DAMSKY CH, 1982, J CELL BIOCHEM, V18, P1, DOI 10.1002/jcb.1982.240180102; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GROBELNY D, 1992, BIOCHEMISTRY-US, V31, P7152, DOI 10.1021/bi00146a017; HENTGARTNER MO, 1994, CELL, V76, P665; KLEINMAN H, 1986, BIOCHEMISTRY-US, V26, P312; KORSMEYER SJ, 1992, CANCER SURV, V5, P105; KRAMER RH, 1985, J CELL PHYSIOL, V123, P1, DOI 10.1002/jcp.1041230102; LI LM, 1987, P NATL ACAD SCI USA, V84, P136; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; PARRY G, 1987, J CELL BIOL, V105, P2043, DOI 10.1083/jcb.105.5.2043; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; STRANGE R, 1992, DEVELOPMENT, V115, P49; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; TALHOUK RS, 1991, DEVELOPMENT, V112, P439; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TAUB M, 1990, P NATL ACAD SCI USA, V87, P4002, DOI 10.1073/pnas.87.10.4002; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	27	1095	1133	0	30	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 10	1995	267	5199					891	893		10.1126/science.7531366	http://dx.doi.org/10.1126/science.7531366			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7531366	Green Submitted, Green Accepted			2022-12-28	WOS:A1995QG20700060
J	WASSON, JH; REDA, DJ; BRUSKEWITZ, RC; ELINSON, J; KELLER, AM; HENDERSON, WG				WASSON, JH; REDA, DJ; BRUSKEWITZ, RC; ELINSON, J; KELLER, AM; HENDERSON, WG			A COMPARISON OF TRANSURETHRAL SURGERY WITH WATCHFUL WAITING FOR MODERATE SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANS-URETHRAL RESECTION; INDEX	Background. Transurethral resection of the prostate is the most common surgical treatment for benign prostatic hyperplasia. We conducted a multicenter randomized trial to compare this surgery with watchful waiting in men with moderate symptoms of benign prostatic hyperplasia. Methods. Of 800 men over the age of 54 years who were screened between July 1986 and July 1989, 556 (mean [+/-SD] age, 66+/-5 years) were studied (280 in the surgery group and 276 in the watchful-waiting group). Patients' symptoms and the degree to which they were bothered by urinary difficulties were measured with standardized questionnaires and medical evaluations. The primary outcome measure was treatment failure, which was defined as the occurrence of any of the following: death, repeated or intractable urinary retention, a residual urinary volume over 350 ml, the development of bladder calculus, new and persistent incontinence, a high symptom score, or a doubling of the serum creatinine concentration. Patients were followed for three years. Results. Of the men randomly assigned to the surgery group, 249 underwent surgery within two weeks after the assignment. Surgery was not associated with impotence or urinary incontinence. The average follow-up period was 2.8 years. In an intention-to-treat analysis, there were 23 treatment failures in the surgery group, as compared with 47 in the watchful-waiting group (relative risk, 0.48; 95 percent confidence interval, 0.30 to 0.77). Of the men assigned to the watchful-waiting group, 65 (24 percent) underwent surgery within three years after the assignment. Surgery was associated with improvement in symptoms and in scores for urinary difficulties and interference with activities of daily living (P < 0.001 for all comparisons). The outcomes of surgery were best for the men who were most bothered by urinary symptoms at base line. Conclusions. For men with moderate symptoms of benign prostatic hyperplasia, surgery is more effective than watchful waiting in reducing the rate of treatment failure and improving genitourinary symptoms. Watchful waiting is usually a safe alternative for men who are less bothered by urinary difficulty or who wish to delay surgery.			WASSON, JH (corresponding author), DEPT VET AFFAIRS MED & REG OFF CTR,WHITE RIVER JCT,VT 05009, USA.			, Domenic/0000-0003-1831-4270				BARRY MJ, 1988, JAMA-J AM MED ASSOC, V259, P3010, DOI 10.1001/jama.259.20.3010; BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; BARRY MJ, 1992, J UROLOGY, V148, P1558, DOI 10.1016/S0022-5347(17)36967-7; CHUTE CG, 1993, J UROLOGY, V150, P85, DOI 10.1016/S0022-5347(17)35405-8; GRAVERSEN PH, 1989, J UROLOGY, V141, P475, DOI 10.1016/S0022-5347(17)40864-0; LEPOR H, 1993, UROLOGY, V42, P483, DOI 10.1016/0090-4295(93)90258-C; LUYAO GL, 1994, UROLOGY, V44, P692, DOI 10.1016/S0090-4295(94)80208-4; MADSEN PO, 1983, BENIGN PROSTATIC HYP, P763; MCCONNELL JD, 1994, AHCPR940583 DEP HLTH; RITTMASTER RS, 1994, NEW ENGL J MED, V330, P120; ROOT MT, 1979, NEW ENGL J MED, V301, P52; Woolson R. F, 1987, STATISTICAL METHODS; 1992, VITAL HLTH STATIS 13, V113; 1990, SAS STAT USERS GUIDE; 1993, J UROLOGY, V150, P1696	15	443	456	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 12	1995	332	2					75	79		10.1056/NEJM199501123320202	http://dx.doi.org/10.1056/NEJM199501123320202			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA241	7527493				2022-12-28	WOS:A1995QA24100002
J	TSUCHIDA, T; ENSINI, M; MORTON, SB; BALDASSARE, M; EDLUND, T; JESSELL, TM; PFAFF, SL				TSUCHIDA, T; ENSINI, M; MORTON, SB; BALDASSARE, M; EDLUND, T; JESSELL, TM; PFAFF, SL			TOPOGRAPHIC ORGANIZATION OF EMBRYONIC MOTOR-NEURONS DEFINED BY EXPRESSION OF LIM HOMEOBOX GENES	CELL			English	Article							MOTONEURON PROJECTION PATTERNS; DIFFERENT SEGMENTAL LEVELS; CHICK HIND LIMB; PATHWAY SELECTION; NEURITE OUTGROWTH; PROTEIN ISL-1; SPINAL-CORD; LUMBOSACRAL LEVEL; PROXIMAL TISSUES; NERVOUS-SYSTEM	Motor neurons located at different positions in the embryonic spinal cord innervate distinct targets in the periphery, establishing a topographic neural map. The topographic organization of motor projections depends on the generation of subclasses of motor neurons that select specific paths to their targets. We have cloned a family of LIM homeobox genes in chick and show here that the combinatorial expression of four of these genes, Islet-1, Islet-2, Lim-1, and Lim-3, defines subclasses of motor neurons that segregate into columns in the spinal cord and select distinct axonal pathways. These genes are expressed prior to the formation of distinct motor axon pathways and before motor columns appear. Our results suggest that LIM homeobox genes contribute to the generation of motor neuron diversity and may confer subclasses of motor neurons with the ability to select specific axon pathways, thereby initiating the topographic organization of motor projections.	COLUMBIA UNIV,CTR NEUROBIOL & BEHAV,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; UMEA UNIV,DEPT MICROBIOL,S-90187 UMEA,SWEDEN	Columbia University; Howard Hughes Medical Institute; Umea University					NIGMS NIH HHS [5T32GMO7367] Funding Source: Medline; NINDS NIH HHS [NS33245] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007367] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033245] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARNES D, 1994, DEV BIOL, V161, P168; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; DUBEY PN, 1968, J ANAT, V102, P407; EISEN JS, 1994, ANNU REV NEUROSCI, V17, P1; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FERGUSON BA, 1983, J NEUROSCI, V3, P1760; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; FUJII T, 1994, DEV DYNAM, V199, P73, DOI 10.1002/aja.1001990108; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GRAHAM A, 1991, DEVELOPMENT, V112, P255; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GUTMAN CR, 1993, BRAIN RES, V609, P129, DOI 10.1016/0006-8993(93)90865-K; HAMBURGER V, 1948, J COMP NEUROL, V88, P221, DOI 10.1002/cne.900880204; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOLLYDAY M, 1977, BRAIN RES, V132, P197, DOI 10.1016/0006-8993(77)90416-4; HOLLYDAY M, 1980, J COMP NEUROL, V194, P143, DOI 10.1002/cne.901940108; HOLLYDAY M, 1990, J COMP NEUROL, V302, P575, DOI 10.1002/cne.903020313; Huber JF, 1936, J COMP NEUROL, V65, P43, DOI 10.1002/cne.900650109; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; HUNT RK, 1990, BRAIN CIRCUITS FUNCT, P19; INOUE A, 1994, DEV DYNAM, V199, P1, DOI 10.1002/aja.1001990102; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KORZH V, 1993, DEVELOPMENT, V118, P417; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P19, DOI 10.1098/rspb.1981.0080; LANCEJONES C, 1980, J PHYSIOL-LONDON, V302, P559; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P1, DOI 10.1098/rspb.1981.0079; LANCEJONES C, 1980, J PHYSIOL-LONDON, V302, P581; LANCEJONES C, 1991, DEV BIOL, V143, P93, DOI 10.1016/0012-1606(91)90057-A; LANDMESSER L, 1978, J PHYSIOL-LONDON, V284, P371, DOI 10.1113/jphysiol.1978.sp012545; LANDMESSER L, 1978, J PHYSIOL-LONDON, V284, P391, DOI 10.1113/jphysiol.1978.sp012546; LANDMESSER LT, 1992, NERVE GROWTH CONE, P373; LANGMAN J, 1970, J COMP NEUROL, V138, P419, DOI 10.1002/cne.901380403; LASKOWSKI MB, 1987, J NEUROSCI, V7, P252; LEVIMONTALCINI R, 1950, J MORPHOL, V86, P253, DOI 10.1002/jmor.1050860203; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; LICHTMAN JW, 1980, J PHYSIOL-LONDON, V298, P285, DOI 10.1113/jphysiol.1980.sp013081; PHELAN KA, 1990, J NEUROSCI, V10, P2699; PRASAD A, 1991, J COMP NEUROL, V307, P237, DOI 10.1002/cne.903070207; PUELLES L, 1993, TRENDS NEUROSCI, V16, P472, DOI 10.1016/0166-2236(93)90080-6; Sanes J R, 1993, Curr Opin Neurobiol, V3, P67, DOI 10.1016/0959-4388(93)90037-Y; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STRAZNICKY C, 1983, ANAT EMBRYOL, V166, P209, DOI 10.1007/BF00305083; SULLIVAN G. E., 1962, AUSTRALIAN JOUR ZOOL, V10, P458, DOI 10.1071/ZO9620458; TAIRA M, 1993, DEV BIOL, V159, P245, DOI 10.1006/dbio.1993.1237; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TOSNEY KW, 1987, DEV BIOL, V122, P540, DOI 10.1016/0012-1606(87)90318-6; TOSNEY KW, 1985, DEV BIOL, V109, P193, DOI 10.1016/0012-1606(85)90360-4; TOSNEY KW, 1985, J NEUROSCI, V5, P2336; TOSNEY KW, 1988, DEV BIOL, V127, P266, DOI 10.1016/0012-1606(88)90314-4; TOSNEY KW, 1984, J NEUROSCI, V4, P2518; TOSNEY KW, 1991, BIOESSAYS, V13, P17; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; Wachtler F., 1992, SEMIN DEV BIOL, V3, P217; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WHITELAW V, 1983, J NEUROSCI, V3, P1226; WHITELAW V, 1983, J NEUROSCI, V3, P1199; WIGSTON DJ, 1985, J NEUROSCI, V5, P1208; WIGSTON DJ, 1982, NATURE, V299, P464, DOI 10.1038/299464a0; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YIP JW, 1990, J NEUROSCI, V10, P2476	65	859	868	0	17	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					957	970		10.1016/0092-8674(94)90027-2	http://dx.doi.org/10.1016/0092-8674(94)90027-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	7528105				2022-12-28	WOS:A1994PY08600006
J	SINGER, MS; GOTTSCHLING, DE				SINGER, MS; GOTTSCHLING, DE			TLC1 - TEMPLATE RNA COMPONENT OF SACCHAROMYCES-CEREVISIAE TELOMERASE	SCIENCE			English	Article							TERMINAL TRANSFERASE-ACTIVITY; HUMAN FIBROBLASTS; ESCHERICHIA-COLI; YEAST TELOMERE; DNA; TETRAHYMENA; REPEATS; SENESCENCE; SEQUENCES; INVIVO	Telomeres, the natural ends of linear eukaryotic chromosomes, are essential for chromosome stability. Because oi the nature of DNA replication, telomeres require a specialized mechanism to ensure their complete duplication. Telomeres are also capable of silencing the transcription of genes that are located near them. In order to identify genes in the budding yeast Saccharomyces cerevisiae that are important for telomere function, a screen was conducted for genes that, when expressed in high amounts, would suppress telomeric silencing. This screen lead to the identification of the gene TLC1 (telomerase component 1). TLC1 encodes the template RNA of telomerase, a ribonucleoprotein required for telomere replication in a variety of organisms. The discovery of TLC1 confirms the existence of telomerase in S. cerevisiae and may facilitate both the analysis of this enzyme and an understanding of telomere structure and function.			SINGER, MS (corresponding author), UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,920 E 58TH ST,CHICAGO,IL 60637, USA.				NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043893] Funding Source: NIH RePORTER; NCI NIH HHS [CA 14599] Funding Source: Medline; NIGMS NIH HHS [GM43893] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; ARES M, 1986, CELL, V47, P49, DOI 10.1016/0092-8674(86)90365-X; AUTEXIER C, 1984, GENE DEV, V8, P563; BEELER T, 1994, J BIOL CHEM, V269, P7279; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLACKBURN EH, 1993, RNA WORLD, P557; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1994, CURR OPIN GENET DEV, V4, P203, DOI 10.1016/S0959-437X(05)80046-2; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Henderson ER, 1991, CURR OPIN GENET DEV, V1, P538, DOI 10.1016/S0959-437X(05)80205-9; HENIKOFF S, 1987, GENETICS, V117, P711; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; KRAMER KM, 1993, GENE DEV, V7, P2345, DOI 10.1101/gad.7.12a.2345; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; LINDSEY J, 1991, MUTAT RES, V256, P45, DOI 10.1016/0921-8734(91)90032-7; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; LINK AJ, 1991, GENETICS, V127, P681; LOUIS EJ, 1990, GENETICS, V124, P533; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MAHONEY DJ, 1989, MOL CELL BIOL, V9, P4621, DOI 10.1128/MCB.9.11.4621; MANTELL LL, 1994, EMBO J, V13, P3211, DOI 10.1002/j.1460-2075.1994.tb06620.x; MARSHALL M, 1987, MOL CELL BIOL, V7, P4441, DOI 10.1128/MCB.7.12.4441; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; PRICE C M, 1992, Current Opinion in Cell Biology, V4, P379, DOI 10.1016/0955-0674(92)90002-T; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RENAULD H, UNPUB; ROMAN H, 1956, COLD SPRING HARB SYM, V21, P175, DOI 10.1101/SQB.1956.021.01.015; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; ROSE M, 1984, GENE, V29, P113, DOI 10.1016/0378-1119(84)90172-0; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P49511; SHAY JW, 1993, ONCOGENE, V8, P1407; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER MS, UNPUB; TENDAM E, 1991, NUCLEIC ACIDS RES, V19, P6951; VAZIRI H, 1993, AM J HUM GENET, V52, P661; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WILLIAMSON VM, 1987, MOL GEN GENET, V209, P374, DOI 10.1007/BF00329668; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	65	561	594	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 21	1994	266	5184					404	409		10.1126/science.7545955	http://dx.doi.org/10.1126/science.7545955			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7545955				2022-12-28	WOS:A1994PN27200025
J	BERRY, GT; NISSIM, I; LIN, ZP; MAZUR, AT; GIBSON, JB; SEGAL, S				BERRY, GT; NISSIM, I; LIN, ZP; MAZUR, AT; GIBSON, JB; SEGAL, S			ENDOGENOUS SYNTHESIS OF GALACTOSE IN NORMAL MEN AND PATIENTS WITH HEREDITARY GALACTOSEMIA	LANCET			English	Note							VEGETABLES; FRUITS	Despite restricted ingestion of lactose, patients with galactose-1-phosphate uridyltransferase deficiency have raised concentrations of galactose metabolites in blood and urine. Endogenous production of galactose may underlie this phenomenon. Using isotopically labelled galactose in a continuous intravenous infusion, we employed the steady-state flux method to calculate endogenous galactose production rate in three normal men and three patients with classic galactosaemia. We found that galactosaemic patients and normal subjects synthesise gram quantities of galactose per day. The rate of synthesis ranged from 0.53-1.05 mg/kg per h. Endogenous production of galactose may be an important factor in the pathogenesis of the complications of the brain and ovary, and could explain the persistent elevation of galactose metabolites in patients despite dietary restriction of galactose.			BERRY, GT (corresponding author), UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT PEDIAT,DIV BIOCHEM DEV & MOLEC DIS,PHILADELPHIA,PA 19104, USA.			Berry, Gerard/0000-0001-5299-3313	NCRR NIH HHS [MO1-RR-00240] Funding Source: Medline; NICHD NIH HHS [P01-HD-29847] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD029847] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000240] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BERRY GT, 1993, J INHERIT METAB DIS, V16, P91, DOI 10.1007/BF00711320; Elsas LJ, 1993, INT PEDIATR, V8, P101; Gitzelmann R, 1975, NORMAL PATHOLOGICAL, P25; GROSS KC, 1991, J INHERIT METAB DIS, V14, P253, DOI 10.1007/BF01800599; HOLTON JB, 1994, LANCET, V344, P1242, DOI 10.1016/S0140-6736(94)90745-5; SCHWEITZER S, 1993, EUR J PEDIATR, V152, P36, DOI 10.1007/BF02072514; Segal S, 1995, METABOLIC MOL BASES, P967; WAGGONER DD, 1990, J INHERIT METAB DIS, V13, P802, DOI 10.1007/BF01800204; WIECKO J, 1976, J AM CHEM SOC, V98, P7631, DOI 10.1021/ja00440a030; YUDKOFF M, 1995, CLIN PERINATOL, V22, P97	10	112	115	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1073	1074		10.1016/S0140-6736(95)91745-4	http://dx.doi.org/10.1016/S0140-6736(95)91745-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564790	hybrid			2022-12-28	WOS:A1995TA69700014
J	STUDITSKY, VM; CLARK, DJ; FELSENFELD, G				STUDITSKY, VM; CLARK, DJ; FELSENFELD, G			OVERCOMING A NUCLEOSOMAL BARRIER TO TRANSCRIPTION	CELL			English	Article							RNA-POLYMERASE-II; ELONGATION COMPLEXES; HISTONE ACETYLATION; CHROMATIN STRUCTURE; BACTERIOPHAGE-T7; INITIATION; INVITRO; DNA; INHIBIT; GENES	We have studied the kinetics of transcription through a nucleosome core. RNA polymerase transcribes the first similar to 25 bp of nucleosomal DNA rapidly, but then hits a barrier and continues slowly to the nucleosomal dyad region. Here, the barrier disappears and the transcript is completed at a rapid rate, as if on free DNA, indicating that histone octamer transfer is completed as polymerase reaches the dyad, If DNA behind the polymerase is removed during transcription, the barrier does not appear until the polymerase has penetrated up to 15 bp farther into the nucleosome. On a longer template, the barrier is almost eliminated. We have shown previously that the octamer is transferred around the transcribing polymerase via an intermediate containing an intranucleosomal DNA loop, Our results exclude the possibility that polymerase has difficulty breaking histone-DNA contacts and suggest instead that polymerase pauses because it has difficulty transcribing DNA in the loop.	NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Studitsky, Vasily/A-9382-2014					ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; AXELROD VD, 1985, BIOCHEMISTRY-US, V24, P5716, DOI 10.1021/bi00342a005; BJORKROTH B, 1988, CHROMOSOMA, V96, P333, DOI 10.1007/BF00330699; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DEBERNARDIN W, 1986, J MOL BIOL, V191, P469, DOI 10.1016/0022-2836(86)90142-7; DING HF, 1994, SCIENCE, V265, P796, DOI 10.1126/science.8047885; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; JORGENSEN ED, 1991, J BIOL CHEM, V266, P645; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KNEZETIC JA, 1988, MOL CELL BIOL, V8, P3114, DOI 10.1128/MCB.8.8.3114; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LORCH Y, 1988, CELL, V55, P203; LOSA R, 1987, CELL, V50, P801, DOI 10.1016/0092-8674(87)90338-2; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MCKNIGHT SL, 1979, CELL, V7, P551; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; MORSE RH, 1992, TRENDS BIOCHEM SCI, V17, P23, DOI 10.1016/0968-0004(92)90422-6; ODONOHUE MF, 1994, NUCLEIC ACIDS RES, V22, P937, DOI 10.1093/nar/22.6.937; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; POSTNIKOV YV, 1991, NUCLEIC ACIDS RES, V19, P717, DOI 10.1093/nar/19.4.717; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; RICHMOND TJ, 1993, COLD SPRING HARB SYM, V58, P265, DOI 10.1101/SQB.1993.058.01.031; SASTRY SS, 1991, J MOL BIOL, V221, P1091, DOI 10.1016/0022-2836(91)90921-R; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; TRAVERS AA, 1994, BIOESSAYS, V16, P657, DOI 10.1002/bies.950160911; TURNER BM, 1991, J CELL SCI, V99, P13; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; WASYLYK B, 1979, EUR J BIOCHEM, V98, P317, DOI 10.1111/j.1432-1033.1979.tb13191.x; WILLIAMSON P, 1978, BIOCHEMISTRY-US, V26, P5695; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	43	128	133	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					19	27		10.1016/0092-8674(95)90230-9	http://dx.doi.org/10.1016/0092-8674(95)90230-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553869	Bronze			2022-12-28	WOS:A1995RY58300006
J	UNANUE, ER				UNANUE, ER			THE CONCEPT OF ANTIGEN-PROCESSING AND PRESENTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							T-CELL; LYMPHOCYTES-T; IDENTIFICATION; MACROPHAGES; LYSOZYME; PEPTIDES; BINDING		WASHINGTON UNIV,SCH MED,CTR IMMUNOL,ST LOUIS,MO 63110	Washington University (WUSTL)	UNANUE, ER (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,660 S EUCLID ST,CAMPUS BOX 8118,ST LOUIS,MO 63110, USA.							ALLEN PM, 1984, P NATL ACAD SCI-BIOL, V81, P2489, DOI 10.1073/pnas.81.8.2489; ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; BABBITT BP, 1986, P NATL ACAD SCI USA, V83, P4509, DOI 10.1073/pnas.83.12.4509; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BENACERRAF B, 1967, COLD SPRING HARB SYM, V32, P569, DOI 10.1101/SQB.1967.032.01.069; BUUS S, 1991, SCIENCE, V235, P1353; CALDERON J, 1975, NATURE, V253, P359, DOI 10.1038/253359a0; KATZ DH, 1973, J EXP MED, V137, P1405, DOI 10.1084/jem.137.6.1405; LORENZ RG, 1988, P NATL ACAD SCI USA, V85, P5220, DOI 10.1073/pnas.85.14.5220; MCDEVITT HO, 1969, SCIENCE, V163, P1207, DOI 10.1126/science.163.3872.1207; NELSON CA, 1992, P NATL ACAD SCI USA, V89, P7380, DOI 10.1073/pnas.89.16.7380; ROSENTHA.AS, 1973, J EXP MED, V138, P1194, DOI 10.1084/jem.138.5.1194; Schwartz R., 1984, FUNDAMENTAL IMMUNOLO, P379; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; UNANUE ER, 1968, IMMUNOLOGY, V15, P287; UNANUE ER, 1981, ADV IMMUNOL, V31, P1, DOI 10.1016/S0065-2776(08)60919-0; ZIEGLER K, 1981, J IMMUNOL, V127, P1869; ZIEGLER K, 1982, P NATL ACAD SCI USA, V78, P175; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	19	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1071	1073		10.1001/jama.274.13.1071	http://dx.doi.org/10.1001/jama.274.13.1071			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX108	7563463				2022-12-28	WOS:A1995RX10800035
J	CUI, KH; HAAN, EA; WANG, LJ; MATTHEWS, CD				CUI, KH; HAAN, EA; WANG, LJ; MATTHEWS, CD			OPTIMAL POLYMERASE CHAIN-REACTION AMPLIFICATION FOR PREIMPLANTATION DIAGNOSIS IN CYSTIC-FIBROSIS (DELTA-F508)	BRITISH MEDICAL JOURNAL			English	Article							PRENATAL SEX DETERMINATION; GENETIC DIAGNOSIS; DNA AMPLIFICATION; EMBRYO BIOPSY; SINGLE CELLS; IDENTIFICATION; PRECONCEPTION; RELIABILITY; CHROMOSOME; MUTATIONS	Objective-To evaluate direct polymerase chain reaction amplification of mutation on single embryo cells for the routine preimplantation diagnosis of cystic fibrosis. Design-Direct polymerase chain reaction amplification of mutation was performed to identify the cystic fibrosis Delta F508 mutation in human blood DNA, single lymphocytes, embryos, and embryo cells obtained by biopsy. Preimplantation diagnosis was performed for a couple who were heterozygous carriers of the Delta F508 mutation. Setting-Laboratory for preimplantation diagnosis in a reproductive medicine unit. Main outcome measure-Correct diagnosis of homozygous normal, heterozygous, and homozygous abnormal DNA of the cystic fibrosis Delta F508 mutation. Results-45 blood samples (18 homozygous normal, 17 heterozygous, and 10 homozygous abnormal) and 204 single lymphocytes from known sources showed 100% amplification and were diagnosed correctly. 17 human embryos and 52 normal nucleated embryo cells obtained by single cell embryo biopsy also showed 100% amplification. After a miscarriage of the initial pregnancy (diagnosed at preimplantation to be homozygous normal) in the heterozygous carrier couple, fetal tissue was confirmed to be homozygous normal. Conclusion-Direct polymerase chain reaction amplification of mutation is a simple, fast, reliable test for the common cystic fibrosis mutation (Delta F508) in blood DNA and single cells and should be applicable to routine programmes of general screening, maternal blood examination, and preimplantation diagnosis.	WOMENS & CHILDRENS HOSP,DEPT MED GENET,ADELAIDE,SA 5006,AUSTRALIA	Womens & Childrens Hospital Australia	CUI, KH (corresponding author), UNIV ADELAIDE,QUEEN ELIZABETH HOSP,DEPT OBSTET & GYNAECOL,ADELAIDE,SA 5011,AUSTRALIA.							Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CIU KH, 1994, LANCET, V343, P79; COUTELLE C, 1989, BRIT MED J, V299, P22, DOI 10.1136/bmj.299.6690.22; CUI KH, 1993, HUM REPROD, V8, P621, DOI 10.1093/oxfordjournals.humrep.a138107; CUI KH, 1993, THSIS U ADELAIDE, P1; CUI KJH, 1994, 13TH P ANN SCI M FER; GRIFO JA, 1992, JAMA-J AM MED ASSOC, V268, P727, DOI 10.1001/jama.268.6.727; HANDYSIDE AH, 1989, LANCET, V1, P347; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; HANDYSIDE AH, 1992, NEW ENGL J MED, V327, P905, DOI 10.1056/NEJM199209243271301; HARRIS A, 1992, BRIT MED BULL, V48, P738, DOI 10.1093/oxfordjournals.bmb.a072575; JARMULOWICZ M, 1989, LANCET, V1, P547; Kawasaki E.S., 1990, PCR PROTOCOLS GUIDE, P146; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; LESKO J, 1991, AM J HUM GENET, V49, P223; LO YMD, 1989, LANCET, V2, P1363; MEYERS RM, 1985, SCIENCE, V230, P1242; MYERS RM, 1985, NATURE, V313, P495, DOI 10.1038/313495a0; NAKAGOME Y, 1990, LANCET, V335, P291, DOI 10.1016/0140-6736(90)90109-I; PICKERING SJ, 1992, HUM REPROD, V7, P630, DOI 10.1093/oxfordjournals.humrep.a137710; ROMMENS J, 1990, AM J HUM GENET, V46, P395; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SHENK TE, 1975, P NATL ACAD SCI USA, V72, P989, DOI 10.1073/pnas.72.3.989; SIMPSON JL, 1992, NEW ENGL J MED, V327, P951, DOI 10.1056/NEJM199209243271309; STROM CM, 1991, J IN VITRO FERTIL EM, V8, P225, DOI 10.1007/BF01130810; STROM CM, 1990, LANCET, V336, P306, DOI 10.1016/0140-6736(90)91835-X; STROM CM, 1991, PREIMPLANTATION GENETICS, P131; TROUNSON AL, 1992, HUM REPROD, V7, P583; VERLINSKY Y, 1992, PRENATAL DIAG, V12, P103, DOI 10.1002/pd.1970120205; WINSTON RML, 1991, HUM REPROD, V6, P281	30	10	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					536	540		10.1136/bmj.311.7004.536	http://dx.doi.org/10.1136/bmj.311.7004.536			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR737	7545043	Green Published			2022-12-28	WOS:A1995RR73700017
J	ALAWQATI, Q				ALAWQATI, Q			REGULATION OF ION CHANNELS BY ABC TRANSPORTERS THAT SECRETE ATP	SCIENCE			English	Editorial Material							TRANSMEMBRANE CONDUCTANCE REGULATOR; DEPENDENT PROTEIN-KINASE; AIRWAY EPITHELIAL-CELLS; CYSTIC-FIBROSIS; CHLORIDE CHANNELS; EXTRACELLULAR ATP; CL CHANNELS; EXPRESSION; ACTIVATION; CLONING				ALAWQATI, Q (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,630 W 168TH ST,NEW YORK,NY 10032, USA.		Al-Awqati, Qais/B-2465-2009					ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; BAER CE, 1992, CELL, V68, P809; CANTIELLO HF, 1990, J BIOL CHEM, V265, P21624; CLAPHAM DE, 1994, ANNU REV NEUROSCI, V17, P441; CLARKE LL, 1992, AM J PHYSIOL, V263, pC348, DOI 10.1152/ajpcell.1992.263.2.C348; DRUMM ML, 1990, CELL, V62, P1277; EGAN F, 1992, NATURE, V338, P581; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HASSESSIAN H, 1993, BRIT J PHARMACOL, V109, P466, DOI 10.1111/j.1476-5381.1993.tb13592.x; HEAURTEAUX C, 1995, P NATL ACAD SCI USA, V92, P4666; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; KARTNER N, 1990, CELL, V64, P681; KIRSCH GE, 1990, AM J PHYSIOL, V259, pH820, DOI 10.1152/ajpheart.1990.259.3.H820; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; LARSSON O, 1993, J PHYSIOL-LONDON, V463, P349, DOI 10.1113/jphysiol.1993.sp019598; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; LI M, 1986, NATURE, V331, P358; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; REISIN IL, 1994, J BIOL CHEM, V269, P20584; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SHEPPARD DN, 1992, J GEN PHYSIOL, V100, P573, DOI 10.1085/jgp.100.4.573; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WANG XY, 1994, CLIN EXP PHARMACOL P, V21, P101, DOI 10.1111/j.1440-1681.1994.tb02475.x; WELSH MJ, 1986, NATURE, V322, P467, DOI 10.1038/322467a0; WILLUMSEN NJ, 1991, AM J PHYSIOL, V261, pC319, DOI 10.1152/ajpcell.1991.261.2.C319	38	161	164	1	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					805	806		10.1126/science.7543697	http://dx.doi.org/10.1126/science.7543697			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7543697				2022-12-28	WOS:A1995RN65000035
J	WEI, XQ; CHARLES, IG; SMITH, A; URE, J; FENG, CJ; HUANG, FP; XU, DM; MULLER, W; MONCADA, S; LIEW, FY				WEI, XQ; CHARLES, IG; SMITH, A; URE, J; FENG, CJ; HUANG, FP; XU, DM; MULLER, W; MONCADA, S; LIEW, FY			ALTERED IMMUNE-RESPONSES IN MICE LACKING INDUCIBLE NITRIC-OXIDE SYNTHASE	NATURE			English	Article							L-ARGININE; INFECTION; CYTOKINE	NITRIC oxide (NO) is important in many biological functions(1-5). It is generated from L-arginine by the enzyme NO synthase (NOS), The cytokine-inducible NOS (iNOS) is activated by several immunological stimuli, leading to the production of large quantities of NO which can be cytotoxic(6). To define the biological role of iNOS further, we generated iNOS mutant mice. These are viable, fertile and without evident histopathological abnormalities, However, in contrast to wild-type and heterozygous mice, which are highly resistant to the protozoa parasite Leishmania major infection, mutant mice are uniformly susceptible, The infected mutant mice developed a significantly stronger Th1 type of immune response than the wild-type or heterozygous mice, The mutant mice showed reduced nonspecific inflammatory response to carrageenin, and were resistant to lipopolysaccharide-induced mortality.	UNIV GLASGOW, DEPT IMMUNOL, GLASGOW G11 6NT, LANARK, SCOTLAND; WELLCOME RES LABS, BECKENHAM BR3 3BS, KENT, ENGLAND; UNIV EDINBURGH, CTR GENOME RES, GENE TARGETING LAB, EDINBURGH EH9 3JQ, MIDLOTHIAN, SCOTLAND; UNIV COLOGNE, INST GENET, D-50931 COLOGNE, GERMANY	University of Glasgow; GlaxoSmithKline; Wellcome Research Laboratories; University of Edinburgh; University of Cologne			Xu, Damo/A-8212-2011; Muller, Werner/B-9044-2008	Muller, Werner/0000-0002-1297-9725; Smith, Austin/0000-0002-3029-4682	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; DEMARIA R, 1994, J EXP MED, V180, P1999, DOI 10.1084/jem.180.5.1999; EFRON DT, 1991, SURGERY, V110, P327; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GREEN SJ, 1993, CURR OPIN INFECT DIS, V6, P384; HIBBS JB, 1990, INT CONGR SER, V897, P189; JAMES SL, 1990, PARASITOL TODAY, V6, P303, DOI 10.1016/0169-4758(90)90261-2; JENKINS DC, IN PRESS P NATN ACAD; LIEW FY, 1991, IMMUNOL TODAY, pA17; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MORRALAYI MD, 1994, INT IMMUN, V6, P931; NATHAN C, 1994, J BIOL CHEM, V269, P13725; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; TAYLORROBINSON AW, 1993, SCIENCE, V260, P1931, DOI 10.1126/science.8100366; TAYLORROBINSON AW, 1994, EUR J IMMUNOL, V24, P980, DOI 10.1002/eji.1830240430; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; VOULDOUKIS I, IN PRESS P NATN ACAD; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; XU D, 1995, IMMUNOLOGY, V85, P1	21	1096	1136	3	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					408	411		10.1038/375408a0	http://dx.doi.org/10.1038/375408a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7539113				2022-12-28	WOS:A1995RB10100054
J	ROSENBERG, WMC; PRINCE, C; KAKLAMANIS, L; FOX, SB; JACKSON, DG; SIMMONS, DL; CHAPMAN, RW; TROWELL, JM; JEWELL, DP; BELL, JI				ROSENBERG, WMC; PRINCE, C; KAKLAMANIS, L; FOX, SB; JACKSON, DG; SIMMONS, DL; CHAPMAN, RW; TROWELL, JM; JEWELL, DP; BELL, JI			INCREASED EXPRESSION OF CD44V6 AND CD44V3 IN ULCERATIVE-COLITIS BUT NOT COLONIC CROHNS-DISEASE	LANCET			English	Article							LYMPHOCYTE; FAMILY	Immune mechanisms, possibly involving cell-surface molecules such as CD44, have been invoked to explain the pathogenesis of inflammatory bowel disease. We used monoclonal antibodies against epitopes encoded within the variable region of CD44 to investigate CD44 isoform expression in colon, small intestine, and liver in patients with various intestinal disorders and in controls. Biopsy samples from patients with ulcerative colitis showed significantly increased epithelial expression of CD44 isoforms containing the v6 and v3 epitopes, detected with antibodies 2F10 and 3G5, respectively. CD44v6 was detected on colonic crypt epithelial cells in 23 of 25 ulcerative colitis samples compared with 3 of 18 colonic Crohn's disease samples (p=3.0x10(-6); odds ratio 57.5 [95% CI 6.83-702]) and 3 of 52 controls (22 normal colon, 10 infective colitis, 2 radiation colitis, and 18 colonic Crohn's disease; p<1x10(-8); odds ratio 199 [25.5-2294]). No significant expression of CD44v6, CD44v3, or CD44v8/9 was found in samples of normal proximal colon from 4 patients with distal ulcerative colitis, whereas samples from the affected area showed staining for CD44v6 and CD44v3. No expression of CD44 variants was found in 15 samples of normal small intestine, 11 small-bowel pouchitis, 8 coeliac disease, 3 small-bowel Crohn's disease, 6 normal liver, 6 primary biliary cirrhosis, or 9 primary sclerosing cholangitis. The high intensity of CD44v6 and v3 epitope expression on crypt epithelial cells in ulcerative colitis suggests that CD44 isoforms may have an important role in ulcerative colitis. Their detection could have diagnostic potential in differentiating ulcerative colitis from other forms of colonic inflammation including Crohn's disease.	JOHN RADCLIFFE HOSP,GASTROENTEROL UNIT,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,DEPT CELLULAR SCI,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford; University of Oxford	ROSENBERG, WMC (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND.		Rosenberg, William/ABA-1071-2021; Fox, Stephen/G-9719-2016	Rosenberg, William/0000-0002-2732-2304; Fox, Stephen/0000-0002-7648-8896; , david/0000-0002-4133-9364				BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; FOX SB, 1994, CANCER RES, V54, P4539; GUNTHERT U, 1991, CELL, V65; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HEIDER KH, 1992, J CELL BIOL, V120, P623; HODGSON HJF, 1983, INFLAMM BOWEL DIS, P86; JACKSON DG, 1995, J CELL BIOL, V128, P673, DOI 10.1083/jcb.128.4.673; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; PODOLSKY DK, 1993, J CLIN INVEST, V92, P372, DOI 10.1172/JCI116575; SATSANGI J, 1994, EUR J GASTROEN HEPAT, V6, P413; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; WAKEFIELD AJ, 1989, LANCET, V2, P1057	19	76	79	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1205	1209		10.1016/S0140-6736(95)91991-0	http://dx.doi.org/10.1016/S0140-6736(95)91991-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7537840				2022-12-28	WOS:A1995QX86100009
J	MIYASHITA, EM; YANG, B; LAM, KMC; CRAWFORD, DH; THORLEYLAWSON, DA				MIYASHITA, EM; YANG, B; LAM, KMC; CRAWFORD, DH; THORLEYLAWSON, DA			A NOVEL FORM OF EPSTEIN-BARR-VIRUS LATENCY IN NORMAL B-CELLS IN-VIVO	CELL			English	Article							POLYMERASE CHAIN-REACTION; SPONTANEOUS OUTGROWTH; VIRAL LATENCY; DNA; INDIVIDUALS; LYMPHOCYTES; EXPRESSION; PHENOTYPE; ANTIGEN; INVITRO	We have developed a PCR assay that can detect a single Epstein-Barr virus (EBV) genome in the presence of 10(6) uninfected cells. Using this assay, we demonstrate that EBV persists, in the peripheral blood of all seropositive individuals tested, in CD19(+), CD23(-), and CD80 (B7)(-) B cells. We further show that the virus in these cells is latent, but readily reactivated to produce infectious immortalizing virus; therefore, these cells represent a true site of latent persistence. EBV was not significantly detected in monocytes or T cells. The frequency of infected cells in nine healthy donors varied from 23 to 625 per 10(7) B cells, but was relatively stable for each individual over the course of 2 years. We conclude that the EBV-infected cells in vivo are B cells with a nonactivated phenotype. This represents a novel form of latency in normal B cells.	TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1E 7HT,ENGLAND	Tufts University; University of London; London School of Hygiene & Tropical Medicine					NCI NIH HHS [CA 31893] Funding Source: Medline; NIAID NIH HHS [AI 18757] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031893, R37CA031893] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018757] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS A, 1979, EPSTEINBARR VIRUS, P156; AMBINDER RF, 1990, MOL CELL PROBE, V4, P397, DOI 10.1016/0890-8508(90)90030-4; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; COEN DMV, 1990, CURRENT PROTOCOLS MO; FREEDMAN AS, 1987, J IMMUNOL, V139, P3260; GRATAMA JW, 1988, P NATL ACAD SCI USA, V85, P8693, DOI 10.1073/pnas.85.22.8693; GREGORY CD, 1987, J IMMUNOL, V139, P313; HURLEY EA, 1988, J EXP MED, V168, P2059, DOI 10.1084/jem.168.6.2059; JONES JF, 1988, NEW ENGL J MED, V318, P733, DOI 10.1056/NEJM198803243181203; KHANNA R, 1992, J EXP MED, V176, P169, DOI 10.1084/jem.176.1.169; KIEFF E, 1990, VIROLOGY, P1889; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KLEIN G, 1994, CELL, V77, P791, DOI 10.1016/0092-8674(94)90125-2; KLEIN G, 1989, CELL, V58, P5, DOI 10.1016/0092-8674(89)90394-2; LAM KMC, 1991, LANCET, V337, P876, DOI 10.1016/0140-6736(91)90203-2; LEWIN N, 1987, INT J CANCER, V39, P472, DOI 10.1002/ijc.2910390411; MILLER G, 1990, VIROLOGY, P1921; RICKINSON AB, 1985, BRIT MED BULL, V41, P75, DOI 10.1093/oxfordjournals.bmb.a072030; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; SAITO I, 1989, J EXP MED, V169, P2191, DOI 10.1084/jem.169.6.2191; SCHLOSSMAN SF, 1994, IMMUNOL TODAY, V15, P98, DOI 10.1016/0167-5699(94)90149-X; SIXBEY JW, 1983, NATURE, V306, P480, DOI 10.1038/306480a0; SUGDEN B, 1979, J VIROL, V31, P590, DOI 10.1128/JVI.31.3.590-595.1979; TELENTI A, 1990, J CLIN MICROBIOL, V28, P2187, DOI 10.1128/JCM.28.10.2187-2190.1990; TEW JG, 1980, IMMUNOL REV, V53, P175; THOMAS JA, 1990, TRANSPLANTATION, V49, P944, DOI 10.1097/00007890-199005000-00022; THORLEYLAWSON DA, 1989, BIOCHIM BIOPHYS ACTA, V948, P263, DOI 10.1016/0304-419X(89)90002-4; WAGNER HJ, 1992, J CLIN MICROBIOL, V30, P2826, DOI 10.1128/JCM.30.11.2826-2829.1992; WYATT RT, 1992, J EXP MED, V175, P1575, DOI 10.1084/jem.175.6.1575; YAO QY, 1989, INT J CANCER, V43, P67, DOI 10.1002/ijc.2910430115; YAO QY, 1991, INT J CANCER, V48, P253, DOI 10.1002/ijc.2910480217; YAO QY, 1985, INT J CANCER, V35, P43, DOI 10.1002/ijc.2910350108; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1	33	273	281	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					593	601		10.1016/0092-8674(95)90513-8	http://dx.doi.org/10.1016/0092-8674(95)90513-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7532548	Bronze			2022-12-28	WOS:A1995QJ60200011
J	SUNTHORNTHEPVARAKUL, T; GOTTSCHALK, ME; HAYASHI, Y; REFETOFF, S				SUNTHORNTHEPVARAKUL, T; GOTTSCHALK, ME; HAYASHI, Y; REFETOFF, S			BRIEF REPORT - RESISTANCE TO THYROTROPIN CAUSED BY MUTATIONS IN THE THYROTROPIN-RECEPTOR GENE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							THYROID ADENOMAS; TSH-RECEPTOR; HORMONE; UNRESPONSIVENESS; AUTOANTIBODIES; EXPRESSION; DISEASE; BINDING; CLONING		UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PEDIAT, CHICAGO, IL 60637 USA; UNIV CHICAGO, JOSEPH P KENNEDY JR MENTAL RETARDAT RES CTR, CHICAGO, IL 60637 USA; LOYOLA UNIV, DEPT PEDIAT, CHICAGO, IL USA	University of Chicago; University of Chicago; University of Chicago; Loyola University Chicago			Refetoff, Samuel/ABB-1263-2021; Hayashi, Yoshitaka/I-6168-2014	Refetoff, Samuel/0000-0003-0164-8231; Hayashi, Yoshitaka/0000-0002-7557-4303	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015070, R37DK015070] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00055] Funding Source: Medline; NIDDK NIH HHS [DK-15070] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CODACCIONI JL, 1980, J CLIN ENDOCR METAB, V50, P932, DOI 10.1210/jcem-50-5-932; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JAMESON JL, 1989, MOL ENDOCRINOL, V3, P763, DOI 10.1210/mend-3-5-763; KOSUGI S, 1993, MOL ENDOCRINOL, V7, P1009, DOI 10.1210/me.7.8.1009; LEWIS GF, 1991, J CLIN ENDOCR METAB, V73, P843, DOI 10.1210/jcem-73-4-843; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; MEDEIROSNETO GA, 1979, ACTA ENDOCRINOL-COP, V92, P62, DOI 10.1530/acta.0.0920062; MIYAI K, 1980, THYROID RES, V7, P33; MORI T, 1991, BIOCHEM BIOPH RES CO, V178, P165, DOI 10.1016/0006-291X(91)91794-D; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; NAGAYAMA Y, 1992, ENDOCRINOLOGY, V131, P548, DOI 10.1210/en.131.2.548; NAGAYAMA Y, 1992, J CLIN ENDOCR METAB, V75, P1425, DOI 10.1210/jc.75.6.1425; NAGAYAMA Y, 1994, THYROID TODAY, V17, P1; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PORCELLINI A, 1994, J CLIN ENDOCR METAB, V79, P657, DOI 10.1210/jc.79.2.657; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; REFETOFF S, 1972, J NUCL MED, V13, P2; ROSENFELD RG, 1994, ENDOCR REV, V15, P369, DOI 10.1210/er.15.3.369; STANBURY JB, 1968, NEW ENGL J MED, V279, P1132, DOI 10.1056/NEJM196811212792103; SUNTHORNTHEPVARAKUL T, 1994, THYROID, V4, P147, DOI 10.1089/thy.1994.4.147; TAKAMATSU J, 1993, J CLIN ENDOCR METAB, V77, P1569, DOI 10.1210/jc.77.6.1569; TAKESHITA A, 1993, THYROID, V3, pT91; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; WEINSTEIN LS, 1993, CLIN BIOCHEM, V26, P333, DOI 10.1016/0009-9120(93)90109-J; WEISS RE, 1993, J CLIN INVEST, V91, P2408, DOI 10.1172/JCI116474	28	238	251	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 19	1995	332	3					155	160		10.1056/NEJM199501193320305	http://dx.doi.org/10.1056/NEJM199501193320305			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB160	7528344				2022-12-28	WOS:A1995QB16000005
J	WOHRL, BM; GEORGIADIS, MM; TELESNITSKY, A; HENDRICKSON, WA; LEGRICE, SFJ				WOHRL, BM; GEORGIADIS, MM; TELESNITSKY, A; HENDRICKSON, WA; LEGRICE, SFJ			FOOTPRINT ANALYSIS OF REPLICATING MURINE LEUKEMIA-VIRUS REVERSE-TRANSCRIPTASE	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; AIDS	Replication complexes that contained either murine leukemia virus reverse transcriptase (MLV RT) or a variant reverse transcriptase without a ribonuclease (RNase) H domain (Delta RH MLV RT) were visualized by enzymatic footprinting. Wild-type MLV RT protected template nucleotides +6 to -27, and primer nucleotides -1 to -26 of primers that had first been extended by one or four nucleotides. Although it catalyzed DNA synthesis, Delta RH MLV RT stably bound template-primer only under conditions of reduced ionic strength and protected the duplex portion only as far as position -15. Despite altered hydrolysis profiles, both enzymes covered primarily the template-primer duplex, contradicting recent predictions based on the structure of rat DNA polymerase beta.	CASE WESTERN RESERVE UNIV, SCH MED, DIV INFECT DIS, CLEVELAND, OH 44106 USA; RUTGERS STATE UNIV, DEPT CHEM, PISCATAWAY, NJ 08855 USA; RUTGERS STATE UNIV, WAKSMAN INST, PISCATAWAY, NJ 08855 USA; UNIV MICHIGAN, SCH MED, DEPT MICROBIOL & IMMUNOL, ANN ARBOR, MI 48109 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA	Case Western Reserve University; Rutgers State University New Brunswick; Rutgers State University New Brunswick; University of Michigan System; University of Michigan; Columbia University; Howard Hughes Medical Institute					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031147] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046623] Funding Source: NIH RePORTER; NCI NIH HHS [CA09021] Funding Source: Medline; NIAID NIH HHS [AI 31147] Funding Source: Medline; NIGMS NIH HHS [GM 46623] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; GEORGIADIS M, UNPUB; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; MURPHEYCORB M, 1986, NATURE, V321, P435, DOI 10.1038/321435a0; NAKAMURA H, 1991, NUCLEIC ACIDS RES, V19, P1817, DOI 10.1093/nar/19.8.1817; Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659; OLMSTED RA, 1989, P NATL ACAD SCI USA, V86, P2448, DOI 10.1073/pnas.86.7.2448; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; RAUSCH JS, UNPUB; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SKALKA AM, 1993, REVERSE TRANSCRIPTAS, P193; STEPHENS RM, 1986, SCIENCE, V231, P589, DOI 10.1126/science.3003905; TELESNITSKY A, 1993, P NATL ACAD SCI USA, V90, P1276, DOI 10.1073/pnas.90.4.1276; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WOHRL BM, 1994, J BIOL CHEM, V269, P8541; WOHRL BM, UNPUB	19	49	50	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 6	1995	267	5194					96	99		10.1126/science.7528942	http://dx.doi.org/10.1126/science.7528942			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA235	7528942				2022-12-28	WOS:A1995QA23500038
J	MANNICK, JB; ASANO, K; IZUMI, K; KIEFF, E; STAMLER, JS				MANNICK, JB; ASANO, K; IZUMI, K; KIEFF, E; STAMLER, JS			NITRIC-OXIDE PRODUCED BY HUMAN B-LYMPHOCYTES INHIBITS APOPTOSIS AND EPSTEIN-BARR-VIRUS REACTIVATION	CELL			English	Article							DNA-BINDING ACTIVITY; L-ARGININE; KAPPA-B; TYROSINE PHOSPHORYLATION; BURKITT-LYMPHOMA; ANTIMICROBIAL ACTIVITY; TRANSCRIPTION FACTOR; PHENYLARSINE OXIDE; NITROGEN-OXIDES; S-NITROSYLATION	Nitric oxide (NO) produced by murine macrophages is important in murine resistance to ectromelia virus, herpes simplex virus, and vaccinia virus infection. In contrast, NO production by human mononuclear cells has been difficult to demonstrate, and a role for NO in human responses to infection is uncertain. We report constitutive, low level, macrophage-type NO synthase (iNOS) expression in Epstein-Barr virus (EBV)-transformed human B lymphocytes and Burkitt's lymphoma cell lines. Immune NOS activity is involved in maintaining EBV latency through down-regulation of the expression of the immediate-early EBV transactivator Zta. NO also inhibits apoptosis in B lymphocyte cell lines. The effects of NO are largely independent of cGMP and influential on signaling pathways regulated by (sulfhydryl) redox status. These results suggest that NO plays a physiological role in human a cell biology by inhibiting programmed cell death and maintaining viral latency.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RESP,BOSTON,MA 02115; DUKE UNIV,MED CTR,DEPT MED,DIV RESP,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DIV CARDIOVASC MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Harvard University; Brigham & Women's Hospital; Duke University; Duke University; Duke University	MANNICK, JB (corresponding author), HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115, USA.			Stamler, Jonathan/0000-0002-6866-1572	NHLBI NIH HHS [HL52529, HL02582] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002582, R01HL052529] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALBINA JE, 1991, J SURG RES, V50, P403, DOI 10.1016/0022-4804(91)90210-D; ALFIERI C, 1991, VIROLOGY, V181, P595, DOI 10.1016/0042-6822(91)90893-G; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; CAMERON ML, 1990, AM REV RESPIR DIS, V142, P1313, DOI 10.1164/ajrccm/142.6_Pt_1.1313; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; CRAPO JD, 1994, J CLIN INVEST, V93, P2304, DOI 10.1172/JCI117233; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; DAIBATA M, 1990, J IMMUNOL, V144, P4788; DENIS M, 1991, J LEUKOCYTE BIOL, V49, P380, DOI 10.1002/jlb.49.4.380; DUNCAN DD, 1989, TOXICOL APPL PHARM, V100, P485, DOI 10.1016/0041-008X(89)90296-2; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FLEMINGTON E, 1990, J VIROL, V64, P1227, DOI 10.1128/JVI.64.3.1227-1232.1990; FREED BM, 1991, TOXICOL APPL PHARM, V107, P173, DOI 10.1016/0041-008X(91)90341-B; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GITSCJ DE, 1994, MOL CELL BIOL, V14, P1939; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; GRANGER DL, 1991, RES IMMUNOL, V142, P570, DOI 10.1016/0923-2494(91)90104-Q; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; GROSS SS, 1990, BIOCHEM BIOPH RES CO, V170, P96, DOI 10.1016/0006-291X(90)91245-N; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENLE W, 1968, J VIROL, V2, P182, DOI 10.1128/JVI.2.3.182-191.1968; HESTON L, 1982, NATURE, V295, P160, DOI 10.1038/295160a0; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HIBBS JB, 1991, RES IMMUNOL, V142, P565, DOI 10.1016/0923-2494(91)90103-P; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOFFMAN RA, 1990, J IMMUNOL, V145, P2220; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANNER J, 1992, LIPIDS, V27, P46, DOI 10.1007/BF02537058; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KIRK SJ, 1990, BIOCHEM BIOPH RES CO, V173, P660, DOI 10.1016/S0006-291X(05)80086-5; KISHISHITA M, 1984, VIROLOGY, V133, P363, DOI 10.1016/0042-6822(84)90402-1; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LANDER HM, 1993, J IMMUNOL, V151, P7182; LANDER HM, 1993, J IMMUNOL, V150, P1509; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LORSBACH RB, 1993, J BIOL CHEM, V268, P908; MANNICK JB, 1991, J VIROL, V65, P6826, DOI 10.1128/JVI.65.12.6826-6837.1991; MENEZES J, 1975, BIOMEDICINE, V22, P276; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; RABSON M, 1982, J VIROL, V44, P834, DOI 10.1128/JVI.44.3.834-844.1982; RADI R, 1991, J BIOL CHEM, V266, P4244; ROONEY C, 1988, P NATL ACAD SCI USA, V85, P9801, DOI 10.1073/pnas.85.24.9801; ROZSNYAY Z, 1993, IMMUNOL LETT, V37, P197, DOI 10.1016/0165-2478(93)90031-V; SANDSTROM PA, 1994, J LEUKOCYTE BIOL, V55, P221, DOI 10.1002/jlb.55.2.221; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SMITH CA, 1989, NATURE, V337, P161; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STAMLER JS, 1994, IN PRESS CURR TOPICS; TAKADA K, 1986, J VIROL, V57, P1016, DOI 10.1128/JVI.57.3.1016-1022.1986; TAKADA K, 1984, INT J CANCER, V33, P27, DOI 10.1002/ijc.2910330106; TAYLORROBINSON AW, 1994, EUR J IMMUNOL, V24, P980, DOI 10.1002/eji.1830240430; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; YOUNG LS, 1991, J VIROL, V65, P2868, DOI 10.1128/JVI.65.6.2868-2874.1991; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	78	457	472	2	21	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1137	1146		10.1016/0092-8674(94)90005-1	http://dx.doi.org/10.1016/0092-8674(94)90005-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	7528106				2022-12-28	WOS:A1994PZ86000005
J	BOAKES, J				BOAKES, J			FALSE MEMORY SYNDROME	LANCET			English	Editorial Material											BOAKES, J (corresponding author), UNIV LONDON ST GEORGES HOSP,NHS TRUST,PATHFINDER MENTAL HLTH SERV,DEPT PSYCHOTHERAPY,LONDON,ENGLAND.							Bass E, 1988, COURAGE HEAL GUIDE W; BRIERE J, 1993, J TRAUMA STRESS, V6, P21, DOI 10.1002/jts.2490060104; CECI SJ, 1993, PSYCHOL BULL, V113, P403, DOI 10.1037/0033-2909.113.3.403; HEDGES LE, 1994, ISSUES CHILD ABUSE A, V6, P1; HERMAN JL, 1987, PSYCHOANAL PSYCHOL, V4, P1, DOI DOI 10.1037/H0079126; Holmes D. S., 1990, REPRESSION DISSOCIAT, P85; LEVITT EE, 1995, INT J CLIN EXP HYP, V43, P14; LINDSAY DS, 1994, APPL COGNITIVE PSYCH, V8, P281, DOI 10.1002/acp.2350080403; LOFTUS EF, 1993, AM PSYCHOL, V48, P518, DOI 10.1037/0003-066X.48.5.518; LOFTUS EF, 1994, PSYCHOL WOMEN QUART, V18, P67, DOI 10.1111/j.1471-6402.1994.tb00297.x; OFSHE RJ, 1994, MAKING MONSTERS FALS, P305; POPE HG, 1995, PSYCHOL MED, V25, P121, DOI 10.1017/S0033291700028142; WILLIAMS LM, 1994, J CONSULT CLIN PSYCH, V62, P1167, DOI 10.1037//0022-006X.63.3.343; YAPKO M, 1994, SUGGESTIONS ABUSE	14	10	10	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1048	1049		10.1016/S0140-6736(95)91736-5	http://dx.doi.org/10.1016/S0140-6736(95)91736-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TA697	7564781				2022-12-28	WOS:A1995TA69700005
J	TFELTHANSEN, P; HENRY, P; MULDER, LJ; SCHELDEWAERT, RG; SCHOENEN, E; CHAZOT, G				TFELTHANSEN, P; HENRY, P; MULDER, LJ; SCHELDEWAERT, RG; SCHOENEN, E; CHAZOT, G			THE EFFECTIVENESS OF COMBINED ORAL LYSINE ACETYLSALICYLATE AND METOCLOPRAMIDE COMPARED WITH ORAL SUMATRIPTAN FOR MIGRAINE	LANCET			English	Article								Aspirin is commonly used to treat migraine attacks, although sumatriptan, a much more expensive treatment, is also effective. We compared a combination of lysine acetylsalicylate (equivalent to 900 mg aspirin) and 10 mg metoclopramide (LAS+MTC) with oral sumatriptan (100 mg) and placebo in 421 patients with migraine. LAS+MTC was as effective as sumatriptan with a decrease of headache from severe or moderate to mild or none of 57% and 53%, respectively, for the first migraine attack treated. Both treatments were better than placebo (success rate 24%, p<0.0001). LAS+MTC was significantly more effective in the treatment of nausea than sumatriptan (p<0.0001) and was better tolerated (adverse events in 18% and 28%, respectively, p<0.05). LAS+MTC is as effective as sumatriptan in the treatment of migraine attacks. It is also much cheaper.	PELLEGRIN TRIOPODE HOSP,BORDEAUX,FRANCE; IKAZIA HOSP,ROTTERDAM,NETHERLANDS; SYNTHELABO RES,LE PLESSIS ROBINS,FRANCE; CITADELLE HOSP,LIEGE,BELGIUM; NEUROL HOSP,LYON,FRANCE	CHU Bordeaux; Ikazia Hospital; Sanofi-Aventis; Sanofi France; CHU Lyon	TFELTHANSEN, P (corresponding author), BISPEBJERG HOSP,DK-2400 COPENHAGEN,DENMARK.							BROWN EG, 1991, EUR NEUROL, V31, P339, DOI 10.1159/000116762; CHABRIAT H, 1994, CEPHALALGIA, V14, P297, DOI 10.1046/j.1468-2982.1994.1404297.x; Headache Classification Committee of the International Headache Society, 1988, CEPHALALGIA S7, V8, P1; OTTERVANGER JP, 1995, CNS DRUGS, V3, P90, DOI 10.2165/00023210-199503020-00002; Simmons VE, 1994, REV CONTEMP PHARMACO, V5, P319; TFELTHANSEN P, 1993, CEPHALALGIA, V13, P238, DOI 10.1046/j.1468-2982.1993.1304238.x; VOLANS GN, 1974, BRIT MED J, V4, P265, DOI 10.1136/bmj.4.5939.265; VOLANS GN, 1975, BRIT J CLIN PHARMACO, V2, P57, DOI 10.1111/j.1365-2125.1975.tb00472.x; WILKINSON M, 1983, CEPHALALGIA, V3, P61, DOI 10.1046/j.1468-2982.1983.0301061.x; 1991, EUR NEUROL, V31, P314; 1992, EUR NEUROL, V32, P177	11	162	166	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					923	926		10.1016/S0140-6736(95)91554-0	http://dx.doi.org/10.1016/S0140-6736(95)91554-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564725				2022-12-28	WOS:A1995RY80800006
J	STROMINGER, JL; WILEY, DC				STROMINGER, JL; WILEY, DC			THE CLASS-I AND CLASS-II PROTEINS OF THE HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MOLECULES; ANTIGEN; PEPTIDE; HLA-A2		DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115; CHILDRENS HOSP,HOWARD HUGHES MED INST,DEPT MED,MOLEC MED LAB,BOSTON,MA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	STROMINGER, JL (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.							BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P513; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MADDEN DR, 1992, CURR OPIN STRUC BIOL, V2, P300; PLOEGH HL, 1981, CELL, V24, P287, DOI 10.1016/0092-8674(81)90318-4; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Urban R G, 1993, Chem Immunol, V57, P197; WUCHERPFENNIG KW, 1995, J EXP MED, V181, P1597, DOI 10.1084/jem.181.5.1597; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; WUCHERPFENNIG KW, IN PRESS P NATL ACAD	16	9	10	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1074	1076		10.1001/jama.274.13.1074	http://dx.doi.org/10.1001/jama.274.13.1074			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX108	7563464				2022-12-28	WOS:A1995RX10800036
J	AITTOMAKI, K; LUCENA, JLD; PAKARINEN, P; SISTONEN, P; TAPANAINEN, J; GROMOLL, J; KASKIKARI, R; SANKILA, EM; LEHVASLAIHO, H; ENGEL, AR; NIESCHLAG, E; HUHTANIEMI, I; DELACHAPELLE, A				AITTOMAKI, K; LUCENA, JLD; PAKARINEN, P; SISTONEN, P; TAPANAINEN, J; GROMOLL, J; KASKIKARI, R; SANKILA, EM; LEHVASLAIHO, H; ENGEL, AR; NIESCHLAG, E; HUHTANIEMI, I; DELACHAPELLE, A			MUTATION IN THE FOLLICLE-STIMULATING-HORMONE RECEPTOR GENE CAUSES HEREDITARY HYPERGONADOTROPIC OVARIAN FAILURE	CELL			English	Article							LUTEINIZING-HORMONE; MOLECULAR-CLONING; GONADOTROPIN-DEFICIENCY; CHORIONIC-GONADOTROPIN; FUNCTIONAL EXPRESSION; PRECOCIOUS PUBERTY; CYCLIC-AMP; CDNA; RAT; LOCALIZATION	Hypergonadotropic ovarian dysgenesis (ODG) with normal karyotype is a heterogeneous condition that in some cases displays Mendelian recessive inheritance, By systematically searching for linkage in multiplex affected families, we mapped a locus for ODG to chromosome 2p, As the previously cloned follicle-stimulating hormone receptor (FSHR) gene had been assigned to 2p, we searched it for mutations, A C566T transition in exon 7 of FSHR predicting an Ala to Val substitution at residue 189 in the extracellular ligand-binding domain segregated perfectly with the disease phenotype. Expression of the gene in transfected cells demonstrated a dramatic reduction of binding capacity and signal transduction, but apparently normal ligand-binding affinity of the mutated receptor. We conclude that the mutation causes ODG in these families.	UNIV TURKU,DEPT PHYSIOL,SF-20520 TURKU,FINLAND; FINNISH RED CROSS & BLOOD TRANSFUS SERV,SF-00310 HELSINKI,FINLAND; UNIV OULU,CENT HOSP,DEPT OBSTET & GYNECOL,SF-90220 OULU,FINLAND; UNIV MUNSTER,INST REPROD MED,D-48149 MUNSTER,GERMANY; UNIV MALAGA,FAC MED,DEPT BIOCHEM & MOLEC BIOL,E-29080 MALAGA,SPAIN; UNIV HELSINKI,CENT HOSP,DEPT CLIN GENET,SF-00290 HELSINKI,FINLAND; UNIV HELSINKI,CENT HOSP,DEPT OBSTET & GYNECOL,SF-00290 HELSINKI,FINLAND	University of Turku; University of Oulu; University of Munster; Universidad de Malaga; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital	AITTOMAKI, K (corresponding author), UNIV HELSINKI,DEPT MED GENET,HAARTMANINKATU 3,SF-00290 HELSINKI,FINLAND.		Gromoll, Joerg/AAB-2146-2019	Gromoll, Joerg/0000-0002-7788-8138; REYES ENGEL, ARMANDO/0000-0002-7294-8103				AIMAN J, 1985, OBSTET GYNECOL, V66, P9; AITTOMAKI K, 1994, AM J HUM GENET, V54, P844; BROOKER G, 1979, ADV CYCLIC NUCLEOTID, P1; CATT K, 1976, METHODS RECEPTOR RES, P175; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUZINET B, 1988, J CLIN ENDOCR METAB, V66, P552, DOI 10.1210/jcem-66-3-552; DAVIS D, 1995, MOL ENDOCRINOL, V9, P169; DELACHAPELLE A, 1993, J MED GENET, V30, P857, DOI 10.1136/jmg.30.10.857; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; GRANAT M, 1983, FERTIL STERIL, V40, P215; GROMOLL J, 1994, J MOL ENDOCRINOL, V12, P265, DOI 10.1677/jme.0.0120265; GROMOLL J, 1993, BIOCHEM BIOPH RES CO, V196, P1066, DOI 10.1006/bbrc.1993.2359; GROMOLL J, 1992, BIOCHEM BIOPH RES CO, V188, P1077, DOI 10.1016/0006-291X(92)91341-M; GUDERMANN T, 1994, ENDOCRINOLOGY, V135, P2204, DOI 10.1210/en.135.5.2204; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALPIN DMG, 1986, J REPROD FERTIL, V78, P119, DOI 10.1530/jrf.0.0780119; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HECKERT LL, 1992, MOL ENDOCRINOL, V6, P70, DOI 10.1210/me.6.1.70; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; JIA XC, 1991, MOL ENDOCRINOL, V5, P759, DOI 10.1210/mend-5-6-759; JONES GS, 1969, AM J OBSTET GYNECOL, V104, P597, DOI 10.1016/S0002-9378(16)34255-7; KARONEN SL, 1975, ANAL BIOCHEM, V67, P1, DOI 10.1016/0003-2697(75)90266-3; KELTON CA, 1992, MOL CELL ENDOCRINOL, V89, P141, DOI 10.1016/0303-7207(92)90220-Z; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KREMER H, 1995, NAT GENET, V9, P160, DOI 10.1038/ng0295-160; KREMER H, 1993, HUM MOL GENET, V2, P1779, DOI 10.1093/hmg/2.11.1779; LAPOLT PS, 1992, ENDOCRINOLOGY, V130, P1289, DOI 10.1210/en.130.3.1289; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEACH FS, 1994, HUM MOL GENET, V3, P2082; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; MATSUMOTO AM, 1989, TESTIS, P181; MATTHEWS CH, 1993, NAT GENET, V5, P83, DOI 10.1038/ng0993-83; MAXSON WS, 1983, SEMIN REPROD ENDOCR, V1, P147, DOI 10.1055/s-2007-1022585; MINEGISH T, 1990, BIOCHEM BIOPH RES CO, V172, P1049, DOI 10.1016/0006-291X(90)91552-4; MINEGISH T, 1991, BIOCHEM BIOPH RES CO, V175, P1125, DOI 10.1016/0006-291X(91)91682-3; Myers R. M., 1988, Genome analysis: a practical approach., P95; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; NEVANLINNA HR, 1972, HEREDITAS-GENETISK A, V71, P195; Norio R., 1981, BIOCULTURAL ASPECTS, P359; PESCHON JJ, 1992, MOL ENDOCRINOL, V6, P1403, DOI 10.1210/me.6.9.1403; RANNIKKO AS, 1995, MOL CELL ENDOCRINOL, V107, P196; REBAR RW, 1990, FERTIL STERIL, V53, P804; REINDOLLAR RH, 1984, J REPROD MED, V29, P391; RICHARDS JS, 1995, ENDOCR REV, V15, P725; ROUSSEAUMERCK MF, 1990, CYTOGENET CELL GENET, V54, P77, DOI 10.1159/000132962; ROUSSEAUMERCK MF, 1993, GENOMICS, V15, P222, DOI 10.1006/geno.1993.1041; Sambrook J, 1989, MOL CLONING LABORATO; SANKILA EM, 1995, HUM MOL GENET, V4, P93, DOI 10.1093/hmg/4.1.93; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SIMPSON J L, 1971, Birth Defects Original Article Series, V7, P215; SIMPSON JL, 1979, GENETIC MECHANISMS S, P365; SMITH A, 1979, FERTIL STERIL, V32, P528; SOKKA T, 1990, J ENDOCRINOL, V127, P297, DOI 10.1677/joe.0.1270297; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; TILLY JL, 1992, ENDOCRINOLOGY, V130, P1296, DOI 10.1210/en.130.3.1296; VANCAMPENHOUT J, 1972, OBSTET GYNECOL, V40, P6; WAHLSTROM T, 1983, J CLIN ENDOCR METAB, V57, P825, DOI 10.1210/jcem-57-4-825; WEINBAUER GF, 1993, MOL BIOL MALE REPROD, P99; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; YANO K, 1995, J CLIN ENDOCR METAB, V80, P1162, DOI 10.1210/jc.80.4.1162; YARNEY TA, 1993, MOL CELL ENDOCRINOL, V93, P219, DOI 10.1016/0303-7207(93)90127-6; ZIRKIN BR, 1994, J ANDROL, V15, P273	64	686	717	0	24	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					959	968		10.1016/0092-8674(95)90275-9	http://dx.doi.org/10.1016/0092-8674(95)90275-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553856	Bronze			2022-12-28	WOS:A1995RW69300012
J	HISLOP, LJ; WYATT, JP; MCNAUGHTON, GW; IRELAND, AJ; RAINER, TH; OLVERMAN, G; LAUGHTON, LM				HISLOP, LJ; WYATT, JP; MCNAUGHTON, GW; IRELAND, AJ; RAINER, TH; OLVERMAN, G; LAUGHTON, LM			URBAN HYPOTHERMIA IN THE WEST OF SCOTLAND	BMJ-BRITISH MEDICAL JOURNAL			English	Article									ROYAL ALEXANDRA HOSP, DEPT ACCID & EMERGENCY MED, PAISLEY PA2 9PL, RENFREW, SCOTLAND; ROYAL INFIRM, DEPT ACCID & EMERGENCY MED, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND; WESTERN INFIRM, DEPT ACCID & EMERGENCY MED, GLASGOW G11 6NT, LANARK, SCOTLAND; GLASGOW ROYAL INFIRM, DEPT ACCID & EMERGENCY MED, GLASGOW G4 0SF, LANARK, SCOTLAND; MONKLANDS DIST GEN HOSP, DEPT ACCID & EMERGENCY MED, AIRDRIE, LANARK ML6 0JS, SCOTLAND; VICTORIA INFIRM, DEPT ACCID & EMERGENCY MED, GLASGOW G42 9TY, LANARK, SCOTLAND; SO GEN HOSP, DEPT ACCID & EMERGENCY MED, GLASGOW G51 4TF, LANARK, SCOTLAND	Royal Infirmary of Edinburgh; University of Glasgow; University of Glasgow			Rainer, Timothy/I-2591-2013	Rainer, Timothy/0000-0003-3355-3237				[Anonymous], 1985, LANCET, V2, P987; OTTY CJ, 1987, BRIT MED J, V295, P419, DOI 10.1136/bmj.295.6595.419; WATT GCM, 1994, BRIT MED J, V309, P1030, DOI 10.1136/bmj.309.6961.1030; WILMSHURST P, 1994, BMJ-BRIT MED J, V309, P1029, DOI 10.1136/bmj.309.6961.1029; 1991, POP CENS	5	31	31	3	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 16	1995	311	7007					725	725		10.1136/bmj.311.7007.725	http://dx.doi.org/10.1136/bmj.311.7007.725			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV874	7549687	Green Published			2022-12-28	WOS:A1995RV87400021
J	MILLMAN, A; LEE, N				MILLMAN, A; LEE, N			ABC OF MEDICAL COMPUTING - CD-ROMS, MULTIMEDIA, AND OPTICAL STORAGE-SYSTEMS	BRITISH MEDICAL JOURNAL			English	Article									HILLINGDON HOSP,HILLINGDON,MIDDX,ENGLAND; GLOUCESTERSHIRE ROYAL HOSP,GLOUCESTER,ENGLAND	Gloucestershire Royal Hospital	MILLMAN, A (corresponding author), WESTERN EYE HOSP,LONDON,ENGLAND.								0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	1995	311	7006					675	678		10.1136/bmj.311.7006.675	http://dx.doi.org/10.1136/bmj.311.7006.675			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU753	7549640	Green Published			2022-12-28	WOS:A1995RU75300030
J	HUBER, R; BURGGRAF, S; MAYER, T; BARNS, SM; ROSSNAGEL, P; STETTER, KO				HUBER, R; BURGGRAF, S; MAYER, T; BARNS, SM; ROSSNAGEL, P; STETTER, KO			ISOLATION OF A HYPERTHERMOPHILIC ARCHAEUM PREDICTED BY IN-SITU RNA ANALYSIS	NATURE			English	Article							SINGLE CELLS; BACTERIA; ARCHAEBACTERIA; MANIPULATION; ORGANISMS; PROBES	A variety of hyperthermophilic bacteria and archaea(1) have been isolated from high-temperature environments by plating and serial dilutions(2). However, these techniques allow only the small percentage of organisms able to form colonies, or those that are predominant within environmental samples, to be obtained in pure culture, Recently, in situ 16S ribosomal RNA analyses of samples from the Obsidian hot pool at Yellowstone National Park, Wyoming, revealed a variety of archaeal sequences, which,were all different from those of previously isolated species(3,4). This suggests substantial diversity of archaea with so far unknown morphological, physiological and biochemical features, which may play an important part within high-temperature ecosystems, Here we describe a procedure to obtain pure cultures of unknown organisms harbouring specific 16S rRNA sequences identified previously within the environment, It combines visual recognition of single cells by phylogenetic staining(5-9) and cloning by 'optical tweezers'(10,11). Our result validates polymerase chain reaction data on the existence of large archaeal communities.	UNIV REGENSBURG,ARCHAEENZENTRUM,D-93053 REGENSBURG,GERMANY; INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405; INDIANA UNIV,INST MOLEC & CELLULAR BIOL,BLOOMINGTON,IN 47405	University of Regensburg; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	HUBER, R (corresponding author), UNIV REGENSBURG,LEHRSTUHL MIKROBIOL,UNIV STR 31,D-93053 REGENSBURG,GERMANY.			Burggraf, Siegfried/0000-0002-2116-0156				AMANN RI, 1990, J BACTERIOL, V172, P762, DOI 10.1128/jb.172.2.762-770.1990; ASHKIN A, 1987, SCIENCE, V235, P1517, DOI 10.1126/science.3547653; ASHKIN A, 1987, NATURE, V330, P769, DOI 10.1038/330769a0; BALCH WE, 1979, MICROBIOL REV, V43, P260, DOI 10.1128/MMBR.43.2.260-296.1979; BARNS SM, 1994, 94 GEN M AM SOC MICR, P253; BARNS SM, 1994, P NATL ACAD SCI USA, V9, P1609; BIOCHL E, 1995, WLD J MICRBIOL BIOTE, V11, P9; BROSIUS J, 1978, P NATL ACAD SCI USA, V75, P4801, DOI 10.1073/pnas.75.10.4801; BURGGRAF S, 1994, APPL ENVIRON MICROB, V60, P3112, DOI 10.1128/AEM.60.9.3112-3119.1994; BURGGRAF S, 1994, APPL ENV MICORBIOL, V330, P3112; DELONG EF, 1989, SCIENCE, V243, P1360, DOI 10.1126/science.2466341; HUBER R, 1989, NATURE, V342, P833, DOI 10.1038/342833a0; HUBER R, 1992, PROKARYOTES, P677; KANE MD, 1993, APPL ENVIRON MICROB, V59, P682, DOI 10.1128/AEM.59.3.682-686.1993; Stahl D.A., 1991, SEQUENCING HYBRIDIZA, P205; STETTER KO, 1982, NATURE, V300, P258, DOI 10.1038/300258a0; STETTER KO, 1981, ZBL BAKT MIK HYG I C, V2, P166, DOI 10.1016/S0721-9571(81)80038-5; STETTER KO, 1987, SCIENCE, V236, P822, DOI 10.1126/science.236.4803.822; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	19	151	162	0	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					57	58		10.1038/376057a0	http://dx.doi.org/10.1038/376057a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7541115				2022-12-28	WOS:A1995RH11100060
J	ROITBERG, A; GERBER, RB; ELBER, R; RATNER, MA				ROITBERG, A; GERBER, RB; ELBER, R; RATNER, MA			ANHARMONIC WAVE-FUNCTIONS OF PROTEINS - QUANTUM SELF-CONSISTENT-FIELD CALCULATIONS OF BPTI	SCIENCE			English	Article							PANCREATIC TRYPSIN-INHIBITOR; NEUTRON-SCATTERING ANALYSIS; VIBRATIONAL-STATES; NORMAL-MODES; DYNAMICS; MYOGLOBIN; LYSOZYME; ENERGY	The harmonic approximation for the potential energy of proteins is known to be inadequate for the calculation of many protein properties. To study the effect of anharmonic terms on protein vibrations, the anharmonic wave functions for the ground state and low-lying excited states of the bovine pancreatic trypsin inhibitor (BPTI) were calculated. The results suggest that anharmonic treatments are essential for protein vibrational spectroscopy. The calculation uses the Vibrational self-consistent field approximation, which includes anharmonicity and interaction among modes in a mean-field sense. Properties obtained include the quantum coordinate fluctuations, zero-point energies, and the vibrational absorption spectrum.	NORTHWESTERN UNIV, DEPT CHEM, EVANSTON, IL 60208 USA; HEBREW UNIV JERUSALEM, DEPT PHYS CHEM, IL-91904 JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, FRITZ HABER INST, IL-91904 JERUSALEM, ISRAEL; UNIV ILLINOIS, DEPT CHEM, CHICAGO, IL 60680 USA	Northwestern University; Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Roitberg, Adrian E/A-2378-2009					AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BOWMAN JM, 1978, J CHEM PHYS, V68, P608, DOI 10.1063/1.435782; BROOKS B, 1983, P NATL ACAD SCI-BIOL, V80, P6571, DOI 10.1073/pnas.80.21.6571; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUCCOLERI RE, 1986, BIOPOLYMERS, V25, P1767, DOI 10.1002/bip.360250916; CUSACK S, 1988, J MOL BIOL, V202, P903, DOI 10.1016/0022-2836(88)90566-9; DEISENHOFER J, 1975, ACTA CRYSTALLOGR B, V31, P238, DOI 10.1107/S0567740875002415; ELBER R, 1987, SCIENCE, V235, P318, DOI 10.1126/science.3798113; ELBER R, IN PRESS COMPUT PHYS; GERBER RB, 1988, ADV CHEM PHYS, V70, P97, DOI 10.1002/9780470141199.ch4; GO N, 1983, P NATL ACAD SCI-BIOL, V80, P3696, DOI 10.1073/pnas.80.12.3696; HORN TR, 1989, J CHEM PHYS, V91, P1813, DOI 10.1063/1.457086; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; LAANE J, 1994, ANNU REV PHYS CHEM, V45, P179; LEVITT M, 1985, J MOL BIOL, V181, P423, DOI 10.1016/0022-2836(85)90230-X; LEVY RM, 1984, J PHYS CHEM-US, V88, P4233, DOI 10.1021/j150663a009; NESBITT DJ, 1994, ANNU REV PHYS CHEM, V45, P367; NISHIKAWA T, 1987, PROTEINS, V2, P308, DOI 10.1002/prot.340020407; QIAN WL, 1994, BIOPOLYMERS, V34, P1377, DOI 10.1002/bip.360341009; RATNER MA, 1986, J PHYS CHEM-US, V90, P20, DOI 10.1021/j100273a008; ROMANOWSKI H, 1985, J CHEM PHYS, V82, P4155, DOI 10.1063/1.448858; SMITH J, 1990, J CHEM PHYS, V93, P2974, DOI 10.1063/1.458885; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051	23	116	119	0	17	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 2	1995	268	5215					1319	1322		10.1126/science.7539156	http://dx.doi.org/10.1126/science.7539156			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7539156				2022-12-28	WOS:A1995RB19800029
J	WANG, DG; MEIER, TI; CHAN, CL; FENG, GH; LEE, DN; LANDICK, R				WANG, DG; MEIER, TI; CHAN, CL; FENG, GH; LEE, DN; LANDICK, R			DISCONTINUOUS MOVEMENTS OF DNA AND RNA IN RNA-POLYMERASE ACCOMPANY FORMATION OF A PAUSED TRANSCRIPTION COMPLEX	CELL			English	Article							ESCHERICHIA-COLI RNA; STRUCTURAL-ANALYSIS; TERNARY COMPLEXES; TERMINATION; BACTERIOPHAGE-T7; DISSECTION; SEQUENCES; CLEAVAGE; PROTEINS; INVITRO	A central enigma of transcriptional regulation is how the normally efficient transcription elongation complex stops at pause and termination signals. One possibility, raised by the discovery that RNA polymerase sometimes contracts its DNA footprint, is that discontinuous movements contribute to recognizing these signals. We report that E. coli RNA polymerase responds to sequences immediately downstream and upstream from the his leader pause site by changing neither its downstream DNA contact nor its upstream RNA contact for 8 bp preceding the pause. This compressed complex isomerizes to a paused conformation by an similar to 10 bp jump of its downstream DNA contact and simultaneous extrusion of an RNA hairpin that stabilizes the paused conformation. We suggest pausing and termination could be alternative outcomes of a similar isomerization that depend on the strength of contacts to 3'-proximal RNA remaining after the jump.	WASHINGTON UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,ST LOUIS,MO 63130	Washington University (WUSTL)	WANG, DG (corresponding author), WASHINGTON UNIV,DEPT BIOL,CAMPUS BOX 1137,ST LOUIS,MO 63130, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038660, R01GM038660, R37GM038660] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-38660] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], [No title captured]; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CHAMBERLIN M, 1983, METHOD ENZYMOL, V101, P540; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; CHAN CL, 1989, J BIOL CHEM, V264, P20796; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; FENG GH, 1994, J BIOL CHEM, V269, P22282; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; Kane C. M., 1994, TRANSCRIPTION MECH R, P279; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LANDICK R, 1987, J MOL BIOL, V196, P363, DOI 10.1016/0022-2836(87)90697-8; LANDICK R, 1987, ESCHERICHIA COLI SAL, P1276; LEE DN, 1990, J BIOL CHEM, V265, P15145; LEE DN, 1994, J BIOL CHEM, V269, P22295; LEE DN, 1992, J MOL BIOL, V228, P759, DOI 10.1016/0022-2836(92)90862-E; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; LOWMAN HB, 1986, J BIOL CHEM, V261, P5396; LUI B, 1994, P NATL ACAD SCI USA, V91, P10660; MASON SW, 1992, J BIOL CHEM, V267, P19418; Maxam A M, 1980, Methods Enzymol, V65, P499; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; RICHARDSON JP, 1993, CRIT REV BIOCHEM MOL, V28, P1, DOI 10.3109/10409239309082571; RING BZ, 1994, CELL, V78, P317, DOI 10.1016/0092-8674(94)90300-X; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; TELESNITSKY A, 1989, BIOCHEMISTRY-US, V28, P5210, DOI 10.1021/bi00438a044; VOGEL U, 1994, J BACTERIOL, V176, P2807, DOI 10.1128/JB.176.10.2807-2813.1994; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; WILSON K, 1995, J MOL BIOL, V244, P36; WRIGHT S, 1993, MOL BIOL CELL, V4, P661, DOI 10.1091/mbc.4.7.661; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739	37	123	127	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					341	350		10.1016/0092-8674(95)90387-9	http://dx.doi.org/10.1016/0092-8674(95)90387-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7537637	Bronze			2022-12-28	WOS:A1995QW89400006
J	SPACH, DH; KANTER, AS; DOUGHERTY, MJ; LARSON, AM; COYLE, MB; BRENNER, DJ; SWAMINATHAN, B; MATAR, GM; WELCH, DF; ROOT, RK; STAMM, WE				SPACH, DH; KANTER, AS; DOUGHERTY, MJ; LARSON, AM; COYLE, MB; BRENNER, DJ; SWAMINATHAN, B; MATAR, GM; WELCH, DF; ROOT, RK; STAMM, WE			BARTONELLA (ROCHALIMAEA) QUINTANA BACTEREMIA IN INNER-CITY PATIENTS WITH CHRONIC-ALCOHOLISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CAT-SCRATCH DISEASE; HENSELAE SP-NOV; BACILLARY ANGIOMATOSIS; PELIOSIS HEPATIS; FEVER; AGENT	Background. Bartonella (Rochalimaea) quintana is a fastidious gram-negative bacterium known to cause trench fever, cutaneous bacillary angiomatosis, and endocarditis. Between January and June 1993 in Seattle, we isolated B. quintana from 34 blood cultures obtained from 10 patients not known to be infected with the human immunodeficiency virus (HIV). Methods. After identifying the isolates as B. quintana by direct immunofluorescence and DNA-hybridization studies, we determined strain hybridization with studies of restriction-fragment-length polymorphisms (RFLPs) of the intergenic spacer (noncoding) region of ribosomal DNA amplified by the polymerase chain reaction (PCR). To characterize the epidemiologic and clinical features of bartonella infections in these patients, we performed a retrospective case-control study using as controls 20 patients from whom blood was obtained for culture at approximately the same time as from the index patients. Results. B. quintana isolates from the 10 patients were indistinguishable by PCR-RFLP typing. All 10 patients had chronic alcoholism, and 8 were homeless (P=0.001 for both comparisons with controls). The six patients who underwent HIV testing were seronegative. At the time of their initial presentation, seven patients had temperatures of at least 38.5 degrees C. Six patients had three or more blood cultures that were positive for B. quintana, and in four of these patients B. quintana was isolated from blood cultures obtained 10 or more days apart. Subacute endocarditis developed in two patients and required surgical removal of the infected aortic valve in one of them. Nine patients recovered; one died of sepsis from Streptococcus pneumoniae infection. Conclusions. B. quintana is a cause of fever, bacteremia, and endocarditis in HIV-seronegative, homeless, inner-city patients with chronic alcoholism.	HARBORVIEW MED CTR,DIV INFECT DIS,SEATTLE,WA; HARBORVIEW MED CTR,DEPT MED,SEATTLE,WA; HARBORVIEW MED CTR,DEPT LAB MED,SEATTLE,WA; UNIV WASHINGTON,MED CTR,DEPT MED,SEATTLE,WA 98195; NATL CTR INFECTIOUS DIS,DIV BACTERIAL & MYCOT DIS,EMERGING BACTERIAL & MYCOT DIS BRANCH,ATLANTA,GA; NATL CTR INFECTIOUS DIS,DIV BACTERIAL & MYCOT DIS,FOODBORNE & DIARRHEAL DIS BRANCH,ATLANTA,GA; UNIV OKLAHOMA,HLTH SCI CTR,DEPT PEDIAT,OKLAHOMA CITY,OK 73190; UNIV OKLAHOMA,HLTH SCI CTR,CLIN MICROBIOL LABS,OKLAHOMA CITY,OK 73190	Harborview Medical Center; Harborview Medical Center; Harborview Medical Center; University of Washington; University of Washington Seattle; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center				Kanter, Andrew/0000-0002-4019-7894				BRENNER DJ, 1993, INT J SYST BACTERIOL, V43, P777, DOI 10.1099/00207713-43-4-777; BRENNER DJ, 1982, J CLIN MICROBIOL, V15, P1133, DOI 10.1128/JCM.15.6.1133-1140.1982; DOLAN MJ, 1993, ANN INTERN MED, V118, P331, DOI 10.7326/0003-4819-118-5-199303010-00002; HADFIELD TL, 1993, HUM PATHOL, V24, P1140, DOI 10.1016/0046-8177(93)90196-N; KOEHLER JE, 1993, CLIN INFECT DIS, V17, P612, DOI 10.1093/clinids/17.4.612; KOEHLER JE, 1994, JAMA-J AM MED ASSOC, V271, P531, DOI 10.1001/jama.271.7.531; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; LARSON AM, 1994, J CLIN MICROBIOL, V32, P1492, DOI 10.1128/JCM.32.6.1492-1496.1994; LUCEY D, 1992, CLIN INFECT DIS, V14, P683, DOI 10.1093/clinids/14.3.683; MATAR GM, 1993, J CLIN MICROBIOL, V31, P1730, DOI 10.1128/JCM.31.7.1730-1734.1993; MAURIN M, 1994, J CLIN MICROBIOL, V32, P1166, DOI 10.1128/JCM.32.5.1166-1171.1994; MYERS WF, 1984, ANTIMICROB AGENTS CH, V25, P690, DOI 10.1128/AAC.25.6.690; PERKOCHA LA, 1990, NEW ENGL J MED, V323, P1581, DOI 10.1056/NEJM199012063232302; RAOULT D, 1994, LANCET, V343, P977, DOI 10.1016/S0140-6736(94)90102-3; REGNERY RL, 1992, J CLIN MICROBIOL, V30, P265, DOI 10.1128/JCM.30.2.265-274.1992; RELMAN DA, 1991, NEW ENGL J MED, V324, P1514; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; SCHWARTZMAN WA, 1992, CLIN INFECT DIS, V15, P893, DOI 10.1093/clind/15.6.893; SLATER LN, 1990, NEW ENGL J MED, V323, P1587, DOI 10.1056/NEJM199012063232303; SLATER LN, 1992, ARCH INTERN MED, V152, P602, DOI 10.1001/archinte.152.3.602; SLATER LN, 1992, J CLIN MICROBIOL, V30, P1722, DOI 10.1128/JCM.30.7.1722-1727.1992; SLATER LN, 1995, PRINCIPLES PRACTICE, P1741; SPACH DH, 1993, J CLIN MICROBIOL, V31, P692, DOI 10.1128/JCM.31.3.692-694.1993; SPACH DH, IN PRESS CLIN INFECT; TAPPERO JW, 1993, ANN INTERN MED, V118, P363, DOI 10.7326/0003-4819-118-5-199303010-00007; VINSON JW, 1969, AM J TROP MED HYG, V18, P713, DOI 10.4269/ajtmh.1969.18.713; WELCH DF, 1992, J CLIN MICROBIOL, V30, P275, DOI 10.1128/JCM.30.2.275-280.1992; ZANGWILL KM, 1993, NEW ENGL J MED, V329, P8, DOI 10.1056/NEJM199307013290102	28	196	204	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 16	1995	332	7					424	428		10.1056/NEJM199502163320703	http://dx.doi.org/10.1056/NEJM199502163320703			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF770	7529895				2022-12-28	WOS:A1995QF77000003
J	BLAJCHMAN, MA; BULL, SB; FEINMAN, SV				BLAJCHMAN, MA; BULL, SB; FEINMAN, SV			POSTTRANSFUSION HEPATITIS - IMPACT OF NON-A, NON-B-HEPATITIS SURROGATE TESTS	LANCET			English	Article							C VIRUS-INFECTION; POSTTRANSFUSION HEPATITIS; RISK; ANTIBODY; TRIALS	Canada has not introduced the non-A, non-B (NANB) surrogate marker tests (antibodies to hepatitis B core antigen and alanine aminotransferase) to screen donated blood. We evaluated the effect of NANB surrogate markers in reducing post-transfusion hepatitis in a prospective randomised intervention study. From 1988 to 1992, 4588 subjects were enrolled into two study groups that received allogeneic blood from which units positive for NANB surrogate markers were either withheld (n=2311) or not withheld (n=2277). We also assessed a simultaneous non-randomised cohort (n=650) of subjects who received only syngeneic blood. All subjects were followed up for 6 months and assessed for the presence of post-transfusion hepatitis due to hepatitis A, B, C, non ABC, Epstein-Barr virus (EBV) and cytomegalovirus (CMV). Withholding of blood containing NANB surrogate positive units reduced the overall posttransfusion hepatitis rate by 40% (p=0.065) and the hepatitis C rate by 70% (p=0.05). Most of the benefit of NANB surrogate testing was due to reduced frequency of hepatitis C virus after transfusion before all donor blood was screened far anti-HCV. During this time the overall post-transfusion hepatitis rate per 1000 transfusion recipients was 20.2 in the no-withhold group compared with 5.0 in the withhold group (p=0.05), and the HCV hepatitis rate was 12.6 and 0 respectively (p=0.06). After the introduction of HCV screening, the overall posttransfusion hepatitis rates were 8.6 and 6.8 per 1000 (p=0.55) respectively. Our study indicates that screening of blood donors with the NANB surrogate markers was of value in reducing HCV infection before HCV screening began, but subsequently the value of screening cannot be clearly established.	MT SINAI HOSP,LIVER STUDY UNIT,TORONTO,ON M5G 1X5,CANADA; MCMASTER UNIV,HAMILTON,ON,CANADA; CANADIAN RED CROSS SOC,HAMILTON,ON,CANADA; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; McMaster University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Bull, Shelley B/A-1920-2013					AACH RD, 1981, NEW ENGL J MED, V304, P989, DOI 10.1056/NEJM198104233041701; BEGG CB, 1984, BIOMETRIKA, V71, P11, DOI 10.2307/2336391; BUKH J, 1992, P NATL ACAD SCI USA, V89, P187, DOI 10.1073/pnas.89.1.187; CHIAVETTA JA, 1989, TRANSFUSION, V29, P81, DOI 10.1046/j.1537-2995.1989.29189101172.x; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; FEINMAN SV, 1988, GASTROENTEROLOGY, V95, P464, DOI 10.1016/0016-5085(88)90505-7; FEINMAN SV, 1991, J HEPATOL, V12, P377, DOI 10.1016/0168-8278(91)90843-Z; FEINMAN SV, 1988, CLIN INVEST MED, V4, P289; GAIL M, 1973, J CHRON DIS, V26, P669, DOI 10.1016/0021-9681(73)90056-8; GELLER NL, 1987, BIOMETRICS, V43, P213, DOI 10.2307/2531962; KLEINMAN S, 1992, NEW ENGL J MED, V327, P1601; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; NELSON KE, 1993, NEW ENGL J MED, V328, P1280; WRIGHT TL, 1992, LANCET, V339, P952, DOI 10.1016/0140-6736(92)91530-L	16	79	83	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					21	25		10.1016/S0140-6736(95)91153-7	http://dx.doi.org/10.1016/S0140-6736(95)91153-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7528310				2022-12-28	WOS:A1995QA29000011
J	DOLE, VP				DOLE, VP			ON FEDERAL-REGULATION OF METHADONE TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MAINTENANCE				DOLE, VP (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.							[Anonymous], 1995, FEDERAL REGULATION M; COOPER JR, 1995, JAMA-J AM MED ASSOC, V273, P1619, DOI 10.1001/jama.273.20.1619; DOLE VP, 1982, NEW ENGL J MED, V306, P169, DOI 10.1056/NEJM198201213060310; DOLE VP, 1992, JAMA-J AM MED ASSOC, V267, P2234, DOI 10.1001/jama.267.16.2234	4	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	1995	274	16					1307	1307						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA104	7563538				2022-12-28	WOS:A1995TA10400028
J	GRUMBACH, K; ANDERSON, GM; LUFT, HS; ROOS, LL; BROOK, R				GRUMBACH, K; ANDERSON, GM; LUFT, HS; ROOS, LL; BROOK, R			REGIONALIZATION OF CARDIAC-SURGERY IN THE UNITED-STATES AND CANADA - GEOGRAPHIC ACCESS, CHOICE, AND OUTCOMES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ARTERY BYPASS-SURGERY; NEW-YORK-STATE; SURGICAL VOLUME; MORTALITY; HOSPITALS; CARE	Objective.-To determine how regionalization of facilities for coronary artery bypass surgery (CABS) affects geographic access to CABS and surgical outcomes. Design.-Computerized hospital discharge records were used to measure hospital CABS volume and in-hospital post-CABS mortality rates. Relationships between surgical volume and age- and sex-adjusted mortality rates were compared using chi(2) tests. Small-area analysis of the association between CABS rates and distances to nearest CABS hospital was performed using multivariate linear regression methods. Setting.-All nonfederal hospitals in New York, California, Ontario, Manitoba, and British Columbia. Patients.-All adult residents of the five jurisdictions who underwent CABS in a hospital in their jurisdiction from 1987 through 1989. Results.-In New York and Canada, approximately 60% of all CABS operations took place in hospitals performing 500 or more CABS operations per year, compared with only 26% in California. The highest mortality rates were found among California hospitals performing fewer than 100 CABS operations per year (adjusted 14-day in-hospital mortality was 4.7% compared with 2.4% in high-volume California hospitals, P<.001). The percentage of the population residing within 25 miles of a CABS hospital was 98% in California, 82% in New York, and less than 60% in Canada. Eliminating very low-volume ((100 cases per year) CABS hospitals in California would increase travel distances to a CABS hospital only slightly for a small number of residents. The Canadian degree of regionalization was not associated with lower CABS rates within provinces for populations living at more remote distances from the nearest CABS hospital. Conclusion.-Regionalization of CABS facilities in New York and Canada largely avoids the problem of low-volume outlier hospitals with high postoperative mortality rates found in California. New York has avoided the redundancy of facilities that exists in California while still providing residents a geographically convenient selection of CABS hospitals. Stricter regionalization in Canada may leave residents with a more narrow choice of facilities, but does not disproportionately affect access to surgery for populations living at remote distances from CABS facilities.	UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; INST CLIN EVALUAT SCI,TORONTO,ON,CANADA; UNIV TORONTO,TORONTO,ON,CANADA; UNIV MANITOBA,MANITOBA CTR HLTH POLICY & EVALUAT,WINNIPEG,MB,CANADA; RAND CORP,HLTH SCI PROGRAM,SANTA MONICA,CA; UNIV CALIF LOS ANGELES,CTR HLTH SCI,LOS ANGELES,CA 90024	University of California System; University of California San Francisco; University of Toronto; University of Toronto; University of Manitoba; RAND Corporation; University of California System; University of California Los Angeles	GRUMBACH, K (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,PRIMARY CARE RES CTR,UCSF BOX 1364,SAN FRANCISCO,CA 94143, USA.		Grumbach, Kevin/L-9222-2016	Roos, Leslie L./0000-0002-4215-8346	AHRQ HHS [HS06503-03, HS07373-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDERSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1661; BLUSTEIN J, 1993, JAMA-J AM MED ASSOC, V270, P344, DOI 10.1001/jama.270.3.344; HANNAN EL, 1992, MED CARE, V30, P892, DOI 10.1097/00005650-199210000-00002; HANNAN EL, 1991, MED CARE, V29, P1094, DOI 10.1097/00005650-199111000-00003; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; HUGHES RG, 1987, MED CARE, V25, P489, DOI 10.1097/00005650-198706000-00004; KATZ SJ, 1991, JAMA-J AM MED ASSOC, V266, P1108, DOI 10.1001/jama.266.8.1108; KLEINBAUM DG, 1987, APPLIED REGRESSION A; LEAPE LL, 1993, JAMA-J AM MED ASSOC, V269, P753, DOI 10.1001/jama.269.6.753; LUFT HS, 1993, JAMA-J AM MED ASSOC, V270, P331, DOI 10.1001/jama.270.3.331; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; LUFT HS, 1987, HEALTH SERV RES, V22, P157; LUFT HS, 1990, HOSPITAL VOLUME PHYS; MCGLYNN EA, 1994, JAMA-J AM MED ASSOC, V272, P934, DOI 10.1001/jama.272.12.934; NAYLOR CD, 1991, HEALTH AFFAIR, V10, P110, DOI 10.1377/hlthaff.10.3.110; ROOS LL, 1993, CAN J CARDIOL, V10, P49; YIP W, 1993, SOC SCI MED, V36, P1455, DOI 10.1016/0277-9536(93)90387-J; 1990, 1990 CENSUS POPULATI; 1991, 1991 CENSUS	19	175	176	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	1995	274	16					1282	1288		10.1001/jama.274.16.1282	http://dx.doi.org/10.1001/jama.274.16.1282			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA104	7563533				2022-12-28	WOS:A1995TA10400023
J	BIRD, TD				BIRD, TD			IDIOPATHIC PROGRESSIVE SPASTIC PARAPARESIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PRIMARY LATERAL SCLEROSIS				BIRD, TD (corresponding author), UNIV WASHINGTON,SCH MED,SEATTLE,WA 98195, USA.							DURR A, 1994, NEUROLOGY, V44, P1274, DOI 10.1212/WNL.44.7.1274; GESSAIN A, 1992, ANN INTERN MED, V117, P933, DOI 10.7326/0003-4819-117-11-933; PRINGLE CE, 1992, BRAIN, V115, P495, DOI 10.1093/brain/115.2.495; YOUNG RR, 1994, NEUROLOGY S9, V44, pS12; YOUNGER DS, 1988, ARCH NEUROL-CHICAGO, V45, P1304, DOI 10.1001/archneur.1988.00520360022005	5	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	1995	274	15					1191	1191						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ120	7563498				2022-12-28	WOS:A1995RZ12000009
J	DROBNIEWSKI, F				DROBNIEWSKI, F			TUBERCULOSIS IN PRISONS - FORGOTTEN PLAGUE	LANCET			English	Editorial Material											DROBNIEWSKI, F (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461, USA.							BELLIN E, 1993, JAMA-J AM MED ASSOC, V270, P940, DOI 10.1001/jama.1993.03510080044026; CHAVES F, 1993, MED CLIN-BARCELONA, V101, P525; DROBNIEWSKI F, IN PRESS TUBERCLE; DROBNIEWSKI FA, 1995, J MED MICROBIOL, V43, P85, DOI 10.1099/00222615-43-2-85; DROBNIEWSKI FA, 1994, J HOSP INFECT, V28, P249, DOI 10.1016/0195-6701(94)90089-2; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; MARTIN V, 1994, TUBERCLE LUNG DIS, V75, P49, DOI 10.1016/0962-8479(94)90102-3; SPENCE DPS, 1993, BRIT MED J, V307, P759, DOI 10.1136/bmj.307.6907.759; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151; VALWAY SE, 1994, AM J EPIDEMIOL, V140, P113, DOI 10.1093/oxfordjournals.aje.a117222; 1995, BRIDGING GAP; 1994, TUBERCULOSIS RUSSIA	12	54	57	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					948	949		10.1016/S0140-6736(95)91562-1	http://dx.doi.org/10.1016/S0140-6736(95)91562-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564733				2022-12-28	WOS:A1995RY80800014
J	OSSIPOW, V; TASSAN, JP; NIGG, EA; SCHIBLER, U				OSSIPOW, V; TASSAN, JP; NIGG, EA; SCHIBLER, U			A MAMMALIAN RNA-POLYMERASE-II HOLOENZYME CONTAINING ALL COMPONENTS REQUIRED FOR PROMOTER-SPECIFIC TRANSCRIPTION INITIATION	CELL			English	Article							TATA-BINDING PROTEIN; ALBUMIN GENE; BASAL TRANSCRIPTION; CATALYTIC SUBUNIT; ACTIVATION DOMAIN; PHOSPHORYLATION; EXPRESSION; KINASE; P40(MO15); P34(CDC2)	The protein kinase MO15/CDK7 has recently been shown to be associated with the general transcription factor TFIIH and to be capable of phosphorylating the RNA polymerase II carboxy-terminal domain. Here, we show that a monoclonal MO15/CDK7 antibody coimmunoprecipitates, from a rat liver nuclear extract, all components of the RNA polymerase II transcription apparatus required for initiation at the albumin and adenovirus major late promoters. The immunoprecipitate includes RNA polymerase II, TFIID, TFIIB, TFIIH, TFIIF, and TFIIE, but is devoid of transcriptional activator proteins, such as HNF1, HNF4, and C/EBP alpha. The finding of an autonomously initiating RNA polymerase II holoenzyme in mammalian cells suggests conceptual similarities between transcription initiation in prokaryotes and eukaryotes.	INST SUISSE RECH EXPTL CANC,CH-1066 EPALINGES,SWITZERLAND		OSSIPOW, V (corresponding author), UNIV GENEVA,DEPT BIOL MOLEC SCI 2,CH-1211 GENEVA 4,SWITZERLAND.			nigg, erich/0000-0003-4835-5719				BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHIANG SY, 1994, BIOCHEMISTRY-US, V33, P7033, DOI 10.1021/bi00189a003; CORDEN JL, 1993, CURR OPIN GENET DEV, V3, P213, DOI 10.1016/0959-437X(93)90025-K; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DAHMUS ME, 1994, PROG NUCLEIC ACID RE, V48, P143, DOI 10.1016/S0079-6603(08)60855-7; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DRAPKIN R, 1994, TRENDS BIOCHEM SCI, V19, P504, DOI 10.1016/0968-0004(94)90139-2; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EICK D, 1994, TRENDS GENET, V10, P292, DOI 10.1016/0168-9525(90)90013-V; EMILI A, 1995, CURR OPIN GENET DEV, V5, P204, DOI 10.1016/0959-437X(95)80009-3; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HEARD JM, 1987, MOL CELL BIOL, V7, P2425, DOI 10.1128/MCB.7.7.2425; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KNAUS R, 1990, NUCLEIC ACIDS MOL BI, V4, P110; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1989, GENE DEV, V2, P786; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MENENDEZ M, 1987, EMBO J, V6, P4227, DOI 10.1002/j.1460-2075.1987.tb02771.x; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; TRUANT R, 1993, J BIOL CHEM, V268, P2284; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WUARIN J, 1994, MOL CELL BIOL, V14, P7219, DOI 10.1128/MCB.14.11.7219; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZHU KY, 1994, BIOTECHNIQUES, V18, P222	61	181	182	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					137	146		10.1016/0092-8674(95)90242-2	http://dx.doi.org/10.1016/0092-8674(95)90242-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553866	Bronze			2022-12-28	WOS:A1995RY58300018
J	TELLING, GC; SCOTT, M; MASTRIANNI, J; GABIZON, R; TORCHIA, M; COHEN, FE; DEARMOND, SJ; PRUSINER, SB				TELLING, GC; SCOTT, M; MASTRIANNI, J; GABIZON, R; TORCHIA, M; COHEN, FE; DEARMOND, SJ; PRUSINER, SB			PRION PROPAGATION IN MICE EXPRESSING HUMAN AND CHIMERIC PRP TRANSGENES IMPLICATES THE INTERACTION OF CELLULAR PRP WITH ANOTHER PROTEIN	CELL			English	Article							CREUTZFELDT-JAKOB DISEASE; GERSTMANN-STRAUSSLER SYNDROME; CULTURED-CELLS; MISSENSE VARIANT; SCRAPIE ISOFORM; REPLICATION; CONVERSION; FORM	Transgenic (Tg) mice expressing human (Hu) and chimeric prion protein (PrP) genes were inoculated with brain extracts from humans with inherited or sporadic prion disease to investigate the mechanism by which PrPC is transformed into PrPSc. Although Tg(HuPrP) mice expressed high levels of HUPrPC, they were resistant to human prions, They became susceptible to human prions upon ablation of the mouse (Mo) PrP gene. In contrast, mice expressing low levels of the chimeric transgene were susceptible to human prions and registered only a modest decrease in incubation times upon MoPrP gene disruption. These and other findings argue that a species-specific macromolecule, provisionally designated protein X, participates in prion formation. While the results demonstrate that PrPSc binds to PrPC in a region delimited by codons 96 to 167, they also suggest that PrPC binds protein X through residues near the C-terminus. Protein X might function as a molecular chaperone in the formation of PrPSc.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MOLEC & CELLULAR PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94143 USA; HADASSAH UNIV HOSP, DEPT NEUROL, IL-91120 JERUSALEM, ISRAEL	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Hebrew University of Jerusalem	TELLING, GC (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT NEUROL, SAN FRANCISCO, CA 94143 USA.		Telling, Glenn C/G-1217-2019	Telling, Glenn C/0000-0002-6294-1805				BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CARLSON GA, 1994, P NATL ACAD SCI USA, V91, P5690, DOI 10.1073/pnas.91.12.5690; CARLSON GA, 1986, CLIN RES, V34, pA675; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CHANDLER RL, 1961, LANCET, V1, P1378; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; GABIZON R, 1993, AM J HUM GENET, V53, P828; GAJDUSEK DC, 1966, NATURE, V209, P794, DOI 10.1038/209794a0; GAJDUSEK DC, 1993, BRIT MED BULL, V49, P913, DOI 10.1093/oxfordjournals.bmb.a072653; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO KK, 1994, P NATL ACAD SCI USA, V91, P9126, DOI 10.1073/pnas.91.19.9126; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KITAMOTO T, 1991, NEUROLOGY, V41, P306, DOI 10.1212/WNL.41.2_Part_1.306; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KURSCHNER C, 1995, MOL BRAIN RES, V30, P165, DOI 10.1016/0169-328X(95)00013-I; Liautard J P, 1993, Arch Virol Suppl, V7, P227; MANUELIDIS EE, 1978, P NATL ACAD SCI USA, V75, P3432, DOI 10.1073/pnas.75.7.3432; MCKINLEY MP, 1991, J VIROL, V65, P1340, DOI 10.1128/JVI.65.3.1340-1351.1991; MURAMOTO T, 1992, AM J PATHOL, V140, P1411; NGUYEN J, 1995, BIOCHEMISTRY-US, V34, P4186, DOI 10.1021/bi00013a006; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pattison I. H., 1965, NINDB MONOGRAPH, V2, P249; PETERSEN RB, 1995, NEUROLOGY, V45, P1062, DOI 10.1212/WNL.45.6.1062; PRUSINER S B, 1987, P83; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; RAEBER AJ, 1992, J VIROL, V66, P6155, DOI 10.1128/JVI.66.10.6155-6163.1992; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TAGLIAVINI F, 1994, CELL, V79, P695, DOI 10.1016/0092-8674(94)90554-1; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TATEISHI J, 1995, BRAIN PATHOL, V5, P53, DOI 10.1111/j.1750-3639.1995.tb00577.x; TATEISHI J, 1983, PROG NEUROPATH, V5, P195; TATEISHI J, 1993, BRIT MED BULL, V49, P971, DOI 10.1093/oxfordjournals.bmb.a072656; TATZELT J, 1995, P NATL ACAD SCI USA, V92, P2944, DOI 10.1073/pnas.92.7.2944; TELLING GC, 1994, P NATL ACAD SCI USA, V91, P9936, DOI 10.1073/pnas.91.21.9936; WELLS GAH, 1995, BRAIN PATHOL, V5, P91, DOI 10.1111/j.1750-3639.1995.tb00580.x; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395	56	727	763	1	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 6	1995	83	1					79	90		10.1016/0092-8674(95)90236-8	http://dx.doi.org/10.1016/0092-8674(95)90236-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553876	Bronze			2022-12-28	WOS:A1995RY58300012
J	CLEMESSY, JL; FAVIER, C; BORRON, SW; HANTSON, PE; VICAUT, E; BAUD, FJ				CLEMESSY, JL; FAVIER, C; BORRON, SW; HANTSON, PE; VICAUT, E; BAUD, FJ			HYPOKALEMIA RELATED TO ACUTE CHLOROQUINE INGESTION	LANCET			English	Article							HEART	Large doses of chloroquine can cause poisoning. Our aim was to determine the possible relation between the plasma potassium concentration on admission with the severity of acute chloroquine poisoning and to assess the mechanism of chloroquine-induced hypokalaemia. We conducted a retrospective study of 191 consecutive cases. The main data included the occurrence of vomiting before admission, plasma, and urinary potassium concentration at admission, whole blood chloroquine concentration on admission, haemodynamic parameters and EGG, administration of catecholamines and outcome. Mean blood chloroquine level was 20.1 mu mol/L (SD 14.3) (therapeutic level less than or equal to 6 mu mol/L). Mean plasma potassium concentration was 3.0 mmol/L (0.8) and was lower in the subjects who died than in those who survived (p=0.0003). Plasma potassium varied directly with the systolic blood pressure and inversely with the QRS and QT. Plasma potassium varied inversely with the blood chloroquine (p=0.0001; tau=-0.42). Acute chloroquine intoxication is responsible for a hypokalaemia which correlates with the gravity of the intoxication and may be due to a transport-dependent mechanism. Plasma potassium concentrations should be carefully observed, particularly among patients who also receive catecholamine infusions. We should keep in mind, however, that overzealous repletion invokes the risk of subsequent hyperkalaemia and thus should be avoided.	HOP ST ROCHE,DEPT ANESTHESE REANIMAT,F-06000 NICE,FRANCE; UNIV NICE,HOP ST ROCH,F-06000 NICE,FRANCE; CLIN UNIV ST LUC,B-1200 BRUSSELS,BELGIUM; HOP FERNAND WIDAL,DEPT BIOPHYS,F-75010 PARIS,FRANCE	CHU Nice; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	CLEMESSY, JL (corresponding author), UNIV PARIS 07,HOP FERNAND WIDAL,200 RUE FAUBOURG ST DENIS,F-75010 PARIS,FRANCE.							AGARWAL SL, 1960, ARCH INT PHARMACOD T, V123, P305; ARMITAGE AK, 1957, BRIT J PHARM CHEMOTH, V12, P74, DOI 10.1111/j.1476-5381.1957.tb01365.x; BAUER P, 1991, J TOXICOL-CLIN TOXIC, V29, P23, DOI 10.3109/15563659109038594; BONDURAND A, 1980, AF MED, V179, P239; BRANDFONBRENER M, 1966, J PHARMACOL EXP THER, V154, P250; BRIVET F, 1987, PRESSE MED, V16, P1433; BROWN MJ, 1983, NEW ENGL J MED, V309, P1414, DOI 10.1056/NEJM198312083092303; ENSINGER H, 1992, EUR J ANAESTH, V9, P435; HOLLAND WC, 1957, AM J PHYSIOL, V190, P492, DOI 10.1152/ajplegacy.1957.190.3.492; JAEGER A, 1987, MED TOXICOL ADV DRUG, V2, P242, DOI 10.1007/BF03259868; LECHAT P, 1988, REAN SOINS INTENS ME, V4, P51; LOFASO F, 1987, PRESSE MED, V16, P22; MICHAEL TAD, 1970, AM HEART J, V79, P831, DOI 10.1016/0002-8703(70)90371-6; MONNET R, 1964, Ann Biol Clin (Paris), V22, P429; RAKOTOSON L, 1973, J EUR TOXICOL, V2, P85; RIOU B, 1988, NEW ENGL J MED, V318, P1, DOI 10.1056/NEJM198801073180101; SOFOLA OA, 1983, CLIN PHYSIOL, V3, P75, DOI 10.1111/j.1475-097X.1983.tb00701.x; SOFOLA OA, 1979, CAN J PHARM, V58, P836; Vitris M, 1983, Dakar Med, V28, P593; 1988, REAN SOINS INTENS ME, V4, P43	20	54	57	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 30	1995	346	8979					877	880		10.1016/S0140-6736(95)92711-5	http://dx.doi.org/10.1016/S0140-6736(95)92711-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX196	7564673				2022-12-28	WOS:A1995RX19600011
J	BRUGGER, W; HEIMFELD, S; BERENSON, RJ; MERTELSANN, R; KANZ, L				BRUGGER, W; HEIMFELD, S; BERENSON, RJ; MERTELSANN, R; KANZ, L			RETRACTED: RECONSTITUTION OF HEMATOPOIESIS AFTER HIGH-DOSE CHEMOTHERAPY BY AUTOLOGOUS PROGENITOR CELLS GENERATED EX-VIVO (RETRACTED ARTICLE. SEE VOL 345, PG 64, 2001)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Retracted Publication							PLATELET RECOVERY; IFOSFAMIDE; CISPLATIN	Background. Autologous peripheral-blood progenitor cells can restore hematopoiesis after high-dose chemotherapy in patients with solid tumors or hematologic cancers. We investigated the ability of peripheral-blood progenitor cells generated ex vivo to restore hematopoiesis in patients with cancer who have undergone high-dose chemotherapy. Methods. Ten patients who had received high-dose chemotherapy were given transplants of autologous progenitor cells that had been generated ex vivo. We used 11 million CD34+ hematopoietic progenitor cells as the starting population for the cell growth. This number corresponds to less than 10 percent of the usual preparation of peripheral-blood CD34+ mononuclear cells used in leukapheresis. The CD34+ cells were grown in medium containing autologous plasma, recombinant human stem-cell factor, interleukin-1 beta, interleukin-3, interleukin-6, and erythropoietin. Results. No toxic effects were observed with the infusion of the generated cells. The cells promoted a rapid and sustained hematopoietic recovery when transplanted after treatment with high-dose etoposide (1500 mg per square meter of body-surface area), ifosfamide (12 g per square meter), carboplatin (750 mg per square meter), and epirubicin (150 mg per square meter), The pattern of hematopoietic reconstitution was identical to that in historical controls treated with unseparated mononuclear cells or positively selected CD34+ cells. Conclusions. A small number of peripheral-blood CD34+ cells, when grown ex vivo, can supply a population of hematopoietic precursors that have the ability to restore blood formation in patients treated with high doses of chemotherapy. This method, which requires only a small volume of the patient's blood, may reduce the risk of tumor-cell contamination, circumvent the need for leukapheresis, and allow repeated cycles of high-dose chemotherapy.	UNIV FREIBURG, MED CTR, DEPT HEMATOL ONCOL, FREIBURG, GERMANY; CELLPRO CORP, BOTHELL, WA USA	University of Freiburg								BRENNER MK, 1993, LANCET, V342, P1134, DOI 10.1016/0140-6736(93)92122-A; BRUGGER W, 1992, J CLIN ONCOL, V10, P1452, DOI 10.1200/JCO.1992.10.9.1452; BRUGGER W, 1993, BRIT J HAEMATOL, V84, P402, DOI 10.1111/j.1365-2141.1993.tb03093.x; BRUGGER W, 1994, BLOOD, V83, P636; BRUGGER W, 1993, BLOOD, V81, P2579; BRUGGER W, 1994, BLOOD, V84, P1421, DOI 10.1182/blood.V84.5.1421.bloodjournal8451421; DEISSEROTH AB, 1994, BLOOD, V83, P3068, DOI 10.1182/blood.V83.10.3068.3068; FISCH P, 1994, BLOOD, V84, pA228; HENSCHLER R, 1994, BLOOD, V84, P2898, DOI 10.1182/blood.V84.9.2898.bloodjournal8492898; KESSINGER A, 1991, BLOOD, V77, P211; RILL DR, 1994, BLOOD, V84, P380; SHERIDAN WP, 1992, LANCET, V339, P640, DOI 10.1016/0140-6736(92)90795-5; SHPALL EJ, 1994, J CLIN ONCOL, V12, P28, DOI 10.1200/JCO.1994.12.1.28; SHPALL EJ, 1994, BLOOD, V83, P623	14	339	357	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 3	1995	333	5					283	287		10.1056/NEJM199508033330503	http://dx.doi.org/10.1056/NEJM199508033330503			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL694	7541111	Bronze			2022-12-28	WOS:A1995RL69400003
J	ADACHI, Y; YOKOYAMA, Y; NANNO, T; YAMAMOTO, T				ADACHI, Y; YOKOYAMA, Y; NANNO, T; YAMAMOTO, T			POTENTIATION OF WARFARIN BY INTERFERON	BRITISH MEDICAL JOURNAL			English	Letter							DRUG-METABOLIZING ACTIVITY; HUMAN LIVER; DEPRESSION				ADACHI, Y (corresponding author), KINKI UNIV,SCH MED,OSAKA 589,JAPAN.							IRIE T, 1987, CLIN REPORT, V17, P6397; OKUNO H, 1990, EUR J CLIN PHARMACOL, V39, P365, DOI 10.1007/BF00315411; OKUNO H, 1993, HEPATOLOGY, V17, P65, DOI 10.1002/hep.1840170113; RENTON KW, 1984, BIOCHEM PHARMACOL, V33, P3899, DOI 10.1016/0006-2952(84)90058-3; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; WILLIAMS SJ, 1987, LANCET, V2, P939	6	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					292	292		10.1136/bmj.311.7000.292a	http://dx.doi.org/10.1136/bmj.311.7000.292a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7543311	Green Published			2022-12-28	WOS:A1995RM71900024
J	GAN, KH; VEEZE, HJ; VANDENOUWELAND, AMW; HALLEY, DJJ; SCHEFFER, H; VANDERHOUT, A; OVERBEEK, SE; DEJONGSTE, JC; BAKKER, W; HEIJERMAN, HGM				GAN, KH; VEEZE, HJ; VANDENOUWELAND, AMW; HALLEY, DJJ; SCHEFFER, H; VANDERHOUT, A; OVERBEEK, SE; DEJONGSTE, JC; BAKKER, W; HEIJERMAN, HGM			A CYSTIC-FIBROSIS MUTATION ASSOCIATED WITH MILD LUNG-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PANCREATIC FUNCTION; CFTR MUTATIONS; GENE; IDENTIFICATION; POPULATION; COMMON; DELTA-F508; PHENOTYPE; SEVERITY; GENOTYPE	Background. Cystic fibrosis is the most common lethal autosomal recessive disorder among whites. Among Dutch patients with cystic fibrosis, Delta F508 is the most common mutation and A455E the second most common mutation of the cystic fibrosis transmembrane conductance regulator gene on chromosome 7. A455E is associated with preserved pancreatic function and residual secretion of chloride across membranes. We investigated whether it is also associated with less severe pulmonary disease in patients with cystic fibrosis. Methods. A total of 33 patients with compound heterozygosity for the A455E mutation were matched according to age and sex with patients who were homozygous for the Delta F508 mutation. The pairs were analyzed with respect to the following outcome variables: age at diagnosis, pulmonary-function values, and the frequency of pseudomonas colonization, pancreatic sufficiency, and diabetes mellitus. Results. Cystic fibrosis was diagnosed at a later age in the patients with the A455E mutation than in the Delta F508 homozygotes (mean age at diagnosis, 15.0 vs. 3.1 years; P<0.001). Fewer patients with the A455E mutation had pancreatic insufficiency (21.2 percent vs. 93.9 percent, P<0.001), and none had diabetes meltitus (0 percent vs. 27.3 percent, P=0.004). Forced expiratory volume in one second (FEV(1)) and forced vital capacity (FVC) were significantly higher in the patients with the A455E mutation (mean FEV(1), 73.9 percent of the predicted value vs. 54.3 percent of the predicted value; P=0.002; mean FVC, 88.7 percent of the predicted value vs. 76.3 percent of the predicted value; P=0.04). Fewer patients with the A455E mutation were colonized with Pseudomonas aeruginosa (33.3 percent vs. 60.6 percent, P=0.02). Conclusions. A455E is a common mutation causing cystic fibrosis in the Netherlands. Although several mutations are known to be associated with less severe pancreatic disease, our findings demonstrate a correlation between the A455E mutation and mild pulmonary disease. Because mortality in this disease depends primarily on the progression of pulmonary disease, patients with the A455E mutation have a better prognosis than patients who are homozygous for the Delta F508 mutation.	LEYENBURG HOSP, CTR ADULT CYST FIBROSIS, DEPT PULMONOL, 2545 CH THE HAGUE, NETHERLANDS; SOPHIA CHILDRENS UNIV HOSP, DEPT PEDIAT, ROTTERDAM, NETHERLANDS; SOPHIA CHILDRENS UNIV HOSP, DIV PEDIAT PULMONOL, ROTTERDAM, NETHERLANDS; UNIV HOSP DIJKZIGT, DEPT CLIN GENET, ROTTERDAM, NETHERLANDS; UNIV HOSP DIJKZIGT, DEPT PULMONOL, ROTTERDAM, NETHERLANDS; UNIV GRONINGEN, DEPT MED GENET, GRONINGEN, NETHERLANDS	Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital; Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of Groningen			Scheffer, Hans/E-4644-2012	Scheffer, Hans/0000-0002-2986-0915; Gan, King Han/0000-0002-8227-6208				ALJADER LN, 1992, J MED GENET, V29, P883, DOI 10.1136/jmg.29.12.883; AUGARTEN A, 1993, LANCET, V342, P25, DOI 10.1016/0140-6736(93)91885-P; BURKE W, 1992, CHEST, V102, P506, DOI 10.1378/chest.102.2.506; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLAUSTRES M, 1992, HUM GENET, V90, P464; CUPPENS H, 1993, GENOMICS, V18, P693, DOI 10.1016/S0888-7543(05)80376-3; CURTIS A, 1991, J MED GENET, V28, P34, DOI 10.1136/jmg.28.1.34; CUTTING GR, 1992, AM J HUM GENET, V50, P1185; DAIGNEAULT J, 1992, HUM BIOL, V64, P115; DORK T, 1992, ACTA PAEDIATR, V81, P82, DOI 10.1111/j.1651-2227.1992.tb12086.x; FERRIE RM, 1992, AM J HUM GENET, V51, P251; GA KH, 1994, NEW ENGL J MED, V330, P865; GAN KH, 1993, PEDIATR PULM S, V9, P256; HAMOSH A, 1993, NEW ENGL J MED, V329, P1308; JOHANSEN HK, 1991, LANCET, V337, P631, DOI 10.1016/0140-6736(91)92449-C; KAZAZIAN HH, 1994, HUM MUTAT, V4, P167; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KEREM E, 1992, NEW ENGL J MED, V326, P1187, DOI 10.1056/NEJM199204303261804; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; LAMERS CBHW, 1990, PANCREAS, V5, P65; LEWIS PA, 1995, CYSTIC FIBROSIS, P1; LIECHTIGALLATI S, 1992, PEDIATR RES, V32, P175, DOI 10.1203/00006450-199208000-00010; LINDNER M, 1992, HUM GENET, V90, P267; OSTEDGAARD LS, 1994, PEDIATR PULM S, V10, P181; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; RIORDAN JR, 1989, SCIENCE, V245, P1437; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROZEN R, 1992, AM J MED GENET, V42, P360, DOI 10.1002/ajmg.1320420322; SANTIS G, 1990, LANCET, V336, P1081, DOI 10.1016/0140-6736(90)92566-Z; SCHEFFER H, 1989, LANCET, V2, P1345; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; SHRIMPTON AE, 1991, J MED GENET, V28, P317, DOI 10.1136/jmg.28.5.317; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; SUPER M, 1992, EUR J PEDIATR, V151, P108, DOI 10.1007/BF01958953; van Wieringen J C, 1985, Tijdschr Kindergeneeskd, V53, P147; VANBIEZEN P, 1992, THORAX, V47, P202, DOI 10.1136/thx.47.3.202; VEEZE HJ, 1994, J CLIN INVEST, V93, P461, DOI 10.1172/JCI116993; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; ZIELENSKI J, 1992, PEDIATR PULM S, V8, P244	42	124	127	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 13	1995	333	2					95	99		10.1056/NEJM199507133330204	http://dx.doi.org/10.1056/NEJM199507133330204			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH225	7539891				2022-12-28	WOS:A1995RH22500004
J	BURKS, DJ; CARBALLADA, R; MOORE, HDM; SALING, PM				BURKS, DJ; CARBALLADA, R; MOORE, HDM; SALING, PM			INTERACTION OF A TYROSINE KINASE FROM HUMAN SPERM WITH THE ZONA-PELLUCIDA AT FERTILIZATION	SCIENCE			English	Article							HEMIZONA ASSAY HZA; HUMAN-SPERMATOZOA; ACROSOME REACTION; RECEPTOR; PROTEIN; MOUSE; PHOSPHOTYROSINE; ANTIBODY; SEQUENCE; BINDING	A 95-kilodalton mouse sperm protein with characteristics of a protein tyrosine kinase has been identified as a receptor for ZP3, a glycoprotein in the egg's extracellular matrix. The structure of the human homolog was determined by screening an expression library from human testis; a testis-specific complementary DNA was isolated that encodes a protein similar to receptor tyrosine kinases and appears to be expressed only in testicular germ cells. Antibodies against a synthetic peptide from the intracellular domain recognized a 95-kilodalton human sperm protein that contains phosphotyrosine; human ZP3 stimulates the kinase activity of this sperm protein. Synthetic peptides corresponding to regions of the predicted extracellular domain inhibited sperm binding to human zona pellucida. Availability of the primary sequence of a receptor for ZP3 provides a rational starting point for sperm-targeted contraceptive development.	DUKE UNIV, MED CTR, DEPT OBSTET & GYNECOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; UNIV SHEFFIELD, DEPT MOLEC BIOL & BIOTECHNOL, SHEFFIELD S10 2UH, S YORKSHIRE, ENGLAND; UNIV SHEFFIELD, DEPT OBSTET & GYNECOL, SHEFFIELD S10 2UH, S YORKSHIRE, ENGLAND	Duke University; Duke University; University of Sheffield; University of Sheffield					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018201, U54HD029125] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 18201, HD 29125] Funding Source: Medline; Wellcome Trust Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust(Wellcome TrustEuropean Commission)		Battey, 1986, BASIC METHODS MOL BI; BLEIL JD, 1980, CELL, V20, P873, DOI 10.1016/0092-8674(80)90334-7; BLEIL JD, 1983, DEV BIOL, V95, P317, DOI 10.1016/0012-1606(83)90032-5; BRIGGS MS, 1986, ADV PROTEIN CHEM, V38, P109, DOI 10.1016/S0065-3233(08)60527-6; BURKMAN LJ, 1988, FERTIL STERIL, V49, P688; BURKS DJ, UNPUB; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHAMBERLIN ME, 1990, P NATL ACAD SCI USA, V87, P6014, DOI 10.1073/pnas.87.16.6014; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FRANKEN DR, 1989, J IN VITRO FERTIL EM, V6, P44, DOI 10.1007/BF01134581; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; KALAB P, 1994, J BIOL CHEM, V269, P3810; KAMPS MP, 1988, ONCOGENE, V2, P305; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETWIN K, 1988, ONCOGENE, V3, P621; LEYTON L, 1989, J CELL BIOL, V108, P2163, DOI 10.1083/jcb.108.6.2163; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LEYTON L, 1992, P NATL ACAD SCI USA, V89, P11692, DOI 10.1073/pnas.89.24.11692; LINDBERG RA, 1991, METHOD ENZYMOL, V200, P557; MAHONY MC, 1991, J REPROD IMMUNOL, V19, P287, DOI 10.1016/0165-0378(91)90041-N; Maniatis T., 1982, MOL CLONING; MOORE HDM, 1987, J REPROD IMMUNOL, V11, P157, DOI 10.1016/0165-0378(87)90054-4; NG FLH, 1992, HUM REPROD, V7, P261, DOI 10.1093/oxfordjournals.humrep.a137628; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OEHNINGER S, 1993, MOL REPROD DEV, V35, P57, DOI 10.1002/mrd.1080350110; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; Pawson T., 1992, CURR OPIN STRUC BIOL, V2, P432; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; RESCIGNO J, 1991, ONCOGENE, V6, P1909; SNYDER M, 1987, METHOD ENZYMOL, V154, P107; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Yanagimachi R., 1994, P189; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	165	171	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 7	1995	269	5220					83	86		10.1126/science.7541556	http://dx.doi.org/10.1126/science.7541556			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7541556				2022-12-28	WOS:A1995RG98000039
J	PEUNOVA, N; ENIKOLOPOV, G				PEUNOVA, N; ENIKOLOPOV, G			NITRIC-OXIDE TRIGGERS A SWITCH TO GROWTH ARREST DURING DIFFERENTIATION OF NEURONAL CELLS	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; SMOOTH-MUSCLE CELLS; RIBONUCLEOTIDE REDUCTASE; NADPH DIAPHORASE; SYNTHASE; PROLIFERATION; CLONING; MACROPHAGES; HEPATOCYTES; GENE	ARREST Of cell division is a prerequisite for cells to enter a program of terminal differentiation. Mitogenesis and cytostasis of neuronal cell precursors can be induced by the same or by different growth or trophic factors(1-9). Response of PC12 cells to nerve growth factor (NGF) involves a proliferative phase that is followed by growth arrest and differentiation. Here we present evidence that the cytostatic effect of NGF is mediated by nitric oxide (NO), a second messenger molecule with both para- and autocrine properties ties that can diffuse freely and act within a restricted volume(10-14). We show that NGF induces different forms of nitric oxide synthase (NOS) in neuronal cells, that nitric oxide (NO) acts as a cytostatic agent in these cells, that inhibition of NOS leads to reversal of NGF-induced cytostasis and thereby prevents full differentiation, and that capacity of a mutant cell line to differentiate can be rescued by exogenous NO, We suggest that induction of NOS is an important step in the commitment of neuronal precursors and that NOS serves as a growth arrest gene, initiating the switch to cytostasis during differentiation.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory			Enikolopov, Grigori/P-5731-2019; Enikolopov, Grigori N/B-7771-2009	Enikolopov, Grigori/0000-0001-8178-8917; Enikolopov, Grigori N/0000-0001-8178-8917				ANDERSON DJA, 1993, REV NEUROSCI, V16, P129; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; BURSTEIN DE, 1982, DEV BIOL, V94, P477, DOI 10.1016/0012-1606(82)90364-5; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DRAGO J, 1991, P NATL ACAD SCI USA, V88, P2199, DOI 10.1073/pnas.88.6.2199; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HIRSCH DB, 1993, CURR BIOL, V3, P749, DOI 10.1016/0960-9822(93)90022-G; HOGAN M, 1992, J CLIN INVEST, V90, P1110, DOI 10.1172/JCI115928; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; Jacobson M., 1991, DEV NEUROBIOLOGY; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; LILIEN LE, 1985, NATURE, V317, P632; MCKAY R, 1990, COLD SH Q B, V55, P291; MCKAY RDG, 1989, CELL, V58, P815, DOI 10.1016/0092-8674(89)90934-3; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; WOOD ER, 1993, BIOCHEM BIOPH RES CO, V191, P767, DOI 10.1006/bbrc.1993.1283; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	28	455	469	1	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					68	73		10.1038/375068a0	http://dx.doi.org/10.1038/375068a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7536899				2022-12-28	WOS:A1995QW60400057
J	BEEKMAN, EM; PORCELLI, SA; MORITA, CT; BEHAR, SM; FURLONG, ST; BRENNER, MB				BEEKMAN, EM; PORCELLI, SA; MORITA, CT; BEHAR, SM; FURLONG, ST; BRENNER, MB			RECOGNITION OF A LIPID ANTIGEN BY CD1-RESTRICTED ALPHA-BETA(+) T-CELLS	NATURE			English	Article							LYMPHOCYTES-T; CORD FACTOR; PEPTIDES; BIOLOGY; GENES	MAJOR histocompatibility complex (MHC) class I and class II molecules bind immunogenic peptides and present them to lymphocytes bearing the alpha beta T-cell antigen receptor (TCR)(1-4). An analogous antigen-presenting function also has been proposed for the non-MHC-encoded CDI molecules: a family of non-polymorphic, beta(2)-microglobulin-associated glycoproteins(5-8) expressed on most professional antigen-presenting cells(9-11). In support of this hypothesis, CD1 molecules are recognized by selected CD4(-)CD8(-)alpha beta or gamma delta TCR(+) T-cell clones(12-14), and we have recently shown that CD1 molecules restrict the recognition of foreign microbial antigens by alpha beta TCR(+) T cells(10). But the substantial structural divergence of CD1 from MHC class I and class II molecules(7), raises the possibility that the antigens presented by the CD1 system may differ fundamentally from those presented by MHC-encoded molecules. Here we report that a purified CD1b-restricted antigen of Mycobacterium tuberculosis presented to alpha beta TCR(+) T cells is mycolic acid, a family of alpha-branched, beta-hydroxy, long-chain fatty acids found in mycobacteria(15-16). This example of non-protein microbial antigen recognition suggests that alpha beta TCR(+) T cells recognize a broader range of antigens than previously appreciated and that at least one member of the CD1 family has evolved the ability to present lipid antigens.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	BEEKMAN, EM (corresponding author), BRIGHAM & WOMENS HOSP, DEPT RHEUMATOL & IMMUNOL, LYMPHOCYTE BIOL SECT, BOSTON, MA 02115 USA.		Morita, Craig T/C-1365-2011	Morita, Craig T/0000-0001-8496-8294; Behar, Samuel/0000-0002-3374-6699				BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BALK SP, 1989, P NATL ACAD SCI USA, V86, P252, DOI 10.1073/pnas.86.1.252; BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; BEKIERKUNST A, 1971, SCIENCE, V174, P1240, DOI 10.1126/science.174.4015.1240; BOUMSELL L, 1989, LEUCOCYTE TYPING, V4, P251; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CALABI F, 1989, EUR J IMMUNOL, V19, P285, DOI 10.1002/eji.1830190211; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; CHRISTIE WW, 1982, LIPID ANAL, P117; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; FAURE F, 1990, EUR J IMMUNOL, V20, P703, DOI 10.1002/eji.1830200336; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; FLOYD MM, 1992, J CLIN MICROBIOL, V30, P1327, DOI 10.1128/JCM.30.5.1327-1330.1992; FOLCH J, 1957, J BIOL CHEM, V226, P497; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; Goren M. B., 1979, TUBERCULOSIS, P63; LECHEVALIER MP, 1977, CRC CR REV MICROBIOL, V5, P109, DOI 10.3109/10408417709102311; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; Minnikin D. E., 1980, MICROBIOLOGICAL CLAS, P189; MINNIKIN DE, 1982, BIOL MYCOBACTERIA, V1, P95; MORITA CT, 1991, EUR J IMMUNOL, V21, P2999, DOI 10.1002/eji.1830211215; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; PARANT M, 1978, INFECT IMMUN, V20, P12, DOI 10.1128/IAI.20.1.12-19.1978; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; RONCAROLO MG, 1988, J EXP MED, V168, P2139, DOI 10.1084/jem.168.6.2139; TANAKA Y, 1994, P NATL ACAD SCI USA, V91, P8175, DOI 10.1073/pnas.91.17.8175; TERHORST C, 1981, CELL, V23, P771, DOI 10.1016/0092-8674(81)90441-4; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0	30	868	889	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 15	1994	372	6507					691	694		10.1038/372691a0	http://dx.doi.org/10.1038/372691a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7527500				2022-12-28	WOS:A1994PX30700090
J	ZHOU, L; DEY, CR; WERT, SE; DUVALL, MD; FRIZZELL, RA; WHITSETT, JA				ZHOU, L; DEY, CR; WERT, SE; DUVALL, MD; FRIZZELL, RA; WHITSETT, JA			CORRECTION OF LETHAL INTESTINAL DEFECT IN A MOUSE MODEL OF CYSTIC-FIBROSIS BY HUMAN CFTR	SCIENCE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; TRANSGENIC MICE; EXPRESSION; CRYPT; CELLS	Cystic fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR). A potential animal model of CF, the CFTR(-/-) mouse, has had limited utility because most mice die from intestinal obstruction during the first month of life. Human CFTR (hCFTR) was expressed in CFTR(-/-) mice under the control of the rat intestinal fatty acid-binding protein gene promoter. The mice survived and showed functional correction of ileal goblet cell and crypt cell hyperplasia and cyclic adenosine monophosphate-stimulated chloride secretion. These results support the concept that transfer of the hCFTR gene may be a useful strategy for correcting physiologic defects in patients with CF.	CHILDRENS HOSP,MED CTR,DIV PULM BIOL,CINCINNATI,OH 45229; UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294	Cincinnati Children's Hospital Medical Center; University of Alabama System; University of Alabama Birmingham					NHLBI NIH HHS [HL51832, HL49004] Funding Source: Medline; NIDDK NIH HHS [DK38518] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049004, P01HL051832] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038518] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; SIEMER C, 1993, PFLUG ARCH EUR J PHY, V424, P321, DOI 10.1007/BF00384359; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STRONG TV, 1994, J CLIN INVEST, V93, P347, DOI 10.1172/JCI116966; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; WELSH MJ, 1982, SCIENCE, V218, P1219, DOI 10.1126/science.6293054; WHITSETT JA, 1992, NAT GENET, V2, P13, DOI 10.1038/ng0992-13	9	204	212	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1705	1708		10.1126/science.7527588	http://dx.doi.org/10.1126/science.7527588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7527588				2022-12-28	WOS:A1994PW30800040
J	BUNDENS, WP; BERGAN, JJ; HALASZ, NA; MURRAY, J; DREHOBL, M				BUNDENS, WP; BERGAN, JJ; HALASZ, NA; MURRAY, J; DREHOBL, M			THE SUPERFICIAL FEMORAL VEIN - A POTENTIALLY LETHAL MISNOMER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							THROMBOSIS; ULTRASOUND; DIAGNOSIS	Objective.-To assess the potential for error in interpretation of venous duplex reports that use the term ''superficial femoral vein.'' Design.-Three surveys conducted by mail. Setting-Three multispecialty medical groups, anatomy departments of all US medical schools, and vascular laboratories. Participants.-A total of 46 family practitioners and general internists, 95 chairpersons of departments of anatomy, and 85 laboratory directors. Main Outcome Measures.-Proposed treatment of a patient with leg pain and an acute thrombosis of the superficial femoral vein; what nomenclature(s) for the deep thigh veins is (are) felt to be correct, what are acceptable alternatives, what is taught to students and which is preferred; and what terminology is being used in lower limb venous duplex reports. Results.-Only 24% (11/46) of the respondents would have administered anticoagulants to the patient as described. Only 3% (3/95) of anatomists felt the term ''superficial femoral vein'' was correct, 22% (21/95) felt it was an acceptable alternative (though only 9% [9/95] taught it to medical students), and only 7% (7/95) of anatomists felt the term was preferred for everyday use, The term ''superficial femoral vein'' is used by 93% (79/85) of vascular laboratories in lower limb venous duplex reports. Conclusion.-Although the overwhelming majority of vascular laboratories use the term ''superficial femoral vein'' in venous duplex reports, the use of this term is potentially hazardous to patients. Most primary care physicians have not been taught and are not aware that the superficial femoral vein is a deep vein and that acute thrombosis of this vessel is potentially life threatening.	USN,MED CTR,SAN DIEGO,CA 92152; USN,CTR HLTH CARE,SAN DIEGO,CA 92152	United States Department of Defense; United States Navy; United States Department of Defense; United States Navy	BUNDENS, WP (corresponding author), UNIV CALIF SAN DIEGO,DEPT SURG,9500 GILMAN DR,0643,ROOM 147,LA JOLLA,CA 92093, USA.							BILLINGS JS, 1890, NATIONAL MED DICT, V1, P507; DOUGHERTY J, 1940, SURG GYNECOL OBSTET, V71, P697; ELIAS A, 1987, INT ANGIOL, V6, P175; Homans J, 1941, NEW ENGL J MED, V224, P179, DOI 10.1056/NEJM194101302240501; Homans J, 1934, N ENGL J MED, V211, P993; HOMANS J, 1937, AM J SURG, V38, P316; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; MARKEL A, 1992, ARCH SURG-CHICAGO, V127, P305; Markel A, 1991, J VASC MED BIOL, V3, P432; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P133; RUBIN BG, 1994, J VASC SURG, V20, P698, DOI 10.1016/S0741-5214(94)70156-3; STRANDNESS DE, 1993, VASCULAR DIAGNOSIS, P772; WHITE RH, 1989, ANN INTERN MED, V111, P297, DOI 10.7326/0003-4819-111-4-297; 1989, NOMINA ANATOMICA, pA65	14	37	38	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	1995	274	16					1296	1298						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA104	7563535				2022-12-28	WOS:A1995TA10400025
J	DRAKE, DF				DRAKE, DF			WHAT DO CLINTON,HILLARY,RODHAM AND GINGRICH,NEWT HAVE IN COMMON	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								In a somewhat tongue-in-cheek style, this article tries to persuade conservatives that it might be in their best interests to consider broader health system reform alternatives in their quest to reduce the cost of federal health entitlements for a balanced budget by 2002. The conventional means for reducing the federal budget by $450 billion in 7 years will inflict much pain on many voters. The substitution of a new, more targeted entitlement, prospectively, for all Americans represents an alternative that provides much gain to many and only some pain to a few.	AMER HOSP ASSOC,CHICAGO,IL 60611									DRAKE DF, 1994, REFORMING HLTH CARE, P180; FELDSTEIN M, 1971, PUBLIC INTEREST, V23, P93; FELDSTEIN MS, 1971, NATIONAL HLTH INSURA; FRUM D, 1994, WALL STREET J   0718, pA19; LUBITZ J, 1995, NEW ENGL J MED, V332, P999, DOI 10.1056/NEJM199504133321506; MEYER H, 1995, AM MED NEWS, V38, P27; MEYER H, 1995, AM MED NEWS, V38, P1	7	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	1995	274	16					1316	1318						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA104	7563541				2022-12-28	WOS:A1995TA10400031
J	BLAND, JM; ALTMAN, DG				BLAND, JM; ALTMAN, DG			COMPARING METHODS OF MEASUREMENT - WHY PLOTTING DIFFERENCE AGAINST STANDARD METHOD IS MISLEADING	LANCET			English	Article								When comparing a new method of measurement with a standard method, one of the things we want to know is whether the difference between the measurements by the two methods is related to the magnitude of the measurement. A plot of the difference against the standard measurement is sometimes suggested, but this will always appear to show a relation between difference and magnitude when there is none. A plot of the difference against the average of the standard and new measurements is unlikely to mislead in this way. We show this theoretically and by a practical example.	IMPERIAL CANC RES FUND,MED STAT LAB,LONDON WC2,ENGLAND		BLAND, JM (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Javed, Nasir/C-2501-2012	Javed, Nasir/0000-0002-6390-431X				ALTMAN DG, 1988, STAT MED, V7, P629, DOI 10.1002/sim.4780070602; ALTMAN DG, 1983, J ROY STAT SOC D-STA, V32, P307, DOI 10.2307/2987937; Bland J. M., 1992, CURRENT CONTENTS CM, VCM20, P8; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; CLOSE A, 1986, BRIT MED J, V293, P775, DOI 10.1136/bmj.293.6550.775; KRINGLE RO, 1994, TIETZ TXB CLIN CHEM, P384; 1984, CLIN LAB HAEMATOL, V6, P69	7	1839	1881	1	78	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1085	1087		10.1016/S0140-6736(95)91748-9	http://dx.doi.org/10.1016/S0140-6736(95)91748-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564793	Green Submitted			2022-12-28	WOS:A1995TA69700017
J	FEU, F; GARCIAPAGAN, JC; BOSCH, J; LUCA, A; TERES, J; ESCORSELL, A; RODES, J				FEU, F; GARCIAPAGAN, JC; BOSCH, J; LUCA, A; TERES, J; ESCORSELL, A; RODES, J			RELATION BETWEEN PORTAL PRESSURE RESPONSE TO PHARMACOTHERAPY AND RISK OF RECURRENT VARICEAL HEMORRHAGE IN PATIENTS WITH CIRRHOSIS	LANCET			English	Article							DISTAL SPLENORENAL SHUNT; THERAPEUTIC PORTACAVAL-SHUNT; BLEEDING ESOPHAGEAL-VARICES; RANDOMIZED CONTROLLED TRIAL; ENDOSCOPIC SCLEROTHERAPY; INJECTION SCLEROTHERAPY; PROPRANOLOL; PREVENTION; HEMORRHAGE; HYPERTENSION	In patients with variceal bleeding as a complication of hepatic cirrhosis, propranolol therapy reduces the risk of recurrent variceal haemorrhage. However, the relation between portal pressure response to pharmacological treatment and clinical events has not been well defined. This relation was prospectively investigated in 69 cirrhotic patients receiving continued propranolol therapy after an episode of variceal bleeding. Hepatic venous pressure gradient (HVPG) was measured before and at 3 months of continued drug therapy. At 3 months HVPG had fallen by 20% or more in 25 patients. During follow-up of 28 (SD 17) months rebleeding occurred in 2 of these 25 patients compared with 23 of 44 who had lesser reductions in HVPG. Cumulative probability of rebleeding at 1, 2, and 3 years was 4%, 9%, and 9% in patients with a decrease in HVPG greater than or equal to 20%,and 28%, 39%, and 66% in patients with a decrease in HVPG <20% (p<0.001, log-rank test), On multivariate analysis, a decrease in HVPG greater than or equal to 20% was the only independent predictor of rebleeding (relative risk 0.09, 95% CI 0.02-0.41. Of the 8 patients in whom the HVPG fell to 12 mm Hg or less, none rebled. This study suggests that measurement of the HVPG response to pharmacotherapy will provide useful prognostic information on the long-term risk of variceal rebleeding.	UNIV BARCELONA,HOSP CLIN & PROV,DEPT MED,LIVER UNIT,HEPAT HAEMODYNAM LAB,E-08036 BARCELONA,SPAIN; UNIV BARCELONA,HOSP CLIN & PROV,DEPT MED,GASTROENTEROL SERV,BARCELONA,SPAIN	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona			Garcia-Pagan, Juan-Carlos/P-6291-2015; Bosch, Jaime/AAF-1006-2022; Bosch, Jaime/AFF-8344-2022	Garcia-Pagan, Juan-Carlos/0000-0001-9032-4954; 				BOSCH J, 1984, HEPATOLOGY, V4, P1200, DOI 10.1002/hep.1840040617; BURROUGHS AK, 1992, BAILLIERE CLIN GASTR, V6, P437, DOI 10.1016/0950-3528(92)90031-9; BURROUGHS AK, 1991, OXFORD TXB CLIN HEPA, P408; CONN HO, 1991, HEPATOLOGY, V13, P902, DOI 10.1002/hep.1840130517; DEFRANCHIS R, 1992, J HEPATOL, V15, P256, DOI 10.1016/0168-8278(92)90044-P; FEU F, 1991, HEPATOLOGY, V13, P917, DOI 10.1002/hep.1840130519; GARCIAPAGAN JC, 1991, ANN INTERN MED, V114, P869, DOI 10.7326/0003-4819-114-10-869; GARCIAPAGAN JC, 1990, HEPATOLOGY, V2, P230; GARCIATSAO G, 1986, HEPATOLOGY, V6, P101, DOI 10.1002/hep.1840060119; GIMSON AES, 1993, LANCET, V342, P391, DOI 10.1016/0140-6736(93)92812-8; GOODENOUGH DJ, 1974, RADIOLOGY, V110, P89, DOI 10.1148/110.1.89; GROSZMANN RJ, 1990, GASTROENTEROLOGY, V99, P1401, DOI 10.1016/0016-5085(90)91168-6; HAYES PC, 1990, LANCET, V336, P153, DOI 10.1016/0140-6736(90)91668-Z; HENDERSON JM, 1990, ANN INTERN MED, V112, P262, DOI 10.7326/0003-4819-112-4-262; JACKSON FC, 1971, ANN SURG, V174, P672, DOI 10.1097/00000658-197110000-00012; LEBREC D, 1981, NEW ENGL J MED, V305, P1371, DOI 10.1056/NEJM198112033052302; LUCA A, 1995, HEPATOLOGY, V21, P83, DOI 10.1002/hep.1840210115; PAGLIARO L, 1989, GASTROENTEROL INT, V2, P71; Pagliaro L, 1994, PORTAL HYPERTENSION, P72; PAQUET KJ, 1982, ENDOSCOPY, V14, P4, DOI 10.1055/s-2007-1021560; PEREZAYUSO RM, 1991, LANCET, V337, P1431, DOI 10.1016/0140-6736(91)93125-S; POYNARD T, 1991, NEW ENGL J MED, V324, P1532, DOI 10.1056/NEJM199105303242202; RESNICK RH, 1974, GASTROENTEROLOGY, V67, P843; REYNOLDS TB, 1981, GASTROENTEROLOGY, V80, P1005; RIKKERS LF, 1987, ANN SURG, V206, P261, DOI 10.1097/00000658-198709000-00004; RUEFF B, 1976, LANCET, V1, P655; SPINA GP, 1990, ANN SURG, V211, P178, DOI 10.1097/00000658-199002000-00010; STIEGMANN GV, 1992, NEW ENGL J MED, V326, P1527, DOI 10.1056/NEJM199206043262304; TERES J, 1987, HEPATOLOGY, V7, P430, DOI 10.1002/hep.1840070303; TERES J, 1993, GASTROENTEROLOGY, V105, P1508, DOI 10.1016/0016-5085(93)90158-9; WESTABY D, 1990, HEPATOLOGY, V11, P353, DOI 10.1002/hep.1840110304; 1984, NEW ENGL J MED, V311, P1594	32	432	442	1	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1056	1059		10.1016/S0140-6736(95)91740-3	http://dx.doi.org/10.1016/S0140-6736(95)91740-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564785				2022-12-28	WOS:A1995TA69700009
J	MARSHALL, BJ				MARSHALL, BJ			HELICOBACTER-PYLORI - THE ETIOLOGIC AGENT FOR PEPTIC-ULCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAMPYLOBACTER-PYLORI; GASTRITIS; ERADICATION; BISMUTH; TRIAL		UNIV VIRGINIA,HLTH SCI CTR,DEPT MED,CHARLOTTESVILLE,VA	University of Virginia				Marshall, Barry/0000-0003-4853-5015				CULLEN DJE, 1993, GUT, V34, P1681, DOI 10.1136/gut.34.12.1681; GRAHAM DY, 1991, ANN INTERN MED, V115, P266, DOI 10.7326/0003-4819-115-4-266; MARSHALL BJ, 1987, AM J GASTROENTEROL, V82, P200; MARSHALL BJ, 1988, J NUCL MED, V29, P11; MARSHALL BJ, 1994, AM J GASTROENTEROL, V89, pS116; MARSHALL BJ, 1987, DIGESTION, V37, P16, DOI 10.1159/000199555; MARSHALL BJ, 1988, LANCET, V2, P1437; MARSHALL BJ, 1984, LANCET, V1, P1311; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MARSHALL BJ, 1986, J INFECT DIS, V52, P650; MARSHALL BJ, 1985, CAMPYLOBACTER, V3, P188; MARSHALL BJ, 1985, MED J AUSTRALIA, V149, P439; The EUROGAST Study Group, 1993, GUT, V34, P1672; WARREN JR, 1983, LANCET, V1, P273; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; 1994, JAMA-J AM MED ASSOC, V272, P65	16	136	139	2	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1064	1066		10.1001/jama.274.13.1064	http://dx.doi.org/10.1001/jama.274.13.1064			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX108	7563460				2022-12-28	WOS:A1995RX10800032
J	BANERJEE, A; SHORTHOUSE, A				BANERJEE, A; SHORTHOUSE, A			TOWARDS EVEN FEWER COLOSTOMIES	LANCET			English	Editorial Material							RECTAL-CANCER; ANASTOMOSIS				BANERJEE, A (corresponding author), ROYAL HALLAMSHIRE HOSP,DEPT COLORECTAL SURG,GLOSSOP RD,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND.		Banerjee, Anjan Kumar/AAL-6375-2020	Banerjee, Anjan Kumar/0000-0002-5935-3404				BAETEN CGMI, 1995, NEW ENGL J MED, V332, P1600, DOI 10.1056/NEJM199506153322403; BANERJEE AK, 1995, BRIT J SURG, V82, P1165, DOI 10.1002/bjs.1800820907; DUDLEY HAF, 1980, BRIT J SURG, V67, P80, DOI 10.1002/bjs.1800670203; FEDOROV VD, 1989, DIS COLON RECTUM, V32, P138, DOI 10.1007/BF02553827; HEALD RJ, 1980, BRIT J SURG, V67, P198, DOI 10.1002/bjs.1800670311; HENTZ VR, 1982, PLAST RECONSTR SURG, V70, P82, DOI 10.1097/00006534-198207000-00017; Kock N G, 1973, Prog Surg, V12, P180; PARC R, 1986, BRIT J SURG, V73, P139, DOI 10.1002/bjs.1800730223; PARKS AG, 1978, BRIT MED J, V2, P85, DOI 10.1136/bmj.2.6130.85; PICKRELL KL, 1952, ANN SURG, V135, P853, DOI 10.1097/00000658-195206000-00010; SIMONSEN SO, 1976, BRIT J SURG, V63, P389; WILLIAMS NS, 1989, BRIT J SURG, V76, P5, DOI 10.1002/bjs.1800760104; WILLIAMS NS, 1992, BRIT J SURG, V79, P733, DOI 10.1002/bjs.1800790804; WILLIAMS NS, 1991, LANCET, V338, P1163	14	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 30	1995	346	8979					859	859		10.1016/S0140-6736(95)92705-0	http://dx.doi.org/10.1016/S0140-6736(95)92705-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX196	7564667				2022-12-28	WOS:A1995RX19600005
J	HOSOYA, T; TAKIZAWA, K; NITTA, K; HOTTA, Y				HOSOYA, T; TAKIZAWA, K; NITTA, K; HOTTA, Y			GLIAL-CELLS MISSING - A BINARY SWITCH BETWEEN NEURONAL AND GLIAL DETERMINATION IN DROSOPHILA	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; GROWTH CONES; GENE ENCODES; NEUROGENESIS; MELANOGASTER; EXPRESSION; PROTEINS; SEQUENCE; CNS; CONSENSUS	In the Drosophila CNS, both neurons and glia are derived from neuroblasts. We have identified a gene, glial cells missing (gcm), that encodes a novel nuclear protein expressed transiently in early glial cells. Its mutation causes presumptive glial cells to differentiate into neurons, whereas its ectopic expression forces virtually all CNS cells to become glial cells. Thus, gem functions as a binary switch that turns on glial fate while inhibiting default neuronal fate of the neuroblasts and their progeny. Similar results are also obtained in the PNS. Analyses of the mutant revealed that ''pioneer neurons'' can find correct pathways without glial cells and that neurons and glia have a common molecular basis for individual identity.	UNIV TOKYO,GRAD SCH SCI,DEPT PHYS,TOKYO 113,JAPAN	University of Tokyo			Hosoya, Toshihiko/Q-2514-2018	Hosoya, Toshihiko/0000-0001-8559-8344				BASTIANI MJ, 1986, J NEUROSCI, V6, P3542; BELLEN HJ, 1992, GENE DEV, V6, P2125, DOI 10.1101/gad.6.11.2125; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BRAND AH, 1993, DEVELOPMENT, V118, P401; BUCHANAN RL, 1993, NEURON, V10, P839, DOI 10.1016/0896-6273(93)90200-B; CAMPBELL G, 1994, DEVELOPMENT, V120, P2957; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHIBA A, 1995, NATURE, V374, P166, DOI 10.1038/374166a0; CONDRON BG, 1994, NEURON, V13, P541, DOI 10.1016/0896-6273(94)90024-8; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; GIANGRANDE A, 1994, DEVELOPMENT, V120, P523; GIANGRANDE A, 1993, DEVELOPMENT, V117, P895; Goodman C. S., 1993, DEV DROSOPHILA MELAN, VII, P1131; HALTER DA, 1995, DEVELOPMENT, V121, P317; ITO K, 1995, ROUX ARCH DEV BIOL, V204, P284, DOI 10.1007/BF02179499; JACOBS JR, 1989, NEURON, V2, P1625; JACOBS JR, 1989, J NEUROSCI, V9, P2402; JACOBS JR, 1993, J NEUROBIOL, V24, P611, DOI 10.1002/neu.480240507; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JONES BW, 1995, CELL, V82, P1013, DOI 10.1016/0092-8674(95)90280-5; KANIA A, 1995, GENETICS, V139, P1663; KLAES A, 1994, CELL, V78, P149, DOI 10.1016/0092-8674(94)90581-9; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLAMBT C, 1991, GLIA, V4, P205, DOI 10.1002/glia.440040212; KLAMBT C, 1993, DEVELOPMENT, V117, P163; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SALZBERG A, 1994, NEURON, V13, P269, DOI 10.1016/0896-6273(94)90346-8; Sambrook J, 1989, MOL CLONING LABORATO; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; UDOLPH G, 1993, DEVELOPMENT, V118, P765; Waddington C. H, 1940, ORG AND GENES; WINBERG ML, 1992, DEVELOPMENT, V115, P903; XIONG WC, 1994, GENE DEV, V8, P981, DOI 10.1101/gad.8.8.981	48	360	366	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					1025	1036		10.1016/0092-8674(95)90281-3	http://dx.doi.org/10.1016/0092-8674(95)90281-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553844	Bronze			2022-12-28	WOS:A1995RW69300018
J	PELOSI, AJ				PELOSI, AJ			AN ETHICAL DEBATE - 2ND OPINIONS - A RIGHT OR A CONCESSION - LIMITATIONS OF PSYCHIATRY	BRITISH MEDICAL JOURNAL			English	Article											PELOSI, AJ (corresponding author), HAIRMYRES HOSP,LANARKSHIRE HEALTHCARE NHS TRUST,E KILBRIDE G75 8RJ,LANARK,SCOTLAND.			Pelosi, Anthony/0000-0002-5501-2661				1985, LANCET, V1, P731; 1995, SERVICES PEOPLE AFFE	2	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	1995	311	7006					670	671		10.1136/bmj.311.7006.670a	http://dx.doi.org/10.1136/bmj.311.7006.670a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RU753	7549639	Green Published			2022-12-28	WOS:A1995RU75300024
J	THRASHER, AJ; CASIMIR, CM; KINNON, C; MORGAN, G; SEGAL, AW; LEVINSKY, RJ				THRASHER, AJ; CASIMIR, CM; KINNON, C; MORGAN, G; SEGAL, AW; LEVINSKY, RJ			GENE-TRANSFER TO PRIMARY CHRONIC GRANULOMATOUS-DISEASE MONOCYTES	LANCET			English	Note								For somatic gene therapy to become a realistic therapeutic strategy for chronic granulomatous disease (CGD),we have to be able to assign the molecular lesion to a specific component of the NADPH oxidase and to confirm that transfer of a functional copy of the corresponding defective gene will result in correction of the cellular defect. We used an adenovirus Vector expressing p47phox to transduce monocytes from patients with CGD. We showed by nitroblue-tetrazolium staining that NADPH-oxidase activity was restored to these cells. This technique offers a rapid means for molecular diagnosis. in the short term, this approach may have therapeutic potential.	UCL, SCH MED, LONDON W1N 8AA, ENGLAND	University of London; University College London; UCL Medical School	THRASHER, AJ (corresponding author), INST CHILD HLTH, MOLEC IMMUNOL UNIT, 30 GUILFORD ST, LONDON WC1N 1EH, ENGLAND.		Kinnon, Christine/A-1585-2010	Segal, Anthony/0000-0001-7602-9043	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BUESCHER ES, 1982, NEW ENGL J MED, V307, P800, DOI 10.1056/NEJM198209233071306; CASIMIR C, 1992, EUR J CLIN INVEST, V22, P403, DOI 10.1111/j.1365-2362.1992.tb01481.x; LEI F, 1994, BLOOD, V84, P53; OCHS HD, 1973, J PEDIATR-US, V83, P77, DOI 10.1016/S0022-3476(73)80316-6; PORTER CD, 1993, BLOOD, V82, P2196; THRASHER A, 1992, BLOOD, V80, P1125; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7	7	15	16	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 8	1995	346	8967					92	93		10.1016/S0140-6736(95)92116-8	http://dx.doi.org/10.1016/S0140-6736(95)92116-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7541496				2022-12-28	WOS:A1995RH22000014
J	BERGES, RR; WINDELER, J; TRAMPISCH, HJ; SENGE, T; AEIKENS, B; ALBRECHT, J; BECKER, C; BRUNDIG, P; DREYER, D; KALDEWEY, W; LATKA, H; REEK, A; SCHNEIDER, HJ; SCHOTER, P; SCHUMACHER, C				BERGES, RR; WINDELER, J; TRAMPISCH, HJ; SENGE, T; AEIKENS, B; ALBRECHT, J; BECKER, C; BRUNDIG, P; DREYER, D; KALDEWEY, W; LATKA, H; REEK, A; SCHNEIDER, HJ; SCHOTER, P; SCHUMACHER, C			RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL-TRIAL OF BETA-SITOSTEROL IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA	LANCET			English	Article							OBSTRUCTION; HYPERTROPHY	Medical treatments have become available for benign hypertrophy of the prostate, including alpha-receptor blocking agents and 5-alpha-reductase inhibitors. Drugs derived from plants, for which no precise mechanism of action has been described, are widely used for this purpose in Europe. In a randomised, double-blind, placebo-controlled multicentre study, 200 patients (recruited between April and October 1993) with symptomatic benign prostatic hyperplasia were treated with either 20 mg beta-sitosterol (which contains a mixture of phytosterols) three times per day or placebo. Primary end-point was a difference of modified Boyarsky score between treatment groups after 6 months; secondary end-points were changes in International Prostate Symptom Score (IPSS), urine flow, and prostate volume. Modified Boyarsky score decreased significantly with a mean of -6.7 (SD 4.0) points in the beta-sitosterol-treated group versus -2.1 (3.2) points in the placebo group p<0.01. There was a decrease in IPSS (-7.4 [3.8] points in the beta-sitosterol-treated group vs -2.1 [3.8] points in the placebo group) and changes in urine flow parameters: beta-sitosterol treatment resulted in increasing peak flow (15.2 [5.7] mL/s from 9.9 [2.5] mL/s), and decrease of mean residual urinary volume (30.4 [39.9] mL from 65.8 [20.8] mL). These parameters did not change in the placebo group (p<0.01). No relevant reduction of prostatic volume was observed in either group. Significant improvement in symptoms and urinary flow parameters show the effectiveness of beta-sitosterol in the treatment of benign prostatic hyperplasia.	RUHR UNIV BOCHUM, DEPT UROL, W-4630 BOCHUM, GERMANY; RUHR UNIV BOCHUM, DEPT BIOSTAT, W-4630 BOCHUM, GERMANY	Ruhr University Bochum; Ruhr University Bochum								ASO Y, 1993, 2ND INTERNATIONAL CONSULTATION ON BENIGN PROSTATIC HYPERPLASIA (BPH): PROCEEDINGS, P345; BERRY SJ, 1984, J UROLOGY, V132, P474, DOI 10.1016/S0022-5347(17)49698-4; Boyarsky S, 1976, Trans Am Assoc Genitourin Surg, V68, P29; CAINE M, 1978, BRIT J UROL, V50, P551, DOI 10.1111/j.1464-410X.1978.tb06210.x; CHAPPLE CR, 1994, BR JUROL, V74, P471; CHRISTENSEN MM, 1993, SCAND J UROL NEPHROL, V27, P39, DOI 10.3109/00365599309180412; COCKETT AT, 1991, P INT CONS BEN PROST, P280; DREIKORN K, 1990, UROLOGE A, V29, P8; FOWLER FJ, 1988, JAMA-J AM MED ASSOC, V259, P3018, DOI 10.1001/jama.259.20.3018; JARDIN A, 1991, LANCET, V337, P1457, DOI 10.1016/0140-6736(91)93140-5; LEPOR H, 1990, PROSTATE, P75; LYTTON B, 1968, J UROLOGY, V99, P639, DOI 10.1016/S0022-5347(17)62763-0; MARTORANA G, 1984, IRCS MED SCI-BIOCHEM, V12, P11; MCCONNELL JD, 1989, J UROLOGY, V141, P239; MOCELLINI AI, 1993, PROSTATE, V22, P291; SCHULZE H, 1992, UROLOGE A, V31, P8	16	187	198	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 17	1995	345	8964					1529	1532		10.1016/S0140-6736(95)91085-9	http://dx.doi.org/10.1016/S0140-6736(95)91085-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7540705				2022-12-28	WOS:A1995RD79000007
J	LOS, M; VANDECRAEN, M; PENNING, LC; SCHENK, H; WESTENDORP, M; BAEUERLE, PA; DROGE, W; KRAMMER, PH; FIERS, W; SCHULZEOSTHOFF, K				LOS, M; VANDECRAEN, M; PENNING, LC; SCHENK, H; WESTENDORP, M; BAEUERLE, PA; DROGE, W; KRAMMER, PH; FIERS, W; SCHULZEOSTHOFF, K			REQUIREMENT OF AN ICE/CED-3 PROTEASE FOR FAS/APO-1-MEDIATED APOPTOSIS	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; CELL-SURFACE ANTIGEN; INTERLEUKIN-1-BETA CONVERTING ENZYME; DEATH GENE CED-3; MOLECULAR-CLONING; MONOCLONAL-ANTIBODY; VIRUS ENCODES; FAS; INDUCTION; RECEPTOR	THE Fas/APO-1 receptor is one of the major regulators of apoptosis(1-7). We report here that Fas/APO-1-mediated apoptosis requires the activation of a new class of cysteine proteases, including interleukin-1 beta-converting enzyme (ICE)(8-10) which are homologous to the product of the Caenorhabditis elegans cell-death gene ced-3 (refs 11, 12). Triggering of Fas/APO-1 rapidly stimulated the proteolytic activity of ICE. Overexpression of ICE, achieved by electroporation and microinjection, strongly potentiated Fas/APO-1-mediated cell death. In addition, inhibition of ICE activity by protease inhibitors, as well as by transient expression of the pox virus-derived serpin inhibitor CrmA or an antisense ICE construct, substantially suppressed Fas/APO-1-triggered cell death. We conclude that activation of ICE or an ICE-related protease is a critical event in Fas/APO-1-mediated cell death.	GERMAN CANC RES CTR,DIV IMMUNOCHEM,W-6900 HEIDELBERG,GERMANY; GERMAN CANC RES CTR,IMMUNOGENET TUMOIMMUNOL PROGRAM,W-6900 HEIDELBERG,GERMANY; UNIV FREIBURG,INST BIOCHEM,D-79104 FREIBURG,GERMANY; STATE UNIV GHENT,MOLEC BIOL LAB,B-9000 GHENT,BELGIUM	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; Ghent University			Łos, Marek J/C-4038-2013; Schulze-Osthoff, Klaus/N-9025-2013; Penning, Louis/AAC-7524-2019	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Los, Marek/0000-0001-9518-1411				CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HARDIN JA, 1992, J IMMUNOL METHODS, V154, P99, DOI 10.1016/0022-1759(92)90217-H; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NETT MA, 1992, J IMMUNOL, V149, P3254; NIWA H, 1994, GENE, V108, P193; OEHM A, 1992, J BIOL CHEM, V267, P10709; PENNINGTON MW, 1994, PEPTIDE RES, V7, P72; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Schulze-Osthoff Klaus, 1994, Trends in Cell Biology, V4, P421, DOI 10.1016/0962-8924(94)90102-3; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SMITH GL, 1989, J GEN VIROL, V70, P2333, DOI 10.1099/0022-1317-70-9-2333; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	26	654	677	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					81	83		10.1038/375081a0	http://dx.doi.org/10.1038/375081a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7536901	Green Submitted			2022-12-28	WOS:A1995QW60400060
J	BERKE, G				BERKE, G			THE CTLS KISS OF DEATH	CELL			English	Review							LYMPHOCYTE-MEDIATED CYTOLYSIS; LYTIC GRANULES; TNF RECEPTOR; CELLS; PERFORIN; DISINTEGRATION; CYTOTOXICITY; MECHANISM; INVITRO				BERKE, G (corresponding author), WEIZMANN INST SCI,DEPT CELL BIOL,POB 26,IL-76100 REHOVOT,ISRAEL.							BERKE G, 1991, IMMUNOL TODAY, V12, P396, DOI 10.1016/0167-5699(91)90138-J; BERKE G, 1993, IMMUNOLOGY, V78, P105; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; BERKE G, 1988, J IMMUNOL, V141, P1429; BURKHARDT JK, 1993, J CELL SCI, V104, P151; CLARK WR, 1995, IN PRESS INT REV IMM; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; HELGASON CD, 1992, EUR J IMMUNOL, V22, P3187, DOI 10.1002/eji.1830221225; HENKART PA, 1994, IMMUNITY, V1, P343, DOI 10.1016/1074-7613(94)90063-9; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KOJIMA H, 1994, IMMUNITY, V1, P357, DOI 10.1016/1074-7613(94)90066-3; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MARTZ E, 1993, CYTOTOXIC CELLS RECO, P9; NISHIOKA WK, 1994, J EXP MED, V179, P769, DOI 10.1084/jem.179.2.769; PODACK ER, 1991, ANNU REV IMMUNOL, V9, P129, DOI 10.1146/annurev.iy.09.040191.001021; RAMSDELL F, 1994, EUR J IMMUNOL, V24, P928, DOI 10.1002/eji.1830240422; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1983, IMMUNOL REV, V72, P97, DOI 10.1111/j.1600-065X.1983.tb01074.x; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; SILICIANO RF, 1978, J IMMUNOL, V121, P186; STRASSER A, 1995, NATURE, V373, P385, DOI 10.1038/373385a0; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; WALSH CM, 1994, J IMMUNOL, V153, P2506; WALSH CM, 1994, P NATL ACAD SCI USA, V91, P10854, DOI 10.1073/pnas.91.23.10854	30	426	439	0	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					9	12		10.1016/0092-8674(95)90365-8	http://dx.doi.org/10.1016/0092-8674(95)90365-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7536631	Bronze			2022-12-28	WOS:A1995QR97000003
J	MCNALLY, E; DELACEY, G; LOVELL, P; WELCH, T				MCNALLY, E; DELACEY, G; LOVELL, P; WELCH, T			POSTERS FOR ACCIDENT DEPARTMENTS - SIMPLE METHOD OF SUSTAINING REDUCTION IN X-RAY EXAMINATIONS	BRITISH MEDICAL JOURNAL			English	Article							GUIDELINES; RADIOGRAPHS	Objective-To assess whether a simple strategy would sustain a reduction in the number of unnecessary x ray examinations. Design-Use of posters to display guidelines encouraging the more effective use of radiology in patients with head injuries, twisted ankles, neck injuries, and abdominal pain. Setting-Accident department of a large metropolitan district general hospital. Patients-15875 patients attending the accident department over two years. Main outcome measure-Proportion of patients having radiography. Results-Referrals for skull. radiography fell from 56% to 20% and those for abdominal radiography fell from 31% to 7%. Referral patterns for adults attending with twisted ankles and cervical spine injuries did not change. Reductions were sustained over two years. Conclusion-Carefully designed posters provide a simple method of reducing unnecessary x ray examinations.	NORTHWICK PK HOSP & CLIN RES CTR,DEPT RADIOL,HARROW HA1 3UJ,MIDDX,ENGLAND; NORTHWICK PK HOSP & CLIN RES CTR,DEPT ACCID & EMERGENCY,HARROW HA1 3UJ,MIDDX,ENGLAND	Imperial College London; Imperial College London			McNally, Elizabeth/W-4909-2019					ANNIS JAD, 1987, BRIT J RADIOL, V60, P1059, DOI 10.1259/0007-1285-60-719-1059; CLARKE JA, 1990, CLIN RADIOL, V41, P152, DOI 10.1016/S0009-9260(05)80957-2; DELACEY G, 1979, BRIT MED J, V1, P1597, DOI 10.1136/bmj.1.6178.1597; DELACEY G, 1991, BRIT J HOSP MED, V45, P259; FIELD S, 1985, BRIT MED J, V290, P1934, DOI 10.1136/bmj.290.6486.1934; FOWKES FGR, 1984, LANCET, V2, P795; FOWKES FGR, 1986, STRATEGIES CHANGING; HAINES A, 1992, BMJ-BRIT MED J, V305, P785, DOI 10.1136/bmj.305.6857.785; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; 1988, CLIN RADIOL, V39, P3; 1983, DHSS8 DEP HLTH SOC S; 1982, IONISING RAD SOURCES; 1992, BRIT MED J, V304, P740; 1991, BRIT MED J, V303, P809; 1983, WHO TECHNICAL REPORT, V689; 1985, BRIT MED J, V291, P1325; 1990, 3 NAT RAD PROT BOARD, V1	17	26	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 11	1995	310	6980					640	642		10.1136/bmj.310.6980.640	http://dx.doi.org/10.1136/bmj.310.6980.640			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL984	7535607	Green Published			2022-12-28	WOS:A1995QL98400021
J	AVIEZER, D; HECHT, D; SAFRAN, M; EISINGER, M; DAVID, G; YAYON, A				AVIEZER, D; HECHT, D; SAFRAN, M; EISINGER, M; DAVID, G; YAYON, A			PERLECAN, BASAL LAMINA PROTEOGLYCAN, PROMOTES BASIC FIBROBLAST GROWTH FACTOR-RECEPTOR BINDING, MITOGENESIS, AND ANGIOGENESIS	CELL			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; NEURAL-TUBE DEFECTS; BASEMENT-MEMBRANE; MOUSE EMBRYOS; CELL-SURFACE; SEQUENCE; EXPRESSION; REQUIREMENT; PROTEIN; REGION	A survey of defined species of cell surface and extracellular matrix heparan sulfate proteoglycans (HSPG) was performed in a search for cellular proteoglycans that can promote bFGF receptor binding and biological activity. Of the various affinity-purified HSPGs tested, perlecan, the large basement membrane HSPG, is found to induce high affinity binding of bFGF both to cells deficient in HS and to soluble FGF receptors. Heparin-dependent mitogenic activity of bFGF is strongly augmented by perlecan. Monoclonal antibodies to perlecan extract the receptor binding promoting activity from active HSPG preparations. In a rabbit ear model for in vivo angiogenesis, perlecan is a potent inducer of bFGF-mediated neovascularization. These results identify perlecan as a major candidate for a bFGF low affinity, accessory receptor and an angiogenic modulator.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; AMER CYANAMID CO,DEPT CELL BIOL,DIV MED RES,PEARL RIVER,NY 10965; CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,B-3000 LOUVAIN,BELGIUM	Weizmann Institute of Science; KU Leuven								AVIEZER D, 1994, J BIOL CHEM, V269, P114; BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; CARSON DD, 1993, DEV BIOL, V155, P97, DOI 10.1006/dbio.1993.1010; COPP AJ, 1988, DEVELOPMENT, V104, P285; COPP AJ, 1988, DEV BIOL, V130, P583, DOI 10.1016/0012-1606(88)90353-3; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; EDELMAN ER, 1991, BIOMATERIALS, V12, P619, DOI 10.1016/0142-9612(91)90107-L; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FRANSSON LA, 1981, J BIOL CHEM, V256, P3039; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; GUELSTEIN VI, 1993, INT J CANCER, V53, P267; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; Howden G F, 1980, Int Endod J, V13, P3, DOI 10.1111/j.1365-2591.1980.tb00832.x; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MALI M, 1993, J BIOL CHEM, V268, P24215; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MERTENS G, 1992, J BIOL CHEM, V267, P20435; NADER HB, 1987, P NATL ACAD SCI USA, V84, P3566; NEUMANN PE, 1994, NAT GENET, V6, P357, DOI 10.1038/ng0494-357; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RESCAN PY, 1993, AM J PATHOL, V142, P199; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WALKER A, 1994, J BIOL CHEM, V269, P931; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	39	473	486	0	20	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					1005	1013		10.1016/0092-8674(94)90031-0	http://dx.doi.org/10.1016/0092-8674(94)90031-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	7528102				2022-12-28	WOS:A1994PY08600010
J	KATELARIS, PH; SALAM, I; FARTHING, MJG				KATELARIS, PH; SALAM, I; FARTHING, MJG			LACTOBACILLI TO PREVENT TRAVELERS DIARRHEA	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									ST BARTHOLOMEWS HOSP,LONDON EC1M 6BQ,ENGLAND	University of London; Queen Mary University London	KATELARIS, PH (corresponding author), CONCORD HOSP,SYDNEY,NSW 2139,AUSTRALIA.							BERNET MF, 1994, GUT, V35, P483, DOI 10.1136/gut.35.4.483; DUPONT HL, 1993, NEW ENGL J MED, V328, P1821, DOI 10.1056/NEJM199306243282507; OKSANEN PJ, 1990, ANN MED, V22, P53, DOI 10.3109/07853899009147242; STEFFEN R, 1986, REV INFECT DIS, V8, pS122	4	93	98	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	1995	333	20					1360	1361		10.1056/NEJM199511163332016	http://dx.doi.org/10.1056/NEJM199511163332016			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE365	7566045				2022-12-28	WOS:A1995TE36500029
J	HENNINGFIELD, JE				HENNINGFIELD, JE			DRUG-THERAPY - NICOTINE MEDICATIONS FOR SMOKING CESSATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RANDOMIZED CONTROLLED TRIAL; DOUBLE-BLIND TRIAL; TOBACCO WITHDRAWAL SYMPTOMS; TRANSDERMAL NICOTINE; CIGARETTE-SMOKING; CHEWING-GUM; REPLACEMENT THERAPY; PLACEBO GUM; SMOKERS; PATCH		JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, BALTIMORE, MD 21205 USA	Johns Hopkins University	HENNINGFIELD, JE (corresponding author), NIDA, ADDICT RES CTR, CLIN PHARMACOL BRANCH, INTRAMURAL RES PROGRAM, POB 5180, BALTIMORE, MD 21224 USA.							[Anonymous], 1994, PREVENTING TOBACCO U; ARMITAGE AK, 1970, NATURE, V226, P1231, DOI 10.1038/2261231a0; BENOWITZ NL, 1989, BRIT MED J, V298, P1075, DOI 10.1136/bmj.298.6680.1075; BENOWITZ NL, 1991, TRENDS CARDIOVAS MED, V1, P315, DOI 10.1016/1050-1738(91)90068-P; BENOWITZ NL, 1994, NEW ENGL J MED, V331, P123, DOI 10.1056/NEJM199407143310212; BENOWITZ NL, 1988, CLIN PHARMACOL THER, V44, P23, DOI 10.1038/clpt.1988.107; BENOWITZ NL, 1993, DRUGS, V45, P157, DOI 10.2165/00003495-199345020-00001; BENOWITZ NL, 1983, NEW ENGL J MED, V309, P139, DOI 10.1056/NEJM198307213090303; BENOWITZ NL, 1991, CLIN PHARMACOL THER, V49, P270, DOI 10.1038/clpt.1991.28; BENOWITZ NL, 1991, JAMA-J AM MED ASSOC, V266, P3174, DOI 10.1001/jama.266.22.3174; BRESLAU N, 1992, AM J PSYCHIAT, V149, P464; BURKE P, 1993, BRIT MED J, V306, P1304; BURLING TA, 1991, BEHAV THER, V22, P31, DOI 10.1016/S0005-7894(05)80241-2; CAMPBELL IA, 1983, BRIT MED J, V286, P595; DALE LC, IN PRESS JAMA; DUBOIS JP, 1989, METHOD FIND EXP CLIN, V11, P187; FAGERSTROM KO, 1993, J DRUG DEV, V5, P191; FAGERSTROM KO, 1994, PSYCHOPHARMACOLOGY, V116, P117, DOI 10.1007/BF02244882; FAGERSTROM KO, 1993, PSYCHOPHARMACOLOGY, V111, P271, DOI 10.1007/BF02244941; FAGERSTROM KO, 1991, J SMOKING RELATED DI, V2, P173; FIORE MC, 1992, MED CLIN N AM, V76, P289, DOI 10.1016/S0025-7125(16)30354-6; FIORE MC, 1992, JAMA-J AM MED ASSOC, V268, P2687, DOI 10.1001/jama.268.19.2687; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; FLEGAL KM, 1995, NEW ENGL J MED, V333, P1165, DOI 10.1056/NEJM199511023331801; GLASSMAN AH, 1993, AM J PSYCHIAT, V150, P546; GORI GB, 1986, PHARMACOL BIOCHEM BE, V25, P1181, DOI 10.1016/0091-3057(86)90108-5; GORSLINE J, 1992, J CLIN PHARMACOL, V32, P576, DOI 10.1177/009127009203200615; GORSLINE J, 1993, HEALTH VALUES, V17, P20; GOTHE B, 1985, CHEST, V87, P11, DOI 10.1378/chest.87.1.11; GROSS J, 1989, PSYCHOPHARMACOLOGY, V98, P334, DOI 10.1007/BF00451684; HALL SM, 1992, AM J PUBLIC HEALTH, V82, P799, DOI 10.2105/AJPH.82.6.799; HALL SM, 1985, J CONSULT CLIN PSYCH, V53, P256, DOI 10.1037/0022-006X.53.2.256; HARTMAN N, 1989, ARCH GEN PSYCHIAT, V46, P289; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; HENNINGFIELD JE, 1991, BRIT J ADDICT, V86, P565; HENNINGFIELD JE, 1993, DRUG ALCOHOL DEPEN, V33, P23, DOI 10.1016/0376-8716(93)90030-T; HENNINGFIELD JE, 1993, J CONSULT CLIN PSYCH, V61, P743, DOI 10.1037/0022-006X.61.5.743; HENNINGFIELD JE, 1990, JAMA-J AM MED ASSOC, V264, P1560, DOI 10.1001/jama.264.12.1560; HENNINGFIELD JE, 1994, JAMA-J AM MED ASSOC, V272, P312, DOI 10.1001/jama.272.4.312; HENNINGFIELD JE, 1994, CNS DRUGS, V1, P317, DOI 10.2165/00023210-199401050-00001; HENNINGFIELD JE, 1995, PSYCHOPHARMACOLOGY 4; Henningfield JE, 1995, TOB CONTROL, V4, P57, DOI DOI 10.1136/TC.4.1.57; HENNINGFIELD JE, 1994, J SMOKING RELATED S1, V5, P261; HENNINGFIELD JE, IN PRESS TOB CONTROL; HJALMARSON AIM, 1984, JAMA-J AM MED ASSOC, V252, P2835, DOI 10.1001/jama.252.20.2835; Hughes J R, 1994, Arch Fam Med, V3, P280, DOI 10.1001/archfami.3.3.280; HUGHES JR, 1993, J CONSULT CLIN PSYCH, V61, P751, DOI 10.1037/0022-006X.61.5.751; HUGHES JR, 1990, RES ADV ALCOHOL DRUG, V10, P317; HUGHES JR, 1993, J SUBST ABUSE TREAT, V10, P181, DOI 10.1016/0740-5472(93)90043-2; HUGHES JR, 1989, JAMA-J AM MED ASSOC, V261, P1300, DOI 10.1001/jama.261.9.1300; HUGHES JR, 1991, ARCH INTERN MED, V151, P1993, DOI 10.1001/archinte.151.10.1993; HUGHES JR, 1992, HEALTH PSYCHOL, V11, P331, DOI 10.1037/0278-6133.11.5.331; HUGHES JR, 1986, AM J PSYCHIAT, V143, P271; HUGHES JR, 1993, DRUG SAFETY, V8, P49, DOI 10.2165/00002018-199308010-00006; HURT RD, 1992, MAYO CLIN PROC, V67, P823, DOI 10.1016/S0025-6196(12)60819-2; HURT RD, 1995, ADDICTION, V90, P407, DOI 10.1046/j.1360-0443.1995.9034079.x; JARVIK ME, 1993, NICOTINE ADDICTION P, P245; JARVIS MJ, 1982, BRIT MED J, V285, P537, DOI 10.1136/bmj.285.6341.537; Jasinski D R, 1988, Prog Clin Biol Res, V261, P13; JASINSKI DR, 1988, PRINCIPLES PRACTICES, P1144; JOHANSSON CJ, 1991, EUR J CLIN PHARMACOL, V41, P585, DOI 10.1007/BF00314989; KENDLER KS, 1993, ARCH GEN PSYCHIAT, V50, P36; KENFORD SL, 1994, JAMA-J AM MED ASSOC, V271, P589, DOI 10.1001/jama.271.8.589; KILLEN JD, 1990, J CONSULT CLIN PSYCH, V58, P85, DOI 10.1037/0022-006X.58.1.85; KORNITZER M, 1995, PREV MED, V24, P41, DOI 10.1006/pmed.1995.1006; KOTTKE TE, 1989, JAMA-J AM MED ASSOC, V261, P2101, DOI 10.1001/jama.261.14.2101; Kozak J, 1995, INT J SMOKING CESSAT, V4, P26; KOZLOWSKI LT, 1993, J SUBST ABUSE TREAT, V10, P171, DOI 10.1016/0740-5472(93)90042-Z; LEE BL, 1987, ANN INTERN MED, V106, P553, DOI 10.7326/0003-4819-106-4-553; LIDE DR, 1991, CRC HDB CHEM PHYSICS; Lynch BS., 1994, GROWING TOBACCO FREE; MALCOLM RE, 1980, PSYCHOPHARMACOLOGY, V70, P295, DOI 10.1007/BF00427889; NEMETHCOSLETT R, 1987, PSYCHOPHARMACOLOGY, V92, P424; NEWHOUSE PA, 1991, BRIT J ADDICT, V86, P521; PALMER KJ, 1992, DRUGS, V44, P498, DOI 10.2165/00003495-199244030-00011; Peto R, 1994, MORTALITY SMOKING DE; PICKWORTH WB, 1989, J PHARMACOL EXP THER, V251, P976; RENNARD S, 1991, JAMA-J AM MED ASSOC, V266, P3133; RENNARD S, 1994, ARCH INTERN MED, V154, P989; ROSS HD, 1991, PHARMACEUT RES, V8, P385, DOI 10.1023/A:1015810019076; RUSSELL MAH, 1991, BRIT J ADDICT, V86, P653; RUSSELL MAH, 1993, BRIT MED J, V306, P1308, DOI 10.1136/bmj.306.6888.1308; Sachs D, 1988, NIDA RES MONOGR, V90, P38; SACHS DP, IN PRESS ARCH INTERN; SACHS DPL, 1993, ARCH INTERN MED, V153, P1881, DOI 10.1001/archinte.153.16.1881; SCHNEIDER NG, 1983, ADDICT BEHAV, V8, P253, DOI 10.1016/0306-4603(83)90020-5; SHIFFMAN S, 1989, PSYCHOPHARMACOLOGY, V97, P539, DOI 10.1007/BF00439561; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; SNYDER FR, 1989, DRUG ALCOHOL DEPEN, V23, P259, DOI 10.1016/0376-8716(89)90090-2; SRIVASTAVA ED, 1991, EUR J GASTROEN HEPAT, V3, P815; SUTHERLAND G, 1992, LANCET, V340, P324, DOI 10.1016/0140-6736(92)91403-U; TONNESEN P, 1993, JAMA-J AM MED ASSOC, V269, P1268, DOI 10.1001/jama.269.10.1268; TONNESEN P, 1991, NEW ENGL J MED, V325, P311, DOI 10.1056/NEJM199108013250503; TONNESEN P, 1988, NEW ENGL J MED, V318, P15, DOI 10.1056/NEJM198801073180104; Tonnesen P, 1992, J SMOKING RELATED DI, V3, P241; WARANCH HR, 1988, LANCET, V1, P49; 1990, DHHS CDC908416 DEP H; 1994, MMWR-MORBID MORTAL W, V43, P745; 1988, DHHS CDC888406 DEP H; 1994, DIAGNOSTIC STATISTIC; 1994, DRUG EVALUATIONS ANN	101	254	284	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 2	1995	333	18					1196	1203		10.1056/NEJM199511023331807	http://dx.doi.org/10.1056/NEJM199511023331807			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TB560	7565976				2022-12-28	WOS:A1995TB56000007
J	STUCK, AE; ARONOW, HU; STEINER, A; ALESSI, CA; BULA, CJ; GOLD, MN; YUHAS, KE; NISENBAUM, R; RUBENSTEIN, LZ; BECK, JC				STUCK, AE; ARONOW, HU; STEINER, A; ALESSI, CA; BULA, CJ; GOLD, MN; YUHAS, KE; NISENBAUM, R; RUBENSTEIN, LZ; BECK, JC			A TRIAL OF ANNUAL IN-HOME COMPREHENSIVE GERIATRIC ASSESSMENTS FOR ELDERLY PEOPLE LIVING IN THE COMMUNITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED TRIAL; INTERVENTION; SURVEILLANCE; CARE	Background and Methods. The prevention of disability in elderly people poses a challenge for health care and social services. We conducted a three-year, randomized, controlled trial of the effect of annual in-home comprehensive geriatric assessments and followup for people living in the community who were 75 years of age or older. The 215 people in the intervention group were seen at home by gerontologic nurse practitioners who, in collaboration with geriatricians, evaluated problems and risk factors for disability, gave specific recommendations, and provided health education. The 199 people in the control group received their regular medical care. The main outcome measures were the prevention of disability, defined as the need for assistance in performing the basic activities of daily living (bathing, dressing, feeding, grooming, transferring from bed to chair, and moving around inside the house) or the instrumental activities of daily living (e.g., cooking, handling finances and medication, housekeeping, and shopping), and the prevention of nursing home admissions. Results. At three years, 20 people in the intervention group (12 percent of 170 surviving participants) and 32 in the control group (22 percent of 147 surviving participants) required assistance in performing the basic activities of daily living (adjusted odds ratio, 0.4; 95 percent confidence interval, 0.2 to 0.8; P = 0.02). The number of persons who were dependent on assistance in performing the instrumental activities of daily living but not the basic activities did not differ significantly between the two groups. Nine people in the intervention group (4 percent) and 20 in the control group (10 percent) were permanently admitted to nursing homes (P = 0.02). Acute care hospital admissions and short-term nursing home admissions did not differ significantly between the two groups. In the second and third years of the study, there were significantly more visits to physicians among the participants in the intervention group than among those in the control group (mean number of visits per month, 1.41 in year 2 and 1.27 in year 3 in the intervention group, as compared with 1.11 and 0.92 visits, respectively, in the control group P = 0.007 and P = 0.001, respectively). The cost of the intervention for each year of disability-free life gained was about $6,000. Conclusions. A program of in-home comprehensive geriatric assessments can delay the development of disability and reduce permanent nursing home stays among elderly people living at home.	UNIV CALIF LOS ANGELES, DEPT MED, MULTICAMPUS PROGRAM GERIATR MED & GERONTOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT BIOSTAT, LOS ANGELES, CA 90024 USA; DEPT VET AFFAIRS, CTR GERIATR RES EDUC & CLIN, SEPULVEDA, CA USA; UNIV SOUTHAMPTON, INST HLTH POLICY STUDIES, SOUTHAMPTON, HANTS, ENGLAND; SENIOR HLTH & PEER COUNSELING, SANTA MONICA, CA USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Geriatric Research Education & Clinical Center; University of Southampton			Bula, Christophe J/ABI-1163-2020	Bula, Christophe J/0000-0002-7501-3442; Aronow, Harriet/0000-0001-9765-872X; Rubenstein, Laurence/0000-0001-5910-0266				ADAMS PF, 1990, VITAL HLTH STATIS 10, V176; AFIFI A, 1990, COMPUTER AIDED MULTI; AITKIN M, 1989, OXFORD STATISTICAL S, V4, P223; [Anonymous], 1989, GUIDE CLIN PREVENTIV; Atchison K A, 1990, J Dent Educ, V54, P680; BENSON V, 1994, VITAL HLTH STATIS 10, V189; BULA CJ, 1995, J AM GERIATR SOC, V43, P1016; CARPENTER GI, 1990, BMJ-BRIT MED J, V300, P1253, DOI 10.1136/bmj.300.6734.1253; CLARKE M, 1992, AM J EPIDEMIOL, V136, P1517, DOI 10.1093/oxfordjournals.aje.a116473; DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS; FABACHER D, 1994, J AM GERIATR SOC, V42, P630, DOI 10.1111/j.1532-5415.1994.tb06862.x; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; HALL N, 1992, CAN J AGING, V11, P72, DOI 10.1017/S0714980800014537; HENDRIKSEN C, 1984, BMJ-BRIT MED J, V289, P1522, DOI 10.1136/bmj.289.6457.1522; Jackson ME, 1991, ALTERNATIVE PROJECTI; KAHN RL, 1960, AM J PSYCHIAT, V117, P326, DOI 10.1176/ajp.117.4.326; KEMPEN GIJM, 1990, GERONTOLOGIST, V30, P497, DOI 10.1093/geront/30.4.497; LACHS MS, 1990, ANN INTERN MED, V112, P699, DOI 10.7326/0003-4819-112-9-699; LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91; LIU KB, 1994, MED CARE, V32, P315, DOI 10.1097/00005650-199404000-00001; MASTER AM, 1960, JAMA-J AM MED ASSOC, V172, P658, DOI 10.1001/jama.1960.03020070016005; MCEWAN RT, 1990, BRIT J GEN PRACT, V40, P94; PATHY MSJ, 1992, LANCET, V340, P890, DOI 10.1016/0140-6736(92)93294-W; REUBEN DB, 1995, NEW ENGL J MED, V332, P1345, DOI 10.1056/NEJM199505183322007; RUBENSTEIN LZ, 1994, AGING-CLIN EXP RES, V6, P105, DOI 10.1007/BF03324224; RUBENSTEIN LZ, 1984, NEW ENGL J MED, V311, P1664, DOI 10.1056/NEJM198412273112604; Rubin D.B., 1987, MULTIPLE IMPUTATION, DOI DOI 10.1002/9780470316696.FMATTER; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; SPECTOR WD, 1987, J CHRON DIS, V40, P481, DOI 10.1016/0021-9681(87)90004-X; STUCK AE, 1995, AGING-CLIN EXP RES, V7, P218, DOI 10.1007/BF03324319; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; STUCK AE, 1994, ARCH INTERN MED, V154, P2195; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; VANROSSUM E, 1993, BMJ-BRIT MED J, V307, P27, DOI 10.1136/bmj.307.6895.27; VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1; VETTER NJ, 1984, BRIT MED J, V288, P369, DOI 10.1136/bmj.288.6414.369; VETTER NJ, 1992, BMJ-BRIT MED J, V304, P888, DOI 10.1136/bmj.304.6831.888; WAGNER EH, 1994, AM J PUBLIC HEALTH, V84, P1800, DOI 10.2105/AJPH.84.11.1800; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788	39	370	372	0	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 2	1995	333	18					1184	1189		10.1056/NEJM199511023331805	http://dx.doi.org/10.1056/NEJM199511023331805			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TB560	7565974				2022-12-28	WOS:A1995TB56000005
J	SISCOVICK, DS; RAGHUNATHAN, TE; KING, I; WEINMANN, S; WICKLUND, KG; ALBRIGHT, J; BOVBJERG, V; ARBOGAST, P; SMITH, H; KUSHI, LH; COBB, LA; COPASS, MK; PSATY, BM; LEMAITRE, R; RETZLAFF, B; CHILDS, M; KNOPP, RH				SISCOVICK, DS; RAGHUNATHAN, TE; KING, I; WEINMANN, S; WICKLUND, KG; ALBRIGHT, J; BOVBJERG, V; ARBOGAST, P; SMITH, H; KUSHI, LH; COBB, LA; COPASS, MK; PSATY, BM; LEMAITRE, R; RETZLAFF, B; CHILDS, M; KNOPP, RH			DIETARY-INTAKE AND CELL-MEMBRANE LEVELS OF LONG-CHAIN N-3 POLYUNSATURATED FATTY-ACIDS AND THE RISK OF PRIMARY CARDIAC-ARREST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VENTRICULAR-FIBRILLATION THRESHOLD; CORONARY HEART-DISEASE; FISH CONSUMPTION; MARMOSET MONKEY; MODULATION; MORTALITY	Objective.-To assess whether the dietary intake of long-chain n-3 polyunsaturated fatty acids from seafood, assessed both directly and indirectly through a biomarker, is associated with a reduced risk of primary cardiac arrest. Design.-Population-based case-control study. Setting.-Seattle and suburban King County, Washington, Participants.-A total of 334 case patients with primary cardiac arrest, aged 25 to 74 years, attended by paramedics during 1988 to 1994 and 493 population-based control cases and controls, matched for age and sex, randomly identified from the community. All cases and controls were free of prior clinical heart disease, major comorbidity, and use of fish oil supplements. Measures of Exposure.-Spouses of case patients and control subjects were interviewed to quantify dietary n-3 polyunsaturated fatty acid intake from seafood during the prior month and other clinical characteristics. Blood specimens from 82 cases (collected in the field) and 108 controls were analyzed to determine red blood cell membrane fatty acid composition, a biomarker of dietary n-3 polyunsaturated fatty acid intake. Results.-Compared with no dietary intake of eicosapentaenoic acid (C-20:5n-3) and docosahexaenoic acid (C-22:6n-3), an intake of 5.5 g of n-3 fatty acids per month (the mean of the third quartile and the equivalent of one fatty fish meal per week) was associated with a 50% reduction in the risk of primary cardiac arrest (odds ratio [OR], 0.5; 95% confidence interval [CI], 0.4 to 0.8), after adjustment for potential confounding factors. Compared with a red blood cell membrane n-3 polyunsaturated fatty acid level of 3.3% of total fatty acids (the mean of the lowest quartile), a red blood cell n-3 polyunsaturated fatty acid level of 5.0% of total fatty acids (the mean of the third quartile) was associated with a 70% reduction in the risk of primary cardiac arrest (OR, 0.3; 95% CI, 0.2 to 0.6). Conclusion.-Dietary intake of n-3 polyunsaturated fatty acids from seafood is associated with a reduced risk of primary cardiac arrest.	WASHINGTON UNIV,DEPT EPIDEMIOL,SEATTLE,WA 98101; WASHINGTON UNIV,DEPT BIOSTAT,SEATTLE,WA 98101; FRED HUTCHINSON CANC RES CTR,DIV PUBL HLTH SCI,SEATTLE,WA 98104; UNIV MICHIGAN,INST SOCIAL RES,ANN ARBOR,MI; UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,MINNEAPOLIS,MN 55455	Fred Hutchinson Cancer Center; University of Michigan System; University of Michigan; University of Minnesota System; University of Minnesota Twin Cities	SISCOVICK, DS (corresponding author), WASHINGTON UNIV,DEPT MED,CARDIOVASC HLTH RES UNIT,METROPOLITAN PK 2 BLDG,SUITE 1360,SEATTLE,WA 98101, USA.			Kushi, Lawrence/0000-0001-9136-1175	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035816] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41993] Funding Source: Medline; NIDDK NIH HHS [DK-35816] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCHERIO A, 1995, NEW ENGL J MED, V332, P977, DOI 10.1056/NEJM199504133321501; BANG HO, 1980, AM J CLIN NUTR, V33, P2657, DOI 10.1093/ajcn/33.12.2657; BILLMAN GE, 1994, P NATL ACAD SCI USA, V91, P4427, DOI 10.1073/pnas.91.10.4427; BURR ML, 1989, LANCET, V9, P757; CHARNOCK JS, 1992, COMP BIOCHEM PHYS A, V101, P387, DOI 10.1016/0300-9629(92)90551-Z; CHARNOCK JS, 1994, NUTRITION, V10, P161; CUMMINGS KM, 1979, PUBLIC OPIN QUART, V43, P233, DOI 10.1086/268514; CURB JD, 1985, NEW ENGL J MED, V313, P821; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; DOWDY A, 1993, J AM DIET ASSOC, V93, pA65; FARQUHAR JW, 1963, J CLIN INVEST, V42, P675, DOI 10.1172/JCI104759; GLOMSET JA, 1985, NEW ENGL J MED, V312, P1253, DOI 10.1056/NEJM198505093121909; HALLAQ H, 1992, P NATL ACAD SCI USA, V89, P1760, DOI 10.1073/pnas.89.5.1760; KANG JX, 1994, P NATL ACAD SCI USA, V91, P9886, DOI 10.1073/pnas.91.21.9886; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; LEAF A, 1988, NEW ENGL J MED, V318, P549, DOI 10.1056/NEJM198803033180905; LEE TH, 1985, NEW ENGL J MED, V312, P1217, DOI 10.1056/NEJM198505093121903; LEPAGE G, 1986, J LIPID RES, V27, P114; MCLENNAN PL, 1992, AM HEART J, V123, P1555, DOI 10.1016/0002-8703(92)90809-A; MCLENNAN PL, 1993, AM J CLIN NUTR, V58, P666, DOI 10.1093/ajcn/58.5.666; MCLENNAN PL, 1989, AUST NZ J MED, V19, P1, DOI 10.1111/j.1445-5994.1989.tb01662.x; Nomenclature and criteria for diagnosis of ischemic heart disease, 1979, CIRCULATION, V59, P607; NORDOY A, 1971, ACTA MED SCAND, V190, P27; NORDOY A, 1987, BIBL NUTR DIET, V40, P33; PEPE S, 1994, P NATL ACAD SCI USA, V91, P8832, DOI 10.1073/pnas.91.19.8832; ROSE HG, 1965, J LIPID RES, V6, P428; SHEKELLE RB, 1985, NEW ENGL J MED, V313, P820; SISCOVICK DS, 1993, ANN EMERG MED, V22, P92, DOI 10.1016/S0196-0644(05)80258-6; VOLLSET SE, 1985, NEW ENGL J MED, V313, P820; 1991, USDA NUTRITION MONIT, V815	30	728	777	0	29	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	1995	274	17					1363	1367		10.1001/jama.274.17.1363	http://dx.doi.org/10.1001/jama.274.17.1363			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB278	7563561				2022-12-28	WOS:A1995TB27800027
J	LABARRERE, CA; PITTS, D; NELSON, DR; FAULK, WP				LABARRERE, CA; PITTS, D; NELSON, DR; FAULK, WP			VASCULAR TISSUE-PLASMINOGEN ACTIVATOR AND THE DEVELOPMENT OF CORONARY-ARTERY DISEASE IN HEART-TRANSPLANT RECIPIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN CARDIAC ALLOGRAFTS; ENDOTHELIAL-CELLS; PROCOAGULANT ACTIVITY; MESSENGER-RNA; VESSEL WALL; ATHEROSCLEROSIS; IMMUNOPATHOLOGY; INTERLEUKIN-1; LOCALIZATION; EXPRESSION	Background. An aggressive and potentially fatal form of coronary artery disease may develop after cardiac transplantation. We studied the role of vascular tissue plasminogen activator (t-PA), the primary mediator of fibrinolysis, in the development of this problem. Methods. We studied 78 consecutive recipients of cardiac allografts over a five-year period, and we collected follow-up data over a mean (+/-SE) of 32.5+/-2.0 months. The patients were studied with ventricular function tests, serial endomyocardial biopsies (16.6+/-0.5 per patient), and annual coronary angiography. Measurements of t-PA and its inhibitor were performed immunocytochemically on unfixed cryostat sections of endomyocardial-biopsy specimens with the use of monoclonal antibodies to t-PA and its inhibitor. Results. In biopsy specimens obtained during the first three months of follow-up, 38 allografts had a normal distribution of t-PA in arteriolar smooth-muscle cells, whereas in 40 allografts there was depletion of t-PA that persisted in subsequent follow-up. Coronary artery disease developed during follow-up in 31 of 40 allografts (78 percent) with depletion of t-PA, but the disease developed in only 9 of the 38 allografts (24 percent) with normal t-PA levels (P<0.001). Allografts with depletion of tPA also had the t-PA inhibitor and were at greater risk for earlier and more severe disease than were allografts with normal arteriolar t-PA levels. Twelve patients whose allografts were depleted of t-PA either received a second transplant or died, whereas only one of the patients whose allografts had persistently normal t-PA levels died (P<0.001). Conclusions. These findings reveal an association between the depletion of t-PA from arteriolar smooth-muscle cells and the subsequent development of coronary artery disease and decreased graft survival. Although we cannot be certain about a cause-and-effect relation, our data suggest a possible role for deficient fibrinolysis in the development of coronary artery disease in transplanted human hearts.	METHODIST HOSP INDIANA,CTR REPROD & TRANSPLANTAT IMMUNOL,INDIANAPOLIS,IN 46202; METHODIST HOSP INDIANA,DEPT TRANSPLANTAT,INDIANAPOLIS,IN 46202; METHODIST HOSP INDIANA,CTR HLTH SERV RES,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University System; Indiana University System				Nelson, David/0000-0002-3240-0725				BAJAJ S, 1993, CIRCULATION, V88, P263; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; Billingham M E, 1990, J Heart Transplant, V9, P587; BILLINGHAM ME, 1987, TRANSPLANT P, V19, P19; BRAUNWALD E, 1992, HEART DISEASE TXB CA, P1; DICHEK D, 1989, BLOOD, V74, P222; FAULK WP, 1993, HAEMOSTASIS, V23, P194; FAULK WP, 1993, J HEART LUNG TRANSPL, V12, P219; FAULK WP, 1995, TRANSPLANT P, V27, P1944; FAULK WP, 1993, J HEART LUNG TRANSPL, V12, pS125; FAULK WP, 1994, SEMIN HEMATOL, V31, P26; FAULK WP, 1992, ARCH PATHOL LAB MED, V116, P1337; FAULK WP, 1994, MAJOR PROBL PATHOL, V30, P49; GAO SZ, 1988, J AM COLL CARDIOL, V12, P334, DOI 10.1016/0735-1097(88)90402-0; HAMSTEN A, 1994, FIBRINOLYSIS, V8, P253, DOI 10.1016/0268-9499(94)90723-4; HASUI Y, 1988, THROMB RES, V51, P453, DOI 10.1016/0049-3848(88)90381-7; HUNT BJ, 1993, TRANSPLANTATION, V55, P309, DOI 10.1097/00007890-199302000-00016; IP JH, 1990, J AM COLL CARDIOL, V15, P1667, DOI 10.1016/0735-1097(90)92845-S; JAMIESON SW, 1992, CIRCULATION, V85, P1211, DOI 10.1161/01.CIR.85.3.1211; JANSSON JH, 1993, CIRCULATION, V88, P2030, DOI 10.1161/01.CIR.88.5.2030; JOHNSON DE, 1989, J HEART TRANSPLANT, V8, P349; KERMAN RH, 1994, TRANSPLANTATION, V57, P884, DOI 10.1097/00007890-199403270-00020; KOOISTRA T, 1991, THROMB HAEMOSTASIS, V65, P565; LABARRERE CA, 1993, TRANSPLANTATION, V55, P1056, DOI 10.1097/00007890-199305000-00021; LABARRERE CA, 1994, CIRCULATION, V89, P1599, DOI 10.1161/01.CIR.89.4.1599; LABARRERE CA, 1995, TRANSPLANT P, V27, P1941; LABARRERE CA, 1995, TRANSPLANT P, V27, P1939; LARSSON A, 1985, J CLIN PATHOL, V38, P140, DOI 10.1136/jcp.38.2.140; Meade TW, 1992, THROMBOSIS CARDIOVAS, P79; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; RIDKER PM, 1994, LANCET, V343, P940, DOI 10.1016/S0140-6736(94)90064-7; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SALOMON RN, 1991, AM J PATHOL, V138, P791; SCHROEDER JS, 1991, NEW ENGL J MED, V324, P1805, DOI 10.1056/NEJM199106203242509; SMITH EB, 1994, THROMB RES, V73, P1, DOI 10.1016/0049-3848(94)90049-3; STOVIN PGI, 1993, J HEART LUNG TRANSPL, V12, P110; TAYLOR PM, 1992, TRANSPLANTATION, V54, P451, DOI 10.1097/00007890-199209000-00013; VANZONNEVELD AJ, 1986, BIOCHEM J, V235, P385, DOI 10.1042/bj2350385; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; WOJTA J, 1993, THROMB HAEMOSTASIS, V70, P469	41	87	87	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 26	1995	333	17					1111	1116		10.1056/NEJM199510263331704	http://dx.doi.org/10.1056/NEJM199510263331704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA372	7565949				2022-12-28	WOS:A1995TA37200004
J	EVANS, I				EVANS, I			SAPPING MATERNAL HEALTH	LANCET			English	Editorial Material																		1994, LANCET, V344, P1377	1	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1046	1046		10.1016/S0140-6736(95)91733-0	http://dx.doi.org/10.1016/S0140-6736(95)91733-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564778				2022-12-28	WOS:A1995TA69700002
J	GONG, YL; KOPLAN, JP; FENG, W; CHEN, CHC; ZHENG, P; HARRIS, JR				GONG, YL; KOPLAN, JP; FENG, W; CHEN, CHC; ZHENG, P; HARRIS, JR			CIGARETTE-SMOKING IN CHINA - PREVALENCE, CHARACTERISTICS, AND ATTITUDES IN MINHANG DISTRICT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							RISK-FACTORS; SHANGHAI; TOBACCO; DOCTOR	Objective.-To determine the prevalence, pattern, and financial implications of cigarette smoking and the attitudes toward and knowledge of the health effects of tobacco use in a population in China. Design.-A two-stage, stratified cluster survey using door-to-door interviews. Setting.-Minhang District, China (near Shanghai), with a population of 506 000. Participants.-A total of 3423 males and 3593 females aged 15 years and older. Main Outcome Measures.-Smoking prevalence, age of initiation of smoking, reasons for smoking, knowledge of tobacco hazards, and costs of smoking. Results.-A total of 2279 males (67%) but only 72 females (2%) smoke. Many males initiate smoking in adulthood. A total of 1156 males (50.7%) began smoking between 20 and 24 years of age, and 666 (29.2%) began between 25 and 39 years of age. Among all respondents, 6202 (88.4%) believe smoking is harmful for both the smoker and those exposed passively to the smoke. Only 332 (14.1%) of all male smokers reported a desire to quit smoking. Current smokers spent an average of 3.65 yuan daily on cigarettes or 1332 yuan yearly (8.5 yuan per US dollar), which represents 60% of personal income and 17% of household income. Conclusions.-The survey reveals a dangerous health situation that in all likelihood will worsen. More than two thirds of men smoke, and people in successive age cohorts start smoking at earlier ages. Smokers spend a substantial proportion of their income on cigarettes. There is a low rate of quitting and a low desire to quit despite high awareness of the health hazards. Tobacco control measures need to be implemented urgently in China.	CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,ATLANTA,GA 30333; SHANGHAI MED UNIV,SHANGHAI 200032,PEOPLES R CHINA; MINHANG DIST BUR HLTH,SHANGHAI,PEOPLES R CHINA; CTR DIS CONTROL & PREVENT,CTR HLTH CARE RES,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Fudan University; Centers for Disease Control & Prevention - USA				Harris, Jeffrey/0000-0001-8728-7195				BARNUM H, 1991, LANCET, V338, P169; CAI GY, 1994, TOBACCO INT      SEP, P26; CHEN ZM, 1991, LANCET, V338, P169, DOI 10.1016/0140-6736(91)90150-N; Cheng I S, 1990, Asia Pac J Public Health, V4, P156; HIBBERT C, 1984, DRAGON WAKES 1793 19, P111; HINMAN AR, 1982, AM J PUBL HLTH S, V72, P1; KOPLAN JP, 1985, AM J PUBLIC HEALTH, V75, P768, DOI 10.2105/AJPH.75.7.768; LEWIT EM, 1990, 7TH WORLD C TOB HLTH; MACKAY J, 1991, BRIT MED J, V303, P381; MACKENZIE TD, 1994, NEW ENGL J MED, V330, P975, DOI 10.1056/NEJM199404073301406; PETO R, 1986, LANCET, V2, P1038; QUN WW, 1992, INT J EPIDEMIOL, V21, P293, DOI 10.1093/ije/21.2.293; RAO KO, 1995, 3RD P S SINO US PUBL; SHAH BV, 1991, SUDAAN USERS MANUAL; Surgeon General, 1992, SMOKING HLTH AM; TEFFT S, 1994, CHRISTIAN SCI M 0525, P6; VARTIAINEN E, 1991, PUBLIC HEALTH REP, V106, P41; WENG XZ, 1988, CHINESE MED J-PEKING, V101, P371; WENG XZ, 1987, CHINESE MED J-PEKING, V100, P886; YANG GH, 1995, 3RD P S SIN US PUBL; YAO CH, 1988, CHINESE MED J-PEKING, V101, P901; 1994, ACTION PLAN TOBACCO; 1993, 1993 WORLD BANK WORL	23	68	71	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	1995	274	15					1232	1234		10.1001/jama.274.15.1232	http://dx.doi.org/10.1001/jama.274.15.1232			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ120	7563514				2022-12-28	WOS:A1995RZ12000033
J	LIEM, KF; TREMML, G; ROELINK, H; JESSELL, TM				LIEM, KF; TREMML, G; ROELINK, H; JESSELL, TM			DORSAL DIFFERENTIATION OF NEURAL PLATE CELLS INDUCED BY BMP-MEDIATED SIGNALS FROM EPIDERMAL ECTODERM	CELL			English	Article							FLOOR PLATE; SPINAL-CORD; HOMEOBOX GENE; CREST CELLS; LIMB BUDS; NOTOCHORD; PATTERN; EXPRESSION; INDUCTION; TUBE	The cellular interactions that control the differentiation of dorsal cell types from neural progenitors have been examined in neural plate explants. Certain genes that are expressed in the dorsal neural tube are initially expressed uniformly within the neural plate and appear to achieve their dorsal restriction through a Sonic hedgehog (SHH)-mediated repressive signal from the notochord. The acquisition of definitive dorsal cell fates, however, requires a contact-dependent signal from the epidermal ectoderm, BMP4 and BMP7 are expressed in the epidermal ectoderm, and both proteins mimic its inductive activity, BMP4 and a related gene, DSL1, are subsequently expressed by cells in the dorsal neural tube. The differentiation of dorsal cell types, therefore, appears to be initiated at the neural plate stage and to involve the opponent activities of a BMP-mediated dorsalizing signal from the epidermal ectoderm and a SHH-mediated ventralizing signal from the notochord.			LIEM, KF (corresponding author), COLUMBIA UNIV,CTR NEUROBIOL & BEHAV,DEPT BIOCHEM & MOLEC BIOPHYS,HOWARD HUGHES MED INST,NEW YORK,NY 10032, USA.			Roelink, Henk/0000-0002-5260-3634	NIGMS NIH HHS [5-T32-GM07367] Funding Source: Medline; NIMH NIH HHS [IP50 MH5000733-2] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007367] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTINGER KB, 1992, DEVELOPMENT, V116, P877; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BRANDSABERI B, 1993, ANAT EMBRYOL, V188, P239; DICKINSON ME, 1995, DEVELOPMENT, V121, P2099; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092-8674(95)90536-7; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOUSTON B, 1994, J MOL ENDOCRINOL, V13, P289, DOI 10.1677/jme.0.0130289; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; JONES CM, 1991, DEVELOPMENT, V111, P531; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LU S, 1992, P NATL ACAD SCI USA, V89, P8053, DOI 10.1073/pnas.89.17.8053; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; MARTINSGREEN M, 1988, DEVELOPMENT, V103, P607; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MAYOR R, 1995, DEVELOPMENT, V121, P767; MOURY JD, 1990, DEV BIOL, V141, P243, DOI 10.1016/0012-1606(90)90380-2; MOURY JD, 1989, DEV BIOL, V133, P44, DOI 10.1016/0012-1606(89)90295-9; NAKAGAWA S, 1995, DEVELOPMENT, V121, P1321; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; RANGINI Z, 1991, MECH DEVELOP, V35, P13, DOI 10.1016/0925-4773(91)90037-7; ROBERT B, 1991, GENE DEV, V5, P2363, DOI 10.1101/gad.5.12b.2363; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SCHERSON T, 1993, DEVELOPMENT, V118, P1049; SELLECK MAJ, 1995, DEVELOPMENT, V121, P525; SMITH JC, 1994, CELL, V76, P193, DOI 10.1016/0092-8674(94)90325-5; STUART ET, 1994, ANNU REV GENET, V28, P219, DOI 10.1146/annurev.ge.28.120194.001251; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; TAKAHASHI Y, 1992, P NATL ACAD SCI USA, V89, P10237, DOI 10.1073/pnas.89.21.10237; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; TRUEB B, 1988, NUCLEIC ACIDS RES, V16, P4723, DOI 10.1093/nar/16.10.4723; TUCKER GC, 1984, CELL DIFFER DEV, V14, P223, DOI 10.1016/0045-6039(84)90049-6; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; VANSTRAATEN HWM, 1991, ANAT EMBRYOL, V184, P55; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YOKOUCHI Y, 1991, DEVELOPMENT, V113, P431; ZIMMERMAN K, 1993, DEVELOPMENT, V119, P221	53	879	901	2	36	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					969	979		10.1016/0092-8674(95)90276-7	http://dx.doi.org/10.1016/0092-8674(95)90276-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553857	hybrid			2022-12-28	WOS:A1995RW69300013
J	SCOTT, DM; EHRMANN, IE; ELLIS, PS; BISHOP, CE; AGULNIK, AI; SIMPSON, E; MITCHELL, MJ				SCOTT, DM; EHRMANN, IE; ELLIS, PS; BISHOP, CE; AGULNIK, AI; SIMPSON, E; MITCHELL, MJ			IDENTIFICATION OF A MOUSE MALE-SPECIFIC TRANSPLANTATION ANTIGEN, H-Y	NATURE			English	Article							UBIQUITIN-ACTIVATING ENZYME-E1; T-CELLS; GENE; EXPRESSION; CHROMOSOME; RESPONSES; LOCATION; EPITOPES; PEPTIDE; MICE	THE male-specific transplantation antigen, H-Y, causes rejection of male tissue grafts by genotypically identical female mice(1) and contributes to the rejection of human leukocyte antigen-matched male organ grafts by human females(2). Although first recognized 40 years ago(1), the identity of H-Y has remained elusive. T cells detect several distinct H-Y epitopes(3-5), and these are probably peptides, derived from intracellular proteins, that are presented at the cell surface with major histocompatibility complex (MHC) molecules(6). In the mouse, the gene(s) controlling H-Y expression (Hya) are located on the short arm of the Y chromosome(7,8) between the zinc-finger genes Zfy-1 and Zfy-2 (ref. 9). We have recently identified Smcy, a ubiquitously expressed gene, in this region(10) and its X-chromosome homologue, Smcx(11). Here we report that Smcy encodes an H-YKk epitope that is defined by the octamer peptide TENSGKDI: no similar peptide is found in Smcx. These findings provide a genetic basis for the antigenic difference between males and females that contributes towards a tissue transplant rejection response.	INSERM, U406, F-13005 MARSEILLE, FRANCE; BAYLOR COLL MED, DEPT OBSTET & GYNAECOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT HUMAN & MOLEC GENET, HOUSTON, TX 77030 USA; UNIV TENNESSEE, DEPT OBSTET & GYNAECOL, MEMPHIS, TN 38105 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Baylor College of Medicine; Baylor College of Medicine; University of Tennessee System; University of Tennessee Health Science Center	SCOTT, DM (corresponding author), HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, MRC, CTR CLIN SCI, DU CANE RD, LONDON W12 0NN, ENGLAND.		Agoulnik, Alexander/AAK-3213-2020; Mitchell, Michael/I-3987-2016	Agoulnik, Alexander/0000-0001-6587-6845; Mitchell, Michael/0000-0003-2052-7347; Simpson, Elizabeth/0000-0002-2118-3139				AGULNIK AI, 1994, HUM MOL GENET, V3, P873, DOI 10.1093/hmg/3.6.873; AGULNIK AI, 1994, HUM MOL GENET, V3, P879, DOI 10.1093/hmg/3.6.879; BURGOYNE PS, 1986, NATURE, V320, P170, DOI 10.1038/320170a0; CHOMEZ P, 1992, IMMUNOGENETICS, V35, P241, DOI 10.1007/BF00166829; EICHWALD EJ, 1955, TRANSPLAN B, V2, P121; FATTAEY AR, 1993, ONCOGENE, V8, P3149; GAVIN MA, 1994, EUR J IMMUNOL, V24, P2124, DOI 10.1002/eji.1830240929; GORDON RD, 1975, J EXP MED, V142, P1108, DOI 10.1084/jem.142.5.1108; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; KAY GF, 1991, NATURE, V354, P486, DOI 10.1038/354486a0; KING TR, 1994, GENOMICS, V24, P159, DOI 10.1006/geno.1994.1593; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MCLAREN A, 1988, P NATL ACAD SCI USA, V85, P6442, DOI 10.1073/pnas.85.17.6442; MITCHELL MJ, 1991, NATURE, V354, P483, DOI 10.1038/354483a0; PFEFFER PF, 1982, TRANSPLANTATION, V33, P52, DOI 10.1097/00007890-198201000-00011; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; ROBERTS C, 1988, P NATL ACAD SCI USA, V85, P6446, DOI 10.1073/pnas.85.17.6446; ROOPENIAN DC, 1992, IMMUNOL TODAY, V13, P7, DOI 10.1016/0167-5699(92)90197-F; ROOPENIAN DC, 1989, IMMUNOGENETICS, V30, P335, DOI 10.1007/BF02425273; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; SCOTT D, 1991, IMMUNOGENETICS, V33, P54, DOI 10.1007/BF00211696; SCOTT DM, 1992, IMMUNOGENETICS, V36, P86, DOI 10.1007/BF00215284; SIBILLE C, 1990, J EXP MED, V172, P35, DOI 10.1084/jem.172.1.35; SIMPSON E, 1982, IMMUNOL TODAY, V3, P97, DOI 10.1016/S0167-5699(82)80025-X; SIMPSON E, 1989, K IMMUNOLOGY S, V2, P42; SIMPSON EM, 1991, GENOMICS, V11, P601, DOI 10.1016/0888-7543(91)90067-O; TOMONARI K, 1983, J IMMUNOL, V131, P1641; WU JS, 1994, HUM MOL GENET, V3, P153, DOI 10.1093/hmg/3.1.153	28	171	178	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	1995	376	6542					695	698		10.1038/376695a0	http://dx.doi.org/10.1038/376695a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7544442				2022-12-28	WOS:A1995RQ67200062
J	KOOYMAN, DL; BYRNE, GW; MCCLELLAN, S; NIELSEN, D; TONE, M; WALDMANN, H; COFFMAN, TM; MCCURRY, KR; PLATT, JL; LOGAN, JS				KOOYMAN, DL; BYRNE, GW; MCCLELLAN, S; NIELSEN, D; TONE, M; WALDMANN, H; COFFMAN, TM; MCCURRY, KR; PLATT, JL; LOGAN, JS			IN-VIVO TRANSFER OF GPI-LINKED COMPLEMENT RESTRICTION FACTORS FROM ERYTHROCYTES TO THE ENDOTHELIUM	SCIENCE			English	Article							DECAY-ACCELERATING FACTOR; VARIANT SURFACE GLYCOPROTEIN; RAPID LATERAL DIFFUSION; TRANSGENIC MICE; MEMBRANE-PROTEIN; HUMAN-HEMOGLOBIN; LYMPHOID-CELLS; GLOBIN GENE; HIGH-LEVEL; EXPRESSION	Many proteins are associated with the outer layer of the cell membrane through a posttranslationally added glycosyl phosphatidylinositol (GPI) anchor. The functional significance of this type of protein linkage is unclear, although it results in increased lateral mobility, sorting to the apical surface of the cell, reinsertion into cell membranes, and possibly cell signaling. Here evidence is presented that GPI-linked proteins can undergo intermembrane transfer in vivo. GPI-linked proteins expressed on the surface of transgenic mouse red blood cells were transferred in a functional form to endothelial cells in vivo. This feature of GPI linkage may be potentially useful for the delivery of therapeutic proteins to vascular endothelium.	UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,OXFORD OX1 3RE,ENGLAND; DUKE UNIV,MED CTR,DURHAM,NC 27705; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT IMMUNOL,DURHAM,NC 27710	University of Oxford; Duke University; Duke University; Duke University; Duke University	KOOYMAN, DL (corresponding author), NEXTRAN,303B COLL RD E,PRINCETON,NJ 08540, USA.		waldmann, herman/W-8051-2019	Waldmann, Herman/0000-0001-7519-6720; Platt, Jeffrey/0000-0002-4915-0419	NHLBI NIH HHS [HL 52297, HL 46810, HL 50985] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL050985, R01HL052297, R37HL052297, R01HL046810] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEHRINGER RR, 1989, SCIENCE, V245, P971, DOI 10.1126/science.2772649; BULOW R, 1988, BIOCHEMISTRY-US, V27, P2384; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALMASSO AP, 1991, TRANSPLANTATION, V52, P530, DOI 10.1097/00007890-199109000-00029; DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637; FALK RJ, 1983, J CLIN INVEST, V72, P560, DOI 10.1172/JCI111004; GREAVES DR, 1990, NATURE, V343, P183, DOI 10.1038/343183a0; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HANSCOMBE O, 1989, GENE DEV, V3, P1572, DOI 10.1101/gad.3.10.1572; HOGAN B, 1986, MANIPULATING MOUSE E; HUANG JH, 1994, IMMUNITY, V1, P607, DOI 10.1016/1074-7613(94)90050-7; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A; LEONG LYW, 1992, EUR J IMMUNOL, V22, P2825, DOI 10.1002/eji.1830221111; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; MERI S, 1990, IMMUNOLOGY, V71, P1; NICHOLSONWELLER A, 1982, J IMMUNOL, V129, P184; PEARCE EJ, 1990, J IMMUNOL, V144, P2751; PLATT JL, 1983, J EXP MED, V158, P1227, DOI 10.1084/jem.158.4.1227; RIFKIN MR, 1990, P NATL ACAD SCI USA, V87, P801, DOI 10.1073/pnas.87.2.801; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; SUGITA Y, 1988, J BIOCHEM-TOKYO, V104, P633, DOI 10.1093/oxfordjournals.jbchem.a122524; TOWNES TM, 1985, EMBO J, V4, P1715, DOI 10.1002/j.1460-2075.1985.tb03841.x; VAKEVA A, 1994, IMMUNOLOGY, V82, P28; WAGNER RC, 1975, MICROVASC RES, V10, P286, DOI 10.1016/0026-2862(75)90033-3; ZHANG F, 1992, P NATL ACAD SCI USA, V89, P5231, DOI 10.1073/pnas.89.12.5231	28	221	228	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					89	92		10.1126/science.7541557	http://dx.doi.org/10.1126/science.7541557			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7541557				2022-12-28	WOS:A1995RG98000041
J	SCHWIEBERT, EM; EGAN, ME; HWANG, TH; FULMER, SB; ALLEN, SS; CUTTING, GR; GUGGINO, WB				SCHWIEBERT, EM; EGAN, ME; HWANG, TH; FULMER, SB; ALLEN, SS; CUTTING, GR; GUGGINO, WB			CFTR REGULATES OUTWARDLY RECTIFYING CHLORIDE CHANNELS THROUGH AN AUTOCRINE MECHANISM INVOLVING ATP	CELL			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; ION-TRANSPORT DEFECT; CYSTIC-FIBROSIS GENE; EPITHELIAL-CELLS; CL CHANNELS; EXTRACELLULAR ATP; PROTEIN-KINASE; ACTIVATION; IDENTIFICATION; EXPRESSION	The cystic fibrosis transmembrane conductance regulator (CFTR) functions to regulate both Cl- and Na+ conductive pathways; however, the cellular mechanisms whereby CFTR acts as a conductance regulator are unknown. CFTR and outwardly rectifying Cl- channels (ORCCs) are distinct channels but are linked functionally via an unknown regulatory mechanism. We present results from whole-cell and single-channel patch-clamp recordings, short-circuit current recordings, and [gamma-P-32]ATP release assays of normal, CF, and wild-type or mutant CFTR-transfected CF airway cultured epithelial cells wherein CFTR regulates ORCCs by triggering the transport of the potent agonist, ATP, out of the cell. Once released, ATP stimulates ORCCs through a P-2U purinergic receptor-dependent signaling mechanism. Our results suggest that CFTR functions to regulate other Cl- secretory pathways in addition to itself conducting Cl-.	JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS MED INST, CTR MED GENET, DEPT PEDIAT, BALTIMORE, MD 21287 USA; YALE UNIV, SCH MED, DEPT PEDIAT, NEW HAVEN, CT 06520 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Yale University	SCHWIEBERT, EM (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA.							ALTON EWFW, 1993, NAT GENET, V5, P135, DOI 10.1038/ng1093-135; AMBUDKAR SV, 1984, J BIOL CHEM, V259, P2576; BARNARD EA, 1994, TRENDS PHARMACOL SCI, V15, P67, DOI 10.1016/0165-6147(94)90280-1; CHINET TC, 1994, AM J PHYSIOL, V266, pC1061, DOI 10.1152/ajpcell.1994.266.4.C1061; CHU CS, 1991, EMBO J, V10, P1355, DOI 10.1002/j.1460-2075.1991.tb07655.x; CLARKE LL, 1992, AM J PHYSIOL, V263, pC348, DOI 10.1152/ajpcell.1992.263.2.C348; CLIFF WH, 1992, AM J PHYSIOL, V262, pC1154, DOI 10.1152/ajpcell.1992.262.5.C1154; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FLOTTE TR, 1993, J BIOL CHEM, V268, P3781; FULMER SB, 1995, IN PRESS P NATL ACAD, V92; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; GRUENERT DC, 1988, P NATL ACAD SCI USA, V85, P5951, DOI 10.1073/pnas.85.16.5951; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; JOHNSON LJ, 1995, IN PRESS J CLIN INVE; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; KUNZELMANN K, 1993, AM J RESP CELL MOL, V8, P522, DOI 10.1165/ajrcmb/8.5.522; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; REISIN IL, 1994, J BIOL CHEM, V269, P20584; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCHWIEBERT EM, 1992, P NATL ACAD SCI USA, V89, P10623, DOI 10.1073/pnas.89.22.10623; SCHWIEBERT EM, 1994, AM J PHYSIOL, V267, pC272, DOI 10.1152/ajpcell.1994.267.1.C272; SCHWIEBERT EM, 1994, AM J PHYSIOL, V266, pC1464, DOI 10.1152/ajpcell.1994.266.5.C1464; SHEPPARD DN, 1993, ANN NY ACAD SCI, V707, P275, DOI 10.1111/j.1749-6632.1993.tb38058.x; SINGH AK, 1993, BIOPHYS J, V64, pA17; STUTTS MJ, 1994, AM J PHYSIOL-CELL PH, V267, pC1442, DOI 10.1152/ajpcell.1994.267.5.C1442; WELSH MJ, 1986, CLIN CHEST MED, V7, P273; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313	36	584	587	1	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 30	1995	81	7					1063	1073		10.1016/S0092-8674(05)80011-X	http://dx.doi.org/10.1016/S0092-8674(05)80011-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7541313	Bronze			2022-12-28	WOS:A1995RG91000011
J	MUKHOPADHYAY, D; TSIOKAS, L; ZHOU, XM; FOSTER, D; BRUGGE, JS; SUKHATME, VP				MUKHOPADHYAY, D; TSIOKAS, L; ZHOU, XM; FOSTER, D; BRUGGE, JS; SUKHATME, VP			HYPOXIC INDUCTION OF HUMAN VASCULAR ENDOTHELIAL GROWTH-FACTOR EXPRESSION THROUGH C-SRC ACTIVATION	NATURE			English	Article							PROTEIN-TYROSINE KINASE; OVEREXPRESSED PP60C-SRC; CELL-TRANSFORMATION; ANGIOGENESIS; GENE; PHOSPHORYLATION; FAMILY	ANGIOGENESIS the formation of new microvasculature by capillary sprouting, is crucial for tumour development(1). Hypoxic regions of solid tumours produce the powerful and directly acting angiogenic protein VEGF/VPF (vascular endothelial growth factor/vascular permeability factor)(2-6). We now investigate the signal transduction pathway involved in hypoxic induction of VEGF expression. Hypoxia is known to induce a tyrosine kinase cascade that results in the activation of nitrogen-fixation genes in Rhizobium meliloti(7), and activation of tyrosine kinases is critical in signalling triggered by growth factors and ultraviolet light. We show here that genistein, an inhibitor of protein tyrosine kinases blocks VEGF induction. Hypoxia increases the kinase activity of pp60(c-src) and its phosphorylation on tyrosine 416 but does not activate Fyn or Yes. Expression of either a dominant-negative mutant form of c-Src or of Raf-1 markedly reduces VEGF induction. VEGF induction by hypoxia in c-src(-) cells is impaired, although there is a compensatory activation of Fyn. Our results provide an insight into hypoxia-triggered intracellular signalling, define VEGF as a new downstream target for c-Src, and suggest a role for c-Src in promoting angiogenesis.	BETH ISRAEL HOSP, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA; ARIAD PHARMACEUT INC, CAMBRIDGE, MA 02139 USA; CUNY HUNTER COLL, NEW YORK, NY 10018 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Takeda Pharmaceutical Company Ltd; Takeda Oncology; City University of New York (CUNY) System; Hunter College (CUNY)			Sukhatme, Vikas/W-2776-2019	Tsiokas, Leonidas/0000-0002-3659-1813				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BREIER G, 1992, DEVELOPMENT, V114, P521; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; CHENG HC, 1992, J BIOL CHEM, V267, P9248; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FOLKMAN J, 1975, ANN INTERN MED, V82, P96, DOI 10.7326/0003-4819-82-1-96; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOONG AC, 1994, CANCER RES, V54, P5273; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; LABOW MA, 1990, MOL CELL BIOL, V10, P3343, DOI 10.1128/MCB.10.7.3343; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; THOMAS JE, 1993, ONCOGENE, V8, P2521; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852	28	540	558	0	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 15	1995	375	6532					577	581		10.1038/375577a0	http://dx.doi.org/10.1038/375577a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7540725				2022-12-28	WOS:A1995RD28700048
J	GEBOES, K; RUTGEERTS, P				GEBOES, K; RUTGEERTS, P			CD44V6 AND CD44V3 VARIANTS IN INFLAMMATORY BOWEL-DISEASE	LANCET			English	Editorial Material									KATHOLIEKE UNIV LEUVEN HOSP, DEPT GASTROENTEROL, LOUVAIN, BELGIUM	Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven	GEBOES, K (corresponding author), KATHOLIEKE UNIV LEUVEN HOSP, DEPT PATHOL, LOUVAIN, BELGIUM.							DOUGHERTY GJ, 1994, J BIOL CHEM, V269, P9074; FOX SB, 1993, LANCET, V342, P548, DOI 10.1016/0140-6736(93)91670-H; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; MULDER JWR, 1995, GUT, V36, P76, DOI 10.1136/gut.36.1.76; Pera A, 1987, GASTROENTEROLOGY, V92, P181, DOI 10.1016/0016-5085(87)90856-0; RYDER SD, 1994, GASTROENTEROLOGY, V106, P117, DOI 10.1016/S0016-5085(94)94775-9; SAXON A, 1990, J ALLERGY CLIN IMMUN, V86, P202, DOI 10.1016/S0091-6749(05)80067-3; TERPE HJ, 1994, J PATHOL, V174, P89, DOI 10.1002/path.1711740205; TERPE HJ, 1994, HISTOCHEMISTRY, V101, P79, DOI 10.1007/BF00269353; WELLS AD, 1991, BRIT J SURG, V78, P179, DOI 10.1002/bjs.1800780214	10	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 13	1995	345	8959					1191	1192		10.1016/S0140-6736(95)91985-6	http://dx.doi.org/10.1016/S0140-6736(95)91985-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7537839				2022-12-28	WOS:A1995QX86100003
J	COLLARD, JF; COTE, F; JULIEN, JP				COLLARD, JF; COTE, F; JULIEN, JP			DEFECTIVE AXONAL-TRANSPORT IN A TRANSGENIC MOUSE MODEL OF AMYOTROPHIC-LATERAL-SCLEROSIS	NATURE			English	Article							DISEASE	AMYOTROPHIC lateral sclerosis (ALS) is a degenerative disease of motor neurons, characterized by depositions of neurofilaments in the perikarya and proximal axons. The pathogenesis of ALS remains poorly understood, but two lines of evidence suggest that neurofilament accumulation may play a causal role. First, transgenic mice that overexpress neurofilament proteins show motor neuron degeneration(1-3) and, second, variant alleles of the neurofilament heavy-subunit gene (NF-H) have been found in some human ALS patients(4). To investigate hom disorganized neurofilaments might cause neurodegeneration, we examined axonal transport of newly synthesized proteins in mice that overexpress the human NF-H gene(1). We observed dramatic defects of axonal transport, not only of neurofilament proteins but also of other proteins, including tubulin and actin. Ultrastructural analysis revealed a paucity of cytoskeletal elements, smooth endoplasmic reticulum and especially mitochondria in the degenerating axons, We therefore propose that the neurofilament accumulations observed in these mice cause axonal degeneration by impeding the transport of components required for axonal maintenance, and that a similar mechanism may account for the pathogenesis of ALS in human patients.	MCGILL UNIV,MONTREAL GEN HOSP,RES INST,CTR RES NEUROSCI,MONTREAL,PQ H3G 1A4,CANADA	McGill University								Chou SM., 1992, HDB AMYOTROPHIC LATE, P133; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; DELISLE M, J NEUROL SCI, V63, P241; FIGLEWICZ DA, 1994, HUM MOL GENET, V3, P1751; GRIFFIN JW, 1978, SCIENCE, V202, P633, DOI 10.1126/science.81524; GRIFFIN JW, 1988, ANN NEUROL, V23, P3, DOI 10.1002/ana.410230103; GUMEY ME, 1994, SCIENCE, V264, P1772; HIRANO A, 1984, J NEUROPATH EXP NEUR, V43, P461, DOI 10.1097/00005072-198409000-00001; HOFFMAN PN, 1975, J CELL BIOL, V66, P315; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; MCQUARRIE IG, 1989, NEUROBIOL AGING, V10, P359, DOI 10.1016/0197-4580(89)90049-3; Nixon RA, 1991, NEURONAL CYTOSKELETO, P283; OBLINGER MM, 1987, J NEUROSCI, V7, P453; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L	14	395	405	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					61	64		10.1038/375061a0	http://dx.doi.org/10.1038/375061a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7536898				2022-12-28	WOS:A1995QW60400055
J	AIDOO, M; LALVANI, A; ALLSOPP, CEM; PLEBANSKI, M; MEISNER, SJ; KRAUSA, P; BROWNING, M; MORRISJONES, S; GOTCH, F; FIDOCK, DA; TAKIGUCHI, M; ROBSON, KJH; GREENWOOD, BM; DRUILHE, P; WHITTLE, HC; HILL, AVS				AIDOO, M; LALVANI, A; ALLSOPP, CEM; PLEBANSKI, M; MEISNER, SJ; KRAUSA, P; BROWNING, M; MORRISJONES, S; GOTCH, F; FIDOCK, DA; TAKIGUCHI, M; ROBSON, KJH; GREENWOOD, BM; DRUILHE, P; WHITTLE, HC; HILL, AVS			IDENTIFICATION OF CONSERVED ANTIGENIC COMPONENTS FOR A CYTOTOXIC T-LYMPHOCYTE-INDUCING VACCINE AGAINST MALARIA	LANCET			English	Article							FALCIPARUM CIRCUMSPOROZOITE PROTEIN; PARASITE PLASMODIUM-FALCIPARUM; CELL RESPONSE; SPOROZOITES; SURFACE; PROTECTION; EXPRESSION; SEQUENCE; PEPTIDES; THROMBOSPONDIN	Several cellular and humoral mechanisms probably play a role in natural immunity to Plasmodium falciparum malaria, but the development of an effective vaccine has been impeded by uncertainty as to which antigens are targeted by protective immune responses. Experimental models of malaria have shown that cytotoxic T lymphocytes (CTL) which kill parasite-infected hepatocytes can provide complete protective immunity against certain species of Plasmodium in mice, and studies in The Gambia have provided indirect evidence that CTL play a protective role against P falciparum in humans. By using an HLA-based approach, termed reverse immunogenetics, we have previously identified peptide epitopes for CTL in liver-stage antigen-1 and the circumsporozoite protein of P falciparum, We have extended this work to identify CTL epitopes for HLA class I antigens that are found in most individuals from Caucasian and African populations. Most of these epitopes are in conserved regions of P falciparum. CTL peptide epitopes were found in a further two antigens, thrombospondin-related anonymous protein and sporozoite threonine and asparagine rich protein, indicating that a subunit vaccine designed to induce a protective CTL response may need to include parts of several parasite antigens. However, CTL levels in both children with malaria and in semi-immune adults from an endemic area were low suggesting that boosting these low levels by immunisation might provide substantial or even complete protection against infection and disease.	UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, OXFORD OX3 9DU, ENGLAND; MRC LABS, Fajara, SENEGAL; INST PASTEUR, PARIS, FRANCE; UNIV TOKYO, INST MED SCI, MINATO KU, TOKYO 108, JAPAN	University of Oxford; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Tokyo			HILL, Adrian V>S>/C-1306-2008; Plebanski, Magdalena/AAU-3144-2021; Takiguchi, Masafumi/E-7468-2013	Lalvani, Ajit/0000-0002-2396-246X; , Magdalena/0000-0001-6889-3667; Fidock, David/0000-0001-6753-8938	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLSOPP CEM, 1992, AM J HUM GENET, V50, P411; ANDO K, 1994, J IMMUNOL, V153, P482; BOURGAULT I, 1994, J IMMUNOL, V152, P2530; BROWN F, 1994, DEV BIOL STAND BASEL, V82, P1; BROWNING MJ, 1993, P NATL ACAD SCI USA, V90, P2842, DOI 10.1073/pnas.90.7.2842; BROWNING MJ, 1995, TISSUE ANTIGENS, V45, P177, DOI 10.1111/j.1399-0039.1995.tb02437.x; COWAN G, 1992, LANCET, V339, P1412, DOI 10.1016/0140-6736(92)91229-2; COX WI, 1993, VIROLOGY, V195, P845, DOI 10.1006/viro.1993.1442; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DOOLAN DL, 1993, INT IMMUNOL, V5, P37, DOI 10.1093/intimm/5.1.37; DOOLAN DL, 1992, INFECT IMMUN, V60, P675, DOI 10.1128/IAI.60.2.675-682.1992; DOOLAN DL, 1991, INT IMMUNOL, V3, P511, DOI 10.1093/intimm/3.6.511; ELVIN J, 1991, EUR J IMMUNOL, V21, P2025, DOI 10.1002/eji.1830210909; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FIDOCK DA, 1994, MOL BIOCHEM PARASIT, V64, P219, DOI 10.1016/0166-6851(94)00012-3; FIDOCK DA, 1994, J IMMUNOL, V153, P190; FIDOCK DA, 1994, MOL BIOCHEM PARASIT, V67, P255, DOI 10.1016/0166-6851(94)00138-3; GOOD MF, 1988, IMMUNOL TODAY, V9, P351, DOI 10.1016/0167-5699(88)91336-9; GOOD MF, 1988, ANNU REV IMMUNOL, V6, P663, DOI 10.1146/annurev.iy.06.040188.003311; HILL AVS, 1994, PHILOS T R SOC B, V346, P379, DOI 10.1098/rstb.1994.0155; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HUCZKO EL, 1993, J IMMUNOL, V151, P2572; KHUSMITH S, 1994, INFECT IMMUN, V62, P2979, DOI 10.1128/IAI.62.7.2979-2983.1994; LALVANI A, 1994, RES IMMUNOL, V145, P461, DOI 10.1016/S0923-2494(94)80177-0; LAYTON GT, 1993, J IMMUNOL, V151, P1097; Marsh K., 1986, Clinics in Tropical Medicine and Communicable Diseases, V1, P91; MCADAM S, IN PRESS J IMMUNOL; MOELANS IIMD, 1991, MOL BIOCHEM PARASIT, V45, P193, DOI 10.1016/0166-6851(91)90086-L; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; NUSSENZWEIG RS, 1969, NATURE, V222, P488, DOI 10.1038/222488a0; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; ROBSON KJH, 1990, P ROY SOC B-BIOL SCI, V242, P205, DOI 10.1098/rspb.1990.0126; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; RODRIGUES M, 1992, J EXP MED, V175, P895, DOI 10.1084/jem.175.4.895; ROGERS WO, 1992, P NATL ACAD SCI USA, V89, P9176, DOI 10.1073/pnas.89.19.9176; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; ROSENBERG R, 1990, T ROY SOC TROP MED H, V84, P209, DOI 10.1016/0035-9203(90)90258-G; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0; SEDEGAH M, 1992, J IMMUNOL, V149, P966; SUTTON J, 1993, EUR J IMMUNOL, V23, P447, DOI 10.1002/eji.1830230222; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573; YASUTOMI Y, 1993, J IMMUNOL, V150, P3101; ZHU JD, 1991, MOL BIOCHEM PARASIT, V48, P223, DOI 10.1016/0166-6851(91)90117-O	46	134	140	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 22	1995	345	8956					1003	1007		10.1016/S0140-6736(95)90754-8	http://dx.doi.org/10.1016/S0140-6736(95)90754-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7536870				2022-12-28	WOS:A1995QU57300006
J	BARR, FG; CHATTEN, J; DCRUZ, CM; WILSON, AE; NAUTA, LE; NYCUM, LM; BIEGEL, JA; WORNER, RB				BARR, FG; CHATTEN, J; DCRUZ, CM; WILSON, AE; NAUTA, LE; NYCUM, LM; BIEGEL, JA; WORNER, RB			MOLECULAR ASSAYS FOR CHROMOSOMAL TRANSLOCATIONS IN THE DIAGNOSIS OF PEDIATRIC SOFT-TISSUE SARCOMAS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERIPHERAL NEUROECTODERMAL TUMOR; ROUND-CELL TUMOR; POLYMERASE CHAIN-REACTION; ALVEOLAR RHABDOMYOSARCOMA; EWINGS-SARCOMA; FUSION; PAX3; GENE; REARRANGEMENT; AMPLIFICATION	Objective.-To compare molecular assays for characteristic chromosomal translocations with standard histopathologic and cytogenetic analysis in the differential diagnosis of pediatric soft tissue sarcomas. Design.-Blinded comparison with histopathologic diagnosis. Setting.-Tertiary care children's hospital. Patients.-A total of 79 soft tissue sarcoma patients with frozen tumor tissue and histopathologic slides available for review. Methods.-The RNA from the tumors was assayed by the reverse transcriptase-polymerase chain reaction. These assays detect PAX3-FKHR and PAX7-FKHR chimeric transcripts in alveolar rhabdomyosarcoma, EWS-FLI1 and EWS-ERG chimeric transcripts in Ewing's sarcoma, and EWS-WT1 chimeric transcripts in desmoplastic small round cell tumor. Main Outcome Measures.-The polymerase chain reaction findings were compared with cytogenetic and histopathologic results. Results.-These assays detected chimeric transcripts in all cases in which translocations were found by standard cytogenetics as well as additional cases without cytogenetically detectable translocations, PAX3-FKHR or PAX7-FKHR fusions were present in 18 of 21 alveolar rhabdomyosarcomas, two of 30 embryonal rhabdomyosarcomas, and one of seven undifferentiated sarcomas. EWS-FLI1 or EWS-ERG fusions were detected in six of eight Ewing's sarcomas and one of seven undifferentiated sarcomas. The EWS-WT1 fusion was found in three of three desmoplastic small round cell tumors. Conclusions.-Molecular assays for specific gene fusions provide a genetic approach to the differential diagnosis of soft tissue sarcomas. The genetic categories correspond closely to the standard histopathologic categories. The polymerase chain reaction assays for chimeric transcripts are useful tools for the rapid and objective assessment of pediatric soft tissue sarcomas.	UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA; CHILDRENS HOSP PHILADELPHIA,DIV PATHOL,PHILADELPHIA,PA; CHILDRENS HOSP PHILADELPHIA,DIV ONCOL,PHILADELPHIA,PA; CHILDRENS HOSP PHILADELPHIA,DIV HUMAN GENET & MOLEC BIOL,PHILADELPHIA,PA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	BARR, FG (corresponding author), UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,37TH ST & HAMILTON WALK,PHILADELPHIA,PA 19104, USA.				NATIONAL CANCER INSTITUTE [U10CA013539, R01CA064202, P01CA047983] Funding Source: NIH RePORTER; NCI NIH HHS [CA47983, CA13539, CA64202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASMAR L, 1994, CANCER, V74, P2579, DOI 10.1002/1097-0142(19941101)74:9<2579::AID-CNCR2820740928>3.0.CO;2-A; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BARR FG, 1992, GENOMICS, V13, P1150, DOI 10.1016/0888-7543(92)90030-V; BIEGEL JA, 1989, CANCER GENET CYTOGEN, V38, P89, DOI 10.1016/0165-4608(89)90169-6; BIEGEL JA, 1993, GENE CHROMOSOME CANC, V7, P119, DOI 10.1002/gcc.2870070210; BIEGEL JA, 1991, GENE CHROMOSOME CANC, V3, P483, DOI 10.1002/gcc.2870030612; BIEGEL JA, IN PRESS GENES CHROM; DAVIS RJ, 1994, CANCER RES, V54, P2869; DEHNER LP, 1993, AM J SURG PATHOL, V17, P1, DOI 10.1097/00000478-199301000-00001; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DESMAZE C, 1992, GENES CHROMOSOM CANC, V50, P30; DOUGLASS EC, 1991, GENE CHROMOSOME CANC, V3, P480, DOI 10.1002/gcc.2870030611; DOWNING JR, 1993, AM J PATHOL, V143, P1294; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GERALD WL, 1991, AM J SURG PATHOL, V15, P499, DOI 10.1097/00000478-199106000-00001; GIOVANNINI M, 1992, J CLIN INVEST, V90, P1911, DOI 10.1172/JCI116068; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; GRAY JW, 1992, CANCER, V69, P1536, DOI 10.1002/1097-0142(19920315)69:6+<1536::AID-CNCR2820691306>3.0.CO;2-J; GRILLO M, 1990, BIOTECHNIQUES, V9, P262; KAWASAKI ES, 1993, PCR PROTOCOLS GUIDE, V3, P71; LADANYI M, 1993, DIAGN MOL PATHOL, V2, P141, DOI 10.1097/00019606-199303000-00021; LADANYI M, 1994, CANCER RES, V54, P2837; NEWTON WA, 1988, J CLIN ONCOL, V6, P67, DOI 10.1200/JCO.1988.6.1.67; Raney Jr RB, 1993, PRINCIPLES PRACTICE, P769; RODRIGUEZ E, 1993, CANCER GENET CYTOGEN, V69, P17, DOI 10.1016/0165-4608(93)90105-U; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; SAWYER JR, 1992, AM J SURG PATHOL, V16, P411, DOI 10.1097/00000478-199204000-00010; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SORENSEN PHB, 1993, DIAGN MOL PATHOL, V2, P147, DOI 10.1097/00019606-199309000-00002; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TAM PE, 1993, PCR METH APPL, V3, P71; TAYLOR C, 1993, BRIT J CANCER, V67, P128, DOI 10.1038/bjc.1993.22; TRICHE TJ, 1993, PRINCIPLES PRACTICE, P115; TSOKOS M, 1992, ARCH PATHOL LAB MED, V116, P847; WHANGPENG J, 1992, GENE CHROMOSOME CANC, V5, P299, DOI 10.1002/gcc.2870050405; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	36	186	187	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	1995	273	7					553	557		10.1001/jama.273.7.553	http://dx.doi.org/10.1001/jama.273.7.553			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF686	7530783				2022-12-28	WOS:A1995QF68600025
J	TURNBULL, JM				TURNBULL, JM			IS LISTENING FOR ABDOMINAL BRUITS USEFUL IN THE EVALUATION OF HYPERTENSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RENOVASCULAR HYPERTENSION				TURNBULL, JM (corresponding author), OTTAWA CIVIC HOSP,DEPT MED,1053 CARLING AVE,OTTAWA,ON K1Y 1J8,CANADA.							ARIDA EJ, 1977, NEW YORK STATE J MED, V77, P987; BLOOM HJG, 1950, BRIT HEART J, V12, P343; CLAIN D, 1966, LANCET, V2, P516; EDWARDS AJ, 1970, BMJ-BRIT MED J, V1, P342, DOI 10.1136/bmj.1.5692.342; EPIER DF, 1976, AM J CARDIOL, V37, P48; ESTES JE, 1950, CIRCULATION, V2, P258, DOI 10.1161/01.CIR.2.2.258; FENTON SSA, 1966, LANCET, V2, P117; GIFFORD RW, 1963, GERIATRICS, V8, P761; GOLDSTEIN LI, 1968, J AMER MED ASSOC, V206, P2518, DOI 10.1001/jama.206.11.2518; GRIM CE, 1979, ANN INTERN MED, V91, P617, DOI 10.7326/0003-4819-91-4-617; HAVEY RJ, 1985, JAMA-J AM MED ASSOC, V254, P388, DOI 10.1001/jama.254.3.388; HUNT JC, 1974, ARCH INTERN MED, V133, P988, DOI 10.1001/archinte.133.6.988; JULIUS S, 1967, NEW ENGL J MED, V276, P1175, DOI 10.1056/NEJM196705252762104; LEE RV, 1967, NEW ENGL J MED, V277, P682, DOI 10.1056/NEJM196709282771305; MARONDE RF, 1975, JAMA-J AM MED ASSOC, V233, P997, DOI 10.1001/jama.233.9.997; MATZ R, 1969, LANCET, V1, P310; MCLOUGHLIN MJ, 1975, JAMA-J AM MED ASSOC, V232, P1238; MOSER RJ, 1962, ANN INTERN MED, V56, P471, DOI 10.7326/0003-4819-56-3-471; PERLOFF D, 1961, CIRCULATION, V24, P1286, DOI 10.1161/01.CIR.24.6.1286; RIVIN AU, 1972, J AMER MED ASSOC, V221, P688, DOI 10.1001/jama.221.7.688; SARR MG, 1980, DIGEST DIS SCI, V25, P761, DOI 10.1007/BF01345295; SEREBRO H, 1965, LANCET, V1, P85; SHUMAKER HB, 1961, SURG GYNECOL OBS APR, P497; SIMON N, 1972, J AMER MED ASSOC, V220, P1209, DOI 10.1001/jama.220.9.1209; SMYTHE C, 1963, NEW ENGL J MED, V2, P1308; WATSON WC, 1973, ANN INTERN MED, V79, P211, DOI 10.7326/0003-4819-79-2-211	26	23	24	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	1995	274	16					1299	1301		10.1001/jama.274.16.1299	http://dx.doi.org/10.1001/jama.274.16.1299			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA104	7563536				2022-12-28	WOS:A1995TA10400026
J	THORNTON, H				THORNTON, H			UNDERSTANDING INFORMED CONSENT	LANCET			English	Editorial Material																		Baum M, 1995, Eur J Surg Oncol, V21, P136, DOI 10.1016/S0748-7983(95)90072-1; BAUM M, 1993, LANCET, V341, P812, DOI 10.1016/0140-6736(93)90573-Y; THORNTON H, 1995, REDUCING BREAST CANC, P205; THORNTON H, 1994, J MED ETHICS, V20, P10; TOBIAS JS, 1944, EUR J CANCER A, V30, P897	5	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1047	1048		10.1016/S0140-6736(95)91735-7	http://dx.doi.org/10.1016/S0140-6736(95)91735-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TA697	7564780				2022-12-28	WOS:A1995TA69700004
J	FEIGEN, A				FEIGEN, A			RESTLESS LEGS SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PERIODIC MOVEMENTS; DOUBLE-BLIND; SLEEP; MYOCLONUS				FEIGEN, A (corresponding author), N SHORE UNIV HOSP,MANHASSET,NY 11030, USA.							AKPINAR S, 1982, ARCH NEUROL-CHICAGO, V39, P739, DOI 10.1001/archneur.1982.00510230065027; BOGHEN D, 1976, ARCH NEUROL-CHICAGO, V33, P368, DOI 10.1001/archneur.1976.00500050054010; BOGHEN D, 1981, ANN NEUROL, V8, P341; BRODEUR C, 1988, NEUROLOGY, V38, P1845, DOI 10.1212/WNL.38.12.1845; BROWN KW, 1987, LANCET, V1, P1234; COLEMAN RM, 1980, ANN NEUROL, V8, P416, DOI 10.1002/ana.410080413; Ekbom KA, 1960, NEUROLOGY, V10, P868, DOI 10.1212/WNL.10.9.868; Ekbom KA, 1945, ACTA MED SCAND, V158, P1; FEIGIN A, 1994, MOV DISORD, V9, P492; HENING WA, 1986, NEUROLOGY, V36, P1363, DOI 10.1212/WNL.36.10.1363; IANNACCONE S, 1995, MOVEMENT DISORD, V10, P2, DOI 10.1002/mds.870100103; MONTPLAISIR J, 1992, SLEEP, V15, P391, DOI 10.1093/sleep/15.5.391; MONTPLAISIR J, 1985, NEUROLOGY, V35, P130, DOI 10.1212/WNL.35.1.130; NORDLANDER NB, 1953, ACTA MED SCAND, V145, P453; OKEEFE ST, 1994, AGE AGEING, V22, P200; PALL HS, 1987, NEUROLOGY, V37, P1436, DOI 10.1212/WNL.37.8.1436; ROGER SD, 1991, LANCET, V337, P1551, DOI 10.1016/0140-6736(91)93248-8; TARSY D, 1992, MOVEMENT DISORDERS N, P397; WALTERS AS, 1988, ANN NEUROL, V24, P455, DOI 10.1002/ana.410240318	19	9	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	1995	274	15					1191	1192						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ120	7563499				2022-12-28	WOS:A1995RZ12000010
J	KILGORE, PE; HOLMAN, RC; CLARKE, MJ; GLASS, RI				KILGORE, PE; HOLMAN, RC; CLARKE, MJ; GLASS, RI			TRENDS OF DIARRHEAL DISEASE - ASSOCIATED MORTALITY IN US CHILDREN, 1968 THROUGH 1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; DEATHS; CARE; INTERVENTIONS; ROTAVIRUS; THERAPY; MEASLES; MEXICO	Objectives.-To describe temporal patterns in mortality related to diarrheal disease in US children and to assess progress toward its prevention and control. Design.-Retrospective analyses of death certificate data on diarrhea of all causes compiled by the National Center for Health Statistics, Centers for Disease Control and Prevention, Atlanta, Ga. Patients.-Children aged 1 month through 4 years who died with diarrhea. Setting.-United States, 1968 through 1991. Results.-A total of 14 137 deaths associated with diarrhea among children were reported in the United States between 1968 and 1991. Of these, 78% occurred in infants (ie, aged 1 to 11 months); the median age at the time of death has declined from 5 to 1.5 months. Diarrheal disease mortality dropped by approximately 75% during the first 18 years of the study, but no decline has occurred since 1985. Infant mortality due to diarrhea (per 100 000 live births) averaged 12.8 and was found to be high for blacks (33.1) and for residents of the southern United States (18.5). The infant mortality due to diarrhea from 1986 through 1991 is 5.9. Peaks in winter deaths previously associated with rotavirus were prominent in the early years among infants aged 4 through 11 months. Such peaks have virtually disappeared since 1985. Diarrhea was the principal cause of death, as the leading associated diagnoses (electrolyte disorders [30%], cardiac arrest [16%], shock [8%], and nausea/vomiting [4%]) were commonly recognized complications of diarrhea. Since 1979, prematurity has emerged as a common associated diagnosis. Conclusions.-Diarrheal deaths nationwide have declined 75% from 1968 to 1985 but stabilized since then at about 300 deaths per year. Because many of these deaths may still be preventable by early rehydration, future prevention efforts should be directed at educating health care providers about the continuing problem and recognition of the high-risk infant and at teaching mothers of such infants to begin rehydration early and to seek medical attention when their infant develops diarrhea.	CTR DIS CONTROL & PREVENT,DIV VIRAL & RICKETTSIAL DIS,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	KILGORE, PE (corresponding author), CTR DIS CONTROL & PREVENT,DIV VIRAL & RICKETTSIAL DIS,VIRAL GASTROENTERITIS SECT,MAILSTOP G-04,ATLANTA,GA 30333, USA.		Kilgore, Paul E/L-1462-2013; Kilgore, Paul/AAD-2869-2019	Kilgore, Paul E/0000-0003-3214-4482; Kilgore, Paul/0000-0003-3214-4482				AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; BERN C, 1993, J PEDIATR-US, V122, P920, DOI 10.1016/S0022-3476(09)90020-8; BERN C, 1992, B WORLD HEALTH ORGAN, V70, P705; CHAMBLEE RF, 1986, VITAL HLTH STAT 1, V20; CHURCH DL, 1995, 95TH GEN M AM SOC MI; Duggan C, 1992, MMWR Recomm Rep, V41, P1; FEACHEM RG, 1983, B WORLD HEALTH ORGAN, V61, P641; GANGAROSA RE, 1992, AM J EPIDEMIOL, V135, P281, DOI 10.1093/oxfordjournals.aje.a116282; GARTHRIGHT WE, 1988, PUBLIC HEALTH REP, V103, P107; GLASS RI, 1991, J PEDIATR, V118, P527; HEMMING VG, 1976, NEW ENGL J MED, V294, P1310, DOI 10.1056/NEJM197606102942403; HO MS, 1988, JAMA-J AM MED ASSOC, V260, P3281, DOI 10.1001/jama.260.22.3281; HOLMAN RC, 1989, AM J PUBLIC HEALTH, V79, P987, DOI 10.2105/AJPH.79.8.987; ISRAEL RA, 1986, AM J EPIDEMIOL, V124, P161, DOI 10.1093/oxfordjournals.aje.a114375; KLEIN JD, 1982, REPORT COMMITTEE INF; KLEINBAUM DG, 1988, APPLIED REGRESSION A; KOSTER FT, 1981, B WORLD HEALTH ORGAN, V59, P901; LEBARON CW, 1990, JAMA-J AM MED ASSOC, V264, P983, DOI 10.1001/jama.264.8.983; LEW JF, 1991, JAMA-J AM MED ASSOC, V265, P3280, DOI 10.1001/jama.265.24.3280; MEYERS A, 1991, JAMA-J AM MED ASSOC, V265, P1724, DOI 10.1001/jama.265.13.1724; Millman M., 1993, ACCESS HLTH CARE AM; MURRAY JL, 1988, NEW ENGL J MED, V319, P1385, DOI 10.1056/NEJM198811243192105; SNYDER J, 1988, JAMA-J AM MED ASSOC, V260, P3329; STPETER RF, 1992, JAMA-J AM MED ASSOC, V267, P2760, DOI 10.1001/jama.267.20.2760; VICTORA CG, 1989, AM J EPIDEMIOL, V129, P1032, DOI 10.1093/oxfordjournals.aje.a115207; WOODS PA, 1992, J CLIN MICROBIOL, V30, P781, DOI 10.1128/JCM.30.4.781-785.1992; 1977, MANUAL INT STATISTIC, P1; 1981, PHS911101 US DEP HLT, P91; 1993, 1991 US DEP HLTH HUM; 1993, MULTIPLE CAUSE DEATH; 1975, INT CLASSIFICATION D, P1; 1985, PEDIATRICS, V75, P358	32	108	116	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1143	1148		10.1001/jama.274.14.1143	http://dx.doi.org/10.1001/jama.274.14.1143			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563485				2022-12-28	WOS:A1995RY05600029
J	COHEN, G; FORBES, J; GARRAWAY, M				COHEN, G; FORBES, J; GARRAWAY, M			INTERPRETING SELF-REPORTED LIMITING LONG-TERM ILLNESS	BRITISH MEDICAL JOURNAL			English	Article							HEALTH SURVEY QUESTIONNAIRE; SF-36	Objective-To examine the association between self reported limiting long term illness and other dimensions of self reported health. Design-Stratified random sample of general population. Setting-Lothian region, Scotland, in 1993. Subjects-6212 men and women aged 16 and over. Main outcome measures-Limiting long term illness was assessed by the same question as used in the 1991 United Kingdom census. The shea form 36 health survey was used to assess other dimensions of health. Results-Rates of limiting long term illness were much higher than reported in the census. Scores on general and physical health scales had strong associations with limiting long term illness, but after adjustment for these associations psychosocial health measures had Little influence on limiting long term illness. Being at the lower rather than the upper quartile on the physical functioning scale more than doubled the odds of having limiting long term illness. Reported prevalence of many common illnesses was between two and three times higher among those with limiting long term illness. Conclusions-A positive response to the question used by the census to define limiting long term illness was strongly associated with physical limitations on activity and less strongly influenced by scores on scales of mental and social wellbeing. Socioeconomic effects on limiting long term illness seem largely mediated through measures of general health and physical limitations on health.			COHEN, G (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PUBL HLTH SCI,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							BRAZIER JE, 1993, BRIT MED J, V305, P160; CHARLTON J, 1994, POPULATION TRENDS, V75, P18; COHEN G, 1994, LOTHIAN HLTH SURVEY; GARRATT AM, 1993, BMJ-BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; JENKINSON CM, 1993, PUBLIC HEALTH, V107, P305, DOI 10.1016/S0033-3506(05)80122-2; KAPLAN GA, 1988, ANN CLIN RES, V20, P131; LYONS RA, 1994, AGE AGEING, V23, P182, DOI 10.1093/ageing/23.3.182; ROSENGREN A, 1993, BRIT MED J, V307, P102; SHELTON TA, 1994, BRIT MED J, V109, P1059; SMITH P, 1994, BRIT MED J, V309, P1050, DOI 10.1136/bmj.309.6961.1050; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; 1993, SAS P243 I TECHN REP; 1994, GENERAL HOUSEHOLD SU, P33	14	89	90	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	1995	311	7007					722	724		10.1136/bmj.311.7007.722	http://dx.doi.org/10.1136/bmj.311.7007.722			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RV874	7549686	Green Published			2022-12-28	WOS:A1995RV87400020
J	RAVINA, JH; HERBRETEAU, D; CIRARUVIGNERON, N; BOURET, JM; HOUDART, E; AYMARD, A; MERLAND, JJ				RAVINA, JH; HERBRETEAU, D; CIRARUVIGNERON, N; BOURET, JM; HOUDART, E; AYMARD, A; MERLAND, JJ			ARTERIAL EMBOLIZATION TO TREAT UTERINE MYOMATA	LANCET			English	Note								Haemorrhage, probably related to hypervascularisation, is the commonest complication of uterine myomata and is difficult to treat. 16 patients, aged 34-48 years, with symptomatic uterine myomata, for which a major surgical procedure was planned after failure of medical treatment, were treated by selective free-flow arterial embolisation of the myomata with Ivalon particles. With a mean follow-up of 20 months (range 11-48) in the responders, symptoms resolved in 11 patients; menstrual cycles returned to normal in ten of these. Three patients had partial improvement. Two failures required surgery. In 14 cases embolisation caused pelvic pain, which required analgesia in all.	UNIV PARIS 07,HOP LARIBOISIERE,RADIOL INTERVENT SERV,F-75475 PARIS 10,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	RAVINA, JH (corresponding author), UNIV PARIS 07,HOP LARIBOISIERE,SERV GYNECOL OBSTET,F-75475 PARIS 10,FRANCE.							COHEN J, 1993, 3RD INT S GNRH AN CA, P25; FARRER-BROWN G, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P967; HERBRETEAU D, 1993, ACTUALITE REANIMATIO, P17; RAVINA JH, 1994, PRESSE MED, V23, P1540; Sampson JA, 1912, SURG GYNECOL OBSTET, V14, P215	5	719	873	1	20	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					671	672		10.1016/S0140-6736(95)92282-2	http://dx.doi.org/10.1016/S0140-6736(95)92282-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7544859				2022-12-28	WOS:A1995RU04800011
J	PANDHA, HS; WASAN, HS; HARRINGTON, K; WAXMAN, J				PANDHA, HS; WASAN, HS; HARRINGTON, K; WAXMAN, J			LESSON OF THE WEEK - FAILURE OF NORMALIZATION OF ALPHA-FETOPROTEIN CONCENTRATION AFTER SUCCESSFUL TREATMENT OF TERATOMA	BRITISH MEDICAL JOURNAL			English	Article							MARKERS; TUMORS; TESTIS; CANCER	The development of successful treatment regimens for germ cell rumours has been one of the important advances in cancer chemotherapy. The effects of such treatment are monitored by measurement of serum concentrations of the tumour markers alpha fetoprotein and human chorionic gonadotrophin, as well as clinical and radiological assessment. The persistence of raised concentrations of alpha fetoprotein during or after treatment requires urgent investigation to delineate teratoma resistant to chemotherapy. We report on a patient with testicular teratoma who relapsed after initial chemotherapy in whom appreciably raised serum concentrations of alpha fetoprotein did not fall despite apparently successful salvage chemotherapy and surgery. An exhaustive search for a further residuum of disease was not fruitful. The finding of raised liver enzyme activities and hepatomegaly led to a liver biopsy, which showed alcoholic hepatitis. The patient decreased his alcohol intake, resulting in normalisation of his alpha fetoprotein concentration and liver enzyme activities.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CLIN ONCOL,LONDON W12 0NN,ENGLAND	Imperial College London				Wasan, Harpreet/0000-0002-6268-2030				BREOROWICZ J, 1988, TUMOR BIOL, V9, P3; BUAMAH PK, 1984, CLIN CHEM, V30, P1257; BUAMAH PK, 1987, CLIN CHIM ACTA, V168, P69, DOI 10.1016/0009-8981(87)90267-1; CHAKROBORTY M, 1991, MOL IMMUNOL, V27, P703; GREENBERG F, 1990, GASTROENTEROLOGY, V98, P1083, DOI 10.1016/0016-5085(90)90037-2; HENDRY WF, 1992, UROLOGICAL ONCOLOGY; KLEIN EA, 1993, UROL CLIN N AM, V20, P67; MINGHETTI PP, 1983, ANN NY ACAD SCI, V417, P1, DOI 10.1111/j.1749-6632.1983.tb32842.x; NEWLANDS ES, 1986, BRIT J UROL, V58, P307, DOI 10.1111/j.1464-410X.1986.tb09061.x; SELL S, 1990, CLIN LAB MED, V10, P1	10	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 12	1995	311	7002					434	435		10.1136/bmj.311.7002.434	http://dx.doi.org/10.1136/bmj.311.7002.434			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP554	7543786	Green Published			2022-12-28	WOS:A1995RP55400021
J	MEISEL, H; REIP, A; FALTUS, B; LU, MJ; PORST, H; WIESE, M; ROGGENDORF, M; KRUGER, DH				MEISEL, H; REIP, A; FALTUS, B; LU, MJ; PORST, H; WIESE, M; ROGGENDORF, M; KRUGER, DH			TRANSMISSION OF HEPATITIS-C VIRUS TO CHILDREN AND HUSBANDS BY WOMEN INFECTED WITH CONTAMINATED ANTI-D IMMUNOGLOBULIN	LANCET			English	Note								In 1978-79 a single-source outbreak of hepatitis C occurred in 2533 women who had received contaminated anti-D immunoglobulin. Children husbands of 74 women with self-limited, and of 86 women with chronic, hepatitis C were followed up for over 10-15 years. In 3 of 231 investigated children (1.3%) serological evidence for HCV infection was found. However, none of the children developed an apparent or chronic hepatitis. Serum samples oi the 94 husbands investigated showed no HCV antibodies or HCV RNA. We consider the risk of intrauterine or perinatal transmission of HCV, as welt as that of transmission through close family contacts, to be low. No evidence was found for sexual transmission from women to. men.	ST GEORGE HOSP, MED CLIN 2, LEIPZIG, GERMANY; CITY HOSP, MED CLIN 3, DRESDEN, GERMANY; UNIV ESSEN GESAMTHSCH, SCH MED, INST VIROL, ESSEN, GERMANY	Technische Universitat Dresden; Municipal Hospital Dresden; University of Duisburg Essen	MEISEL, H (corresponding author), HUMBOLDT UNIV BERLIN, CHARITE MED SCH, INST MED VIROL, D-10098 BERLIN, GERMANY.		Lu, Mengji/ABF-9410-2020					ALTER MJ, 1993, INFECT AGENT DIS, V2, P155; BRESTERS D, 1993, LANCET, V342, P210, DOI 10.1016/0140-6736(93)92300-I; DITTMANN S, 1991, J HEPATOL, V13, P323, DOI 10.1016/0168-8278(91)90076-N; GARSON JA, 1990, LANCET, V336, P878, DOI 10.1016/0140-6736(90)92384-T; KOFF RS, 1992, ANN INTERN MED, V117, P967, DOI 10.7326/0003-4819-117-11-967; NI YH, 1994, J HEPATOL, V20, P641, DOI 10.1016/S0168-8278(05)80353-8; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; POWER JP, 1994, LANCET, V344, P1166, DOI 10.1016/S0140-6736(94)90679-3; Roggendorf M, 1993, Arch Virol Suppl, V7, P27; TANZI E, 1993, ARCH VIROL, P229	10	121	122	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 13	1995	345	8959					1209	1211		10.1016/S0140-6736(95)91992-9	http://dx.doi.org/10.1016/S0140-6736(95)91992-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7537841				2022-12-28	WOS:A1995QX86100010
J	BENDELAC, A; LANTZ, O; QUIMBY, ME; YEWDELL, JW; BENNINK, JR; BRUTKIEWICZ, RR				BENDELAC, A; LANTZ, O; QUIMBY, ME; YEWDELL, JW; BENNINK, JR; BRUTKIEWICZ, RR			CD1 RECOGNITION BY MOUSE NK1(+) T-LYMPHOCYTES	SCIENCE			English	Article							ALPHA-BETA+ THYMOCYTES; LYMPHOKINE SECRETION; ANTIGEN; EXPRESSION; CELLS; THYMUS; CD4+; EPITHELIUM; SELECTION; MOLECULES	Rare major histocompatibility complex (MHC) class I-like CD1-specific T cells have been isolated from human blood, but it has not been determined whether these clones are part of a defined subset of CD1-specific T cells selected during T cell development, or whether their recognition of CD1 is a fortuitous cross-reaction. In mice, an entire subset of alpha beta thymocytes with a unique phenotype was found to be CD1-specific. This particular subset, and its human counterpart, provide evidence that CD1 has a general role in selecting and interacting with specialized alpha beta T cells.	NIAID,CELLULAR & MOLEC IMMUNOL LAB,BETHESDA,MD 20892; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544; NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Princeton University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	BENDELAC, A (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.		Lantz, Olivier J/J-4960-2012; yewdell, jyewdell@nih.gov jonathan/A-1702-2012	Lantz, Olivier J/0000-0003-3161-7719; Brutkiewicz, Randy/0000-0002-7396-480X				AHOUSE JJ, 1993, J IMMUNOL, V151, P6076; ARASE H, 1994, J EXP MED, V180, P423, DOI 10.1084/jem.180.2.423; ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; ARASE H, 1993, EUR J IMMUNOL, V23, P307, DOI 10.1002/eji.1830230151; BALK SP, 1991, J IMMUNOL, V146, P768; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BENDELAC A, 1991, NATURE, V353, P68, DOI 10.1038/353068a0; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; BENDELAC A, 1994, SCIENCE, V263, P1774, DOI 10.1126/science.7907820; Bendelac A, 1992, Semin Immunol, V4, P187; BENDELAC A, UNPUB; BIX M, 1993, J EXP MED, V178, P901, DOI 10.1084/jem.178.3.901; BLEICHER PA, 1990, SCIENCE, V250, P679, DOI 10.1126/science.1700477; Blumberg R S, 1994, Int Rev Immunol, V11, P15, DOI 10.3109/08830189409061714; BRADBURY A, 1988, EMBO J, V7, P3081, DOI 10.1002/j.1460-2075.1988.tb03173.x; CALABI F, 1989, EUR J IMMUNOL, V19, P285, DOI 10.1002/eji.1830190211; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; COLES MC, 1994, J EXP MED, V180, P395, DOI 10.1084/jem.180.1.395; COOK RG, 1983, J EXP MED, V158, P1012, DOI 10.1084/jem.158.3.1012; DELLABONA P, 1994, J EXP MED, V180, P1171, DOI 10.1084/jem.180.3.1171; DELLABONA P, 1993, J EXP MED, V177, P1763, DOI 10.1084/jem.177.6.1763; HAYAKAWA K, 1992, J EXP MED, V176, P269, DOI 10.1084/jem.176.1.269; HERSHBERG R, 1990, P NATL ACAD SCI USA, V87, P9527; KOYASU S, 1994, J EXP MED, V179, P1957, DOI 10.1084/jem.179.6.1957; KOYASU S, 1992, J EXP MED, V175, P203, DOI 10.1084/jem.175.1.203; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LEVITSKY HI, 1991, J IMMUNOL, V146, P1113; MARRACK P, 1989, NATURE, V338, P503, DOI 10.1038/338503a0; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MATZINGER P, UNPUB; OHTEKI T, 1994, J EXP MED, V180, P699, DOI 10.1084/jem.180.2.699; PANJA A, 1993, J EXP MED, V178, P1115, DOI 10.1084/jem.178.3.1115; PORCELLI S, 1993, J EXP MED, V178, P1, DOI 10.1084/jem.178.1.1; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; QUILL H, 1987, J IMMUNOL, V138, P3704; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SYKES M, 1990, J IMMUNOL, V145, P3209; TAKAHAMA Y, 1991, J IMMUNOL, V146, P1134; TAKAHAMA Y, 1992, J IMMUNOL, V147, P2883; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285	42	805	828	0	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 12	1995	268	5212					863	865		10.1126/science.7538697	http://dx.doi.org/10.1126/science.7538697			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7538697				2022-12-28	WOS:A1995QX85000035
J	XU, FF; COHEN, SN				XU, FF; COHEN, SN			RNA DEGRADATION IN ESCHERICHIA-COLI REGULATED BY 3' ADENYLATION AND 5' PHOSPHORYLATIAN	NATURE			English	Article							ANTISENSE RNAI; COPY NUMBER; GENE; STABILITY; PLASMIDS; PCNB; REPLICATION; TRANSCRIPT; EXPRESSION; INVIVO	ALTHOUGH polyadenylation has commonly been regarded as a special feature of eukaryotic messenger RNA(1,2), there are many reports of polyA tails on bacterial RNA (for example, refs 3-8). In Escherichia coli, adenylation mediated by the pcnB gene greatly accelerates decay of RNA I-8, an antisense repressor of replication of ColE1 type plasmids that resembles highly structured transfer RNA but shows the rapid turnover characteristic: of mRNA, Here we report that both 3' adenylation and 5' phosphorylation affect the rate of digestion of RNA I by the 3' exonuclease, polynucleotide phosphorylase(9); conversely, mutation of the polynucleotide phosphorylase-encoding pnp gene affects ribonuclease acting at the 5' end. Together these findings indicate that enzymes attacking RNA I at its separate termini can interact functionally, Additionally, our discovery that adenylation-mediated degradation by polynucleotide phosphorylase imparts an mRNA-like half-life to RNA I suggests a possible mechanism to account for the rapid decay of mRNA(10) in E. coli.	STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305	Stanford University								Baker EJ, 1993, CONTROL MESSENGER RN, P367; BELASCO JG, 1985, CELL, V40, P171, DOI 10.1016/0092-8674(85)90320-4; BELTCHEV B, 1971, EUR J BIOCHEM, V19, P194, DOI 10.1111/j.1432-1033.1971.tb01304.x; BROWN JW, 1985, J BACTERIOL, V162, P909, DOI 10.1128/JB.162.3.909-917.1985; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P10380, DOI 10.1073/pnas.89.21.10380; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P7546, DOI 10.1073/pnas.89.16.7546; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; GOPALAKRISHNA Y, 1981, BIOCHEM BIOPH RES CO, V103, P454, DOI 10.1016/0006-291X(81)90474-5; HAJNSDORF E, IN PRESS P NATN ACAD; HE L, 1993, MOL MICROBIOL, V9, P1131, DOI 10.1111/j.1365-2958.1993.tb01243.x; HELMERCITTERICH M, 1988, EMBO J, V7, P557, DOI 10.1002/j.1460-2075.1988.tb02845.x; KELLY KO, 1992, J BIOL CHEM, V267, P16015; KING TC, 1987, CELLULAR MOL BIOL, P703; KLUG G, 1987, EMBO J, V6, P3515, DOI 10.1002/j.1460-2075.1987.tb02677.x; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LITTAUER UZ, 1982, ENZYMES, P518; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; MCLAREN RS, 1991, J MOL BIOL, V221, P81, DOI 10.1016/0022-2836(91)90806-H; NAKAZATO H, 1975, NATURE, V256, P144, DOI 10.1038/256144a0; NEWBURY SF, 1987, CELL, V51, P1131, DOI 10.1016/0092-8674(87)90599-X; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; SACHS A, 1993, J BIOL CHEM, V268, P22955; SHEN V, 1982, ENZYMES, P518; SIPPEL AE, 1973, EUR J BIOCHEM, V37, P31, DOI 10.1111/j.1432-1033.1973.tb02953.x; THANG MN, 1971, EUR J BIOCHEM, V19, P184, DOI 10.1111/j.1432-1033.1971.tb01303.x; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756; YU PL, 1982, FEMS MICROBIOL LETT, V14, P233	29	177	179	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					180	183		10.1038/374180a0	http://dx.doi.org/10.1038/374180a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7533264				2022-12-28	WOS:A1995QL39700064
J	ZANETTI, AR; TANZI, E; PACCAGNINI, S; PRINCIPI, N; PIZZOCOLO, G; CACCAMO, ML; DAMICO, E; CAMBIE, G; VECCHI, L; BRESCIANI, S; MARIN, MG; PADULA, D; RODELLA, A; BULGARELLI, I; CHIODO, F; MAGLIANO, E; MIOTTO, G; MUGGIASCA, ML; PILLOTON, E; POZZOLI, R; PREGLIASCO, F; ROMANO, L; STRINGHI, C; DAGOSTINO, F; PAOLILLO, F; ZAPPAROLI, B				ZANETTI, AR; TANZI, E; PACCAGNINI, S; PRINCIPI, N; PIZZOCOLO, G; CACCAMO, ML; DAMICO, E; CAMBIE, G; VECCHI, L; BRESCIANI, S; MARIN, MG; PADULA, D; RODELLA, A; BULGARELLI, I; CHIODO, F; MAGLIANO, E; MIOTTO, G; MUGGIASCA, ML; PILLOTON, E; POZZOLI, R; PREGLIASCO, F; ROMANO, L; STRINGHI, C; DAGOSTINO, F; PAOLILLO, F; ZAPPAROLI, B			MOTHER-TO-INFANT TRANSMISSION OF HEPATITIS-C VIRUS	LANCET			English	Note							VERTICAL TRANSMISSION	To assess the risk of mother-to-infant transmission of hepatitis C virus (HCV), we followed up 116 babies of anti-HCV positive mothers, of whom 22 were coinfected with HIV and 94 had HCV alone. None of the babies whose mothers had HCV alone required HCV, while 8 babies (36%; p<0.001) of mothers co-infected with HIV acquired HCV (5 babies) or HCV and HIV (3). There was no association between any specific maternal HCV genotype and enhanced risk of neonatal infection. HCV-RNA levels were significantly higher (p<0.05) in mothers with HIV coinfection than in those with HCV alone. These data indicate that maternal HIV status correlates with enhanced level of viraemia which favours neonatal infection.	UNIV MILAN,DEPT PAEDIAT 4,I-20133 MILAN,ITALY; UNIV BRESCIA,SCH MED,INST CHEM,BRESCIA,ITALY; UNIV MILAN,HOSP L MANGIAGALLI,DEPT OBSTET & GYNAECOL,MILAN,ITALY; HOSP NIGUARDA CA GRANDA,DEPT PAEDIAT,MILAN,ITALY; HOSP MAGGIORE,CTR BLOOD TRANSFUS,LODI,ITALY; HOSP S GERARDO,CLIN PATHOL LAB,MONZA,ITALY	University of Milan; University of Brescia; University of Milan	ZANETTI, AR (corresponding author), UNIV MILAN,INST VIROL,VIA C PASCAL 38,I-20133 MILAN,ITALY.		Pregliasco, Fabrizio Ernesto/D-1642-2012; pregliasco, fabrizio/AAD-7499-2022	Pregliasco, Fabrizio Ernesto/0000-0002-3919-0679; 				KUROKI T, 1991, J INFECT DIS, V164, P427, DOI 10.1093/infdis/164.2.427; LAM JPH, 1993, J INFECT DIS, V167, P572, DOI 10.1093/infdis/167.3.572; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; PUOTI M, 1992, HEPATOLOGY, V4, P877; REINUS JF, 1992, ANN INTERN MED, V117, P881, DOI 10.7326/0003-4819-117-11-881; ROMANO L, 1994, INFECTION, V22, P350, DOI 10.1007/BF01715545; THALER MM, 1991, LANCET, V338, P17, DOI 10.1016/0140-6736(91)90006-B; WEINTRUB PS, 1991, J PEDIATR-US, V119, P869, DOI 10.1016/S0022-3476(05)83035-5; Wejstal R, 1992, ANN INTERN MED, V117, P887, DOI 10.7326/0003-4819-117-11-887; 1992, MMWR-MORBID MORTAL W, V41, P1	10	315	323	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					289	291		10.1016/S0140-6736(95)90277-5	http://dx.doi.org/10.1016/S0140-6736(95)90277-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7530793				2022-12-28	WOS:A1995QE73100011
J	JU, ST; PANKA, DJ; CUI, HL; ETTINGER, R; ELKHATIB, M; SHERR, DH; STANGER, BZ; MARSHAKROTHSTEIN, A				JU, ST; PANKA, DJ; CUI, HL; ETTINGER, R; ELKHATIB, M; SHERR, DH; STANGER, BZ; MARSHAKROTHSTEIN, A			FAS(CD95) FASL INTERACTIONS REQUIRED FOR PROGRAMMED CELL-DEATH AFTER T-CELL ACTIVATION	NATURE			English	Article							THYMOCYTE DEVELOPMENT; CYCLOSPORINE-A; HYBRIDOMAS; EXPRESSION; MICE; ANTIGEN; LYMPHOCYTE; PATHWAYS; SUICIDE; LPR	RECEPTOR crosslinking of T-cell hybridomas induces cell activation followed by apoptosis(1-6). This activation-induced cell death requires de novo synthesis of RNA and proteins(1-3), but the actual gene products that provide the death signal have not been identified(4-6). We show here that receptor crosslinking induces Fas ligand and upregulates Fas, and that the ensuing engagement of Fas by Fas ligand activates the cell-death programme. Cell death, but not activation, can be selectively prevented by a soluble Fas-immunoglobulin fusion protein. Thus, Fas and Fas ligand are the death-gene products, and their interaction accounts for the molecular mechanism of activation-induced T-cell death.	BOSTON UNIV,SCH MED,DEPT PATHOL & LAB MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MICROBIOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,SCH PUBL HLTH,BOSTON,MA 02118; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Boston University; Boston University; Boston University; Harvard University; Harvard Medical School	JU, ST (corresponding author), BOSTON UNIV,SCH MED,CTR ARTHRITIS,80 E CONCORD ST,BOSTON,MA 02118, USA.			Sherr, David/0000-0003-3353-0553				ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BRINER TJ, 1989, THESIS MIT; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GAO EK, 1988, NATURE, V336, P176, DOI 10.1038/336176a0; JENKINS MK, 1988, SCIENCE, V241, P1655, DOI 10.1126/science.3262237; JU ST, 1990, J IMMUNOL, V144, P23; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; JU ST, 1988, CELL IMMUNOL, V117, P399, DOI 10.1016/0008-8749(88)90129-3; KOZIN RL, 1988, J EXP MED, V168, P2221; LEO O, 1986, J IMMUNOL, V137, P3874; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MOHLER KM, 1993, J IMMUNOL, V151, P1548; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SARIN A, 1994, J IMMUNOL, V153, P862; SHEN MM, 1992, P NATL ACAD SCI USA, V89, P8240, DOI 10.1073/pnas.89.17.8240; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SIDMAN CL, 1992, EUR J IMMUNOL, V22, P499, DOI 10.1002/eji.1830220231; SINGER PA, 1989, J EXP MED, V170, P1869, DOI 10.1084/jem.170.6.1869; STALDER T, 1994, J IMMUNOL, V152, P1127; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; UCKER DS, 1989, J IMMUNOL, V143, P3461; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; YANG YL, 1993, P NATL ACAD SCI USA, V90, P6170, DOI 10.1073/pnas.90.13.6170; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347; ZHOU T, 1991, J IMMUNOL, V147, P466	30	1424	1485	2	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					444	448		10.1038/373444a0	http://dx.doi.org/10.1038/373444a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7530337				2022-12-28	WOS:A1995QE67000061
J	HUIZINGA, JD; THUNEBERG, L; KLUPPEL, M; MALYSZ, J; MIKKELSEN, HB; BERNSTEIN, A				HUIZINGA, JD; THUNEBERG, L; KLUPPEL, M; MALYSZ, J; MIKKELSEN, HB; BERNSTEIN, A			W/KIT GENE REQUIRED FOR INTERSTITIAL-CELLS OF CAJAL AND FOR INTESTINAL PACEMAKER ACTIVITY	NATURE			English	Article							C-KIT; CANINE COLON; W-LOCUS; PROTO-ONCOGENE; PROTOONCOGENE; EXPRESSION; MUSCLE	THE pacemaker activity in the mammalian gut is responsible for generating anally propagating phasic contractions, The cellular basis for this intrinsic activity is unknown. The smooth muscle cells of the external muscle layers and the innervated cellular network of interstitial cells of Cajal, which is closely associated with the external muscle layers of the mammalian gut, have both been proposed to stimulate pacemaker activity(1-5). The interstitial cells of Cajal were identified in the last century but their developmental origin and function have remained unclear. Here we show that the interstitial cells of Cajal express the Kit receptor tyrosine kinase. Furthermore, mice with mutations in the dominant white spotting (W) locus, which have cellular defects in haematopoiesis, melanogenesis and gametogenesis(6) as a result of mutations in the Kit gene(7,8) also lack the network of intestitial cells of Cajal associated with Auerbach's nerve plexus and intestinal pacemaker activity.	UNIV COPENHAGEN,DEPT ANAT,COPENHAGEN,DENMARK; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON,CANADA	University of Copenhagen; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	HUIZINGA, JD (corresponding author), MCMASTER UNIV,DEPT BIOMED SCI,INTESTINAL DIS RES UNIT,1200 MAIN ST W,HAMILTON,ON L8N 3Z5,CANADA.							BOLOGNIA JL, 1988, J AM ACAD DERMATOL, V19, P217, DOI 10.1016/S0190-9622(88)70168-1; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; DURDLE NG, 1983, GASTROENTEROLOGY, V84, P375; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FLEISCHMAN RA, 1991, P NATL ACAD SCI USA, V88, P10885, DOI 10.1073/pnas.88.23.10885; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; HUIZINGA JD, 1991, J PHYSIOL-LONDON, V442, P15, DOI 10.1113/jphysiol.1991.sp018779; LIU LWC, 1993, J PHYSIOL-LONDON, V470, P445, DOI 10.1113/jphysiol.1993.sp019868; LIU LWC, 1994, AM J PHYSIOL, V266, pG485, DOI 10.1152/ajpgi.1994.266.3.G485; MAEDA H, 1992, DEVELOPMENT, V116, P369; MIKKELSEN HB, 1993, CELL TISSUE RES, V274, P249, DOI 10.1007/BF00318744; MIKKELSEN HB, 1988, ANAT EMBRYOL, V17, P191; MOTRO B, 1991, DEVELOPMENT, V113, P1207; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; REITH AD, 1991, GENOME ANAL, V3, P105; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; THUNEBERG L, 1982, ADV ANAT EMBRYOL CEL, V71, P1; THUNEBERG L, 1992, GASTROENTEROLOGY, V103, P1388, DOI 10.1016/0016-5085(92)91601-Y; THUNEBERG L, 1989, HDB PHYSL GASTROINTE, P349	21	1132	1176	0	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					347	349						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7530333				2022-12-28	WOS:A1995QD40400061
J	BROOKS, PC; MONTGOMERY, AMP; ROSENFELD, M; REISFELD, RA; HU, TH; KLIER, G; CHERESH, DA				BROOKS, PC; MONTGOMERY, AMP; ROSENFELD, M; REISFELD, RA; HU, TH; KLIER, G; CHERESH, DA			INTEGRIN ALPHA(V)BETA(3) ANTAGONISTS PROMOTE TUMOR-REGRESSION BY INDUCING APOPTOSIS OF ANGIOGENIC BLOOD-VESSELS	CELL			English	Article							EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; VONWILLEBRAND-FACTOR; VITRONECTIN; ADHESION; EXPRESSION; FIBRINOGEN; CARCINOMA; ATTACHMENT; MIGRATION	A single intravascular injection of a cyclic peptide or monoclonal antibody antagonist of integrin alpha(v) beta(3) disrupts ongoing angiogenesis on the chick chorioallantoic membrane (CAM). This leads to the rapid regression of histologically distinct human tumors transplanted onto the CAM. Induction of angiogenesis by a tumor or cytokine promotes vascular cell entry into the cell cycle and expression of integrin alpha(v) beta(3). After angiogenesis is initiated, antagonists of this integrin induce apoptosis of the proliferative angiogenic vascular cells, leaving preexisting quiescent blood vessels unaffected. We demonstrate therefore that ligation of integrin alpha(v) beta(3) is required for the survival and maturation of newly forming blood vessels, an event essential for the proliferation of tumors.	SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	BROOKS, PC (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.				NCI NIH HHS [CA45726, CA50286] Funding Source: Medline; NIAID NIH HHS [T32 AI 072 44-11] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA050286, R01CA045726, R01CA050286] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007244] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; BASSON CT, 1992, J CELL PHYSIOL, V153, P118, DOI 10.1002/jcp.1041530116; BIANCHINE PJ, 1992, J IMMUNOL, V149, P3665; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CHERESH DA, 1991, CANCER METAST REV, V10, P3, DOI 10.1007/BF00046839; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DAMORE PA, 1987, ANNU REV PHYSIOL, V49, P453; DEFILIPPI P, 1994, CELL ADHES COMMUN, V2, P75, DOI 10.3109/15419069409014203; ENENSTEIN J, 1992, EXP CELL RES, V203, P499, DOI 10.1016/0014-4827(92)90028-7; ENENSTEIN J, 1994, J INVEST DERMATOL, V103, P381, DOI 10.1111/1523-1747.ep12395390; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1992, Semin Cancer Biol, V3, P65; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; INGBER D, 1991, J CELL BIOCHEM, V47, P236, DOI 10.1002/jcb.240470309; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; INGBER DE, 1986, ENDOCRINOLOGY, V119, P1768, DOI 10.1210/endo-119-4-1768; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KOYAMA N, 1994, J CELL PHYSIOL, V158, P1, DOI 10.1002/jcp.1041580102; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MIGNATTI P, 1991, J CELL BIOCHEM, V47, P201, DOI 10.1002/jcb.240470303; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; PAKU S, 1991, LAB INVEST, V65, P334; PFAFF M, 1994, J BIOL CHEM, V269, P20233; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; TELFORD WG, 1992, CYTOMETRY, V13, P137, DOI 10.1002/cyto.990130205; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1993, AM J PATHOL, V143, P401; WEINSTATSASLOW D, 1994, FASEB J, V8, P401, DOI 10.1096/fasebj.8.6.7513289	48	2050	2230	2	95	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1157	1164		10.1016/0092-8674(94)90007-8	http://dx.doi.org/10.1016/0092-8674(94)90007-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	7528107				2022-12-28	WOS:A1994PZ86000007
J	DALE, LC; HURT, RD; OFFORD, KP; LAWSON, GM; CROGHAN, IT; SCHROEDER, DR				DALE, LC; HURT, RD; OFFORD, KP; LAWSON, GM; CROGHAN, IT; SCHROEDER, DR			HIGH-DOSE NICOTINE PATCH THERAPY - PERCENTAGE OF REPLACEMENT AND SMOKING CESSATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COTININE; DEPENDENCE; SALIVA; TRIAL; SERUM	Objective.-To assess the level of nicotine replacement, evidence of nicotine toxicity, and withdrawal symptom relief with placebo and 11-, 22-, and 44-mg/d doses of transdermal nicotine. A secondary objective was to assess short- and long-term smoking cessation rates. Design.-Randomized, double-blind, placebo-controlled inpatient/outpatient trial. Subjects.-Seventy-one cigarette smokers stratified according to light (n=23), moderate (n=24), and heavy (n=24) smoking rates. Interventions.-After baseline measures were obtained, subjects were randomly assigned to placebo or an 11-, 22-, or 44-mg/d dose of transdermal nicotine and admitted to a special hospital unit for intensive inpatient treatment of nicotine dependence. During the 6-day inpatient stay, daily nicotine and cotinine levels were determined from trough and peak blood samples. Outpatient patch therapy continued for 7 weeks following the hospital stay, and those initially assigned to placebo were randomly assigned to 11 or 22 mg/d. At week 4, the dosage of those initially assigned to 44 mg/d was reduced to 22 mg/d. Main Outcome Measures.-Percentage of replacement of cotinine was calculated by dividing the steady-state levels attained during patch therapy by the corresponding baseline levels. Abstinence from smoking was verified by expired air carbon monoxide. Withdrawal symptoms and nicotine toxicity were assessed daily through questionnaires during the inpatient stay. Follow-up visits were at 3, 6, 9, and 12 months. Results.-There was a statistically significant relationship between baseline smoking rate and baseline trough and peak blood cotinine levels (r(s)=0.39, r(s)=0.45; P<.001 in both instances). A dose-response relationship was observed with higher patch doses, which produced a higher percentage of cotinine replacement and better withdrawal symptom relief. Only one subject (a light smoker assigned to the 44-mg dose) developed signs of nicotine toxicity. There was a positive association between the week 2 patch dose and the biochemically confirmed abstinence at the end of patch therapy (P=.007) but not for subsequent follow-up times, A higher percentage of cotinine replacement was associated with the higher 8-week smoking abstinence rate (P=.03), an association not found at long-term follow-up. Conclusion.-A 44-mg/d dose of nicotine patch therapy appears to be safe for use in heavy smokers. Cigarette smoking rates can be used to estimate the initial nicotine patch dose. Monitoring blood cotinine levels at baseline and steady state can be used for assessing the adequacy of nicotine replacement. Withdrawal symptom relief can be improved with more complete nicotine replacement. Achieving a greater percentage of nicotine replacement may increase the efficacy of nicotine patch therapy.	MAYO CLIN & MAYO FDN, NICOTINE RES CTR, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, BIOSTAT SECT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT LAB MED & PATHOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, NICOTINE RES CTR, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	DALE, LC (corresponding author), MAYO CLIN & MAYO FDN, DIV COMMUNITY INTERNAL MED, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							ABELIN T, 1989, METHOD FIND EXP CLIN, V11, P205; BANNON YB, 1989, EUR J CLIN PHARMACOL, V37, P285, DOI 10.1007/BF00679785; BASKIN LB, 1991, CLIN CHEM, V37, P467; BENOWITZ NL, 1991, BRIT J ADDICT, V86, P495; BENOWITZ NL, 1986, RES ADV ALCOHOL DRUG, V9, P1; ELLENHORN MJ, 1988, MED TOXICOLOGY DIAGN, P912; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; FREDERICKSON PA, IN PRESS PSYCHOPHARM; HUGHES JR, 1986, ARCH GEN PSYCHIAT, V43, P289; HURT RD, 1992, MED CLIN N AM, V76, P495, DOI 10.1016/S0025-7125(16)30364-9; HURT RD, 1990, MAYO CLIN PROC, V65, P1529, DOI 10.1016/S0025-6196(12)62186-7; HURT RD, 1994, JAMA-J AM MED ASSOC, V271, P595, DOI 10.1001/jama.271.8.595; HURT RD, 1993, CLIN PHARMACOL THER, V54, P98, DOI 10.1038/clpt.1993.117; HURT RD, 1992, MAYO CLIN PROC, V67, P823, DOI 10.1016/S0025-6196(12)60819-2; MACHACEK DA, 1986, CLIN CHEM, V32, P979; MOYER TP, 1986, TXB CLIN CHEM, P1615; MULLIGAN SC, 1990, CLIN PHARMACOL THER, V47, P331, DOI 10.1038/clpt.1990.36; RENNARD S, 1991, JAMA-J AM MED ASSOC, V266, P3133; SACHS DPL, 1993, ARCH INTERN MED, V153, P1881, DOI 10.1001/archinte.153.16.1881; TONNESEN P, 1991, NEW ENGL J MED, V325, P311, DOI 10.1056/NEJM199108013250503; WALL MA, 1988, AM J PUBLIC HEALTH, V78, P699, DOI 10.2105/AJPH.78.6.699	21	192	193	1	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	1995	274	17					1353	1358		10.1001/jama.274.17.1353	http://dx.doi.org/10.1001/jama.274.17.1353			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TB278	7563559				2022-12-28	WOS:A1995TB27800025
J	LEE, WM				LEE, WM			MEDICAL PROGRESS - DRUG-INDUCED HEPATOTOXICITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; FULMINANT HEPATIC-FAILURE; AMIODARONE HEPATOTOXICITY; CYTOCHROME-P-450 ENZYMES; LIVER-TRANSPLANTATION; N-ACETYLCYSTEINE; VITAMIN-A; ACETAMINOPHEN; TOXICITY; CYTOCHROMES-P450				LEE, WM (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,LIVER UNIT,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.							ALBERTIFLOR JJ, 1989, AM J GASTROENTEROL, V84, P1577; BAERG RD, 1970, ANN INTERN MED, V73, P713, DOI 10.7326/0003-4819-73-5-713; BARKER JD, 1977, ANN INTERN MED, V87, P299, DOI 10.7326/0003-4819-87-3-299; BARNETT CR, 1992, BIOCHEM PHARMACOL, V43, P1868, DOI 10.1016/0006-2952(92)90724-W; BEAUNE PH, 1993, ANN NY ACAD SCI, V685, P641, DOI 10.1111/j.1749-6632.1993.tb35929.x; BLUM A, 1991, SOUTHERN MED J, V84, P1158, DOI 10.1097/00007611-199109000-00027; BONKOVSKY HL, 1994, HEPATOLOGY, V19, P1141, DOI 10.1002/hep.1840190511; BOYER CS, 1990, ALCOHOL CLIN EXP RES, V14, P28, DOI 10.1111/j.1530-0277.1990.tb00441.x; BROTODIHARDJO AE, 1992, MED J AUSTRALIA, V157, P382, DOI 10.5694/j.1326-5377.1992.tb137246.x; CARSON JL, 1993, ANN INTERN MED, V119, P576, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00005; CHATTHA G, 1993, ANN INTERN MED, V118, P37, DOI 10.7326/0003-4819-118-1-199301010-00007; CHIU J, 1990, ANN INTERN MED, V113, P358, DOI 10.7326/0003-4819-113-5-358; DALTON TA, 1992, AM J MED, V93, P102, DOI 10.1016/0002-9343(92)90689-9; DAVIES MH, 1994, J HEPATOL, V20, P112, DOI 10.1016/S0168-8278(05)80476-3; FALLON MB, 1990, J GASTROEN HEPATOL, V5, P334, DOI 10.1111/j.1440-1746.1990.tb01635.x; Farrell G., 1994, DRUG INDUCED LIVER D; FREIMAN JP, 1993, AIDS, V7, P379, DOI 10.1097/00002030-199303000-00012; FRENCH SW, 1993, EXP MOL PATHOL, V58, P61, DOI 10.1006/exmp.1993.1006; GARIBALDI RA, 1972, AM REV RESPIR DIS, V106, P357, DOI 10.1164/arrd.1972.106.3.357; GEHENOT M, 1994, J HEPATOL, V20, P842, DOI 10.1016/S0168-8278(05)80159-X; GEUBEL AP, 1991, GASTROENTEROLOGY, V100, P1701, DOI 10.1016/0016-5085(91)90672-8; GONZALEZ FJ, 1992, TRENDS PHARMACOL SCI, V13, P346, DOI 10.1016/0165-6147(92)90107-H; GRADON JD, 1992, J INTERN MED, V231, P317, DOI 10.1111/j.1365-2796.1992.tb00542.x; GRIMM IS, 1994, AM J GASTROENTEROL, V89, P279; GUENGERICH FP, 1992, LIFE SCI, V50, P1471; GUT J, 1993, PHARMACOL THERAPEUT, V58, P133, DOI 10.1016/0163-7258(93)90047-H; HEBBARD GS, 1992, MED J AUSTRALIA, V156, P285, DOI 10.5694/j.1326-5377.1992.tb139752.x; HENRY JA, 1992, LANCET, V340, P384, DOI 10.1016/0140-6736(92)91469-O; HULL M, 1994, BRIT MED J, V309, P378; HUNT CM, 1992, MECH AGEING DEV, V64, P189, DOI 10.1016/0047-6374(92)90106-N; HUNT CM, 1992, BIOCHEM PHARMACOL, V44, P275, DOI 10.1016/0006-2952(92)90010-G; IKEMOTO S, 1992, BIOCHEM PHARMACOL, V43, P2407, DOI 10.1016/0006-2952(92)90320-I; KANO Y, 1994, J AM ACAD DERMATOL, V31, P133, DOI 10.1016/S0190-9622(09)80252-1; KAPLOWITZ N, 1991, LIVER BILIARY DISEAS; KATZ M, 1990, J CLIN GASTROENTEROL, V12, P203, DOI 10.1097/00004836-199004000-00021; KEEGAN AD, 1993, AUST NZ J MED, V23, P523, DOI 10.1111/j.1445-5994.1993.tb01843.x; KELLNER M, 1993, AM J PSYCHIAT, V150, P985; KLECKNER HB, 1975, ANN INTERN MED, V83, P522, DOI 10.7326/0003-4819-83-4-522; KLEIN AS, 1989, AM J MED, V86, P187, DOI 10.1016/0002-9343(89)90267-2; KNIGHT TE, 1991, J AM ACAD DERMATOL, V25, P398, DOI 10.1016/0190-9622(91)70214-M; KUROKOHCHI K, 1992, BIOCHEM PHARMACOL, V44, P1669; LAI KK, 1991, ANN INTERN MED, V115, P283, DOI 10.7326/0003-4819-115-4-283; LARREY D, 1990, GASTROENTEROLOGY, V99, P1832, DOI 10.1016/0016-5085(90)90496-N; LARREY D, 1992, GUT, V33, P368, DOI 10.1136/gut.33.3.368; LARREY D, 1992, ANN INTERN MED, V117, P129, DOI 10.7326/0003-4819-117-2-129; Lee W M, 1989, J S C Med Assoc, V85, P75; LEE WM, 1993, NEW ENGL J MED, V329, P1862, DOI 10.1056/NEJM199312163292508; LEWIS JH, 1989, HEPATOLOGY, V9, P679, DOI 10.1002/hep.1840090504; LINDENBAUM J, 1963, NEW ENGL J MED, V268, P525, DOI 10.1056/NEJM196303072681004; LOEPER J, 1994, GASTROENTEROLOGY, V106, P464, DOI 10.1016/0016-5085(94)90606-8; LOPEZNAVIDAD A, 1990, J HEPATOL, V11, P277, DOI 10.1016/0168-8278(90)90125-B; MACGREGOR FB, 1989, BRIT MED J, V299, P1156, DOI 10.1136/bmj.299.6708.1156; MACILWAIN C, 1993, NATURE, V364, P275, DOI 10.1038/364275d0; MAZURYK H, 1993, AM J GASTROENTEROL, V88, P1960; MCDONALD GB, 1993, ANN INTERN MED, V118, P255, DOI 10.7326/0003-4819-118-4-199302150-00003; MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702; MEADOW P, 1989, CLIN PHARMACY, V8, P470; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; MICHELSON EL, 1991, ANN INTERN MED, V114, P341, DOI 10.7326/0003-4819-114-4-341; MITCHELL I, 1995, LANCET, V345, P555, DOI 10.1016/S0140-6736(95)90468-9; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P211; MORELLI S, 1991, CARDIOLOGY, V78, P291, DOI 10.1159/000174796; MURRAY M, 1992, CLIN PHARMACOKINET, V23, P132, DOI 10.2165/00003088-199223020-00005; NEWMAN M, 1989, ARCH DERMATOL, V125, P1218, DOI 10.1001/archderm.125.9.1218; OCONNOR GT, 1989, ARCH DERMATOL, V125, P1209, DOI 10.1001/archderm.125.9.1209; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; PICON M, 1991, GASTROEN CLIN BIOL, V15, P463; PLANAS R, 1990, AM J GASTROENTEROL, V85, P468; POHL LR, 1990, SEMIN LIVER DIS, V10, P305, DOI 10.1055/s-2008-1040486; POWERS BJ, 1986, ARCH INTERN MED, V146, P1183, DOI 10.1001/archinte.146.6.1183; PRESCOTT LF, 1979, BRIT MED J, V2, P1097, DOI 10.1136/bmj.2.6198.1097; PURCELL P, 1991, GUT, V32, P1381, DOI 10.1136/gut.32.11.1381; QUINN PG, 1994, AM J GASTROENTEROL, V89, P781; RAMAKRISHNA B, 1994, LIVER, V14, P83; RAVEH D, 1992, ISRAEL J MED SCI, V28, P101; REINHART HH, 1992, GASTROENTEROLOGY, V102, P1396; REYNOLDS TB, 1971, NEW ENGL J MED, V285, P813, DOI 10.1056/NEJM197110072851501; RIGAS B, 1986, ANN INTERN MED, V104, P348, DOI 10.7326/0003-4819-104-3-348; ROE AL, 1993, BIOCHEM BIOPH RES CO, V190, P15, DOI 10.1006/bbrc.1993.1003; SALIBA B, 1994, ANN INTERN MED, V120, P1048, DOI 10.7326/0003-4819-120-12-199406150-00018; SCHEIDER DM, 1993, J CLIN GASTROENTEROL, V17, P168, DOI 10.1097/00004836-199309000-00017; SCHIFF ER, 1994, GASTROINTEST DIS TOD, V3, P7; SEEFF LB, 1986, ANN INTERN MED, V104, P399, DOI 10.7326/0003-4819-104-3-399; SILVA MO, 1991, J HEPATOL, V12, P312, DOI 10.1016/0168-8278(91)90832-V; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; SMILKSTEIN MJ, 1994, NEW ENGL J MED, V331, P1310; TAKAHASHI T, 1993, HEPATOLOGY, V17, P236, DOI 10.1016/0270-9139(93)90083-Y; TOUCHETTE N, 1993, J NIH RES, V5, P33; TRAN A, 1991, J HEPATOL, V12, P36, DOI 10.1016/0168-8278(91)90905-Q; Van Thiel D H, 1992, Recent Dev Alcohol, V10, P335; WATKINS PB, 1992, GASTROENTEROL CLIN N, V21, P511; WESTPHAL JF, 1994, J ANTIMICROB CHEMOTH, V33, P387, DOI 10.1093/jac/33.3.387; WHITCOMB DC, 1994, JAMA-J AM MED ASSOC, V272, P1845, DOI 10.1001/jama.272.23.1845; WOLFF T, 1992, EXP TOXICOL PATHOL, V44, P263, DOI 10.1016/S0940-2993(11)80241-1; WOOLF GM, 1994, ANN INTERN MED, V121, P729, DOI 10.7326/0003-4819-121-10-199411150-00001; WRIGHTON SA, 1992, CRIT REV TOXICOL, V22, P1, DOI 10.3109/10408449209145319; WYSOWSKI DK, 1993, ANN INTERN MED, V118, P860, DOI 10.7326/0003-4819-118-11-199306010-00006; YOO JSH, 1992, BIOCHEM PHARMACOL, V43, P2535, DOI 10.1016/0006-2952(92)90141-5; ZIMMERMAN HJ, 1984, HEPATOLOGY, V4, P315, DOI 10.1002/hep.1840040223; ZIMMERMAN HJ, 1993, DISEASES LIVER; 1992, MMWR-MORBID MORTAL W, V41, P812	101	266	278	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 26	1995	333	17					1118	1127		10.1056/NEJM199510263331706	http://dx.doi.org/10.1056/NEJM199510263331706			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA372	7565951				2022-12-28	WOS:A1995TA37200006
J	WU, JC; CHOO, KB; CHEN, CM; CHEN, TZ; HUE, TL; LEE, SD				WU, JC; CHOO, KB; CHEN, CM; CHEN, TZ; HUE, TL; LEE, SD			GENOTYPING OF HEPATITIS-D VIRUS BY RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISM AND RELATION TO OUTCOME OF HEPATITIS-D	LANCET			English	Article							DELTA-VIRUS; MOLECULAR-CLONING; RNA; SEQUENCE; EXPRESSION; LIVER	The outcome of hepatitis D virus (HDV) superinfection varies among patients and in different geographical areas. To find out whether HDV genotype affects outcome, we used a simple genotyping method based on restriction-fragment length polymorphism with enzymes Xhol and SacII for cleavage of PCR products of the HDV genome. Of samples from 88 patients studied, the genotypes of 61 were confirmed by two methods-analysis with both enzymes or by combined restriction-enzyme and direct sequencing analyses-with consistent results. No genotype III HDV was detected among these patients. The majority of patients with acute HDV infection (35/41 [85%]) had genotype II HDV. Among the 41 patients with acute infection, four of six with genotype I had fulminant disease compared with two of 35 with genotype II. Among patients in chronic stage, cirrhosis or hepatocellular carcinoma were found in 12 of 18 with genotype I HDV and eight of 29 with genotype II. Thus genotype II was the predominant HDV genotype in this study in Taiwan. Genotype II HDV was less frequently associated with fulminant hepatitis at the acute stage or with an unfavourable long-term clinical outcome at the chronic stage than was genotype I.	NATL YANG MING UNIV,SCH MED,DEPT MED,TAIPEI,TAIWAN; NATL YANG MING UNIV,SCH MED,GRAD INST CLIN MED,TAIPEI,TAIWAN; VET GEN HOSP,DEPT MED RES,TAIPEI 112,TAIWAN	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	WU, JC (corresponding author), VET GEN HOSP,DEPT MED,DIV GASTROENTEROL,TAIPEI 112,TAIWAN.		Chen, Chuan-Mu/K-7049-2013	Chen, Chuan-Mu/0000-0003-2461-9150				CASEY JL, 1993, P NATL ACAD SCI USA, V90, P9016, DOI 10.1073/pnas.90.19.9016; CHAO YC, 1991, HEPATOLOGY, V13, P345, DOI 10.1016/0270-9139(91)92451-D; CHAO YC, 1990, VIROLOGY, V178, P384; GOVINDARAJAN S, 1986, HEPATOLOGY, V6, P640, DOI 10.1002/hep.1840060415; GOVINDARAJAN S, 1984, GASTROENTEROLOGY, V86, P1417; HADLER SC, 1984, ANN INTERN MED, V100, P339, DOI 10.7326/0003-4819-100-3-339; IMAZEKI F, 1990, J VIROL, V64, P5594, DOI 10.1128/JVI.64.11.5594-5599.1990; KUO MYP, 1988, J VIROL, V62, P1855, DOI 10.1128/JVI.62.6.1855-1861.1988; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LEE CM, 1992, VIROLOGY, V188, P266; LEE HH, 1992, ANAL BIOCHEM, V205, P289, DOI 10.1016/0003-2697(92)90437-C; MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0; RIZZETTO M, 1983, ANN INTERN MED, V98, P437, DOI 10.7326/0003-4819-98-4-437; SALDANHA JA, 1990, J GEN VIROL, V71, P1603, DOI 10.1099/0022-1317-71-7-1603; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WU JC, 1995, GASTROENTEROLOGY, V108, P796, DOI 10.1016/0016-5085(95)90453-0; WU JC, 1994, HEPATOLOGY, V19, P836, DOI 10.1002/hep.1840190406	17	120	124	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					939	941		10.1016/S0140-6736(95)91558-3	http://dx.doi.org/10.1016/S0140-6736(95)91558-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564729				2022-12-28	WOS:A1995RY80800010
J	HUMMEL, M; ZIEMANN, K; LAMMERT, H; PILERI, S; SABATTINI, E; STEIN, H				HUMMEL, M; ZIEMANN, K; LAMMERT, H; PILERI, S; SABATTINI, E; STEIN, H			HODGKINS-DISEASE WITH MONOCLONAL AND POLYCLONAL POPULATIONS OF REED-STERNBERG CELLS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECEPTOR BETA-CHAIN; GENE REARRANGEMENTS; LYMPHOID-TISSUE; BIOPSY MATERIAL; IMMUNOGLOBULIN; EXPRESSION; PHENOTYPE; INFECTION; ANTIGENS; GENOTYPE	Background. There is strong evidence that Reed-Sternberg cells have a lymphoid phenotype, but clonally rearranged genes for B-cell and T-cell antigen receptors have not been demonstrable in tumor tissue from most patients with Hodgkin's disease. To elucidate this issue, we assayed single Reed-Sternberg cells from 12 patients with classic Hodgkin's disease of a B-cell immunophenotype to detect rearranged immunoglobulin variable-region heavy-chain (V-H) genes. Methods. We isolated single Reed-Sternberg cells from frozen sections that had been immunostained for CD30. The rearranged V-H genes of these cells were amplified by the polymerase chain reaction and analyzed by gel electrophoresis and nucleotide sequencing. Results. In all 12 patients, the Reed-Sternberg cells studied contained rearranged V-H genes. Three patterns were observed: in three patients the rearrangements in each patient were identical, in six patients all the rearrangements were unrelated and unique, and in three patients both identical and unrelated rearrangements were detected. Apparently somatic mutations of V-H genes were present in some Reed-Sternberg cells but absent in others. Conclusions. Reed-Sternberg cells with B-cell phenotypes have rearranged V-H genes; therefore, these cells arise from B cells. The pattern of V-H gene mutations suggests that Reed-Sternberg cells can correspond to either immunologically naive or memory B cells. In half our patients the population of Reed-Sternberg cells was polyclonal; in the other half, monoclonal or mixed cell populations were found. Correlation with the clinical stage suggests that polyclonal Hodgkin's disease can present as a widespread lymphoma.	FREE UNIV BERLIN, KLINIKUM BENJAMIN FRANKLIN, INST PATHOL, D-12200 BERLIN, GERMANY; UNIV BOLOGNA, SERV PATHOL ANAT 2, HEMATOPATHOL UNIT, BOLOGNA, ITALY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Bologna			Pileri, Stefano/AAP-6337-2020; Sabattini, Elena/K-6720-2016	Sabattini, Elena/0000-0002-4136-3591				ANAGNOSTOPOULOS I, 1989, BLOOD, V74, P810; BARRIOS L, 1988, HUM GENET, V78, P320, DOI 10.1007/BF00291727; BEREK C, 1993, IMMUNOL TODAY, V14, P400, DOI 10.1016/0167-5699(93)90143-9; BEREK C, 1993, IMMUNOL TODAY, V14, P479; CIBULL ML, 1989, HISTOPATHOLOGY, V15, P597, DOI 10.1111/j.1365-2559.1989.tb01625.x; COOK GP, 1995, IMMUNOL TODAY, V16, P237, DOI 10.1016/0167-5699(95)80166-9; DALLENBACH FE, 1989, LANCET, V2, P828; DELABIE J, 1994, BLOOD, V84, P3291; DIEHL V, 1989, MED ONCOL TUMOR PHAR, V6, P155; DREXLER HG, 1992, LEUKEMIA LYMPHOMA, V8, P283, DOI 10.3109/10428199209051008; FALINI B, 1987, HISTOPATHOLOGY, V11, P1229, DOI 10.1111/j.1365-2559.1987.tb01869.x; FALK MH, 1987, INT J CANCER, V40, P262, DOI 10.1002/ijc.2910400223; GUPTA RK, 1993, P NATL ACAD SCI USA, V90, P2817, DOI 10.1073/pnas.90.7.2817; HABER MM, 1992, BLOOD, V80, P2851; HALUSKA FG, 1994, BLOOD, V84, P1005, DOI 10.1182/blood.V84.4.1005.bloodjournal8441005; HERBST H, 1989, LEUKEMIA RES, V13, P103, DOI 10.1016/0145-2126(89)90134-3; HESSOL NA, 1992, ANN INTERN MED, V117, P309, DOI 10.7326/0003-4819-117-4-309; HUMMEL M, 1994, BLOOD, V84, P403; HUMMEL M, 1992, BRIT J HAEMATOL, V82, P689, DOI 10.1111/j.1365-2141.1992.tb06945.x; INGHIRAMI G, 1994, P NATL ACAD SCI USA, V91, P9842, DOI 10.1073/pnas.91.21.9842; KADIN ME, 1988, AM J PATHOL, V130, P345; KAPP U, 1993, BLOOD, V82, P1247; KLITZ W, 1994, AM J HUM GENET, V54, P497; KNOWLES DM, 1986, P NATL ACAD SCI USA, V83, P7942, DOI 10.1073/pnas.83.20.7942; KODURU PRK, 1989, CANCER GENET CYTOGEN, V43, P109, DOI 10.1016/0165-4608(89)90134-9; KUPPERS R, 1994, P NATL ACAD SCI USA, V91, P10962, DOI 10.1073/pnas.91.23.10962; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; MACK TM, 1995, NEW ENGL J MED, V332, P413, DOI 10.1056/NEJM199502163320701; MARKS JD, 1991, EUR J IMMUNOL, V21, P985, DOI 10.1002/eji.1830210419; MASIH A, 1991, AM J PATHOL, V139, P37; PASMAN PC, 1994, ANN ONCOL, V5, pS89, DOI 10.1093/annonc/5.suppl_1.S89; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; RAMASAMY I, 1992, J CLIN PATHOL, V45, P770, DOI 10.1136/jcp.45.9.770; RAPHAEL MM, 1994, AM J CLIN PATHOL, V101, P773, DOI 10.1093/ajcp/101.6.773; ROTH J, 1994, INT J CANCER, V57, P799, DOI 10.1002/ijc.2910570607; STEIN H, 1982, INT J CANCER, V30, P445, DOI 10.1002/ijc.2910300411; STEIN H, 1985, BLOOD, V66, P848; Stein H, 1983, Hematol Oncol, V1, P21; TAMARU J, 1994, BLOOD, V84, P708; Teale J M, 1992, Int Rev Immunol, V8, P95, DOI 10.3109/08830189209055566; TEERENHOVI L, 1988, CANCER GENET CYTOGEN, V34, P305, DOI 10.1016/0165-4608(88)90277-4; WEISS LM, 1986, HUM PATHOL, V17, P1009, DOI 10.1016/S0046-8177(86)80084-3; WEISS LM, 1987, AM J PATHOL, V129, P86; WOLF J, 1994, ANN ONCOL, V5, pS105, DOI 10.1093/annonc/5.suppl_1.S105	44	179	180	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 5	1995	333	14					901	906		10.1056/NEJM199510053331403	http://dx.doi.org/10.1056/NEJM199510053331403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX199	7545266				2022-12-28	WOS:A1995RX19900003
J	HACKE, W; KASTE, M; FIESCHI, C; TONI, D; LESAFFRE, E; VONKUMMER, R; BOYSEN, G; BLUHMKI, E; HOXTER, G; MAHAGNE, MH; HENNERICI, M				HACKE, W; KASTE, M; FIESCHI, C; TONI, D; LESAFFRE, E; VONKUMMER, R; BOYSEN, G; BLUHMKI, E; HOXTER, G; MAHAGNE, MH; HENNERICI, M			INTRAVENOUS THROMBOLYSIS WITH RECOMBINANT TISSUE-PLASMINOGEN ACTIVATOR FOR ACUTE HEMISPHERIC STROKE - THE EUROPEAN COOPERATIVE ACUTE STROKE STUDY (ECASS)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MIDDLE CEREBRAL-ARTERY; ACUTE ISCHEMIC STROKE; LOCAL INTRAARTERIAL THROMBOLYSIS; EMBOLIC STROKE; MYOCARDIAL-INFARCTION; FIBRINOLYTIC THERAPY; TERRITORY STROKE; RANDOMIZED TRIAL; CLINICAL-TRIALS; BRAIN EDEMA	Objective.-To evaluate the efficacy and safety of intravenous thrombolysis using recombinant tissue plasminogen activator (rt-PA) in patients with acute ischemic stroke. Design.-Randomized, prospective, multicenter, double-blind, placebo-controlled clinical trial. Setting.-A total of 75 hospitals in 14 European countries. Patients.-A total of 620 patients with acute ischemic hemispheric stroke and moderate to severe neurologic deficit and without major early infarct signs on initial computed tomography (CT). Intervention.-Patients were randomized to treatment with 1.1 mg per kilogram of body weight of rt-PA (alteplase) or placebo within 6 hours from the onset of symptoms. Outcome Measures.-Primary end points included Barthel Index (BI) and modified Rankin Scale (RS) at 90 days. Secondary end points included combined BI and RS, Scandinavian Stroke Scale (SSS) at 90 days, and 30-day mortality. Tertiary end points included early neurologic recovery (SSS) and duration of in-hospital stay. Safety parameters included mortality and incidence of intracranial or extracranial hemorrhage. Results.-The distribution of demographic variables was similar among patients in the rt-PA and placebo treatment arms in both the intention-to-treat (ITT) analysis and the explanatory analysis for the target population (TP). A total of 109 patients (17.4%) were included in the trial despite major protocol violations but excluded from the TP. There was no difference in the primary end points in the ITT analysis, while the TP analysis revealed a significant difference in the RS in favor of rt-PA-treated patients (P=.035). Of the secondary end points, the combined BI and RS showed a difference in favor of rt-PA-treated patients in both analyses (P<.001). Neurologic recovery at 90 days was significantly better for rt-PA-treated patients in the TP (P=.03). The speed of neurologic recovery assessed by the SSS was significantly better up to 7 days in the ITT analysis and up to 30 days for the TP in the rt-PA treatment arm. In-hospital stay was significantly shorter in the rt-PA treatment arm in both analyses. There were no statistically significant differences in the mortality rate at 30 days or in the overall incidence of intracerebral hemorrhages among the rt-PA and placebo treatment arms in either analysis. However, the occurrence of large parenchymal hemorrhages was significantly more frequent in the rt-PA-treated patients. Conclusions.-Intravenous thrombolysis in acute ischemic stroke is effective in improving some functional measures and neurologic outcome in a defined subgroup of stroke patients with moderate to severe neurologic deficit and without extended infarct signs on the initial CT scan. However, the identification of this subgroup is difficult and depends on recognition of early major CT signs of early infarction. Therefore, since treating ineligible patients is associated with an unacceptable increase of hemorrhagic complications and death, intravenous thrombolysis cannot currently be recommended for use in an unselected population of acute ischemic stroke patients.	UNIV HEIDELBERG, DEPT NEURORADIOL, HEIDELBERG, GERMANY; HELSINKI UNIV, DEPT NEUROL, HELSINKI, FINLAND; UNIV ROME, DEPT NEUROL, ROME, ITALY; UNIV LEUVEN, BIOSTAT CTR CLIN TRIALS, LOUVAIN, BELGIUM; UNIV COPENHAGEN, HVIDOVRE HOSP, DEPT NEUROL, COPENHAGEN, DENMARK; DR KARL THOMAE GMBH, BIBERACH, GERMANY; BOEHRINGER INGELHEIM KG, BIBERACH, GERMANY; INNOVEX BIODESIGN GMBH, FREIBURG, GERMANY; UNIV NICE, DEPT NEUROL, NICE, FRANCE; UNIV HEIDELBERG, KLINIKUM MANNHEIM, DEPT NEUROL, HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg; University of Helsinki; Sapienza University Rome; KU Leuven; University of Copenhagen; Boehringer Ingelheim; UDICE-French Research Universities; Universite Cote d'Azur; Ruprecht Karls University Heidelberg	HACKE, W (corresponding author), UNIV HEIDELBERG, DEPT NEUROL, NEUENHEIMER FELD 400, D-69120 HEIDELBERG, GERMANY.		Hacke, Werner/ABE-8661-2020; von Kummer, Rüdiger/AAA-4478-2019; Toni, Danilo/K-3151-2016	von Kummer, Rüdiger/0000-0003-0119-4604; Toni, Danilo/0000-0003-2735-8427				ARGENTINO C, 1989, STROKE, V20, P1143, DOI 10.1161/01.STR.20.9.1143; ASPLUND K, 1986, ACTA NEUROL SCAND, V73, P530; BABIKIAN VL, 1989, STROKE, V20, P1500, DOI 10.1161/01.STR.20.11.1500; BASTIANELLO S, 1991, NEURORADIOLOGY, V33, P207, DOI 10.1007/BF00588219; BOCKENHEIMER S, 1991, RADIOLOGE, V31, P210; Boysen G, 1995, Eur J Neurol, V1, P213, DOI 10.1111/j.1468-1331.1995.tb00074.x; BOZZAO L, 1989, STROKE, V20, P735, DOI 10.1161/01.STR.20.6.735; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; BROTT TG, 1992, STROKE, V23, P632, DOI 10.1161/01.STR.23.5.632; CASTO L, 1992, ACTA NEUROL SCAND, V86, P308, DOI 10.1111/j.1600-0404.1992.tb05091.x; DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113; DELZOPPO GJ, 1988, STROKE, V19, P307, DOI 10.1161/01.STR.19.3.307; DELZOPPO GJ, 1991, SEMIN NEUROL, V11, P368, DOI 10.1055/s-2008-1041241; FIESCHI C, 1988, ANN NY ACAD SCI, V522, P662; FIESCHI C, 1989, J NEUROL SCI, V91, P311, DOI 10.1016/0022-510X(89)90060-9; FORSTING M, 1993, THROMBOLYTIC THERAPY, V2, P160; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; GRANGER CV, 1989, ARCH PHYS MED REHAB, V70, P100; GROTTA JC, 1989, STROKE, V20, P317; GROTTA JC, 1987, NEW ENGL J MED, V317, P1505, DOI 10.1056/NEJM198712103172405; GUPTA SS, 1963, ANN MATH STAT, V34, P792, DOI 10.1214/aoms/1177704004; HACKE W, 1994, CEREBROVASC DIS, V4, P385, DOI 10.1159/000108517; HACKE W, 1988, STROKE, V19, P1216, DOI 10.1161/01.STR.19.10.1216; HACKE W, 1994, FIBRINOLYSIS, V8, P216, DOI 10.1016/0268-9499(94)90719-6; HACKE W, 1993, THROMBOLYTIC THERAPY, V2, P151; HALEY EC, 1993, STROKE, V24, P1000, DOI 10.1161/01.STR.24.7.1000; HENNERICI M, 1991, CEREBROVASC DIS, V1, P124, DOI 10.1159/000108907; HOMMEL M, 1995, LANCET, V345, P57, DOI 10.1016/S0140-6736(95)91179-0; HORNIG CR, 1986, STROKE, V17, P179, DOI 10.1161/01.STR.17.2.179; KASTE M, 1994, STROKE, V25, P1348, DOI 10.1161/01.STR.25.7.1348; KASTE M, 1995, STROKE, V26, P249, DOI 10.1161/01.STR.26.2.249; KOUDSTAAL PJ, 1988, BRIT MED J, V297, P1571, DOI 10.1136/bmj.297.6663.1571; LESAFFRE E, 1993, STAT MED, V12, P1063; LEVY DE, 1994, STROKE, V25, P291, DOI 10.1161/01.STR.25.2.291; LEYS D, 1992, STROKE, V23, P317, DOI 10.1161/01.STR.23.3.317; LINDENSTROM E, 1991, CEREBROVASC DIS, V1, P103, DOI 10.1159/000108825; MAHONEY F I, 1965, Md State Med J, V14, P61; Matsumoto K, 1991, THROMBOLYTIC THERAPY, P207; MOBIUS E, 1989, AKTUEL NEUROL, V16, P184, DOI 10.1055/s-2007-1020608; MOHR JP, 1994, CEREBROVASC DIS, V4, P197, DOI 10.1159/000108482; MORI E, 1992, NEUROLOGY, V42, P976, DOI 10.1212/WNL.42.5.976; MORI E, 1988, STROKE, V19, P802, DOI 10.1161/01.STR.19.7.802; NENCI GG, 1983, ANGIOLOGY, V34, P561, DOI 10.1177/000331978303400901; OKADA Y, 1989, STROKE, V20, P598, DOI 10.1161/01.STR.20.5.598; ORGOGOZO JM, 1991, CEREBROVASC DIS, V1, P100, DOI 10.1159/000108904; PESSIN MS, 1990, CLIN NEUROPHARMACOL, V13, P271, DOI 10.1097/00002826-199008000-00001; POCOCK SJ, 1987, BIOMETRICS, V43, P487, DOI 10.2307/2531989; RANKIN J, 1957, Scott Med J, V2, P200; RINGELSTEIN EB, 1992, NEUROLOGY, V42, P289, DOI 10.1212/WNL.42.2.289; ROPPER AH, 1984, ARCH NEUROL-CHICAGO, V41, P26, DOI 10.1001/archneur.1984.04050130032017; SENN S, 1994, STAT MED, V13, P1715, DOI 10.1002/sim.4780131703; SILVER FL, 1984, STROKE, V15, P492, DOI 10.1161/01.STR.15.3.492; SMALLING RW, 1990, J AM COLL CARDIOL, V15, P915, DOI 10.1016/0735-1097(90)90216-C; TAUB NA, 1994, STROKE, V25, P352, DOI 10.1161/01.STR.25.2.352; TOMSICK TA, 1989, NEURORADIOLOGY, V31, P312, DOI 10.1007/BF00344173; TONI D, 1995, ARCH NEUROL-CHICAGO, V52, P670, DOI 10.1001/archneur.1995.00540310040014; TONI D, IN PRESS NEUROLOGY; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; VONKUMMER R, 1992, STROKE, V23, P646, DOI 10.1161/01.STR.23.5.646; VONKUMMER R, 1994, AM J NEURORADIOL, V15, P9; WARDLAW JM, 1992, STROKE, V23, P1826, DOI 10.1161/01.STR.23.12.1826; WOLPERT SM, 1993, AM J NEURORADIOL, V14, P3; YAMAGUCHI T, 1993, CEREBROVASC DIS, V3, P269, DOI 10.1159/000108714; ZEUMER H, 1993, NEURORADIOLOGY, V35, P159, DOI 10.1007/BF00593977; ZEUMER H, 1983, AM J NEURORADIOL, V4, P401; ZEUMER H, 1989, NEURORADIOLOGY, V31, P336, DOI 10.1007/BF00344178; ZEUMER H, 1985, J NEUROL, V231, P287, DOI 10.1007/BF00313704; 1991, STROKE, V22, P153	68	2532	2647	3	167	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1017	1025		10.1001/jama.274.13.1017	http://dx.doi.org/10.1001/jama.274.13.1017			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX108	7563451				2022-12-28	WOS:A1995RX10800023
J	WU, H; KLINGMULLER, U; BESMER, P; LODISH, HF				WU, H; KLINGMULLER, U; BESMER, P; LODISH, HF			INTERACTION OF THE ERYTHROPOIETIN AND STEM-CELL-FACTOR RECEPTORS	NATURE			English	Article							C-KIT; KINASE; PROTEIN; EXPRESSION; PHOSPHORYLATION	MUTATIONS in the KIT transmembrane protein-tyrosine kinase receptor(1) affect erythropoiesis, resulting in fewer committed late progenitors (colony-forming unit erythroid, CFU-E) in the fetal liver(2). As the survival and proliferation of CFU-Es depend absolutely on erythropoietin (EPO)(3), these results suggest that CFU-Es cannot proliferate or mature further unless both the KIT and EPO receptor(4) signalling pathways are functional. How KIT affects proliferation or differentiation of CFU-Es is not clear. Here we show that the KIT ligand SCF (for stem-cell factor) can replace EPO in supporting the growth and survival of HCD57 cells, an EPO-dependent erythroid-progenitor cell line expressing high levels of KIT5. SCF supports the proliferation of 32D cells(6) that express KIT only if they also express the EPO receptor. In HCD57 cells, SCF rapidly induces tyrosine phosphorylation of the EPO receptor, and KIT physically associates with the extended box 2 region(7) in the cytoplasmic domain of the EPO receptor. Our results indicate that KIT may activate the EPO receptor by tyrosine phosphorylation to induce further proliferation and maturation of CFU-Es.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Memorial Sloan Kettering Cancer Center			Klingmüller, Ursula/G-8477-2013	Klingmüller, Ursula/0000-0001-9845-3099				Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; GREGORY CJ, 1976, J CELL PHYSIOL, V89, P289, DOI 10.1002/jcp.1040890212; HE TC, 1994, J BIOL CHEM, V269, P18291; HILTON DJ, 1995, P NATL ACAD SCI USA, V92, P190, DOI 10.1073/pnas.92.1.190; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LETWIN K, 1988, ONCOGENE, V3, P621; LIU L, 1994, J BIOL CHEM, V269, P16774; MAJUMDER S, 1988, MOL CELL BIOL, V8, P4896, DOI 10.1128/MCB.8.11.4896; MIURA Y, 1994, J BIOL CHEM, V269, P29962; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SAWYER ST, 1993, P NATL ACAD SCI USA, V90, P6849, DOI 10.1073/pnas.90.14.6849; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SPIVAK JL, 1991, BLOOD, V77, P1228; TSUJIMURA T, 1994, BLOOD, V83, P2619; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706	21	241	245	1	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					242	246		10.1038/377242a0	http://dx.doi.org/10.1038/377242a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7545788				2022-12-28	WOS:A1995RV87200043
J	BLASCO, MA; FUNK, W; VILLEPONTEAU, B; GREIDER, CW				BLASCO, MA; FUNK, W; VILLEPONTEAU, B; GREIDER, CW			FUNCTIONAL-CHARACTERIZATION AND DEVELOPMENTAL REGULATION OF MOUSE TELOMERASE RNA	SCIENCE			English	Article							IDENTIFICATION; SEQUENCES	Telomerase synthesizes telomeric DNA repeats onto chromosome ends de novo. The mouse telomerase RNA component was cloned and contained only 65 percent sequence identity with the human telomerase RNA. Alteration of the template region in vivo generated altered telomerase products. The shorter template regions of the mouse and other rodent telomerase RNAs could account for the shorter distribution of products (processivity) generated by the mouse enzyme relative to the human telomerase. Amounts of telomerase RNA increased in immortal cells derived from primary mouse fibroblasts. RNA was detected in all newborn mouse tissues tested but was decreased during postnatal development.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; GERON CORP,MENLO PK,CA 94025	Cold Spring Harbor Laboratory; Geron Corporation			Blasco, Maria A./M-1694-2014	Blasco, Maria A./0000-0002-4211-233X	NATIONAL INSTITUTE ON AGING [R37AG009383, R01AG009383] Funding Source: NIH RePORTER; NIA NIH HHS [AG09383] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CHADENEAU C, 1995, ONCOGENE, V11, P841; FENG J, UNPUB; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; MACIEIRACOELHO A, 1988, ANTICANCER RES, V8, P669; MCEACHEM MJ, 1995, NATURE, V346, P403; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHUMYATSKY G, 1992, NUCLEIC ACIDS RES, V20, P2159, DOI 10.1093/nar/20.suppl.2159; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	15	336	347	0	15	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1267	1270		10.1126/science.7544492	http://dx.doi.org/10.1126/science.7544492			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7544492				2022-12-28	WOS:A1995RR84200035
J	CHANG, HY; TAKEI, K; SYDOR, AM; BORN, T; RUSNAK, F; JAY, DG				CHANG, HY; TAKEI, K; SYDOR, AM; BORN, T; RUSNAK, F; JAY, DG			ASYMMETRIC RETRACTION OF GROWTH CONE FILOPODIA FOLLOWING FOCAL INACTIVATION OF CALCINEURIN	NATURE			English	Article							GRASSHOPPER PIONEER NEURONS; CYCLOSPORINE-A; NERVE GROWTH; LASER INACTIVATION; FASCICLIN-I; INHIBITION; PHOSPHORYLATION; TRANSDUCTION; PHOSPHATASE; COMPLEXES	THE neuronal growth cone is thought to be the site of decision making in nerve growth and guidance(1,2). One likely mechanism of how the growth cone translates various extracellular cues into directed motility involves rises in intracellular calcium, A variety of physiological cues, such as adhesion molecules and neurotransmitters, increases intracellular calcium(1), and artificial manipulations of growth cone calcium levels affect growth cone morphology and neurite outgrowth(3). The molecular events downstream of calcium fluxes are incompletely understood, Here we show that calcineurin, a protein phosphatase enriched in growth cones that is dependent on calcium ions and calmodulin(4), functions in neurite outgrowth and directed filopodial motility in cultured chick dorsal root ganglia neurons. Cyclosporin A and FK506, inhibitors of calcineurin(5), delayed neuritogenesis and inhibited neurite extension, Chromophore-assisted laser inactivation of calcineurin io regions of growth cones causes localized filopodial and lamellipodial retraction and influences the direction of subsequent outgrowth. We suggest that a spatial distribution of calcineurin activity within the growth cone can regulate motility and direct outgrowth.	MAYO CLIN & MAYO FDN,HEMATOL RES SECT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	CHANG, HY (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.							BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BRAY D, 1991, CULTURING NERVE CELL, P104; CLARKE MSF, 1992, J CELL SCI, V102, P533; CLIPSTONE NA, 1993, NATURE, V357, P695; DAVENPORT RW, 1993, NATURE, V361, P721, DOI 10.1038/361721a0; DIAMOND P, 1993, NEURON, V11, P409, DOI 10.1016/0896-6273(93)90146-I; FERREIRA A, 1993, MOL BIOL CELL, V4, P1225, DOI 10.1091/mbc.4.12.1225; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HADDY A, 1992, FEBS LETT, V314, P37, DOI 10.1016/0014-5793(92)81456-V; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JAY DG, 1990, NATURE, V348, P548, DOI 10.1038/348548a0; KLEE CB, 1983, METHOD ENZYMOL, V102, P227; LETOURNEAU PC, 1989, DEVELOPMENT, V105, P505; LIAO JC, 1994, P NATL ACAD SCI USA, V91, P2659, DOI 10.1073/pnas.91.7.2659; LINDEN KG, 1992, BIOPHYS J, V61, P956, DOI 10.1016/S0006-3495(92)81902-1; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; REHDER V, 1992, J NEUROSCI, V12, P3175, DOI 10.1523/JNEUROSCI.12-08-03175.1992; Sambrook J, 1989, MOL CLONING LABORATO; SCHMUCKER D, 1994, P NATL ACAD SCI USA, V91, P2664, DOI 10.1073/pnas.91.7.2664; SELDEN SC, 1983, J BIOL CHEM, V258, P7064; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; STRITTMATTER SM, 1991, BIOESSAYS, V13, P127, DOI 10.1002/bies.950130306; SYDOR AM, 1994, ABS SOC NEUR, V20, P1474; VANHOOFF COM, 1988, J NEUROSCI, V8, P1789; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	30	143	144	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 24	1995	376	6542					686	690		10.1038/376686a0	http://dx.doi.org/10.1038/376686a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7544441				2022-12-28	WOS:A1995RQ67200060
J	STUTTS, MJ; CANESSA, CM; OLSEN, JC; HAMRICK, M; COHN, JA; ROSSIER, BC; BOUCHER, RC				STUTTS, MJ; CANESSA, CM; OLSEN, JC; HAMRICK, M; COHN, JA; ROSSIER, BC; BOUCHER, RC			CFTR AS A CAMP-DEPENDENT REGULATOR OF SODIUM-CHANNELS	SCIENCE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMAN NASAL EPITHELIUM; FIBROSIS; TRANSPORT; MEMBRANE; CELLS; PROTEIN	Cystic fibrosis transmembrane regulator (CFTR), the gene product that is mutated in cystic fibrosis (CF) patients, has a well-recognized function as a cyclic adenosine 3',5'-monophosphate (cAMP)-regulated chloride channel, but this property does not account for the abnormally high basal rate and cAMP sensitivity of sodium ion absorption in CF airway epithelia. Expression of complementary DNAs for rat epithelial Na+ channel (rENaC) alone in Madin Darby canine kidney (MDCK) epithelial cells generated large amiloride-sensitive sodium currents that were stimulated by cAMP, whereas coexpression of human CFTR with rENaC generated smaller basal sodium currents that were inhibited by cAMP. Parallel studies that measured regulation of sodium permeability in fibroblasts showed similar results. In CF airway epithelia, the absence of this second function of CFTR as a cAMP-dependent regulator likely accounts for abnormal sodium transport.	UNIV LAUSANNE, INST PHARMACOL & TOXICOL, CH-1005 LAUSANNE, SWITZERLAND; DUKE UNIV, DURHAM, NC 27710 USA; VET ADM MED CTR, DURHAM, NC 27710 USA	University of Lausanne	STUTTS, MJ (corresponding author), UNIV N CAROLINA, CYST FIBROSIS PULM RES & TREATMENT CTR, CHAPEL HILL, NC 27599 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042384, P01HL034322] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 42384, HL 34322] Funding Source: Medline; PHS HHS [CFF R026] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; BURCH LH, IN PRESS AM J PHYSL; CANESSA C, UNPUB; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHAMPIGNY G, 1994, EMBO J, V13, P2177, DOI 10.1002/j.1460-2075.1994.tb06494.x; CHINET TC, 1994, AM J PHYSIOL, V266, pC1061, DOI 10.1152/ajpcell.1994.266.4.C1061; COHN JA, 1991, BIOCHEM BIOPH RES CO, V181, P36, DOI 10.1016/S0006-291X(05)81378-6; COTTON CU, 1987, J CLIN INVEST, V79, P80, DOI 10.1172/JCI112812; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; GRUBB BR, 1994, NATURE, V371, P802, DOI 10.1038/371802a0; GRUBB BR, 1994, AM J PHYSIOL, V267, pC293, DOI 10.1152/ajpcell.1994.267.1.C293; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIRT RP, 1992, GENE, V111, P199, DOI 10.1016/0378-1119(92)90687-K; LAFERTE S, 1992, BIOCHEM J, V283, P193, DOI 10.1042/bj2830193; OLSEN JC, 1992, HUM GENE THER, V3, P253, DOI 10.1089/hum.1992.3.3-253; ONEAL W, 1994, PEDIATR PULM S, V10, P194; REISIN IL, 1994, J BIOL CHEM, V269, P20584; RIOS RM, 1992, EMBO J, V11, P1723, DOI 10.1002/j.1460-2075.1992.tb05224.x; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SCHWIEBERT EM, 1994, AM J PHYSIOL, V266, pC1464, DOI 10.1152/ajpcell.1994.266.5.C1464; STUTTS MJ, 1994, J BIOL CHEM, V269, P8667; STUTTS MJ, 1993, J BIOL CHEM, V268, P20653; TALBOT CR, 1995, FASEB J, V9, pA304; USSING HH, 1949, PHYSIOL REV, V29, P127, DOI 10.1152/physrev.1949.29.2.127; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1033, DOI 10.1152/ajpcell.1989.256.5.C1033; WILLUMSEN NJ, 1991, AM J PHYSIOL, V261, pC319, DOI 10.1152/ajpcell.1991.261.2.C319; WILLUMSEN NJ, 1991, AM J PHYSIOL, V261, pC332, DOI 10.1152/ajpcell.1991.261.2.C332	31	902	921	0	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	1995	269	5225					847	850		10.1126/science.7543698	http://dx.doi.org/10.1126/science.7543698			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7543698				2022-12-28	WOS:A1995RN65000047
J	TARAKHOVSKY, A; KANNER, SB; HOMBACH, J; LEDBETTER, JA; MULLER, W; KILLEEN, N; RAJEWSKY, K				TARAKHOVSKY, A; KANNER, SB; HOMBACH, J; LEDBETTER, JA; MULLER, W; KILLEEN, N; RAJEWSKY, K			A ROLE FOR CD5 IN TCR-MEDIATED SIGNAL-TRANSDUCTION AND THYMOCYTE SELECTION	SCIENCE			English	Article							RECEPTOR TRANSGENIC MICE; PROTEIN-TYROSINE KINASES; T-CELL; POSITIVE SELECTION; CD4+8+ THYMOCYTES; ANTIGEN; ACTIVATION; COMPLEX; PHOSPHORYLATION; STIMULATION	CD5 is a transmembrane protein that is expressed on the surface of T cells and a subset of B cells. The absence of CD5 rendered thymocytes hyperresponsive to stimulation through the T cell antigen receptor (TCR) in vitro. Selection of T cells expressing three distinct transgenic TCRs was also abnormal in CD5-deficient mice. These observations indicate that CD5 can influence the fate of developing thymocytes by acting as a negative regulator of TCR-mediated signal transduction.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; UNIV ZURICH,DEPT PATHOL,INST EXPTL IMMUNOL,CH-8091 ZURICH,SWITZERLAND; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	Bristol-Myers Squibb; University of Zurich; University of California System; University of California San Francisco	TARAKHOVSKY, A (corresponding author), UNIV COLOGNE,INST GENET,D-50937 COLOGNE,GERMANY.		Muller, Werner/B-9044-2008	Muller, Werner/0000-0002-1297-9725; Rajewsky, Klaus/0000-0002-6633-6370				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BURGESS KE, 1992, P NATL ACAD SCI USA, V89, P9311, DOI 10.1073/pnas.89.19.9311; CEUPPENS JL, 1986, J IMMUNOL, V137, P1816; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CROMPTON T, 1993, P NATL ACAD SCI USA, V90, P8982, DOI 10.1073/pnas.90.19.8982; DAVIES AA, 1992, P NATL ACAD SCI USA, V89, P6368, DOI 10.1073/pnas.89.14.6368; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; JAMESON SC, 1995, IMMUNITY, V2, P1, DOI 10.1016/1074-7613(95)90074-8; KANNER SB, 1992, J IMMUNOL, V148, P2023; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; KANNER SB, 1992, IMMUNOLOGY, V75, P441; KEARSE KP, 1965, J EXP MED, V181, P193; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LEDBETTER JA, 1985, J IMMUNOL, V135, P2331; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MAMALAKI C, 1992, P NATL ACAD SCI USA, V89, P11342, DOI 10.1073/pnas.89.23.11342; MCATEER MJ, 1988, EUR J IMMUNOL, V18, P1111, DOI 10.1002/eji.1830180721; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; PIRCHER H, 1994, EUR J IMMUNOL, V24, P1982, DOI 10.1002/eji.1830240907; RAAB M, 1994, MOL CELL BIOL, V14, P2862, DOI 10.1128/MCB.14.5.2862; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SWAT W, 1993, EUR J IMMUNOL, V23, P739, DOI 10.1002/eji.1830230326; SWAT W, 1992, EUR J IMMUNOL, V22, P2367, DOI 10.1002/eji.1830220928; TARAKHOVSKY A, 1994, EUR J IMMUNOL, V24, P1678, DOI 10.1002/eji.1830240733; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1986, P NATL ACAD SCI USA, V83, P6998, DOI 10.1073/pnas.83.18.6998; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	35	362	365	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 28	1995	269	5223					535	537		10.1126/science.7542801	http://dx.doi.org/10.1126/science.7542801			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7542801				2022-12-28	WOS:A1995RL49500026
J	GIAID, A; SALEH, D				GIAID, A; SALEH, D			REDUCED EXPRESSION OF ENDOTHELIAL NITRIC-OXIDE SYNTHASE IN THE LUNGS OF PATIENTS WITH PULMONARY-HYPERTENSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RELAXING FACTOR; RELAXATION; IMPAIRMENT; CLONING; DISEASE	Background. Pulmonary hypertension is characterized by abnormal thickening of the pulmonary arteries and increased pulmonary vascular resistance. Nitric oxide is a potent endothelium-derived vasorelaxant substance and an inhibitor of smooth-muscle-cell growth. Nitric oxide is produced in various cell types by the action of an enzyme, nitric oxide synthase. We compared the expression of endothelial nitric oxide synthase in the lungs of control subjects with that in the lungs of patients with pulmonary hypertension. Methods. We investigated the expression of endothelial nitric oxide synthase by histochemical and immunohistochemical analysis, in situ hybridization, and Northern blot analysis in the lungs of 22 patients with plexogenic pulmonary arteriopathy (arteriopathy of grades 4 through 6), 24 patients with secondary pulmonary hypertension (arteriopathy of grades 1 through 3), and 23 control subjects. Results. In the lungs of the control subjects, nitric oxide synthase was expressed at a high level in the vascular endothelium of all types of vessels and in the pulmonary epithelium. In contrast, little or no expression of the enzyme was found in the vascular endothelium of pulmonary arteries with severe histologic abnormalities (i.e., plexiform lesions) in patients with pulmonary hypertension. The intensity of the enzyme immunoreactivity correlated inversely with the severity of histologic changes. There was an inverse correlation between the arterial expression of the enzyme and total pulmonary resistance in patients with plexogenic pulmonary arteriopathy (r = -0.766, P = 0.004). Conclusions. Pulmonary hypertension is associated with diminished expression of endothelial nitric oxide synthase. It is possible that decreased expression of nitric oxide synthase may contribute to pulmonary vasoconstriction and to the excessive growth of the tunica media observed in this disease.	MCGILL UNIV, MONTREAL, PQ, CANADA	McGill University	GIAID, A (corresponding author), MONTREAL GEN HOSP, DEPT PATHOL, 1650 CEDAR AVE, MONTREAL, PQ H3G 1A4, CANADA.							BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHRISTMAN BW, 1992, NEW ENGL J MED, V327, P70, DOI 10.1056/NEJM199207093270202; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DINHXUAN AT, 1993, BRIT J PHARMACOL, V109, P587, DOI 10.1111/j.1476-5381.1993.tb13611.x; DINHXUAN AT, 1991, NEW ENGL J MED, V324, P1539, DOI 10.1056/NEJM199105303242203; FINEMAN JR, 1994, J CLIN INVEST, V93, P2675, DOI 10.1172/JCI117281; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GLANTZ SA, 1987, PRIMER BIOSTATISTICS, P287; GOLDIE RG, 1990, TRENDS PHARMACOL SCI, V11, P67, DOI 10.1016/0165-6147(90)90320-8; GRIFFITH TM, 1988, J AM COLL CARDIOL, V12, P797, DOI 10.1016/0735-1097(88)90324-5; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; HEATH D, 1958, CIRCULATION, V18, P533, DOI 10.1161/01.CIR.18.4.533; HEATH D, 1993, EUR RESPIR REV, V3, P555; HIGENBOTTAM T, 1993, EUR RESPIR J, V6, P1207; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IVY DD, 1994, AM J CARDIOL, V74, P414, DOI 10.1016/0002-9149(94)90420-0; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; JANSSENS SP, 1992, J BIOL CHEM, V267, P22964; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; KOUYOUMDJIAN C, 1994, J CLIN INVEST, V94, P578, DOI 10.1172/JCI117372; LAMONTAGNE D, 1992, CIRC RES, V70, P123, DOI 10.1161/01.RES.70.1.123; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MILLER VM, 1992, AM J PHYSIOL, V263, pH103, DOI 10.1152/ajpheart.1992.263.1.H103; MONCADA S, 1978, PHARMACOL REV, V30, P293; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAGASAKA Y, 1984, CIRC RES, V54, P90, DOI 10.1161/01.RES.54.1.90; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; Reeves JT, 1984, PULMONARY HYPERTENSI, P1; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; ROBBINS RA, 1994, BIOCHEM BIOPH RES CO, V198, P835, DOI 10.1006/bbrc.1994.1119; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; STUARTSMITH K, 1987, J APPL PHYSIOL, V63, P2510, DOI 10.1152/jappl.1987.63.6.2510; WAGENVOORT CA, 1981, HISTOPATHOLOGY, V5, P595, DOI 10.1111/j.1365-2559.1981.tb01826.x; WOOD P, 1958, BRIT HEART J, V20, P557; ZAPOL WM, 1994, AM J RESP CRIT CARE, V149, P1375, DOI 10.1164/ajrccm.149.5.8173780	38	1010	1062	1	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 27	1995	333	4					214	221		10.1056/NEJM199507273330403	http://dx.doi.org/10.1056/NEJM199507273330403			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK423	7540722				2022-12-28	WOS:A1995RK42300003
J	LAIRD, PW; JACKSONGRUSBY, L; FAZELI, A; DICKINSON, SL; JUNG, WE; LI, E; WEINBERG, RA; JAENISCH, R				LAIRD, PW; JACKSONGRUSBY, L; FAZELI, A; DICKINSON, SL; JUNG, WE; LI, E; WEINBERG, RA; JAENISCH, R			SUPPRESSION OF INTESTINAL NEOPLASIA BY DNA HYPOMETHYLATION	CELL			English	Article							CYTOSINE METHYLTRANSFERASES; 5-METHYLCYTOSINE CONTENT; INDUCED DEAMINATION; RAS ONCOGENES; HUMAN CANCERS; COLON-CANCER; CPG ISLANDS; METHYLATION; MOUSE; GENE	We have used a combination of genetics and pharmacology to assess the effects of reduced DNA methyltransferase activity on Apc(Min)-induced intestinal neoplasia in mice. A reduction in the DNA methyltransferase activity in Min mice due to heterozygosity of the DNA methyltransferase gene, in conjunction with a weekly dose of the DNA methyltransferase inhibitor 5-azadeoxycytidine, reduced the average number of intestinal adenomas from 113 in the control mice to only 2 polyps in the treated heterozygotes. Hence, DNA methyltransferase activity contributes substantially to tumor development in this mouse model of intestinal neoplasia. Our results argue against an oncogenic effect of DNA hypomethylation. Moreover, they are consistent with a role for DNA methyltransferase in the generation of the C to T transitions seen at high frequency in human colorectal tumors.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142; MASSACHUSETTS GEN HOSP E,CARDIOVASC RES CTR,BOSTON,MA 02129	Massachusetts Institute of Technology (MIT)	LAIRD, PW (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.		Laird, Peter W/G-8683-2012	Laird, Peter W/0000-0001-9117-3641	NCI NIH HHS [F32 CA 09097, R35 CA 44339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA009097, R35CA044339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS RLP, 1982, CRC CR REV BIOCH MOL, V13, P349, DOI 10.3109/10409238209108714; ANTEQUERA F, 1993, DNA METHYLATION MOL, P169; BARLOW DP, 1993, SCIENCE, V260, P309, DOI 10.1126/science.8469984; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; BREWSTER SF, 1994, J UROLOGY, V151, P1073, DOI 10.1016/S0022-5347(17)35186-8; BROWN TC, 1989, MUTAT RES, V227, P233, DOI 10.1016/0165-7992(89)90102-4; CHAPMAN V, 1984, NATURE, V307, P284, DOI 10.1038/307284a0; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; EHRLICH M, 1986, BIOSCIENCE REP, V6, P387, DOI 10.1007/BF01116426; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; FEINBERG AP, 1988, CANCER RES, V48, P1159; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P875, DOI 10.1093/jnci/85.11.875; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HANADA M, 1993, BLOOD, V82, P1820; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Leonhardt H., 1993, DNA methylation: molecular biology and biological significance., P109; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; LUONGO C, 1993, GENOMICS, V15, P3, DOI 10.1006/geno.1993.1002; LUONGO C, 1994, CANCER RES, V54, P5947; MIKOL YB, 1983, CARCINOGENESIS, V4, P1619, DOI 10.1093/carcin/4.12.1619; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; MONK M, 1990, DEVELOPMENT S, P66; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; NAKAMURA Y, 1993, ADV CANCER RES, V62, P65, DOI 10.1016/S0065-230X(08)60315-2; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RAO PM, 1989, CARCINOGENESIS, V10, P933, DOI 10.1093/carcin/10.5.933; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; Scrable H J, 1990, Adv Cancer Res, V54, P25, DOI 10.1016/S0065-230X(08)60807-6; SELIG S, 1988, EMBO J, V7, P419, DOI 10.1002/j.1460-2075.1988.tb02829.x; SHEN JC, 1994, NUCLEIC ACIDS RES, V22, P972, DOI 10.1093/nar/22.6.972; SHEN JC, 1992, CELL, V71, P1073, DOI 10.1016/S0092-8674(05)80057-1; SHENOY S, 1987, J MOL BIOL, V197, P617, DOI 10.1016/0022-2836(87)90468-2; SHIVAPURKAR N, 1986, J NATL CANCER I, V77, P213; SILVERMAN AL, 1989, CANCER RES, V49, P3468; Singer-Sam J., 1993, DNA methylation: molecular biology and biological significance., P358; SPRUCK CH, 1993, DNA METHYLATION MOL, P487; SU LK, 1992, SCIENCE, V256, P1114, DOI 10.1126/science.256.5060.1114-c; TAMURA G, 1994, CANCER RES, V54, P1149; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; VORCE RL, 1991, J TOXICOL ENV HEALTH, V34, P367, DOI 10.1080/15287399109531574; WANG RYH, 1982, BIOCHIM BIOPHYS ACTA, V697, P371, DOI 10.1016/0167-4781(82)90101-4; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Yeivin A, 1993, EXS, V64, P523	74	636	653	0	20	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					197	205		10.1016/0092-8674(95)90329-1	http://dx.doi.org/10.1016/0092-8674(95)90329-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7537636	Bronze			2022-12-28	WOS:A1995QV41000008
J	CHENG, Y; DAHLBERG, JE; LUND, E				CHENG, Y; DAHLBERG, JE; LUND, E			DIVERSE EFFECTS OF THE GUANINE-NUCLEOTIDE EXCHANGE FACTOR RCC1 ON RNA TRANSPORT	SCIENCE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEINS; VESICULAR STOMATITIS-VIRUS; CHROMOSOME CONDENSATION; MESSENGER-RNA; BINDING PROTEIN; PORE COMPLEX; CELL-CYCLE; DNA; REGULATOR; MUTANT	Transport of RNAs within nuclei and through nuclear pore complexes (NPCs) are essential, but poorly understood, steps in gene expression. In experiments with mammalian cells, RCC1, the abundant nuclear guanine nucleotide exchange factor for the guanosine triphosphatase Ran/TC4, was shown to be required for nucleocytoplasmic transport of precursors of spliceosomal small nuclear RNAs (snRNAs), intranuclear transport of U3 snRNA, and processing of ribosomal RNAs, but not for export of transfer RNAs. It is proposed that guanosine triphosphate (GTP)-bound Ran/TC4 associates with ribonucleoprotein particles (RNPs) during intranuclear movement, and that GTP hydrolysis promotes deposition of RNPs at targeted sites such as NPCs or nucleoli.	UNIV WISCONSIN, DEPT BIOMOLEC CHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM 30220] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030220, R01GM030220] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BREWER G, 1990, METHOD ENZYMOL, V181, P202; BRINGMANN P, 1983, EMBO J, V2, P1129, DOI 10.1002/j.1460-2075.1983.tb01557.x; Cheng Y., UNPUB; CLARK MW, 1987, J CELL BIOL, V105, P1515, DOI 10.1083/jcb.105.4.1515; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; CRONE DE, 1989, J VIROL, V63, P4172, DOI 10.1128/JVI.63.10.4172-4180.1989; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DEVEGVAR HEN, 1990, MOL CELL BIOL, V10, P3365, DOI 10.1128/MCB.10.7.3365; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; ELLIOTT DJ, 1994, CURR OPIN GENET DEV, V4, P305, DOI 10.1016/S0959-437X(05)80058-9; FILIPOWICZ W, 1993, MOL BIOL REP, V18, P149, DOI 10.1007/BF00986770; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; FORRESTER W, 1992, GENE DEV, V6, P1914, DOI 10.1101/gad.6.10.1914; FOURNIER MJ, 1993, TRENDS BIOCHEM SCI, V18, P131, DOI 10.1016/0968-0004(93)90020-N; FRESCO LD, 1987, MOL CELL BIOL, V7, P1148, DOI 10.1128/MCB.7.3.1148; GURNEY T, 1980, J CELL BIOL, V87, P398, DOI 10.1083/jcb.87.2.398; HUANG SD, COMMUNICATION; Izaurralde E, 1992, Semin Cell Biol, V3, P279, DOI 10.1016/1043-4682(92)90029-U; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; KLEINSCHMIDT AM, 1987, MOL CELL BIOL, V7, P3131, DOI 10.1128/MCB.7.9.3131; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; Maquat LE, 1991, CURR OPIN CELL BIOL, V3, P1004, DOI 10.1016/0955-0674(91)90121-E; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MUNNS TW, 1982, BIOCHEMISTRY-US, V21, P2922, DOI 10.1021/bi00541a018; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; PANTE N, 1993, J CELL BIOL, V122, P977, DOI 10.1083/jcb.122.5.977; PATTON JR, 1987, MOL CELL BIOL, V7, P4030, DOI 10.1128/MCB.7.11.4030; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; REIMER G, 1987, ARTHRITIS RHEUM, V30, P793, DOI 10.1002/art.1780300709; ROSBASH M, 1993, CELL, V75, P399, DOI 10.1016/0092-8674(93)90373-X; ROSS J, 1976, J MOL BIOL, V106, P403, DOI 10.1016/0022-2836(76)90093-0; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; TARTAKOFF A, COMMUNICATION; TERNS MP, 1994, SCIENCE, V264, P959, DOI 10.1126/science.8178154; ZACHAR Z, 1993, J CELL BIOL, V121, P729, DOI 10.1083/jcb.121.4.729; ZIEVE GW, 1990, CRIT REV BIOCHEM MOL, V25, P1, DOI 10.3109/10409239009090604; ZIEVE GW, 1987, J CELL PHYSIOL, V131, P247, DOI 10.1002/jcp.1041310215	48	113	114	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	1995	267	5205					1807	1810		10.1126/science.7534442	http://dx.doi.org/10.1126/science.7534442			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7534442				2022-12-28	WOS:A1995QN70200035
J	DRANCOURT, M; MAINARDI, JL; BROUQUI, P; VANDENESCH, F; CARTA, A; LEHNERT, F; ETIENNE, J; GOLDSTEIN, F; ACAR, J; RAOULT, D				DRANCOURT, M; MAINARDI, JL; BROUQUI, P; VANDENESCH, F; CARTA, A; LEHNERT, F; ETIENNE, J; GOLDSTEIN, F; ACAR, J; RAOULT, D			BARTONELLA (ROCHALIMAEA) QUINTANA ENDOCARDITIS IN 3 HOMELESS MEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HENSELAE SP-NOV; BACILLARY ANGIOMATOSIS; PATIENT; DNA; IDENTIFICATION; AMPLIFICATION; VINSONII; BLOOD	Background. Bartonella (Rochalimaea) quintana is the agent of trench fever and is transmitted by the body louse, We-searched for this organism in three alcoholic homeless men with endocarditis. Methods. Blood samples were cultured on a human endothelial cell line and on blood agar. Bacteria were identified by sequencing the amplified 16S ribosomal RNA gene. The presence of bartonella in tissue was assessed by Gram's staining, immunostaining, and polymerase-chain-reaction amplification. Serologic studies for antibodies to bartonella species were performed by indirect immunofluorescence and Western immunoblotting. Results. B. quintana was isolated from one patient in the blood-agar culture and from the other two patients in the endothelial-cell culture. The organism was also identified by both immunostaining and molecular techniques in the valvular vegetations from the three patients and in a cervical lymph node from one patient. The 16S ribosomal RNA gene sequences of the three isolates were almost identical to that of the prototype strain of B. quintana. High titers of antibodies to B. quintana were detected in all three patients, but so were cross-reacting antibodies to chlamydia species. In all three patients studies were repeatedly negative for antibodies to the human immunodeficiency virus. Conclusions. B. quintana is a cause of endocarditis in homeless patients and may be serologically misdiagnosed as a chlamydial infection.	FAC MED MARSEILLE,UNITE RICKETTSIES,F-13385 MARSEILLE 5,FRANCE; HOP ST JOSEPH,MICROBIOL MED LAB,F-75674 PARIS,FRANCE; HOP ST JOSEPH,SERV CARDIOL,F-75674 PARIS,FRANCE; HOP F HOUPHOUET BOUIGNY,SERV MALAD INFECT & TROP,MARSEILLE,FRANCE; HOP LOUIS PRADEL,BACTERIOL LAB,LYON,FRANCE	UDICE-French Research Universities; Aix-Marseille Universite; Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite; Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite; CHU Lyon			Brouqui, Philippe/P-5771-2016; MAINARDI, Jean-Luc/E-2714-2014; ETIENNE, Jerome/C-5471-2014; RAOULT, Didier/A-8434-2008	MAINARDI, Jean-Luc/0000-0002-4159-0129; ETIENNE, Jerome/0000-0002-3348-3315; RAOULT, Didier/0000-0002-0633-5974				BAKER JA, 1946, J EXP MED, V84, P37, DOI 10.1084/jem.84.1.37; BRENNER DJ, 1993, INT J SYST BACTERIOL, V43, P777, DOI 10.1099/00207713-43-4-777; DALY JS, 1993, J CLIN MICROBIOL, V31, P872, DOI 10.1128/JCM.31.4.872-881.1993; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DUMLER JS, 1991, NEW ENGL J MED, V325, P1109, DOI 10.1056/NEJM199110103251517; ETIENNE J, 1992, EUR HEART J, V13, P1422, DOI 10.1093/oxfordjournals.eurheartj.a060077; GIMENEZ DF, 1964, STAIN TECHNOL, V39, P135, DOI 10.3109/10520296409061219; HADFIELD TL, 1993, HUM PATHOL, V24, P1140, DOI 10.1016/0046-8177(93)90196-N; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOLLINGDALE MR, 1978, J INFECT DIS, V137, P578, DOI 10.1093/infdis/137.5.578; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; KNOBLOCH J, 1988, AM J TROP MED HYG, V39, P427, DOI 10.4269/ajtmh.1988.39.427; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; KOSTRZEWSKI J, 1950, MED DOSW MIKROBIOL, V11, P233; LARSON AM, 1994, J CLIN MICROBIOL, V32, P1492, DOI 10.1128/JCM.32.6.1492-1496.1994; MAURIN M, 1993, J ANTIMICROB CHEMOTH, V32, P587, DOI 10.1093/jac/32.4.587; MAURIN M, 1994, J CLIN MICROBIOL, V32, P1166, DOI 10.1128/JCM.32.5.1166-1171.1994; MILLER L, 1985, 22841 HEWL PACK APPL; MYERS W F, 1973, Pan American Health Organization Scientific Publication, V263, P79; RAOULT D, 1994, LANCET, V343, P977, DOI 10.1016/S0140-6736(94)90102-3; REGNERY RL, 1992, J CLIN MICROBIOL, V30, P265, DOI 10.1128/JCM.30.2.265-274.1992; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; SHAPIRO DS, 1992, NEW ENGL J MED, V326, P1192, DOI 10.1056/NEJM199204303261805; SLATER LN, 1992, J CLIN MICROBIOL, V30, P1722, DOI 10.1128/JCM.30.7.1722-1727.1992; SPACH DH, 1993, J CLIN MICROBIOL, V31, P692, DOI 10.1128/JCM.31.3.692-694.1993; STEIN A, 1992, NUCLEIC ACIDS RES, V20, P5237, DOI 10.1093/nar/20.19.5237; Swift HF, 1920, ARCH INTERN MED, V26, P76, DOI 10.1001/archinte.1920.00100010079006; TAKAHASHI K, 1990, IN VITRO CELL DEV B, V26, P265; VINSON JW, 1966, B WORLD HEALTH ORGAN, V35, P155; WEISBURG WG, 1991, J BACTERIOL, V173, P697, DOI 10.1128/JB.173.2.697-703.1991; WELCH DF, 1992, J CLIN MICROBIOL, V30, P275, DOI 10.1128/JCM.30.2.275-280.1992	31	285	291	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 16	1995	332	7					419	423		10.1056/NEJM199502163320702	http://dx.doi.org/10.1056/NEJM199502163320702			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF770	7529894				2022-12-28	WOS:A1995QF77000002
J	OESTERLING, JE				OESTERLING, JE			DRUG-THERAPY - BENIGN PROSTATIC HYPERPLASIA - MEDICAL AND MINIMALLY INVASIVE TREATMENT OPTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GONADOTROPIN-RELEASING-HORMONE; TRANS-URETHRAL RESECTION; TRANSURETHRAL MICROWAVE THERMOTHERAPY; BLADDER OUTFLOW OBSTRUCTION; ALPHA-ADRENERGIC BLOCKERS; ASSOCIATION SYMPTOM INDEX; URINARY FLOW-RATE; 5-ALPHA-REDUCTASE INHIBITOR; MALE PSEUDOHERMAPHRODITISM; NATURAL-HISTORY				OESTERLING, JE (corresponding author), UNIV MICHIGAN, MICHIGAN PROSTATE CTR, 1500 E MED CTR DR, ANN ARBOR, MI 48109 USA.							ABRAMS P, 1991, Journal of Urology, V145, p373A; BAERT L, 1991, PROSTATE, V18, P315, DOI 10.1002/pros.2990180405; BALL AJ, 1981, BRIT J UROL, V53, P613, DOI 10.1111/j.1464-410X.1981.tb03273.x; BARNES RW, 1983, BENIGN PROSTATIC HYP, P711; BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; BARRY MJ, 1990, UROL CLIN N AM, V17, P495; BARRY MJ, 1992, J UROLOGY, V148, P1558, DOI 10.1016/S0022-5347(17)36967-7; BDESHA AS, 1993, BRIT MED J, V306, P1293, DOI 10.1136/bmj.306.6888.1293; Birkhoff J D, 1976, Urology, V7, P48, DOI 10.1016/0090-4295(76)90560-4; BLUM JJ, 1982, P NATL ACAD SCI-BIOL, V79, P7307, DOI 10.1073/pnas.79.23.7307; BLUTE ML, 1993, J UROLOGY, V150, P1591, DOI 10.1016/S0022-5347(17)35852-4; Boyarsky S, 1976, Trans Am Assoc Genitourin Surg, V68, P29; BRUSKEWITZ RC, 1986, J UROLOGY, V136, P613, DOI 10.1016/S0022-5347(17)44991-3; CAINE M, 1978, BRIT J UROL, V50, P551, DOI 10.1111/j.1464-410X.1978.tb06210.x; CAINE M, 1975, BRIT J UROL, V47, P193, DOI 10.1111/j.1464-410X.1975.tb03947.x; CAINE M, 1976, BRIT J UROL, V48, P255, DOI 10.1111/j.1464-410X.1976.tb03013.x; CAINE M, 1986, J UROLOGY, V136, P1; CAINE M, 1975, J UROLOGY, V114, P564, DOI 10.1016/S0022-5347(17)67083-6; CHAPPLE CR, 1989, BRIT MED J, V299, P795, DOI 10.1136/bmj.299.6702.795-c; CHRISTENSEN MM, 1993, SCAND J UROL NEPHROL, V27, P39, DOI 10.3109/00365599309180412; CHRISTENSEN MM, 1990, UROL CLIN N AM, V17, P621; CLARKE R, 1937, BRIT J UROL, V9, P254; CONN PM, 1991, NEW ENGL J MED, V324, P93; COSTELLO AJ, 1992, BRIT J UROL, V69, P603, DOI 10.1111/j.1464-410X.1992.tb15631.x; Craigen A A, 1969, J R Coll Gen Pract, V18, P226; DEBRUYNE FMJ, 1993, J UROL S, V149, pA150; DEVONEC M, 1991, Journal of Endourology, V5, P129, DOI 10.1089/end.1991.5.129; Devonec Marian, 1993, Journal of Urology, V149, p249A; Dixon C M, 1992, Semin Urol, V10, P273; Dixon Christopher, 1993, Journal of Urology, V149, p215A; DORFLINGER T, 1987, SCAND J UROL NEPHROL, P77; DOTTER CT, 1969, INVEST RADIOL, V4, P329, DOI 10.1097/00004424-196909000-00008; DRACH GW, 1979, J UROLOGY, V122, P210, DOI 10.1016/S0022-5347(17)56333-8; DRACH GW, 1982, J UROLOGY, V128, P960, DOI 10.1016/S0022-5347(17)53301-7; FOWLER FJ, 1988, JAMA-J AM MED ASSOC, V259, P3018, DOI 10.1001/jama.259.20.3018; Fuselier H. Anthony, 1993, Journal of Urology, V149, p215A; GILLENWATER JY, 1993, J UROLOGY, V149, P35, DOI 10.1016/S0022-5347(17)35991-8; GORMLEY GJ, 1992, NEW ENGL J MED, V327, P1185, DOI 10.1056/NEJM199210223271701; GRAVERSEN PH, 1989, J UROLOGY, V141, P475, DOI 10.1016/S0022-5347(17)40864-0; GRIFFIN J E, 1985, P259; GUESS HA, 1993, PROSTATE, V22, P31, DOI 10.1002/pros.2990220105; GUESS HA, 1993, UROL CLIN N AM, V20, P627; HALD T, 1989, PROSTATE, P69; HARADA T, 1985, UROLOGY, V26, P572, DOI 10.1016/0090-4295(85)90364-4; HELLSTROM P, 1986, SCAND J UROL NEPHROL, V20, P187, DOI 10.3109/00365598609024492; HOLTGREWE HL, 1989, J UROLOGY, V141, P248, DOI 10.1016/S0022-5347(17)40732-4; Huggins C, 1940, J UROLOGY, V43, P705, DOI 10.1016/S0022-5347(17)71453-X; Huggins C, 1940, J EXP MED, V72, P747, DOI 10.1084/jem.72.6.747; IMPERATO.J, 1974, SCIENCE, V186, P1213, DOI 10.1126/science.186.4170.1213; ISAACS JT, 1990, PROSTATE, P1; JANKNEGT RA, 1993, EUR UROL, V24, P319; JARDIN A, 1991, LANCET, V337, P1457, DOI 10.1016/0140-6736(91)93140-5; KABALIN JN, 1993, J UROLOGY, V150, P95, DOI 10.1016/S0022-5347(17)35407-1; Kaplan S A, 1993, Contemp Urol, V5, P19; KAPLAN SA, 1993, J UROLOGY, V150, P1624, DOI 10.1016/S0022-5347(17)35860-3; KAWABE K, 1990, J UROLOGY, V144, P908, DOI 10.1016/S0022-5347(17)39620-9; KEITZER WA, 1961, J UROLOGY, V86, P242, DOI 10.1016/S0022-5347(17)65147-4; KEMPPAINEN E, 1993, UROL RES, V21, P235, DOI 10.1007/BF00590042; KIRBY RS, 1987, BRIT J UROL, V60, P136, DOI 10.1111/j.1464-410X.1987.tb04950.x; KIRBY RS, 1992, J UROLOGY, V148, P1195, DOI 10.1016/S0022-5347(17)36858-1; Kiyota Hiroshi, 1994, Journal of Urology, V151, p397A; Kletscher B A, 1992, Semin Urol, V10, P265; LAMB JC, 1992, ENDOCRINOLOGY, V130, P685, DOI 10.1210/en.130.2.685; LARSEN EH, 1987, SCAND J UROL NEPHROL, P83; LEPOR H, 1993, PROSTATE, V22, P301, DOI 10.1002/pros.2990220404; LEPOR H, 1988, UROLOGY, V32, P21; LEPOR H, 1992, J UROLOGY, V148, P1467, DOI 10.1016/S0022-5347(17)36941-0; LEPOR H, 1992, J UROLOGY, V147, P639, DOI 10.1016/S0022-5347(17)37331-7; LEPOR H, 1990, J UROLOGY, V143, P533, DOI 10.1016/S0022-5347(17)40012-7; LEPOR H, 1993, J UROLOGY, V149, P640, DOI 10.1016/S0022-5347(17)36170-0; LEPOR H, 1993, UROLOGY, V42, P483, DOI 10.1016/0090-4295(93)90258-C; LINDNER A, 1990, J UROLOGY, V144, P1390, DOI 10.1016/S0022-5347(17)39750-1; MADERSBACHER S, 1993, EUR UROL, V23, P39; MADSEN PO, 1983, BENIGN PROSTATIC HYP, P763; MALENKA DJ, 1990, J UROLOGY, V144, P224, DOI 10.1016/S0022-5347(17)39416-8; MATZKIN H, 1991, J UROLOGY, V145, P309, DOI 10.1016/S0022-5347(17)38324-6; MCCONNELL JD, 1990, UROL CLIN N AM, V17, P661; MCCONNELL JD, 1994, AHCPRD940583 DEP HLT; MCCULLOUGH DL, 1993, J UROLOGY, V150, P1607, DOI 10.1016/S0022-5347(17)35855-X; MCGUIRE EJ, 1992, J UROLOGY, V148, P1133, DOI 10.1016/S0022-5347(17)36841-6; MEBUST WK, 1989, J UROLOGY, V141, P243, DOI 10.1016/S0022-5347(17)40731-2; MILROY E, 1993, J UROLOGY, V150, P1630, DOI 10.1016/S0022-5347(17)35861-5; MILROY EJG, 1988, LANCET, V1, P1424; MINNEMAN KP, 1988, MOL PHARMACOL, V33, P509; MOCELLINI AI, 1993, PROSTATE, V22, P291; MONDA JM, 1992, CURR PROBL UROL, V2, P100; Mori Katsushi, 1994, Journal of Urology, V151, p398A; NERI R, 1989, UROLOGY, V34, P19, DOI 10.1016/0090-4295(89)90230-6; Oesterling J E, 1992, Arch Fam Med, V1, P257, DOI 10.1001/archfami.1.2.257; OESTERLING JE, 1993, UROLOGY, V41, P10, DOI 10.1016/0090-4295(93)90189-H; OESTERLING JE, 1991, J ANDROL, V12, P381; OESTERLING JE, 1991, J ANDROL, V12, P423; OESTERLING JE, 1993, JAMA-J AM MED ASSOC, V270, P860, DOI 10.1001/jama.270.7.860; Oesterling Joseph E., 1993, Journal of Urology, V149, p216A; OGDEN CW, 1993, LANCET, V341, P14, DOI 10.1016/0140-6736(93)92482-9; ORANDI A, 1973, J UROLOGY, V110, P229, DOI 10.1016/S0022-5347(17)60172-1; PALMAZ JC, 1987, RADIOLOGY, V164, P705, DOI 10.1148/radiology.164.3.2956628; PETERS CA, 1987, NEW ENGL J MED, V317, P599, DOI 10.1056/NEJM198709033171004; PETERS CA, 1988, NEW ENGL J MED, V318, P580; RITTMASTER RS, 1994, NEW ENGL J MED, V330, P120; ROOS NP, 1989, NEW ENGL J MED, V320, P1120, DOI 10.1056/NEJM198904273201705; SAPOZINK MD, 1990, J UROLOGY, V143, P944, DOI 10.1016/S0022-5347(17)40146-7; SCHROEDER FH, 1986, EUR UROL, V12, P318; SCHULMAN CC, 1993, EUR UROL, V24, P415; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; SERVADIO C, 1990, EUR UROL, V18, P169; SERVADIO C, 1984, PROSTATE, V5, P205; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; SIROKY MB, 1980, J UROLOGY, V123, P208, DOI 10.1016/S0022-5347(17)55859-0; STONE NN, 1989, UROLOGY, V34, P64, DOI 10.1016/0090-4295(89)90236-7; STONE NN, 1991, J ANDROL, V12, P376; STONER E, 1990, J STEROID BIOCHEM, V37, P375, DOI 10.1016/0960-0760(90)90487-6; STONER E, 1994, UROLOGY, V43, P284, DOI 10.1016/0090-4295(94)90068-X; SUFRIN G, 1976, INVEST UROL, V13, P429; Walsh P C, 1984, Prog Clin Biol Res, V145, P1; WALSH PC, 1974, NEW ENGL J MED, V291, P944, DOI 10.1056/NEJM197410312911806; WASSON JH, 1995, NEW ENGL J MED, V332, P75, DOI 10.1056/NEJM199501123320202; WEBER JP, 1989, J UROLOGY, V141, P987, DOI 10.1016/S0022-5347(17)41083-4; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933; White J W, 1895, Ann Surg, V22, P1, DOI 10.1097/00000658-189507000-00001; YERUSHALMI A, 1982, PROSTATE, V3, P623, DOI 10.1002/pros.2990030612; YERUSHALMI A, 1985, J UROLOGY, V133, P873, DOI 10.1016/S0022-5347(17)49270-6; 1989, VITAL HLTH STATIS 13, V100, P295	123	181	192	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 12	1995	332	2					99	109		10.1056/NEJM199501123320207	http://dx.doi.org/10.1056/NEJM199501123320207			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA241	7527494				2022-12-28	WOS:A1995QA24100007
J	WEI, XP; GHOSH, SK; TAYLOR, ME; JOHNSON, VA; EMINI, EA; DEUTSCH, P; LIFSON, JD; BONHOEFFER, S; NOWAK, MA; HAHN, BH; SAAG, MS; SHAW, GM				WEI, XP; GHOSH, SK; TAYLOR, ME; JOHNSON, VA; EMINI, EA; DEUTSCH, P; LIFSON, JD; BONHOEFFER, S; NOWAK, MA; HAHN, BH; SAAG, MS; SHAW, GM			VIRAL DYNAMICS IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION	NATURE			English	Article							PRIMARY HIV-1 INFECTION; POLYMERASE CHAIN-REACTION; REVERSE-TRANSCRIPTASE; MESSENGER-RNA; PLASMA; VIREMIA; DISEASE; DNA; INDIVIDUALS; RESISTANT	The dynamics of HIV-1 replication in vivo are largely unknown yet they are critical to our understanding of disease pathogenesis. Experimental drugs that are potent inhibitors of viral replication can be used to show that the composite lifespan of plasma virus and virus-producing cells is remarkably short (half-life similar to 2 days). Almost complete replacement of wild-type virus in plasma by drug-resistant variants occurs after fourteen days, indicating that HIV-1 viraemia is sustained primarily by a dynamic process involving continuous rounds of de novo virus infection and replication and rapid cell turnover.	UNIV ALABAMA,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DIV INFECT DIS,BIRMINGHAM,AL 35294; MERCK SHARP & DOHME LTD,RES LABS,DEPT ANTIVIRAL RES,W POINT,PA 19486; MERCK SHARP & DOHME LTD,RES LABS,DEPT CLIN PHARMACOL,W POINT,PA 19486; GENELABS TECHNOL INC,DIV HIV & EXPLORATORY RES,REDWOOD CITY,CA 94063; UNIV OXFORD,DEPT ZOOL,OXFORD OX1 3PS,ENGLAND	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Merck & Company; Merck & Company; University of Oxford			Nowak, Martin A/A-6977-2008; Yang, Chen/G-1379-2010; Bonhoeffer, Sebastian/A-2735-2008	Bonhoeffer, Sebastian/0000-0001-8052-3925; Ghosh, Sajal/0000-0002-1187-6994; Hahn, Beatrice/0000-0002-9400-9887	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AOKISEI S, 1992, AIDS RES HUM RETROV, V8, P1263, DOI 10.1089/aid.1992.8.1263; BAGNARELLI P, 1994, J VIROL, V68, P2495, DOI 10.1128/JVI.68.4.2495-2502.1994; BAGNARELLI P, 1992, J VIROL, V66, P7328, DOI 10.1128/JVI.66.12.7328-7335.1992; BALZARINI J, 1994, P NATL ACAD SCI USA, V91, P6599, DOI 10.1073/pnas.91.14.6599; CAO Y, IN PRESS AIDS RES HU; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; GRAZIOSI C, 1993, P NATL ACAD SCI USA, V90, P6405, DOI 10.1073/pnas.90.14.6405; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; JAPOUR AJ, 1993, ANTIMICROB AGENTS CH, V37, P1095, DOI 10.1128/AAC.37.5.1095; KEMPF D, IN PRESS P NATN ACAD; LARDER BA, 1993, NATURE, V365, P671, DOI 10.1038/365671a0; MCLEAN AR, 1992, AIDS, V6, P71, DOI 10.1097/00002030-199201000-00009; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MICHAEL NL, 1992, J VIROL, V66, P310, DOI 10.1128/JVI.66.1.310-316.1992; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; MYEERS GK, 1993, HUMAN RETROVIRUSES A; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; PIATAK M, 1993, LANCET, V341, P1099, DOI 10.1016/0140-6736(93)92463-4; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PRASAD VR, 1989, J BIOL CHEM, V284, P16689; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; SAAG MS, 1991, J INFECT DIS, V164, P72, DOI 10.1093/infdis/164.1.72; SAAG MS, 1993, NEW ENGL J MED, V329, P1065, DOI 10.1056/NEJM199310073291502; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SCHNITTMAN SM, 1991, AIDS RES HUM RETROV, V7, P361, DOI 10.1089/aid.1991.7.361; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; SIMMONDS P, 1991, J VIROL, V65, P6266, DOI 10.1128/JVI.65.11.6266-6276.1991; SMITH MS, 1993, J INFECT DIS, V167, P445, DOI 10.1093/infdis/167.2.445; SPRENT J, 1994, SCIENCE, V265, P1395, DOI 10.1126/science.8073282; VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096; WAINHOBSON S, 1993, CURR OPIN GENET DEV, V3, P878, DOI 10.1016/0959-437X(93)90008-D; WINTERS MA, 1993, J CLIN MICROBIOL, V31, P2960, DOI 10.1128/JCM.31.11.2960-2966.1993; ZHANG YM, 1994, J VIROL, V68, P425, DOI 10.1128/JVI.68.1.425-432.1994	44	2879	2947	4	210	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					117	122		10.1038/373117a0	http://dx.doi.org/10.1038/373117a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7529365				2022-12-28	WOS:A1995QB06300048
J	HILLMEN, P; LEWIS, SM; BESSLER, M; LUZZATTO, L; DACIE, JV				HILLMEN, P; LEWIS, SM; BESSLER, M; LUZZATTO, L; DACIE, JV			NATURAL-HISTORY OF PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELL-LINES; MARROW TRANSPLANTATION; ANCHOR BIOSYNTHESIS; APLASTIC-ANEMIA; RED-CELLS; PIG-A; PHOSPHATIDYLINOSITOL; DEFICIENCY; DEFECT; PROTEIN	Background. Paroxysmal nocturnal hemoglobinuria (PNH), which is characterized by intravascular hemolysis and venous thrombosis, is an acquired clonal disorder associated with a somatic mutation in a totipotent hematopoietic stem cell, An understanding of the natural history of PNH is essential to improve therapy. Methods. We have followed a group of 80 consecutive patients with PNH who were referred to Hammersmith Hospital, London, between 1940 and 1970. They were treated with supportive measures, such as oral anticoagulant therapy after established thromboses, and transfusions. Results. The median age of the patients at the time of diagnosis was 42 years (range, 16 to 75), and the median survival after diagnosis was 10 years, with 22 patients (28 percent) surviving for 25 years. Sixty patients have died; 28 of the 48 patients for whom the cause of death is known died from either venous thrombosis or hemorrhage. Thirty-one patients (39 percent) had one or more episodes of venous thrombosis during their illness. Of the 35 patients who survived for 10 years or more, 12 had a spontaneous clinical recovery, No PNH-affected cells were found among the erythrocytes or neutrophils of the patients in prolonged remission, but a few PNH-affected lymphocytes were detectable in three of the four patients tested. Leukemia did not develop in any of the patients. Conclusions. PNH is a chronic disorder that curtails life, A spontaneous long-term remission can occur, which must be taken into account when considering potentially dangerous treatments, such as bone marrow transplantation. Platelet transfusions should be given, as appropriate, and long-term anticoagulation therapy should be considered for all patients.	ROYAL POSTGRAD MED SCH,DEPT HAEMATOL,LONDON W12 0HS,ENGLAND; HAMMERSMITH HOSP,LONDON,ENGLAND; MEM SLOAN KETTERING CANC CTR,DEPT HUMAN GENET,NEW YORK,NY 10021	Imperial College London; Imperial College London; Memorial Sloan Kettering Cancer Center	HILLMEN, P (corresponding author), GEN INFIRM,INST PATHOL,HAEMATOL MALIGNANCY DIAGNOST SERV,GREAT GEORGE ST,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARMITAGE JO, 1994, NEW ENGL J MED, V330, P827, DOI 10.1056/NEJM199403243301206; ARMSTRONG C, 1992, J BIOL CHEM, V267, P25347; BESSLER M, 1994, EMBO J, V13, P110, DOI 10.1002/j.1460-2075.1994.tb06240.x; BESSLER M, 1994, LANCET, V343, P951, DOI 10.1016/S0140-6736(94)90068-X; CHARACHE S, 1969, BLOOD-J HEMATOL, V33, P877, DOI 10.1182/blood.V33.6.877.877; CROSBY WH, 1951, BLOOD, V6, P270, DOI 10.1182/blood.V6.3.270.270; CROSBY WH, 1953, BLOOD, V8, P769, DOI 10.1182/blood.V8.9.769.769; Dacie J, 1980, Sangre (Barc), V25, P890; DACIE J V, 1972, Series Haematologica, V5, P3; Dacie J V, 1944, Arch Dis Child, V19, P155; DACIE JV, 1961, BRIT J HAEMATOL, V7, P442, DOI 10.1111/j.1365-2141.1961.tb00354.x; DACIE JV, 1963, P ROY SOC MED, V56, P587, DOI 10.1177/003591576305600723; DACIE JV, 1954, HAEMOLYTIC ANAEMIA, P412; DEVINE DV, 1987, J CLIN INVEST, V79, P314, DOI 10.1172/JCI112802; FERGUSON MAJ, 1992, BIOCHEM SOC T, V20, P243, DOI 10.1042/bst0200243; HILLMEN P, 1993, BLOOD, V81, P193; HILLMEN P, 1993, P NATL ACAD SCI USA, V90, P5272, DOI 10.1073/pnas.90.11.5272; HILLMEN P, 1992, BRIT J HAEMATOL, V80, P399, DOI 10.1111/j.1365-2141.1992.tb08151.x; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; KAWAHARA K, 1992, AM J HEMATOL, V39, P283, DOI 10.1002/ajh.2830390409; KURNICK JE, 1971, P SOC EXP BIOL MED, V137, P917; LETMAN H, 1952, BLOOD, V7, P842, DOI 10.1182/blood.V7.8.842.842; LONGO L, 1994, BRIT J HAEMATOL, V87, P401, DOI 10.1111/j.1365-2141.1994.tb04930.x; LUZZATTO L, 1995, PRACTICAL HAEMATOLOG, P287; MCMULLIN MF, 1994, J INTERN MED, V235, P85, DOI 10.1111/j.1365-2796.1994.tb01037.x; MIYATA T, 1994, NEW ENGL J MED, V330, P249, DOI 10.1056/NEJM199401273300404; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; MOORE JG, 1986, EXP HEMATOL, V14, P222; ONI SB, 1970, BLOOD-J HEMATOL, V36, P145, DOI 10.1182/blood.V36.2.145.145; ROSSE WF, 1991, BLOOD, V78, P547, DOI 10.1182/blood.V78.3.547.bloodjournal783547; ROSSE WF, 1990, BLOOD, V75, P1595; ROTOLI B, 1989, SEMIN HEMATOL, V26, P201; Rotoli B, 1989, Baillieres Clin Haematol, V2, P113, DOI 10.1016/S0950-3536(89)80010-1; ROTOLI B, 1982, BLOOD, V60, P157; STORB R, 1973, BRIT J HAEMATOL, V24, P743, DOI 10.1111/j.1365-2141.1973.tb01701.x; TAKAHASHI M, 1993, J EXP MED, V177, P517, DOI 10.1084/jem.177.2.517; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; TICHELLI A, 1988, BRIT J HAEMATOL, V69, P413, DOI 10.1111/j.1365-2141.1988.tb02382.x; VANKAMP H, 1994, BRIT J HAEMATOL, V87, P399, DOI 10.1111/j.1365-2141.1994.tb04929.x; YAMASHINA M, 1990, NEW ENGL J MED, V323, P1184, DOI 10.1056/NEJM199010253231707	40	601	630	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	1995	333	19					1253	1258		10.1056/NEJM199511093331904	http://dx.doi.org/10.1056/NEJM199511093331904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC715	7566002				2022-12-28	WOS:A1995TC71500004
J	NEWMAN, LS				NEWMAN, LS			CURRENT CONCEPTS - OCCUPATIONAL ILLNESS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BERYLLIUM DISEASE; ENVIRONMENTAL MEDICINE; HEALTH; EXPOSURE; HISTORY; INJURY; QUESTIONNAIRE; RECOGNITION; VALIDATION; VALIDITY		NATL JEWISH CTR IMMUNOL & RESP MED,DIV PULM,DENVER,CO 80206; UNIV COLORADO,SCH MED,DEPT MED,DENVER,CO; UNIV COLORADO,SCH MED,DEPT PREVENT MED & BIOMETR,DENVER,CO	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	NEWMAN, LS (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DIV ENVIRONM & OCCUPAT MED,RM D-104,1400 JACKSON ST,DENVER,CO 80206, USA.				NHLBI NIH HHS [HL27353] Funding Source: Medline; NIEHS NIH HHS [ES06538] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL027353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES006538, R01ES006538] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALSTON PG, 1991, DATABASE, V14, P34; BARNHART S, 1987, WESTERN J MED, V147, P37; BAXTER RH, 1990, ENVIRON HEALTH PERSP, V86, P261, DOI 10.2307/3430962; BOND GG, 1988, AM J EPIDEMIOL, V128, P343, DOI 10.1093/oxfordjournals.aje.a114974; BOURBONNAIS R, 1988, BRIT J IND MED, V45, P29; BRESNITZ EA, 1985, ANN INTERN MED, V103, P967, DOI 10.7326/0003-4819-103-6-967; BRESNITZ EA, 1986, ANN INTERN MED, V104, P290; BROOKS DR, 1993, AM J IND MED, V24, P313, DOI 10.1002/ajim.4700240308; CASTORINA JS, 1990, ANN INTERN MED, V113, P983, DOI 10.7326/0003-4819-113-12-983; CORNES P, 1992, J ROY SOC MED, V85, P329; CULLEN MR, 1990, NEW ENGL J MED, V322, P594, DOI 10.1056/NEJM199003013220905; CULLEN MR, 1990, NEW ENGL J MED, V322, P675, DOI 10.1056/NEJM199003083221007; DEREBERY VJ, 1983, J OCCUP ENVIRON MED, V25, P829; FAHS MC, 1989, AM J IND MED, V16, P437, DOI 10.1002/ajim.4700160409; FLEMING LE, 1991, J OCCUP ENVIRON MED, V33, P818, DOI 10.1097/00043764-199107000-00018; FRANK AL, 1992, ATSDR MONOGRAPH, V26; GENNART JP, 1991, SCAND J WORK ENV HEA, V17, P386, DOI 10.5271/sjweh.1689; Hathaway G, 1991, CHEM HAZARDS WORKPLA; HIMMELSTEIN JS, 1985, NEW ENGL J MED, V312, P687, DOI 10.1056/NEJM198503143121104; HIRVONEN A, 1995, J OCCUP ENVIRON MED, V37, P37, DOI 10.1097/00043764-199501000-00006; HOFFMAN RE, 1993, AM J PUBLIC HEALTH, V83, P89, DOI 10.2105/AJPH.83.1.89; HU H, 1991, AM J IND MED, V20, P723, DOI 10.1002/ajim.4700200603; JOFFE M, 1992, AM J EPIDEMIOL, V135, P564, DOI 10.1093/oxfordjournals.aje.a116323; KOSNETT MJ, 1994, JAMA-J AM MED ASSOC, V271, P197, DOI 10.1001/jama.271.3.197; KREISS K, 1993, J OCCUP ENVIRON MED, V35, P267; LANDRIGAN PJ, 1991, JAMA-J AM MED ASSOC, V266, P676, DOI 10.1001/jama.266.5.676; Levy B.S., 1988, OCCUPATIONAL HLTH RE; LEVY BS, 1985, AM J PUBLIC HEALTH, V75, P79, DOI 10.2105/AJPH.75.1.79; MENZIES D, 1995, NEW ENGL J MED, V332, P92, DOI 10.1056/NEJM199501123320206; MROZ MM, 1991, J ALLERGY CLIN IMMUN, V88, P54, DOI 10.1016/0091-6749(91)90300-D; NEUMARK D, 1991, J OCCUP ENVIRON MED, V33, P971; NEWMAN LS, 1993, SCIENCE, V262, P197, DOI 10.1126/science.8105535; OSTERLOH J, 1994, WESTERN J MED, V161, P187; PAGGIARO PL, 1994, EUR RESPIR J, V7, P761, DOI 10.1183/09031936.94.07040761; POLLACK ES, 1987, COUNTING INJURIES IL; REMPEL DM, 1992, JAMA-J AM MED ASSOC, V267, P838, DOI 10.1001/jama.267.6.838; RICHELDI L, 1993, SCIENCE, V262, P242, DOI 10.1126/science.8105536; ROSENSTOCK L, 1991, NEW ENGL J MED, V325, P924, DOI 10.1056/NEJM199109263251305; ROSENSTOCK L, 1984, J OCCUP ENVIRON MED, V26, P50, DOI 10.1097/00043764-198401000-00012; RUTSTEIN DD, 1983, AM J PUBLIC HEALTH, V73, P1054, DOI 10.2105/AJPH.73.9.1054; SCHULTE PA, 1991, AM J IND MED, V20, P435, DOI 10.1002/ajim.4700200402; SCHWARTZ DA, 1991, AM J MED, V90, P315, DOI 10.1016/0002-9343(91)90571-E; SULLIVAN JB, 1992, HAZARDOUS MATERIALS; VANDAMME K, 1995, J OCCUP ENVIRON MED, V37, P91, DOI 10.1097/00043764-199501000-00013; WINDAU J, 1991, J OCCUP ENVIRON MED, V33, P1060; 1991, JAMA-J AM MED ASSOC, V266, P1827; 1990, ANN INTERN MED, V113, P974; 1992, MULTIPLE CHEM SENSIT; 1984, TOXICITY TESTING STR; 1992, BIOL MARKERS IMMUNOT; 1992, ACCIDENT FACTS; 1994, J OCCUP MED, V36, P779; 1986, DEPT LABOR B; 1993, GUIDES EVALUATION PE	54	62	65	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 26	1995	333	17					1128	1134		10.1056/NEJM199510263331707	http://dx.doi.org/10.1056/NEJM199510263331707			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA372	7565952				2022-12-28	WOS:A1995TA37200007
J	RITCHIE, K; KILDEA, D				RITCHIE, K; KILDEA, D			IS SENILE DEMENTIA AGE-RELATED OR AGING-RELATED - EVIDENCE FROM METAANALYSIS OF DEMENTIA PREVALENCE IN THE OLDEST-OLD	LANCET			English	Article								The observation of an exponential increase in senile dementia prevalence with age has led to the conclusion that this disease may be inevitable in those who live long enough. The alternative view is that at very high ages the prevalence rate levels off. Studies conducted to date have not included sufficient numbers of very old people to resolve this difference of opinion. The question is important both to our understanding of the biological mechanisms involved and for public health planning. We have carried out a meta-analysis of nine epidemiological studies of senile dementia that used DSM III diagnostic criteria and that included samples of elderly people over age 80. The resulting curve was best described as a flattened S curve that fitted a modified logistic function rather than an exponential pattern. The rate of increase in senile dementia prevalence was found to fall in the age range 80-84, and at around the age of 95 prevalence was seen to level off to about 40%. It seems that senile dementia is better conceptualised as an ''age-related'' tie, occurring within a specific age range) rather than as an ''ageing-related'' disorder (that is, caused by the ageing process itself). Very elderly survivors may be at diminishing risk of dementia and this has implications for public health policy.	ROYAL MELBOURNE INST TECHNOL,DEPT STAT & OPERAT RES,MELBOURNE,VIC 3001,AUSTRALIA	Royal Melbourne Institute of Technology (RMIT)	RITCHIE, K (corresponding author), CTR REG LUTTE CANC VAL AURELLE,INSERM,EQUIPE VIEILLISSEMENT COGNIT,PARC EUROMED,F-34298 MONTPELLIER 5,FRANCE.		Ritchie, Karen/G-3571-2013	Ritchie, Karen/0000-0002-0688-8982				BRETELER MMB, 1992, NEUROEPIDEMIOLOGY S1, V111, P23; COPELAND JRM, 1987, BRIT J PSYCHIAT, V150, P815, DOI 10.1192/bjp.150.6.815; DARTIGUES JF, 1990, GROUPE TRAVAIL PAQUI; HEEREN TJ, 1988, P INT S ALZHEIMERS D; HUPPERT FA, 1994, DEMENTIA NORMAL AGEI; JORM AF, 1987, ACTA PSYCHIAT SCAND, V76, P465, DOI 10.1111/j.1600-0447.1987.tb02906.x; JORM AF, 1990, EPIDEMIOLOGY ALZHEIM; LIVINGSTON G, 1990, PSYCHOL MED, V20, P137, DOI 10.1017/S0033291700013313; MINAMI Y, 1993, J EPIDEMIOL, V3, P83; OCONNOR DW, 1989, ACTA PSYCHIAT SCAND, V79, P190, DOI 10.1111/j.1600-0447.1989.tb08587.x; PAYNE CD, 1987, GENERALISED LINEAR I; PRESTON GAN, 1986, J GERONTOL, V41, P261, DOI 10.1093/geronj/41.2.261; RITCHIE K, 1992, INT J EPIDEMIOL, V21, P763, DOI 10.1093/ije/21.4.763; RITCHIE K, 1992, J CLIN EPIDEMIOL, V45, P1391, DOI 10.1016/0895-4356(92)90201-W; RITCHIE K, 1993, INT J GERIATR PSYCH, V8, P969, DOI 10.1002/gps.930081203; RITCHIE K, 1944, MED SCI, V10, P680; SELKOE DJ, 1992, SCI AM, V9, P97; SKOOG I, 1993, NEW ENGL J MED, V328, P153, DOI 10.1056/NEJM199301213280301; STORANDT M, 1994, JUN INT WORKSH BORD; Tukey J. W., 1977, EXPLORATORY DATA ANA; 1994, CAN MED ASSOC J, V150, P899; [No title captured]; 1980, DIAGNOSTIC STATISTIC	23	264	269	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					931	934		10.1016/S0140-6736(95)91556-7	http://dx.doi.org/10.1016/S0140-6736(95)91556-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RY808	7564727				2022-12-28	WOS:A1995RY80800008
J	ACHARYA, U; JACOBS, R; PETERS, JM; WATSON, N; FARQUHAR, MG; MALHOTRA, V				ACHARYA, U; JACOBS, R; PETERS, JM; WATSON, N; FARQUHAR, MG; MALHOTRA, V			THE FORMATION OF GOLGI STACKS FROM VESICULATED GOLGI MEMBRANES REQUIRES 2 DISTINCT FUSION EVENTS	CELL			English	Article							GTP-BINDING PROTEINS; VESICLE FUSION; STOMATITIS-VIRUS; TRANSPORT; PURIFICATION; ENDOCYTOSIS; INVITRO; FAMILY; YEAST; NSF	We have reconstituted the fusion and assembly of vesiculated Golgi membranes (VGMs) into functionally active stacks of cisternae. A kinetic analysis of this assembly process revealed that highly dispersed VGMs of 60-90 nm diameter first fuse to form larger vesicles of 200-300 nm diameter that are clustered together. These vesicles then fuse to form tubular elements and short cisternae, which finally assemble into stacks of cisternae. We now provide evidence that the sequential stack formation from VGMs reflects two distinct fusion processes: the first event is N-ethylmaleimide (NEM)-sensitive factor (NSF) dependent, and the second fusion event requires an NSF-like NEM-sensitive ATPase called p97. Interestingly, while the earliest steps in stack formation share some similarities with events catalyzing fusion of transport vesicles to its target membrane, neither GTP IS nor Rab-GDI, inhibitors of vesicular protein traffic, inhibit stack formation.	UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093; SALK INST BIOL STUDIES,MOLEC & NEUROBIOL LABS,LA JOLLA,CA 92093; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	University of California System; University of California San Diego; Salk Institute; Harvard University; Harvard Medical School	ACHARYA, U (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.		Malhotra, Vivek/O-9811-2014	Malhotra, Vivek/0000-0001-6198-7943	NCI NIH HHS [CA58689] Funding Source: Medline; NIGMS NIH HHS [GM46224] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHARYA U, 1995, J CELL BIOL, V129, P577, DOI 10.1083/jcb.129.3.577; BALCH WE, 1986, J BIOL CHEM, V261, P4681; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DIRACSVEJSTRUP AB, 1994, J BIOL CHEM, V269, P15427; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HEYMAN JA, 1994, J CELL BIOL, V127, P1259, DOI 10.1083/jcb.127.5.1259; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAFAY F, 1974, J VIROL, V14, P1220, DOI 10.1128/JVI.14.5.1220-1228.1974; LATTERICH M, 1994, CELL, V78, P87, DOI 10.1016/0092-8674(94)90575-4; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SPONG AP, 1993, J CELL BIOL, V123, P535, DOI 10.1083/jcb.123.3.535; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; VEIT B, 1993, J CELL BIOL, V122, P1197, DOI 10.1083/jcb.122.6.1197; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39	31	178	179	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					895	904		10.1016/0092-8674(95)90269-4	http://dx.doi.org/10.1016/0092-8674(95)90269-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553850	Bronze			2022-12-28	WOS:A1995RW69300006
J	GOGA, A; MCLAUGHLIN, J; AFAR, DEH; SAFFRAN, DC; WITTE, ON				GOGA, A; MCLAUGHLIN, J; AFAR, DEH; SAFFRAN, DC; WITTE, ON			ALTERNATIVE SIGNALS TO RAS FOR HEMATOPOIETIC TRANSFORMATION BY THE BCR-ABL ONCOGENE	CELL			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; PHILADELPHIA-CHROMOSOME; BONE-MARROW; SH2 DOMAIN; CELL LINE; C-ABL; PROTEIN; MICE; BCR/ABL	Biological function of the BCR-ABL oncogene is dependent on its activated tyrosine kinase. Mutations that Inactivate the SRC homology 2 (SH2) domain, the GRB2-binding site in BCR, or the major autophosphorylation site of the kinase domain selectively disrupt downstream signaling but not tyrosine kinase activity. Despite a loss of fibroblast transformation activity, all three mutants retain the ability to render hematopoietic cell lines growth factor independent and transform primary bone marrow cells in vitro. In vivo tests of malignant potential reveal a most critical role for signals dependent on the BCR-ABL SH2 domain. The efficiency of both fibroblast and hematopoietic transformation by BCR-ABL is strongly affected by increased dosage of the SHC adapter protein, which can connect tyrosine kinase signals to RAS. The BCR-ABL oncogene activates multiple alternative pathways to RAS for hematopoietic transformation.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	GOGA, A (corresponding author), UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90095 USA.				NATIONAL CANCER INSTITUTE [R35CA053867] Funding Source: NIH RePORTER; NCI NIH HHS [CA-53867] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; AFAR DEH, 1995, IN PRESS P NATL ACAD; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DICK JE, 1991, IMMUNOL REV, V124, P25, DOI 10.1111/j.1600-065X.1991.tb00614.x; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; KELLIHER M, 1991, MOL CELL BIOL, V11, P4710, DOI 10.1128/MCB.11.9.4710; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MANDANAS RA, 1993, BLOOD, V82, P1838; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NICHOLS GL, 1994, BLOOD, V84, P2912; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RENNICK D, 1987, BLOOD, V69, P682; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SALCINI AE, 1994, ONCOGENE, V9, P2827; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TENHOEVE J, 1994, BLOOD, V84, P1731; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; WHITLOCK CA, 1981, J VIROL, V40, P577, DOI 10.1128/JVI.40.2.577-584.1981; YOUNG JC, 1991, MOL CELL BIOL, V11, P854, DOI 10.1128/MCB.11.2.854	45	248	251	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 22	1995	82	6					981	988		10.1016/0092-8674(95)90277-5	http://dx.doi.org/10.1016/0092-8674(95)90277-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553858	Bronze			2022-12-28	WOS:A1995RW69300014
J	SLATER, S; WOLD, S; LU, M; BOYE, E; SKARSTAD, K; KLECKNER, N				SLATER, S; WOLD, S; LU, M; BOYE, E; SKARSTAD, K; KLECKNER, N			ESCHERICHIA-COLI SEQA PROTEIN BINDS ORIC IN 2 DIFFERENT METHYL-MODULATED REACTIONS APPROPRIATE TO ITS ROLES IN DNA-REPLICATION INITIATION AND ORIGIN SEQUESTRATION	CELL			English	Article							ESCHERICHIA-COLI; CHROMOSOME-REPLICATION; FIS PROTEIN; MEMBRANE; PREVENTS; DOMAINS; HYBRID; SITES; IHF; HU	The seqA gene negatively modulates replication initiation at the E. coli origin, oriC. seqA is also essential for sequestration, which acts at oriC and the dnaA promoter to ensure that replication initiation occurs exactly once per chromosome per cell cycle. Initiation is promoted by full methylation of GATC sites clustered in oriC; sequestration is specific to the hemimethylated forms generated by replication, SeqA protein purification and DNA binding are described. SeqA interacts with fully methylated oriC strongly and specifically, This reaction requires multiple molecules of SeqA and determinants throughout oriC, including segments involved in open complex formation. SeqA interacts more strongly with hemimethylated DNA; in this case, oriC and non-oriC sequences are bound similarly. Also, binding of hemimethylated oriC by membrane fractions is due to SeqA. Direct interaction of SeqA protein with the replication origin is likely to be involved in both replication initiation and sequestration.	INST CANC RES,DEPT BIOPHYS,N-0310 MONTEBELLO,NORWAY		SLATER, S (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025326] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM25326] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachmann B.J., 1987, ESCHERICHIA COLI SAL, P1190; BAKER TA, 1902, ANNU REV GENET, V26, P447; BONNEFOY E, 1992, EMBO J, V11, P4489, DOI 10.1002/j.1460-2075.1992.tb05550.x; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRENDLER T, 1995, IN PRESS EMBO J; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; CHAKRABORTI A, 1992, J BACTERIOL, V174, P7202, DOI 10.1128/jb.174.22.7202-7206.1992; FILUTOWICZ M, 1990, New Biologist, V2, P818; FILUTOWICZ M, 1992, J BACTERIOL, V174, P398, DOI 10.1128/jb.174.2.398-407.1992; GILLE H, 1991, NUCLEIC ACIDS RES, V19, P4167, DOI 10.1093/nar/19.15.4167; GILLE H, 1991, EMBO J, V10, P1579, DOI 10.1002/j.1460-2075.1991.tb07678.x; HANSEN FG, 1991, RES MICROBIOL, V142, P161, DOI 10.1016/0923-2508(91)90025-6; HERRICK J, 1994, EMBO J, V13, P4695, DOI 10.1002/j.1460-2075.1994.tb06793.x; HORIUCHI K, 1972, P NATL ACAD SCI USA, V69, P3220, DOI 10.1073/pnas.69.11.3220; HWANG DS, 1992, J BIOL CHEM, V267, P23083; ISHIDATE K, 1986, J BIOL CHEM, V261, P428; KOPPES L, 1986, CELL, V44, P117, DOI 10.1016/0092-8674(86)90490-3; KUSANO T, 1984, J BACTERIOL, V158, P313, DOI 10.1128/JB.158.1.313-316.1984; LANDOULSI A, 1990, CELL, V63, P1053, DOI 10.1016/0092-8674(90)90508-C; LOBNEROLESEN A, 1994, EMBO J, V13, P1856; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; MESSER W, 1985, EMBO J, V4, P1327, DOI 10.1002/j.1460-2075.1985.tb03780.x; MESSER W, 1995, IN PRESS ESCHERICHIA; OGDEN GB, 1988, CELL, V54, P127, DOI 10.1016/0092-8674(88)90186-9; POLACZEK P, 1990, New Biologist, V2, P265; RUSSELL DW, 1987, CELL, V50, P1071, DOI 10.1016/0092-8674(87)90173-5; Sambrook J, 1989, MOL CLONING LABORATO; SKARSTAD K, 1986, EMBO J, V5, P1711, DOI 10.1002/j.1460-2075.1986.tb04415.x; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THEISEN PW, 1993, MOL MICROBIOL, V10, P575, DOI 10.1111/j.1365-2958.1993.tb00929.x; VONFREIESLEBEN U, 1994, MOL MICROBIOL, V14, P763; YUNG BYM, 1989, J BIOL CHEM, V264, P6146	35	238	241	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					927	936		10.1016/0092-8674(95)90272-4	http://dx.doi.org/10.1016/0092-8674(95)90272-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553853	Bronze			2022-12-28	WOS:A1995RW69300009
J	PATEL, P; MENDALL, MA; CARRINGTON, D; STRACHAN, DP; LEATHAM, E; MOLINEAUX, N; LEVY, J; BLAKESTON, C; SEYMOUR, CA; CAMM, AJ; NORTHFIELD, TC				PATEL, P; MENDALL, MA; CARRINGTON, D; STRACHAN, DP; LEATHAM, E; MOLINEAUX, N; LEVY, J; BLAKESTON, C; SEYMOUR, CA; CAMM, AJ; NORTHFIELD, TC			ASSOCIATION OF HELICOBACTER-PYLORI AND CHLAMYDIA-PNEUMONIAE INFECTIONS WITH CORONARY HEART-DISEASE AND CARDIOVASCULAR RISK-FACTORS	BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; CELL COUNT; FIBRINOGEN; PLAQUES; HEALTH; LIFE	Objective-To investigate the relation between seropositivity to chronic infections with Helicobacter pylori and Chlamydia pneumoniae and both coronary heart disease and cardiovascular risk factors. Design-Cross sectional study of a population based random sample of men. Coronary heart disease was assessed by electrocardiography, Rose angina questionnaire, and a history of myocardial infarction; serum antibody levels to H pylori and C pneumoniae were measured, risk factor levels determined, and a questionnaire administered. Setting-General practices in Merton, Sutton, and Wandsworth, south London. Subjects-388 white south London men aged 50-69. Main outcome measures-Evidence of coronary risk factors and infection with H pylori or C pneumoniae. Results-47 men (12.1%) had electrocardiographic evidence of ischaemia or infarction. 36 (76.6%) and 18 (38.3%) were seropositive for H pylori and C pneumoniae, respectively, compared with 155 (45.5%) and 62 (18.2%) men with normal electrocardiograms. Odds ratios for abnormal electrocardiograms were 3.82 (95% confidence interval 1.60 to 9.10) and 3.06 (1.33 to 7.01) in men seropositive for H pylori and C pneumoniae, respectively, after adjustment for a range of socioeconomic indicators and risk factors for coronary heart disease. Cardiovascular risk factors that were independently associated with seropositivity to H pylori included fibrinogen concentration and total leucocyte count. Seropositivity to C pneumoniae was independently associated with raised fibrinogen and malondialdehyde concentrations. Conclusions-Both H pylori and C pneumoniae infections are associated with coronary heart disease. These relations are not explained by a wide range of confounding factors. Possible mechanisms include an increase in risk factor levels due to a low grade chronic inflammatory response.	UNIV LONDON ST GEORGES HOSP,SCH MED,DIV BIOCHEM MED,LONDON SW17 0RE,ENGLAND	St Georges University London								BAKER RJ, 1978, GLIM SYSTEM; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; CRABTREE JE, 1991, GUT, V32, P1473, DOI 10.1136/gut.32.12.1473; DAROUGAR S, 1983, BRIT MED BULL, V39, P117, DOI 10.1093/oxfordjournals.bmb.a071801; ELFORD J, 1991, INT J EPIDEMIOL, V20, P833, DOI 10.1093/ije/20.4.833; GLYNN JR, 1994, LANCET, V344, P146, DOI 10.1016/S0140-6736(94)92754-5; HENDRIKS T, 1988, CLIN CHIM ACTA, V174, P263, DOI 10.1016/0009-8981(88)90052-6; KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841; KWEIDER M, 1993, SCOT MED J, V38, P73, DOI 10.1177/003693309303800304; LEE AJ, 1990, J CLIN EPIDEMIOL, V43, P913, DOI 10.1016/0895-4356(90)90075-Z; LINDBERG G, 1991, BRIT MED J, V302, P143, DOI 10.1136/bmj.302.6769.143; MATTILA KJ, 1989, BRIT MED J, V298, P779, DOI 10.1136/bmj.298.6676.779; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MENDALL MA, 1994, BRIT HEART J, V71, P437; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; MENDALL MA, 1995, J INFECTION, V30, P121, DOI 10.1016/S0163-4453(95)80006-9; MENDALL MA, 1992, EUR J GASTROEN HEPAT, V4, P713; MORRISSEY JH, 1993, BLOOD, V81, P734; PATEL P, 1994, LANCET, V343, P1634, DOI 10.1016/S0140-6736(94)93084-8; PUOLAKKAINEN M, 1993, J CLIN MICROBIOL, V31, P2212, DOI 10.1128/JCM.31.8.2212-2214.1993; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; ROSE GA, 1982, WHO MONOGR SER, V56, P123; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; SHAPER AG, 1984, BRIT HEART J, V51, P595, DOI 10.1136/hrt.51.6.595; THOM DH, 1992, JAMA-J AM MED ASSOC, V268, P68, DOI 10.1001/jama.268.1.68; TIPPING PG, 1989, ATHEROSCLEROSIS, V79, P237, DOI 10.1016/0021-9150(89)90129-9; WANG SP, 1994, J INFECT DIS, V130, P388; WILLIAMS D, 1989, INFECT IMMUN, V58, P1351; XU QB, 1993, LANCET, V341, P255, DOI 10.1016/0140-6736(93)92613-X; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; 1985, SAS USERS GUIDE STAT	32	514	530	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	1995	311	7007					711	714		10.1136/bmj.311.7007.711	http://dx.doi.org/10.1136/bmj.311.7007.711			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV874	7549683	Green Published			2022-12-28	WOS:A1995RV87400017
J	EVANS, EN; MAJER, RV				EVANS, EN; MAJER, RV			LESSON OF THE WEEK - ACQUIRED HEMOPHILIA - AN IMPORTANT BUT OFTEN UNRECOGNIZED CAUSE OF BLEEDING IN ELDERLY PEOPLE	BRITISH MEDICAL JOURNAL			English	Article											EVANS, EN (corresponding author), PRINCE PHILIP HOSP,LLANELLI SA14 8QF,DYFED,WALES.							GREEN D, 1981, THROMB HAEMOSTASIS, V45, P200; MORRISON AE, 1991, AM J MED S5A, V91, P235; 1981, LANCET, V1, P255	3	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	1995	311	7006					679	679		10.1136/bmj.311.7006.679	http://dx.doi.org/10.1136/bmj.311.7006.679			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU753	7549641	Green Published			2022-12-28	WOS:A1995RU75300032
J	FENG, JL; FUNK, WD; WANG, SS; WEINRICH, SL; AVILION, AA; CHIU, CP; ADAMS, RR; CHANG, E; ALLSOPP, RC; YU, JH; LE, SY; WEST, MD; HARLEY, CB; ANDREWS, WH; GREIDER, CW; VILLEPONTEAU, B				FENG, JL; FUNK, WD; WANG, SS; WEINRICH, SL; AVILION, AA; CHIU, CP; ADAMS, RR; CHANG, E; ALLSOPP, RC; YU, JH; LE, SY; WEST, MD; HARLEY, CB; ANDREWS, WH; GREIDER, CW; VILLEPONTEAU, B			THE RNA COMPONENT OF HUMAN TELOMERASE	SCIENCE			English	Article							U3 SNRNA GENES; HUMAN FIBROBLASTS; TETRAHYMENA; REPEATS; DNA; SENESCENCE; REDUCTION; CELLS	Eukaryotic chromosomes are capped with repetitive telomere sequences that protect the ends from damage and rearrangements. Telomere repeats are synthesized by telomerase, a ribonucleic acid (RNA)-protein complex. Here, the cloning of the RNA component of human telomerase, termed hTR, is described. The template region of hTR encompasses 11 nucleotides (5'-CUAACCCUAAC) complementary to the human telomere sequence (TTAGGG)(n). Germline tissues and tumor cell lines expressed more hTR than normal somatic cells and tissues, which have no detectable telomerase activity. Human cell lines that expressed hTR mutated in the template region generated the predicted mutant telomerase activity. HeLa cells transfected with an antisense hTR lost telomeric DNA and began to die after 23 to 26 doublings. Thus, human telomerase is a critical enzyme for the long-term proliferation of immortal tumor cells.	GERON CORP,MENLO PK,CA 94025; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Geron Corporation; Cold Spring Harbor Laboratory				West, Michael/0000-0002-4842-5468	NIA NIH HHS [AG09383] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG009383, R01AG009383] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMSON DJA, 1992, CANCER GENET CYTOGEN, V61, P204, DOI 10.1016/0165-4608(92)90088-P; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; AUTEXIER C, 1994, GENE DEV, V8, P563, DOI 10.1101/gad.8.5.563; AVILION AA, 1992, DEV GENET, V13, P80, DOI 10.1002/dvg.1020130113; AVILION AA, 1995, THESIS STATE U NEW Y; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; BROCCOLI D, IN PRESS P NATL ACAD; CHADENEAU C, 1995, ONCOGENE, V11, P841; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; FENG J, UNPUB; FUNK W, UNPUB; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hernandez N, 1992, TRANSCRIPTIONAL REGU, P281; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; HOLZMANN K, 1993, GENE CHROMOSOME CANC, V6, P178, DOI 10.1002/gcc.2870060308; IRVING J, 1992, EXP CELL RES, V202, P161, DOI 10.1016/0014-4827(92)90415-5; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KISS T, 1991, CELL, V65, P517, DOI 10.1016/0092-8674(91)90469-F; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; LIN JH, 1994, GENE, V147, P287, DOI 10.1016/0378-1119(94)90083-3; LINDSEY J, 1991, MUTAT RES, V256, P45, DOI 10.1016/0921-8734(91)90032-7; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; MARSHALLSAY C, 1992, PLANT MOL BIOL, V19, P973, DOI 10.1007/BF00040529; McClintock B, 1939, P NATL ACAD SCI USA, V25, P405, DOI 10.1073/pnas.25.8.405; MCEACHERN MJ, IN PRESS NATURE; MILLER RA, 1991, CANCER, V68, P2496, DOI 10.1002/1097-0142(19911201)68:11+<2496::AID-CNCR2820681503>3.0.CO;2-B; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Muller H.J., 1938, COLLECTING NET, V13, P181; NILSSON P, 1994, ONCOGENE, V9, P3043; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PEREZ HD, 1994, J BIOL CHEM, V269, P22485; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ HS, 1993, CANCER GENET CYTOGEN, V71, P132, DOI 10.1016/0165-4608(93)90018-H; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; SMITH JK, 1992, AM J OBSTET GYNECOL, V167, P1883, DOI 10.1016/0002-9378(92)91791-8; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	49	1997	2254	4	170	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1236	1241		10.1126/science.7544491	http://dx.doi.org/10.1126/science.7544491			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7544491				2022-12-28	WOS:A1995RR84200024
J	WEN, ZL; ZHONG, Z; DARNELL, JE				WEN, ZL; ZHONG, Z; DARNELL, JE			MAXIMAL ACTIVATION OF TRANSCRIPTION BY STAT1 AND STAT3 REQUIRES BOTH TYROSINE AND SERINE PHOSPHORYLATION	CELL			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; INTERFERON REGULATORY FACTOR; PROTEIN-KINASE; CYCLIC-AMP; SUBSTRATE RECOGNITION; ALPHA-INTERFERON; SWISS 3T3-CELLS; BINDING PROTEIN; GENE PROMOTER; CELL-LINE	Stat1 and Stat3 are latent transcriptional factors activated initially through phosphorylation on single tyrosine residues induced by cytokine and growth factor occupation of cell surface receptors. Here we show that phosphorylation on a single serine (residue 727) in each protein is also required for maximal transcriptional activity. Both cytokines and growth factors are capable of inducing the serine phosphorylation of Stat1 and Stat3. These experiments show that gene activation by Stat1 and Stat3, which obligatorily require tyrosine phosphorylation to become active, also depends for maximal activation on one or more of the many serine kinases.			WEN, ZL (corresponding author), ROCKEFELLER UNIV,MOLEC CELL BIOL LAB,NEW YORK,NY 10021, USA.		Yang, Chen/G-1379-2010		NIAID NIH HHS [AI32489] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032489] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BOULTON TG, 1995, IN PRESS P NATL ACAD; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUNTER T, 1985, CIBA F SYMP, V116, P188; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LUI MK, 1994, INFECT IMMUNE, V62, P2622; MARUYAMA M, 1989, NUCLEIC ACIDS RES, V17, P3292, DOI 10.1093/nar/17.8.3292; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Sambrook J, 1989, MOL CLONING LABORATO; SASSONECORSI P, 1994, EMBO J, V13, P4717, DOI 10.1002/j.1460-2075.1994.tb06797.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAI K, 1992, SCIENCE, V259, P1808; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WALAAS SI, 1989, J MOL NEUROSCI, V1, P117, DOI 10.1007/BF02918897; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YAN RQ, 1995, NUCLEIC ACIDS RES, V23, P459, DOI 10.1093/nar/23.3.459; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	60	1698	1734	0	58	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					241	250		10.1016/0092-8674(95)90311-9	http://dx.doi.org/10.1016/0092-8674(95)90311-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7543024	Bronze			2022-12-28	WOS:A1995RL76000011
J	DALE, DC				DALE, DC			WHERE NOW FOR COLONY-STIMULATING FACTORS	LANCET			English	Editorial Material							GRANULOCYTE; NEUTROPENIA				DALE, DC (corresponding author), UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195, USA.							BENSINGER WI, 1993, BLOOD, V81, P1883, DOI 10.1182/blood.V81.7.1883.1883; BIESMA DH, 1994, LANCET, V344, P367, DOI 10.1016/S0140-6736(94)91401-X; DALE DC, 1993, BLOOD, V81, P2496; DALE DC, 1995, STEM CELLS, V13, P94, DOI 10.1002/stem.5530130201; Demirer T, 1995, Curr Opin Hematol, V2, P219; ESCHBACH JW, 1994, KIDNEY INT, V45, pS70; Jones E A, 1993, JAMA, V270, P1132, DOI 10.1001/jama.270.9.1132; Kaushansky K, 1995, Curr Opin Hematol, V2, P172; KUHNS DB, 1995, J INFECT DIS, V171, P145, DOI 10.1093/infdis/171.1.145; NELSON S, 1994, CLIN INFECT DIS, V18, pS197, DOI 10.1093/clinids/18.Supplement_2.S197; STEWARD WP, 1993, LANCET, V342, P153, DOI 10.1016/0140-6736(93)91350-U; TO LB, 1994, BLOOD, V84, P2930; WELTE K, 1990, BLOOD, V75, P1056	13	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 15	1995	346	8968					135	136		10.1016/S0140-6736(95)91206-1	http://dx.doi.org/10.1016/S0140-6736(95)91206-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7541497				2022-12-28	WOS:A1995RJ03100006
J	FUNG, DC; BERG, HC				FUNG, DC; BERG, HC			POWERING THE FLAGELLAR MOTOR OF ESCHERICHIA-COLI WITH AN EXTERNAL VOLTAGE-SOURCE	NATURE			English	Article							BACTERIAL FLAGELLA; OPTICAL TWEEZERS; ROTATION; TORQUE; FORCE; STREPTOCOCCUS; LIGHT	ROTARY motors of bacterial flagella are driven by ions that move across the cytoplasmic membrane down an electrochemical gradient(1-4). For Escherichia coli, the ions are protons, and the maximum work per unit charge that they can do is the protonmotive force. To test whether motor efficiency is limited by proton leakage or mechanical nonlinearities, we measured torque as a function of protonmotive force. Filamentous cells were drawn into micropipettes and energized with an external voltage source. Torque was proportional to protonmotive force up to -150 mV, twice the span accessible by earlier techniques(5-9). This is consistent with a mechanism in which a fixed number of protons, working at unit efficiency, carry the motor through each revolution. We also found that individual torque-generating elements inactivate at low potentials or potentials of reverse sign. When normal potentials are restored, they reactivate sequentially.	UNIV HARTFORD, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE 02138, ENGLAND									ARMITAGE JP, 1985, BIOCHIM BIOPHYS ACTA, V806, P42, DOI 10.1016/0005-2728(85)90080-5; BERG HC, 1993, BIOPHYS J, V65, P2201, DOI 10.1016/S0006-3495(93)81278-5; BERG HC, 1982, SYM SOC EXP BIOL, P1; BERG HC, 1990, BIOPHYS J, V58, P919, DOI 10.1016/S0006-3495(90)82436-X; Blair D F, 1990, Semin Cell Biol, V1, P75; BLAIR DF, 1988, SCIENCE, V242, P1678, DOI 10.1126/science.2849208; BLOCK SM, 1984, NATURE, V309, P470, DOI 10.1038/309470a0; BLOCK SM, 1991, CYTOMETRY, V12, P492, DOI 10.1002/cyto.990120605; BLOCK SM, 1989, NATURE, V338, P514, DOI 10.1038/338514a0; Brown KT, 1986, ADV MICROPIPETTE TEC; CONLEY MP, 1984, J BACTERIOL, V158, P832, DOI 10.1128/JB.158.3.832-843.1984; FUNG DCY, 1994, THESIS HARVARD U CAM; ISHIHARA A, 1983, J BACTERIOL, V155, P228, DOI 10.1128/JB.155.1.228-237.1983; JONES CJ, 1991, ADV MICROB PHYSIOL, V32, P109, DOI 10.1016/S0065-2911(08)60007-7; KAMIIKE N, 1991, BIOPHYS J, V60, P1350, DOI 10.1016/S0006-3495(91)82172-5; KASHKET ER, 1985, ANNU REV MICROBIOL, V39, P219, DOI 10.1146/annurev.mi.39.100185.001251; KATSU T, 1986, BIOCHIM BIOPHYS ACTA, V860, P608, DOI 10.1016/0005-2736(86)90560-2; KHAN S, 1983, CELL, V32, P913, DOI 10.1016/0092-8674(83)90076-4; KHAN S, 1985, J MOL BIOL, V184, P645, DOI 10.1016/0022-2836(85)90310-9; KHAN S, 1990, BIOPHYS J, V57, P779, DOI 10.1016/S0006-3495(90)82598-4; MACNAB RM, 1992, ANNU REV GENET, V26, P131, DOI 10.1146/annurev.ge.26.120192.001023; MANSON MD, 1980, J MOL BIOL, V138, P541, DOI 10.1016/S0022-2836(80)80017-9; MEISTER M, 1987, CELL, V49, P643, DOI 10.1016/0092-8674(87)90540-X; MEISTER M, 1987, BIOPHYS J, V52, P413, DOI 10.1016/S0006-3495(87)83230-7; MEISTER M, 1987, THESIS CALTECH PASAD; OVCHINNIKOV YA, 1982, PROTEINS, V5, P307; RAVID S, 1984, J BACTERIOL, V158, P222, DOI 10.1128/JB.158.1.222-230.1984; SCHUSTER SC, 1994, ANNU REV BIOPH BIOM, V23, P509, DOI 10.1146/annurev.bb.23.060194.002453	28	83	83	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 29	1995	375	6534					809	812		10.1038/375809a0	http://dx.doi.org/10.1038/375809a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7541114				2022-12-28	WOS:A1995RF98900084
J	ORNITZ, DM; HERR, AB; NILSSON, M; WESTMAN, J; SVAHN, CM; WAKSMAN, G				ORNITZ, DM; HERR, AB; NILSSON, M; WESTMAN, J; SVAHN, CM; WAKSMAN, G			FGF BINDING AND FGF RECEPTOR ACTIVATION BY SYNTHETIC HEPARAN-DERIVED DISACCHARIDES AND TRISACCHARIDES	SCIENCE			English	Article							FIBROBLAST GROWTH-FACTOR; 3-DIMENSIONAL STRUCTURE; SULFATE; REFINEMENT; DOMAINS; CELLS	Fibroblast growth factors (FGFs) require a polysaccharide cofactor, heparin or heparan sulfate (HS), for receptor binding and activation. To probe the molecular mechanism by which heparin or HS (heparin/HS) activates FGF, small nonsulfated oligosaccharides found within heparin/HS were assayed for activity, These synthetic and isomerically pure compounds can activate the FGF signaling pathway. The crystal structures of complexes between FGF and these heparin/HS oligosaccharides reveal several binding sites on FGF and constrain possible mechanisms by which heparin/HS can activate the FGF receptor. These studies establish a framework for the molecular design of compounds capable of modulating FGF activity.	WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, ST LOUIS, MO 63110 USA; PHARMACIA AB, DEPT ORGAN CHEM, S-11287 STOCKHOLM, SWEDEN	Washington University (WUSTL); Pfizer; Pharmacia Corporation	ORNITZ, DM (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA.		Herr, Andrew/R-3049-2019	Herr, Andrew/0000-0002-3598-3399; Ornitz, David/0000-0003-1592-7629	NATIONAL CANCER INSTITUTE [R01CA060673] Funding Source: NIH RePORTER; NCI NIH HHS [CA60673] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIEZER D, 1994, J BIOL CHEM, V269, P114; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; BURRUS LW, 1989, J BIOL CHEM, V264, P18647; CASU B, 1989, ANN NY ACAD SCI, V556, P1; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; FOLKMAN J, 1991, ANN SURG, V214, P414, DOI 10.1097/00000658-199110000-00006; GLABE CG, 1983, ANAL BIOCHEM, V130, P287, DOI 10.1016/0003-2697(83)90590-0; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HEATH WF, 1991, BIOCHEMISTRY-US, V30, P5608, DOI 10.1021/bi00236a039; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROSSMANN MG, 1972, INT SCI REV SERIES, V13; Roussel A, 1991, SILICON GRAPHICS GEO, P86; SVAHN C, UNPUB; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; WESTMAN J, 1995, J CARBOHYD CHEM, V14, P95, DOI 10.1080/07328309508006439; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	37	269	288	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 21	1995	268	5209					432	436		10.1126/science.7536345	http://dx.doi.org/10.1126/science.7536345			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7536345				2022-12-28	WOS:A1995QU57200045
J	FIELDS, BA; GOLDBAUM, FA; YSERN, X; POLJAK, RJ; MARIUZZA, RA				FIELDS, BA; GOLDBAUM, FA; YSERN, X; POLJAK, RJ; MARIUZZA, RA			MOLECULAR-BASIS OF ANTIGEN MIMICRY BY AN ANTI-IDIOTOPE	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; IDIOTYPIC ANTIBODIES; COMPLEX; LYSOZYME; D1.3	IDIOTOPES are antigenic determinants, unique to an antibody or group of antibodies, defined by the reaction of anti-idiotopic antibodies with the antibodies bearing the idiotopes. The ensemble of idiotopes of an antibody constitutes its idiotype. Idiotypes are useful as markers to follow specific antibodies and clones of cells in immune responses and the inheritance of immunoglobulin genes. As external antigens and anti-idiotypic antibodies can competitively bind the combining site of specific antibodies, some antiidiotypic antibodies may resemble the external antigen, thus mimicking its structure. It has been proposed(1-5) that an anti-idiotypic antibody, anti-anti-X, may resemble the external antigen X and thus carry its 'internal image', but this idea is not unequivocally supported by the three-dimensional structures of anti-idiotopic antibodies(6-9), either because the structures of the external antigen(8) or of the anti-idiotopic antibody(7) were unknown, or because the anti-idiotopic antibodies showed no resemblance to the external antigens(6,9) (reviewed in ref. 10). Functional mimicry of ligands of biological receptors by anti-idiotypic antibodies has been described in several systems (reviewed in ref. 11). But how closely can antibodies mimic antigens at the molecular level? Here we present the crystal structure of an idiotope-anti-idiotope complex between the Fv fragments of the anti-lysozyme antibody D1.3 and the anti-D1.3 antibody E5.2. D1.3 contacts the antigen, lysozyme and the anti-idiotopic E5.2 through essentially the same combining-site residues, In addition, E5.2 interacts with D1.3, making contacts similar to those between lysozyme and D1.3. Thus, the anti-idiotopic antibody E5.2 mimics lysozyme in its binding interactions with D1.3. Validating these observations, E5.2, used as an immunogen, induces an anti-lysozyme response.	US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857	US Food & Drug Administration (FDA)	FIELDS, BA (corresponding author), UNIV MARYLAND,CTR ADV RES BIOTECHNOL,INST BIOTECHNOL,9600 GUDELSKY DR,ROCKVILLE,MD 20850, USA.			Goldbaum, Fernando/0000-0001-6235-3002; Fields, Barry/0000-0003-0628-1328				AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BAN N, 1994, P NATL ACAD SCI USA, V91, P1604, DOI 10.1073/pnas.91.5.1604; BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BOULOT G, 1987, J MOL BIOL, V194, P577, DOI 10.1016/0022-2836(87)90685-1; BOULOT G, 1990, J MOL BIOL, V213, P617, DOI 10.1016/S0022-2836(05)80248-7; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; EVANS SV, 1994, J MOL BIOL, V241, P691, DOI 10.1006/jmbi.1994.1544; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; GAULTON GN, 1986, ANNU REV IMMUNOL, V4, P253, DOI 10.1146/annurev.iy.04.040186.001345; GOLDBAUM FA, 1994, J MOL BIOL, V241, P739, DOI 10.1006/jmbi.1994.1549; HARPER M, 1987, MOL IMMUNOL, V2, P97; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KABAT EA, 1991, NIH913242 US DEP HLT; LEU JG, 1994, P NATL ACAD SCI USA, V91, P10690, DOI 10.1073/pnas.91.22.10690; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NISONOFF A, 1981, CLIN IMMUNOL IMMUNOP, V21, P397, DOI 10.1016/0090-1229(81)90228-2; POLJAK RJ, 1994, P NATL ACAD SCI USA, V91, P1599, DOI 10.1073/pnas.91.5.1599; ROITT IM, 1981, LANCET, V1, P1041; SACKS DL, 1983, SPRINGER SEMIN IMMUN, V6, P79, DOI 10.1007/BF01857368; Tello Diana, 1994, Journal of Molecular Recognition, V7, P57, DOI 10.1002/jmr.300070108	21	152	160	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 20	1995	374	6524					739	742		10.1038/374739a0	http://dx.doi.org/10.1038/374739a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7536303				2022-12-28	WOS:A1995QU30400055
J	JERMANN, TM; OPITZ, JG; STACKHOUSE, J; BENNER, SA				JERMANN, TM; OPITZ, JG; STACKHOUSE, J; BENNER, SA			RECONSTRUCTING THE EVOLUTIONARY HISTORY OF THE ARTIODACTYL RIBONUCLEASE SUPERFAMILY	NATURE			English	Article							AMINO-ACID-SEQUENCE; PANCREATIC RIBONUCLEASE; ESCHERICHIA-COLI; LYSOZYMES; PROTEIN; TUMOR	THE sequences of proteins from ancient organisms can be reconstructed from the sequences of their descendants by a procedure that assumes that the descendant proteins arose from the extinct ancestor by the smallest number of independent evolutionary events ('parsimony')(1,2). Tbe reconstructed sequences can then be prepared in the laboratory and studied(3,4). Thirteen ancient ribonucleases (RNases) have been reconstructed as intermediates in the evolution of the RNase protein family in artiodactyls (the mammal order that includes pig, camel, deer, sheep and ox)(5). The properties of the reconstructed proteins suggest that parsimony yields plausible ancient sequences. Going back in time, a significant change in behaviour, namely a fivefold increase in catalytic activity against double-stranded RNA, appears in the RNase reconstructed for the founding ancestor of the artiodactyl lineage, which lived about 40 million years ago(6). This corresponds to the period when ruminant digestion arose in the artiodactyls, suggests that contemporary artiodactyl digestive RNases arose from a non-digestive ancestor, and illustrates how evolutionary reconstructions can help in tbe understanding of physiological function within a protein family(7-9).			JERMANN, TM (corresponding author), ETH ZURICH,DEPT CHEM,CH-8092 ZURICH,SWITZERLAND.							ADEY NB, 1994, P NATL ACAD SCI USA, V91, P1569, DOI 10.1073/pnas.91.4.1569; ARDELT W, 1991, J BIOL CHEM, V266, P245; BARNARD EA, 1969, NATURE, V221, P340, DOI 10.1038/221340a0; BELNTEMA JJ, 1986, MOL BIOL EVOL, V3, P262; Blackburn P, 1982, ENZYMES, VXV, P317; BREUKELMAN HJ, 1993, J MOL EVOL, V37, P29; Carroll RL, 1988, VERTEBRATE PALEONTOL; CIGLIC M, 1994, THESIS ETH ZURICH; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; GRAUR D, 1993, FEBS LETT, V325, P152, DOI 10.1016/0014-5793(93)81432-Y; HILLIS DM, 1994, SCIENCE, V264, P671, DOI 10.1126/science.8171318; Ipata P L., 1968, FEBS Lett, V1, P29, DOI 10.1016/0014-5793(68)80010-9; JOLLES J, 1989, J MOL EVOL, V28, P528, DOI 10.1007/BF02602933; LANG K, 1986, EUR J BIOCHEM, V159, P275, DOI 10.1111/j.1432-1033.1986.tb09864.x; LIBONATI M, 1969, EUR J BIOCHEM, V8, P81, DOI 10.1111/j.1432-1033.1969.tb00498.x; MALCOLM BA, 1990, NATURE, V345, P86, DOI 10.1038/345086a0; MATOUSEK J, 1973, EXPERIENTIA, V29, P858, DOI 10.1007/BF01946329; MCGEEHAN GM, 1989, FEBS LETT, V247, P55, DOI 10.1016/0014-5793(89)81239-6; NAMBIAR KP, 1984, SCIENCE, V223, P1299, DOI 10.1126/science.6322300; NAMBIAR KP, 1987, EUR J BIOCHEM, V163, P67, DOI 10.1111/j.1432-1033.1987.tb10737.x; OKABE Y, 1991, J BIOCHEM-TOKYO, V109, P786, DOI 10.1093/oxfordjournals.jbchem.a123457; PAULING I, 1963, ACTA CHEM SCAND S1, V17, pS9; ROSE KD, 1982, SCIENCE, V216, P621, DOI 10.1126/science.216.4546.621; SORRENTINO S, 1980, BIOCHIM BIOPHYS ACTA, V609, P40, DOI 10.1016/0005-2787(80)90199-9; SOUCEK J, 1986, NAT IMMUN CELL GROW, V5, P250; STACKHOUSE J, 1990, FEBS LETT, V262, P104, DOI 10.1016/0014-5793(90)80164-E; Stevens CE., 1988, COMP PHYSL VERTEBRAT; STRYDOM DJ, 1985, BIOCHEMISTRY-US, V24, P5486, DOI 10.1021/bi00341a031; TRAUTWEIN K, 1991, SITE-DIRECTED MUTAGENESIS AND PROTEIN ENGINEERING, P53; WATANABE H, 1988, J BIOCHEM-TOKYO, V104, P939, DOI 10.1093/oxfordjournals.jbchem.a122587	30	184	190	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					57	59		10.1038/374057a0	http://dx.doi.org/10.1038/374057a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7532788				2022-12-28	WOS:A1995QK07900050
J	FU, MLX; HERLITZ, H; WALLUKAT, G; HILME, E; HEDNER, T; HOEBEKE, J; HJALMARSON, A				FU, MLX; HERLITZ, H; WALLUKAT, G; HILME, E; HEDNER, T; HOEBEKE, J; HJALMARSON, A			FUNCTIONAL AUTOIMMUNE EPITOPE ON ALPHA(1)-ADRENEGIC RECEPTORS IN PATIENTS WITH MALIGNANT HYPERTENSION	LANCET			English	Article							IDIOPATHIC DILATED CARDIOMYOPATHY; MOLECULAR-CLONING; CDNA; AUTOANTIBODIES; EXPRESSION	Because of the growing evidence that hypertensive disease is accompanied by immunological dysfunction, we have investigated autoimmunity in patients with malignant hypertension. Peptides corresponding to the sequences of the second extracellular loops of the human alpha(1)-adrenergic receptor and the M(2)-muscarinic receptor were used as antigens in an ELISA. Serum from 4 (12%) of 33 healthy controls, 3 (20%) of 15 patients with malignant essential hypertension, and 7 (64%) of 11 with secondary hypertension showed positive responses in the ELISA for the alpha(1)-adrenergic receptor peptide. Positive responses were significantly more common among the patients with secondary hypertension than in the other two groups (p<0.01). By contrast, no autoantibodies against the M(2)-muscarinic receptor peptide were detected in either hypertensive group. Autoantibodies against the alpha(1)-adrenergic receptor, affinity-purified from patients with positive responses, specifically recognised bands with molecular masses of 68, 40, and 37 kDa on immunoblotted membrane proteins of rat ventricles. The patients' autoantibodies caused a decrease in tritiated prazosin binding sites and an increase in heart beating frequency of neonatal cultured rat cardiomyocytes; antibodies purified from the controls had no effect. Circulating autoantibodies against the alpha(1)-adrenergic receptor are present in a subgroup of patients with malignant hypertension. These autoantibodies have pharmacological activity in vitro, which suggests that they may be involved in the pathogenesis of malignant hypertension.	GOTHENBURG UNIV,SAHLGRENS HOSP,DEPT NEPHROL,S-41345 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,SAHLGRENS HOSP,DEPT CLIN PHARMACOL,S-41345 GOTHENBURG,SWEDEN; MAX DELBRUCK CTR MOLEC MED,BERLIN,GERMANY; UNIV TOURS,ENZYMOL & CHIM PROT LAB,TOURS,FRANCE	Sahlgrenska University Hospital; University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Universite de Tours	FU, MLX (corresponding author), GOTHENBURG UNIV,SAHLGRENS HOSP,WALLENBERG LAB CARDIOVASC RES,S-41345 GOTHENBURG,SWEDEN.							BRUNO JF, 1991, BIOCHEM BIOPH RES CO, V179, P1485, DOI 10.1016/0006-291X(91)91740-4; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; FU LX, 1993, J CLIN INVEST, V91, P1964, DOI 10.1172/JCI116416; FU LX, 1991, BASIC RES CARDIOL, V86, P117, DOI 10.1007/BF02190544; FU LXM, 1994, CLIN IMMUNOL IMMUNOP, V72, P15; FU LXM, 1994, CLIN EXP IMMUNOL, V97, P146; FU LXM, 1994, RECEPTOR CHANNEL, V2, P121; GUDBRANDSSON T, 1981, LANCET, V1, P406; HILME E, 1989, J HYPERTENS, V7, P91; KRISTENSEN BO, 1978, ACTA MED SCAND, V203, P55; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; MAGNUSSON Y, 1990, J CLIN INVEST, V86, P1658, DOI 10.1172/JCI114888; MARTIN C, 1990, HYPERTENSION, V16, P107; WILSON JD, 1978, LANCET, V2, P996; 1978, WHO TECH REP SER, V628	15	92	127	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 17	1994	344	8938					1660	1663		10.1016/S0140-6736(94)90456-1	http://dx.doi.org/10.1016/S0140-6736(94)90456-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX302	7527885				2022-12-28	WOS:A1994PX30200007
J	FLEGAL, KM; TROIANO, RP; PAMUK, ER; KUCZMARSKI, RJ; CAMPBELL, SM				FLEGAL, KM; TROIANO, RP; PAMUK, ER; KUCZMARSKI, RJ; CAMPBELL, SM			THE INFLUENCE OF SMOKING CESSATION ON THE PREVALENCE OF OVERWEIGHT IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUITTING CIGARETTE-SMOKING; BODY-WEIGHT; GENDER DIFFERENCES; HIGH-SCHOOL; GAIN; POPULATION; MORTALITY; CONSUMPTION; PREVENTION; FRAMINGHAM	Background. The proportion of U.S. adults, 35 to 74 years of age who were overweight increased by 9.6 percent for men and 8.0 percent for women between 1978 and 1990. Since the prevalence of smoking declined over the same period, smoking cessation has been suggested as a factor contributing to the increasing prevalence of overweight. Methods. To estimate the influence of smoking cessation on the increase in the prevalence of overweight, we analyzed data on current and past weight and smoking status for a national sample of 5247 adults 35 years of age or older who participated in the third National Health and Nutrition Examination Survey, conducted from 1988 through 1998. The results were adjusted for age, sociodemographic characteristics, level of physical activity, alcohol consumption, and (for women) parity. Results. The weight gain over a 10-year period that was associated with the cessation of smoking (i.e., the gain among smokers who quit that was in excess of the gain among continuing smokers) was 4.4 kg for men and 5.0 kg for women. Smokers who had quit within the past 10 years were significantly more likely than respondents who had never smoked to become overweight (odds ratios, 2.4 for men and 2.0 for women). For men, about a quarter (2.3 of 9.6 percentage points) and for women, about a sixth (1.3 of 8.0 percentage points) of the increase in the prevalence of overweight could be attributed to smoking cessation within the past 10 years. Conclusions. Although its health benefits are undeniable, smoking cessation may nevertheless be associated with a small increase in the prevalence of overweight.			FLEGAL, KM (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, 6525 BELCREST RD, RM 900, HYATTSVILLE, MD 20782 USA.		Troiano, Richard/AAK-3540-2021; Flegal, Katherine M/A-4608-2013	Troiano, Richard/0000-0002-6807-989X; Flegal, Katherine/0000-0002-0838-469X				AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; BIENER L, 1992, HEALTH PSYCHOL, V11, P52; BOYLE CA, 1994, INT J OBESITY, V18, P55; CAMP DE, 1993, HEALTH PSYCHOL, V12, P24, DOI 10.1037/0278-6133.12.1.24; CASEY VA, 1991, AM J CLIN NUTR, V53, P1493, DOI 10.1093/ajcn/53.6.1493; DYER AR, 1975, J CHRON DIS, V28, P109, DOI 10.1016/0021-9681(75)90067-3; FISHER M, 1991, J ADOLESCENT HEALTH, V12, P377, DOI 10.1016/0197-0070(91)90051-M; FRENCH SA, 1994, AM J PUBLIC HEALTH, V84, P1818, DOI 10.2105/AJPH.84.11.1818; FRIEDMAN GD, 1980, CIRCULATION, V61, P716, DOI 10.1161/01.CIR.61.4.716; GARRISON RJ, 1985, ANN INTERN MED, V103, P1006, DOI 10.7326/0003-4819-103-6-1006; GORDON T, 1975, AM HEART J, V90, P322, DOI 10.1016/0002-8703(75)90320-8; GRITZ ER, 1992, HEALTH PSYCHOL, V11, P17, DOI 10.1037/h0090341; GRITZ ER, 1991, HEALTH PSYCHOL, V10, P330, DOI 10.1037/0278-6133.10.5.330; GROSS J, 1989, J CONSULT CLIN PSYCH, V57, P87, DOI 10.1037/0022-006X.57.1.87; HALL SM, 1989, J CONSULT CLIN PSYCH, V57, P81, DOI 10.1037/0022-006X.57.1.81; HALL SM, 1992, AM J PUBLIC HEALTH, V82, P799, DOI 10.2105/AJPH.82.6.799; Higgins M, 1988, ACTA MED SCAND, V723, P23; KLESGES RC, 1989, PSYCHOL BULL, V106, P204, DOI 10.1037/0033-2909.106.2.204; KLESGES RC, 1988, INT J EAT DISORDER, V7, P413, DOI 10.1002/1098-108X(198805)7:3<413::AID-EAT2260070314>3.0.CO;2-D; KLESGES RC, 1987, INT J EAT DISORDER, V6, P409, DOI 10.1002/1098-108X(198705)6:3<409::AID-EAT2260060311>3.0.CO;2-O; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; MOFFATT RJ, 1991, METABOLISM, V40, P465, DOI 10.1016/0026-0495(91)90225-L; MUST A, 1993, AM J EPIDEMIOL, V138, P56, DOI 10.1093/oxfordjournals.aje.a116777; NOPPA H, 1980, PREV MED, V9, P534, DOI 10.1016/0091-7435(80)90048-1; PERKINS KA, 1993, J CONSULT CLIN PSYCH, V61, P768, DOI 10.1037/0022-006X.61.5.768; PERKINS KA, 1992, J APPL PHYSIOL, V72, P401, DOI 10.1152/jappl.1992.72.2.401; PIRIE PL, 1991, AM J PUBLIC HEALTH, V81, P324, DOI 10.2105/AJPH.81.3.324; PIRIE PL, 1992, AM J PUBLIC HEALTH, V82, P1238, DOI 10.2105/AJPH.82.9.1238; PISUNYER FX, 1994, JAMA-J AM MED ASSOC, V272, P238; SHAH BV, 1991, SUDAAN USERS MANUAL; STAMFORD BA, 1986, AM J CLIN NUTR, V43, P486, DOI 10.1093/ajcn/43.4.486; STEVENS J, 1990, AM J EPIDEMIOL, V132, P1156, DOI 10.1093/oxfordjournals.aje.a115758; TUOMILEHTO J, 1987, BRIT MED J, V295, P623, DOI 10.1136/bmj.295.6599.623; WALDRON I, 1991, SOC SCI MED, V32, P989, DOI 10.1016/0277-9536(91)90157-8; WANNAMETHEE G, 1989, BRIT MED J, V299, P1497, DOI 10.1136/bmj.299.6714.1497; WILLIAMSON DF, 1991, NEW ENGL J MED, V324, P739, DOI 10.1056/NEJM199103143241106; 1990, DHHS CDC908416 DEP H; 1994, VITAL HLTH STATIST 1, V32; 1990, SAS PROCEDURES GUIDE; 1993, JAMA-J AM MED ASSOC, V269, P1931; 1987, VITAL HLTH STATIS 11, V238; 1993, JAMA-J AM MED ASSOC, V269, P2198	42	344	355	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 2	1995	333	18					1165	1170		10.1056/NEJM199511023331801	http://dx.doi.org/10.1056/NEJM199511023331801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TB560	7565970				2022-12-28	WOS:A1995TB56000001
J	GODDARD, AD; COVELLO, R; LUOH, SM; CLACKSON, T; ATTIE, KM; GESUNDHEIT, N; RUNDLE, AC; WELLS, JA; CARLSSON, LMS				GODDARD, AD; COVELLO, R; LUOH, SM; CLACKSON, T; ATTIE, KM; GESUNDHEIT, N; RUNDLE, AC; WELLS, JA; CARLSSON, LMS			MUTATIONS OF THE GROWTH-HORMONE RECEPTOR IN CHILDREN WITH IDIOPATHIC SHORT STATURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LARON-TYPE DWARFISM; SERUM BINDING-PROTEIN; EXTRACELLULAR DOMAIN; PURIFICATION; ASSAY	Background. Short stature in children who are not deficient in growth hormone (GH) is probably caused by a variety of defects. Some children with idiopathic short stature have low serum concentrations of GH-binding protein, which is derived from the GH receptor. The possibility that low serum concentrations of GH-binding protein might indicate partial insensitivity to GH led us to investigate possible defects in the gene for the GH receptor in children with idiopathic short stature and low serum concentrations of GH-binding protein. Methods. We studied 14 children with idiopathic short stature who were selected on the basis of normal GH secretion and low serum concentrations of GH-binding protein. Analysis of single-strand conformation polymorphisms and DNA sequencing were both used to identify mutations in the GH-receptor gene. Results. Mutations in the region of the GH-receptor gene that codes for the extracellular domain of the receptor were found in 4 of the 14 children, but in none of 24 normal subjects. One of the four children with mutations was a compound heterozygote, with one mutation that reduced the affinity of the receptor for GH and a second mutation that may affect a function other than ligand binding. The remaining three children had single mutations in one allele of the gene. One mutation introduced a premature termination codon, and two caused substitutions of single amino acids in a structurally conserved domain of the receptor. Conclusions. Some children with idiopathic short stature may have partial insensitivity to GH due to mutations in the GH-receptor gene.	GENENTECH INC,DEPT ENDOCRINE RES,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PROT ENGN,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MED AFFAIRS,S SAN FRANCISCO,CA 94080; GOTHENBURG UNIV,DEPT INTERNAL MED,ENDOCRINOL & METAB RES CTR,GOTHENBURG,SWEDEN; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; University of Gothenburg; Roche Holding; Genentech			Wells, Jim A/O-9854-2016; Carlsson, Lena/F-7570-2018	Carlsson, Lena/0000-0003-4145-6242				AGUIRRE A, 1990, HORM RES, V34, P4, DOI 10.1159/000181786; AMIT T, 1990, J CLIN ENDOCR METAB, V71, P474, DOI 10.1210/jcem-71-2-474; AMSELEM S, 1993, HUM MOL GENET, V2, P355, DOI 10.1093/hmg/2.4.355; ATTIE KM, 1995, J PEDIATR-US, V127, P244, DOI 10.1016/S0022-3476(95)70302-0; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAUMGARTNER JW, 1994, J BIOL CHEM, V269, P29094; CARLSSON LMS, 1994, J CLIN ENDOCR METAB, V78, P1325, DOI 10.1210/jc.78.6.1325; CARLSSON LMS, 1991, J CLIN ENDOCR METAB, V73, P1216, DOI 10.1210/jcem-73-6-1216; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUH G, 1990, J BIOL CHEM, V265, P3111; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HOPWOOD NJ, 1993, J PEDIATR-US, V123, P215, DOI 10.1016/S0022-3476(05)81691-9; KATZ BZ, 1989, J INFECT DIS, V160, P589, DOI 10.1093/infdis/160.4.589; LARON Z, 1989, ACTA ENDOCRINOL-COP, V121, P603, DOI 10.1530/acta.0.1210603; LARON Z, 1993, ENDOCRINOLOGIST, V3, P21; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LIPPE BM, 1993, RECENT PROG HORM RES, V48, P179; MAURAS N, 1994, METABOLISM, V43, P357, DOI 10.1016/0026-0495(94)90104-X; RAVNIKGLAVAC M, 1994, HUM MOL GENET, V3, P801, DOI 10.1093/hmg/3.5.801; ROSENBLOOM AL, 1994, ACTA PAEDIATR S, V399, P125; ROSENFELD RG, 1994, ENDOCR REV, V15, P369, DOI 10.1210/er.15.3.369; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; VIDALPUIG A, 1994, BIOTECHNIQUES, V17, P490	27	227	238	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 26	1995	333	17					1093	1098		10.1056/NEJM199510263331701	http://dx.doi.org/10.1056/NEJM199510263331701			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA372	7565946				2022-12-28	WOS:A1995TA37200001
J	SHORT, PF; BANTHIN, JS				SHORT, PF; BANTHIN, JS			NEW ESTIMATES OF THE UNDERINSURED YOUNGER THAN 65 YEARS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								We estimate that at least 29 million Americans with private insurance are underinsured. That figure identifies the underinsured younger than 65 years by the risk of large out-of-pocket expenditures for an unusually expensive, catastrophic illness. A slightly smaller number, about 25 million, are underinsured by an alternate definition: they have insurance that pays a smaller proportion of claims than the plan with the largest enrollment in the federal employee program. The federal employee plan was the insurance standard proposed in several recent health system reform bills. Our estimate of the number of people who are underinsured for catastrophic illness is almost half again larger than the number that was widely cited during last year's debates on health system reform. That estimate was based on the same concept but was projected from a study published 10 years ago.	US DEPT HHS,AGCY HLTH CARE POLICY & RES,CTR INTRAMURAL RES,ROCKVILLE,MD 20852	Agency for Healthcare Research & Quality								Bashshur R, 1993, Med Care Rev, V50, P199, DOI 10.1177/107755879305000204; BERK ML, 1992, HEALTH AFFAIR, V11, P145, DOI 10.1377/hlthaff.11.4.145; CHAFEE JH, 1994, WASHINGTON POST 0802, pC9; EDWARDS W, 1989, DHHS PHS893450 PUBL; EMMONS C, 1994, AHCPR940016 PUBL; FARLEY PJ, 1985, MILBANK FUND Q, V63, P476, DOI 10.2307/3349844; GABEL J, 1994, TRENDS HLTH INSURANC; HAHN B, 1992, PHS AHCPR930007 AG H; HARVEY H, IN PRESS AHCPR HLTH; KASPER J, 1987, DHHS PHS8 PUBL; SHORT PF, 1988, HLTH AFFAIRS     SUM, P186; 1990, CALL ACTION; 1978, STATISTICAL ABSTRACT, P449; 1991, STATISTICAL ABSTRACT, P442; 1994, PRELIMINARY ANAL MIT	15	75	75	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	1995	274	16					1302	1306						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA104	7563537				2022-12-28	WOS:A1995TA10400027
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PROPOSED RULE RESTRICTING SALE OF TOBACCO PRODUCTS TO CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1995, FED REG         0811, V60, P41313	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1109	1109						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563473				2022-12-28	WOS:A1995RY05600007
J	HUNTER, T				HUNTER, T			WHEN IS A LIPID KINASE NOT A LIPID KINASE - WHEN IT IS A PROTEIN-KINASE	CELL			English	Review							PHOSPHATIDYLINOSITOL 3-KINASE; GENE				HUNTER, T (corresponding author), SALK INST BIOL STUDIES,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.							BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; BROWN EJ, 1995, IN PRESS NATURE; CARDENAS ME, 1995, IN PRESS EMBO J; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; LAM K, 1994, J BIOL CHEM, V269, P20648; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; SABATINI DM, 1995, J BIOL CHEM, V270, P20875, DOI 10.1074/jbc.270.36.20875; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; STARCK JH, 1994, J BIOL CHEM, V269, P31552; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZHOU K, 1995, IN PRESS MOL CELL BI	19	258	288	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					1	4		10.1016/0092-8674(95)90225-2	http://dx.doi.org/10.1016/0092-8674(95)90225-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553860	Bronze			2022-12-28	WOS:A1995RY58300001
J	MELLMAN, I				MELLMAN, I			ENIGMA VARIATIONS - PROTEIN MEDIATORS OF MEMBRANE-FUSION	CELL			English	Review							YEAST; SECRETION; INVITRO; MEMBER; FAMILY				MELLMAN, I (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL,333 CEDAR ST,NEW HAVEN,CT 06520, USA.		Mellman, Ira/ABG-5896-2020					ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; LATTERICH M, 1994, CELL, V78, P87, DOI 10.1016/0092-8674(94)90575-4; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0	17	39	39	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					869	872		10.1016/0092-8674(95)90018-7	http://dx.doi.org/10.1016/0092-8674(95)90018-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553845	Bronze			2022-12-28	WOS:A1995RW69300001
J	BARUCH, DI; PASLOSKE, BL; SINGH, HB; BI, XH; MA, XC; FELDMAN, M; TARASCHI, TF; HOWARD, RJ				BARUCH, DI; PASLOSKE, BL; SINGH, HB; BI, XH; MA, XC; FELDMAN, M; TARASCHI, TF; HOWARD, RJ			CLONING THE PLASMODIUM-FALCIPARUM GENE ENCODING PFEMP1, A MALARIAL VARIANT ANTIGEN AND ADHERENCE RECEPTOR ON THE SURFACE OF PARASITIZED HUMAN ERYTHROCYTES	CELL			English	Article							PLASMODIUM-FALCIPARUM; INFECTED ERYTHROCYTES; MEMBRANE; EXPRESSION; PROTEINS; CELLS; CD36; SEQUESTRATION; ASSOCIATION; PHENOTYPES	Plasmodium falciparum-infected human erythrocytes evade host immunity by expression of a cell-surface variant antigen and receptors for adherence to endothelial cells. These properties have been ascribed to P. falciparum erythrocyte membrane protein 1 (PfEMP1), an antigenically diverse malarial protein of 200-350 kDa on the surface of parasitized erythrocytes (PEs). We describe the cloning of two related PfEMP1 genes from the Malayan Camp (MC) parasite strain. Antibodies generated against recombinant protein fragments of the genes were specific for MC strain PfEMP1 protein. These antibodies reacted only with the surface of MC strain PEs and blocked adherence of these cells to CD36 but without effect on adherence to thrombospondin. Multiple forms of the PfEMP1 gene are apparent in MC parasites. The molecular basis for antigenic variation in malaria and adherence of infected erythrocytes to host cells can now be pursued.	AFFYMAX RES INST, SANTA CLARA, CA 95051 USA; JEFFERSON MED COLL, DEPT PATHOL ANAT & CELL BIOL, PHILADELPHIA, PA 19107 USA	Jefferson University					NIAID NIH HHS [AI 27247] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027247, R22AI027247] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUIAR JC, 1992, AM J TROP MED HYG, V47, P621; ALEY SB, 1984, J EXP MED, V160, P1585, DOI 10.1084/jem.160.5.1585; [Anonymous], REFORMA MED; BARNWELL JW, 1983, INFECT IMMUN, V40, P985, DOI 10.1128/IAI.40.3.985-994.1983; BIGGS BA, 1992, J IMMUNOL, V149, P2047; BRANNAN LR, 1994, P ROY SOC B-BIOL SCI, V256, P71, DOI 10.1098/rspb.1994.0051; BROWN KN, 1965, NATURE, V208, P1286, DOI 10.1038/2081286a0; CHITNIS CE, 1994, J EXP MED, V180, P497, DOI 10.1084/jem.180.2.497; ELLIOTT JF, 1990, P NATL ACAD SCI USA, V87, P6363, DOI 10.1073/pnas.87.16.6363; GIBBONS IR, 1991, P NATL ACAD SCI USA, V88, P8563, DOI 10.1073/pnas.88.19.8563; GILKS CF, 1990, PARASITE IMMUNOL, V12, P45, DOI 10.1111/j.1365-3024.1990.tb00935.x; GORMLEY JA, 1992, J CELL BIOL, V119, P1481, DOI 10.1083/jcb.119.6.1481; HANDUNNETTI SM, 1992, AM J TROP MED HYG, V46, P371, DOI 10.4269/ajtmh.1992.46.371; HANDUNNETTI SM, 1987, J EXP MED, V165, P1269, DOI 10.1084/jem.165.5.1269; HASLER T, 1993, AM J TROP MED HYG, V48, P332, DOI 10.4269/ajtmh.1993.48.332; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOMMEL M, 1983, J EXP MED, V157, P1137, DOI 10.1084/jem.157.4.1137; HOWARD RJ, 1989, BLOOD, V74, P2603; HOWARD RJ, 1988, MOL BIOCHEM PARASIT, V27, P207, DOI 10.1016/0166-6851(88)90040-0; Kuhn K, 1994, Trends Cell Biol, V4, P256, DOI 10.1016/0962-8924(94)90124-4; KUTNER S, 1985, J CELL PHYSIOL, V125, P521, DOI 10.1002/jcp.1041250323; LEECH JH, 1984, J CELL BIOL, V98, P1256, DOI 10.1083/jcb.98.4.1256; LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315; MENDIS KN, 1988, AM J TROP MED HYG, V38, P42, DOI 10.4269/ajtmh.1988.38.42; MILLER LH, 1969, AM J TROP MED HYG, V18, P860, DOI 10.4269/ajtmh.1969.18.860; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; NAKAMURA KI, 1992, J HISTOCHEM CYTOCHEM, V40, P1419, DOI 10.1177/40.9.1380530; OCKENHOUSE CF, 1991, J INFECT DIS, V164, P163, DOI 10.1093/infdis/164.1.163; PASLOSKE BL, 1993, MOL BIOCHEM PARASIT, V59, P59, DOI 10.1016/0166-6851(93)90007-K; PASLOSKE BL, 1994, ANNU REV MED, V45, P283; PATNAIK JK, 1994, AM J TROP MED HYG, V51, P642, DOI 10.4269/ajtmh.1994.51.642; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; UDEINYA IJ, 1981, SCIENCE, V213, P555, DOI 10.1126/science.7017935; VANSCHRAVENDIJK MR, 1993, AM J TROP MED HYG, V49, P552, DOI 10.4269/ajtmh.1993.49.552; VANSCHRAVENDIJK MR, 1991, BLOOD, V78, P226	39	843	853	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 14	1995	82	1					77	87		10.1016/0092-8674(95)90054-3	http://dx.doi.org/10.1016/0092-8674(95)90054-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7541722	Bronze			2022-12-28	WOS:A1995RK42400011
J	JIA, ZC; BARFORD, D; FLINT, AJ; TONKS, NK				JIA, ZC; BARFORD, D; FLINT, AJ; TONKS, NK			STRUCTURAL BASIS FOR PHOSPHOTYROSINE PEPTIDE RECOGNITION BY PROTEIN-TYROSINE-PHOSPHATASE 1B	SCIENCE			English	Article							HUMAN-PLACENTA; MAP KINASE; SPECIFICITY; PHOSPHORYLATION; PURIFICATION; DOMAIN; LAR	The crystal structures of a cysteine-215 --> serine mutant of protein tyrosine phosphatase 1B complexed with high-affinity peptide substrates corresponding to an autophosphorylation site of the epidermal growth factor receptor were determined. Peptide binding to the protein phosphatase was accompanied by a conformational change of a surface loop that created a phosphotyrosine recognition pocket and induced a catalytically competent form of the enzyme. The phosphotyrosine side chain is buried within the protein and anchors the peptide substrate to its binding site. Hydrogen bonds between peptide main-chain atoms and the protein contribute to binding affinity, and specific interactions of acidic residues of the peptide with basic residues on the surface of the enzyme confer sequence specificity.	UNIV OXFORD, MOLEC BIOPHYS LAB, OXFORD OX1 3QU, ENGLAND; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	University of Oxford; Cold Spring Harbor Laboratory					NCI NIH HHS [CA53840] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053840, R01CA053840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1993, ONCOGENE, V8, P2015; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BARFORD D, 1994, J MOL BIOL, V239, P726, DOI 10.1006/jmbi.1994.1409; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1993, XPLOR; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHO HJ, 1993, PROTEIN SCI, V2, P977, DOI 10.1002/pro.5560020611; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HIPPEN KL, 1993, BIOCHEMISTRY-US, V32, P12405, DOI 10.1021/bi00097a019; JIA ZF, UNPUB; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LOGAN TM, 1994, BIOCHEMISTRY-US, V33, P11087, DOI 10.1021/bi00203a005; Madhusudan Elzbieta A. Trafny, 1994, Protein Science, V3, P176; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PALLEN CJ, 1991, BIOCHEM J, V276, P315, DOI 10.1042/bj2760315; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PINNA LA, 1994, BBA-MOL CELL RES, V1222, P415, DOI 10.1016/0167-4889(94)90050-7; POT DA, 1992, J AM CHEM SOC, V114, P7296; RUZZENE M, 1993, EUR J BIOCHEM, V211, P289, DOI 10.1111/j.1432-1033.1993.tb19897.x; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TADDEI N, 1994, FEBS LETT, V350, P328, DOI 10.1016/0014-5793(94)00805-1; Tonks N K, 1993, Semin Cell Biol, V4, P373, DOI 10.1006/scel.1993.1044; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006; ZHANG ZT, 1994, J BIOL CHEM, V269, P25947; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; [No title captured]	47	532	545	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 23	1995	268	5218					1754	1758		10.1126/science.7540771	http://dx.doi.org/10.1126/science.7540771			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7540771				2022-12-28	WOS:A1995RE66800043
J	AULD, VJ; FETTER, RD; BROADIE, K; GOODMAN, CS				AULD, VJ; FETTER, RD; BROADIE, K; GOODMAN, CS			GLIOTACTIN, A NOVEL TRANSMEMBRANE PROTEIN ON PERIPHERAL GLIA, IS REQUIRED TO FORM THE BLOOD-NERVE BARRIER IN DROSOPHILA	CELL			English	Article							CELL-ADHESION; MOLECULAR-GENETICS; SERINE ESTERASES; RUTHENIUM RED; MELANOGASTER; GLYCOPROTEIN; EXPRESSION; MUSCLES; CLONING; AXON	Peripheral glia help ensure that motor and sensory axons are bathed in the appropriate ionic and biochemical environment. In Drosophila, peripheral glia help shield these axons against the high K+ concentration of the hemolymph, which would largely abolish their excitability. Here, we describe the molecular genetic analysis of gliotactin, a novel transmembrane protein that is transiently expressed on peripheral glia and that is required for the formation of the peripheral blood-nerve barrier, In gliotactin mutant embryos, the peripheral glia develop normally in many respects, except that ultrastructurally and physiologically they do not form a complete blood-nerve barrier. As a result, peripheral motor axons are exposed to the high K+ hemolymph, action potentials fail to propagate, and the embryos are nearly paralyzed.	UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, DIV NEUROBIOL, BERKELEY, CA 94720 USA; UNIV CAMBRIDGE, DEPT ZOOL, CAMBRIDGE CB2 3EJ, ENGLAND	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Cambridge				Auld, Vanessa/0000-0003-3976-9186	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHBURNER M, 1989, DROSOPHILA LABORATOR; ATWOOD HL, 1993, J NEUROBIOL, V24, P1008, DOI 10.1002/neu.480240803; BARTHALAY Y, 1990, EMBO J, V9, P3603, DOI 10.1002/j.1460-2075.1990.tb07571.x; BATE M, 1990, DEVELOPMENT, V110, P791; BROADIE KS, 1993, J NEUROSCI, V13, P144; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CAMPBELL G, 1994, DEVELOPMENT, V120, P2957; Doyle JP, 1993, CURR OPIN CELL BIOL, V5, P779, DOI 10.1016/0955-0674(93)90025-L; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GRENNINGLOH G, 1990, COLD SH Q B, V55, P327; GROSSMAN Y, 1979, J PHYSIOL-LONDON, V295, P307, DOI 10.1113/jphysiol.1979.sp012970; HALL LMC, 1986, EMBO J, V5, P2949, DOI 10.1002/j.1460-2075.1986.tb04591.x; HORTSCH M, 1990, DEVELOPMENT, V110, P1327; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLAMBT C, 1991, GLIA, V4, P205, DOI 10.1002/glia.440040212; KOCSIS JD, 1983, J PHYSIOL-LONDON, V334, P225, DOI 10.1113/jphysiol.1983.sp014491; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOPCZYNSKI CC, 1992, J CELL BIOL, V119, P503, DOI 10.1083/jcb.119.3.503; LANE NJ, 1975, J CELL SCI, V18, P179; LEMKE G, 1993, GLIA, V7, P263, DOI 10.1002/glia.440070402; LONG RM, 1991, LIFE SCI, V48, P43; LUFT JH, 1971, ANAT RECORD, V171, P369, DOI 10.1002/ar.1091710303; LUFT JH, 1971, ANAT REC, V171, P347, DOI 10.1002/ar.1091710302; MACPHEEQUIGLEY K, 1985, J BIOL CHEM, V260, P2185; Maniatis T., 1982, MOL CLONING; Manning Gerards, 1993, P609; MESSING A, 1992, NEURON, V8, P507, DOI 10.1016/0896-6273(92)90279-M; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; OLSON PF, 1990, EMBO J, V9, P1219, DOI 10.1002/j.1460-2075.1990.tb08229.x; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; ROBERTSON HM, 1988, GENETICS, V118, P461; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sato T, 1968, J Electron Microsc (Tokyo), V17, P158; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SOREQ H, 1990, P NATL ACAD SCI USA, V87, P9688, DOI 10.1073/pnas.87.24.9688; TEPASS U, 1993, DEV BIOL, V159, P311, DOI 10.1006/dbio.1993.1243; Treherne J.E., 1972, Advances Insect Physiol, V9, P257, DOI 10.1016/S0065-2806(08)60278-7; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	39	223	228	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 2	1995	81	5					757	767		10.1016/0092-8674(95)90537-5	http://dx.doi.org/10.1016/0092-8674(95)90537-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7539719	Bronze			2022-12-28	WOS:A1995RB96100014
J	SINGER, PA; COOPER, DS; LEVY, EG; LADENSON, PW; BRAVERMAN, LE; DANIELS, G; GREENSPAN, FS; MCDOUGALL, IR; NIKOLAI, TF				SINGER, PA; COOPER, DS; LEVY, EG; LADENSON, PW; BRAVERMAN, LE; DANIELS, G; GREENSPAN, FS; MCDOUGALL, IR; NIKOLAI, TF			TREATMENT GUIDELINES FOR PATIENTS WITH HYPERTHYROIDISM AND HYPOTHYROIDISM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THYROXINE	Objective.-To develop a set of minimum clinical guidelines for use by primary care physicians in the evaluation and management of patients with hyperthyroidism and hypothyroidism. Participants.-Guidelines were developed by a nine-member ad hoc Standards of Care Committee of the American Thyroid Association (the authors of this article). The participants were selected by the committee chair and the president of the American Thyroid Association on the basis of their clinical experience. The committee members represented different geographic areas within the United States, in order to take. into account different practice styles. Evidence.-Guideline were developed on the basis of expert opinion of the participants, as well as on available published information. Consensus Process.-Input was obtained from all of the participants, each of whom wrote an initial section of the document. A complete draft document was then written by three participants (P.A.S., D.S.C., and E.G.L.) and resubmitted to the entire committee for revision. The revised document was then submitted to the entire membership of the American Thyroid Association for written comments, which were then reviewed (mainly by P.A.S., D.S.C., and E.G.L.). Many of the suggestions of the American Thyroid Association members were incorporated into the final draft, which was then approved by the Executive Council of the American Thyroid Association. The entire process, from initial drafts to final approval, took approximately 18 months. Conclusions.-A set of minimum clinical guidelines for the diagnosis and treatment of hyperthyroidism and hypothyroidism were developed by consensus of a group of experienced thyroidologists. The guidelines are intended to be used by physicians in their care of patients with thyroid disorders, with the expectation that more effective care can be provided, and at a cost savings.	JOHNS HOPKINS UNIV,SCH MED,DIV ENDOCRINOL,BALTIMORE,MD; MT SINAI HOSP,DIV ENDOCRINOL,BALTIMORE,MD; UNIV MIAMI,SCH MED,DIV ENDOCRINOL,MIAMI,FL; UNIV MASSACHUSETTS,SCH MED,DIV ENDOCRINOL,WORCESTER,MA; MASSACHUSETTS GEN HOSP,THYROID UNIT,BOSTON,MA 02114; UNIV CALIF SAN FRANCISCO,SCH MED,DIV ENDOCRINOL,SAN FRANCISCO,CA; STANFORD UNIV,SCH MED,DIV NUCL MED,STANFORD,CA; MARSHFIELD CLIN FDN MED RES & EDUC,MARSHFIELD,WI	Johns Hopkins University; Icahn School of Medicine at Mount Sinai; University of Miami; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Massachusetts General Hospital; University of California System; University of California San Francisco; Stanford University; Marshfield Clinic	SINGER, PA (corresponding author), UNIV SO CALIF,SCH MED,DIV ENDOCRINOL DIABET & HYPERTENS,1355 S SAN PABLO ST,ROOM 120,LOS ANGELES,CA 90033, USA.			Braverman, Lewis/0000-0003-1263-1099				BURCH HB, 1993, ENDOCR REV, V14, P747, DOI 10.1210/er.14.6.747; BURROW GN, 1993, ENDOCR REV, V14, P194, DOI 10.1210/er.14.2.194; COOPER DS, 1984, NEW ENGL J MED, V311, P1353, DOI 10.1056/NEJM198411223112106; COOPER DS, 1991, THYROID, P887; GAVIN LA, 1991, MED CLIN N AM, V75, P179, DOI 10.1016/S0025-7125(16)30478-3; HENNEMANN G, 1986, LANCET, V325, P1369; MANDEL SJ, 1990, NEW ENGL J MED, V323, P91, DOI 10.1056/NEJM199007123230204; MANDEL SJ, 1993, ANN INTERN MED, V119, P492, DOI 10.7326/0003-4819-119-6-199309150-00009; PATWARDHAN NA, 1993, SURGERY, V114, P1108; ROTI E, 1993, ENDOCR REV, V14, P401, DOI 10.1210/er.14.4.401; SAWIN CT, 1991, ADV INTERNAL MED, V37, P223; STALL GM, 1990, ANN INTERN MED, V113, P265, DOI 10.7326/0003-4819-113-4-265; SURKS MI, 1990, JAMA-J AM MED ASSOC, V263, P1529, DOI 10.1001/jama.263.11.1529	13	315	336	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	1995	273	10					808	812		10.1001/jama.273.10.808	http://dx.doi.org/10.1001/jama.273.10.808			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ750	7532241				2022-12-28	WOS:A1995QJ75000034
J	COGHLAN, VM; PERRINO, BA; HOWARD, M; LANGEBERG, LK; HICKS, JB; GALLATIN, WM; SCOTT, JD				COGHLAN, VM; PERRINO, BA; HOWARD, M; LANGEBERG, LK; HICKS, JB; GALLATIN, WM; SCOTT, JD			ASSOCIATION OF PROTEIN-KINASE-A AND PROTEIN-PHOSPHATASE-2B WITH A COMMON ANCHORING PROTEIN	SCIENCE			English	Article							HIGH-AFFINITY BINDING; REGULATORY SUBUNIT RII; IMMUNOCYTOCHEMICAL LOCALIZATION; POSTSYNAPTIC DENSITIES; CATALYTIC SUBUNIT; CALCINEURIN-A; RAT-BRAIN; II-BETA; CALMODULIN; PHOSPHORYLATION	Specificity of protein kinases and phosphatases may be achieved through compartmentalization with preferred substrates. In neurons, adenosine 3',5'-monophosphate (cAMP)-dependent protein kinase (PKA) is localized at postsynaptic densities by association of its regulatory subunit with an A kinase anchor protein, AKAP79. Interaction cloning experiments demonstrated that AKAP79 also binds protein phosphatase 2B, or calcineurin (CaN). A ternary complex of PKA, AKAP, and CaN was isolated from bovine brain, and colocalization of the kinase and the phosphatase was established in neurites of cultured hippocampal neurons. The putative CaN-binding domain of AKAP79 is similar to that of the immunophilin FKBP-12, and AKAP79 inhibited CaN phosphatase activity. These results suggest that both PKA and CaN are targeted to subcellular sites by association with a common anchor protein and thereby regulate the phosphorylation state of key neuronal substrates.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; ICOS CORP,BOTHELL,WA 98021	Oregon Health & Science University; Icos Corporation					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048231, R37GM048231] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09059] Funding Source: Medline; NIGMS NIH HHS [GM48231] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; BRAUTIGAN DL, 1994, RECENT PROG HORM RES, V49, P197; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COGHLAN VM, 1993, MOL CELL BIOCHEM, V128, P309, DOI 10.1007/BF01076780; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; COGHLAN VM, THESIS; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; GRAB DJ, 1979, J BIOL CHEM, V254, P8690; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HATHAWAY DR, 1981, J BIOL CHEM, V256, P8183; HEMMINGS HC, 1989, FASEB J, V3, P1583, DOI 10.1096/fasebj.3.5.2493406; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KUNO T, 1989, BIOCHEM BIOPH RES CO, V165, P1352, DOI 10.1016/0006-291X(89)92752-6; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; LUDVIG N, 1990, BRAIN RES, V520, P90, DOI 10.1016/0006-8993(90)91694-C; PERRINO BA, 1992, J BIOL CHEM, V267, P15965; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; Stemmer P, 1991, Curr Opin Neurobiol, V1, P53, DOI 10.1016/0959-4388(91)90010-5; WOOD JG, 1980, J CELL BIOL, V84, P66, DOI 10.1083/jcb.84.1.66	32	498	516	2	12	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 6	1995	267	5194					108	111		10.1126/science.7528941	http://dx.doi.org/10.1126/science.7528941			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA235	7528941				2022-12-28	WOS:A1995QA23500041
J	PAAUW, DS; WENRICH, MD; CURTIS, JR; CARLINE, JD; RAMSEY, PG				PAAUW, DS; WENRICH, MD; CURTIS, JR; CARLINE, JD; RAMSEY, PG			ABILITY OF PRIMARY-CARE PHYSICIANS TO RECOGNIZE PHYSICAL FINDINGS ASSOCIATED WITH HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ORAL HAIRY LEUKOPLAKIA; KAPOSIS SARCOMA; AIDS; VIRUS	Objective.-To assess the ability of primary care physicians to identify physical findings associated with human immunodeficiency virus (HIV) infection. Design.-Standardized patient examination. Participants.-A total of 134 general internists and family practitioners were randomly selected after stratifying by year of medical school graduation, specialty, and experience caring for patients with HIV infection. Main Outcome Measures.-Recognition of physical findings of Kaposi's sarcoma, oral hairy leukoplakia, and diffuse lymphadenopathy. Results.-Despite being directed by presenting histories to sites of prominent physical abnormalities, only 23 (25.8%) of 89 physicians evaluating a patient with Kaposi's sarcoma and 22 (22.7%) of 97 physicians evaluating a patient with oral hairy leukoplakia detected and correctly diagnosed the abnormalities. Twenty-th ree (17%) of 133 physicians detected diffuse lymphadenopathy in a patient complaining of fatigue, fever, and arthralgias. Physicians with the most experience treating patients with HIV infection more frequently identified oral hairy leukoplakia, but HIV experience did not influence identification of Kaposi's sarcoma or detection of lymphadenopathy. There were no differences between general internists and family practitioners or among physicians by year of medical school graduation in identifying the three physical findings associated with HIV infection. Conclusions.-Primary care physicians may frequently miss important physical findings related to HIV infection during patient examinations,	UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MED EDUCAT,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					AHRQ HHS [HS-06454-03] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABRAMS JE, 1993, 1ST NAT C HUM RETR W; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; CALABRESE LH, 1991, ARCH INTERN MED, V151, P1157, DOI 10.1001/archinte.151.6.1157; COONEY TG, 1991, J GEN INTERN MED, V6, pS12, DOI 10.1007/BF02599252; CURTIS JR, 1995, J GEN INTERN MED, V10, P395, DOI 10.1007/BF02599841; GALLANT JE, 1995, CHEST, V107, P1018, DOI 10.1378/chest.107.4.1018; GREENSPAN D, 1987, J INFECT DIS, V155, P475, DOI 10.1093/infdis/155.3.475; GREENSPAN D, 1984, LANCET, V2, P831; GREENSPAN JS, 1989, ORAL SURG ORAL MED O, V67, P396, DOI 10.1016/0030-4220(89)90381-2; HUTCHINSON CM, 1991, JAMA-J AM MED ASSOC, V266, P253, DOI 10.1001/jama.266.2.253; KROWN SE, 1987, B NEW YORK ACAD MED, V63, P679; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCCANCE KL, 1991, AM J PREV MED, V7, P141, DOI 10.1016/S0749-3797(18)30929-2; RAMSEY PG, 1994, FINAL REPORT AGENCY; SAFAI B, 1985, ANN INTERN MED, V103, P744, DOI 10.7326/0003-4819-103-5-744; STILLMAN P, 1991, ANN INTERN MED, V114, P393, DOI 10.7326/0003-4819-114-5-393; van der Vleuten C.P., 1990, TEACH LEARN MED, V2, P58, DOI [https://doi.org/10.1080/10401339009539432, DOI 10.1080/10401339009539432]; WENRICH MD, IN PRESS AM J PREV M	18	92	94	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	1995	274	17					1380	1382		10.1001/jama.274.17.1380	http://dx.doi.org/10.1001/jama.274.17.1380			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB278	7563564				2022-12-28	WOS:A1995TB27800030
J	NISHIGUCHI, S; KUROKI, T; NAKATANI, S; MORIMOTO, H; TAKEDA, T; NAKAJIMA, S; SHIOMI, S; SEKI, S; KOBAYASHI, K; OTANI, S				NISHIGUCHI, S; KUROKI, T; NAKATANI, S; MORIMOTO, H; TAKEDA, T; NAKAJIMA, S; SHIOMI, S; SEKI, S; KOBAYASHI, K; OTANI, S			RANDOMIZED TRIAL OF EFFECTS OF INTERFERON-ALPHA ON INCIDENCE OF HEPATOCELLULAR-CARCINOMA IN CHRONIC ACTIVE HEPATITIS-C WITH CIRRHOSIS	LANCET			English	Article							POST-TRANSFUSION HEPATITIS; NON-B-HEPATITIS; NON-A; LIVER-DISEASES; VIRUS; ANTIBODY; PREVALENCE; JAPAN; PROTEIN; MICE	Patients with chronic active hepatitis C and cirrhosis often develop hepatocellular carcinoma. Interferon (IFN) seems to be effective in some patients but whether it prevents carcinogenesis is unknown. In a prospective randomised controlled trial, we evaluated the effects of IFN-alpha in cirrhotic patients with HCV infection because of their high risk of hepatocellular carcinoma. 90 patients with compensated chronic active hepatitis C with cirrhosis were randomly allocated to receive IFN-alpha (6 MU three times weekly for 12-24 weeks) (45 patients) or symptomatic treatment (45 controls), and were followed up for 2-7 years. In nine controls, alanine aminotransferase (ALT) decreased to less than 80 IU/L but did not stay in the normal range. In 19 patients given IFN-alpha, AFT decreased to less than 80 IU/L(in seven patients, it became and stayed normal; p=0.011, Wilcoxon rank-sum test). However, the mean change in ALT was not significantly different between the two groups. The mean change in peak alpha-fetoprotein values was smaller in patients given IFN-alpha than in controls (p=0.021). The mean change in the serum albumin level was higher in the IFN-alpha group (p<0.001). The histological activity index in the 12 IFN-alpha patients undergoing a second biopsy after therapy was improved (p=0.031). Hepatitis C viral RNA disappeared in seven (16%) of the 45 IFN-alpha patients (95% CI, 7-29%) and in none of the 45 controls (0-8%; p=0.018). Hepatocellular carcinoma was detected in two (4%, 1-15%) IFN-alpha patients and 17 (38%, 24-54%) controls (p=0.002, Wilcoxon signed-rank test). The risk ratio of IFN-alpha treatment versus symptomatic treatment was 0.067 (0.009-0.530; p=0.010 Cox's proportional hazards). IFN-alpha improved liver function in chronic active hepatitis C with cirrhosis, and its use was associated with a decreased incidence of hepatocellular carcinoma.	OSAKA CITY UNIV, SCH MED, DEPT BIOCHEM 2, ABENO KU, OSAKA 545, JAPAN	Osaka Metropolitan University	NISHIGUCHI, S (corresponding author), OSAKA CITY UNIV, SCH MED, DEPT INTERNAL MED 3, ABENO KU, 1-5-7 ASAHIMACHI, OSAKA 545, JAPAN.		Yang, Chen/G-1379-2010					BEASLEY RP, 1982, HEPATOLOGY, V2, pS21; BRUIX J, 1989, LANCET, V2, P1004; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COLOMBO M, 1989, LANCET, V2, P1006; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DUNK AA, 1987, SCAND J GASTROENTERO, V22, P1245, DOI 10.3109/00365528708996471; ESTEBAN JI, 1989, LANCET, V2, P294; FURUTA T, 1990, CANCER-AM CANCER SOC, V66, P2395, DOI 10.1002/1097-0142(19901201)66:11<2395::AID-CNCR2820661125>3.0.CO;2-T; GILLIAM JH, 1984, ANN INTERN MED, V101, P794, DOI 10.7326/0003-4819-101-6-794; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; IKEDA K, 1993, HEPATOLOGY, V18, P47, DOI 10.1016/0270-9139(93)90505-H; JOUET P, 1994, GASTROENTEROLOGY, V106, P686, DOI 10.1016/0016-5085(94)90703-X; KATO Y, 1982, HEPATOLOGY, V2, P789, DOI 10.1002/hep.1840020607; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; KIYOSAWA K, 1984, AM J GASTROENTEROL, V79, P777; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LAI CL, 1993, HEPATOLOGY, V17, P389; NISHIGUCHI S, 1992, ANN INTERN MED, V116, P21, DOI 10.7326/0003-4819-116-1-21; NISHIOKA K, 1991, CANCER, V67, P429, DOI 10.1002/1097-0142(19910115)67:2<429::AID-CNCR2820670218>3.0.CO;2-#; NISHIOKA K, 1991, LIVER, V11, P65; OKA H, 1990, HEPATOLOGY, V12, P680, DOI 10.1002/hep.1840120411; OKAMOTO H, 1993, J GEN VIROL, V74, P2835; OKUDA K, 1992, HEPATOLOGY, V15, P948, DOI 10.1002/hep.1840150532; OKUDA K, 1987, CANCER RES, V47, P4967; PARKIN DM, 1984, B WORLD HEALTH ORGAN, V62, P163, DOI 10.1139/b84-027; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; REID LM, 1981, P NATL ACAD SCI-BIOL, V78, P1171, DOI 10.1073/pnas.78.2.1171; RESNICK RH, 1983, DIGEST DIS SCI, V28, P908, DOI 10.1007/BF01317042; SHERLOCK S, 1993, DISEASES LIVER BILIA, P367; SHINDO M, 1992, HEPATOLOGY, V15, P1013, DOI 10.1002/hep.1840150607; TAKEDA T, 1991, BIOCHEM BIOPH RES CO, V178, P378, DOI 10.1016/0006-291X(91)91824-V; TREMOLADA F, 1990, LANCET, V335, P300, DOI 10.1016/0140-6736(90)90129-S; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	37	801	822	1	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 21	1995	346	8982					1051	1055		10.1016/S0140-6736(95)91739-X	http://dx.doi.org/10.1016/S0140-6736(95)91739-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564784				2022-12-28	WOS:A1995TA69700008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PATIENT EDUCATION-PROGRAM PROPOSED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1995, FED REG         0823, V60, P44182	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1109	1109						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563473				2022-12-28	WOS:A1995RY05600009
J	VONANDRIAN, UH; HASSLEN, SR; NELSON, RD; ERLANDSEN, SL; BUTCHER, EC				VONANDRIAN, UH; HASSLEN, SR; NELSON, RD; ERLANDSEN, SL; BUTCHER, EC			A CENTRAL ROLE FOR MICROVILLOUS RECEPTOR PRESENTATION IN LEUKOCYTE ADHESION UNDER FLOW	CELL			English	Article							ENDOTHELIAL CELL RECOGNITION; NODE HOMING RECEPTOR; L-SELECTIN; LYMPH-NODE; NEUTROPHIL ADHESION; MESENTERIC VENULES; LECAM-1; INVIVO; GLYCOPROTEIN; LYMPHOCYTES	Leukocyte adhesion to endothelium requires specialized mechanisms for contact initiation under flow, L-selectin (CD62L), an efficient initiator of adhesion, is clustered on the tips of leukocyte microvilli. To test whether microvillous presentation is critical for contact formation (''tethering''), we transfected lymphoid cells with chimeras of L-selectin and CD44, an adhesion molecule that is excluded from microvilli, CD44 transmembrane and intracellular (TM-IC) domains targeted the L-selectin ectodomain to the planar body, whereas L-selectin TM-IC segments conferred CD44 ectodomain clustering on microvilli. Wild-type and chimeric transfectants bound similarly to anti-ectodomain MAbs in static assays, but MAb binding under Row was much more efficient in the context of microvillous presentation, Similarly, wild-type and chimeric L-selectin possessed equivalent lectin activity, but microvillous presentation dramatically enhanced contact initiation on a native ligand. These findings demonstrate a critical role for receptor topography in leukocyte adhesion and suggest a novel regulatory mechanism of leukocyte trafficking.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; STANFORD UNIV,SCH MED,DEPT PATHOL,IMMUNOL & VASC BIOL LAB,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT MED,CTR DIGEST DIS,STANFORD,CA 94305; VET AFFAIRS PALO ALTO HLTH CARE SYST,FOOTHILL RES CTR,CTR MOLEC BIOL & MED,PALO ALTO,CA 94304; UNIV MINNESOTA,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT DERMATOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455	Harvard University; Harvard Medical School; Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	VONANDRIAN, UH (corresponding author), HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115, USA.		von Andrian, Ulrich H/A-5775-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037832, R01AI019957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037734, R01GM037734] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37832, AI19957] Funding Source: Medline; NIGMS NIH HHS [GM37734] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; ARFORS KE, 1987, BLOOD, V69, P338; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; BEESLEY JE, 1979, J CELL SCI, V38, P237; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; BUTCHER EC, 1994, RES IMMUNOL, V144, P695; ERLANDSEN SL, 1993, J HISTOCHEM CYTOCHEM, V41, P327, DOI 10.1177/41.3.7679125; FIRRELL JC, 1989, AM J PHYSIOL, V256, pH1667, DOI 10.1152/ajpheart.1989.256.6.H1667; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; HAMMER DA, 1987, BIOPHYS J, V52, P475, DOI 10.1016/S0006-3495(87)83236-8; HAMMER DA, 1992, BIOPHYS J, V63, P35, DOI 10.1016/S0006-3495(92)81577-1; HASSLEN SR, 1995, HISTOCHEM J, V27, P547; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JACOBSON K, 1984, J CELL BIOL, V99, P1613, DOI 10.1083/jcb.99.5.1613; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; KALOMIRIS EL, 1988, J CELL BIOL, V106, P319, DOI 10.1083/jcb.106.2.319; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KISHIMOTO TK, 1991, BLOOD, V78, P805; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LEY K, 1991, BLOOD, V77, P2553; LICHTMAN MA, 1970, BLOOD-J HEMATOL, V35, P12, DOI 10.1182/blood.V35.1.12.12; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NOBIS U, 1985, MICROVASC RES, V29, P295, DOI 10.1016/0026-2862(85)90020-2; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; PELIKAN P, 1979, ATHEROSCLEROSIS, V32, P69, DOI 10.1016/0021-9150(79)90148-5; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; ROSENMAN SJ, 1993, J LEUKOCYTE BIOL, V53, P1; SCHMIDSCHONBEIN GW, 1980, MICROVASC RES, V19, P45, DOI 10.1016/0026-2862(80)90083-7; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; VANEWIJK W, 1980, BLOOD CELLS VESSEL W, P21; VONANDRIAN UH, 1993, J CLIN INVEST, V91, P2893, DOI 10.1172/JCI116535; VONANDRIAN UH, 1993, BLOOD, V82, P182, DOI 10.1182/blood.V82.1.182.bloodjournal821182; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; YADNOCK TA, 1987, J CEL LBIOL, V104, P713	46	326	330	1	14	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					989	999		10.1016/0092-8674(95)90278-3	http://dx.doi.org/10.1016/0092-8674(95)90278-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553859	Bronze			2022-12-28	WOS:A1995RW69300015
J	MORROW, DM; MORROW, M; TAGLE, DA; SHILOH, Y; COLLINS, FS; HIETER, P				MORROW, DM; MORROW, M; TAGLE, DA; SHILOH, Y; COLLINS, FS; HIETER, P			TEL1, AN SACCHAROMYCES-CEREVISIAE HOMOLOG OF THE HUMAN GENE MUTATED IN ATAXIA-TELANGIECTASIA, IS FUNCTIONALLY RELATED TO THE YEAST CHECKPOINT GENE MEC1	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL 3-KINASE; RADIATION SENSITIVITY; PROTEIN; CELLS; CANCER; DNA; RAPAMYCIN; VPS34; IDENTIFICATION	Patients with the genetic disorder ataxia telangiectasia (AT) have mutations in the AT mutated (ATM) gene, which is homologous to TEL1 and the checkpoint gene MEC1. A tel1 deletion mutant, unlike a mec1 deletion, is viable and does not exhibit increased sensitivity to DNA-damaging agents. However, increased dosage of TEL1 rescues sensitivity of a mec1 mutant, mec1-1, to DNA-damaging agents and rescues viability of a mec1 disruption. mec1-1 tel1 Delta 1 double mutants are synergistically sensitive to DNA-damaging agents, including radiomimetic drugs. These data indicate that TEL1 and MEC1 are functionally related and that functions of the ATM gene are apparently divided between at least two S. cerevisiae homologs.	NIH,NATL CTR HUMAN GENOME RES,GENE TRANSFER LAB,BETHESDA,MD 20892; TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN GENET,IL-69978 TEL AVIV,ISRAEL	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Tel Aviv University; Sackler Faculty of Medicine	MORROW, DM (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.				NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER; NCI NIH HHS [CA16519] Funding Source: Medline; NIGMS NIH HHS [GM162283] Funding Source: Medline; NINDS NIH HHS [NS31763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BOEKE JD, 1984, MOL GEN GENET, V197, P3445; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FRIEDBERG EC, 1995, DNA REPAIR; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEHMANN AR, 1979, NUCLEIC ACIDS RES, V6, P1953, DOI 10.1093/nar/6.5.1953; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MORRELL D, 1986, J NATL CANCER I, V77, P89; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; PAINTER RB, 1982, MECHANISMS CHEM CARC; PAINTER RB, 1985, ATAXIA TELANGIECTASI; PANDITA TK, 1995, IN PRESS CYTOGENET C; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; REENAN RAG, 1992, GENETICS, V132, P963; Rose MD., 1990, METHODS YEAST GENETI; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; SHANI N, 1995, P NATL ACAD SCI USA, V92, P6012, DOI 10.1073/pnas.92.13.6012; SHILOH Y, 1983, CARCINOGENESIS, V4, P1317, DOI 10.1093/carcin/4.10.1317; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; SIKORSKI RS, 1989, GENETICS, V122, P19; SWIFT M, 1986, AM J HUM GENET, V39, P573; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TAYLOR AMR, 1983, CANCER RES, V43, P2700; TAYLOR AMR, 1979, CANCER RES, V39, P1046; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652	48	336	343	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					831	840		10.1016/0092-8674(95)90480-8	http://dx.doi.org/10.1016/0092-8674(95)90480-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7545545	hybrid			2022-12-28	WOS:A1995RU75500018
J	GRIFFITH, JP; KIM, JL; KIM, EE; SINTCHAK, MD; THOMSON, JA; FITZGIBBON, MJ; FLEMING, MA; CARON, PR; HSIAO, K; NAVIA, MA				GRIFFITH, JP; KIM, JL; KIM, EE; SINTCHAK, MD; THOMSON, JA; FITZGIBBON, MJ; FLEMING, MA; CARON, PR; HSIAO, K; NAVIA, MA			X-RAY STRUCTURE OF CALCINEURIN INHIBITED BY THE IMMUNOPHILIN IMMUNOSUPPRESSANT FKBP12-FK506 COMPLEX	CELL			English	Article							LYMPHOCYTE-T ACTIVATION; CYCLOSPORINE-A; BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; 3-DIMENSIONAL STRUCTURE; FK-506-BINDING PROTEIN; CATALYTIC SUBUNIT; ATOMIC-STRUCTURE; CELL ACTIVATION; PEPTIDE COMPLEX	The X-ray structure of the ternary complex of a calcineurin A fragment, calcineurin B, FKBP12, and the immunosuppressant drug FK506 (also known as tacrolimus) has been determined at 2.5 Angstrom resolution, providing a description of how FK506 functions at the atomic level. In the structure, the FKBP12-FK506 binary complex does not contact the phosphatase active site on calcineurin A that is more than 10 Angstrom removed. Instead, FKBP12-FK506 is so positioned that it can inhibit the dephosphorylation of its macromolecular substrates by physically hindering their approach to the active site. The ternary complex described here represents the three-dimensional structure of a Ser/Thr protein phosphatase and provides a structural basis for understanding calcineurin inhibition by FKBP12-FK506.			GRIFFITH, JP (corresponding author), VERTEX PHARMACEUT INC,40 ALLSTON ST,CAMBRIDGE,MA 02139, USA.							ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BECKER JW, 1993, J BIOL CHEM, V268, P11335; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BOREL JF, 1989, PHARMACOL REV, V41, P259; BOREL JF, 1976, AGENTS ACTIONS, V6, P468, DOI 10.1007/BF01973261; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1993, X PLOR SYSTEM XRAY C; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; Di Padova F. E., 1994, Perspectives in Drug Discovery and Design, V2, P49; DONELLADEANA A, 1994, EUR J BIOCHEM, V219, P109, DOI 10.1111/j.1432-1033.1994.tb19920.x; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; FUTER O, 1995, J BIOL CHEM, V270, P18935, DOI 10.1074/jbc.270.32.18935; GORDON JI, 1991, J BIOL CHEM, V266, P8647; Goulet Mark T., 1994, Perspectives in Drug Discovery and Design, V2, P145, DOI 10.1007/BF02171741; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; ITO A, 1989, BIOCHEM BIOPH RES CO, V163, P1492, DOI 10.1016/0006-291X(89)91148-0; ITOH S, 1995, IN PRESS BIOORG MED, V5; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KAKALIS LT, 1995, FEBS LETT, V362, P55, DOI 10.1016/0014-5793(95)00207-P; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KING MM, 1984, J BIOL CHEM, V259, P8847; KINO T, 1987, J ANTIBIOT, V40, P1249, DOI 10.7164/antibiotics.40.1249; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MARTIN BL, 1994, BBA-PROTEIN STRUCT M, V1206, P136, DOI 10.1016/0167-4838(94)90082-5; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; MUELLER EG, 1993, J AM CHEM SOC, V115, P2974, DOI 10.1021/ja00060a055; NARGANG CE, 1994, DNA SEQUENCE, V4, P313, DOI 10.3109/10425179409020857; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OEFNER C, 1986, J MOL BIOL, V192, P605, DOI 10.1016/0022-2836(86)90280-9; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; REED RJ, 1986, ACTA CRYSTALLOGR A, V42, P140; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SHARMA RK, 1986, J BIOL CHEM, V261, P1322; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SIKKINK R, 1995, BIOCHEMISTRY-US, V34, P8348, DOI 10.1021/bi00026a016; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TOCCI MJ, 1989, J IMMUNOL, V143, P718; VANDUYNE GD, 1991, J AM CHEM SOC, V113, P7433, DOI 10.1021/ja00019a057; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; VEZINA C, 1975, J ANTIBIOT, V28, P721, DOI 10.7164/antibiotics.28.721; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WILSON KP, 1995, ACTA CRYSTALLOGR D, V51, P511, DOI 10.1107/S0907444994014514; YANG D, 1993, J AM CHEM SOC, V115, P819, DOI 10.1021/ja00055a081; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	75	752	786	5	25	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					507	522		10.1016/0092-8674(95)90439-5	http://dx.doi.org/10.1016/0092-8674(95)90439-5			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7543369	Bronze			2022-12-28	WOS:A1995RP24200020
J	ANDERSON, K				ANDERSON, K			ONE SIGNAL, 2 BODY AXES	SCIENCE			English	Editorial Material							DROSOPHILA; OOGENESIS				ANDERSON, K (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.							CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; NEUMANSILBERBER.FS, 1993, CELL, V75, P265; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; ROTH S, 1994, CURR BIOL, V4, P755, DOI 10.1016/S0960-9822(00)00170-6; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923	8	14	14	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 28	1995	269	5223					489	490		10.1126/science.7542799	http://dx.doi.org/10.1126/science.7542799			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7542799				2022-12-28	WOS:A1995RL49500015
J	GORDON, M; SINGER, PA				GORDON, M; SINGER, PA			DECISIONS AND CARE AT THE END OF LIFE	LANCET			English	Article							ADVANCE DIRECTIVES; CARDIOPULMONARY-RESUSCITATION; OUTCOMES		MT SINAI HOSP,DIV GERIATR,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA; UNIV TORONTO,CTR BIOETH,TORONTO,ON,CANADA; TORONTO HOSP,TORONTO,ON M5T 2S8,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	GORDON, M (corresponding author), BAYCREST CTR GERIATR CARE,560 BATHURST ST,N YORK,ON M6A 2E1,CANADA.							APPELBAUM PS, 1988, NEW ENGL J MED, V319, P1635, DOI 10.1056/NEJM198812223192504; AWOKE S, 1992, J AM GERIATR SOC, V40, P593, DOI 10.1111/j.1532-5415.1992.tb02109.x; BEDELL SE, 1983, NEW ENGL J MED, V309, P570; CALLAHAN D, 1994, GERONTOLOGIST, V34, P393, DOI 10.1093/geront/34.3.393; CAMPION EW, 1994, NEW ENGL J MED, V330, P1819, DOI 10.1056/NEJM199406233302509; CASSEL CK, 1992, HEALTH AFFAIR, V11, P87, DOI 10.1377/hlthaff.11.2.87; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DAVIDSON KW, 1989, JAMA-J AM MED ASSOC, V262, P2415, DOI 10.1001/jama.262.17.2415; DAVIES AM, 1988, EPIDEMIOLOGY AGING I, P1; DECTER M, 1994, HEALING MEDICARE MAN; EMANUEL EJ, 1993, AM J MED, V95, P619, DOI 10.1016/0002-9343(93)90358-V; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FARRELL C, 1994, BUSINESS WEEK   0912, P60; FRIED TR, 1994, J AM GERIATR SOC, V42, P303, DOI 10.1111/j.1532-5415.1994.tb01756.x; GORDON M, 1995, CARDIOL ELDER, V3, P53; GORDON M, 1992, CAN MED ASSOC J, V148, P393; LOWY FH, 1993, CANADIAN PHYSICIANS; MADDOCKS I, 1990, MED J AUSTRALIA, V152, P535, DOI 10.5694/j.1326-5377.1990.tb125356.x; MURPHY DJ, 1988, JAMA-J AM MED ASSOC, V260, P2098, DOI 10.1001/jama.260.14.2098; PELLEGRINO ED, 1995, ANN INTERN MED, V122, P377, DOI 10.7326/0003-4819-122-5-199503010-00010; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1982, MAKING HLTH CARE DEC, V1; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2354; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; SILBERFELD M, 1994, MIND FAILS; SINGER PA, 1994, LANCET, V344, P594, DOI 10.1016/S0140-6736(94)91971-2; SMITH EM, 1992, J ROY COLL PHYS LOND, V26, P377; SOLOMON DH, 1990, J AM GERIATR SOC, V38, P259, DOI 10.1111/j.1532-5415.1990.tb03500.x; TRESCH D, 1994, J AM GERIATR SOC, V42, P137, DOI 10.1111/j.1532-5415.1994.tb04940.x; TRESCH DD, 1993, AM J MED, V95, P123, DOI 10.1016/0002-9343(93)90252-K; WEINBERGER M, 1993, AM J PUBLIC HEALTH, V83, P338, DOI 10.2105/AJPH.83.3.338	31	21	21	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 15	1995	346	8968					163	166		10.1016/S0140-6736(95)91215-0	http://dx.doi.org/10.1016/S0140-6736(95)91215-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RJ031	7541498				2022-12-28	WOS:A1995RJ03100015
J	BENDELAC, A				BENDELAC, A			CD1 - PRESENTING UNUSUAL ANTIGENS TO UNUSUAL T-LYMPHOCYTES	SCIENCE			English	Editorial Material							LYMPHOKINE SECRETION; CELLS; EXPRESSION; CD4+; RECOGNITION; THYMOCYTES; SELECTION; SUBSET; FAMILY; GENES				BENDELAC, A (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.							ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; ARASE H, 1993, EUR J IMMUNOL, V23, P307, DOI 10.1002/eji.1830230151; BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BENDELAC A, 1991, NATURE, V353, P68, DOI 10.1038/353068a0; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; BENDELAC A, 1994, SCIENCE, V263, P1774, DOI 10.1126/science.7907820; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; BIX M, 1993, J EXP MED, V178, P901, DOI 10.1084/jem.178.3.901; BLEICHER PA, 1990, SCIENCE, V250, P679, DOI 10.1126/science.1700477; BRADBURY A, 1990, EUR J IMMUNOL, V20, P1831, DOI 10.1002/eji.1830200830; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; CALABI F, 1989, EUR J IMMUNOL, V19, P285, DOI 10.1002/eji.1830190211; CARDELL S, IN PRESS J EXP MED; CASTANO AR, 1995, SCIENCE, V269, P223, DOI 10.1126/science.7542403; COLES MC, 1994, J EXP MED, V180, P395, DOI 10.1084/jem.180.1.395; DELLABONA P, 1994, J EXP MED, V180, P1171, DOI 10.1084/jem.180.3.1171; DELLABONA P, 1993, J EXP MED, V177, P1763, DOI 10.1084/jem.177.6.1763; HAYAKAWA K, 1992, J EXP MED, V176, P269, DOI 10.1084/jem.176.1.269; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; LACASSE J, 1992, J HISTOCHEM CYTOCHEM, V40, P1527, DOI 10.1177/40.10.1382091; LAFFERTY KJ, 1975, AUST J EXP BIOL MED, V53, P27, DOI 10.1038/icb.1975.3; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; LEVITSKY HI, 1990, J IMMUNOL, V146, P1113; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MCMICHAEL AJ, 1979, EUR J IMMUNOL, V9, P205, DOI 10.1002/eji.1830090307; NOLL H, 1956, BIOCHIM BIOPHYS ACTA, V20, P299, DOI 10.1016/0006-3002(56)90289-X; PORCELLI S, 1993, J EXP MED, V178, P1, DOI 10.1084/jem.178.1.1; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SHARTON TM, 1993, J EXP MED, V178, P567; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; SYKES M, 1990, J IMMUNOL, V145, P3209; YOKOYAMA WM, 1995, P NATL ACAD SCI USA, V92, P3081, DOI 10.1073/pnas.92.8.3081; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285	36	120	122	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					185	186		10.1126/science.7542402	http://dx.doi.org/10.1126/science.7542402			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7542402				2022-12-28	WOS:A1995RJ02900028
J	TYCKO, R; BARRETT, SE; DABBAGH, G; PFEIFFER, LN; WEST, KW				TYCKO, R; BARRETT, SE; DABBAGH, G; PFEIFFER, LN; WEST, KW			ELECTRONIC STATES IN GALLIUM-ARSENIDE QUANTUM-WELLS PROBED BY OPTICALLY PUMPED NMR	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SPIN-LATTICE RELAXATION; FIELD DEPENDENCE; GAS; DIFFUSION; ENERGIES	An optical pumping technique was used to enhance and localize nuclear magnetic resonance (NMR) signals from an n-doped GaAs/Al0.1Ga0.9As multiple quantum well structure, permitting direct radio-frequency measurements of gallium-71 NMR spectra and nuclear spin-lattice relaxation rates (1/T-1) as functions of temperature (1.6 K < T < 4.2 K) and the Landau level filling factor (0.66 < nu < 1.76). The measurements reveal effects of electron-electron interactions on the energy levels and spin states of the two-dimensional electron system confined in the GaAs wells. Minima in 1/T-1 at nu approximate to 1 and nu approximate to 2/3 indicate energy gaps for electronic excitations in both integer and fractional quantum Hall states. Rapid, temperature-independent relaxation at intermediate v values indicates a manifold of low-lying electronic states with mixed spin polarizations.	AT&T BELL LABS,MURRAY HILL,NJ 07974	AT&T; Nokia Corporation; Nokia Bell Labs			Barrett, Sean E/F-1274-2015	Barrett, Sean E/0000-0002-0498-2027				ANTONIOU D, 1991, PHYS REV B, V43, P11686, DOI 10.1103/PhysRevB.43.11686; BARRETT SE, 1994, PHYS REV LETT, V72, P1368, DOI 10.1103/PhysRevLett.72.1368; BARRETT SE, IN PRESS PHYS REV LE; BERG A, 1990, PHYS REV LETT, V64, P2563, DOI 10.1103/PhysRevLett.64.2563; BOEBINGER GS, 1985, PHYS REV LETT, V55, P1606, DOI 10.1103/PhysRevLett.55.1606; BURATTO SK, 1992, J VAC SCI TECHNOL B, V10, P1740, DOI 10.1116/1.586233; BURATTO SK, 1991, PHYS REV B, V44, P9035, DOI 10.1103/PhysRevB.44.9035; DEVREESE JT, 1987, PHYSICS 2 DIMENSIONA; EISENSTEIN JP, 1990, SCIENCE, V248, P1510, DOI 10.1126/science.248.4962.1510; EISENSTEIN JP, 1994, SCIENCE, V266, P1199; FERTIG HA, 1994, PHYS REV B, V50, P11018, DOI 10.1103/PhysRevB.50.11018; FLINN GP, 1990, SEMICOND SCI TECH, V5, P533, DOI 10.1088/0268-1242/5/6/012; FURNEAUX JE, 1989, PHYS REV LETT, V63, P1098, DOI 10.1103/PhysRevLett.63.1098; IORDANSKII SV, 1991, PHYS REV B, V44, P6554, DOI 10.1103/PhysRevB.44.6554; KALEVICH VK, 1990, JETP LETT+, V52, P349; KIM JH, 1994, PHYS REV B, V49, P16777, DOI 10.1103/PhysRevB.49.16777; KRAPF M, 1991, SOLID STATE COMMUN, V78, P459, DOI 10.1016/0038-1098(91)90704-Y; LAMPEL G, 1968, PHYS REV LETT, V20, P491, DOI 10.1103/PhysRevLett.20.491; MARTINDALE JA, 1992, PHYS REV LETT, V68, P702, DOI 10.1103/PhysRevLett.68.702; OVCHINNIKOV YN, 1994, JETP LETT+, V59, P569; PAGET D, 1977, PHYS REV B, V15, P5780, DOI 10.1103/PhysRevB.15.5780; RICHARDSON SL, 1986, PHYS REV B, V33, P1177, DOI 10.1103/PhysRevB.33.1177; SUTER D, 1985, PHYS REV B, V32, P5608, DOI 10.1103/PhysRevB.32.5608; TYCKO R, 1991, SCIENCE, V253, P884, DOI 10.1126/science.253.5022.884; TYCKO R, 1992, ISRAEL J CHEM, V32, P179; TYCKO R, 1993, J PHYS CHEM SOLIDS, V54, P1713, DOI 10.1016/0022-3697(93)90286-Z; WALSTEDT RE, 1990, SCIENCE, V248, P1082, DOI 10.1126/science.248.4959.1082; WEISBUCH C, 1991, QUANTUM SEMICONDUCTO, P123; Winter J., 1971, MAGNETIC RESONANCE M	30	246	247	1	32	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1460	1463		10.1126/science.7539550	http://dx.doi.org/10.1126/science.7539550			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7539550				2022-12-28	WOS:A1995RC19000029
J	BERLIN, C; BARGATZE, RF; CAMPBELL, JJ; VONANDRIAN, UH; SZABO, MC; HASSLEN, SR; NELSON, RD; BERG, EL; ERLANDSEN, SL; BUTCHER, EC				BERLIN, C; BARGATZE, RF; CAMPBELL, JJ; VONANDRIAN, UH; SZABO, MC; HASSLEN, SR; NELSON, RD; BERG, EL; ERLANDSEN, SL; BUTCHER, EC			ALPHA-4 INTEGRINS MEDIATE LYMPHOCYTE ATTACHMENT AND ROLLING UNDER PHYSIOLOGICAL FLOW	CELL			English	Article							HIGH ENDOTHELIAL VENULES; VASCULAR ADDRESSIN; SELECTIN; ADHESION; MADCAM-1; LECAM-1; SPECIFICITY; LEUKOCYTES; MECHANISMS; EXPRESSION	Of the several families of adhesion receptors involved in leukocyte-endoethelial cell interactions, only the selectins have been shown to initiate leukocyte interaction under physiologic shear; indeed, beta 2 (CD18) integrins responsible for neutrophil arrest are unable to engage without prior selectin-mediated rolling. In contrast, alpha 4 (CD49d) integrins are shown here to initiate lymphocyte contact (''tethering'') In vitro under shear and in the absence of a selectin contribution. The alpha 4 integrin ligands MAdCAM-1 and VCAM-1 support loose reversible interactions including rolling, as well as rapid sticking and arrest that is favored following integrin activation. Moreover, alpha 4 beta 7 mediates L-selectin (CD62L)-independent attachment of blood-borne lymphocytes to lamina propria venules in situ. Scanning electron microscopy of alpha 4 beta 7(hi) lymphoid cells reveals that, like L-selectin, alpha 4 beta 7 is highly concentrated on microvillous sites of initial cellular contact, whereas the beta 2 integrin LFA-1 is excluded from villi. Thus, alpha 4 but not beta 2 integrins can initiate leukocyte adhesion under flow, a capacity that may be in part a function of topographic presentation on microvilli.	VET AFFAIRS MED CTR,CTR MOLEC BIOL & MED,FOOTHILL RES CTR,PALO ALTO,CA 94304; MONTANA STATE UNIV,VET MOLEC BIOL LAB,BOZEMAN,MT 59717; UNIV MINNESOTA,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT DERMATOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455; CTR BLOOD RES,BOSTON,MA 02115; PROT DESIGN LABS,MT VIEW,CA 94043	US Department of Veterans Affairs; Veterans Health Administration (VHA); Montana State University System; Montana State University Bozeman; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)	BERLIN, C (corresponding author), STANFORD UNIV,DEPT PATHOL,IMMUNOL & VASC BIOL LAB,STANFORD,CA 94305, USA.		Berg, Ellen/T-8827-2019; Berg, Ellen/D-9076-2014; von Andrian, Ulrich H/A-5775-2008	Berg, Ellen/0000-0001-5149-6665; 	NIAID NIH HHS [AI19957, AI37832] Funding Source: Medline; NIGMS NIH HHS [GM37734] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037832, R01AI019957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037734, R01GM037734] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABASSI O, 1993, BLOOD CELLS, V19, P245; ALON R, 1995, IN PRESS J CELL BIOL; ANDREW DP, 1994, J IMMUNOL, V153, P3847; ATHERTON A, 1972, J PHYSIOL-LONDON, V222, P447, DOI 10.1113/jphysiol.1972.sp009808; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; BUTCHER EC, 1980, EUR J IMMUNOL, V10, P556, DOI 10.1002/eji.1830100713; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; DUNON D, 1993, BLOOD, V81, P1; ERLANDSEN SL, 1993, J HISTOCHEM CYTOCHEM, V41, P327, DOI 10.1177/41.3.7679125; ERLE DJ, 1994, J IMMUNOL, V153, P517; HAMANN A, 1994, J IMMUNOL, V52, P3282; HU MCT, 1992, P NATL ACAD SCI USA, V89, P8254, DOI 10.1073/pnas.89.17.8254; JONES DA, 1995, IN PRESS J CLIN INVE; JUTILA MA, 1989, CELL IMMUNOL, V132, P201; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; MACKAY CR, 1993, CURR OPIN IMMUNOL, V5, P423, DOI 10.1016/0952-7915(93)90063-X; NAKACHE M, 1988, NATURE, V304, P32; PERRY MA, 1991, J CLIN INVEST, V87, P1798, DOI 10.1172/JCI115200; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; POSTIGO AA, 1993, RES IMMUNOL, V144, P723, DOI 10.1016/S0923-2494(93)80057-6; SCHWEIGHOFFER T, 1993, J IMMUNOL, V151, P717; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SRIRAMARAO P, 1994, J IMMUNOL, V153, P4238; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; VANEWIJK WV, 1980, DIBA F S, V71, P21; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; VONANDRIAN UH, 1993, AGENT ACTION SUPPL, V41, P153; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WOLBER F, 1993, FASEB J, V7, P3704	38	868	890	0	22	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					413	422		10.1016/0092-8674(95)90491-3	http://dx.doi.org/10.1016/0092-8674(95)90491-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7532110	Bronze			2022-12-28	WOS:A1995QG47000007
J	UCKUN, FM; EVANS, WE; FORSYTH, CJ; WADDICK, KG; AHLGREN, LT; CHELSTROM, LM; BURKHARDT, A; BOLEN, J; MYERS, DE				UCKUN, FM; EVANS, WE; FORSYTH, CJ; WADDICK, KG; AHLGREN, LT; CHELSTROM, LM; BURKHARDT, A; BOLEN, J; MYERS, DE			BIOTHERAPY OF B-CELL PRECURSOR LEUKEMIA BY TARGETING GENISTEIN TO CD19-ASSOCIATED TYROSINE KINASES	SCIENCE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; POKEWEED ANTIVIRAL PROTEIN; SEVERE COMBINED IMMUNODEFICIENCY; DISCRETE DEVELOPMENTAL STAGES; EXPRESS FUNCTIONAL RECEPTORS; BONE-MARROW TRANSPLANTATION; SIGNAL-TRANSDUCTION COMPLEX; LYMPHOCYTES-B; GROWTH-FACTOR; PROGENITOR CELLS	B-cell precursor (BCP) leukemia is the most common form of childhood cancer and the second most common form of acute leukemia in adults. Human BCP leukemia was treated in a severe combined immunodeficient mouse model by targeting of the tyrosine kinase inhibitor Genistein (Gen) to the B cell-specific receptor CD19 with the monoclonal antibody B43. The B43-Gen immunoconjugate bound with high affinity to BCP leukemia cells, selectively inhibited CD19-associated tyrosine kinases, and triggered rapid apoptotic cell death. At less than one-tenth the maximum tolerated dose more than 99.999 percent of human BCP leukemia cells were killed, which led to 100 percent long-term event-free survival from an otherwise invariably fatal leukemia. The B43-Gen immunoconjugate might be useful in eliminating leukemia cells in patients who have failed conventional therapy.	UNIV MINNESOTA, DEPT PEDIAT, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT PHARMACOL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, CHILDRENS CANC GRP, CENTRALIZED IMMUNOCONJUGATE REFERENCE LAB, MINNEAPOLIS, MN 55455 USA; ST JUDE CHILDRENS RES HOSP, DEPT PHARMACEUT, MEMPHIS, TN 38101 USA; UNIV MINNESOTA, DEPT CHEM, MINNEAPOLIS, MN 55455 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, SIGNAL TRANSDUCT LAB, PRINCETON, NJ 08543 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; St Jude Children's Research Hospital; University of Minnesota System; University of Minnesota Twin Cities; Bristol-Myers Squibb	UCKUN, FM (corresponding author), UNIV MINNESOTA, DEPT THERAPEUT RADIOL RADIAT ONCOL, BIOTHERAPY PROGRAM, MINNEAPOLIS, MN 55455 USA.		Evans, William E./C-2069-2012	Evans, William E./0000-0002-9333-5322; Uckun, Fatih M./0000-0001-9334-183X	NCI NIH HHS [CA-42111, CA-51425, CA-42633] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA042111, R01CA042111, R01CA042633, R01CA051425] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLERCREUTZ H, 1991, AM J CLIN NUTR, V54, P1093, DOI 10.1093/ajcn/54.6.1093; ADLERCREUTZ H, 1991, CLIN CHIM ACTA, V199, P263, DOI 10.1016/0009-8981(91)90120-2; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BRADBURY LE, 1993, J IMMUNOL, V151, P2915; BURKE TR, 1993, J MED CHEM, V36, P425, DOI 10.1021/jm00056a001; CALLARD RE, 1992, J IMMUNOL, V148, P2983; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CHALUPNY NJ, 1993, EMBO J, V12, P2691, DOI 10.1002/j.1460-2075.1993.tb05930.x; COHEN DI, 1992, SCIENCE, V256, P542, DOI 10.1126/science.1570514; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Cope FO., 1991, APOPTOSIS MOL BASIS, P47; CUSHMAN M, 1991, J MED CHEM, V34, P798, DOI 10.1021/jm00106a047; CUSHMAN M, 1994, J MED CHEM, V37, P3353, DOI 10.1021/jm00046a020; DARGENIO DZ, 1979, COMPUT PROG BIOMED, V9, P115, DOI 10.1016/0010-468X(79)90025-4; DICKSON RB, 1983, BIOCHEMISTRY-US, V22, P5667, DOI 10.1021/bi00293a033; EVANS CA, 1993, CANCER RES, V53, P1735; GERLOWSKI LE, 1983, J PHARM SCI, V72, P1103, DOI 10.1002/jps.2600721003; GREAVES M, 1993, BLOOD, V82, P1043; GREAVES MF, 1986, SCIENCE, V234, P697, DOI 10.1126/science.3535067; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Jin J., UNPUB; KAUFMANN SH, 1989, CANCER RES, V49, P5870; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P1897, DOI 10.1073/pnas.85.6.1897; MANSKE J, 1986, THESIS U MINNESOTA; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; MYERS DE, UNPUB KINASE RENATUR; MYERS DE, 1987, BLOOD, V70, P1020; NADLER LM, 1983, J IMMUNOL, V131, P244; OTANI H, 1993, J BIOL CHEM, V268, P22733; PASTAN I, 1986, CELL, V47, P641, DOI 10.1016/0092-8674(86)90506-4; PETTERSSON H, 1984, J ASSOC OFF ANA CHEM, V67, P503; REAMAN G, IN PRESS LEUKEMIA LY; RENNER C, 1994, SCIENCE, V264, P833, DOI 10.1126/science.8171337; RIVERA GK, 1993, NEW ENGL J MED, V329, P1289, DOI 10.1056/NEJM199310283291801; SCHEUERMANN RH, 1994, P NATL ACAD SCI USA, V91, P4048, DOI 10.1073/pnas.91.9.4048; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; STAMENKOVIC I, 1988, J EXP MED, V168, P1205, DOI 10.1084/jem.168.3.1205; TEDDER TF, 1989, J IMMUNOL, V143, P712; TRAIL PA, 1993, SCIENCE, V261, P212, DOI 10.1126/science.8327892; TREVILLYAN JM, 1990, J IMMUNOL, V145, P3223; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; UCKUN FM, 1992, BLOOD, V79, P3369; UCKUN FM, 1993, BRIT J HAEMATOL, V85, P435; UCKUN FM, 1985, J IMMUNOL, V134, P3504; UCKUN FM, 1992, BLOOD, V79, P2201; UCKUN FM, 1992, BLOOD, V79, P3116; UCKUN FM, 1993, BLOOD, V81, P1323; UCKUN FM, 1993, NEW ENGL J MED, V329, P1296, DOI 10.1056/NEJM199310283291802; UCKUN FM, 1989, BLOOD, V73, P533; UCKUN FM, 1988, P NATL ACAD SCI USA, V85, P8603, DOI 10.1073/pnas.85.22.8603; UCKUN FM, 1989, BLOOD, V74, P761; UCKUN FM, 1991, J BIOL CHEM, V266, P17478; UCKUN FM, 1986, J EXP MED, V163, P347, DOI 10.1084/jem.163.2.347; UCKUN FM, 1990, BLOOD, V76, P1908; UCKUN FM, 1988, BLOOD, V71, P13; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; UCKUN FM, UNPUB; VITETTA ES, 1987, SCIENCE, V238, P1098, DOI 10.1126/science.3317828	64	256	284	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	1995	267	5199					886	891		10.1126/science.7531365	http://dx.doi.org/10.1126/science.7531365			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7531365				2022-12-28	WOS:A1995QG20700059
J	ILLANGASEKARE, M; SANCHEZ, G; NICKLES, T; YARUS, M				ILLANGASEKARE, M; SANCHEZ, G; NICKLES, T; YARUS, M			AMINOACYL-RNA SYNTHESIS CATALYZED BY AN RNA	SCIENCE			English	Article							NUCLEOTIDES; TETRAHYMENA; POLYMERASE; BINDING	An RNA has been selected that rapidly aminoacylates its 2'(3') terminus when provided with phenylalanyl-adenosine monophosphate. That is, the RNA accelerates the same aminoacyl group transfer catalyzed by protein aminoacyl-transfer RNA synthetases. The best characterized RNA reaction requires both Mg2+ and Ca2+. These results confirm a necessary prediction of the RNA world hypothesis and represent efficient RNA reaction (greater than or equal to 10(5) times accelerated) at a carbonyl carbon, exemplifying a little explored type of RNA catalysis.			ILLANGASEKARE, M (corresponding author), UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, BOULDER, CO 80309 USA.		Yarus, Michael/Q-9813-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030881, R01GM048080, R37GM030881] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30881, GM48080] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BELRHALI H, 1994, SCIENCE, V263, P1432, DOI 10.1126/science.8128224; BERG P, 1958, J BIOL CHEM, V233, P608; BROWN EA, 1980, ACTA CRYSTALLOGR B, V36, P2597, DOI 10.1107/S0567740880009508; CAVARELLI J, 1994, EMBO J, V13, P327, DOI 10.1002/j.1460-2075.1994.tb06265.x; CONNELL GJ, 1993, BIOCHEMISTRY-US, V32, P5497, DOI 10.1021/bi00072a002; CONNELL GJ, 1994, SCIENCE, V264, P1137, DOI 10.1126/science.7513905; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GILLAM I, 1968, BIOCHEMISTRY-US, V7, P3459, DOI 10.1021/bi00850a022; GOTTIKH BP, 1970, TETRAHEDRON, V26, P4419, DOI 10.1016/S0040-4020(01)93090-X; JAEGER JA, 1990, METHOD ENZYMOL, V183, P281; MAJERFELD I, 1994, NAT STRUCT BIOL, V1, P287, DOI 10.1038/nsb0594-287; MCLAUGHLIN CS, 1965, BIOCHEMISTRY-US, V4, P1442, DOI 10.1021/bi00883a032; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; SCHOFIEL.P, 1968, BIOCHIM BIOPHYS ACTA, V155, P410, DOI 10.1016/0005-2787(68)90185-8; STEINSCHNEIDER A, 1966, BIOCHEMISTRY-US, V5, P2729, DOI 10.1021/bi00872a033; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WEBER AL, 1975, J MOL EVOL, V6, P309, DOI 10.1007/BF01794637; WELCH M, 1995, BIOCHEMISTRY-US, V34, P385, DOI 10.1021/bi00002a001; WICKRAMASINGHE NSMD, 1991, BIOCHEMISTRY-US, V30, P2768, DOI 10.1021/bi00225a005; WOLFENDEN R, 1964, BIOCHEMISTRY-US, V3, P329, DOI 10.1021/bi00891a006; YARUS M, 1993, FASEB J, V7, P31, DOI 10.1096/fasebj.7.1.8422972; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; Yarus M., 1993, RNA WORLD, P205	28	269	286	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	1995	267	5198					643	647		10.1126/science.7530860	http://dx.doi.org/10.1126/science.7530860			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7530860				2022-12-28	WOS:A1995QE73300028
J	BLECHMAN, JM; LEV, S; BARG, J; EISENSTEIN, M; VAKS, B; VOGEL, Z; GIVOL, D; YARDEN, Y				BLECHMAN, JM; LEV, S; BARG, J; EISENSTEIN, M; VAKS, B; VOGEL, Z; GIVOL, D; YARDEN, Y			THE 4TH IMMUNOGLOBULIN DOMAIN OF THE STEM-CELL FACTOR-RECEPTOR COUPLES LIGAND-BINDING TO SIGNAL-TRANSDUCTION	CELL			English	Article							GROWTH-FACTOR RECEPTORS; ACTIN REORGANIZATION; INDUCED DIMERIZATION; CRYSTAL-STRUCTURE; KIT RECEPTOR; ACTIVATION; PROTEIN; KINASE; SITE; HETERODIMERIZATION	Receptor dimerization is ubiquitous to the action of all receptor tyrosine kinases, and in the case of dimeric ligands, such as the stem cell factor (SCF), it was attributed to ligand bivalency. However, by using a dimerization-inhibitory monoclonal antibody to the SCF receptor, we confined a putative dimerization site to the nonstandard fourth immunoglobulin-like domain of the receptor. Deletion of this domain not only abolished ligand-induced dimerization and completely inhibited signal transduction, but also provided insights into the mechanism of the coupling of ligand binding to dimer formation. These results identify an intrinsic receptor dimerization site and suggest that similar sites may exist in other receptors.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT BIOL STRUCT,IL-76100 REHOVOT,ISRAEL; TEL AVIV UNIV,EDITH WOLFSON MED CTR,SCH MED,CARDIOVASC & HYPERTENS RES LAB,IL-58100 HOLON,ISRAEL; BIOMAKOR,IL-76326 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Tel Aviv University			YARDEN, YOSEF/K-1467-2012; Lev, Sima/AAP-7880-2020	Lev, Sima/0000-0002-2108-3330				AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; BENLEVY R, 1992, J BIOL CHEM, V265, P17304; BERKERS JAM, 1991, J BIOL CHEM, V266, P922; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BLECHMAN JM, 1993, J BIOL CHEM, V268, P4399; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BRADY RL, 1993, SCIENCE, V260, P979, DOI 10.1126/science.8493535; CARLBERG K, 1994, MOL BIOL CELL, V5, P81, DOI 10.1091/mbc.5.1.81; COCHET C, 1988, J BIOL CHEM, V263, P3290; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V420, P2361; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HERREN B, 1993, J BIOL CHEM, V268, P15088; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KRAUTWALD S, 1993, BIOCHEM BIOPH RES CO, V192, P720, DOI 10.1006/bbrc.1993.1474; LEV S, 1993, MOL CELL BIOL, V13, P2224, DOI 10.1128/MCB.13.4.2224; LEV S, 1992, J BIOL CHEM, V267, P15970; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LEV S, 1992, J BIOL CHEM, V267, P10866; LEVITT M, 1983, J MOL BIOL, V168, P595, DOI 10.1016/S0022-2836(83)80304-0; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; RAMACHANDRAN GN, 1968, ADV PROTEIN CHEM, V28, P283; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	35	131	146	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					103	113		10.1016/0092-8674(95)90455-7	http://dx.doi.org/10.1016/0092-8674(95)90455-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7529140	Bronze			2022-12-28	WOS:A1995QB91000014
J	BERARDI, AC; WANG, AL; LEVINE, JD; LOPEZ, P; SCADDEN, DT				BERARDI, AC; WANG, AL; LEVINE, JD; LOPEZ, P; SCADDEN, DT			FUNCTIONAL ISOLATION AND CHARACTERIZATION OF HUMAN HEMATOPOIETIC STEM-CELLS	SCIENCE			English	Article							ERYTHROPOIETIN RECEPTOR GENE; IL-6 SIGNAL TRANSDUCER; COLONY-FORMING CELLS; MURINE BONE-MARROW; LONG-TERM CULTURE; PROGENITOR CELLS; LIMITING-DILUTION; C-KIT; MONOCLONAL-ANTIBODY; SOYBEAN AGGLUTININ	Hematopoietic cells differentiate in steps marked by the acquisition or loss of specific phenotypic characteristics. Human bone marrow cells that were responsive to the early-acting cytokines Kit ligand and interleukin-3 were forced to a metabolic death. The subfraction remaining represented 1 in 10(5) bone marrow mononuclear cells, was determined to be quiescent by cell cycle analysis, and had a stem cell immunophenotype, The cells were highly enriched for long-term culture-initiating cells, were capable of secondary colony formation, and produced both myeloid and lymphoid progeny. Thus, this technically simple strategy led to the efficient purification of cells with characteristics of hematopoietic stem cells.	HARVARD UNIV, DEACONESS HOSP, SCH MED, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, CELL SORTING FACIL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Berardi, Anna Concetta/M-6769-2019; Cosset, François-Loïc/M-5862-2019; Lopez, Peter/AAP-7234-2020	Berardi, Anna Concetta/0000-0002-5078-6158; Cosset, François-Loïc/0000-0001-8842-3726; Lopez, Peter/0000-0002-8587-7148	NHLBI NIH HHS [R01-HL44851] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044851] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADY G, 1990, Methods in Molecular and Cellular Biology, V2, P17; BRANDT J, 1992, BLOOD, V79, P634; BRIDDELL RA, 1992, BLOOD, V79, P3159; CHIBA S, 1990, CELL REGUL, V1, P327, DOI 10.1091/mbc.1.4.327; CIVIN CI, 1984, J IMMUNOL, V133, P157; CIVIN CI, 1987, EXP HEMATOL, V15, P10; COULOMBEL L, 1983, BLOOD, V62, P291; CRAIG W, 1993, J EXP MED, V177, P1331, DOI 10.1084/jem.177.5.1331; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; EBELL W, 1985, BLOOD, V65, P1105; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GORDON MY, 1985, LEUKEMIA RES, V9, P1017, DOI 10.1016/0145-2126(85)90072-4; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HUANG S, 1994, BLOOD, V83, P1515, DOI 10.1182/blood.V83.6.1515.bloodjournal8361515; INABA M, 1990, JPN J CANCER RES, V81, P1039, DOI 10.1111/j.1349-7006.1990.tb03343.x; KATAYAMA N, 1993, BLOOD, V81, P610; KRIEGLER AB, 1994, EXP HEMATOL, V22, P432; LEMIEUX ME, 1993, BLOOD, V82, pA13; LERNER C, 1990, EXP HEMATOL, V18, P114; MCNIECE IK, 1990, INT J CELL CLONING, V8, P146, DOI 10.1002/stem.5530080302; MUENCH MO, 1992, EXP HEMATOL, V20, P339; NAKAGUA Y, 1994, D26616 GENB ACC; OGATA H, 1992, BLOOD, V80, P91; PLOEMACHER RE, 1988, EXP HEMATOL, V16, P903; PLOEMACHER RE, 1989, BLOOD, V74, P2755; Pollack A, 1990, Methods Cell Biol, V33, P19; PORTER EH, 1963, BRIT J CANCER, V17, P583, DOI 10.1038/bjc.1963.78; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REISNER Y, 1982, BLOOD, V59, P360; SATO N, 1993, BLOOD, V82, P3600; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SISTONEN P, 1993, HUM GENET, V92, P299, DOI 10.1007/BF00244476; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; SMITH C, 1991, BLOOD, V77, P2122; SPANGRUDE GJ, 1990, P NATL ACAD SCI USA, V87, P7433, DOI 10.1073/pnas.87.19.7433; SROUR EF, 1993, BLOOD, V82, P3333; STEWART FM, 1993, BLOOD, V81, P2283; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; SUTHERLAND HJ, 1993, BLOOD, V81, P1465; TAKIMOTO CH, 1993, J BIOL CHEM, V268, P21438; TASWELL C, 1981, J IMMUNOL, V126, P1614; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; TESTA U, 1993, BLOOD, V81, P1442; TRUMPER LH, 1993, BLOOD, V81, P3097; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; WHITLOCK CA, 1984, J IMMUNOL METHODS, V67, P353, DOI 10.1016/0022-1759(84)90475-7; WICKREMA A, 1992, BLOOD, V80, P1940, DOI 10.1182/blood.V80.8.1940.1940; WOLF NS, 1993, EXP HEMATOL, V21, P614; YAMAGUCHI Y, 1993, EXP HEMATOL, V21, P1233; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223; ZIPORI D, 1988, BLOOD, V71, P586	55	358	385	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 6	1995	267	5194					104	108		10.1126/science.7528940	http://dx.doi.org/10.1126/science.7528940			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA235	7528940				2022-12-28	WOS:A1995QA23500040
J	DEMARCO, PJ; KEATING, RM				DEMARCO, PJ; KEATING, RM			CHOLESTEROL CRYSTALS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											DEMARCO, PJ (corresponding author), USN,MED CTR,SAN DIEGO,CA 92134, USA.								0	1	1	1	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	1995	333	20					1325	1325		10.1056/NEJM199511163332005	http://dx.doi.org/10.1056/NEJM199511163332005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE365	7566024				2022-12-28	WOS:A1995TE36500005
J	PUTTERMAN, C; BENCHETRIT, E				PUTTERMAN, C; BENCHETRIT, E			TESTING, TESTING, TESTING	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							HYPEREOSINOPHILIC SYNDROME		YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED, DIV RHEUMATOL, BRONX, NY 10461 USA; HADASSAH UNIV HOSP, DIV MED, RHEUMATOL UNIT, IL-91120 JERUSALEM, ISRAEL	Yeshiva University; Albert Einstein College of Medicine; Hebrew University of Jerusalem								ALLMAN RM, 1985, JAMA-J AM MED ASSOC, V254, P246, DOI 10.1001/jama.254.2.246; EISENBERG JM, 1984, ARCH INTERN MED, V144, P715, DOI 10.1001/archinte.144.4.715; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; KASSIRER JP, 1989, NEW ENGL J MED, V320, P1489, DOI 10.1056/NEJM198906013202211; PARRILLO JE, 1978, ANN INTERN MED, V89, P167, DOI 10.7326/0003-4819-89-2-167; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; THIBAULT GE, 1994, NEW ENGL J MED, V331, P1216, DOI 10.1056/NEJM199411033311809; WELLER PF, 1994, BLOOD, V83, P2759, DOI 10.1182/blood.V83.10.2759.2759	8	16	16	1	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 2	1995	333	18					1208	1211		10.1056/NEJM199511023331809	http://dx.doi.org/10.1056/NEJM199511023331809			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB560	7565978				2022-12-28	WOS:A1995TB56000009
J	MARGOLIS, HS; COLEMAN, PJ; BROWN, RE; MAST, EE; SHEINGOLD, SH; AREVALO, JA				MARGOLIS, HS; COLEMAN, PJ; BROWN, RE; MAST, EE; SHEINGOLD, SH; AREVALO, JA			PREVENTION OF HEPATITIS-B VIRUS TRANSMISSION BY IMMUNIZATION - AN ECONOMIC-ANALYSIS OF CURRENT RECOMMENDATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COST-EFFECTIVENESS ANALYSIS; UNITED-STATES; CARRIER STATE; FOLLOW-UP; HEPATOCELLULAR-CARCINOMA; VACCINATION STRATEGIES; IMMUNE GLOBULIN; NATURAL-HISTORY; LIVER-DISEASE; DOUBLE-BLIND	Objective.-To evaluate the outcome of immunization strategies to prevent hepatitis B virus (HBV) transmission. Design and Setting.-A decision model was used to determine the incremental effects of the following hepatitis B immunization strategies in a birth cohort receiving immunization services in the public sector: (1) prevention of perinatal HBV infection, (2) routine infant vaccination, or (3) routine adolescent vaccination. Main Outcome Measures.-Over the lifetime of the cohort, the reduction in infections and medical and work-loss costs of HBV-related liver disease were determined for each strategy and compared with the outcome without immunization. Results.-Prevention of perinatal infection and routine infant vaccination would lower the 4.8% lifetime risk of HBV infection by at least 68%, compared with a 45% reduction for adolescent vaccination. From a societal perspective, each strategy was found to be cost saving, but was not cost saving with respect to direct medical costs. The estimated cost per year of life saved was $164 to prevent perinatal HBV infection, $1522 for infant vaccination, and $3730 for adolescent vaccination. Conclusions.-Routine vaccination of infants in successive birth cohorts to prevent HBV transmission is cost-effective over a wide range of assumptions. While economically less attractive than infant vaccination, adolescent vaccination could serve to protect those children who were not vaccinated as infants.	BATTELLE HUMAN AFFAIRS RES CTR,WASHINGTON,DC; US HLTH CARE FINANCING ADM,BUR POLICY DEV,OFF TECHNOL & SPECIAL ANAL,WASHINGTON,DC; PLANNED PARENTHOOD SACRAMENTO VALLEY,SACRAMENTO,CA		MARGOLIS, HS (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,HEPATITIS BRANCH A-33,ATLANTA,GA 30333, USA.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257				ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; ANDRE FE, 1994, J MED VIROL, V44, P144, DOI 10.1002/jmv.1890440206; AREVALO JA, 1988, JAMA-J AM MED ASSOC, V259, P365, DOI 10.1001/jama.259.3.365; BEASLEY RP, 1983, HEPATOLOGY, V3, P135; BEASLEY RP, 1983, LANCET, V2, P1099; BEASLEY RP, 1983, J INFECT DIS, V147, P185, DOI 10.1093/infdis/147.2.185; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BEASLEY RP, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P532; BLOOM BS, 1993, ANN INTERN MED, V118, P298, DOI 10.7326/0003-4819-118-4-199302150-00009; BRUCE BR, 1990, STANDARDS SOCIOECONO; BUYLE MH, 1983, NEW ENGL J MED, V308, P1330; CHEN DS, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P716; CHOTARD J, 1992, J INFECT DIS, V166, P764, DOI 10.1093/infdis/166.4.764; COCHI SL, 1985, JAMA-J AM MED ASSOC, V253, P521, DOI 10.1001/jama.253.4.521; DEJONGH FE, 1992, GASTROENTEROLOGY, V103, P1630, DOI 10.1016/0016-5085(92)91188-A; FATTOVICH G, 1991, GUT, V32, P294, DOI 10.1136/gut.32.3.294; FRANKS AL, 1989, NEW ENGL J MED, V321, P1301, DOI 10.1056/NEJM198911093211905; GANIATS TG, 1993, J FAM PRACTICE, V36, P147; GOH KT, 1992, B WORLD HEALTH ORGAN, V70, P233; GREENBERG DP, 1992, 32ND INT C ANT AG CH; HADLER SC, 1986, NEW ENGL J MED, V215, P209; HADLER SC, 1992, CURRENT CLIN TOPICS, P282; HEYWARD WL, 1985, AM J EPIDEMIOL, V121, P914, DOI 10.1093/oxfordjournals.aje.a114061; HOOFNAGLE JH, 1987, HEPATOLOGY, V7, P758, DOI 10.1002/hep.1840070424; HORNEY JT, 1977, GASTROENTEROLOGY, V73, P639; HSIEH CC, 1992, AM J EPIDEMIOL, V136, P1115, DOI 10.1093/oxfordjournals.aje.a116577; HURIE MB, 1992, PEDIATRICS, V89, P269; JONAS MM, 1987, ANN INTERN MED, V107, P335, DOI 10.7326/0003-4819-107-2-335; KARVOUNTZIS GG, 1974, GASTROENTEROLOGY, V67, P870; KRAHN M, 1993, MED DECIS MAKING, V13, P4, DOI 10.1177/0272989X9301300103; LASHNER BA, 1988, AM J MED, V85, P609; LIAW YF, 1988, HEPATOLOGY, V8, P493, DOI 10.1002/hep.1840080310; LO KJ, 1982, J INFECT DIS, V146, P205, DOI 10.1093/infdis/146.2.205; MAHONEY FJ, 1993, J INFECT DIS, V167, P203, DOI 10.1093/infdis/167.1.203; MARGOLIS HS, 1991, SEMIN LIVER DIS, V11, P84, DOI 10.1055/s-2008-1040427; MARGOLIS HS, 1993, J INFECT DIS, V168, P9, DOI 10.1093/infdis/168.1.9; MARGOLIS HS, 1990, VACCINE, V8, pS81, DOI 10.1016/0264-410X(90)90224-A; MARGOLIS HS, 1993, PEDIATR INFECT DIS J, V12, P542; MARION SA, 1994, AM J EPIDEMIOL, V140, P734, DOI 10.1093/oxfordjournals.aje.a117321; MAST EE, 1990, JAMA-J AM MED ASSOC, V264, P2529, DOI 10.1001/jama.264.19.2529; MCMAHON BJ, 1985, J INFECT DIS, V151, P599, DOI 10.1093/infdis/151.4.599; MCMAHON BJ, 1987, LANCET, V2, P1134; MCMAHON BJ, 1990, ARCH INTERN MED, V150, P1051, DOI 10.1001/archinte.150.5.1051; MCQUILLAN GM, 1989, AM J MED S3A, V87, P5; MULLEY AG, 1982, NEW ENGL J MED, V307, P644, DOI 10.1056/NEJM198209093071103; SCHARTZ G, 1990, PROGR HEPATITIS B IM, P533; SINGH S, 1989, PRENATAL CARE US STA; SISK JE, 1986, ANN INTERN MED, V104, P79, DOI 10.7326/0003-4819-104-1-79; STEVENS CE, 1992, PEDIATRICS, V90, P170; STEVENS CE, 1995, UNPUB INFANTS HIGH R; STRATTON KR, 1994, ADVERSE EVENTS ASS C, P211; TONG MJ, 1984, J PEDIATR-US, V105, P945, DOI 10.1016/S0022-3476(84)80084-0; TORRANCE GW, 1984, CLIN PERINATOL, V11, P267, DOI 10.1016/S0095-5108(18)30920-5; VIOLA LA, 1981, LANCET, V2, P1156; WAINWRIGHT RB, 1989, JAMA-J AM MED ASSOC, V261, P2362, DOI 10.1001/jama.261.16.2362; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; Weinstein MC, 1980, CLIN DECISION ANAL; WEISSBERG JI, 1984, ANN INTERN MED, V101, P613, DOI 10.7326/0003-4819-101-5-613; WEST DJ, 1992, PEDIATR INFECT DIS J, V11, P866, DOI 10.1097/00006454-199210000-00012; XU ZY, 1985, PEDIATRICS, V76, P713; 1992, PEDIATRICS, V89, P795; 1991, FED REGISTER, V56, P64004; 1994, MMWR-MORBID MORTAL W, V43, P605; 1991, EMPLOY EARN, P37; 1990, 52 CTR DIS CONTR HEP; [No title captured]; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1994, MMWR-MORBID MORTAL W, V43, P317; 1988, MMWR-MORBID MORTAL W, V37, P341; 1994, MMWR-MORBID MORTAL W, V43, P311; 1991, MMWR-MORBID MORTAL W, V40, P1; 1991, MMWR-MORBID MORTAL W, V40, P700	72	232	239	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	1995	274	15					1201	1208		10.1001/jama.274.15.1201	http://dx.doi.org/10.1001/jama.274.15.1201			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ120	7563509				2022-12-28	WOS:A1995RZ12000028
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PHARMACEUTICAL PROMOTION HEARINGS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1995, FED REG         0814, V60, P41891; 1995, FED REG         0816, V60, P42581	2	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1109	1109						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563473				2022-12-28	WOS:A1995RY05600006
J	OMAHONY, D				OMAHONY, D			PATHOPHYSIOLOGY OF CAROTID-SINUS HYPERSENSITIVITY IN ELDERLY PATIENTS	LANCET			English	Note							BLOOD-PRESSURE; CLINICAL CHARACTERISTICS; BAROREFLEX SENSITIVITY; AGE; SYNCOPE	Carotid sinus hypersensitivity (CSH) is recognised in up to 45% of elderly patients with syncope, falls, and dizziness that may not be attributed to specific myocardial sinus node dysfunction, various diseases that affect pacemaker activity, cardiac output and blood supply to the brain. The pathophysiology of CSH is unclear but it is associated with ageing, hypertension, and ischaemic heart disease. CSH is potentially treatable with dual chamber pacing for prolonged sinus arrest (cardio-inhibitory CSH) but therapy for the more prevalent hypotension (vasodepressor CSH) is unsatisfactory. However, hypersensitivity of the carotid sinus is not consistent with the known blunting effects of senescence and hypertension on baroreflex sensitivity. The present hypothesis proposes that CSH patients results from up-regulation of postsynaptic alpha-2 adrenoceptors. Reduced carotid sinus compliance in elderly arteriosclerotic hypertensive patients will reduce afferent impulse traffic in the baroreflex pathway. Such relative deafferentation may be expected to cause baroreflex postsynaptic hypersensitivity, mediated by up-regulation of the dominant postsynaptic receptor population in the baroreflex pathway, ie, alpha-2 adrenoceptors. Vigorous carotid sinus stimulation, eg, massage, could thus cause an overshoot baroreflex efferent response, resulting in profound hypotension and bradycardia. Hypotension and bradycardia are compounded by the effects of age, hypertension, ischaemic heart disease and arteriosclerosis on rapid cardiovascular compensation, resulting in cerebral hypoperfusion and syncope. Thus, CSH in elderly patients should be considered as a clinical marker of widespread arteriosclerotic disease, rather than as a distinct disease entity. If correct, this hypothesis has potentially important implications for the pharmacotherapy of hypotension-related symptoms in elderly arteriosclerotic patients.			OMAHONY, D (corresponding author), UNIV BIRMINGHAM,DEPT GERIATR MED,BIRMINGHAM B29 6JD,W MIDLANDS,ENGLAND.							BRIGNOLE M, 1992, AM J CARDIOL, V69, P1039, DOI 10.1016/0002-9149(92)90860-2; CLIFFORD JM, 1989, BRIT J CLIN PHARMACO, V28, pP224; DEHN TCB, 1984, J PHYSL, V49, P37; GILLIS RA, 1985, J CARDIOVASC PHARM, V7, pS38; GRIBBIN B, 1971, CIRC RES, V29, P424, DOI 10.1161/01.RES.29.4.424; HAEUSLER G, 1974, N-S ARCH PHARMACOL, V286, P97, DOI 10.1007/BF00499107; HALLIDAY CA, 1991, BRIT J PHARMACOL, V102, P887, DOI 10.1111/j.1476-5381.1991.tb12272.x; HYLAND L, 1985, EUR J PHARMACOL, V114, P361, DOI 10.1016/0014-2999(85)90381-4; KANNEL WB, 1985, HDB BIOL AGING, P859; KAPOOR WN, 1994, J AM GERIATR SOC, V42, P426, DOI 10.1111/j.1532-5415.1994.tb07493.x; KENNY RA, 1991, AGE AGEING, V20, P449, DOI 10.1093/ageing/20.6.449; KOBINGER W, 1976, EUR J PHARMACOL, V40, P311, DOI 10.1016/0014-2999(76)90068-6; LIPSITZ LA, 1985, CLIN SCI, V69, P337, DOI 10.1042/cs0690337; MCGARRY K, 1983, HYPERTENSION, V5, P8763; MCINTOSH S, 1993, AGE AGEING, V22, P53, DOI 10.1093/ageing/22.1.53; MCINTOSH SJ, 1993, AM J MED, V95, P203, DOI 10.1016/0002-9343(93)90261-M; MINAKER KL, 1980, GERONTOLOGIST, V20, P163; MORLEY CA, 1984, INT J CARDIOL, V6, P287, DOI 10.1016/0167-5273(84)90188-8; REIFFEL JA, 1983, PACE, V6, P1143, DOI 10.1111/j.1540-8159.1983.tb04451.x; ROBERTSON HA, 1985, CAN J PHYSIOL PHARM, V63, P1190, DOI 10.1139/y85-195; ROSS RT, 1988, MAJOR PROBLEMS NEURO, V18, P107; RUFFOLO RR, 1994, PHARMACOL THERAPEUT, V61, P1, DOI 10.1016/0163-7258(94)90058-2; Schmitt H, 1971, Actual Pharmacol (Paris), V24, P93; SHIMADA K, 1986, CLIN SCI, V70, P489, DOI 10.1042/cs0700489; SMYTH HS, 1969, CIRC RES, V24, P109, DOI 10.1161/01.RES.24.1.109; STRASBERG B, 1989, PROG CARDIOVASC DIS, V31, P379, DOI 10.1016/0033-0620(89)90032-7; Wallin B.G., 1992, AUTONOMIC FAILURE TX, P359; WIEDEMANN G, 1985, J NEUROL, V232, P318, DOI 10.1007/BF00313874	29	56	57	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					950	952		10.1016/S0140-6736(95)91563-X	http://dx.doi.org/10.1016/S0140-6736(95)91563-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564734				2022-12-28	WOS:A1995RY80800015
J	RUIZ, J; BLANCHE, H; JAMES, RW; GARIN, MCB; VAISSE, C; CHARPENTIER, G; COHEN, N; MORABIA, A; PASSA, P; FROGUEL, P				RUIZ, J; BLANCHE, H; JAMES, RW; GARIN, MCB; VAISSE, C; CHARPENTIER, G; COHEN, N; MORABIA, A; PASSA, P; FROGUEL, P			GLN-ARG192 POLYMORPHISM OF PARAOXONASE AND CORONARY HEART-DISEASE IN TYPE-2 DIABETES	LANCET			English	Article							LOW-DENSITY-LIPOPROTEIN; SERUM; MELLITUS	Paraoxonase is a high-density-lipoprotein-associated enzyme capable of hydrolysing lipid peroxides. Thus it might protect lipoproteins from oxidation. It has two isoforms, which arise from a glutamine (A isoform) to arginine (B isoform) interchange at position 199. The relevance of this polymorphism to coronary heart disease (CHD) in non-insulin-dependent diabetic patients was investigated in case-control study. Of the 434 patients, 171 had confirmed coronary artery disease; the other 263 had no history of such disease. The B allele and AB+BB genotypes were associated with an increased risk of coronary heart disease. Compared with subjects homozygous for the A allele (AA genotype), the odds ratio of CHD for subjects homozygous for the B allele was 2.5 (95% CI 1.2-5.3) and that for those heterozygous for the B allele was 1.6 (95% CI 1.1-2.4), suggesting a codominant effect on cardiovascular risk. When subjected to multivariate analysis, the B allele remained significantly associated with CHD (odds ratio 1.94, p=0.03). The paraoxonase gene polymorphism is thus an independent cardiovascular risk factor in non-insulin-dependent diabetic patients. A possible explanation for this finding is that activity of the paraoxonase B isotype does not protect well against lipid oxidation, a major atherogenic pathway.	UNIV HOSP GENEVA, DIV CLIN EPIDEMIOL, GENEVA, SWITZERLAND; FDN JEAN DAUSSET, CEPH, PARIS, FRANCE; UNIV HOSP GENEVA, DIV ENDOCRINOL & DIABETOL, GENEVA, SWITZERLAND; HOP CORBEIL, CORBEIL ESSONNES, FRANCE; ST LOUIS HOSP, SERV DIABETOL, PARIS, FRANCE; INST PASTEUR, CNRS, EP 10, LILLE, FRANCE	University of Geneva; Foundation Jean Dausset-CEPH; University of Geneva; Centre Hospitalier Sud Francilien; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Vaisse, Christian/F-1067-2011; FROGUEL, Philippe/O-6799-2017	FROGUEL, Philippe/0000-0003-2972-0784				ASSMANN G, 1988, AM HEART J, V116, P1713, DOI 10.1016/0002-8703(88)90220-7; BELLOMO G, 1995, DIABETES, V44, P60, DOI 10.2337/diabetes.44.1.60; BLATTER MC, 1993, EUR J BIOCHEM, V211, P871, DOI 10.1111/j.1432-1033.1993.tb17620.x; BUCALA R, 1993, P NATL ACAD SCI USA, V90, P6434, DOI 10.1073/pnas.90.14.6434; CHISOLM GM, 1992, DIABETES, V41, P61, DOI 10.2337/diab.41.2.S61; GARIN MCB, 1994, BIOCHEM J, V304, P549, DOI 10.1042/bj3040549; HAFFNER SM, 1995, DIABETES CARE, V18, P646, DOI 10.2337/diacare.18.5.646; HEGELE RA, 1995, ARTERIOSCL THROM VAS, V15, P89, DOI 10.1161/01.ATV.15.1.89; HUMBERT R, 1993, NAT GENET, V3, P73, DOI 10.1038/ng0193-73; HUNT JV, 1990, DIABETES, V39, P1420, DOI 10.2337/diabetes.39.11.1420; LORENTZ K, 1979, CLIN CHEM, V25, P1714; LYONS TJ, 1991, DIABETIC MED, V8, P411, DOI 10.1111/j.1464-5491.1991.tb01624.x; MACKNESS MI, 1991, FEBS LETT, V286, P152, DOI 10.1016/0014-5793(91)80962-3; MACKNESS MI, 1991, ATHEROSCLEROSIS, V86, P193, DOI 10.1016/0021-9150(91)90215-O; MACKNESS MI, 1993, ATHEROSCLEROSIS, V104, P129, DOI 10.1016/0021-9150(93)90183-U; MARRE M, 1994, DIABETES, V43, P384, DOI 10.2337/diabetes.43.3.384; NISHIGAKI I, 1981, BIOCHEM MED METAB B, V25, P373, DOI 10.1016/0006-2944(81)90096-X; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; RUIZ J, 1994, P NATL ACAD SCI USA, V91, P3662, DOI 10.1073/pnas.91.9.3662; Sambrook J, 1989, MOL CLONING LABORATO; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STEINBERG D, 1990, JAMA-J AM MED ASSOC, V264, P3047, DOI 10.1001/jama.264.23.3047; TAS S, 1994, LANCET, V343, P1194, DOI 10.1016/S0140-6736(94)92402-3; WALTER SD, 1978, INT J EPIDEMIOL, V7, P175, DOI 10.1093/ije/7.2.175; WATSON AD, 1994, CIRCULATION, V90, P353; 1985, WHO TECH REP SER, V727	26	326	344	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 30	1995	346	8979					869	872		10.1016/S0140-6736(95)92709-3	http://dx.doi.org/10.1016/S0140-6736(95)92709-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX196	7564671				2022-12-28	WOS:A1995RX19600009
J	WARNER, JO				WARNER, JO			REVIEW OF PRESCRIBED TREATMENT FOR CHILDREN WITH ASTHMA IN 1990	BRITISH MEDICAL JOURNAL			English	Article							BECLOMETHASONE DIPROPIONATE; CHILDHOOD	Objective-To review treatment prescribed to asthmatic children in Great Britain during the 12 months after publication of the first guidelines and to assess effectiveness of prophylactic treatment. Design-Review of prescribing information from January 1990 to June 1991 in a representative sample of general practices in Great Britain with a Compufile/AAH Meditel computer. Subjects-17 846 children with asthma aged 4-17 years. Main outcome measures-Numbers of children prescribed different asthma treatments; estimated use of inhaled beta agonists in those receiving prophylactic treatment. Results-From January to December 1990, 9362 (52.5%) children were prescribed preventive treatments. 16211 (90.8%) children were prescribed bronchodilators of some kind. 3055 (17.1%) were prescribed sodium cromoglycate, and the proportion decreased significantly during the study (from 19.5% (95% confidence interval 18.6% to 20.4%) to 17.2% (16.4% to 18.1%), P<0.001, in children aged 4-11 years and from 14.9% (14.0% to 15.9%) to 11.3% (10.4% to 12.2%), P<0.001, in those aged 12-17 during January-July 1991). 6952 (39.0%) were prescribed inhaled steroids, and the proportion increased during the study (from 35.1% (34.0% to 36.2%) to 44.1% (43.0% to 45.2%), P<0.001, in children aged 4-11 years and hem 38.7% (37.40% to 40.0%) to 44.1% (42.7% to 45.5%), P<0.001, in those aged 12-17 during January-July 1991). Only 1358 of the 9362 children (14.5%) received sufficient repeat prescriptions to suggest that they might be taking the prophylactic treatment regularly. Among these children short acting inhaled beta agonists were being used on average four to eight times a day. Conclusions-These results are useful baseline data for audit of the impact of published clinical guidelines, particularly in terms of reducing the need for short acting inhaled beta agonists with prophylactic treatment.			WARNER, JO (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT CHILD HLTH,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.		Warner, John/AAF-9587-2020					ANDERSON HR, 1994, BRIT MED J, V308, P1600, DOI 10.1136/bmj.308.6944.1600; ANDERSON SD, 1976, AM REV RESPIR DIS, V114, P493; BEARDON PHG, 1993, BRIT MED J, V307, P846, DOI 10.1136/bmj.307.6908.846; British Thoracic Society (BTS), 1993, THORAX, V48, pS1; CHAPMAN KR, 1994, LANCET, V343, P1379, DOI 10.1016/S0140-6736(94)92520-8; GODFREY S, 1978, J ALLERGY CLIN IMMUN, V62, P335, DOI 10.1016/0091-6749(78)90133-1; HILL RA, 1989, ARCH DIS CHILD, V64, P246, DOI 10.1136/adc.64.2.246; JONES K, 1989, PRACTITIONER, V233, P265; KAARGAREN RJ, 1994, RESP MED, V88, P883; KAARSGAREN RJ, 1994, RESP MED, V88, P383, DOI 10.1016/0954-6111(94)90045-0; LAW CM, 1986, LANCET, V1, P942; REISER J, 1985, LANCET, V1, P206; ROBERTSON CF, 1993, AM REV RESPIR DIS, V147, pA372; SPEIGHT ANP, 1983, BRIT MED J, V286, P1253, DOI 10.1136/bmj.286.6373.1253; WARNER JO, 1989, RESP MED, V83, P33, DOI 10.1016/S0954-6111(89)80248-3; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; WARNER JO, 1994, EUR RESPIR REV, V4, P21; 1993, SCOTTISH HLTH STATIS; 1992, ARCH DIS CHILD, V67, P240; 1992, CLIN EXP ALLERGY S1, V22, P1; 1993, HLTH PERSONAL SOCIAL; 1994, HLTH PERSONAL SOCIAL, V20	22	71	74	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	1995	311	7006					663	666		10.1136/bmj.311.7006.663	http://dx.doi.org/10.1136/bmj.311.7006.663			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU753	7549637	Green Published			2022-12-28	WOS:A1995RU75300021
J	LARDER, BA; KEMP, SD; HARRIGAN, PR				LARDER, BA; KEMP, SD; HARRIGAN, PR			POTENTIAL MECHANISM FOR SUSTAINED ANTIRETROVIRAL EFFICACY OF AZT-3TC COMBINATION THERAPY	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIGH-LEVEL RESISTANCE; TYPE-1 REVERSE-TRANSCRIPTASE; ZIDOVUDINE AZT; MUTATION; SENSITIVITY; SUSCEPTIBILITIES; INHIBITORS; AGENTS	Combinations of antiretroviral drugs that prevent or delay the appearance of drug-resistant human immunodeficiency virus-type 1 (HIV-1) mutants are urgently required. Mutants resistant to 3'-azidothymidine (ATT, zidovudine) became phenotypically sensitive in vitro by mutation of residue 184 of viral reverse transcriptase to valine, which also induced resistance to (-)2'-deoxy-3'-thiacytidine (3TC). Furthermore, AZT-3TC coresistance was not observed during extensive in vitro selection with both drugs. In vivo AZT-3TC combination therapy resulted in a markedly greater decrease in serum HIV-1 RNA concentrations than treatment with AZT alone, even though valine-184 mutants rapidly emerged. Most samples assessed from the combination group remained ATT sensitive at 24 weeks of therapy, consistent with in vitro mutation studies.			LARDER, BA (corresponding author), WELLCOME RES LABS,ANTIVIRAL THERAPEUT RES UNIT,LANGLEY COURT,BECKENHAM BR3 3BS,KENT,ENGLAND.		Larder, Brendan/AAB-3106-2020		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; BOUCHER CAB, 1993, ANTIMICROB AGENTS CH, V37, P2231, DOI 10.1128/AAC.37.10.2231; BYRNES VW, 1994, ANTIMICROB AGENTS CH, V38, P1404, DOI 10.1128/AAC.38.6.1404; ERON JJ, 1993, ANTIMICROB AGENTS CH, V37, P1487; FITZGIBBON JE, 1993, J VIROL, V67, P7271, DOI 10.1128/JVI.67.12.7271-7275.1993; GAO Q, 1993, ANTIMICROB AGENTS CH, V37, P875; HARADA S, 1985, SCIENCE, V2229, P563; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; KELLAM P, 1994, J GEN VIROL, V75, P341, DOI 10.1099/0022-1317-75-2-341; KELLAM P, 1994, ANTIMICROB AGENTS CH, V38, P23, DOI 10.1128/AAC.38.1.23; LARDER BA, 1994, J GEN VIROL, V75, P951, DOI 10.1099/0022-1317-75-5-951; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1993, NATURE, V365, P671, DOI 10.1038/365671a0; LARDER BA, 1992, ANTIMICROB AGENTS CH, V36, P2664, DOI 10.1128/AAC.36.12.2664; LARDER BA, 1990, ANTIMICROB AGENTS CH, V34, P436, DOI 10.1128/AAC.34.3.436; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LARDER BA, 1993, REVERSE TRANSCRIPTAS, P205; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; RICHMAN DD, 1993, ANTIMICROB AGENTS CH, V37, P1207, DOI 10.1128/AAC.37.6.1207; SCHOOLEY RT, UNPUB; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; STASZEWSKI S, 1994, 2ND INT C DRUG THER; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; VARTANIAN JP, 1994, P NATL ACAD SCI USA, V91, P3092, DOI 10.1073/pnas.91.8.3092; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	29	566	583	1	15	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					696	699		10.1126/science.7542804	http://dx.doi.org/10.1126/science.7542804			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7542804				2022-12-28	WOS:A1995RM70200036
J	SMITH, HO; TOMB, JF; DOUGHERTY, BA; FLEISCHMANN, RD; VENTER, JC				SMITH, HO; TOMB, JF; DOUGHERTY, BA; FLEISCHMANN, RD; VENTER, JC			FREQUENCY AND DISTRIBUTION OF DNA UPTAKE SIGNAL SEQUENCES IN THE HAEMOPHILUS-INFLUENZAE RD GENOME	SCIENCE			English	Article							HEMOPHILUS TRANSFORMATION; RECOGNITION SITES; SPECIFICITY	The naturally transformable, Gram-negative bacterium Haemophilus influenzae Rd preferentially takes up DNA of its own species by recognizing a 9-base pair sequence, 5'-AAGTGCGGT, carried in multiple copies in its chromosome. With the availability of the complete genome sequence, 1465 copies of the 9-base pair uptake site have been identified. Alignment of these sites unexpectedly reveals an extended consensus region of 29 base pairs containing the core 9-base pair region and two downstream 6- base pair A/T-rich regions, each spaced about one helix turn apart. Seventeen percent of the sites are in inverted repeat pairs, many of which are located downstream to gene termini and are capable of forming stem-loop structures in messenger RNA that might function as signals for transcription termination.	INST GENOM RES,GAITHERSBURG,MD 20878	J. Craig Venter Institute	SMITH, HO (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.							BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; DANNER DB, 1980, GENE, V11, P311, DOI 10.1016/0378-1119(80)90071-2; DANNER DB, 1982, P NATL ACAD SCI-BIOL, V79, P2393, DOI 10.1073/pnas.79.7.2393; FITZMAURICE WP, 1984, GENE, V31, P187, DOI 10.1016/0378-1119(84)90209-9; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRIEDMAN EA, 1972, J BIOL CHEM, V247, P2846; GOODGAL SH, 1990, J BACTERIOL, V172, P5924, DOI 10.1128/jb.172.10.5924-5928.1990; GOODMAN SD, 1988, P NATL ACAD SCI USA, V85, P6982, DOI 10.1073/pnas.85.18.6982; HIGGINS CF, 1988, GENE, V72, P3, DOI 10.1016/0378-1119(88)90122-9; KAHN ME, 1984, J MEMBRANE BIOL, V81, P89, DOI 10.1007/BF01868974; KAUC L, 1990, GENE, V95, P149, DOI 10.1016/0378-1119(90)90427-S; REDFIELD RJ, 1991, NATURE, V352, P25, DOI 10.1038/352025b0; SCOCCA JJ, 1974, J BACTERIOL, V118, P369, DOI 10.1128/JB.118.2.369-373.1974; SISCO KL, 1979, P NATL ACAD SCI USA, V76, P972, DOI 10.1073/pnas.76.2.972; SMITH GR, 1994, EXPERIENTIA, V50, P234, DOI 10.1007/BF01924006; TOMB JF, 1991, GENE, V104, P1, DOI 10.1016/0378-1119(91)90457-M; WILCOX KW, 1976, J BIOL CHEM, V251, P6127	17	167	174	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 28	1995	269	5223					538	540		10.1126/science.7542802	http://dx.doi.org/10.1126/science.7542802			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7542802				2022-12-28	WOS:A1995RL49500027
J	FRENCH, RR; HAMBLIN, TJ; BELL, AJ; TUTT, AL; GLENNIE, MJ				FRENCH, RR; HAMBLIN, TJ; BELL, AJ; TUTT, AL; GLENNIE, MJ			TREATMENT OF B-CELL LYMPHOMAS WITH COMBINATION OF BISPECIFIC ANTIBODIES AND SAPORIN	LANCET			English	Note							IMMUNOTOXIN	We report the use of a bispecific F(ab')(2) antibody to target the ribosome-inactivating protein saporin to the surface antigen CD22 in the treatment of low-grade, end-stage, B-cell lymphoma. Four patients were treated. Toxic effects were minimal (grade I), with mild fever, weakness, and myalgia for 1-2 days after treatment. One patient showed an antibody response to mouse Fab' and saporin. All patients showed rapid and beneficial responses to treatment with improvements in most disease sites and in peripheral blood cytopenia. The responses were short-lived (less than 28 days) but further study of this targeting system is warranted.	ROYAL BOURNEMOUTH HOSP,DEPT HAEMATOL,BOURNEMOUTH BH7 7DW,DORSET,ENGLAND; SOUTHAMPTON GEN HOSP,TENOVUS RES LAB,SOUTHAMPTON,HANTS,ENGLAND; POOLE GEN HOSP,POOLE,DORSET,ENGLAND	University of Southampton; Poole Hospital								AMLOT PL, 1993, BLOOD, V82, P2624; BONARDI MA, 1993, CANCER RES, V53, P3015; FALINI B, 1992, LANCET, V339, P1195, DOI 10.1016/0140-6736(92)91135-U; FRENCH RR, 1991, CANCER RES, V51, P2353; GLENNIE MJ, 1993, TUMOUR IMMUNOBIOLOGY, P225; GROSSBARD ML, 1991, BLOOD, V78, P174; STANSFELD AG, 1988, LANCET, V1, P292; VITETTA ES, 1993, IMMUNOL TODAY, V14, P252, DOI 10.1016/0167-5699(93)90041-I; 1979, WHO OFFSET PUBLICATI, V48	9	37	38	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					223	224		10.1016/S0140-6736(95)91271-1	http://dx.doi.org/10.1016/S0140-6736(95)91271-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7542357				2022-12-28	WOS:A1995RK41900013
J	MCHEYZERWILLIAMS, MG; DAVIS, MM				MCHEYZERWILLIAMS, MG; DAVIS, MM			ANTIGEN-SPECIFIC DEVELOPMENT OF PRIMARY AND MEMORY T-CELLS IN-VIVO	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; POLYMERASE CHAIN-REACTION; PRIMARY IMMUNE-RESPONSE; B-CELLS; FINE SPECIFICITY; CELLULAR BASIS; CYTOCHROME-C; RECEPTOR; RECOGNITION; INVIVO	The expansion and contraction of specific helper T cells in the draining lymph nodes of normal mice after injection with antigen was followed. T cell receptors from purified primary and memory responder cells had highly restricted junctional regions, indicating antigen-driven selection. Selection for homogeneity in the length of the third complementarity-determining region (CDR3) occurs before selection for some of the characteristic amino acids, indicating the importance of this parameter in T cell receptor recognition. Ultimately, particular T cell receptor sequences come to predominate in the secondary response and others disappear, showing the selective presentation or expansion of specific T cell clones.	STANFORD UNIV, MED CTR, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	MCHEYZERWILLIAMS, MG (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA.			Davis, Mark/0000-0001-6868-657X				Ahmed R, 1992, Semin Immunol, V4, P105; BARTH RK, 1985, NATURE, V316, P517, DOI 10.1038/316517a0; BEVERLEY PCL, 1990, CURR TOP MICROBIOL, V159, P111; BRADLEY LM, 1993, J IMMUNOL, V150, P3119; BRADLEY LM, 1991, J EXP MED, V174, P547, DOI 10.1084/jem.174.3.547; BUDD RC, 1987, J IMMUNOL, V138, P3120; Burnet F., 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; CELADA F, 1971, PROG ALLERGY, V15, P223; CEROTTINI JC, 1989, ANNU REV IMMUNOL, V7, P77, DOI 10.1146/annurev.iy.07.040189.000453; CHANG HL, 1989, J IMMUNOL, V143, P315; CHIEN YH, 1984, NATURE, V309, P322, DOI 10.1038/309322a0; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; COCHET M, 1992, EUR J IMMUNOL, V22, P2639, DOI 10.1002/eji.1830221025; CORRADIN G, 1979, J EXP MED, V149, P436, DOI 10.1084/jem.149.2.436; DONG RP, 1992, TISSUE ANTIGENS, V39, P106, DOI 10.1111/j.1399-0039.1992.tb01918.x; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; FORD JE, 1994, EUR J IMMUNOL, V24, P1816, DOI 10.1002/eji.1830240814; FORD JE, 1994, GENE, V142, P279, DOI 10.1016/0378-1119(94)90275-5; FULLER KA, 1993, J IMMUNOL, V151, P4505; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; HAYAKAWA K, 1987, P NATL ACAD SCI USA, V84, P1379, DOI 10.1073/pnas.84.5.1379; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; HEDRICK SM, 1988, SCIENCE, V239, P1541, DOI 10.1126/science.2832942; HOU S, 1993, J IMMUNOL, V150, P5494; HOU S, 1992, NATURE, V369, P651; HSIEH CL, 1991, MOL CELL BIOL, V11, P3972, DOI 10.1128/MCB.11.8.3972; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; JAMESON SC, 1991, J IMMUNOL, V147, P3185; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; KELSO A, 1991, IMMUNOL REV, V123, P85, DOI 10.1111/j.1600-065X.1991.tb00607.x; KOOP BF, 1994, GENOMICS, V19, P478, DOI 10.1006/geno.1994.1097; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; MACDONALD HR, 1993, J EXP MED, V177, P1487, DOI 10.1084/jem.177.5.1487; MACKAY CR, 1993, ADV IMMUNOL, V53, P217, DOI 10.1016/S0065-2776(08)60501-5; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MCHEYZERWILLIAMS MG, 1991, NATURE, V350, P502, DOI 10.1038/350502a0; MCHEYZERWILLIAMS MG, 1993, J EXP MED, V178, P295, DOI 10.1084/jem.178.1.295; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; OEHEN S, 1992, J EXP MED, V176, P1273, DOI 10.1084/jem.176.5.1273; PADLAN EA, 1977, Q REV BIOPHYS, V10, P35, DOI 10.1017/S0033583500000135; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; REAY PA, UNPUB; REINER SL, 1993, SCIENCE, V259, P1457, DOI 10.1126/science.8451641; ROCK EP, 1994, J EXP MED, V179, P323, DOI 10.1084/jem.179.1.323; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SPRENT J, 1994, CELL, V76, P315, DOI 10.1016/0092-8674(94)90338-7; SPRENT J, 1976, CELL IMMUNOL, V21, P278, DOI 10.1016/0008-8749(76)90057-5; STRENT J, 1994, SCIENCE, V265, P1395; Swain S L, 1992, Semin Immunol, V4, P59; SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; VITETTA ES, 1991, ANNU REV IMMUNOL, V9, P193, DOI 10.1146/annurev.iy.09.040191.001205; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; WURZBURG U, 1973, EUR J IMMUNOL, V3, P762, DOI 10.1002/eji.1830031205; ZHENG B, 1994, NATURE, V372, P556, DOI 10.1038/372556a0; ZINKERNAGEL RM, 1993, IMMUNOL REV, V133, P199, DOI 10.1111/j.1600-065X.1993.tb01517.x	64	389	396	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 7	1995	268	5207					106	111		10.1126/science.7535476	http://dx.doi.org/10.1126/science.7535476			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7535476				2022-12-28	WOS:A1995QR45400037
J	SAITOU, M; SUGAI, S; TANAKA, T; SHIMOUCHI, K; FUCHS, E; NARUMIYA, S; KAKIZUKA, A				SAITOU, M; SUGAI, S; TANAKA, T; SHIMOUCHI, K; FUCHS, E; NARUMIYA, S; KAKIZUKA, A			INHIBITION OF SKIN DEVELOPMENT BY TARGETED EXPRESSION OF A DOMINANT-NEGATIVE RETINOLE ACID RECEPTOR	NATURE			English	Article							KERATIN EXPRESSION; EPIDERMAL DIFFERENTIATION; TERMINAL DIFFERENTIATION; TRANSGENIC MICE; GENE; MOUSE; ALPHA; TRANSCRIPTION; TISSUE	ALTHOUGH pharmacological doses of retinoic acid (RA) have a wide variety of actions in vivo(1), experimental difficulties have prevented a definitive assignment of its physiological functions, We recently made a dominant-negative retinoic acid receptor (RAR) by a single amino-acid substitution(2) which creates a dominant-negative thyroid hormone receptor(3). The mutated RAR efficiently inhibited the endogenous activities of RARs (alpha, beta, gamma)(2). Thus, targeted expression of the mutated receptor should reveal RA functions during organogenesis by blocking RA signalling in the tissues concerned. To address this possibility, we expressed the dominant-negative RAR in the epidermis, a potential target organ of RA(4). We report here that the resultant transgenic mice exhibited dramatic suppression of epidermal maturation, demonstrating the requirement of RA in normal skin development.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 60601,JAPAN; KYOTO UNIV,FAC MED,DEPT DERMATOL,KYOTO 60601,JAPAN; ONO PHARMACEUT,FUKUI INST SAFETY RES,FUKUI 913,JAPAN; UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637	Kyoto University; Kyoto University; Ono Pharmaceutical Co Ltd; Howard Hughes Medical Institute; University of Chicago			Fuchs, Elaine/G-1565-2016					Armstrong Robert B., 1994, P545; BYRNE C, 1994, DEVELOPMENT, V120, P2369; DALE BA, 1985, J CELL BIOL, V101, P1257, DOI 10.1083/jcb.101.4.1257; DAVIDSON P, 1952, J ANAT, V86, P342; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1981, CELL, V25, P617, DOI 10.1016/0092-8674(81)90169-0; GORDON JW, 1993, GUIDE TECHNIQUES MOU, P174; Gruneberg H, 1943, J HERED, V34, P89, DOI 10.1093/oxfordjournals.jhered.a105255; HANSON J, 1947, J ANAT, V81, P174; HARDISON RC, 1979, CELL, V18, P1285, DOI 10.1016/0092-8674(79)90239-3; IVANYI D, 1989, J PATHOL, V159, P7, DOI 10.1002/path.1711590105; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAKIZUKA A, 1992, GENE DEV, V6, P578, DOI 10.1101/gad.6.4.578; KOPAN R, 1989, J CELL BIOL, V109, P295, DOI 10.1083/jcb.109.1.295; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; OHKUBO H, 1990, P NATL ACAD SCI USA, V87, P5153, DOI 10.1073/pnas.87.13.5153; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; Peck Gary L., 1994, P631; SAITOU M, 1994, J BIOL CHEM, V269, P19101; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; STEINERT PM, 1975, BIOCHEM J, V149, P39, DOI 10.1042/bj1490039; STOLER A, 1989, J INVEST DERMATOL, V93, P728, DOI 10.1111/1523-1747.ep12284397; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753	29	158	160	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					159	162		10.1038/374159a0	http://dx.doi.org/10.1038/374159a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7533262				2022-12-28	WOS:A1995QL39700058
J	STEEGMAIER, M; LEVINOVITZ, A; ISENMANN, S; BORGES, E; LENTER, M; KOCHER, HP; KLEUSER, B; VESTWEBER, D				STEEGMAIER, M; LEVINOVITZ, A; ISENMANN, S; BORGES, E; LENTER, M; KOCHER, HP; KLEUSER, B; VESTWEBER, D			THE E-SELECTIN-LIGAND ESL-1 IS A VARIANT OF A RECEPTOR FOR FIBROBLAST GROWTH-FACTOR	NATURE			English	Article							LEUKOCYTE ADHESION MOLECULE-1; P-SELECTIN; GLYCOPROTEIN LIGAND; EXPRESSION; CELLS; ANTIGEN; IDENTIFICATION; SPECIFICITIES; DISTINCT; SURFACE	E-SELECTIN is an inducible cell-adhesion molecule on endothelial cells, which mediates the binding of neutrophils and functions as a Ca2+-dependent lectin(1-3). We have recently identified a 150K glycoprotein as the major ligand for E-selectin on myeloid cells, using a recombinant antibody-like form of mouse E-selectin as an affinity probe(4,5). Here we report the isolation of a mouse complementary DNA for this E-selectin ligand (ESL-1). The predicted amino-acid sequence of ESL-1 is 94% identical (over 1,078 amino acids) to the recently identified chicken cysteine-rich fibroblast growth-factor receptor(6), except for a unique 70-amino-acid amino-terminal domain of mature ESL-1. Fucosylation of ESL-1 is imperative for affinity isolation with E-selectin-IgG. A fucosylated, recombinant antibody-like form of ESL-1, but not for L-selectin, supports adhesion of E-selectin-transfected Chinese hamster ovary cells. Antibodies against ESL-1 block the binding of mouse myeloid cells to E-selectin. ESL-1, with a structure essentially identical to that of a receptor, thus functions as a cell adhesion ligand of E-selectin.	MAX PLANCK INST IMMUNBIOL,HANS SPEMANN LAB,D-79108 FREIBURG,GERMANY; SANDOZ PHARMA LTD,CH-4002 BASEL,SWITZERLAND	Max Planck Society; Novartis; Sandoz			Isenmann, Stefan/AAJ-3788-2020					BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; BURRUS LW, 1992, MOL CELL BIOL, V12, P5600, DOI 10.1128/MCB.12.12.5600; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; KISHIMOTO TK, 1991, BLOOD, V78, P805; KOTOVUORI P, 1993, GLYCOBIOLOGY, V3, P131, DOI 10.1093/glycob/3.2.131; KUIJPERS TW, 1992, J CELL BIOL, V118, P457, DOI 10.1083/jcb.118.2.457; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SAWADA R, 1993, J BIOL CHEM, V268, P12675; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; VESTWEBER D, 1994, RES IMMUNOL, V144, P704; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WELLER A, 1992, J BIOL CHEM, V267, P15176; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WILLIAMS RL, 1988, CELL, V52, P121	24	322	328	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					615	620		10.1038/373615a0	http://dx.doi.org/10.1038/373615a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7531823				2022-12-28	WOS:A1995QG99700055
J	SPIVAKKROIZMAN, T; LEMMON, MA; DIKIC, I; LADBURY, JE; PINCHASI, D; HUANG, J; JAYE, M; CRUMLEY, G; SCHLESSINGER, J; LAX, I				SPIVAKKROIZMAN, T; LEMMON, MA; DIKIC, I; LADBURY, JE; PINCHASI, D; HUANG, J; JAYE, M; CRUMLEY, G; SCHLESSINGER, J; LAX, I			HEPARIN-INDUCED OLIGOMERIZATION OF FGF MOLECULES IS RESPONSIBLE FOR FGF RECEPTOR DIMERIZATION, ACTIVATION, AND CELL-PROLIFERATION	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; LIGAND-BINDING DOMAIN; EXTRACELLULAR DOMAIN; EGF RECEPTOR; HORMONE RECEPTOR; MAMMALIAN-CELLS; AFFINITY; TRANSFORMATION; ECTODOMAIN; CLONING	Heparin is required for fibroblast growth factor (FGF) stimulation of biological responses. Using isothermal titration calorimetry, we show that acidic FGF (aFGF) forms a 1:1 complex with the soluble extracellular domain of FGF receptor (FGFR). Heparin exerts its effect by binding to many molecules of aFGF. The resulting aFGF-heparin complex can bind to several receptor molecules, leading to FGFR dimerization. In two cell lines lacking endogenous heparan sulfate, exogenous heparin is required for FGFR dimerization, tyrosine kinase activation, c-fos mRNA transcription, and cell proliferation. Moreover, a synthetic heparin analog that binds monovalently to aFGF blocks FGFR dimerization, activation, and signaling via FGFR. We propose that heparin causes oligomerization of aFGF such that its binding to FGFR results in dimerization and activation. This represents a novel mechanism for transmembrane signaling and may account for the action of many heparin-bound growth factors.	NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; RHONE POULENC RORER, CENT RES, COLLEGEVILLE, PA 19426 USA	New York University			Dikic, Ivan/O-4650-2015	Dikic, Ivan/0000-0001-8156-9511; Ladbury, John/0000-0002-6328-7200; Lemmon, Mark/0000-0002-3379-5319	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM004725] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM04725] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; JAYE M, 1987, J BIOL CHEM, V262, P16612; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LAX I, 1991, J BIOL CHEM, V266, P13828; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LEV S, 1992, J BIOL CHEM, V267, P10866; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; SCHAEFER EM, 1992, J BIOL CHEM, V267, P23393; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; WAGNER JA, 1991, CURR TOP MICROBIOL, V165, P95; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YEH JI, 1993, J BIOL CHEM, V268, P9787; ZHOU M, 1993, BIOCHEMISTRY-US, V32, P8193, DOI 10.1021/bi00083a020; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	39	589	597	1	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 16	1994	79	6					1015	1024		10.1016/0092-8674(94)90032-9	http://dx.doi.org/10.1016/0092-8674(94)90032-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	7528103				2022-12-28	WOS:A1994PY08600011
